PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Li, Z; Jiang, HP; Xie, W; Zhang, ZC; Smrcka, AV; Wu, DQ				Li, Z; Jiang, HP; Xie, W; Zhang, ZC; Smrcka, AV; Wu, DQ			Roles of PLC-beta 2 and -beta 3 and PI3K gamma in chemoattractant-mediated signal transduction	SCIENCE			English	Article							PROTEIN-KINASE-C; NADPH OXIDASE; 3-KINASE	The roles of phosphoinositide 3-kinase (PI3K) and phospholipase C (PLC) in chemoattractant-elicited responses were studied in mice lacking these key enzymes. PI3K gamma was required for chemoattractant-induced production of phosphatidylinositol 3,4,5-trisphosphate [Ptdlns (3,4,5)P-3] and has an important role in chemoattractant-induced superoxide production and chemotaxis in mouse neutrophils and in production of T cell-independent antigen-specific antibodies composed of the immunoglobulin lambda Light chain (Tl-Ig lambda(L). The study of the mice Lacking PLC-beta 2 and -beta 3 revealed that the PLC pathways have an important role in chemoattractant-mediated production of superoxide and regulation of protein kinases, but not chemotaxis. The PLC pathways also appear to inhibit the chemotactic activity induced by certain chemoattractants and to suppress TI-Ig lambda(L) production.	Univ Rochester, Dept Pharmacol, Rochester, NY 14642 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Rochester; University of Connecticut	Wu, DQ (corresponding author), Univ Rochester, Dept Pharmacol, Rochester, NY 14642 USA.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hawkins PT, 1997, BIOCHEM SOC T, V25, P1147, DOI 10.1042/bst0251147; Jiang HP, 1997, P NATL ACAD SCI USA, V94, P7971, DOI 10.1073/pnas.94.15.7971; Jung S, 1999, CURR OPIN IMMUNOL, V11, P319, DOI 10.1016/S0952-7915(99)80051-X; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li Z.B., UNPUB; PARK JW, 1992, J BIOL CHEM, V267, P19901; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Xie W, 1999, P NATL ACAD SCI USA, V96, P10385, DOI 10.1073/pnas.96.18.10385	23	703	754	3	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1046	1049		10.1126/science.287.5455.1046	http://dx.doi.org/10.1126/science.287.5455.1046			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669417				2022-12-01	WOS:000085245400049
J	Modell, B; Harris, R; Lane, B; Khan, M; Darlison, M; Petrou, M; Old, J; Layton, M; Varnavides, L				Modell, B; Harris, R; Lane, B; Khan, M; Darlison, M; Petrou, M; Old, J; Layton, M; Varnavides, L			Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRENATAL-DIAGNOSIS; DISORDERS	Objective National audit of informed choice in antenatal screening for thalassaemia. Design Audit from the UK Confidential Enquiry into Counselling for Genetic Disorders. Setting Thalassaemia module of the UK Confidential Enquiry into Counselling for Genetic Disorders. Subjects 138 of 156 couples who had had a pregnancy affected by a major beta thalassaemia from 1990 to 1994. Main outcome measures How and when genetic risk was identified for each couple, and whether and when prenatal diagnosis was offered. Results Risk was detected by screening before or during the first pregnancy in 49% (68/138) of couples and by diagnosis of an affected child in 28% (38/138) of couples. Prenatal diagnosis was offered in 69% (274/400) of pregnancies, ranging from 94% (122/130) fur British Cypriots to 54% (80/149) for British Pakistanis and from 90% in the south east of England to 39% in the West Midlands. Uptake of prenatal diagnosis was 80% (216/274), ranging from 98% (117/120) among British Cypriots in either the first or second trimester to 73% (35/48) among British Pakistanis in the first trimester and 39% (11/28) in the second trimester. A demonstrable service failure occurred in 28% (110/400) of pregnancies, including 110 of 126 where prenatal diagnosis was not offered and 48 of 93 that ended with an affected liveborn infant. Conclusion Although antenatal screening and counselling fur haemoglobin disorders are standard practices in the United Kingdom, they are delivered inadequately and inequitably. An explicit national policy is needed, aiming to make prenatal diagnosis in the first trimester available to all couples and including ongoing national audit.	UCL Royal Free & UCL Med Sch, Dept Primary Care & Populat Sci, Whittington Hosp, London N19 5NF, England; St Marys Hosp, Manchester M13 0JH, Lancs, England; UCL Royal Free & UCL Med Sch, Ctr Hlth Informat & Mutiprofess Educ, Whittington Hosp, London N19 5NF, England; UCL Royal Free & UCL Med Sch, Dept Obstet & Gynaecol, London WC1E 6HX, England; Kings Coll Hosp London, Sch Med, Dept Haematol Med, London SE5 9RS, England; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England	University of London; University College London; University of Manchester; University of London; University College London; University of London; University College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of Oxford	Modell, B (corresponding author), UCL Royal Free & UCL Med Sch, Dept Primary Care & Populat Sci, Whittington Hosp, London N19 5NF, England.	b.modell@ucl.ac.uk	Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANIONWU EN, 1996, RES CULTURAL DIFFERE; Bain BJ, 1998, BRIT J HAEMATOL, V101, P783, DOI 10.1046/j.1365-2141.1998.00809.x; HARRIS R, 1991, BRIT MED J, V303, P1412, DOI 10.1136/bmj.303.6815.1412; Harris R, 1999, BRIT J OBSTET GYNAEC, V106, P658, DOI 10.1111/j.1471-0528.1999.tb08364.x; Hickman M, 1999, BRIT J HAEMATOL, V104, P860, DOI 10.1046/j.1365-2141.1999.01275.x; *HLTH ED AUTH, 1998, SICKL CELL THAL ACH; Jones D, 1998, BRIT MED J, V316, P1476, DOI 10.1136/bmj.316.7143.1476; Modell B, 1997, BRIT MED J, V315, P779, DOI 10.1136/bmj.315.7111.779; MODELL B, 1993, HLTH SERVICES RES; MODELL B, 1980, BRIT MED J, V2, P737; MODELL B, 2000, IN PRESS LANCET; MODELL B, 1985, LANCET, V2, P1383; Modell M, 1998, BMJ-BRIT MED J, V317, P788, DOI 10.1136/bmj.317.7161.788; *NAT CONF ENQ COUN, 1998, HOM BET THAL GREAT B; Neuenschwander H, 1997, BRIT MED J, V315, P784; *NUFF COUNC BIOETH, GEN SCREEN ETH ISS; OLD JM, 1990, LANCET, V336, P834, DOI 10.1016/0140-6736(90)92338-I; PETROV RV, 1995, BIOSCIENCE REP, V15, P1, DOI 10.1007/BF01200210; *STAND MED ADV COM, 1994, SICKL CELL THAL OTH	19	82	87	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	2000	320	7231					337	341		10.1136/bmj.320.7231.337	http://dx.doi.org/10.1136/bmj.320.7231.337			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657326	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000085211400021
J	Sacher, RA; Schreiber, GB; Kleinman, SH				Sacher, RA; Schreiber, GB; Kleinman, SH			Prevention of transfusion-transmitted hepatitis	LANCET			English	Editorial Material							POSTTRANSFUSION HEPATITIS; VIRUS-INFECTION; RISK		Georgetown Univ, Med Ctr, Dept Lab Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA; WESTAT, Rockville, MD USA; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Georgetown University; Georgetown University; Georgetown University; Westat; University of British Columbia	Sacher, RA (corresponding author), Georgetown Univ, Med Ctr, Dept Lab Med, Washington, DC 20007 USA.							Allain JP, 1999, BRIT J HAEMATOL, V107, P186, DOI 10.1046/j.1365-2141.1999.01665.x; ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; Busch MP, 1998, VOX SANG, V74, P147, DOI 10.1111/j.1423-0410.1998.tb05413.x; Busch MP, 1998, TRANSFUSION, V38, p72S; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; Flanagan P, 1999, TRANSFUS MED REV, V13, P164, DOI 10.1016/S0887-7963(99)80030-3; HOOFNAGLE JH, 1990, TRANSFUSION, V30, P384, DOI 10.1046/j.1537-2995.1990.30590296367.x; JAGODZINSKI L, 1994, TRANSFUSION, V34, pS37; Matsumoto A, 1999, HEPATOLOGY, V30, P283, DOI 10.1002/hep.510300118; Rawal BD, 1998, TRANSFUSION, V38, p91S; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Schuttler CG, 2000, LANCET, V355, P41, DOI 10.1016/S0140-6736(99)04719-4	13	14	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					331	332		10.1016/S0140-6736(99)00391-8	http://dx.doi.org/10.1016/S0140-6736(99)00391-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665547				2022-12-01	WOS:000085122100003
J	Druss, BG; Bradford, DW; Rosenheck, RA; Radford, MJ; Krumholz, HM				Druss, BG; Bradford, DW; Rosenheck, RA; Radford, MJ; Krumholz, HM			Mental disorders and use of cardiovascular procedures after myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC-CATHETERIZATION FACILITIES; CORONARY HEART-DISEASE; UNITED-STATES; MEDICARE PATIENTS; ELDERLY PATIENTS; RACIAL-DIFFERENCES; ANXIETY DISORDERS; OUTCOMES; ANGIOGRAPHY; CARE	Context A number of studies have found race- and sex-based differences in rates of cardiovascular procedures in the United States, Similarly, mental disorders might be expected to be associated with lower rates of such procedures on the basis of clinical, socioeconomic, patient, and provider factors, Objective To assess whether having a comorbid mental disorder is associated with a lower likelihood of cardiac catheterization and/or revascularization after acute myocardial infarction. Design Retrospective cohort study using data from medical charts and administrative files as part of the Cooperative Cardiovascular Project. Setting Acute care nongovernmental hospitals in the United States. Patients National cohort of 113 653 eligible patients 65 years or older who were hospitalized for confirmed acute myocardial infarction between February 1994 and July 1995. Main Outcome Measures Likelihood of cardiac catheterization, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass graft (CABG) surgery during the index hospitalization, comparing patients with and without mental disorders (classified as schizophrenia, major affective disorder, substance abuse/ dependence disorder, or other mental disorder). Results Compared with the remainder of the sample, patients with any comorbid mental disorder (n = 5365; 4.7%) were significantly less likely to undergo PTCA (11.8% vs 16.8%; P<.001) or CABG (8.2% vs 12.6%; P<.001), After adjusting for demographic, clinical, hospital, and regional factors, individuals with mental disorders were 41% (for schizophrenia) to 78% (for substance use) as likely to undergo cardiac catheterization as those without mental disorders (P<.001 for all). Among those undergoing catheterization, rates of PTCA or CABG for patients with mental disorders were not significantly different from rates for patients without mental disorders (for those with any mental disorder, P =.12 for PTCA and P =.06 for CABG), In multivariate models, the 30-day mortality did not differ between patients with and without mental disorders. Conclusions In this study, individuals with comorbid mental disorders were substantially less likely to undergo coronary revascularization procedures than those without mental disorders. Further research is needed to understand the degree to which patient and provider factors contribute to this difference and its implications for quality and long-term outcomes of care.	Yale Univ, Sch Med, VA NE Program Evaluat Ctr, Dept Psychiat, New Haven, CT 06520 USA; Yale Univ, Sch Med, VA NE Program Evaluat Ctr, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT USA; VA Connecticut Mental Illness Res Educ & Clin Ctr, New Haven, CT USA; Yale Univ, Dept Med, Sect Cardiovasc med, New Haven, CT 06520 USA; Qualidigm, Middletown, CT USA; Med Univ S Carolina, Ctr Hlth Care Res, Charleston, SC 29425 USA	Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Medical University of South Carolina	Druss, BG (corresponding author), 950 Campbell Ave 116A, W Haven, CT 06516 USA.		, Harlan/AAI-2875-2020	Radford, Martha/0000-0001-7503-9557	NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001556] Funding Source: NIH RePORTER; NIMH NIH HHS [K08 MH01556] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARO S, 1995, BRIT J PSYCHIAT, V166, P759, DOI 10.1192/bjp.166.6.759; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Ayanian JZ, 1997, J GEN INTERN MED, V12, P311, DOI 10.1046/j.1525-1497.1997.012005311.x; BAUGHAN DM, 1995, AM FAM PHYSICIAN, V52, P447; BEHAR S, 1995, ARCH INTERN MED, V155, P813, DOI 10.1001/archinte.155.8.813; BLUMENTHAL JA, 1982, PSYCHOSOM MED, V44, P519, DOI 10.1097/00006842-198212000-00003; Callahan CM, 1997, ANN INTERN MED, V126, P426, DOI 10.7326/0003-4819-126-6-199703150-00002; CARNEY RM, 1995, HEALTH PSYCHOL, V14, P88, DOI 10.1037/0278-6133.14.1.88; Clark RE, 1996, HEALTH SERV RES, V31, P153; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; Druss BG, 1998, AM J PSYCHIAT, V155, P1775, DOI 10.1176/ajp.155.12.1775; Druss BG, 1999, AM J PSYCHIAT, V156, P477; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; FORD ES, 1995, HEALTH SERV RES, V30, P237; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; GUTHEIL TG, 1986, AM J PSYCHIAT, V143, P1020; Henk HJ, 1996, ARCH GEN PSYCHIAT, V53, P899; Huff ED, 1997, J CLIN EPIDEMIOL, V50, P1395, DOI 10.1016/S0895-4356(97)00218-7; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; Jeste DV, 1996, SCHIZOPHRENIA BULL, V22, P413, DOI 10.1093/schbul/22.3.413; KATON W, 1990, Journal of Clinical Psychiatry, V51, P3; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Krumholz HM, 1997, NEW ENGL J MED, V336, P1522, DOI 10.1056/NEJM199705223362111; Krumholz HM, 1998, CIRCULATION, V98, P2010, DOI 10.1161/01.CIR.98.19.2010; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; O'Connor GT, 1999, JAMA-J AM MED ASSOC, V281, P627, DOI 10.1001/jama.281.7.627; Olfson M, 1999, HEALTH AFFAIR, V18, P79, DOI 10.1377/hlthaff.18.2.79; Penn DL, 1998, PSYCHIAT QUART, V69, P235, DOI 10.1023/A:1022153327316; Pilote L, 1996, NEW ENGL J MED, V335, P1198, DOI 10.1056/NEJM199610173351606; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Schwartz LM, 1999, NEW ENGL J MED, V341, P279, DOI 10.1056/NEJM199907223410411; SIMON G, 1995, AM J PSYCHIAT, V152, P352; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618; US Dept of Health and Human Services . International Classification of Diseases, 1988, INT CLASS DIS; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; Whittle J, 1997, J GEN INTERN MED, V12, P267, DOI 10.1007/s11606-006-5062-0; Wirshing DA, 1998, AM J PSYCHIAT, V155, P1508, DOI 10.1176/ajp.155.11.1508; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zubenko GS, 1997, AM J PSYCHIAT, V154, P1360	46	388	393	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					506	511		10.1001/jama.283.4.506	http://dx.doi.org/10.1001/jama.283.4.506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	276LT	10659877	Bronze			2022-12-01	WOS:000084879800030
J	Huard, B; Karlsson, L				Huard, B; Karlsson, L			KIR expression on self-reactive CD8(+) T cells is controlled by T-cell receptor engagement	NATURE			English	Article							NATURAL-KILLER-CELLS; CLASS-I MOLECULES; INHIBITORY RECEPTORS; HLA-E; LYMPHOCYTES; CD94/NKG2A; CYTOTOXICITY	Natural killer cell tolerance is maintained by the interaction of killer inhibitory receptors (KIRs) with self-major histocompatibility complex class I gene products. A subset of T cells also expresses inhibitory receptors, but the functional significance of these receptors on T cells is unclear(1-3). Here we show that, in the absence of T-cell receptor (TCR) engagement, KIRs expressed on CD8(+) T cells are slowly downregulated by KIR ligands expressed on antigen-presenting cells. The resulting expression levels of KIR are no longer able to inhibit T-cell function. In contrast, TCR engagement sustains KIR expression, and re-induces functional levels of KIR expression after ligand-induced downregulation of KIR. Our data indicate that KIR expression on CD8(+) T cells in vivo maybe maintained through continuous encounters with antigen. As KIR-mediated inhibition of T-cell activation can be bypassed at high antigen concentrations, dynamic KIR expression may mediate T-cell tolerance to self-antigens by sparing self-reactive T cells, thus enabling them to mediate potentially useful immune functions to quantitatively or qualitatively different antigens.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Fac Pharm Chatenay Malabry, Lab Immunol Tumeurs, F-92296 Chatenay Malabry, France	Johnson & Johnson; Johnson & Johnson USA; UDICE-French Research Universities; Universite Paris Saclay	Huard, B (corresponding author), Ctr Med Univ Geneva, Dermatol Lab 5 222, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.		huard, bertrand/L-8011-2013	huard, bertrand/0000-0003-1358-6576				Borrego F, 1998, J EXP MED, V187, P813, DOI 10.1084/jem.187.5.813; Boullier S, 1998, EUR J IMMUNOL, V28, P3399, DOI 10.1002/(SICI)1521-4141(199811)28:11<3399::AID-IMMU3399>3.0.CO;2-W; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Cai ZL, 1996, P NATL ACAD SCI USA, V93, P14736, DOI 10.1073/pnas.93.25.14736; Carena I, 1997, J EXP MED, V186, P1769, DOI 10.1084/jem.186.10.1769; FALK CS, 1995, J EXP MED, V182, P1005, DOI 10.1084/jem.182.4.1005; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; Gumperz JE, 1996, J EXP MED, V183, P1817, DOI 10.1084/jem.183.4.1817; Hoglund P, 1997, IMMUNOL REV, V155, P11, DOI 10.1111/j.1600-065X.1997.tb00936.x; HUARD B, 1995, EUR J IMMUNOL, V25, P2718, DOI 10.1002/eji.1830250949; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Le Drean E, 1998, EUR J IMMUNOL, V28, P264, DOI 10.1002/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Mingari MC, 1998, IMMUNOL TODAY, V19, P153, DOI 10.1016/S0167-5699(97)01236-X; Mingari MC, 1997, INT IMMUNOL, V9, P485, DOI 10.1093/intimm/9.4.485; Mingari MC, 1996, P NATL ACAD SCI USA, V93, P12433, DOI 10.1073/pnas.93.22.12433; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; Muller U, 1997, NEUROGENETICS, V1, P1; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; Ponte M, 1999, P NATL ACAD SCI USA, V96, P5674, DOI 10.1073/pnas.96.10.5674; Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093; SHIMIZU Y, 1989, J IMMUNOL, V142, P3320; Speiser DE, 1999, EUR J IMMUNOL, V29, P1990, DOI 10.1002/(SICI)1521-4141(199906)29:06<1990::AID-IMMU1990>3.0.CO;2-9; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; vanDeurs B, 1996, EUR J CELL BIOL, V69, P343	26	120	124	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					325	328		10.1038/35002105	http://dx.doi.org/10.1038/35002105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659853				2022-12-01	WOS:000084899700056
J	Martina, M; Vida, I; Jonas, P				Martina, M; Vida, I; Jonas, P			Distal initiation and active propagation of action potentials in interneuron dendrites	SCIENCE			English	Article							CA1 PYRAMIDAL NEURONS; HIPPOCAMPUS IN-VITRO; RAT HIPPOCAMPUS; INHIBITORY NEURONS; CELL DENDRITES; MITRAL CELLS; SODIUM; ACTIVATION; SYNAPSES; CHANNELS	Fast and reliable activation of inhibitory interneurons is critical for the stability of cortical neuronal networks. Active conductances in dendrites may facilitate interneuron activation, but direct experimental evidence was unavailable. Patch-clamp recordings from dendrites of hippocampal oriens-alveus interneurons revealed high densities of voltage-gated sodium and potassium ion channels. Simultaneous recordings from dendrites and somata suggested that action potential initiation occurs preferentially in the axon with long threshold stimuli, but can be shifted to somatodendritic sites when brief stimuli are applied. After initiation, action potentials propagate over the somatodendritic domain with constant amplitude, high velocity, and reliability, even during high-frequency trains.	Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany; Univ Freiburg, Inst Anat, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Jonas, P (corresponding author), Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany.		Vida, Imre/F-8275-2012	Vida, Imre/0000-0003-3214-2233; martina, marco/0000-0002-9648-2918; Jonas, Peter/0000-0001-5001-4804				Ali AB, 1998, J PHYSIOL-LONDON, V507, P185, DOI 10.1111/j.1469-7793.1998.185bu.x; ANDERSEN P, 1963, NATURE, V198, P540, DOI 10.1038/198540a0; Bischofberger J, 1997, J PHYSIOL-LONDON, V504, P359, DOI 10.1111/j.1469-7793.1997.359be.x; BLASCOIBANEZ JM, 1995, EUR J NEUROSCI, V7, P2170, DOI 10.1111/j.1460-9568.1995.tb00638.x; CALLAWAY JC, 1995, J NEUROPHYSIOL, V74, P1395, DOI 10.1152/jn.1995.74.4.1395; Cash S, 1999, NEURON, V22, P383, DOI 10.1016/S0896-6273(00)81098-3; Chen WR, 1997, SCIENCE, V278, P463, DOI 10.1126/science.278.5337.463; COLQUHOUN D, 1995, SINGLE CHANNEL RECOR, pCH19; COOMBS JS, 1957, J PHYSIOL-LONDON, V139, P232, DOI 10.1113/jphysiol.1957.sp005888; Csicsvari J, 1998, NEURON, V21, P179, DOI 10.1016/S0896-6273(00)80525-5; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Galarreta M, 1999, NATURE, V402, P72, DOI 10.1038/47029; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; GEIGER JRP, 1999, HDB EXPT PHARM, V141, pCH11; Gibson JR, 1999, NATURE, V402, P75, DOI 10.1038/47035; Golding NL, 1998, NEURON, V21, P1189, DOI 10.1016/S0896-6273(00)80635-2; HAUSSER M, 1995, NEURON, V15, P637, DOI 10.1016/0896-6273(95)90152-3; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; Katona I, 1999, NEUROSCIENCE, V88, P37, DOI 10.1016/S0306-4522(98)00302-9; KOSAKA T, 1983, BRAIN RES, V271, P157, DOI 10.1016/0006-8993(83)91377-X; Lipowsky R, 1996, J NEUROPHYSIOL, V76, P2181, DOI 10.1152/jn.1996.76.4.2181; Martina M, 1997, J PHYSIOL-LONDON, V505, P593, DOI 10.1111/j.1469-7793.1997.593ba.x; MCBAIN CJ, 1994, J NEUROSCI, V14, P4433; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; MILES R, 1990, J PHYSIOL-LONDON, V428, P61, DOI 10.1113/jphysiol.1990.sp018200; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; OUARDOUZ M, 1995, J NEUROPHYSIOL, V73, P810, DOI 10.1152/jn.1995.73.2.810; PEREZ Y, 1999, 29 M SOC NEUR MIAM B; SAKMANN B, 1995, SINGLE CHANNEL RECOR, pCH21; SIK A, 1995, J NEUROSCI, V15, P6651; SOFTKY W, 1994, NEUROSCIENCE, V58, P13, DOI 10.1016/0306-4522(94)90154-6; SOMOGYI P, 1985, J HISTOCHEM CYTOCHEM, V33, P249, DOI 10.1177/33.3.2579124; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; Stuart G, 1997, TRENDS NEUROSCI, V20, P125, DOI 10.1016/S0166-2236(96)10075-8; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Traub RD, 1995, J COMPUT NEUROSCI, V2, P291, DOI 10.1007/BF00961441; Vida I, 1998, J PHYSIOL-LONDON, V506, P755, DOI 10.1111/j.1469-7793.1998.755bv.x; West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4; ZHANG L, 1995, J PHYSIOL-LONDON, V488, P661, DOI 10.1113/jphysiol.1995.sp020998; ZILBERTER Y, 1999, 29 M SOC NEUR MIAM B	46	249	252	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2000	287	5451					295	300		10.1126/science.287.5451.295	http://dx.doi.org/10.1126/science.287.5451.295			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634782				2022-12-01	WOS:000084769600037
J	Pawlowski, B; Dunbar, RIM; Lipowicz, A				Pawlowski, B; Dunbar, RIM; Lipowicz, A			Evolutionary fitness - Tall men have more reproductive success	NATURE			English	Article							SHORT STATURE; ATTRACTIVENESS		Univ Wroclaw, Dept Anthropol, PL-50138 Wroclaw, Poland; Univ Liverpool, Sch Biol Sci, ESRC Res Ctr Econ Learning & Social Evolut, Liverpool L69 3BX, Merseyside, England; Polish Acad Sci, Inst Anthropol, PL-50951 Wroclaw, Poland	University of Wroclaw; UK Research & Innovation (UKRI); Economic & Social Research Council (ESRC); University of Liverpool; Polish Academy of Sciences	Pawlowski, B (corresponding author), Univ Wroclaw, Dept Anthropol, Ul Kuznicza 35, PL-50138 Wroclaw, Poland.	rimd@liv.ac.uk	Pawlowski, Boguslaw/C-1088-2013; Lipowicz, Anna M/A-1730-2017	Pawlowski, Boguslaw/0000-0002-7418-475X; Lipowicz, Anna M/0000-0002-9182-6953				BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; Bielicki T, 1999, J BIOSOC SCI, V31, P525, DOI 10.1017/S0021932099005258; Bogin Barry, 1988, PATTERNS HUMAN GROWT; HEBERT PR, 1993, CIRCULATION, V88, P1437, DOI 10.1161/01.CIR.88.4.1437; HOLL RW, 1991, DEUT MED WOCHENSCHR, V116, P928, DOI 10.1055/s-2008-1063699; Kee F, 1997, INT J EPIDEMIOL, V26, P748, DOI 10.1093/ije/26.4.748; Komlos J, 1994, STATURE LIVING STAND; MACINTYRE S, 1991, SOCIOL HEALTH ILL, V13, P149, DOI 10.1111/1467-9566.ep11340769; *MIEJSK URS STAT W, 1971, ROCZNIK STAT MIAST W; Perrett DI, 1998, NATURE, V394, P884, DOI 10.1038/29772; SCHUMACHER A, 1982, J HUM EVOL, V11, P697, DOI 10.1016/S0047-2484(82)80058-4; TEASDALE TW, 1991, HUM BIOL, V63, P19	12	233	236	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2000	403	6766					156	156		10.1038/35003107	http://dx.doi.org/10.1038/35003107			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	275TB	10646589	Bronze			2022-12-01	WOS:000084835300040
J	Banfi, B; Maturana, A; Jaconi, S; Arnaudeau, S; Laforge, T; Sinha, B; Ligeti, E; Demaurex, N; Krause, KH				Banfi, B; Maturana, A; Jaconi, S; Arnaudeau, S; Laforge, T; Sinha, B; Ligeti, E; Demaurex, N; Krause, KH			A mammalian H+ channel generated through alternative splicing of the NADPH oxidase homolog NOH-1	SCIENCE			English	Article							HYDROGEN-ION CURRENTS; HUMAN-NEUTROPHILS; EPITHELIAL-CELLS; INTRACELLULAR PH; PROTON CURRENT; MEMBRANE; CONDUCTANCE; LEUKOCYTES	Voltage-gated proton (H+) channels are found in many human and animal tissues and play an important role in cellular defense against acidic stress. However, a molecular identification of these unique ion conductances has so far not been achieved. A 191-amino acid protein is described that, upon heterologous expression, has properties indistinguishable from those of native H+ channels. This protein is generated through alternative splicing of messenger RNA derived from the gene NOH-1 (NADPH oxidase homolog 1, where NADPH is the reduced form of nicotinamide adenine dinucleotide phosphate).	Univ Hosp Geneva, Geneva Med Sch, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Hosp Geneva, Geneva Med Sch, Dept Geriatr, Biol Aging Lab, CH-1211 Geneva 4, Switzerland; Univ Hosp Geneva, Geneva Med Sch, Fdn Rech Med, CH-1211 Geneva 4, Switzerland; Univ Hosp Geneva, Geneva Med Sch, Div Infect Dis, CH-1211 Geneva 4, Switzerland; Semmelweis Univ, Dept Physiol, H-1444 Budapest 8, Hungary	University of Geneva; University of Geneva; University of Geneva; University of Geneva; Semmelweis University	Demaurex, N (corresponding author), Univ Hosp Geneva, Geneva Med Sch, Dept Physiol, CH-1211 Geneva 4, Switzerland.	Nicolas.Demaurex@medecine.unige.ch	Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768; Banfi, Botond/0000-0001-9273-1318; Sinha, Bhanu/0000-0003-1634-0010; Demaurex, Nicolas/0000-0002-9933-6772				Banfi B, 1999, J EXP MED, V190, P183, DOI 10.1084/jem.190.2.183; BANFI B, UNPUB; BERNHEIM L, 1993, J PHYSIOL-LONDON, V470, P313, DOI 10.1113/jphysiol.1993.sp019860; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; DECOURSEY TE, 1991, BIOPHYS J, V60, P1243, DOI 10.1016/S0006-3495(91)82158-0; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; DECOURSEY TE, 1994, J MEMBRANE BIOL, V141, P203; Decoursey Thomas E., 1998, Frontiers in Bioscience, V3, pD477; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; Henderson LM, 1999, J GEN PHYSIOL, V114, P771, DOI 10.1085/jgp.114.6.771; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; Henderson LM, 1998, J BIOL CHEM, V273, P33216, DOI 10.1074/jbc.273.50.33216; Hille B., 1992, IONIC CHANNELS EXCIT; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; Kuno M, 1997, J GEN PHYSIOL, V109, P731, DOI 10.1085/jgp.109.6.731; NANDA A, 1994, J BIOL CHEM, V269, P27280; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; Roos D, 1986, Methods Enzymol, V132, P250; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; THOMAS RC, 1982, NATURE, V299, P826, DOI 10.1038/299826a0; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	26	240	252	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					138	142		10.1126/science.287.5450.138	http://dx.doi.org/10.1126/science.287.5450.138			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615049				2022-12-01	WOS:000084578400054
J	McCarron, P; Harvey, I; Brogan, R; Peters, TJ				McCarron, P; Harvey, I; Brogan, R; Peters, TJ			Self reported health of people in an area contaminated by chromium waste: interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY EXPOSURE; SITES	Objectives To compare the self reported health of a group of individuals living in an area contaminated by chromium (chromium group) wtih a group living in an uncontaminated area (control group), and to assess the effects of perception of risk from exposure to chromium ori health. Design Cross sectional study using the SF-36 validated quality of life questionnaire. Further questions were added to examine the relations between perceptions about living on or near land contaminated with chromium and the effects on self reported health. Setting An area contaminated with chromium (Cambuslang, Carmyle, and Rutherglen) and a control area (Barrmulloch and Pollok). Participants Residents of an area containing chromium landfill and residents of an uncontaminated control area. Main outcome measures Scores on SF-36. Results Little difference was found in health scores between the two groups, and only for general health was there a significantly higher score in the chromium group. Health scores for the chromium group were significantly worse across all dimensions for chose who believed that chromium adversely affected health. Most of the chromium group (68%) would prefer money to be spent on improving amenities rather than on chromium remediation. Conclusions Similar self reported health among residents of the chromium and control groups indicates that there is no evidence of harm to health from exposure to chromium in this setting. Noticeably lower scores in participants who believed chromium to be harmful to health point to the potential importance of perception and possible anxiety. Given the overall greater desire for better amenities rather than remedial action, policy makers and planners should discuss with residents how best to spend resources before instigating expensive cleaning up programmes.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ E Anglia, Sch Hlth Policy & Practice, Norwich R4 7TJ, Norfolk, England; Greater Glasgow Hlth Board, Glasgow G3 8YZ, Lanark, Scotland	University of Bristol; University of East Anglia	McCarron, P (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	P.McCarron@bristol.ac.uk						ANDERSON RA, 1993, J TOXICOL ENV HEALTH, V40, P555, DOI 10.1080/15287399309531819; Barnhart J, 1997, REGUL TOXICOL PHARM, V26, pS3, DOI 10.1006/rtph.1997.1132; BIDSTRUP P L, 1956, Br J Ind Med, V13, P260; BIDSTRUP PL, 1951, BRIT J IND MED, V8, P302; BIDSTRUP PL, 1983, ENCY OCCUPATIONAL HL; Carstairs V., 1991, DEPRIVATION HLTH SCO; DAVID AS, 1995, J PSYCHOSOM RES, V39, P1, DOI 10.1016/0022-3999(94)00085-J; *DEP PUBL HLTH, 1991, ASS RISK HUM HLTH LA; Dolk H, 1998, LANCET, V352, P423, DOI 10.1016/S0140-6736(98)01352-X; EIZAGUIRRE D, 1993, USE ROUTINE HLTH DAT; EIZAGUIRRE D, 1996, THESIS U GLASGOW GLA; EIZAGUIRRE D, 1999, IN PRESS J PUBLIC HL; Fagliano JA, 1997, REGUL TOXICOL PHARM, V26, pS13, DOI 10.1006/rtph.1997.1134; HUGHES K, 1994, ENVIRON CARCIN ECO R, V12, P237; *INT AG RES CANC, 1990, IARC MON EV CARC RIS, V38, P49; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; LANGARD S, 1975, HDB TOXICOLOGY METAL; PASTIDES H, 1994, AM J IND MED, V25, P663, DOI 10.1002/ajim.4700250506; *PUBL AN STRATHCL, 1989, SOILS RUTH SIT INV; ROHT LH, 1985, AM J EPIDEMIOL, V122, P418, DOI 10.1093/oxfordjournals.aje.a114123; SHUSTERMAN D, 1991, ENVIRON HEALTH PERSP, V94, P25, DOI 10.2307/3431288; SLOVIC P, 1997, ENV HLTH, V54, P22; Ware J.E., 1993, SCORING SF 36 SF 36, DOI DOI 10.6-10.7	23	30	30	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2000	320	7226					11	15		10.1136/bmj.320.7226.11	http://dx.doi.org/10.1136/bmj.320.7226.11			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617516	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000084621600013
J	Sgro, CM; Partridge, L				Sgro, CM; Partridge, L			A delayed wave of death from reproduction in Drosophila	SCIENCE			English	Article							MORTALITY-RATES; LIFE-HISTORY; MELANOGASTER; LONGEVITY; SENESCENCE; EVOLUTION; SELECTION; COST; EXPOSURE; MALES	Mortality rates typically increase rapidly at the onset of aging but can decelerate at Later ages. Reproduction increases the death rate in many organisms. To test the idea that a delayed impact of earlier reproduction contributes to both an increase in death rates and a Later deceleration in mortality, the timing of the surplus mortality produced by an increased Level of egg production was measured in female Drosophila. Reproduction produced a delayed wave of mortality, coincident with the sharp increase in death rates at the onset of aging and the subsequent deceleration of mortality. These results suggest that aging has evolved primarily because of the damaging effects of reproduction earlier in Life, rather than because of mutations that have detrimental effects only at Late ages.	UCL, Dept Biol, London NW1 2HE, England	University of London; University College London	Partridge, L (corresponding author), UCL, Dept Biol, 4 Stephenson Way, London NW1 2HE, England.	l.partridge@ucl.ac.uk	Sgro, Carla M/G-5166-2010; Partridge, Linda/A-5501-2010; Partridge, Linda/E-7342-2015; Sgro, Carla/A-2495-2010	Sgro, Carla/0000-0001-7950-2246; Partridge, Linda/0000-0001-9615-0094				Ashburner M., 1989, DROSOPHILA LAB HDB; Bell G., 1986, Oxford Surveys in Evolutionary Biology, V3, P83; BROOKS A, 1994, SCIENCE, V263, P668, DOI 10.1126/science.8303273; CAREY JR, 1992, SCIENCE, V258, P457, DOI 10.1126/science.1411540; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; Charlesworth B., 1994, EVOLUTION AGE STRUCT; CURTSINGER JW, 1992, SCIENCE, V258, P461, DOI 10.1126/science.1411541; FOWLER K, 1989, NATURE, V338, P760, DOI 10.1038/338760a0; HOULE D, 1994, GENETICS, V138, P773; KIRKWOOD TBL, 1979, PROC R SOC SER B-BIO, V205, P531, DOI 10.1098/rspb.1979.0083; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; LAMB MJ, 1964, J INSECT PHYSIOL, V10, P487, DOI 10.1016/0022-1910(64)90072-1; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; Medawar P., 1952, UNSOLVED PROBLEM BIO; MEVELNINIO M, 1991, EMBO J, V10, P2259, DOI 10.1002/j.1460-2075.1991.tb07762.x; Miller R.G., 1981, SURVIVAL ANAL; OLIVER B, 1987, GENE DEV, V1, P913, DOI 10.1101/gad.1.9.913; Partridge L, 1999, P ROY SOC B-BIOL SCI, V266, P255, DOI 10.1098/rspb.1999.0630; PARTRIDGE L, 1990, J INSECT PHYSIOL, V36, P419, DOI 10.1016/0022-1910(90)90059-O; PARTRIDGE L, 1985, J INSECT PHYSIOL, V31, P393, DOI 10.1016/0022-1910(85)90084-8; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; Pletcher SD, 1998, GENETICS, V148, P287; Prowse N, 1997, J INSECT PHYSIOL, V43, P501, DOI 10.1016/S0022-1910(97)00014-0; REZNICK D, 1985, OIKOS, V44, P257, DOI 10.2307/3544698; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; ROSE MR, 1981, GENETICS, V97, P187; SMITH JM, 1958, J EXP BIOL, V35, P832; TATAR M, 1993, EVOLUTION, V47, P1302, DOI [10.2307/2410149, 10.1111/j.1558-5646.1993.tb02156.x]; TREVITT S, 1988, J INSECT PHYSIOL, V34, P821, DOI 10.1016/0022-1910(88)90157-6; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; WILLIAMS GC, 1966, AM NAT, V100, P687, DOI 10.1086/282461; ZWAAN B, 1995, EVOLUTION, V49, P649, DOI [10.2307/2410318, 10.1111/j.1558-5646.1995.tb02301.x]	33	197	205	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2521	2524		10.1126/science.286.5449.2521	http://dx.doi.org/10.1126/science.286.5449.2521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617470	Green Submitted			2022-12-01	WOS:000084429700053
J	Prenzel, N; Zwick, E; Daub, H; Leserer, M; Abraham, R; Wallasch, C; Ullrich, A				Prenzel, N; Zwick, E; Daub, H; Leserer, M; Abraham, R; Wallasch, C; Ullrich, A			EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; DIPHTHERIA-TOXIN RECEPTOR; KINASE; PHOSPHORYLATION; EXPRESSION; ACTIVATION; SECRETION; DOMAIN; ALPHA; CELLS	Cross-communication between different signalling systems allows the integration of the great diversity of stimuli that a cell receives under varying physiological situations. The transactivation of epidermal growth factor receptor (EGFR)-dependent signalling pathways upon stimulation of G-protein-coupled receptors (GPCRs), which are critical for the mitogenic activity of ligands such as lysophosphatidic acid, endothelin, thrombin, bombesin and carbachol, provides evidence for such an interconnected communication network(1-4). Here we show that EGFR transactivation upon GPCR stimulation involves proHB-EGF and a metalloproteinase activity that is rapidly induced upon GPCR-ligand interaction. We show that inhibition of proHB-EGF processing blocks GPCR-induced EGFR transactivation and downstream signals, The pathophysiological significance of this mechanism is demonstrated by inhibition of constitutive EGFR activity upon treatment of PC3 prostate carcinoma cells with the metalloproteinase inhibitor batimastat. Together, our results establish a new mechanistic concept for cross-communication among different signalling systems.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	Ullrich@biochem.mpg.de						BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHING KZ, 1993, MOL CELL BIOCHEM, V126, P151, DOI 10.1007/BF00925693; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; GOLSHI K, 1995, MOL BIOL CELL, V6, P967; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HOOSEIN NM, 1993, J UROLOGY, V149, P1209, DOI 10.1016/S0022-5347(17)36349-8; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; KOVALENKO M, 1994, CANCER RES, V54, P6106; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Mateo C, 1997, IMMUNOTECHNOLOGY, V3, P71, DOI 10.1016/S1380-2933(97)00065-1; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	29	1443	1490	2	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 23	1999	402	6764					884	888		10.1038/47260	http://dx.doi.org/10.1038/47260			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622253				2022-12-01	WOS:000084482000035
J	Anderson, JF; Andreadis, TG; Vossbrinck, CR; Tirrell, S; Wakem, EM; French, RA; Garmendia, AE; Van Kruiningen, HJ				Anderson, JF; Andreadis, TG; Vossbrinck, CR; Tirrell, S; Wakem, EM; French, RA; Garmendia, AE; Van Kruiningen, HJ			Isolation of West Nile virus from mosquitoes, crows, and a Cooper's hawk in Connecticut	SCIENCE			English	Article							ENCEPHALITIS	West Nile (WN) virus, a mosquito-transmitted virus native to Africa. Asia. and Europe, was isolated from two species of mosquitoes, Culex pipiens and Aedes vexans, and from brain tissues of 28 American crows, Corvus brachyrhynchos, and one Cooper's hawk, Accipiter cooperii, in Connecticut. A portion of the genome of virus isolates from four different hosts was sequenced and analyzed by comparative phylogenetic analysis. Our isolates from Connecticut were similar to one another and most closely related to two WN isolates from Romania (2.8 and 3.6 percent difference). If established in North America, WN virus will likely have severe effects on human health and on the health of populations of birds.	Connecticut Agr Expt Stn, Dept Entomol, New Haven, CT 06504 USA; Connecticut Agr Expt Stn, Dept Soil & Water, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06512 USA; Univ Connecticut, Dept Pathobiol, Storrs, CT 06269 USA	Connecticut Agricultural Experiment Station; Connecticut Agricultural Experiment Station; Yale University; University of Connecticut	Anderson, JF (corresponding author), Connecticut Agr Expt Stn, Dept Entomol, POB 1106, New Haven, CT 06504 USA.	john.f.anderson@po.state.ct.us; theodore.andreadis@po.state.ct.us; charles.vossbrinck@po.state.ct.us			NIAID NIH HHS [P01-AI-30548] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030548] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andreadis TG, 1998, J MED ENTOMOL, V35, P296, DOI 10.1093/jmedent/35.3.296; ANSARI MZ, 1993, J CLIN LAB ANAL, V7, P230, DOI 10.1002/jcla.1860070408; Berthet FX, 1997, J GEN VIROL, V78, P2293, DOI 10.1099/0022-1317-78-9-2293; Briese T, 1999, LANCET, V354, P1261, DOI 10.1016/S0140-6736(99)04576-6; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P845; CHAYES CG, 1989, ARBOVIRUSES EPIDEMIO, V5, pCH49; Hubalek Z, 1999, EMERG INFECT DIS, V5, P643, DOI 10.3201/eid0505.990505; KITAOKA MASAMI, 1950, JAPANESE MED JOUR, V3, P77; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Philip CB, 1943, P SOC EXP BIOL MED, V53, P49, DOI 10.3181/00379727-53-14180; Savage HM, 1999, AM J TROP MED HYG, V61, P600, DOI 10.4269/ajtmh.1999.61.600; Sibley CG, 1990, DISTRIBUTION TAXONOM; SMITHBURN K. C, 1940, AMER JOUR TROP MED, V20, P471; Swofford D., 1998, PAUP PHYLOGENETIC AN; TAYLOR RM, 1956, AM J TROP MED HYG, V5, P579, DOI 10.4269/ajtmh.1956.5.579; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; WORK TH, 1955, AM J TROP MED HYG, V4, P872, DOI 10.4269/ajtmh.1955.4.872; WORK TH, 1953, P SOC EXP BIOL MED, V84, P719, DOI 10.3181/00379727-84-20764	19	267	299	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2331	2333		10.1126/science.286.5448.2331	http://dx.doi.org/10.1126/science.286.5448.2331			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600741				2022-12-01	WOS:000084318500058
J	Riccio, A; Ahn, S; Davenport, CM; Blendy, JA; Ginty, DD				Riccio, A; Ahn, S; Davenport, CM; Blendy, JA; Ginty, DD			Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons	SCIENCE			English	Article							NERVE GROWTH-FACTOR; C-FOS; BCL-2; DEATH; PHOSPHORYLATION; MECHANISM; PROTEIN	Nerve growth factor (NGF) and other neurotrophins support survival of neurons through processes that are incompletely understood. The transcription factor CREB is a critical mediator of NGF-dependent gene expression, but whether CREB family transcription factors regulate expression of genes that contribute to NGF-dependent survival of sympathetic neurons is unknown. CREB-mediated gene expression was both necessary for NGF-dependent survival and sufficient on its own to promote survival of sympathetic neurons, Moreover, expression of Bcl-2 was activated by NGF and other neurotrophins by a CREB-dependent transcriptional mechanism. Overexpression of Bcl-2 reduced the death-promoting effects of CREB inhibition. Together, these data support a model in which neurotrophins promote survival of neurons, in part through a mechanism involving CREB family transcription factor-dependent expression of genes encoding prosurvival factors.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA	Johns Hopkins University; University of Pennsylvania	Ginty, DD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.			Davenport, Christopher/0000-0003-2639-6392	NINDS NIH HHS [NS34814-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034814, R01NS034814, R37NS034814] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; CAMPENOT RB, 1977, P NATL ACAD SCI USA, V74, P4516, DOI 10.1073/pnas.74.10.4516; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Lanahan A, 1997, J NEUROSCI, V17, P2876; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; MAINS RE, 1973, J CELL BIOL, V59, P329, DOI 10.1083/jcb.59.2.329; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Reichardt L. F., 1997, MOL CELLULAR APPROAC, P220; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; RICCIO A, UNPUB; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Somers JP, 1999, MOL ENDOCRINOL, V13, P1364, DOI 10.1210/me.13.8.1364; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Wilson BE, 1996, MOL CELL BIOL, V16, P5546	23	663	682	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2358	2361		10.1126/science.286.5448.2358	http://dx.doi.org/10.1126/science.286.5448.2358			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600750				2022-12-01	WOS:000084318500067
J	Chen, GQ; Cui, CH; Mayer, ML; Gouaux, E				Chen, GQ; Cui, CH; Mayer, ML; Gouaux, E			Functional characterization of a potassium-selective prokaryotic glutamate receptor	NATURE			English	Article							ACID-BINDING PROTEINS; AMPA RECEPTORS; EXPRESSION; CHANNELS; FAMILY; DESENSITIZATION; CONDUCTION; SEQUENCE; MUTATION; KAINATE	Ion channels are molecular pores that facilitate the passage of ions across cell membranes and participate in a range of biological processes, from excitatory signal transmission in the mammalian nervous system to the modulation of swimming behaviour in the protozoan Paramecium(1). Two particularly important families of ion channels are ionotropic glutamate receptors (GluRs)(2) and potassium channels(3,4). GluRs are permeable to Na+, K+ and Ca2+ are gated by glutamate, and have previously been found only in eukaryotes(2), In contrast, potassium channels are selective for K+, are gated by a range of stimuli, and are found in both prokaryotes and eukaryotes(3,4). Here we report the discovery and functional characterization of GluR0 from Synechocystis PCC 6803, which is the first GluR found in a prokaryote. GluR0 binds glutamate, forms potassium-selective channels and is related in amino-acid sequence to both eukaryotic GluRs and potassium channels. On the basis of amino-acid sequence and functional relationships between GluR0 and eukaryotic GluRs, we propose that a prokaryotic GluR was the precursor to eukaryotic GluRs. GluR0 provides evidence for the missing link between potassium channels and GluRs, and we suggest that their ion channels have a similar architecture, that GluRs are tetramers and that the gating mechanisms of GluRs and potassium channels have some essential features in common.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; NICHHD, Lab Cellular & Mol Neurophysiol, NIH, Bethesda, MD 20892 USA	Columbia University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Gouaux, E (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.	jeg52@columbia.edu	Mayer, Mark L/H-5500-2013; Gouaux, Eric/Y-4370-2019; Mayer, Mark/AAE-7356-2019	Gouaux, Eric/0000-0002-8549-2360; Mayer, Mark/0000-0003-4378-8451				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Baro DJ, 1996, GENE, V170, P267, DOI 10.1016/0378-1119(95)00876-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Dingledine R, 1999, PHARMACOL REV, V51, P7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Hille B., 1992, IONIC CHANNELS EXCIT; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; Kaneko T, 1996, DNA Res, V3, P109; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEINANEN K, 1994, BIO-TECHNOL, V12, P802, DOI 10.1038/nbt0894-802; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Lam HM, 1998, NATURE, V396, P125, DOI 10.1038/24066; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOMELI H, 1993, FEBS LETT, V315, P318, DOI 10.1016/0014-5793(93)81186-4; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; VYKLICKY L, 1990, J PHYSIOL-LONDON, V428, P313, DOI 10.1113/jphysiol.1990.sp018214; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882; Yellen G, 1999, CURR OPIN NEUROBIOL, V9, P267, DOI 10.1016/S0959-4388(99)80039-7; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	30	269	282	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					817	821		10.1038/45568	http://dx.doi.org/10.1038/45568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617203				2022-12-01	WOS:000084330500067
J	Zorio, DAR; Blumenthal, T				Zorio, DAR; Blumenthal, T			Both subunits of U2AF recognize the 3 ' splice site in Caenorhabditis elegans	NATURE			English	Article							RIBONUCLEOPROTEIN AUXILIARY FACTOR; FUNCTIONAL-ANALYSIS; RNA; CLONING; DOMAIN; GENE	Introns are defined by sequences that bind components of the splicing machinery. The branchpoint consensus, polypyrimidine (poly(Y)) tract, and AG at the splice boundary comprise the mammalian 3' splice site(1), Although the AG is crucial for the recognition of introns with relatively short poly(Y) tracts, which are termed 'AG-dependent introns'(2), the molecule responsible for AG recognition has never been identified. A key player in 3' splice site definition is the essential heterodimeric splicing factor U2AF, which facilitates the interaction of the U2 small nuclear ribonucleoprotein particle with the branch point. The U2AF subunit with a relative molecular mass (M-r 65K) of 65,000 (U2AF(65)) binds to the poly(Y) tract(3-7), whereas the role of the 35K subunit (U2AF(35))(8) has not been clearly defined. It is not required for splicing in vitro(4) but it plays a critical role in vivo(9,10) Caenorhabiditis elegans introns have a highly conserved U(4)CAG/R at their 3' splice sites instead of branch-point and poly(Y) consensus sequences(11). Nevertheless, C. elegans has U2AF (refs 10, 12). Here we show that both U2AF subunits crosslink to the 3' splice site. Our results suggest that the U2AF(65)-U2AF(35) complex identifies the U(4)CAG/R, with U2AF35 being responsible for recognition of the canonical AG.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Indiana University System; Indiana University Bloomington	Blumenthal, T (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.							BLUMENTHAL T, 1997, C ELEGANS, V2, P117; CONRAD R, 1993, NUCLEIC ACIDS RES, V21, P913, DOI 10.1093/nar/21.4.913; JONES D, 1986, J BIOL CHEM, V261, P2006; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; MacMorris MA, 1999, P NATL ACAD SCI USA, V96, P3813, DOI 10.1073/pnas.96.7.3813; Moore M., 1993, RNA WORLD, P303; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Rudner DZ, 1996, P NATL ACAD SCI USA, V93, P10333, DOI 10.1073/pnas.93.19.10333; Rudner DZ, 1998, MOL CELL BIOL, V18, P4004, DOI 10.1128/MCB.18.7.4004; RUSKIN B, 1988, CELL, V52, P201; STROEHER VL, 1994, DEV BIOL, V163, P367, DOI 10.1006/dbio.1994.1155; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZAMORE PD, 1991, EMBO J, V10, P210; Zhang HB, 1996, RNA, V2, P380; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zorio DAR, 1997, MOL CELL BIOL, V17, P946, DOI 10.1128/MCB.17.2.946; Zorio DAR, 1999, RNA, V5, P487, DOI 10.1017/S1355838299982225	20	194	220	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					835	838		10.1038/45597	http://dx.doi.org/10.1038/45597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617207				2022-12-01	WOS:000084330500071
J	Ochsenbein, AF; Fehr, T; Lutz, C; Suter, M; Brombacher, F; Hengartner, H; Zinkernagel, RM				Ochsenbein, AF; Fehr, T; Lutz, C; Suter, M; Brombacher, F; Hengartner, H; Zinkernagel, RM			Control of early viral and bacterial distribution and disease by natural antibodies	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CELL-DEFICIENT MICE; B-CELLS; ANTIVIRAL PROTECTION; IMMUNE-RESPONSE; CRUCIAL ROLE; COMPLEMENT; INFECTION; MEMORY	Natural antibodies are often dismissed from immunological analysis as "background," but they may play an important role in conferring immunity against infections. In antibody-free mice infected with various viruses or with Listeria monocytogenes, viral or bacterial titers in peripheral organs, including the kidney and brain, were 10 to 100 times greater than in antibody-competent mice (and enhanced their susceptibility to some infections), and titers in secondary Lymphoid organs were 10 to 100 times lower than in antibody-competent mice. Thus, natural antibodies play a crucial role by preventing pathogen dissemination to vital organs and by improving immunogenicity through enhanced antigen-trapping in secondary Lymphoid organs.	Univ Hosp Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Max Planck Inst Immunobiol, Freiburg, Germany; Univ Zurich, Inst Virol, CH-8006 Zurich, Switzerland; Univ Cape Town, Groote Schuur Hosp, Dept Immunol, ZA-7925 Cape Town, South Africa	University of Zurich; University Zurich Hospital; Max Planck Society; University of Zurich; University of Cape Town	Ochsenbein, AF (corresponding author), Univ Hosp Zurich, Inst Expt Immunol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Fehr, Thomas/AFQ-9308-2022	Fehr, Thomas/0000-0003-1668-1800; Ochsenbein, Adrian/0000-0003-1773-5436				AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; Brundler MA, 1996, EUR J IMMUNOL, V26, P2257, DOI 10.1002/eji.1830260943; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; COHEN IR, 1986, IMMUNOL REV, V94, P5, DOI 10.1111/j.1600-065X.1986.tb01161.x; COUTINHO A, 1989, IMMUNOL REV, V110, P63, DOI 10.1111/j.1600-065X.1989.tb00027.x; DIETZSCHOLD B, 1995, VIROLOGY, P1137; Ehrenstein MR, 1998, P NATL ACAD SCI USA, V95, P10089, DOI 10.1073/pnas.95.17.10089; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fehr T, 1996, CELL IMMUNOL, V168, P184, DOI 10.1006/cimm.1996.0065; Fehr T, 1998, J EXP MED, V188, P145, DOI 10.1084/jem.188.1.145; Fehr T, 1997, J EXP MED, V185, P921, DOI 10.1084/jem.185.5.921; FREI PC, 1968, J IMMUNOL, V101, P605; Frigg R, 1999, J VIROL, V73, P9584, DOI 10.1128/JVI.73.11.9584-9588.1999; GOBET R, 1988, EXP CELL BIOL, V56, P175; HERZENBERG LA, 1993, IMMUNOL TODAY, V14, P79, DOI 10.1016/0167-5699(93)90063-Q; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; LAMERS MC, 1981, EUR J IMMUNOL, V11, P764, DOI 10.1002/eji.1830111006; Lutz C, 1998, NATURE, V393, P797, DOI 10.1038/31716; Mims C.A., 1974, BIOL ANIMAL VIRUSES; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; Reid RR, 1997, J IMMUNOL, V159, P970; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; STEINHOFF U, 1995, J VIROL, V69, P2153, DOI 10.1128/JVI.69.4.2153-2158.1995; Thomsen AR, 1996, J IMMUNOL, V157, P3074; Thomsen AR, 1997, INT IMMUNOL, V9, P1757, DOI 10.1093/intimm/9.11.1757; THORNTON BP, 1994, J IMMUNOL, V152, P1727; VIEIRA P, 1988, EUR J IMMUNOL, V18, P313, DOI 10.1002/eji.1830180221; WAGNER RR, 1987, RHABDOVIRUSES; Weigle W O, 1973, Adv Immunol, V16, P61, DOI 10.1016/S0065-2776(08)60296-5; WILSON GS, 1961, PRINCIPLES BACTERIOL, P1223	39	701	738	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2156	2159		10.1126/science.286.5447.2156	http://dx.doi.org/10.1126/science.286.5447.2156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591647				2022-12-01	WOS:000084157300052
J	Friedlander, AM; Pittman, PR; Parker, GW				Friedlander, AM; Pittman, PR; Parker, GW			Anthrax vaccine - Evidence for safety and efficacy against inhalational anthrax	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROTECTIVE ANTIGEN; GUINEA-PIGS; SPORE CHALLENGE; ADJUVANTS		USA, Med Res Inst Infect Dis, Ft Detrick, Frederick, MD 21702 USA		Friedlander, AM (corresponding author), USA, Med Res Inst Infect Dis, Ft Detrick, 1425 Porter St, Frederick, MD 21702 USA.	friedlan@ncifcrf.gov	Pittman, Phillip/S-3203-2019; Pittman, Phillip/ADI-6097-2022	Pittman, Phillip/0000-0003-1787-759X; 				AUERBACH S, 1955, J IMMUNOL, V75, P129; Brachman P. S., 1999, VACCINES, P629; BRACHMAN PS, 1962, AM J PUBLIC HEALTH N, V52, P632, DOI 10.2105/AJPH.52.4.632; FELLOWS PF, 1998, 3 INT C ANTHR SEPT P; FRIEDLANDER A, 1997, TXB MILITARY MED MED, P467; FRITZ DL, 1995, LAB INVEST, V73, P691; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Ivins B, 1995, VACCINE, V13, P1779, DOI 10.1016/0264-410X(95)00139-R; Ivins B.E., 1996, SALISBURY MED B, V87, P125; IVINS BE, 1992, INFECT IMMUN, V60, P662, DOI 10.1128/IAI.60.2.662-668.1992; Ivins BE, 1998, VACCINE, V16, P1141, DOI 10.1016/S0264-410X(98)80112-6; IVINS BE, 1994, VACCINE, V12, P872, DOI 10.1016/0264-410X(94)90027-2; IVINS BE, 1999, COMMUNICATION    JUL; LITTLE SF, 1986, INFECT IMMUN, V52, P509, DOI 10.1128/IAI.52.2.509-512.1986; PITT ML, 1999, COMMUNICATION    JUL; Pitt MLM, 1999, J APPL MICROBIOL, V87, P304, DOI 10.1046/j.1365-2672.1999.00897.x; PITT MLM, 1996, SALISBURY MED B S, V87, P130; PITTMAN PR, 1999, COMMUNICATION    JUL; STRAWDER G, 1999, COMMUNICATION    AUG; TURNBULL PCB, 1986, INFECT IMMUN, V52, P356, DOI 10.1128/IAI.52.2.356-363.1986; 1985, FED REG, V50, P51058	21	131	137	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2104	2106		10.1001/jama.282.22.2104	http://dx.doi.org/10.1001/jama.282.22.2104			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591317				2022-12-01	WOS:000083971400002
J	Lissauer, JJ				Lissauer, JJ			How common are habitable planets?	NATURE			English	Article							IMPACTS; ASTEROIDS; SYSTEMS; COMETS; EARTH	The Earth is teeming with life, which occupies a diverse array of environments; other bodies in our Solar System offer fewer, if any, niches that are habitable by life as we know it. Nonetheless, astronomical studies suggest that many habitable planets may be present within our Galaxy.	NASA, Ames Res Ctr, Div Space Sci, Moffett Field, CA 94035 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Lissauer, JJ (corresponding author), NASA, Ames Res Ctr, Div Space Sci, MS 245-3, Moffett Field, CA 94035 USA.							CHAPMAN CR, 1994, NATURE, V367, P33, DOI 10.1038/367033a0; Joshi MM, 1997, ICARUS, V129, P450, DOI 10.1006/icar.1997.5793; LEWIS JS, 1998, WORLDS END EXPLORATI; Lissauer JJ, 1999, REV MOD PHYS, V71, P835, DOI 10.1103/RevModPhys.71.835; LISSAUER JJ, 1995, ICARUS, V114, P217, DOI 10.1006/icar.1995.1057; McKay CP, 1997, ORIGINS LIFE EVOL B, V27, P263, DOI 10.1023/A:1006500116990; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; SAFRONOV VS, 1972, PUBLICATION NASA; SLEEP NH, 1989, NATURE, V342, P139, DOI 10.1038/342139a0; Toon OB, 1997, REV GEOPHYS, V35, P41, DOI 10.1029/96RG03038; Weidenschilling S.J., 1993, PROTOSTARS PLANETS, P1031; WETHERILL GW, 1994, ASTROPHYS SPACE SCI, V212, P23, DOI 10.1007/BF00984505	12	17	18	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C11	C14		10.1038/35011503	http://dx.doi.org/10.1038/35011503			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591221	Green Submitted			2022-12-01	WOS:000084014100002
J	Sutovsky, P; Moreno, RD; Ramalho-Santos, J; Dominko, T; Simerly, C; Schatten, G				Sutovsky, P; Moreno, RD; Ramalho-Santos, J; Dominko, T; Simerly, C; Schatten, G			Development - Ubiquitin tag for sperm mitochondria	NATURE			English	Article							DNA; INHERITANCE; FATE		Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Cell Dev Biol, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Obstet Gynecol, Beaverton, OR 97006 USA; Int Ctr Canc Res & Dev Biol, Santiago, Chile; Univ Coimbra, Dept Zool, Ctr Neurosci, Coimbra, Portugal	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University; Universidade de Coimbra	Sutovsky, P (corresponding author), Oregon Reg Primate Res Ctr, 505 NW 185th Ave, Beaverton, OR 97006 USA.	schatten@ohsu.edu	Schatten, Gerald/B-3253-2009; Ramalho-Santos, João/F-8641-2012; simerly, Calvin/AAC-9564-2021; Moreno, Ricardo R/C-6802-2011	Schatten, Gerald/0000-0001-5206-7782; Ramalho-Santos, João/0000-0002-1172-4018; Moreno, Ricardo/0000-0002-7499-5501; Sutovsky, Peter/0000-0002-9231-2823				BARRIT J, 1999, FERTIL STERIL, V72, P31; CHOONGKITTAWORN NM, 1993, BIOL REPROD, V49, P300, DOI 10.1095/biolreprod49.2.300; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cummins JM, 1997, ZYGOTE, V5, P301, DOI 10.1017/S0967199400003889; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0; HUTCHINSON SA, 1974, NATURE, V251, P536; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; PERREAULT SD, 1984, DEV BIOL, V101, P160, DOI 10.1016/0012-1606(84)90126-X; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; Sutovsky P, 1996, BIOL REPROD, V55, P1195, DOI 10.1095/biolreprod55.6.1195; SZOLLOSI D, 1965, J EXP ZOOL, V159, P367, DOI 10.1002/jez.1401590309	14	446	474	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					371	372		10.1038/46466	http://dx.doi.org/10.1038/46466			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586873				2022-12-01	WOS:000083913600042
J	Ohnuma, S; Philpott, A; Wang, K; Holt, CE; Harris, WA				Ohnuma, S; Philpott, A; Wang, K; Holt, CE; Harris, WA			p27(Xic1), a cdk inhibitor, promotes the determination of glial cells in Xenopus retina	CELL			English	Article							DEPENDENT-KINASE INHIBITOR; PROGENITOR CELLS; RAT RETINA; ROD PHOTORECEPTORS; NERVOUS-SYSTEM; PROTEIN-KINASE; MOUSE RETINA; MICE LACKING; CYCLIN-A; P27(KIP1)	p27(Xic1), a member of the Cip/Kip family of Cdk inhibitors, besides its known function of inhibiting cell division, induces Muller glia from retinoblasts. This novel gliogenic function of p27(Xic1) is mediated by part of the N-terminal domain near but distinct from the region that inhibits cyclin-dependent kinases. Cotransfections with dominant-negative and constitutively active Delta and Notch constructs indicate that the gliogenic effects of p27(Xic1) work within the context of an active Notch pathway. The gradual increase of p27(Xic1) in the developing retina thus not only limits the number of retinal cells but also increasingly favors the fate of the last cell type to be born in the retina, the Muller glia.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Cambridge, Dept Oncol, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge	Harris, WA (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.			Ohnuma, Shin-ichi/0000-0002-3305-5126; Philpott, Anna/0000-0003-3789-2463; Holt, Christine Elizabeth/0000-0003-2829-121X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Belliveau MJ, 1999, DEVELOPMENT, V126, P555; Bohner AP, 1997, DEVELOPMENT, V124, P915; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Cepko CL, 1999, CURR OPIN NEUROBIOL, V9, P37, DOI 10.1016/S0959-4388(99)80005-1; Chang WS, 1998, J NEUROBIOL, V35, P227; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Dorsky RI, 1997, NATURE, V385, P67, DOI 10.1038/385067a0; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; Dowling J.E., 1987, RETINA APPROACHABLE; DRAGER UC, 1984, J NEUROSCI, V4, P2025; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ezzeddine ZD, 1997, DEVELOPMENT, V124, P1055; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARPER JW, 1993, CELL, V75, P805; HARRIS WA, 1991, NEURON, V6, P499, DOI 10.1016/0896-6273(91)90053-3; Harris WA, 1997, CURR OPIN GENET DEV, V7, P651, DOI 10.1016/S0959-437X(97)80013-5; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Jensen AM, 1997, DEV BIOL, V188, P267, DOI 10.1006/dbio.1997.8645; Kanekar S, 1997, NEURON, V19, P981, DOI 10.1016/S0896-6273(00)80391-8; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lillien L, 1998, MOL CELL NEUROSCI, V10, P296, DOI 10.1006/mcne.1997.0659; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; McFarlane S, 1998, DEVELOPMENT, V125, P3967; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Morrow EM, 1999, DEVELOPMENT, V126, P23; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NEBREDA AR, 1995, EMBO J, V14, P5597, DOI 10.1002/j.1460-2075.1995.tb00247.x; Nieuwkoop P.D., 1994, SYSTEMATICAL CHRONOL, DOI 10.1201/9781003064565-29; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; Park DS, 1997, J NEUROSCI, V17, P8975; Perron M, 1998, DEV BIOL, V199, P185, DOI 10.1006/dbio.1998.8939; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; PICKHAM KM, 1992, MOL CELL BIOL, V12, P3192, DOI 10.1128/MCB.12.7.3192; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Raff MC, 1998, INT J DEV BIOL, V42, P263; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Tikoo R, 1998, J NEUROBIOL, V36, P431, DOI 10.1002/(SICI)1097-4695(19980905)36:3<431::AID-NEU10>3.3.CO;2-N; Tikoo R, 1997, J BIOL CHEM, V272, P442; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N; Welcker M, 1998, CANCER RES, V58, P5053; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhao SL, 1996, BRAIN RES, V723, P169, DOI 10.1016/0006-8993(96)00237-5; Zuber ME, 1999, CELL, V98, P341, DOI 10.1016/S0092-8674(00)81963-7	62	189	189	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 24	1999	99	5					499	510		10.1016/S0092-8674(00)81538-X	http://dx.doi.org/10.1016/S0092-8674(00)81538-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589678	Bronze			2022-12-01	WOS:000083986300009
J	Herrmann, BG; Koschorz, B; Wertz, K; McLaughlin, KJ; Kispert, A				Herrmann, BG; Koschorz, B; Wertz, K; McLaughlin, KJ; Kispert, A			A protein kinase encoded by the t complex responder gene causes non-mendelian inheritance	NATURE			English	Article							TRANSMISSION RATIO DISTORTION; DYNEIN LIGHT-CHAIN; TERT-HAPLOTYPES; TRANSGENIC MICE; SPERM MOTILITY; MEIOTIC DRIVE; MOUSE; LOCUS; IDENTIFICATION; FAMILY	Males heterozygous for the t-haplotype form of mouse chromosome 17 preferentially transmit the t-chromosome to their progeny. Several distorter/sterility loci carried on the t-haplotype together impair flagellar function in all spermatozoa whereas the responder, Tcr, rescues t-sperm but not wild-type sperm. Thus, t-sperm have an advantage over wild-type sperm in fertilizing egg cells. We have isolated Tcr by positional cloning and show that it is a member of a novel protein kinase gene family, designated Smok, which is expressed late during spermiogenesis, Smok kinases are components of a signal cascade which may control sperm motility, Tcr has a reduced kinase activity, which may allow it to counterbalance a signalling impairment caused by the distorter/sterility loci, Tcr transgene constructs cause non-mendelian transmission of chromosomes on which they are carried, which leads to sex-ratio distortion when Tcr cosegregates with the Y chromosome.	Max Planck Inst Immunbiol, D-79108 Freiburg, Germany	Max Planck Society	Herrmann, BG (corresponding author), Max Planck Inst Immunbiol, Stubeweg 51, D-79108 Freiburg, Germany.		McLaughlin, Kenneth/E-3648-2011					Albanesi C, 1996, DEVELOPMENT, V122, P1291; BENNETT D, 1983, GENET RES, V41, P29, DOI 10.1017/S0016672300021042; Bracho GE, 1998, BIOCHEM BIOPH RES CO, V242, P231, DOI 10.1006/bbrc.1997.7937; BRAUN RE, 1989, NATURE, V337, P373, DOI 10.1038/337373a0; BULLARD DC, 1992, MAMM GENOME, V3, P579, DOI 10.1007/BF00350625; Carrera A, 1996, DEV BIOL, V180, P284, DOI 10.1006/dbio.1996.0301; Cosson J, 1996, CELL BIOL INT, V20, P83, DOI 10.1006/cbir.1996.0012; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Ewulonu UK, 1996, GENETICS, V144, P785; FOX HS, 1985, CELL, V40, P63, DOI 10.1016/0092-8674(85)90309-5; Fraser LR, 1999, BIOESSAYS, V21, P304, DOI 10.1002/(SICI)1521-1878(199904)21:4<304::AID-BIES6>3.0.CO;2-H; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; HUW LY, 1995, DEV BIOL, V170, P183, DOI 10.1006/dbio.1995.1206; Kispert A, 1999, MAMM GENOME, V10, P794, DOI 10.1007/s003359901094; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LYON MF, 1990, GENET RES, V55, P13, DOI 10.1017/S0016672300025143; LYON MF, 1987, GENET RES, V50, P29, DOI 10.1017/S0016672300023302; LYON MF, 1986, CELL, V44, P357, DOI 10.1016/0092-8674(86)90770-1; LYON MF, 1984, CELL, V37, P621, DOI 10.1016/0092-8674(84)90393-3; MAZARAKIS N, 1909, DEVELOPMENT, V111, P561; OLDSCLARKE P, 1993, DEV BIOL, V155, P14, DOI 10.1006/dbio.1993.1002; PatelKing RS, 1997, J CELL BIOL, V137, P1081, DOI 10.1083/jcb.137.5.1081; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; ROSEN LL, 1990, GENOMICS, V8, P134, DOI 10.1016/0888-7543(90)90235-M; ROSSI P, 1992, DEV BIOL, V152, P203, DOI 10.1016/0012-1606(92)90172-D; Rugh R, 1990, MOUSE ITS REPROD DEV; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIMENTI J, 1987, J MOL BIOL, V194, P583, DOI 10.1016/0022-2836(87)90235-X; SCHIMENTI J, 1988, CELL, V55, P71, DOI 10.1016/0092-8674(88)90010-4; SILVER LM, 1993, TRENDS GENET, V9, P250, DOI 10.1016/0168-9525(93)90090-5; SILVER LM, 1987, GENET RES, V49, P51, DOI 10.1017/S0016672300026720; TASH JS, 1988, J CELL BIOL, V106, P1625, DOI 10.1083/jcb.106.5.1625; TASH JS, 1984, CELL, V38, P551, DOI 10.1016/0092-8674(84)90509-9; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4	38	128	139	4	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					141	146		10.1038/45970	http://dx.doi.org/10.1038/45970			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647005				2022-12-01	WOS:000083716400038
J	Yasui, M; Hazama, A; Kwon, TH; Nielsen, S; Guggino, WB; Agre, P				Yasui, M; Hazama, A; Kwon, TH; Nielsen, S; Guggino, WB; Agre, P			Rapid gating and anion permeability of an intracellular aquaporin	NATURE			English	Article							MAJOR INTRINSIC PROTEIN; CD WATER CHANNELS; KIDNEY; MEMBRANE; CLONING; CONDUCTANCE; CHIP28; PUMP; LENS	Aquaporin (AQP) water-channel proteins are freely permeated by water but not bg ions or charged solutes(1), Although mammalian aquaporins were believed to be located in plasma membranes, rat AQP6 is restricted to intracellular vesicles in renal epithelia(2). Here we show that AQP6 is functionally distinct from other known aquaporins. When expressed in Xenopus laevis oocytes, AQP6 exhibits low basal water permeability; however, when treated with the known water channel inhibitor, Hg2+, the water permeability of AQP6 oocytes rapidly rises up to tenfold and is accompanied by ion conductance. AQP6 colocalizes with H+-ATPase in intracellular vesicles of acid-secreting alpha-intercalated cells in renal collecting duct. At pH less than 5.5, anion conductance is rapidly and reversibly activated in AQP6 oocytes. Site-directed mutation of lysine to glutamate at position 72 in the cytoplasmic mouth of the pore changes the cation/anion selectivity: but leaves low pH activation intact, Our results demonstrate unusual biophysical properties of an aquaporin, and indicate that anion-channel function may now be explored in a protein with known structure.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Aarhus Univ, Inst Anat, Dept Cell Biol, DK-8000 Aarhus, Denmark	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Aarhus University	Agre, P (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.		Yasui, Masato/L-3312-2013; Kwon, Tae-Hwan/ABA-1981-2020					Agre P, 1997, SCIENCE, V275, P1490, DOI 10.1126/science.275.5305.1490; Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; Jena BP, 1997, P NATL ACAD SCI USA, V94, P13317, DOI 10.1073/pnas.94.24.13317; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Ma TH, 1996, GENOMICS, V35, P543, DOI 10.1006/geno.1996.0396; MA TH, 1993, BIOCHEM BIOPH RES CO, V197, P654, DOI 10.1006/bbrc.1993.2529; MITSUOKA K, IN PRESS J STRUCT BI; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; ROOS N, 1982, BIOCHIM BIOPHYS ACTA, V686, P204, DOI 10.1016/0005-2736(82)90114-6; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; Yasui M, 1999, P NATL ACAD SCI USA, V96, P5808, DOI 10.1073/pnas.96.10.5808; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216	23	370	377	1	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					184	187		10.1038/46045	http://dx.doi.org/10.1038/46045			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647010				2022-12-01	WOS:000083716400051
J	Pahlow, M; Riebesell, U				Pahlow, M; Riebesell, U			Temporal trends in deep ocean Redfield ratios	SCIENCE			English	Article							EQUATORIAL PACIFIC-OCEAN; NORTH-ATLANTIC; NUTRIENT LIMITATION; IRON; NITROGEN; PHYTOPLANKTON; PRODUCTIVITY; NITRATE; OXYGEN; GROWTH	The Redfield ratio [carbon:nitrogen:phosphorus (C:N:P)] of particle flux to the deep ocean is a key factor in marine biogeochemical cycling. Changes in oceanic carbon sequestration have been Linked to variations in the Redfield ratio on geological time scales, but this ratio generally is assumed to be constant with time in the modern ocean. However, deep-water Redfield ratios in the northern hemisphere show evidence for temporal trends over the past five decades. The North Atlantic Ocean exhibits a rising N:P ratio, which may be related to increased deposition of atmospheric nitrous oxides from anthropogenic N emissions. In the North Pacific Ocean, increasing C:N and C:P ratios are accompanied by rising remineralization rates, which suggests intensified export production. Stronger export of carbon in this region may be due to enhanced bioavailability of aeolian iron. These findings imply that the biological part of the marine carbon cycle currently is not in steady state.	Alfred Wegener Inst Polar & Marine Res, D-27515 Bremerhaven, Germany	Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research	Pahlow, M (corresponding author), Alfred Wegener Inst Polar & Marine Res, POB 120161, D-27515 Bremerhaven, Germany.		Pahlow, Markus/AAC-4919-2020; Riebesell, Ulf/AAC-9717-2020					ANDERSON LA, 1994, GLOBAL BIOGEOCHEM CY, V8, P65, DOI 10.1029/93GB03318; ANDERSON LA, 1995, DEEP-SEA RES PT I, V42, P1675, DOI 10.1016/0967-0637(95)00072-E; Bacon S, 1998, NATURE, V394, P871, DOI 10.1038/29736; Behrenfeld MJ, 1999, SCIENCE, V283, P840, DOI 10.1126/science.283.5403.840; BROECKER WS, 1985, J GEOPHYS RES-OCEANS, V90, P6925, DOI 10.1029/JC090iC04p06925; BROECKER WS, 1980, DEEP-SEA RES, V27, P591, DOI 10.1016/0198-0149(80)90076-X; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; Coale KH, 1996, NATURE, V379, P621, DOI 10.1038/379621a0; DOERING PH, 1995, MAR ECOL PROG SER, V124, P271, DOI 10.3354/meps124271; Duce RA, 1991, GLOBAL BIOGEOCHEM CY, V5, P193, DOI 10.1029/91GB01778; Duce R.A., 1986, ROLE AIR SEA EXCHANG, P497, DOI DOI 10.1007/978-94-009-4738-2_; DUCE RA, 1991, LIMNOL OCEANOGR, V36, P1715, DOI 10.4319/lo.1991.36.8.1715; FANNING KA, 1992, J GEOPHYS RES-OCEANS, V97, P5693, DOI 10.1029/92JC00007; FANNING KA, 1989, NATURE, V339, P460, DOI 10.1038/339460a0; GRASSHOFF K, 1968, REPORT INTERCALIBRAT; Gruber N, 1997, GLOBAL BIOGEOCHEM CY, V11, P235, DOI 10.1029/97GB00077; HAGER SW, 1972, LIMNOL OCEANOGR, V17, P931, DOI 10.4319/lo.1972.17.6.0931; HECKY RE, 1993, LIMNOL OCEANOGR, V38, P709, DOI 10.4319/lo.1993.38.4.0709; HECKY RE, 1988, LIMNOL OCEANOGR, V33, P796, DOI 10.4319/lo.1988.33.4_part_2.0796; KNAP A, 1986, NATURE, V320, P158, DOI 10.1038/320158a0; LOGAN JA, 1983, J GEOPHYS RES-OCEANS, V88, P785, DOI 10.1029/JC088iC15p10785; LONGHURST A, 1995, J PLANKTON RES, V17, P1245, DOI 10.1093/plankt/17.6.1245; LONGHURST AR, 1991, LIMNOL OCEANOGR, V36, P1507, DOI 10.4319/lo.1991.36.8.1507; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; MARTIN JH, 1988, DEEP-SEA RES, V35, P177, DOI 10.1016/0198-0149(88)90035-0; MOREL FMM, 1991, LIMNOL OCEANOGR, V36, P1742, DOI 10.4319/lo.1991.36.8.1742; PRICE NM, 1991, DEEP-SEA RES, V38, P1361, DOI 10.1016/0198-0149(91)90011-4; Redfield A.C., 1963, SEA IDEA OBSERV, V2; RHEE GY, 1978, LIMNOL OCEANOGR, V23, P10, DOI 10.4319/lo.1978.23.1.0010; SAKSHAUG E, 1977, J EXP MAR BIOL ECOL, V29, P1, DOI 10.1016/0022-0981(77)90118-6; SARMIENTO JL, 1990, J GEOPHYS RES-OCEANS, V95, P18303, DOI 10.1029/JC095iC10p18303; WATSON AJ, 1985, DEEP-SEA RES, V32, P1023, DOI 10.1016/0198-0149(85)90060-3; WEISS RF, 1970, DEEP-SEA RES, V17, P721, DOI 10.1016/0011-7471(70)90037-9; YENTSCH CS, 1990, J PLANKTON RES, V12, P717, DOI 10.1093/plankt/12.4.717; Young RW, 1991, GLOBAL BIOGEOCHEM CY, V5, P119, DOI 10.1029/91GB00927; Zhu Z. D., 1993, Desertification Control Bulletin, P27; ZHUANG G, 1990, J GEOPHYS RES-OCEANS, V95, P16207, DOI 10.1029/JC095iC09p16207; ZHUANG GS, 1992, NATURE, V355, P537, DOI 10.1038/355537a0	38	87	92	5	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					831	833		10.1126/science.287.5454.831	http://dx.doi.org/10.1126/science.287.5454.831			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657291	Green Submitted			2022-12-01	WOS:000085136400038
J	Rivera, VM; Wang, XR; Wardwell, S; Courage, NL; Volchuk, A; Keenan, T; Holt, DA; Gilman, M; Orci, L; Cerasoli, F; Rothman, JE; Clackson, T				Rivera, VM; Wang, XR; Wardwell, S; Courage, NL; Volchuk, A; Keenan, T; Holt, DA; Gilman, M; Orci, L; Cerasoli, F; Rothman, JE; Clackson, T			Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum	SCIENCE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; INTRAMUSCULAR INJECTION; GENE-EXPRESSION; MAMMALIAN-CELLS; SKELETAL-MUSCLE; MICE; INSULIN; BINDING; ERYTHROPOIETIN; TRANSDUCTION	A system for direct pharmacologic control of protein secretion was developed to allow rapid and pulsatile delivery of therapeutic proteins. A protein was engineered so that it accumulated as aggregates in the endoplasmic reticulum. Secretion was then stimulated by a synthetic small-molecule drug that induces protein disaggregation. Rapid and transient secretion of growth hormone and insulin was achieved in vitro and in vivo. A regulated pulse of insulin secretion resulted in a transient correction of serum glucose concentrations in a mouse model of hyperglycemia. This approach may make gene therapy a viable method for delivery of polypeptides that require rapid and regulated delivery.	ARIAD Pharmaceut Inc, Gene Therapeut, Cambridge, MA 02139 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva, Switzerland	Takeda Pharmaceutical Company Ltd; Takeda Oncology; Memorial Sloan Kettering Cancer Center; University of Geneva	Rivera, VM (corresponding author), ARIAD Pharmaceut Inc, Gene Therapeut, 26 Landsdowne St, Cambridge, MA 02139 USA.			Rivera, Victor/0000-0002-7258-3001				ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BELL GI, 1979, NATURE, V282, P525, DOI 10.1038/282525a0; Bohl D, 1998, BLOOD, V92, P1512, DOI 10.1182/blood.V92.5.1512.417k43_1512_1517; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; CLACKSON T, UNPUB; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; DREJER K, 1992, DIABETES METAB REV, V8, P259, DOI 10.1002/dmr.5610080305; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GROSKREUTZ DJ, 1994, J BIOL CHEM, V269, P6241; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Herzog RW, 1997, P NATL ACAD SCI USA, V94, P5804, DOI 10.1073/pnas.94.11.5804; HOLT DA, UNPUB; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Li FQ, 1996, J CELL BIOL, V135, P1043, DOI 10.1083/jcb.135.4.1043; MARTIAL JA, 1979, SCIENCE, V205, P602, DOI 10.1126/science.377496; Murphy JE, 1997, P NATL ACAD SCI USA, V94, P13921, DOI 10.1073/pnas.94.25.13921; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; POLONSKY KS, 1988, J CLIN INVEST, V81, P442, DOI 10.1172/JCI113339; Rendahl KG, 1998, NAT BIOTECHNOL, V16, P757, DOI 10.1038/nbt0898-757; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; Rivera VM, 1999, P NATL ACAD SCI USA, V96, P8657, DOI 10.1073/pnas.96.15.8657; RIVERA VM, UNPUB; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; Song S, 1998, P NATL ACAD SCI USA, V95, P14384, DOI 10.1073/pnas.95.24.14384; Spencer DM, 1996, TRENDS GENET, V12, P181, DOI 10.1016/0168-9525(96)10013-5; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; WARDWELL S, UNPUB; Yang TT, 1996, NUCLEIC ACIDS RES, V24, P4592, DOI 10.1093/nar/24.22.4592; Ye XH, 1999, SCIENCE, V283, P88, DOI 10.1126/science.283.5398.88	37	253	283	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					826	830		10.1126/science.287.5454.826	http://dx.doi.org/10.1126/science.287.5454.826			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657290				2022-12-01	WOS:000085136400037
J	Henney, JE				Henney, JE			Alternative supply of penicillin G	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Commissioner Food & Drugs, Rockville, MD 20857 USA		Henney, JE (corresponding author), Commissioner Food & Drugs, HF 1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					596	596		10.1001/jama.283.5.596-b	http://dx.doi.org/10.1001/jama.283.5.596-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665687				2022-12-01	WOS:000084956500005
J	Seltzer, EG; Gerber, MA; Cartter, ML; Freudigman, K; Shapiro, ED				Seltzer, EG; Gerber, MA; Cartter, ML; Freudigman, K; Shapiro, ED			Long-term outcomes of persons with Lyme disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BORRELIA-BURGDORFERI; INCORRECT DIAGNOSIS; SEROLOGIC TESTS; ARTHRITIS; CHILDREN; FIBROMYALGIA; OVERDIAGNOSIS; MISDIAGNOSIS; CONNECTICUT; POPULATION	Context Few data exist about the long-term outcomes of patients with Lyme disease. Objective To assess the long-term outcomes of patients with Lyme disease. Design Two-part project including a community-based longitudinal cohort study and a matched cohort study, Setting and Participants Six hundred seventy-eight patients identified from a random sample of all reports of Connecticut residents with suspected Lyme disease submitted to the Connecticut Department of Public Health from 1984-1991 were evaluated in the longitudinal study; for a random subsample of 212 patients from the larger study, 212 age-matched controls without Lyme disease also were enrolled. Main Outcome Measures Self-reports or parents' reports of symptoms and ability to perform certain daily activities since diagnosis of Lyme disease; scores on the 36-item Short-Form Health Survey and the Center for Epidemiologic Studies-Depression scale, for adults, by case-definition status and between patients and controls. Results Of the 678 patients, 51.6% were female, 34.4% were children, and 64.3% met the national surveillance case definition for Lyme disease. Most patients (85.5%) were treated with antimicrobial agents, Interviews were conducted a median of 51 months after diagnosis (range, 15-135 months). An increased frequency of symptoms (eg, pain, fatigue) or of difficulty with daily activities (eg, performing housework, exercising) was reported by 69% of the patients, although few (19%) of these problems were attributed to Lyme disease. Whenever there was a statistically significant difference in the frequencies of either increased symptoms or increased difficulties with typical activities between those who did or did not meet the surveillance case definition, in all instances the greater frequency of problems was in the group that did not meet the case definition. The frequencies of reports of both increased symptoms and increased difficulties with typical activities among patients who had been diagnosed as having Lyme disease were similar to those among age-matched controls without Lyme disease. Conclusions: In this cohort, although many patients reported increases in symptoms and/or increased difficulties with typical daily activities between 1 and 11 years after diagnosis of Lyme disease, the frequencies of these reports were similar to the frequencies of such reports among age-matched controls without Lyme disease.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Childrens Clin Res Ctr, New Haven, CT 06520 USA; Univ Connecticut, Sch Med, Dept Pediat, Farmington, CT 06032 USA; Connecticut Dept Publ Hlth & Addict Serv, Hartford, CT 06106 USA	Yale University; Yale University; Yale University; Yale University; University of Connecticut	Shapiro, ED (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St, New Haven, CT 06520 USA.							Adams WV, 1999, J RHEUMATOL, V26, P1190; Bakken LL, 1997, J CLIN MICROBIOL, V35, P537, DOI 10.1128/JCM.35.3.537-543.1997; BURLINGTON DB, 1997, PUBLICATION FDA PUBL; *CDCP BACT ZOON BR, 1991, LYME DIS SURVEILL SU, V2, P1; CROFT P, 1993, J RHEUMATOL, V20, P710; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; Gerber MA, 1998, PEDIATRICS, V102, P905, DOI 10.1542/peds.102.4.905; Gerber MA, 1996, NEW ENGL J MED, V335, P1270, DOI 10.1056/NEJM199610243351703; GERBER MA, 1992, 5 INT C LYM BORR MAY; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; GUSTAFSON TL, 1994, TRUE EPISTAT; HEDBERG CW, 1990, ARCH INTERN MED, V150, P732; HSU VM, 1993, ARTHRITIS RHEUM, V36, P1493, DOI 10.1002/art.1780361103; ITOMAA M, 1998, SCAND J INFECT DIS, V30, P269; LIGHTFOOT RW, 1993, ANN INTERN MED, V119, P503, DOI 10.7326/0003-4819-119-6-199309150-00010; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; LUFT BJ, 1993, ANN INTERN MED, V119, P518; MacDonald KL, 1996, AM J MED, V100, P548, DOI 10.1016/S0002-9343(96)00017-4; MEHTA C, 1991, STATXACT COMPUTER PR; PETERSEN LR, 1989, YALE J BIOL MED, V62, P253; [Prevention Centers for Disease C], 1998, MMWR-MORBID MORTAL W, V46, P3; Radloff L, 1977, APPL PSYCH MEAS, V1, P385, DOI DOI 10.1177/014662167700100306; Reid MC, 1998, ANN INTERN MED, V128, P354, DOI 10.7326/0003-4819-128-5-199803010-00003; ROSE CD, 1994, CLIN PEDIATR, V33, P663, DOI 10.1177/000992289403301105; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; Seltzer EG, 1996, PEDIATR INFECT DIS J, V15, P762, DOI 10.1097/00006454-199609000-00003; SELVIN S, 1996, STAT ANAL EPIDEMIOLO, P197; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; Shadick NA, 1999, ANN INTERN MED, V131, P919, DOI 10.7326/0003-4819-131-12-199912210-00003; SIGAL LH, 1992, PEDIATRICS, V90, P523; Sigal LH, 1996, ARCH INTERN MED, V156, P1493, DOI 10.1001/archinte.156.14.1493; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SIGAL LH, 1994, AM J MED, V96, P365, DOI 10.1016/0002-9343(94)90068-X; SIGAL LH, 1995, AM J MED, V98, pS74, DOI 10.1016/S0002-9343(99)80048-5; SIGAL LH, 1998, NEW ENGL J MED, V339, P571; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; TUKEY JW, 1977, SCIENCE, V198, P679, DOI 10.1126/science.333584; Wang TJ, 1998, J RHEUMATOL, V25, P2249; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; [No title captured]	43	113	116	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					609	616		10.1001/jama.283.5.609	http://dx.doi.org/10.1001/jama.283.5.609			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665700	Bronze			2022-12-01	WOS:000084956500026
J	Lundgren, O; Peregrin, AT; Persson, K; Kordasti, S; Uhnoo, I; Svensson, L				Lundgren, O; Peregrin, AT; Persson, K; Kordasti, S; Uhnoo, I; Svensson, L			Role of the enteric nervous system in the fluid and electrolyte secretion of rotavirus diarrhea	SCIENCE			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; INFECTED MOUSE INTESTINE; CHOLERA SECRETION; MURINE ROTAVIRUS; MICE; PATHOGENESIS; INVOLVEMENT; TRANSPORT; BLOCKADE; CHILDREN	The mechanism underlying the intestinal fluid loss in rotavirus diarrhea, which often afflicts children in developing countries, is not known. One hypothesis is that the rotavirus evokes intestinal fluid and electrolyte secretion by activation of the nervous system in the intestinal wall, the enteric nervous system (ENS). Four different drugs that inhibit ENS functions were used to obtain experimental evidence for this hypothesis in mice in vitro and in vivo, The involvement of the ENS in rotavirus diarrhea indicates potential sites of action for drugs in the treatment of the disease.	Univ Gothenburg, Dept Physiol, S-40530 Gothenburg, Sweden; Univ Uppsala Hosp, Dept Med Sci, Infect Dis Sect, S-75185 Uppsala, Sweden; Swedish Inst Infect Dis Control, Dept Virol, S-17182 Solna, Sweden	University of Gothenburg; Uppsala University; Uppsala University Hospital; Swedish Institute for Infectious Disease Control	Lundgren, O (corresponding author), Univ Gothenburg, Dept Physiol, Box 432, S-40530 Gothenburg, Sweden.		svensson, lennart/K-6163-2019					Ball JM, 1996, SCIENCE, V272, P101, DOI 10.1126/science.272.5258.101; BRUNSSON I, 1987, ACTA PHYSIOL SCAND, V131, P609, DOI 10.1111/j.1748-1716.1987.tb08282.x; BRUNSSON I, 1987, ACTA PHYSIOL SCAND, V130, P633, DOI 10.1111/j.1748-1716.1987.tb08186.x; CASSUTO J, 1981, SCAND J GASTROENTERO, V16, P377, DOI 10.3109/00365528109181984; CASSUTO J, 1982, ACTA PHYSIOL SCAND, V114, P573, DOI 10.1111/j.1748-1716.1982.tb07026.x; CASSUTO J, 1982, SCAND J GASTROENTERO, V17, P695, DOI 10.3109/00365528209181081; CASTAGLIUOLO I, 1994, GASTROENTEROLOGY, V107, P657, DOI 10.1016/0016-5085(94)90112-0; COELHO KIR, 1981, ULTRASTRUCT PATHOL, V2, P59, DOI 10.3109/01913128109031504; COOPER H, 1966, GASTROENTEROLOGY, V50, P1; DAVIDSON GP, 1979, ACTA PAEDIATR SCAND, V68, P181, DOI 10.1111/j.1651-2227.1979.tb04986.x; DAVIDSON GP, 1975, J CLIN PATHOL, V28, P263, DOI 10.1136/jcp.28.4.263; EKLUND S, 1988, ACTA PHYSIOL SCAND, V133, P551, DOI 10.1111/j.1748-1716.1988.tb08440.x; Hille B., 1992, IONIC CHANNELS EXCIT; JODAL M, 1993, GUT, V34, P1526, DOI 10.1136/gut.34.11.1526; JODAL M, 1995, REGULATORY MECH GAST, P99; KOHLER VT, 1990, KINDERARZTL PRAX, V58, P323; LITTLE LM, 1982, INFECT IMMUN, V38, P755, DOI 10.1128/IAI.38.2.755-763.1982; LUNDGREN O, UNPUB; MATHIAS JR, 1989, HDB PHYSL GASTROINTE, V1, P1153; OFFIT PA, 1984, J VIROL, V51, P233, DOI 10.1128/JVI.51.1.233-236.1984; OSBORNE MP, 1991, J PEDIATR GASTR NUTR, V12, P111, DOI 10.1097/00005176-199101000-00021; OSBORNE MP, 1988, J PEDIATR GASTR NUTR, V7, P236, DOI 10.1097/00005176-198803000-00014; Peregrin AT, 1997, ACTA PHYSIOL SCAND, V160, P379, DOI 10.1046/j.1365-201X.1997.00173.x; Ruggeri FM, 1998, J VIROL, V72, P2708, DOI 10.1128/JVI.72.4.2708-2714.1998; SJOQVIST A, 1988, ACTA PHYSIOL SCAND, V133, P289, DOI 10.1111/j.1748-1716.1988.tb08410.x; SPENCER AJ, 1990, J PEDIATR GASTR NUTR, V10, P516, DOI 10.1097/00005176-199005000-00016; STARKEY WG, 1986, J GEN VIROL, V67, P2625, DOI 10.1099/0022-1317-67-12-2625; STARKEY WG, 1990, J PEDIATR GASTR NUTR, V11, P254, DOI 10.1097/00005176-199008000-00016; STEPHEN J, 1989, P 9 BSG SK F INT WOR; SVENSSON L, 1991, J VIROL, V65, P4190, DOI 10.1128/JVI.65.8.4190-4197.1991; Weclewicz K, 1998, BRAIN RES BULL, V46, P353, DOI 10.1016/S0361-9230(98)00013-6; 1999, WHO WEEKLY EPIDEMIOL, P33	32	178	191	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					491	495		10.1126/science.287.5452.491	http://dx.doi.org/10.1126/science.287.5452.491			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642552				2022-12-01	WOS:000084929900050
J	Stathopoulos, C; Li, T; Longman, R; Vothknecht, UC; Becker, HD; Ibba, M; Soll, D				Stathopoulos, C; Li, T; Longman, R; Vothknecht, UC; Becker, HD; Ibba, M; Soll, D			One polypeptide with two aminoacyl-tRNA synthetase activities	SCIENCE			English	Article							TRANSFER-RNA SYNTHETASES; COMPLETE GENOME SEQUENCE; PARTITION; CODE	The genome sequences of certain archaea do not contain recognizable cysteinyl-transfer RNA (tRNA) synthetases, which are essential for messenger RNA-encoded protein synthesis. However, a single cysteinyl-tRNA synthetase activity was detected and purified from one such organism, Methanococcus jannaschii. The amino-terminal sequence of this protein corresponded to the predicted sequence of prolyl-tRNA synthetase. Biochemical and genetic analyses indicated that this archaeal form of prolyl-tRNA synthetase can synthesize both cysteinyl-tRNA(Cys) and prolyl-tRNA(Pro). The ability of one enzyme to provide two aminoacyl-tRNAs for protein synthesis raises questions about concepts of substrate specificity in protein synthesis and may provide insights into the evolutionary origins of this process.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Univ Copenhagen, Panum Inst, Ctr Biomol Recognit, Dept Med Biochem & Genet,Lab B, DK-2200 Copenhagen N, Denmark	Yale University; Yale University; Yale University; University of Copenhagen	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu	Vothknecht, Ute C/F-4678-2014	Vothknecht, Ute C/0000-0002-8930-0127; Becker, Hubert/0000-0002-4102-7520; Stathopoulos, Constantinos/0000-0002-5699-4118				BOHMAN K, 1979, MOL GEN GENET, V176, P53, DOI 10.1007/BF00334295; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BUSIELLO V, 1979, BIOCHIM BIOPHYS ACTA, V564, P311, DOI 10.1016/0005-2787(79)90228-4; Commans S, 1999, FEMS MICROBIOL REV, V23, P335, DOI 10.1111/j.1574-6976.1999.tb00403.x; CURNOW AW, UNPUB; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; Delarue M, 1995, J MOL EVOL, V41, P703; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; GRUNDY FJ, 1993, CELL, V74, P475, DOI 10.1016/0092-8674(93)80049-K; Hamann CS, 1999, J BACTERIOL, V181, P5880, DOI 10.1128/JB.181.18.5880-5884.1999; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; Jakubowski H, 1999, BIOCHEMISTRY-US, V38, P8088, DOI 10.1021/bi990629i; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; Jakubowski H, 1997, BIOCHEMISTRY-US, V36, P11077, DOI 10.1021/bi970589n; Kim HS, 1998, J BACTERIOL, V180, P6446, DOI 10.1128/JB.180.24.6446-6449.1998; LACEY JC, 1999, CHEMTRACTS, V12, P398; Li T, 1999, FEBS LETT, V462, P302, DOI 10.1016/S0014-5793(99)01550-1; NAGEL GM, 1995, J MOL EVOL, V40, P487; Nomanbhoy TK, 1999, MOL CELL, V4, P519, DOI 10.1016/S1097-2765(00)80203-8; PEARSON RL, 1971, BIOCHIM BIOPHYS ACTA, V228, P770, DOI 10.1016/0005-2787(71)90748-9; Reeve JN, 1999, J BACTERIOL, V181, P3613, DOI 10.1128/JB.181.12.3613-3617.1999; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Springer M, 1998, COLD SPRING HARBOR M, P377; Stehlin C, 1998, BIOCHEMISTRY-US, V37, P8605, DOI 10.1021/bi980364s; WHITFELD PR, 1953, NATURE, V171, P1151, DOI 10.1038/1711151a0; WOESE CR, 1966, COLD SPRING HARB SYM, V31, P723, DOI 10.1101/SQB.1966.031.01.093; Wolf YI, 1999, GENOME RES, V9, P689	28	65	71	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2000	287	5452					479	482		10.1126/science.287.5452.479	http://dx.doi.org/10.1126/science.287.5452.479			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642548				2022-12-01	WOS:000084929900046
J	Graves, LM; Guy, HI; Kozlowski, P; Huang, M; Lazarowski, E; Pope, RM; Collins, MA; Dahlstrand, EN; Earp, HS; Evans, DR				Graves, LM; Guy, HI; Kozlowski, P; Huang, M; Lazarowski, E; Pope, RM; Collins, MA; Dahlstrand, EN; Earp, HS; Evans, DR			Regulation of carbamoyl phosphate synthetase by MAP kinase	NATURE			English	Article							PYRIMIDINE NUCLEOTIDE BIOSYNTHESIS; PROTEIN-KINASE; MULTIFUNCTIONAL PROTEIN; ESCHERICHIA-COLI; PHOSPHORYLATION; ACTIVATION; CELLS; ENZYMES; CAD	The de novo synthesis of pyrimidine nucleotides is required for mammalian cells to proliferate. The rate-limiting step in this pathway is catalysed by carbamoyl phosphate synthetase (CPS II), part of the multifunctional enzyme CAD(1,2). Here we describe the regulation of CAD by the mitogen-activated protein (MAP) kinase cascade. When phosphorylated by MAP kinase in vitro or activated by epidermal growth factor in vivo, CAD lost its feedback inhibition (which is dependent on uridine triphosphate) and became more sensitive to activation (which depends upon phosphoribosyl pyrophosphate). Both these allosteric regulatory changes favour biosynthesis of pyrimidines for growth(2). They were accompanied by increased epidermal growth factor-dependent phosphorylation of CAD in vivo and were prevented by inhibition of MAP kinase. Mutation of a consensus MAP kinase phosphorylation site abolished the changes in CAD allosteric regulation that were stimulated by growth factors. Finally, consistent with an effect of MAP kinase signalling on CPS II activity, epidermal growth factor increased cellular uridine triphosphate and this increase was reversed by inhibition of MAP kinase. Hence these studies may indicate a direct link between activation of the MAP kinase cascade and de novo biosynthesis of pyrimidine nucleotides.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University	Graves, LM (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.		Graves, Lee/AAG-5470-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060371] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM060371] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; AOKI T, 1981, SCIENCE, V212, P463, DOI 10.1126/science.7209543; Banerjei LC, 1997, SOMAT CELL MOLEC GEN, V23, P37, DOI 10.1007/BF02679954; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Evans D.R., 1986, MULTIDOMAIN PROTEINS, P283; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GUY HI, 1994, J BIOL CHEM, V269, P23808; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; PATTERSON D, 1977, SOMAT CELL GENET, V3, P483, DOI 10.1007/BF01539120; Resing KA, 1997, METHOD ENZYMOL, V283, P29; Sahay N, 1998, J BIOL CHEM, V273, P31195, DOI 10.1074/jbc.273.47.31195; SHAW SM, 1992, EUR J BIOCHEM, V207, P957, DOI 10.1111/j.1432-1033.1992.tb17130.x; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SMITH KA, 1995, PHILOS T ROY SOC B, V347, P49, DOI 10.1098/rstb.1995.0008; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173	23	161	168	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					328	332		10.1038/35002111	http://dx.doi.org/10.1038/35002111			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659854				2022-12-01	WOS:000084899700057
J	Seeff, LB; Miller, RN; Rabkin, CS; Buskell-Bales, Z; Straley-Eason, KD; Smoak, BL; Johnson, LD; Lee, SR; Kaplan, EL				Seeff, LB; Miller, RN; Rabkin, CS; Buskell-Bales, Z; Straley-Eason, KD; Smoak, BL; Johnson, LD; Lee, SR; Kaplan, EL			45-year follow-up of hepatitis C virus infection in healthy young adults	ANNALS OF INTERNAL MEDICINE			English	Article							NON-B-HEPATITIS; POST-TRANSFUSION HEPATITIS; VOLUNTEER BLOOD-DONORS; NON-A; HEPATOCELLULAR-CARCINOMA; POSTTRANSFUSION HEPATITIS; ALANINE AMINOTRANSFERASE; ANTIBODIES; PREVALENCE; EPIDEMIOLOGY	Background: The sequelae during the first two decades after acute hepatitis C virus (HCV) infection have been well studied, but the outcome thereafter is unknown. Objective: To conduct an extended study of the natural history of HCV infection by using archived serum specimens originally collected between 1948 and 1954. Design: Retrospective cohort study. Setting: A university, a Veterans Affairs medical center, and a medical follow-up agency that had access to the serum specimens and accompanying demographic and medical records. Participants: 8568 military recruits who were evaluated for group A streptococcal infection and acute rheumatic fever between 1948 and 1954. Blood samples were taken from the recruits and, after testing, were stored frozen for almost 45 years. Measurements: The presence of antibodies to HCV was determined by enzyme-linked immunoassay, supplementary recombinant immunoblot assay, and polymerase chain reaction for HCV RNA. Morbidity and mortality were also assessed. Results: Of 8568 persons, 17 (0.2%) had positive results on enzyme-linked immunosorbent assay and recombinant immunoblot assay. The rate was 1.8% among the African-American persons and 0.1% among the white persons in the total sample (relative risk, 25.9 [95% CI, 8.4 to 80.01]). During the 45-year follow-up, liver disease occurred in 205 of the 17 HCV-positive persons (11.8%) and 205 of the 8551 HCV-negative persons (2.4%) (ethnicity-adjusted relative risk, 3.56 [CI, 0.94 to 13.52]). Seven of the 17 HCV-positive persons (41 %) and 2226 of the 8551 HCV-negative persons (26%) had died by December 1996 (ethnicity-adjusted relative risk, 1.48 [CI, 0.8 to 2.61]). Of persons who were HCV-positive, 1 (5.9%) died of liver disease 42 years after the original phlebotomy, 5 (29%) died of non-liver-related disease a median of 37 years after the original phlebotomy, and 1 (5.9%) died of unknown causes. One hundred nineteen HCV-negative persons (1.4%) died of liver disease. Conclusions: The rate of HCV infection from 1948 to 1954 among a sample of military recruits parallels that among present-day military recruits and volunteer blood donors. During 45 years of follow-up, HCV-positive persons had low liver-related morbidity and mortality rates. This suggests that healthy HCV-positive persons may be at less risk for progressive liver disease than is currently thought.	Vet Affairs Med Ctr, Washington, DC 20422 USA; Georgetown Univ, Sch Med, Inst Med, Washington, DC USA; Walter Reed Army Inst Res, Washington, DC USA; NCI, NIH, Bethesda, MD 20892 USA; NIAID, NIH, Bethesda, MD 20892 USA; Ortho Clin Diagnost, Raritan, NJ USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Georgetown University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Minnesota System; University of Minnesota Twin Cities	Seeff, LB (corresponding author), NIDDKD, NIH, Room 9A-18,31 Ctr Dr, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [ZIACP005782, Z01CP005782] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; Alter HJ, 1997, HEPATOLOGY, V26, pS29, DOI 10.1002/hep.510260705; ALTER HJ, 1978, P 2 S VIR HEP U CALF, P359; BRUIX J, 1989, LANCET, V2, P1004; BUKH J, 1992, P NATL ACAD SCI USA, V89, P187, DOI 10.1073/pnas.89.1.187; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; CUCCHERINI B, 1983, J LAB CLIN MED, V102, P370; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; DEAN AG, 1995, WORD PROCESSING DATA; DENNY FW, 1950, JAMA-J AM MED ASSOC, V143, P151, DOI 10.1001/jama.1950.02910370001001; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; DITTMANN S, 1991, J HEPATOL, V13, P323, DOI 10.1016/0168-8278(91)90076-N; ELSERAG HB, 1999, RISING INCIDENCE HEP, V340, P745; HYAMS KC, 1992, MIL MED, V157, P579, DOI 10.1093/milmed/157.11.579; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KNODELL RG, 1976, LANCET, V1, P557; KORETZ RL, 1993, ANN INTERN MED, V119, P110, DOI 10.7326/0003-4819-119-2-199307150-00003; MCQUILLAN GM, 1997, P IC TRIENN INT S VI, P267; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MOYER LA, 1989, AM J EPIDEMIOL, V130, P1024, DOI 10.1093/oxfordjournals.aje.a115403; NISHIOKA K, 1991, CANCER, V67, P429, DOI 10.1002/1097-0142(19910115)67:2<429::AID-CNCR2820670218>3.0.CO;2-#; Page WF, 1996, ANN EPIDEMIOL, V6, P102, DOI 10.1016/1047-2797(95)00126-3; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; RLES LA, 1998, ANN CAC REV 1973 199; SEEFF LB, 1977, GASTROENTEROLOGY, V72, P111; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Seeff LB, 1997, HEPATOLOGY, V26, pS21, DOI 10.1002/hep.510260704; SEEFF LB, 1978, P 2 S VIR HEP U CALF, P371; SHAKIL AO, 1995, ANN INTERN MED, V123, P330, DOI 10.7326/0003-4819-123-5-199509010-00002; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKAHASHI M, 1993, AM J GASTROENTEROL, V88, P240; TAKANO S, 1995, HEPATOLOGY, V21, P650; THOMAS RJ, 1988, REV INFECT DIS, V10, P125; TOBLER LH, 1994, TRANSFUSION, V34, P130, DOI 10.1046/j.1537-2995.1994.34294143940.x; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; UYTTENDAELE S, 1994, VOX SANG, V66, P122, DOI 10.1111/j.1423-0410.1994.tb00293.x; YANO M, 1993, GUT, V34, pS13, DOI 10.1136/gut.34.2_Suppl.S13	42	272	282	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2000	132	2					105	111		10.7326/0003-4819-132-2-200001180-00003	http://dx.doi.org/10.7326/0003-4819-132-2-200001180-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	275ZZ	10644270				2022-12-01	WOS:000084852300002
J	Fulton, S; Woodside, B; Shizgal, P				Fulton, S; Woodside, B; Shizgal, P			Modulation of brain reward circuitry by leptin	SCIENCE			English	Article							MELANIN-CONCENTRATING HORMONE; HYPOTHALAMIC SELF-STIMULATION; RECEPTOR MESSENGER-RNA; FOOD-RESTRICTED RATS; OBESE GENE; LATERAL HYPOTHALAMUS; FEEDING-BEHAVIOR; NEUROPEPTIDE-Y; BODY-WEIGHT; PROTEIN	Leptin, a hormone secreted by fat cells, suppresses food intake and promotes weight Loss, To assess the action of this hormone on brain reward circuitry, changes in the rewarding effect of Lateral hypothalamic stimulation were measured after leptin administration. At five stimulation sites near the fornix, the effectiveness of the rewarding electrical stimulation was enhanced by chronic food restriction and attenuated by intracerebroventricular infusion of leptin. In contrast, the rewarding effect of stimulating neighboring sites was insensitive to chronic food restriction and was enhanced by leptin in three of four cases. These opposing effects of Leptin may mirror complementary changes in the rewarding effects of feeding and of competing behaviors.	Concordia Univ, Ctr Studies Behav Neurobiol, Montreal, PQ H3G 1M8, Canada	Concordia University - Canada	Shizgal, P (corresponding author), Concordia Univ, Ctr Studies Behav Neurobiol, Montreal, PQ H3G 1M8, Canada.	shizgal@CSBN.concordia.ca	Shizgal, Peter/H-9823-2013; Shizgal, Peter/V-5602-2019	Shizgal, Peter/0000-0003-4265-0792				ABRAHAMSEN GC, 1995, BRAIN RES, V695, P186, DOI 10.1016/0006-8993(95)00764-H; Arvanitogiannis A, 1999, PHYSIOL BEHAV, V65, P805; Arvanitogiannis A, 1996, PHYSIOL BEHAV, V59, P795, DOI 10.1016/0031-9384(95)02157-4; BLUNDELL JE, 1968, NATURE, V219, P627, DOI 10.1038/219627a0; Broberger C, 1998, J COMP NEUROL, V402, P460; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CARR KD, 1993, BRAIN RES, V607, P141, DOI 10.1016/0006-8993(93)91499-I; CONOVER KL, 1994, BEHAV NEUROSCI, V108, P559; Cusin I, 1996, DIABETES, V45, P1446, DOI 10.2337/diabetes.45.10.1446; De Vaca SC, 1998, PHYSIOL BEHAV, V64, P251, DOI 10.1016/S0031-9384(98)00050-X; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Elmquist JK, 1998, J COMP NEUROL, V395, P535; FULTON S, UNPUB; GALLISTEL CR, 1987, PHARMACOL BIOCHEM BE, V26, P731, DOI 10.1016/0091-3057(87)90605-8; Gillard ER, 1998, J NEUROSCI, V18, P2646; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Herrnstein RJ, 1970, J EXP ANAL BEHAV, V13, P243, DOI 10.1901/jeab.1970.13-243; Horvath TL, 1999, J NEUROSCI, V19, P1072; LEIBOWITZ SF, 1979, BRAIN RES, V172, P115, DOI 10.1016/0006-8993(79)90899-0; LEIBOWITZ SF, 1975, BRAIN RES, V98, P529, DOI 10.1016/0006-8993(75)90371-6; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775; OLDS ME, 1963, J COMP NEUROL, V120, P259, DOI 10.1002/cne.901200206; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Seeley RJ, 1996, HORM METAB RES, V28, P664, DOI 10.1055/s-2007-979874; Shizgal P, 1997, CURR OPIN NEUROBIOL, V7, P198, DOI 10.1016/S0959-4388(97)80008-6; STANLEY BG, 1993, BRAIN RES, V604, P304; Watts AG, 1999, J NEUROSCI, V19, P6111, DOI 10.1523/JNEUROSCI.19-14-06111.1999; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	33	316	317	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					125	128		10.1126/science.287.5450.125	http://dx.doi.org/10.1126/science.287.5450.125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615045				2022-12-01	WOS:000084578400050
J	Marian, AJ				Marian, AJ			Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy	LANCET			English	Article							EXPRESSION; MUTATIONS; DEATH	Myocardial contractility is generally believed to be increased in hypertrophic cardiomyopathy. I propose the opposite-that cardiac myocyte contractility Is decreased in this disorder. Accordingly, the contractile deficit provides the primary stimulus for increased expression of trophic factors in the heart, which leads to hypertrophy, interstitial fibrosis, and other phenotypes. Variation among individuals in expression of trophic factors would account for the variability of phenotypes. Gene transfer studies in cardiac myocytes showing impaired contractility and increased expression of trophic factors in the myocardium of patients with hypertrophic cardiomyopathy support this hypothesis. Testing of the hypothesis would require measurement of contractility of cardiac myocytes isolated from patients with hypertrophic cardiomyopathy, identification of the main trophic factors in the hearts of these patients, and investigation of whether their inhibition can prevent or lead to regression of the cardiac phenotypes.	Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA	Baylor College of Medicine	Marian, AJ (corresponding author), Baylor Coll Med, Dept Med, Cardiol Sect, 1 Baylor Plaza,543E, Houston, TX 77030 USA.			Marian, AJ/0000-0002-1252-7120	NHLBI NIH HHS [P50-HL42267-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abchee A, 1997, J INVEST MED, V45, P191; Brugada R, 1997, J INVEST MED, V45, P542; DAVIES MJ, 1995, HISTOPATHOLOGY, V26, P493, DOI 10.1111/j.1365-2559.1995.tb00267.x; Hasegawa K, 1996, HYPERTENSION, V27, P259, DOI 10.1161/01.HYP.27.2.259; HIROTA Y, 1982, AM J CARDIOL, V50, P990, DOI 10.1016/0002-9149(82)90407-6; LECHIN M, 1995, CIRCULATION, V92, P1808, DOI 10.1161/01.CIR.92.7.1808; Li RK, 1997, CIRCULATION, V96, P874; Marian AJ, 1998, J CARDIOVASC ELECTR, V9, P88, DOI 10.1111/j.1540-8167.1998.tb00871.x; Marian AJ, 1997, CIRC RES, V81, P76, DOI 10.1161/01.RES.81.1.76; MARIAN AJ, 1993, LANCET, V342, P1073; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Rust EM, 1999, J CLIN INVEST, V103, P1459, DOI 10.1172/JCI6377; Tesson F, 1997, J MOL CELL CARDIOL, V29, P831, DOI 10.1006/jmcc.1996.0332; WYNNE J, 1992, HEART DISEASE TXB CA, P1394	15	168	197	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					58	60		10.1016/S0140-6736(99)06187-5	http://dx.doi.org/10.1016/S0140-6736(99)06187-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615904				2022-12-01	WOS:000085049200041
J	Pell, JP; Pell, ACH; Norrie, J; Ford, I; Cobbe, SM				Pell, JP; Pell, ACH; Norrie, J; Ford, I; Cobbe, SM			Effect of socioeconomic deprivation on waiting time for cardiac surgery: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article						a	REVASCULARIZATION RATES; CORONARY; ACCESS	Objective To determine whether the priority given to patients referred for cardiac surgery is associated with socioeconomic status. Design Retrospective study with multivariate logistic regression analysis of the association between deprivation and classification of urgency with allowance for age, sex, and type of operation. Multivariate linear regression analysis was used to determine association between deprivation and waiting time within each category of urgency, with allowance for age, sex, and type of operation. Setting NHS waiting lists in Scotland. Participants 26 642 patients waiting for cardiac surgery, 1 January 1986 to 31 December 1997. Main outcome measures Deprivation as measured by Carstairs deprivation category. Time spent on NHS waiting list. Results Patients who were most deprived tended to be younger and were more likely to be female. Patients in deprivation categories 6 and 7 (most deprived) waited about three weeks longer for surgery than those in category 1 (mean difference 24 days, 95% confidence interval 15 to 32), Deprived patients had an odds ratio of 0.5 (0.46 to 0.61) for having their operations classified as urgent compared with the least deprived, after allowance for age, sex, and type of operation. When urgent and routine cases were considered separately, there was no significant difference in waiting times between the most and least deprived categories. Conclusions Socioeconomically deprived patients are thought to be more likely to develop coronary heart disease but are less likely to be investigated and offered surgery once it has developed. Such patients may be further disadvantaged by having to wait longer for surgery because of being given lower priority.	Royal Infirm, Dept Cardiol, Glasgow G31 2ER, Lanark, Scotland; Monklands Hosp, Dept Cardiol, Airdrie ML6 0JS, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	Royal Infirmary of Edinburgh; Monklands Hospital; University of Glasgow	Pell, JP (corresponding author), Greater Glasgow Hlth Board, Dalian House,350 St Vincents St, Glasgow G3 8YU, Lanark, Scotland.		Ford, Ian/ABE-6145-2020	Pell, Jill/0000-0002-8898-7035				BENSHLOMO Y, 1995, J EPIDEMIOL COMMUN H, V49, P200, DOI 10.1136/jech.49.2.200; Carstairs V., 1991, DEPRIVATION HLTH SCO; DREVER F, 1996, POPUL TRENDS, V86, P15; DREVER F, 1997, HLTH INEQUALITIES; FINDLAY IN, 1990, BRIT HEART J, V64, P43; FINDLAY IN, 1991, BRIT HEART J, V66, pA70; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; KAGUSKAR S, 1997, CORONARY HEART DIS S; Keskimaki I, 1997, EUR J PUBLIC HEALTH, V7, P392, DOI 10.1093/eurpub/7.4.392; MacLeod MCM, 1999, HEART, V81, P252, DOI 10.1136/hrt.81.3.252; Manson-Siddle CJ, 1998, J EPIDEMIOL COMMUN H, V52, P507, DOI 10.1136/jech.52.8.507; *OFF POP CENS SURV, 1995, 1991 CENS; Payne N, 1997, BRIT MED J, V314, P257, DOI 10.1136/bmj.314.7076.257; VAGERO D, 1989, LANCET, V2, P35, DOI 10.1016/S0140-6736(89)90266-3	14	84	84	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					15	18		10.1136/bmj.320.7226.15	http://dx.doi.org/10.1136/bmj.320.7226.15			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617517	Bronze, Green Accepted, Green Published, Green Submitted			2022-12-01	WOS:000084621600014
J	Watkins, SJ				Watkins, SJ			Conviction by mathematical error? Doctors and lawyers should get probability theory right	BRITISH MEDICAL JOURNAL			English	Editorial Material							INFANT-DEATH-SYNDROME; SUBSEQUENT SIBLINGS; RECURRENCE RISK; SUDDEN		Stockport Hlth Author, Stockport SK7 5BY, England		Watkins, SJ (corresponding author), Stockport Hlth Author, Stockport SK7 5BY, England.							BEAL SM, 1988, ARCH DIS CHILD, V63, P924, DOI 10.1136/adc.63.8.924; EMERY JL, 1986, LANCET, V1, P313; GUNTHEROTH WG, 1990, J PEDIATR-US, V116, P520, DOI 10.1016/S0022-3476(05)81596-3; IRGENS LM, 1984, J PEDIATR-US, V104, P349, DOI 10.1016/S0022-3476(84)81093-8; McKenzie G, 1984, BR J SOC PREV MED, V25, P119; Oyen N, 1996, AM J EPIDEMIOL, V144, P300, DOI 10.1093/oxfordjournals.aje.a008925; PETERSON DR, 1986, J PEDIATR-US, V108, P911, DOI 10.1016/S0022-3476(86)80926-X; REESE A, 1999, STAT JUSTICE; WOLKIND S, 1993, ACTA PAEDIATR, V82, P873, DOI 10.1111/j.1651-2227.1993.tb12583.x	9	30	30	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					2	3		10.1136/bmj.320.7226.2	http://dx.doi.org/10.1136/bmj.320.7226.2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617504	Green Published			2022-12-01	WOS:000084621600002
J	Woods, CW; Armstrong, G; Sackey, SO; Tetteh, C; Bugri, S; Perkins, BA; Rosenstein, NE				Woods, CW; Armstrong, G; Sackey, SO; Tetteh, C; Bugri, S; Perkins, BA; Rosenstein, NE			Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa	LANCET			English	Article							FAILURE	Background Recurrent epidemics of meningococcal disease have been reported throughout the African meningitis belt since description of the disease in 1912, Meningococcal polysaccharide vaccines can effectively prevent disease but the optimum strategy for their use in this setting has been controversial. We used data from an outbreak of meningococcal disease in northern Ghana in 1997 to assess the potential effect of different vaccination strategies. Methods We identified all reported cases of meningococcal meningitis and estimated the number of cases and deaths that could have been prevented by vaccination through use of a simple mathematical model. We then assessed the potential effect of different vaccination strategies and the burden of these strategies on the public-health system. Findings In the three affected regions in northern Ghana there were 18 703 cases and 1356 deaths reported between November, 1996, and May, 1997. Vaccination began in the third week of February and continued to April, reaching 72% of the at-risk population and preventing an estimated 23% of cases and 18% of deaths. A strategy of routine childhood and adult immunisation would have prevented 61% of cases had this same rate of vaccine coverage been achieved and maintained before the epidemic. If vaccination had started after the onset of the epidemic in January, as currently advocated by WHO guidelines, a similar proportion (61%) of cases could have been prevented. Interpretation Prevention of epidemics of meningococal disease in west Africa will be difficult until long-lasting conjugate vaccines capable of interrupting transmission of Neisseria meningitidis can be incorporated into routine infant-immunisation schedules, Until then, the strategy of surveillance and response advocated by WHO is as effective and more practical than a strategy of routine childhood and adult vaccination with currently available polysaccharide vaccines.	Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Off Surveillance, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ghana Minist Hlth, Accra, Ghana	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Rosenstein, NE (corresponding author), Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, 1600 Clifton Rd NE,MS-C23, Atlanta, GA 30333 USA.		Sackey, Samuel Oko/I-9207-2019					ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; BLAKEBROUGH IS, 1983, ANN TROP MED PARASIT, V77, P175, DOI 10.1080/00034983.1983.11811694; BOSMANS E, 1980, ANN SOC BELG MED TR, V60, P297; CAMPAGNE G, 1997, INT C ANT AG CHEM SA; *COMM DIS CTR, 1999, MMWR-MORBID MORTAL W, V48, P513; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P536, DOI 10.1016/0035-9203(87)90397-X; HASSANKING MKA, 1988, J INFECTION, V16, P55, DOI 10.1016/S0163-4453(88)96117-8; Kaninda AV, 1997, LANCET, V350, P1708, DOI 10.1016/S0140-6736(05)64315-2; KAPLAN SL, 1985, BACTERIAL MENINGITIS, P83; Lapeyssonnie L., 1963, B WHO              S, V28, P3; LEAKE JAD, 1998, INT C EM INF DIS ATL; MOORE PS, 1992, INT J EPIDEMIOL, V21, P155, DOI 10.1093/ije/21.1.155; PINNER RW, 1992, J INFECT DIS, V166, P359, DOI 10.1093/infdis/166.2.359; REIDO FX, 1995, PEDIATR INFECT DIS J, V14, P643; REINGOLD AL, 1985, LANCET, V2, P114; Robbins JB, 1997, LANCET, V350, P880, DOI 10.1016/S0140-6736(97)03227-3; SMITH AW, 1988, T ROY SOC TROP MED H, V82, P312, DOI 10.1016/0035-9203(88)90459-2; SPIEGEL A, 1993, B WORLD HEALTH ORGAN, V71, P311; TWUMASI PA, 1995, J INFECT DIS, V171, P632, DOI 10.1093/infdis/171.3.632; VARAINE F, 1997, T R SOC TROP MED HYG, V51, P3; Veeken H, 1998, B WORLD HEALTH ORGAN, V76, P135; WAHDAN MH, 1973, B WORLD HEALTH ORGAN, V48, P667; Wenger J, 1997, LANCET, V350, P1709, DOI 10.1016/S0140-6736(05)64316-4; *WHO, 1995, CONTR MEN DIS WHO PR; WILKINS J, 1979, PEDIATRICS, V94, P828; World Health Organization, 1997, WKLY EPIDEMIOL REC, V72, P313	26	58	59	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					30	33		10.1016/S0140-6736(99)03366-8	http://dx.doi.org/10.1016/S0140-6736(99)03366-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615888				2022-12-01	WOS:000085049200013
J	Cheetham, GMT; Steitz, TA				Cheetham, GMT; Steitz, TA			Structure of a transcribing T7 RNA polymerase initiation complex	SCIENCE			English	Article							DNA-POLYMERASE; T7-RNA POLYMERASE; CRYSTAL-STRUCTURE; REVERSE-TRANSCRIPTASE; ANGSTROM RESOLUTION; BINDING-SITES; PROMOTER; BACTERIOPHAGE-T7; REPLICATION; MITOCHONDRIAL	The structure of a T7 RNA polymerase (T7 RNAP) initiation complex captured transcribing a trinucleotide of RNA from a 17-base pair promoter DNA containing a 5-nucleotide single-strand template extension was determined at a resolution of 2.4 angstroms, Binding of the upstream duplex portion of the promoter occurs in the same manner as that in the open promoter complex. but the single-stranded template is repositioned to place the +4 base at the catalytic active site. Thus, synthesis of RNA in the initiation phase Leads to accumulation or "scrunching" of the template in the enclosed active site pocket of T7 RNAP, Only three base pairs of heteroduplex are formed before the RNA peels off the template.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009		NIGMS NIH HHS [GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; Gardner LP, 1997, BIOCHEMISTRY-US, V36, P2908, DOI 10.1021/bi962397i; Hedtke B, 1997, SCIENCE, V277, P809, DOI 10.1126/science.277.5327.809; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Lykke-Andersen J, 1998, NUCLEIC ACIDS RES, V26, P5630, DOI 10.1093/nar/26.24.5630; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; OAKLEY JL, 1979, BIOCHEMISTRY-US, V18, P528, DOI 10.1021/bi00570a023; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; RECHINSKY VO, 1992, FEBS LETT, V306, P129, DOI 10.1016/0014-5793(92)80983-N; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; Tjian R, 1996, PHILOS T R SOC B, V351, P491, DOI 10.1098/rstb.1996.0047; TRACY RL, 1995, CURR GENET, V28, P205, DOI 10.1007/BF00309779; Villemain J, 1998, J MOL BIOL, V281, P793, DOI 10.1006/jmbi.1998.1989; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG AHJ, 1982, NATURE, V299, P601, DOI 10.1038/299601a0; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2	37	277	290	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2305	2309		10.1126/science.286.5448.2305	http://dx.doi.org/10.1126/science.286.5448.2305			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600732				2022-12-01	WOS:000084318500049
J	Lanciotti, RS; Roehrig, JT; Deubel, V; Smith, J; Parker, M; Steele, K; Crise, B; Volpe, KE; Crabtree, MB; Scherret, JH; Hall, RA; MacKenzie, JS; Cropp, CB; Panigrahy, B; Ostlund, E; Schmitt, B; Malkinson, M; Banet, C; Weissman, J; Komar, N; Savage, HM; Stone, W; McNamara, T; Gubler, DJ				Lanciotti, RS; Roehrig, JT; Deubel, V; Smith, J; Parker, M; Steele, K; Crise, B; Volpe, KE; Crabtree, MB; Scherret, JH; Hall, RA; MacKenzie, JS; Cropp, CB; Panigrahy, B; Ostlund, E; Schmitt, B; Malkinson, M; Banet, C; Weissman, J; Komar, N; Savage, HM; Stone, W; McNamara, T; Gubler, DJ			Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; ANTIGENIC DETERMINANTS; MAXIMUM-LIKELIHOOD; E-GLYCOPROTEIN; DNA-SEQUENCES; IDENTIFICATION; EVOLUTION; TREES; KUNJIN; GENE	In Late summer 1999, an outbreak of human encephalitis occurred in the northeastern United States that was concurrent with extensive mortality in crows (Corvus species) as well as the deaths of several exotic birds at a zoological park in the same area. Complete genome sequencing of a flavivirus isolated from the brain of a dead Chilean flamingo (Phoenicopterus chilensis), together with partial sequence analysis of envelope glycoprotein (E-glycoprotein) genes amplified from several other species including mosquitoes and two fatal human cases, revealed that West Nile (WN) virus circulated in natural transmission cycles and was responsible for the human disease. Antigenic mapping with E-glycoprotein-specific monoclonal antibodies and E-glycoprotein phylogenetic analysis confirmed these viruses as WN. This North American WN virus was most closely related to a WN virus isolated from a dead goose in Israel in 1998.	Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO 80522 USA; Inst Pasteur, Unite Arbovirus & Virus Fievres Hemorragiques, F-75724 Paris 15, France; USA, Med Res Inst Infect Dis, Div Virol & Pathol, Frederick, MD 21701 USA; USA, Med Res Inst Infect Dis, Div Virol, Frederick, MD 21701 USA; Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia; USDA, Natl Vet Serv Labs, Anim & Plant Hlth Inspect Serv, Ames, IA 50010 USA; Minist Agr & Rural Dev, Kimron Vet Inst, Div Avian Dis, IL-50250 Bet Dagan, Israel; New York State Dept Environm Conservat, Div Fish Wildlife & Marine Resources, Wildlife Pathol Unit, Delmar, NY 12054 USA; Wildlife Conservat Soc, Bronx, NY 10460 USA	Centers for Disease Control & Prevention - USA; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Queensland; United States Department of Agriculture (USDA); Kimron Veterinary Institute; Wildlife Conservation Society	Lanciotti, RS (corresponding author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO 80522 USA.		Smith, Jane/B-6254-2009; /S-4986-2019	/0000-0002-5918-2190; Roehrig, John/0000-0001-7581-0479				ADAMS SC, 1995, VIROLOGY, V206, P49, DOI 10.1016/S0042-6822(95)80018-2; [Anonymous], 1993, MEGA MOL EVOLUTIONAR; Berthet FX, 1997, J GEN VIROL, V78, P2293, DOI 10.1099/0022-1317-78-9-2293; Briese T, 1999, LANCET, V354, P1261, DOI 10.1016/S0140-6736(99)04576-6; CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; GENTRY MK, 1982, AM J TROP MED HYG, V31, P548, DOI 10.4269/ajtmh.1982.31.548; GOULD EA, 1990, ARCH VIROL, V1, P137; HALL RA, 1991, IMMUNOL CELL BIOL, V69, P47, DOI 10.1038/icb.1991.7; HAWKES RA, 1988, J GEN VIROL, V69, P1105, DOI 10.1099/0022-1317-69-5-1105; HENCHAL EA, 1985, AM J TROP MED HYG, V34, P162, DOI 10.4269/ajtmh.1985.34.162; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; ROEHRIG JT, 1983, VIROLOGY, V128, P118, DOI 10.1016/0042-6822(83)90323-9; ROEHRIG JT, 1990, AM J TROP MED HYG, V42, P394, DOI 10.4269/ajtmh.1990.42.394; RZHETSKY A, 1992, MOL BIOL EVOL, V9, P945; RZHETSKY A, 1993, MOL BIOL EVOL, V10, P1073; SAVAGE HM, IN PRESS AM J TROP M; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; WORK TH, 1955, AM J TROP MED HYG, V4, P872, DOI 10.4269/ajtmh.1955.4.872	21	1163	1242	2	256	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2333	2337		10.1126/science.286.5448.2333	http://dx.doi.org/10.1126/science.286.5448.2333			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600742				2022-12-01	WOS:000084318500059
J	Kraft, GH				Kraft, GH			Rehabilitation still the only way to improve function in multiple sclerosis	LANCET			English	Editorial Material							COGNITIVE DYSFUNCTION; IMPACT		Univ Washington, MS Ctr, Dept Rehabil Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kraft, GH (corresponding author), Univ Washington, MS Ctr, Dept Rehabil Med, Seattle, WA 98195 USA.							Freeman JA, 1997, ANN NEUROL, V42, P236, DOI 10.1002/ana.410420216; Freeman JA, 1999, NEUROLOGY, V52, P50, DOI 10.1212/WNL.52.1.50; Heide AC, 1998, AM J NEURORADIOL, V19, P1047; Kraft G H, 1998, J Spinal Cord Med, V21, P117; KRAFT GH, 1996, VETERANS AFFAIRS REH, V33, P329; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Petajan JH, 1996, ANN NEUROL, V39, P432, DOI 10.1002/ana.410390405; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; Rumrill Jr P. D., 1996, EMPLOYMENT ISSUES MU; Schwartz L, 1999, AM J PHYS MED REHAB, V78, P525, DOI 10.1097/00002060-199911000-00006; Solari A, 1999, NEUROLOGY, V52, P57, DOI 10.1212/WNL.52.1.57; Stolz W, 1994, CHRONIC DIS DISABILI, P3; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502	15	60	60	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2016	2017		10.1016/S0140-6736(99)90035-1	http://dx.doi.org/10.1016/S0140-6736(99)90035-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636362				2022-12-01	WOS:000084183300005
J	Lee, SH; Hava, DL; Waldor, MK; Camilli, A				Lee, SH; Hava, DL; Waldor, MK; Camilli, A			Regulation and temporal expression patterns of Vibrio cholerae virulence genes during infection	CELL			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; TOXIN-COREGULATED PILUS; SUICIDE VECTOR; EL-TOR; REGULON; CONSTRUCTION; COLONIZATION; ACTIVATION; IDENTIFY; PROMOTER	The temporal expression patterns of the critical Vibrio cholerae virulence genes, tcpA and ctxA, were determined during infection using a recombinase reporter. TcpA was induced biphasically in two temporally and spatially separable events in the small intestine, whereas ctxA was induced monophasically only after, and remarkably, dependent upon, tcpA expression; however, this dependence was not observed during in vitro growth. The requirements of the virulence regulators, ToxR, TcpP, and ToxT, for expression of tcpA and ctxA were determined and were found to differ significantly during infection versus during growth in vitro. These results illustrate the importance of examining virulence gene expression in the context of bona fide host-pathogen interactions.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Div Geog Med & Infect Dis, Boston, MA 02111 USA	Tufts University; Tufts University	Camilli, A (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.				NIAID NIH HHS [AI 40262, AI 42347, AI 07422] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042347, R29AI040262] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angelichio MJ, 1999, INFECT IMMUN, V67, P3733, DOI 10.1128/IAI.67.8.3733-3739.1999; Bieber D, 1998, SCIENCE, V280, P2114, DOI 10.1126/science.280.5372.2114; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; CAMILLI A, 1994, P NATL ACAD SCI USA, V91, P2634, DOI 10.1073/pnas.91.7.2634; Carroll PA, 1997, MOL MICROBIOL, V25, P1099, DOI 10.1046/j.1365-2958.1997.5371901.x; Chakrabarti S, 1999, INFECT IMMUN, V67, P1025, DOI 10.1128/IAI.67.3.1025-1033.1999; Champion GA, 1997, MOL MICROBIOL, V23, P323, DOI 10.1046/j.1365-2958.1997.2191585.x; Crawford JA, 1998, MOL MICROBIOL, V29, P235, DOI 10.1046/j.1365-2958.1998.00925.x; Davis BM, 1999, J BACTERIOL, V181, P6779, DOI 10.1128/JB.181.21.6779-6787.1999; DIRITA VJ, 1991, P NATL ACAD SCI USA, V88, P5403, DOI 10.1073/pnas.88.12.5403; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Hase CC, 1998, P NATL ACAD SCI USA, V95, P730, DOI 10.1073/pnas.95.2.730; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; HIGGINS DE, 1994, MOL MICROBIOL, V14, P17, DOI 10.1111/j.1365-2958.1994.tb01263.x; Higgins DE, 1996, J BACTERIOL, V178, P1080, DOI 10.1128/jb.178.4.1080-1087.1996; IWANAGA M, 1986, MICROBIOL IMMUNOL, V30, P1075, DOI 10.1111/j.1348-0421.1986.tb03037.x; Klose KE, 1998, J BACTERIOL, V180, P303, DOI 10.1128/JB.180.2.303-316.1998; Lee SH, 1998, J BACTERIOL, V180, P2298, DOI 10.1128/JB.180.9.2298-2305.1998; Medrano AI, 1999, INFECT IMMUN, V67, P2178, DOI 10.1128/IAI.67.5.2178-2183.1999; MILLER VL, 1984, P NATL ACAD SCI-BIOL, V81, P3471, DOI 10.1073/pnas.81.11.3471; MILLER VL, 1989, J BACTERIOL, V171, P1288, DOI 10.1128/jb.171.3.1288-1293.1989; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schuhmacher DA, 1999, J BACTERIOL, V181, P1508, DOI 10.1128/JB.181.5.1508-1514.1999; Skorupski K, 1997, MOL MICROBIOL, V25, P1003, DOI 10.1046/j.1365-2958.1997.5481909.x; SUN D, 1991, INFECT IMMUN, V59, P114, DOI 10.1128/IAI.59.1.114-118.1991; Surette MG, 1999, P NATL ACAD SCI USA, V96, P1639, DOI 10.1073/pnas.96.4.1639; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Thelin KH, 1996, INFECT IMMUN, V64, P2853, DOI 10.1128/IAI.64.7.2853-2856.1996; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910	30	220	232	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					625	634		10.1016/S0092-8674(00)81551-2	http://dx.doi.org/10.1016/S0092-8674(00)81551-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612398	Bronze			2022-12-01	WOS:000084278700009
J	Beck, T; Hall, MN				Beck, T; Hall, MN			The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; KINASE; RAPAMYCIN; PROTEINS; MODULES; STRESS; GROWTH; MSN2P	The rapamycin-sensitive TOR signalling pathway in Saccharomyces cerevisiae activates a cell-growth program in response to nutrients such as nitrogen and carbon(1-4). The TOR1 and TOR2 kinases (TOR) control cytoplasmic protein synthesis and degradation through the conserved TAP42 protein(5-8). Upon phosphorylation by TOR, TAP42 binds and possibly inhibits type 2A and type-2A-related phosphatases(6-8); however, the mechanism by which TOR controls nuclear events such as global repression of starvation-specific transcription is unknown. Here we show that TOR prevents transcription of genes expressed upon nitrogen limitation by promoting the association of the GATA transcription factor GLN3 with the cytoplasmic protein URE2. The binding of GLN3 to URE2 requires TOR-dependent phosphorylation of GLN3, Phosphorylation and cytoplasmic retention of GLN3 are also dependent on the TOR effector TAP42, and are antagonized by the type-2A-related phosphatase SIT4. TOR inhibits expression of carbon-source-regulated genes by stimulating the binding of the transcriptional activators MSN2 and MSN4 to the cytoplasmic 14-3-3 protein BMH2, Thus, the TOR signalling pathway broadly controls nutrient metabolism by sequestering several transcription factors in the cytoplasm.	Univ Basel, Bioctr, Dept Biochem, CH-4056 Basel, Switzerland	University of Basel	Hall, MN (corresponding author), Univ Basel, Bioctr, Dept Biochem, CH-4056 Basel, Switzerland.			Hall, Michael N/0000-0002-2998-0757				Ausubel FM, 1998, CURRENT PROTOCOLS MO; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Bertram PG, 1998, CURR BIOL, V8, P1259, DOI 10.1016/S0960-9822(07)00535-0; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Hara K, 1998, J BIOL CHEM, V273, P22160; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.0.CO;2-U; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Marzluf GA, 1997, MICROBIOL MOL BIOL R, V61, P17, DOI 10.1128/.61.1.17-32.1997; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SHERMAN F, 1991, P3; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	26	769	787	1	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					689	692		10.1038/45287	http://dx.doi.org/10.1038/45287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604478				2022-12-01	WOS:000084189800072
J	Henney, JE				Henney, JE			Review of generic bioequivalence studies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					1995	1995		10.1001/jama.282.21.1995	http://dx.doi.org/10.1001/jama.282.21.1995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591372				2022-12-01	WOS:000083908700005
J	Hildebrand, JD; Soriano, P				Hildebrand, JD; Soriano, P			Shroom, a PDZ domain-containing actin-binding protein, is required for neural tube morphogenesis in mice	CELL			English	Article							ABNORMAL BRAIN-DEVELOPMENT; EMBRYONIC STEM-CELLS; E-CADHERIN; ALPHA-CATENIN; XENOPUS-LAEVIS; F-ACTIN; GENE; DEFECTS; NEURULATION; ADHESION	Using gene trap mutagenesis, we have identified a mutation in mice that causes exencephaly, acrania, facial clefting, and spina bifida, all of which can be attributed to failed neural tube closure. This mutation is designated shroom (shrm) because the neural folds "mushroom" outward and do not converge at the dorsal midline. shrm encodes a PDZ domain protein that is involved at several levels in regulating aspects of cytoarchitecture. First, endogenous Shrm localizes to adherens junctions and the cytoskeleton. Second, ectopically expressed Shrm alters the subcellular distribution of F-actin. Third, Shrm directly binds F-actin. Finally, cytoskeletal polarity within the neuroepithelium is perturbed in mutant embryos. In concert, these observations suggest that Shrm is a critical determinant of the cellular architecture required for proper neurulation.	Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Soriano, P (corresponding author), Fred Hutchinson Canc Res Ctr, Program Dev Biol, 1100 Fairview Ave N, Seattle, WA 98109 USA.	psoriano@fhcrc.org	Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X	NICHD NIH HHS [HD24875] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; BREEN E, 1993, CELL ADHES COMMUN, V1, P239, DOI 10.3109/15419069309097257; Bubeck P, 1997, J CELL SCI, V110, P1361; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chen JM, 1996, P NATL ACAD SCI USA, V93, P6275, DOI 10.1073/pnas.93.13.6275; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GOLDEN JA, 1995, PEDIATRICS, V95, P506; Grapin-Botton A, 1998, DEVELOPMENT, V125, P1173; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUMBINER BM, 1993, J CELL SCI, P155; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hogan B., 2014, MANIPULATING MOUSE E; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KARFUNKEL P, 1971, DEV BIOL, V25, P30, DOI 10.1016/0012-1606(71)90018-2; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; OYAMA T, 1994, CANCER RES, V54, P6282; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Prat AG, 1996, J BIOL CHEM, V271, P18045, DOI 10.1074/jbc.271.30.18045; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SAKAI Y, 1989, ANAT RECORD, V223, P194, DOI 10.1002/ar.1092230212; SCHIAFFINO MV, 1995, HUM MOL GENET, V4, P373, DOI 10.1093/hmg/4.3.373; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; Smith JL, 1997, TRENDS NEUROSCI, V20, P510, DOI 10.1016/S0166-2236(97)01121-1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1991, J VIROL, V65, P2314, DOI 10.1128/JVI.65.5.2314-2319.1991; STANISSTREET M, 1990, POSTIMPLANTATION MAM; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Torres M, 1997, P NATL ACAD SCI USA, V94, P901, DOI 10.1073/pnas.94.3.901; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Wu M, 1996, P NATL ACAD SCI USA, V93, P2110, DOI 10.1073/pnas.93.5.2110; Xu WM, 1998, DEVELOPMENT, V125, P327; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Ybot-Gonzalez P, 1999, DEV DYNAM, V215, P273, DOI 10.1002/(SICI)1097-0177(199907)215:3<273::AID-AJA9>3.0.CO;2-H; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275	54	263	269	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					485	497		10.1016/S0092-8674(00)81537-8	http://dx.doi.org/10.1016/S0092-8674(00)81537-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589677	Bronze			2022-12-01	WOS:000083986300008
J	Xiao, T; Towb, P; Wasserman, SA; Sprang, SR				Xiao, T; Towb, P; Wasserman, SA; Sprang, SR			Three-dimensional structure of a complex between the death domains of Pelle and Tube	CELL			English	Article							DROSOPHILA EMBRYO; DORSOVENTRAL POLARITY; NMR STRUCTURE; MACROMOLECULAR STRUCTURES; TNF RECEPTOR; PROTEIN; DORSAL; MUTAGENESIS; KINASE; TRANSDUCTION	The interaction of the serine/threonine kinase Pelle and adaptor protein Tube through their N-terminal death domains leads to the nuclear translocation of the transcription factor Dorsal and activation of zygotic patterning genes during Drosophila embryogenesis. Crystal structure of the Pelle and Tube death domain heterodimer reveals that the two death domains adopt a six-helix bundle fold and are arranged in an open-ended linear array with plastic interfaces mediating their interactions. The Tube death domain has an insertion between helices 2 and 3, and a C-terminal tail making significant and indispensable contacts in the heterodimer. In vivo assays of Pelle and Tube mutants confirmed that the integrity of the major heterodimer interface is critical to the activity of these molecules.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego	Sprang, SR (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA.	sprang@chop.swmed.edu	Xiao, Tsan Sam/A-8590-2010; Xiao, Tsan/I-7616-2013	Xiao, Tsan Sam/0000-0001-9688-475X; Xiao, Tsan/0000-0001-9688-475X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050545] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK046371] Funding Source: Medline; NIGMS NIH HHS [R01 GM050545, GM50545] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang HY, 1999, P NATL ACAD SCI USA, V96, P1252, DOI 10.1073/pnas.96.4.1252; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Edwards DN, 1997, DEVELOPMENT, V124, P3855; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; Grosshans J, 1999, MECH DEVELOP, V81, P127, DOI 10.1016/S0925-4773(98)00236-6; HECHT PM, 1993, GENETICS, V135, P405; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; JONES TA, 1993, O VERSION 5 9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Towb P, 1998, DEVELOPMENT, V125, P2443; Wieschaus E., 1986, P199; YANG W, 1990, J BIOL CHEM, V265, P13553	48	151	153	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					545	555		10.1016/S0092-8674(00)81542-1	http://dx.doi.org/10.1016/S0092-8674(00)81542-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589682	Green Accepted, Bronze			2022-12-01	WOS:000083986300013
J	[Anonymous]				[Anonymous]			Cell surgery	SCIENCE			English	Editorial Material																		Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1498	1498		10.1126/science.286.5444.1498	http://dx.doi.org/10.1126/science.286.5444.1498			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10610553				2022-12-01	WOS:000083768300039
J	GrandPre, T; Nakamura, F; Vartanian, T; Strittmatter, SM				GrandPre, T; Nakamura, F; Vartanian, T; Strittmatter, SM			Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein	NATURE			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; FAMILY ENCODING RETICULONS; GROWTH CONE COLLAPSE; NEURITE GROWTH; GENOMIC ORGANIZATION; GENE; EXPRESSION	Adult mammalian axon regeneration is generally successful in the peripheral nervous system (PNS) but is dismally poor in the central nervous system (CNS), However, many classes of CNS axons can extend for long distances in peripheral nerve grafts(1). A comparison of myelin from the CNS and the PNS has revealed that CNS white matter is selectively inhibitory for axonal outgrowth(2). Several components of CNS white matter, NI35, NI250(Nogo) and MAG, that have inhibitory activity for axon extension have been described(3-7) The IN-1 antibody, which recognizes NI35 and NI250(Nogo), allows moderate degrees of axonal regeneration and functional recovery after spinal cord injury(8,9). Here we identify Nogo as a member of the Reticulon family, Reticulon 4-A. Nogo is expressed by oligodendrocytes but not by Schwann cells, and associates primarily with the endoplasmic reticulum. A 66-residue lumenal/extracellular domain inhibits axonal extension and collapses dorsal root ganglion growth cones. In contrast to Nogo, Reticulon 1 and 3 ape not expressed by oligodendrocytes, and the 66-residue lumenal/extracellular domains from Reticulon 1, 2 and 3 do not inhibit axonal regeneration. These data provide a molecular basis to assess the contribution of Nogo to the failure of axonal regeneration in the adult CNS.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA USA	Yale University; Yale University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, 333 Cedar St, New Haven, CT 06510 USA.	stephen.strittmatter@yale.edu	Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				Bandtlow CE, 1997, EUR J NEUROSCI, V9, P2743, DOI 10.1111/j.1460-9568.1997.tb01703.x; BENFEY M, 1982, NATURE, V296, P150, DOI 10.1038/296150a0; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Jin Z, 1997, J NEUROSCI, V17, P6256; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Moreira EF, 1999, GENOMICS, V58, P73, DOI 10.1006/geno.1999.5807; MORRIS NJ, 1991, BIOCHIM BIOPHYS ACTA, V1450, P68; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Roebroek AJM, 1998, GENOMICS, V51, P98, DOI 10.1006/geno.1997.5175; Roebroek AJM, 1996, GENOMICS, V32, P191, DOI 10.1006/geno.1996.0105; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Senden NHM, 1996, EUR J CELL BIOL, V69, P197; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; Vartanian T, 1999, P NATL ACAD SCI USA, V96, P731, DOI 10.1073/pnas.96.2.731; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 2000, CONT NEUROS, P131	25	932	1052	3	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					439	444		10.1038/35000226	http://dx.doi.org/10.1038/35000226			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667797				2022-12-01	WOS:000085121100053
J	Elowitz, MB; Leibler, S				Elowitz, MB; Leibler, S			A synthetic oscillatory network of transcriptional regulators	NATURE			English	Article							GREEN FLUORESCENT PROTEIN; ESCHERICHIA-COLI; TAGGING SYSTEM; DEGRADATION; ELEMENTS	Networks of interacting biomolecules carry out many essential functions in living cells(1), but the 'design principles' underlying the functioning of such intracellular networks remain poorly understood, despite intensive efforts including quantitative analysis of relatively simple systems(2). Here we present a complementary approach to this problem: the design and construction of a synthetic network to implement a particular function. We used three transcriptional repressor systems that are not part of any natural biological clock(3-5) to build an oscillating network, termed the repressilator, in Escherichia coli. The network periodically induces the synthesis of green fluorescent protein as a readout of its state in individual cells. The resulting oscillations, with typical periods of hours, are slower than the cell-division cycle, so the state of the oscillator has to be transmitted from generation to generation. This artificial clock displays noisy behaviour, possibly because of stochastic fluctuations of its components. Such 'rational network design' may lead both to the engineering of new cellular behaviours and to an improved understanding of naturally occurring networks.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University; Princeton University	Elowitz, MB (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Andersen JB, 1998, APPL ENVIRON MICROB, V64, P2240; Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Elowitz MB., 1999, THESIS PRINCETON U P; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Glascock CB, 1998, GENE, V223, P221, DOI 10.1016/S0378-1119(98)00240-6; Goldbeter A., 1996, BIOCH OSCILLATIONS C; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; Koshland DE, 1998, SCIENCE, V280, P852, DOI 10.1126/science.280.5365.852; KUSHNER SR, 1996, ESCHERICHIA COLI SAL; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; Thomas R., 1990, BIOL FEEDBACK; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Winfree AT, 1990, GEOMETRY BIOL TIME	20	3024	3203	22	701	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					335	338		10.1038/35002125	http://dx.doi.org/10.1038/35002125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659856				2022-12-01	WOS:000084899700059
J	Houghton, RA; Skole, DL; Nobre, CA; Hackler, JL; Lawrence, KT; Chomentowski, WH				Houghton, RA; Skole, DL; Nobre, CA; Hackler, JL; Lawrence, KT; Chomentowski, WH			Annual fluxes or carbon from deforestation and regrowth in the Brazilian Amazon	NATURE			English	Article							PASTURE SOILS; LAND-USE; FOREST; BIOMASS; BUDGET	The distribution of sources and sinks of carbon among the world's ecosystems is uncertain. Some analyses show northern midlatitude lands to be a large sink, whereas the tropics are a net source(1); other analyses show the tropics to be nearly neutral. whereas northern mid-latitudes are a small sink(2,3). Here we show that the annual flux of carbon from deforestation and abandonment of agricultural lands in the Brazilian Amazon was a source of about 0.2 g C yr(-1) over the period 1989-1998 (1 Pg is 10(15) g). This estimate is based on annual rates of deforestation and spatially detailed estimates of deforestation, regrowing forests and biomass. Logging may add another 5-10% to this estimate(4), and fires may double the magnitude of the source in years following a drought(4), The annual source of carbon from land-use change and fire approximately offsets the sink calculated for natural ecosystems in the region(5,6). Thus this large area of tropical forest is nearly balanced with respect to carbon, but has an interannual variability of +/- 0.2 PgC yr(-1).	Woods Hole Res Ctr, Woods Hole, MA 02543 USA; Michigan State Univ, Dept Geog, E Lansing, MI 48824 USA; Inst Nacl Pesquisas Espaciais, BR-12201970 Sao Jose Dos Campos, SP, Brazil	Woods Hole Research Center; Michigan State University; Instituto Nacional de Pesquisas Espaciais (INPE)	Houghton, RA (corresponding author), Woods Hole Res Ctr, POB 296, Woods Hole, MA 02543 USA.			skole, david/0000-0002-8575-3540				Alves DS, 1996, INT J REMOTE SENS, V17, P835, DOI 10.1080/01431169608949049; *BRAZ MIN MIN EN D, 1973, LEV REC NAT, V1; BROWN S, 1992, INTERCIENCIA, V17, P8; BROWN S, 1990, J TROP ECOL, V6, P1, DOI 10.1017/S0266467400003989; BROWN S, 1989, FOREST SCI, V35, P881; Cairns MA, 1997, OECOLOGIA, V111, P1, DOI 10.1007/s004420050201; Carrera-Rotllan J, 1998, MECH AGEING DEV, V103, P13, DOI 10.1016/S0047-6374(98)00007-4; CIAIS P, 1995, J GEOPHYS RES-ATMOS, V100, P5051, DOI 10.1029/94JD02847; Cochrane MA, 1999, SCIENCE, V284, P1832, DOI 10.1126/science.284.5421.1832; DAVIDSON EA, 1995, NATURE, V376, P472, DOI 10.1038/376472a0; Delaney M, 1998, BIOTROPICA, V30, P2, DOI 10.1111/j.1744-7429.1998.tb00364.x; Fearnside P., 1986, HUMAN CARRYING CAPAC; Fearnside Philip M., 1998, Forest Ecology and Management, V108, P147, DOI 10.1016/S0378-1127(98)00222-9; Fearnside PM, 1997, CLIMATIC CHANGE, V35, P321, DOI 10.1023/A:1005336724350; FEARNSIDE PM, 1992, INTERCIENCIA, V17, P19; FEARNSIDE PM, 1993, J GEOPHYS RES-ATMOS, V98, P16733, DOI 10.1029/93JD01140; FISHER MJ, 1994, NATURE, V371, P236, DOI 10.1038/371236a0; HALL CAS, 1991, CAN J FOREST RES, V21, P118, DOI 10.1139/x91-016; HOUGHTON R A, 1987, Tellus Series B Chemical and Physical Meteorology, V39, P122; Houghton RA, 1999, TELLUS B, V51, P298, DOI 10.1034/j.1600-0889.1999.00013.x; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; MORAN EF, 1994, BIOSCIENCE, V44, P329, DOI 10.2307/1312383; Neill C, 1996, OECOLOGIA, V107, P113, DOI 10.1007/BF00582241; NEPSTAD DC, 1991, AMBIO, V20, P248; Nepstad DC, 1999, NATURE, V398, P505, DOI 10.1038/19066; Prentice IC, 1998, NATURE, V396, P619, DOI 10.1038/25224; Rayner PJ, 1999, TELLUS B, V51, P213, DOI 10.1034/j.1600-0889.1999.t01-1-00008.x; SCHROEDER PE, 1995, FOREST ECOL MANAG, V75, P87, DOI 10.1016/0378-1127(95)03533-G; SKOLE DL, 1994, BIOSCIENCE, V44, P314, DOI 10.2307/1312381; Tian HQ, 1998, NATURE, V396, P664, DOI 10.1038/25328	30	502	610	6	173	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					301	304		10.1038/35002062	http://dx.doi.org/10.1038/35002062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659847				2022-12-01	WOS:000084899700050
J	Pestova, TV; Lomakin, IB; Lee, JH; Choi, SK; Dever, TE; Hellen, CUT				Pestova, TV; Lomakin, IB; Lee, JH; Choi, SK; Dever, TE; Hellen, CUT			The joining of ribosomal subunits in eukaryotes requires eIF5B	NATURE			English	Article							TRANSLATION INITIATION; PROTEIN-SYNTHESIS; RABBIT RETICULOCYTES; FACTOR-5; PURIFICATION; COMPLEX; BINDING; CODON	Initiation of eukaryotic protein synthesis begins with the ribosome separated into its 40S and 60S subunits(1). The 40S subunit first binds eukaryotic initiation factor (eIF) 3 and an eIF2-GTP-initiator transfer RNA ternary complex. The resulting complex requires eIF1, eIF1A, eIF4A, eIF4B and eIF4F to bind to a messenger RNA and to scan to the initiation codon(2). eIF5 stimulates hydrolysis of eIF2-bound GTP and eIF2 is released from the 48S complex formed at the initiation codon before it is joined by a 60S subunit to form an active 80S ribosome(3-8). Here we show that hydrolysis of eIF2-bound GTP induced by eIF5 in 48S complexes is necessary but not sufficient for the subunits to join. A second factor termed eIF5B (relative molecular mass 175,000) is essential for this process. It is a homologue of the prokaryotic initiation factor IF2 (refs 6, 7) and, like it(8-12), mediates joining of subunits and has a ribosome-dependent GTPase activity that is essential for its function.	SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Brooklyn, NY 11203 USA; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Lomonosov Moscow State University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Pestova, TV (corresponding author), SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, 450 Clarkson Ave, Brooklyn, NY 11203 USA.		Dever, Thomas/GSE-0966-2022	Lomakin, Ivan/0000-0001-6528-5068; Dever, Thomas/0000-0001-7120-9678	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004, ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010, Z01HD001004] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENNE R, 1978, J BIOL CHEM, V253, P3070; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; Choi SK, 1998, SCIENCE, V280, P1757, DOI 10.1126/science.280.5370.1757; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; GODEFROYCOLBURN T, 1975, J MOL BIOL, V94, P461, DOI 10.1016/0022-2836(75)90215-6; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; KOLAKOFSKY D, 1968, P NATL ACAD SCI USA, V61, P1066, DOI 10.1073/pnas.61.3.1066; Lee JH, 1999, P NATL ACAD SCI USA, V96, P4342, DOI 10.1073/pnas.96.8.4342; LOCKWOOD AH, 1972, P NATL ACAD SCI USA, V69, P3602, DOI 10.1073/pnas.69.12.3602; Luchin S, 1999, J BIOL CHEM, V274, P6074, DOI 10.1074/jbc.274.10.6074; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; SACERDOT C, 1984, P NATL ACAD SCI-BIOL, V81, P7787, DOI 10.1073/pnas.81.24.7787; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8	17	295	299	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					332	335		10.1038/35002118	http://dx.doi.org/10.1038/35002118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659855				2022-12-01	WOS:000084899700058
J	Lee, TH; Cleeman, JI; Grundy, SM; Gillett, C; Pasternak, RC; Seidman, J; Sennett, C				Lee, TH; Cleeman, JI; Grundy, SM; Gillett, C; Pasternak, RC; Seidman, J; Sennett, C			Clinical coals and performance measures for cholesterol management in secondary prevention of coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERUM-CHOLESTEROL; LOWERING THERAPY; EVENTS; RISK; PRAVASTATIN; REDUCTION; PROGRAM; TRIAL; DEATH	Guidelines from the National Cholesterol Education Program (NCEP) recommend reduction of low-density lipoprotein cholesterol (LDL-C) to 100 mg/dL (2.59 mmol/l)or less in patients with established coronary heart disease (CHD), However, the National Committee for Quality Assurance (NCQA) is implementing a new performance measure as part of the Health Plan Employer and Data Information Set (HEDIS) that appears to endorse a different target. The new HEDIS measure will require managed care organizations seeking NCQA accreditation to measure and report the percentage of patients who have had major CHD events who achieve LDL-C levels less than 130 mg/dL (3.36 mmol/L) between 60 and 365 days after discharge. These different LDL-C thresholds emphasize the difference between a clinical goal for the management of individual patients (less than or equal to 100 mg/dL) and a performance measure used to evaluate the care of a population of patients (<130 mg/dL), This article discusses the rationale for each threshold and explains the use of 2 different thresholds for these 2 purposes. Both the NCQA and NCEP expect that the new HEDIS measure will encourage managed care organizations to develop systems that improve secondary prevention of CHD.	Partners Community HealthCare Inc, Boston, MA 02199 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; NHLBI, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Grp Hlth Cooperat Puget Sound, Clin Planning & Improvement, Seattle, WA 98121 USA; Natl Comm Qual Assurance, Washington, DC USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Group Health Cooperative	Lee, TH (corresponding author), Partners Community HealthCare Inc, Prudential Tower,Suite 1150,800 Boylston St, Boston, MA 02199 USA.	thlee@partners.org						BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; Campeau L, 1997, NEW ENGL J MED, V336, P153; Grundy SM, 1998, CIRCULATION, V97, P1436; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; McBride P, 1998, ARCH INTERN MED, V158, P1238, DOI 10.1001/archinte.158.11.1238; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 1998, CIRCULATION, V97, P1453, DOI 10.1161/01.CIR.97.15.1453; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sacks FM, 1998, CIRCULATION, V97, P1446; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SMITH SC, 1995, CIRCULATION, V92, P2; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	16	36	37	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					94	98		10.1001/jama.283.1.94	http://dx.doi.org/10.1001/jama.283.1.94			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632286				2022-12-01	WOS:000084514400031
J	Davis, SJ; Vener, AV; Vierstra, RD				Davis, SJ; Vener, AV; Vierstra, RD			Bacteriophytochromes: Phytochrome-like photoreceptors from nonphotosynthetic eubacteria	SCIENCE			English	Article							DEINOCOCCUS-RADIODURANS	Phytochromes are a family of photoreceptors used by green plants to entrain their development to the light environment. The distribution of these chromoproteins has been expanded beyond photoautotrophs with the discovery of phytochrome-like proteins in the nonphotosynthetic eubacteria Deinococcus radiodurans and Pseudomonas aeruginosa. Like plant phytochromes, the D. radiodurans receptor covalently binds Linear tetrapyrroles autocatalytically to generate a photochromic holoprotein. However, the attachment site is distinct, using a histidine to potentially form a Schiff base Linkage. Sequence homology and mutational analysis suggest that D. radiodurans bacteriophytochrome functions as a Light-regulated histidine kinase, which helps protect the bacterium from visible Light.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Hort, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Vierstra, RD (corresponding author), Univ Wisconsin, Genet Lab, 1575 Linden Dr, Madison, WI 53706 USA.							Bhoo SH, 1997, J AM CHEM SOC, V119, P11717, DOI 10.1021/ja972875s; Davis S.M, UNPUB; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Gupta RS, 1998, J MOL EVOL, V46, P716, DOI 10.1007/PL00006352; GUTMAN PD, 1993, J BACTERIOL, V175, P3581, DOI 10.1128/jb.175.11.3581-3590.1993; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jiang ZY, 1999, SCIENCE, V285, P406, DOI 10.1126/science.285.5426.406; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Lamparter T, 1997, P NATL ACAD SCI USA, V94, P11792, DOI 10.1073/pnas.94.22.11792; Lemee L, 1997, TETRAHEDRON, V53, P919, DOI 10.1016/S0040-4020(96)01036-8; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Schneider-Poetsch HAW, 1998, PHYSIOL PLANTARUM, V102, P612, DOI 10.1034/j.1399-3054.1998.1020417.x; VIERSTRA RD, 1983, BIOCHEMISTRY-US, V22, P2498, DOI 10.1021/bi00279a029; vonLintig J, 1997, PLANT J, V12, P625, DOI 10.1046/j.1365-313X.1997.00625.x; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	18	275	292	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2517	2520		10.1126/science.286.5449.2517	http://dx.doi.org/10.1126/science.286.5449.2517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617469				2022-12-01	WOS:000084429700052
J	Burke, R; Nellen, D; Bellotto, M; Hafen, E; Senti, KA; Dickson, BJ; Basler, K				Burke, R; Nellen, D; Bellotto, M; Hafen, E; Senti, KA; Dickson, BJ; Basler, K			Dispatched, a novel sterol-sensing domain protein dedicated to the release of cholesterol-modified hedgehog from signaling cells	CELL			English	Article							DROSOPHILA-MELANOGASTER; SONIC HEDGEHOG; TRANSDUCING HEDGEHOG; GENE-EXPRESSION; PATCHED HOMOLOG; EGF RECEPTOR; PATTERN; POLARITY; INDUCTION; MUTATIONS	Members of the Hedgehog (Hh) family of secreted signaling proteins function as potent short-range organizers in animal development. Their range of action is limited by a C-terminal cholesterol tether and the upregulation of Patched (Ptc) receptor levels. Here we identify a novel segment-polarity gene in Drosophila, dispatched (disp), and demonstrate that its product is required in sending cells for normal Hh function. In the absence of Disp, cholesterol-modified but not cholesterol-free Hh is retained in these cells, indicating that Disp functions to release cholesterol-anchored Hh. Despite their opposite roles, Disp and Ptc share structural homology in the form of a sterol-sensing domain, suggesting that release and sequestration of cholesterol-modified Hh may be based on related molecular pathways.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich	Basler, K (corresponding author), Univ Zurich, Inst Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Dickson, Barry/AAE-7632-2019; Senti, Kirsten-Andre/AAB-3036-2020	Dickson, Barry/0000-0003-0715-892X; Basler, Konrad/0000-0003-3534-1529; Senti, Kirsten-Andre/0000-0002-7208-7593; Burke, Richard/0000-0003-0086-0767				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Beachy PA, 1997, COLD SPRING HARB SYM, V62, P191; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1998, DEVELOPMENT, V125, P4943; Chou TB, 1996, GENETICS, V144, P1673; COUSO JP, 1994, DEVELOPMENT, V120, P621; Deak P, 1997, GENETICS, V147, P1697; FORBES AJ, 1993, DEVELOPMENT, P115; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Golembo M, 1996, DEVELOPMENT, V122, P3363; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Marigo V, 1996, DEVELOPMENT, V122, P1225; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Mullor JL, 1997, DEVELOPMENT, V124, P1227; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; NEWSOME TP, 2000, IN PRESS DEVELOPMENT; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Osborne TF, 1998, CURR OPIN LIPIDOL, V9, P137, DOI 10.1097/00041433-199804000-00010; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Pignoni F, 1997, DEVELOPMENT, V124, P271; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; SLUSARSKI DC, 1995, GENETICS, V139, P229; Strigini M, 1997, DEVELOPMENT, V124, P4697; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	54	413	433	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					803	815		10.1016/S0092-8674(00)81677-3	http://dx.doi.org/10.1016/S0092-8674(00)81677-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619433	Bronze, Green Accepted			2022-12-01	WOS:000084488200013
J	Santoro, F; Kennedy, PE; Locatelli, G; Malnati, MS; Berger, EA; Lusso, P				Santoro, F; Kennedy, PE; Locatelli, G; Malnati, MS; Berger, EA; Lusso, P			CD46 is a cellular receptor for human herpesvirus 6	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; COFACTOR PROTEIN CD46; ACCELERATING FACTOR CD55; MEASLES-VIRUS; MARROW TRANSPLANTATION; FATAL ENCEPHALITIS; EXANTHEM-SUBITUM; DOWN-REGULATION; VARIANT-A; INFECTION	Human herpesvirus 6 (HHV-6) is the etiologic agent of exanthema subitum, causes opportunistic infections in immunocompromised patients, and has been implicated in multiple sclerosis and in the progression of AIDS. Here, we show that the two major HHV-6 subgroups (A and B) use human CD46 as a cellular receptor. Downregulation of surface CD46 was documented during the course of HHV-6 infection. Both acute infection and cell fusion mediated by HHV-6 were specifically inhibited by a monoclonal antibody to CD46; fusion was also blocked by soluble CD46. Nonhuman cells that were resistant to HHV-6 fusion and entry became susceptible upon expression of recombinant human CD46. The use of a ubiquitous immunoregulatory receptor opens novel perspectives for understanding the tropism and pathogenicity of HHV-6.	San Raffaele Sci Inst, DIBIT, Unit Human Virol, I-20132 Milan, Italy; Univ Bologna, Dept Clin & Expt Med, I-40138 Bologna, Italy; NIAID, Viral Dis Lab, Bethesda, MD 20894 USA	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Bologna; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lusso, P (corresponding author), San Raffaele Sci Inst, DIBIT, Unit Human Virol, I-20132 Milan, Italy.		Malnati, Mauro/AAN-4207-2020	Malnati, mauro/0000-0001-5355-1680	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000733, ZIAAI000733] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABLASHI DV, 1991, VIROLOGY, V184, P545, DOI 10.1016/0042-6822(91)90424-A; ASANO Y, 1992, ARCH DIS CHILD, V67, P1484, DOI 10.1136/adc.67.12.1484; AUBIN JT, 1991, J CLIN MICROBIOL, V29, P367, DOI 10.1128/JCM.29.2.367-372.1991; BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Braun DK, 1997, CLIN MICROBIOL REV, V10, P521, DOI 10.1128/CMR.10.3.521; BRODER CC, 1993, J VIROL, V67, P913, DOI 10.1128/JVI.67.2.913-926.1993; Buckland R, 1997, VIRUS RES, V48, P1, DOI 10.1016/S0168-1702(96)01421-9; Campadelli-Fiume G, 1999, EMERG INFECT DIS, V5, P353, DOI 10.3201/eid0503.990306; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CHEN M, 1994, J VIROL, V68, P1173, DOI 10.1128/JVI.68.2.1173-1178.1994; CONE RW, 1993, NEW ENGL J MED, V329, P156, DOI 10.1056/NEJM199307153290302; CORBELLINO M, 1993, LANCET, V342, P1242, DOI 10.1016/0140-6736(93)92226-J; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Dorig Ruth E., 1994, Trends in Microbiology, V2, P312, DOI 10.1016/0966-842X(94)90447-2; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; DROBYSKI WR, 1994, NEW ENGL J MED, V330, P1356, DOI 10.1056/NEJM199405123301905; Emery VC, 1999, J MED VIROL, V57, P278, DOI 10.1002/(SICI)1096-9071(199903)57:3&lt;278::AID-JMV11&gt;3.0.CO;2-3; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; Ghali M, 1998, J NEUROVIROL, V4, P521, DOI 10.3109/13550289809113496; Gobbi A, 1999, J EXP MED, V189, P1953, DOI 10.1084/jem.189.12.1953; Hall CB, 1998, CLIN INFECT DIS, V26, P132, DOI 10.1086/516280; Hirano A, 1999, J VIROL, V73, P4776, DOI 10.1128/JVI.73.6.4776-4785.1999; ISHIGURO N, 1990, ACTA PAEDIATR SCAND, V79, P987, DOI 10.1111/j.1651-2227.1990.tb11369.x; Jacobson S, 1998, J NEUROVIROL, V4, P471, DOI 10.3109/13550289809113491; JARVIS JN, 1995, J ACQ IMMUN DEF SYND, V9, P249; Kallstrom H, 1997, MOL MICROBIOL, V25, P639, DOI 10.1046/j.1365-2958.1997.4841857.x; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; KNOX KK, 1995, CLIN INFECT DIS, V20, P406, DOI 10.1093/clinids/20.2.406; KNOX KK, 1994, LANCET, V343, P577, DOI 10.1016/S0140-6736(94)91524-5; KNOX KK, 1995, J MED VIROL, V45, P288, DOI 10.1002/jmv.1890450309; Kositanont U, 1999, J INFECT DIS, V180, P50, DOI 10.1086/314826; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; LOPEZ C, 1988, J INFECT DIS, V157, P1271, DOI 10.1093/infdis/157.6.1271; Lusso P, 1996, ANTIVIR RES, V31, P1, DOI 10.1016/0166-3542(96)00949-7; LUSSO P, 1994, P NATL ACAD SCI USA, V91, P3872, DOI 10.1073/pnas.91.9.3872; LUSSO P, 1989, LANCET, V1, P730; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; MONTEFIORI DC, 1994, VIROLOGY, V205, P82, DOI 10.1006/viro.1994.1622; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NUSSBAUM O, 1995, J VIROL, V69, P3341, DOI 10.1128/JVI.69.6.3341-3349.1995; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; OKADA N, 1995, P NATL ACAD SCI USA, V92, P2489, DOI 10.1073/pnas.92.7.2489; Oldstone MBA, 1999, CELL, V98, P629, DOI 10.1016/S0092-8674(00)80050-1; QAVI HB, 1992, CURR EYE RES, V11, P315, DOI 10.3109/02713689209001785; Randhawa PS, 1997, AM J SURG PATHOL, V21, P847, DOI 10.1097/00000478-199707000-00014; Sakata H, 1998, BIOL PHARM BULL, V21, P1121; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHIRMER EC, 1991, P NATL ACAD SCI USA, V88, P5922, DOI 10.1073/pnas.88.13.5922; SCHNORR JJ, 1995, EUR J IMMUNOL, V25, P976, DOI 10.1002/eji.1830250418; SEYA T, 1995, MICROBIOL IMMUNOL, V39, P295, DOI 10.1111/j.1348-0421.1995.tb02205.x; Tsujimura A, 1998, BIOCHEM J, V330, P163, DOI 10.1042/bj3300163; Tufaro F, 1997, TRENDS MICROBIOL, V5, P257, DOI 10.1016/S0966-842X(97)01057-3; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; YAMANISHI K, 1988, LANCET, V1, P1065; YEFENOF E, 1976, INT J CANCER, V17, P693, DOI 10.1002/ijc.2910170602	60	394	413	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					817	827		10.1016/S0092-8674(00)81678-5	http://dx.doi.org/10.1016/S0092-8674(00)81678-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619434	Bronze			2022-12-01	WOS:000084488200014
J	Shadick, NA; Phillips, CB; Sangha, O; Logigian, EL; Kaplan, RF; Wright, EA; Fossel, AH; Fossel, K; Berardi, V; Lew, RA; Liang, MH				Shadick, NA; Phillips, CB; Sangha, O; Logigian, EL; Kaplan, RF; Wright, EA; Fossel, AH; Fossel, K; Berardi, V; Lew, RA; Liang, MH			Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease	ANNALS OF INTERNAL MEDICINE			English	Article							ARTHRITIS; SERODIAGNOSIS; FIBROMYALGIA; POPULATION; FEATURES; CHILDREN	Background: Previous follow-up studies of patients with Lyme disease suggest that disseminated infection may be associated with long-term neurologic and musculoskeletal morbidity. Objective: To determine clinical and functional outcomes in persons who were treated for Lyme disease in the late 1980s. Design: Population-based, retrospective cohort study. Setting: Nantucket Island, Massachusetts. Participants: 186 persons who had a history of Lyme disease (case-patients) and 167 persons who did not (controls). Measurements: Standardized medical history, physical examination, functional status measure (Medical Outcomes Study 36-item Short Form Health Survey [SF-36]), mood state assessment (Profile of Mood States), neurocognitive tests, and serologic examination. Results: The prevalence of Lyme disease among adults on Nantucket Island was estimated to be 14.3% (95% CI, 9.3% to 19.1%). In multivariate analyses, persons with previous Lyme disease (mean time from infection to study evaluation, 6.0 years) had more joint pain (odds ratio for having joint pain in any joint, 2.1 [CI, 1.2 to 3.5]; P = 0.007), more symptoms of memory impairment (odds ratio for having any memory problem, 1.9 [CI, 1.1 to 3.5]; P = 0.003), and poorer functional status due to pain (odds ratio for 1 point on the SF-36 scale, 1.02 [CI, 1.01 to 1.03]; P < 0.001) than persons without previous Lyme disease. However, on physical examination, case-patients and controls did not differ in musculoskeletal abnormalities, neurologic abnormalities, or neurocognitive performance. Persons with previous Lyme disease who had persistent symptoms after receiving treatment (n = 67) were more likely than those who had completely recovered to have had fever, headache, photosensitivity, or neck stiffness during their acute illness (87% compared with 13%; odds ratio, 2.4 [CI, 1.0 to 5.5]; P = 0.045); however, the performance of the two groups on neurocognitive tests did not significantly differ. Conclusions: Because persons with previous Lyme disease exhibited no sequelae on physical examination and neurocognitive tests a mean of 6.0 years after infection, musculoskeletal and neurocognitive outcomes seem to be favorable. However, long-term impairment of functional status can occur.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Rochester, Sch Med & Dent, Rochester, NY USA; Univ Munich, Bavarian Publ Hlth Res Ctr, Sch Med, Munich, Germany; Univ Connecticut, Ctr Hlth, Farmington, CT USA; IMUGEN Inc, Norwood, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Rochester; University of Munich; University of Connecticut	Shadick, NA (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36308] Funding Source: Medline; PHS HHS [02033] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*ACR GLOSS COMM, 1982, DICT RHEUM DIS, V1; ASCH ES, 1994, J RHEUMATOL, V21, P454; BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; BOLLA KI, 1991, ARCH NEUROL-CHICAGO, V48, P61, DOI 10.1001/archneur.1991.00530130069022; BROADBENT DE, 1992, BR J CLIN PSYCHOL, V21, P1; Bujak DI, 1996, J RHEUMATOL, V23, P1392; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DELIS D, 1988, PSYCHOL CORPORATION; Dillman DA, 1978, MAIL TELEPHONE SURVE; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; Gerber MA, 1996, NEW ENGL J MED, V335, P1270, DOI 10.1056/NEJM199610243351703; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HERMAN D, 1988, CLIN NEUROPSYCHOL, V2, P102; KALISH RA, 1993, INFECT IMMUN, V61, P2774, DOI 10.1128/IAI.61.7.2774-2779.1993; Kaplan RF, 1997, SEMIN NEUROL, V17, P31, DOI 10.1055/s-2008-1040910; LARRABEE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P275, DOI 10.1080/01688638608401318; LOGIGIAN EL, 1992, NEUROLOGY, V42, P303, DOI 10.1212/WNL.42.2.303; MCNAIR DM, 1996, MANUAL PROFILE MOOD; MILLER GL, 1992, 5 INT C LYM BORR ARL; NOKOA K, 1990, GEN SOCIAL SURVEY ME, V70, P1; *PURD RES FDN, 1948, EX MAN PURD PEGB; S.A.S. Institute, 1990, SAS STAT US GUID; Sangha O, 1998, ANN INTERN MED, V128, P346, DOI 10.7326/0003-4819-128-5-199803010-00002; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; *STAT CT DEP PUBL, 1995, CONNECTICUT EPIDEMIO, V15, P185; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; US Army, 1944, ARM IND TEST BATT MA; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; 1996, MMWR MORB MORTAL WKL, V45, P481; 1990, MMWR MORB MORTAL WKL, V39, P19	37	114	114	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					919	+		10.7326/0003-4819-131-12-199912210-00003	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610642				2022-12-01	WOS:000084374400002
J	Couse, JF; Hewitt, SC; Bunch, DO; Sar, M; Walker, VR; Davis, BJ; Korach, KS				Couse, JF; Hewitt, SC; Bunch, DO; Sar, M; Walker, VR; Davis, BJ; Korach, KS			Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta	SCIENCE			English	Article							MULLERIAN-INHIBITING SUBSTANCE; TARGETED DISRUPTION; SERTOLI CELLS; MOUSE; GENE; EXPRESSION; HORMONE; DIFFERENTIATION; TESTIS; DIETHYLSTILBESTROL	Mice lacking estrogen receptors alpha and beta were generated to clarify the roles of each receptor in the physiology of estrogen target tissues. Both sexes of alpha beta estrogen receptor knockout (alpha beta ERKO) mutants exhibit normal reproductive tract development but are infertile. Ovaries of adult alpha beta ERKO females exhibit follicle transdifferentiation to structures resembling seminiferous tubules of the testis, including Sertoli-like cells and expression of Mullerian inhibiting substance, sulfated glycoprotein-2, and Sox9, Therefore, Loss of both receptors Leads to an ovarian phenotype that is distinct from that of the individual ERKO mutants, which indicates that both receptors are required for the maintenance of germ and somatic cells in the postnatal ovary.	NIEHS, Receptor Biol Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Expt Pathol, NIH, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Dept Cell Biol, Reprod Biol Lab, Chapel Hill, NC 27599 USA; Chem Ind Inst Toxicol, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	Korach, KS (corresponding author), NIEHS, Receptor Biol Sect, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	korach@niehs.nih.gov	Hewitt, Sylvia/W-8752-2019	Hewitt, Sylvia/0000-0001-7713-0805; Bunch, Donna/0000-0002-3638-0522; Korach, Kenneth/0000-0002-7765-418X				BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; FITZPATRICK L, 1990, ENDOCRINOLOGY, V140, P2581; Flaws JA, 1997, BIOL REPROD, V57, P1233, DOI 10.1095/biolreprod57.5.1233; GRECO TL, 1993, ENDOCR REV, V14, P59, DOI 10.1210/er.14.1.59; GUERRIER D, 1990, J REPROD FERTIL, V88, P695; GURAYA SS, 1995, INT REV CYTOL, V160, P163, DOI 10.1016/S0074-7696(08)61555-7; HASHIMOTO N, 1990, J EXP ZOOL, V253, P61, DOI 10.1002/jez.1402530109; JOST A, 1970, MAMMALIAN REPRODUCTI, P4; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; KURODA T, 1991, ENDOCRINOLOGY, V129, P2985, DOI 10.1210/endo-129-6-2985; Lindzey J, 1998, ENDOCRINOLOGY, V139, P4092, DOI 10.1210/en.139.10.4092; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; Robertson KM, 1999, P NATL ACAD SCI USA, V96, P7986, DOI 10.1073/pnas.96.14.7986; Sharma SC, 1999, ENDOCRINOLOGY, V140, P4320, DOI 10.1210/en.140.9.4320; TAKETO T, 1991, ANN NY ACAD SCI, V637, P74, DOI 10.1111/j.1749-6632.1991.tb27302.x; VIGIER B, 1987, DEVELOPMENT, V100, P43; Visser JA, 1998, ENDOCRINOLOGY, V139, P4244, DOI 10.1210/en.139.10.4244; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WENIGER JP, 1990, J DEV PHYSIOL, V14, P303; Whitworth DJ, 1998, TRENDS ENDOCRIN MET, V9, P2, DOI 10.1016/S1043-2760(98)00002-2; WU TCJ, 1992, MOL REPROD DEV, V33, P407, DOI 10.1002/mrd.1080330406; WU TCJ, 1993, FERTIL STERIL, V59, P54; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759	28	427	445	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2328	2331		10.1126/science.286.5448.2328	http://dx.doi.org/10.1126/science.286.5448.2328			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600740	Green Submitted			2022-12-01	WOS:000084318500057
J	Lin, XY; Kaul, SS; Rounsley, S; Shea, TP; Benito, MI; Town, CD; Fujii, CY; Mason, T; Bowman, CL; Barnstead, M; Feldblyum, TV; Buell, CR; Ketchum, KA; Lee, J; Ronning, CM; Koo, HL; Moffat, KS; Cronin, LA; Shen, M; Pai, G; Van Aken, S; Umayam, L; Tallon, LJ; Gill, JE; Adams, MD; Carrera, AJ; Creasy, TH; Goodman, HM; Somerville, CR; Copenhaver, GP; Preuss, D; Nierman, WC; White, O; Eisen, JA; Salzberg, SL; Fraser, CM; Venter, JC				Lin, XY; Kaul, SS; Rounsley, S; Shea, TP; Benito, MI; Town, CD; Fujii, CY; Mason, T; Bowman, CL; Barnstead, M; Feldblyum, TV; Buell, CR; Ketchum, KA; Lee, J; Ronning, CM; Koo, HL; Moffat, KS; Cronin, LA; Shen, M; Pai, G; Van Aken, S; Umayam, L; Tallon, LJ; Gill, JE; Adams, MD; Carrera, AJ; Creasy, TH; Goodman, HM; Somerville, CR; Copenhaver, GP; Preuss, D; Nierman, WC; White, O; Eisen, JA; Salzberg, SL; Fraser, CM; Venter, JC			Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana	NATURE			English	Article							REPETITIVE DNA; MITOCHONDRIAL GENOME; REGIONS; LIBRARY; MAP; RNA; CONSTRUCTION; DUPLICATION; PREDICTION; CENTROMERE	Arabidopsis thaliana (Arabidopsis) is unique among plant model organisms in having a small genome (130-140 Mb), excellent physical and genetic maps, and little repetitive DNA. Here we report the sequence of chromosome 2 from the Columbia ecotype in two gap-free assemblies (contigs) of 3.6 and 16 megabases (Mb). The latter represents the longest published stretch of uninterrupted DNA sequence assembled from any organism to date. Chromosome 2 represents 15% of the genome and encodes 4,037 genes, 49% of which have no predicted function. Roughly 250 tandem gene duplications were found in addition to large-scale duplications of about 0.5 and 4.5 Mb between chromosomes 2 and 1 and between chromosomes 2 and 4, respectively. Sequencing of nearly 2 Mb within the genetically defined centromere revealed a low density of recognizable genes, and a high density and diverse range of vestigial and presumably inactive mobile elements. More unexpected is what appears to be a recent insertion of a continuous stretch of 75% of the mitochondrial genome into chromosome 2.	Inst Genom Res, Rockville, MD 20850 USA	J. Craig Venter Institute	Venter, JC (corresponding author), Cereon Genom, 270 Albany St, Cambridge, MA 02139 USA.	jcventer@celera.com	Eisen, Jonathan A./H-2706-2019; Salzberg, Steven L/F-6162-2011; Copenhaver, Gregory/AAH-2031-2022; Copenhaver, Gregory/AFL-9831-2022; Copenhaver, Gregory P/A-7549-2014; Salzberg, Steven/Q-6514-2019; Somerville, Christopher R/A-4048-2009	Eisen, Jonathan A./0000-0002-0159-2197; Salzberg, Steven L/0000-0002-8859-7432; Copenhaver, Gregory/0000-0002-7962-3862; Copenhaver, Gregory/0000-0002-7962-3862; Copenhaver, Gregory P/0000-0002-7962-3862; Salzberg, Steven/0000-0002-8859-7432; Somerville, Christopher R/0000-0003-4647-0094; Fraser, Claire/0000-0003-1462-2428; Buell, C Robin/0000-0002-6727-4677				Bevan M, 1997, PLANT CELL, V9, P476, DOI 10.1105/tpc.9.4.476; BEVAN M, 1998, NATURE, V391, P485; BLANCHARD JL, 1995, J MOL EVOL, V41, P397, DOI 10.1007/BF00160310; Brandes A, 1997, CHROMOSOME RES, V5, P238, DOI 10.1023/A:1018415502795; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Copenhaver GP, 1996, PLANT J, V9, P273, DOI 10.1046/j.1365-313X.1996.09020273.x; COPENHAVER GP, 1995, PLANT J, V7, P273, DOI 10.1046/j.1365-313X.1995.7020273.x; Copenhaver GP, 1996, PLANT J, V9, P259, DOI 10.1046/j.1365-313X.1996.09020259.x; COPENHAVER GP, IN PRESS SCIENCE; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P2369, DOI 10.1093/nar/27.11.2369; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Huang XQ, 1997, GENOMICS, V46, P37, DOI 10.1006/geno.1997.4984; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; KLEIN M, 1994, PLANT J, V6, P447, DOI 10.1046/j.1365-313X.1994.06030447.x; LEETE E, 1990, PLANTA MED, V56, P339, DOI 10.1055/s-2006-960979; LIU YG, 1995, PLANT J, V7, P351, DOI 10.1046/j.1365-313X.1995.7020351.x; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MALUSZYNSKA J, 1991, PLANT J, V1, P159, DOI 10.1111/j.1365-313X.1991.00159.x; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; RICHARDS EJ, 1992, NUCLEIC ACIDS RES, V20, P4039, DOI 10.1093/nar/20.15.4039; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; SCHMIDT R, 1993, BIOESSAYS, V15, P63, DOI 10.1002/bies.950150110; Schweizer D, 1987, Results Probl Cell Differ, V14, P235; SIMOENS CR, 1988, NUCLEIC ACIDS RES, V16, P6753, DOI 10.1093/nar/16.14.6753; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; Sutton G.G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Terryn N, 1999, FEBS LETT, V445, P237, DOI 10.1016/S0014-5793(99)00097-6; Thompson H, 1996, MOL GEN GENET, V253, P247, DOI 10.1007/s004380050319; Thompson HL, 1996, NUCLEIC ACIDS RES, V24, P3017, DOI 10.1093/nar/24.15.3017; Thompson HL, 1996, PLANT MOL BIOL, V32, P553, DOI 10.1007/BF00019109; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Unseld M, 1997, NAT GENET, V15, P57, DOI 10.1038/ng0197-57; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yamada Y., 1990, SECONDARY PRODUCTS P, P227; Zachgo EA, 1996, GENOME RES, V6, P19, DOI 10.1101/gr.6.1.19	50	535	3223	6	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					761	+		10.1038/45471	http://dx.doi.org/10.1038/45471			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617197	Bronze			2022-12-01	WOS:000084330500053
J	Mayer, K; Schuller, C; Wambutt, R; Murphy, G; Volckaert, G; Pohl, T; Dusterhoft, A; Stiekema, W; Entian, KD; Terryn, N; Harris, B; Ansorge, W; Brandt, P; Grivell, L; Rieger, M; Weichselgartner, M; de Simone, V; Obermaier, B; Mache, R; Muller, M; Kreis, M; Delseny, M; Puigdomenech, P; Watson, M; Schmidtheini, T; Reichert, B; Portatelle, D; Perez-Alonso, M; Boutry, M; Bancroft, I; Vos, P; Hoheisel, J; Zimmermann, W; Wedler, H; Ridley, P; Langham, SA; McCullagh, B; Bilham, L; Robben, J; Van der Schueren, J; Grymonprez, B; Chuang, YJ; Vandenbussche, F; Braeken, M; Weltjens, I; Voet, M; Bastiaens, I; Aert, R; Defoor, E; Weitzenegger, T; Bothe, G; Ramsperger, U; Hilbert, H; Braun, M; Holzer, E; Brandt, A; Peters, S; van Staveren, M; Dirkse, W; Mooijman, P; Lankhorst, RK; Rose, M; Hauf, J; Kotter, P; Berneiser, S; Hempel, S; Feldpausch, M; Lamberth, S; Van den Daele, H; De Keyser, A; Buysshaert, C; Gielen, J; Villarroel, R; De Clercq, R; Van Montagu, M; Rogers, J; Cronin, A; Quail, M; Bray-Allen, S; Clark, L; Doggett, J; Hall, S; Kay, M; Lennard, N; McLay, K; Mayes, R; Pettett, A; Rajandream, MA; Lyne, M; Benes, V; Rechmann, S; Borkova, D; Blocker, H; Scharfe, M; Grimm, M; Lohnert, TH; Dose, S; de Haan, M; Maarse, A; Schafer, M; Muller-Auer, S; Gabel, C; Fuchs, M; Fartmann, B; Granderath, K; Dauner, D; Herzl, A; Neumann, S; Argiriou, A; Vitale, D; Liguori, R; Piravandi, E; Massenet, O; Quigley, F; Clabauld, G; Mundlein, A; Felber, R; Schnabl, S; Hiller, R; Schmidt, W; Lecharny, A; Aubourg, S; Chefdor, F; Cooke, R; Berger, C; Montfort, A; Casacuberta, E; Gibbons, T; Weber, N; Vandenbol, M; Bargues, M; Terol, J; Torres, A; Perez-Perez, A; Purnelle, B; Bent, E; Johnson, S; Tacon, D; Jesse, T; Heijnen, L; Schwarz, S; Scholler, P; Heber, S; Francs, P; Bielke, C; Frishman, D; Haase, D; Lemcke, K; Mewes, HW; Stocker, S; Zaccaria, P; Bevan, M; Wilson, RK; de la Bastide, M; Habermann, K; Parnell, L; Dedhia, N; Gnoj, L; Schutz, K; Huang, E; Spiegel, L; Sehkon, M; Murray, J; Sheet, P; Cordes, M; Abu-Threideh, J; Stoneking, T; Kalicki, J; Graves, T; Harmon, G; Edwards, J; Latreille, P; Courtney, L; Cloud, J; Abbott, A; Scott, K; Johnson, D; Minx, P; Bentley, D; Fulton, B; Miller, N; Greco, T; Kemp, K; Kramer, J; Fulton, L; Mardis, E; Dante, M; Pepin, K; Hillier, L; Nelson, J; Spieth, J; Ryan, E; Andrews, S; Geisel, C; Layman, D; Du, H; Ali, J; Berghoff, A; Jones, K; Drone, K; Cotton, M; Joshu, C; Antonoiu, B; Zidanic, M; Strong, C; Sun, H; Lamar, B; Yordan, C; Ma, P; Zhong, J; Preston, R; Vil, D; Shekher, M; Matero, A; Shah, R; Swaby, I				Mayer, K; Schuller, C; Wambutt, R; Murphy, G; Volckaert, G; Pohl, T; Dusterhoft, A; Stiekema, W; Entian, KD; Terryn, N; Harris, B; Ansorge, W; Brandt, P; Grivell, L; Rieger, M; Weichselgartner, M; de Simone, V; Obermaier, B; Mache, R; Muller, M; Kreis, M; Delseny, M; Puigdomenech, P; Watson, M; Schmidtheini, T; Reichert, B; Portatelle, D; Perez-Alonso, M; Boutry, M; Bancroft, I; Vos, P; Hoheisel, J; Zimmermann, W; Wedler, H; Ridley, P; Langham, SA; McCullagh, B; Bilham, L; Robben, J; Van der Schueren, J; Grymonprez, B; Chuang, YJ; Vandenbussche, F; Braeken, M; Weltjens, I; Voet, M; Bastiaens, I; Aert, R; Defoor, E; Weitzenegger, T; Bothe, G; Ramsperger, U; Hilbert, H; Braun, M; Holzer, E; Brandt, A; Peters, S; van Staveren, M; Dirkse, W; Mooijman, P; Lankhorst, RK; Rose, M; Hauf, J; Kotter, P; Berneiser, S; Hempel, S; Feldpausch, M; Lamberth, S; Van den Daele, H; De Keyser, A; Buysshaert, C; Gielen, J; Villarroel, R; De Clercq, R; Van Montagu, M; Rogers, J; Cronin, A; Quail, M; Bray-Allen, S; Clark, L; Doggett, J; Hall, S; Kay, M; Lennard, N; McLay, K; Mayes, R; Pettett, A; Rajandream, MA; Lyne, M; Benes, V; Rechmann, S; Borkova, D; Blocker, H; Scharfe, M; Grimm, M; Lohnert, TH; Dose, S; de Haan, M; Maarse, A; Schafer, M; Muller-Auer, S; Gabel, C; Fuchs, M; Fartmann, B; Granderath, K; Dauner, D; Herzl, A; Neumann, S; Argiriou, A; Vitale, D; Liguori, R; Piravandi, E; Massenet, O; Quigley, F; Clabauld, G; Mundlein, A; Felber, R; Schnabl, S; Hiller, R; Schmidt, W; Lecharny, A; Aubourg, S; Chefdor, F; Cooke, R; Berger, C; Montfort, A; Casacuberta, E; Gibbons, T; Weber, N; Vandenbol, M; Bargues, M; Terol, J; Torres, A; Perez-Perez, A; Purnelle, B; Bent, E; Johnson, S; Tacon, D; Jesse, T; Heijnen, L; Schwarz, S; Scholler, P; Heber, S; Francs, P; Bielke, C; Frishman, D; Haase, D; Lemcke, K; Mewes, HW; Stocker, S; Zaccaria, P; Bevan, M; Wilson, RK; de la Bastide, M; Habermann, K; Parnell, L; Dedhia, N; Gnoj, L; Schutz, K; Huang, E; Spiegel, L; Sehkon, M; Murray, J; Sheet, P; Cordes, M; Abu-Threideh, J; Stoneking, T; Kalicki, J; Graves, T; Harmon, G; Edwards, J; Latreille, P; Courtney, L; Cloud, J; Abbott, A; Scott, K; Johnson, D; Minx, P; Bentley, D; Fulton, B; Miller, N; Greco, T; Kemp, K; Kramer, J; Fulton, L; Mardis, E; Dante, M; Pepin, K; Hillier, L; Nelson, J; Spieth, J; Ryan, E; Andrews, S; Geisel, C; Layman, D; Du, H; Ali, J; Berghoff, A; Jones, K; Drone, K; Cotton, M; Joshu, C; Antonoiu, B; Zidanic, M; Strong, C; Sun, H; Lamar, B; Yordan, C; Ma, P; Zhong, J; Preston, R; Vil, D; Shekher, M; Matero, A; Shah, R; Swaby, I		European Union Arabidopsis Genome; Washington Univ; PE Biosystems Arabidopsis Sequenci	Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana	NATURE			English	Article							FISSION YEAST; DNA-SEQUENCES; GENOMIC DNA; MODEL-PLANT; REGIONS; RFLP; RNA; RECOMBINATION; PREDICTION; TELOMERE	The higher plant Arabidopsis thaliana (Arabidopsis) is an important model for identifying plant genes and determining their function. To assist biological investigations and to define chromosome structure, a coordinated effort to sequence the Arabidopsis genome was initiated in late 1996, Here we report one of the first milestones of this project, the sequence of chromosome 4. Analysis of 17.38 megabases of unique sequence, representing about 17% of the genome, reveals 3,744 protein coding genes, 81 transfer RNAs and numerous repeat elements. Heterochromatic regions surrounding the putative centromere, which has not yet been completely sequenced, are characterized by an increased frequency of a variety of repeats, new repeats, reduced recombination, lowered gene density and lowered gene expression. Roughly 60% of the predicted protein-coding genes have been functionally characterized on the basis of their homology to known genes. Many genes encode predicted proteins that are homologous to human and Caenorhabditis elegans proteins.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; GSF Forschungszentrum Umwelt & Gesundheit, Munich Informat Ctr Prot Sequences, Max Planck Inst Biochem, D-82152 Munich, Germany; AGOWA GmbH, D-12489 Berlin, Germany; Katholieke Univ Leuven, Lab Gene Technol, B-3001 Louvain, Belgium; GATC GmbH, D-78467 Constance, Germany; QIAGEN GmbH, D-40724 Hilden, Germany; DLO, CPRO, NL-6700 AA Wageningen, Netherlands; SRD GmbH, D-61440 Oberursel, Germany; Univ Ghent, Dept Genet, B-3000 Louvain, Belgium; Wellcome Trust Genome Campus, Hinxton CB10 1SA, Cambs, England; European Mol Biol Lab, Biochem Instrumentat Programme, D-69117 Heidelberg, Germany; GBF, D-38124 Braunschweig, Germany; Univ Amsterdam, Mol Biol Sect, Swammerdam Inst Life Sci, NL-1098 SM Amsterdam, Netherlands; Genotype GmbH, D-69259 Wilhelmsfeld, Germany; MWG AG Biotech, D-85554 Ebersberg, Germany; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Naples Federico II, CEINGE, I-80131 Naples, Italy; MediGenomix GmbH, DNA Analyt & Genom, D-82152 Planegg Martinsried, Germany; Univ Grenoble 1, Lab Plastes & Differenciat Cellulaire, UMR5575, F-38041 Grenoble, France; CNRS, F-38041 Grenoble, France; Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria; Univ Paris Sud, UMR CNRS 8618, Inst Biotechnol Plantes, F-91405 Orsay, France; Univ Perpignan, UMR CNRS 5545, Lab Physiol & Biol Mol Plantes, F-66860 Perpignan, France; CSIC, Inst Biol Mol Barcelona, Dept Mol Genet, Barcelona, Spain; Univ Durham, Dept Biol Sci, Durham DH1 3LE, England; Microsynth GmbH, CH-9436 Balgach, Switzerland; Baseclear, Leiden, Netherlands; Fac Univ Sci Agronom, Microbiol Unit, B-5030 Gembloux, Belgium; Univ Valencia, Dept Genet, Valencia 46100, Spain; Catholic Univ Louvain, FYSA, B-1348 Louvain, Belgium; Keygene NV, NL-6700 AE Wageningen, Netherlands; Deutsch Krebsforschungszentrum, Funct Genome Anal, D-69120 Heidelberg, Germany; Inst Plant Genet & Crop Plant Res IPK, D-06466 Gatersleben, Germany; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Cold Spring Harbor Lab, Lita Annenberg Hazen Genome Ctr, Cold Spring Harbor, NY 11724 USA; Cold Spring Harbor Lab, Cold Spring Harbor Plant Biol Grp, Cold Spring Harbor, NY 11724 USA; Appl Biosyst Inc, Foster City, CA 94494 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; KU Leuven; QIAGEN GmbH; Ghent University; Wellcome Trust Sanger Institute; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Helmholtz-Center for Infection Research; University of Amsterdam; University of Naples Federico II; CEINGE Biotecnologie Avanzate; University of Naples Federico II; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Vienna Biocenter (VBC); UDICE-French Research Universities; Universite Paris Saclay; Universite Perpignan Via Domitia; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Durham University; University of Valencia; Universite Catholique Louvain; Keygene N.V.; Helmholtz Association; German Cancer Research Center (DKFZ); Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Washington University (WUSTL); Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory; Thermo Fisher Scientific; Applied Biosystems	Bevan, M (corresponding author), John Innes Ctr Plant Sci Res, Colney Lane, Norwich NR4 7UH, Norfolk, England.	bevan@bbsrc.ac.uk	Muendlein, Axel/AAS-5313-2021; Mayer, Klaus FX/M-7941-2015; Marra, Marco A/B-5987-2008; Frishman, Dmitrij/AAT-7815-2020; Terol, Javier/H-6401-2013; Pérez-Alonso, Manuel/M-3333-2014; Bancroft, Ian/AAH-3831-2020; Quail, michael/ABE-6131-2020; Monfort, Amparo/K-1356-2015; Mardis, Elaine/W-2202-2019; Ansorge, Wilhelm/AAN-8780-2020; Entian, Karl-Dieter/D-3080-2011; Wilson, Richard K./AAF-4139-2019; Mewes, Hans-Werner/A-8204-2019	Mayer, Klaus FX/0000-0001-6484-1077; Marra, Marco A/0000-0001-7146-7175; Terol, Javier/0000-0003-3345-0078; Pérez-Alonso, Manuel/0000-0002-3266-0340; Monfort, Amparo/0000-0001-7106-7745; Wilson, Richard K./0000-0002-1992-1358; Casacuberta, Elena/0000-0002-8203-8357; Muendlein, Axel/0000-0002-5582-4125; Sander, Peters/0000-0002-2663-5149; Argiriou, Anagnostis/0000-0002-9164-632X; Kay, Mike/0000-0002-3282-0834; Bancroft, Ian/0000-0001-7707-1171; Schmidt, Wolfgang/0000-0002-6944-2443; Van den Daele, Hilde/0000-0002-4271-6694; Boutry, Marc/0000-0002-2315-6900; Benes, Vladimir/0000-0002-0352-2547; Mewes, Hans-Werner/0000-0002-9713-6398				ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bent E, 1998, PLANT J, V13, P849, DOI 10.1046/j.1365-313X.1998.00082.x; BEVAN M, 1998, NATURE, V391, P485; BORODOVSKY M, 1994, COMPUT CHEM, V18, P259, DOI 10.1016/0097-8485(94)85022-4; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; *C EL SEQ CONS, 1998, SCIENCE, V282, P2012; CHOI S, 1995, WEEDS WORLD, V2, P17; Copenhaver GP, 1996, PLANT J, V9, P273, DOI 10.1046/j.1365-313X.1996.09020273.x; Copenhaver GP, 1998, P NATL ACAD SCI USA, V95, P247, DOI 10.1073/pnas.95.1.247; Copenhaver GP, 1996, PLANT J, V9, P259, DOI 10.1046/j.1365-313X.1996.09020259.x; Douglas SE, 1998, CURR OPIN GENET DEV, V8, P655, DOI 10.1016/S0959-437X(98)80033-6; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; FICHANT GA, 1991, J MOL BIOL, V220, P659, DOI 10.1016/0022-2836(91)90108-I; Fransz P, 1998, PLANT J, V13, P867, DOI 10.1046/j.1365-313X.1998.00086.x; Gamas P, 1996, MOL PLANT MICROBE IN, V9, P233, DOI 10.1094/MPMI-9-0233; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gerstein M, 1997, J MOL BIOL, V274, P562, DOI 10.1006/jmbi.1997.1412; Grewal SIS, 1997, GENETICS, V146, P1221; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Henning KA, 1999, P NATL ACAD SCI USA, V96, P592, DOI 10.1073/pnas.96.2.592; Hubbard TJP, 1999, NUCLEIC ACIDS RES, V27, P254, DOI 10.1093/nar/27.1.254; Jensen RB, 1998, FEBS LETT, V436, P283, DOI 10.1016/S0014-5793(98)01143-0; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; Kotani H, 1997, DNA Res, V4, P291, DOI 10.1093/dnares/4.4.291; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mara M, 1999, NAT GENET, V22, P265, DOI 10.1038/10327; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Mewes HW, 1999, NUCLEIC ACIDS RES, V27, P44, DOI 10.1093/nar/27.1.44; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Mizutani M, 1998, PLANT MOL BIOL, V37, P39, DOI 10.1023/A:1005921406884; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Mozo T, 1999, NAT GENET, V22, P271, DOI 10.1038/10334; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Richards EJ, 1998, CURR OPIN PLANT BIOL, V1, P130, DOI 10.1016/S1369-5266(98)80014-9; RICHARDS EJ, 1991, NUCLEIC ACIDS RES, V19, P3351, DOI 10.1093/nar/19.12.3351; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; SCHAFFER AA, IN PRESS BIOINFORMAT; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X; Xu XJ, 1995, PLANT CELL, V7, P2151, DOI 10.1105/tpc.7.12.2151	50	291	2757	5	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					769	+		10.1038/47134	http://dx.doi.org/10.1038/47134			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617198				2022-12-01	WOS:000084330500054
J	Johnson, AP; Livermore, DM				Johnson, AP; Livermore, DM			Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal	LANCET			English	Editorial Material							STAPHYLOCOCCUS-AUREUS; VANCOMYCIN; BACTERIA		Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England	Public Health England	Johnson, AP (corresponding author), Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England.		Johnson, Alan P/F-4420-2014					Leclercq R, 1998, LANCET, V352, P591, DOI 10.1016/S0140-6736(05)79570-2; Low DE, 1997, J ANTIMICROB CHEMOTH, V39, P53, DOI 10.1093/jac/39.suppl_1.53; Moellering RC, 1999, J ANTIMICROB CHEMOTH, V44, P25, DOI 10.1093/jac/44.suppl_1.25; Moellering RC, 1999, J ANTIMICROB CHEMOTH, V44, P251, DOI 10.1093/jac/44.2.251; NADLER H, 1999, CLIN MICROBIOL NEWSL, V13, P103; Nichols RL, 1999, J ANTIMICROB CHEMOTH, V44, P19, DOI 10.1093/jac/44.suppl_1.19; Nichols RL, 1999, J ANTIMICROB CHEMOTH, V44, P263, DOI 10.1093/jac/44.2.263; Ploy MC, 1998, LANCET, V351, P1212, DOI 10.1016/S0140-6736(05)79166-2; Rubinstein E, 1999, J ANTIMICROB CHEMOTH, V44, P37, DOI 10.1093/jac/44.suppl_1.37; Tenover FC, 1998, J CLIN MICROBIOL, V36, P1020, DOI 10.1128/JCM.36.4.1020-1027.1998; Thal LA, 1999, J ANTIMICROB CHEMOTH, V43, P171, DOI 10.1093/jac/43.2.171; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725	12	28	29	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1999	354	9195					2012	2013		10.1016/S0140-6736(99)00344-X	http://dx.doi.org/10.1016/S0140-6736(99)00344-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636359				2022-12-01	WOS:000084183300002
J	Higashi, M; Takimoto, G; Yamamura, N				Higashi, M; Takimoto, G; Yamamura, N			Sympatric speciation by sexual selection	NATURE			English	Article							COSTLY MATE PREFERENCES; EVOLUTION; CHOICE; MODEL; DIVERSIFICATION; REINFORCEMENT; CICHLIDS		Kyoto Univ, Ctr Ecol Res, Kyoto 6068502, Japan	Kyoto University	Higashi, M (corresponding author), Kyoto Univ, Ctr Ecol Res, Kyoto 6068502, Japan.							Albertson RC, 1999, P NATL ACAD SCI USA, V96, P5107, DOI 10.1073/pnas.96.9.5107; BUSH GL, 1994, TRENDS ECOL EVOL, V9, P285, DOI 10.1016/0169-5347(94)90031-0; Deutsch JC, 1997, BIOL J LINN SOC, V62, P1; Dieckmann U, 1999, NATURE, V400, P354, DOI 10.1038/22521; Doebeli M, 1996, J EVOLUTION BIOL, V9, P893, DOI 10.1046/j.1420-9101.1996.9060893.x; Fisher R.A., 1930, GENETICAL THEORY NAT; IWASA Y, 1991, EVOLUTION, V45, P1431, DOI [10.2307/2409890, 10.1111/j.1558-5646.1991.tb02646.x]; Kawecki TJ, 1997, EVOLUTION, V51, P1751, DOI [10.2307/2410998, 10.1111/j.1558-5646.1997.tb05099.x]; KODRASHOV AS, 1999, NATURE, V400, P351; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; LIOU LW, 1994, EVOLUTION, V48, P1451, DOI 10.1111/j.1558-5646.1994.tb02187.x; MAYNARD SMITH J., 1966, AMER NATUR, V100, P637; POMIANKOWSKI A, 1991, EVOLUTION, V45, P1422, DOI 10.1111/j.1558-5646.1991.tb02645.x; POMIANKOWSKI A, 1987, J THEOR BIOL, V128, P195, DOI 10.1016/S0022-5193(87)80169-8; Ritchie MG, 1998, ENDLESS FORMS, P291; Seehausen O, 1997, SCIENCE, V277, P1808, DOI 10.1126/science.277.5333.1808; Seehausen O, 1998, BEHAV ECOL SOCIOBIOL, V42, P1, DOI 10.1007/s002650050405; SEGER J, 1985, EVOLUTION, V39, P1185, DOI [10.2307/2408776, 10.1111/j.1558-5646.1985.tb05685.x]; Tauber C.A., 1989, P307; TAUBER CA, 1977, NATURE, V268, P702, DOI 10.1038/268702a0; Turner G.F., 1994, Advances in Limnology, V44, P139; TURNER GF, 1995, P ROY SOC B-BIOL SCI, V260, P287, DOI 10.1098/rspb.1995.0093; WU GI, 1985, EVOLUTION, V39, P66	23	256	264	0	94	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					523	526		10.1038/990087	http://dx.doi.org/10.1038/990087			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591210				2022-12-01	WOS:000084013200054
J	Jernstrom, H; Lerman, C; Ghadirian, P; Lynch, HT; Weber, B; Garber, J; Daly, M; Olopade, OI; Foulkes, WD; Warner, E; Brunet, JS; Narod, SA				Jernstrom, H; Lerman, C; Ghadirian, P; Lynch, HT; Weber, B; Garber, J; Daly, M; Olopade, OI; Foulkes, WD; Warner, E; Brunet, JS; Narod, SA			Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2	LANCET			English	Article							FAMILY HISTORY; MUTATION CARRIERS; AGE; DIFFERENTIATION; PATTERN; PARITY; WOMEN	Background Early age at first full-term pregnancy and increasing parity are associated with a reduced risk of breast cancer. However, whether pregnancy decreases the risk of early-onset hereditary breast cancer is unknown. There is concern that pregnancy may increase breast-cancer risk in carriers of BRCA1 and BRCA2 germline mutations. We aimed to establish whether pregnancy is a risk factor for hereditary breast cancer. Methods We did a matched case-control study of breast cancer in women who carry deleterious BRCA1 or BRCA2 mutations. Cases were carriers who developed breast cancer by age 40 years, and controls were carriers of the same age without breast cancer, or who were diagnosed with breast cancer after age 40 years. Women who had undergone preventive mastectomy, hysterectomy, or oophorectomy, or who were diagnosed with ovarian cancer before the age at which breast cancer was diagnosed in the matched case were excluded. Information about pregnancies and pregnancy outcome was derived from a questionnaire completed by women in the course of genetic counselling. Findings A higher proportion of cases than controls had had a full term pregnancy (173/236 vs 146/236; odds ratio 1.71 [95% CI 1.13-2.62], p=0.01). The mean number of births was also greater for cases than for controls (1.62 vs 1.38, p=0.04). The risk increased with the number of births and did not diminish with time since last pregnancy. There were no significant differences in age at first birth or age at last birth between cases and controls. Interpretation Carriers of the BRCA1 and BRCA2 mutations who have children are significantly more likely to develop breast cancer by age 40 than carriers who are nulliparous. Each pregnancy is associated with an increased cancer risk. An early first pregnancy does not confer protection for carriers of BRCA1 or BRCA2 mutations.	Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Ctr Hosp Univ Montreal, Epidemiol Res Unit, Res Ctr, Montreal, PQ, Canada; Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Dana Farber Canc Inst, Div Canc Epidemiol & Control, Boston, MA 02115 USA; Fox Chase Canc Ctr, Div Basic Sci & Populat Sci, Philadelphia, PA 19111 USA; Univ Chicago, Med Ctr, Canc Risk Clin, Sect Hematol & Oncol, Chicago, IL 60637 USA; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Human Genet, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON, Canada; Univ Lund Hosp, Dept Oncol, Jubileum Inst, S-22185 Lund, Sweden	University of Toronto; University Toronto Affiliates; Womens College Hospital; Georgetown University; Universite de Montreal; Creighton University; University of Pennsylvania; University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; Fox Chase Cancer Center; University of Chicago; University of Chicago Medical Center; McGill University; McGill University; McGill University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Lund University; Skane University Hospital	Narod, SA (corresponding author), Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, 790 Bay St,Room 750, Toronto, ON M5G 1N8, Canada.	steven.narod@swchsc.on.ca	Narod, Steven A/AAA-6112-2022; Foulkes, William D./AAR-9586-2021	Foulkes, William D./0000-0001-7427-4651	NCI NIH HHS [R01 CA63682, CA63678, CA57601] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063678, R01CA063682, R01CA057601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bassler R, 1970, Curr Top Pathol, V53, P1; BERAL V, 1993, LANCET, V341, P1102, DOI 10.1016/0140-6736(93)92469-A; Colditz GA, 1996, J NATL CANCER I, V88, P365, DOI 10.1093/jnci/88.6.365; DICKSON R, 1996, DIS BREAST, P15; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; EASTON DF, 1995, AM J HUM GENET, V56, P265; Egan KM, 1998, CANCER EPIDEM BIOMAR, V7, P359; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; Jernstrom H, 1998, BREAST, V7, P320, DOI 10.1016/S0960-9776(98)90074-1; Johannsson O, 1998, LANCET, V352, P1359, DOI 10.1016/S0140-6736(05)60750-7; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; LYNCH HT, 1984, J MED GENET, V21, P96, DOI 10.1136/jmg.21.2.96; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; Magnusson C, 1998, CANCER CAUSE CONTROL, V9, P259, DOI 10.1023/A:1008817018942; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; McCredie M, 1997, INT J CANCER, V73, P503, DOI 10.1002/(SICI)1097-0215(19971114)73:4<503::AID-IJC8>3.0.CO;2-3; McCredie MRE, 1998, CANCER CAUSE CONTROL, V9, P189, DOI 10.1023/A:1008886328352; Narod SA, 1995, INT J CANCER, V64, P394, DOI 10.1002/ijc.2910640608; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; RUSSO J, 1994, CANCER EPIDEM BIOMAR, V3, P219; RUSSO J, 1992, BREAST CANCER RES TR, V23, P211, DOI 10.1007/BF01833517; RUSSO J, 1994, CANCER EPIDEM BIOMAR, V3, P353; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Russo J, 1997, PROG CLIN BIOL RES, V396, P1; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TONIN P, 1995, J MED GENET, V32, P982, DOI 10.1136/jmg.32.12.982; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	30	150	155	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1999	354	9193					1846	1850		10.1016/S0140-6736(99)04336-6	http://dx.doi.org/10.1016/S0140-6736(99)04336-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584720				2022-12-01	WOS:000083909100009
J	Houry, WA; Frishman, D; Eckerskorn, C; Lottspeich, F; Hartl, FU				Houry, WA; Frishman, D; Eckerskorn, C; Lottspeich, F; Hartl, FU			Identification of in vivo substrates of the chaperonin GroEL	NATURE			English	Article							COLI RNA-POLYMERASE; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; POLYPEPTIDE BINDING; ATP HYDROLYSIS; GENE-PRODUCTS; IN-VIVO; SEQUENCE; DOMAIN	The chaperonin GroEL has an essential role in mediating protein folding in the cytosol of Escherichia coli. Here we show that GroEL interacts strongly with a well-defined set of approximately 300 newly translated polypeptides, including essential components of the transcription/translation machinery and metabolic enzymes. About one third of these proteins are structurally unstable and repeatedly return to GroEL for conformational maintenance. GroEL substrates consist preferentially of two or more domains with ap-folds, which contain a-helices and buried P-sheets with extensive hydrophobic surfaces. These proteins are expected to fold slowly and be prone to aggregation. The hydrophobic binding regions of GroEL may be well adapted to interact with the non-native states of ap-domain proteins.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Max Planck Inst Biochem, GSF Forschungszentrum Umwelt & Gesundheit, Munich Informat Ctr Prot Sequences, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Prot Analyt, D-82152 Martinsried, Germany; Toplab GmbH, Proteom Div, D-82152 Martinsried, Germany	Max Planck Society; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; Max Planck Society	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Hartl, F. Ulrich/Y-8206-2019; Frishman, Dmitrij/AAT-7815-2020					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1998, NUCLEIC ACIDS RES, V26, P38, DOI 10.1093/nar/26.1.38; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1357, DOI 10.1002/elps.11501401209; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Coyle JE, 1997, FOLD DES, V2, pR93, DOI 10.1016/S1359-0278(97)00046-1; EISENBERG D, 1986, J CELL BIOCHEM, V31, P11, DOI 10.1002/jcb.240310103; Ellis RJ, 1997, CURR BIOL, V7, pR531, DOI 10.1016/S0960-9822(06)00273-9; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ELLIS RJ, 1994, CURR OPIN STRUC BIOL, V4, P117, DOI 10.1016/S0959-440X(94)90069-8; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fountoulakis M, 1997, ANAL BIOCHEM, V250, P153, DOI 10.1006/abio.1997.2213; Frishman D, 1997, TRENDS GENET, V13, P415, DOI 10.1016/S0168-9525(97)01224-9; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; GENTRY DR, 1986, GENE, V48, P33, DOI 10.1016/0378-1119(86)90349-5; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cellbio.9.1.601; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hubbard TJP, 1999, NUCLEIC ACIDS RES, V27, P254, DOI 10.1093/nar/27.1.254; Huynen M, 1998, J MOL BIOL, V280, P323, DOI 10.1006/jmbi.1998.1884; Karp PD, 1998, NUCLEIC ACIDS RES, V26, P50, DOI 10.1093/nar/26.1.50; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; LABEDAN B, 1995, MOL BIOL EVOL, V12, P980; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; Meyer S.L., 1975, DATA ANAL SCI ENG; NAKASHIMA H, 1986, J BIOCHEM-TOKYO, V99, P153, DOI 10.1093/oxfordjournals.jbchem.a135454; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Orengo CA, 1999, NUCLEIC ACIDS RES, V27, P275, DOI 10.1093/nar/27.1.275; PEDERSEN S, 1984, EMBO J, V3, P2895, DOI 10.1002/j.1460-2075.1984.tb02227.x; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Smith KE, 1998, J BIOL CHEM, V273, P28677, DOI 10.1074/jbc.273.44.28677; VANBOGELEN RA, 1992, ELECTROPHORESIS, V13, P1014, DOI 10.1002/elps.11501301203; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716; WADA M, 1987, J BACTERIOL, V169, P1102, DOI 10.1128/jb.169.3.1102-1106.1987; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X; Xu D, 1998, FOLD DES, V3, P11, DOI 10.1016/S1359-0278(98)00004-2; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zhang GY, 1998, SCIENCE, V281, P262, DOI 10.1126/science.281.5374.262; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	48	415	442	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					147	154		10.1038/45977	http://dx.doi.org/10.1038/45977			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647006				2022-12-01	WOS:000083716400039
J	Reiner, DJ; Newton, EM; Tian, H; Thomas, JH				Reiner, DJ; Newton, EM; Tian, H; Thomas, JH			Diverse behavioural defects caused by mutations in Caenorhabditis elegans unc-43 CaM kinase II	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; C-ELEGANS; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; NERVOUS-SYSTEM; MUTANT MICE; CALMODULIN; DROSOPHILA; MICROSCOPY; FREQUENCY	Calcium/calmodulin-dependent serine/threonine kinase type II (CaMKII) is one of the most abundant proteins in the mammalian brain, where it is thought to regulate synaptic plasticity and other processes(1-3). Activation of the multisubunit kinase(4) by calcium is effectively cooperative and can persist long after transient calcium rises(1,5,6). Despite extensive biochemical characterization of CaMKII and identification of numerous in vitro kinase targets(1), little is known about its function in vivo. Here we report that unc-43 encodes the only Caenorhabditis elegans CaMKII. A gain-of-function unc-43 mutation reduces locomotory activity, alters excitation of three muscle types and lengthens the period of the motor output of a behavioural clock. Null unc-43 mutations cause phenotypes generally opposite to those of the gain-of-function mutation. Mutations in the unc-103 potassium channel gene suppress a gain-of-function phenotype of unc-43 in one tissue without affecting other tissues; thus, UNC-103 may be a tissue-specific target of CaMKII in vivo.	Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Thomas, JH (corresponding author), Univ Washington, Dept Genet, Box 357360, Seattle, WA 98195 USA.	jht@genetics.washington.edu		Reiner, David/0000-0002-0344-7161	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085309] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM085309] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BROCKE L, 1995, J NEUROSCI, V15, P6797; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHO KO, 1991, NEURON, V7, P439, DOI 10.1016/0896-6273(91)90296-C; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Dal Santo P, 1999, CELL, V98, P757, DOI 10.1016/S0092-8674(00)81510-X; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; GRIFFITH LC, 1993, J NEUROCHEM, V61, P1534, DOI 10.1111/j.1471-4159.1993.tb13650.x; GRIFFITH LC, 1994, P NATL ACAD SCI USA, V91, P10044, DOI 10.1073/pnas.91.21.10044; GUTAROY B, 1996, J NEUROCHEM, V66, P1282; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Johnstone DB, 1997, NEURON, V19, P151, DOI 10.1016/S0896-6273(00)80355-4; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; LIU DWC, 1994, J NEUROSCI, V14, P1953; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; Miller DM, 1995, METHOD CELL BIOL, V48, P365; PARK EC, 1986, GENETICS, V113, P821; REINER DJ, 1986, GENETICS, V113, P821; Rongo C, 1999, NATURE, V402, P195, DOI 10.1038/46065; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SCHULMAN H, 1993, NEUROCHEM RES, V18, P65, DOI 10.1007/BF00966924; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; THOMAS JH, 1990, GENETICS, V124, P855; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	31	102	114	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	1999	402	6758					199	203		10.1038/46072	http://dx.doi.org/10.1038/46072			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647014				2022-12-01	WOS:000083716400055
J	Mange, KC; Cizman, B; Joffe, M; Feldman, HI				Mange, KC; Cizman, B; Joffe, M; Feldman, HI			Arterial hypertension and renal allograft survival	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; DISEASE; PROGRESSION; RECIPIENTS; FAILURE	Context Several observational studies have investigated the significance of hypertension in renal allograft failure; however, these studies have been complicated by the lack of adjustment for baseline renal function, leaving the role of elevated blood pressure in allograft failure unclear. Objective To examine the relationship between blood pressure adjusted for renal function and survival after cadaveric allograft transplantation. Design Nonconcurrent historical cohort study conducted from 1985 through 1997. Setting University teaching hospital. Participants A total of 277 patients aged 18 years or older who underwent cadaveric renal transplantation without another simultaneous organ transplantation and whose allograft was functioning for a minimum of 1 year. Follow-up continued through 1997 (mean follow-up, 5.7 years). Main Outcome Measure Time to allograft failure (defined as death, return to dialysis, or retransplantation) by systolic, diastolic, and mean arterial blood pressure measurements at 1 year after transplantation. Results Multivariate Cox proportional hazards modeling demonstrated that nonwhite ethnicity, history of acute rejection, and nondiabetic kidney disease were significant predictors of failure (P = .01 for all), In addition, the calculated creatinine clearance at 1 year had an adjusted rate ratio (RR) for allograft failure per 10 mL/min (0.17 mL/s) of 0.74 (95% confidence interval [CI], 0.62-0.88). The RR per 10-mm Hg in crease in blood pressure measured at 1 year after transplantation, after adjustment for creatinine clearance, was 1.15 (95% CI, 1.02-1.30) for systolic pressure, 1.27 (95% CI, 1.01-1.60) for diastolic pressure, and 1.30 (95% CI, 1.05-1.61) for mean arterial pressure. Supplemental analyser that did not include death as a failure event or reduce the minimum allograft survival time for study subjects to 6 months yielded results consistent with the primary analysis. There was no evidence of modification of the blood pressure-allograft failure relationship by ethnicity or diabetes mellitus. Conclusions Systolic, diastolic, and mean arterial blood pressures at 1 year posttransplantation strongly predict allograft survival adjusted for baseline renal function. More aggressive control of blood pressure may prolong cadaveric allograft survival.	Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Feldman, HI (corresponding author), Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, 423 Guardian Dr,720 Blockley Hall, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007006, P50DK045191] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-07006, DK-45191] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAGNAC A, 1992, TRANSPLANTATION, V53, P766, DOI 10.1097/00007890-199204000-00012; Chertow GM, 1996, JAMA-J AM MED ASSOC, V276, P1732, DOI 10.1001/jama.276.21.1732; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; COSIO FG, 1995, KIDNEY INT, V47, P1136, DOI 10.1038/ki.1995.162; COX DR, 1972, J R STAT SOC B, V34, P187; Feldman HI, 1996, J AM SOC NEPHROL, V7, P151; Giatras I, 1997, ANN INTERN MED, V127, P337, DOI 10.7326/0003-4819-127-5-199709010-00001; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; LEE E, 1994, BIOMETRIKA, V81, P515; Opelz G, 1998, KIDNEY INT, V53, P217, DOI 10.1046/j.1523-1755.1998.00744.x; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; RUGGENENTI P, 1993, KIDNEY INT, V43, P706, DOI 10.1038/ki.1993.101; VIANELLO A, 1993, AM J KIDNEY DIS, V21, P79, DOI 10.1016/0272-6386(93)70099-K; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085	15	229	241	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					633	638		10.1001/jama.283.5.633	http://dx.doi.org/10.1001/jama.283.5.633			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665703				2022-12-01	WOS:000084956500029
J	Shakespeare, J; Neve, E; Hodder, K				Shakespeare, J; Neve, E; Hodder, K			Is norethisterone a lifestyle drug? Results of database analysis	BRITISH MEDICAL JOURNAL			English	Article									Summertown Hlth Ctr, Oxford OX2 7BS, England; Oxfordshire Hlth Author, Oxford OX3 9LG, England		Shakespeare, J (corresponding author), Summertown Hlth Ctr, 160 Banbury Rd, Oxford OX2 7BS, England.							[Anonymous], 1999, CONCISE OXFORD DICT; COULTER A, 1995, INT J TECHNOL ASSESS, V11, P456, DOI 10.1017/S0266462300008679; *NHS CTR REV DISS, 1995, EFF HLTH CAR, V9; *ROYAL COLL OBST G, 1998, IN MAN MEN EV BAS CL, V1; *STAT OFF, 1999, DRUG TAR	5	24	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 29	2000	320	7230					291	291		10.1136/bmj.320.7230.291	http://dx.doi.org/10.1136/bmj.320.7230.291			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280ZB	10650028	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000085132700025
J	Lata, R; Conway, JF; Cheng, NQ; Duda, RL; Hendrix, RW; Wikoff, WR; Johnson, JE; Tsuruta, H; Steven, AC				Lata, R; Conway, JF; Cheng, NQ; Duda, RL; Hendrix, RW; Wikoff, WR; Johnson, JE; Tsuruta, H; Steven, AC			Maturation dynamics of a viral capsid: Visualization of transitional intermediate states	CELL			English	Article							CRYOELECTRON MICROSCOPY; STRUCTURAL TRANSITIONS; BIOLOGICAL MACROMOLECULES; ELECTRON CRYOMICROSCOPY; CONFORMATIONAL-CHANGES; BACTERIAL-VIRUS; IN-VITRO; PROTEIN; DNA; BACTERIOPHAGE-T4	Typical of DNA bacteriophages and herpesviruses, HK97 assembles in two stages: polymerization and maturation. First, capsid protein polymerizes into closed shells; then, these precursors mature into larger, stabler particles. Maturation is initiated by proteolysis, producing a metastable particle primed for expansion-the major structural transition. We induced expansion in vitro by acidic pH and monitored the resulting changes by time-resolved X-ray diffraction and cryo-electron microscopy. The transition, which is not synchronized over the population, proceeds in a series of stochastically triggered subtransitions. Three distinct intermediates were identified, which are comparable to transitional states in protein folding. The intermediates' structures reveal the molecular events occurring during expansion. Integrated into a movie (see Dynamic Visualization below), they show capsid maturation as a dynamic process.	NIAMSD, Struct Biol Lab, Bethesda, MD 20892 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Stanford Univ, Stanford Linear Accelerator Ctr, SSRL, Palo Alto, CA 94309 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Scripps Research Institute; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Steven, AC (corresponding author), NIAMSD, Struct Biol Lab, Bethesda, MD 20892 USA.		Conway, James F/A-2296-2010	Conway, James F/0000-0002-6581-4748; Duda, Robert/0000-0002-9517-2731	NCRR NIH HHS [P41 RR01209] Funding Source: Medline; NIAID NIH HHS [R01 AI040101, R01 AI40101] Funding Source: Medline; NIGMS NIH HHS [R01 GM47795, R01 GM047795] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR027002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047795] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; BAYER ME, 1973, VIROLOGY, V54, P465, DOI 10.1016/0042-6822(73)90157-8; Belnap DM, 1997, J STRUCT BIOL, V120, P44, DOI 10.1006/jsbi.1997.3896; BERRIMAN J, 1994, ULTRAMICROSCOPY, V56, P241, DOI 10.1016/0304-3991(94)90012-4; Butcher SJ, 1997, EMBO J, V16, P4477, DOI 10.1093/emboj/16.14.4477; Conway JF, 1997, NATURE, V386, P91, DOI 10.1038/386091a0; CONWAY JF, 1995, J MOL BIOL, V253, P86, DOI 10.1006/jmbi.1995.0538; Conway JF, 1999, J STRUCT BIOL, V128, P106, DOI 10.1006/jsbi.1999.4168; COOKE R, 1995, FASEB J, V9, P636, DOI 10.1096/fasebj.9.8.7768355; DOKLAND T, 1993, J MOL BIOL, V233, P682, DOI 10.1006/jmbi.1993.1545; DUDA RL, 1995, J MOL BIOL, V247, P636, DOI 10.1006/jmbi.1994.0169; DUDA RL, 1995, J MOL BIOL, V247, P618, DOI 10.1016/S0022-2836(05)80143-3; Duda RL, 1998, CELL, V94, P55, DOI 10.1016/S0092-8674(00)81221-0; Flynn DL, 1997, CURR OPIN CHEM BIOL, V1, P190, DOI 10.1016/S1367-5931(97)80009-9; Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9; Fuller SD, 1996, J STRUCT BIOL, V116, P48, DOI 10.1006/jsbi.1996.0009; GALISTEO ML, 1993, BIOPHYS J, V65, P227, DOI 10.1016/S0006-3495(93)81073-7; Hendrix RW, 1998, ADV VIRUS RES, V50, P235, DOI 10.1016/S0065-3527(08)60810-6; HOHN B, 1983, P NATL ACAD SCI-BIOL, V80, P7456, DOI 10.1073/pnas.80.24.7456; Jardine PJ, 1998, J MOL BIOL, V284, P661, DOI 10.1006/jmbi.1998.2179; KING J, 1997, STRUCTURAL BIOL VIRU, P288; MULLER M, 1994, J STRUCT BIOL, V112, P199, DOI 10.1006/jsbi.1994.1021; Nermut MV, 1998, J STRUCT BIOL, V123, P143, DOI 10.1006/jsbi.1998.4024; Newcomb WW, 1996, J MOL BIOL, V263, P432, DOI 10.1006/jmbi.1996.0587; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SERWER P, 1978, J VIROL, V28, P917, DOI 10.1128/JVI.28.3.917-928.1978; SHIBATA H, 1987, J MOL BIOL, V196, P845, DOI 10.1016/0022-2836(87)90409-8; STEVEN AC, 1992, J MOL BIOL, V228, P870, DOI 10.1016/0022-2836(92)90871-G; STEVEN AC, 1990, BIOCHEMISTRY-US, V29, P5556, DOI 10.1021/bi00475a020; STEVEN AC, 1979, J SUPRAMOL STR CELL, V10, P1, DOI 10.1002/jss.400100102; Tao YZ, 1998, CELL, V95, P431, DOI 10.1016/S0092-8674(00)81773-0; Trus BL, 1997, NAT STRUCT BIOL, V4, P413, DOI 10.1038/nsb0597-413; Trus BL, 1996, J MOL BIOL, V263, P447, DOI 10.1016/S0022-2836(96)80018-0; Tsuruta H, 1998, J APPL CRYSTALLOGR, V31, P672, DOI 10.1107/S0021889898002702; Tuma R, 1996, BIOCHEMISTRY-US, V35, P4619, DOI 10.1021/bi952793l; Tuma R, 1998, P NATL ACAD SCI USA, V95, P9885, DOI 10.1073/pnas.95.17.9885; VALPUESTA JM, 1994, Q REV BIOPHYS, V27, P107, DOI 10.1017/S0033583500004510; WALKER M, 1995, BIOPHYS J, V68, pS87; White HE, 1997, NAT STRUCT BIOL, V4, P690, DOI 10.1038/nsb0997-690; Wikoff WR, 1998, VIROLOGY, V243, P113, DOI 10.1006/viro.1998.9040; Wikoff WR, 1999, ACTA CRYSTALLOGR D, V55, P763, DOI 10.1107/S0907444998017661; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; XIE ZH, 1995, J MOL BIOL, V253, P74, DOI 10.1006/jmbi.1995.0537; Yeager M, 1998, P NATL ACAD SCI USA, V95, P7299, DOI 10.1073/pnas.95.13.7299; Zlotnick A, 1996, BIOCHEMISTRY-US, V35, P7412, DOI 10.1021/bi9604800	46	120	127	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					253	263		10.1016/S0092-8674(00)81563-9	http://dx.doi.org/10.1016/S0092-8674(00)81563-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660048	Bronze			2022-12-01	WOS:000084932200009
J	Murakami, Y; Tsuyama, M; Kobayashi, Y; Kodama, H; Iba, K				Murakami, Y; Tsuyama, M; Kobayashi, Y; Kodama, H; Iba, K			Trienoic fatty acids and plant tolerance of high temperature	SCIENCE			English	Article							CHLOROPLAST OMEGA-3-FATTY-ACID DESATURASE; ENHANCED THERMAL TOLERANCE; ARABIDOPSIS DEFICIENT; GROWTH TEMPERATURE; MUTANT; LIPIDS; PHOTOSYNTHESIS; ACCLIMATION; STABILITY; MEMBRANES	The chloroplast membrane of higher plants contains an unusually high concentration of trienoic fatty acids. Plants grown in colder temperatures have a higher content of trienoic fatty acids. Transgenic tobacco plants in which the gene encoding chloroplast omega-3 fatty acid desaturase, which synthesizes trienoic fatty acids, was silenced contained a lower level of trienoic fatty acids than wild-type plants and were better able to acclimate to higher temperatures.	Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; Kyushu Univ, Dept Forestry, Fukuoka 8128581, Japan	Kyushu University; Kyushu University	Iba, K (corresponding author), Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan.	koibascb@mbox.nc.kyushu-u.ac.jp						BERRY J, 1980, ANNU REV PLANT PHYS, V31, P491, DOI 10.1146/annurev.pp.31.060180.002423; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HUGLY S, 1992, PLANT PHYSIOL, V99, P197, DOI 10.1104/pp.99.1.197; HUGLY S, 1989, PLANT PHYSIOL, V90, P1134, DOI 10.1104/pp.90.3.1134; IBA K, 1993, J BIOL CHEM, V268, P24099; KOBAYASHI Y, 1994, PHOTOSYNTH RES, V41, P419, DOI 10.1007/BF02183044; KODAMA H, 1994, PLANT PHYSIOL, V105, P601, DOI 10.1104/pp.105.2.601; KODAMA H, 1995, PLANT PHYSIOL, V107, P1177, DOI 10.1104/pp.107.4.1177; KUNST L, 1989, PLANT PHYSIOL, V91, P401, DOI 10.1104/pp.91.1.401; LEE JH, 1995, PLANT J, V8, P603, DOI 10.1046/j.1365-313X.1995.8040603.x; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; McConn M, 1996, PLANT CELL, V8, P403, DOI 10.1105/tpc.8.3.403; MCCONN M, 1994, PLANT PHYSIOL, V106, P1609, DOI 10.1104/pp.106.4.1609; MURAKAMI Y, UNPUB; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PEARCY RW, 1978, PLANT PHYSIOL, V61, P484, DOI 10.1104/pp.61.4.484; RAISON JK, 1982, BIOCHIM BIOPHYS ACTA, V688, P218, DOI 10.1016/0005-2736(82)90597-1; SOMERVILLE C, 1991, SCIENCE, V252, P80, DOI 10.1126/science.252.5002.80; SOMERVILLE C, 1995, P NATL ACAD SCI USA, V92, P6215, DOI 10.1073/pnas.92.14.6215; THOMAS PG, 1986, BIOCHIM BIOPHYS ACTA, V849, P131, DOI 10.1016/0005-2728(86)90104-0; WEIS E, 1988, SYM SOC EXP BIOL, V42, P329	21	294	351	1	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					476	479		10.1126/science.287.5452.476	http://dx.doi.org/10.1126/science.287.5452.476			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642547				2022-12-01	WOS:000084929900045
J	Bellentani, S; Saccoccio, G; Masutti, F; Croce, LS; Brandi, G; Sasso, F; Cristanini, G; Tiribelli, C				Bellentani, S; Saccoccio, G; Masutti, F; Croce, LS; Brandi, G; Sasso, F; Cristanini, G; Tiribelli, C			Prevalence of and risk factors for hepatic steatosis in northern Italy	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	33rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver	APR 15-18, 1998	LISBON, PORTUGAL	European Assoc Study Liver			ALCOHOLIC LIVER-DISEASE; JEJUNOILEAL BYPASS; OBESE SUBJECTS; FATTY LIVER; WEIGHT-LOSS; ABNORMALITIES; FIBROSIS	Background: Although hepatic steatosis is seen with increasing frequency in clinical practice, its prevalence and risk factors are unknown. Objective: To investigate the prevalence of and risk factors for hepatic steatosis, such as alcohol consumption and obesity. Design: Cross-sectional, observational study. Setting: Participants in the Dionysos Study. Patients: 257 participants assigned to one of four categories (67 controls, 66 obese persons, 69 heavy drinkers, and 55 obese heavy drinkers). Measurements: Ethanol intake, assessed by a validated questionnaire and expressed as daily (g/d) and lifetime (kg) consumption, and body mass, expressed as body mass index. Biochemical tests of liver and metabolic function and hepatic ultrasonography were done. Results: The prevalence of steatosis was increased in heavy drinkers (46.4% [95% CI, 34% to 59%]) and obese persons (75.8% [CI, 63% to 85%]) compared with controls (16.4% [CI, 8% to 25%]). Steatosis was found in 94.5% (CI, 85% to 99%) of obese heavy drinkers. Compared with controls, the risk for steatosis was higher by 2.8-fold (CI, 1.4-fold to 7.1-fold) in heavy drinkers, 4.6-fold (CI, 2.5-fold to 11.0-fold) in obese persons, and 5.8-fold (CI, 3.2-fold to 12.3-fold) in persons who were obese and drank heavily. In heavy drinkers, obesity increased the risk for steatosis by twofold (CI, 1.5-fold to 3.0-fold) (P < 0.001), but heavy drinking was associated with only a 1.3-fold (CI, 1.02-fold to 1.6-fold) increase in risk in obese persons (P = 0.0053). Elevated alanine aminotransferase and triglyceride levels are the most reliable markers of steatosis. Conclusions: Steatosis is frequently encountered in healthy persons and is almost always present in obese persons who drink more than 60 g of alcohol per day. Steatosis is more strongly associated with obesity than with heavy drinking, suggesting a greater role of overweight than alcohol consumption in accumulation of fat in the liver.	Univ Trieste, Ctr Studi Fegato, Dept Biochem Biophys & Chem Macromol, I-34100 Trieste, Italy; Fondo Studio Malattie Fegato, Trieste, Italy	University of Trieste	Tiribelli, C (corresponding author), Univ Trieste, Ctr Studi Fegato, Dept Biochem Biophys & Chem Macromol, Via Giorgieri 1, I-34100 Trieste, Italy.	liver@fmc.univ.trieste.it	croce', lory saveria l/E-2565-2011; Brandi, Giovanni/AAD-6327-2021; Bellentani, Stefano/L-3600-2019; Tiribelli, Claudio/A-4716-2014	croce', lory saveria l/0000-0001-9890-7011; Brandi, Giovanni/0000-0003-0013-2858; Bellentani, Stefano/0000-0003-2836-8870; Tiribelli, Claudio/0000-0001-6596-7595				ADLER M, 1979, AM J MED, V67, P811, DOI 10.1016/0002-9343(79)90740-X; ANDERSEN T, 1991, J HEPATOL, V12, P224, DOI 10.1016/0168-8278(91)90942-5; Bellentani S, 1997, GUT, V41, P845, DOI 10.1136/gut.41.6.845; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BOULTON R, 1995, GASTROENTEROLOGY, V109, P1324, DOI 10.1016/0016-5085(95)90595-2; BRAILLON A, 1985, GUT, V26, P133, DOI 10.1136/gut.26.2.133; CONTE D, 1995, ITAL J GASTROENTEROL, V27, P363; CUBEAU J, 1980, REV EPIDEMIOL SANTE, V28, P367; DAY CP, 1994, BBA-LIPID LIPID MET, V1215, P33, DOI 10.1016/0005-2760(94)90089-2; Fleiss JL, 1981, STAT METHODS RATES P, P83; GODDARD CJR, 1992, DIGEST DIS, V10, P218, DOI 10.1159/000171360; HAINES NW, 1981, HEPATOLOGY, V1, P161, DOI 10.1002/hep.1840010212; HOSMER DW, 1989, APPL LOGISTIC; IKAI E, 1995, J HUM HYPERTENS, V9, P101; JOSEPH AEA, 1991, CLIN RADIOL, V43, P26, DOI 10.1016/S0009-9260(05)80350-2; LELBACH WK, 1976, PROGR LIVER DIS, P434; Luyckx FH, 1998, INT J OBESITY, V22, P222, DOI 10.1038/sj.ijo.0800571; MARUBBIO AT, 1976, AM J CLIN PATHOL, V66, P684; Matsuura K, 1995, Nihon Shokakibyo Gakkai Zasshi, V92, P1743; MEIER P, 1988, ANAL CLIN MED, P7; Mezey E, 1998, HEPATOLOGY, V28, P901, DOI 10.1002/hep.510280401; MIDANIK L, 1982, BRIT J ADDICT, V77, P357; Naveau S, 1997, HEPATOLOGY, V25, P108, DOI 10.1002/hep.510250120; NOMURA H, 1988, JPN J MED, V27, P142, DOI 10.2169/internalmedicine1962.27.142; PATON A, 1981, BRIT MED J, V283, P1248, DOI 10.1136/bmj.283.6301.1248; Perry IJ, 1998, DIABETES CARE, V21, P732, DOI 10.2337/diacare.21.5.732; PETERS RL, 1977, AM J CLIN NUTR, V30, P53, DOI 10.1093/ajcn/30.1.53; Ricci C, 1997, J HEPATOL, V27, P108, DOI 10.1016/S0168-8278(97)80288-7; SAVERYMUTTU SH, 1986, BRIT MED J, V292, P13, DOI 10.1136/bmj.292.6512.13; Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1016/0270-9139(95)90196-5; TIETZ NW, 1987, DUNDAMENTALS CLIN CH; VANTHIEL DH, 1985, CURR CONCEPTS GASTRO, V10, P3	33	949	995	2	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2000	132	2					112	117		10.7326/0003-4819-132-2-200001180-00004	http://dx.doi.org/10.7326/0003-4819-132-2-200001180-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	275ZZ	10644271				2022-12-01	WOS:000084852300003
J	Gupta, A; Wang, Y; Markram, H				Gupta, A; Wang, Y; Markram, H			Organizing principles for a diversity of GABAergic interneurons and synapses in the neocortex	SCIENCE			English	Article							RAT FRONTAL-CORTEX; CAT VISUAL-CORTEX; SYNAPTIC CONNECTIONS; NONPYRAMIDAL CELLS; PYRAMIDAL NEURONS; BASKET CELL; FACILITATION; CIRCUITS	A puzzling feature of the neocortex is the rich array of inhibitory interneurons. Multiple neuron recordings revealed numerous electrophysiological-anatomical subclasses of neocortical gamma-aminobutyric acid-ergic (GABAergic) interneurons and three types of GABAergic synapses. The type of synapse used by each interneuron to influence its neighbors follows three functional organizing principles. These principles suggest that inhibitory synapses could shape the impact of different interneurons according to their specific spatiotemporal patterns of activity and that GABAergic interneuron and synapse diversity may enable: combinatorial inhibitory effects in the neocortex.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Markram, H (corresponding author), Univ Calif San Francisco, Keck Ctr Integrat Neurosci, 828-HSE, San Francisco, CA 94143 USA.							CAJAL SRY, 1911, HISTOLOGY DUE SYSTEM, V2; Cauli B, 1997, J NEUROSCI, V17, P3894; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; DEFELIPE J, 1993, CEREB CORTEX, V3, P273, DOI 10.1093/cercor/3.4.273; DEFELIPE J, 1982, BRAIN RES, V244, P9, DOI 10.1016/0006-8993(82)90898-8; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; FELDMAN ML, 1978, J COMP NEUROL, V179, P761, DOI 10.1002/cne.901790406; FLEIDERVISH IA, 1995, J NEUROPHYSIOL, V73, P2591, DOI 10.1152/jn.1995.73.6.2591; GUPTA A, UNPUB; Kawaguchi Y, 1998, J NEUROSCI, V18, P6963; KAWAGUCHI Y, 1995, J NEUROSCI, V15, P2638; KAWAGUCHI Y, 1997, CEREB CORTEX, V7, P47; KISVARDAY ZF, 1985, J COMP NEUROL, V241, P111, DOI 10.1002/cne.902410202; MAGLEBY KL, 1987, SYNAPTIC FUNCTION, P21; Markram H, 1998, P NATL ACAD SCI USA, V95, P5323, DOI 10.1073/pnas.95.9.5323; Markram H, 1997, J PHYSIOL-LONDON, V500, P409, DOI 10.1113/jphysiol.1997.sp022031; Martinotti C, 1889, ANN FRENIATR SCI AFF, V1, P314; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; SHOLL DA, 1953, J ANAT, V87, P387; Siegel M.R., 1988, NONPARAMETRIC STAT B; SOMOGYI P, 1983, NEUROSCIENCE, V10, P261, DOI 10.1016/0306-4522(83)90133-1; Steriade M, 1998, J NEUROPHYSIOL, V79, P483, DOI 10.1152/jn.1998.79.1.483; STORM JF, 1988, NATURE, V336, P379, DOI 10.1038/336379a0; Tamas G, 1997, J PHYSIOL-LONDON, V500, P715, DOI 10.1113/jphysiol.1997.sp022054; Thomson AM, 1997, CEREB CORTEX, V7, P510, DOI 10.1093/cercor/7.6.510; White E.L., 1989, CORTICAL CIRCUITS SY; White EL, 1997, SOMATOSENS MOT RES, V14, P34, DOI 10.1080/08990229771204	27	774	780	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2000	287	5451					273	278		10.1126/science.287.5451.273	http://dx.doi.org/10.1126/science.287.5451.273			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634775				2022-12-01	WOS:000084769600030
J	Foley, K				Foley, K			Dismantling the barriers: Providing palliative and pain care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ASSISTED SUICIDE; CANCER PAIN; ATTITUDES		Cornell Univ, Coll Med, New York, NY 10021 USA	Cornell University	Foley, K (corresponding author), Cornell Univ, Coll Med, New York, NY 10021 USA.							Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Carron A T, 1999, Ann Intern Med, V130, P82; Foley Kathleen M., 1997, P2807; FOLEY KM, 1995, PAIN FORUM, V4, P163; *GALL I, 1997, SPIR BEL DYING PROC; *I MED DIV HLTH CA, 1997, APPROACHING DEATH IM; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LEVIN DN, 1985, CANCER, V56, P2337, DOI 10.1002/1097-0142(19851101)56:9<2337::AID-CNCR2820560935>3.0.CO;2-W; MEIER DE, 1997, ANN INTERN MED, V127, P3; Mount B, 1996, J PALLIAT CARE, V12, P31, DOI 10.1177/082585979601200405; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; World Health Organization, 1990, CANC PAIN REL PALL C	12	19	19	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					115	115		10.1001/jama.283.1.115	http://dx.doi.org/10.1001/jama.283.1.115			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632292	hybrid			2022-12-01	WOS:000084514400037
J	Sulkowski, MS; Thomas, DL; Chaisson, RE; Moore, RD				Sulkowski, MS; Thomas, DL; Chaisson, RE; Moore, RD			Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV PROTEASE INHIBITORS; CD4 CELL COUNTS; COMBINATION THERAPY; CUBIC MILLIMETER; CONTROLLED TRIAL; ADVERSE EVENTS; DRUG-THERAPY; RITONAVIR; DISEASE; INDINAVIR	Context Use of antiretroviral drugs, including protease inhibitors, for treatment of human immunodeficiency virus (HIV) infection has been anecdotally associated with hepatotoxicity, particularly in persons coinfected with hepatitis C or B virus. Objectives To ascertain if incidence of severe hepatotoxicity during antiretroviral therapy is similar for ail antiretroviral drug combinations, and to define the role of chronic viral hepatitis in its development. Design Prospective cohort study. Setting University-based urban HIV clinic. Patients A total of 298 patients who were prescribed new antiretroviral therapies between January 1996 and January 1998, 211 (71%) of whom received protease inhibitors as part of combination therapy (median follow-up, 182 days) and 87 (29%) of whom received dual nucleoside analog regimens (median follow-up, 167 days). Chronic hepatitis C and B virus infection was present in 154 (52%) and 8 (2.7%) patients, respectively. Main Outcome Measure Severe hepatotoxicity, defined as a grade 3 or 4 change in levels of serum alanine aminotransferase and aspartate aminotransferase, evaluated before and during therapy. Results Severe hepatotoxicity was observed in 31 (10.4%) of 298 patients (95% confidence interval [CI], 7.2%-14.4%). Ritonavir use was associated with a higher incidence of toxicity (30%; 95% CI, 17.9%-44.6%). However, no significant difference was detected in hepatotoxicity incidence in other treatment groups, ie, nucleoside analogs (5.7%; 95% CI, 1.2%-12.9%), nelfinavir (5.9%; 95% CI, 1.2%-16.2%), saquinavir (5.9%; 95% Cl, 0.15%-28.7%), and indinavir (6.8%; 95% CI, 3.0%-13.1%). Although chronic viral hepatitis was associated with an increased risk of severe hepatotoxicity among patients prescribed nonritonavir regimens (relative risk, 3.7; 95% CI, 1.0-11.8), most patients with chronic hepatitis C or B virus infection (88%) did not experience significant toxic effects. Rate of severe toxicity with use of any protease inhibitor in patients with hepatitis C infection was 12.2% (13/107; 95% CI, 6.6%-19.9%). In multivariate logistic regression, only ritonavir (adjusted odds ratio [AOR], 8.6; 95% CI, 3.0-24.6) and a CD4 cell count increase of more than 0.05 x 10(9)/L (AOR, 3.6; 95% CI, 1.0-12.9) were associated with severe hepatotoxicity. No irreversible outcomes were seen in patients with severe hepatotoxicity. Conclusions Our data indicate that use of ritonavir may increase risk of severe hepatotoxicity. Although hepatotoxicity may be more common in persons with chronic viral hepatitis, these data do not support withholding protease inhibitor therapy from persons coinfected with hepatitis B or C virus.	Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Epidemiol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Sulkowski, MS (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, 1830 E Monument St,Suite 450 C, Baltimore, MD 21287 USA.	msulkows@jhmi.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011602] Funding Source: NIH RePORTER; AHRQ HHS [HS-07809] Funding Source: Medline; NIDA NIH HHS [DA-11602] Funding Source: Medline; FDA HHS [FD-U-000977] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); FDA HHS		*AIDS CLIN TRIALS, 1996, TABL GRAD SEV AD ADV; [Anonymous], 1996, Lancet, V348, P283; Arribas JR, 1998, AIDS, V12, P1722; Bangsberg D, 1997, JAMA-J AM MED ASSOC, V278, P63, DOI 10.1001/jama.278.1.63; BODSWORTH NJ, 1991, J INFECT DIS, V163, P1138, DOI 10.1093/infdis/163.5.1138; Brau N, 1997, LANCET, V349, P924, DOI 10.1016/S0140-6736(05)62700-6; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; CAMERON DW, 1998, 5 C RETR OPP INF FEB; Carroll DS, 1998, PALLIATIVE MED, V12, P51, DOI 10.1191/026921698666041220; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DELMAS C, 1998, 12 WORLD AIDS C JUN; Gill MJ, 1998, AIDS, V12, P1400; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; John M, 1998, AIDS, V12, P2289, DOI 10.1097/00002030-199817000-00010; Kumar GN, 1996, J PHARMACOL EXP THER, V277, P423; LEE BL, 1992, CLIN INFECT DIS, V14, P773, DOI 10.1093/clinids/14.3.773-a; LEE C, IN PRESS J ACQUIR IM; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Markowitz M, 1998, J INFECT DIS, V177, P1533, DOI 10.1086/515312; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; Matsuda J, 1997, LANCET, V350, P364, DOI 10.1016/S0140-6736(05)63416-2; Miwa LJ, 1997, ARCH INTERN MED, V157, P2129, DOI 10.1001/archinte.157.18.2129; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; Moore RD, 1996, AM J MED, V101, P34, DOI 10.1016/S0002-9343(96)00077-0; PERRILLO RP, 1986, ANN INTERN MED, V105, P382, DOI 10.7326/0003-4819-105-3-382; Rodriguez-Rosado R, 1998, AIDS, V12, P1256, DOI 10.1097/00002030-199810000-00025; Rutschmann OT, 1998, J INFECT DIS, V177, P783, DOI 10.1086/517808; Thomas DL, 1998, HEPATOLOGY, V28, p568A; Ungo JR, 1998, AM J RESP CRIT CARE, V157, P1871, DOI 10.1164/ajrccm.157.6.9711039; Vento S, 1998, AIDS, V12, P116; VERDON R, 1998, 38 INT C ANT AG CHEM; Zylberberg H, 1996, CLIN INFECT DIS, V23, P1117, DOI 10.1093/clinids/23.5.1117; Zylberberg H, 1998, CLIN INFECT DIS, V26, P1104, DOI 10.1086/520281; 1998, MMWR MORB MORTAL WKL, V47, P38	39	690	710	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					74	80		10.1001/jama.283.1.74	http://dx.doi.org/10.1001/jama.283.1.74			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632283				2022-12-01	WOS:000084514400028
J	Schultz, WW; van Andel, P; Sabelis, I; Mooyaart, E				Schultz, WW; van Andel, P; Sabelis, I; Mooyaart, E			Magnetic resonance imaging of male and female genitals during coitus and female sexual arousal	BRITISH MEDICAL JOURNAL			English	Article								Objective To find out whether taking images of the male and female genitals during coitus is feasible and to find out whether former and current ideas about the anatomy during sexual intercourse and during female sexual arousal are based on assumptions or on facts. Design Observational study Setting University hospital in the Netherlands. Methods Magnetic resonance imaging was used to study are female sexual response and the male and female genitals during coitus. Thirteen experiments were performed with eight couples and three single women. Results The images obtained showed that during intercourse in the "missionary position" the penis has the shape of a boomerang and 1/3 of its length consists of the root of the penis. During female sexual arousal without intercourse the uterus was raised and the anterior vaginal wall lengthened. The size of the uterus did not increase during sexual arousal. Conclusion Taking magnetic resonance images of the male and female genitals during coitus is feasible and contributes to understanding of anatomy.	Univ Groningen Hosp, Dept Gynaecol, NL-9700 RB Groningen, Netherlands; Univ Groningen Hosp, Lab Cell Biol & Electron Microscopy, NL-9700 RB Groningen, Netherlands; Univ Groningen Hosp, Dept Radiol, NL-9700 RB Groningen, Netherlands; Dept Business Anthropol VU, NL-1081 HV Amsterdam, Netherlands	University of Groningen; University of Groningen; University of Groningen	Schultz, WW (corresponding author), Univ Groningen Hosp, Dept Gynaecol, POB 30 001, NL-9700 RB Groningen, Netherlands.	w.c.m.weymar.schultz@oprit.rug.nl	Sabelis, Ida/F-8893-2013; Sabelis, Ida/G-4830-2013	Sabelis, Ida/0000-0003-0109-0127; Sabelis, Ida/0000-0003-0109-0127				ALZATE H, 1984, J SEX MARITAL THER, V10, P49, DOI 10.1080/00926238408405789; CHIANCHI M, 1998, LEONARDO ANATOMY, P56; Clark K, 1968, CATALOGUE DRAWINGS L, V2nd; Dickinson RL, 1949, HUMAN SEX ANATOMY TO, P84; FLECK L, 1979, GENESIS DEV SCI FACT, P35; HILLIGES M, 1995, ACTA ANAT, V153, P119; HOCH Z, 1986, ACTA OBSTET GYN SCAN, V65, P767, DOI 10.3109/00016348609161498; Johnson Virginia E., 1964, MANUAL CONTRACEPTIVE, P138; KRANTZ KE, 1958, OBSTET GYNECOL, V12, P382; LEVIN RJ, 1998, INT J IMPOT RES S1, V10, P14; Masters W. H., 1966, HUMAN SEXUAL RESPONS; MINH MH, 1981, CAHIERS SEXUOL CLIN, V7, P169; O'Connell HE, 1998, J UROLOGY, V159, P1892, DOI 10.1016/S0022-5347(01)63188-4; RILEY AJ, 1992, INT CONGR SER, P29; SCHULTZ WCMW, 1989, ARCH SEX BEHAV, V18, P87, DOI 10.1007/BF01543115; SOHN MH, 1991, IMPOTENCE RES, V3, P36; VANANDEL P, 1994, BRIT J PHILOS SCI, V45, P631	17	74	75	6	87	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1596	1600		10.1136/bmj.319.7225.1596	http://dx.doi.org/10.1136/bmj.319.7225.1596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	270XN	10600954	Bronze, Green Published			2022-12-01	WOS:000084562600007
J	DeBose-Boyd, RA; Brown, MS; Li, WP; Nohturfft, A; Goldstein, JL; Espenshade, PJ				DeBose-Boyd, RA; Brown, MS; Li, WP; Nohturfft, A; Goldstein, JL; Espenshade, PJ			Transport-dependent proteolysis of SREBP: Relocation of Site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi	CELL			English	Article							CLEAVAGE-ACTIVATING PROTEIN; ELEMENT-BINDING PROTEINS; BOUND TRANSCRIPTION FACTOR; HAMSTER OVARY CELLS; ALZHEIMERS-DISEASE; STEROL RESISTANCE; MEMBRANE-PROTEIN; BREFELDIN-A; IDENTIFICATION; SECRETION	Cholesterol homeostasis in animal cells is achieved by regulated cleavage of membrane-bound transcription factors, designated SREBPs. Proteolytic release of the active domains of SREBPs from membranes requires a sterol-sensing protein, SCAP, which forms a complex with SREBPs. In sterol-depleted cells, SCAP escorts SREBPs from ER to Golgi, where SREBPs are cleaved by Site-1 protease (S1P). Sterols block this transport and abolish cleavage. Relocating active S1P from Golgi to ER by treating cells with brefeldin A or by fusing the ER retention signal KDEL to S1P obviates the SCAP requirement and renders cleavage insensitive to sterols. Transport-dependent proteolysis may be a common mechanism to regulate the processing of membrane proteins.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, MS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75216 USA.			Nohturfft, Axel/0000-0001-9484-3209	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, F32HL009993] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-09993, HL-20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOLLAG DM, 1991, PROTEIN METHODS, P1; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cheng D, 1999, J BIOL CHEM, V274, P22805, DOI 10.1074/jbc.274.32.22805; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Harlow E., 1999, USING ANTIBODIES LAB, P1; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KOMFELD R, 1985, ANNU REV BIOCHEM, V54, P631; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; PELHAM HRB, 1992, P ROY SOC B-BIOL SCI, V250, P1, DOI 10.1098/rspb.1992.0123; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; RIDGWAY ND, 1995, J BIOL CHEM, V270, P8023, DOI 10.1074/jbc.270.14.8023; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208	37	244	250	1	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					703	712		10.1016/S0092-8674(00)81668-2	http://dx.doi.org/10.1016/S0092-8674(00)81668-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619424	Bronze			2022-12-01	WOS:000084488200004
J	Foley, D				Foley, D			Sorting out sleep in patients with Alzheimer's disease	LANCET			English	Editorial Material									NIA, Epidemiol Demog & Biometry Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Foley, D (corresponding author), NIA, Epidemiol Demog & Biometry Program, Bethesda, MD 20892 USA.							ANCOLIISRAEL S, 1991, SLEEP, V14, P486, DOI 10.1093/sleep/14.6.486; Bliwise DL, 1996, J AM GERIATR SOC, V44, P1407; Dunkin JJ, 1998, NEUROLOGY, V51, pS53, DOI 10.1212/WNL.51.1_Suppl_1.S53; Foley DJ, 1999, J AM GERIATR SOC, V47, P524, DOI 10.1111/j.1532-5415.1999.tb02564.x; FOLEY DJ, 1995, SLEEP, V18, P425, DOI 10.1093/sleep/18.6.425; McCurry SM, 1999, J GERIATR PSYCH NEUR, V12, P53, DOI 10.1177/089198879901200203; Pollak C P, 1991, J Geriatr Psychiatry Neurol, V4, P204, DOI 10.1177/089198879100400405; Redline S, 1998, SLEEP, V21, P759; Taylor, 1997, Semin Clin Neuropsychiatry, V2, P113; VanSomeren EJW, 1997, BIOL PSYCHIAT, V41, P955, DOI 10.1016/S0006-3223(97)89928-3; VITIELLO MV, 1992, NEUROLOGY, V42, P83; Wilcox S, 1999, J GERONTOL B-PSYCHOL, V54, pP189, DOI 10.1093/geronb/54B.3.P189	12	7	7	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2098	2099		10.1016/S0140-6736(99)00413-4	http://dx.doi.org/10.1016/S0140-6736(99)00413-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	266UG	10609812				2022-12-01	WOS:000084318200006
J	Rice, S; Lin, AW; Safer, D; Hart, CL; Naber, N; Carragher, BO; Cain, SM; Pechatnikova, E; Wilson-Kubalek, EM; Whittaker, M; Pate, E; Cooke, R; Taylor, EW; Milligan, RA; Vale, RD				Rice, S; Lin, AW; Safer, D; Hart, CL; Naber, N; Carragher, BO; Cain, SM; Pechatnikova, E; Wilson-Kubalek, EM; Whittaker, M; Pate, E; Cooke, R; Taylor, EW; Milligan, RA; Vale, RD			A structural change in the kinesin motor protein that drives motility	NATURE			English	Article							CRYSTAL-STRUCTURE; DIMERIC KINESIN; MYOSIN MOTOR; CRYOELECTRON MICROSCOPY; ATP HYDROLYSIS; MICROTUBULE; DOMAIN; MECHANISM; COMPLEX; NCD	Kinesin motors power many motile processes by converting ATP energy into unidirectional motion along microtubules, The force-generating and enzymatic properties of conventional kinesin have been extensively studied; however, the structural basis of movement is unknown. Here we have detected and visualized a large conformational change of a similar to 15-amino-acid region (the neck linker) in kinesin using electron paramagnetic resonance, fluorescence resonance energy transfer, pre-steady state kinetics and cryo-electron microscopy, This region becomes immobilized and extended towards the microtubule 'plus' end when kinesin binds microtubules and ATP, and reverts to a more mobile conformation when gamma-phosphate is released after nucleotide hydrolysis, This conformational change explains both the direction of kinesin motion and processive movement by the kinesin dimer.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Illinois, Beckman Inst, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Washington State Univ, Dept Pure & Appl Math, Pullman, WA 99164 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Scripps Research Institute; University of Pennsylvania; University of Illinois System; University of Illinois Urbana-Champaign; University of Chicago; Washington State University	Vale, RD (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	vale@phy.uscf.edu	Gelfand, Vladimir I/D-2545-2013	Gelfand, Vladimir I/0000-0002-6361-2798; Carragher, Bridget/0000-0002-0624-5020				AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12954, DOI 10.1021/bi971477z; Arnal I, 1998, STRUCTURE, V6, P33, DOI 10.1016/S0969-2126(98)00005-7; BARNETT VA, 1986, BIOPHYS J, V49, P144, DOI 10.1016/S0006-3495(86)83628-1; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; DOSREMEDIOS CG, 1995, J STRUCT BIOL, V115, P175, DOI 10.1006/jsbi.1995.1042; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FUJIWARA S, 1995, BIOPHYS J, V69, P1563, DOI 10.1016/S0006-3495(95)80028-7; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; Hirose K, 1999, MOL BIOL CELL, V10, P2063, DOI 10.1091/mbc.10.6.2063; HOENGER A, 1998, CURR BIOL, V8, P191; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Jiang W, 1997, J BIOL CHEM, V272, P5616, DOI 10.1074/jbc.272.9.5616; Kozielski F, 1998, CURR BIOL, V8, P191, DOI 10.1016/S0960-9822(98)70083-1; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Marx A, 1998, EUR BIOPHYS J BIOPHY, V27, P455, DOI 10.1007/s002490050156; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Naber N, 1997, BIOCHEMISTRY-US, V36, P9681, DOI 10.1021/bi9706881; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Safer D, 1999, J STRUCT BIOL, V127, P101, DOI 10.1006/jsbi.1999.4110; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Stone DB, 1999, BIOCHEMISTRY-US, V38, P4938, DOI 10.1021/bi982374z; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; THOMAS DD, 1995, BIOPHYS J, V68, pS135; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	50	616	640	1	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					778	784		10.1038/45483	http://dx.doi.org/10.1038/45483			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617199				2022-12-01	WOS:000084330500055
J	Stewart, GS; Maser, RS; Stankovic, T; Bressan, DA; Kaplan, MI; Jaspers, NGJ; Raams, A; Byrd, PJ; Petrini, JHJ; Taylor, AMR				Stewart, GS; Maser, RS; Stankovic, T; Bressan, DA; Kaplan, MI; Jaspers, NGJ; Raams, A; Byrd, PJ; Petrini, JHJ; Taylor, AMR			The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder	CELL			English	Article							FIELD GEL-ELECTROPHORESIS; ACTIVATED PROTEIN-KINASE; IONIZING-RADIATION; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; HUMAN FIBROBLASTS; HUMAN MRE11; CELLS; YEAST; IDENTIFICATION	We show that hypomorphic mutations in hMRE11, but not in ATM, are present in certain individuals with an ataxia-telangiectasia-like disorder (ATLD). The cellular features resulting from these hMRE11 mutations are similar to those seen in A-T as well as NBS and include hypersensitivity to ionizing radiation, radioresistant DNA synthesis, and abrogation of ATM-dependent events, such as the activation of Jun kinase following exposure to gamma irradiation. Although the mutant hMre11 proteins retain some ability to interact with hRad50 and Nbs1, formation of ionizing radiation-induced hMre11 and Nbs1 fool was absent in hMRE11 mutant cells. These data demonstrate that ATM and the hMre11/h Rad50/Nbs1 protein complex act in the same DNA damage response pathway and link hMre11 to the complex pathology of A-T.	Univ Birmingham, Sch Med, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Univ Wisconsin, Sch Med, Madison, WI 53706 USA; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	University of Birmingham; University of Wisconsin System; University of Wisconsin Madison; Erasmus University Rotterdam	Taylor, AMR (corresponding author), Univ Birmingham, Sch Med, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	jpetrini@facstaff.wisc.edu; a.m.r.taylor@bham.ac.uk	Maser, Richard/B-2970-2012	Stewart, Grant/0000-0002-0960-3241; Stankovic, Tatjana/0000-0002-3780-274X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059413, R01GM056888, R37GM059413] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59413, GM56888] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		AGER DD, 1990, INT J RADIAT BIOL, V58, P249, DOI 10.1080/09553009014551601; AJIMURA M, 1993, GENETICS, V133, P51; [Anonymous], 1991, Methods Enzymol, V194, P1; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; Bressan DA, 1998, GENETICS, V150, P591; BRESSAN DA, 1999, IN PRESS MOL CELL BI; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CORNFORTH MN, 1983, SCIENCE, V222, P1141, DOI 10.1126/science.6648528; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; HERNANDEZ D, 1993, J MED GENET, V30, P135, DOI 10.1136/jmg.30.2.135; JASPERS NGJ, 1982, CANCER RES, V42, P335; Jorgensen TJ, 1996, INT J RADIAT BIOL, V69, P527, DOI 10.1080/095530096145535; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; KLEIJER WJ, 1994, INT J RADIAT BIOL, V66, pS167, DOI 10.1080/09553009414552001; Klein C, 1996, MOVEMENT DISORD, V11, P217, DOI 10.1002/mds.870110217; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; McConville CM, 1996, AM J HUM GENET, V59, P320; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; NEVALDINE B, 1993, RADIAT RES, V133, P370, DOI 10.2307/3578224; NOVE J, 1986, MUTAT RES, V163, P255, DOI 10.1016/0027-5107(86)90023-0; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; RYDBERG B, 1994, RADIAT RES, V139, P133, DOI 10.2307/3578657; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Taylor A. M. R., 1996, P138; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yamazaki V, 1998, CANCER RES, V58, P2316; ZHUO S, 1993, J BIOL CHEM, V268, P17754; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	46	776	792	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					577	587		10.1016/S0092-8674(00)81547-0	http://dx.doi.org/10.1016/S0092-8674(00)81547-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612394	Bronze			2022-12-01	WOS:000084278700005
J	Fine, JT; Colditz, GA; Coakley, EH; Moseley, G; Manson, JAE; Willett, WC; Kawachi, I				Fine, JT; Colditz, GA; Coakley, EH; Moseley, G; Manson, JAE; Willett, WC; Kawachi, I			A prospective study of weight change and health-related quality of life in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; SYMPTOMATIC GALLSTONES; DIABETES-MELLITUS; OLDER WOMEN; RISK FACTOR; OF-LIFE; QUESTIONNAIRE; OBESE; ASSOCIATION; MORTALITY	Context The mean body weight of US adults increased by 3.6 kg (7.6 lb) during the past 15 years, but few studies exist that examine the impact of such weight change on functional health status. Objective To investigate, prospectively, the association between weight change and health-related quality of life in women. Design and Setting Nurses' Health Study, a 4-year prospective observational study from 1992 to 1996, using the Medical Outcomes Study Short-Form 36 Health Status Survey (a self-administered 36-item questionnaire) to measure quality of life. Participants A cohort of 40 098 women (from 46-71 years old in 1992) grouped according to 3 patterns of weight change over the 4-year period: women whose weight remained within 2.25 kg (5 lb) of their baseline weight, women who lost 2.25 kg (5 lb) or more, and women who gained 2.25 kg (5 lb) or more. Main Outcome Measures Change in scores on 7 health-related quality-of-life dimensions: physical functioning, vitality, bodily pain, limitations in role functioning due to emotional or physical problems, social functioning, and mental health, measured by the Short-Form 36 Health Status Survey, Results A total of 15 602 women (39%) maintained their weight, 15 160 (38%) gained between 2.25 and 9.0 kg (5-20 lb), and 6667 (17%) lost between 2.25 and 9.0 kg (5-20 Ib), Weight gain was associated with decreased physical function and vitality, and increased bodily pain regardless of baseline weight. For example, the odds ratio for developing role limitations due to physical problems was 2.05 (95% confidence interval, 1.69-2.49) for the leanest women who gained 9.0 kg (20 lb) or more. Weight loss in overweight women was associated with improved physical function and vitality as well as decreased bodily pain. Weight change was more strongly associated with physical rather than mental health. The impact of weight change, especially weight gain, was just as strong in women 65 years and older as in women younger than 65 years. Conclusions These longitudinal data support current US guidelines for women of all body mass index levels to avoid weight gain. Weight maintenance and, in cases of overweight, weight loss are desirable and likely to be beneficial for physical function, vitality, and bodily pain.	Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Kawachi, I (corresponding author), Harvard Univ, Sch Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	ichiro.kawachi@channing.harvard.edu	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012806] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline; NIA NIH HHS [AG 12806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Coakley EH, 1998, INT J OBESITY, V22, P958, DOI 10.1038/sj.ijo.0800698; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; Fontaine KR, 1996, J FAM PRACTICE, V43, P265; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HENRY RR, 1986, DIABETES, V35, P990, DOI 10.2337/diabetes.35.9.990; Huang ZP, 1998, ANN INTERN MED, V128, P81, DOI 10.7326/0003-4819-128-2-199801150-00001; KATZEL LI, 1995, JAMA-J AM MED ASSOC, V274, P1915, DOI 10.1001/jama.274.24.1915; KOLOTKIN RL, 1995, OBES RES, V3, P49, DOI 10.1002/j.1550-8528.1995.tb00120.x; KRAL JG, 1992, AM J CLIN NUTR, V55, P611, DOI 10.1093/ajcn/55.2.611s; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAUNER LJ, 1994, JAMA-J AM MED ASSOC, V271, P1093, DOI 10.1001/jama.271.14.1093; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MARTON KI, 1981, ANN INTERN MED, V95, P568, DOI 10.7326/0003-4819-95-5-568; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; Rexrode KM, 1997, JAMA-J AM MED ASSOC, V277, P1539, DOI 10.1001/jama.277.19.1539; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RUMPEL C, 1994, INT J OBESITY, V18, P179; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Ware J.E., 1993, LINC RI QUAL METR IN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991	30	294	300	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2136	2142		10.1001/jama.282.22.2136	http://dx.doi.org/10.1001/jama.282.22.2136			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591335	Bronze			2022-12-01	WOS:000083971400032
J	Lord, J; Ducharme, FM; Stamp, RJ; Littlejohns, P; Churchill, R				Lord, J; Ducharme, FM; Stamp, RJ; Littlejohns, P; Churchill, R			Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY; ACCIDENT		Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, Hlth Care Evaluat Unit, London SW17 0RE, England; McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada; McGill Univ, Montreal Childrens Hosp, Dept Epidemiol & Biostat, Montreal, PQ H3H 1P3, Canada; Univ Southampton, Wessex Inst Hlth Res & Dev, Biomed Serv, Southampton SO16 7PX, Hants, England	St Georges University London; McGill University; McGill University; University of Southampton	Lord, J (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, Hlth Care Evaluat Unit, London SW17 0RE, England.		Ducharme, Francine/N-8332-2013; Lord, Joanne/H-1417-2011	Ducharme, Francine/0000-0001-5096-0614; Lord, Joanne/0000-0003-1086-1624; Churchill, Rachel/0000-0002-1751-0512				BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Lord J, 1999, HEALTH ECON, V8, P323, DOI 10.1002/(SICI)1099-1050(199906)8:4<323::AID-HEC431>3.0.CO;2-0; Partridge MR, 1997, J ACCID EMERG MED, V14, P16; Plotnick LH, 1998, BMJ-BRIT MED J, V317, P971, DOI 10.1136/bmj.317.7164.971; Stell IM, 1996, J ACCID EMERG MED, V13, P392	5	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1470	1471		10.1136/bmj.319.7223.1470	http://dx.doi.org/10.1136/bmj.319.7223.1470			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582930	Bronze, Green Published			2022-12-01	WOS:000084129200022
J	Nichols, MJ; Newsome, WT				Nichols, MJ; Newsome, WT			The neurobiology of cognition	NATURE			English	Article							HUMAN BRAIN; STIMULATION; PERCEPTION; CORTEX; SIGNAL; REWARD	Perhaps the deepest mysteries facing the natural sciences concern the higher functions of the central nervous system. Understanding how the brain gives rise to mental experiences looms as one of the central challenges for science in the new millennium.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Nichols, MJ (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.		Newsome, William T./W-7171-2019					Colby CL, 1999, ANNU REV NEUROSCI, V22, P319, DOI 10.1146/annurev.neuro.22.1.319; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Fuster J.M., 1995, MEMORY CEREBRAL CORT; GALLISTEL CR, 1994, COGNITION, V50, P151, DOI 10.1016/0010-0277(94)90026-4; GEORGE JS, 1995, J CLIN NEUROPHYSIOL, V12, P406, DOI 10.1097/00004691-199509010-00002; GoldmanRakic PS, 1996, P NATL ACAD SCI USA, V93, P13473, DOI 10.1073/pnas.93.24.13473; Hubel D.H., 1995, EYE BRAIN VISION; Hubener M, 1997, J NEUROSCI, V17, P9270; JACKSON F, 1982, PHILOS QUART, V32, P127, DOI 10.2307/2960077; MARTINEZ, 1999, NATURE NEUROSCI, V2, P364; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; NAGEL T, 1974, PHILOS REV, V83, P435, DOI 10.2307/2183914; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Parker AJ, 1998, ANNU REV NEUROSCI, V21, P227, DOI 10.1146/annurev.neuro.21.1.227; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Posner MI, 1998, P NATL ACAD SCI USA, V95, P763, DOI 10.1073/pnas.95.3.763; Romo R, 1999, CURR OPIN NEUROBIOL, V9, P487, DOI 10.1016/S0959-4388(99)80073-7; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; Schall JD, 1999, ANNU REV NEUROSCI, V22, P241, DOI 10.1146/annurev.neuro.22.1.241; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; Sell LA, 1999, EUR J NEUROSCI, V11, P1042, DOI 10.1046/j.1460-9568.1999.00522.x; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; Svoboda K, 1999, NAT NEUROSCI, V2, P65, DOI 10.1038/4569; Tanaka K, 1992, Curr Opin Neurobiol, V2, P502, DOI 10.1016/0959-4388(92)90187-P; THOMPSON E, 1992, PHILOS STUD, V68, P321, DOI 10.1007/BF00694850; Wandell BA, 1999, ANNU REV NEUROSCI, V22, P145, DOI 10.1146/annurev.neuro.22.1.145; WANG SSH, 1995, NEURON, V15, P755, DOI 10.1016/0896-6273(95)90167-1	28	42	43	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C35	C38		10.1038/35011531	http://dx.doi.org/10.1038/35011531			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	261MZ	10591223	Bronze			2022-12-01	WOS:000084014100005
J	Dano, S; Sorensen, PG; Hynne, F				Dano, S; Sorensen, PG; Hynne, F			Sustained oscillations in living cells	NATURE			English	Article							BELOUSOV-ZHABOTINSKY REACTION; BRIGGS-RAUSCHER REACTION; METABOLIC OSCILLATIONS; GLYCOLYTIC OSCILLATIONS; HOPF-BIFURCATION; HEART-CELLS; YEAST-CELLS; BETA-CELLS; MAKE-UP; MUSCLE	Glycolytic oscillations in yeast have been studied for many years simply by adding a glucose pulse to a suspension of cells and measuring the resulting transient oscillations of NADH(1-12). Here we show, using a suspension of yeast cells, that living cells can be kept ia a well defined oscillating state indefinitely when starved cells, glucose and cyanide are pumped into a cuvette with outflow of surplus liquid. Our results show that the transitions between stationary and oscillatory behaviour are uniquely described mathematically by the Hopf bifurcation(13). This result characterizes the dynamical properties close to the transition point. Our perturbation experiments show that the cells remain strongly coupled very close to the transition. Therefore, the transition takes place in each of the cells and is not a desynchronization phenomenon. With these two observations, a study of the kinetic details of glycolysis, as it actually takes place in a living cell, is possible using experiments designed in the framework of nonlinear dynamics. Acetaldehyde is known to synchronize the oscillations(10). Our results show that glucose is another messenger substance, as long as the glucose transporter is not saturated.	Univ Copenhagen, HC Orsted Inst, Dept Chem & CATS, DK-2100 Copenhagen, Denmark	University of Copenhagen	Dano, S (corresponding author), Univ Copenhagen, HC Orsted Inst, Dept Chem & CATS, Univ Pk 5, DK-2100 Copenhagen, Denmark.							ALDRIDGE J, 1976, NATURE, V259, P670, DOI 10.1038/259670a0; CHOU HF, 1992, AM J PHYSIOL, V262, pE800, DOI 10.1152/ajpendo.1992.262.6.E800; Civelek VN, 1997, DIABETES, V46, P51, DOI 10.2337/diabetes.46.1.51; DUYSENS LNM, 1957, BIOCHIM BIOPHYS ACTA, V24, P19, DOI 10.1016/0006-3002(57)90141-5; FRENKEL R, 1968, ARCH BIOCHEM BIOPHYS, V125, P157, DOI 10.1016/0003-9861(68)90650-4; GHOSH A, 1964, BIOCHEM BIOPH RES CO, V16, P174, DOI 10.1016/0006-291X(64)90357-2; GHOSH AK, 1971, ARCH BIOCHEM BIOPHYS, V145, P319, DOI 10.1016/0003-9861(71)90042-7; GOLDBETER A, 1996, BIOCH OSCILLATIONS C, P6; HESS B, 1968, H-S Z PHYSIOL CHEM, V349, P1567, DOI 10.1515/bchm2.1968.349.2.1567; HYNNE F, 1993, J CHEM PHYS, V98, P219, DOI 10.1063/1.464667; HYNNE F, 1990, J CHEM PHYS, V92, P1747, DOI 10.1063/1.458056; KOSEK J, 1994, J PHYS CHEM-US, V98, P6128, DOI 10.1021/j100075a015; KREUZBERG KH, 1979, J INTERDISCIPL CYCLE, V10, P41; MATTHEWS PC, 1991, PHYSICA D, V52, P293, DOI 10.1016/0167-2789(91)90129-W; OROURKE B, 1994, SCIENCE, V265, P962, DOI 10.1126/science.8052856; OROURKE B, 1995, ADV EXP MED BIOL, V382, P165; PYE EK, 1969, CAN J BOTANY, V47, P271, DOI 10.1139/b69-040; Richard P, 1996, YEAST, V12, P731; Richard P, 1996, EUR J BIOCHEM, V235, P238, DOI 10.1111/j.1432-1033.1996.00238.x; RICHARD P, 1994, FEBS LETT, V341, P223, DOI 10.1016/0014-5793(94)80461-3; RICHARD P, 1993, FEBS LETT, V318, P80, DOI 10.1016/0014-5793(93)81332-T; Siegel G, 1997, INT J MICROCIRC, V17, P360, DOI 10.1159/000179252; Teusink B, 1996, J BIOL CHEM, V271, P24442, DOI 10.1074/jbc.271.40.24442; TORNHEIM K, 1973, J BIOL CHEM, V248, P2670; Tornheim K, 1997, DIABETES, V46, P1375, DOI 10.2337/diabetes.46.9.1375; VUKOJEVIC V, 1993, J PHYS CHEM-US, V97, P4091, DOI 10.1021/j100118a027; Vukojevic V, 1996, J PHYS CHEM-US, V100, P17175, DOI 10.1021/jp960785o; WINFREE AT, 1972, ARCH BIOCHEM BIOPHYS, V149, P388, DOI 10.1016/0003-9861(72)90337-2	28	208	210	2	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					320	322		10.1038/46329	http://dx.doi.org/10.1038/46329			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580506				2022-12-01	WOS:000083813700056
J	Chua, K; Reed, R				Chua, K; Reed, R			The RNA splicing factor hSlu7 is required for correct 3 ' splice-site choice	NATURE			English	Article							2ND CATALYTIC STEP; U5 SNRNA LOOP-1; CROSS-LINKING; YEAST; PROTEIN; 3'-SPLICE-SITE; MUTATIONS; SELECTION; SUGGEST; SLU7	The production of correctly spliced messenger RNA requires two catalytic splicing steps(1-3). During step II, exon 1 attacks an adenine-guanine (AG) dinucleotide at the 3' splice site. This AG is usually located between 18 and 40 nucleotides downstream from the branch site, and closer AGs are skipped in favour of AGs located more optimally downstream(4-6). At present, little is understood about how the correct AG is distinguished from other AGs. Here we describe a metazoan splicing factor (hSlu7) that is required for selection of the correct AG. In the absence of hSlu7, use of the correct AG is suppressed and incorrect AGs are activated. We investigated this loss of fidelity by analysing spliceosomes assembled in the absence of hSlu7. These studies reveal that exon 1 is loosely associated with these spliceosomes. Thus, the improperly held exon cannot access the correct AG, but can attack other AGs indiscriminately. We conclude that hSlu7 is required to hold exon 1 tightly within the spliceosome for attack on a prespecified AG.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Reed, R (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							Brys A, 1996, RNA, V2, P707; Burge C.B., 1999, RNA WORLD, V37, P525; Chiara MD, 1997, EMBO J, V16, P4746, DOI 10.1093/emboj/16.15.4746; Chua K, 1999, GENE DEV, V13, P841, DOI 10.1101/gad.13.7.841; CORTES JJ, 1993, EMBO J, V12, P5181, DOI 10.1002/j.1460-2075.1993.tb06213.x; DAS R, IN PRESS RNA; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; FRANK D, 1992, GENE DEV, V6, P2112, DOI 10.1101/gad.6.11.2112; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; Horowitz DS, 1997, GENE DEV, V11, P139, DOI 10.1101/gad.11.1.139; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; MOORE MJ, 1993, RNA WORLD, P306; Newman AJ, 1995, RNA, V1, P968; Newman AJ, 1997, EMBO J, V16, P5797, DOI 10.1093/emboj/16.19.5797; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; O'Keefe RT, 1998, EMBO J, V17, P565, DOI 10.1093/emboj/17.2.565; OKeefe RT, 1996, CELL, V86, P679, DOI 10.1016/S0092-8674(00)80140-3; REED R, 1997, EUKARYOTIC MRNA PROC, P103; Segault V, 1999, MOL CELL BIOL, V19, P2782; SMITH CW, 1993, MOL CELL BIOL, V13, P4949; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; Umen JG, 1996, GENETICS, V143, P723; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Umen JG, 1995, RNA, V1, P869; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542	27	76	78	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					207	210		10.1038/46086	http://dx.doi.org/10.1038/46086			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647016				2022-12-01	WOS:000083716400057
J	Regan, FAM; Hewitt, P; Barbara, JAJ; Contreras, M				Regan, FAM; Hewitt, P; Barbara, JAJ; Contreras, M		TTI Study Grp	Prospective investigation of transfusion transmitted infection in recipients of over 20 000 units of blood	BRITISH MEDICAL JOURNAL			English	Article							HEPATITIS-C VIRUS; TRANSMISSION; DONORS; RISK; SURGEON; HIV	Objectives To follow up recipients of 20 000 units of blood to identify any transmissions of infections through blood transfusion. Design Follow up study of recipients of transfusion. Setting 22 hospitals in north London. Participant Adult patients who had recently been transfused. Main outcome measures Patients had further blood samples taken at 9 months that were tested for markers of hepatitis B and C and HIV and human T cell leukaemia/lymphoma virus type I or II (HTLV) infections. Recent infections were distinguished from pre-existing infections by comparison with blood samples taken before transfusion. Results 9220 patients were recruited, and 5579 recipients of 21 923 units of blood were followed up. No transfusion transmitted infections were identified. The incidence of transfusion transmitted infections was 0 in 21 043 units (95% confidence interval for risk 0 to 1 in 5706 recipients) for hepatitis B; 0 in 21 800 units (0 to 1 in 5911 recipients) for hepatitis C; 0 in 21 923 units (0 to 1 in 5944 recipients) for HIV; and 0 in 21 902 units (0 to 1 in 5939 recipients) for human T cell leukaemia/lymphoma virus. Three patients acquired hepatitis B during or after hospital admission but not through transfusion; 176 (3%) had pre-existing hepatitis B infection. Sixteen (0.29%) patients had hepatitis C, and five (0.09%) had human T cell leukaemia/lymphoma virus. Conclusions The current risk of transfusion transmitted infections in the United Kingdom is very small, though hospital acquired infections may arise from sources other than transfusion. A considerable proportion of patients have pre-existing infections.	Natl Blood Serv, N London Ctr, London NW9 5BG, England		Hewitt, P (corresponding author), Natl Blood Serv, N London Ctr, London & S East Zone, London NW9 5BG, England.							ALLAIN JP, 1995, TRANSFUSION MED, V5, P259, DOI 10.1111/j.1365-3148.1995.tb00211.x; ALLANDER T, 1995, LANCET, V345, P603, DOI 10.1016/S0140-6736(95)90518-9; ALTER HJ, 1992, HEPATOLOGY, V15, P350, DOI 10.1002/hep.1840150228; BELL DM, 1993, J PUBLIC HEALTH DENT, V53, P170, DOI 10.1111/j.1752-7325.1993.tb02697.x; BLAJCHMAN MA, 1995, LANCET, V345, P21, DOI 10.1016/S0140-6736(95)91153-7; BRENNAN M, 1993, BRIT MED J, V307, P1235, DOI 10.1136/bmj.307.6914.1235; COHEN ND, 1989, NEW ENGL J MED, V320, P1172, DOI 10.1056/NEJM198905043201803; CONTRERAS M, 1991, LANCET, V337, P753, DOI 10.1016/0140-6736(91)91370-A; CONTRERAS M, 1993, CURRENT MED LIT RSM, V4, P67; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; FLANAGAN P, 1995, VOX SANG, V68, P220, DOI 10.1111/j.1423-0410.1995.tb02576.x; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; KOJIMA M, 1991, VOX SANG, V60, P34, DOI 10.1111/j.1423-0410.1991.tb00868.x; Korelitz JJ, 1996, TRANSFUSION, V36, P203, DOI 10.1046/j.1537-2995.1996.36396182135.x; MOSELY JW, 1995, TRANSFUSION, V35, P5; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; WILLIAMSON LM, 1998, SHOT ANN REPORT 1996; 1995, NIH CONSENSUS STATEM, V13, P1	19	63	72	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					403	406		10.1136/bmj.320.7232.403	http://dx.doi.org/10.1136/bmj.320.7232.403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669443	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000085377400020
J	Bruce, MC; Donnelly, CA; Alpers, MP; Galinski, MR; Barnwell, JW; Walliker, D; Day, KP				Bruce, MC; Donnelly, CA; Alpers, MP; Galinski, MR; Barnwell, JW; Walliker, D; Day, KP			Cross-species interactions between malaria parasites in humans	SCIENCE			English	Article							PAPUA-NEW-GUINEA; PLASMODIUM-FALCIPARUM; DENSITY-DEPENDENCE; IMMUNITY; VIVAX; RESISTANCE; DYNAMICS; CHILDREN; MADANG; TESTS	The dynamics of multiple Plasmodium infections in asymptomatic children Living under intense malaria transmission pressure provide evidence for a density-dependent regulation that transcends species as well as genotype. This regulation, in combination with species- and genotype-specific immune responses, results in nonindependent, sequential episodes of infection with each species.	Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England; Papua New Guinea Inst Med Res, Madang, Papua N Guinea; Emory Univ, Sch Med, Emory Vaccine Ctr Yerkes, Dept Med,Div Infect Dis, Atlanta, GA 30329 USA; Ctr Dis Control & Prevent, Biol & Diagnost Branch, Div Parasit Dis, Atlanta, GA 30341 USA; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JN, Midlothian, Scotland	University of Oxford; PNG Institute Of Medical Research; Emory University; Centers for Disease Control & Prevention - USA; University of Edinburgh	Bruce, MC (corresponding author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England.		Day, Karen/F-3697-2015	Day, Karen/0000-0002-6115-6135; Donnelly, Christl/0000-0002-0195-2463	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024710, R21AI137545, U01AI037545, R22AI024710] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24710, AI37545] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABIKER H, 1994, T ROY SOC TROP MED H, V88, P328, DOI 10.1016/0035-9203(94)90103-1; BABIKER HA, 1991, T ROY SOC TROP MED H, V85, P578, DOI 10.1016/0035-9203(91)90349-4; Boyd M. F., 1937, American Journal of Tropical Medicine, V17, P855; BOYD MARK F., 1938, AMER JOUR TROP MED, V18, P521; BROWN KN, 1990, IMMUNOL LETT, V25, P97, DOI 10.1016/0165-2478(90)90098-B; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; BRUCE M, IN PRESS PARASITOLOG; Bruce MC, 1999, AM J TROP MED HYG, V61, P518, DOI 10.4269/ajtmh.1999.61.518; BULMER MG, 1975, BIOMETRICS, V31, P901, DOI 10.2307/2529815; BURKOT TR, 1987, B WORLD HEALTH ORGAN, V65, P375; CATTANI JA, 1986, AM J TROP MED HYG, V35, P3, DOI 10.4269/ajtmh.1986.35.3; Ciuca M., 1934, Transactions of the Royal Society of Tropical Medicine and Hygiene London, V27, P619, DOI 10.1016/S0035-9203(34)90111-5; COHEN JE, 1973, Q REV BIOL, V48, P467, DOI 10.1086/407705; COX MJ, 1994, T ROY SOC TROP MED H, V88, P191, DOI 10.1016/0035-9203(94)90292-5; Farnert A, 1997, AM J TROP MED HYG, V56, P538, DOI 10.4269/ajtmh.1997.56.538; FOX DR, 1995, OECOLOGIA, V103, P435, DOI 10.1007/BF00328681; Galinski MR, 1999, MOL BIOCHEM PARASIT, V101, P131, DOI 10.1016/S0166-6851(99)00063-8; GUNEWARDENA DM, 1994, MEM I O CRUZ, V89, P61; JEFFERY GM, 1966, B WORLD HEALTH ORGAN, V35, P873; Karunaweera ND, 1998, AM J TROP MED HYG, V58, P204, DOI 10.4269/ajtmh.1998.58.204; KWIATKOWSKI D, 1995, PARASITOL TODAY, V11, P206, DOI 10.1016/0169-4758(95)80079-4; KYES S, 1993, EXP PARASITOL, V77, P473, DOI 10.1006/expr.1993.1108; Maitland K, 1997, PARASITOL TODAY, V13, P227, DOI 10.1016/S0169-4758(97)01061-2; MOLINEAUX L, 1980, AM J TROP MED HYG, V29, P725, DOI 10.4269/ajtmh.1980.29.725; NTOUMI F, 1995, AM J TROP MED HYG, V52, P81, DOI 10.4269/ajtmh.1995.52.81; Ockenhouse CF, 1998, J INFECT DIS, V177, P1664, DOI 10.1086/515331; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; RITCHIE TL, 1988, PARASITOLOGY, V96, P607; Staalsoe T, 1998, PARASITOL TODAY, V14, P177, DOI 10.1016/S0169-4758(98)01228-9; TALIAFERRO WH, 1939, MELARIOLOGY; WOLDA H, 1993, OECOLOGIA, V95, P581, DOI 10.1007/BF00317444	31	180	183	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					845	848		10.1126/science.287.5454.845	http://dx.doi.org/10.1126/science.287.5454.845			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657296				2022-12-01	WOS:000085136400043
J	Yangco, BG; Von Bargen, JC; Moorman, AC; Holmberg, SD				Yangco, BG; Von Bargen, JC; Moorman, AC; Holmberg, SD		HIV Outpatient Study Investigators	Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article								Background: HIV-infected patients with sustained immunologic improvement from antiretroviral therapy may be able to discontinue chemoprophylaxis against Pneumocystis carinii pneumonia (PCP). Objective: To compare PCP incidence in HIV-infected patients who had sustained CD4(+) lymphocyte counts greater than 200 cells/mm(3) and who either discontinued or continued PCP prophylaxis. Design: Nonrandomized prospective cohort study. Setting::10 HIV clinics in eight U.S, cities. Patients: 146 patients had follow-up visits for a mean of 18.2 months after discontinuation of PCP prophylaxis, and 345 patients who continued PCP prophylaxis had follow-up visits for a mean of 14.0 months. Measurements: Incidence of PCP. Results: Patients who discontinued PCP prophylaxis had higher maximum and minimum CD4(+) cell counts and lower vira I loads than patients who continued PCP prophylaxis. Pneumocystis carinii pneumonia did not develop in either group (upper 95% exact binomial confidence limit of incidence for those who discontinued PCP prophylaxis, 2.3/100 person-yea rs). Conclusions: Discontinuation of PCP chemoprophylaxis may be appropriate for some HIV-infected ambulatory patients.	Infect Dis Res Inst, Tampa, FL USA; Ctr Dis Control & Prevent, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Yangco, BG (corresponding author), 4728 N Habana Ave,Suite 303, Tampa, FL 33614 USA.			Moorman, Anne/0000-0003-2411-2798	PHS HHS [U64/CCU5096889] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; GARCIAVAZQUEZ E, 1998, 38 INT C ANT AG CHEM; LOPEZ JC, 1999, 6 C RETR OPP INF 31; MARADONA JA, 1998, 38 INT C ANT AG CHEM; Moorman AC, 1998, J ACQ IMMUN DEF SYND, V19, P182, DOI 10.1097/00042560-199810010-00013; Moorman AC, 1999, ANN EPIDEMIOL, V9, P349, DOI 10.1016/S1047-2797(99)00005-8; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; RAVAUX I, 1998, 38 INT C ANT AG CHEM; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; Von Bargen J, 1998, JAMA-J AM MED ASSOC, V280, P29, DOI 10.1001/jama.280.1.29; 1999, MMWR MORB MORTAL WKL, V48, P4	11	37	38	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2000	132	3					201	205		10.7326/0003-4819-132-3-200002010-00005	http://dx.doi.org/10.7326/0003-4819-132-3-200002010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276XE	10651600				2022-12-01	WOS:000084903000004
J	Chadwick, D				Chadwick, D			Seizures and epilepsy after traumatic brain injury	LANCET			English	Editorial Material							POPULATION				Chadwick, D (corresponding author), Univ Liverpool, Walton Ctr Neurol & Neurosurg, Liverpool L9 7LJ, Merseyside, England.							Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; GODDARD GV, 1969, EXP NEUROL, V25, P294; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; Jennett B., 1975, EPILEPSY NONMISSILE, V2nd; King MA, 1998, LANCET, V352, P1007, DOI 10.1016/S0140-6736(98)03543-0; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593	10	23	24	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					334	336		10.1016/S0140-6736(99)00452-3	http://dx.doi.org/10.1016/S0140-6736(99)00452-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665550				2022-12-01	WOS:000085122100006
J	Delfs, JM; Zhu, Y; Druhan, JP; Aston-Jones, G				Delfs, JM; Zhu, Y; Druhan, JP; Aston-Jones, G			Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion	NATURE			English	Article							NUCLEUS-ACCUMBENS; OPIOID WITHDRAWAL; CLONIDINE; RATS; LESIONS; MEDULLA; LOCUS; RETROGRADE; MORPHINE; NALOXONE	Cessation of drug use in chronic opiate abusers produces a severe withdrawal syndrome that is highly aversive, and avoidance of withdrawal or associated stimuli is a major factor contributing to opiate abuse(1,2). Increased noradrenaline in the brain has long been implicated in opiate withdrawal(3), but it has not been clear which noradrenergic systems are invoked. Here we show that microinjection of beta-noradrenergic-receptor antagonists, or of an alpha 2-receptor agonist, into the bed nucleus of the stria terminalis (BNST) in rats markedly attenuates opiate-withdrawal-induced conditioned place aversion, Immunohistochemical studies revealed that numerous BNST-projecting cells in the A1 and A2 noradrenergic cell groups of the caudal medulla were activated during withdrawal Lesion of these ascending medullary projections also greatly reduced opiate-withdrawal-induced place aversion. whereas lesion of locus coeruleus noradrenergic projections had no effect on opiate-withdrawal behaviour. We conclude that noradrenergic inputs to the BNST from the caudal medulla are critically involved in the aversiveness of opiate withdrawal.	Univ Penn, Sch Med, Dept Psychiat, VA Med Ctr 151, Philadelphia, PA 19104 USA	University of Pennsylvania	Aston-Jones, G (corresponding author), Univ Penn, Sch Med, Dept Psychiat, VA Med Ctr 151, Univ & Woodland Ave, Philadelphia, PA 19104 USA.							Akaoka H., 1992, Society for Neuroscience Abstracts, V18, P374; Alheid George F., 1995, P495; ASTONJONES G, 1993, NEUROBIOLOGY OPIATES, P175; Bechara A, 1998, PHARMACOL BIOCHEM BE, V59, P1, DOI 10.1016/S0091-3057(97)00047-6; Blessing WW, 1997, LOWER BRAINSTEM BODI; BRITTON KT, 1984, LIFE SCI, V34, P133, DOI 10.1016/0024-3205(84)90583-6; Brownstein MJ, 1984, HDB CHEM NEUROANAT 1, P23; Caille S, 1999, J PHARMACOL EXP THER, V290, P881; Chen S, 1996, NEUROSCIENCE, V71, P443, DOI 10.1016/0306-4522(95)00437-8; CHIENG B, 1995, NEUROSCI LETT, V186, P37, DOI 10.1016/0304-3940(95)11276-3; Christie MJ, 1997, TRENDS PHARMACOL SCI, V18, P134, DOI 10.1016/S0165-6147(97)01045-6; DROLET G, 1992, J NEUROSCI, V12, P3162, DOI 10.1523/JNEUROSCI.12-08-03162.1992; EVERITT BJ, 1983, NEUROSCIENCE, V10, P397, DOI 10.1016/0306-4522(83)90142-2; FRITSCHY JM, 1990, J CHEM NEUROANAT, V3, P309; GOLD MS, 1978, LANCET, V2, P599; GROSZ HJ, 1972, LANCET, V2, P564; HARRIS GC, 1994, NATURE, V371, P155, DOI 10.1038/371155a0; HARRIS GC, 1993, NEUROPSYCHOPHARMACOL, V9, P303, DOI 10.1038/npp.1993.66; HIGGINS GA, 1994, PHARMACOL BIOCHEM BE, V48, P1, DOI 10.1016/0091-3057(94)90489-8; Maldonado R, 1997, NEUROSCI BIOBEHAV R, V21, P91, DOI 10.1016/0149-7634(95)00061-5; McKittrick C. R., 1999, Society for Neuroscience Abstracts, V25, P948; Nader K, 1996, BEHAV NEUROSCI, V110, P389, DOI 10.1037/0735-7044.110.2.389; O'Brien C P, 1988, NIDA Res Monogr, V84, P44; POTHOS E, 1991, BRAIN RES, V566, P348, DOI 10.1016/0006-8993(91)91724-F; ROEHRICH H, 1987, AM J PSYCHIAT, V144, P1099; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; STINUS L, 1990, NEUROSCIENCE, V37, P767, DOI 10.1016/0306-4522(90)90106-E; STORNETTA RL, 1993, BRAIN RES, V624, P19, DOI 10.1016/0006-8993(93)90055-R; TEJANIBUTT SM, 1992, J PHARMACOL EXP THER, V260, P427; TERENZI MG, 1995, BRAIN RES, V672, P289, DOI 10.1016/0006-8993(94)01453-O	30	359	365	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					430	434		10.1038/35000212	http://dx.doi.org/10.1038/35000212			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667795				2022-12-01	WOS:000085121100051
J	Glezen, WP; Greenberg, SB; Atmar, RL; Piedra, PA; Couch, RB				Glezen, WP; Greenberg, SB; Atmar, RL; Piedra, PA; Couch, RB			Impact of respiratory virus infections on persons with chronic underlying conditions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYNCYTIAL VIRUS; AIR-POLLUTION; DISEASE HOSPITALIZATIONS; INFLUENZA EPIDEMICS; VIRAL-INFECTIONS; ASTHMA; CHILDREN; ADULTS; ILLNESS; VACCINE	Context While hospitalization rates have declined overall, hospitalizations for acute lower respiratory tract infections have increased steadily since 1980. Development of new approaches for prevention of acute respiratory tract conditions requires studies of the etiologies of infections and quantification of the risk of hospitalization for vulnerable patients. Objective To determine the frequency of specific virus infections associated with acute respiratory tract conditions leading to hospitalization of chronically ill patients. Design Analysis of viral etiology of patients hospitalized with acute respiratory tract conditions between July 1991 and June 1995. Setting Four large clinics and related hospitals serving diverse populations representative of Harris County, Texas. Patients A total of 1029 patients who were hospitalized for pneumonia, tracheobronchitis, bronchiolitis, croup, exacerbations of asthma or chronic obstructive pulmonary disease, and/or congestive heart failure. Main Outcome Measure Virus infection, defined by culture, antigen detection, and significant rise in serum antibodies, by underlying condition; hospitalization rates by low- vs middle-income status. Results Ninety-three percent of patients older than 5 years had a chronic underlying condition; a chronic pulmonary condition was most common. Patients with chronic pulmonary disease from low-income populations were hospitalized at a rate of 398.6 per 10 000, almost 8 times higher than the rate for patients from middle-income groups (52.2 per 10 000; P<.001). Of the 403 patients (44.4% of adults and 32.3% of children) who submitted convalescent serum specimens for antibody testing, respiratory tract virus infections were detected in 181 (44.9%). influenza, parainfluenza, and respiratory syncytial virus (RSV) infections accounted for 75% of all virus infections. Conclusions Our study suggests that respiratory virus infections commonly trigger serious acute respiratory conditions that result in hospitalization of patients with chronic underlying conditions, highlighting the need for development of effective vaccines for these viruses, especially for parainfluenza and RSV.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Glezen, WP (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.	wglezen@bcm.tmc.edu	Atmar, Robert/AFQ-5392-2022	Atmar, Robert/0000-0001-9989-6772	NIAID NIH HHS [AI15103] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015103] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON M, 1994, J ASTHMA, V31, P367, DOI 10.3109/02770909409061316; AGIUS G, 1990, J MED VIROL, V30, P117, DOI 10.1002/jmv.1890300208; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; BAXTER BD, 1977, J CLIN MICROBIOL, V6, P19; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42, DOI 10.1164/ajrccm/145.1.42; BUSSE WW, 1993, ASTHMA, P345; Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137; ENGLUND JA, 1988, ANN INTERN MED, V109, P203, DOI 10.7326/0003-4819-109-3-203; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; Fleiss J.L., 1981, STAT METHODS RATES P; FRANK AL, 1979, J CLIN MICROBIOL, V10, P32, DOI 10.1128/JCM.10.1.32-36.1979; FRANK AL, 1980, J CLIN MICROBIOL, V12, P426, DOI 10.1128/JCM.12.3.426-432.1980; GARDNER G, 1984, J EPIDEMIOL COMMUN H, V38, P42, DOI 10.1136/jech.38.1.42; GILL EP, 1994, J CLIN MICROBIOL, V32, P2372, DOI 10.1128/JCM.32.10.2372-2376.1994; GLEZEN WP, 1987, J INFECT DIS, V155, P1119, DOI 10.1093/infdis/155.6.1119; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GLEZEN WP, 1977, PEDIATR RES, V11, P239; GLEZEN WP, 1984, CLIN CHEST MED, V5, P635; HALFON N, 1993, PEDIATRICS, V91, P56; Han LL, 1999, J INFECT DIS, V179, P25, DOI 10.1086/314567; Kim PE, 1996, CLIN INFECT DIS, V22, P100, DOI 10.1093/clinids/22.1.100; LAMY ME, 1973, CHEST, V63, P336, DOI 10.1378/chest.63.3.336; Marx A, 1999, CLIN INFECT DIS, V29, P134, DOI 10.1086/520142; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124; Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Pamuk E, 1998, SOCIOECONOMIC STATUS; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; PHILIT F, 1992, REV MAL RESPIR, V9, P191; PIEDRA PA, 1993, VACCINE, V11, P1415, DOI 10.1016/0264-410X(93)90170-3; PIEDRA PA, 1995, VACCINE, V13, P1095, DOI 10.1016/0264-410X(95)00034-X; Piedra PA, 1996, PEDIATR INFECT DIS J, V15, P23, DOI 10.1097/00006454-199601000-00006; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123, DOI 10.1164/ajrccm/145.5.1123; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; Simonsen L, 1998, ARCH INTERN MED, V158, P1923, DOI 10.1001/archinte.158.17.1923; SMITH CB, 1980, J INFECT DIS, V141, P271, DOI 10.1093/infdis/141.3.271; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; WOOD PR, 1993, PEDIATRICS, V91, P62	42	386	402	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					499	505		10.1001/jama.283.4.499	http://dx.doi.org/10.1001/jama.283.4.499			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659876	Bronze			2022-12-01	WOS:000084879800029
J	Schairer, C; Lubin, J; Troisi, R; Sturgeon, S; Brinton, L; Hoover, R				Schairer, C; Lubin, J; Troisi, R; Sturgeon, S; Brinton, L; Hoover, R			Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROLIFERATION; WOMEN	Context Whether menopausal hormone replacement therapy using a combined estrogen-progestin regimen increases risk of breast cancer beyond that associated with estrogen alone is unknown. Objective To determine whether increases in risk associated with the estrogen-progestin regimen are greater than those associated with estrogen alone. Design Cohort study of follow-up data for 1980-1995 from the Breast Cancer Detection Demonstration Project, a nationwide breast cancer screening program. Setting Twenty-nine screening centers throughout the United States. Participants A total of 46 355 postmenopausal women (mean age at start of followup, 58 years). Main Outcome Measure Incident breast cancers by recency, duration, and type of hormone use. Results During follow-up, 2082 cases of breast cancer were identified. Increases in risk with estrogen only and estrogen-progestin only were restricted to use within the previous 4 years (relative risk [RR], 1.2 [95% confidence interval {CI}, 1.0-1.4] and 1.4 [95% CI, 1.1-1.8], respectively); the relative risk increased by 0.01 (95% CI, 0.002-0.03) with each year of estrogen-only use and by 0.08 (95% CI, 0.02-0.16) with each year of estrogen-progestin-only use among recent users, after adjustment for mammographic screening, age at menopause, body mass index (BMI), education, and age. The P value associated with the test of homogeneity of these estimates was .02. Among women with a BMI of 24.4 kg/m(2) or less, increases in RR with each year of estrogen-only use and estrogen-progestin-only use among recent users were 0.03 (95% CI, 0.01-0.06) and 0.12 (95% CI, 0.02-0.25), respectively. These associations were evident for the majority of invasive tumors with ductal histology and regardless of extent of invasive disease. Risk in heavier women did not increase with use of estrogen only or estrogen-progestin only. Conclusion Our data suggest that the estrogen-progestin regimen increases breast cancer risk beyond that associated with estrogen alone.	NCI, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA; Social & Sci Syst Inc, Bethesda, MD USA; Univ Massachusetts, Dept Biostat & Epidemiol, Amherst, MA 01003 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Social & Scientific Systems; University of Massachusetts System; University of Massachusetts Amherst	Schairer, C (corresponding author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS Room 7080,MSC 7234, Rockville, MD 20852 USA.		Brinton, Louise A/G-7486-2015	Brinton, Louise A/0000-0003-3853-8562	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP010113] Funding Source: NIH RePORTER	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Breslow NE, 1987, STAT METHODS CANC RE; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Gapstur SM, 1999, JAMA-J AM MED ASSOC, V281, P2091, DOI 10.1001/jama.281.22.2091; Greendale GA, 1997, AM J EPIDEMIOL, V146, P763; Hargreaves DF, 1998, BRIT J CANCER, V78, P945, DOI 10.1038/bjc.1998.606; LAIDLAW IJ, 1995, ENDOCRINOLOGY, V136, P164, DOI 10.1210/en.136.1.164; Persson I, 1999, CANCER CAUSE CONTROL, V10, P253, DOI 10.1023/A:1008909128110; Pike MC, 1998, AM J EPIDEMIOL, V147, P718; Poutanen M, 1995, J STEROID BIOCHEM, V55, P525, DOI 10.1016/0960-0760(95)00201-4; PRESTON DL, 1996, EPICURE SOFTWARE REL; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; Schairer C, 1999, J NATL CANCER I, V91, P264, DOI 10.1093/jnci/91.3.264	15	786	821	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					485	491		10.1001/jama.283.4.485	http://dx.doi.org/10.1001/jama.283.4.485			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659874	Bronze			2022-12-01	WOS:000084879800027
J	Haslberger, AG				Haslberger, AG			Genetic technologies - Monitoring and labeling for genetically modified products	SCIENCE			English	Article									Fed Chancellory, Sci Sect Biotechnol, A-1030 Vienna, Austria		Haslberger, AG (corresponding author), Fed Chancellory, Sci Sect Biotechnol, Radetzkystr 2, A-1030 Vienna, Austria.	hasi1@via.at	Haslberger, Alexander G/B-9120-2013	Haslberger, Alexander/0000-0001-9699-537X				Butler D, 1999, NATURE, V398, P651, DOI [10.1038/19348, 10.1038/19381]; *EUR COMM SCI COMM, 1999, OP SCP BT RES MON; Ewen SWB, 1999, LANCET, V354, P684, DOI 10.1016/S0140-6736(05)77668-6; *HOUS COMM ENV AUD, 1999, GMOS ENV COORD GOV P; KILMAN S, WALL STREET J; Lehrman S, 1999, NATURE, V401, P107, DOI 10.1038/43536; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; Miller HI, 1999, SCIENCE, V284, P1471, DOI 10.1126/science.284.5419.1471; Mitchell P, 1999, LANCET, V353, P1769, DOI 10.1016/S0140-6736(99)90090-9; MITSCH FJ, 1999, DTSCH BANC A BR 0712; Reichhardt T, 1999, NATURE, V400, P298, DOI 10.1038/22371; Roush RT, 1997, NAT BIOTECHNOL, V15, P816, DOI 10.1038/nbt0997-816; *UK HOUS COMM SCI, 1999, SCI ADV SYST GEN MOD; 1999, AGRAFOOD BIOTEC 1110, P15; 1999, AGRAFOOD BIOTEC 0914, P11	15	26	28	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2000	287	5452					431	432		10.1126/science.287.5452.431	http://dx.doi.org/10.1126/science.287.5452.431			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10671171				2022-12-01	WOS:000084929900026
J	Maddox, J				Maddox, J			Positioning the goalposts - The best environmental policy depends on how you frame the question.	NATURE			English	Editorial Material																			0	6	6	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					139	139		10.1038/35003065	http://dx.doi.org/10.1038/35003065			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646578	Bronze			2022-12-01	WOS:000084835300028
J	Watnick, RS; Gottesman, ME				Watnick, RS; Gottesman, ME			Binding of transcription termination protein nun to nascent RNA and template DNA	SCIENCE			English	Article							ESCHERICHIA-COLI; ANTITERMINATION; POLYMERASE	The amino-terminal arginine-rich motif of coliphage HK022 Nun binds phage lambda nascent transcript, whereas the carboxyl-terminal domain interacts with RNA polymerase (RNAP) and blocks transcription elongation. RNA binding is inhibited by zinc (Zn2+) and stimulated by Escherichia coli NusA, To study these interactions. the Nun carboxyl terminus was extended by a cysteine residue conjugated to a photochemical cross-linker. The carboxyl terminus contacted NusA and made Zn2+-dependent intramolecular contacts. When Nun was added to a paused transcription elongation complex, it cross-linked to the DNA template. Nun may arrest transcription by anchoring RNAP to DNA.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Inst Canc Res, New York, NY 10032 USA	Columbia University; Columbia University	Gottesman, ME (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.							BULLARD JM, 1995, J MOL BIOL, V252, P572, DOI 10.1006/jmbi.1995.0521; Burova E, 1999, MOL MICROBIOL, V31, P1783, DOI 10.1046/j.1365-2958.1999.01315.x; CHEN CHB, 1993, P NATL ACAD SCI USA, V90, P4206, DOI 10.1073/pnas.90.9.4206; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; Hung SC, 1997, GENE DEV, V11, P2670, DOI 10.1101/gad.11.20.2670; HUNG SC, 1995, J MOL BIOL, V247, P428; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; WATNICK R, UNPUB; Watnick RS, 1998, P NATL ACAD SCI USA, V95, P1546, DOI 10.1073/pnas.95.4.1546	12	24	24	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2337	2339		10.1126/science.286.5448.2337	http://dx.doi.org/10.1126/science.286.5448.2337			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600743				2022-12-01	WOS:000084318500060
J	Boggon, TJ; Shan, WS; Santagata, S; Myers, SC; Shapiro, L				Boggon, TJ; Shan, WS; Santagata, S; Myers, SC; Shapiro, L			Implication of tubby proteins as transcription factors by structure-based functional analysis	SCIENCE			English	Article							RECESSIVE RETINITIS-PIGMENTOSA; GENE FAMILY; MOLECULAR CHARACTERIZATION; ANOMALOUS DIFFRACTION; RETINAL DEGENERATION; MOUSE; MUTATIONS; TULP1; ACTIVATOR; SUGGESTS	Tubby-like proteins (TULPs) are found in a broad range of multicellular organisms. In mammals, genetic mutation of tubby or other TULPs can result in one dr more of three disease phenotypes: obesity (from which the name "tubby" is derived), retinal degeneration, and hearing loss. These disease phenotypes indicate a vital role for tubby proteins; however, no biochemical function has yet been ascribed to any member of this protein family. A structure-directed approach was employed to investigate the biological function of these proteins. The crystal structure of the core domain from mouse tubby was determined at a resolution of 1.9 angstroms. From primarily structural clues, experiments were devised, the results of which suggest that TULPs are a unique family of bipartite transcription factors.	NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University	Shapiro, L (corresponding author), NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA.		Santagata, Sandro/A-7714-2009	Santagata, Sandro/0000-0002-7528-9668				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Banerjee P, 1998, NAT GENET, V18, P177, DOI 10.1038/ng0298-177; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Berg OG, 1990, BIOL NONSPECIFIC DNA, P71; BRUGER AT, 1992, X PLOR VERSION 3 1 S; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; *DNASTAR, 1996, MOL BIOTECHNOL, V5, P185; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goslin K., 1991, CULTURING NERVE CELL, P251; Gu SM, 1998, LANCET, V351, P1103, DOI 10.1016/S0140-6736(05)79384-3; Hagstrom SA, 1998, NAT GENET, V18, P174, DOI 10.1038/ng0298-174; HECKENLIVELY JR, 1995, P NATL ACAD SCI USA, V92, P11100, DOI 10.1073/pnas.92.24.11100; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Ikeda S, 1999, INVEST OPHTH VIS SCI, V40, P2706; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kapeller R, 1999, J BIOL CHEM, V274, P24980, DOI 10.1074/jbc.274.35.24980; Kim SH, 1998, NAT STRUCT BIOL, V5, P643, DOI 10.1038/1334; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis CA, 1999, INVEST OPHTH VIS SCI, V40, P2106; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishina PM, 1998, GENOMICS, V54, P215, DOI 10.1006/geno.1998.5567; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; North MA, 1997, P NATL ACAD SCI USA, V94, P3128, DOI 10.1073/pnas.94.7.3128; OHLEMILLER KK, 1995, NEUROREPORT, V6, P845, DOI 10.1097/00001756-199504190-00005; Ohlemiller KK, 1997, AUDIOL NEURO-OTOL, V2, P175, DOI 10.1159/000259242; Ohlemiller KK, 1998, CELL TISSUE RES, V291, P489, DOI 10.1007/s004410051018; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; PORSCH P, 1993, ANAL BIOCHEM, V211, P133; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; Rost B, 1996, METHOD ENZYMOL, V266, P525; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Shapiro L, 1998, STRUCTURE, V6, P265, DOI 10.1016/S0969-2126(98)00030-6; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Terwilliger TC, 1998, PROTEIN SCI, V7, P1851, DOI 10.1002/pro.5560070901; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189	47	148	163	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2119	2125		10.1126/science.286.5447.2119	http://dx.doi.org/10.1126/science.286.5447.2119			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591637				2022-12-01	WOS:000084157300042
J	Brand, M; Leurent, C; Mallouh, V; Tora, L; Schultz, P				Brand, M; Leurent, C; Mallouh, V; Tora, L; Schultz, P			Three-dimensional structures of the TAF(II)-containing complexes TFIID and TFTC	SCIENCE			English	Article							RNA-POLYMERASE-II; ACETYLASE COMPLEX; HISTONE OCTAMER; TRANSCRIPTION; DISTINCT; CORE; TAFS; MICROSCOPY; SIMILARITY; SUBUNITS	TBP (TATA-binding protein)-associated factors (TAF(II)s) are components of Large multiprotein complexes such as TFIID, TFTC, STAGA, PCAF/GCN5, and SAGA, which play a key role in the regulation of gene expression by RNA polymerase II. The structures of TFIID and TFTC have been determined at 3.5-nanometer resolution by electron microscopy and digital image analysis of single particles. Human TFIID resembles a macromolecular clamp that contains four globular domains organized around a solvent-accessible groove of a size suitable to bind DNA. TFTC is Larger and contains five domains, four of which are similar to TFIID.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Schultz, P (corresponding author), Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, Boite Postale 163, F-67404 Illkirch, France.		Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250; schultz, patrick/0000-0002-7310-6186				Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; GANGLOFF YG, IN PRESS MOL CELL BI; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; Kingston RE, 1999, NATURE, V399, P199, DOI 10.1038/20302; Klinger C, 1996, EMBO J, V15, P4643, DOI 10.1002/j.1460-2075.1996.tb00841.x; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Nakatani Y, 1996, J BIOL CHEM, V271, P6575, DOI 10.1074/jbc.271.12.6575; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/S0304-3991(81)80197-0; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	31	102	106	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2151	2153		10.1126/science.286.5447.2151	http://dx.doi.org/10.1126/science.286.5447.2151			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591645				2022-12-01	WOS:000084157300050
J	Bibb, JA; Snyder, GL; Nishi, A; Yan, Z; Meijer, L; Fienberg, AA; Tsai, LH; Kwon, YT; Girault, JA; Czernik, AJ; Huganir, RL; Hemmings, HC; Nairn, AC; Greengard, P				Bibb, JA; Snyder, GL; Nishi, A; Yan, Z; Meijer, L; Fienberg, AA; Tsai, LH; Kwon, YT; Girault, JA; Czernik, AJ; Huganir, RL; Hemmings, HC; Nairn, AC; Greengard, P			Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons	NATURE			English	Article							CYCLIN-DEPENDENT KINASE-5; CAMP-REGULATED PHOSPHOPROTEIN; PROTEIN-KINASE; INHIBITOR; SCAFFOLD; SUBUNIT; POTENT	The physiological state of the cell is controlled by signal transduction mechanisms which regulate the balance between protein kinase and protein phosphatase activities(1). Here we report that a single protein can, depending on which particular amino-acid residue is phosphorylated, function either as a kinase or phosphatase inhibitor. DARPP-32 (dopamine and cyclic AMP-regulated phospho-protein, relative molecular mass 32,000) is converted into an inhibitor of protein phosphatase 1 when it is phosphorylated by protein kinase A (PKA) at threonine 34 (refs 2, 3), We find that DARPP-32 is converted into an inhibitor of PKA when phosphorylated at threonine 75 by cyclin-dependent kinase 5 (Cdk5), Cdk5 phosphorylates DARPP-32 in vitro and in intact brain cells. Phospho-Thr 75 DARPP-32 inhibits PKA in vitro by a competitive mechanism. Decreasing phospho-Thr 75 DARPP-32 in striatal slices, either by a Cdk5-specific inhibitor or by using genetically altered mice, results in increased dopamine-induced phosphorylation of PKA substrates and augmented peak voltage-gated calcium currents. Thus DARPP-32 is a bifunctional signal transduction molecule which, by distinct mechanisms, controls a serine/threonine kinase and a serine/threonine phosphatase.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Kurume Univ, Sch Med, Dept Physiol, Fukuoka 8300011, Japan; CNRS, Biol Stn, F-29682 Roscoff, France; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Coll France, INSERM, U114, F-75231 Paris 05, France; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Baltimore, MD 21205 USA; Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Rockefeller University; Kurume University; Centre National de la Recherche Scientifique (CNRS); Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Howard Hughes Medical Institute; Johns Hopkins University; Cornell University; Cornell University	Greengard, P (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.		Girault, Jean-Antoine/F-7518-2013	Girault, Jean-Antoine/0000-0002-7900-1705; Nairn, Angus/0000-0002-7075-0195; , laurent/0000-0003-3511-4916	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA010044] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		CAPORASO G, IN PRESS NEUROPHARMA; Czernik A. J., 1997, REGULATORY PROTEIN M, V30, P219; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HEMMINGS HC, 1989, J BIOL CHEM, V264, P7726; HORIUCHI A, 1990, J BIOL CHEM, V265, P9476; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; NICOLA SM, IN PRESS ANN REV NEU; Nishi A, 1997, J NEUROSCI, V17, P8147; Ouimet CC, 1998, BRAIN RES, V808, P8, DOI 10.1016/S0006-8993(98)00724-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258	23	460	481	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					669	671		10.1038/45251	http://dx.doi.org/10.1038/45251			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604473				2022-12-01	WOS:000084189800067
J	Sasaki, T; Irie-Sasaki, J; Jones, RG; Oliveira-dos-Santos, AJ; Stanford, WL; Bolon, B; Wakeham, A; Itie, A; Bouchard, D; Kozieradzki, I; Joza, N; Mak, TW; Ohashi, PS; Suzuki, A; Penninger, JM				Sasaki, T; Irie-Sasaki, J; Jones, RG; Oliveira-dos-Santos, AJ; Stanford, WL; Bolon, B; Wakeham, A; Itie, A; Bouchard, D; Kozieradzki, I; Joza, N; Mak, TW; Ohashi, PS; Suzuki, A; Penninger, JM			Function of PI3K gamma in thymocyte development, T cell activation, and neutrophil migration	SCIENCE			English	Article							3-KINASE; KINASE; PHOSPHORYLATION; INHIBITION; WORTMANNIN; PEPTIDE; SYSTEM; PI3K	Phosphoinositide 3-kinases (PI3Ks) regulate fundamental cellular responses such as proliferation, apoptosis, cell motility, and adhesion. Viable gene-targeted mice Lacking the p110 catalytic subunit of PI3K gamma were generated. We show that PI3K gamma controls thymocyte survival and activation of mature T cells but has no role in the development or function of B cells. PI3K gamma-deficient neutrophils exhibited severe defects in migration and respiratory burst in response to heterotrimeric CTP-binding protein (G protein)-coupled receptor (GPCR) agonists and chemotactic agents. PI3K gamma Links GPCR stimulation to the formation of phosphatidylinositol 3,4,5-triphosphate and the activation of protein kinase B, ribosomal protein S6 kinase, and extracellular signal-regulated kinases 1 and 2. Thus, PI3K gamma regulates thymocyte development, T cell activation, neutrophil migration, and the oxidative burst.	Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Genet, Toronto, ON M5G 2C1, Canada; Univ Toronto, Mt Sinai Hosp, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Mt Sinai Hosp, Dept Immunol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Amgen, Dept Pathol, Thousand Oaks, CA 91320 USA	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Amgen	Penninger, JM (corresponding author), Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Jones, Russell Graham/ABD-5261-2021; Jones, Russell/AAC-2861-2022; Penninger, Josef M/I-6860-2013; Suzuki, Akira/GYD-6697-2022	Jones, Russell Graham/0000-0003-2250-4675; Penninger, Josef M/0000-0002-8194-3777; Suzuki, Akira/0000-0002-5950-8808; Stanford, William/0000-0002-5813-8016; Ohashi, Pamela S./0000-0003-2915-9317; Sasaki, Takehiko/0000-0003-1837-3748				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; COURNOYER D, 1993, ANNU REV IMMUNOL, V11, P297; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Mariathasan S, 1999, SEMIN IMMUNOL, V11, P263, DOI 10.1006/smim.1999.0182; OKADA T, 1994, J BIOL CHEM, V269, P3563; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; Sasaki T, 1996, BIOCHEM J, V315, P1035, DOI 10.1042/bj3151035; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648	23	890	987	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1040	1046		10.1126/science.287.5455.1040	http://dx.doi.org/10.1126/science.287.5455.1040			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669416				2022-12-01	WOS:000085245400048
J	Verhage, M; Maia, AS; Plomp, JJ; Brussaard, AB; Heeroma, JH; Vermeer, H; Toonen, RF; Hammer, RE; van den Berg, TK; Missler, M; Geuze, HJ; Sudhof, TC				Verhage, M; Maia, AS; Plomp, JJ; Brussaard, AB; Heeroma, JH; Vermeer, H; Toonen, RF; Hammer, RE; van den Berg, TK; Missler, M; Geuze, HJ; Sudhof, TC			Synaptic assembly of the brain in the absence of neurotransmitter secretion	SCIENCE			English	Article							ACETYLCHOLINE-RELEASE; HIPPOCAMPAL-NEURONS; TRANSMITTER RELEASE; VESICLE EXOCYTOSIS; EMBRYONIC NEURON; AXON GUIDANCE; SYNAPSIN-I; RAT-BRAIN; PROTEIN; SYNTAXIN	Brain function requires precisely orchestrated connectivity between neurons. Establishment of these connections is believed to require signals secreted from outgrowing axons, followed by synapse formation between selected neurons. Deletion of a single protein, Munc18-1, in mice Leads to a complete Loss of neurotransmitter secretion from synaptic vesicles throughout development. However, this does not prevent normal brain assembly, including formation of Layered structures, fiber pathways, and morphologically defined synapses. After assembly is completed, neurons undergo apoptosis, leading to widespread neurodegeneration. Thus, synaptic connectivity does not depend on neurotransmitter secretion, but its maintenance does. Neurotransmitter secretion probably functions to validate already established synaptic connections.	Univ Utrecht, Med Ctr, Rudolf Magnus Inst, Utrecht, Netherlands; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Physiol, Leiden, Netherlands; Vrije Univ Amsterdam, Inst Neurosci, Dept Neurophysiol, Amsterdam, Netherlands; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Vrije Univ Amsterdam, Dept Cell Biol & Immunol, Amsterdam, Netherlands; Univ Utrecht, Dept Cell Biol, Utrecht, Netherlands	Utrecht University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Vrije Universiteit Amsterdam; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vrije Universiteit Amsterdam; Utrecht University	Verhage, M (corresponding author), Univ Utrecht, Med Ctr, Rudolf Magnus Inst, Utrecht, Netherlands.		Heeroma, Joost/AFI-8727-2022; van den Berg, Timo K/AAC-2479-2022; Heeroma, Joost/C-1749-2008; Heeroma, Joost/AAF-4310-2022	verhage, matthijs/0000-0002-6085-7503; Missler, Markus/0000-0001-8008-984X				[Anonymous], 1990, SYNAPTIC ORG BRAIN; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Brussaard AB, 1997, NEURON, V19, P1103, DOI 10.1016/S0896-6273(00)80401-8; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Calakos N, 1996, PHYSIOL REV, V76, P1; CATSICAS S, 1994, TRENDS NEUROSCI, V17, P368, DOI 10.1016/0166-2236(94)90045-0; Coco S, 1998, J NEUROCHEM, V71, P1987; Daly C, 1997, J NEUROSCI, V17, P2365; de Vries J., UNPUB; Fernandez-Chacon R, 1999, ANNU REV PHYSIOL, V61, P753, DOI 10.1146/annurev.physiol.61.1.753; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; Hallonet M, 1998, DEVELOPMENT, V125, P2599; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HUME DA, 1983, J EXP MED, V157, P1704, DOI 10.1084/jem.157.5.1704; Igarashi M, 1997, J NEUROSCI, V17, P1460; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KONIG N, 1975, ANAT EMBRYOL, V148, P73, DOI 10.1007/BF00315564; MAIA AS, UNPUB; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; Milner LD, 1999, J NEUROSCI, V19, P3007; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OsenSand A, 1996, J COMP NEUROL, V367, P222, DOI 10.1002/(SICI)1096-9861(19960401)367:2<222::AID-CNE5>3.0.CO;2-7; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PLOMP JJ, 1994, J PHYSIOL-LONDON, V478, P125, DOI 10.1113/jphysiol.1994.sp020236; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUN YA, 1987, P NATL ACAD SCI USA, V84, P2540, DOI 10.1073/pnas.84.8.2540; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Williamson LC, 1998, J NEUROSCI RES, V52, P569, DOI 10.1002/(SICI)1097-4547(19980601)52:5<569::AID-JNR9>3.0.CO;2-A; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069	42	944	973	0	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					864	869		10.1126/science.287.5454.864	http://dx.doi.org/10.1126/science.287.5454.864			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657302				2022-12-01	WOS:000085136400049
J	Baptiste, KE; Naylor, JM; Bailey, J; Barber, EM; Post, K; Thornhill, J				Baptiste, KE; Naylor, JM; Bailey, J; Barber, EM; Post, K; Thornhill, J			Physiology - A function for guttural pouches in the horse	NATURE			English	Article							BLOOD-FLOW; EXERCISE; HEAT		Univ Saskatchewan, Dept Vet Internal Med, Saskatoon, SK S7N 5B4, Canada; Univ Saskatchewan, Dept Vet Anaesthesia Radiol & Surg, Saskatoon, SK S7N 5B4, Canada; Univ Saskatchewan, Dept Agr Engn, Saskatoon, SK S7N 5B4, Canada; Univ Saskatchewan, Dept Physiol, Saskatoon, SK S7N 5B4, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Baptiste, KE (corresponding author), Danish Vet Lab, Bulowsvej 27, Copenhagen, Denmark.	keb@svs.dk						BAKER MA, 1982, ANNU REV PHYSIOL, V44, P85, DOI 10.1146/annurev.ph.44.030182.000505; BRANDT JF, 1863, B ACAD IMPERIAL SCI, V5, P508; Day M, 1999, NEW SCI, V161, P7; Ghoshal N, 1981, VENOUS DRAINAGE DOME; HINCHCLIFFE R, 1969, J ZOOL, V157, P277; HODGSON DR, 1993, J APPL PHYSIOL, V74, P1161, DOI 10.1152/jappl.1993.74.3.1161; McConaghy F F, 1996, Equine Vet J Suppl, P42; McConaghy FF, 1995, J APPL PHYSIOL, V79, P1849, DOI 10.1152/jappl.1995.79.6.1849; ORR JA, 1983, AM J PHYSIOL, V244, pH142, DOI 10.1152/ajpheart.1983.244.1.H142; PARKS CM, 1983, AM J VET RES, V44, P1861	10	36	37	0	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					382	383		10.1038/35000284	http://dx.doi.org/10.1038/35000284			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667779				2022-12-01	WOS:000085121100035
J	Reacher, MH; Shah, A; Livermore, DM; Wale, MCJ; Graham, C; Johnson, AP; Heine, H; Monnickendam, MA; Barker, KF; James, D; George, RC				Reacher, MH; Shah, A; Livermore, DM; Wale, MCJ; Graham, C; Johnson, AP; Heine, H; Monnickendam, MA; Barker, KF; James, D; George, RC			Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTIMICROBIAL RESISTANCE; BLOOD	Objectives Determination of causes, trends, and antibiotic resistance in reports of bacterial pathogens isolated from blood in England and Wales from 1990 to 1998. Design Description of bacterial isolates from blood, judged to be clinically significant by microbiology staff, reported to the Communicable Disease Surveillance Centre. Setting Microbiology laboratories in England and Wales. Subjects Patients yielding clinically significant isolates from blood. Main outcome measures Frequency and Poisson regression analyses for trend of reported causes of bacteraemia and proportions of antibiotic resistant isolates. Results There was an upward trend in total numbers of reports of bacteraemia. The five most cited organisms accounted for over 60% of reports each year. There was a substantial increase in the proportion of reports of Staphylococcus aureus resistant to methicillin, Streptococcus pneumoniae resistance to penicillin and erythromycin, and Enterococcus faecalis and Enterococcus faecium resistance to vancomycin. No increase was seen in resistance of Escherichia coli to gentamicin. Conclusions Reports from laboratories provide Valuable information on trends and antibiotic resistance in bacteraemia and show a worrying increase in resistance to important antibiotics.	Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England; PHLS Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England; PHLS Cent Publ Hlth Lab, Resp & Systemat Infect Lab, London NW9 5HT, England; Queens Med Ctr, PHLS Antimicrobial Susceptibil Surveillance Unit, Nottingham NG7 2UH, England; PHLS Stat Unit, London NW9 5EQ, England; PHLS Headquarters, London NW9 5DF, England; SmithKline Beecham Pharmaceut, Int Med Dept, Brentford TW8 9BD, Middx, England	Public Health England; University of Nottingham; GlaxoSmithKline	Reacher, MH (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England.	mreacher@phls.nhs.uk	Reacher, Mark/Y-6979-2018; Johnson, Alan P/F-4420-2014	Reacher, Mark/0000-0001-6871-7903; 				*ASS MED MICR, 1998, AMM DIR MED MICR SER, P139; Ayliffe GAJ, 1998, J HOSP INFECT, V39, P253, DOI 10.1016/S0195-6701(98)90293-6; BANERJEE SN, 1991, AM J MED, V91, pS86, DOI 10.1016/0002-9343(91)90349-3; Cockerill FR, 1997, CLIN INFECT DIS, V24, P403, DOI 10.1093/clinids/24.3.403; Grant A D, 1993, Commun Dis Rep CDR Rev, V3, pR75; Hargreaves RM, 1996, BRIT MED J, V312, P160; Henry R., 1996, PHLS Microbiology Digest, V13, P26; *HOSP INF WORK GRO, 1995, HOSP INF CONTR GUID; Jarvis WR, 1998, AM J INFECT CONTROL, V26, P522; Johnson AP, 1998, J HOSP INFECT, V40, P17, DOI 10.1016/S0195-6701(98)90020-2; Johnson AP, 1999, J ANTIMICROB CHEMOTH, V43, P160, DOI 10.1093/jac/43.1.160; Laurichesse H, 1998, Commun Dis Public Health, V1, P22; Livermore DM, 1998, BRIT MED J, V317, P614, DOI 10.1136/bmj.317.7159.614; LIVERMORE DM, INPRESS J ANTIMICROB; PITTET D, 1995, ARCH INTERN MED, V155, P1177, DOI 10.1001/archinte.155.11.1177; Speller DCE, 1997, LANCET, V350, P323, DOI 10.1016/S0140-6736(97)12148-1; Standing Medical Advisory Committee: Sub-group on Antimicrobial Resistance, 1998, PATH LEAST RES; Wise R, 1998, BMJ-BRIT MED J, V317, P609, DOI 10.1136/bmj.317.7159.609; Young L. S., 1995, PRINCIPLES PRACTICE, P690; 1999, COMMUN DIS REP CDR W, V9, P185; [No title captured]; [No title captured]; 1996, COMMUN DIS REPORT CD, V6, P83; 1997, COMMUN DIS REPORT CD, V7, P13	24	235	245	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	2000	320	7229					213	216		10.1136/bmj.320.7229.213	http://dx.doi.org/10.1136/bmj.320.7229.213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279DR	10642227	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000085029600022
J	Barth, JH				Barth, JH			Should men still go bald gracefully?	LANCET			English	Editorial Material							ANDROGENETIC ALOPECIA; RECEPTOR; WOMEN		Gen Infirm, Dept Clin Biochem & Immunol, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary	Barth, JH (corresponding author), Gen Infirm, Dept Clin Biochem & Immunol, Leeds LS1 3EX, W Yorkshire, England.		Barth, Julian H/F-6028-2010					GRINO PB, 1990, ENDOCRINOLOGY, V126, P1165, DOI 10.1210/endo-126-2-1165; Hamilton JB, 1942, AM J ANAT, V71, P451, DOI 10.1002/aja.1000710306; Kaufman KD, 1998, J AM ACAD DERMATOL, V39, P578, DOI 10.1016/S0190-9622(98)70007-6; Orme S, 1999, BRIT J DERMATOL, V141, P521; Price VH, 1999, J AM ACAD DERMATOL, V41, P717, DOI 10.1016/S0190-9622(99)70006-X; Reynolds AJ, 1999, NATURE, V402, P33, DOI 10.1038/46938; Roberts JL, 1999, J AM ACAD DERMATOL, V41, P555, DOI 10.1016/S0190-9622(99)80052-8; RUSHTON DH, 1992, CLIN ENDOCRINOL, V36, P421; RUSHTON DH, 1991, CLIN EXP DERMATOL, V16, P188, DOI 10.1111/j.1365-2230.1991.tb00343.x; Sawaya ME, 1997, J INVEST DERMATOL, V109, P296, DOI 10.1111/1523-1747.ep12335779	10	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2000	355	9199					161	162		10.1016/S0140-6736(99)00412-2	http://dx.doi.org/10.1016/S0140-6736(99)00412-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675111				2022-12-01	WOS:000084879700005
J	Britton-Davidian, J; Catalan, J; Ramalhinho, MD; Ganem, G; Auffray, JC; Capela, R; Biscoito, M; Searle, JB; Mathias, MD				Britton-Davidian, J; Catalan, J; Ramalhinho, MD; Ganem, G; Auffray, JC; Capela, R; Biscoito, M; Searle, JB; Mathias, MD			Environmental genetics - Rapid chromosomal evolution in island mice	NATURE			English	Article							MUS-MUSCULUS-DOMESTICUS		Univ Montpellier 2, ISEM, Lab Genet & Environm, CNRS,UMR 5554, F-34095 Montpellier 5, France; Museo Nacl Hist Nat, Ctr Biol Ambiental, P-1200 Lisbon, Portugal; Univ Madeira, Dept Biol, P-9000 Funchal, Madeira, Portugal; CITMA, P-9000 Funchal, Madeira, Portugal; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Univ Lisbon, Fac Ciencias, Dept Zool & Anthropol, P-1700 Lisbon, Portugal	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Universidade da Madeira; University of York - UK; Universidade de Lisboa	Britton-Davidian, J (corresponding author), Univ Montpellier 2, ISEM, Lab Genet & Environm, CNRS,UMR 5554, F-34095 Montpellier 5, France.		Auffray, jean-christophe/HCI-4881-2022; Auffray, Jean-Christophe/AAW-1052-2020; Ganem, Guila/AAC-1872-2022; AUFFRAY, Jean-Christophe/H-1907-2011; Auffray, Jean-Christophe/AAH-6131-2019; Biscoito, Manuel/AAC-4390-2021; da Luz Mathias, Maria/V-9931-2018	Auffray, Jean-Christophe/0000-0002-5184-0507; Ganem, Guila/0000-0002-5244-4979; Biscoito, Manuel/0000-0002-9347-0823; da Luz Mathias, Maria/0000-0003-3876-958X				BAKER RJ, 1986, P NATL ACAD SCI USA, V83, P8245, DOI 10.1073/pnas.83.21.8245; GARAGNA S, 1997, NATURE, V390, P242; Grant P.R., 1998, EVOLUTION ISLANDS; Hauffe HC, 1998, GENETICS, V150, P1143; HAUFFE HC, 1993, EVOLUTION, V47, P1374, DOI 10.1111/j.1558-5646.1993.tb02161.x; Losos JB, 1998, SCIENCE, V279, P2115, DOI 10.1126/science.279.5359.2115; MATHIAS MD, 1992, BIOL J LINN SOC, V46, P13, DOI 10.1111/j.1095-8312.1992.tb00846.x; NACHMAN MW, 1995, TRENDS ECOL EVOL, V10, P397, DOI 10.1016/S0169-5347(00)89155-7; Provine W.B., 1989, P43	9	130	135	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					158	158		10.1038/35003116	http://dx.doi.org/10.1038/35003116			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646592				2022-12-01	WOS:000084835300043
J	Murray, TJ				Murray, TJ			Personal time: The patient's experience	ANNALS OF INTERNAL MEDICINE			English	Article								When a life-threatening or chronic disease is diagnosed, patients may find that their sense of time, the passage of days, and their view of the future are altered. Most of the time, people live in a sense of linear time, or kronos. When illness strikes, they may begin to spend more time in kairos, a sense of soul-satisfying time, such as the feeling one gets when walking on the seashore with a grandchild, working in the garden, or talking with friends over good food and wine. This article comments on two patients, one who explores kairos through a diary that documents her positive attitude toward coping with multiple sclerosis, and one, a young artist with Hodgkin disease, who explores his condition through 96 paintings of his experience of the disease. Rather than "the devouring tyrant of linear time," life can be seen in a circular fashion, the eternal braid of Hofstadter. Patients begin to see life more in terms of cycles of daily events, routines, and the change of seasons. Illness brings one "close to the bone" of the soul's needs, with a reappraisal of the journey of life as a continuous line, to life spread out on a landscape that includes the past and the future.	Dalhousie Univ, Sch Med, Halifax, NS B3H 4H7, Canada	Dalhousie University	Murray, TJ (corresponding author), Dalhousie Univ, Sch Med, Sir Charles Tupper Med Bldg, Halifax, NS B3H 4H7, Canada.	jock.murray@dal.ca						AMIS M, 1998, TIMES ARROW; [Anonymous], ECCLESIASTES, V3; BOLEN JS, 1996, CLOSE BONE, P86; CAPPELLA B, 1977, PERCEPT MOTOR SKILL, V44, P787, DOI 10.2466/pms.1977.44.3.787; Dossey L., 1982, SPACE TIME MED; EDDINGTON AS, 1957, MATH THEORY RELATIVI, P23; Hofstadter D.R., 1979, GODEL ESCHER BACH ET; JANTSCH E, 1980, SELF ORG UNIVERSE SC, P97; McLuhan M, 1964, UNDERSTANDING MEDIA; Pope R, 1991, ILLNESS HEALING IMAG; Priestley J.B., 1978, MAN TIME; Shallis M., 1983, TIME INVESTIGATION S; SZAMOSI G, 1986, ORIGIN TIME MEDIEVAL, P33	13	14	14	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2000	132	1					58	62		10.7326/0003-4819-132-1-200001040-00010	http://dx.doi.org/10.7326/0003-4819-132-1-200001040-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270CV	10627253				2022-12-01	WOS:000084518600009
J	Chin-Sang, ID; George, SE; Ding, M; Moseley, SL; Lynch, AS; Chisholm, AD				Chin-Sang, ID; George, SE; Ding, M; Moseley, SL; Lynch, AS; Chisholm, AD			The ephrin VAB-2/EFN-1 functions in neuronal signaling to regulate epidermal morphogenesis in C-elegans	CELL			English	Article							RECEPTOR TYROSINE KINASES; CAENORHABDITIS-ELEGANS; TRANSMEMBRANE LIGANDS; NERVOUS-SYSTEM; CELL LINEAGE; ATTACHMENT; ZEBRAFISH; FAMILY; EXPRESSION; HYPODERMIS	The Eph receptor VAB-1 is required in neurons for epidermal morphogenesis during C. elegans embryogenesis. Two models were proposed for the nonautonomous role of VAB-1: neuronal VAB-1 might signal directly to epidermis, or VAB-1 signaling between neurons might be required for epidermal development. We show that the ephrin VAB-2 (also known as EFN-1) is a ligand for VAB-1 and can function in neurons to regulate epidermal morphogenesis. In the absence of VAB-1 signaling, ephrin-expressing neurons are disorganized. vab-2/efn-1 mutations synergize with vab-1 kinase alleles, suggesting that VAB-2/EFN-1 may partly function in a kinase-independent VAB-1 pathway. Our data indicate that ephrin signaling between neurons is required nonautonomously for epidermal morphogenesis in C. elegans.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Chisholm, AD (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.			Chisholm, Andrew/0000-0001-5091-0537; Chin-Sang, Ian/0000-0001-7480-9775	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054657] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM54657] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araujo M, 1998, DEVELOPMENT, V125, P4195; BARD JB, 1992, MORPHOGENESIS; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BRENNER S, 1974, GENETICS, V77, P71; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Cerretti DP, 1998, GENOMICS, V47, P131, DOI 10.1006/geno.1997.5088; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; CHEN G, 1994, BIOL CONTROL, V4, P157, DOI 10.1006/bcon.1994.1025; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Conway G, 1997, P NATL ACAD SCI USA, V94, P3082, DOI 10.1073/pnas.94.7.3082; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; GUARENTE L, 1993, TRENDS GENET, V9, P395; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Hodgkin Jonathan, 1997, V33, P881; Holder N, 1999, DEVELOPMENT, V126, P2033; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Kane DA, 1996, DEVELOPMENT, V123, P47; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; MADURO M, 1995, GENETICS, V141, P977; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mohler WA, 1998, CURR BIOL, V8, P1087, DOI 10.1016/S0960-9822(98)70447-6; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Thomas C, 1996, SCIENCE, V273, P603, DOI 10.1126/science.273.5275.603; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang XM, 1999, MOL CELL, V4, P903, DOI 10.1016/S1097-2765(00)80220-8; WilliamsMasson EM, 1997, DEVELOPMENT, V124, P2889; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452	46	126	131	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					781	790		10.1016/S0092-8674(00)81675-X	http://dx.doi.org/10.1016/S0092-8674(00)81675-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619431	Bronze			2022-12-01	WOS:000084488200011
J	Priscu, JC; Adams, EE; Lyons, WB; Voytek, MA; Mogk, DW; Brown, RL; McKay, CP; Takacs, CD; Welch, KA; Wolf, CF; Kirshtein, JD; Avci, R				Priscu, JC; Adams, EE; Lyons, WB; Voytek, MA; Mogk, DW; Brown, RL; McKay, CP; Takacs, CD; Welch, KA; Wolf, CF; Kirshtein, JD; Avci, R			Geomicrobiology of subglacial ice above Lake Vostok, Antarctica	SCIENCE			English	Article							PCR	Data from ice 3590 meters below Vostok Station indicate that the ice was accreted from liquid water associated with Lake Vostok. Microbes were observed at concentrations ranging from 2.8 x 10(3) to 3.6 x 10(4) cells per milliliter; no biological incorporation of selected organic substrates or bicarbonate was detected. Bacterial 16S ribosomal DNA genes revealed Low diversity in the gene population. The phylotypes were closely related to extant members of the alpha- and beta-Proteobacteria and the Actinomycetes. Extrapolation of the data from accretion ice to Lake Vostok implies that Lake Vostok may support a microbial population, despite more than 10(6) years of isolation from the atmosphere.	Montana State Univ, Dept Biol Sci, Bozeman, MT 59717 USA; Montana State Univ, Dept Civil Engn, Bozeman, MT 59717 USA; Montana State Univ, Dept Earth Sci, Bozeman, MT 59717 USA; Montana State Univ, Dept Phys, Bozeman, MT 59717 USA; Univ Alabama, Dept Geol, Tuscaloosa, AL 35487 USA; US Geol Survey, Reston, VA 20192 USA; NASA, Ames Res Ctr, Div Space Sci, Moffett Field, CA 94035 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; University of Alabama System; University of Alabama Tuscaloosa; United States Department of the Interior; United States Geological Survey; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Priscu, JC (corresponding author), Montana State Univ, Dept Biol Sci, Bozeman, MT 59717 USA.			Welch, Kathleen/0000-0003-1028-3086				ABYZOV SS, 1993, ANTARCTIC MICROBIOLO, P265; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Brunk CF, 1996, APPL ENVIRON MICROB, V62, P872, DOI 10.1128/AEM.62.3.872-879.1996; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; DREVER JI, 1988, GEOCHMISTRY NATURAL; HYNDMAN DW, 1985, PETROLOGY IGNEOUS ME; Jouzel J, 1999, SCIENCE, V286, P2138, DOI 10.1126/science.286.5447.2138; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; Karl DM, 1999, SCIENCE, V286, P2144, DOI 10.1126/science.286.5447.2144; Kawamura K, 1996, GEOPHYS RES LETT, V23, P2665, DOI 10.1029/96GL02428; Killawee JA, 1998, GEOCHIM COSMOCHIM AC, V62, P3637, DOI 10.1016/S0016-7037(98)00268-3; LANGWAY CC, 1959, 62 SIPRE ARM COLD RE; LIESACK W, 1991, MICROBIAL ECOL, V21, P191, DOI 10.1007/BF02539153; Maidak BL, 1999, NUCLEIC ACIDS RES, V27, P171, DOI 10.1093/nar/27.1.171; *NAT SCI FDN WORKS, 1998, LAK VOST STUD CUR FO; ONEIL JR, 1968, J PHYS CHEM-US, V72, P3683, DOI 10.1021/j100856a060; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Priscu JC, 1998, SCIENCE, V280, P2095, DOI 10.1126/science.280.5372.2095; Siegert MJ, 1996, ANTARCT SCI, V8, P281, DOI 10.1017/S0954102096000405; TWICKLER MS, 1986, NATURE, V320, P156, DOI 10.1038/320156a0; VOYTEK MA, 1995, APPL ENVIRON MICROB, V56, P2430; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; WEDEPOHL KH, 1995, GEOCHIM COSMOCHIM AC, V59, P1217, DOI 10.1016/0016-7037(95)00038-2; Welch KA, 1996, J CHROMATOGR A, V739, P257, DOI 10.1016/0021-9673(96)00044-1	24	289	317	4	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2141	2144		10.1126/science.286.5447.2141	http://dx.doi.org/10.1126/science.286.5447.2141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591642				2022-12-01	WOS:000084157300047
J	Stepp, SE; Dufourcq-Lagelouse, R; Le Deist, F; Bhawan, S; Certain, S; Mathew, PA; Henter, JI; Bennett, M; Fischer, A; Saint Basile, GD; Kumar, V				Stepp, SE; Dufourcq-Lagelouse, R; Le Deist, F; Bhawan, S; Certain, S; Mathew, PA; Henter, JI; Bennett, M; Fischer, A; Saint Basile, GD; Kumar, V			Perforin gene defects in familiar hemophagocytic lymphohistiocytosis	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CYTOTOXIC T-LYMPHOCYTES; DENDRITIC CELLS; LYMPHOPROLIFERATIVE SYNDROME; FAS; AUTOIMMUNITY; EXHAUSTION; MUTATIONS; CHILDREN; MICE	Familiar hemophagocytic Lymphohistiocytosis (FHL) is a rare, rapidly fatal, autosomal recessive immune disorder characterized by uncontrolled activation of T cells and macrophages and overproduction of inflammatory cytokines. Linkage analyses indicate that FHL is genetically heterogeneous and Linked to 9q21.3-22, 10q21-22, or another as yet undefined Locus. Sequencing of the coding regions of the perforin gene of eight unrelated 10q21-22-linked FHL patients revealed homozygous nonsense mutations in four patients and missense mutations in the other four patients. Cultured Lymphocytes from patients had defective cytotoxic activity, and immunostaining revealed Little or no perforin in the granules. Thus, defects in perforin are responsible for 10q21-22-linked FHL. Perforin-based effector systems are, therefore, involved not only in the Lysis of abnormal cells but also in the downregulation of cellular immune activation.	INSERM, U429, Unite Rech Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France; Univ Texas, SW Med Sch, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Grad Program Immunol, Dallas, TX 75235 USA; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, F-75015 Paris, France; Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; Karolinska Inst, Karolinska Hosp, Dept Pediat Hematol & Oncol, S-17177 Stockholm, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of North Texas System; University of North Texas Health Science Center; Karolinska Institutet; Karolinska University Hospital	Saint Basile, GD (corresponding author), INSERM, U429, Unite Rech Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France.	sbasile@necker.fr	de Saint Basile, Genevieve/G-9731-2017	de Saint Basile, Genevieve/0000-0002-1913-5269; DOGNIAUX, Stephanie/0000-0003-3309-1204; Nandwana, Sadhna/0000-0002-3021-3715; Henter, Jan-Inge/0000-0002-0629-2126				Arico M, 1996, LEUKEMIA, V10, P197; Binder D, 1998, J EXP MED, V187, P1903, DOI 10.1084/jem.187.11.1903; BORROW P, 1995, J VIROL, V69, P1059, DOI 10.1128/JVI.69.2.1059-1070.1995; Dufourcq-Lagelouse R, 1999, AM J HUM GENET, V64, P172, DOI 10.1086/302194; Egeler RM, 1996, J PEDIAT HEMATOL ONC, V18, P340, DOI 10.1097/00043426-199611000-00002; Fadeel B, 1999, BRIT J HAEMATOL, V106, P406, DOI 10.1046/j.1365-2141.1999.01538.x; FAVARA BE, 1992, SEMIN DIAGN PATHOL, V9, P63; FINK TM, 1992, GENOMICS, V13, P1300, DOI 10.1016/0888-7543(92)90050-3; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Geldhof AB, 1998, BLOOD, V91, P196, DOI 10.1182/blood.V91.1.196.196_196_206; GILBERTSON SM, 1986, J IMMUNOL, V136, P3567; HENTER JI, 1993, ACTA PAEDIATR, V82, P369, DOI 10.1111/j.1651-2227.1993.tb12699.x; Henter JI, 1998, HEMATOL ONCOL CLIN N, V12, P417, DOI 10.1016/S0889-8588(05)70520-7; Hoang MP, 1998, HUM PATHOL, V29, P1074, DOI 10.1016/S0046-8177(98)90416-6; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Knight SC, 1997, ADV EXP MED BIOL, V417, P389; LANDMANPARKER J, 1993, BRIT J HAEMATOL, V85, P37, DOI 10.1111/j.1365-2141.1993.tb08642.x; Le Deist F., UNPUB; Matloubian M, 1999, J VIROL, V73, P2527, DOI 10.1128/JVI.73.3.2527-2536.1999; Ohadi M, 1999, AM J HUM GENET, V64, P165, DOI 10.1086/302187; Peng SL, 1998, J IMMUNOL, V160, P652; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Sambhara S, 1998, CELL IMMUNOL, V187, P13, DOI 10.1006/cimm.1998.1314; Spaner D, 1998, J IMMUNOL, V160, P2655; Spaner D, 1999, J IMMUNOL, V162, P1192; Spielman J, 1998, J IMMUNOL, V161, P7063; Sullivan KE, 1998, PEDIATR RES, V44, P465, DOI 10.1203/00006450-199810000-00001; von Herrath M, 1999, J VIROL, V73, P5918, DOI 10.1128/JVI.73.7.5918-5925.1999	29	885	936	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1957	1959		10.1126/science.286.5446.1957	http://dx.doi.org/10.1126/science.286.5446.1957			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583959				2022-12-01	WOS:000084003400052
J	Baysal, BE; Ferrell, RE; Willett-Brozick, JE; Lawrence, EC; Myssiorek, D; Bosch, A; van der Mey, A; Taschner, PEM; Rubinstein, WS; Myers, EN; Richard, CW; Cornelisse, CJ; Devilee, P; Devlin, B				Baysal, BE; Ferrell, RE; Willett-Brozick, JE; Lawrence, EC; Myssiorek, D; Bosch, A; van der Mey, A; Taschner, PEM; Rubinstein, WS; Myers, EN; Richard, CW; Cornelisse, CJ; Devilee, P; Devlin, B			Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma	SCIENCE			English	Article							SUCCINATE-UBIQUINONE OXIDOREDUCTASE; CAROTID-BODY CHEMORECEPTORS; CHROMOSOME 11Q23; ESCHERICHIA-COLI; HIGH-ALTITUDES; NECK REGION; HYPOXIA; CELLS; HEAD; HYPERPLASIA	Hereditary paraganglioma (PGL) is characterized by the development of benign, vascularized tumors in the head and neck. The most common tumor site is the carotid body (CB), a chemoreceptive organ that senses oxygen Levels in the blood. Analysis of families carrying the PGL1 gene, described here, revealed germ line mutations in the SDHD gene on chromosome 11q23. SDHD encodes a mitochondrial respiratory chain protein-the small subunit of cytochrome b in succinate-ubiquinone oxidoreductase (cybS). In contrast to expectations based on the inheritance pattern of PGL, the SDHD gene showed no evidence of imprinting. These findings indicate that mitochondria play an important role in the pathogenesis of certain tumors and that cybS plays a role in normal CB physiology.	Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Human Genet, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA; Long Isl Jewish Med Ctr, Dept Otolaryngol & Communicat Disorders, New York, NY 11040 USA; Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Otolaryngol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands; Wyeth Ayerst Res, Genet Inst, Cambridge, MA 02140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwell Health; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Pfizer	Baysal, BE (corresponding author), Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA.	baysalbe@msx.upmc.edu	Brozick, Joan/AAA-5785-2019; DEVILEE, PETER/ABR-2140-2022; Taschner, Peter/J-8853-2014	Taschner, Peter/0000-0001-9621-465X	NIMH NIH HHS [MH57881] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057881] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARIASSTELLA J, 1976, ARCH PATHOL LAB MED, V100, P636; ARIASSTELLA J, 1976, HUM PATHOL, V7, P361, DOI 10.1016/S0046-8177(76)80052-4; Baysal BE, 1997, AM J HUM GENET, V60, P121; Baysal BE, 1998, GENE, V217, P107, DOI 10.1016/S0378-1119(98)00350-3; Baysal BE, 1999, HUM GENET, V104, P219, DOI 10.1007/s004390050939; Baysal BE, 1997, GENOMICS, V44, P214, DOI 10.1006/geno.1997.4880; BAYSAL BE, UNPUB; BEE D, 1986, ACTA ANAT, V126, P226; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVILEE P, 1994, GENE CHROMOSOME CANC, V11, P71, DOI 10.1002/gcc.2870110202; EDWARDS C, 1971, J PATHOL, V104, P231, DOI 10.1002/path.1711040404; Farr JE, 1999, AM J HUM GENET, V65, pA271; GONZALEZ C, 1994, PHYSIOL REV, V74, P829, DOI 10.1152/physrev.1994.74.4.829; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HEUTINK P, 1992, HUM MOL GENET, V1, P7, DOI 10.1093/hmg/1.1.7; Heutink Peter, 1994, European Journal of Human Genetics, V2, P148; Hirawake H, 1997, CYTOGENET CELL GENET, V79, P132, DOI 10.1159/000134700; Koreth J, 1999, J PATHOL, V187, P28, DOI 10.1002/(SICI)1096-9896(199901)187:1<28::AID-PATH166>3.0.CO;2-R; LACK EE, 1979, HUM PATHOL, V10, P191, DOI 10.1016/S0046-8177(79)80008-8; LACK EE, 1985, AM J PATHOL, V119, P301; LACK EE, 1978, AM J PATHOL, V91, P497; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Milunsky J, 1997, AM J MED GENET, V72, P66, DOI 10.1002/(SICI)1096-8628(19971003)72:1<66::AID-AJMG14>3.0.CO;2-S; MORELLI L, 1994, SCI TOTAL ENVIRON, V150, P215, DOI 10.1016/0048-9697(94)90153-8; Morison IM, 1998, HUM MOL GENET, V7, P1599, DOI 10.1093/hmg/7.10.1599; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Nurse CA, 1997, DEV BIOL, V184, P197, DOI 10.1006/dbio.1997.8539; SALDANA MJ, 1973, HUM PATHOL, V4, P251, DOI 10.1016/S0046-8177(73)80012-7; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Shenoy SK, 1999, J BIOL CHEM, V274, P8717, DOI 10.1074/jbc.274.13.8717; STILLER D, 1975, VIRCHOWS ARCH A, V365, P163, DOI 10.1007/BF00432387; van Schothorst EM, 1998, AM J HUM GENET, V63, P468, DOI 10.1086/301951; van Schothorst EM, 1998, HUM PATHOL, V29, P1045, DOI 10.1016/S0046-8177(98)90411-7; VANDERMEY AGL, 1989, LANCET, V2, P1291; Vaupel P, 1998, STRAHLENTHER ONKOL, V174, P6; Vibat CRT, 1998, BIOCHEMISTRY-US, V37, P4148, DOI 10.1021/bi9716635; Vu TH, 1997, NAT GENET, V17, P12, DOI 10.1038/ng0997-12; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9	41	1229	1269	4	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2000	287	5454					848	851		10.1126/science.287.5454.848	http://dx.doi.org/10.1126/science.287.5454.848			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657297				2022-12-01	WOS:000085136400044
J	Henney, JE				Henney, JE			Sertraline approved for posttraumatic stress disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Commissioner Food & Drugs, Rockville, MD 20857 USA		Henney, JE (corresponding author), Commissioner Food & Drugs, HF 1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					596	596		10.1001/jama.283.5.596-b	http://dx.doi.org/10.1001/jama.283.5.596-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665687				2022-12-01	WOS:000084956500007
J	Jamieson, DJ; Meikle, SF; Hillis, SD; Mtsuko, D; Mawji, S; Duerr, A				Jamieson, DJ; Meikle, SF; Hillis, SD; Mtsuko, D; Mawji, S; Duerr, A			An evaluation of poor pregnancy outcomes among Burundian refugees in Tanzania	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; LOW-BIRTH-WEIGHT; MALAWI; RISK; PREVENTION; MORTALITY; MALARIA; INFANT; WOMEN	Context Little is known about pregnancy outcomes among the approximately 11 million refugees worldwide, 25% of whom are women of reproductive age. Objective To estimate incidence of and determine risk factors for poor pregnancy outcomes and to calculate the contribution of mortality from neonatal and maternal deaths to overall mortality in a refugee camp. Design Cross-sectional review of records and survey, conducted in February and March 1998, Setting Mtendeli refugee camp, Tanzania, Participants For the overall assessment, 664 Burundi women who had a pregnancy outcome during a recent 5-month period (September 1, 1997-January 31, 1998) and their 679 infants; 538 women (81%) completed the survey. Main Outcome Measures Incidence of fetal death (fetus born greater than or equal to 500 g or greater than or equal to 22 weeks' gestation with no signs of life), low birth weight (<2500 g), neonatal death (death <28 days of life), and maternal death (deaths during or within 42 days of pregnancy from any cause related to or aggravated by the pregnancy or its management). Results The fetal death rate was 45.6 per 1000 births, the neonatal mortality rate was 29.3 per 1000 live births, and 22.4% of all live births were low birth weight. Compared with women without poor pregnancy outcome, those with poor pregnancy outcome were more likely to report prior high socioeconomic status (adjusted odds ratio [OR], 1.6; 95 % confidence interval [CI], 1.1-2.4), having a first or second pregnancy (OR, 2.2; 95% CI, 1.4-3.4), and having 3 or more episodes of malaria during pregnancy (OR, 2.0; 95% CI, 1.4-3.1). Neonatal and maternal deaths accounted for 16% of all deaths during the period studied. Conclusions Poor pregnancy outcomes were common in this refugee setting, and neonatal and maternal deaths, 2 important components of reproductive health-related deaths, contributed substantially to overall mortality.	Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30341 USA; Int Rescue Comm, New York, NY USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Jamieson, DJ (corresponding author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,Mailstop K 34, Atlanta, GA 30341 USA.			Jamieson, Denise/0000-0003-2597-1201				Abouzahr Carla, 1996, World Health Statistics Quarterly, V49, P77; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; Basso O, 1997, BRIT MED J, V315, P1498, DOI 10.1136/bmj.315.7121.1498; *CDCP, 1991, EP APPR REPR HLTH; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P705; DALLABETTA GA, 1993, J INFECT DIS, V167, P36, DOI 10.1093/infdis/167.1.36; *M STOP INT, 1998, REPR HLTH CAR REF SE; *MAT HLTH SAF MOTH, 1992, LOW BIRTH WEIGHT TAB; PANETH NS, 1995, FUTURE CHILD, V5, P19, DOI 10.2307/1602505; Sachs L, 1997, Afr Health, V19, P24; SCHULZ KF, 1987, GENITOURIN MED, V63, P320; SEIDMAN DS, 1988, OBSTET GYNECOL, V72, P158; Steketee RW, 1996, AM J TROP MED HYG, V55, P33, DOI 10.4269/ajtmh.1996.55.33; TAHA TE, 1995, INT J EPIDEMIOL, V24, P1022, DOI 10.1093/ije/24.5.1022; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; *UN HIGH COMM REF, 1999, REG OTH CONC UNHCR 1; *UN HIGH COMM REF, 1995, REPR HLTH REF SIT IN; VANDERSTUYFT P, 1993, ANN SOC BELG MED TR, V73, P81; *WOM COMM REF WOM, 1996, FACT SHEET; Zocchetti C, 1997, INT J EPIDEMIOL, V26, P220, DOI 10.1093/ije/26.1.220	20	37	37	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2000	283	3					397	402		10.1001/jama.283.3.397	http://dx.doi.org/10.1001/jama.283.3.397			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273WM	10647805				2022-12-01	WOS:000084732400034
J	Crowley, MP; Fahrer, AM; Baumgarth, N; Hampl, J; Gutgemann, I; Teyton, L; Chien, YH				Crowley, MP; Fahrer, AM; Baumgarth, N; Hampl, J; Gutgemann, I; Teyton, L; Chien, YH			A population of murine gamma delta T cells that recognize an inducible MHC class lb molecule	SCIENCE			English	Article							LYMPHOCYTES; ACTIVATION; ANTIGEN; GAMMA/DELTA; DEFICIENT; INFECTION; INDUCTION; TOLERANCE; RESPONSES; PRODUCT	Although gamma delta T cells are implicated in regulating immune responses, gamma delta T cell-ligand pairs that could mediate such regulatory functions have not been identified. Here, the expression of the major histocompatibility complex (MHC) class Ib T22 and the closely related T10 molecules is shown to be activation-induced, and they confer specificity to about 0.4% of the gamma delta T cells in normal mice. Thus, the increased expression of T22 and/or T'10 might trigger immunoregulatory gamma delta T cells during immune responses. Furthermore, the fast on-rates and slow off-rates that characterize this receptor/ligand interaction would compensate for the low ligand stability and suggest a high threshold for gamma delta T cell activation.	Stanford Univ, Sch Med, Program Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Stanford University; Stanford University; Stanford University; Scripps Research Institute	Chien, YH (corresponding author), Stanford Univ, Sch Med, Program Immunol, Stanford, CA 94305 USA.	chien@leland.stanford.edu	Gütgemann, Ines/ABH-6426-2020; Fahrer, Aude M/C-9318-2009; Baumgarth, Nicole/AAI-6949-2020	Fahrer, Aude/0000-0001-8556-0223	NIAID NIH HHS [AI42267, AI34762-34, AI33431] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034762, R21AI142267, R01AI042267, R01AI033431] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; BAUMGARTH N, UNPUB; Bigos A, 1999, CYTOMETRY, V36, P36; Born W, 1999, Adv Immunol, V71, P77; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; CROWLEY MP, UNPUB; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; EMOTO M, 1995, INFECT IMMUN, V63, P3736, DOI 10.1128/IAI.63.9.3736-3738.1995; Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; GUTGEMANN I, UNPUB; HOULDEN BA, 1989, COLD SH Q B, V54, P45; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; KAUFMANN SHE, 1993, P NATL ACAD SCI USA, V90, P9620, DOI 10.1073/pnas.90.20.9620; Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272; Ke Y, 1997, J IMMUNOL, V158, P3610; MAVADDAT N, 1995, THESIS U W AUSTR NED; MCKEARN TJ, 1979, TRANSPLANT P, V11, P932; MCMENAMIN C, 1995, J IMMUNOL, V154, P4390; Ogg GS, 1998, CURR OPIN IMMUNOL, V10, P393, DOI 10.1016/S0952-7915(98)80110-6; Roberts SJ, 1996, P NATL ACAD SCI USA, V93, P11774, DOI 10.1073/pnas.93.21.11774; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; Scott CA, 1996, J EXP MED, V183, P2087, DOI 10.1084/jem.183.5.2087; SPANER D, 1995, J IMMUNOL, V155, P3866; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; WEINTRAUB BC, 1994, J IMMUNOL, V153, P3051; Wingren C, 2000, SCIENCE, V287, P310, DOI 10.1126/science.287.5451.310; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730	29	150	150	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					314	316		10.1126/science.287.5451.314	http://dx.doi.org/10.1126/science.287.5451.314			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634788				2022-12-01	WOS:000084769600043
J	Wu, G; Chen, YG; Ozdamar, B; Gyuricza, CA; Chong, PA; Wrana, JL; Massague, J; Shi, YG				Wu, G; Chen, YG; Ozdamar, B; Gyuricza, CA; Chong, PA; Wrana, JL; Massague, J; Shi, YG			Structural basis of Smad2 recognition by the Smad anchor for receptor activation	SCIENCE			English	Article							TGF-BETA RECEPTOR; PROTEINS; COMPLEX; SPECIFICITY	The Smad proteins mediate transforming growth factor-beta (TGF beta) signaling from the transmembrane serine-threonine receptor kinases to the nucleus. The Smad anchor for receptor activation (SARA) recruits Smad2 to the TGF beta receptors for phosphorylation. The crystal structure of a Smad2 MH2 domain in complex with the Smad-binding domain (SBD) of SARA has been determined at 2.2 angstrom resolution. SARA SBD, in an extended conformation comprising a rigid coil, an alpha helix, and a beta strand, interacts with the beta sheet and the three-helix bundle of Smad2 Recognition between the SARA rigid coil and the Smad2 beta sheet is essential for specificity, whereas interactions between the SARA beta strand and the Smad2 three-helix bundle contribute significantly to binding affinity. Comparison of the structures between Smad2 and a comediator Smad suggests a model for how receptor-regulated Smads are recognized by the type I receptors.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, New York, NY 10021 USA; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst,Dept Med Genet & Microb, Program Mol Biol & Microbiol, Toronto, ON M5G 1X5, Canada	Princeton University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA.	yshi@molbio.princeton.edu	Wrana, Jeffrey/F-8857-2013	Shi, Yigong/0000-0003-2030-168X; Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [F31CA085171] Funding Source: NIH RePORTER; NCI NIH HHS [CA85171] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Liu B, 1999, MOL CELL BIOL, V19, P424; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	19	225	249	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					92	97		10.1126/science.287.5450.92	http://dx.doi.org/10.1126/science.287.5450.92			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615055				2022-12-01	WOS:000084578400041
J	Schrag, SJ; Zywicki, S; Farley, MM; Reingold, AL; Harrison, LH; Lefkowitz, LB; Hadler, JL; Danila, R; Cieslak, PR; Schuchat, A				Schrag, SJ; Zywicki, S; Farley, MM; Reingold, AL; Harrison, LH; Lefkowitz, LB; Hadler, JL; Danila, R; Cieslak, PR; Schuchat, A			Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREVENTION; INFECTION; MENINGITIS; STRATEGIES	Background: Group B streptococcal infections are a leading cause of neonatal mortality, and they also affect pregnant women and the elderly. Many cases of the disease in newborns can be prevented by the administration of prophylactic intrapartum antibiotics. In the 1990s, prevention efforts increased. In 1996, consensus guidelines recommended use of either a risk-based or a screening-based approach to identify candidates for intrapartum antibiotics. To assess the effects of the preventive efforts, we analyzed trends in the incidence of group B streptococcal disease from 1993 to 1998. Methods: Active, population-based surveillance was conducted in selected counties of eight states. A case was defined by the isolation of group B streptococci from a normally sterile site. Census and live-birth data were used to calculate the race-specific incidence of disease; national projections were adjusted for race. Results: Disease in infants less than seven days old accounted for 20 percent of all 7867 group B streptococcal infections. The incidence of early-onset neonatal infections decreased by 65 percent, from 1.7 per 1000 live births in 1993 to 0.6 per 1000 in 1998. The excess incidence of early-onset disease in black infants, as compared with white infants, decreased by 75 percent. Projecting our findings to the entire United States, we estimate that 3900 early-onset infections and 200 neonatal deaths were prevented in 1998 by the use of intrapartum antibiotics. Among pregnant girls and women, the incidence of invasive group B streptococcal disease declined by 21 percent. The incidence among nonpregnant adults did not decline. Conclusions: Over a six-year period, there has been a substantial decline in the incidence of group B streptococcal disease in newborns, including a major reduction in the excess incidence of these infections in black infants. These improvements coincide with the efforts to prevent perinatal disease by the wider use of prophylactic intrapartum antibiotics. (N Engl J Med 2000;342:15-20.).	Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Resp Dis Branch, Atlanta, GA 30333 USA; Emory Univ, Sch Med, Atlanta, GA USA; Vet Affairs Med Serv, Atlanta, GA USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Johns Hopkins Sch Hyg & Publ Hlth, Baltimore, MD USA; Vanderbilt Med Ctr, Nashville, TN USA; Connecticut Dept Publ Hlth, Hartford, CT USA; Minnesota Dept Hlth, Minneapolis, MN USA; Dept Human Resources, Portland, OR USA	Centers for Disease Control & Prevention - USA; Emory University; University of California System; University of California Berkeley; Johns Hopkins University; Vanderbilt University; Minnesota Department of Health (MHD)	Schrag, SJ (corresponding author), Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Resp Dis Branch, MS-C23,1600 clifton Rd, Atlanta, GA 30333 USA.							Baker CJ, 1999, J INFECT DIS, V179, P142, DOI 10.1086/314574; BAKER CJ, 1973, J PEDIATR-US, V82, P724, DOI 10.1016/S0022-3476(73)80606-7; BARTON LL, 1973, J PEDIATR-US, V82, P719, DOI 10.1016/S0022-3476(73)80605-5; BOYER KM, 1986, NEW ENGL J MED, V314, P1665, DOI 10.1056/NEJM198606263142603; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P679; *COMM OBST PRACT, 173 ACOG COMM OBST P; *DEP HLTH HUM SERV, IN PRESS HLTH PEOPL; DILLON HC, 1987, J PEDIATR-US, V110, P31, DOI 10.1016/S0022-3476(87)80283-4; Fernandez M, 1998, ANTIMICROB AGENTS CH, V42, P1517, DOI 10.1128/AAC.42.6.1517; FRANCIOSI RA, 1973, J PEDIATR-US, V82, P707, DOI 10.1016/S0022-3476(73)80604-3; Halsey NA, 1997, PEDIATRICS, V99, P489, DOI 10.1542/peds.99.3.489; JACKSON LA, 1995, ANN INTERN MED, V123, P415, DOI 10.7326/0003-4819-123-6-199509150-00003; Krohn MA, 1999, J INFECT DIS, V179, P1410, DOI 10.1086/314756; Locksmith GJ, 1999, AM J OBSTET GYNECOL, V180, P416, DOI 10.1016/S0002-9378(99)70225-5; MCCRACKEN GH, 1973, J PEDIATR-US, V82, P703, DOI 10.1016/S0022-3476(73)80603-1; Mohle-Boetani JC, 1999, PEDIATRICS, V103, P703, DOI 10.1542/peds.103.4.703; MOHLEBOETANI JC, 1993, JAMA-J AM MED ASSOC, V270, P1442, DOI 10.1001/jama.270.12.1442; Pearlman MD, 1998, OBSTET GYNECOL, V92, P258, DOI 10.1016/S0029-7844(98)00155-0; ROBBINS JB, 1995, ANN NY ACAD SCI, V754, P68, DOI 10.1111/j.1749-6632.1995.tb44439.x; ROUSE DJ, 1994, OBSTET GYNECOL, V83, P483, DOI 10.1097/00006250-199404000-00001; Schuchat A, 1999, LANCET, V353, P51, DOI 10.1016/S0140-6736(98)07128-1; Towers CV, 1998, AM J OBSTET GYNECOL, V179, P879, DOI 10.1016/S0002-9378(98)70182-6; YANCEY MK, 1994, OBSTET GYNECOL, V83, P367; YANCEY MK, 1994, OBSTET GYNECOL, V84, P816; Zangwill Kenneth M., 1992, Morbidity and Mortality Weekly Report, V41, P25; 1996, MMWR MORB MORTAL WKL, V45, P1; 1997, MMWR MORB MORTAL WKL, V46, P473; 1998, MMWR MORB MORTAL WKL, V47, P665	28	698	728	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2000	342	1					15	20		10.1056/NEJM200001063420103	http://dx.doi.org/10.1056/NEJM200001063420103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271CE	10620644				2022-12-01	WOS:000084575600003
J	Samet, JM				Samet, JM			Concepts of time in clinical research	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MULTICENTER AIDS COHORT; HIV-INFECTION; LUNG-CANCER; SEROCONVERSION; MODELS; PERIOD; AGE; INTERMEDIATE; INCUBATION	The study of events in time is fundamental to biomedical research and public health surveillance. Clinicians have an intuitive appreciation for the relevance of time to health and disease, and patients invariably ask questions relating to time for which clinicians need answers. An appreciation of the picture of health and disease over time is equally fundamental to public health. Research designs that incorporate time have long been in use; the cohort study, which involves follow-up of persons over time, is the fundamental design. Analysis of longitudinal data, generated by cohort studies and related approaches, has been enhanced by new statistical methods that are appropriate to data collected over time from repeated observations. In the next millennium, new and increasingly complex questions will undoubtedly require investigation. The research designs and analytic methods used to address clinical questions in time will continue to evolve and will provide better, sharper answers.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA	Johns Hopkins University	Samet, JM (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, 615 N Wolfe St,Suite 6041, Baltimore, MD 21205 USA.							*ACT SOC AM, 1903, SPEC MORT INV; ANDVORD K. F., 1930, Norsk Magazin for Laegevidenskaben, V91, P642; Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61; BROWN L, 1904, AM MED, V8, P879; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; *COMM HLTH RISKS E, 1998, BEIR, V5; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; COX DR, 1972, J R STAT SOC B, V34, P187; Dawber TR, 1980, FRAMINGHAM STUDY EPI, P1; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Diggle P., 2002, ANAL LONGITUDINAL DA; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; DOLL R, 1954, BMJ-BRIT MED J, V1, P1451, DOI 10.1136/bmj.1.4877.1451; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; EYLER JM, 1978, TIMES PLACES PERSONS, P1; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; Frost WH, 1939, AM J HYG, V30, P91, DOI 10.1093/oxfordjournals.aje.a118570; Gange SJ, 1996, STAT MED, V15, P2323, DOI 10.1002/(SICI)1097-0258(19961115)15:21<2323::AID-SIM451>3.0.CO;2-P; GANGE SJ, 1997, J ACQ IMMUN DEF SYND, V15, pS5; Goldberg RJ, 1999, NEW ENGL J MED, V340, P1162, DOI 10.1056/NEJM199904153401504; Goldhaber SZ, 1999, LANCET, V353, P1386, DOI 10.1016/S0140-6736(98)07534-5; HOLFORD TR, 1991, ANNU REV PUBL HEALTH, V12, P425, DOI 10.1146/annurev.pu.12.050191.002233; Hu FB, 1999, JAMA-J AM MED ASSOC, V281, P1387, DOI 10.1001/jama.281.15.1387; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; LAST JM, 1995, DICT EPIDEMIOLOGY; LUNDIN FD, 1979, P WORK GROUP 2 C SOC, P243; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Miller R.G., 1981, SURVIVAL ANAL; Munoz A, 1998, EPIDEMIOL REV, V20, P29, DOI 10.1093/oxfordjournals.epirev.a017970; MUNOZ A, 1992, STAT MED, V11, P939, DOI 10.1002/sim.4780110711; MUNOZ A, 1995, J ACQ IMMUN DEF SYND, V8, P496, DOI 10.1097/00042560-199504120-00010; Munoz A, 1996, STAT MED, V15, P2459, DOI 10.1002/(SICI)1097-0258(19961130)15:22<2459::AID-SIM464>3.0.CO;2-Q; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; Munoz A, 1997, AIDS, V11, pS69; MUNOZ A, 1993, AM J EPIDEMIOL, V137, P423, DOI 10.1093/oxfordjournals.aje.a116691; MUNOZ A, 1995, USE COHORT STUDIES E, P423; *NCI, 1998, SEER CANC STAT REV 1; Nieto FJ, 1998, AM J EPIDEMIOL, V148, P937, DOI 10.1093/oxfordjournals.aje.a009570; Pearl R, 1938, SCIENCE, V87, P216, DOI 10.1126/science.87.2253.216; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; Samet JM, 1998, EPIDEMIOL REV, V20, P1; SARTWELL PE, 1951, AM REV TUBERC PULM, V63, P608; SCHULL WJ, 1995, EFFECTS ATOMIC RAD H, P1; Singer R B, 1985, Natl Cancer Inst Monogr, V67, P15; Speizer F E, 1979, Epidemiol Rev, V1, P124; Strong JP, 1999, JAMA-J AM MED ASSOC, V281, P727, DOI 10.1001/jama.281.8.727; TAYLOR JMG, 1990, STAT MED, V9, P505, DOI 10.1002/sim.4780090504; Thomas D, 1998, EPIDEMIOL REV, V20, P122, DOI 10.1093/oxfordjournals.epirev.a017967; *US DHEW, 1964, DHEW PUBL, V1103; Vogelstein B., 1998, GENETIC BASIS HUMAN; WHITE C, 1990, YALE J BIOL MED, V63, P29; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; Wynder EL, 1997, AM J EPIDEMIOL, V146, P687	61	8	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2000	132	1					37	44		10.7326/0003-4819-132-1-200001040-00007	http://dx.doi.org/10.7326/0003-4819-132-1-200001040-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270CV	10627250				2022-12-01	WOS:000084518600006
J	Bohn, LM; Lefkowitz, RJ; Gainetdinov, RR; Peppel, K; Caron, MG; Lin, FT				Bohn, LM; Lefkowitz, RJ; Gainetdinov, RR; Peppel, K; Caron, MG; Lin, FT			Enhanced morphine analgesia in mice lacking beta-arrestin 2	SCIENCE			English	Article							ADRENERGIC-RECEPTOR KINASE; OPIOID-RECEPTOR; OPIATE RECEPTOR; MU-RECEPTOR; HOT-PLATE; DESENSITIZATION; GENE; INTERNALIZATION; STIMULATION; MECHANISMS	The ability of morphine to alleviate pain is mediated through a heterotrimeric guanine nucleotide binding protein (G protein)-coupled heptahelical receptor (GPCR), the mu opioid receptor (mu OR). The efficiency of GPCR signaling is tightly regulated and ultimately Limited by the coordinated phosphorylation of the receptors by specific GPCR kinases and the subsequent interaction of the phosphorylated receptors with beta-arrestin 1 and beta-arrestin 2. Functional deletion of the beta-arrestin 2 gene in mice resulted in remarkable potentiation and prolongation of the analgesic effect of morphine, suggesting that mu OR desensitization was impaired. These results provide evidence in vivo for the physiological importance of beta-arrestin 2 in regulating the function of a specific GPCR, the mu OR. Moreover, they suggest that inhibition of beta-arrestin 2 function might lead to enhanced analgesic effectiveness of morphine and provide potential new avenues for the study and treatment of pain, narcotic tolerance, and dependence.	Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst Labs, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst Labs, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu; caron002@mc.duke.edu	Gainetdinov, Raul R/G-5875-2011; Bohn, Laura/A-4412-2008; Bohn, Laura M/A-7483-2014; Lefkowitz, Robert/AAW-2649-2021	Gainetdinov, Raul R/0000-0003-2951-6038; Bohn, Laura M/0000-0002-6474-8179; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F32DA006023] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDA NIH HHS [F32 DA006023] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER MW, 1988, ANNU REV PHARMACOL, V28, P429, DOI 10.1146/annurev.pa.28.040188.002241; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BELKNAP JK, 1989, PHYSIOL BEHAV, V46, P69, DOI 10.1016/0031-9384(89)90324-7; BOHN LM, UNPUB; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; Conner DA, 1997, CIRC RES, V81, P1021; Corbett A.D., 1993, OPIOIDS, P645, DOI [10.1007/978-3-642-77460-7_26, DOI 10.1007/978-3-642-77460-7_26]; Elmer GI, 1998, PAIN, V75, P129, DOI 10.1016/S0304-3959(97)00215-7; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/cjpp-74-10-1095; Fumagalli F, 1998, J NEUROSCI, V18, P4861; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; GAINETDINOV RR, UNPUB; Gardmark M, 1998, PHARMACOL TOXICOL, V83, P252, DOI 10.1111/j.1600-0773.1998.tb01478.x; Iaccarino G, 1998, AM J PHYSIOL-HEART C, V275, pH1298, DOI 10.1152/ajpheart.1998.275.4.H1298; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LIN FC, UNPUB; Matthes HWD, 1998, J NEUROSCI, V18, P7285; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MAYER DJ, 1976, PAIN, V2, P379, DOI 10.1016/0304-3959(76)90080-4; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Mundell SJ, 1999, BIOCHEMISTRY-US, V38, P8723, DOI 10.1021/bi990361v; Pan YX, 1999, MOL PHARMACOL, V56, P396, DOI 10.1124/mol.56.2.396; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PORRECA F, 1984, J PHARMACOL EXP THER, V230, P341; PORTOGHESE PS, 1990, J MED CHEM, V33, P1547, DOI 10.1021/jm00168a004; PORTOGHESE PS, 1993, HDB EXPT PHARM OPIOI, V1, P279; Rockman HA, 1998, J BIOL CHEM, V273, P18180, DOI 10.1074/jbc.273.29.18180; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; Selley DE, 1997, MOL PHARMACOL, V51, P87, DOI 10.1124/mol.51.1.87; SMITH DJ, 1988, EUR J PHARMACOL, V156, P47, DOI 10.1016/0014-2999(88)90145-8; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; Walker JKL, 1999, AM J PHYSIOL-REG I, V276, pR1214, DOI 10.1152/ajpregu.1999.276.4.R1214; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; YAKSH TL, 1988, PROG BRAIN RES, V77, P371; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	39	746	766	1	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2495	2498		10.1126/science.286.5449.2495	http://dx.doi.org/10.1126/science.286.5449.2495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617462				2022-12-01	WOS:000084429700045
J	Foster, BA; Coffey, HA; Morin, MJ; Rastinejad, F				Foster, BA; Coffey, HA; Morin, MJ; Rastinejad, F			Pharmacological rescue of mutant p53 conformation and function	SCIENCE			English	Article							DNA-BINDING; CELL-LINES; WILD-TYPE; PROTEIN; MUTATIONS; INVITRO; DOMAIN	Compounds that stabilize the DNA binding domain of p53 in the active conformation were identified. These small synthetic molecules not only promoted the stability of wild-type p53 but also allowed mutant p53 to maintain an active conformation. A prototype compound caused the accumulation of conformationally active p53 in cells with mutant p53, enabling it to activate transcription and to slow tumor growth in mice. With further work aimed at improving potency, this class of compounds may be developed into anticancer drugs of broad utility.	Pfizer Inc, Cent Res, Dept Genom Targets & Canc Res, Groton, CT 06340 USA	Pfizer	Rastinejad, F (corresponding author), Pfizer Inc, Cent Res, Dept Genom Targets & Canc Res, Eastern Point Rd, Groton, CT 06340 USA.							BARTEK J, 1990, ONCOGENE, V5, P893; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DANIELS DA, 1994, J MOL BIOL, V243, P639, DOI 10.1016/0022-2836(94)90038-8; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LEGROS Y, 1994, ONCOGENE, V9, P3689; MILNER J, 1990, ONCOGENE, V5, P1683; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; Nielsen LL, 1997, CANCER GENE THER, V4, P129; OConnor PM, 1997, CANCER RES, V57, P4285; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PRUSINER SB, 1997, SCIENCE, V278, P243; ROSENFELD MR, 1995, NEUROLOGY, V45, P1533, DOI 10.1212/WNL.45.8.1533; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6	24	652	690	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2507	2510		10.1126/science.286.5449.2507	http://dx.doi.org/10.1126/science.286.5449.2507			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617466				2022-12-01	WOS:000084429700049
J	Thurston, G; Suri, C; Smith, K; McClain, J; Sato, TN; Yancopoulos, GD; McDonald, DM				Thurston, G; Suri, C; Smith, K; McClain, J; Sato, TN; Yancopoulos, GD; McDonald, DM			Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY; ANGIOGENESIS; SKIN; INFLAMMATION; VENULES; TIE2	Angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF) are endothelial cell-specific growth factors. Direct comparison of transgenic mice overexpressing these factors in the skin revealed that the VEGF-induced blood vessels were Leaky, whereas those induced by Ang1 were nonleaky. Moreover, vessels in Ang1-overexpressing mice were resistant to Leaks caused by inflammatory agents. Coexpression of Ang1 and VEGF had an additive effect on angiogenesis but resulted in Leakage-resistant vessels typical of Ang1. Ang1 therefore may be useful for reducing microvascular Leakage in diseases in which the Leakage results from chronic inflammation or elevated VEGF and, in combination with VEGF, for promoting growth of nonleaky vessels.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dallas, TX 75235 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Regeneron	Thurston, G (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.				NHLBI NIH HHS [HL-59157, HL-24136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136, R01HL059157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baluk P, 1999, BRIT J PHARMACOL, V126, P522, DOI 10.1038/sj.bjp.0702323; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; BERGMAN RK, 1975, J ALLERGY CLIN IMMUN, V55, P378, DOI 10.1016/0091-6749(75)90076-7; Cunha-Vaz J, 1998, EUR J OPHTHALMOL, V8, P127, DOI 10.1177/112067219800800301; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Erjefalt JS, 1998, CLIN EXP ALLERGY, V28, P1013; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FUJII E, 1994, N-S ARCH PHARMACOL, V350, P361; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Inoue H, 1997, EUR J PHARMACOL, V333, P231, DOI 10.1016/S0014-2999(97)01040-6; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P607, DOI 10.1083/jcb.11.3.607; MCDONALD DM, 1994, AM J PHYSIOL, V266, pL61, DOI 10.1152/ajplung.1994.266.1.L61; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; OHRUI T, 1992, J ALLERGY CLIN IMMUN, V89, P933, DOI 10.1016/0091-6749(92)90215-N; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Schainfeld RM, 1999, ANN INTERN MED, V130, P442, DOI 10.7326/0003-4819-130-5-199903020-00017; Shiels IA, 1998, MED HYPOTHESES, V50, P113, DOI 10.1016/S0306-9877(98)90195-5; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; SVENSJO E, 1986, FASEB J, V45, P89; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; Thurston G, 1998, AM J PATHOL, V153, P1099, DOI 10.1016/S0002-9440(10)65654-4; WADSWORTH JDF, 1993, BIOCHEM J, V295, P537, DOI 10.1042/bj2950537; ZWEIFACH BW, 1973, ANNU REV PHYSIOL, V35, P117, DOI 10.1146/annurev.ph.35.030173.001001	31	1087	1167	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2511	2514		10.1126/science.286.5449.2511	http://dx.doi.org/10.1126/science.286.5449.2511			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617467				2022-12-01	WOS:000084429700050
J	Breukink, E; Wiedemann, I; van Kraaij, C; Kuipers, OP; Sahl, HG; de Kruijff, B				Breukink, E; Wiedemann, I; van Kraaij, C; Kuipers, OP; Sahl, HG; de Kruijff, B			Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic	SCIENCE			English	Article							C-TERMINAL PART; ANTIMICROBIAL PEPTIDE; BACTERIAL-MEMBRANES; NISIN; TRANSLOCATION; VANCOMYCIN; VESICLES; BILAYERS	Resistance to antibiotics is increasing in some groups of clinically important pathogens. For instance, high vancomycin resistance has emerged in enterococci. Promising alternative antibiotics are the peptide antibiotics, abundant in host defense systems, which kill their targets by permeabilizing the plasma membrane, These peptides generally do not act via specific receptors and are active in the micromolar range. Here it is shown that vancomycin and the antibacterial peptide nisin Z use the same target: the membrane-anchored cell wall precursor Lipid II, Nisin combines high affinity for Lipid II with its pore-forming ability, thus causing the peptide to be highly active (in the nanomolar range).	Univ Utrecht, Biomembrane Inst, Dept Membrane Biochem, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands; Univ Bonn, Inst Med Microbiol & Immunol, D-53105 Bonn, Germany; NIZO, Food Res Microbial Ingredients Sect, NL-6710 BA Ede, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands	Utrecht University; University of Bonn; NIZO Food Research; University of Groningen	Breukink, E (corresponding author), Univ Utrecht, Biomembrane Inst, Dept Membrane Biochem, Ctr Biomembranes & Lipid Enzymol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	e.j.breukink@chem.uu.nl	Kuipers, Oscar/B-6752-2009; Breukink, Eefjan/I-3039-2016	Kuipers, Oscar/0000-0001-5596-7735; Breukink, Eefjan/0000-0002-7311-0660				Breukink E, 1998, BIOCHEMISTRY-US, V37, P8153, DOI 10.1021/bi972797l; Breukink E, 1997, BIOCHEMISTRY-US, V36, P6968, DOI 10.1021/bi970008u; Brotz H, 1997, EUR J BIOCHEM, V246, P193, DOI 10.1111/j.1432-1033.1997.t01-1-00193.x; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; KONINGS WN, 1971, J BIOL CHEM, V246, P5857; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; Novak R, 1999, NATURE, V399, P590, DOI 10.1038/21202; SAHL HG, 1987, ARCH MICROBIOL, V149, P120, DOI 10.1007/BF00425076; SHELDRICK GM, 1978, NATURE, V271, P223, DOI 10.1038/271223a0; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; STONE KJ, 1973, J BIOL CHEM, V249, P1823; van Kraaij C, 1998, BIOCHEMISTRY-US, V37, P16033, DOI 10.1021/bi980931b; VANHEIJENOORT Y, 1992, J BACTERIOL, V174, P3549, DOI 10.1128/JB.174.11.3549-3557.1992; VanKraaij C, 1997, EUR J BIOCHEM, V247, P114; WILLIAMS DH, 1988, BIOCHEM PHARMACOL, V37, P133, DOI 10.1016/0006-2952(88)90765-4; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	17	612	632	2	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2361	2364		10.1126/science.286.5448.2361	http://dx.doi.org/10.1126/science.286.5448.2361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600751	Green Submitted			2022-12-01	WOS:000084318500068
J	Apfeld, J; Kenyon, C				Apfeld, J; Kenyon, C			Regulation of lifespan by sensory perception in Caenorhabditis elegans	NATURE			English	Article							NUCLEOTIDE-GATED CHANNEL; DAUER LARVA FORMATION; C-ELEGANS; NERVOUS-SYSTEM; LONGEVITY; DAF-2; GENES; SPAN; DIAPAUSE; PATHWAY	Caenorhabditis elegans senses environmental signals through ciliated sensory neurons located primarily in sensory organs in the head and tail. Cilia function as sensory receptors, and mutants with defective sensory cilia have impaired sensory perception(1,2) Cilia are membrane-bound microtubule-based structures and in C. elegans are only found at the dendritic endings of sensory neurons(3). Here we show that mutations that cause defects in sensory cilia or their support cells, or in sensory signal transduction, extend lifespan. Our findings imply that sensory perception regulates the lifespan of this animal, and suggest that in nature, its Lifespan may be regulated by environmental cues.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	ckenyon@biochem.ucsf.edu		Apfeld, Javier/0000-0001-9897-5671				Ailion M, 1999, P NATL ACAD SCI USA, V96, P7394, DOI 10.1073/pnas.96.13.7394; ALBERT PS, 1981, J COMP NEUROL, V198, P435, DOI 10.1002/cne.901980305; Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; Coburn CM, 1998, DEVELOPMENT, V125, P249; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Collet J, 1998, GENETICS, V148, P187; DORMAN JB, 1995, GENETICS, V141, P1399; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Komatsu H, 1999, BRAIN RES, V821, P160, DOI 10.1016/S0006-8993(99)01111-7; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; LARSEN PL, 1995, GENETICS, V139, P1567; LAWLESS JF, 1982, MODELS METHODS LIFET; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Peckol EL, 1999, DEVELOPMENT, V126, P1891; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; TABISH M, 1995, J MOL BIOL, V247, P377, DOI 10.1006/jmbi.1994.0146; VOWELS JJ, 1992, GENETICS, V130, P105; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	27	392	436	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					804	809		10.1038/45544	http://dx.doi.org/10.1038/45544			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617200				2022-12-01	WOS:000084330500064
J	Forbes, RB; Lees, A; Waugh, N; Swingler, RJ				Forbes, RB; Lees, A; Waugh, N; Swingler, RJ			Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL COURSE; GUIDELINES; CARE	Objective To evaluate the cost utility of interferon beta-1b in secondary progressive multiple sclerosis. Design Population based cost utility model (healthcare perspective). Data on use of health services were obtained from case records and routine morbidity data and utility values from a EuroQol survey Local and published costs were used. Effectiveness was modelled using data on relative risk reductions from a randomised trial of interferon beta-lb. Setting Tayside region, 1993-5. Subjects 132 ambulatory people with secondary; progressive multiple sclerosis. Main outcome measures Cost per quality adjusted life lear (QALY) gained. Rate of relapse and proportion becoming wheelchair dependent ol:er three years. Results The number needed to treat for 30 months to delay time to wheelchair dependence in one per-son by nine months was 18 (95% confidence interval 5 to 26), For every 18 people treated for 30 months, sh relapses would be prevented, gaining 0.397 discounted QALYs. The cost per QALY gained was pound 1 024 667 (pound 276 466 to pound 1 485 499). If treatment was restricted to patients attending neurology services, the number needed to treat was 14 (cost per QALY gained pound 833 514 (pound 161 358 to infinity)). The cost per QALY gained was not sensitive to changes in cost which took account of a societal perspective. Conclusions The cost per QALY; gained from interferon beta is high because of the high drug cost and modest clinical effect Resources could be used more efficiently elsewhere.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Neurol, Dundee DD1 9SY, Scotland; Argyll & Clyde Hlth Board, Paisley PA2 7BN, Renfrew, Scotland; Scottish Hlth Purchasing Informat Ctr, Aberdeen AB15 6RE, Scotland	University of Dundee	Forbes, RB (corresponding author), Royal Victoria Hosp, Dept Neurol, Belfast BT12 6BA, Antrim, North Ireland.	raeburn.forbes@royalhospitals.n-i-nhs.uk		Forbes, Raeburn/0000-0002-1444-7909				Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Auty A, 1998, CAN J NEUROL SCI, V25, P23; Blumhardt L., 1996, BR J MED EC, V10, P99; *BRIT MED ASS, 1995, BRIT NAT FORM; BROWN MG, 1996, THERAPEUTIC EC ASSES; Busch MP, 1997, TRANSFUSION, V37, P1003, DOI 10.1046/j.1537-2995.1997.371098016437.x; Carton H, 1998, J NEUROL NEUROSUR PS, V64, P444, DOI 10.1136/jnnp.64.4.444; Dolan P, 1995, SOCIAL TARIFF EUROQO; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177; Forbes RB, 1999, AM J EPIDEMIOL, V149, P1016; FREEMAN J, 1997, STANDARDS HEALTHCARE; Gardner MJ, 1989, STAT CONFIDENCE, P28; Gerard K, 1993, Health Econ, V2, P59, DOI 10.1002/hec.4730020108; Goodkin DE, 1998, LANCET, V352, P1486, DOI 10.1016/S0140-6736(98)00057-9; Graham B, 1997, BRIT J GEN PRACT, V47, P170; Holmes J, 1997, BRIT MED J, V314, P601; HOLMES J, 1998, J NEUROL NEUROSUR PS, V64, P420; Holmes J., 1995, BR J MED EC, V8, P181; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; MCALPINE D, 1952, Q J MED, V21, P135; MOONEY C, 1992, EC MED HLTH CARE, P5; OBRIEN B, 1997, MULT SCLER, V47, P170; PARKIN D, 1998, HLTH TECHNOL ASSESSM, V2; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Richards RG, 1996, BRIT MED J, V313, P1159, DOI 10.1136/bmj.313.7066.1159; SACKETT DL, 1996, PRACTICE TEACH EVIDE; Stolp-Smith KA, 1998, NEUROLOGY, V50, P1594, DOI 10.1212/WNL.50.6.1594; Tolley KH, 1997, PHARMACOECONOMICS, V11, P210, DOI 10.2165/00019053-199711030-00002; Tremlett HL, 1998, J NEUROL NEUROSUR PS, V65, P362, DOI 10.1136/jnnp.65.3.362; VICKREY BG, 1995, QUAL LIFE RES, V4, P187, DOI 10.1007/BF02260859; Vickrey BG, 1997, J CLIN EPIDEMIOL, V50, P557, DOI 10.1016/S0895-4356(97)00001-2; WEINSHENKER BG, 1989, BRAIN, V112, P1419, DOI 10.1093/brain/112.6.1419; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; 1998, MS MATTERS       NOV	39	69	69	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	1999	319	7224					1529	1533		10.1136/bmj.319.7224.1529	http://dx.doi.org/10.1136/bmj.319.7224.1529			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591710	Green Published, Bronze			2022-12-01	WOS:000084245600020
J	Stopfer, M; Laurent, G				Stopfer, M; Laurent, G			Short-term memory in olfactory network dynamics	NATURE			English	Article							OSCILLATING NEURAL ASSEMBLIES; VISUAL-CORTEX; INFORMATION; SYNCHRONIZATION; INSECTS; BULB; CAT	Neural assemblies in a number of animal species display self-organized, synchronized oscillations in response to sensory stimuli in a variety of brain areas.(1-5). In the olfactory system of insects, odour-evoked oscillatory synchronization of antennal lobe projection neurons (PNs) is superimposed on slower and stimulus-specific temporal activity patterns. Hence, each odour activates a specific and dynamic projection neuron assembly whose evolution during a stimulus is locked to the oscillation clock(6,7). Here we examine, using locusts, the changes in population dynamics of projection-neuron assemblies over repeated odour stimulations, as would occur when an animal first encounters and then repeatedly samples an odour for identification or localization. We find that the responses of these assemblies rapidly decrease in intensity, while they show a marked increase in spike time precision and inter-neuronal oscillatory coherence. Once established, this enhanced precision in the representation endures for several minutes. This change is stimulus-specific, and depends on events within the antennal lobe circuits, independent of olfactory receptor adaptation: it may thus constitute a form of sensory memory. Our results suggest that this progressive change in olfactory network dynamics serves to converge, over repeated odour samplings, on a more precise and readily classifiable odour representation, using relational information contained across neural assemblies.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Laurent, G (corresponding author), CALTECH, Div Biol, 139-74, Pasadena, CA 91125 USA.		Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X; Stopfer, Mark/0000-0001-9200-1884				Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FREEMAN WJ, 1978, ELECTROEN CLIN NEURO, V44, P586, DOI 10.1016/0013-4694(78)90126-8; GELPERIN A, 1990, NATURE, V345, P437, DOI 10.1038/345437a0; GRAY CM, 1988, EXP BRAIN RES, V69, P378; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Kay S. M., 1988, MODERN SPECTRAL ESTI; LAURENT G, 1994, J NEUROSCI, V14, P2993; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; LAWLESS H, 1997, TASTING SMELLING; MacLeod K, 1996, SCIENCE, V274, P976, DOI 10.1126/science.274.5289.976; MacLeod K, 1998, NATURE, V395, P693, DOI 10.1038/27201; MASSON C, 1990, PHYSIOL REV, V70, P199, DOI 10.1152/physrev.1990.70.1.199; Mellon D, 1997, J COMP PHYSIOL A, V180, P553, DOI 10.1007/s003590050072; MURLIS J, 1992, ANNU REV ENTOMOL, V37, P505, DOI 10.1146/annurev.en.37.010192.002445; PRECHTL JC, 1994, P NATL ACAD SCI USA, V91, P12467, DOI 10.1073/pnas.91.26.12467; SLIFER EH, 1965, J MORPHOL, V114, P393; Stopfer M, 1997, NATURE, V390, P70, DOI 10.1038/36335; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; WEHT M, 1999, J NEUROSCI, V19, P381	21	190	192	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					664	668		10.1038/45244	http://dx.doi.org/10.1038/45244			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604472				2022-12-01	WOS:000084189800066
J	Shin, MK; Levorse, JM; Ingram, RS; Tilghman, SM				Shin, MK; Levorse, JM; Ingram, RS; Tilghman, SM			The temporal requirement for endothelin receptor-B signalling during neural crest development	NATURE			English	Article							GENE-EXPRESSION; TRANSGENIC MICE; ENTERIC NEURONS; MAMMALIAN-CELLS; MOUSE EMBRYO; PIGMENTATION; MELANOCYTES; MUTATIONS; PROLIFERATION; DROSOPHILA	Endothelin receptor B (EDNRB) is a G-protein-coupled receptor with seven transmembrane domains which is required for the development of melanocytes and enteric neurons. Mice that are homozygous for a null mutation in the Ednrb gene are almost completely white and die as juveniles from megacolon, To determine when EDNRB signalling is required during embryogenesis, we have exploited the tetracycline-inducible system to generate strains of mice in which the endogenous Ednrb locus is under the control of the tetracycline-dependant transactivators tTa or rtTA. By using this system to express Ednrb at different stages of embryogenesis, we have determined that EDNRB is required during a restricted period of neural crest development between embryonic days 10 and 12.5. Moreover, our results imply that EDNRB is required for the migration of both melanoblasts and enteric neuroblasts.	Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Princeton University	Tilghman, SM (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.							Anderson DJ, 1997, COLD SPRING HARB SYM, V62, P493; Baron U, 1999, P NATL ACAD SCI USA, V96, P1013, DOI 10.1073/pnas.96.3.1013; Barsh GS, 1996, TRENDS GENET, V12, P299, DOI 10.1016/0168-9525(96)10031-7; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Bedell MA, 1997, GENE DEV, V11, P11, DOI 10.1101/gad.11.1.11; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gingrich JR, 1998, ANNU REV NEUROSCI, V21, P377, DOI 10.1146/annurev.neuro.21.1.377; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hearn CJ, 1998, DEV BIOL, V197, P93, DOI 10.1006/dbio.1998.8876; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Jackson IJ, 1997, HUM MOL GENET, V6, P1613, DOI 10.1093/hmg/6.10.1613; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; KAPUR RP, 1995, DEVELOPMENT, V121, P3787; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Lahav R, 1996, P NATL ACAD SCI USA, V93, P3892, DOI 10.1073/pnas.93.9.3892; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Le Douarin N.M., 1982, NEURAL CREST; Leibl MA, 1999, GUT, V44, P246, DOI 10.1136/gut.44.2.246; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; Mansuy IM, 1998, NEURON, V21, P257, DOI 10.1016/S0896-6273(00)80533-4; MAYER TC, 1973, DEV BIOL, V34, P39, DOI 10.1016/0012-1606(73)90337-0; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; Newgreen DF, 1995, ACTA ANAT, V154, P243; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; Reid K, 1996, DEVELOPMENT, V122, P3911; Rossant J, 1999, GENE DEV, V13, P142, DOI 10.1101/gad.13.2.142; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; Shin MK, 1997, P NATL ACAD SCI USA, V94, P13105, DOI 10.1073/pnas.94.24.13105; Silvers WK., 1979, COAT COLORS MICE MOD; STEEL KP, 1992, DEVELOPMENT, V115, P1111; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Wu JJ, 1999, DEVELOPMENT, V126, P1161; Yoshida H, 1996, DEVELOPMENT, V122, P1207	44	262	267	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					496	501		10.1038/990040	http://dx.doi.org/10.1038/990040			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591209				2022-12-01	WOS:000084013200046
J	Sloan, FA; Taylor, DH				Sloan, FA; Taylor, DH			Private and public choices in end-of-life care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TRENDS		Duke Univ, Ctr Hlth Policy & Management, Durham, NC 27706 USA	Duke University	Sloan, FA (corresponding author), Duke Univ, Ctr Hlth Policy & Management, Durham, NC 27706 USA.							COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; Gramelspacher GP, 1997, J GEN INTERN MED, V12, P346, DOI 10.1046/j.1525-1497.1997.00058.x; *I MED, 1997, APPR DEATH IMPR CAR; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163	8	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2078	2078		10.1001/jama.282.21.2078	http://dx.doi.org/10.1001/jama.282.21.2078			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591394	hybrid			2022-12-01	WOS:000083908700031
J	Pratt, KP; Shen, BW; Takeshima, K; Davie, EW; Fujikawa, K; Stoddard, BL				Pratt, KP; Shen, BW; Takeshima, K; Davie, EW; Fujikawa, K; Stoddard, BL			Structure of the C2 domain of human factor VIII at 1.5 angstrom resolution	NATURE			English	Article							COAGULATION FACTOR-V; VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODY; BINDING; PHOSPHATIDYLSERINE; INACTIVATION; MECHANISM; INHIBITOR; PEPTIDE; MODELS	Human factor VIII is a plasma glycoprotein that has a Critical role in blood Coagulation(1,2). Factor VIII circulates as a complex with von Willebrand factor(3). After cleavage by thrombin, factor VIIIa associates with factor IXa at the surface of activated platelets or endothelial cells(4,5). This complex activates factor X (refs 6, 7), which in turn converts prothrombin to thrombin in the presence of factor Va (refs 8, 9). The carboxyl-terminal C2 domain of factor VIII contains sites that are essential for its binding to von Willebrand factor and to negatively charged phospholipid surfaces(4,10,11). Here we report the structure of human factor VIII C2 domain at 1.5 Angstrom resolution. The structure reveals a beta-sandwich core, from which two beta-turns and a loop display a group of solvent-exposed hydrophobic residues. Behind the hydrophobic surface lies a ring. of positively charged residues. This motif suggests a mechanism for membrane binding involving both hydrophobic and electrostatic interactions. The structure explains, in part, mutations in the C2 region of factor VIII that lead to bleeding disorders in haemophilia A.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Program Struct Biol, Seattle, WA 98109 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Stoddard, BL (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Program Struct Biol, 1100 Fairview Ave N A3-023, Seattle, WA 98109 USA.	bstoddar@fhcrc.org	Pratt, Kathleen P/E-9489-2019	Pratt, Kathleen/0000-0001-6837-6133				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; GILBERT GE, 1995, BIOCHEMISTRY-US, V34, P3022, DOI 10.1021/bi00009a033; Healey JF, 1998, BLOOD, V92, P3701, DOI 10.1182/blood.V92.10.3701.422k22_3701_3709; HOYER LW, 1994, SEMIN HEMATOL, V31, P1; *IMP COLL MED SCH, HAEM MUT DAT; Jacquemin MG, 1998, BLOOD, V92, P496, DOI 10.1182/blood.V92.2.496.414k16_496_506; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANE WH, 1988, BLOOD, V71, P539; KAUFMAN RJ, 1992, ANNU REV MED, V43, P325, DOI 10.1146/annurev.med.43.1.325; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; Kuwabara I, 1999, J IMMUNOL METHODS, V224, P89, DOI 10.1016/S0022-1759(99)00012-5; LAFORTELLE E, 1997, CRYSTALLOGRAPHIC COM, V7, P100; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANN KG, 1990, BLOOD, V76, P1; NIEH YP, IN PRESS ACTA CRYS D; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellequer JL, 1998, BLOOD CELL MOL DIS, V24, P448, DOI 10.1006/bcmd.1998.0214; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; TAKESHMA K, UNPUB J BIOL CHEM; VANDERBEEKEN Y, 1981, AM J REPROD IMMUNOL, V1, P236, DOI 10.1111/j.1600-0897.1981.tb00047.x; Veeraraghavan S, 1998, BIOCHEM J, V332, P549, DOI 10.1042/bj3320549; WOLFENDEN R, 1981, BIOCHEMISTRY-US, V20, P849, DOI 10.1021/bi00507a030	30	270	288	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					439	442		10.1038/46601	http://dx.doi.org/10.1038/46601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586887				2022-12-01	WOS:000083913600063
J	Weigert, R; Silletta, MG; Spano, S; Turacchio, G; Cericola, C; Colanzi, A; Senatore, S; Mancini, R; Polishchuk, EV; Salmona, M; Facchiano, F; Burger, KNJ; Mironov, A; Luini, A; Corda, D				Weigert, R; Silletta, MG; Spano, S; Turacchio, G; Cericola, C; Colanzi, A; Senatore, S; Mancini, R; Polishchuk, EV; Salmona, M; Facchiano, F; Burger, KNJ; Mironov, A; Luini, A; Corda, D			CtBP/BARS induces fission of Golgi membranes by acylating lysophosphatidic acid	NATURE			English	Article							TRANSPORT VESICLES; COATED VESICLES; PROTEIN; DYNAMIN	Membrane fission is essential in intracellular transport. Acyl-coenzyme As (acyl-CoAs) are important in lipid remodelling and are required for fission of COPI-coated vesicles(1). Here we show that CtBP/BARS, a protein that functions in the dynamics of Golgi tubules(2), is an essential component of the fission machinery operating at Golgi tubular networks, including Golgi compartments involved in protein transport and sorting. CtBP/BARS-induced fission was preceded by the formation of constricted sites in Golgi tubules, whose extreme curvature is likely to involve local changes in the membrane lipid composition. We find that CtBP/BARS uses acyl-CoA to selectively catalyse the acylation of lysophosphatidic acid to phosphatidic acid both in pure lipidic systems and in Golgi membranes, and that this reaction is essential for fission. Our results indicate a key role for lipid metabolic pathways in membrane fission.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy; Ist Ric Farmacol Mario Negri, Dept Mol Pharmacol & Biochem, I-20157 Milan, Italy; Ist Dermopat Immacolata, Lab Vasc Pathol, Rome, Italy; Univ Utrecht, Inst Biomembranes, Dept Biochem Membranes, NL-3584 CH Utrecht, Netherlands	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Utrecht University	Luini, A (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy.	luini@cmns.mnegri.it; corda@cmns.mnegri.it	salmona, mario/ABI-4066-2020; Facchiano, Francesco/K-8716-2016; salmona, mario/AAA-7116-2020; Corda, Daniela/K-6385-2016; Spanò, Stefania/F-4951-2011; Colanzi, Antonino/D-6821-2012	Facchiano, Francesco/0000-0003-4313-0617; salmona, mario/0000-0002-9098-9873; Corda, Daniela/0000-0002-3614-751X; Spanò, Stefania/0000-0001-9154-7463; Colanzi, Antonino/0000-0002-5643-0216	Telethon [E.0982, E.1105] Funding Source: Medline	Telethon(Fondazione Telethon)		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Bar-Tana J, 1975, Methods Enzymol, V35, P117, DOI 10.1016/0076-6879(75)35146-X; BOGGS JM, 1987, BIOCHIM BIOPHYS ACTA, V906, P353, DOI 10.1016/0304-4157(87)90017-7; Buccione R, 1996, J BIOL CHEM, V271, P3523; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; CLUETT EB, 1992, J CELL SCI, V103, P773; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; Kelly RB, 1999, NAT CELL BIOL, V1, pE8, DOI 10.1038/8957; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Griffiths Gareth, 1993, Trends in Cell Biology, V3, P214, DOI 10.1016/0962-8924(93)90114-G; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Rambourg A., 1997, GOLGI APPARATUS, P37; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Simon JP, 1998, P NATL ACAD SCI USA, V95, P11181, DOI 10.1073/pnas.95.19.11181; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Vance D., 1996, BIOCH LIPIDS LIPOPRO, V31, P1; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3	23	259	269	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					429	433		10.1038/46587	http://dx.doi.org/10.1038/46587			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586885				2022-12-01	WOS:000083913600061
J	Tomasec, P; Braud, VM; Rickards, C; Powell, MB; McSharry, BP; Gadola, S; Cerundolo, V; Borysiewicz, LK; McMichael, AJ; Wilkinson, GWG				Tomasec, P; Braud, VM; Rickards, C; Powell, MB; McSharry, BP; Gadola, S; Cerundolo, V; Borysiewicz, LK; McMichael, AJ; Wilkinson, GWG			Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I HOMOLOG; SEQUENCE-DERIVED PEPTIDES; E BINDS; REPLICATION; RECEPTOR; LYSIS; TAP; TRANSLOCATION; TRANSPORTER	The nonclassical major histocompatibility complex (MHC) class I molecule HLA-E inhibits natural killer (NK) cell-mediated lysis by interacting with CD94/ NKG2A receptors. Surface expression of HLA-E depends on binding of conserved peptides derived from MHC class I molecules. The same peptide is present in the leader sequence of the human cytomegalovirus (HCMV) glycoprotein UL40 (gpUL40). It is shown that, independently of the transporter associated with antigen processing, gpUL40 can up-regulate expression of HLA-E, which protects targets from NK cell Lysis. While classical MHC class I molecules are down-regulated, HLA-E is up-regulated by HCMV. induction of HLA-E surface expression by gpUL40 may represent an escape route for HCMV.	John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England; Univ Wales, Coll Med, Dept Med, Cardiff CF14 4XN, S Glam, Wales	University of Oxford; Cardiff University	Braud, VM (corresponding author), John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.		Wilkinson, Gavin WG/J-6388-2015; McSharry, Brian/AAE-3351-2019; braud, veronique M/I-4597-2013	Wilkinson, Gavin WG/0000-0002-5623-0126; McSharry, Brian/0000-0003-0473-2789; braud, veronique M/0000-0001-8213-3947; Cerundolo, Vincenzo/0000-0003-0040-3793				Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Biron CA, 1997, CURR OPIN IMMUNOL, V9, P24, DOI 10.1016/S0952-7915(97)80155-0; Borrego F, 1998, J EXP MED, V187, P813, DOI 10.1084/jem.187.5.813; BORYSIEWICZ LK, 1985, J IMMUNOL, V134, P2695; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brown MG, 1999, J IMMUNOL, V163, P1991; BROWNE H, 1992, J VIROL, V66, P6784, DOI 10.1128/JVI.66.11.6784-6787.1992; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; Cretney E, 1999, J EXP MED, V190, P435, DOI 10.1084/jem.190.3.435; Farrell HE, 1997, NATURE, V386, P510, DOI 10.1038/386510a0; Fletcher JM, 1998, J IMMUNOL, V161, P2365; Hengel H, 1997, IMMUNITY, V6, P623, DOI 10.1016/S1074-7613(00)80350-7; Kubota A, 1999, CELL IMMUNOL, V191, P145, DOI 10.1006/cimm.1998.1424; Lee N, 1998, J IMMUNOL, V160, P4951; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; Leong CC, 1998, J EXP MED, V187, P1681, DOI 10.1084/jem.187.10.1681; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; Moins-Teisserenc HT, 1999, LANCET, V354, P1598, DOI 10.1016/S0140-6736(99)04206-3; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Plachter B, 1996, ADV VIRUS RES, V46, P195, DOI 10.1016/S0065-3527(08)60073-1; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Polic B, 1998, J EXP MED, V188, P1047, DOI 10.1084/jem.188.6.1047; Reyburn HT, 1997, NATURE, V386, P514, DOI 10.1038/386514a0; Robertson MJ, 1996, EXP HEMATOL, V24, P406; SCALZO AA, 1992, J IMMUNOL, V149, P581; SCALZO AA, 1990, J EXP MED, V171, P1469, DOI 10.1084/jem.171.5.1469; TOMASEC P, UNPUB; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; [No title captured]	34	478	496	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1031	1033		10.1126/science.287.5455.1031	http://dx.doi.org/10.1126/science.287.5455.1031			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669413				2022-12-01	WOS:000085245400045
J	Stallard, S; Litherland, JC; Cordiner, C; Dobson, HM; George, WD; Mallon, EA; Hole, D				Stallard, S; Litherland, JC; Cordiner, C; Dobson, HM; George, WD; Mallon, EA; Hole, D			Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									N Glasgow Hosp Univ NHS Trust, Univ Dept Surg, Glasgow G11 6NT, Lanark, Scotland; N Glasgow Hosp Univ NHS Trust, Univ Dept Pathol, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Dept Publ Hlth, W Scotland Canc Surveillance Unit, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Stallard, S (corresponding author), N Glasgow Hosp Univ NHS Trust, Univ Dept Surg, Glasgow G11 6NT, Lanark, Scotland.							Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; GAMBRELL RD, 1992, AM FAM PHYSICIAN S5, V46, P87; Harding C, 1996, BRIT MED J, V312, P1646, DOI 10.1136/bmj.312.7047.1646; Litherland JC, 1999, CLIN RADIOL, V54, P285, DOI 10.1016/S0009-9260(99)90555-X	5	33	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					348	349		10.1136/bmj.320.7231.348	http://dx.doi.org/10.1136/bmj.320.7231.348			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10657329	Green Submitted, Green Published, Bronze, Green Accepted			2022-12-01	WOS:000085211400025
J	Dai, SD; Schwendtmayer, C; Schurmann, P; Ramaswamy, S; Eklund, H				Dai, SD; Schwendtmayer, C; Schurmann, P; Ramaswamy, S; Eklund, H			Redox signaling in chloroplasts: Cleavage of disulfides by an iron-sulfur cluster	SCIENCE			English	Article							FERREDOXIN-THIOREDOXIN REDUCTASE; SPINACH FERREDOXIN; PROTEIN MODELS; PHOTOSYSTEM-I; CRYSTALLOGRAPHY; POTENTIALS; RESOLUTION; REFINEMENT; DOMAINS; PEPTIDE	Light generates reducing equivalents in chloroplasts that are used not only for carbon reduction, but also for the regulation of the activity of chloroplast enzymes by reduction of regulatory disulfides via the ferredoxin:thioredoxin reductase (FTR) system, FTR, the key electron/thiol transducer enzyme in this pathway, is unique in that it can reduce disulfides by an iron-sulfur cluster, a property that is explained by the tight contact of its active-site disulfide and the iron-sulfur center. The thin, flat FTR molecule makes the two-electron reduction possible by forming on one side a mixed disulfide with thioredoxin and by providing on the opposite side access to ferredoxin for delivering electrons.	Swedish Univ Agr Sci, Dept Mol Biol, Ctr Biomed, S-75124 Uppsala, Sweden; Univ Neuchatel, Lab Biochim Vegetale, CH-2007 Neuchatel, Switzerland	Swedish University of Agricultural Sciences; University of Neuchatel	Eklund, H (corresponding author), Swedish Univ Agr Sci, Dept Mol Biol, Ctr Biomed, Box 590, S-75124 Uppsala, Sweden.	hasse@xray.bmc.uu.se	Subramanian, Ramaswamy/Q-8671-2019	Subramanian, Ramaswamy/0000-0002-6709-190X				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; BUCHANAN BB, 1994, ARCH BIOCHEM BIOPHYS, V314, P257, DOI 10.1006/abbi.1994.1439; Capitani G, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1939; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; Chiadmi M, 1999, EMBO J, V18, P6809, DOI 10.1093/emboj/18.23.6809; CIURLI S, 1990, J AM CHEM SOC, V112, P2654, DOI 10.1021/ja00163a028; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; FALZONE CJ, 1994, BIOCHEMISTRY-US, V33, P6052, DOI 10.1021/bi00186a004; Hampton MB, 1998, BIOFACTORS, V8, P1, DOI 10.1002/biof.5520080101; Hirasawa M, 1999, BIOCHEMISTRY-US, V38, P5200, DOI 10.1021/bi982783v; HIRASAWA M, 1998, BIOCHIM BIOPHYS ACTA, V935, P1; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; JACOBSON BL, 1993, BIOCHEMISTRY-US, V32, P6788, DOI 10.1021/bi00077a033; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LANGEN R, 1992, J BIOL CHEM, V267, P25625; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; LEVINGS CS, 1995, SCIENCE, V268, P695, DOI 10.1126/science.268.5211.695; Mayer KL, 1999, BIOCHEMISTRY-US, V38, P13736, DOI 10.1021/bi9910373; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; SALAMON Z, 1995, BBA-BIOENERGETICS, V1230, P114, DOI 10.1016/0005-2728(95)00042-H; Schubert WD, 1998, J MOL BIOL, V280, P297, DOI 10.1006/jmbi.1998.1824; Schwendtmayer C, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1927; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; Staples CR, 1998, BIOCHEMISTRY-US, V37, P4612, DOI 10.1021/bi9729763; Stout CD, 1998, J MOL BIOL, V278, P629, DOI 10.1006/jmbi.1998.1732; van Thor JJ, 1999, BIOCHEMISTRY-US, V38, P12735, DOI 10.1021/bi9903502; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23	45	161	169	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2000	287	5453					655	658		10.1126/science.287.5453.655	http://dx.doi.org/10.1126/science.287.5453.655			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10649999	Green Submitted			2022-12-01	WOS:000084989400048
J	Malouf, AJ; Norton, CS; Engel, AF; Nicholls, RJ; Kamm, MA				Malouf, AJ; Norton, CS; Engel, AF; Nicholls, RJ; Kamm, MA			Long-term results of overlapping anterior anal-sphincter repair for obstetric trauma	LANCET			English	Article							POSTOBSTETRIC FECAL INCONTINENCE; ENDOSONOGRAPHY; DEFECTS; INJURY; ULTRASOUND; NEUROPATHY; SURGERY	Background Anterior structural damage to the anal sphincter occurs in up to a third of women at first vaginal delivery, and of these a third have new bowel symptoms. The standard treatment for such structural damage is anterior overlapping anal-sphincter repair. We aimed to assess the long-term results of this operation. Methods We assessed the long-term results in 55 consecutive patients who had had repair a minimum of 5 years (median 77 months [range 60-96]) previously. Questionnaire and telephone interview assessed current bowel function and continence, restriction in activities related to bowel control, and overall satisfaction with the results of surgery, 42 of these patients had been continent of solid and liquid stool at a median of 15 months after the repair. Findings We were able to contact 47 (86%) of the 55 patients. One of these patients had required a proctectomy and end ileostomy for Crohn's disease. Of the remaining 46 patients, 27 reported improved bowel control without the need for further surgery, and 23 rated their symptom improvement as 50% or greater. Seven patients had undergone further surgery for incontinence and one patient had not had a covering stoma closed. Thus, the rang-term functional outcome of the sphincter repair alone could be assessed in 38 patients. Of these patients, none was fully continent to both stool and flatus; only four were totally continent to solid and liquid stool; six had no faecal urgency; and eight had no passive soiling. Of the 38 patients, 20 still wore a pad for incontinence and 25 reported lifestyle restriction. 14 reported the onset of a new evacuation disorder after sphincter repair. 23 of the 46 patients contacted had a successful long-term outcome (defined as no further surgery and urge faecal incontinence monthly or less). Interpretation The results of overlapping sphincter repair for obstetric anal-sphincter damage seem to deteriorate with time. Preoperative counselling should emphasise that although most patients will improve after the procedure, continence is rarely perfect, many have residual symptoms, and some may develop new evacuation disorders.	St Marks Hosp, Harrow HA1 3UJ, Middx, England	Imperial College London	Kamm, MA (corresponding author), St Marks Hosp, Harrow HA1 3UJ, Middx, England.							Briel JW, 1998, DIS COLON RECTUM, V41, P209, DOI 10.1007/BF02238250; BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; Cook TA, 1998, BRIT J SURG, V85, P293; CTERCTEKO G C, 1988, Australian and New Zealand Journal of Surgery, V58, P703, DOI 10.1111/j.1445-2197.1988.tb01100.x; DEEN KI, 1993, ANN SURG, V218, P201, DOI 10.1097/00000658-199308000-00013; ENGEL AF, 1994, BRIT J SURG, V81, P1231, DOI 10.1002/bjs.1800810853; FLESHMAN JW, 1991, DIS COLON RECTUM, V34, P1061, DOI 10.1007/BF02050062; GEE AS, 1995, BRIT J SURG, V82, P1179, DOI 10.1002/bjs.1800820910; Gilliland R, 1998, DIS COLON RECTUM, V41, P1516, DOI 10.1007/BF02237299; Jensen LL, 1997, DIS COLON RECTUM, V40, P197, DOI 10.1007/BF02054988; Korsgen S, 1997, DIS COLON RECTUM, V40, P835, DOI 10.1007/BF02055443; LONDONOSCHIMMER EE, 1994, INT J COLORECTAL DIS, V9, P110, DOI 10.1007/BF00699424; MARCIO J, 1993, DIS COLON RECTUM, V36, P77; Meyenberger C, 1996, ENDOSCOPY, V28, P217, DOI 10.1055/s-2007-1005431; Norton C, 1999, BRIT J SURG, V86, P1159, DOI 10.1046/j.1365-2168.1999.01215.x; PARKS AG, 1977, GUT, V18, P656, DOI 10.1136/gut.18.8.656; Peterli R, 1997, Swiss Surg, V3, P112; Romano G, 1996, BRIT J RADIOL, V69, P6, DOI 10.1259/0007-1285-69-817-6; SANGALLI MR, 1994, J AM COLL SURGEONS, V179, P583; Sentovich SM, 1997, DIS COLON RECTUM, V40, P1430, DOI 10.1007/BF02070707; Sitzler PJ, 1996, DIS COLON RECTUM, V39, P1356, DOI 10.1007/BF02054524; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1994, BRIT J SURG, V81, P463, DOI 10.1002/bjs.1800810349; Vaizey CJ, 1999, GUT, V44, P77, DOI 10.1136/gut.44.1.77; Young CJ, 1998, DIS COLON RECTUM, V41, P344, DOI 10.1007/BF02237489	25	298	302	1	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					260	265		10.1016/S0140-6736(99)05218-6	http://dx.doi.org/10.1016/S0140-6736(99)05218-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675072				2022-12-01	WOS:000085045600008
J	Basden, AM; Young, GC; Coates, MI; Ritchie, A				Basden, AM; Young, GC; Coates, MI; Ritchie, A			The most primitive osteichthyan braincase?	NATURE			English	Article							FISHES	Most living vertebrates, from teleosts to tetrapods, are osteichthyans (bony fishes)(1), but the origin of this major group is poorly understood(2). The actinopterygians (ray-finned bony fishes) are the most successful living vertebrates in terms of diversity. They appear in the fossil record in the Late Silurian but are poorly known before the Late Devonian. Here we report the discovery of the oldest and most primitive actinopterygian-like osteichthyan braincase known, from 400-million-year-old limestone in southeastern Australia. This specimen displays previously unknown primitive conditions, in particular, an opening for a cartilaginous eyestalk. It provides an important and unique counterpart to the similarly aged and recently described Psarolepis from China and Vietnam(3,4). The contrasting features of these specimens, and the unusual anatomy of the new specimen in particular, provide new insights into anatomical conditions close to the evolutionary radiation of all modern osteichthyan groups.	Macquarie Univ, Dept Earth & Planetary Sci, Ctr Ecostratig & Palaeobiol, N Ryde, NSW 2109, Australia; Australian Natl Univ, Dept Geol, Canberra, ACT 0200, Australia; UCL, Dept Biol Sci, London WC1E 6BT, England; Australian Museum, Sydney S, NSW 2000, Australia	Macquarie University; Australian National University; University of London; University College London; Australian Museum	Basden, AM (corresponding author), Macquarie Univ, Dept Earth & Planetary Sci, Ctr Ecostratig & Palaeobiol, N Ryde, NSW 2109, Australia.	abasden@laurel.ocs.mq.edu.au	Coates, Michael/AAO-3810-2020	Coates, Michael/0000-0003-2843-1075				Ahlberg PE, 1999, NATURE, V397, P564, DOI 10.1038/17484; BASDEN AM, IN PRESS COUR FORSCH; Chang M.-M., 1982, THESIS U STOCKHOLM; Coates MI, 1998, T ROY SOC EDIN-EARTH, V89, P63, DOI 10.1017/S026359330000701X; de Beer G., 1937, DEV VERTEBRATE SKULL; Gardiner B.G., 1984, Bulletin of the British Museum (Natural History) Geology, V37, P173; Gardiner B.G., 1984, Journal of Vertebrate Paleontology, V4, P379; Gardiner B.G., 1977, PROBLEMS EARLY VERTE, P227; Goujet D, 1982, GEOBIOS MEMOIRE SPEC, V15, P27; Goujet D.F., 1984, Proceedings of the Linnean Society of New South Wales, V107, P211; Gross W., 1937, Senckenbergiana Frankfurt a M, V19, P80; Janvier P, 1996, OXFORD MONOGRAPHS GE, V33; Miles R.S., 1973, Zoological J Linn Soc, V53, P63; PATTERSON C, 1975, PHILOS T R SOC B, V269, P275, DOI 10.1098/rstb.1975.0001; SCHAEFFER B, 1937, AM MUS NOVIT, P1; SCHULTZE H-P, 1968, Bulletin of the British Museum (Natural History) Geology, V16, P343; Swofford D., 1998, PAUP PHYLOGENETIC AN; YOUNG G C, 1980, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V167, P10; YOUNG GC, 1986, ZOOL J LINN SOC-LOND, V88, P1, DOI 10.1111/j.1096-3642.1986.tb00876.x; YOUNG GC, 1979, Z J LINN SOC, V66, P307; Yu XB, 1998, J VERTEBR PALEONTOL, V18, P261, DOI 10.1080/02724634.1998.10011055; Zhu M, 1999, NATURE, V397, P607, DOI 10.1038/17594	22	59	63	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					185	188		10.1038/35003183	http://dx.doi.org/10.1038/35003183			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646601				2022-12-01	WOS:000084835300052
J	Rabinowitz, D; Helin, E; Lawrence, K; Pravdo, S				Rabinowitz, D; Helin, E; Lawrence, K; Pravdo, S			A reduced estimate of the number of kilometre-sized near-Earth asteroids	NATURE			English	Article								Near-Earth asteroids are small (diameters < 10 km), rocky bodies with orbits that approach that of the Earth (they come within 1.3 AU Of the Sun). Most have a chance of approximately 0.5% of colliding with the Earth in the next million years. The total number of such bodies with diameters > 1 km has been estimated to be in the range 1,000-2,000, which translates to an approximately 1% chance of a catastrophic collision with the Earth in the next millennium(1,2). These numbers are, however, poorly constrained because of the limitations of previous searches using photographic plates. (One kilometre is below the size of a body whose impact on the Earth would produce global effects(3).) Here we report an analysis of our survey for near-Earth asteroids that uses improved detection technologies. We find that the total number of asteroids with diameters > 1 km is about half the earlier estimates. At the current rate of discovery of near-Earth asteroids, 90% will probably have been detected within the next 20 years.	Yale Univ, Dept Phys, New Haven, CT 06511 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	Yale University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Rabinowitz, D (corresponding author), Yale Univ, Dept Phys, 266 Whitney Ave,JWG 552, New Haven, CT 06511 USA.	david.rabinowitz@yale.edu						Bowell E., 1994, HAZARDS DUE COMETS A, P149; Bowell E, 1989, ASTEROIDS, VII-1, P524; GEHRELS T, 1991, SPACE SCI REV, V58, P347, DOI 10.1007/BF01206004; HARRIS AW, IN PRESS COLLISIONAL; Helin E. F., 1990, Vistas in Astronomy, V33, P21, DOI 10.1016/0083-6656(90)90030-C; HELIN EF, 1979, ICARUS, V40, P321, DOI 10.1016/0019-1035(79)90021-6; MARSDEN BG, ELECT LISTING MINOR; MCFADDEN LA, 1989, ASTEROIDS, V2, P442; Pravdo SH, 1999, ASTRON J, V117, P1616, DOI 10.1086/300769; RABINOWITZ DL, 1994, ICARUS, V111, P364, DOI 10.1006/icar.1994.1150; RABINOWITZ DL, 1993, ASTROPHYS J, V407, P412, DOI 10.1086/172524; SHOEMAKER EM, 1990, GEOL S AM S, V247, P155; [No title captured]	13	103	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					165	166		10.1038/35003128	http://dx.doi.org/10.1038/35003128			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646594				2022-12-01	WOS:000084835300045
J	Glauner, KS; Mannuzzu, LM; Gandhi, CS; Isacoff, EY				Glauner, KS; Mannuzzu, LM; Gandhi, CS; Isacoff, EY			Spectroscopic mapping of voltage sensor movement in the Shaker potassium channel	NATURE			English	Article							K+ CHANNEL; SODIUM-CHANNELS; ENERGY-TRANSFER; MOLECULAR-BASIS; S4 SEGMENT; CONFORMATIONS; FLUORESCENCE; CHARGE	Voltage-gated ion channels underlie the generation of action potentials and trigger neurosecretion and muscle contraction. These channels consist of an inner pore-forming domain, which contains the ion permeation pathway and elements of its gates, together with four voltage-sensing domains, which regulate the gates(1-6). To understand the mechanism of voltage sensing it is necessary to define the structure and motion of the S4 segment, the portion of each voltage-sensing domain that moves charged residues across the membrane in response to voltage change(7-14) We have addressed this problem by using fluorescence resonance energy transfer as a spectroscopic ruler(15-17) to determine distances between S4s in the Shaker K+ channel in different gating states. Here we provide evidence consistent with S4 being a tilted helix that twists during activation. We propose that helical twist contributes to the movement of charged side chains across the membrane electric field and that it is involved in coupling voltage sensing to gating.	Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Isacoff, EY (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, 271 Life Sci Addit, Berkeley, CA 94720 USA.		isacoff, ehud/AAP-1459-2020	Isacoff, Ehud Y./0000-0003-4775-9359				Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Cantor C. R., 1980, BIOPHYSICAL CHEM 2; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; FRETCH GC, 1989, NATURE, V340, P642; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Jovin T.M, 1989, CELL STRUCT FUNCT, P99; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; PeledZehavi H, 1996, BIOCHEMISTRY-US, V35, P6828, DOI 10.1021/bi952988t; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253	26	243	255	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					813	817		10.1038/45561	http://dx.doi.org/10.1038/45561			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617202				2022-12-01	WOS:000084330500066
J	Hutchison, CA; Peterson, SN; Gill, SR; Cline, RT; White, O; Fraser, CM; Smith, HO; Venter, JC				Hutchison, CA; Peterson, SN; Gill, SR; Cline, RT; White, O; Fraser, CM; Smith, HO; Venter, JC			Global transposon mutagenesis and a minimal mycoplasma genome	SCIENCE			English	Article							SEQUENCE; GENITALIUM; SPIROCHETE; PNEUMONIAE; ARCHAEON; COPIES; IS256	Mycoplasma genitalium with 517 genes has the smallest gene complement of any independently replicating cell so far identified. Global transposon mutagenesis was used to identify nonessential genes in an effort to Learn whether the naturally occurring gene complement is a true minimal genome under Laboratory growth conditions. The positions of 2209 transposon insertions in the completely sequenced genomes of M. genitalium and its close relative M. pneumoniae were determined by sequencing across the junction of the transposon and the genomic DNA. These junctions defined 1354 distinct sites of insertion that were not Lethal. The analysis suggests that 265 to 350 of the 480 protein-coding genes of M. genitalium are essential under Laboratory growth conditions, including about 100 genes of unknown function.	Inst Gen Res, Rockville, MD 20850 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Venter, JC (corresponding author), Celera Gen, 45 W Gude Dr, Rockville, MD 20850 USA.			Fraser, Claire/0000-0003-1462-2428				Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cho MK, 1999, SCIENCE, V286, P2087, DOI 10.1126/science.286.5447.2087; COLMAN SD, 1990, MOL MICROBIOL, V4, P683, DOI 10.1111/j.1365-2958.1990.tb00638.x; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P2369, DOI 10.1093/nar/27.11.2369; DYKE KGH, 1992, PLASMID, V28, P235, DOI 10.1016/0147-619X(92)90055-F; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; GOFFEAU A, 1997, NATURE, V387; Himmelreich R, 1997, NUCLEIC ACIDS RES, V25, P701, DOI 10.1093/nar/25.4.701; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; ITAYA M, 1995, FEBS LETT, V362, P257, DOI 10.1016/0014-5793(95)00233-Y; Kaneko T, 1996, DNA Res, V3, P109; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KNUDTSON KL, 1993, GENE, V137, P217, DOI 10.1016/0378-1119(93)90009-R; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P128, DOI 10.1016/0968-0004(96)30007-8; Krause DC, 1996, MOL MICROBIOL, V20, P247, DOI 10.1111/j.1365-2958.1996.tb02613.x; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; MOROWITZ HJ, 1984, ISRAEL J MED SCI, V20, P750; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; Reddy SP, 1996, FEMS IMMUNOL MED MIC, V15, P199, DOI 10.1016/0928-8244(96)00060-0; RICE LB, 1995, ANTIMICROB AGENTS CH, V39, P1147, DOI 10.1128/AAC.39.5.1147; Romero-Arroyo CE, 1999, J BACTERIOL, V181, P1079, DOI 10.1128/JB.181.4.1079-1087.1999; Saurin W, 1996, MOL MICROBIOL, V22, P389; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483	29	661	709	2	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2165	2169		10.1126/science.286.5447.2165	http://dx.doi.org/10.1126/science.286.5447.2165			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591650				2022-12-01	WOS:000084157300055
J	Zaal, KJM; Smith, CL; Polishchuk, RS; Altan, N; Cole, NB; Ellenberg, J; Hirschberg, K; Presley, JF; Roberts, TH; Siggia, E; Phair, RD; Lippincott-Schwartz, J				Zaal, KJM; Smith, CL; Polishchuk, RS; Altan, N; Cole, NB; Ellenberg, J; Hirschberg, K; Presley, JF; Roberts, TH; Siggia, E; Phair, RD; Lippincott-Schwartz, J			Golgi membranes are absorbed into and reemerge from the ER during mitosis	CELL			English	Article							ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; LIVING CELLS; BREFELDIN-A; HELA-CELLS; MATRIX PROTEIN; APPARATUS; FRAGMENTATION; DYNAMICS; COMPLEX	Quantitative imaging and photobleaching were used to measure ER/Golgi recycling of GFP-tagged Golgi proteins in interphase cells and to monitor the dissolution and reformation of the Golgi during mitosis. In interphase, recycling occurred every 1.5 hr, and blocking ER egress trapped cycling Golgi enzymes in the ER with loss of Golgi structure. In mitosis, when ER export stops, Golgi proteins redistributed into the ER as shown by quantitative imaging in vivo and immuno-EM. Comparison of the mobilities of Golgi proteins and lipids ruled out the persistence of a separate mitotic Golgi vesicle population and supported the idea that all Golgi components are absorbed into the ER. Moreover, reassembly of the Golgi complex after mitosis failed to occur when ER export was blocked. These results demonstrate that in mitosis the Golgi disperses and reforms through the intermediary of the ER, exploiting constitutive recycling pathways. They thus define a novel paradigm for Golgi genesis and inheritance.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA; BioInformat Serv, Rockville, MD 20854 USA; NINCDS, Light Imaging Facil, NIH, Bethesda, MD 20892 USA; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Mol Neurobiol Lab, I-66030 Santa Maria Imbaro, Italy	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Lippincott-Schwartz, J (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.		Hirschberg, Koret/AAF-4566-2019; Ellenberg, Jan/I-4688-2014; Ward, Theresa H./E-9650-2013	Ellenberg, Jan/0000-0001-5909-701X; Ward, Theresa H./0000-0002-9881-8649; Polishchuk, Roman/0000-0002-7698-1955	NIGMS NIH HHS [R01 GM59018-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059018] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BRANDS R, 1985, J CELL BIOL, V101, P1724, DOI 10.1083/jcb.101.5.1724; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cole NB, 1998, J CELL BIOL, V140, P1, DOI 10.1083/jcb.140.1.1; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; Edidin M., 1994, MOBILITY PROXIMITY B, P109; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Farmaki T, 1999, J CELL SCI, V112, P589; FEATHERSTONE C, 1985, J CELL BIOL, V101, P2036, DOI 10.1083/jcb.101.6.2036; FOSTER DM, 1994, BMES BULL, V18, P19; GRIFFITHS G, 1984, J CELL BIOL, V98, P2133, DOI 10.1083/jcb.98.6.2133; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; JACQUEZ JA, 1996, COMPARTMENTAL ANAL B; Jesch SA, 1998, MOL BIOL CELL, V9, P623, DOI 10.1091/mbc.9.3.623; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Lee TH, 1999, MOL BIOL CELL, V10, P1445, DOI 10.1091/mbc.10.5.1445; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Love HD, 1998, J CELL BIOL, V140, P541, DOI 10.1083/jcb.140.3.541; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; LUCOCQ J, 1992, J CELL SCI, V103, P875; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Polishchuk RS, 1999, EUR J CELL BIOL, V78, P170, DOI 10.1016/S0171-9335(99)80096-X; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; SOUTER E, 1993, J CELL BIOL, V122, P533, DOI 10.1083/jcb.122.3.533; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; Tanner VA, 1996, J HISTOCHEM CYTOCHEM, V44, P1481, DOI 10.1177/44.12.8985140; THYBERG J, 1992, J SUBMICR CYTOL PATH, V24, P495; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; WADSWORTH P, 1983, J CELL BIOL, V97, P1249, DOI 10.1083/jcb.97.4.1249; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Wooding S, 1998, MOL BIOL CELL, V9, P2667, DOI 10.1091/mbc.9.9.2667; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	48	265	274	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					589	601		10.1016/S0092-8674(00)81548-2	http://dx.doi.org/10.1016/S0092-8674(00)81548-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612395	Bronze			2022-12-01	WOS:000084278700006
J	Dupont, S; Sharova, N; DeHoratius, C; Virbasius, CMA; Zhu, XC; Bukrinskaya, AG; Stevenson, M; Green, MR				Dupont, S; Sharova, N; DeHoratius, C; Virbasius, CMA; Zhu, XC; Bukrinskaya, AG; Stevenson, M; Green, MR			A novel nuclear export activity in HIV-1 matrix protein required for viral replication	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; INTRACELLULAR-TRANSPORT; LOCALIZATION SIGNAL; NONDIVIDING CELLS; RNA DIMERIZATION; MESSENGER-RNA; LEPTOMYCIN-B; INFECTION; CRM1; ENCAPSIDATION	An important aspect of the pathophysiology of human immunodeficiency virus type-1 (HIV-1) infection is the ability of the virus to replicate in non-dividing cells(1-3). HIV-1 matrix (MA), the amino-terminal domain of the Pr55 gag polyprotein (Pr55), bears a nuclear localization signal that promotes localization of the viral preintegration complex to the nucleus of non-dividing cells following virus entry(3-5). However, late during infection, MA, as part of Pr55, directs unspliced viral RNA to the plasma membrane(6), the site of virus assembly. How MA can mediate these two opposing targeting functions is not understood. Here we demonstrate that MA has a previously undescribed nuclear export activity. Although MA lacks the canonical leucine-rich nuclear export signal, nuclear export is mediated through the conserved Crmlp pathway and functions in both mammalian cells and yeast. A mutation that disrupts the MA nuclear export signal (MA-M4) mislocalizes Pr55 and genomic viral RNA to the nucleus, thereby severely impairing viral replication. Furthermore, we show that MA-M4 can act in a dominant-negative fashion to mislocalize genomic viral RNA even in the presence of wild-type MA, We conclude that the MA nuclear export signal is required to counteract the MA nuclear localization signal, thus ensuring the cytoplasmic availability of the components required for virion assembly.	Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Green, MR (corresponding author), Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, 373 Plantat St,Suite 309, Worcester, MA 01605 USA.							Berkowitz R, 1996, CURR TOP MICROBIOL, V214, P177; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; Fornerod M, 1997, CELL, V90, P1051; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; Krausslich HG, 1996, CURR TOP MICROBIOL, V214, P25; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; MASSIAH MA, 1994, J MOL BIOL, V244, P198, DOI 10.1006/jmbi.1994.1719; MATTHEWS S, 1994, NATURE, V370, P666, DOI 10.1038/370666a0; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paillart JC, 1996, J VIROL, V70, P8348, DOI 10.1128/JVI.70.12.8348-8354.1996; Sakuragi J, 1997, J VIROL, V71, P3250, DOI 10.1128/JVI.71.4.3250-3254.1997; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	26	102	105	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					681	685		10.1038/45272	http://dx.doi.org/10.1038/45272			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604476				2022-12-01	WOS:000084189800070
J	Thommes, EW; Duncan, MJ; Levison, HF				Thommes, EW; Duncan, MJ; Levison, HF			The formation of Uranus and Neptune in the Jupiter-Saturn region of the Solar System	NATURE			English	Article							GIANT PLANETS; FAMILY COMETS; KUIPER BELT; ORIGIN; ACCRETION	Planets are believed to have formed through the accumulation of a large number of small bodies(1-4). In the case of the gas-giant planets Jupiter and Saturn, they accreted a significant amount of gas directly from the protosolar nebula after accumulating solid cores of about 5-15 Earth masses(5,6). Such models, however, have been unable to produce the smaller ice giants(7,8) Uranus and Neptune at their present locations, because in that region of the Solar System the small planetary bodies will have been more widely spaced, and less tightly bound gravitationally to the Sun. When applied to the current Jupiter-Saturn zone, a recent theory predicts that, in addition to the solid cores of Jupiter and Saturn, two or three other solid bodies of comparable mass are likely to have formed(9). Here we report the results of model calculations that demonstrate that such cores will have been gravitationally scattered outwards as Jupiter, and perhaps Saturn, accreted nebular gas. The orbits of these cores then evolve into orbits that resemble those of Uranus and Neptune, as a result of gravitational interactions with the small bodies in the outer disk of the protosolar nebula.	Queens Univ, Dept Phys, Kingston, ON K7L 3N6, Canada; SW Res Inst, Space Studies Dept, Boulder, CO 80302 USA	Queens University - Canada	Duncan, MJ (corresponding author), Queens Univ, Dept Phys, Kingston, ON K7L 3N6, Canada.		Levison, Harold F/C-6061-2013	Levison, Harold F/0000-0001-5847-8099				Agnor CB, 1999, ICARUS, V142, P219, DOI 10.1006/icar.1999.6201; BODENHEIMER P, 1986, ICARUS, V67, P391, DOI 10.1016/0019-1035(86)90122-3; Chambers JE, 1998, ICARUS, V136, P304, DOI 10.1006/icar.1998.6007; Duncan MJ, 1997, SCIENCE, V276, P1670, DOI 10.1126/science.276.5319.1670; Duncan MJ, 1998, ASTRON J, V116, P2067, DOI 10.1086/300541; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; Hahn JM, 1999, ASTRON J, V117, P3041, DOI 10.1086/300891; Kokubo E, 1998, ICARUS, V131, P171, DOI 10.1006/icar.1997.5840; Levison HF, 1998, ASTRON J, V116, P1998, DOI 10.1086/300557; Levison HF, 1997, ICARUS, V127, P13, DOI 10.1006/icar.1996.5637; Lin DNC, 1997, ASTROPHYS J, V477, P781, DOI 10.1086/303738; LISSAUER JJ, 1996, NEPTUNE TRITON, P37; Luu J, 1997, NATURE, V387, P573, DOI 10.1038/42413; MALHOTRA R, 1995, ASTRON J, V110, P420, DOI 10.1086/117532; Morbidelli A, 1998, ASTR SOC P, V149, P83; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; Rasio FA, 1996, SCIENCE, V274, P954, DOI 10.1126/science.274.5289.954; Safronov V. S., 1969, EVOLUTION PROTOPLANE; STEWART G, 1998, P LUN PLAN SCI C 29; Weidenschilling SJ, 1996, NATURE, V384, P619, DOI 10.1038/384619a0; WETHERILL GW, 1992, ICARUS, V100, P307, DOI 10.1016/0019-1035(92)90103-E	21	207	210	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					635	638		10.1038/45185	http://dx.doi.org/10.1038/45185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604469				2022-12-01	WOS:000084189800057
J	Visser, M; Bouter, LM; McQuillan, GM; Wener, MH; Harris, TB				Visser, M; Bouter, LM; McQuillan, GM; Wener, MH; Harris, TB			Elevated C-reactive protein levels in overweight and obese adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; FAT DISTRIBUTION; NATIONAL-HEALTH; ADIPOSE-TISSUE; US ADULTS; RISK; INTERLEUKIN-6; MEN; ASSOCIATION	Context Human adipose tissue expresses and releases the proinflammatory cytokine interleukin 6, potentially inducing low-grade systemic inflammation in persons with excess body fat. Objective To test whether overweight and obesity are associated with low-grade systemic inflammation as measured by serum C-reactive protein (CRP) level. Design and Setting The Third National Health and Nutrition Examination Survey, representative of the US population from 1988 to 1994, Participants A total of 16 616 men and nonpregnant women aged 17 years or older Main Outcome Measures Elevated CRP level of 0.22 mg/dL or more and a more stringent clinically raised CRP level of more than 1.00 mg/dL. Results Elevated CRP levels and clinically raised CRP levels were present in 27.6% and 6.7% of the population, respectively. Both overweight (body mass index [BMI], 25-29.9 kg/m(2)) and obese (BMI, greater than or equal to 30 kg/m(2)) persons were more likely to have elevated CRP levels than their normal-weight counterparts (BMI, <25 kg/m(2)). After adjustment for potential confounders, including smoking and health status, the odds ratio (OR) for elevated CRP was 2.13 (95% confidence interval [CI], 1.56-2.91) for obese men and 6.21 (95% CI, 4.94-7.81) for obese women. In addition, BMI was associated with clinically raised CRP levels in women, with an OR of 4.76 (95% CI, 3.42-6.61) for obese women. Waist-to-hip ratio was positively associated with both elevated and clinically raised CRP levels, independent of BMI. Restricting the analyses to young adults (aged 17-39 years) and excluding smokers, persons with inflammatory disease, cardiovascular disease, or diabetes mellitus and estrogen users did not change the main findings. Conclusion Higher BMI is associated with higher CRP concentrations, even among young adults aged 17 to 39 years. These findings suggest a state of low-grade systemic inflammation in overweight and obese persons.	Vrije Univ Amsterdam, Fac Med, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; NIA, Epidemiol Demog & Biometry Program, NIH, Bethesda, MD USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Vrije Universiteit Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Visser, M (corresponding author), Vrije Univ Amsterdam, Fac Med, Inst Res Extramural Med, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.		Visser, Marjolein/AAP-3224-2020; Wener, Mark/ABE-4491-2021	Visser, Marjolein/0000-0002-5136-298X; Bouter, Lex/0000-0002-2659-5482				Anzai T, 1997, CIRCULATION, V96, P778; BANKS RE, 1995, CLIN EXP IMMUNOL, V102, P217; Bernert John T. Jr., 1994, Clinical Chemistry, V40, P1075; Blackburn Jr W.D., 1994, J RHEUMATOL S, V42, P9; CASSANO PA, 1992, AM J EPIDEMIOL, V136, P1474, DOI 10.1093/oxfordjournals.aje.a116468; CERMAK J, 1993, BLOOD, V82, P513, DOI 10.1182/blood.V82.2.513.513; Clark LW, 1997, CLIN CHEM, V43, P52; *CTR DIS CONTR PRE, 1996, 3 NAT HLTH NUTR EX S; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; Folsom AR, 1998, AM J EPIDEMIOL, V148, P1187, DOI 10.1093/oxfordjournals.aje.a009608; Franzini C, 1998, CLIN CHEM LAB MED, V36, P131, DOI 10.1515/CCLM.1998.024; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Gallagher D, 1996, AM J EPIDEMIOL, V143, P228, DOI 10.1093/oxfordjournals.aje.a008733; Gavin JR, 1997, DIABETES CARE, V20, P1183; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Lohman TG, 1988, ANTROPOMETRIC STANDA; Mendall MA, 1996, BRIT MED J, V312, P1061; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; National Center for Health Statistics, 1994, PLAN OP 3 NAT HLTH N; National Institutes of Health, 1998, CLIN GUID ID EV TREA; Papanicolaou DA, 1998, ANN INTERN MED, V128, P127, DOI 10.7326/0003-4819-128-2-199801150-00009; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; PISUNYER FX, 1991, AM J CLIN NUTR, V53, pS1595; PUROHIT A, 1995, J CLIN ENDOCR METAB, V80, P3052, DOI 10.1210/jc.80.10.3052; Rexrode KM, 1998, JAMA-J AM MED ASSOC, V280, P1843, DOI 10.1001/jama.280.21.1843; Ridker PM, 1998, CIRCULATION, V97, P425; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; Rose G.A., 1982, CARDIOVASCULAR SURVE; Schreiner PJ, 1996, AM J EPIDEMIOL, V144, P335, DOI 10.1093/oxfordjournals.aje.a008934; Sebastian-Gambaro MA, 1997, EUR J CLIN CHEM CLIN, V35, P845; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; VOIGT LF, 1994, EPIDEMIOLOGY, V5, P525; WENER MH, 1997, MANUAL CLIN LAB IMMU; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	45	1720	1781	0	73	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2131	2135		10.1001/jama.282.22.2131	http://dx.doi.org/10.1001/jama.282.22.2131			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591334	Bronze			2022-12-01	WOS:000083971400031
J	Taylor, RS; Belli, AM; Jacob, S				Taylor, RS; Belli, AM; Jacob, S			Distal venous arterialisation for salvage of critically ischaemic inoperable limbs	LANCET			English	Article								Background Amputation remains the only option in patients with extensive arterial disease in whom conventional bypass operations are not feasible. Up to 10 000 amputations for vascular disease are estimated to be done annually. We investigated the use of venous perfusion as an alternative method of limb salvage. Methods Over 28 months, 18 patients with critical-limb ischaemia underwent bypass procedures to the venous bed of the foot with vein, synthetic graft, or a combination of these as the conduit. Various methods were used to destroy the valves of the venous system. We followed up patients for a mean of 17 months. Findings Three grafts failed immediately after surgery and necessitated major amputation, with orie death. One late failure did not necessitate amputation. 15 patients had relief of symptoms and retained a useful pain-free limb with healing of ulcers and gangrene. Two patients with functioning grafts died at 5 months and 13 months, respectively. Three patients had successful further radiological intervention. The overall limb-salvage rate was 83% and 1-year limb-salvage rate was 75%. Interpretation Distal venous arterialisation is a unique procedure that has exciting possibilities for limb salvage and merits further investigation. Increased use of this procedure may help to lower the number of limbs amputated for vascular disease.	Univ London St Georges Hosp, Dept Vasc Surg, London SW17 0QT, England	St Georges University London	Taylor, RS (corresponding author), Univ London St Georges Hosp, Dept Vasc Surg, London SW17 0QT, England.							BAFFOUR R, 1988, SURG GYNECOL OBSTET, V166, P28; Bernheim BM, 1912, ANN SURG, V55, P195, DOI 10.1097/00000658-191202000-00002; BLAISDELL FW, 1966, AM J SURG, V112, P166, DOI 10.1016/0002-9610(66)90005-5; CARREL A, 1902, LYON MED, V99, P153; CUTTINO JT, 1975, BASIC RES CARDIOL, V70, P568, DOI 10.1007/BF01906387; DORMANDY JA, 1995, VASC MED REV, V5, P331; Francois-Franck M, 1896, COMPT REND HEBD SOC, V48, P150; GERARD DF, 1981, SURGERY, V89, P485; GOLDSMITH HS, 1984, JAMA-J AM MED ASSOC, V252, P2034, DOI 10.1001/jama.252.15.2034; Halstead AE, 1912, SURG GYNECOL OBSTET, V14, P1; KUMAR S, 1983, LANCET, V2, P364; LENGUA F, 1993, J CHIR-PARIS, V130, P12; Lengua F, 1975, NOUV PRESSE MED, V4, P1039; MATOLO NM, 1976, ANN SURG, V184, P622, DOI 10.1097/00000658-197611000-00016; Pokrovsky AV, 1996, ANN VASC SURG, V4, P73; ROBERTSON RL, 1950, SURGERY, V27, P1; ROOT HD, 1965, J AMER MED ASSOC, V191, P645, DOI 10.1001/jama.1965.03080080035008; SANMARTIN Y, 1902, JURADO MED FARMACOL, V12, P1641; SHEIL AGR, 1977, BRIT J SURG, V64, P197, DOI 10.1002/bjs.1800640314; SZILAGYI DE, 1951, AMA ARCH SURG, V63, P435, DOI 10.1001/archsurg.1951.01250040445003; WOLFE JHN, 1986, BRIT J SURG, V73, P321	21	34	43	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1999	354	9194					1962	1965		10.1016/S0140-6736(99)03164-5	http://dx.doi.org/10.1016/S0140-6736(99)03164-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622299				2022-12-01	WOS:000084034700013
J	Mundy, G; Garrett, R; Harris, S; Chan, J; Chen, D; Rossini, G; Boyce, B; Zhao, M; Gutierrez, G				Mundy, G; Garrett, R; Harris, S; Chan, J; Chen, D; Rossini, G; Boyce, B; Zhao, M; Gutierrez, G			Stimulation of bone formation in vitro and in rodents by statins	SCIENCE			English	Article							GROWTH-FACTOR-BETA; NORMAL MICE; CONTAINING BISPHOSPHONATES; IN-VITRO; INTERLEUKIN-1; OSTEOBLASTS; CHOLESTEROL; RESORPTION; TURNOVER; INVITRO	Osteoporosis and other diseases of bone Loss are a major public health problem. Here it is shown that the statins, drugs widely used for Lowering serum cholesterol, also enhance new bone formation in vitro and in rodents. This effect was associated with increased expression of the bone morphogenetic protein-2 (BMP-2) gene in bone cells. Lovastatin and simvastatin increased bone formation when injected subcutaneously over the calvaria of mice and increased cancellous bone volume when orally administered to rats. Thus, in appropriate doses, statins may have therapeutic applications for the treatment of osteoporosis.	OsteoScreen, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Mundy, G (corresponding author), OsteoScreen, 2040 Babcock Rd, San Antonio, TX 78229 USA.	mundy@uthscsa.edu	Chan, Jeannie/B-5060-2013					Bauer DC, 1999, J BONE MINER RES, V14, pS179; BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo-125-3-1142; CUEVAS P, 1991, SCIENCE, V254, P1208, DOI 10.1126/science.1957172; DUNSTAN CR, IN PRESS J BONE MINE; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; GARRETT IR, UNPUB; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; GOWEN M, 1986, J IMMUNOL, V136, P2478; HARRIS SE, 1994, J BONE MINER RES, V9, P855; Harris Stephen E., 1995, Molecular and Cellular Differentiation, V3, P137; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; MARCELLI C, 1990, J BONE MINER RES, V5, P1087; MELTON LJ, 1995, J BONE MINER RES, V10, P175; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Rogers MJ, 1996, J BONE MINER RES, V11, P1482; ROGERS MJ, 1995, MOL PHARMACOL, V47, P398; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SABATINI M, 1988, P NATL ACAD SCI USA, V85, P5235, DOI 10.1073/pnas.85.14.5235; Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178; YATES AJP, 1988, J CLIN INVEST, V81, P932, DOI 10.1172/JCI113406	22	1400	1626	2	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1946	1949		10.1126/science.286.5446.1946	http://dx.doi.org/10.1126/science.286.5446.1946			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583956				2022-12-01	WOS:000084003400049
J	Raucher, D; Stauffer, T; Chen, W; Shen, K; Guo, SL; York, JD; Sheetz, MP; Meyer, T				Raucher, D; Stauffer, T; Chen, W; Shen, K; Guo, SL; York, JD; Sheetz, MP; Meyer, T			Phosphatidylinositol 4,5-bisphoshate functions as a second messenger that regulates cytoskeleton-plasma membrane adhesion	CELL			English	Article							PANCREATIC ACINAR-CELLS; ACTIN POLYMERIZATION; F-ACTIN; IN-VIVO; BINDING; GROWTH; U73122; POLYPHOSPHOINOSITIDES; JASPLAKINOLIDE; TETHERS	Binding interactions between the plasma membrane and the cytoskeleton define cell functions such as cell shape, formation of cell processes, cell movement, and endocytosis. Here we use optical tweezers tether force measurements and show that plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2) acts as a second messenger that regulates the adhesion energy between the cytoskeleton and the plasma membrane. Receptor stimuli that hydrolyze PIP2 lowered adhesion energy, a process that could be mimicked by expressing PH domains that sequester PIP2 or by targeting a 5'-PIP2-phosphatase to the plasma membrane to selectively lower plasma membrane PIP2 concentration. Our study suggests that plasma membrane PIP2 controls dynamic membrane functions and cell shape by locally increasing and decreasing the adhesion between the actin-based cortical cytoskeleton and the plasma membrane.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University	Meyer, T (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.		Raucher, Drazen/AAE-4540-2022	Meyer, Tobias/0000-0003-4339-3804	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM048113, R01GM048113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55672] Funding Source: Medline; NIGMS NIH HHS [GM 362277, GM 48113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERK DA, 1992, BIOPHYS J, V61, P9, DOI 10.1016/S0006-3495(92)81811-8; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; DAI J, 1999, IN PRESS BIOPHYS J; DAI JW, 1995, BIOPHYS J, V68, P988, DOI 10.1016/S0006-3495(95)80274-2; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Hochmuth RM, 1996, BIOPHYS J, V70, P358, DOI 10.1016/S0006-3495(96)79577-2; Holzinger A, 1997, CELL MOTIL CYTOSKEL, V38, P365, DOI 10.1002/(SICI)1097-0169(1997)38:4<365::AID-CM6>3.3.CO;2-P; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1995, CHEM BIOL, V2, P61, DOI 10.1016/1074-5521(95)90276-7; JIN WZ, 1994, BRAIN RES, V642, P237, DOI 10.1016/0006-8993(94)90927-X; Kandzari D E, 1996, Subcell Biochem, V26, P97; Keller H, 1998, CELL MOTIL CYTOSKEL, V41, P181, DOI 10.1002/(SICI)1097-0169(1998)41:2<181::AID-CM8>3.3.CO;2-M; KLEINIG H, 1970, J CELL BIOL, V46, P396, DOI 10.1083/jcb.46.2.396; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; Lee E, 1998, CELL MOTIL CYTOSKEL, V39, P122, DOI 10.1002/(SICI)1097-0169(1998)39:2<122::AID-CM3>3.0.CO;2-8; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; Mogami H, 1997, BIOCHEM J, V324, P645, DOI 10.1042/bj3240645; Raucher D, 1999, J CELL BIOL, V144, P497, DOI 10.1083/jcb.144.3.497; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; TRAN D, 1993, CELL SIGNAL, V5, P565, DOI 10.1016/0898-6568(93)90052-N; WAUGH RE, 1995, ANN BIOMED ENG, V23, P308, DOI 10.1007/BF02584431; WAUGH RE, 1987, BIOPHYS J, V52, P391, DOI 10.1016/S0006-3495(87)83227-7; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YULE DI, 1992, J BIOL CHEM, V267, P13830	30	559	570	1	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					221	228		10.1016/S0092-8674(00)81560-3	http://dx.doi.org/10.1016/S0092-8674(00)81560-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660045				2022-12-01	WOS:000084932200006
J	Belin, P; Zatorre, RJ; Lafaille, P; Ahad, P; Pike, B				Belin, P; Zatorre, RJ; Lafaille, P; Ahad, P; Pike, B			Voice-selective areas in human auditory cortex	NATURE			English	Article							RHESUS-MONKEY; PERCEPTION; SPEAKER	The human voice contains in its acoustic structure a wealth of information on the speaker's identity and emotional state which we perceive with remarkable ease and accuracy(1-3). Although the perception of speaker-related features of voice plays a major role in human communication, little is known about its neural basis(4-7) Here:we show, using functional magnetic resonance imaging in human volunteers, that voice-selective regions can be found bilaterally along the upper bank of the superior temporal sulcus (STS), These regions showed greater neuronal activity when subjects listened passively to vocal sounds, whether speech or non-speech, than to non-vocal environmental sounds. Central STS regions also displayed a high degree of selectivity by responding significantly more to vocal sounds than to matched control stimuli, including scrambled voices and amplitude-modulated noise. Moreover, their response to stimuli degraded by frequency filtering paralleled the subjects' behavioural performance in voice-perception tasks that used these stimuli. The voice-selective areas in the STS may represent the counterpart of the face-selective areas in human visual cortex(8,9); their existence sheds new light on the functional architecture of the human auditory cortex.	McGill Univ, Montreal Neurol Inst, Neuropsychol Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Psychol, Montreal, PQ H3A 2B4, Canada; McGill Univ, McConnel Brain Imaging Ctr, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University; McGill University	Belin, P (corresponding author), McGill Univ, Montreal Neurol Inst, Neuropsychol Cognit Neurosci Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	pascal@bic.mni.mcgill.ca	Belin, Pascal/C-6247-2009; Pike, Bruce/K-5562-2014	Belin, Pascal/0000-0002-7578-6365; Pike, Bruce/0000-0001-8924-683X				ASSAL G, 1981, REV NEUROL, V137, P255; Belin P, 1999, NEUROIMAGE, V10, P417, DOI 10.1006/nimg.1999.0480; BINDER JR, 1999, J COGNITIVE NEUROS S, V11, P99; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Dehaene S, 1997, NEUROREPORT, V8, P3809, DOI 10.1097/00001756-199712010-00030; DOEHRING DG, 1971, NEUROPSYCHOLOGIA, V9, P425, DOI 10.1016/0028-3932(71)90006-6; Ellis A.W., 1989, HDB RES FACE PROCESS, P207; Hall DA, 1999, HUM BRAIN MAPP, V7, P213, DOI 10.1002/(SICI)1097-0193(1999)7:3<213::AID-HBM5>3.0.CO;2-N; Imaizumi S, 1997, NEUROREPORT, V8, P2809, DOI 10.1097/00001756-199708180-00031; JONES EG, 1995, J COMP NEUROL, V362, P153, DOI 10.1002/cne.903620202; Kaas JH, 1999, CURR OPIN NEUROBIOL, V9, P164, DOI 10.1016/S0959-4388(99)80022-1; Kanwisher N, 1997, J NEUROSCI, V17, P4302; KLATT DH, 1990, J ACOUST SOC AM, V87, P820, DOI 10.1121/1.398894; McCarthy G, 1997, J COGNITIVE NEUROSCI, V9, P605, DOI 10.1162/jocn.1997.9.5.605; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; PANDYA DN, 1995, REV NEUROL, V151, P486; PAPCUN G, 1989, J ACOUST SOC AM, V85, P913, DOI 10.1121/1.397564; Rauschecker JP, 1998, AUDIOL NEURO-OTOL, V3, P86, DOI 10.1159/000013784; Rendall D, 1998, J ACOUST SOC AM, V103, P602, DOI 10.1121/1.421104; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TURNER R, 1994, FUNCTIONAL NEUROIMAG, P69; Van Lancker D R, 1982, Brain Cogn, V1, P185, DOI 10.1016/0278-2626(82)90016-1; VANDOMMELEN WA, 1990, LANG SPEECH, V33, P259, DOI 10.1177/002383099003300302; VANLANCKER DR, 1989, J CLIN EXP NEUROPSYC, V11, P665, DOI 10.1080/01688638908400923; WATZLAWICKI P, 1967, STUDY INTERACTIONAL; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767	28	1231	1248	5	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2000	403	6767					309	312		10.1038/35002078	http://dx.doi.org/10.1038/35002078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	276VU	10659849				2022-12-01	WOS:000084899700052
J	Gardner, TS; Cantor, CR; Collins, JJ				Gardner, TS; Cantor, CR; Collins, JJ			Construction of a genetic toggle switch in Escherichia coli	NATURE			English	Article							LOGICAL ANALYSIS; NETWORKS; DYNAMICS; EXPRESSION; CIRCUITS; SYSTEMS; LAMBDA	It has been proposed(1) that gene-regulatory circuits with virtually any desired property can be constructed from networks of simple regulatory elements. These properties, which include multistability and oscillations, have been found in specialized gene circuits such as the bacteriophage lambda switch(2) and the Cyanobacteria circadian oscillator(3), However, these behaviours have not been demonstrated in networks of non-specialized regulatory components. Here we present the construction of a genetic toggle switch-a synthetic, bistable gene-regulatory network-in Escherichia coli and provide a simple theory that predicts the conditions necessary for bistability, The toggle is constructed from any two repressible promoters arranged in a mutually inhibitory network. It is flipped between stable states using transient chemical or thermal induction and exhibits a nearly ideal switching threshold. As a practical device, the toggle switch forms a synthetic, addressable cellular memory unit and has implications for biotechnology, biocomputing and gene therapy.	Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA; Boston Univ, Ctr BioDynam, Boston, MA 02215 USA; Boston Univ, Ctr Adv Biotechnol, Boston, MA 02215 USA	Boston University; Boston University; Boston University	Collins, JJ (corresponding author), Boston Univ, Dept Biomed Engn, 44 Cummington St, Boston, MA 02215 USA.	jcollins@bu.edu						Arkin A, 1998, GENETICS, V149, P1633; ARKIN A, 1994, BIOPHYS J, V67, P560, DOI 10.1016/S0006-3495(94)80516-8; Ausubel F.M., 1994, CURRENT PROTOCOLS MO; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Edelstein-Keshet L, 1988, MATH MODELS BIOL; GLASS L, 1973, J THEOR BIOL, V39, P103, DOI 10.1016/0022-5193(73)90208-7; GLASS L, 1975, J THEOR BIOL, V54, P85, DOI 10.1016/S0022-5193(75)80056-7; GLASS L, 1975, J CHEM PHYS, V63, P1325, DOI 10.1063/1.431518; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; KAPLAN D, 1995, UNDERSTANDING NONLIN; KAUFFMAN S, 1974, J THEOR BIOL, V44, P167, DOI 10.1016/S0022-5193(74)80037-8; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; McAdams HH, 1998, ANNU REV BIOPH BIOM, V27, P199, DOI 10.1146/annurev.biophys.27.1.199; MODOD J, 1961, COLD SPRING HARB SYM, V26, P389; Ptashne M, 1992, GENETIC SWITCH PHAGE; Rubinow S. I., 2002, INTRO MATH BIOL, VDover; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Schellenberger W, 1980, Adv Enzyme Regul, V19, P257; SHEA MA, 1985, J MOL BIOL, V181, P211, DOI 10.1016/0022-2836(85)90086-5; SMITH TF, 1977, MATH BIOSCI, V36, P61, DOI 10.1016/0025-5564(77)90016-5; TCHURAEV RN, 1991, J THEOR BIOL, V151, P71, DOI 10.1016/S0022-5193(05)80144-4; THOMAS R, 1978, J THEOR BIOL, V73, P631, DOI 10.1016/0022-5193(78)90127-3; THOMAS R, 1991, J THEOR BIOL, V153, P1, DOI 10.1016/S0022-5193(05)80350-9; YAGIL G, 1971, BIOPHYS J, V11, P11, DOI 10.1016/S0006-3495(71)86192-1	26	2834	3014	41	694	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2000	403	6767					339	342		10.1038/35002131	http://dx.doi.org/10.1038/35002131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659857				2022-12-01	WOS:000084899700060
J	Keppler, F; Eiden, R; Niedan, V; Pracht, J; Scholer, HF				Keppler, F; Eiden, R; Niedan, V; Pracht, J; Scholer, HF			Halocarbons produced by natural oxidation processes during degradation of organic matter	NATURE			English	Article								Volatile halogenated organic compounds (VHOC) play an important role in atmospheric chemical processes-contributing, for example, to stratospheric ozone depletion(1-4), For anthropogenic VHOC whose sources are well known(5), the global atmospheric input can be estimated from industrial production data. Halogenated compounds of natural origin can also contribute significantly to the levels of VHOC in the atmosphere(6). The oceans have been implicated as one of the main natural sources(7-10), where organisms such as macroalgae and microalgae can release large quantities of VHOC to the atmosphere(11,12), Some terrestrial sources have also been identified, such as wood-rotting fungi(13), biomass burning(14) and volcanic emissions(15). Here we report the identification of a different terrestrial source of naturally occurring VHOC, We find that, in soils and sediments, halide ions can be alkylated during the oxidation of organic matter by an electron acceptor such as Fe(III): sunlight or microbial mediation are not required for these reactions. When the available halide ion is chloride, the reaction products are CH3Cl, C2H5Cl, C3H7Cl and C4H9Cl. (The corresponding alkyl bromides or alkyl iodides are produced when bromide or iodide are present.) Such abiotic processes could make a significant contribution to the budget of the important atmospheric compounds CH3Cl, CH3Br and CH3I.	Univ Heidelberg, Inst Environm Geochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Keppler, F (corresponding author), Univ Heidelberg, Inst Environm Geochem, Neuenheimer Feld 236, D-69120 Heidelberg, Germany.		Keppler, Frank/F-4401-2012	Keppler, Frank/0000-0003-2766-8812				ANDERSON JG, 1991, SCIENCE, V251, P39, DOI 10.1126/science.251.4989.39; Andreae MO, 1996, J GEOPHYS RES-ATMOS, V101, P23603, DOI 10.1029/95JD01733; Butler JH, 1999, NATURE, V399, P749, DOI 10.1038/21586; CLASS TH, 1988, J ATMOS CHEM, V6, P35, DOI 10.1007/BF00048330; CRUTZEN PJ, 1986, NATURE, V324, P651, DOI 10.1038/324651a0; Desjardins S, 1999, J SOIL CONTAM, V8, P175; GRIBBLE GW, 1992, J NAT PROD, V55, P1353, DOI 10.1021/np50088a001; HARPER DB, 1985, NATURE, V315, P55, DOI 10.1038/315055a0; HOEKSTRA EJ, 1993, NATURALLY PRODUCED O, P149; Laturnus F, 1998, GEOPHYS RES LETT, V25, P773, DOI 10.1029/98GL00490; LOVELOCK JE, 1975, NATURE, V256, P193, DOI 10.1038/256193a0; LOVLEY DR, 1991, MICROBIOL REV, V55, P259, DOI 10.1128/MMBR.55.2.259-287.1991; Moore RM, 1996, J GEOPHYS RES-OCEANS, V101, P28529, DOI 10.1029/96JC02915; POST WM, 1982, NATURE, V298, P156, DOI 10.1038/298156a0; RASMUSSEN RA, 1980, J GEOPHYS RES-OCEANS, V85, P7350, DOI 10.1029/JC085iC12p07350; SINGH AK, 1984, THORAC CARDIOV SURG, V32, P89, DOI 10.1055/s-2007-1023355; SOLOMON S, 1990, NATURE, V347, P347, DOI 10.1038/347347a0; STURGES WT, 1993, TELLUS B, V45, P120, DOI 10.1034/j.1600-0889.1993.t01-1-00004.x; WEVER R, 1988, SCIENCE, V355, P501	19	272	288	7	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					298	301		10.1038/35002055	http://dx.doi.org/10.1038/35002055			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659846				2022-12-01	WOS:000084899700049
J	Rossi, A; Kapahi, P; Natoli, G; Takahashi, T; Chen, Y; Karin, M; Santoro, MG				Rossi, A; Kapahi, P; Natoli, G; Takahashi, T; Chen, Y; Karin, M; Santoro, MG			Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I kappa B kinase	NATURE			English	Article							TRANSCRIPTION FACTOR; ANTIVIRAL ACTIVITY; HUMAN-CELLS; ACTIVATION; GAMMA; IKK; MECHANISMS; EXPRESSION; COMPLEX; ALPHA	NF-kappa B is a critical activator of genes involved in inflammation and immunity(1,2). Pro-inflammatory cytokines activate the I kappa B kinase (IKK) complex that phosphorylates the NF-kappa B inhibitors, triggering their conjugation with ubiquitin and subsequent degradation(3,4). Freed NF-kappa B dimers translocate to the nucleus and induce target genes, including the one for cyclo-oxygenase 2 (COX2), which catalyses the synthesis of pro-inflammatory prostaglandins, in particular pGE(5,6). At late stages of inflammatory episodes, however, COX2 directs the synthesis of anti-inflammatory cyclopentenone prostaglandins, suggesting a role for these molecules in the resolution of inflammation(7). Cyclopentenone prostaglandins have been suggested to exert anti-inflammatory activity through the activation of peroxisome proliferator-activated receptor-gamma (refs 8, 9). Here we demonstrate a novel mechanism of antiinflammatory activity which is based on the direct inhibition and modification of the IKK beta subunit of IKK, As IKK beta is responsible for the activation of NF-kappa B by pro-inflammatory stimuli(10,11), our findings explain how cyclopentenone prostaglandins function and can be used to improve the utility of COX2 inhibitors.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Univ Roma Tor Vergata, Dept Biol, Virol Lab, I-00133 Rome, Italy; Italian Natl Council Res, Inst Expt Med, I-00133 Rome, Italy	University of California System; University of California San Diego; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR)	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Natoli, gioacchino/J-2100-2018; Natoli, gioacchino/ABB-8679-2020	Santoro, Maria Gabriella/0000-0003-1432-4949; ROSSI, ANTONIO/0000-0003-0383-3828; Natoli, Gioacchino/0000-0003-0711-2411				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; CALDERWOOD SK, 1989, J CELL PHYSIOL, V141, P325, DOI 10.1002/jcp.1041410214; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; Hirose S, 1998, J AM SOC NEPHROL, V9, P408; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; LEUNG DYM, 1988, J IMMUNOL, V140, P84; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; OFFENBACHER S, 1986, J PERIODONTAL RES, V21, P101, DOI 10.1111/j.1600-0765.1986.tb01443.x; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 1996, J BIOL CHEM, V271, P32192, DOI 10.1074/jbc.271.50.32192; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rozera C, 1996, J CLIN INVEST, V97, P1795, DOI 10.1172/JCI118609; SANTORO MG, 1980, SCIENCE, V209, P1032, DOI 10.1126/science.6157190; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; Santoro MG, 1997, TRENDS MICROBIOL, V5, P276, DOI 10.1016/S0966-842X(97)01066-4; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; WANG CY, 1998, SCIENCE, V274, P786; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	30	1148	1229	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					103	108		10.1038/47520	http://dx.doi.org/10.1038/47520			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638762				2022-12-01	WOS:000084687400052
J	Morrison, I				Morrison, I			The future of physicians' time	ANNALS OF INTERNAL MEDICINE			English	Article								Physicians' lime is under assault in the current health care system. In particular, managed care payers are reducing compensation to physicians on a discounted fee-for service basis. More demanding consumers, complex new technologies, and increased managerial and administrative burdens are placing further constraints on physicians' time. As we look ahead, it seems likely that these pressures will intensify and transform the ways in which physicians spend their time. Physicians will play eight key roles in the future: clinical data collector, shaman, health advisor and wellness coach, knowledge navigator, proceduralist, diagnostician, physician manager, and quality assurance specialist. They will need to lead the redesign of these roles and define the ways in which they should spend their time in the health care system of the new millennium.	Inst Future, Menlo Pk, CA USA		Morrison, I (corresponding author), 1635 Bay Laurel Dr, Menlo Pk, CA 94025 USA.	seccurve@aol.com						*HARR INT, 1999, HARR POLL; MORRISON I, 2000, JOS-BAS HEA, P1; Wadland WC, 1999, J FAM PRACTICE, V48, P711	3	23	23	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2000	132	1					80	84		10.7326/0003-4819-132-1-200001040-00013	http://dx.doi.org/10.7326/0003-4819-132-1-200001040-00013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270CV	10627256				2022-12-01	WOS:000084518600012
J	Scannell, KA				Scannell, KA			Leave of absence	ANNALS OF INTERNAL MEDICINE			English	Article									Kaiser Permanente, Oakland, CA 94611 USA	Kaiser Permanente	Scannell, KA (corresponding author), Kaiser Permanente, 280 W MacArthur Blvd, Oakland, CA 94611 USA.								0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2000	132	1					55	57		10.7326/0003-4819-132-1-200001040-00009	http://dx.doi.org/10.7326/0003-4819-132-1-200001040-00009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270CV	10627252				2022-12-01	WOS:000084518600008
J	Lohr, F				Lohr, F			On losing your molecular privacy	BRITISH MEDICAL JOURNAL			English	Editorial Material													Lohr, Frank/AAC-2528-2022	Lohr, Frank/0000-0003-1014-5556					0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1651	1652		10.1136/bmj.319.7225.1651	http://dx.doi.org/10.1136/bmj.319.7225.1651			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600984	Green Published			2022-12-01	WOS:000084562600035
J	Ross, SE				Ross, SE			"Memes" as infectious agents in psychosomatic illness	ANNALS OF INTERNAL MEDICINE			English	Article							ANOREXIA-NERVOSA; CHRONIC FATIGUE; FIBROMYALGIA; EPIDEMIC; DISORDERS; NEURASTHENIA; LABEL		Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Ross, SE (corresponding author), Univ Colorado, Hlth Sci Ctr, Box F414,4200 E 9th Ave, Denver, CO 80262 USA.	steve.ross@uchsc.edu						ACOCELLA J, 1998, POLITICS HYSTERIA, P64; ANGELL M, 1996, CLASH MED EVIDENCE L; [Anonymous], 1999, LANCET, V354, P173; ARONOWITZ RA, 1992, STUDIES CULTURAL HIS; Barsky AJ, 1999, ANN INTERN MED, V130, P910, DOI 10.7326/0003-4819-130-11-199906010-00016; BARSKY AJ, 1979, ANN INTERN MED, V91, P63, DOI 10.7326/0003-4819-91-1-63; Binkley KE, 1997, J ALLERGY CLIN IMMUN, V99, P570, DOI 10.1016/S0091-6749(97)70086-1; Boss LP, 1997, EPIDEMIOL REV, V19, P233, DOI 10.1093/oxfordjournals.epirev.a017955; BRODSKY CM, 1988, OCCUP MED, V3, P653; BRUMBERG JJ, 1988, EMERGENCE ANOREXIA N; CHEW P K, 1976, SMJ Singapore Medical Journal, V17, P10; CLELAND LG, 1987, MED J AUSTRALIA, V147, P236, DOI 10.5694/j.1326-5377.1987.tb133417.x; COLLIGAN M, 1982, MASS PSYCHOGENIC ILL; Dawkins R., 1976, SELFISH GENE; FAVA M, 1989, AM J PSYCHIAT, V146, P963; GOTHE CJ, 1995, PSYCHOSOMATICS, V36, P1; GREENBERG DB, 1990, PSYCHOSOMATICS, V31, P129, DOI 10.1016/S0033-3182(90)72185-8; HADLER NM, 1990, J OCCUP ENVIRON MED, V32, P38; Hadler NM, 1997, POSTGRAD MED, V102, P161, DOI 10.3810/pgm.1997.08.284; Hadler NM, 1996, CLEV CLIN J MED, V63, P85, DOI 10.3949/ccjm.63.2.85; Hadler NM, 1996, SPINE, V21, P2397, DOI 10.1097/00007632-199610150-00021; HALL W, 1988, SOC SCI MED, V27, P645, DOI 10.1016/0277-9536(88)90013-5; Mehler PS, 1996, HOSP PRACT, V31, P109; Nemery B, 1999, LANCET, V354, P77, DOI 10.1016/S0140-6736(05)75348-4; Osterweis M., 1987, PAIN DISABILITY CLIN; Riley JL, 1998, PAIN, V74, P181, DOI 10.1016/S0304-3959(97)00199-1; Showalter E., 1997, HYSTORIES; SIROIS F, 1982, MASS PSYCHOGENIC ILL; WELCH MS, 1971, LADIES HOME J    NOV, P98; WESSELY S, 1990, PSYCHOL MED, V20, P35, DOI 10.1017/S0033291700013210; Wilke WS, 1996, CLEV CLIN J MED, V63, P87, DOI 10.3949/ccjm.63.2.87; YAGER J, 1974, NEW ENGL J MED, V291, P907, DOI 10.1056/NEJM197410242911713; YASSI A, 1989, CAN MED ASSOC J, V140, P816; 1981, AM HER DICT ENGLISH, P834; 1990, MMWR MORB MORTAL WKL, V39, P301; 1996, MMWR MORB MORTAL WKL, V45, P6	36	16	16	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					867	871		10.7326/0003-4819-131-11-199912070-00019	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00019			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	262ET	10610639				2022-12-01	WOS:000084053200018
J	Seymour, K; Pettit, S; O'Flaherty, E; Charnley, RM; Kirby, JA				Seymour, K; Pettit, S; O'Flaherty, E; Charnley, RM; Kirby, JA			Selection of metastatic tumour phenotypes by host immune systems	LANCET			English	Article							E-CADHERIN; FAS COUNTERATTACK; TAP-1 EXPRESSION; T-CELLS; CANCER; INTEGRIN; CARCINOMA; LIGAND; LYMPHOCYTES; MECHANISMS	Metastasis and the processes underlying this phenomenon make epithelial cancers so malignant. Local control of cancers by surgery is sometimes possible but locoregional and distant recurrence commonly lead to the failure of treatment with ensuing morbidity and mortality. Tumour cells express a range of new antigens during growth and there are opportunities for the host immune system to interact with these antigens. This immune interaction eliminates the tumour or allows selection of phenotypic variants. Cell phenotypes selected by an incomplete immune response resemble the cell type commonly associated with metastases. Thus we propose that the host immune system may be responsible for selection of this phenotype and progression of the disease.	Univ Newcastle Upon Tyne, Sch Med, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Freeman Rd Hosp, Dept Gastrointestinal Surg, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England	Newcastle University - UK; Newcastle Freeman Hospital; Newcastle University - UK	Seymour, K (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Surg & Reprod Sci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Kirby, John/0000-0003-2543-4131; Seymour, Keith/0000-0003-0850-2745				Aizawa K, 1999, INT J ONCOL, V14, P85; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett MW, 1998, J IMMUNOL, V160, P5669; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CROMME FV, 1994, BRIT J CANCER, V69, P1176, DOI 10.1038/bjc.1994.231; Dudley ME, 1996, INT J CANCER, V65, P249, DOI 10.1002/(SICI)1097-0215(19960117)65:2<249::AID-IJC20>3.0.CO;2-7; Fey MF, 1996, ANN ONCOL, V7, P121; GARRIDO F, 1993, IMMUNOL TODAY, V14, P491, DOI 10.1016/0167-5699(93)90264-L; Grossman D, 1997, ARCH DERMATOL, V133, P1263, DOI 10.1001/archderm.133.10.1263; Hadley GA, 1997, J IMMUNOL, V159, P3748; Hedger M P, 1997, Rev Reprod, V2, P38, DOI 10.1530/revreprod/2.1.38; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Itoh K, 1996, J BIOCHEM-TOKYO, V119, P385; Jiang WG, 1996, BRIT J SURG, V83, P437, DOI 10.1002/bjs.1800830404; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; KEATING PJ, 1995, BRIT J CANCER, V72, P405, DOI 10.1038/bjc.1995.346; Kuwabara K, 1998, JPN J CANCER RES, V89, P40, DOI 10.1111/j.1349-7006.1998.tb00477.x; LEHMANN F, 1995, EUR J IMMUNOL, V25, P340, DOI 10.1002/eji.1830250206; OConnell J, 1997, MOL MED, V3, P294, DOI 10.1007/BF03401808; Pang M, 1998, ARTHRITIS RHEUM, V41, P1456, DOI 10.1002/1529-0131(199808)41:8<1456::AID-ART16>3.0.CO;2-0; Ricote M, 1997, MUTAT RES-FUND MOL M, V374, P153, DOI 10.1016/S0027-5107(97)00002-X; Rowan S, 1997, LEUKEMIA, V11, P457, DOI 10.1038/sj.leu.2400626; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Svane IM, 1996, EUR J IMMUNOL, V26, P1844, DOI 10.1002/eji.1830260827; TaylorPapadimitriou J, 1997, IMMUNOL TODAY, V18, P105, DOI 10.1016/S0167-5699(97)01028-1; YAMAMOTO K, 1995, J IMMUNOL, V154, P1804; YOUNG D, 1989, DRUG RESISTANCE CANC; Zhang K, 1997, CELL IMMUNOL, V176, P158, DOI 10.1006/cimm.1997.1085	31	14	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1989	1991		10.1016/S0140-6736(99)04435-9	http://dx.doi.org/10.1016/S0140-6736(99)04435-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622313				2022-12-01	WOS:000084034700043
J	Robinson, RC; Mejillano, M; Le, VP; Burtnick, LD; Yin, HL; Choe, S				Robinson, RC; Mejillano, M; Le, VP; Burtnick, LD; Yin, HL; Choe, S			Domain movement in gelsolin: A calcium-activated switch	SCIENCE			English	Article							PLASMA GELSOLIN; BINDING-SITE; ACTIN; COMPLEX; IDENTIFICATION; FILAMENT	The actin-binding protein gelsolin is involved in remodeling the actin cytoskeleton during growth-factor signaling, apoptosis, cytokinesis, and cell movement. Calcium-activated gelsolin severs and caps actin filaments, The 3.4 angstrom x-ray structure of the carboxyl-terminal half of gelsolin (G4-G6) in complex with actin reveals the basis for gelsolin activation. Calcium binding induces a conformational rearrangement in which domain G6 is flipped over and translated by about 40 angstroms relative to G4 and G5. The structural reorganization tears apart the continuous beta sheet core of G4 and G6. This exposes the actin-binding site on G4, enabling severing and capping of actin filaments to proceed.	Salk Inst Biol Studies, Struct Biol Lab, San Diego, CA 92186 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	Salk Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of British Columbia	Choe, S (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, POB 85800, San Diego, CA 92186 USA.		Robinson, Robert/G-9702-2011	Robinson, Robert/0000-0001-6367-6903				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; McGough A, 1998, BIOPHYS J, V74, P764, DOI 10.1016/S0006-3495(98)74001-9; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WEEDS AG, 1995, FEBS LETT, V360, P227, DOI 10.1016/0014-5793(95)00109-M; 1994, ACTA CRYSTALLOGR D, V55, P760	18	134	139	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1939	1942		10.1126/science.286.5446.1939	http://dx.doi.org/10.1126/science.286.5446.1939			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583954				2022-12-01	WOS:000084003400047
J	Olson, ES				Olson, ES			Direct measurement of intra-cochlear pressure waves	NATURE			English	Article							BASILAR-MEMBRANE; MECHANICS; POSITION; BASE	The cochlear travelling wave is fundamental to the ability of the mammalian auditory system to resolve frequency. The seashell-shaped outer bone of the cochlea (the auditory inner ear) contains a spiral of cochlear fluid and the sensory tissue known as the cochlear partition. Sound travels down the ear canal to the eardrum, causing its flexible tympanic membrane to vibrate. This vibration is transmitted to the cochlea via the ossicles. Motion of the stapes (the stirrup ossicle) sets the cochlear fluid in motion, which in turn sets the cochlear partition near the stapes in motion. The motion of the cochlear partition ripples down the cochlear spiral as a travelling wave, stimulating the cochlea's sensory hair cells. The wave peaks near the base (the stapes end) of the cochlea for high frequency tones and near the apex for low frequencies'. The fundamental elements of the cochlear travelling wave are fluid pressure and motion and partition forces and motion. However, the wave's direct experimental study has to date relied almost solely on measurements of the partition motion. Here I report finely spaced measurements of intracochlear pressure close to the partition, which reveal the fluid component of the cochlear wave. The penetration depth of the wave is very limited, similar to 15 mu m. Over a range of frequencies at least an octave wide, the depth is independent of frequency.	Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University	Olson, ES (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.				NIDCD NIH HHS [R29 DC003130] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC003130] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BROWNELL WE, 1985, SCIENCE, V227, P195; COOPER NP, 1992, HEARING RES, V63, P163, DOI 10.1016/0378-5955(92)90083-Y; DANCER A, 1980, HEARING RES, V2, P191, DOI 10.1016/0378-5955(80)90057-X; DEBOER E, 1984, PHYS REP, V105, P141, DOI 10.1016/0370-1573(84)90108-X; LIBERMAN MC, 1984, HEARING RES, V16, P55, DOI 10.1016/0378-5955(84)90025-X; LIGHTHILL J, 1981, J FLUID MECH, V106, P149, DOI 10.1017/S0022112081001560; Muller M, 1996, HEARING RES, V94, P148, DOI 10.1016/0378-5955(95)00230-8; Olson ES, 1998, J ACOUST SOC AM, V103, P3445, DOI 10.1121/1.423083; PLASSMANN W, 1987, BRAIN BEHAV EVOLUT, V30, P82, DOI 10.1159/000118639; RHODE WS, 1971, J ACOUST SOC AM, V49, P1218, DOI 10.1121/1.1912485; Ruggero MA, 1997, J ACOUST SOC AM, V101, P2151, DOI 10.1121/1.418265; SELLICK PM, 1983, HEARING RES, V10, P101, DOI 10.1016/0378-5955(83)90020-5; SPOENDLIN H, 1972, ACTA OTO-LARYNGOL, V73, P235, DOI 10.3109/00016487209138937; STEELE CR, 1979, J ACOUST SOC AM, V65, P1007, DOI 10.1121/1.382570; von Bekesy G., 1960, EXPT HEARING; XUE SW, 1995, J ACOUST SOC AM, V97, P3030, DOI 10.1121/1.413103	16	95	96	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					526	529		10.1038/990092	http://dx.doi.org/10.1038/990092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591211				2022-12-01	WOS:000084013200055
J	Xu, GL; Bestor, TH; Bourc'his, D; Hsieh, CL; Tommerup, N; Bugge, M; Hulten, M; Qu, XY; Russo, JJ; Viegas-Pequignot, E				Xu, GL; Bestor, TH; Bourc'his, D; Hsieh, CL; Tommerup, N; Bugge, M; Hulten, M; Qu, XY; Russo, JJ; Viegas-Pequignot, E			Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene	NATURE			English	Article							ICF SYNDROME; METHYLATION PATTERN; HETEROCHROMATIN; HYPOMETHYLATION; FISH; SET	The recessive autosomal disorder known as ICF syndrome(1-3) (for immunodeficiency, centromere instability and facial anomalies; Mendelian Inheritance in Man number 242860) is characterized by variable reductions in serum immunoglobulin levels which cause most ICF patients to succumb to infectious diseases before adulthood. Mild facial anomalies include hypertelorism, low-set ears, epicanthal folds and macroglossia. The cytogenetic abnormalities in lymphocytes are exuberant: juxtacentromeric heterochromatin is greatly elongated and thread-like in metaphase chromosomes, which is associated with the formation of complex multiradiate chromosomes. The same juxtacentromeric regions are subject to persistent interphase self-associations and are extruded into nuclear blebs or micronuclei. Abnormalities are largely confined to tracts of classical satellites 2 and 3 at juxtacentromeric regions of chromosomes 1, 9 and 16. Classical satellite DNA is normally heavily methylated at cytosine residues, but in ICF syndrome it is almost completely unmethylated in all tissues(4) ICF syndrome is the only genetic disorder known to involve constitutive abnormalities of genomic methylation patterns. Here we show that five unrelated ICF patients have mutations in both alleles of the gene that encodes DNA methyltransferase 3B (refs 5, 6). Cytosine methylation is essential for the organization and stabilization of a specific type of heterochromatin, and this methylation appears to be carried out by an enzyme specialized for the purpose.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Hop Necker Enfants Malad, INSERM, U383, F-75743 Paris 15, France; Univ So Calif, Sch Med, Dept Urol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Copenhagen, Inst Med Biochem & Genet, Dept Med Genet, DK-2600 Glostrup, Denmark; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Columbia Univ Coll Phys & Surg, Columbia Genome Ctr, New York, NY 10032 USA	Columbia University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Southern California; University of Southern California; University of Copenhagen; University of Warwick; Columbia University	Bestor, TH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.		Tommerup, Niels/T-8776-2017	Tommerup, Niels/0000-0003-2304-0112; Bourc'his, Deborah/0000-0001-9499-7291				Bestor TH, 1998, CIBA F SYMP, V214, P187; Bourc'his D, 1999, CYTOGENET CELL GENET, V84, P245, DOI 10.1159/000015269; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; HSIEH CL, IN PRESS MOL CELL BI; HULTEN M, 1978, CLIN GENET, V14, P294; JEANPIERRE M, 1994, ANN GENET-PARIS, V37, P163; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LUBIT BW, 1976, CELL, V9, P503, DOI 10.1016/0092-8674(76)90032-5; MARASCHIO P, 1988, J MED GENET, V25, P173, DOI 10.1136/jmg.25.3.173; MARASCHIO P, 1992, ANN HUM GENET, V56, P273, DOI 10.1111/j.1469-1809.1992.tb01152.x; MINIOU P, 1994, HUM MOL GENET, V3, P2093, DOI 10.1093/hmg/3.12.2093; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; REYNAUD C, 1992, CANCER LETT, V61, P255, DOI 10.1016/0304-3835(92)90296-8; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; SCHUFFENHAUER S, 1995, HUM GENET, V96, P562, DOI 10.1007/BF00197412; Schulz WG, 1997, CHEM ENG NEWS, V75, P64, DOI 10.1021/cen-v075n018.p064; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Sumner AT, 1998, J MED GENET, V35, P833, DOI 10.1136/jmg.35.10.833; TIEPOLO L, 1978, CLIN GENET, V14, P313; Wijmenga C, 1998, AM J HUM GENET, V63, P803, DOI 10.1086/302021; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	29	880	921	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					187	191		10.1038/46052	http://dx.doi.org/10.1038/46052			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647011				2022-12-01	WOS:000083716400052
J	Saether, BE; Tufto, J; Engen, S; Jerstad, K; Rostad, OW; Skatan, JE				Saether, BE; Tufto, J; Engen, S; Jerstad, K; Rostad, OW; Skatan, JE			Population dynamical consequences of climate change for a small temperate songbird	SCIENCE			English	Article							NORTH-ATLANTIC OSCILLATION; ENVIRONMENTAL STOCHASTICITY	Predicting the effects of an expected climatic change requires estimates and modeling of stochastic factors as well as density-dependent effects in the population dynamics. In a population of a small songbird, the dipper (Cinclus cinclus), environmental stochasticity and density dependence both influenced the population growth rate. About half of the environmental variance was explained by variation in mean winter temperature. Including these results in a stochastic model shows that an expected change In climate will strongly affect the dynamics of the population, Leading to a nonlinear increase in the carrying capacity and in the expected mean population size.	Norwegian Univ Sci & Technol, Dept Zool, N-7491 Trondheim, Norway; Norwegian Univ Sci & Technol, Dept Math Sci, N-7491 Trondheim, Norway; Aurebekk, N-4500 Mandal, Norway; Agr Univ Norway, Dept Biol & Nat Conservat, N-1432 As, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Life Sciences	Saether, BE (corresponding author), Norwegian Univ Sci & Technol, Dept Zool, N-7491 Trondheim, Norway.	Bernt-Erik.Sathere@chembio.ntnu.no	Tufto, Jarle/I-4817-2013					ATHREYA KB, 1971, ANN MATH STAT, V42, P1499, DOI 10.1214/aoms/1177693150; Bartlett MS., 1960, STOCHASTIC POPULATIO; Berger JO., 1985, STAT DECISION THEORY; Bjornstad ON, 1999, TRENDS ECOL EVOL, V14, P427, DOI 10.1016/S0169-5347(99)01677-8; Chatfield C, 2016, ANAL TIME SERIES INT; Corti S, 1999, NATURE, V398, P799, DOI 10.1038/19745; Crick HQP, 1997, NATURE, V388, P526, DOI 10.1038/41453; DUNHAM AE, 1993, BIOTIC INTERACTIONS AND GLOBAL CHANGE, P95; Engen S, 1998, OIKOS, V83, P345, DOI 10.2307/3546848; Forchhammer MC, 1998, NATURE, V391, P29, DOI 10.1038/34070; Gilks WR, 1996, MARKOV CHAIN MONTE C; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Hurrell JW, 1997, CLIMATIC CHANGE, V36, P301, DOI 10.1023/A:1005314315270; Intergovernmental Panel on Climate Change, 1996, CLIM CHANG 1995 SCI; IVES AR, 1993, BIOTIC INTERACTIONS AND GLOBAL CHANGE, P120; LAMB PJ, 1987, B AM METEOROL SOC, V68, P1218, DOI 10.1175/1520-0477(1987)068<1218:NAOCAA>2.0.CO;2; Lande R, 1999, AM NAT, V154, P271, DOI 10.1086/303240; Lande R, 1998, OIKOS, V83, P353, DOI 10.2307/3546849; MAY RM, 1973, AM NAT, V107, P621, DOI 10.1086/282863; McCleery RH, 1998, NATURE, V391, P30, DOI 10.1038/34073; Newton I., 1998, POPULATION LIMITATIO; ORMEROD SJ, 1994, DIPPERS; Post E, 1999, ECOLOGY, V80, P1322, DOI 10.1890/0012-9658(1999)080[1322:CVPPAN]2.0.CO;2; Ranta E, 1998, ENVIRONM INTELL UNIT, P47; ROGERS JC, 1984, MON WEATHER REV, V112, P1999, DOI 10.1175/1520-0493(1984)112<1999:TABTNA>2.0.CO;2; Saether BE, 1997, TRENDS ECOL EVOL, V12, P143, DOI 10.1016/S0169-5347(96)10068-9; Saether BE, 1998, AM NAT, V151, P441, DOI 10.1086/286131; SCHLESINGER ME, 1994, NATURE, V367, P723, DOI 10.1038/367723a0; Shindell DT, 1999, NATURE, V399, P452, DOI 10.1038/20905; Solbreck Christer, 1995, P279, DOI 10.1016/B978-012159270-7/50015-4; SPIEGELHALTER DJ, 1996, BUGS 5 0 BAYESIAN IN; Tufto J, 2000, OIKOS, V88, P273, DOI 10.1034/j.1600-0706.2000.880205.x; Turchin Peter, 1995, P19, DOI 10.1016/B978-012159270-7/50003-8	33	252	256	1	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2000	287	5454					854	856		10.1126/science.287.5454.854	http://dx.doi.org/10.1126/science.287.5454.854			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657299				2022-12-01	WOS:000085136400046
J	Jiang, Y; Haxby, JV; Martin, A; Ungerleider, LG; Parasuraman, R				Jiang, Y; Haxby, JV; Martin, A; Ungerleider, LG; Parasuraman, R			Complementary neural mechanisms for tracking items in human working memory	SCIENCE			English	Article							PREFRONTAL CORTEX; RETRIEVAL; FMRI	Recognition of a specific visual target among equally familiar distracters requires neural mechanisms for tracking items in working memory. Event-related functional magnetic resonance imaging revealed evidence for two such mechanisms: (i) Enhanced neural responses, primarily in the frontal cortex, were associated with the target and were maintained across repetitions of the target. (ii) Reduced responses, primarily in the extrastriate visual cortex, were associated with stimulus repetition, regardless of whether the stimulus was a target or a distracter, These complementary neural mechanisms track the status of familiar items in working memory, allowing for the efficient recognition of a currently relevant object and rejection of irrelevant distracters.	NIMH, Lab Brain & Cognit, Bethesda, MD 20892 USA; Catholic Univ Amer, Cognit Sci Lab, Washington, DC 20064 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Catholic University of America	Jiang, Y (corresponding author), NIMH, Lab Brain & Cognit, Bethesda, MD 20892 USA.		martin, alex/B-6176-2009	JIANG, Yang/0000-0003-4589-0097	NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002588, ZIAMH002035, Z01MH002035, Z01MH002588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007569] Funding Source: NIH RePORTER; NIA NIH HHS [AG07569] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Buchel C, 1999, SCIENCE, V283, P1538, DOI 10.1126/science.283.5407.1538; BUCKNER RL, 1995, J NEUROSCI, V15, P12; Clark VP, 1998, J NEUROPHYSIOL, V79, P3257, DOI 10.1152/jn.1998.79.6.3257; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; Dale AM, 1997, HUM BRAIN MAPP, V5, P329, DOI 10.1002/(SICI)1097-0193(1997)5:5<329::AID-HBM1>3.0.CO;2-5; DEMB JB, 1995, J NEUROSCI, V15, P5870; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Haxby JV, 1999, NEURON, V22, P189, DOI 10.1016/S0896-6273(00)80690-X; Haxby JV, 1995, HUM BRAIN MAPP, V3, P68, DOI 10.1002/hbm.460030204; HAXBY JV, MAPPING MODELING HUM; MILLER EK, 1993, J NEUROSCI, V13, P1460; MILLER EK, 1994, SCIENCE, V263, P520, DOI 10.1126/science.8290960; Miller EK, 1996, J NEUROSCI, V16, P5154; Parasuraman R, 1998, ATTENTIVE BRAIN, P3; Schacter DL, 1998, PHILOS T ROY SOC B, V353, P1861, DOI 10.1098/rstb.1998.0338; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Suzuki WA, 1999, NEURON, V24, P295, DOI 10.1016/S0896-6273(00)80844-2; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; Wiggs CL, 1998, CURR OPIN NEUROBIOL, V8, P227, DOI 10.1016/S0959-4388(98)80144-X	21	141	157	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	2000	287	5453					643	646		10.1126/science.287.5453.643	http://dx.doi.org/10.1126/science.287.5453.643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10649996				2022-12-01	WOS:000084989400045
J	Koide, S; Huang, XL; Link, K; Koide, A; Bu, ZM; Engelman, DM				Koide, S; Huang, XL; Link, K; Koide, A; Bu, ZM; Engelman, DM			Design of single-layer beta-sheets without a hydrophobic core	NATURE			English	Article							ROTATIONAL DIFFUSION ANISOTROPY; HETERONUCLEAR NMR-SPECTROSCOPY; BORRELIA-BURGDORFERI OSPA; PROTEIN DESIGN; STRUCTURAL CHARACTERIZATION; BACKBONE DYNAMICS; RELAXATION; N-15; SCATTERING; DOMAIN	The hydrophobic effect is the main thermodynamic driving force in the folding of water-soluble proteins(1,2), Exclusion of nonpolar moieties from aqueous solvent results in the formation of a hydrophobic core in a protein, which has been generally considered essential for specifying and stabilizing the folded structures of proteins(1-6). Outer surface protein A (OspA) from Borrelia burgdorferi contains a three-stranded beta-sheet segment which connects two globular domains(7). Although this single-layer beta- sheet segment is exposed to solvent on both faces and thus does not contain a hydrophobic core, the segment has a high conformational stability(8), Here we report the engineering of OspA variants that contain larger single-layer beta-sheets (comprising five and seven beta-strands) by duplicating a beta-hairpin unit within the beta-sheet, Nuclear magnetic resonance and small-angle X-ray scattering analyses reveal that these extended single-layer beta-sheets are formed as designed, and amide hydrogen-deuterium exchange and chemical denaturation show that they are stable. Thus, interactions within the beta-hairpin unit and those between adjacent units, which do not involve the formation of a hydrophobic core, are sufficient to specify and stabilize the single-layer beta-sheet structure. Our results provide an expanded view of protein folding, misfolding and design.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA	University of Rochester; Yale University	Koide, S (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.							Beasley JR, 1997, J BIOL CHEM, V272, P2031, DOI 10.1074/jbc.272.4.2031; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Bu ZM, 1998, PROTEIN SCI, V7, P2681, DOI 10.1002/pro.5560071223; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; Kataoka M, 1997, PROTEIN SCI, V6, P422; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Koepf EK, 1999, PROTEIN SCI, V8, P841, DOI 10.1110/ps.8.4.841; Koide S, 1999, BIOCHEMISTRY-US, V38, P4757, DOI 10.1021/bi982443+; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lacroix E, 1999, CURR OPIN STRUC BIOL, V9, P487, DOI 10.1016/S0959-440X(99)80069-4; LATTMAN EE, 1994, CURR OPIN STRUC BIOL, V4, P87, DOI 10.1016/S0959-440X(94)90064-7; Lee LK, 1997, J BIOMOL NMR, V9, P287, DOI 10.1023/A:1018631009583; Li H, 1997, P NATL ACAD SCI USA, V94, P3584, DOI 10.1073/pnas.94.8.3584; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Pham TN, 1998, NAT STRUCT BIOL, V5, P115, DOI 10.1038/nsb0298-115; Pham TN, 1998, J BIOMOL NMR, V11, P407, DOI 10.1023/A:1008246908142; Tjandra N, 1997, NAT STRUCT BIOL, V4, P443, DOI 10.1038/nsb0697-443; WISCHART DS, 1994, J BIOMOL NMR, V4, P171	30	47	49	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					456	460		10.1038/35000255	http://dx.doi.org/10.1038/35000255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667801				2022-12-01	WOS:000085121100057
J	Sun, LF; Xie, SS; Liu, W; Zhou, WY; Liu, ZQ; Tang, DS; Wang, G; Qian, LX				Sun, LF; Xie, SS; Liu, W; Zhou, WY; Liu, ZQ; Tang, DS; Wang, G; Qian, LX			Materials - Creating the narrowest carbon nanotubes	NATURE			English	Article									Chinese Acad Sci, Inst Phys, Ctr Condensed Matter Phys, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Physics, CAS	Sun, LF (corresponding author), Chinese Acad Sci, Inst Phys, Ctr Condensed Matter Phys, POB 603, Beijing 100080, Peoples R China.							AJAYAN PM, 1992, NATURE, V358, P23, DOI 10.1038/358023a0; Chang BH, 1998, SCI CHINA SER A, V41, P431, DOI 10.1007/BF02879035; Endo M., 1996, CARBON NANOTUBES; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Piskoti C, 1998, NATURE, V393, P771, DOI 10.1038/31668; SAITO R, 1992, APPL PHYS LETT, V60, P2204, DOI 10.1063/1.107080; SAWADA S, 1992, SOLID STATE COMMUN, V83, P917, DOI 10.1016/0038-1098(92)90911-R	7	136	153	3	75	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					384	384		10.1038/35000290	http://dx.doi.org/10.1038/35000290			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667781	Bronze			2022-12-01	WOS:000085121100037
J	Kawai, N; Matsuzawa, T				Kawai, N; Matsuzawa, T			Cognition - Numerical memory span in a chimpanzee	NATURE			English	Article							PAN-TROGLODYTES		Kyoto Univ, Primate Res Inst, Aichi 4848506, Japan	Kyoto University	Kawai, N (corresponding author), Kyoto Univ, Primate Res Inst, Aichi 4848506, Japan.		Kawai, Nobuyuki/M-4902-2014	Kawai, Nobuyuki/0000-0003-0372-1703				Biro D, 1999, J COMP PSYCHOL, V113, P178, DOI 10.1037/0735-7036.113.2.178; Boysen ST, 1999, ANIM LEARN BEHAV, V27, P229, DOI 10.3758/BF03199679; Brannon EM, 1998, SCIENCE, V282, P746, DOI 10.1126/science.282.5389.746; MATSUZAWA T, 1985, NATURE, V315, P57, DOI 10.1038/315057a0; MATSUZAWA T, 1991, PRIMATOLOGY TODAY, P317; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/0033-295X.101.2.343; Murofushi K, 1997, JPN PSYCHOL RES, V39, P140, DOI 10.1111/1468-5884.00050; RUMBAUGH DM, 1987, J EXP PSYCHOL ANIM B, V13, P107, DOI 10.1037/0097-7403.13.2.107; Tomonaga M., 1993, PRIMATE RES, V9, P67; TOMONAGA M, IN PRESS ANIM COGN	10	125	129	0	44	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					39	40		10.1038/47405	http://dx.doi.org/10.1038/47405			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	273BM	10638743				2022-12-01	WOS:000084687400033
J	Williams, KA				Williams, KA			Three-dimensional structure of the ion-coupled transport protein NhaA	NATURE			English	Article							ELECTRON CRYSTALLOGRAPHY; 3-DIMENSIONAL STRUCTURE; NA+/H+ ANTIPORTER; ESCHERICHIA-COLI; WATER CHANNEL; RESOLUTION; BACTERIORHODOPSIN; CRYOMICROSCOPY; CONFORMATION; AQUAPORIN-1	Ion-coupled membrane-transport proteins, or secondary transporters, comprise a diverse and abundant group of membrane proteins that are found in all organisms. These proteins facilitate solute accumulation and toxin removal against concentration gradients using energy supplied by ion gradients across membranes. NhaA is a Na+/H+ antiporter of relative molecular mass 42,000, which is found in the inner membrane of Escherichia coli, and which has been cloned and characterized(1,2). NhaA uses the H+ electrochemical gradient to expel Na+ from the cytoplasm, and functions primarily in the adaptation to high salinity at alkaline pH(1,2). Most secondary transporters, including NhaA(3), are predicted to have 12 transmembrane helices. Here we report the structure of NhaA, at 7 Angstrom resolution in the membrane plane and at 14 Angstrom vertical resolution, determined from two-dimensional crystals(4) using electron cryo-microscopy. The three-dimensional map of NhaA reveals 12 tilted, bilayer-spanning helices. A roughly linear arrangement of six helices is adjacent to a compact bundle of six helices, with the density for one helix in the bundle not continuous through the membrane. The molecular organization of NhaA represents a new membrane-protein structural motif and offers the first insights into the architecture of an ion-coupled transport protein.	Max Planck Inst Biophys, Dept Biol Struct, D-60528 Frankfurt, Germany	Max Planck Society	Williams, KA (corresponding author), Max Planck Inst Biophys, Dept Biol Struct, Heinrich Hoffmann Str 7, D-60528 Frankfurt, Germany.							Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; BLAKELY RD, 1994, J EXP BIOL, V196, P263; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HAVELKA WA, 1995, J MOL BIOL, V247, P726, DOI 10.1006/jmbi.1995.0176; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P899; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; Li HL, 1997, NAT STRUCT BIOL, V4, P263, DOI 10.1038/nsb0497-263; Padan E, 1999, NOVART FDN SYMP, V221, P183; Padan E., 1996, HDB BIOL PHYS, V2, P501; PERUSE E, 1999, SCIENCE, V285, P73; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; Rothman A, 1997, BIOCHEMISTRY-US, V36, P14572, DOI 10.1021/bi971800y; Saier MH, 1998, FASEB J, V12, P265, DOI 10.1096/fasebj.12.3.265; Schloss P, 1998, J PSYCHOPHARMACOL, V12, P115, DOI 10.1177/026988119801200201; SHAW PJ, 1981, MICRON, V12, P279, DOI 10.1016/0047-7206(81)90081-9; Subramaniam S, 1999, J MOL BIOL, V287, P145, DOI 10.1006/jmbi.1999.2589; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; WANG DN, 1991, J MOL BIOL, V217, P691, DOI 10.1016/0022-2836(91)90526-C; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Wright EM, 1998, AM J PHYSIOL-GASTR L, V275, P879; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	30	191	194	0	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					112	115		10.1038/47534	http://dx.doi.org/10.1038/47534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638764				2022-12-01	WOS:000084687400054
J	Henney, JE				Henney, JE			FDA's proposed strategy on reuse of single-use devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					46	46		10.1001/jama.283.1.46	http://dx.doi.org/10.1001/jama.283.1.46			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632269				2022-12-01	WOS:000084514400007
J	Chiswick, ML				Chiswick, ML			Assessment of pain in neonates	LANCET			English	Editorial Material							SKIN		St Marys Hosp Women & Children, Reg Neonatal Med Unit, Manchester M13 0JH, Lancs, England		Chiswick, ML (corresponding author), St Marys Hosp Women & Children, Reg Neonatal Med Unit, Manchester M13 0JH, Lancs, England.							ANDREWS K, 1994, PAIN, V56, P95, DOI 10.1016/0304-3959(94)90154-6; Andrews K, 1999, DEV MED CHILD NEUROL, V41, P696, DOI 10.1017/S0012162299001425; BARKER DP, 1995, ARCH DIS CHILD-FETAL, V72, pF47, DOI 10.1136/fn.72.1.F47; CONSTANTINOU J, 1994, NEUROREPORT, V5, P2281, DOI 10.1097/00001756-199411000-00019; Johnston CC, 1996, PEDIATRICS, V98, P925; Porter FL, 1998, PEDIATRICS, V102, P1383, DOI 10.1542/peds.102.6.1383; Porter FL, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e13; REYNOLDS ML, 1995, J COMP NEUROL, V358, P487, DOI 10.1002/cne.903580403; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Scott CS, 1999, J PEDIATR-US, V135, P423, DOI 10.1016/S0022-3476(99)70163-0	10	18	23	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					6	8		10.1016/S0140-6736(99)00392-X	http://dx.doi.org/10.1016/S0140-6736(99)00392-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615882				2022-12-01	WOS:000085049200007
J	Garrow, J				Garrow, J			Christmas factor and snacking	LANCET			English	Editorial Material							WEIGHT; WOMEN		Dial House, Rickmansworth WD3 2DQ, England		Garrow, J (corresponding author), Dial House, Rickmansworth WD3 2DQ, England.							ANDERSSON I, 1992, INT J OBESITY, V16, P1013; Friedman JM, 1999, PROG OBES R, P307; Marmonier C, 1999, AM J CLIN NUTR, V70, P854; RODIN J, 1977, J COMP PHYSIOL PSYCH, V91, P586, DOI 10.1037/h0077354; SMITH S, 1855, LADY HOLLAND MEMOIR, P376; Stock M, 1982, OBESITY LEANNESS BAS; Tuomisto T, 1998, APPETITE, V30, P211, DOI 10.1006/appe.1997.0142; VANSTAVEREN WA, 1986, INT J OBESITY, V10, P133; WOOLEY OW, 1972, J COMP PHYSIOL PSYCH, V80, P250, DOI 10.1037/h0033069; ZAHORSKAMARKIEWICZ B, 1980, INT J OBESITY, V4, P139	10	6	6	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	2000	355	9197					8	8		10.1016/S0140-6736(99)90449-X	http://dx.doi.org/10.1016/S0140-6736(99)90449-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615883				2022-12-01	WOS:000085049200008
J	Andel, F; Ladurner, AG; Inouye, C; Tjian, R; Nogales, E				Andel, F; Ladurner, AG; Inouye, C; Tjian, R; Nogales, E			Three-dimensional structure of the human TFIID-IIA-IIB complex	SCIENCE			English	Article							RNA-POLYMERASE-II; TATA-BINDING-PROTEIN; MEDIATE TRANSCRIPTIONAL ACTIVATION; YEAST TFIIA/TBP/DNA COMPLEX; CRYSTAL-STRUCTURE; PROMOTER SELECTIVITY; IN-VITRO; COACTIVATOR; INITIATION; DROSOPHILA	The multisubunit transcription factor IID (TFIID) is an essential component of the eukaryotic RNA polymerase II machinery that works in concert with TFIIA (IIA) and TFIIB (IIB) to assemble initiation complexes at core eukaryotic promoters. Here the structures of human TFIID and the TFIID-IIA-IIB complex that were obtained by electron microscopy and image analysis to 35 angstrom resolution are presented. TFIID is a trilobed, horseshoe-shaped structure, with TFIIA and TFIIB bound on opposite Lobes and flanking a central cavity. Antibody studies Locate the TATA-binding protein (TBP) between TFIIA and TFIIB at the top of the cavity that most Likely encompasses the TATA DNA binding region of the supramolecular complex.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Nogales, E (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.	enogales@lbl.gov		Ladurner, Andreas/0000-0003-3835-232X				Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; ANDEL F, UNPUB; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chen JL, 1996, METHOD ENZYMOL, V273, P208; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Emami KH, 1997, GENE DEV, V11, P3007, DOI 10.1101/gad.11.22.3007; FRANK J, 1990, Q REV BIOPHYS, V23, P281, DOI 10.1017/S0033583500005564; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HARAUZ G, 1986, OPTIK, V73, P146; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; Lavigne AC, 1999, MOL CELL BIOL, V19, P5486; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; Lieberman PM, 1997, MOL CELL BIOL, V17, P6624, DOI 10.1128/MCB.17.11.6624; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/S0968-0004(96)10050-5; Ruppert SML, 1996, HYBRIDOMA, V15, P55, DOI 10.1089/hyb.1996.15.55; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Ryu SJ, 1999, P NATL ACAD SCI USA, V96, P7137, DOI 10.1073/pnas.96.13.7137; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235	47	110	112	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2153	2156		10.1126/science.286.5447.2153	http://dx.doi.org/10.1126/science.286.5447.2153			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591646				2022-12-01	WOS:000084157300051
J	Cichowski, K; Shih, TS; Schmitt, E; Santiago, S; Reilly, K; McLaughlin, ME; Bronson, RT; Jacks, T				Cichowski, K; Shih, TS; Schmitt, E; Santiago, S; Reilly, K; McLaughlin, ME; Bronson, RT; Jacks, T			Mouse models of tumor development in neurofibromatosis type 1	SCIENCE			English	Article							NF1 GENE; SUPPRESSOR GENE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; CELLS; MUTATIONS; DELETIONS; SCHWANN; PRODUCT; ALLELES; CANCER	Neurofibromatosis type 1 (NF1) is a prevalent familiar cancer syndrome resulting from germ Line mutations in the NF1 tumor suppressor gene. Hallmark features of the disease are the development of benign peripheral nerve sheath tumors (neurofibromas), which can progress to malignancy. Unlike humans, mice that are heterozygous for a mutation in Nf1 do not develop neurofibromas. However, as described here, chimeric mice composed in part of Nf1(-/-) cells do, which demonstrates that loss of the wild-type Nf1 allele is rate-limiting in tumor formation. In addition, mice that carry Linked germ line mutations in Nf1 and p53 develop malignant peripheral nerve sheath tumors (MPNSTs), which supports a cooperative and causal role for p53 mutations in MPNST development. These two mouse models provide the means to address fundamental aspects of disease development and to test: therapeutic strategies.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Merck & Co Inc, Whitehouse Stn, NJ 08889 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Merck & Company; Baylor College of Medicine; Harvard University; Brigham & Women's Hospital; Tufts University; Tufts University	Jacks, T (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tjacks@mit.edu	Reilly, Karlyne/V-4475-2019	Reilly, Karlyne/0000-0001-9109-4409				[Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BADER JL, 1986, ANN NY ACAD SCI, V486, P57, DOI 10.1111/j.1749-6632.1986.tb48062.x; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCHBERG AM, 1992, MAMM GENOME, V3, pS162, DOI 10.1007/BF00648429; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; COLMAN SD, 1995, NAT GENET, V11, P90, DOI 10.1038/ng0995-90; Daschner K, 1997, BIOCHEM BIOPH RES CO, V234, P346, DOI 10.1006/bbrc.1997.6645; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; FRIEDRICH G, 1993, METHOD ENZYMOL, V225, P681; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guha A, 1996, ONCOGENE, V12, P507; Gutmann DH, 1995, PROG BRAIN RES, V105, P327; Hope D G, 1981, Adv Neurol, V29, P33; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LOTHE RA, 1995, J NEUROPATH EXP NEUR, V54, P65, DOI 10.1097/00005072-199501000-00008; LUONGO C, 1994, CANCER RES, V54, P5947; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; Riccardi V. M., 1992, NEUROFIBROMATOSIS PH; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Sawada S, 1996, NAT GENET, V14, P110, DOI 10.1038/ng0996-110; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; STARK M, 1995, HUM GENET, V96, P619; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WICK MR, 1987, AM J CLIN PATHOL, V87, P425, DOI 10.1093/ajcp/87.4.425; WOODRUFF JM, 1996, SOFT TISSUE TUMORS; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	42	321	328	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2172	2176		10.1126/science.286.5447.2172	http://dx.doi.org/10.1126/science.286.5447.2172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591652				2022-12-01	WOS:000084157300057
J	Randolph, DA; Huang, GM; Carruthers, CJL; Bromley, LE; Chaplin, DD				Randolph, DA; Huang, GM; Carruthers, CJL; Bromley, LE; Chaplin, DD			The role of CCR7 in T(H)1 and T(H)2 cell localization and delivery of B cell help in vivo	SCIENCE			English	Article							INDUCER LYMPHOCYTES-T; CHEMOKINE RECEPTOR; LYMPHOID-TISSUES; PERTUSSIS TOXIN; DENDRITIC CELLS; EXPRESSION; MIGRATION; RESPONSES; SUBSETS; CLONES	Subsets of murine CD4(+) T cells Localize to different areas of the spleen after adoptive transfer. Naive and T helper 1 (T(H)1) cells, which express the chemokine receptor CCR7, are home to the periarteriolar Lymphoid sheath, whereas activated T(H)2 cells, which lack CCR7, form rings at the periphery of the T cell zones near B cell follicles. Retroviral transduction of T(H)2 cells with CCR7 forces them to localize in a T(H)1-like pattern and inhibits their participation in B cell help in vivo but not in vitro. Thus, differential expression of chemokine receptors results in unique cellular migration patterns that are important for effective Immune responses.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Chaplin, DD (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.			Chaplin, David/0000-0002-1354-3069	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034580, U01AI034580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34580] Funding Source: Medline; NIGMS NIH HHS [T32 GM07200] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas A K, 1993, Semin Immunol, V5, P441, DOI 10.1006/smim.1993.1050; ABBAS AK, 1990, J IMMUNOL, V144, P2031; Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; DELPRETE GF, 1991, J EXP MED, V174, P809, DOI 10.1084/jem.174.4.809; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KILLAR L, 1987, J IMMUNOL, V138, P1674; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; MacLennan ICM, 1997, IMMUNOL REV, V156, P53, DOI 10.1111/j.1600-065X.1997.tb00958.x; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; PABST R, 1991, SCANNING MICROSCOPY, V5, P1075; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Pulendran B, 1997, J IMMUNOL, V159, P2222; RANDOLPH D, UNPUB; Randolph DA, 1999, J IMMUNOL, V162, P2375; Ranganath S, 1998, J IMMUNOL, V161, P3822; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Soto H, 1998, P NATL ACAD SCI USA, V95, P8205, DOI 10.1073/pnas.95.14.8205; SPANGRUDE GJ, 1985, J IMMUNOL, V135, P4135; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; van den Eertwegh A J, 1994, Semin Immunol, V6, P327, DOI 10.1006/smim.1994.1041; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; WILLFUHR KU, 1990, EUR J IMMUNOL, V20, P903, DOI 10.1002/eji.1830200428; Willimann K, 1998, EUR J IMMUNOL, V28, P2025, DOI 10.1002/(SICI)1521-4141(199806)28:06<2025::AID-IMMU2025>3.0.CO;2-C; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	40	153	160	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2159	2162		10.1126/science.286.5447.2159	http://dx.doi.org/10.1126/science.286.5447.2159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591648				2022-12-01	WOS:000084157300053
J	White, KP; Rifkin, SA; Hurban, P; Hogness, DS				White, KP; Rifkin, SA; Hurban, P; Hogness, DS			Microarray analysis of Drosophila development during metamorphosis	SCIENCE			English	Article							STEROID-RECEPTOR SUPERFAMILY; GENE-EXPRESSION PATTERNS; ECDYSONE-INDUCIBLE GENE; CELL-DEATH; MOLECULAR CHARACTERIZATION; TYROSINE PHOSPHATASE; DNA MICROARRAY; EARLY PUFF; ENCODES 2; MELANOGASTER	Metamorphosis is an integrated set of developmental processes controlled by a transcriptional hierarchy that coordinates the action of hundreds of genes. In order to identify and analyze the expression of these genes, high-density DNA microarrays containing several thousand Drosophila melanogaster gene sequences were constructed. Many differentially expressed genes can be assigned to developmental pathways known to be active during metamorphosis, whereas others can be assigned to pathways not previously associated with metamorphosis. Additionally, many genes of unknown function were identified that may be involved in the control and execution of metamorphosis. The utility of this genome-based approach is demonstrated for studying a set of complex biological processes in a multicellular organism.	Stanford Univ, Sch Med, Beckman Ctr B300, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University	White, KP (corresponding author), Stanford Univ, Med Ctr, Beckman Ctr B400, Dept Biochem, Stanford, CA 94305 USA.			Rifkin, Scott/0000-0001-8476-3256				Allard JD, 1996, DEVELOPMENT, V122, P1137; Artero R, 1998, DEV BIOL, V195, P131, DOI 10.1006/dbio.1997.8833; Ashburner M, 1999, GENETICS, V153, P179; BARNETT SW, 1990, DEV BIOL, V140, P362, DOI 10.1016/0012-1606(90)90086-X; BARTHALAY Y, 1990, EMBO J, V9, P3603, DOI 10.1002/j.1460-2075.1990.tb07571.x; BATE M, 1993, DEV DROSOPHILA METAN, V2, P1013; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; BODMER R, 1993, DEVELOPMENT, V118, P719; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; DELAESCALERA S, 1990, EMBO J, V9, P3593, DOI 10.1002/j.1460-2075.1990.tb07570.x; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FINELLI L, 1995, GENETICS, V141, P271; Fristrom D., 1993, DEV DROSOPHILA MELAN, P843; GARBE JC, 1993, DEVELOPMENT, V119, P1237; GUILD GM, 1984, J MOL BIOL, V179, P289, DOI 10.1016/0022-2836(84)90067-6; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jiang CG, 1997, DEVELOPMENT, V124, P4673; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Lam GT, 1997, DEVELOPMENT, V124, P1757; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; MARONI G, 1983, DROS INFORM SERV, V59, P142; MEYEROWITZ EM, 1987, TRENDS GENET, V3, P288, DOI 10.1016/0168-9525(87)90270-8; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; MURTHA MT, 1989, DEV BIOL, V135, P66, DOI 10.1016/0012-1606(89)90158-9; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OHTA K, 1995, NEURON, V14, P1189, DOI 10.1016/0896-6273(95)90266-X; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Riddiford L., 1993, DEV DROSOPHILA MELAN, V2, P899; Robertson CW, 1936, J MORPHOL, V59, P351, DOI 10.1002/jmor.1050590207; ROGULSKI KR, 1995, J MOL BIOL, V249, P298, DOI 10.1006/jmbi.1995.0298; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Speicher S, 1998, NEURON, V20, P221, DOI 10.1016/S0896-6273(00)80451-1; STRYER L, 1988, BIOCHEMISTRY; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; Truman James W., 1993, P1245; WALLRATH LL, 1990, MOL CELL BIOL, V10, P5114, DOI 10.1128/MCB.10.10.5114; Weaver TA, 1995, DEVELOPMENT, V121, P4149; WHITE K, UNPUB; White KP, 1997, SCIENCE, V276, P114, DOI 10.1126/science.276.5309.114; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0; Wright LG, 1996, J MOL BIOL, V255, P387, DOI 10.1006/jmbi.1996.0032	54	350	362	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2179	2184		10.1126/science.286.5447.2179	http://dx.doi.org/10.1126/science.286.5447.2179			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591654				2022-12-01	WOS:000084157300059
J	Brahams, D				Brahams, D			End of compensation for unwanted healthy children	LANCET			English	Editorial Material									Old Sq Chambers, London WC1R 5LQ, England		Brahams, D (corresponding author), Old Sq Chambers, London WC1R 5LQ, England.							JOHNSTONE H, 1999, TIMES           1126; 1999, TIMES           1126	2	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 4	1999	354	9194					1924	1924		10.1016/S0140-6736(99)00434-1	http://dx.doi.org/10.1016/S0140-6736(99)00434-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622293				2022-12-01	WOS:000084034700007
J	Mangus, RS; Dipiero, A; Hawkins, CE				Mangus, RS; Dipiero, A; Hawkins, CE			Medical students' attitudes toward physician-assisted suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EUTHANASIA	Context In November 1994, Oregon became the first US state to legalize physician-assisted suicide (PAS) as an option for end-of-life care. Objective This study compares the attitudes and experiences of medical students in Oregon regarding PAS to those of fourth-year medical students in the United States outside Oregon. Design A survey of all students at the Oregon Health Sciences University and fourth-year medical students at 3 non-Oregonian US medical schools. Participants Oregon medical students returned 227 questionnaires (58%), and 113 were returned from control schools (33%). Results A similar percentage of both study groups favored the legalization of PAS (64% vs 66%; P=.74). If the practice were legal, 55% of the total surveyed reported they "might be willing to write a lethal prescription," (50% Oregon students vs 60% control; P=.13 and 44% fourth-year Oregon students vs 60% control; P=.04). Among fourth-year students, 20% reported a request by a patient to the student or a preceptor for a lethal prescription in the past year (26% vs 16%; P=.09). Conclusions This study demonstrates support for and willingness by many medical students to participate in PAS. Some medical students reported observation of PAS during their training experience. Fourth-year Oregon students reported significantly less willingness than other students to provide a patient with a lethal prescription, perhaps indicating hesitancy to include PAS in clinical practice.	Oregon Hlth Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	Mangus, RS (corresponding author), Oregon Hlth Sci Univ, Portland, OR 97201 USA.		Mangus, Richard S/M-1446-2018	Mangus, Richard S/0000-0003-4300-2594				Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Muller MT, 1996, MED EDUC, V30, P428, DOI 10.1111/j.1365-2923.1996.tb00863.x; *MULTN COUNT EL DI, 1994, OR VOT PAMPHL BALL M, V16; Skolnick AA, 1997, JAMA-J AM MED ASSOC, V278, P967, DOI 10.1001/jama.278.12.967; Steinberg MA, 1997, MED J AUSTRALIA, V166, P131, DOI 10.5694/j.1326-5377.1997.tb140042.x; Verhoef MJ, 1996, CAN MED ASSOC J, V155, P885	10	20	22	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2080	2081		10.1001/jama.282.21.2080	http://dx.doi.org/10.1001/jama.282.21.2080			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	259TB	10591396	hybrid			2022-12-01	WOS:000083908700033
J	Wilson, D; Cawthorne, P; Ford, N; Aongsonwang, S				Wilson, D; Cawthorne, P; Ford, N; Aongsonwang, S			Global trade and access to medicines: AIDS treatments in Thailand	LANCET			English	Editorial Material									Med Sans Frontieres, Bangkok 10240, Thailand		Wilson, D (corresponding author), Med Sans Frontieres, 311 Ladprao 101, Bangkok 10240, Thailand.							AONGSONWANG S, 1999, NGO M COMP LIC ESS M; Correa CM, 1997, URUGUAY ROUND DRUGS; *EC INT UN, 1999, THAIL COUNTR REP; Hemachudha T, 1999, CLIN INFECT DIS, V28, P143, DOI 10.1086/517179; KUNANUSONT C, 1996, HIV AIDS THAILAND 19, P82; LOMAR A, 1999, CUSTOS DIRECTOS TRAT; McGregor A, 1999, LANCET, V353, P1165, DOI 10.1016/S0140-6736(05)74394-4; *SAT S 21, 1995, P 3 INT C AIDS AS PA, P88; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; Suwanjandee J, 1999, LANCET, V354, P343, DOI 10.1016/S0140-6736(05)75255-7; *THAI FDA, 1995, THAI DRUG SYST SIT A; *THAI MIN PUBL HLT, 1997, GUID CLIN MAN HIV IN; UNDP, 1995, HUMAN DEV REPORT 199; *WHO, 1997, WHODAP989 TRIPS; World Health Organization, 1999, 52 WORLD HLTH ASS 52 WORLD HLTH ASS	16	20	20	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1893	1895		10.1016/S0140-6736(99)06114-0	http://dx.doi.org/10.1016/S0140-6736(99)06114-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584741				2022-12-01	WOS:000083909100043
J	Ross-Macdonald, P; Coelho, PSR; Roemer, T; Agarwal, S; Kumar, A; Jansen, R; Cheung, KH; Sheehan, A; Symoniatis, D; Umansky, L; Heldtman, M; Nelson, FK; Iwasaki, H; Hager, K; Gerstein, M; Miller, P; Roeder, GS; Snyder, M				Ross-Macdonald, P; Coelho, PSR; Roemer, T; Agarwal, S; Kumar, A; Jansen, R; Cheung, KH; Sheehan, A; Symoniatis, D; Umansky, L; Heldtman, M; Nelson, FK; Iwasaki, H; Hager, K; Gerstein, M; Miller, P; Roeder, GS; Snyder, M			Large-scale analysis of the yeast genome by transposon tagging and gene disruption	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN LOCALIZATION; EXPRESSION; RECOMBINATION; BINDS	Economical methods by which gene function maybe analysed on a genomic scale are relatively scarce. To fill this need, we have developed a transposon-tagging strategy for the genome-wide analysis of disruption phenotypes, gene expression and protein localization, and have applied this method to the large-scale analysis of gene function in the budding yeast Saccharomyces cerevisiae. Here we present the largest collection of defined yeast mutants ever generated within a single genetic background-a collection of over 11,000 strains, each carrying a transposon inserted within a region of the genome expressed during vegetative growth and/or sporulation. These insertions affect nearly 2,000 annotated genes, representing about one-third of the 6,200 predicted genes in the yeast genome(1,2). We have used this collection to determine disruption phenotypes for nearly 8,000 strains using 20 different growth conditions; the resulting data sets were clustered to identify groups of functionally related genes. We have also identified over 300 previously non-annotated open reading frames and analysed by indirect immunofluorescence over 1,300 transposon-tagged proteins. In total, our study encompasses over 260,000 data points, constituting the largest functional analysis of the yeast genome ever undertaken.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Anesthesiol, Ctr Med Informat, New Haven, CT 06510 USA; Yale Univ, Keck Fdn, Biotechnol Resource Lab, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Snyder, M (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, POB 208103, New Haven, CT 06520 USA.			Kumar, Anuj/0000-0002-8923-297X; Snyder, Michael/0000-0003-0784-7987				Adams A, 1997, METHODS YEAST GENETI; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; Evangelista CC, 1996, GENETICS, V142, P1083; Feisenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; Kaufman L, 2009, FINDING GROUPS DATA; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LODI T, 1995, MICROBIOL-SGM, V141, P2201, DOI 10.1099/13500872-141-9-2201; Lussier M, 1997, GENETICS, V147, P435; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; PAGE BD, 1992, GENE DEV, V6, P1414, DOI 10.1101/gad.6.8.1414; RossMacdonald P, 1995, METHOD MOL CELL BIOL, V5, P298; RossMacdonald P, 1997, P NATL ACAD SCI USA, V94, P190, DOI 10.1073/pnas.94.1.190; Sambrook J., 1989, MOL CLONING LAB MANU; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; STEARNS T, 1990, GENETICS, V124, P251; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; White WH, 1997, GENETICS, V147, P43	30	403	430	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					413	418		10.1038/46558	http://dx.doi.org/10.1038/46558			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586881				2022-12-01	WOS:000083913600057
J	Li, LM; Lindquist, S				Li, LM; Lindquist, S			Creating a protein-based element of inheritance	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PRION-LIKE FACTOR; SUP35 GENE; GLUCOCORTICOID RECEPTOR; PSI; PROPAGATION; DETERMINANT; TRANSLATION; TERMINATION; URE3	Proteins capable of self-perpetuating changes in conformation and function (known as prions) can serve as genetic elements. To test whether novel prions could be created by recombinant methods, a yeast prion determinant was fused to the rat glucocorticoid receptor. The fusion protein existed in different heritable functional states, switched between states at a Low spontaneous rate, and could be induced to switch by experimental manipulations. The complete change in phenotype achieved by transferring a prion determinant from one protein to another confirms the protein-only nature of prion inheritance and establishes a mechanism for engineering heritable changes in phenotype that should be broadly applicable.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Lindquist, S (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave MC 1028, Chicago, IL 60637 USA.							CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Derkatch IL, 1996, GENETICS, V144, P1375; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; Liu J., UNPUB; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; PATINO M, UNPUB; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; TUITE MF, 1981, GENETICS, V98, P691; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	23	146	151	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	2000	287	5453					661	664		10.1126/science.287.5453.661	http://dx.doi.org/10.1126/science.287.5453.661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10650001				2022-12-01	WOS:000084989400050
J	Espinal, RA; Perez, EN; Baez, J; Henriquez, L; Fernandez, K; Lopez, M; Olivo, P; Reingold, AL				Espinal, RA; Perez, EN; Baez, J; Henriquez, L; Fernandez, K; Lopez, M; Olivo, P; Reingold, AL			Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: a prospective study	LANCET			English	Article							PULMONARY TUBERCULOSIS; IMMUNODEFICIENCY; HIV	Background Previous studies concerning the relative infectiousness of HIV-1-positive individuals with pulmonary tuberculosis have produced conflicting results, Thus, we assessed the effect of HIV-1 on the infectiousness of Mycobacterium tuberculosis in a prospective study. Methods We organised in Santo Domingo, Dominican Republic, a cohort study of household contacts of HIV-1-positive and HIV-1-negative individuals with newly diagnosed pulmonary tuberculosis. Household contacts were assessed at their houses at baseline and followed up for 14 months for evidence of M tuberculosis infection and tuberculosis with a multi-step tuberculin skin test, anergy skin test, physical examinations, chest radiographs, and sputum smears. Findings Tuberculin induration of 5 mm or greater was seen in 153 (61%) of 252 household contacts of HIV-1-positive index cases and in 418 (76%) of 551 household contacts of HIV-1-negative index cases (odds ratio 0.49 [95% CI 0.35-0.67], p=0.00001). In multivariate logistic-regression analysis after allowance for between-household variation in tuberculin response, HIV-1 infection of the index case remained inversely associated with the tuberculin response of the household contacts (0.52 [0.29-0.93], p=0.02). When the analysis was restricted to household contacts aged between 2 years and 15 years the adjusted association remained significant (0.37 [0.14-0.98], p=0.04). Among household contacts who had a negative tuberculin skin test at baseline, conversion to tuberculin skin test positivity was less frequent among household contacts of HIV-1-posilive index cases (cut-off greater than or equal to 5 mm: 32/131 [24%] vs 71/204 [35%], p=0.05; cut-off greater than or equal to 10 mm: 23/153 [15%] vs 55/245 [22%0], p=0.07). Interpretation These data suggest that HIV-1-positive individuals with tuberculosis are less likely than HIV-1-negative individuals with tuberculosis to transmit M tuberculosis to their close contacts. No changes in the current policy regarding tuberculosis contact tracing are needed in the presence of HIV-1.	Natl Ctr Res Maternal & Child Hlth, Santo Domingo, Dominican Rep; Antituberculosis Dispensary, Santo Domingo, Dominican Rep; Padre Billini Hosp, Santo Domingo, Dominican Rep; Francisco Moscoso Puello Hosp, Santo Domingo, Dominican Rep; Univ Calif Berkeley, Sch Publ Hlth, Div Publ Hlth Biol & Epidemiol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Espinal, RA (corresponding author), WHO Communicable Dis Surveillance & Response, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	espinalm@who.ch		Perez-Then, Eddy/0000-0001-7724-0668	FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW00003] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		*AM THOR SOC, 1981, AM REV RESPIR DIS, V124, P356; CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; Cayla J, 1993, 9 INT C AIDS BERL GE; ELLIOTT AM, 1993, AIDS, V7, P981, DOI 10.1097/00002030-199307000-00012; Espinal M, 1994, Bol Oficina Sanit Panam, V116, P452; Espinal MA, 1996, J ACQ IMMUN DEF SYND, V13, P155, DOI 10.1097/00042560-199610010-00006; GAUTHEN GM, 1996, AM J EPIDEMIOL, V144, P69; GUWATUDDE D, 1998, 12 INT C AIDS GEN SW, P138; HUEBNER RE, 1994, CLIN INFECT DIS, V19, P26, DOI 10.1093/clinids/19.1.26; KALENDE P, 1988, MED TROP, V48, P19; KLAUSNER JD, 1993, J INFECT DIS, V168, P106, DOI 10.1093/infdis/168.1.106; LOUDON RG, 1969, AM REV RESPIR DIS, V99, P109; MANFRIN V, 1993, 9 INT C AIDS BERL GE; NARAIN R, 1966, B WORLD HEALTH ORGAN, V34, P639; NUNN P, 1994, TUBERCLE LUNG DIS, V75, P25, DOI 10.1016/0962-8479(94)90098-1; ROUILLON A, 1976, TUBERCLE, V57, P275, DOI 10.1016/S0041-3879(76)80006-2; SHAW JB, 1954, AM REV TUBERC PULM, V69, P724; STANDAERT B, 1989, AIDS RES HUM RETROV, V5, P247, DOI 10.1089/aid.1989.5.247; Toman K, 1979, TUBERCULOSIS CASE FI, P65; *WHO, 1992, WKLY EPIDEMIOL REC, V67, P145; *WHO, 1991, WHO WORK GROUP M GEN	21	73	74	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2000	355	9200					275	280		10.1016/S0140-6736(99)04402-5	http://dx.doi.org/10.1016/S0140-6736(99)04402-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675075				2022-12-01	WOS:000085045600011
J	Smith, GN; Kingdom, JC; Penning, DH; Matthews, SG				Smith, GN; Kingdom, JC; Penning, DH; Matthews, SG			Antenatal corticosteroids: is more better?	LANCET			English	Editorial Material							BRAIN; GROWTH; GLUCOCORTICOIDS; DEXAMETHASONE; BETAMETHASONE; SINGLE		Queens Univ, Dept Obstet & Gynaecol, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Anat, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Cell Biol, Kingston, ON K7L 2V7, Canada; Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Duke Univ, Dept Anaesthesia, Durham, NC 27706 USA	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; University of Toronto; University of Toronto; Duke University	Smith, GN (corresponding author), Queens Univ, Dept Obstet & Gynaecol, Kingston, ON K7L 2V7, Canada.		Kingdom, John/A-3247-2013; Smith, Graeme Neil/ABB-6863-2021; Matthews, Stephen/R-5147-2019; Matthews, Stephen G/N-7555-2018; Kingdom, John/AAF-2145-2020	Smith, Graeme Neil/0000-0002-3128-4523; Matthews, Stephen/0000-0002-9654-9940; Matthews, Stephen G/0000-0002-9654-9940; Penning, Donald/0000-0001-7010-2430				Banks BA, 1999, AM J OBSTET GYNECOL, V181, P709, DOI 10.1016/S0002-9378(99)70517-X; Baud O, 1999, NEW ENGL J MED, V341, P1190, DOI 10.1056/NEJM199910143411604; Brocklehurst P, 1999, BRIT J OBSTET GYNAEC, V106, P977, DOI 10.1111/j.1471-0528.1999.tb08440.x; CROWLEY P, 1999, COCHRANE LIB; Dean F, 1999, BRAIN RES, V846, P253, DOI 10.1016/S0006-8993(99)02064-8; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; French NP, 1999, AM J OBSTET GYNECOL, V180, P114, DOI 10.1016/S0002-9378(99)70160-2; Huang WL, 1999, OBSTET GYNECOL, V94, P213, DOI 10.1016/S0029-7844(99)00265-3; Ikegami M, 1997, AM J RESP CRIT CARE, V156, P178, DOI 10.1164/ajrccm.156.1.9612036; Jobe AH, 1998, AM J OBSTET GYNECOL, V178, P880, DOI 10.1016/S0002-9378(98)70518-6; Levitt NS, 1996, NEUROENDOCRINOLOGY, V64, P412, DOI 10.1159/000127146; LIGGINS GC, 1969, J ENDOCRINOL, V45, P515, DOI 10.1677/joe.0.0450515; MACARTHUR BA, 1982, PEDIATRICS, V70, P99; Matthews SG, 1998, DEV BRAIN RES, V107, P123, DOI 10.1016/S0165-3806(98)00008-X; Pratt L, 1999, AM J OBSTET GYNECOL, V180, P995, DOI 10.1016/S0002-9378(99)70672-1; Quinlivan JA, 1999, PRENAT NEONAT MED, V4, P47; Stewart JD, 1998, AM J OBSTET GYNECOL, V179, P1241, DOI 10.1016/S0002-9378(98)70140-1; UNO H, 1990, DEV BRAIN RES, V53, P157, DOI 10.1016/0165-3806(90)90002-G; UNO H, 1994, HORM BEHAV, V28, P336, DOI 10.1006/hbeh.1994.1030	19	38	39	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					251	252		10.1016/S0140-6736(99)00448-1	http://dx.doi.org/10.1016/S0140-6736(99)00448-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675070				2022-12-01	WOS:000085045600006
J	Majeed, A; Lehmann, P; Kirby, L; Knight, R; Coleman, M				Majeed, A; Lehmann, P; Kirby, L; Knight, R; Coleman, M			Extent of misclassification of death from Creutzfeldt-Jakob disease in England 1979-96: retrospective examination of clinical records	BRITISH MEDICAL JOURNAL			English	Article							PRION DISEASE; VARIANT; WALES	Objective To investigate the extent to which deaths from Creutzfeldt-Jakob,disease were misclassified during 1979-96. Design Structured review of clinical records based on predetermined criteria to determine whether death could have been due to sporadic or variant Creutzfeldt-Jakob disease. Setting 100 health authorities and 275 NHS trusts in England. Subjects 1485 people who died aged 15-44 years from selected neurological disorders in England during 1979-96. Main outcome measure Cause of death. Results The clinical records of 705 (48%) subjects were successfully traced. Tracing of clinical records was highest in subjects who died during 1990-6. There was sufficient information in the records of 640 (91%) of the 705 subjects to exclude Creutzfeldt-Jakob disease as a cause of death. In 61 (9%) subjects, there was insufficient information to reach any conclusion about the validity of the cause of death recorded on the death certificate. The clinical records of four subjects were examined further by the National Creutzfeldt-Jakob Disease Surveillance Unit; none was thought to have died from Creutzfeldt-Jakob disease. Conclusions No new cases of sporadic or variant Creutzfeldt-Jakob disease were detected in a sample of deaths most likely to have included misclassified cases. This suggests that the surveillance system is unlikely to have missed a significant number of cases among people aged 15-44 years. Hence, any rapid increase in the number of cases of variant Creutzfeldt-Jakob disease in this age group is likely to be real not artefactual.	Off Natl Stat, London SW1V 2QQ, England; Western Gen Hosp, Natl Creutzfeldt Jakob Dis Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of Edinburgh; University of London; London School of Hygiene & Tropical Medicine	Majeed, A (corresponding author), Off Natl Stat, London SW1V 2QQ, England.		Greiver, Michelle/N-8764-2015; Coleman, Michel/AAA-9543-2020	Greiver, Michelle/0000-0001-8957-0285; Coleman, Michel/0000-0001-8940-3807; Majeed, Azeem/0000-0002-2357-9858				AYLIN P, 1996, POPUL TRENDS, V85, P34; Baker HF, 1996, BRAIN RES BULL, V40, P237, DOI 10.1016/0361-9230(96)00162-1; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Collinge J, 1996, LANCET, V347, P916, DOI 10.1016/S0140-6736(96)91407-5; Cousens SN, 1997, BRIT MED J, V315, P389, DOI 10.1136/bmj.315.7105.389; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; Kirby L., 1998, POPULATION TRENDS, V92, P23; Majeed A, 1998, BRIT MED J, V317, P320, DOI 10.1136/bmj.317.7154.320; SOUTHWOOD R, 1989, REPORT WORKING PARTY; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134; Will RG, 1999, LANCET, V353, P979, DOI 10.1016/S0140-6736(99)01160-5	12	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	2000	320	7228					145	147		10.1136/bmj.320.7228.145	http://dx.doi.org/10.1136/bmj.320.7228.145			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276DL	10634732	Green Published, Green Submitted			2022-12-01	WOS:000084860300022
J	Ahmed, S; Hodgkin, J				Ahmed, S; Hodgkin, J			MRT-2 checkpoint protein is required for germline immortality and telomere replication in C-elegans	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE RAD1(+); DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; ATAXIA-TELANGIECTASIA; YEAST TELOMERE; FISSION YEAST; MAINTENANCE; HOMOLOG; LENGTH	The germ line is an immortal cell lineage that is passed indefinitely from one generation to the next. To identify the genes that are required for germline immortality, we isolated Caenorhabditis elegans mutants with mortal germ lines-worms that can reproduce for several healthy generations but eventually become sterile. One of these mortal germline (mrt) mutants, mrt-2, exhibits progressive telomere shortening and accumulates end-to-end chromosome fusions in later generations, indicating that the MRT-2 protein is required for telomere replication. In addition, the germ line of mrt-2 is hypersensitive to X-rays and to transposon activity. Therefore, mrt-2 has defects in responding both to damaged DNA and to normal double-strand breaks present at telomeres. mrt-2 encodes a homologue of a checkpoint gene that is required to sense DMA damage in yeast. These results indicate that telomeres may be identified as a type of DNA damage and then repaired by the telomere-replication enzyme telomerase.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Ahmed, S (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							Albertson DG, 1993, CHROMOSOME RES, V1, P15, DOI 10.1007/BF00710603; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; Anderson P, 1995, METHOD CELL BIOL, V48, P31; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bluyssen HAR, 1998, GENOMICS, V54, P331, DOI 10.1006/geno.1998.5582; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Dahlen M, 1998, MOL BIOL CELL, V9, P611, DOI 10.1091/mbc.9.3.611; Dean FB, 1998, GENOMICS, V54, P424, DOI 10.1006/geno.1998.5587; di Fagagna FD, 1999, NAT GENET, V23, P76; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FANG GW, 1995, J CELL BIOL, V130, P243, DOI 10.1083/jcb.130.2.243; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HENDERSON E, 1995, TELOMERES, P35; HERMAN RK, 1982, GENETICS, V102, P379; Hodgkin J, 1997, GENETICS, V146, P149; HODGKIN J, 1979, GENETICS, V91, P67; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Marathi UK, 1998, GENOMICS, V54, P344, DOI 10.1006/geno.1998.5589; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Matsuura A, 1999, GENETICS, V152, P1501; McClintock B, 1941, GENETICS, V26, P234; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PLASTERK RHA, 1997, TRANSPORSONS C ELEGA, V2, P97; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Sprung CN, 1997, MUTAT RES-FUND MOL M, V379, P177, DOI 10.1016/S0027-5107(97)00119-X; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; WEINERT TA, 1993, GENETICS, V134, P63; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wicky C, 1996, P NATL ACAD SCI USA, V93, P8983, DOI 10.1073/pnas.93.17.8983; Wylie C, 1999, CELL, V96, P165, DOI 10.1016/S0092-8674(00)80557-7	50	211	215	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					159	164		10.1038/35003120	http://dx.doi.org/10.1038/35003120			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646593				2022-12-01	WOS:000084835300044
J	Jones, TF; Craig, AS; Hoy, D; Gunter, EW; Ashley, DL; Barr, DB; Brock, JW; Schaffner, W				Jones, TF; Craig, AS; Hoy, D; Gunter, EW; Ashley, DL; Barr, DB; Brock, JW; Schaffner, W			Mass psychogenic illness attributed to toxic exposure at a high school	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	37th Annual Meeting of the Infectious-Diseases-Society-of-America	NOV 18-21, 1999	PHILADELPHIA, PENNSYLVANIA	Infect Dis Soc Amer			EPIDEMIC HYSTERIA; ELEMENTARY-SCHOOL	Background: Mass psychogenic illness may be difficult to differentiate from illness caused by bioterrorism, rapidly spreading infection, or toxic substances. We investigated symptoms attributed to exposure to toxic gas at a high school in Tennessee. Methods: In November 1998, a teacher noticed a "gasoline-like'' smell in her classroom, and soon thereafter she had a headache, nausea, shortness of breath, and dizziness. The school was evacuated, and 80 students and 19 staff members went to the emergency room at the local hospital; 38 persons were hospitalized overnight. Five days later, after the school had reopened, another 71 persons went to the emergency room. An extensive investigation was performed by several government agencies. Results: We were unable to find a medical or environmental explanation for the reported illnesses. The persons who reported symptoms on the first day came from 36 classrooms scattered throughout the school. The most frequent symptoms (in this group and the group of people who reported symptoms five days later) were headache, dizziness, nausea, and drowsiness. Blood and urine specimens showed no evidence of carbon monoxide, volatile organic compounds, pesticides, polychlorinated biphenyls, paraquat, or mercury. There was no evidence of toxic compounds in the environment. A questionnaire administered a month later showed that the reported symptoms were significantly associated with female sex, seeing another ill person, knowing that a classmate was ill, and reporting an unusual odor at the school. Conclusions: This illness, attributed to toxic exposure, had features of mass psychogenic illness - notably, widespread subjective symptoms thought to be associated with environmental exposure to a toxic substance in the absence of objective evidence of an environmental cause. (N Engl J Med 2000;342:96-100.) (C) 2000, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA; Ctr Dis Control & Prevent, Environm Hlth Labs, Natl Ctr Environm Hlth, Atlanta, GA USA; Tennessee Dept Hlth, CEDS, Nashville, TN 37247 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; Tennessee Dept Hlth, Cookeville, TN USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Tennessee Department Health; Vanderbilt University; Tennessee Department Health	Jones, TF (corresponding author), Tennessee Dept Hlth, CEDS, 4th Fl,Cordell Hull Bldg,425 5th Ave N, Nashville, TN 37247 USA.		Barr, Dana B/E-6369-2011; Barr, Dana B/E-2276-2013					ALEXANDER RW, 1986, J OCCUP ENVIRON MED, V28, P42, DOI 10.1097/00043764-198601000-00011; ARAKI S, 1986, ARCH ENVIRON HEALTH, V41, P159, DOI 10.1080/00039896.1986.9935771; Boss LP, 1997, EPIDEMIOL REV, V19, P233, DOI 10.1093/oxfordjournals.epirev.a017955; CARTTER ML, 1989, AM J DIS CHILD, V143, P269, DOI 10.1001/archpedi.1989.02150150019001; *CTR ENV RES INF, 1999, COMP METH DET TOX OR; DAVID AS, 1995, J PSYCHOSOM RES, V39, P1, DOI 10.1016/0022-3999(94)00085-J; Dean A.G., 1994, EPI INFO VERSION 6 W; DICKER RC, 1996, FIELD EPIDEMIOLOGY, P92; HEFEZ A, 1985, AM J PSYCHIAT, V142, P833; LANDRIGAN PJ, 1983, LANCET, V2, P1474; Nitzkin J L, 1976, J Fla Med Assoc, V63, P357; *OFF SOL WAST EM R, 1986, SW846 EPA OFF SOL WA; PHILEN RM, 1989, LANCET, V2, P1372; ROBINSON P, 1984, ARCH INTERN MED, V144, P1959, DOI 10.1001/archinte.144.10.1959; SANDY, 1991, MED DETECTIVES, P317; SELDEN BS, 1989, ANN EMERG MED, V18, P892, DOI 10.1016/S0196-0644(89)80221-5; Small G W, 1994, Arch Fam Med, V3, P711, DOI 10.1001/archfami.3.8.711; WASON S, 1983, LANCET, V2, P731	18	94	100	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2000	342	2					96	100		10.1056/NEJM200001133420206	http://dx.doi.org/10.1056/NEJM200001133420206			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273TQ	10631279				2022-12-01	WOS:000084723900006
J	Schroeder, BC; Waldegger, S; Fehr, S; Bleich, M; Warth, R; Greger, R; Jentsch, TJ				Schroeder, BC; Waldegger, S; Fehr, S; Bleich, M; Warth, R; Greger, R; Jentsch, TJ			A constitutively open potassium channel formed by KCNQ1 and KCNE3	NATURE			English	Article							INHERITED CARDIAC-ARRHYTHMIAS; LONG QT SYNDROME; K+ CONDUCTANCE; CL SECRETION; RABBIT COLON; MUTATIONS; KVLQT1; GENE; CELLS; EPITHELIA	Mutations in all four known KCNQ potassium channel or-subunit genes lead to human diseases(1-6). KCNQ1 (KvLQT1)(1) interacts with the beta-subunit KCNE1 (IsK, minK)(7) to form the slow, depolarization-activated potassium current I-Ks(8,9) that is affected in some forms of cardiac arrhythmia. Here we show that the novel beta-subunit KCNE3 markedly changes KCNQ1 properties to yield currents that are nearly instantaneous and depend linearly on voltage, It also suppresses the currents of KCNQ4 and HERG potassium channels. In the intestine, KCNQ1 and KCNE3 messenger RNAs colocalized in crypt cells. This localization and the pharmacology, voltage-dependence and stimulation by cyclic AMP of KCNQ1/KCNE3 currents indicate that these proteins may assemble to form the potassium channel that is important for cyclic AMP-stimulated intestinal chloride secretion and that is involved in secretory diarrhoea and cystic fibrosis.	Univ Hamburg, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany; Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Freiburg	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Martinistr 85, D-20246 Hamburg, Germany.	Jentsch@plexus.uke.uni-hamburg.de	Bleich, Markus/A-2812-2010; Warth, Richard/N-7119-2014	Bleich, Markus/0000-0002-1745-2295; Warth, Richard/0000-0001-6084-0659; Jentsch, Thomas/0000-0002-3509-2553				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Busch AE, 1997, BRIT J PHARMACOL, V122, P187, DOI 10.1038/sj.bjp.0701434; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Devor DC, 1997, AM J PHYSIOL-CELL PH, V273, pC531, DOI 10.1152/ajpcell.1997.273.2.C531; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; Diener M, 1996, BRIT J PHARMACOL, V118, P1477, DOI 10.1111/j.1476-5381.1996.tb15563.x; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; LOHRMANN E, 1995, PFLUG ARCH EUR J PHY, V429, P517, DOI 10.1007/BF00704157; MacVinish LJ, 1998, J PHYSIOL-LONDON, V510, P237, DOI 10.1111/j.1469-7793.1998.237bz.x; Mall M, 1998, AM J PHYSIOL-GASTR L, V275, pG1274, DOI 10.1152/ajpgi.1998.275.6.G1274; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; OFFNER FF, 1987, HEARING RES, V29, P117, DOI 10.1016/0378-5955(87)90160-2; Rufo PA, 1997, J CLIN INVEST, V100, P3111, DOI 10.1172/JCI119866; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Suessbrich H, 1996, FEBS LETT, V396, P271, DOI 10.1016/0014-5793(96)01113-1; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Warth R, 1996, PFLUG ARCH EUR J PHY, V432, P81, DOI 10.1007/s004240050108; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	30	360	378	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2000	403	6766					196	199		10.1038/35003200	http://dx.doi.org/10.1038/35003200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646604				2022-12-01	WOS:000084835300055
J	Strahl, BD; Allis, CD				Strahl, BD; Allis, CD			The language of covalent histone modifications	NATURE			English	Article							MITOTIC CHROMOSOME CONDENSATION; CHROMATIN STRUCTURE; LYSINE RESIDUES; ACETYLATION; H3; PHOSPHORYLATION; NUCLEOSOME; H4; HETEROCHROMATIN; TRANSCRIPTION	Histone proteins and the nucleosomes they form with DNA are the fundamental building blocks of eukaryotic chromatin. A diverse array of post-translational modifications that often occur on tail domains of these proteins has been well documented. Although the function of these highly conserved modifications has remained elusive, converging biochemical and genetic evidence suggests functions in several chromatin-based processes. We propose that distinct histone modifications, on one or more tails, act sequentially or in combination to form a 'histone code' that is, read by other proteins to bring about distinct downstream events.	Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Allis, CD (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	allis@virginia.edu	Strahl, Brian/C-7601-2012	Strahl, Brian/0000-0002-4947-6259				ALLIS CD, 1985, P NATL ACAD SCI USA, V82, P8048, DOI 10.1073/pnas.82.23.8048; ANNUNZIATO AT, 1993, NUCLEUS, P31; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CLARK D, 1993, COLD SPRING HARB SYM, V58, P1; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; DeRubertis F, 1996, NATURE, V384, P589; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Jin Y, 1999, MOL CELL, V4, P129, DOI 10.1016/S1097-2765(00)80195-1; Kimura A, 1998, FEBS LETT, V431, P131, DOI 10.1016/S0014-5793(98)00752-2; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; LOIDL P, 1994, CHROMOSOMA, V103, P441; LOPEZRODAS G, 1993, FEBS LETT, V317, P175, DOI 10.1016/0014-5793(93)81271-Z; Lucchesi JC, 1998, CURR OPIN GENET DEV, V8, P179, DOI 10.1016/S0959-437X(98)80139-1; LUDUENA R F, 1992, Current Opinion in Cell Biology, V4, P53, DOI 10.1016/0955-0674(92)90058-K; Luduena RF, 1998, INT REV CYTOL, V178, P207; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mizzen C, 1998, COLD SPRING HARB SYM, V63, P469, DOI 10.1101/sqb.1998.63.469; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Roberts SM, 1997, GENETICS, V147, P451; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Sternglanz R, 1999, P NATL ACAD SCI USA, V96, P8807, DOI 10.1073/pnas.96.16.8807; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; TORDERA V, 1993, EXPERIENTIA, V49, P780, DOI 10.1007/BF01923548; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/0092-8674(93)90673-E; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; VANHOLDE KE, 1988, CHROMATIN, P111; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	69	6114	6407	12	791	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					41	45		10.1038/47412	http://dx.doi.org/10.1038/47412			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638745				2022-12-01	WOS:000084687400035
J	Rankin, JM; Spinelli, JJ; Carere, RG; Ricci, DR; Penn, IM; Hilton, JD; Henderson, MA; Hayden, RI; Buller, CE				Rankin, JM; Spinelli, JJ; Carere, RG; Ricci, DR; Penn, IM; Hilton, JD; Henderson, MA; Hayden, RI; Buller, CE			Improved clinical outcome after widespread use of coronary-artery stenting in Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WAVE MYOCARDIAL-INFARCTION; BALLOON ANGIOPLASTY; RANDOMIZED TRIAL; BYPASS-SURGERY; ADMINISTRATIVE DATA; COMORBIDITY INDEX; FOLLOW-UP; DISEASE; PLACEMENT; THROMBOLYSIS	Background: The introduction and refinement of coronary-artery stenting dramatically changed the practice of percutaneous coronary revascularization in the mid-1990s. We analyzed one-year follow-up data for all percutaneous coronary interventions performed in a large, unselected population in Canada to determine whether the use of coronary stenting has been associated with improved outcomes. Methods: Prospectively collected data on all percutaneous coronary interventions performed on residents of British Columbia, Canada, between April 1994 and June 1997 were linked to province-wide health care data bases to provide the date of the following end points: subsequent target-vessel revascularization, myocardial infarction, and death. Base-line characteristics and procedural variables were identified and Kaplan-Meier survival curves were generated for 9594 procedures divided into seven groups, one for each sequential half-year period. Results: The overall burden of coexisting illnesses remained stable throughout the study period. A large increase in the rate of coronary stenting (from 14.2 percent in the period from April to June 1994 to 58.7 percent in the period from January to June 1997) was associated with a significant reduction in the rate of adverse cardiac events at one year (from 28.8 percent to 22.8 percent; adjusted relative risk, 0.79; 95 percent confidence interval, 0.69 to 0.90; P<0.001). This reduction in adverse events was exclusively due to a large reduction in subsequent target-vessel revascularization (from 24.4 percent to 17.0 percent; adjusted relative risk, 0.72; 95 percent confidence interval, 0.62 to 0.83; P<0.001) without significant changes in the overall rates of myocardial infarction (5.4 percent, P=0.28) or death (3.9 percent, P=0.65). Conclusions: The need for target-vessel revascularization during one year of follow-up after percutaneous coronary intervention decreased during the mid-1990s. The reduction was coincident with the introduction and subsequent widespread use of coronary stenting. (N Engl J Med 1999;341:1957-65.) (C)1999, Massachusetts Medical Society.	Vancouver Gen Hosp, Vancouver, BC, Canada; British Columbian Cardiac Registries, Vancouver, BC, Canada; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; Royal Jubilee Hosp, Victoria, BC, Canada; Royal Columbian Hosp, New Westminster, BC, Canada	University of British Columbia; St. Paul's Hospital; University of Saskatchewan	Buller, CE (corresponding author), Intervent Cardiol Res, 865 W 10th Ave, Vancouver, BC V5Z 1L7, Canada.		Spinelli, John J./B-6210-2013	Spinelli, John J./0000-0002-9119-3287				Alderman EL, 1996, NEW ENGL J MED, V335, P217; ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boden WE, 1998, NEW ENGL J MED, V339, P1091; Buller CE, 1999, CIRCULATION, V100, P236, DOI 10.1161/01.CIR.100.3.236; *BYP ANG REV INV I, 1996, NEW ENGL J MED, V336, P147; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; Commission on Professional and Hospital Activities, 1992, INT CLASS DIS; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Erbel R, 1998, NEW ENGL J MED, V339, P1672, DOI 10.1056/NEJM199812033392304; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Folland ED, 1997, J AM COLL CARDIOL, V29, P1505, DOI 10.1016/S0735-1097(97)00097-1; Ghali WA, 1996, J CLIN EPIDEMIOL, V49, P273, DOI 10.1016/0895-4356(95)00564-1; Gruntzig A, 1980, G Ital Cardiol, V10, P261; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; Iezzoni LI, 1997, ANN INTERN MED, V127, P666, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00048; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; Landon B, 1996, INQUIRY-J HEALTH CAR, V33, P155; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Macaya C, 1996, J AM COLL CARDIOL, V27, P255, DOI 10.1016/0735-1097(95)00473-4; Pitt B, 1998, CIRCULATION, V98, P636; *PRINC INV CASS TH, 1981, CIRCULATION S1, V63, P1; RICKARDS AF, 1995, LANCET, V346, P1179; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; Savage MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Serruys P, 1998, LANCET, V352, P1478; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; Sirnes PA, 1996, J AM COLL CARDIOL, V28, P1444, DOI 10.1016/S0735-1097(96)00349-X; TERRIN ML, 1993, J AM COLL CARDIOL, V22, P1763, DOI 10.1016/0735-1097(93)90755-P; Topol EJ, 1998, CIRCULATION, V98, P1802, DOI 10.1161/01.CIR.98.17.1802; Topol EJ, 1998, NEW ENGL J MED, V339, P1702, DOI 10.1056/NEJM199812033392311; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; Williams JI, 1996, 9603TR I CLIN EV SCI	37	102	105	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1957	1965		10.1056/NEJM199912233412602	http://dx.doi.org/10.1056/NEJM199912233412602			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607812				2022-12-01	WOS:000084399400002
J	Bifani, PJ; Mathema, B; Liu, ZY; Moghazeh, SL; Shopsin, B; Tempalski, B; Driscoll, J; Frothingham, R; Musser, JM; Alcabes, P; Kreiswirth, BN				Bifani, PJ; Mathema, B; Liu, ZY; Moghazeh, SL; Shopsin, B; Tempalski, B; Driscoll, J; Frothingham, R; Musser, JM; Alcabes, P; Kreiswirth, BN			Identification of a W variant outbreak of Mycobacterium tuberculosis via population-based molecular epidemiology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-CITY; MULTIDRUG-RESISTANT TUBERCULOSIS; STRAIN DIFFERENTIATION; TRANSMISSION; POLYMORPHISM; ELEMENT; IS6110; PROBE	Context Typing of Mycobacterium tuberculosis could provide a more sensitive means of identifying outbreaks than use of conventional surveillance techniques alone. Variants of the New York City W strain of M tuberculosis were identified in New Jersey. Objective To describe the spread of the W family of M tuberculosis strains in New Jersey identified by molecular typing and surveillance data. Design Population-based cross-sectional study. Setting and Subjects All incident culture-positive tuberculosis cases reported in New Jersey from January 1996 to September 1998, for which the W family was defined by insertion sequence (IS) IS6110 DNA fingerprinting, polymorph ic GC-rich repetitive sequence (PGRS) typing, spacer oligotyping (spoligotyping), and variable number tandem repeat (VNTR) analysis. Main Outcome Measure Identification and characterization of W family clones supplemented by surveillance data. Results Isolates from 1207 cases were analyzed, of which 68 isolates (6%) belonged to the W family based on IS6110 and spoligotype hybridization patterns. The IS6110 hybridization patterns or fingerprints revealed that 43 patients (designated group A) shared a unique banding motif not present in other W family isolates. Strains collected from the remaining 25 patients (designated group B), while related to W, displayed a variety of IS6110 patterns and did not share this motif, The PGRS and VNTR typing confirmed the division of the W family into groups A and B and again showed group A strains to be closely related and group B strains to be more diverse. The demographic characteristics of individuals from groups A and B were specific and defined. Group A patients were more likely than group B patients to be US born (91% vs 24%, P < .001), black (76% vs 16%, P < .001), human immunodeficiency virus positive (40% vs 0%, P = .007), and residents of urban northeast New Jersey counties (P < .001), Patients with group B strains were primarily non-US born, of Asian descent, and more dispersed throughout New Jersey. No outbreak had been detected using conventional surveillance alone. Conclusions The implementation of multiple molecular techniques in conjunction with surveillance data enabled us to identify a previously undetected outbreak in a defined geographical setting. The outbreak isolates comprise members of a distinct branch of the W family phylogenetic lineage. The use of molecular strain typing provides a proactive approach that may be used to initiate, and not just augment, traditional surveillance outbreak investigations.	Publ Hlth Res Inst City New York Inc, TB Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Dept Environm Med, New York, NY USA; New Jersey Dept Hlth & Senior Serv, Div Communicable Dis, Trenton, NJ USA; Univ Washington, Dept Geog, Seattle, WA 98195 USA; New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA; Durham Vet Affairs Med Ctr, Durham, NC USA; Baylor Coll Med, Dept Pathol, Inst Study Human Bacterial Pathogenesis, Houston, TX 77030 USA	New York University; New York University; New Jersey Department of Health & Senior Services; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; Wadsworth Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Baylor College of Medicine	Kreiswirth, BN (corresponding author), Publ Hlth Res Inst City New York Inc, TB Ctr, 455 1st Ave, New York, NY 10016 USA.			Tempalski, Barbara/0000-0002-6128-2510; Mathema, Barun/0000-0003-2772-479X; Bifani, Pablo/0000-0001-9651-6439	NIAID NIH HHS [AI27742] Funding Source: Medline; NIDA NIH HHS [DA09238] Funding Source: Medline; PHS HHS [NL51517] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009238] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Agerton TB, 1999, CLIN INFECT DIS, V29, P85, DOI 10.1086/520187; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; Bishai WR, 1998, JAMA-J AM MED ASSOC, V280, P1679, DOI 10.1001/jama.280.19.1679; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845; Frothingham R, 1998, MICROBIOL-UK, V144, P1189, DOI 10.1099/00221287-144-5-1189; GROENEN PMA, 1993, MOL MICROBIOL, V10, P1057, DOI 10.1111/j.1365-2958.1993.tb00976.x; Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907, DOI 10.1128/JCM.35.4.907-914.1997; KLINE SE, 1995, NEW ENGL J MED, V333, P222, DOI 10.1056/NEJM199507273330404; KREISWIRTH BN, 1996, TUBERCULOSIS, P199; Kurepina N. E., 1998, Tubercle and Lung Disease, V79, P31, DOI 10.1054/tuld.1998.0003; LIN R, 1996, INT J INFECT DIS, V1, P18; Moss AR, 1997, INT J TUBERC LUNG D, V1, P115; Palittapongarnpim P, 1997, INT J TUBERC LUNG D, V1, P370; PLIKAYTIS BB, 1994, J CLIN MICROBIOL, V32, P1542, DOI 10.1128/JCM.32.6.1542-1546.1994; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; TORREA G, 1995, J CLIN MICROBIOL, V33, P1899, DOI 10.1128/JCM.33.7.1899-1904.1995; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Yaganehdoost A, 1999, J INFECT DIS, V180, P1245, DOI 10.1086/314991	27	138	151	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2321	2327		10.1001/jama.282.24.2321	http://dx.doi.org/10.1001/jama.282.24.2321			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612319				2022-12-01	WOS:000084261700025
J	Go, AS; Hylek, EM; Borowsky, LH; Phillips, KA; Selby, JV; Singer, DE				Go, AS; Hylek, EM; Borowsky, LH; Phillips, KA; Selby, JV; Singer, DE			Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study	ANNALS OF INTERNAL MEDICINE			English	Article							STROKE PREVENTION; PHYSICIAN ATTITUDES; NATIONAL PATTERNS; COMMUNITY; PROPHYLAXIS; PREVALENCE; HOSPITALS; ASPIRIN	Background: Warfarin dramatically reduces the risk for ischemic stroke in nonvalvular atrial fibrillation, but its use among ambulatory patients with atrial fibrillation has not been widely studied. Objective: To assess the rates and predictors of warfarin use in ambulatory patients with nonvalvular atrial fibrillation. Design: Cross-sectional study. Setting: Large health maintenance organization. Patients: 13428 patients with a confirmed ambulatory diagnosis of nonvalvular atrial fibrillation and known warfarin status between 1 July 1996 and 31 December 1997. Measurements: Data from automated pharmacy, laboratory, and clinical-administrative databases were used to determine the prevalence and determinants of warfarin use in the 3 months before or after the identified diagnosis of atrial fibrillation. Results: Of 11082 patients with nonvalvular atrial fibrillation and no known contraindications, 55% received warfarin. Warfarin use was substantially lower in patients who were younger than 55 years of age (44.3%) and those who were 85 years of age or older (35.4%). Only 59.3% of patients with one or more risk factors for stroke and no contraindications were receiving warfarin. Among a subset of "ideal" candidates to receive warfarin (persons 65 to 74 years of age who had no contraindications and had previous stroke, hypertension, or both), 62.1% had evidence of warfarin use. Among our entire cohort, the strongest predictors of receiving warfarin were previous stroke (adjusted odds ratio, 2.55 [95% CI, 2.23 to 2.92]), heart failure (odds ratio, 1.63 [CI, 1.51 to 1.77]), previous intracranial hemorrhage (odds ratio, 0.33 [CI, 0.21 to 0.52]), age 85 years or older (odds ratio, 0.35 [CI, 0.31 to 0.40]), and previous gastrointestinal hemorrhage (odds ratio, 0.47 [CI, 0.40 to 0.57]). Conclusions: In a large, contemporary cohort of ambulatory patients with atrial fibrillation who received care within a health maintenance organization, warfarin use was considerably higher than in other reported studies. Although the reasons why physicians did not prescribe warfarin could not be elucidated, many apparently eligible patients with atrial fibrillation and at least one additional risk factor for stroke, especially hypertension, did not receive anticoagulation. Interventions are needed to increase the use of warfarin for stroke prevention among appropriate candidates.	Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Kaiser Permanente; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Go, AS (corresponding author), Kaiser Permanente Med Care Program, Div Res, 3505 Broadway St,12th Floor, Oakland, CA 94611 USA.	axg@dor.kaiser.org	Go, Alan S./AAE-7745-2019	Hylek, Elaine/0000-0001-8263-8304	NATIONAL INSTITUTE ON AGING [R01AG015478] Funding Source: NIH RePORTER; NIA NIH HHS [AG15478] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albers GW, 1996, ARCH INTERN MED, V156, P2311, DOI 10.1001/archinte.156.20.2311; *AM SOC HLTH SYST, 1998, AM J HEALTH-SYST PH, V55, P376; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; Antani MR, 1996, J GEN INTERN MED, V11, P713, DOI 10.1007/BF02598984; Arnsten JH, 1997, AM J MED, V103, P11, DOI 10.1016/S0002-9343(97)90048-6; Beyth RJ, 1996, J GEN INTERN MED, V11, P721, DOI 10.1007/BF02598985; BEYTH RJ, 1995, DRUG AGING, V6, P45, DOI 10.2165/00002512-199506010-00004; Blackshear JL, 1996, LANCET, V348, P633; Brass LM, 1998, ARCH INTERN MED, V158, P2093, DOI 10.1001/archinte.158.19.2093; Brass LM, 1997, STROKE, V28, P2382, DOI 10.1161/01.STR.28.12.2382; Cleves M A, 1997, Jt Comm J Qual Improv, V23, P550; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; Diggle P., 2002, ANAL LONGITUDINAL DA; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Flaker GC, 1999, AM HEART J, V137, P307, DOI 10.1053/hj.1999.v137.91403; Fleiss J.L., 1981, STAT METHODS RATES P; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; Greenberg MK, 1998, NEUROLOGY, V51, P671; Gullov AL, 1998, ARCH INTERN MED, V158, P1513, DOI 10.1001/archinte.158.14.1513; Gurwitz JH, 1997, ARCH INTERN MED, V157, P978, DOI 10.1001/archinte.157.9.978; Kerr C, 1996, EUR HEART J, V17, P48, DOI 10.1093/eurheartj/17.suppl_C.48; Kerr CR, 1998, AM J CARDIOL, V82, p82N, DOI 10.1016/S0002-9149(98)00589-X; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; Lackner T E, 1995, Arch Fam Med, V4, P1017, DOI 10.1001/archfami.4.12.1017; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lawson F, 1996, J AM GERIATR SOC, V44, P708, DOI 10.1111/j.1532-5415.1996.tb01837.x; Man-Son-Hing M, 1999, ARCH INTERN MED, V159, P677, DOI 10.1001/archinte.159.7.677; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCCRORY DC, 1995, ARCH INTERN MED, V155, P277, DOI 10.1001/archinte.155.3.277; Mendelson G, 1998, J AM GERIATR SOC, V46, P1423, DOI 10.1111/j.1532-5415.1998.tb06011.x; Monette J, 1997, J AM GERIATR SOC, V45, P1060, DOI 10.1111/j.1532-5415.1997.tb05967.x; Munschauer FE, 1997, STROKE, V28, P72, DOI 10.1161/01.STR.28.1.72; PETERSEN P, 1989, LANCET, V1, P175; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; Smith NL, 1999, ARCH INTERN MED, V159, P1574, DOI 10.1001/archinte.159.14.1574; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; Stafford RS, 1996, ARCH INTERN MED, V156, P2537, DOI 10.1001/archinte.156.22.2537; Stafford RS, 1998, CIRCULATION, V97, P1231, DOI 10.1161/01.CIR.97.13.1231; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Teo K, 1998, CAN J CARDIOL, V14, P695; White RH, 1999, AM J MED, V106, P165, DOI 10.1016/S0002-9343(98)00389-1; Whittle J, 1997, ARCH INTERN MED, V157, P441, DOI 10.1001/archinte.157.4.441	48	495	508	2	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					927	+		10.7326/0003-4819-131-12-199912210-00004	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610643				2022-12-01	WOS:000084374400003
J	Kelly, M; Bedell, R				Kelly, M; Bedell, R			Assessment of international medical evacuations in Macedonia	LANCET			English	Editorial Material									Med Sans Frontieres, NL-100 EA Amsterdam, Netherlands	Doctors Without Borders	Kelly, M (corresponding author), Med Sans Frontieres, Max Euwepl 40,POB 10014, NL-100 EA Amsterdam, Netherlands.		Bedell, Richard/AAC-2595-2020	Bedell, Richard/0000-0002-5687-8053					0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2076	2077		10.1016/S0140-6736(05)76814-8	http://dx.doi.org/10.1016/S0140-6736(05)76814-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636389				2022-12-01	WOS:000084183300049
J	Head, JW; Hiesinger, H; Ivanov, MA; Kreslavsky, MA; Pratt, S; Thomson, BJ				Head, JW; Hiesinger, H; Ivanov, MA; Kreslavsky, MA; Pratt, S; Thomson, BJ			Possible ancient oceans on Mars: Evidence from Mars Orbiter Laser Altimeter data	SCIENCE			English	Article							TOPOGRAPHY; UTOPIA	High-resolution altimetric data define the detailed topography of the northern lowlands of Mars, and a range of data is consistent with the hypothesis that a Lowland-encircling geologic contact represents the ancient shoreline of a Large standing body of water present in middle Mars history. The contact altitude is close to an equipotential Line, the topography is smoother at all scales below the contact than above it, the volume enclosed by this contact is within the range of estimates of available water on Mars, and a series of extensive terraces parallel the contact in many places.	Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Russian Acad Sci, Vernadsky Inst, Moscow 117975, Russia; Kharkov State Univ, Kharkov Astron Observ, UA-310022 Kharkov, Ukraine	Brown University; Russian Academy of Sciences; Vernadsky Institute of Geochemistry & Analytical Chemistry; Ministry of Education & Science of Ukraine; VN Karazin Kharkiv National University	Head, JW (corresponding author), Brown Univ, Dept Geol Sci, Providence, RI 02912 USA.		Thomson, Bradley/AAA-3496-2022; Kreslavsky, Mikhail/J-3425-2013	Thomson, Bradley/0000-0001-8635-8932; Kreslavsky, Mikhail/0000-0002-1900-826X; Ivanov, Mikhail/0000-0001-5696-8131				Aharonson O, 1998, GEOPHYS RES LETT, V25, P4413, DOI 10.1029/1998GL900057; Baker V.R., 1992, CHANNELS VALLEY NETW, P493; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BANERDT WB, 1992, MARS, P249; Banin A., 1992, MARS, P594; BIRD EC, 1976, BEACH PROCESSES SEDI; Carr M. H., 1977, Journal of Geophysical Research, V82, P4055, DOI 10.1029/JS082i028p04055; Carr M.H, 1996, WATER MARS; CLIFFORD SM, 1999, LUNAR PLANET SCI, V30, P1619; Garvin JB, 1999, GEOPHYS RES LETT, V26, P381, DOI 10.1029/1998GL900309; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; GREELEY R, 1987, US GEOL SUR VMISC IN; HEARD JW, 1998, GEOPHYS RES LETT, V25, P4401; IVANOV MA, 1999, 5 INT C MARS; Kreslavsky MA, 1999, J GEOPHYS RES-PLANET, V104, P21911, DOI 10.1029/1999JE001051; KUZMIN RO, 1988, SOLAR SYST RES, V22, P195; LUCCHITTA BK, 1986, J GEOPHYS RES, V91, P166; Malin MC, 1999, GEOPHYS RES LETT, V26, P3049, DOI 10.1029/1999GL002342; Masursky H., 1977, Journal of Geophysical Research, V82, P4016, DOI 10.1029/JS082i028p04016; MCGILL GE, 1986, GEOPHYS RES LETT, V13, P705, DOI 10.1029/GL013i008p00705; MCGILL GE, 1989, J GEOPHYS RES-SOLID, V94, P2753, DOI 10.1029/JB094iB03p02753; McSween HY, 1998, INT GEOL REV, V40, P774, DOI 10.1080/00206819809465238; McSween HY, 1999, J GEOPHYS RES-PLANET, V104, P8679, DOI 10.1029/98JE02551; MUTCH TA, 1976, SCIENCE, V194, P1277, DOI 10.1126/science.194.4271.1277; MUTCH TA, 1976, SCIENCE, V193, P791, DOI 10.1126/science.193.4255.791; PARKER TJ, 1989, ICARUS, V82, P111, DOI 10.1016/0019-1035(89)90027-4; PARKER TJ, 1993, J GEOPHYS RES-PLANET, V98, P11061, DOI 10.1029/93JE00618; ROTTO S, 1995, US GEOL SURV MISC IN; SCOTT DH, 1992, P LUNAR PLANET SCI, V22, P53; SCOTT DH, 1995, US GEOL SURV MISC IN; SCOTT DH, 1986, US GEOL SURV MISC IN; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; Squyres S. W., 1992, MARS, P523; Tanaka KL, 1997, J GEOPHYS RES-PLANET, V102, P4131, DOI 10.1029/96JE02862; TANAKA KL, 1992, US GEOL SURV MISC IN; TANAKA KL, 1987, US GEOL SURV MISC IN; Thomas P., 1992, MARS, P767; THOMSON BJ, 1999, LUNAR PLANET SCI C, V30, P1894; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053	41	291	293	2	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2134	2137		10.1126/science.286.5447.2134	http://dx.doi.org/10.1126/science.286.5447.2134			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591640				2022-12-01	WOS:000084157300045
J	Jee, SH; Suh, I; Kim, IS; Appel, LJ				Jee, SH; Suh, I; Kim, IS; Appel, LJ			Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol - The Korea Medical Insurance Corporation Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CIGARETTE-SMOKING; RISK-FACTORS; JAPANESE MEN; MORTALITY; STROKE; FRAMINGHAM; HAWAII; DEATH	Context Few studies have examined the interactive effects of smoking and serum cholesterol level on morbidity and mortality from cardiovascular dieseases. In East Asia, where the prevalence of smoking is among the highest in the world, morbidity and mortality from ischemic heart disease (IHD) is rapidly escalating. Objectives To determine whether cigarette smoking is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) in the Republic of Korea (South Korea), a population that has relatively low levels of serum cholesterol, and to determine whether serum cholesterol levels modify the risk relationship between smoking and ASCVD, Design Prospective cohort study with a follow-up period of 6 years (1993-1998). Setting and Subjects A total of 106745 Korean men aged 35 to 59 years who received health insurance from the Korea Medical Insurance Corporation and who had biennial medical evaluations in 1990 and 1992. Main Outcome Measures Hospital admissions and deaths from IHD, cerebrovascular disease (CVD), and total ASCVD. Results At baseline, 61 389 (58%) were current cigarette smokers and 64 482 (60%) had a total cholesterol level of less than 5.17 mmol/L (200 mg/dL). Between 1993 and 1998, 1006 IHD events (176 per 100 000 person-years), 1364 CVD events (238 per 100 000 person-years), and 716 other ASCVD events (125 per 100 000 person-years) occurred. In multivariate Cox proportional hazard models controlling for age, hypertension, hypercholesterolemia, and diabetes, current smoking increased the risk of IHD (risk ratio [RR], 2.2; 95% confidence interval [CI], 1.8-2.8), CVD (RR, 1.6, 95% CI, 1.4-1.8), and total ASCVD (RR, 1.6, 95% CI, 1.5-1.8). For each outcome, there were significant dose-response relationships with amount and duration of smoking. Throughout the range of serum cholesterol levels, current smoking significantly increased the risk of IHD and CVD. In the lowest quartile of serum cholesterol levels (<4.42 mmol/L [171 mg/dL]), the RR from current smoking was 3.3 (95% CI, 1.7-6.2) for IHD and 1.6 (95% CI, 1.2-2.3) for CVD. There was no evidence of an interaction between smoking and serum cholesterol (P for interaction = .75, .87, and .92 for IHD, CVD, and total ASCVD, respectively). Conclusions This study demonstrates that in Korea smoking is a major independent risk factor for IHD, CVD, and ASCVD and that a low cholesterol level confers no protective benefit against smoking-related ASCVD.	Yonsei Univ, Grad Sch Hlth Sci & Management, Dept Epidemiol & Dis Control, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Prevent Med & Publ Hlth, Seoul, South Korea; Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA	Yonsei University; Yonsei University; Yonsei University Health System; Johns Hopkins University; Johns Hopkins Medicine	Appel, LJ (corresponding author), Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-600, Baltimore, MD 21205 USA.		Appel, Larry/GLT-2608-2022	Jee, Sun Ha/0000-0001-9519-3068; Suh, Il/0000-0002-9689-7849				ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; BRESLOW NE, 1980, IARC SCI PUBL, V32, P146; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; *GALL KOR, 1994, KOR GALL REP 1994; Gavin JR, 1997, DIABETES CARE, V20, P1183; GOLDBERG RJ, 1992, PREVENTION CORONARY, P3; GORDON T, 1974, J CHRON DIS, V27, P329, DOI 10.1016/0021-9681(74)90013-7; Jee SH, 1998, ANN EPIDEMIOL, V8, P14, DOI 10.1016/S1047-2797(97)00131-2; Kannel W.B., 1984, J CARDIAC REHABIL, V4, P267; Kawane H, 1998, THORAX, V53, P328, DOI 10.1136/thx.53.4.328a; KIYOHARA Y, 1990, J HYPERTENS, V8, pS9; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; *NAT CHOL ED PROGR, 1994, NIH PUBL; *NAT STAT OFF, 1996, ANN REP CAUS DEATH S; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; *NIH, 1997, NIH PUBL; OKUMIYA N, 1985, AM J CARDIOL, V56, P62, DOI 10.1016/0002-9149(85)90567-3; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; ROBERTSON TL, 1977, AM J CARDIOL, V39, P244, DOI 10.1016/S0002-9149(77)80198-7; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; SUH I, 1996, J HYPERTENS S1, V14, pS234; WIHELMSEN L, 1977, BRIT MED J, V39, P1179; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YANO K, 1988, AM J EPIDEMIOL, V127, P476, DOI 10.1093/oxfordjournals.aje.a114824; Yuan JM, 1996, JAMA-J AM MED ASSOC, V275, P1646, DOI 10.1001/jama.275.21.1646	27	154	157	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2149	2155		10.1001/jama.282.22.2149	http://dx.doi.org/10.1001/jama.282.22.2149			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591337	Bronze, Green Published			2022-12-01	WOS:000083971400034
J	Cagir, B; Gelmann, A; Park, J; Fava, T; Tankelevitch, A; Bittner, EW; Weaver, EJ; Palazzo, JP; Weinberg, D; Fry, RD; Waldman, SA				Cagir, B; Gelmann, A; Park, J; Fava, T; Tankelevitch, A; Bittner, EW; Weaver, EJ; Palazzo, JP; Weinberg, D; Fry, RD; Waldman, SA			Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer	ANNALS OF INTERNAL MEDICINE			English	Article						RNA, messenger; colorectal neoplasms; guanylate cyclase; neoplasm recurrence, local; lymph nodes	STABLE ENTEROTOXIN RECEPTORS; LYMPH-NODES; CARCINOEMBRYONIC ANTIGEN; ADJUVANT THERAPY; COLON-CANCER; OCCULT MICROMETASTASES; CARCINOMA; TUMORS; BREAST; FLUOROURACIL	Background: Patients with stage II colorectal cancer and no histologic evidence of lymph node invasion develop recurrent disease, presumably because of undetected micrometastases. Guanylyl cyclase C is expressed by intestinal and colorectal cancer cells but not by extraintestinal tissues or tumors. Objective: To examine the expression of guanylyl cyclase C messenger RNA (mRNA) in lymph nodes of patients with node-negative colorectal cancer who did and did not have recurrent disease. Design: Case-control study. Setting: Tertiary care academic medical center. Patients: Paraffin-embedded lymph nodes were obtained from 21 patients with histologically confirmed node-negative colorectal cancer who had undergone resection. Controls included 11 patients without disease recurrence 6 or more yea rs after resection, a nd case-patients included 10 patients whose disease recurred up to 3 years after resection. Measurements: Sections of paraffin-embedded lymph nodes were obtained from each patient and were pooled, and their RNA was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR). Results: Guanylyl cyclase C mRNA was expressed in lymph nodes from all patients with recurrent disease but not in those from patients without recurrent disease (P = 0.004). Nested RT-PCR that used primers for carcinoembryonic antigen, a marker for colorectal cancer, identified carcinoembryonic antigen mRNA in lymph nodes from only 1 of 10 patients with recurrent disease and those from 0 of 11 patients without recurrent disease. The odds ratio for death associated with expression of guanylyl cyclase C mRNA in regional lymph nodes was 15.0 (95% Cl, 1.1 to 756.7). Conclusions: Expression of guanylyl cyclase C mRNA in lymph nodes is associated with recurrence of colorectal cancer in patients with stage II disease. Analysis of guanylyl cyclase mRNA expression by RT-PCR may be useful for colorectal cancer staging.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Clin Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Surg, Div Colorectal Surg, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol & Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Med, Div Gastroenterol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University	Waldman, SA (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Clin Pharmacol, 132 S 10th St,1170 Main, Philadelphia, PA 19107 USA.	scott.waldman@mail.tju.edu		Waldman, Scott/0000-0001-6619-175X; Park, Jason/0000-0001-6797-4000	NATIONAL CANCER INSTITUTE [R21CA079663, R01CA075123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008562] Funding Source: NIH RePORTER; NCI NIH HHS [CA79663, CA75123] Funding Source: Medline; NIGMS NIH HHS [5T32 GM08562] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abati A, 1996, CANCER, V78, P1; ALMENOFF JS, 1993, MOL MICROBIOL, V8, P865, DOI 10.1111/j.1365-2958.1993.tb01633.x; BEATTY JD, 1992, CANCER PHILA S5, V75, P1425; BORDES M, 1973, DIGESTION, V9, P106, DOI 10.1159/000197436; Bostick PJ, 1998, NEW ENGL J MED, V339, P1643; Bostick PJ, 1998, J CLIN ONCOL, V16, P2632, DOI 10.1200/JCO.1998.16.8.2632; CARRITHERS SL, 1994, GASTROENTEROLOGY, V107, P1653, DOI 10.1016/0016-5085(94)90804-4; Carrithers SL, 1996, P NATL ACAD SCI USA, V93, P14827, DOI 10.1073/pnas.93.25.14827; Carrithers SL, 1996, DIS COLON RECTUM, V39, P171, DOI 10.1007/BF02068072; CHEN ZL, 1993, JNCI-J NATL CANCER I, V85, P493, DOI 10.1093/jnci/85.6.493; CRESANTA JL, 1992, PRIMARY CARE, V19, P419; DEMASCAREL I, 1992, BRIT J CANCER, V66, P523, DOI 10.1038/bjc.1992.306; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; FUCHS CS, 1995, SEMIN ONCOL, V22, P472; Ghossein RA, 1998, NEW ENGL J MED, V339, P1642; GOLDENBERG DM, 1978, CANCER, V42, P1546, DOI 10.1002/1097-0142(197809)42:3+<1546::AID-CNCR2820420829>3.0.CO;2-D; Goldstein NS, 1996, AM J CLIN PATHOL, V106, P209; GREENSON JK, 1994, CANCER-AM CANCER SOC, V73, P563, DOI 10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO;2-D; GREENWALD P, 1992, CANCER, V70, P1206, DOI 10.1002/1097-0142(19920901)70:3+<1206::AID-CNCR2820701504>3.0.CO;2-J; GUARINO A, 1987, DIGEST DIS SCI, V32, P1017, DOI 10.1007/BF01297193; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jessup JM, 1996, CANCER-AM CANCER SOC, V78, P918; KROCZEK RA, 1993, J CHROMATOGR-BIOMED, V618, P133, DOI 10.1016/0378-4347(93)80031-X; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; Liefers GJ, 1998, NEW ENGL J MED, V339, P223, DOI 10.1056/NEJM199807233390403; Maehara Y, 1996, SURGERY, V119, P397, DOI 10.1016/S0039-6060(96)80138-3; Merrie AEH, 1998, NEW ENGL J MED, V339, P1642; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; RUBIO CA, 1977, SURG GYNECOL OBSTET, V145, P682; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SLOANE JP, 1995, LANCET, V345, P1255, DOI 10.1016/S0140-6736(95)90921-4; Waldman SA, 1998, CANCER EPIDEM BIOMAR, V7, P505; Waldman SA, 1998, DIS COLON RECTUM, V41, P310, DOI 10.1007/BF02237484; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; Zippelius A, 1997, J CLIN ONCOL, V15, P2701, DOI 10.1200/JCO.1997.15.7.2701	36	89	98	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					805	+		10.7326/0003-4819-131-11-199912070-00002	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610624				2022-12-01	WOS:000084053200001
J	Wessner, DR				Wessner, DR			Planning plasmids	SCIENCE			English	Software Review									Davidson Coll, Dept Biol, Davidson, NC 28036 USA	Davidson College	Wessner, DR (corresponding author), Davidson Coll, Dept Biol, POB 1719, Davidson, NC 28036 USA.								0	3	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1495	1496		10.1126/science.286.5444.1495	http://dx.doi.org/10.1126/science.286.5444.1495			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10610552				2022-12-01	WOS:000083768300036
J	Carbone, C; Mace, GM; Roberts, SC; Macdonald, DW				Carbone, C; Mace, GM; Roberts, SC; Macdonald, DW			Energetic constraints on the diet of terrestrial carnivores	NATURE			English	Article							CONSUMPTION	Species in the mammalian order Carnivora exhibit a huge diversity of life histories with body sizes spanning more than three orders of magnitude. Despite this diversity, most terrestrial carnivores can be classified as either feeding on invertebrates and small vertebrates or on large vertebrates. Small carnivores feed predominantly on invertebrates probably because they are a superabundant: resource (sometimes 90% of animal biomass(1-3)); however, intake rates of invertebrate feeders are low, about one tenth of those of vertebrate feeders(4,5). Although small carnivores can subsist on this diet because of low absolute energy requirements, invertebrate feeding appears to be unsustainable for larger carnivores. Here we show, by reviewing the most common live prey in carnivore diets, that there is a striking transition from feeding on small prey (less than half of predator mass) to large prey (near predator mass), occurring at predator masses of 21.5-25kg. We test the hypothesis that this dichotomy is the consequence of mass-related energetic requirements and we determine the predicted maximum mass that an invertebrate diet can sustain. Using a simple energetic model and known invertebrate intake rates, we predict a maximum sustainable mass of 21.5 kg, which matches the point where predators shift from small to large prey.	Zool Soc London, Inst Zool, London NW1 4RY, England; Univ Oxford, Dept Zool, Wildlife Conservat Res Unit, Oxford OX1 3PS, England	Zoological Society of London; University of Oxford	Carbone, C (corresponding author), Zool Soc London, Inst Zool, Regents Pk, London NW1 4RY, England.		Mace, Georgina M/I-3072-2016; Roberts, Craig/E-6919-2011	Mace, Georgina M/0000-0001-8965-5211; Roberts, Craig/0000-0002-9641-6101				BININDAEDMONDS ORP, 1994, BIOL REV, V74, P143; BININDAEMONDS ORP, 1998, THESIS U OXFORD; Estes RD., 1991, BEHAV GUIDE AFRICAN, P1; Gittleman J.L., 1989, P183; GITTLEMAN JL, 1995, OECOLOGIA, V67, P50; Gorman ML, 1998, NATURE, V391, P479, DOI 10.1038/35131; GRIFFITHS D, 1980, AM NAT, V116, P743, DOI 10.1086/283666; Joshi AR, 1997, J MAMMAL, V78, P584, DOI 10.2307/1382910; KAVANAU JL, 1975, AM NAT, V109, P391, DOI 10.1086/283009; Kingdon J, 1997, KINGDON FIELD GUIDE, P1; Kruuk H., 1989, SOCIAL BADGER; LAMPRECHT J, 1978, Z SAUGETIERKD, V43, P210; MACDONALD D. W., 1995, ENCY MAMMALS; MACDONALD DW, 1980, Z TIERPSYCHOL, V52, P171; MALCOLM JR, 1986, J ZOOL LOND, V208, P743; MAY RM, 1988, SCIENCE, V241, P1441, DOI 10.1126/science.241.4872.1441; Nowak RM, 1991, WALKERS MAMMALS WORL; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; PURVIS A, IN PRESS CARNIVORE C; RICHARDSON PRK, 1987, Z SAUGETIERKD, V52, P307; ROOD J P, 1975, East African Wildlife Journal, V13, P89; Schaller G., 1972, SERENGETI LION STUDY, P1; SCHMIDTNIELSEN, 1984, SCALING WHY ANIMAL S, P1; Skinner J. D., 1990, MAMMALS SO AFRICAN S; TAYLOR CR, 1982, J EXP BIOL, V97, P1; WASER PM, 1980, AFR J ECOL, V18, P167, DOI 10.1111/j.1365-2028.1980.tb00640.x; Williams JB, 1997, ECOLOGY, V78, P2588; Wilson E.O., 1987, Conservation Biology, V1, P344, DOI 10.1111/j.1523-1739.1987.tb00055.x; Wilson E.O, 1990, SUCCESS DOMINANCE EC	29	410	426	3	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					286	288		10.1038/46266	http://dx.doi.org/10.1038/46266			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580498				2022-12-01	WOS:000083813700047
J	Tang, L; Shah, S; Chung, L; Carney, J; Katz, L; Khosla, C; Julien, B				Tang, L; Shah, S; Chung, L; Carney, J; Katz, L; Khosla, C; Julien, B			Cloning and heterologous expression of the epothilone gene cluster	SCIENCE			English	Article							ENGINEERED BIOSYNTHESIS; POLYKETIDES	The polyketide epothilone is a potential anticancer agent that stabilizes microtubules in a similar manner to Taxol. The gene cluster responsible for epothilone biosynthesis in the myxobacterium Sorangium cellulosum was cloned and completely sequenced. It encodes six multifunctional proteins composed of a loading module, one nonribosomal peptide synthetase module, eight polyketide synthase modules, and a P450 epoxidase that converts desoxyepothilone into epothilone. Concomitant expression of these genes in the actinomycete Streptomyces coelicolor produced epothilones A and B. Streptomyces coelicolor is more amenable to strain improvement and grows about 10-fold as rapidly as the natural producer, so this heterologous expression system portends a plentiful supply of this important agent.	KOSAN Biosci, Hayward, CA 94545 USA	Bristol-Myers Squibb; Kosan Biosciences, Inc.	Julien, B (corresponding author), KOSAN Biosci, 3832 Bay Ctr Pl, Hayward, CA 94545 USA.			Khosla, Chaitan/0000-0001-6529-495X; Carney, John/0000-0002-0461-8890	NATIONAL CANCER INSTITUTE [R43CA079228] Funding Source: NIH RePORTER; NCI NIH HHS [1 R43 CA79228-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balog A, 1996, ANGEW CHEM INT EDIT, V35, P2801, DOI 10.1002/anie.199628011; BEDFORD DJ, 1995, J BACTERIOL, V177, P4544, DOI 10.1128/jb.177.15.4544-4548.1995; Betlach MC, 1998, BIOCHEMISTRY-US, V37, P14937, DOI 10.1021/bi981699c; BOLLAG DM, 1995, CANCER RES, V55, P2325; CASPERS P, 1994, CELL MOL BIOL, V40, P635; Chou TC, 1998, P NATL ACAD SCI USA, V95, P15798, DOI 10.1073/pnas.95.26.15798; Chou TC, 1998, P NATL ACAD SCI USA, V95, P9642, DOI 10.1073/pnas.95.16.9642; FU H, 1994, J AM CHEM SOC, V116, P4166, DOI 10.1021/ja00089a003; Gehring AM, 1998, CHEM BIOL, V5, P573, DOI 10.1016/S1074-5521(98)90115-6; Gerth K, 1996, J ANTIBIOT, V49, P560, DOI 10.7164/antibiotics.49.560; Hendrickson L, 1999, CHEM BIOL, V6, P429, DOI 10.1016/S1074-5521(99)80061-1; Hopwood D. A., 1985, GENETIC MANIPULATION; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; Kennedy J, 1999, SCIENCE, V284, P1368, DOI 10.1126/science.284.5418.1368; Konz D, 1999, CHEM BIOL, V6, pR39, DOI 10.1016/S1074-5521(99)80002-7; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; McDaniel R, 1999, P NATL ACAD SCI USA, V96, P1846, DOI 10.1073/pnas.96.5.1846; Nicolaou KC, 1997, ANGEW CHEM INT EDIT, V36, P2097, DOI 10.1002/anie.199720971; Proctor RH, 1999, FUNGAL GENET BIOL, V27, P100, DOI 10.1006/fgbi.1999.1141; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; Su DS, 1997, ANGEW CHEM INT EDIT, V36, P2093, DOI 10.1002/anie.199720931; Tang L., UNPUB; Xue Q, 1999, P NATL ACAD SCI USA, V96, P11740, DOI 10.1073/pnas.96.21.11740; YANG Z, 1995, ANGEW CHEM INT EDIT, V35, P2399; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658	25	338	400	2	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	2000	287	5453					640	642		10.1126/science.287.5453.640	http://dx.doi.org/10.1126/science.287.5453.640			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10649995				2022-12-01	WOS:000084989400044
J	Freire-de-Lima, CG; Nascimento, DO; Soares, MBP; Bozza, PT; Castro-Faria-Neto, HC; de Mello, FG; DosReis, GA; Lopes, MF				Freire-de-Lima, CG; Nascimento, DO; Soares, MBP; Bozza, PT; Castro-Faria-Neto, HC; de Mello, FG; DosReis, GA; Lopes, MF			Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages	NATURE			English	Article							FACTOR-BETA; TGF-BETA; VITRONECTIN RECEPTOR; CRUZI; ACTIVATION; DECARBOXYLASE; IDENTIFICATION; INVOLVEMENT; LYMPHOCYTES; INHIBITION	After apoptosis, phagocytes prevent inflammation and tissue damage by the uptake and removal of dead cells(1). In addition, apoptotic cells evoke an anti-inflammatory response through macrophages(2,3). We have previously shown that there is intense lymphocyte apoptosis in an experimental model of Chagas' disease(4), a debilitating cardiac illness caused by the protozoan Trypanosoma cruzi. Here we show that the interaction of apoptotic, but not necrotic T lymphocytes with macrophages infected with I: cruzi fuels parasite growth in a manner dependent on prostaglandins, transforming growth factor-beta (TGF-beta) and polyamine biosynthesis. We show that the vitronectin receptor is critical, in both apoptotic-cell cytoadherence and the induction of prostaglandin E-2/TGF-beta release and ornithine decarboxylase activity in macrophages. A single injection of apoptotic cells in infected mice increases parasitaemia, whereas treatment with cyclooxygenase inhibitors almost completely ablates it in vivo. These results suggest that continual lymphocyte apoptosis and phagocytosis of apoptotic cells by macrophages have a role in parasite persistence in the host, and that cyclooxygenase inhibitors have potential therapeutic application in the control of parasite replication and spread in Chagas' disease.	Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21944970 Rio De Janeiro, Brazil; Fiocruz MS, Ctr Pesquisas Goncalo Moniz, BR-40295001 Salvador, BA, Brazil; Fiocruz MS, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz	DosReis, GA (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21944970 Rio De Janeiro, Brazil.	gdosreis@biof.ufrj.br; mlopes@niaid.nih.gov	Bozza, Patricia T./AAM-4537-2021; NASCIMENTO, DANIELLE/ABE-1057-2020; de Lima, Celio Geraldo Freire/A-9057-2012; Lopes, Marcela Freitas/E-2201-2012; Soares, Milena B. P./O-3771-2018; Bozza, Patricia T./AAE-2933-2021	Bozza, Patricia T./0000-0001-8349-9529; NASCIMENTO, DANIELLE/0000-0001-8946-6998; Lopes, Marcela Freitas/0000-0002-4508-0505; Soares, Milena/0000-0001-7549-2992; DosReis, George/0000-0002-8924-4727				BOUTARD V, 1995, J IMMUNOL, V155, P2077; CELENTANO AM, 1995, PROSTAGLANDINS, V49, P141, DOI 10.1016/0090-6980(95)00002-R; CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8; Corraliza IM, 1997, BBA-GEN SUBJECTS, V1334, P123, DOI 10.1016/S0304-4165(96)00081-5; De Mello F G, 1976, J Neurochem, V27, P847; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FUTAKI N, 1993, J PHARM PHARMACOL, V45, P753, DOI 10.1111/j.2042-7158.1993.tb07103.x; GAZZINELLI RT, 1992, EUR J IMMUNOL, V22, P2501, DOI 10.1002/eji.1830221006; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; HUNTER KJ, 1994, EUR J BIOCHEM, V226, P1019, DOI 10.1111/j.1432-1033.1994.t01-1-01019.x; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KIERSZENBAUM F, 1987, P NATL ACAD SCI USA, V84, P4278, DOI 10.1073/pnas.84.12.4278; LOPES MF, 1995, J IMMUNOL, V154, P744; MAMONT PS, 1976, P NATL ACAD SCI USA, V73, P1626, DOI 10.1073/pnas.73.5.1626; MAXFIELD SR, 1989, J EXP MED, V169, P2173, DOI 10.1084/jem.169.6.2173; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; Nunes MP, 1998, J IMMUNOL, V160, P1313; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PROSSER EH, 1998, ARCH BIOCHEM BIOPHYS, V260, P218; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; Soares MBP, 1997, INFECT IMMUN, V65, P2837, DOI 10.1128/IAI.65.7.2837-2845.1997; STURMER AM, 1992, J IMMUNOL METHODS, V146, P105, DOI 10.1016/0022-1759(92)90053-V; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369	29	349	358	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2000	403	6766					199	203		10.1038/35003208	http://dx.doi.org/10.1038/35003208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646605	Green Published			2022-12-01	WOS:000084835300056
J	Kessel, A; Watts, C; Weiss, HA				Kessel, A; Watts, C; Weiss, HA			Bad blood? Survey of public's views on unlinked anonymous testing of blood for HIV and other diseases	BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, Epidemiol Unit, London WC1E 7HT, England; Barking & Havering Hlth Author, Directorate Publ Hlth, Barking IG11 8EY, England; Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Kessel, A (corresponding author), Univ London London Sch Hyg & Trop Med, Epidemiol Unit, Keppel St, London WC1E 7HT, England.		weiss, helen/ABC-7823-2021	weiss, helen/0000-0003-3547-7936				Berridge V., 1996, AIDS UK MAKING POLIC; *DEP HLTH HUM SERV, 1997, CHILD MALTR 1995 REP, P2; GILL ON, 1989, BRIT MED J, V299, P1297; Kessel Anthony S, 1997, Sci Eng Ethics, V3, P297, DOI 10.1007/s11948-997-0036-0; KOPELMAN LM, 1994, J MED PHILOS, V19, P525, DOI 10.1093/jmp/19.6.525	5	6	6	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					90	91		10.1136/bmj.320.7227.90	http://dx.doi.org/10.1136/bmj.320.7227.90			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625262	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000084746600017
J	Sheridan, RL; Hinson, MI; Liang, MH; Nackel, AF; Schoenfeld, DA; Ryan, CM; Mulligan, JL; Tompkins, RG				Sheridan, RL; Hinson, MI; Liang, MH; Nackel, AF; Schoenfeld, DA; Ryan, CM; Mulligan, JL; Tompkins, RG			Long-term outcome of children surviving massive burns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SF-36 HEALTH SURVEY; THERMAL-INJURY; FULL-THICKNESS; BODY-SURFACE; VALIDITY; QUALITY; LIFE; MORTALITY; EXCISION; DETERMINANTS	Context Major advances in treatment of burn injuries in the last 20 years have made it possible to save the lives of children with massive burns, but whether their survival comes at the cost of impaired quality of life is unknown. Objective To investigate the long-term quality of life in children who have survived massive burns. Design and Setting Retrospective, cross-sectional study conducted in a regional pediatric burn center. Patients Eighty subjects who were younger than 18 years at the time of injury, who survived massive burns involving greater than or equal to 70% of the body surface, and who were admitted to the burn center between 1969 and 1992 were evaluated an average (SD) of 14.7 (6.0) years after injury. Main Outcome Measures Short Form 36 (SF-36) scores of the 60 patients aged at least 14 years were compared with national norms and the impact of clinical variables on individual domain scores was assessed. Results The SF-36 domain scores of the study patients, who had survived massive burns at a mean (SD) age of 8.8 (5.5) years, were generally similar to the normal population). However, 15% and 20% of the burn patients had scores in the physical functioning and physical role domains, respectively, that were more than 2 SDs below the relevant norm, indicating that a few patients had continuing serious physical disability. Better functional status of the family predicted a higher score in physical role (P = .04). The child's early reintegration with preburn activities predicted higher scores in general health (P = .03), physical functioning (P = .003), and physical role (P = .01). Children followed up consistently in the multidisciplinary burn clinic for 2 years had higher physical functioning (P = .04). Conclusions In this study, while some children surviving severe burns had lingering physical disability, most had a satisfying quality of life. Comprehensive burn care that included experienced multidisciplinary aftercare played an important role in recovery.	Massachusetts Gen Hosp, Burn Serv, Boston, MA 02114 USA; Shriners Burns Hosp Children, Boston, MA USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Tompkins, RG (corresponding author), Massachusetts Gen Hosp, Burn Serv, GRB1302,55 Fruit St, Boston, MA 02114 USA.			Ryan, Colleen/0000-0002-6455-936X	NIGMS NIH HHS [GM P50-21700, GM T32-07035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007035, P50GM021700] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aaronson N K, 1988, Oncology (Williston Park), V2, P69; ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771; Anderson C, 1996, STROKE, V27, P1812, DOI 10.1161/01.STR.27.10.1812; BLAKENEY P, 1990, Journal of Burn Care and Rehabilitation, V11, P472, DOI 10.1097/00004630-199009000-00018; BROWNE G, 1985, BURNS, V12, P28, DOI 10.1016/0305-4179(85)90180-9; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; BURKE JF, 1976, SURG CLIN N AM, V56, P477; Byrne C, 1986, J Burn Care Rehabil, V7, P247, DOI 10.1097/00004630-198605000-00011; EYLES P, 1984, BURNS, V10, P427, DOI 10.1016/0305-4179(84)90084-6; Fratianne R B, 1992, J Burn Care Rehabil, V13, P600, DOI 10.1097/00004630-199209000-00018; HERNDON DN, 1986, J TRAUMA, V26, P609, DOI 10.1097/00005373-198607000-00004; HERNDON DN, 1987, J TRAUMA, V27, P208, DOI 10.1097/00005373-198702000-00020; JENKINSON C, 1994, QUAL LIFE RES, V3, P7, DOI 10.1007/BF00647843; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; PERNEGER TV, 1995, J CLIN EPIDEMIOL, V48, P1051, DOI 10.1016/0895-4356(94)00227-H; PINNEGAR MD, 1986, BURNS, V12, P508, DOI 10.1016/0305-4179(86)90079-3; Ryan CM, 1998, NEW ENGL J MED, V338, P362, DOI 10.1056/NEJM199802053380604; SAWYER MG, 1983, BURNS, V9, P205, DOI 10.1016/0305-4179(83)90040-2; Sheridan R L, 1994, J Intensive Care Med, V9, P6; Sheridan R L, 1998, Curr Probl Pediatr, V28, P105, DOI 10.1016/S0045-9380(98)80021-2; Sheridan R L, 1998, Curr Probl Pediatr, V28, P139, DOI 10.1016/S0045-9380(98)80061-3; SHERIDAN RL, 1995, J TRAUMA, V38, P48, DOI 10.1097/00005373-199501000-00014; STODDARD FJ, 1989, J AM ACAD CHILD PSY, V28, P589, DOI 10.1097/00004583-198907000-00020; Stoll T, 1997, J RHEUMATOL, V24, P1608; SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q; TOMPKINS RG, 1988, ANN SURG, V208, P577, DOI 10.1097/00000658-198811000-00006; VANDAM F, 1986, B CANCER, V73, P607; Warden Glenn D., 1993, Journal of Burn Care and Rehabilitation, V14, P581, DOI 10.1097/00004630-199311000-00001; WARE JE, 1993, SF 36 HLTH SURVEY MA, V3, P4; Wolf SE, 1997, ANN SURG, V225, P554, DOI 10.1097/00000658-199705000-00012; WRIGHT L, 1974, PEDIATR RES, V8, P931, DOI 10.1203/00006450-197412000-00003; [No title captured]	32	188	193	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					69	73		10.1001/jama.283.1.69	http://dx.doi.org/10.1001/jama.283.1.69			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	270AZ	10632282	Bronze			2022-12-01	WOS:000084514400027
J	Chaudhry, FA; Reimer, RJ; Krizaj, D; Barber, D; Storm-Mathisen, J; Copenhagen, DR; Edwards, RH				Chaudhry, FA; Reimer, RJ; Krizaj, D; Barber, D; Storm-Mathisen, J; Copenhagen, DR; Edwards, RH			Molecular analysis of system N suggests novel physiological roles in nitrogen metabolism and synaptic transmission	CELL			English	Article							AMINO-ACID TRANSPORTER; VESICULAR GABA TRANSPORTER; GLUTAMINE TRANSPORT; NEUROTRANSMITTER TRANSPORTERS; DOPAMINE TRANSPORTER; CEREBRAL-CORTEX; GLIAL-CELLS; RAT-LIVER; ARABIDOPSIS; IMMUNOCYTOCHEMISTRY	The amino acid glutamine has a central role in nitrogen metabolism. Although the molecular mechanisms responsible for its transport across cell membranes remain poorly understood, classical amino acid transport system N appears particularly important. Using intracellular pH measurements, we have now identified an orphan protein related to a vesicular neurotransmitter transporter as system N. Functional analysis shows that this protein (SN1) involves H+ exchange as well as Na+ cotransport and, under physiological conditions, mediates glutamine efflux as well as uptake. Together with the pattern of SN1 expression, these unusual properties suggest novel physiological roles for system N in nitrogen metabolism and synaptic transmission.	Univ Calif San Francisco, Sch Med, Grad Program Neurosci, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Grad Program Cell Biol, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Grad Program Biomed Sci, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Univ Oslo, Inst Basic Med Sci, Dept Anat, N-0317 Oslo, Norway	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Oslo	Edwards, RH (corresponding author), Univ Calif San Francisco, Sch Med, Grad Program Neurosci, Dept Neurol, San Francisco, CA 94143 USA.		Krrr, Daa/ABG-2688-2020	Krrr, Daa/0000-0003-4468-3029; Storm-Mathisen, Jon/0000-0002-2930-3262				ALBRECHT J, 1989, NEUROPHARMACOLOGY, V28, P885, DOI 10.1016/0028-3908(89)90183-4; Amara S G, 1993, Curr Opin Neurobiol, V3, P337, DOI 10.1016/0959-4388(93)90126-J; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; Bender D.A., 1975, AMINO ACID METABOLIS; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; Boorer KJ, 1997, J BIOL CHEM, V272, P13040, DOI 10.1074/jbc.272.20.13040; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; Chang HC, 1997, J BIOL CHEM, V272, P30552, DOI 10.1074/jbc.272.48.30552; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Chaudhry FA, 1998, J NEUROSCI, V18, P9733; Chen LS, 1997, PLANT PHYSIOL, V115, P1127, DOI 10.1104/pp.115.3.1127; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; COLLARINI EJ, 1987, ANNU REV NUTR, V7, P75, DOI 10.1146/annurev.nu.07.070187.000451; CONTI F, 1994, J HISTOCHEM CYTOCHEM, V42, P717, DOI 10.1177/42.6.7910617; Dehnes Y, 1998, J NEUROSCI, V18, P3606; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; Ennis SR, 1998, J NEUROCHEM, V71, P2565; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; Fishman RA., 1992, CEREBROSPINAL FLUID; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GUIDOTTI GG, 1992, MAMMALIAN AMINO ACID TRANSPORT, P3; Gundersen V, 1996, EUR J NEUROSCI, V8, P758, DOI 10.1111/j.1460-9568.1996.tb01261.x; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HUNDAL HS, 1987, J PHYSIOL-LONDON, V393, P283, DOI 10.1113/jphysiol.1987.sp016824; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; KANNER BI, 1994, J EXP BIOL, V196, P237; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; Krizaj D, 1998, NEURON, V21, P249, DOI 10.1016/S0896-6273(00)80531-0; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; Nagaraja TN, 1996, J NEUROCHEM, V66, P1665; OTTERSEN OP, 1992, NEUROSCIENCE, V46, P519, DOI 10.1016/0306-4522(92)90141-N; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pouyssegur J, 1987, Methods Enzymol, V151, P131, DOI 10.1016/S0076-6879(87)51014-X; RAMAHAROBANDRO N, 1982, BRAIN RES, V244, P113, DOI 10.1016/0006-8993(82)90909-X; Rentsch D, 1996, PLANT CELL, V8, P1437, DOI 10.1105/tpc.8.8.1437; Rose CR, 1998, J NEUROSCI, V18, P3554; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; ROTHSTEIN JD, 1984, J NEUROCHEM, V43, P1438, DOI 10.1111/j.1471-4159.1984.tb05406.x; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; STORMMATHISEN J, 1986, MED BIOL, V64, P127; Tamarappoo BK, 1997, J NEUROCHEM, V68, P954; TATE SS, 1973, ENZYMES GLUTAMINE ME, P77; TAYLOR PM, 1992, J BIOL CHEM, V267, P3873; THANKI CM, 1983, J NEUROCHEM, V41, P611, DOI 10.1111/j.1471-4159.1983.tb04785.x; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Xiang JM, 1998, BRAIN RES, V783, P37, DOI 10.1016/S0006-8993(97)01194-3; Young GB, 1999, BBA-BIOMEMBRANES, V1415, P306, DOI 10.1016/S0005-2736(98)00196-5; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991	52	259	265	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					769	780		10.1016/S0092-8674(00)81674-8	http://dx.doi.org/10.1016/S0092-8674(00)81674-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619430	Bronze			2022-12-01	WOS:000084488200010
J	Lugovskoy, AA; Zhou, P; Chou, JJ; McCarty, JS; Li, P; Wagner, G				Lugovskoy, AA; Zhou, P; Chou, JJ; McCarty, JS; Li, P; Wagner, G			Solution structure of the CIDE-N domain of CIDE-B and a model for CIDE-N/CIDE-N interactions in the DNA fragmentation pathway of apoptosis	CELL			English	Article							NMR STRUCTURE; CELL-DEATH; PROTEIN; ACTIVATION; MITOCHONDRIA; MUTAGENESIS; RESONANCE; INHIBITOR; CASPASE-3; DYNAMICS	Apoptotic DNA fragmentation and chromatin condensation are mediated by the caspase-activated DFF40/ CAD nuclease, which is chaperoned and inhibited by DFF45/ICAD. CIDE proteins share a homologous regulatory CIDE-N domain with DFF40/CAD and DFF45/ ICAD. Here we report the solution structure of CIDE-N of human CIDE-B. We show that the CIDE-N of CIDE-B interacts with CIDE-N domains of both DFF40 and DFF45. The binding epitopes are similar and map to a highly charged bipolar surface region of CIDE-B. Furthermore, we demonstrate that the CIDE-N of CIDE-B regulates enzymatic activity of the DFF40/ DFF45 complex in vitro. Based on these results and mutagenesis data, we propose a model for the CIDE-N/ CIDE-N complex and discuss the role of this novel bipolar interaction in mediating downstream events of apoptosis.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Comm Higher Degrees Biophys, Cambridge, MA 02138 USA; Inst Mol & Cell Biol, Lab Apoptosis Regulat, Singapore 117609, Singapore	Harvard University; Harvard Medical School; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Wagner, G (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	gerhard_wagner@hms.harvard.edu	Chou, James J/N-9840-2013; Chou, James/AAD-6230-2022; Zhou, Pei/O-6704-2019	Chou, James J/0000-0002-4442-0344; Chou, James/0000-0002-4442-0344; Zhou, Pei/0000-0002-7823-3416	NIGMS NIH HHS [GM 38608] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038608] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BRUNGER AT, 1994, XPLOR MANUAL 3 851 S; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEVITT M, 1983, J MOL BIOL, V168, P595, DOI 10.1016/S0022-2836(83)80304-0; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; LEVITT M, 1995, LOOK VERSION 2 0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liang H, 1997, J MOL BIOL, V274, P291, DOI 10.1006/jmbi.1997.1415; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P181, DOI 10.1006/bbrc.1999.1498; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P176, DOI 10.1006/bbrc.1999.1497; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sun ZYJ, 1999, EMBO J, V18, P2941, DOI 10.1093/emboj/18.11.2941; SZYPERSKI T, 1992, J BIOMOL NMR, V2, P323, DOI 10.1007/BF01874811; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	41	95	97	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1999	99	7					747	755		10.1016/S0092-8674(00)81672-4	http://dx.doi.org/10.1016/S0092-8674(00)81672-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619428	Bronze			2022-12-01	WOS:000084488200008
J	Koenig, RE				Koenig, RE			AIDS in paradise	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		GOMEZ E, 1996, ESTIMACIONES PROYECC	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2195	2196		10.1001/jama.282.23.2195	http://dx.doi.org/10.1001/jama.282.23.2195			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263RG	10605958				2022-12-01	WOS:000084138600001
J	Senzaki, K; Ogawa, M; Yagi, T				Senzaki, K; Ogawa, M; Yagi, T			Proteins of the CNR family are multiple receptors for reelin	CELL			English	Article							DEVELOPING CEREBELLAR CORTEX; CAJAL-RETZIUS CELLS; HIPPOCAMPAL DEVELOPMENT; EXPRESSION; MOUSE; ORGANIZATION; MIGRATION; NEURONS; BRAIN; MICE	Layering and positioning of neurons require Reelin-and Src family-associated mammalian Disabled (mDab1). Cadherin-related neuronal receptor (CNR) genes are expressed in neurons of the cortical layer, but not in Cajal-Retzius cells expressing Reelin. This leads us to hypothesize that CNRs bound to Fyn of the Src family are receptors for Reelin. Herein we confirm the association and colocalization of CNR proteins with Reelin. This binding is blocked by CR-50 antibody against Reelin, as well as by monoclonal antibodies produced against CNRs. Both disturb the signaling pathway from Reelin to mDab1 and the positioning of cortical neurons in vitro. These results strongly suggest that the CNR family proteins are multiple Reelin receptors. In addition, differential conservation of the Reelin-binding domain among terrestrial vertebrates may be pertinent to the diversity or complexity of brains.	Natl Inst Physiol Sci, Lab Neurobiol & Behav Genet, Okazaki, Aichi 4448585, Japan; RIKEN, Lab Cell Culture Dev, Brain Sci Inst, Wako, Saitama 35101, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); RIKEN	Yagi, T (corresponding author), Natl Inst Physiol Sci, Lab Neurobiol & Behav Genet, Okazaki, Aichi 4448585, Japan.	yagi@nips.ac.jp						Alcantara S, 1998, J NEUROSCI, V18, P7779; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; DELONG GR, 1970, DEV BIOL, V22, P563, DOI 10.1016/0012-1606(70)90169-7; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Komuro H, 1998, J NEUROSCI, V18, P1478; Marin-Padilla M, 1998, TRENDS NEUROSCI, V21, P64, DOI 10.1016/S0166-2236(97)01164-8; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nakajima K, 1997, P NATL ACAD SCI USA, V94, P8196, DOI 10.1073/pnas.94.15.8196; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; Prince VE, 1998, DEVELOPMENT, V125, P407; Rakic P, 1996, P NATL ACAD SCI USA, V93, P9218, DOI 10.1073/pnas.93.17.9218; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RIVAS RJ, 1995, J NEUROSCI, V15, P981; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; YAGI T, 1993, ONCOGENE, V8, P3343; Yagi T, 1999, BIOCHEM PHARMACOL, V57, P845; [No title captured]	42	241	244	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					635	647		10.1016/S0092-8674(00)81552-4	http://dx.doi.org/10.1016/S0092-8674(00)81552-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612399	Bronze			2022-12-01	WOS:000084278700010
J	Mitchell, E				Mitchell, E			Commentary: Cot death-the story so far	BRITISH MEDICAL JOURNAL			English	Editorial Material							SLEEPING POSITION		Univ Auckland, Fac Med & Hlth Sci, Dept Paediat, Auckland 1, New Zealand	University of Auckland	Mitchell, E (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Paediat, Postbag 92019, Auckland 1, New Zealand.							Fleming PJ, 1999, ARCH DIS CHILD, V81, P112, DOI 10.1136/adc.81.2.112; L'Hoir MP, 1998, EUR J PEDIATR, V157, P681, DOI 10.1007/s004310050911; MITCHELL EA, 1999, INT CONSULTATION ENV, P105; NELSON EAS, 1989, LANCET, V1, P199; Scragg RKR, 1998, ANN MED, V30, P345, DOI 10.3109/07853899809029933	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1461	1462						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10644147				2022-12-01	WOS:000084129200017
J	Bush, RM; Bender, CA; Subbarao, K; Cox, NJ; Fitch, WM				Bush, RM; Bender, CA; Subbarao, K; Cox, NJ; Fitch, WM			Predicting the evolution of human influenza A	SCIENCE			English	Article							VIRUS HEMAGGLUTININ	Eighteen codons in the HA1 domain of the hemagglutinin genes of human influenza A subtype H3 appear to be under positive selection to change the amino acid they encode. Retrospective tests show that viral Lineages undergoing the greatest number of mutations in the positively selected codons were the progenitors of future H3 Lineages in 9 of 11 recent influenza seasons. Codons under positive selection were associated with antibody combining site A or B or the sialic acid receptor binding site. However, not all codons in these sites had predictive value. Monitoring new H3 isolates for additional changes in positively selected codons might help identify the most fit extant viral strains that arise during antigenic drift.	Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; Ctr Dis Control & Prevent, Influenza Branch, Atlanta, GA 30333 USA	University of California System; University of California Irvine; Centers for Disease Control & Prevention - USA	Bush, RM (corresponding author), Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA.			Subbarao, Kanta/0000-0003-1713-3056				BENDER CM, UNPUB; Bush RM, 1999, MOL BIOL EVOL, V16, P1457, DOI 10.1093/oxfordjournals.molbev.a026057; Cox NJ, 1995, SEMIN VIROL, V6, P359, DOI 10.1016/S1044-5773(05)80013-7; Fitch WM, 1997, P NATL ACAD SCI USA, V94, P7712, DOI 10.1073/pnas.94.15.7712; SWOFFORD DL, PAUP PHYLOGENETIC AN; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.iy.08.040190.003513	8	368	390	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1921	1925		10.1126/science.286.5446.1921	http://dx.doi.org/10.1126/science.286.5446.1921			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583948				2022-12-01	WOS:000084003400041
J	Pappu, R; Cheng, AM; Li, B; Gong, Q; Chiu, C; Griffin, N; White, M; Sleckman, BP; Chan, AC				Pappu, R; Cheng, AM; Li, B; Gong, Q; Chiu, C; Griffin, N; White, M; Sleckman, BP; Chan, AC			Requirement for B cell linker protein (BLNK) in B cell development	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; SYK TYROSINE KINASE; POSITIVE SELECTION; MICE LACKING; AGAMMAGLOBULINEMIA; ZAP-70; GENE; BTK; DEFICIENCY; ACTIVATION	Linker proteins function as molecular scaffolds to Localize enzymes with substrates. In B cells, B cell Linker protein (BLNK) Links the B cell receptor (BCR)activated Syk kinase to the phosphoinositide and mitogen-activated kinase pathways. To examine the in vivo role of BLNK, mice deficient in BLNK were generated. B cell development in BLNK-/- mice was blocked at the transition from B220(+) CD43(+) progenitor B to B220(+) CD43(-) precursor B cells. Only a small percentage of immunoglobulin M++ (IgM(++)), but not mature IgM(lo)lgD(hi), B cells were detected in the periphery. Hence, BLNK is an essential component of BCR signaling pathways and is required to promote B cell development.	Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Rheumatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Chan, AC (corresponding author), Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA.		Childs, James E/B-4002-2012	Chiu, Christopher W./0000-0001-9744-991X	NATIONAL CANCER INSTITUTE [R01CA071516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042787] Funding Source: NIH RePORTER; NCI NIH HHS [CA71516] Funding Source: Medline; NIAID NIH HHS [AI42787] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Benschop RJ, 1999, CURR OPIN IMMUNOL, V11, P143, DOI 10.1016/S0952-7915(99)80025-9; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1999, J IMMUNOL, V163, P2610; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gangi-Peterson L, 1998, MOL IMMUNOL, V35, P55, DOI 10.1016/S0161-5890(98)00008-X; Goitsuka R, 1998, J IMMUNOL, V161, P5804; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Hendriks RW, 1996, EMBO J, V15, P4862, DOI 10.1002/j.1460-2075.1996.tb00867.x; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; KANTOR AB, 1992, P NATL ACAD SCI USA, V89, P3320, DOI 10.1073/pnas.89.8.3320; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LEDBETTER JA, 1979, IMMUNOGENETICS, V8, P347, DOI 10.1007/BF01561445; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; PAPPU R, UNPUB; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; von Boehmer H, 1999, CURR OPIN IMMUNOL, V11, P135, DOI 10.1016/S0952-7915(99)80024-7; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791	37	237	241	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1949	1954		10.1126/science.286.5446.1949	http://dx.doi.org/10.1126/science.286.5446.1949			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583957				2022-12-01	WOS:000084003400050
J	Liu, F; Wan, Q; Pristupa, ZB; Yu, XM; Wang, YT; Niznik, HB				Liu, F; Wan, Q; Pristupa, ZB; Yu, XM; Wang, YT; Niznik, HB			Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors	NATURE			English	Article							GABA(A) RECEPTORS; BETA-SUBUNITS; PHOSPHORYLATION; SUBTYPES; CURRENTS; D1; SCHIZOPHRENIA; MODULATION; DIVERSITY; SYNAPSES	GABAA (gamma-aminobutyric-acid A) and dopamine D1 and D5 receptors represent two structurally and functionally divergent families of neurotransmitter receptors, The former comprises a class of multi-subunit ligand-gated channels mediating fast interneuronal synaptic transmission, whereas the latter belongs to the seven-transmembrane-domain single-polypeptide receptor superfamily that exerts its biological effects, including the modulation of GABA(A) receptor function, through the activation of second-messenger signalling cascades by G proteins, Here we show that GABA(A)-ligand-gated channels complex selectively with D5 receptors through the direct binding of the D5 carboxy-terminal domain with the second intracellular loop of the GABA(A) gamma 2(short) receptor subunit, This physical association enables mutually inhibitory functional interactions between these receptor systems, The data highlight a previously unknown signal transduction mechanism whereby subtype-selective G-protein-coupled receptors dynamically regulate synaptic strength independently of classically defined second-messenger systems, and provide a heuristic framework in which to view these receptor systems in the maintenance of psychomotor disease states.	Hosp Sick Children, Program Brain & Behav, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Oral Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Mol Neurobiol Sect, Toronto, ON M5T 1R8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	Wang, YT (corresponding author), Hosp Sick Children, Program Brain & Behav, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Wang, Yu Tian/J-8255-2015; Wang, Yu Tian/A-4729-2008					Barnard EA, 1998, PHARMACOL REV, V50, P291; Benes FM, 1997, J PSYCHIATR RES, V31, P257, DOI 10.1016/S0022-3956(96)00044-1; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Brunig I, 1999, P NATL ACAD SCI USA, V96, P2456, DOI 10.1073/pnas.96.5.2456; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Costa E, 1998, ANNU REV PHARMACOL, V38, P321, DOI 10.1146/annurev.pharmtox.38.1.321; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; GoldmanRakic PS, 1997, SCHIZOPHRENIA BULL, V23, P437, DOI 10.1093/schbul/23.3.437; Gorrie GH, 1997, J NEUROSCI, V17, P6587; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Huntsman MM, 1998, P NATL ACAD SCI USA, V95, P15066, DOI 10.1073/pnas.95.25.15066; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Keverne EB, 1999, BRAIN RES BULL, V48, P467, DOI 10.1016/S0361-9230(99)00025-8; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MARSHALL FH, 1999, TRENDS PHARMACOL SCI, V10, P369; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; MCDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; MONIYAMA T, 1996, J NEUROSCI, V16, P7502; Moore H, 1999, BIOL PSYCHIAT, V46, P40, DOI 10.1016/S0006-3223(99)00078-5; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; NIZNIK HB, IN PRESS HDB EXPT PH; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; NUSSER Z, 1995, EUR J NEUROSCI, V7, P60; Okubo Y, 1997, NATURE, V385, P634, DOI 10.1038/385634a0; Poisbeau P, 1999, J NEUROSCI, V19, P674; Radnikow G, 1998, J NEUROSCI, V18, P2009; Sibley DR, 1999, ANNU REV PHARMACOL, V39, P313, DOI 10.1146/annurev.pharmtox.39.1.313; Sidhu A, 1998, MOL NEUROBIOL, V16, P125, DOI 10.1007/BF02740640; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Sperk G, 1997, NEUROSCIENCE, V80, P987, DOI 10.1016/S0306-4522(97)00146-2; Sugamori KS, 1998, J NEUROCHEM, V71, P2593; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; Tretter V, 1997, J NEUROSCI, V17, P2728; UNWIN N, 1991, CELL S, V72, P653; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Wan Q, 1997, J NEUROSCI, V17, P5062; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Yan Z, 1997, NEURON, V19, P1115, DOI 10.1016/S0896-6273(00)80402-X; Yu XM, 1998, NATURE, V396, P469, DOI 10.1038/24877	49	366	380	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					274	280		10.1038/35002014	http://dx.doi.org/10.1038/35002014			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659839				2022-12-01	WOS:000084899700042
J	van Ginneken, VJT; van den Thillart, GEEJM				van Ginneken, VJT; van den Thillart, GEEJM			Physiology - Eel fat stores are enough to reach the Sargasso	NATURE			English	Article							SEA		Inst Ecol & Evolutionary Sci Integrat Zool, Van Der Klaauw Lab, NL-2300 RA Leiden, Netherlands		van Ginneken, VJT (corresponding author), Inst Ecol & Evolutionary Sci Integrat Zool, Van Der Klaauw Lab, POB 9511, NL-2300 RA Leiden, Netherlands.							BOETIUS I, 1980, Dana, V1, P1; Castonguay Martin, 1994, Fisheries Oceanography, V3, P197, DOI 10.1111/j.1365-2419.1994.tb00097.x; ELLIOTT JM, 1975, OECOLOGIA, V19, P195, DOI 10.1007/BF00345305; FRICKE H, 1995, NATURWISSENSCHAFTEN, V82, P32, DOI 10.1007/s001140050136; MILLER MJ, 1994, J MAR RES, V52, P743, DOI 10.1357/0022240943076948; Schmidt J, 1923, NATURE, V111, P51, DOI 10.1038/111051a0; SCHMIDTNIELSEN K, 1972, SCIENCE, V177, P222, DOI 10.1126/science.177.4045.222; Svedang H, 1997, J FISH BIOL, V50, P475, DOI 10.1111/j.1095-8649.1997.tb01943.x; Tesch F.-W., 1977, EEL BIOL MANAGEMENT; VANDIJK PLM, 1993, J FISH BIOL, V42, P661, DOI 10.1006/jfbi.1993.1075; Wootton RJ, 1979, S ZOOL SOC LOND, P133	11	97	108	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					156	157		10.1038/35003110	http://dx.doi.org/10.1038/35003110			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646590				2022-12-01	WOS:000084835300041
J	Mulryan, K; Gitterman, DP; Lewis, CJ; Vial, C; Leckie, BJ; Cobb, AL; Brown, JE; Conley, EC; Buell, G; Pritchard, CA; Evans, RJ				Mulryan, K; Gitterman, DP; Lewis, CJ; Vial, C; Leckie, BJ; Cobb, AL; Brown, JE; Conley, EC; Buell, G; Pritchard, CA; Evans, RJ			Reduced vas deferens contraction and male infertility in mice lacking P2X(1) receptors	NATURE			English	Article							GATED ION CHANNELS; ALPHA,BETA-METHYLENE ATP; PURINE NUCLEOTIDES; GUINEA-PIG; RAT; MOUSE	P2X(1) receptors for ATP are ligand-gated cation channels, present on many excitable cells including vas deferens smooth muscle cells(1-5). A substantial component of the contractile response of the vas deferens to sympathetic nerve stimulation, which propels sperm into the ejaculate. is mediated through P2X receptors'. Here we show that male fertility is reduced by similar to 90% in mice with a targeted deletion of the P2X(1) receptor gene. Male mice copulate normally-reduced fertility results from a reduction of sperm in the ejaculate and not from sperm dysfunction. Female mice and heterozygote mice are unaffected. In P2X(1)-receptor-deficient mice, contraction of the vas deferens to sympathetic nerve stimulation is reduced by up to 60% and responses to P2X receptor agonists are abolished. These results show that P2X(1) receptors are essential for normal male reproductive function and suggest that the development of selective P2X(1) receptor antagonists may provide an effective non-hormonal male contraceptive pill. Also, agents that potentiate the actions of ATP at P2X(1) receptors may be useful in the treatment of male infertility.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Med, Transgen Unit, Biomed Serv, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Pathol, Leicester LE1 9HN, Leics, England; Univ Leicester, Ctr Mechanisms Human Tox, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; Glaxo Wellcome Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland	University of Leicester; University of Leicester; University of Leicester; University of Leicester; University of Leicester; GlaxoSmithKline	Evans, RJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Med Sci Bldg, Leicester LE1 9HN, Leics, England.			Pritchard, Catrin/0000-0003-1859-4487				ALLCORN RJ, 1986, BRIT J PHARMACOL, V89, P647, DOI 10.1111/j.1476-5381.1986.tb11169.x; ANDERSON RA, 1983, J REPROD FERTIL, V68, P1, DOI 10.1530/jrf.0.0680001; BRADING AF, 1990, BRIT J PHARMACOL, V99, P493, DOI 10.1111/j.1476-5381.1990.tb12956.x; BURNSTOCK G, 1961, J PHYSIOL-LONDON, V155, P115, DOI 10.1113/jphysiol.1961.sp006617; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Collo G, 1996, J NEUROSCI, V16, P2495; Costa SL, 1997, BIOL REPROD, V56, P985, DOI 10.1095/biolreprod56.4.985; Evans RJ, 1996, SEMIN NEUROSCI, V8, P217, DOI 10.1006/smns.1996.0028; HEDLUND H, 1985, J AUTON PHARMACOL, V5, P261, DOI 10.1111/j.1474-8673.1985.tb00127.x; HOFFMAN BB, 1996, PHARMACOL BASIS THER, V9, P199; Hogan B., 1986, MANIPULATING MOUSE E; Jacobson KA, 1998, J MED CHEM, V41, P2201, DOI 10.1021/jm980183o; KENAKIN T, 1997, PHARM ANAL DRUG RECE, V3, P63; KHAKH BS, 1995, BRIT J PHARMACOL, V115, P177, DOI 10.1111/j.1476-5381.1995.tb16336.x; LEWIS C, 1998, BRIT J PHARMACOL, P1463; Ralevic V, 1998, PHARMACOL REV, V50, P413; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VONKUGELGEN I, 1990, N-S ARCH PHARMACOL, V342, P198, DOI 10.1007/BF00166965; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; Yang LY, 1998, PHYSIOL BEHAV, V63, P675, DOI 10.1016/S0031-9384(97)00523-4	21	309	311	4	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					86	89		10.1038/47495	http://dx.doi.org/10.1038/47495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638758				2022-12-01	WOS:000084687400048
J	Xu, T; Rammner, B; Margittai, M; Artalejo, AR; Neher, E; Jahn, R				Xu, T; Rammner, B; Margittai, M; Artalejo, AR; Neher, E; Jahn, R			Inhibition of SNARE complex assembly differentially affects kinetic components of exocytosis	CELL			English	Article							ADRENAL CHROMAFFIN CELLS; MEMBRANE-FUSION; SYNAPTIC EXOCYTOSIS; NEUROTRANSMITTER RELEASE; FLASH-PHOTOLYSIS; CAGED CA2+; SECRETION; SYNTAXIN; VESICLES; PROTEINS	In chromaffin cells, an increase in intracellular Ca2+ leads to an exocytotic burst followed by sustained secretion. The burst can be further resolved into two kinetically distinct components, which suggests the presence of two separate pools of vesicles. To investigate how these components relate to SNARE complex formation, we introduced an antibody that blocks SNARE assembly but not disassembly. In the presence of the antibody, the sustained component was largely blocked, the burst was slightly reduced, and one of its kinetic components was eliminated. We conclude that SNARE complexes form before Ca2+-triggered membrane fusion and exist in a dynamic equilibrium between a loose and a tight state, both of which support exocytosis. Interaction of the antibody with preformed SNARE complexes favors the loose state.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany	Max Planck Society; Max Planck Society	Jahn, R (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Am Fassberg 2, D-37077 Gottingen, Germany.	rjahn@gwdg.de	Oka, Yoshitaka/C-9670-2010; Neher, Erwin/A-2109-2013; Artalejo, Antonio R./H-4378-2015; Margittai, Martin/D-5039-2014; Artalejo, Antonio R./ABG-2009-2020	Oka, Yoshitaka/0000-0002-3482-3051; Artalejo, Antonio R./0000-0001-9720-9190; Margittai, Martin/0000-0003-1903-5927; Artalejo, Antonio R./0000-0001-9720-9190; Jahn, Reinhard/0000-0003-1542-3498				Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; Bruns D, 1997, J NEUROSCI, V17, P1898; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Gillis Kevin D., 1995, P155; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; Henkel AW, 1996, CURR OPIN NEUROBIOL, V6, P350, DOI 10.1016/S0959-4388(96)80119-X; HESS DT, 1992, J NEUROSCI, V12, P4634; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Margittai M, 1999, FEBS LETT, V446, P40, DOI 10.1016/S0014-5793(99)00028-9; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Rizo J, 1998, NAT STRUCT BIOL, V5, P839, DOI 10.1038/2280; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Ryan TA, 1998, NAT NEUROSCI, V1, P175, DOI 10.1038/621; Schulte A, 1996, ANAL CHEM, V68, P3054, DOI 10.1021/ac960210n; Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Terrian DM, 1997, EUR J CELL BIOL, V73, P198; THEAN ET, 1989, ANAL BIOCHEM, V177, P256, DOI 10.1016/0003-2697(89)90048-1; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Xu T, 1997, BIOPHYS J, V73, P532, DOI 10.1016/S0006-3495(97)78091-3; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Xu T, 1999, EMBO J, V18, P3293, DOI 10.1093/emboj/18.12.3293	58	243	254	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	1999	99	7					713	722		10.1016/S0092-8674(00)81669-4	http://dx.doi.org/10.1016/S0092-8674(00)81669-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619425	Bronze			2022-12-01	WOS:000084488200005
J	Collins, MW; Lovell, MR; Mckeag, DB				Collins, MW; Lovell, MR; Mckeag, DB			Current issues in managing sports-related concussion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Henry Ford Hlth Syst, Div Neuropsychol, Detroit, MI 48202 USA; Indiana Univ, Sch Med, Dept Family Med, Indianapolis, IN USA	Henry Ford Health System; Henry Ford Hospital; Indiana University System; Indiana University-Purdue University Indianapolis	Collins, MW (corresponding author), Henry Ford Hlth Syst, Div Neuropsychol, 1 Ford Pl 1E, Detroit, MI 48202 USA.	mcollin1@hfhs.org						CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; *COL MED SOC, 1991, REP SPORTS MED COMM; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; COLLINS MW, 1999, P MIDW AM COLL SPORT; Hovda D. A., 1994, Society for Neuroscience Abstracts, V20, P845; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, IN PRESS CLIN J SPOR; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MCKEAG DB, 1999, P ANN M AM MED SOC S; *QUAL STAND SUBC A, 1997, NEUROBIOLOGY, V48, P1; RICE SG, 1998, HEAD INJURED ATHLETE; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	15	87	89	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1999	282	24					2283	2285		10.1001/jama.282.24.2283	http://dx.doi.org/10.1001/jama.282.24.2283			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265TK	10612307				2022-12-01	WOS:000084261700001
J	Landgraf, M; Augustsson, K; Grun, E; Gustafson, BAS				Landgraf, M; Augustsson, K; Grun, E; Gustafson, BAS			Deflection of the local interstellar dust flow by solar radiation pressure	SCIENCE			English	Article							INTER-STELLAR GRAINS; ULYSSES; GALILEO; PARTICLES; FORCES; SYSTEM; CLOUD; GAS	Interstellar dust grains intercepted by the dust detectors on the Ulysses and Galileo spacecrafts at heliocentric distances from 2 to 4 astronomical units show a deficit of grains with masses from 1 x 10(-17) to 3 x 10(-16) kilograms relative to grains intercepted outside 4 astronomical units. To divert grains out of the 2- to 4-astronomical unit region, the solar radiation pressure must be 1.4 to 1.8 times the force of solar gravity. These figures are consistent with the optical properties of spherical or elongated grains that consist of astronomical silicates or organic refractory material. Pure graphite grains with diameters of 0.2 to 0.4 micrometer experience a solar radiation pressure force as much as twice the force of solar gravity.	NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; ESA, European Space Operat Ctr, D-64293 Darmstadt, Germany; Royal Inst Technol, Dept Comp Sci & Syst, S-16440 Kista, Sweden; Stockholm Univ, S-16440 Kista, Sweden; Max Planck Inst Kernphys, D-69117 Heidelberg, Germany; Univ Florida, Dept Astron, Gainesville, FL 32661 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; European Space Agency; Royal Institute of Technology; Stockholm University; Max Planck Society; State University System of Florida; University of Florida	Landgraf, M (corresponding author), NASA, Lyndon B Johnson Space Ctr, Mailcode SN2, Houston, TX 77058 USA.	mlandgra@esoc.esa.de	Gustafson, Bo/B-9526-2011					Baguhl M, 1996, SPACE SCI REV, V78, P165, DOI 10.1007/BF00170803; BAGUHL M, 1995, SCIENCE, V268, P1016, DOI 10.1126/science.268.5213.1016; BEHANNON KW, 1989, J GEOPHYS RES-SPACE, V94, P1245, DOI 10.1029/JA094iA02p01245; BERTAUX JL, 1985, ASTRON ASTROPHYS, V150, P1; BERTAUX JL, 1976, NATURE, V262, P263, DOI 10.1038/262263a0; Bradley JP, 1999, SCIENCE, V285, P1716, DOI 10.1126/science.285.5434.1716; BREITSCHWERDT D, 1998, LECT NOTE PHYS, V506, P381; BROWNLEE DE, 1975, P LUNAR PLANET SCI C, P3409; BURNS JA, 1979, ICARUS, V40, P1, DOI 10.1016/0019-1035(79)90050-2; DRAINE BT, 1984, ASTROPHYS J, V285, P89, DOI 10.1086/162480; Frisch PC, 1999, ASTROPHYS J, V525, P492, DOI 10.1086/307869; GREENBERG JM, 1995, ASTROPHYS J, V455, pL177, DOI 10.1086/309834; GRUN E, 1993, NATURE, V362, P428, DOI 10.1038/362428a0; GRUN E, 1994, ASTRON ASTROPHYS, V286, P915; Grun E, 1997, ICARUS, V129, P270, DOI 10.1006/icar.1997.5789; GRUN E, 1992, SPACE SCI REV, V60, P317, DOI 10.1007/BF00216860; GRUN E, 1995, PLANET SPACE SCI, V43, P941, DOI 10.1016/0032-0633(94)00232-G; GRUN E, 1992, ASTRON ASTROPHYS SUP, V92, P411; GUSTAFSON BAS, 1994, ANNU REV EARTH PL SC, V22, P553, DOI 10.1146/annurev.ea.22.050194.003005; GUSTAFSON BAS, 1979, NATURE, V282, P276, DOI 10.1038/282276a0; Gustafson BAS, 1996, ASTR SOC P, V104, P35; JONES AP, 1994, ASTROPHYS J, V433, P797, DOI 10.1086/174689; LALLEMENT R, 1992, ASTRON ASTROPHYS, V266, P479; Landgraf M, 1999, PLANET SPACE SCI, V47, P1029, DOI 10.1016/S0032-0633(99)00031-8; LANDGRAF M, 1997, P IAU C, V166; LEVY EH, 1976, NATURE, V264, P423, DOI 10.1038/264423a0; Li AG, 1997, ASTRON ASTROPHYS, V323, P566; MCDONNELL JAM, 1975, SPACE RES, V15, P555; MORFILL GE, 1979, PLANET SPACE SCI, V27, P1283, DOI 10.1016/0032-0633(79)90106-5; MUKAI T, 1992, ASTRON ASTROPHYS, V262, P315; MUKAI T, 1981, ASTRON ASTROPHYS, V99, P1; WELLER CS, 1974, ASTROPHYS J, V193, P471, DOI 10.1086/153182; WITTE M, 1993, ADV SPACE RES-SERIES, V13, P121, DOI 10.1016/0273-1177(93)90401-V; Xu YL, 1999, ASTROPHYS J, V513, P894, DOI 10.1086/306892; Zook HA, 1996, SCIENCE, V274, P1501, DOI 10.1126/science.274.5292.1501; [No title captured]	36	64	65	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2319	2322		10.1126/science.286.5448.2319	http://dx.doi.org/10.1126/science.286.5448.2319			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600737				2022-12-01	WOS:000084318500054
J	Vogel, KS; Klesse, LJ; Velasco-Miguel, S; Meyers, K; Rushing, EJ; Parada, LF				Vogel, KS; Klesse, LJ; Velasco-Miguel, S; Meyers, K; Rushing, EJ; Parada, LF			Mouse tumor model for neurofibromatosis type 1	SCIENCE			English	Article							MICE DEFICIENT; NEURAL CREST; COLORECTAL-CANCER; GENE; RAS; P53; MUTATION; CELL; NF1; GAP	Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterized by increased incidence of benign and malignant tumors of neural crest origin. Mutations that activate the protooncogene ras, such as Loss of Nf1, cooperate with inactivating mutations at the p53 tumor suppressor gene during malignant transformation, One hundred percent of mice harboring null Nf1 and p53 alleles in cis synergize to develop soft tissue sarcomas between 3 and 7 months of age. These sarcomas exhibit Loss of heterozygosity at both gene loci and express phenotypic traits characteristic of neural crest derivatives and human NF1 malignancies.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Parada, LF (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.	parada@utsw.swmed.edu	Parada, luis F/B-9400-2014	Klesse, Laura/0000-0003-1323-7720	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034296] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34296, R01 NS034296-04, R01 NS034296] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Bernardis V, 1999, DIGESTION, V60, P82, DOI 10.1159/000007594; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; Guha A, 1996, ONCOGENE, V12, P507; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Halling KC, 1996, AM J CLIN PATHOL, V106, P282; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; ISHIZAKI Y, 1992, SURGERY, V111, P706; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; JHANWAR SC, 1994, CANCER GENET CYTOGEN, V78, P138, DOI 10.1016/0165-4608(94)90081-7; Kamijo T, 1999, CANCER RES, V59, P2217; KEMP CJ, 1994, COLD SPRING HARB SYM, V59, P427, DOI 10.1101/SQB.1994.059.01.048; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Orlow I, 1999, INT J ONCOL, V15, P17; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; RICCARDI VM, 1994, AM J PATHOL, V145, P994; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; TANAKA M, 1994, J SURG ONCOL, V57, P57, DOI 10.1002/jso.2930570115; Vogel KS, 1998, MOL CELL NEUROSCI, V11, P19, DOI 10.1006/mcne.1998.0670; VOGEL KS, UNPUB; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	40	259	263	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2176	2179		10.1126/science.286.5447.2176	http://dx.doi.org/10.1126/science.286.5447.2176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591653	Green Accepted			2022-12-01	WOS:000084157300058
J	Lalani, AS; Masters, J; Zeng, W; Barrett, J; Pannu, R; Everett, H; Arendt, CW; McFadden, G				Lalani, AS; Masters, J; Zeng, W; Barrett, J; Pannu, R; Everett, H; Arendt, CW; McFadden, G			Use of chemokine receptors by poxviruses	SCIENCE			English	Article							VACCINIA VIRUS-INFECTION; CC-CHEMOKINE; HIV-1 CORECEPTOR; T1/35KDA FAMILY; GROWTH-FACTOR; A27L PROTEIN; ANIMAL-CELLS; MYXOMA VIRUS; RESISTANCE; ALLELE	Chemokine receptors serve as portals of entry for certain intracellular pathogens, most notably human immunodeficiency virus (HIV). Myxoma virus is a member of the poxvirus family that induces a Lethal systemic disease in rabbits, but no poxvirus receptor has ever been defined. Rodent fibroblasts (3T3) that cannot be infected with myxoma virus could be made fully permissive for myxoma virus infection by expression of any one of several human chemokine receptors, including CCR1, CCR5, and CXCR4. Conversely, infection of 3T3-CCR5; cells can be inhibited by RANTES, anti-CCR5 polyclonal antibody, or herbimycin A but not by monoclonal antibodies that block HIV-1 infection or by pertussis toxin. These findings suggest that poxviruses, Like HIV, are able to use chemokine receptors to infect specific cell subtypes, notably migratory Leukocytes, but that their mechanisms of receptor interactions are distinct.	Univ Western Ontario, John P Robarts Res Inst, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Immunol, London, ON N6G 2V4, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; NYU, Med Ctr, Skirball Inst, New York, NY 10016 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Alberta; New York University	McFadden, G (corresponding author), Univ Western Ontario, John P Robarts Res Inst, London, ON N6G 2V4, Canada.	mcfadden@rri.on.ca	Everett, Helen E/D-7123-2011	Everett, Helen/0000-0002-1233-4265				Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berson JF, 1998, SEMIN IMMUNOL, V10, P237, DOI 10.1006/smim.1998.0130; Carrington M, 1999, HUM MOL GENET, V8, P1939, DOI 10.1093/hmg/8.10.1939; Cecilia D, 1998, J VIROL, V72, P6988, DOI 10.1128/JVI.72.9.6988-6996.1998; CHANG W, 1995, J VIROL, V69, P517, DOI 10.1128/JVI.69.1.517-522.1995; Chung CS, 1998, J VIROL, V72, P1577, DOI 10.1128/JVI.72.2.1577-1585.1998; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cundell DR, 1996, ADV EXP MED BIOL, V416, P89; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DOMS RW, 1990, J VIROL, V64, P4884, DOI 10.1128/JVI.64.10.4884-4892.1990; EPPSTEIN DA, 1985, NATURE, V318, P663, DOI 10.1038/318663a0; Fenner F., 1965, MYXOMATOSIS; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; Graham KA, 1997, VIROLOGY, V229, P12, DOI 10.1006/viro.1996.8423; GRIST NR, 1988, J INFECTION, V16, P117, DOI 10.1016/S0163-4453(88)93822-4; Hollinshead M, 1999, J VIROL, V73, P1503, DOI 10.1128/JVI.73.2.1503-1517.1999; Holmes Kathryn V., 1997, P35; Horuk R, 1999, IMMUNOL TODAY, V20, P89, DOI 10.1016/S0167-5699(98)01396-6; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Hsiao JC, 1999, J VIROL, V73, P8750, DOI 10.1128/JVI.73.10.8750-8761.1999; Hsiao JC, 1998, J VIROL, V72, P8374, DOI 10.1128/JVI.72.10.8374-8379.1998; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; JANECZKO RA, 1987, ARCH VIROL, V92, P135, DOI 10.1007/BF01310068; Klasse PJ, 1998, ADV DRUG DELIVER REV, V34, P65, DOI 10.1016/S0169-409X(98)00002-7; Kuhmann SE, 1997, J VIROL, V71, P8642, DOI 10.1128/JVI.71.11.8642-8656.1997; Lalani AS, 1998, VIROLOGY, V250, P173, DOI 10.1006/viro.1998.9340; Lalani AS, 1997, J VIROL, V71, P4356, DOI 10.1128/JVI.71.6.4356-4363.1997; Lalani AS, 1997, J LEUKOCYTE BIOL, V62, P570, DOI 10.1002/jlb.62.5.570; LALANI AS, UNPUB; Libert F, 1998, HUM MOL GENET, V7, P399, DOI 10.1093/hmg/7.3.399; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; MOSS B, 1996, REPLICATION POXVIRUS, P2637; Nash P, 1999, IMMUNOL REV, V168, P103, DOI 10.1111/j.1600-065X.1999.tb01286.x; OPGENORTH A, 1992, J VIROL, V66, P4720, DOI 10.1128/JVI.66.8.4720-4731.1992; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Pease JE, 1998, SEMIN IMMUNOL, V10, P169, DOI 10.1006/smim.1998.0129; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Siciliano SJ, 1999, J BIOL CHEM, V274, P1905, DOI 10.1074/jbc.274.4.1905; Smith GL, 1998, ADV EXP MED BIOL, V440, P395; Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867; Trkola A, 1999, J VIROL, V73, P6370, DOI 10.1128/JVI.73.8.6370-6379.1999; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; Vanderplasschen A, 1997, J VIROL, V71, P4032, DOI 10.1128/JVI.71.5.4032-4041.1997; Vanderplasschen A, 1998, J GEN VIROL, V79, P877, DOI 10.1099/0022-1317-79-4-877; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	50	124	128	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1968	1971		10.1126/science.286.5446.1968	http://dx.doi.org/10.1126/science.286.5446.1968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583963				2022-12-01	WOS:000084003400056
J	Holgate, ST				Holgate, ST			The epidemic of allergy and asthma	NATURE			English	Editorial Material								Allergic diseases, such as asthma, rhinitis, eczema and food allergies, are reaching epidemic proportions in both the developed and developing world. Key factors driving these rising trends are increased exposure to sensitizing allergens and reduced stimulation of the immune system during critical periods of development. In allergic disease, there is a polarization of T-lymphocyte responses, and enhanced secretion of cytokines involved in regulation of immunoglobulin E, mast cells, basophils and eosinophils, ultimately leading to inflammation and disease. A clear understanding of the cellular and molecular mechanisms of allergic disease and the complex interplay between genetic and environmental factors will undoubtedly create new opportunities for public health and therapeutic interventions.	Univ Southampton, Southampton Gen Hosp, Sch Med, Resp Cell & Mol Biol Res Div, Southampton SO16 6YD, Hants, England	University of Southampton	Holgate, ST (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Resp Cell & Mol Biol Res Div, Mail Point 810,Tremona Rd, Southampton SO16 6YD, Hants, England.	sth@soton.ac.uk						Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; COHEN SG, 1992, CLASSICS ALLERGY; CORRIS PA, 1993, LANCET, V341, P1369, DOI 10.1016/0140-6736(93)90941-9; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Davies DE, 1999, ALLERGY, V54, P771; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; EVANS MJ, IN PRESS AM J RESP C; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HOLGATE ST, 1998, 30 YEARS IGE, P91; Jones CA, 1998, CLIN EXP ALLERGY, V28, P655; Kapsenberg ML, 1999, CLIN EXP ALLERGY, V29, P33, DOI 10.1046/j.1365-2222.1999.00006.x-i2; Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9; Leckie MJ, 1999, AM J RESP CRIT CARE, V159, pA624; Lee SC, 1999, J IMMUNOL, V162, P6867; Mattey DL, 1997, ANN RHEUM DIS, V56, P426, DOI 10.1136/ard.56.7.426; O'Byrne PM, 1999, CLIN EXP ALLERGY, V29, P27, DOI 10.1046/j.1365-2222.1999.00005.x-i2; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; Schulz O, 1999, CLIN EXP ALLERGY, V29, P439, DOI 10.1046/j.1365-2222.1999.00464.x; WALLS AF, IN PRESS ASTHMA RHIN; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	23	455	478	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760		S			B2	B4		10.1038/35037000	http://dx.doi.org/10.1038/35037000			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VD	10586888				2022-12-01	WOS:000083913900002
J	Lima, CD; Wang, LK; Shuman, S				Lima, CD; Wang, LK; Shuman, S			Structure and mechanism of yeast RNA triphosphatase: An essential component of the mRNA capping apparatus	CELL			English	Article							CARBOXY-TERMINAL DOMAIN; MESSENGER-RNA; POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; NUCLEOSIDE TRIPHOSPHATASE; CAP METHYLTRANSFERASE; MUTATIONAL ANALYSIS; ENZYME BINDS; DNA-LIGASE; PROTEIN	RNA triphosphatase is an essential mRNA processing enzyme that catalyzes the first step in cap formation. The 2.05 Angstrom crystal structure of yeast RNA triphosphatase Cet1p reveals a novel active site fold whereby an eight-stranded beta barrel forms a topologically closed triphosphate tunnel. Interactions of a sulfate in the center of the tunnel with a divalent cation and basic amino acids projecting into the tunnel suggest a catalytic mechanism that is supported by mutational data. Discrete surface domains mediate Cet1p homodimerization and Cet1p binding to the guanylyltransferase component of the capping apparatus. The structure and mechanism of fungal RNA triphosphatases are completely different from those of mammalian mRNA capping enzymes. Hence, RNA triphosphatase presents an ideal target for structure-based antifungal drug discovery.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org		Lima, Christopher/0000-0002-9163-6092				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; HO CK, 1999, IN PRESS NUCL ACIDS; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Mao XD, 1996, MOL CELL BIOL, V16, P475; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Rodriguez CR, 1999, NUCLEIC ACIDS RES, V27, P2181, DOI 10.1093/nar/27.10.2181; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; Yu L, 1997, J VIROL, V71, P9837, DOI 10.1128/JVI.71.12.9837-9843.1997; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	42	108	109	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					533	543		10.1016/S0092-8674(00)81541-X	http://dx.doi.org/10.1016/S0092-8674(00)81541-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589681	Bronze			2022-12-01	WOS:000083986300012
J	Ashkar, S; Weber, GF; Panoutsakopoulou, V; Sanchirico, ME; Jansson, M; Zawaideh, S; Rittling, SR; Denhardt, DT; Glimcher, MJ; Cantor, H				Ashkar, S; Weber, GF; Panoutsakopoulou, V; Sanchirico, ME; Jansson, M; Zawaideh, S; Rittling, SR; Denhardt, DT; Glimcher, MJ; Cantor, H			Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity	SCIENCE			English	Article							HERPES STROMAL KERATITIS; DENDRITIC CELLS; IN-VITRO; SECRETED PHOSPHOPROTEIN; BACTERIAL-INFECTION; GRANULOMA-FORMATION; GENETIC-RESISTANCE; AUTOIMMUNE-DISEASE; ESCHERICHIA-COLI; UP-REGULATION	Cell-mediated (type-1) immunity is necessary for immune protection against most intracellular pathogens and, when excessive, can mediate organ-specific autoimmune destruction. Mice deficient in Eta-1 (also called osteopontin) gene expression have severely impaired type-1 immunity to viral infection [herpes simplex virus-type 1 (KOS strain)] and bacterial infection (Listeria monocytogenes) and do not develop sarcoid-type granulomas. Interleukin-12 (IL-12) and interferon-gamma production is diminished, and IL-10 production is increased. A phosphorylation-dependent interaction between the amino-terminal portion of Eta-1 and its integrin receptor stimulated IL-12 expression, whereas a phosphorylation-independent interaction with CD44 inhibited IL-10 expression. These findings identify Eta-1 as a key cytokine that sets the stage for efficient type-1 immune responses through differential regulation of macrophage IL-12 and IL-10 cytokine expression.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp,Dept Orthoped Surg, Lab Skeletal Disorders & Rehabil, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Rutgers State Univ, Fac Arts & Sci, Div Life Sci, Piscataway, NJ 08854 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Rutgers State University New Brunswick	Cantor, H (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.	Harvey_Cantor@DFCl.harvard.edu	Eckhardt, Erik/G-1567-2010	Panoutsakopoulou, Vily/0000-0002-1569-1508	NATIONAL CANCER INSTITUTE [R29CA076176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037833, R37AI012184, R01AI012184] Funding Source: NIH RePORTER; NCI NIH HHS [CA76176] Funding Source: Medline; NIAID NIH HHS [AI37833, AI12184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V194, P274, DOI 10.1006/bbrc.1993.1815; ASHKAR S, 1995, ANN NY ACAD SCI, V760, P296, DOI 10.1111/j.1749-6632.1995.tb44639.x; ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V191, P126, DOI 10.1006/bbrc.1993.1193; AVERY AC, 1995, NATURE, V376, P431, DOI 10.1038/376431a0; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CONSTANT SL, 1999, ANNU REV IMMUNOL, V15, P297; Cousens LP, 1999, J EXP MED, V189, P1315, DOI 10.1084/jem.189.8.1315; Daheshia M, 1997, J IMMUNOL, V159, P1945; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; JERRELLS TR, 1981, INFECT IMMUN, V31, P1014, DOI 10.1128/IAI.31.3.1014-1022.1981; Kelly JL, 1997, SURGERY, V122, P146, DOI 10.1016/S0039-6060(97)90003-9; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; KUBOTA T, 1989, BIOCHEM BIOPH RES CO, V162, P1453, DOI 10.1016/0006-291X(89)90837-1; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Lyons A, 1997, ANN SURG, V226, P450, DOI 10.1097/00000658-199710000-00006; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Medzhitov R, 1998, SEMIN IMMUNOL, V10, P351, DOI 10.1006/smim.1998.0136; Murphy KM, 1998, CURR OPIN IMMUNOL, V10, P226, DOI 10.1016/S0952-7915(98)80253-7; Nau GJ, 1997, P NATL ACAD SCI USA, V94, P6414, DOI 10.1073/pnas.94.12.6414; NEMIR M, 1989, J BIOL CHEM, V264, P18202; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; O'Regan AW, 1999, J IMMUNOL, V162, P1024; Oxenius A, 1999, J IMMUNOL, V162, P965; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PATARCA R, 1993, CRIT REV IMMUNOL, V13, P225; Ria F, 1998, EUR J IMMUNOL, V28, P2003, DOI 10.1002/(SICI)1521-4141(199806)28:06<2003::AID-IMMU2003>3.0.CO;2-S; Rittling SR, 1999, EXP NEPHROL, V7, P103; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; Salih E, 1997, J BIOL CHEM, V272, P13966, DOI 10.1074/jbc.272.21.13966; SCHEICHER C, 1995, EUR J IMMUNOL, V25, P1566, DOI 10.1002/eji.1830250615; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; SCHULTZ JF, 1995, J BIOL CHEM, V270, P11522, DOI 10.1074/jbc.270.19.11522; Segal BM, 1998, J EXP MED, V187, P537, DOI 10.1084/jem.187.4.537; Sharma MD, 1998, J IMMUNOL, V161, P5357; SINGH RP, 1990, J EXP MED, V171, P1931, DOI 10.1084/jem.171.6.1931; SORENSEN ES, 1994, BIOCHEM BIOPH RES CO, V198, P200, DOI 10.1006/bbrc.1994.1028; Stordeur P, 1998, Int Rev Immunol, V16, P501, DOI 10.3109/08830189809043006; STORDEUR P, 1995, MOL IMMUNOL, V32, P233, DOI 10.1016/0161-5890(94)00158-W; Streilein JW, 1997, IMMUNOL TODAY, V18, P443, DOI 10.1016/S0167-5699(97)01114-6; TRIPP CS, 1994, J IMMUNOL, V152, P1883; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; TRIPP CS, 1995, J IMMUNOL, V155, P3427; Unanue ER, 1997, IMMUNOL REV, V158, P11, DOI 10.1111/j.1600-065X.1997.tb00988.x; VANDENBOGERT C, 1986, VIRCHOWS ARCH B, V51, P39; Weber GF, 1997, P ASSOC AM PHYSICIAN, V109, P1; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Yin ZH, 1997, ARTHRITIS RHEUM, V40, P1788, DOI 10.1002/art.1780401010; Yu XQ, 1998, P ASSOC AM PHYSICIAN, V110, P50; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	52	920	983	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	2000	287	5454					860	864		10.1126/science.287.5454.860	http://dx.doi.org/10.1126/science.287.5454.860			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657301				2022-12-01	WOS:000085136400048
J	Urano, F; Wang, XZ; Bertolotti, A; Zhang, YH; Chung, P; Harding, HP; Ron, D				Urano, F; Wang, XZ; Bertolotti, A; Zhang, YH; Chung, P; Harding, HP; Ron, D			Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1	SCIENCE			English	Article							NF-KAPPA-B; C-JUN; ENDOPLASMIC-RETICULUM; TERMINAL KINASE; TNF RECEPTOR-1; PATHWAY; TRAF2; NUCLEUS; PHOSPHORYLATION; REQUIRES	Malfolded proteins in the endoplasmic reticulum (ER) induce cellular stress and activate c-Jun amino-terminal kinases (JNKs or SAPKs), Mammalian homologs of yeast IRE1, which activate chaperone genes in response to ER stress, also activated INK, and IRE1 alpha(-/-) fibroblasts were impaired in JNK activation by ER stress. The cytoplasmic part of IRE1 bound TRAF2, an adaptor protein that couples plasma membrane receptors to JNK activation. Dominant-negative TRAF2 inhibited activation of JNK by IRE1. Activation of JNK by endogenous signals initiated in the ER proceeds by a pathway similar to that initiated by cell surface receptors in response to extracellular signals.	NYU, Sch Med, Skirball Inst Biomol Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, Dept Med, New York, NY 10016 USA	New York University; New York University	Ron, D (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Dept Med, New York, NY 10016 USA.	ron@saturn.med.nyu.edu	Urano, Fumihiko/AAF-4492-2020; Longo, Kenneth A/A-5631-2010	Harding, Heather P/0000-0002-7359-7974; Ron, David/0000-0002-3014-5636	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047119, R29DK047119, R37DK047119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008681] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47119] Funding Source: Medline; NIEHS NIH HHS [ES08681] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Goberdhan DCI, 1998, BIOESSAYS, V20, P1009, DOI 10.1002/(SICI)1521-1878(199812)20:12<1009::AID-BIES7>3.0.CO;2-D; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MORI K, 1993, CELL, V74, P743; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; YAN MH, 1994, NATURE, V372, P798; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	33	2056	2125	9	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2000	287	5453					664	666		10.1126/science.287.5453.664	http://dx.doi.org/10.1126/science.287.5453.664			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10650002				2022-12-01	WOS:000084989400051
J	Koskelainen, A; Ala-Laurila, P; Fyhrquist, N; Donner, K				Koskelainen, A; Ala-Laurila, P; Fyhrquist, N; Donner, K			Measurement of thermal contribution to photoreceptor sensitivity	NATURE			English	Article							FROG RETINA; NOISE; CONE; PIGMENTS; VISION	Activation of a visual pigment molecule to initiate phototransduction requires a minimum energy, E-a, that need not be wholly derived from a photon, but may be supplemented by heat(1), Theory(2,3) predicts that absorbance at very long wavelengths declines with the fraction of molecules that have a sufficient complement of thermal energy, and that E-a is inversely related to the wavelength of maximum absorbance (lambda(max)) of the pigment, Consistent with the first of these predictions, warming increases relative visual sensitivity to long wavelengths(4-8). Here we measure this effect in amphibian photoreceptors with different pigments to estimate E-a (refs 2, 5-7) and test experimentally the predictions of an inverse relation between E-a and lambda(max). For rods and 'red' cones in the adult frog retina, we find no significant difference in E-a between the two pigments involved, although their lambda(max) values are very different. We also determined E-a for the rhodopsin in toad retinal rods--spectrally similar to frog rhodopsin hut differing in amino-acid sequence-and found that it was significantly higher. In addition, we estimated E-a for two pigments whose lambda(max) difference was due only to a chromophore difference (A1 and A2 pigment, in adult and larval bag cones), Here E-a for A2 was lower than for Al. Our results refute the idea of a necessary relation between lambda(max) and E-a but show that the A1 --> A2 chromophore substitution decreases E-a.	Aalto Univ, Biomed Engn Lab, FIN-02015 Espoo, Finland; Univ Helsinki, Dept Biosci, Div Anim Physiol, FIN-00014 Helsinki, Finland	Aalto University; University of Helsinki	Koskelainen, A (corresponding author), Aalto Univ, Biomed Engn Lab, POB 2200, FIN-02015 Espoo, Finland.	ari.koskelainen@hut.fi	Ala-Laurila, Petri/AAE-1203-2019	Ala-Laurila, Petri/0000-0002-6139-6825; Fyhrquist, Nanna Theresia/0000-0002-5408-0005				BARLOW HB, 1956, J OPT SOC AM, V46, P634, DOI 10.1364/JOSA.46.000634; BARLOW HB, 1957, NATURE, V179, P255, DOI 10.1038/179255b0; BARLOW RB, 1993, NATURE, V366, P64, DOI 10.1038/366064a0; BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529; BOWMAKER JK, 1994, VISION RES, V34, P591, DOI 10.1016/0042-6989(94)90015-9; Bridges C.D.B., 1972, HDB SENSORY PHYSIOLO, P417, DOI DOI 10.1007/978-3-642-65066-6_11; COOPER A, 1979, NATURE, V282, P531, DOI 10.1038/282531a0; Dartnall H. J. A., 1965, Vision Research, V5, P81, DOI 10.1016/0042-6989(65)90057-X; DENTON EJ, 1954, J PHYSIOL-LONDON, V125, P181, DOI 10.1113/jphysiol.1954.sp005149; DONNER K, 1990, J PHYSIOL-LONDON, V428, P673, DOI 10.1113/jphysiol.1990.sp018234; Donner K, 1998, VISION RES, V38, P19, DOI 10.1016/S0042-6989(97)00144-2; DONNER K, 1992, VISION RES, V32, P853, DOI 10.1016/0042-6989(92)90028-H; FIRSOV ML, 1990, SENSORY SYSTEMS, V4, P25; Fyhrquist N, 1998, EXP EYE RES, V66, P295, DOI 10.1006/exer.1997.0430; Goldsmith T.H., 1989, P1; GOVARDOVSKII VI, IN PRESS VIS NEUROSC; HAHN H, 1948, PFLUG ARCH GES PHYS, V250, P357, DOI 10.1007/BF00369741; KOSKELAINEN A, 1994, ACTA PHYSIOL SCAND, V152, P115, DOI 10.1111/j.1748-1716.1994.tb09790.x; LAMB TD, 1977, J PHYSIOL-LONDON, V272, P435, DOI 10.1113/jphysiol.1977.sp012053; LAMB TD, 1984, J PHYSIOL-LONDON, V346, P557, DOI 10.1113/jphysiol.1984.sp015041; LEWIS PR, 1955, J PHYSIOL-LONDON, V130, P45, DOI 10.1113/jphysiol.1955.sp005391; LUTHGOE JN, 1988, SENSORY BIOL AQUATIC, P57; Lythgoe RJ, 1938, J PHYSIOL-LONDON, V93, P24, DOI 10.1113/jphysiol.1938.sp003622; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; Reuter T., 1969, Acta Zoologica Fennica, V122, P1; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; SREBRO R, 1966, J PHYSIOL-LONDON, V187, P417, DOI 10.1113/jphysiol.1966.sp008099; STGEORGE RCC, 1952, J GEN PHYSIOL, V35, P495, DOI 10.1085/jgp.35.3.495; Stiles W. S., 1948, T OPTICAL CONVENTION, P97; WILLIAMS TP, 1968, VISION RES, V8, P359, DOI 10.1016/0042-6989(68)90105-3	30	31	33	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2000	403	6766					220	223		10.1038/35003242	http://dx.doi.org/10.1038/35003242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646610				2022-12-01	WOS:000084835300061
J	Lipper, GM; Arndt, KA; Dover, JS				Lipper, GM; Arndt, KA; Dover, JS			Recent therapeutic advances in dermatology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON SYNDROME; BURN CENTER; TOPICAL TACROLIMUS; IMIQUIMOD; INHIBITION; INTERFERON		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Dover, JS (corresponding author), Harvard Univ, Med Fac Phys, Cosmet Surg & Laser Ctr, Beth Israel Deaconess Med Ctr, 25 Boylston St,Suite 104, Chestnut Hill, MA 02167 USA.							Chaidemenos GC, 1997, INT J DERMATOL, V36, P218, DOI 10.1046/j.1365-4362.1997.00192.x; DEPAULIS A, 1992, J INVEST DERMATOL, V99, P723, DOI 10.1111/1523-1747.ep12614216; Edwards L, 1998, ARCH DERMATOL, V134, P25, DOI 10.1001/archderm.134.1.25; Egan CA, 1999, J AM ACAD DERMATOL, V40, P458, DOI 10.1016/S0190-9622(99)70497-4; HALEBIAN PH, 1986, ANN SURG, V204, P503, DOI 10.1097/00000658-198611000-00001; HENG MCY, 1991, J AM ACAD DERMATOL, V25, P778, DOI 10.1016/S0190-9622(08)80969-3; KELEMEN JJ, 1995, J AM COLL SURGEONS, V180, P273; McGee T, 1998, PLAST RECONSTR SURG, V102, P1018, DOI 10.1097/00006534-199809040-00014; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; Reich K, 1998, BRIT J DERMATOL, V139, P755; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Ruzicka T, 1999, ARCH DERMATOL, V135, P574, DOI 10.1001/archderm.135.5.574; Rzany B, 1996, BRIT J DERMATOL, V135, P6; Rzany B, 1999, LANCET, V353, P2190, DOI 10.1016/S0140-6736(98)05418-X; SIDKY YA, 1992, CANCER RES, V52, P3528; STANLEY MA, 1999, PAPILLOMAVIRUS REP, V10, P23; Syed Tanweer A., 1998, Journal of Dermatology (Tokyo), V25, P309; Tyring SK, 1998, J INFECT DIS, V178, P551, DOI 10.1086/517472; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; WEEKS CE, 1994, J INTERFERON RES, V14, P81, DOI 10.1089/jir.1994.14.81; Wolkenstein P, 1998, LANCET, V352, P1586, DOI 10.1016/S0140-6736(98)02197-7; Zonneveld IM, 1998, ARCH DERMATOL, V134, P1101, DOI 10.1001/archderm.134.9.1101	23	14	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2000	283	2					175	177		10.1001/jama.283.2.175	http://dx.doi.org/10.1001/jama.283.2.175			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272QA	10634322				2022-12-01	WOS:000084661400002
J	Ram, PT; Horvath, CM; Iyengar, R				Ram, PT; Horvath, CM; Iyengar, R			Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L G alpha(o) protein	SCIENCE			English	Article							MAP KINASE KINASE; PC12 CELLS; NEURITE OUTGROWTH; V-SRC; STAT3; ACTIVATION; DIFFERENTIATION; INTERLEUKIN-6; LOCALIZATION; ASSOCIATION	Expression of Q205L G alpha(o) (G alpha(o)*), an alpha subunit of heterotrimeric guanine nucleotide-binding proteins (G proteins) that lacks guanosine triphosphatase (GTPase) activity in NIH-3T3 cells, results in transformation. Expression of G alpha(o)* in NIH-3T3 cells activated signal transducer and activator of transcription 3 (Stat3) but not mitogen-activated protein (MAP) kinases 1 or 2, Coexpression of dominant negative Stat3 inhibited G alpha(o)*-induced transformation of NIH-3T3 cells and activation of endogenous Stat3, Furthermore, G alpha(o)* expression increased activity of the tyrosine kinase c-Src, and the G alpha(o)*-induced activation of Stat3 was blocked by expression of Csk (carboxyl-terminal Src kinase), which inactivates c-Src. The results indicate that Stat3 can function as a downstream effector for G alpha(o)* and mediate its biological effects.	Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Ram, PT (corresponding author), Mt Sinai Sch Med, Dept Pharmacol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	ramp01@doc.mssm.edu		Ram, Prahlad/0000-0003-4739-3166; Horvath, Curt/0000-0003-2449-225X	NATIONAL CANCER INSTITUTE [F32CA079134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER; NCI NIH HHS [1F32 CA79134-01] Funding Source: Medline; NIDDK NIH HHS [DK-38671] Funding Source: Medline; NIGMS NIH HHS [GM-54508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1996, MOL CELL BIOCHEM, V127, P201; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Nusse O, 1996, J CELL SCI, V109, P221; RAM P, UNPUB; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Smith PD, 1998, BIOCHEM J, V331, P381, DOI 10.1042/bj3310381; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZUBIAUR M, 1993, J NEUROSCI RES, V35, P207, DOI 10.1002/jnr.490350212	25	89	89	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					142	144		10.1126/science.287.5450.142	http://dx.doi.org/10.1126/science.287.5450.142			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615050				2022-12-01	WOS:000084578400055
J	Hong, K; Nishiyama, M; Henley, J; Tessier-Lavigne, M; Poo, MM				Hong, K; Nishiyama, M; Henley, J; Tessier-Lavigne, M; Poo, MM			Calcium signalling in the guidance of nerve growth by netrin-1	NATURE			English	Article							CONES; CELLS; INHIBITION; MODULATION; RECEPTOR; NEURONS; CA-2+	Pathfinding by growing axons in the developing nervous system is guided by diffusible or bound factors that attract or repel the axonal growth cone(1,2). The cytoplasmic signalling mechanisms that trigger the responses of the growth cone to guidance factors are mostly unknown(3). Previous studies have shown that the level and temporal patterns of cytoplasmic Ca2+ can regulate the rate of growth-cone extension in vitro(4-8) and in vivo(9). Here we report that Ca2+ also mediates the turning behaviour of the growth cones of cultured Xenopus neurons that are induced by an extracellular gradient of netrin-1, an established diffusible guidance factor in vivo(1,10). The netrin-1-induced turning response depends on Ca2+ influx through plasma membrane Ca2+ channels, as well as Ca2+-induced Ca2+ release from cytoplasmic stores(11). Reduction of Ca2+ signals by blocking either of these two Ca2+ sources converted the netrin-1-induced response from attraction to repulsion. Activation of Ca2+-induced Ca2+ release from internal stores with a gradient of ryanodine in the absence of netrin-1 was Sufficient to trigger either attractive or repulsive responses, depending on the ryanodine concentration used. These results support the model that cytoplasmic Ca2+ signals mediate growth-cone guidance by netrin-1, and different patterns of Ca2+ elevation trigger attractive and repulsive turning responses.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Dept Anat, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Poo, MM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Henley, John/D-7171-2011	Henley, John/0000-0003-1846-5941				ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BIXBY JL, 1984, DEV BIOL, V106, P89, DOI 10.1016/0012-1606(84)90065-4; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Culotti JG, 1998, CURR OPIN CELL BIOL, V10, P609, DOI 10.1016/S0955-0674(98)80036-7; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; KATER SB, 1988, TRENDS NEUROSCI, V11, P317; Lau PM, 1999, J CELL BIOL, V145, P1265, DOI 10.1083/jcb.145.6.1265; Leis HJ, 1996, BRIT J PHARMACOL, V117, P540, DOI 10.1111/j.1476-5381.1996.tb15224.x; Lin KD, 1999, BIOTECHNIQUES, V26, P318, DOI 10.2144/99262rr02; LOHOF AM, 1992, J NEUROSCI, V12, P1253; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MARCHETTI C, 1995, J NEUROPHYSIOL, V73, P1169, DOI 10.1152/jn.1995.73.3.1169; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Yang SN, 1999, J NEUROPHYSIOL, V81, P781, DOI 10.1152/jn.1999.81.2.781; Zheng JQ, 2000, NATURE, V403, P89, DOI 10.1038/47501; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0; Zucchi R, 1997, PHARMACOL REV, V49, P1	30	299	307	0	14	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					93	98		10.1038/47507	http://dx.doi.org/10.1038/47507			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638760				2022-12-01	WOS:000084687400050
J	Zheng, JQ				Zheng, JQ			Turning of nerve growth cones induced by localized increases in intracellular calcium ions	NATURE			English	Article							SPINAL NEURONS; GUIDANCE; RESPONSES	Guidance of developing axons involves turning of the motile tip, the growth cone, in response to a variety of extracellular cues(1,2) Little is known about the intracellular mechanism by which the directional signal is transduced, Ca2+ is a key second messenger in growth cone extension(3,4) and has been implicated in growth-cone turning(5,6). Here I report that a direct, spatially restricted elevation of intracellular Ca2+ concentration ([Ca2+](i)) on one side of the growth cone by focal laser-induced photolysis (FLIP) of caged Ca2+ consistently induced turning of the growth cone to the side with elevated [Ca2+](i) (attraction). Furthermore, when the resting [Ca2+](i) at the growth cone was decreased by the removal of extracellular Ca2+, the same focal elevation of [Ca2+](i) by FLIP induced repulsion. These results provide direct evidence that a localized Ca2+ signal in the growth cone can provide the intracellular directional cue for extension and is sufficient to initiate both attraction and repulsion. By integrating local and global Ca2+ signals, a growth cone could thus generate different turning responses under different environmental conditions during guidance.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Zheng, JQ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, 675 Hoes Lane, Piscataway, NJ 08854 USA.							AHMED Z, 1988, CELL CALCIUM, V9, P57, DOI 10.1016/0143-4160(88)90025-5; BASHAW GJ, 1999, NEURON, V97, P917; BIXBY JL, 1984, DEV BIOL, V106, P89, DOI 10.1016/0012-1606(84)90065-4; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; CONNOR JA, 1984, CELL MOL NEUROBIOL, V4, P53, DOI 10.1007/BF00710942; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; GUNDERSEN RW, 1980, J CELL BIOL, V87, P546, DOI 10.1083/jcb.87.3.546; HONG K, 1999, NEURON, V97, P427; Ishihara A, 1997, BIOTECHNIQUES, V23, P268, DOI 10.2144/97232st01; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kater S. B., 1995, Current Opinion in Neurobiology, V5, P68, DOI 10.1016/0959-4388(95)80089-1; KATER SB, 1991, J NEUROSCI, V11, P891; LANKFORD KL, 1991, CELL MOTIL CYTOSKEL, V20, P7, DOI 10.1002/cm.970200103; LOHOF AM, 1992, J NEUROSCI, V12, P1253; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Ming GL, 1997, J NEUROSCI, V17, P7860; SNOW DM, 1994, DEV BIOL, V166, P87, DOI 10.1006/dbio.1994.1298; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; TABTI N, 1990, CULTURING NERVE CELL, P137; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TSIEN RY, 1988, TRENDS NEUROSCI, V11, P419, DOI 10.1016/0166-2236(88)90192-0; Wang Q, 1998, J NEUROSCI, V18, P4973; Zheng B, 1996, J CLIN IMMUNOL, V16, P1, DOI 10.1007/BF01540967; Zheng JQ, 1996, PERSPECT DEV NEUROBI, V4, P205; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	28	227	233	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					89	93		10.1038/47501	http://dx.doi.org/10.1038/47501			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638759				2022-12-01	WOS:000084687400049
J	Henderson, SW				Henderson, SW			The unnatural nature of pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Illinois, Coll Med, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Henderson, SW (corresponding author), Univ Illinois, Coll Med, Chicago, IL 60680 USA.							BATES MS, 1993, PAIN, V52, P101, DOI 10.1016/0304-3959(93)90120-E; DANTE, DIVINE COMEDY, V1; France CR, 1999, PAIN, V81, P77, DOI 10.1016/S0304-3959(98)00272-3; HOOPER E, 1999, RIVER JOURNEY SOURCE, P151; MERSKEY H, 1980, PAIN, V9, P3, DOI 10.1016/0304-3959(80)90024-X; MILTON J, PARADISE LOST; Scarry Elaine, 1985, BODY PAIN MAKING UNM, P4; Shakespeare William, HAMLET; Sheiner EK, 1999, PAIN, V81, P299, DOI 10.1016/S0304-3959(99)00019-6	9	9	9	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					117	117		10.1001/jama.283.1.117	http://dx.doi.org/10.1001/jama.283.1.117			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632294	hybrid			2022-12-01	WOS:000084514400039
J	Rees, G; Russell, C; Frith, CD; Driver, J				Rees, G; Russell, C; Frith, CD; Driver, J			Inattentional blindness versus inattentional amnesia for fixated but ignored words	SCIENCE			English	Article							SELECTIVE ATTENTION; PICTURES; PERCEPTION; HUMANS; LOAD; TASK	People often are unable to report the content of ignored in Formation, but it is unknown whether this reflects a complete failure to perceive it (inattentional blindness) or merely that it is rapidly forgotten (inattentional amnesia). Here functional imaging is used to address this issue by measuring brain activity for unattended words. When attention is fully engaged with other material, the brain no Longer differentiates between meaningful words and random letters, even when they are looked at directly. These results demonstrate true inattentional blindness for words and show that visual recognition wholly depends on attention even for highly familiar and meaningful stimuli at the center of gaze.	UCL, Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England; CALTECH, Div Biol 139 74, Pasadena, CA 91125 USA; UCL, Dept Psychol, Inst Cognit Neurosci, London WC1N 3AR, England	University of London; University College London; California Institute of Technology; University of London; University College London	Rees, G (corresponding author), UCL, Inst Neurol, Wellcome Dept Cognit Neurol, 12 Queen Sq, London WC1N 3BG, England.	geraint@klab.caltech.edu	Rees, Geraint/C-1493-2008; Driver, Jon/A-4779-2010; Frith, Chris D/A-2171-2009	Rees, Geraint/0000-0002-9623-7007; Frith, Chris D/0000-0002-8665-0690; Russell, Charlotte/0000-0002-8194-8033	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Broadbent D.E., 1958, PERCEPTION COMMUNICA; Buchel C, 1998, NATURE, V394, P274, DOI 10.1038/28389; Cherry C., 1957, HUMAN COMMUNICATION, DOI [10.2307/1292231, DOI 10.2307/1292231]; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DERENZI E, 1987, BRAIN, V110, P1099, DOI 10.1093/brain/110.5.1099; DEUTSCH JA, 1963, PSYCHOL REV, V70, P80, DOI 10.1037/h0039515; DRIVER J, 1995, CURR OPIN NEUROBIOL, V5, P191, DOI 10.1016/0959-4388(95)80026-3; Fiez JA, 1998, P NATL ACAD SCI USA, V95, P914, DOI 10.1073/pnas.95.3.914; Fink GR, 1996, NATURE, V382, P626, DOI 10.1038/382626a0; HOLENDER D, 1986, BEHAV BRAIN SCI, V9, P1, DOI 10.1017/S0140525X00021269; JOHNSTON WA, 1986, ANNU REV PSYCHOL, V37, P43, DOI 10.1146/annurev.ps.37.020186.000355; LAVIE N, 1995, J EXP PSYCHOL HUMAN, V21, P451, DOI 10.1037/0096-1523.21.3.451; LAVIE N, IN PRESS J EXP PSYCH; LEWIS JL, 1970, J EXP PSYCHOL, V85, P225, DOI 10.1037/h0029518; Luck SJ, 1996, NATURE, V383, P616, DOI 10.1038/383616a0; Mack A., 1998, INATTENTIONAL BLINDN; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Martinez A, 1999, NAT NEUROSCI, V2, P364, DOI 10.1038/7274; Menard MT, 1996, NEUROPSYCHOLOGIA, V34, P185, DOI 10.1016/0028-3932(95)00099-2; Pashler H., 1998, PSYCHOL ATTENTION; Posner MI., 1978, CHRONOMETRIC EXPLORA; Price CJ, 1996, CEREB CORTEX, V6, P62, DOI 10.1093/cercor/6.1.62; Price CJ, 1998, TRENDS COGN SCI, V2, P281, DOI 10.1016/S1364-6613(98)01201-7; Rees G, 1997, SCIENCE, V278, P1616, DOI 10.1126/science.278.5343.1616; ROCK I, 1981, J EXP PSYCHOL HUMAN, V7, P275, DOI 10.1037/0096-1523.7.2.275; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Somers DC, 1999, P NATL ACAD SCI USA, V96, P1663, DOI 10.1073/pnas.96.4.1663; TIPPER SP, 1988, MEM COGNITION, V16, P64, DOI 10.3758/BF03197746; TREISMAN A, 1974, MEM COGNITION, V2, P641, DOI 10.3758/BF03198133; Treisman A., 1996, ATTENTION PERFORM, VXVI, P15; TREISMAN AM, 1969, PSYCHOL REV, V76, P282, DOI 10.1037/h0027242; Treue S, 1999, NATURE, V399, P575, DOI 10.1038/21176; Vandenberghe R, 1996, NATURE, V383, P254, DOI 10.1038/383254a0; VANORDEN GC, 1988, J EXP PSYCHOL LEARN, V14, P371, DOI 10.1037/0278-7393.14.3.371; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; Wolfe JM, 1999, MIT BRAD COGN PSYCH, P71	37	185	190	3	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2504	2507		10.1126/science.286.5449.2504	http://dx.doi.org/10.1126/science.286.5449.2504			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	268RQ	10617465				2022-12-01	WOS:000084429700048
J	Barroso, I; Gurnell, M; Crowley, VEF; Agostini, M; Schwabe, JW; Soos, MA; Maslen, GL; Williams, TDM; Lewis, H; Schafer, AJ; Chatterjee, VKK; O'Rahilly, S				Barroso, I; Gurnell, M; Crowley, VEF; Agostini, M; Schwabe, JW; Soos, MA; Maslen, GL; Williams, TDM; Lewis, H; Schafer, AJ; Chatterjee, VKK; O'Rahilly, S			Dominant negative mutations in human PPAR gamma associated with severe insulin resistance, diabetes mellitus and hypertension	NATURE			English	Article							ACTIVATED RECEPTOR-GAMMA; SMOOTH-MUSCLE CELLS; TRANSCRIPTIONAL ACTIVATION; HORMONE RECEPTORS; RETINOIC ACID; LIGAND; GENE; THIAZOLIDINEDIONES; IDENTIFICATION; PPAR-GAMMA-2	Thiazolidinediones are a new class of antidiabetic agent that improve insulin sensitivity and reduce plasma glucose and blood pressure in subjects with type 2 diabetes(1). Although these agents can bind and activate an orphan nuclear receptor, peroxisome proliferator-activated receptor gamma (PPAR gamma), there is no direct evidence to conclusively implicate this receptor in the regulation of mammalian glucose homeostasis(2). Here we report two different heterozygous mutations in the ligand-binding domain of PPAR gamma in three subjects with severe insulin resistance. In the PPAR gamma crystal structure, the mutations destabilize helix 12 which mediates transactivation. Consistent with this, both receptor mutants are markedly transcriptionally impaired and, moreover, are able to inhibit the action of coexpressed wild-type PPAR gamma in a dominant negative manner. In addition to insulin resistance, all three subjects developed type 2 diabetes mellitus and hypertension at an unusually early age. Our findings represent the first germline loss-of-function mutations in PPAR gamma and provide compelling genetic evidence that this receptor is important in the control of insulin sensitivity, glucose homeostasis and blood pressure in man.	Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2QQ, England; Incyte Europe Ltd, Cambridge CB4 0WA, England; MRC, Mol Biol Lab, Cambridge CB2 2QQ, England; Prince Philip Hosp, Llanelli SA14 8QF, Wales; Selly Oak Hosp, Birmingham B29 6JD, W Midlands, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Incyte; MRC Laboratory Molecular Biology	O'Rahilly, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med, Hills Rd, Cambridge CB2 2QQ, England.	kkcl@mole.bio.cam.ac.uk; sorahill@hgmp.mrc.ac.uk	Schwabe, John WR/A-9132-2008; O'Rahilly, Stephen/ABF-6509-2020	Schwabe, John WR/0000-0003-2865-4383; O'Rahilly, Stephen/0000-0003-2199-4449; Chatterjee, Vengalil Krishna/0000-0002-2654-8854; Barroso, Ines/0000-0001-5800-4520; Maslen, Gareth/0000-0001-7318-3678	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Beamer BA, 1998, DIABETES, V47, P1806, DOI 10.2337/diabetes.47.11.1806; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464-5491.1999.00023.x; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Doi K, 1998, CIRCULATION, V98, P39; FLIER JS, 1992, DIABETES, V41, P1207, DOI 10.2337/diabetes.41.9.1207; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Iijima K, 1998, BIOCHEM BIOPH RES CO, V247, P353, DOI 10.1006/bbrc.1998.8794; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIBBY P, 1999, ARTEROISCLER THROMB, V19, P546; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Nakamura Y, 1998, BRIT J PHARMACOL, V123, P675, DOI 10.1038/sj.bjp.0701669; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OGIHARA T, 1995, AM J HYPERTENS, V8, P316, DOI 10.1016/0895-7061(95)96214-5; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Satoh H, 1999, BIOCHEM BIOPH RES CO, V254, P757, DOI 10.1006/bbrc.1998.0126; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Whitehead JP, 1998, DIABETES, V47, P837, DOI 10.2337/diabetes.47.5.837; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Young PW, 1998, J PHARMACOL EXP THER, V284, P751	30	1026	1077	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 23	1999	402	6764					880	883		10.1038/47254	http://dx.doi.org/10.1038/47254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622252				2022-12-01	WOS:000084482000034
J	Friborg, J; Kong, WP; Hottiger, MO; Nabel, GJ				Friborg, J; Kong, WP; Hottiger, MO; Nabel, GJ			p53 inhibition by the LANA protein of KSHV protects against cell death	NATURE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; KAPOSIS-SARCOMA; TRANSCRIPTIONAL ACTIVATION; DNA-SEQUENCES; NUCLEAR ANTIGEN; EXPRESSION; HUMAN-HERPESVIRUS-8; IDENTIFICATION; COACTIVATORS	Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8, has been implicated in the development of Kaposi's sarcoma (KS) and several B-cen lymphoproliferative diseases(1-3) Most cells in lesions derived from these malignancies are latently infected, and different viral gene products have been identified in association with lytic or latent infection by KSHV4,5. The latency-associated nuclear antigen (LANA), encoded by open reading frame 73 of the KSHV genome, is a highly immunogenic protein that is expressed predominantly during viral latency, in most KS spindle cells and in cell lines established from body-cavity-based lymphomas(6,7). Antibodies to LANA can be detected in a high percentage of HIV-infected individuals who subsequently develop KS8,9, although its role in disease pathogenesis is not completely understood. p53 is a potent transcriptional regulator of cell growth whose induction leads either to cell-cycle arrest or apoptosis. Loss of p53 function correlates with cell transformation and oncogenesis(10,11), and several viral oncoproteins interact with p53 and modulate its biological activity(12-13). Here we show that LANA interacts with the tumour suppressor protein p53 and represses its transcriptional activity. This viral gene product further inhibits the ability of p53 to induce cell death. We propose that LANA contributes to viral persistence and oncogenesis in KS through its ability to promote cell survival by altering p53 function.	NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Nabel, GJ (corresponding author), NIH, Vaccine Res Ctr, 40 Convent Dr,MSC 3005, Bethesda, MD 20892 USA.		Hottiger, Michael O./J-7747-2013	Hottiger, Michael O./0000-0002-7323-2270				Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li JJ, 1997, AM J DERMATOPATH, V19, P373, DOI 10.1097/00000372-199708000-00009; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Moore PS, 1998, TRENDS GENET, V14, P144, DOI 10.1016/S0168-9525(98)01408-5; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; NOEL JC, 1997, AM J DERMATOPATH, V19, P322; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255	30	539	558	0	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 23	1999	402	6764					889	894		10.1038/47266	http://dx.doi.org/10.1038/47266			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622254				2022-12-01	WOS:000084482000036
J	Preckel, T; Fung-Leung, WP; Cai, ZL; Vitiello, A; Salter-Cid, L; Winqvist, O; Wolfe, TC; Von Herrath, M; Angulo, A; Ghazal, P; Lee, JD; Fourie, AM; Wu, Y; Pang, J; Ngo, K; Peterson, PA; Fruh, K; Yang, Y				Preckel, T; Fung-Leung, WP; Cai, ZL; Vitiello, A; Salter-Cid, L; Winqvist, O; Wolfe, TC; Von Herrath, M; Angulo, A; Ghazal, P; Lee, JD; Fourie, AM; Wu, Y; Pang, J; Ngo, K; Peterson, PA; Fruh, K; Yang, Y			Impaired immunoproteasome assembly and immune responses in PA28(-/-) mice	SCIENCE			English	Article							PROTEASOME REGULATOR PA28; REG-ALPHA; PEPTIDE; BETA; PA28-ALPHA; ACTIVATOR; COMPLEXES; CELLS	In vitro PA28 binds and activates proteasomes. It is shown here that mice with a disrupted PA28b gene Lack PA28a and PA28b polypeptides, demonstrating that PA28 functions as a hetero-oligomer in vivo. Processing of antigenic epitopes derived from exogenous or endogenous antigens is altered in PA28(-/-) mice. Cytotoxic T Lymphocyte responses are impaired, and assembly of immunoproteasomes is greatly inhibited in mice lacking PA28. These results show that PA28 is necessary for immunoproteasome assembly and is required for efficient antigen processing, thus demonstrating the importance of PA28-mediated proteasome function in immune responses.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	Fruh, K (corresponding author), RW Johnson Pharmaceut Res Inst, 3210 Merryfield Row, San Diego, CA 92121 USA.		Pang, Jesse CS/H-3549-2013	Pang, Jesse CS/0000-0002-8716-4045; Angulo, Ana/0000-0002-5792-1164; Fung-Leung, Wai-Ping/0000-0001-7013-8855; winqvist, Ola/0000-0003-0842-4441; Frueh, Klaus/0000-0001-8014-3877				Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; Borrow Persephone, 1997, P593; BUCHMEIER MJ, 1999, PERSISTENT VIRAL INF, P575; Conconi M, 1999, ARCH BIOCHEM BIOPHYS, V362, P325, DOI 10.1006/abbi.1998.1037; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; Flad T, 1998, CANCER RES, V58, P5803; Fruh K, 1999, CURR OPIN IMMUNOL, V11, P76, DOI 10.1016/S0952-7915(99)80014-4; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Ho M., 1991, CYTOMEGALOVIRUS BIOL; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JACOBY W, 1984, J INVEST DERMATOL, V83, P302, DOI 10.1111/1523-1747.ep12340431; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; Knowlton JR, 1997, NATURE, V390, P639, DOI 10.1038/37670; Li YH, 1999, IMMUNOGENETICS, V49, P149, DOI 10.1007/s002510050476; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; PRECKEL T, UNPUB; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Song XL, 1997, J BIOL CHEM, V272, P27994, DOI 10.1074/jbc.272.44.27994; Vitiello A, 1997, EUR J IMMUNOL, V27, P671, DOI 10.1002/eji.1830270315; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	26	143	147	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1999	286	5447					2162	2165		10.1126/science.286.5447.2162	http://dx.doi.org/10.1126/science.286.5447.2162			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591649				2022-12-01	WOS:000084157300054
J	Hampson, RE; Simeral, JD; Deadwyler, SA				Hampson, RE; Simeral, JD; Deadwyler, SA			Distribution of spatial and nonspatial information in dorsal hippocampus	NATURE			English	Article							TO-SAMPLE PERFORMANCE; SHORT-TERM-MEMORY; ENSEMBLE ACTIVITY; PLACE CELLS; SEMANTIC MEMORY; AMPAKINE CX516; ORGANIZATION; NAVIGATION; BRAIN; RATS	The hippocampus in the mammalian brain is required for the encoding of current and the retention of past experience, Previous studies have shown that the hippocampus contains neurons that encode information required to perform spatial and nonspatial short-term memory tasks. A more detailed understanding of the functional anatomy of the hippocampus would provide important insight into how such encoding occurs. Here we show that hippocampal neurons in the rat are distributed anatomically in distinct segments along the length of the hippocampus. Each longitudinal segment contains clusters of neurons that become active when the animal performs a task with spatial attributes. Within these same segments are ordered arrangements of neurons that encode the nonspatial aspects of the task appropriate to those spatial features. Thus, anatomical segregation of spatial information, together with the interleaved representation of nonspatial information, represents a structural framework that may help to resolve conflicting views of hippocampal function.	Wake Forest Univ, Sch Med, Program Neurosci, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	Wake Forest University	Hampson, RE (corresponding author), Wake Forest Univ, Sch Med, Program Neurosci, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA.		Simeral, John/CCI-2624-2022					AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANDERSEN P, 1971, EXP BRAIN RES, V13, P222; Burgess N, 1996, HIPPOCAMPUS, V6, P749; Burwell RD, 1995, HIPPOCAMPUS, V5, P390, DOI 10.1002/hipo.450050503; Cohen N J, 1991, Hippocampus, V1, P265, DOI 10.1002/hipo.450010312; Cohen NJ, 1999, HIPPOCAMPUS, V9, P83, DOI 10.1002/(SICI)1098-1063(1999)9:1<83::AID-HIPO9>3.0.CO;2-7; Colombo M, 1998, J NEUROPHYSIOL, V80, P1002, DOI 10.1152/jn.1998.80.2.1002; Deadwyler SA, 1996, J NEUROSCI, V16, P354; DEADWYLER SA, 1995, SCIENCE, V270, P1316, DOI 10.1126/science.270.5240.1316; Deadwyler SA, 1997, ANNU REV NEUROSCI, V20, P217, DOI 10.1146/annurev.neuro.20.1.217; Dolorfo CL, 1998, J COMP NEUROL, V398, P25; EICHENBAUM H, 1989, J NEUROSCI, V9, P2764; EICHENBAUM H, 1993, SCIENCE, V261, P993, DOI 10.1126/science.8351525; Gabrieli JDE, 1998, NEUROBIOL LEARN MEM, V70, P275, DOI 10.1006/nlme.1998.3853; Gothard KM, 1996, J NEUROSCI, V16, P823; Hampson RE, 1996, P NATL ACAD SCI USA, V93, P13487, DOI 10.1073/pnas.93.24.13487; Hampson RE, 1996, HIPPOCAMPUS, V6, P281, DOI 10.1002/(SICI)1098-1063(1996)6:3<281::AID-HIPO6>3.0.CO;2-Q; Hampson RE, 1998, J NEUROSCI, V18, P2740; Hampson RE, 1998, J NEUROSCI, V18, P2748; Hampson RE, 1999, J NEUROSCI, V19, P1492; Hirsch JA, 1998, J NEUROSCI, V18, P9517; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; Kohonen T, 1999, TRENDS NEUROSCI, V22, P135, DOI 10.1016/S0166-2236(98)01342-3; Lepage M, 1998, HIPPOCAMPUS, V8, P313, DOI 10.1002/(SICI)1098-1063(1998)8:4<313::AID-HIPO1>3.0.CO;2-I; LI XM, 1994, POTENTIAL ANAL, V3, P339, DOI 10.1007/BF01049807; McClelland JL, 1998, ANN NY ACAD SCI, V843, P153, DOI 10.1111/j.1749-6632.1998.tb08212.x; MORRIS RG, 1997, PHIL T R SOC LOND B, V29, P1489; Moser MB, 1998, HIPPOCAMPUS, V8, P608, DOI 10.1002/(SICI)1098-1063(1998)8:6<608::AID-HIPO3>3.0.CO;2-7; Moser MB, 1998, J NEUROSCI, V18, P7535; Muller R, 1996, NEURON, V17, P813, DOI 10.1016/S0896-6273(00)80214-7; Muller RU, 1996, J GEN PHYSIOL, V107, P663, DOI 10.1085/jgp.107.6.663; Nadel L., 1991, Hippocampus, V1, P221, DOI 10.1002/hipo.450010302; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; PEDHAZUR EJ, 1991, MEASUREMENT DESIGN A; Rawlins JNP, 1999, NATURE, V397, P561, DOI 10.1038/17481; RAWLINS JNP, 1982, BEHAV BRAIN RES, V5, P331, DOI 10.1016/0166-4328(82)90039-0; Samsonovich A, 1997, J NEUROSCI, V17, P5900; Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K; Shapiro ML, 1997, HIPPOCAMPUS, V7, P624, DOI 10.1002/(SICI)1098-1063(1997)7:6<624::AID-HIPO5>3.0.CO;2-E; Squire LR, 1998, HIPPOCAMPUS, V8, P205, DOI 10.1002/(SICI)1098-1063(1998)8:3<205::AID-HIPO3>3.0.CO;2-I; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; Touretzky DS, 1996, HIPPOCAMPUS, V6, P247; Tulving E, 1997, CURR OPIN NEUROBIOL, V7, P209, DOI 10.1016/S0959-4388(97)80009-8; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; Wallenstein GV, 1998, TRENDS NEUROSCI, V21, P317, DOI 10.1016/S0166-2236(97)01220-4; Wood ER, 1999, NATURE, V397, P613, DOI 10.1038/17605	48	234	240	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					610	614		10.1038/45154	http://dx.doi.org/10.1038/45154			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604466				2022-12-01	WOS:000084189800053
J	Smith, CA; McClive, PJ; Western, PS; Reed, KJ; Sinclair, AH				Smith, CA; McClive, PJ; Western, PS; Reed, KJ; Sinclair, AH			Evolution - Conservation of a sex-determining gene	NATURE			English	Article									Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Melbourne, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Ctr Hormone Res, Melbourne, Vic 3052, Australia	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne	Smith, CA (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Melbourne, Vic 3052, Australia.		Sinclair, Andrew H/A-3598-2010	Sinclair, Andrew H/0000-0003-2741-7992; Smith, Craig/0000-0002-1670-5545; Western, Patrick/0000-0002-7587-8227				Bull J.J., 1983, EVOLUTION SEX DETERM; Flejter WL, 1998, AM J HUM GENET, V63, P794, DOI 10.1086/302016; Guioli S, 1998, AM J HUM GENET, V63, P905, DOI 10.1086/302017; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Nanda I, 1999, NAT GENET, V21, P258, DOI 10.1038/6769; Raymond CS, 1999, HUM MOL GENET, V8, P989, DOI 10.1093/hmg/8.6.989; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0	8	304	332	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1999	402	6762					601	602		10.1038/45130	http://dx.doi.org/10.1038/45130			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604464				2022-12-01	WOS:000084189800045
J	Kobe, B; Kemp, BE				Kobe, B; Kemp, BE			Active site-directed protein regulation	NATURE			English	Article							TYROSINE KINASE HCK; CRYSTAL-STRUCTURE; BOVINE TRYPSINOGEN; KARYOPHERIN-ALPHA; INSULIN-RECEPTOR; DOMAIN; ACTIVATION; SRC; RESOLUTION; INSIGHTS	Regulation of protein function is vital for the control of cellular processes. Proteins are often regulated by allosteric mechanisms, in which effecters bind to regulatory sites distinct from the active sites and alter protein function. Intrasteric regulation, directed at the active site and thus the counterpart of allosteric control, is now emerging as an important regulatory mechanism.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research	Kobe, B (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.		Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014; Kobe, Bostjan/D-1292-2009	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082; Kobe, Bostjan/0000-0001-9413-9166				Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CIGNOLANI G, 1999, NATURE, V399, P221; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; Johnson LN, 1997, ADV SEC MESS PHOSPH, V31, P11; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1994, PROTEIN KINASES, P30; Khan AR, 1998, PROTEIN SCI, V7, P815; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; KOSSIAKOFF AA, 1977, BIOCHEMISTRY-US, V16, P654, DOI 10.1021/bi00623a016; Lin K, 1997, STRUCTURE, V5, P1511, DOI 10.1016/S0969-2126(97)00300-6; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHANG F, 1993, NATURE, V367, P704	46	163	165	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					373	376		10.1038/46478	http://dx.doi.org/10.1038/46478			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586874				2022-12-01	WOS:000083913600045
J	Soltis, PS; Soltis, DE; Chase, MW				Soltis, PS; Soltis, DE; Chase, MW			Angiosperm phylogeny inferred from multiple genes as a tool for comparative biology	NATURE			English	Article							LARGE DATA SETS; COMPLEX PHYLOGENIES; SEQUENCES; EVOLUTION; PARSIMONY; ORIGIN; RBCL	Comparative biology requires a firm phylogenetic foundation to uncover and understand patterns of diversification and evaluate hypotheses of the processes responsible for these patterns. In the angiosperms, studies of diversification in floral form(1,2), stamen organization(3), reproductive biology(4), photosynthetic pathway(5), nitrogen-fixing symbioses(6) and life histories(7) have relied on either explicit or implied phylogenetic trees, Furthermore, to understand the evolution of specific genes and gene families, evaluate the extent of conservation of plant genomes and make proper sense of the huge volume of molecular genetic data available for model organisms(8) such as Arabidopsis, Antirrhinum, maize, rice and wheat, a phylogenetic perspective is necessary. Here we report the results of parsimony analyses of DNA sequences of the plastid genes rbcL and atpB and the nuclear 18S rDNA for 560 species of angiosperms and seven non-flowering seed plants and show a well-resolved and well-supported phylogenetic tree for the angiosperms for use in comparative biology.	Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA; Royal Bot Gardens, Jodrell Lab, Richmond TW9 3DS, Surrey, England	Washington State University; Royal Botanic Gardens, Kew	Soltis, PS (corresponding author), Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA.	psoltis@wsu.edu	Soltis, Pamela S/L-5184-2015; Soltis, Pamela S/GNH-5557-2022; Soltis, Douglas/L-5957-2015; Chase, Mark W/A-6642-2011	Soltis, Pamela S/0000-0001-9310-8659; Chase, Mark/0000-0002-9927-4938				CHASE MW, 1993, ANN MO BOT GARD, V80, P528, DOI 10.2307/2399846; Chase MW, 1998, AUST SYST BOT, V11, P215, DOI 10.1071/SB97010; CHASE MW, IN PRESS P MON 2 2 I, V2; Crepet WL, 1998, AM J BOT, V85, P1122, DOI 10.2307/2446345; CRONQUIST A., 1981, INTEGRATED SYSTEM CL; Cronquist A., 1988, EVOLUTION CLASSIFICA, V2; Dodd ME, 1999, EVOLUTION, V53, P732, DOI 10.2307/2640713; Donoghue MJ, 1998, TRENDS PLANT SCI, V3, P311, DOI 10.1016/S1360-1385(98)01278-3; DOYLE JA, 1994, ANN MO BOT GARD, V81, P419, DOI 10.2307/2399899; ENDRESS PK, 1994, PLANT SYST EVOL, V192, P79, DOI 10.1007/BF00985910; Farris JS, 1996, CLADISTICS, V12, P99, DOI 10.1111/j.1096-0031.1996.tb00196.x; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Gale MD, 1998, SCIENCE, V282, P656, DOI 10.1126/science.282.5389.656; Graybeal A, 1998, SYST BIOL, V47, P9, DOI 10.1080/106351598260996; Hillis DM, 1996, NATURE, V383, P130, DOI 10.1038/383130a0; KELLOGG EA, 1998, BIOL C4 PHOTOSYNTHES, P411; Kramer EM, 1998, GENETICS, V149, P765; Mathews S, 1999, SCIENCE, V286, P947, DOI 10.1126/science.286.5441.947; Nandi OI, 1998, ANN MO BOT GARD, V85, P137, DOI 10.2307/2992003; Qiu YL, 1999, NATURE, V402, P404, DOI 10.1038/46536; Rice KA, 1997, SYST BIOL, V46, P554, DOI 10.2307/2413696; RONSEDECRAENE LP, 1987, NORD J BOT, V7, P239; SAVOLAINEN V, IN PRESS SYST BIOL; Soltis DE, 1997, ANN MO BOT GARD, V84, P1, DOI 10.2307/2399952; SOLTIS DE, 1995, P NATL ACAD SCI USA, V92, P2647, DOI 10.1073/pnas.92.7.2647; Soltis DE, 1998, SYST BIOL, V47, P32, DOI 10.1080/106351598261012; Swofford DL, 2002, PAUP PHYLOGENETIC AN; Takhtajan A., 1991, EVOLUTIONARY TRENDS; Takhtajan A.L., 1997, DIVERSITY CLASSIFICA; WELLER SG, 1995, MONOG SYST BOTAN, V53, P355	30	653	696	0	106	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					402	404		10.1038/46528	http://dx.doi.org/10.1038/46528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586878				2022-12-01	WOS:000083913600053
J	Bortolotto, ZA; Clarke, VRJ; Delany, CM; Parry, MC; Smolders, I; Vignes, M; Ho, KH; Miu, P; Brinton, BT; Fantaske, R; Ogden, A; Gates, M; Ornstein, PL; Lodge, D; Bleakman, D; Collingridge, GL				Bortolotto, ZA; Clarke, VRJ; Delany, CM; Parry, MC; Smolders, I; Vignes, M; Ho, KH; Miu, P; Brinton, BT; Fantaske, R; Ogden, A; Gates, M; Ornstein, PL; Lodge, D; Bleakman, D; Collingridge, GL			Kainate receptors are involved in synaptic plasticity	NATURE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; GLUR5 SUBTYPE; TRANSMISSION; ACTIVATION; AMPA; ACID; CA3; DESENSITIZATION; ANTAGONISTS	The ability of synapses to modify their synaptic strength in response to activity is a fundamental property of the nervous system and may be an essential component of learning and memory(1). There are three classes of ionotropic glutamate receptor, namely NMDA (N-methyl-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-4-propionic acid) and kainate receptors(2); critical roles in synaptic plasticity have been identified for two of these. Thus, at many synapses in the brain, transient activation of NMDA receptors leads to a persistent modification in the strength of synaptic transmission mediated by AMPA receptors(3,4). Here, to determine whether kainate receptors(5-7) are involved in synaptic plasticity, we have used a new antagonist, LY382884 ((3S, 4aR, 6S, 8aR)-6-( (4-carboxyphenyl)methyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid), which antagonizes kainate receptors at concentrations that do not affect AMPA or NMDA receptors. We find that LY382884 is a selective antagonist at neuronal kainate receptors containing the GluR5 subunit. it has no effect on long-term potentiation (LTP) that is dependent on NMDA receptors but prevents the induction of mossy fibre LTP, which is independent of NMDA receptors. Thus, kainate receptors can act as the induction trigger for longterm changes in synaptic transmission.	Univ Bristol, Sch Med, Dept Anat, MRC Ctr Synapt Plast, Bristol BS8 1TD, Avon, England; Free Univ Brussels, Inst Pharmaceut, Dept Pharmaceut Chem & Drug Anal, B-1090 Brussels, Belgium; Univ Montpellier 2, Lab Plasticite Cerebrale, CNRS, F-34095 Montpellier, France; Allelix Biopharmaceut, Mississauga, ON L4V 1V7, Canada; Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA	University of Bristol; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Eli Lilly	Bortolotto, ZA (corresponding author), Univ Bristol, Sch Med, Dept Anat, MRC Ctr Synapt Plast, Bristol BS8 1TD, Avon, England.		Ornstein, Paul/E-4212-2016; collingridge, graham/AAI-8362-2020; Smolders, Ilse J/J-9399-2013; Collingridge, Graham L/C-4605-2015; Vignes, Michel/AAA-7693-2019	Ornstein, Paul/0000-0002-4335-1877; Smolders, Ilse J/0000-0003-2140-0751; Collingridge, Graham L/0000-0002-9572-5359; Vignes, Michel/0000-0003-0969-2966; Clarke, Vernon/0000-0002-6154-6555				BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Bleakman D, 1998, NEUROPHARMACOLOGY, V37, P1187, DOI 10.1016/S0028-3908(98)00139-7; Bleakman D, 1996, MOL PHARMACOL, V49, P581; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; Clarke VRJ, 1997, NATURE, V389, P599, DOI 10.1038/39315; Cossart R, 1998, NAT NEUROSCI, V1, P470, DOI 10.1038/2185; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; Hebb D.O., 2002, CLIN PSYCHOL; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; Li H, 1998, NEUROPHARMACOLOGY, V37, P1279, DOI 10.1016/S0028-3908(98)00109-9; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; O'Neill MJ, 1998, NEUROPHARMACOLOGY, V37, P1211, DOI 10.1016/S0028-3908(98)00134-8; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; Procter MJ, 1998, NEUROPHARMACOLOGY, V37, P1287, DOI 10.1016/S0028-3908(98)00136-1; Simmons RMA, 1998, NEUROPHARMACOLOGY, V37, P25, DOI 10.1016/S0028-3908(97)00188-3; Vignes M, 1997, NEUROPHARMACOLOGY, V36, P1477, DOI 10.1016/S0028-3908(97)00158-5; Vignes M, 1998, NEUROPHARMACOLOGY, V37, P1269, DOI 10.1016/S0028-3908(98)00148-8; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180	30	259	264	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					297	301		10.1038/46290	http://dx.doi.org/10.1038/46290			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580501				2022-12-01	WOS:000083813700051
J	Migliaccio, E; Giorgio, M; Mele, S; Pelicci, G; Reboidl, P; Pandolfi, PP; Lanfrancone, L; Pelicci, PG				Migliaccio, E; Giorgio, M; Mele, S; Pelicci, G; Reboidl, P; Pandolfi, PP; Lanfrancone, L; Pelicci, PG			The p66(shc) adaptor protein controls oxidative stress response and life span in mammals	NATURE			English	Article							DROSOPHILA-MELANOGASTER; DIETARY RESTRICTION; PATHWAY; MICE; RESISTANCE; ACTIVATION; MUTATION; UV; EXPRESSION; EXTENSION	Gene mutations in invertebrates have been identified that extend Life span and enhance resistance to environmental stresses such as ultraviolet light or reactive oxygen species(1). In mammals, the mechanisms that regulate stress response are poorly understood and no genes are known to increase individual life span. Here we report that targeted mutation of the mouse p66(shc) gene induces stress resistance and prolongs life span. p66(shc) is a splice variant of p52(shc)/p46(shc) (ref. 2), a cytoplasmic signal transducer involved in the transmission of mitogenic signals from activated receptors to Ras(3). We show that: (1) p66(shc) is serine phosphorylated upon treatment with hydrogen peroxide (H2O2) Or irradiation with ultraviolet light; (2) ablation of p66(shc) enhances cellular resistance to apoptosis induced by H2O2 or ultraviolet light; (3) a serine-phosphorylation defective mutant of p66(shc) cannot restore the normal stress response in p66(shc-/-) cells; (4) the p53 and p21 stress response is impaired in p66(shc-/-) cells; (5) p66(shc-/-) mice have increased resistance to paraquat and a 30% increase in life span. We propose that p66(shc) is part of a signal transduction pathway that regulates stress apoptotic responses and life span in mammals.	Mem Sloan Kettering Canc Ctr, Dept Human Genet, Program Mol Biol, Sloan Kettering Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, Cell Biol Program, Sloan Kettering Inst, New York, NY 10021 USA; Univ Perugia, Ist Patol Med, I-06100 Perugia, Italy; Univ Perugia, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Perugia; University of Perugia	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Migliaccio, Enrica/AAQ-8880-2020; Franzeck, Fabian C/B-5055-2011; Giorgio, Marco/I-9425-2012; Reboldi, Gianpaolo/A-3444-2009; Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Pelicci, Giuliana/AAA-8921-2022	Giorgio, Marco/0000-0002-5842-6042; Reboldi, Gianpaolo/0000-0002-9877-0702; Lanfrancone, Luisa/0000-0002-4523-3815; Pelicci, Giuliana/0000-0003-0986-8255				Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; LARSEN PL, 1995, GENETICS, V139, P1576; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; Lithgow GJ, 1996, SCIENCE, V273, P80, DOI 10.1126/science.273.5271.80; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Marubini E, 1995, ANAL SURVIVAL DATA C; Medawar P. B., 1952, MODERN Q, V1, P30; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Murakami S, 1996, GENETICS, V143, P1207; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Renzing J, 1996, J CELL SCI, V109, P1105; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SERVICE PM, 1985, PHYSIOL ZOOL, V58, P380, DOI 10.1086/physzool.58.4.30156013; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; STEVENSON MA, 1994, CANCER RES, V54, P12; SUN JY, 1994, J BIOL CHEM, V269, P18638; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	30	1384	1454	1	72	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					309	313		10.1038/46311	http://dx.doi.org/10.1038/46311			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580504				2022-12-01	WOS:000083813700054
J	Kyne, L; Warny, M; Qamar, A; Kelly, CP				Kyne, L; Warny, M; Qamar, A; Kelly, CP			Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITALIZED-PATIENTS; RISK-FACTORS; DIARRHEA; INFECTION; COLITIS; COLONIZATION; ACQUISITION; COHORT; EPIDEMIOLOGY; PURIFICATION	Background: Clostridium difficile infection can result in asymptomatic carriage, mild diarrhea, or fulminant pseudomembranous colitis. We studied whether antibody responses to C. difficile toxins affect the risks of colonization, diarrhea, and asymptomatic carriage. Methods: We prospectively studied C. difficile infections in hospitalized patients who were receiving antibiotics. Serial stool samples were tested for C. difficile colonization by cytotoxin assay and culture. Serum antibody (IgA, IgG, and IgM) levels and fecal antibody (IgA and IgG) levels against C. difficile toxin A, toxin B, and nontoxin antigens were measured by an enzyme-linked immunosorbent assay (ELISA). Results: Of 271 patients, 37 (14 percent) were colonized with C. difficile at the time of admission, 18 of whom were asymptomatic carriers. An additional 47 patients (17 percent) became infected in the hospital, 19 of whom remained asymptomatic. The base-line antibody levels were similar in the patients who later became colonized and those who did not. After colonization, those who became asymptomatic carriers had significantly greater increases in serum levels of IgG antibody against toxin A than did the patients in whom C. difficile diarrhea developed (P<0.001). The adjusted odds ratio for diarrhea was 48.0 (95 percent confidence interval, 3.4 to 678) among patients with colonization who had a serum level of IgG antibody against toxin A of 3.00 ELISA units or less, as compared with patients with colonization who had a level of more than 3.00 ELISA units. Conclusions: We find no evidence of immune protection against colonization by C. difficile. However, after colonization there is an association between a systemic anamnestic response to toxin A, as evidenced by increased serum levels of IgG antibody against toxin A, and asymptomatic carriage of C. difficile. (N Engl J Med 2000;342:390-7.) (C)2000, Massachusetts Medical Society.	Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kelly, CP (corresponding author), Beth Israel Deaconess Med Ctr, Div Gastroenterol, Dana 601,330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG016956, P60AG008812, P30AG008812] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01032] Funding Source: Medline; NIA NIH HHS [AG16956, AG08812] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BACON AE, 1994, DIAGN MICR INFEC DIS, V18, P205, DOI 10.1016/0732-8893(94)90021-3; Bliss DZ, 1998, ANN INTERN MED, V129, P1012, DOI 10.7326/0003-4819-129-12-199812150-00004; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cheng SH, 1997, CLIN INFECT DIS, V25, P157, DOI 10.1086/516891; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; GEORGE WL, 1979, J CLIN MICROBIOL, V9, P214; GERDING DN, 1995, INFECT CONT HOSP EP, V16, P459; Guerrant R. L., 1990, REV INFECT DIS, V12, P41; HANFF PA, 1993, CLIN INFECT DIS, V16, pS245, DOI 10.1093/clinids/16.Supplement_4.S245; HOHMANN A, 1983, J IMMUNOL METHODS, V64, P199, DOI 10.1016/0022-1759(83)90398-8; HORN SD, 1983, MED CARE, V21, P14, DOI 10.1097/00005650-198301000-00002; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; JOHNSON S, 1992, J INFECT DIS, V166, P1287, DOI 10.1093/infdis/166.6.1287; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Kelly CP, 1996, ANTIMICROB AGENTS CH, V40, P373, DOI 10.1128/AAC.40.2.373; Kelly CP, 1996, EUR J GASTROEN HEPAT, V8, P1048, DOI 10.1097/00042737-199611000-00004; KELLY CP, 1992, GASTROENTEROLOGY, V102, P35, DOI 10.1016/0016-5085(92)91781-X; Kent KC, 1998, ANN SURG, V227, P296, DOI 10.1097/00000658-199802000-00021; Kyne L, 1999, AGE AGEING, V28, P107, DOI 10.1093/ageing/28.2.107; Kyne L, 1998, BIODRUGS, V10, P173, DOI 10.2165/00063030-199810030-00001; Kyne L, 1998, AGE AGEING, V27, P339, DOI 10.1093/ageing/27.3.339; LEUNG DYM, 1991, J PEDIATR-US, V118, P633, DOI 10.1016/S0022-3476(05)83393-1; MCFARLAND LV, 1991, INFECT IMMUN, V59, P2456, DOI 10.1128/IAI.59.7.2456-2462.1991; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MCFARLAND LV, 1987, J CLIN MICROBIOL, V25, P2241, DOI 10.1128/JCM.25.11.2241-2242.1987; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; MCFARLAND LV, 1995, AM J INFECT CONTROL, V23, P295, DOI 10.1016/0196-6553(95)90060-8; MULLIGAN ME, 1993, CLIN INFECT DIS, V16, pS239, DOI 10.1093/clinids/16.Supplement_4.S239; Pothoulakis C, 1996, EUR J GASTROEN HEPAT, V8, P1041, DOI 10.1097/00042737-199611000-00003; RIEGLER M, 1995, J CLIN INVEST, V95, P2004, DOI 10.1172/JCI117885; RUBIN MS, 1995, DIS COLON RECTUM, V38, P350, DOI 10.1007/BF02054220; Salcedo J, 1997, GUT, V41, P366, DOI 10.1136/gut.41.3.366; SAMORE MH, 1994, CLIN INFECT DIS, V18, P181, DOI 10.1093/clinids/18.2.181; Shim JK, 1998, LANCET, V351, P633, DOI 10.1016/S0140-6736(97)08062-8; Starr JM, 1997, LANCET, V349, P426, DOI 10.1016/S0140-6736(97)80053-0; SULLIVAN NM, 1982, INFECT IMMUN, V35, P1032, DOI 10.1128/IAI.35.3.1032-1040.1982; VISCIDI R, 1983, J INFECT DIS, V148, P93, DOI 10.1093/infdis/148.1.93; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; WARNY M, 1994, INFECT IMMUN, V62, P384, DOI 10.1128/IAI.62.2.384-389.1994	40	694	747	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					390	397		10.1056/NEJM200002103420604	http://dx.doi.org/10.1056/NEJM200002103420604			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666429				2022-12-01	WOS:000085205200004
J	Schrag, D; Kuntz, KM; Garber, JE; Weeks, JC				Schrag, D; Kuntz, KM; Garber, JE; Weeks, JC			Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Conference of the Society-for-Medical-Decision-Making	OCT 24-28, 1998	BOSTON, MASSACHUSETTS	Soc Med Decis Making			CORONARY HEART-DISEASE; 20-YEAR FOLLOW-UP; OVARIAN-CANCER; DECISION-ANALYSIS; PROPHYLACTIC MASTECTOMY; COST-EFFECTIVENESS; RISK FACTOR; MORTALITY; SURVIVAL; CARCINOMA	Context Women with BRCA1- or BRCA2-associated breast cancer are at increased risk for contralateral breast cancer and ovarian cancer and therefore may consider secondary cancer prevention strategies, such as prophylactic surgery and tamoxifen therapy. It is not proven to what extent these strategies reduce risk of second cancers in such patients. Objective To examine the effect of tamoxifen therapy, bilateral prophylactic oophorectomy (PO), prophylactic contralateral mastectomy (PCM), and combinations of these strategies on life expectancy for women with unilateral breast cancer and a BRCA1 or BRCA2 gene mutation. Design and Setting Decision analysis using a Markov model. Probabilities for developing contralateral breast cancer and ovarian cancer, dying from these cancers, dying from primary breast cancer, and the reduction in cancer incidence and mortality due to prophylactic surgeries and/or tamoxifen were estimated from published studies. Participants Hypothetical breast cancer patients with BRCA1 or BRCA2 mutations facing decisions about secondary cancer prevention strategies. Interventions Seven strategies, including 5 years of tamoxifen use, PO, PCM, and combinations of these strategies, compared with careful surveillance. Main Outcome Measures Total and incremental life expectancy (LE) with each intervention strategy. Results Depending on the assumed penetrance of the BRCA mutation, compared with surveillance alone, 30-year-old early-stage breast cancer patients with BRCA mutations gain in LE 0.4 to 1.3 years from tamoxifen therapy, 0.2 to 1.8 years from PO, and 0.6 to 2.1 years from PCM, The magnitude of these gains is least for women with low-penetrance mutations (assumed contralateral breast cancer risk of 24% and ovarian cancer risk of 6%) and greatest for those with high-penetrance mutations (assumed contralateral breast cancer risk of 65% and ovarian cancer risk of 40%.) Older age and poorer prognosis from primary breast cancer further attenuate these gains. Conclusions Interventions to prevent second cancers, particularly PCM, may offer substantial LE gain for young women with BRCA-associated early-stage breast cancer. Estimates of LE gain may help women and their physicians consider the uncertainties, risks, and advantages of these interventions and lead to more informed choices about cancer prevention strategies.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health	Schrag, D (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, 1275 York Ave, New York, NY 10021 USA.		Kleibl, Zdenek/A-2009-2008	Kleibl, Zdenek/0000-0003-2050-9667				Abe O, 1998, LANCET, V352, P930; Bandera CA, 1998, OBSTET GYNECOL, V92, P596, DOI 10.1016/S0029-7844(98)00223-3; BARTLETT K, 1993, LANCET, V341, P1293; BROET P, 1995, J CLIN ONCOL, V13, P1578, DOI 10.1200/JCO.1995.13.7.1578; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; Clarke M, 1996, LANCET, V348, P1189; Clarke M, 1998, LANCET, V351, P1451; Colditz G A, 1997, Oncology (Williston Park), V11, P1491; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; Cooper GS, 1998, ANN EPIDEMIOL, V8, P229, DOI 10.1016/S1047-2797(97)00207-X; DePriest PD, 1997, GYNECOL ONCOL, V65, P408, DOI 10.1006/gyno.1997.4705; DISAIA PJ, 1995, CANCER, V76, P2075, DOI 10.1002/1097-0142(19951115)76:10+<2075::AID-CNCR2820761328>3.0.CO;2-2; EASTON DF, 1995, AM J HUM GENET, V56, P265; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; Fodor FH, 1998, AM J HUM GENET, V63, P45, DOI 10.1086/301903; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Grann VR, 1998, J CLIN ONCOL, V16, P979, DOI 10.1200/JCO.1998.16.3.979; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; HEALEY EA, 1993, J CLIN ONCOL, V11, P1545, DOI 10.1200/JCO.1993.11.8.1545; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; Johannsson OT, 1998, J CLIN ONCOL, V16, P397, DOI 10.1200/JCO.1998.16.2.397; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(97)89007-7; Khovidhunkit W, 1999, ANN INTERN MED, V130, P431, DOI 10.7326/0003-4819-130-5-199903020-00015; Lakhani SR, 1997, LANCET, V349, P1505; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Landis SH, 1998, CA-CANCER J CLIN, V48, P329; Landis SH, 1998, CA-CANCER J CLIN, V48, P192; Lee JS, 1999, JNCI-J NATL CANCER I, V91, P259, DOI 10.1093/jnci/91.3.259; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; LINDFORS KK, 1995, JAMA-J AM MED ASSOC, V274, P881, DOI 10.1001/jama.274.11.881; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; RIES LAG, 1993, CANCER-AM CANCER SOC, V71, P524; Rivkin SE, 1996, J CLIN ONCOL, V14, P46, DOI 10.1200/JCO.1996.14.1.46; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Robson M, 1998, J CLIN ONCOL, V16, P1642, DOI 10.1200/JCO.1998.16.5.1642; ROSEN PP, 1991, J CLIN ONCOL, V9, P1650, DOI 10.1200/JCO.1991.9.9.1650; ROSEN PP, 1989, SURGERY, V106, P904; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; Schairer C, 1997, INT J CANCER, V70, P150, DOI 10.1002/(SICI)1097-0215(19970117)70:2<150::AID-IJC2>3.0.CO;2-W; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; Smart CR, 1997, CA-CANCER J CLIN, V47, P134, DOI 10.3322/canjclin.47.3.134; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Struewing J P, 1995, J Natl Cancer Inst Monogr, P33; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tengs TO, 1998, MED DECIS MAKING, V18, P365, DOI 10.1177/0272989X9801800402; Thorlacius S, 1998, LANCET, V352, P1337, DOI 10.1016/S0140-6736(98)03300-5; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; *US SURV EP END RE, 1996, SEER PUBL US DAT 197; vanderSchouw YT, 1996, LANCET, V347, P714, DOI 10.1016/S0140-6736(96)90075-6; VENTURA SJ, 1998, NATL VITAL STAT REPO, V47, P1; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7; Whittemore AS, 1997, AM J HUM GENET, V60, P496; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606	57	157	159	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					617	624		10.1001/jama.283.5.617	http://dx.doi.org/10.1001/jama.283.5.617			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665701	Bronze			2022-12-01	WOS:000084956500027
J	Li, XP; Bjorkman, O; Shih, C; Grossman, AR; Rosenquist, M; Jansson, S; Niyogi, KK				Li, XP; Bjorkman, O; Shih, C; Grossman, AR; Rosenquist, M; Jansson, S; Niyogi, KK			A pigment-binding protein essential for regulation of photosynthetic light harvesting	NATURE			English	Article							PHOTOSYSTEM-II; ENERGY-DISSIPATION; XANTHOPHYLL CYCLE; CHLOROPHYLL FLUORESCENCE; VIOLAXANTHIN DEEPOXIDATION; CHLORINA MUTANTS; ANTENNA PROTEINS; HIGHER-PLANTS; GREEN PLANTS; S PROTEIN	Photosynthetic light harvesting in plants is regulated in response to changes in incident light intensity. Absorption of light that exceeds a plant's capacity for fixation of CO2 results in thermal dissipation of excitation energy in the pigment antenna of photosystem II by a poorly understood mechanism. This regulatory process, termed nonphotochemical quenching, maintains the balance between dissipation and utilization of light energy to minimize generation of oxidizing molecules, thereby protecting the plant against photo-oxidative damage. To identify specific proteins that are involved in nonphotochemical quenching, we have isolated mutants of Arabidopsis thaliana that cannot dissipate excess absorbed light energy. Here we show that the gene encoding PsbS, an intrinsic chlorophyll-binding protein of photosystem II, is necessary for nonphotochemical quenching but not for efficient light harvesting and photosynthesis, These results indicate that PsbS may be the site for nonphotochemical quenching, a finding that has implications for the functional evolution of pigment-binding proteins.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA; Umea Univ, Dept Plant Physiol, Umea Plant Sci Ctr, S-90187 Umea, Sweden	University of California System; University of California Berkeley; Carnegie Institution for Science; Umea University	Niyogi, KK (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	niyogi@nature.berkeley.edu	Jansson, Stefan/A-1119-2009	Jansson, Stefan/0000-0002-7906-6891; Rosenquist, Magnus/0000-0001-7795-9728				BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BELL WR, 1994, SEMIN HEMATOL, V31, P19; BILGER W, 1994, PLANTA, V193, P238, DOI 10.1007/BF00192536; Bossmann B, 1997, PHOTOSYNTH RES, V52, P127, DOI 10.1023/A:1005823711838; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; CROFTS AR, 1994, FEBS LETT, V352, P265, DOI 10.1016/0014-5793(94)00976-7; DAU H, 1994, J PHOTOCH PHOTOBIO B, V26, P3, DOI 10.1016/1011-1344(94)85032-1; Demmig-Adams B, 1998, PLANT CELL PHYSIOL, V39, P474, DOI 10.1093/oxfordjournals.pcp.a029394; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DEMMIGADAMS B, 1994, AUST J PLANT PHYSIOL, V21, P575, DOI 10.1071/PP9940575; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; Douglas SE, 1998, CURR OPIN GENET DEV, V8, P655, DOI 10.1016/S0959-437X(98)80033-6; Espineda CE, 1999, P NATL ACAD SCI USA, V96, P10507, DOI 10.1073/pnas.96.18.10507; FUNK C, 1995, J BIOL CHEM, V270, P30141; FUNK C, 1995, BIOCHEMISTRY-US, V34, P11133, DOI 10.1021/bi00035a019; GHANOTAKIS DF, 1987, PHOTOSYNTH RES, V14, P191, DOI 10.1007/BF00032704; Gilmore AM, 1996, PHOTOSYNTH RES, V48, P171, DOI 10.1007/BF00041007; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; GREEN BR, 1995, PHOTOSYNTH RES, V44, P139, DOI 10.1007/BF00018304; GREEN BR, 1994, PHOTOSYNTH RES, V39, P149, DOI 10.1007/BF00029382; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; HORTON P, 1991, FEBS LETT, V292, P1, DOI 10.1016/0014-5793(91)80819-O; HORTON P, 1992, PHOTOSYNTH RES, V34, P375, DOI 10.1007/BF00029812; Hurry V, 1997, PLANT PHYSIOL, V113, P639, DOI 10.1104/pp.113.2.639; JAHNS P, 1994, PLANTA, V192, P176, DOI 10.1007/BF01089032; Jansson S, 1997, BBA-BIOENERGETICS, V1320, P297, DOI 10.1016/S0005-2728(97)00033-9; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JOHNSON GN, 1993, PLANT CELL ENVIRON, V16, P673, DOI 10.1111/j.1365-3040.1993.tb00485.x; KIM KH, 1992, MED CHEM RES, V2, P22; KIM S, 1994, BBA-BIOENERGETICS, V1188, P339, DOI 10.1016/0005-2728(94)90054-X; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Niyogi KK, 1997, P NATL ACAD SCI USA, V94, P14162, DOI 10.1073/pnas.94.25.14162; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; OTTANDER C, 1995, PLANTA, V197, P176, DOI 10.1007/BF00239954; Owens T. G., 1994, PHOTOINHIBITION PHOT, P95; Phillip D, 1996, P NATL ACAD SCI USA, V93, P1492, DOI 10.1073/pnas.93.4.1492; Ruban AV, 1999, PLANT PHYSIOL, V119, P531, DOI 10.1104/pp.119.2.531; Ruban AV, 1996, BIOCHEMISTRY-US, V35, P674, DOI 10.1021/bi9524878; RUBAN AV, 1993, PLANT PHYSIOL, V102, P741, DOI 10.1104/pp.102.3.741; Tardy F, 1996, J PHOTOCH PHOTOBIO B, V34, P87, DOI 10.1016/1011-1344(95)07272-1; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; YAMAMOTO HY, 1972, BIOCHIM BIOPHYS ACTA, V267, P538, DOI 10.1016/0005-2728(72)90182-X	47	1124	1182	13	309	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					391	395		10.1038/35000131	http://dx.doi.org/10.1038/35000131			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667783				2022-12-01	WOS:000085121100039
J	Neuzil, KM; Mellen, BG; Wright, PF; Mitchel, EF; Griffin, MR				Neuzil, KM; Mellen, BG; Wright, PF; Mitchel, EF; Griffin, MR			The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYNCYTIAL VIRUS-INFECTION; RESPIRATORY-DISEASE; YOUNG-CHILDREN; OTITIS-MEDIA; A-VIRUS; IMPACT; VACCINE; EPIDEMIOLOGY; MORTALITY; AGE	Background: Despite high annual rates of influenza in children, influenza vaccines are given to children infrequently. We measured the disease burden of influenza in a large cohort of healthy children in the Tennessee Medicaid program who were younger than 15 years of age. Methods: We determined the rates of hospitalization for acute cardiopulmonary conditions, outpatient visits, and courses of antibiotics over a period of 19 consecutive years. Using the differences in the rates of these events when influenzavirus was circulating and the rates from November through April when there was no influenza in the community, we calculated morbidity attributable to influenza. There was a total of 2,035,143 person-years of observation. Results: During periods when influenzavirus was circulating, the average number of hospitalizations for cardiopulmonary conditions in excess of the expected number was 104 per 10,000 children per year for children younger than 6 months of age, 50 per 10,000 per year for those 6 months to less than 12 months, 19 per 10,000 per year for those 1 year to less than 3 years, 9 per 10,000 per year for those 3 years to less than 5 years, and 4 per 10,000 per year for those 5 years to less than 15 years. For every 100 children, an annual average of 6 to 15 outpatient visits and 3 to 9 courses of antibiotics were attributable to influenza. In winter, 10 to 30 percent of the excess number of courses of antibiotics occurred during periods when influenzavirus was circulating. Conclusions: Healthy children younger than one year of age are hospitalized for illness attributable to influenza at rates similar to those for adults at high risk for influenza. The rate of hospitalization decreases markedly with age. Influenza accounts for a substantial number of outpatient visits and courses of antibiotics in children of all ages. (N Engl J Med 2000; 342:225-31.) (C)2000, Massachusetts Medical Society.	Dept Vet Affairs, Puget Sound Hlth Care Syst, Div Infect Dis 111, Seattle, WA 98108 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA	University of Washington; University of Washington Seattle; Vanderbilt University; Vanderbilt University; Vanderbilt University	Neuzil, KM (corresponding author), Dept Vet Affairs, Puget Sound Hlth Care Syst, Div Infect Dis 111, 1660 S Columbian Way, Seattle, WA 98108 USA.	kneuzil@u.washington.edu			PHS HHS [U50/CCU41398-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355, DOI 10.1093/oxfordjournals.aje.a121565; CLEMENTS DA, 1995, ARCH PEDIAT ADOL MED, V149, P1113, DOI 10.1001/archpedi.1995.02170230067009; Clements ML, 1996, J INFECT DIS, V173, P44, DOI 10.1093/infdis/173.1.44; COUCH RB, 1986, J INFECT DIS, V153, P431, DOI 10.1093/infdis/153.3.431; EDWARDS KM, 1994, J INFECT DIS, V169, P68, DOI 10.1093/infdis/169.1.68; Fisher RG, 1997, PEDIATRICS, V99, pE71, DOI 10.1542/peds.99.2.e7; FOX JP, 1982, AM J EPIDEMIOL, V116, P212, DOI 10.1093/oxfordjournals.aje.a113407; FOY HM, 1973, AM J EPIDEMIOL, V97, P93, DOI 10.1093/oxfordjournals.aje.a121493; GLEZEN WP, 1991, AM J EPIDEMIOL, V133, P296, DOI 10.1093/oxfordjournals.aje.a115874; GLEZEN WP, 1980, JAMA-J AM MED ASSOC, V243, P1345; GLEZEN WP, 1987, J INFECT DIS, V155, P1119, DOI 10.1093/infdis/155.6.1119; GLEZEN WP, 1978, NEW ENGL J MED, V298, P587, DOI 10.1056/NEJM197803162981103; GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005; GLEZEN WP, 1982, J INFECT DIS, V146, P313, DOI 10.1093/infdis/146.3.313; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; KARRON RA, 1995, PEDIATR INFECT DIS J, V14, P10, DOI 10.1097/00006454-199501000-00002; KIM HW, 1979, AM J EPIDEMIOL, V109, P464, DOI 10.1093/oxfordjournals.aje.a112704; KIM HW, 1973, AM J EPIDEMIOL, V98, P216, DOI 10.1093/oxfordjournals.aje.a121550; LONGINI IM, 1982, AM J EPIDEMIOL, V115, P736, DOI 10.1093/oxfordjournals.aje.a113356; MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779; MONTO AS, 1971, AM J EPIDEMIOL, V94, P280, DOI 10.1093/oxfordjournals.aje.a121321; MULLOOLY JP, 1982, AM J PUBLIC HEALTH, V72, P1008, DOI 10.2105/AJPH.72.9.1008; *NAT CTR HLTH STAT, 1995, VIT HLTH STAT 10, V193; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; Neuzil KM, 1999, JAMA-J AM MED ASSOC, V281, P901, DOI 10.1001/jama.281.10.901; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; Piper J M, 1991, Paediatr Perinat Epidemiol, V5, P402, DOI 10.1111/j.1365-3016.1991.tb00726.x; PUCK JM, 1980, J INFECT DIS, V142, P844, DOI 10.1093/infdis/142.6.844; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3; Simonsen L, 1997, EPIDEMIOLOGY, V8, P390, DOI 10.1097/00001648-199707000-00007; Simonsen L, 1997, AM J PUBLIC HEALTH, V87, P1944, DOI 10.2105/AJPH.87.12.1944; WRIGHT PF, 1980, AM J EPIDEMIOL, V112, P814, DOI 10.1093/oxfordjournals.aje.a113053; WRIGHT PF, 1977, NEW ENGL J MED, V296, P829, DOI 10.1056/NEJM197704142961501	36	829	867	2	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2000	342	4					225	231		10.1056/NEJM200001273420401	http://dx.doi.org/10.1056/NEJM200001273420401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277PB	10648763				2022-12-01	WOS:000084941000001
J	Ye, XD; Al-Babili, S; Kloti, A; Zhang, J; Lucca, P; Beyer, P; Potrykus, I				Ye, XD; Al-Babili, S; Kloti, A; Zhang, J; Lucca, P; Beyer, P; Potrykus, I			Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm	SCIENCE			English	Article							VITAMIN-A-DEFICIENCY; NARCISSUS-PSEUDONARCISSUS; FUNCTIONAL EXPRESSION; PLANT TRANSFORMATION; PHYTOENE SYNTHASE; VECTORS	Rice (Oryza sativa), a major staple food, is usually milled to remove the oil-rich aleurone layer that turns rancid upon storage, especially in tropical areas. The remaining edible part of rice grains, the endosperm, Lacks several essential nutrients, such as provitamin A. Thus, predominant rice consumption promotes vitamin A deficiency, a serious public health problem in at least 26 countries, including highly populated areas of Asia, Africa, and Latin America. Recombinant DNA technology was used to improve its nutritional value in this respect. A combination of transgenes enabled biosynthesis of provitamin A in the endosperm.	Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland; Univ Freiburg, Ctr Appl Biosci, D-79104 Freiburg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Freiburg	Beyer, P (corresponding author), Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland.			Al-Babili, Salim/0000-0003-4823-2882				BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Beyer P, 1996, PLANT PHYSIOL, V112, P1398; Bonk M, 1997, EUR J BIOCHEM, V247, P942, DOI 10.1111/j.1432-1033.1997.00942.x; Burkhardt PK, 1997, PLANT J, V11, P1071, DOI 10.1046/j.1365-313X.1997.11051071.x; GRANT JP, 1991, STATE WORLDS CHILDRE; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; HOEKEMA A, 1983, NATURE, V303, P179, DOI 10.1038/303179a0; HUMPHREY JH, 1992, B WORLD HEALTH ORGAN, V70, P225; Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309; MISAWA N, 1993, PLANT J, V4, P833, DOI 10.1046/j.1365-313X.1993.04050833.x; PIRIE A, 1983, P NUTR SOC, V42, P53, DOI 10.1079/PNS19830007; Schledz M, 1996, PLANT J, V10, P781, DOI 10.1046/j.1365-313X.1996.10050781.x; SOMMER A, 1989, J NUTR, V119, P96, DOI 10.1093/jn/119.1.96; SOMMER A, 1989, ELEVATED DOSAGES VIT, P37; Uze M, 1997, PLANT SCI, V130, P87, DOI 10.1016/S0168-9452(97)00211-2; WEST KP, 1989, ANNU REV NUTR, V9, P63, DOI 10.1146/annurev.nu.09.070189.000431; WUENN J, 1996, BIOTECHNOLOGY, V14, P171; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	18	1452	1696	18	626	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2000	287	5451					303	305		10.1126/science.287.5451.303	http://dx.doi.org/10.1126/science.287.5451.303			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634784				2022-12-01	WOS:000084769600039
J	Teeling, EC; Scally, M; Kao, DJ; Romagnoli, ML; Springer, MS; Stanhope, MJ				Teeling, EC; Scally, M; Kao, DJ; Romagnoli, ML; Springer, MS; Stanhope, MJ			Molecular evidence regarding the origin of echolocation and flight in bats	NATURE			English	Article							MAMMALS; COST	Bats (order Chiroptera) are one of the few orders of mammals that echolocate and the only group with the capacity for powered flight. The order is subdivided into Microchiroptera and Megachiroptera, with an array of characteristics defining each group(1), including complex laryngeal echolocation systems in microbats and enhanced visual acuity in megabats. The respective monophylies of the two suborders have been tacitly assumed, although microbat monophyly is uncorroborated by molecular data, Here we present a phylogenetic analysis of bat relationships using DNA sequence data from four nuclear genes and three mitochondrial genes (total of 8,230 base pairs), indicating that microbat families in the superfamily Rhinolophoidea are more closely related to megabats than they are to other microbats, This implies that echolocation systems either evolved independently in rhinolophoids and other microbats or were lost in the evolution of megabats, Our data also reject flying lemur (order Dermoptera) as the bat sister group, indicating that presumed shared derived characters for flying lemurs and bats(2) are convergent features that evolved in association with gliding and flight, respectively.	Queens Univ Belfast, Belfast BT9 7BL, Antrim, North Ireland; Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	Queens University Belfast; University of California System; University of California Riverside	Springer, MS (corresponding author), Queens Univ Belfast, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	mark.springer@ucr.edu; Michael_J_Stanhope@sbphrd.com		Teeling, Emma/0000-0002-3309-1346				Altringham J.D., 1996, BATS BIOL BEHAV; Beard K. C., 1993, PRIMATES THEIR RELAT, P63, DOI DOI 10.1007/978-1-4899-2388-2; CUMMINGS MP, 1995, MOL BIOL EVOL, V12, P814; FORSMAN KA, 1988, J ZOOL, V216, P655, DOI 10.1111/j.1469-7998.1988.tb02463.x; GOULD EDWIN, 1965, PROC AMER PHIL SOC, V109, P352; Hill JE, 1984, BATS NATURAL HIST; Hutcheon JM, 1998, PHILOS T R SOC B, V353, P607, DOI 10.1098/rstb.1998.0229; KALKO EKV, 1994, FOLIA ZOOL, V43, P363; KISHINO H, J MOL EVOL, V29, P170; LyonsWeiler J, 1996, MOL BIOL EVOL, V13, P749, DOI 10.1093/oxfordjournals.molbev.a025635; Miller Jr G.S., 1907, B US NAT MUS, V57, P1; NOVACEK M J, 1986, Cladistics, V2, P257, DOI 10.1111/j.1096-0031.1986.tb00463.x; NOVACEK MJ, 1980, P 5 INT BAT RES C, P317; Pumo DE, 1998, J MOL EVOL, V47, P709, DOI 10.1007/PL00006430; RAYNER JMV, 1991, NATURE, V350, P383, DOI 10.1038/350383a0; Simmons NB, 1998, B AM MUS NAT HIST, P1; Simmons NB, 1995, SYM ZOOL S, P27; SPEAKMAN JR, 1991, NATURE, V350, P421, DOI 10.1038/350421a0; Springer MS, 1997, NATURE, V388, P61, DOI 10.1038/40386; Springer MS, 1999, SYST BIOL, V48, P65, DOI 10.1080/106351599260445; Stanhope MJ, 1998, P NATL ACAD SCI USA, V95, P9967, DOI 10.1073/pnas.95.17.9967; Swofford David L., 1996, P407; SWOFFORD DL, 1998, PAUP PHYLOGENEITC AN; TEMPLETON AR, 1983, EVOLUTION, V37, P221, DOI 10.1111/j.1558-5646.1983.tb05533.x; TOMASI TE, 1979, J MAMMAL, V60, P751, DOI 10.2307/1380190; WOODBURNE MO, 1995, SOC EC PALEONTOLOGIS, V54, P335, DOI DOI 10.2110/PEC.95.04.0335)	26	210	213	1	170	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2000	403	6766					188	192		10.1038/35003188	http://dx.doi.org/10.1038/35003188			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646602				2022-12-01	WOS:000084835300053
J	Bennett, MJ; Lebron, JA; Bjorkman, PJ				Bennett, MJ; Lebron, JA; Bjorkman, PJ			Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor	NATURE			English	Article							HEMOCHROMATOSIS GENE-PRODUCT; CELL-SURFACE EXPRESSION; INSULIN-RECEPTOR; LIGAND-BINDING; IRON RELEASE; HLA-H; ASSOCIATION; PROGRAM; BETA(2)-MICROGLOBULIN; REFINEMENT	HFE is related to major histocompatibility complex (MHC) class I proteins and is mutated in the iron-overload disease hereditary haemochromatosis. HFE binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded transferrin. The 2.8 Angstrom crystal structure of a complex between the extracellular portions of HFE and TfR shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer. On a cell membrane containing both proteins, HFE would 'lie down' parallel to the membrane, such that the HFE helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the TfR dimerization domain. The structures of TfR alone and complexed with HFE differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between TfR chains. The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Bjorkman, PJ (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	bjorkman@cco.caltech.edu						Aisen P, 1999, CURR OPIN CHEM BIOL, V3, P200, DOI 10.1016/S1367-5931(99)80033-7; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; Andrews NC, 1998, BLOOD, V92, P1845, DOI 10.1182/blood.V92.6.1845.418k35_1845_1851; Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; Barton JC, 1999, BLOOD CELL MOL DIS, V25, P146; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchegger F, 1996, EUR J BIOCHEM, V235, P9, DOI 10.1111/j.1432-1033.1996.0009u.x; Creighton TE, 1993, PROTEINS STRUCTURES; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dubljevic V, 1999, BIOCHEM J, V341, P11, DOI 10.1042/0264-6021:3410011; EGAN TJ, 1993, BIOCHEMISTRY-US, V32, P8162, DOI 10.1021/bi00083a016; ENNS CA, 1981, J BIOL CHEM, V256, P9820; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; Fuchs H, 1998, STRUCTURE, V6, P1235, DOI 10.1016/S0969-2126(98)00124-5; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Henry J.B, 1996, CLIN DIAGNOSIS MANAG, V9th; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Kleywegt GJ, 1997, ACTA CRYSTALLOGR D, V53, P179, DOI 10.1107/S0907444996012279; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lebron JA, 1999, J MOL BIOL, V294, P239, DOI 10.1006/jmbi.1999.3252; Lebron JA, 1999, J MOL BIOL, V289, P1109, DOI 10.1006/jmbi.1999.2842; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; SIPE DM, 1991, J BIOL CHEM, V266, P8002; STAGSTED J, 1990, CELL, V62, P297, DOI 10.1016/0092-8674(90)90367-N; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P16309; VERLAND S, 1989, J IMMUNOL, V143, P945; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Waheed A, 1999, P NATL ACAD SCI USA, V96, P1579, DOI 10.1073/pnas.96.4.1579; Wilson IA, 1998, CURR OPIN IMMUNOL, V10, P67, DOI 10.1016/S0952-7915(98)80034-4; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	47	275	283	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					46	53		10.1038/47417	http://dx.doi.org/10.1038/47417			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638746				2022-12-01	WOS:000084687400036
J	Rothwell, PM; Villagra, R; Gibson, R; Donders, RCJM; Warlow, CP				Rothwell, PM; Villagra, R; Gibson, R; Donders, RCJM; Warlow, CP			Evidence of a chronic systemic cause of instability of atherosclerotic plaques	LANCET			English	Article							CAROTID STENOSIS; 1001 ANGIOGRAMS; ULCERATION; REPRODUCIBILITY; INFARCTION; MECHANISMS; DISEASE; LINK	Background Major thrombotic and embolic complications of atherosclerosis are closely associated with irregularity and rupture of atheromatous plaques in both the carotid and coronary arteries. Plaque instability is partly determined by local factors, but systemic factors, such as infection, autoimmunity, or genes, may also be important. If plaque stability is influenced by systemic factors that are present in only a proportion of patients, some individuals should be more prone to rupture of plaques than others-ie, irregular plaques should occur in multiple vascular beds in some individuals more frequently than would be expected by chance alone. Methods We studied 5393 carotid bifurcation angiograms from 3007 patients with a recently symptomatic carotid stenosis. We assessed the extent to which plaque-surface irregularity at the symptomatic carotid artery was associated with irregularity at a distant site, the contralateral carotid artery, and the extent to which plaque irregularity at these sites was associated with previous myocardial infarction or subsequent non-stroke vascular death (due mainly to coronary-artery disease). Findings Patients with plaque-surface irregularity (n=1897) in the symptomatic carotid artery were more likely than those with smooth plaque (n=110) to have irregularity in the contralateral carotid artery (odds ratio 2.21 [95% CI 1.62-3.01], p<0.001). Patients with irregular plaques in both arteries were more likely to have had a previous myocardial infarction than patients with smooth plaques (hazard ratio 1.82 [1.23-2.64], p<0.001), and were more likely to have a non-stroke vascular death on follow-up (hazard ratio 1.67 [1.15-2.44], p=0.007). However, there was no difference in the risk of non-vascular death (hazard ratio 0.92 [0.57-1.45], p=0.5). These associations were not explicable on the basis of differences in traditional vascular risk factors. Interpretation These data suggest that some individuals have a systemic predisposition to irregularity and rupture of atherosclerotic plaques that is independent of traditional vascular risk factors. This finding supports the hypothesis that other systemic factors are important in the cause of plaque instability.	Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	Radcliffe Infirmary; University of Edinburgh	Rothwell, PM (corresponding author), Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England.		Rothwell, Peter/ABE-5913-2020; Donders, A.R.T./L-4277-2015	Rothwell, Peter/0000-0001-9739-9211; Donders, A.R.T./0000-0002-0484-1419				Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; DAVIES MJ, 1985, BRIT HEART J, V53, P363; EIKELBOOM BC, 1983, STROKE, V14, P882, DOI 10.1161/01.STR.14.6.882; ELIASZIW M, 1994, STROKE, V25, P304, DOI 10.1161/01.STR.25.2.304; EPSTEIN SE, 1996, LANCET S, V348, P13; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FISHER M, 1987, ANGIOLOGY, V38, P116, DOI 10.1177/000331978703800204; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; JULIAN OC, 1963, ARCH SURG-CHICAGO, V86, P131; Lammie GA, 1999, STROKE, V30, P1319, DOI 10.1161/01.STR.30.7.1319; LIBBY P, 1996, LANCET, V348, P4; RICHARDSON PD, 1989, LANCET, V2, P941; ROSS R, 1992, OXFORD TXB PATHOLOGY; Rothwell P. M., 1996, CEREBROVASC DIS, V6, P1; ROTHWELL PM, 1994, STROKE, V25, P2440, DOI 10.1161/01.STR.25.12.2440; ROTHWELL PM, 1994, STROKE, V25, P2435, DOI 10.1161/01.STR.25.12.2435; Rothwell PM, 1998, CLIN RADIOL, V53, P439, DOI 10.1016/S0009-9260(98)80273-0; SAFIAN RD, 1990, CIRCULATION, V82, P69, DOI 10.1161/01.CIR.82.1.69; SITZER M, 1995, STROKE, V26, P1231, DOI 10.1161/01.STR.26.7.1231; STREIFLER JY, 1994, STROKE, V25, P1130, DOI 10.1161/01.STR.25.6.1130; THOMPSON WD, 1988, J CLIN EPIDEMIOL, V41, P949, DOI 10.1016/0895-4356(88)90031-5; TOUBOUL PJ, 1994, CEREBROVASC DIS, V4, P8, DOI 10.1159/000108544; Vallance P, 1997, LANCET, V349, P1391, DOI 10.1016/S0140-6736(96)09424-X	23	179	184	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					19	24		10.1016/S0140-6736(99)04470-0	http://dx.doi.org/10.1016/S0140-6736(99)04470-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615886				2022-12-01	WOS:000085049200011
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Cell biology - Sorting on silicon	SCIENCE			English	Article																		Fu AY, 1999, NAT BIOTECHNOL, V17, P1109, DOI 10.1038/15095	1	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2293	2294						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10636792				2022-12-01	WOS:000084318500044
J	Wu, SP; Romfo, CM; Nilsen, TW; Green, MR				Wu, SP; Romfo, CM; Nilsen, TW; Green, MR			Functional recognition of the 3 ' splice site AG by the splicing factor U2AF(35)	NATURE			English	Article							PRE-MESSENGER-RNA; SMALL-SUBUNIT; BRANCH POINT; IDENTIFICATION; U2AF(65); PROTEIN; DROSOPHILA; SEQUENCES	In metazoans, spliceosome assembly is initiated through recognition of the 5' splice site by U1 snRNP and the polypyrimidine tract by the U2 small nuclear ribonucleoprotein particle (snRNP) auxiliary factor, U2AF (refs 1, 2), U2AF is a heterodimer comprising a large subunit, U2AF(65), and a small subunit, U2AF(35) (ref. 3). U2AF65 directly contacts the polypyrimidine tract and is required for splicing in vitro(4). In comparison, the role of U2AF35 has been puzzling: U2AF(35) is highly conserved(5-7) and is required for viabilit(6,7), but can be dispensed with for splicing in vitro(4,8,9). Here we use sire-specific crosslinking to show that very early during spliceosome assembly U2AF directly contacts the 3' splice site. Mutational analysis and in vitro genetic selection indicate that U2AF35 has a sequence-specific RNA-binding activity that recognizes the 3'-splice-site consensus, AG/G. We show that for introns with weak polypyrimidine tracts, the U2AF(35)-3'-splice-site interaction is critical for U2AF binding and splicing. Our results demonstrate a new biochemical activity of U2AF(35) identify the factor that initially recognizes the 3' splice site, and explain why the AG dinucleotide is required for the first step of splicing for some but not all introns.	Univ Massachusetts, Med Ctr, Program Mol Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Ctr RNA Mol Biol, Cleveland, OH 44106 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Case Western Reserve University	Green, MR (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Howard Hughes Med Inst, 373 Plantat St, Worcester, MA 01605 USA.	michael.green@umassmed.edu						Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; NILSEN TW, 1997, TRANSSPLICING EUKARY, P310; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; REED R, 1997, SPLICEOSOME ASSEMBLY, P103; Romfo CM, 1997, NUCLEIC ACIDS RES, V25, P4658, DOI 10.1093/nar/25.22.4658; Rudner DZ, 1996, P NATL ACAD SCI USA, V93, P10333, DOI 10.1073/pnas.93.19.10333; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; WentzHunter K, 1996, NUCLEIC ACIDS RES, V24, P1849, DOI 10.1093/nar/24.10.1849; Wu SP, 1997, EMBO J, V16, P4421, DOI 10.1093/emboj/16.14.4421; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; Zorio DAR, 1999, RNA, V5, P487, DOI 10.1017/S1355838299982225; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	21	321	330	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1999	402	6763					832	835		10.1038/45590	http://dx.doi.org/10.1038/45590			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617206				2022-12-01	WOS:000084330500070
J	Jouzel, J; Petit, JR; Souchez, R; Barkov, NI; Lipenkov, VY; Raynaud, D; Stievenard, M; Vassiliev, NI; Verbeke, V; Vimeux, F				Jouzel, J; Petit, JR; Souchez, R; Barkov, NI; Lipenkov, VY; Raynaud, D; Stievenard, M; Vassiliev, NI; Verbeke, V; Vimeux, F			More than 200 meters of lake ice above subglacial lake Vostok, Antarctica	SCIENCE			English	Article							CENTRAL EAST-ANTARCTICA; ISOTOPIC COMPOSITION; AIR CONTENT; DELTA-O-18; WATER	Isotope studies show that the Vostok ice core consists of ice refrozen from Lake Vostok water, from 3539 meters below the surface of the Antarctic ice sheet to its bottom at about 3750 meters. Additional evidence comes from the total gas content, crystal size, and electrical conductivity of the ice. The Vostok site is a likely place for water freezing at the Lake-ice interface, because this interface occurs at a higher Level here than anywhere else above the Lake. Isotopic data suggest that subglacial Lake Vostok is an open system with an efficient circulation of water that was formed during periods that were slightly warmer than those of the past 420,000 years. Lake ice recovered by deep drilling is of interest for preliminary investigations of Lake chemistry and bedrock properties and for the search for indigenous lake microorganisms. This latter aspect is of potential importance for the exploration of icy planets and moons.	CEA Saclay, Lab Sci Climat & Environm, CNRS, UMR 1572, F-91191 Gif Sur Yvette, France; Lab Glaciol & Geophys Environm, CNRS, F-38402 St Martin Dheres, France; Free Univ Brussels, Fac Sci, Dept Sci Terre, B-1050 Brussels, Belgium; Arctic & Antarctic Res Inst, St Petersburg 199397, Russia; St Petersburg Min Inst, St Petersburg 199026, Russia	UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite Libre de Bruxelles; Vrije Universiteit Brussel; Arctic & Antarctic Research Institute; Saint Petersburg Mining University	Jouzel, J (corresponding author), CEA Saclay, Lab Sci Climat & Environm, CNRS, UMR 1572, F-91191 Gif Sur Yvette, France.		raynaud, dominique/ABG-4718-2020; Raynaud, Dominique/H-9626-2016; Lipenkov, Vladimir Y/Q-8262-2016; Vasilyev, Nikolay I./AAS-2261-2020	Lipenkov, Vladimir Y/0000-0003-4221-5440; Vasilyev, Nikolay I./0000-0002-2279-699X				CARSEY F, 1998, NAT SCI FDN WORKSH L, P21; CRAIG H, 1961, SCIENCE, V133, P1702, DOI 10.1126/science.133.3465.1702; JOUZEL J, 1982, J GLACIOL, V28, P35, DOI 10.3189/S0022143000011771; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; Karl DM, 1999, SCIENCE, V286, P2144, DOI 10.1126/science.286.5447.2144; KERN RG, 1998, NAT SCI FDN WORKSH L, P24; LIPENKOV V, 1995, J GLACIOL, V41, P423, DOI 10.3189/S0022143000016294; LIPENKOV V, 1998, P INT WORKSH LAK VOS, P31; MARTINERIE P, 1994, J GEOPHYS RES-ATMOS, V99, P10565, DOI 10.1029/93JD03223; Paillard D, 1998, NATURE, V391, P378, DOI 10.1038/34891; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Priscu JC, 1999, SCIENCE, V286, P2141, DOI 10.1126/science.286.5447.2141; SALAMATIN A, 1998, DATA GLACIOL STUD, V85, P233; Siegert MJ, 1998, J GEOPHYS RES-SOL EA, V103, P10195, DOI 10.1029/98JB00390; SOUCHEZ R, 1987, GEOPHYS RES LETT, V14, P599, DOI 10.1029/GL014i006p00599; SOUCHEZ RA, 1984, J GLACIOL, V30, P369, DOI 10.3189/S0022143000006249; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; TIEDJIE JM, 1998, NAT SCI FDN WORKSH L, P19; Vimeux F, 1999, NATURE, V398, P410, DOI 10.1038/18860; WHITE DC, 1998, NAT SCI FDN WORKSH L, P22; 1998, NAT SCI FDN WORKSH L	21	139	144	4	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2138	2141		10.1126/science.286.5447.2138	http://dx.doi.org/10.1126/science.286.5447.2138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591641				2022-12-01	WOS:000084157300046
J	Tonks, NK; Myers, MP				Tonks, NK; Myers, MP			Cancer - Structural assets of a tumor suppressor	SCIENCE			English	Editorial Material							PHOSPHATASE; PTEN; GENE		Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Tonks, NK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.							Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; FUNARI FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292	11	9	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2096	2097		10.1126/science.286.5447.2096	http://dx.doi.org/10.1126/science.286.5447.2096			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10617421				2022-12-01	WOS:000084157300037
J	Keen, RW				Keen, RW			Effects of lifestyle interventions on bone health	LANCET			English	Editorial Material							OSTEOPOROTIC FRACTURES; RISK-FACTORS; WOMEN; MASS; EXERCISE; DENSITY		UCL, Bone & Mineral Ctr, London WC1E 6JJ, England	University of London; University College London	Keen, RW (corresponding author), UCL, Bone & Mineral Ctr, London WC1E 6JJ, England.							COMPSTON JE, 1992, CLIN SCI, V82, P429, DOI 10.1042/cs0820429; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107; Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224; Heinonen A, 1996, LANCET, V348, P1343, DOI 10.1016/S0140-6736(96)04214-6; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; *NAT OST FDN, 1998, PHYS GUID PREV TREAT; Ralston SH, 1997, BMJ-BRIT MED J, V315, P469, DOI 10.1136/bmj.315.7106.469; REID IR, 1995, J CLIN ENDOCR METAB, V80, P1764, DOI 10.1210/jc.80.6.1764; Royal College of Physicians, 1999, OST CLIN GUID PREV T; Salamone LM, 1999, AM J CLIN NUTR, V70, P97; TORGERSON DJ, 1995, BRIT J RHEUMATOL, V34, P620	12	18	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1999	354	9194					1923	1924		10.1016/S0140-6736(99)00406-7	http://dx.doi.org/10.1016/S0140-6736(99)00406-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261XA	10622292				2022-12-01	WOS:000084034700006
J	Holland, PWH				Holland, PWH			The future of evolutionary developmental biology	NATURE			English	Article							HOX GENES; DROSOPHILA; ULTRABITHORAX; ANTENNAPEDIA; COMPLEXES; SEQUENCE; PLAN	Combining fields as diverse as comparative embryology, palaeontology, molecular phylogenetics and genome analysis, the new discipline of evolutionary developmental biology aims at explaining how developmental processes and mechanisms become modified during evolution, and how these modifications produce changes in animal morphology and body plans. In the next century this should give us far greater mechanistic insight into how evolution has produced the vast diversity of living organisms, past and present.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of Reading	Holland, PWH (corresponding author), Univ Reading, Sch Anim & Microbial Sci, POB 228, Reading RG6 6AJ, Berks, England.			Holland, Peter/0000-0003-1533-9376				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Aldridge RJ, 1996, TRENDS ECOL EVOL, V11, P463, DOI 10.1016/0169-5347(96)10048-3; Aparicio S, 1997, NAT GENET, V16, P79, DOI 10.1038/ng0597-79; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Budd GE, 1999, BIOESSAYS, V21, P326, DOI 10.1002/(SICI)1521-1878(199904)21:4<326::AID-BIES9>3.0.CO;2-0; BURKE AC, 1995, DEVELOPMENT, V121, P333; COATES MI, 1994, DEVELOPMENT, P169; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Cohn MJ, 1999, NATURE, V399, P474, DOI 10.1038/20944; Darwin C., 1859, ORIGIN SPECIES MEANS; de Rosa R, 1999, NATURE, V399, P772, DOI 10.1038/21631; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Force A, 1999, GENETICS, V151, P1531; Gaunt SJ, 1999, MECH DEVELOP, V82, P109, DOI 10.1016/S0925-4773(99)00018-0; HAECKEL E, 1903, PEDIGREE MAN OTHER E; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Mackay TFC, 1996, BIOESSAYS, V18, P113, DOI 10.1002/bies.950180207; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1994, GENETICS, V137, P607; MORRIS SC, 1995, PHILOS T ROY SOC B, V347, P305, DOI 10.1098/rstb.1995.0029; Mouchel-Vielh E, 1998, MOL PHYLOGENET EVOL, V9, P382, DOI 10.1006/mpev.1998.0498; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; Shashikant CS, 1998, P NATL ACAD SCI USA, V95, P15446, DOI 10.1073/pnas.95.26.15446; Simmen MW, 1998, P NATL ACAD SCI USA, V95, P4437, DOI 10.1073/pnas.95.8.4437; Stern DL, 1998, NATURE, V396, P463, DOI 10.1038/24863; Willmer P, 1990, INVERTEBRATE RELATIO	29	56	59	2	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C41	C44		10.1038/35011536	http://dx.doi.org/10.1038/35011536			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591224	Bronze			2022-12-01	WOS:000084014100006
J	Saxena, D; Flores, S; Stotzky, G				Saxena, D; Flores, S; Stotzky, G			Transgenic plants - Insecticidal toxin in root exudates from Bt corn	NATURE			English	Article							THURINGIENSIS SUBSP KURSTAKI; BACILLUS-THURINGIENSIS; SOIL; TENEBRIONIS		NYU, Dept Biol, Microbial Ecol Lab, New York, NY 10003 USA; Inst Venezolano Invest Cient, Caracas 1020A, Venezuela	New York University; Venezuelan Institute Science Research	Saxena, D (corresponding author), NYU, Dept Biol, Microbial Ecol Lab, New York, NY 10003 USA.	gs5@is2.nyu.edu	Saxena, Deepak/K-1864-2019					BENIZRI E, 1995, SOIL BIOL BIOCHEM, V27, P71, DOI 10.1016/0038-0717(94)00131-J; Crecchio C, 1998, SOIL BIOL BIOCHEM, V30, P463, DOI 10.1016/S0038-0717(97)00147-8; Hilbeck A, 1998, ENVIRON ENTOMOL, V27, P480, DOI 10.1093/ee/27.2.480; Koskella J, 1997, APPL ENVIRON MICROB, V63, P3561, DOI 10.1128/AEM.63.9.3561-3568.1997; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; LOWRY OH, 1951, J BIOL CHEM, V193, P265; TAPP H, 1994, SOIL BIOL BIOCHEM, V26, P663, DOI 10.1016/0038-0717(94)90258-5; Tapp H, 1998, SOIL BIOL BIOCHEM, V30, P471, DOI 10.1016/S0038-0717(97)00148-X; TAPP H, 1995, APPL ENVIRON MICROB, V61, P1786, DOI 10.1128/AEM.61.5.1786-1790.1995; Wadman M, 1999, NATURE, V397, P639, DOI 10.1038/17655	10	282	391	0	93	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 2	1999	402	6761					480	480		10.1038/44997	http://dx.doi.org/10.1038/44997			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591205	Bronze			2022-12-01	WOS:000084013200041
J	Onishi, A; Koike, S; Ida, M; Imai, H; Shichida, Y; Takenaka, O; Hanazawa, A; Konatsu, H; Mikami, A; Goto, S; Suryobroto, B; Kitahara, K; Yamamori, T				Onishi, A; Koike, S; Ida, M; Imai, H; Shichida, Y; Takenaka, O; Hanazawa, A; Konatsu, H; Mikami, A; Goto, S; Suryobroto, B; Kitahara, K; Yamamori, T			Vision - Dichromatism in macaque monkeys	NATURE			English	Article							VISUAL PIGMENT GENES; LINKED COLOR-VISION; MOLECULAR-GENETICS; OLD; EVOLUTION; ANCESTRY; PRIMATE; DEFECTS; GREEN; BLUE		Natl Inst Basic Biol, Lab Speciat Mechanisms J, Okazaki, Aichi 4448585, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Tokyo Metropolitan Inst Neurosci, Dept Microbiol & Immunol, Tokyo 1838526, Japan; Primate Res Inst, Dept Cellular & Mol Biol, Aichi 4848506, Japan; Primate Res Inst, Dept Behav & Brain Sci, Aichi 4848506, Japan; Primate Res Inst, Ctr Appl Primatol & Human Evolutionary Modelling, Aichi 4848506, Japan; Natl Inst Physiol Sci, Neural Control Lab, Okazaki, Aichi 4448585, Japan; Bogor Agr Univ, Dept Biol, Bogor 16143, Indonesia; Jikei Univ, Sch Med, Dept Ophthalmol, Minato Ku, Tokyo 1050003, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kyoto University; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Bogor Agricultural University; Jikei University	Onishi, A (corresponding author), Natl Inst Basic Biol, Lab Speciat Mechanisms J, 38 Myodaijicho, Okazaki, Aichi 4448585, Japan.		Yamamori, Tetsuo/N-6536-2015	Yamamori, Tetsuo/0000-0001-5016-0078; Imai, Hiroo/0000-0003-0729-0322; Suryobroto, Bambang/0000-0002-9393-4085				BOWMAKER JK, 1980, J PHYSIOL-LONDON, V298, P131, DOI 10.1113/jphysiol.1980.sp013071; DEEB SS, 1992, AM J HUM GENET, V51, P687; DRUMMONDBORG M, 1989, P NATL ACAD SCI USA, V86, P983, DOI 10.1073/pnas.86.3.983; DULAI KS, 1994, VISION RES, V34, P2483, DOI 10.1016/0042-6989(94)90233-X; Fletcher R., 1985, DEFECTIVE COLOUR VIS; Jacobs GH, 1997, VISUAL NEUROSCI, V14, P921, DOI 10.1017/S0952523800011639; JACOBS GH, 1989, AM J PRIMATOL, V18, P35, DOI 10.1002/ajp.1350180104; JORGENSEN AL, 1990, P NATL ACAD SCI USA, V87, P6512, DOI 10.1073/pnas.87.17.6512; Kojima D, 1996, BIOCHEMISTRY-US, V35, P2625, DOI 10.1021/bi9511548; MERBS SL, 1992, SCIENCE, V258, P464, DOI 10.1126/science.1411542; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Neitz J, 1996, SCIENCE, V274, P801, DOI 10.1126/science.274.5288.801; TOVEE MJ, 1994, TRENDS NEUROSCI, V17, P30, DOI 10.1016/0166-2236(94)90032-9; VOLLRATH D, 1988, SCIENCE, V240, P1669, DOI 10.1126/science.2837827	14	55	56	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					139	140		10.1038/45966	http://dx.doi.org/10.1038/45966			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647004				2022-12-01	WOS:000083716400037
J	Schauser, L; Roussis, A; Stiller, J; Stougaard, J				Schauser, L; Roussis, A; Stiller, J; Stougaard, J			A plant regulator controlling development of symbiotic root nodules	NATURE			English	Article							LIPO-OLIGOSACCHARIDE SIGNALS; LOTUS-JAPONICUS; LEUCINE ZIPPER; RHIZOBIUM-LOTI; DNA; IDENTIFICATION; CHLAMYDOMONAS; GENES; TRANSCRIPTION; NODULATION	Symbiotic nitrogen-fixing root nodules on legumes are founded by root cortical cells that de-differentiate and restart cell division to establish nodule primordia. Bacterial microsymbionts invade these primordia through infection threads laid down by the plant and, after endocytosis, membrane-enclosed bacteroids occupy cells in the nitrogen-fixing tissue of functional nodules, The bacteria excrete lipochitin oligosaccharides(1,2), triggering a developmental process that is controlled by the plant and can be suppressed, Nodule inception initially relies on cell competence in a narrow infection zone located just behind the growing root tip. Older nodules then regulate the number of nodules on a root system by suppressing the development of nodule primordia(3), To identify the regulatory components that act early in nodule induction, ive characterized a transposon-tagged Lotus japonicus mutant, nin (for nodule inception), arrested at the stage of bacterial recognition. We show that rlin is required for the formation of infection threads and the initiation of primordia, NlN protein has regional similarity to transcription factors, and the predicted DNA-binding/dimerization domain identifies and typifies a consensus motif conserved in plant proteins with a function in nitrogen-controlled development.	Aarhus Univ, Dept Mol & Struct Biol, Lab Gene Express, DK-8000 Aarhus C, Denmark	Aarhus University	Stougaard, J (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, Lab Gene Express, Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.		Roussis, Andreas/AAZ-2468-2021; Stiller, Jiri/E-1564-2012	Roussis, Andreas/0000-0003-2346-7132; Stougaard, Jens/0000-0002-9312-2685				Beck CF, 1996, INT REV CYTOL, V168, P259, DOI 10.1016/S0074-7696(08)60886-4; BOIVIN C, 1990, PLANT CELL, V2, P1157, DOI 10.1105/tpc.2.12.1157; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CAETANOANOLLES G, 1991, ANNU REV MICROBIOL, V45, P345, DOI 10.1146/annurev.mi.45.100191.002021; EARP DJ, 1990, NUCLEIC ACIDS RES, V18, P3271, DOI 10.1093/nar/18.11.3271; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Ferris PJ, 1997, GENETICS, V146, P859; Ferris PJ, 1997, P NATL ACAD SCI USA, V94, P8634, DOI 10.1073/pnas.94.16.8634; HANDBERG K, 1992, PLANT J, V2, P487, DOI 10.1111/j.1365-313X.1992.00487.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEHMBECK J, 1986, PLANT MOL BIOL, V7, P3, DOI 10.1007/BF00020126; LOPEZLARA IM, 1995, MOL MICROBIOL, V15, P627, DOI 10.1111/j.1365-2958.1995.tb02372.x; Papadopoulou K, 1996, PLANT MOL BIOL, V30, P403, DOI 10.1007/BF00049320; PLANO GV, 1991, J BACTERIOL, V173, P3389, DOI 10.1128/jb.173.11.3389-3396.1991; PUYET A, 1993, J BIOL CHEM, V268, P25402; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Schauser L, 1998, MOL GEN GENET, V259, P414, DOI 10.1007/s004380050831; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; SPAINK HP, 1996, PLANT CELL, V8, P1885; SULLIVAN JT, 1995, P NATL ACAD SCI USA, V92, P8985, DOI 10.1073/pnas.92.19.8985; THYKJAER T, 1995, PLANT MOL BIOL, V27, P981, DOI 10.1007/BF00037025; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	25	601	643	6	121	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					191	195		10.1038/46058	http://dx.doi.org/10.1038/46058			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647012				2022-12-01	WOS:000083716400053
J	Meigs, JB; Mittleman, MA; Nathan, DM; Tofler, GH; Singer, DE; Murphy-Sheehy, PM; Lipinsky, I; D'Angostino, R; Wilson, PWF				Meigs, JB; Mittleman, MA; Nathan, DM; Tofler, GH; Singer, DE; Murphy-Sheehy, PM; Lipinsky, I; D'Angostino, R; Wilson, PWF			Hyperinsulinemia, hyperglucemia, and impaired hemostasis - The Framingham offspring study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; INSULIN-RESISTANCE SYNDROME; CORONARY-HEART-DISEASE; LINKED IMMUNOSORBENT-ASSAY; VON-WILLEBRAND-FACTOR; RISK FACTOR; VASCULAR COMPLICATIONS; CARDIOVASCULAR-DISEASE; OBESE SUBJECTS; MYOCARDIAL-INFARCTION	Context Increased risk for cardiovascular disease in persons with glucose intolerance (impaired glucose tolerance and type 2 diabetes mellitus) is not fully explained by concomitant elevations in traditional atherosclerosis risk factors. Hyperinsulinemia associated with glucose intolerance may increase risk directly, or its effect could be mediated through impaired hemostatic function. Objective To evaluate associations between fasting insulin levels and hemostatic factors in subjects with normal and impaired glucose homeostasis. Design Cross-sectional analysis conducted between January 1991 and June 1995. Setting The population-based Framingham Offspring Study. Subjects A total of 1331 men and 1631 women aged 26 to 82 years, without diagnosed diabetes or cardiovascular disease and classified as having normal glucose tolerance (80.2%) or glucose intolerance (impaired glucose tolerance and impaired fasting glucose combined, 15.2%; previously undiagnosed diabetes, 4.7%) using an oral glucose tolerance test. Main Outcome Measures Trends across quintiles of fasting insulin in levels of plasminogen activator inhibitor 1 (PAI-1) antigen, tissue-type plasminogen activator (tPA) antigen, von Willebrand factor (VWF) antigen, factor VII antigen, fibrinogen, and plasma viscosity. We stratified analyses by sex and glucose tolerance status and adjusted hemostatic factor levels for obesity, lipid levels, and traditional cardiovascular disease risk factors. Results Mean levels of all hemostatic factors (except for fibrinogen in men) increased across fasting insulin quintiles among subjects with normal glucose tolerance (P<.001 for trend). Levels of PAI-1 and tPA antigens, but not other hemostatic factors, were higher comparing subjects with glucose intolerance with those with normal glucose tolerance (P<.001). Among subjects with glucose intolerance, levels of PAI-1 and tPA antigen in men and women (P<.01 for trend) and VWF antigen in men (P<.05 for trend) increased significantly across insulin quintiles, but levels of factor VII antigen, fibrinogen, and plasma viscosity did not increase. Conclusions Elevated levels of fasting insulin are associated with impaired fibrinolysis and hypercoagulability in subjects with normal glucose tolerance. Hyperinsulinemia is associated primarily with impaired fibrinolysis in subjects with glucose intolerance. Excess risk for cardiovascular disease associated with hyperinsulinemia and glucose intolerance may be mediated in part by enhanced potential for acute thrombosis.	Massachusetts Gen Hosp, Gen Internal Med Unit S50 9, Div Gen Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Inst Prevent & Cardiovasc Dis, Cardiovasc Div,Beth Israel Deaconess Med Ctr, Boston, MA USA; Boston Univ, Dept Math, Stat & Consulting Unit, Boston, MA 02215 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Framingham Heart Dis Epidemiol Study, Framingham, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; Boston University; Framingham Heart Study	Meigs, JB (corresponding author), Massachusetts Gen Hosp, Gen Internal Med Unit S50 9, Div Gen Med, Boston, MA 02114 USA.	jmeigs@partners.org	Meigs, James/P-3927-2019	Meigs, James/0000-0002-2439-2657; Mittleman, Murray/0000-0001-9788-7274	NHLBI NIH HHS [N01-HC-38083, R01 HL48157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraira C, 1997, ARCH INTERN MED, V157, P181, DOI 10.1001/archinte.157.2.181; ALESSI MC, 1988, THROMB HAEMOSTASIS, V60, P491; Alessi MC, 1997, DIABETES, V46, P860, DOI 10.2337/diabetes.46.5.860; ANDERSON RL, 1995, AM J EPIDEMIOL, V142, P724, DOI 10.1093/aje/142.7.724; [Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; [Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.157.21.2413; ASPLUNDCARLSON A, 1993, DIABETOLOGIA, V36, P817, DOI 10.1007/BF00400356; BarrettConnor E, 1997, DIABETES CARE, V20, P1620, DOI 10.2337/diacare.20.10.1620; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Calles-Escandon J, 1998, DIABETES, V47, P290, DOI 10.2337/diabetes.47.2.290; CIGOLINI M, 1994, ATHEROSCLEROSIS, V106, P139, DOI 10.1016/0021-9150(94)90119-8; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; CUPPLES LA, 1988, FRAMINGHAM STUDY EPI; DECLERCK PJ, 1988, BLOOD, V71, P220; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; DONAHUE RP, 1987, DIABETES, V36, P689, DOI 10.2337/diabetes.36.6.689; Eliasson M, 1997, DIABETES CARE, V20, P1252, DOI 10.2337/diacare.20.8.1252; ELIASSON M, 1994, METABOLISM, V43, P1579, DOI 10.1016/0026-0495(94)90020-5; Emanuele N, 1998, ARCH INTERN MED, V158, P2485, DOI 10.1001/archinte.158.22.2485; Folsom AR, 1997, CIRCULATION, V96, P1102, DOI 10.1161/01.CIR.96.4.1102; FULLER JH, 1979, BMJ-BRIT MED J, V2, P964, DOI 10.1136/bmj.2.6196.964; GANDA OP, 1992, DIABETES CARE, V15, P1245, DOI 10.2337/diacare.15.10.1245; Gavin JR, 1997, DIABETES CARE, V20, P1183; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; GRANT PJ, 1990, CLIN SCI, V79, P513, DOI 10.1042/cs0790513; Haffner SM, 1998, STROKE, V29, P1498, DOI 10.1161/01.STR.29.8.1498; HAFFNER SM, 1994, J CLIN ENDOCR METAB, V79, P1806, DOI 10.1210/jc.79.6.1806; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; JUHANVAGUE I, 1991, DIABETOLOGIA, V34, P457, DOI 10.1007/BF00403280; JUHANVAGUE I, 1993, ARTERIOSCLER THROMB, V13, P1865, DOI 10.1161/01.ATV.13.12.1865; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KNATTERUD GL, 1978, JAMA-J AM MED ASSOC, V240, P37, DOI 10.1001/jama.240.1.37; LATRON Y, 1991, ARTERIOSCLER THROMB, V11, P1821, DOI 10.1161/01.ATV.11.6.1821; Lindahl B, 1996, INT J EPIDEMIOL, V25, P291, DOI 10.1093/ije/25.2.291; Mansfield MW, 1996, CIRCULATION, V94, P2171, DOI 10.1161/01.CIR.94.9.2171; MCGILL JB, 1994, DIABETES, V43, P104, DOI 10.2337/diabetes.43.1.104; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEDVESCEK M, 1990, FIBRINOLYSIS, V4, P89, DOI 10.1016/0268-9499(90)90371-P; Meigs JB, 1997, DIABETES, V46, P1594, DOI 10.2337/diabetes.46.10.1594; Missov RM, 1996, DIABETES CARE, V19, P157, DOI 10.2337/diacare.19.2.157; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; MYKKANEN L, 1994, ARTERIOSCLER THROMB, V14, P1264, DOI 10.1161/01.ATV.14.8.1264; MYKKANEN L, 1997, DIABETES S1, V46, pA72; Nagi DK, 1996, DIABETIC MED, V13, P59, DOI 10.1002/(SICI)1096-9136(199601)13:1<59::AID-DIA2>3.0.CO;2-Z; NAGI DK, 1993, DIABETES CARE, V16, P621, DOI 10.2337/diacare.16.4.621; NATHAN DM, 1981, CLIN CHEM, V27, P1261; NORDT TK, 1994, CIRCULATION, V89, P321, DOI 10.1161/01.CIR.89.1.321; Pandolfi A, 1996, DIABETOLOGIA, V39, P1425, DOI 10.1007/s001250050594; PENNY WF, 1991, CIRCULATION, V83, P1630, DOI 10.1161/01.CIR.83.5.1630; Pyorala M, 1998, CIRCULATION, V98, P398, DOI 10.1161/01.CIR.98.5.398; RANBY M, 1986, CLIN CHEM, V32, P2160; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REWERS M, 1996, DIABETES S2, V45, pA52; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; SAS Institute Inc, 1989, SAS STAT US GUID; Savage PJ, 1996, ANN INTERN MED, V124, P123, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00008; SCHNEIDER DJ, 1993, DIABETES, V42, P1, DOI 10.2337/diabetes.42.1.1; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; Sobel BE, 1999, CIRCULATION, V99, P2496, DOI 10.1161/01.CIR.99.19.2496; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; UK Prospective Diabetes Study Group, 1996, ANN INTERN MED, V124, P136; VAGUE P, 1986, METABOLISM, V35, P250, DOI 10.1016/0026-0495(86)90209-X; VERHEUGT FWA, 1987, AM J CARDIOL, V59, P1075, DOI 10.1016/0002-9149(87)90851-4; VUORINENMARKKOLA H, 1992, THROMB HAEMOSTASIS, V67, P117; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WINGARD DL, 1995, DIABETES CARE, V18, P1299, DOI 10.2337/diacare.18.9.1299; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972	77	421	449	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2000	283	2					221	228		10.1001/jama.283.2.221	http://dx.doi.org/10.1001/jama.283.2.221			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272QA	10634338	Bronze			2022-12-01	WOS:000084661400028
J	Blau, J; Young, MW				Blau, J; Young, MW			Cycling vrille expression is required for a functional Drosophila clock	CELL			English	Article							NERVOUS-SYSTEM; CIRCADIAN-RHYTHMS; TRANSCRIPTION FACTORS; GENE-PRODUCT; BZIP FAMILY; DOUBLE-TIME; PERIOD; MELANOGASTER; PROTEIN; CRYPTOCHROME	We identified a novel regulatory loop within Drosophila's circadian clock. A screen for clock-controlled genes recovered vrille (vri), a transcription factor essential for embryonic development. vri iss expressed in circadian pacemaker cells in larval and adult brains. vri RNA levels oscillate with a circadian rhythm. Cycling is directly regulated by the transcription factors dCLOCK and CYCLE, which are also required for oscillations of period and timeless RNA. Eliminating the normal vri cycle suppresses period and timeless expression and causes long-period behavioral rhythms and arrhythmicity, indicating that cycling vri is required for a functional Drosophila clock. We also show that dCLOCK and VRI independently regulate levels of a neuropeptide, pigment dispersing factor, which appears to regulate overt behavior.	Rockefeller Univ, Genet Lab, New York, NY 10021 USA	Rockefeller University	Young, MW (corresponding author), Rockefeller Univ, Genet Lab, 1230 York Ave, New York, NY 10021 USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054339] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54339] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Cheng YZ, 1998, J NEUROSCI, V18, P741; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; George H, 1997, GENETICS, V146, P1345; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Helfrich-Forster C, 1998, J COMP PHYSIOL A, V182, P435, DOI 10.1007/s003590050192; HelfrichForster C, 1997, J COMP NEUROL, V380, P335, DOI 10.1002/(SICI)1096-9861(19970414)380:3<335::AID-CNE4>3.0.CO;2-3; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kaneko M, 1997, J NEUROSCI, V17, P6745; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; McNeil GP, 1998, NEURON, V20, P297, DOI 10.1016/S0896-6273(00)80457-2; NEWBY LM, 1993, GENETICS, V135, P1077; Park JH, 1998, J BIOL RHYTHM, V13, P219, DOI 10.1177/074873098129000066; Petri B, 1997, J NEUROSCI, V17, P4087; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SEHGAL A, 1992, P NATL ACAD SCI USA, V89, P1423, DOI 10.1073/pnas.89.4.1423; SMITH RF, 1981, MOL GEN GENET, V183, P243, DOI 10.1007/BF00270625; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	45	331	339	1	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					661	671		10.1016/S0092-8674(00)81554-8	http://dx.doi.org/10.1016/S0092-8674(00)81554-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612401	Bronze			2022-12-01	WOS:000084278700012
J	Sabatini, S; Beis, D; Wolkenfelt, H; Murfett, J; Guilfoyle, T; Malamy, J; Benfey, P; Leyser, O; Bechtold, N; Weisbeek, P; Scheres, B				Sabatini, S; Beis, D; Wolkenfelt, H; Murfett, J; Guilfoyle, T; Malamy, J; Benfey, P; Leyser, O; Bechtold, N; Weisbeek, P; Scheres, B			An auxin-dependent distal organizer of pattern and polarity in the Arabidopsis root	CELL			English	Article							CELL-DIFFERENTIATION; TRANSCRIPTION FACTOR; VASCULAR DEVELOPMENT; RESPONSE ELEMENTS; AUX/IAA PROTEINS; FLORAL MERISTEM; GENE MONOPTEROS; THALIANA; ENCODES; EMBRYO	Root formation in plants involves the continuous interpretation of positional cues. Physiological studies have linked root formation to auxins. An auxin response element displays a maximum in the Arabidopsis root and we investigate its developmental significance. Auxin response mutants reduce the maximum or its perception, and interfere with distal root patterning. Polar auxin transport mutants affect its localization and distal pattern. Polar auxin transport inhibitors cause dramatic relocalization of the maximum, and associated changes in pattern and polarity. Auxin application and laser ablations correlate root pattern with a maximum adjacent to the vascular bundle. Our data indicate that an auxin maximum at a vascular boundary establishes a distal organizer in the root.	Univ Utrecht, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; NYU, Dept Biol, New York, NY 10003 USA; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; INRA, Ctr Versailles, Lab Genet & Ameliorat Plantes, F-78026 Versailles, France	Utrecht University; University of Missouri System; University of Missouri Columbia; New York University; University of York - UK; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Scheres, B (corresponding author), Univ Utrecht, Dept Mol Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	b.scheres@bio.uu.nl	Leyser, Ottoline/AAC-5577-2019	SABATINI, Sabrina/0000-0002-9691-6595; Scheres, Ben/0000-0001-5400-9578; Beis, Dimitris/0000-0003-2579-7848; Leyser, Ottoline/0000-0003-2161-3829				BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; BERLETH T, 1993, DEVELOPMENT, V118, P575; CELENZA JL, 1995, GENE DEV, V9, P2131, DOI 10.1101/gad.9.17.2131; Chen RJ, 1998, P NATL ACAD SCI USA, V95, P15112, DOI 10.1073/pnas.95.25.15112; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Davies P. J, 1995, PLANT HORMONES; Delbarre A, 1996, PLANTA, V198, P532, DOI 10.1007/BF00262639; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; DOLAN L, 1993, DEVELOPMENT, V119, P71; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Hadfi K, 1998, DEVELOPMENT, V125, P879; Hamann T, 1999, DEVELOPMENT, V126, P1387; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; HOBBIE L, 1995, PLANT J, V7, P211, DOI 10.1046/j.1365-313X.1995.7020211.x; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; KELLY MO, 1986, PLANT PHYSIOL, V82, P713, DOI 10.1104/pp.82.3.713; Kim J, 1997, P NATL ACAD SCI USA, V94, P11786, DOI 10.1073/pnas.94.22.11786; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; Malamy JE, 1997, DEVELOPMENT, V124, P33; Malamy JE, 1997, PLANT J, V12, P957, DOI 10.1046/j.1365-313X.1997.12040957.x; Marchant A, 1999, EMBO J, V18, P2066, DOI 10.1093/emboj/18.8.2066; Mattsson J, 1999, DEVELOPMENT, V126, P2979; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; Przemeck GKH, 1996, PLANTA, V200, P229, DOI 10.1007/BF00208313; Rouse D, 1998, SCIENCE, V279, P1371, DOI 10.1126/science.279.5355.1371; RUBERY PH, 1990, SYM SOC EXP BIOL, V44, P119; Ruegger M, 1998, GENE DEV, V12, P198, DOI 10.1101/gad.12.2.198; SACHS T, 1991, DEVELOPMENT, P83; SCHERES B, 1994, DEVELOPMENT, V120, P2475; Sessions A, 1997, DEVELOPMENT, V124, P4481; SKOOG F, 1957, Symp Soc Exp Biol, V11, P118; Steeves TA, 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STJOHNSTON D, 1992, CELL, V68, P201; Tian Q, 1999, DEVELOPMENT, V126, P711; Uggla C, 1996, P NATL ACAD SCI USA, V93, P9282, DOI 10.1073/pnas.93.17.9282; Ulmasov T, 1999, P NATL ACAD SCI USA, V96, P5844, DOI 10.1073/pnas.96.10.5844; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; vandenBerg C, 1997, NATURE, V390, P287, DOI 10.1038/36856; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; Walker L, 1998, CURR OPIN PLANT BIOL, V1, P434, DOI 10.1016/S1369-5266(98)80269-0; Willemsen V, 1998, DEVELOPMENT, V125, P521	50	1010	1052	9	161	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					463	472		10.1016/S0092-8674(00)81535-4	http://dx.doi.org/10.1016/S0092-8674(00)81535-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589675	Bronze, Green Published			2022-12-01	WOS:000083986300006
J	Russell, DF; Wilkens, LA; Moss, F				Russell, DF; Wilkens, LA; Moss, F			Use of behavioural stochastic resonance by paddle fish for feeding	NATURE			English	Article							NOISE; MECHANORECEPTORS; CRAYFISH; SYSTEM	Stochastic resonance is the phenomenon whereby the addition of an optimal level of noise to a weak information-carrying input to certain nonlinear systems can enhance the information content at their outputs(1-4). Computer analysis of spike trains has been needed to reveal stochastic resonance in the responses of sensory receptors(5-7) except for one study on human psychophysics(8). But is an animal aware of, and can it make use of, the enhanced sensory information from stochastic resonance? Here, we show that stochastic resonance enhances the normal feeding behaviour of paddlefish (Polyodon spathula)(9,10), which use passive electroreceptors(11,12) to detect electrical signals from planktonic prey(13). We demonstrate significant broadening of the spatial range for the detection of plankton when a noisy electric field of optimal amplitude is applied in the water. We also show that swarms of Daphnia plankton are a natural source of electrical noise. Our demonstration of stochastic resonance at the level of a vital animal behaviour, feeding, which has probably evolved for functional success, provides evidence that stochastic resonance in sensory nervous systems is an evolutionary adaptation(14).			Russell, DF (corresponding author), Univ Missouri, Ctr Neurodynam, St Louis, MO 63121 USA.							Bezrukov SM, 1997, NATURE, V385, P319, DOI 10.1038/385319a0; BOUCHERLE MM, 1976, OHIO J SCI, V56, P90; Bullock T.H., 1986, P651; BULLOCK TH, 1982, ANNU REV NEUROSCI, V5, P121, DOI 10.1146/annurev.ne.05.030182.001005; Bulsara AR, 1996, PHYS TODAY, V49, P39, DOI 10.1063/1.881491; BURGGREN WW, 1992, PHYSIOL ZOOL, V65, P515, DOI 10.1086/physzool.65.3.30157967; Collins JJ, 1996, J NEUROPHYSIOL, V76, P642, DOI 10.1152/jn.1996.76.1.642; Collins JJ, 1996, NATURE, V383, P770, DOI 10.1038/383770a0; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; Gammaitoni L, 1998, REV MOD PHYS, V70, P223, DOI 10.1103/RevModPhys.70.223; GIBBONS JD, 1976, NONPARAMETRIC METHOD, P223; Gluckman BJ, 1996, PHYS REV LETT, V77, P4098, DOI 10.1103/PhysRevLett.77.4098; Jaramillo F, 1998, NAT NEUROSCI, V1, P384, DOI 10.1038/1597; JORGENSEN JM, 1972, Z ZELLFORSCH MIK ANA, V130, P362; Laming PR, 1981, BRAIN MECHANISMS BEH, P203; Levin JE, 1996, NATURE, V380, P165, DOI 10.1038/380165a0; MARASCUILO LA, 1977, NONPARAMETRIC DISTRI, P290; NEW JG, 1985, BRAIN RES, V336, P89, DOI 10.1016/0006-8993(85)90419-6; POUGH FH, 1996, VERTEBRATE LIFE, P258; Robbins Trevor W., 1995, P703; RUELLE R, 1977, T AM FISH SOC, V106, P609, DOI 10.1577/1548-8659(1977)106<609:PPS>2.0.CO;2; STEMMLER M, 1995, SCIENCE, V269, P1877, DOI 10.1126/science.7569930; TEETER JH, 1980, J COMP PHYSIOL, V138, P213, DOI 10.1007/BF00657039; Tricas TC, 1998, J COMP PHYSIOL A, V182, P89; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; Wilkens LA, 1997, P ROY SOC B-BIOL SCI, V264, P1723, DOI 10.1098/rspb.1997.0239	26	388	397	0	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					291	294		10.1038/46279	http://dx.doi.org/10.1038/46279			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580499				2022-12-01	WOS:000083813700049
J	Hein, L; Altman, JD; Kobilka, BK				Hein, L; Altman, JD; Kobilka, BK			Two functionally distinct alpha(2)-adrenergic receptors regulate sympathetic neurotransmission	NATURE			English	Article							PRESYNAPTIC ALPHA(2)-AUTORECEPTORS; HEART-FAILURE; ALPHA(2A)-ADRENERGIC RECEPTOR; SUBTYPE; RAT; BRAIN; MICE; GENE; INHIBITION; ALPHA(2D)	The sympathetic nervous system regulates cardiovascular function by activating adrenergic receptors in the heart, blood vessels and kidney(1), alpha(2)-Adrenergic receptors are known to have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system(2-5); however, the individual roles of the three highly homologous alpha(2)-adrenergic-receptor subtypes (alpha(2A), alpha(2B), alpha(2C)) in this process are not known. We have now studied neurotransmitter release in mice in which the genes encoding the three alpha(z)-adrenergic-receptor subtypes were disrupted. Here we show that both the alpha(2A)- and alpha(2C)-subtypes are required for normal presynaptic control of transmitter release from sympathetic nerves in the heart and from central noradrenergic neurons. alpha(2A)-Adrenergic receptors inhibit transmitter release at high stimulation frequencies, whereas the a,c-subtype modulates neurotransmission at lower levels of nerve activity. Both low- and high-frequency regulation seem to be physiologically important, as mice lacking both alpha(2A)- and alpha(2C)-receptor subtypes have elevated plasma noradrenaline concentrations and develop cardiac hypertrophy with decreased left ventricular contractility by four months of age.	Stanford Univ, Beckman Ctr B157, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Univ Wurzburg, Dept Pharmacol & Toxicol, D-97078 Wurzburg, Germany	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; University of Wurzburg	Kobilka, BK (corresponding author), Stanford Univ, Beckman Ctr B157, Howard Hughes Med Inst, Stanford, CA 94305 USA.			Kobilka, Brian/0000-0001-5958-3990				Altman JD, 1999, MOL PHARMACOL, V56, P154, DOI 10.1124/mol.56.1.154; BYLUND DB, 1994, PHARMACOL REV, V46, P121; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Graefe KH, 1997, N-S ARCH PHARMACOL, V356, P115, DOI 10.1007/PL00005018; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Lakhlani PP, 1997, P NATL ACAD SCI USA, V94, P9950, DOI 10.1073/pnas.94.18.9950; Langer SZ, 1997, TRENDS PHARMACOL SCI, V18, P95, DOI 10.1016/S0165-6147(96)01034-6; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; LIMBERGER N, 1995, N-S ARCH PHARMACOL, V352, P43; LINK R, 1992, MOL PHARMACOL, V42, P16; LINK RE, 1995, MOL PHARMACOL, V48, P48; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; McLachlan EM, 1997, J PHYSIOL-LONDON, V501, P165, DOI 10.1111/j.1469-7793.1997.165bo.x; Miller RJ, 1998, ANNU REV PHARMACOL, V38, P201, DOI 10.1146/annurev.pharmtox.38.1.201; MOLDERINGS GJ, 1995, N-S ARCH PHARMACOL, V352, P483; PACKER M, 1992, J AM COLL CARDIOL, V20, P248, DOI 10.1016/0735-1097(92)90167-L; Sallinen J, 1997, MOL PHARMACOL, V51, P36, DOI 10.1124/mol.51.1.36; Sallinen J, 1998, J NEUROSCI, V18, P3035; SINGER EA, 1988, TRENDS PHARMACOL SCI, V9, P274, DOI 10.1016/0165-6147(88)90004-1; SMITH K, 1995, BRIT J PHARMACOL, V115, P316, DOI 10.1111/j.1476-5381.1995.tb15879.x; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; STJARNE L, 1989, REV PHYSL BIOCH PHAR, V112, P4; TAUBE HD, 1977, N-S ARCH PHARMACOL, V299, P123, DOI 10.1007/BF00498554; TAYLOR AA, 1994, J CLIN PHARMACOL, V34, P363, DOI 10.1002/j.1552-4604.1994.tb04976.x; Trendelenburg AU, 1997, N-S ARCH PHARMACOL, V356, P721, DOI 10.1007/PL00005111; TRENDELENBURG AU, 1993, N-S ARCH PHARMACOL, V348, P35, DOI 10.1007/BF00168534; Wahl CA, 1996, N-S ARCH PHARMACOL, V354, P253	30	394	410	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					181	184		10.1038/46040	http://dx.doi.org/10.1038/46040			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647009				2022-12-01	WOS:000083716400050
J	Cowen, RK; Lwiza, KMM; Sponaugle, S; Paris, CB; Olson, DB				Cowen, RK; Lwiza, KMM; Sponaugle, S; Paris, CB; Olson, DB			Connectivity of marine populations: Open or closed?	SCIENCE			English	Article							GREAT-BARRIER-REEF; LARVAL FISHES; CORAL-REEFS; WEST-INDIES; RECRUITMENT; DIFFUSION; DISPERSAL; PACIFIC; DISTRIBUTIONS; CIRCULATION	Most marine populations are thought to be well connected via long-distance dispersal of larval stages. Eulerian and Lagrangian flow models, coupled with Linear mortality estimates, were used to examine this assumption. The findings show that when simple advection models are used, Larval exchange rates may be overestimated; such simplistic models fail to account for a decrease of up to nine orders of magnitude in larval concentrations resulting from diffusion and mortality. The alternative process of larval retention near local populations is shown to exist and may be of great importance in the maintenance of marine population structure and management of coastal marine resources.	Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; SUNY Stony Brook, Marine Sci Res Ctr, Stony Brook, NY 11794 USA	University of Miami; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Cowen, RK (corresponding author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, 4600 Rickenbacker Causeway, Miami, FL 33149 USA.			Lwiza, Kamazima/0000-0003-2790-9284; Paris, Claire B./0000-0002-0637-1334; Olson, Donald/0000-0001-7180-5672				BLACK KP, 1991, MAR ECOL PROG SER, V74, P1, DOI 10.3354/meps074001; BOEHLERT GW, 1992, DEEP-SEA RES, V39, P439, DOI 10.1016/0198-0149(92)90082-5; BOEHLERT GW, 1987, ESTUAR COAST SHELF S, V25, P261, DOI 10.1016/0272-7714(87)90071-0; CARR MH, 1993, CAN J FISH AQUAT SCI, V50, P2019, DOI 10.1139/f93-226; CHOAT JH, 1988, 6 INT COR REEF S EX, P149; COWEN RK, 1985, J MAR RES, V43, P719, DOI 10.1357/002224085788440376; COWEN RK, 1994, B MAR SCI, V54, P228; DOHERTY PJ, 1995, ECOLOGY, V76, P2373, DOI 10.2307/2265814; DORSEY S, UNPUB; DUTKIEWICZ S, 1993, J GEOPHYS RES-OCEANS, V98, P16487, DOI 10.1029/93JC01364; Govoni John J., 1994, Fisheries Oceanography, V3, P120, DOI 10.1111/j.1365-2419.1994.tb00054.x; Helbig JA, 1998, CAN J FISH AQUAT SCI, V55, P2206, DOI 10.1139/cjfas-55-10-2206; HILL AE, 1991, MAR ECOL PROG SER, V70, P117, DOI 10.3354/meps070117; HOUDE ED, 1989, FISH B-NOAA, V87, P471; JOHNS WE, 1990, J GEOPHYS RES-OCEANS, V95, P22103, DOI 10.1029/JC095iC12p22103; Jones GP, 1999, NATURE, V402, P802, DOI 10.1038/45538; Lee TN, 1999, B MAR SCI, V64, P35; Leis JM, 1997, MAR ECOL PROG SER, V159, P165, DOI 10.3354/meps159165; LEIS JM, 1991, MAR BIOL, V109, P157, DOI 10.1007/BF01320243; MEEKAN MG, 1993, MAR ECOL PROG SER, V93, P217, DOI 10.3354/meps093217; MORSE WW, 1989, FISH B-NOAA, V87, P417; OKUBO A, 1971, DEEP-SEA RES, V18, P789, DOI 10.1016/0011-7471(71)90046-5; OLSON DB, 1985, J MAR RES, V43, P113, DOI 10.1357/002224085788437325; Paiva AM, 1999, J MARINE SYST, V21, P307, DOI 10.1016/S0924-7963(99)00020-2; Polovina JJ, 1999, FISH B-NOAA, V97, P132; RICHARDSON PL, 1994, J GEOPHYS RES-OCEANS, V99, P5081, DOI 10.1029/93JC03486; Roberts CM, 1997, SCIENCE, V278, P1454, DOI 10.1126/science.278.5342.1454; Robertson DR, 1996, CORAL REEFS, V15, P121, DOI 10.1007/s003380050032; ROSENBLATT RH, 1986, COPEIA, P275, DOI 10.2307/1444988; ROUGHGARDEN J, 1985, ECOLOGY, V66, P54, DOI 10.2307/1941306; SCHELTEMA RS, 1986, B MAR SCI, V39, P290; SCHULTZ ET, 1994, MAR ECOL PROG SER, V109, P15, DOI 10.3354/meps109015; SHULMAN MJ, 1995, EVOLUTION, V49, P897, DOI 10.1111/j.1558-5646.1995.tb02325.x; Sinclair M, 1988, MARINE POPULATIONS E; Sponaugle S, 1996, MAR FRESHWATER RES, V47, P433, DOI 10.1071/MF9960433; Stansfield KL, 1995, J GEOPHYS RES-OCEANS, V100, P24819, DOI 10.1029/95JC02749; Stobutzki IC, 1997, MAR ECOL PROG SER, V149, P35, DOI 10.3354/meps149035; Swearer SE, 1999, NATURE, V402, P799, DOI 10.1038/45533; Taggart C.T., 1990, P151; THORSON G, 1950, MEDD DOMM DAN FISK P, V4, P1; WARNER RR, 1988, P 6 INT COR REEF S T, V1; Werner Francisco E., 1993, Fisheries Oceanography, V2, P43, DOI 10.1111/j.1365-2419.1993.tb00120.x; Wing SR, 1998, LIMNOL OCEANOGR, V43, P1710, DOI 10.4319/lo.1998.43.7.1710; Wolanski E, 1997, NATURWISSENSCHAFTEN, V84, P262, DOI 10.1007/s001140050394	44	904	921	2	245	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					857	859		10.1126/science.287.5454.857	http://dx.doi.org/10.1126/science.287.5454.857			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657300				2022-12-01	WOS:000085136400047
J	Bodelier, PLE; Roslev, P; Henckel, T; Frenzel, P				Bodelier, PLE; Roslev, P; Henckel, T; Frenzel, P			Stimulation by ammonium-based fertilizers of methane oxidation in soil around rice roots	NATURE			English	Article							METHANOTROPHIC BACTERIA; ORYZA-SATIVA; FOREST SOILS; INHIBITION; CONSUMPTION; KINETICS; PLANTS	Methane is involved in a number of chemical and physical processes in the Earths atmosphere, including global warming(1), Atmospheric methane originates mainly from biogenic sources, such as rice paddies and natural wetlands; the former account for at least 30% of the global annual emission of methane to the atmosphere(2). As an increase of rice production by 60% is the most appropriate way to sustain the estimated increase of the human population during the next three decades(3), intensified global fertilizer application will be necessary(3): but it is known that an increase of the commonly used ammonium-based fertilizers can enhance methane emission from rice agriculture. Approximately 10-30% of the methane produced by methanogens in rice paddies is consumed by methane-oxidizing bacteria associated with the roots of rice(4,5); these bacteria are generally thought to be inhibited by ammonium-based fertilizers, as tvas demonstrated for soils(6-8) and sediments(9,10). In contrast, we show here that the activity and growth of such bacteria in the root zone of rice plants are stimulated after fertilization. Using a combination of radioactive fingerprinting(11) and molecular biology(12) techniques, we identify the bacteria responsible for this effect. We expect that our results will make necessary a re-evaluation of the link between fertilizer use and methane emissions, with effects on global warming studies.	Netherlands Inst Ecol, Ctr Limnol, NL-3631 AC Nieuwersluis, Netherlands; Max Planck Inst Terr Microbiol, Dept Biogeochem, D-35043 Marburg, Germany; Univ Aalborg, Environm Engn Lab, DK-9000 Aalborg, Denmark	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); Max Planck Society; Aalborg University	Bodelier, PLE (corresponding author), Netherlands Inst Ecol, Ctr Limnol, Rijksstr Weg 6, NL-3631 AC Nieuwersluis, Netherlands.		Bodelier, Paul/AAF-8353-2020; Bodelier, Paul L/A-9591-2011	Bodelier, Paul/0000-0002-5757-5572; Bodelier, Paul L/0000-0002-5757-5572				Banik A, 1996, BIOL FERT SOILS, V21, P319, DOI 10.1007/BF00334910; Bodelier PLE, 1999, APPL ENVIRON MICROB, V65, P1826; Bodelier PLE, 1997, PLANT SOIL, V190, P91, DOI 10.1023/A:1004212814097; BODELIER PLE, UNPUB BIOGEOCHEMISTR; BOSSE U, 1993, FEMS MICROBIOL ECOL, V13, P123, DOI 10.1016/0168-6496(93)90030-B; Bosse U, 1997, APPL ENVIRON MICROB, V63, P1199, DOI 10.1128/AEM.63.4.1199-1207.1997; Cassman KG, 1998, FIELD CROP RES, V56, P7, DOI 10.1016/S0378-4290(97)00140-8; CRUTZEN PJ, RUMINANT PHYSL DIGES, P291; DUNFIELD P, 1995, APPL ENVIRON MICROB, V61, P3129, DOI 10.1128/AEM.61.8.3129-3135.1995; Gilbert B, 1998, SOIL BIOL BIOCHEM, V30, P1903, DOI 10.1016/S0038-0717(98)00061-3; Gulledge J, 1997, SOIL BIOL BIOCHEM, V29, P13, DOI 10.1016/S0038-0717(96)00265-9; Gulledge J, 1998, APPL ENVIRON MICROB, V64, P4291; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; Henckel T, 1999, APPL ENVIRON MICROB, V65, P1980; King GM, 1998, APPL ENVIRON MICROB, V64, P253; KING GM, 1994, APPL ENVIRON MICROB, V60, P3220, DOI 10.1128/AEM.60.9.3220-3227.1994; KING GM, 1994, NATURE, V370, P282, DOI 10.1038/370282a0; LINDAU CW, 1991, PLANT SOIL, V136, P195, DOI 10.1007/BF02150050; Ludwig W, 1998, ELECTROPHORESIS, V19, P554, DOI 10.1002/elps.1150190416; Neue HU, 1997, SOIL USE MANAGE, V13, P258, DOI 10.1111/j.1475-2743.1997.tb00597.x; Roslev P, 1999, APPL ENVIRON MICROB, V65, P4064; Roslev P, 1998, J MICROBIOL METH, V31, P99, DOI 10.1016/S0167-7012(97)00094-8; STEUDLER PA, 1989, NATURE, V341, P314, DOI 10.1038/341314a0; Strunk O, 1996, ARB SOFTWARE ENV SEQ; SUNDH I, 1995, FEMS MICROBIOL ECOL, V18, P103, DOI 10.1111/j.1574-6941.1995.tb00167.x; vanderGon HACD, 1996, BIOL FERT SOILS, V22, P359, DOI 10.1007/BF00334584; vanderNat FJWA, 1997, APPL ENVIRON MICROB, V63, P4734, DOI 10.1128/AEM.63.12.4734-4740.1997	27	370	418	12	203	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					421	424		10.1038/35000193	http://dx.doi.org/10.1038/35000193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667792				2022-12-01	WOS:000085121100048
J	Morrow, M; Schnitt, SJ				Morrow, M; Schnitt, SJ			Treatment selection in ductal carcinoma in situ	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BREAST-CANCER; IN-SITU; INSITU; LESIONS; AUTOPSY; THERAPY		Northwestern Univ, Sch Med, Dept Surg, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Lynn Sage Comprehens Breast Ctr, Chicago, IL USA; Harvard Univ, Sch Med, Beth Israel Hosp, Dept Pathol, Boston, MA USA	Northwestern University; Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Morrow, M (corresponding author), NW Mem Hosp, Lynn Sage Comprehens Breast Ctr, 251 E Huron St,Galter 13-174, Chicago, IL 60611 USA.							BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher B, 1998, J CLIN ONCOL, V16, P441, DOI 10.1200/JCO.1998.16.2.441; Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y; Gapstur SM, 1999, JAMA-J AM MED ASSOC, V281, P2091, DOI 10.1001/jama.281.22.2091; Hiramatsu H, 1995, Cancer J Sci Am, V1, P55; HOLLAND R, 1990, LANCET, V335, P519, DOI 10.1016/0140-6736(90)90747-S; Jordan VC, 1999, ENDOCR REV, V20, P253, DOI 10.1210/edrv.20.3.0368; KINNE DW, 1989, ARCH SURG-CHICAGO, V124, P33; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; MORROW M, 2000, DIS BREAST, P383; NIELSEN M, 1984, CANCER-AM CANCER SOC, V54, P612, DOI 10.1002/1097-0142(1984)54:4<612::AID-CNCR2820540403>3.0.CO;2-B; Pandya S, 1998, BREAST J, V4, P146; Ravdin PM, 1998, J CLIN ONCOL, V16, P515, DOI 10.1200/JCO.1998.16.2.515; ROSNER D, 1980, ANN SURG, V192, P139, DOI 10.1097/00000658-198008000-00001; Silverstein MJ, 1999, NEW ENGL J MED, V340, P1455, DOI 10.1056/NEJM199905133401902; SILVERSTEIN MJ, 1997, DUCTAL CARCINOMA IN, P443; Solin LJ, 1996, J CLIN ONCOL, V14, P754, DOI 10.1200/JCO.1996.14.3.754	19	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					453	455		10.1001/jama.283.4.453	http://dx.doi.org/10.1001/jama.283.4.453			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LT	10659859				2022-12-01	WOS:000084879800002
J	Alexander, JH; Sparapani, RA; Mahaffey, KW; Deckers, JW; Newby, LK; Ohman, EM; Corbalan, R; Chierchia, SL; Boland, JB; Simoons, ML; Califf, RM; Topol, EJ; Harrington, RA				Alexander, JH; Sparapani, RA; Mahaffey, KW; Deckers, JW; Newby, LK; Ohman, EM; Corbalan, R; Chierchia, SL; Boland, JB; Simoons, ML; Califf, RM; Topol, EJ; Harrington, RA		PURSUIT Steering Comm	Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIAC TROPONIN-T; PROGNOSTIC-SIGNIFICANCE; CK-MB; SIZE; ISOENZYME; ISCHEMIA; RELEASE; INTERVENTIONS; PHOSPHOKINASE	Context Controversy surrounds the diagnostic and prognostic importance of slightly elevated cardiac markers in patients with acute coronary syndromes without ST-segment elevation. Objectives To investigate the relationship between peak creatine kinase (CK)-MB level and outcome and to determine whether a threshold CK-MB level exists below which risk is not increased. Design and Setting Retrospective observational analysis of data from the international Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, conducted from November 1995 to January 1997, Patients A total of 8250 patients with acute coronary sydromes without ST-segment elevation who had at least 1 CK-MB sample collected during their index hospitalization. Main Outcome Measure Mortality at 30 days and 6 months, was assessed by category of index-hospitalization peak CK-MB level (0-1, >1-2, >2-3, >3-5, >5-10, or >10 times the upper limit of normal). Multivariable logistic regression was used to determine the independent prognostic significance of peak CK-MB level after adjustment for baseline predictors of 30-day and 6-month mortality. Results Mortality at 30 days and 6 months increased from 1.8% and 4.0%, respectively, in patients with normal peak CK-MB levels, to 3.3% and 6.2% at peak CK-MB levels 1 to 2 times normal, to 5.1% and 7.5% at peak CK-MB levels 3 to 5 times normal, and to 8.3% and 11.0% at peak CK-MB levels greater than 10 times normal. Log-transformed peak CK-MB levels were predictive of adjusted 30-day and 6-month mortality (P<.001 for both). Conclusions Our data show that elevation of CK-MB level is strongly related to mortality in patients with acute coronary syndromes without ST-segment elevation, and that the increased risk begins with CK-MB levels just above normal. in the appropriate clinical context, even minor CK-MB elevations should be considered indicative of myocardial infarction.	Duke Clin Res Inst, Durham, NC 27715 USA; Catholic Univ Chile, Santiago, Chile; Univ Milan, Osped San Raffaele, I-20127 Milan, Italy; Hop Citadelle, Liege, Belgium; Cardialysis, Rotterdam, Netherlands; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Duke University; Pontificia Universidad Catolica de Chile; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Cardialysis; Cleveland Clinic Foundation	Alexander, JH (corresponding author), Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.		Alexander, John/GVS-7271-2022	Topol, Eric/0000-0002-1478-4729; Sparapani, Rodney/0000-0002-7780-6825; Alexander, John/0000-0002-1444-2462				Abdelmeguid AE, 1996, CIRCULATION, V94, P1528, DOI 10.1161/01.CIR.94.7.1528; ADAMS JE, 1993, CIRCULATION, V88, P750, DOI 10.1161/01.CIR.88.2.750; Adgey AAJ, 1999, CLIN CARDIOL, V22, P257; AHMED SA, 1976, CIRCULATION, V54, P187, DOI 10.1161/01.CIR.54.2.187; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; BENHORIN J, 1990, J AM COLL CARDIOL, V15, P253, DOI 10.1016/S0735-1097(10)80043-9; BITTL JA, 1985, J BIOL CHEM, V260, P208; BLEIFELD W, 1977, CIRCULATION, V55, P303, DOI 10.1161/01.CIR.55.2.303; Boersma Eric, 1999, Journal of the American College of Cardiology, V33, p359A; Califf RM, 1998, J AM COLL CARDIOL, V31, P241, DOI 10.1016/S0735-1097(97)00506-8; CLYNE CA, 1989, AM HEART J, V118, P901, DOI 10.1016/0002-8703(89)90221-4; COHEN L, 1984, PRINCIPLES PRACTICE, P383; COX JR, 1976, CIRCULATION, V53, P150; Cutlip D. E., 1997, Journal of the American College of Cardiology, V29, p187A; FIORETTI P, 1985, EUR HEART J, V6, P473, DOI 10.1093/oxfordjournals.eurheartj.a061892; GELTMAN EM, 1979, AM J CARDIOL, V43, P370; GEWIRTZ H, 1979, CIRCULATION, V59, P707, DOI 10.1161/01.CIR.59.4.707; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; Hamm CW, 1999, NEW ENGL J MED, V340, P1623, DOI 10.1056/NEJM199905273402103; HARRINGTON RA, 1995, J AM COLL CARDIOL, V25, P1693, DOI 10.1016/0735-1097(95)00091-H; HONG RA, 1986, AM HEART J, V111, P1041, DOI 10.1016/0002-8703(86)90004-9; Hudson Michael P., 1999, Journal of the American College of Cardiology, V33, p325A; Koch KC, 1999, J AM COLL CARDIOL, V33, P998, DOI 10.1016/S0735-1097(98)00659-7; Kong DF, 1998, CIRCULATION, V98, P2829, DOI 10.1161/01.CIR.98.25.2829; Kong TQ, 1997, JAMA-J AM MED ASSOC, V277, P461, DOI 10.1001/jama.277.6.461; KORNOWSKI R, 1993, AM J CARDIOL, V72, P883, DOI 10.1016/0002-9149(93)91100-V; MARMOR A, 1978, LANCET, V2, P812; MATHEY D, 1974, BRIT HEART J, V36, P271; MERCER DW, 1975, CLIN CHEM, V21, P1088; MUELLER HS, 1995, J AM COLL CARDIOL, V26, P900, DOI 10.1016/0735-1097(95)00270-1; NORRIS RM, 1975, CIRCULATION, V51, P614, DOI 10.1161/01.CIR.51.4.614; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; ROBERTS R, 1975, BRIT HEART J, V37, P1169; ROGERS WJ, 1977, CIRCULATION, V56, P199, DOI 10.1161/01.CIR.56.2.199; Savonitto Stefano, 1999, Journal of the American College of Cardiology, V33, p346A; SHELL WE, 1976, CIRCULATION, V53, P98; Simoons ML, 1999, EUR HEART J, V20, P1112, DOI 10.1053/euhj.1999.1521; SOBEL BE, 1972, CIRCULATION, V46, P640, DOI 10.1161/01.CIR.46.4.640; Stone Gregg W., 1999, Journal of the American College of Cardiology, V33, p80A; Tardiff BE, 1999, J AM COLL CARDIOL, V33, P88, DOI 10.1016/S0735-1097(98)00551-8; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1996, NEW ENGL J MED, V335, P775; van Domburg R. T., 1998, European Heart Journal, V19, P166; Wagner GS, 1982, ARCH INTERN MED, V140, P33; WHITE RD, 1985, AM J CARDIOL, V55, P1478, DOI 10.1016/0002-9149(85)90957-9; YUSUF S, 1987, AM J CARDIOL, V59, P245, DOI 10.1016/0002-9149(87)90793-4	46	88	93	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2000	283	3					347	353		10.1001/jama.283.3.347	http://dx.doi.org/10.1001/jama.283.3.347			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273WM	10647797	Green Published, Bronze			2022-12-01	WOS:000084732400026
J	Le Naour, F; Rubinstein, E; Jasmin, C; Prenant, M; Boucheix, C				Le Naour, F; Rubinstein, E; Jasmin, C; Prenant, M; Boucheix, C			Severely reduced female fertility in CD9-deficient mice	SCIENCE			English	Article							INTEGRIN COMPLEXES; ZONA-PELLUCIDA; MOUSE OOCYTES; CELL-SURFACE; CD9 ANTIGEN; HB-EGF; GENE; EXPRESSION; PROTEINS; LOCALIZATION	CD9 is a widely expressed cell surface molecule that belongs to the tetraspanin superfamily of proteins. The tetraspanins CD9, KAI-1/CD82, and CD63 are involved in metastasis suppression, an effect that may be related to their association with beta 1 integrins. Knockout mice lacking CD9 were created to evaluate the physiological importance of CD9. CD9(-/-) females displayed a severe reduction of fertility. Oocytes were ovulated but were not successfully fertilized because sperm did not fuse with the oocytes from CD9(-/-) females. Thus, CD9 appears to be essential for sperm-egg fusion, a process involving the CD9-associated integrin alpha 6 beta 1.	Hop Paul Brousse, INSERM, U 268, F-94800 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Boucheix, C (corresponding author), Hop Paul Brousse, INSERM, U 268, F-94800 Villejuif, France.	boucheix@infoblogen.fr	Rubinstein, Eric/B-4650-2019	Rubinstein, Eric/0000-0001-7623-9665; Boucheix, Claude/0000-0003-4184-7008				ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Capmany G, 1998, MOL HUM REPROD, V4, P951, DOI 10.1093/molehr/4.10.951; CONOVER JC, 1988, J REPROD FERTIL, V82, P681, DOI 10.1530/jrf.0.0820681; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EVANS JP, 1995, MOL REPROD DEV, V40, P211, DOI 10.1002/mrd.1080400210; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hogan B., 2014, MANIPULATING MOUSE E; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KUBIAK JZ, 1992, J CELL SCI, V102, P457; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; LANZA F, 1991, J BIOL CHEM, V266, P10638; LeNaour F, 1997, LEUKEMIA, V11, P1290, DOI 10.1038/sj.leu.2400721; LeNaour F, 1996, ONCOGENE, V13, P481; LENAOUR F, UNPUB; Liu CY, 1996, P NATL ACAD SCI USA, V93, P5431, DOI 10.1073/pnas.93.11.5431; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Monget P, 1999, M S-MED SCI, V15, P141, DOI 10.4267/10608/1304; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Rankin T, 1996, DEVELOPMENT, V122, P2903; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404; TARONE G, 1993, DEVELOPMENT, V117, P1369; Zuccotti M, 1998, DEV BIOL, V200, P27, DOI 10.1006/dbio.1998.8923	30	507	522	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					319	321		10.1126/science.287.5451.319	http://dx.doi.org/10.1126/science.287.5451.319			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634790				2022-12-01	WOS:000084769600045
J	Li, JX; Wang, XQ; Watson, MB; Assmann, SM				Li, JX; Wang, XQ; Watson, MB; Assmann, SM			Regulation of abscisic acid-induced stomatal closure and anion channels by guard cell AAPK kinase	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; PROTEIN-KINASE; ARABIDOPSIS-THALIANA; CALCIUM; PHOSPHATASE; RESPONSES; BLOCKERS; PLANTS; GENE; ABI1	Abscisic acid (ABA) stimulates stomatal closure and thus supports water conservation by plants during drought. Mass spectrometry-generated peptide sequence information was used to clone a Vicia faba complementary DNA, AAPK, encoding a guard cell-specific ABA-activated serine-threonine protein kinase.(AAPK). Expression in transformed guard cells of AAPK altered by one amino acid (lysine 43 to alanine 43) renders stomata insensitive to ABA-induced closure by eliminating ABA activation of plasma membrane anion channels. This information should allow cell-specific, targeted biotechnological manipulation of crop water status.	Penn State Univ, Mueller Lab 208, Dept Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Assmann, SM (corresponding author), Penn State Univ, Mueller Lab 208, Dept Biol, University Pk, PA 16802 USA.			Wang, Xi-Qing/0000-0003-4477-9557				ANDERBERG RJ, 1992, P NATL ACAD SCI USA, V89, P10183, DOI 10.1073/pnas.89.21.10183; ASSMANN SM, 1993, ANNU REV CELL BIOL, V9, P345, DOI 10.1146/annurev.cb.09.110193.002021; Assmann SM, 1998, J EXP BOT, V49, P163, DOI 10.1093/jexbot/49.319.163; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; DAVIES WJ, 1991, ABSCISIC ACID PHYSIO; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Gomez-Cadenas A, 1999, P NATL ACAD SCI USA, V96, P1767, DOI 10.1073/pnas.96.4.1767; Gosti F, 1999, PLANT CELL, V11, P1897, DOI 10.1105/tpc.11.10.1897; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holappa LD, 1997, PLANT MOL BIOL, V33, P935, DOI 10.1023/A:1005720203535; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P22; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; Li JX, 1996, PLANT CELL, V8, P2359, DOI 10.1105/tpc.8.12.2359; Li JX, 1998, PLANT PHYSIOL, V116, P785, DOI 10.1104/pp.116.2.785; LOO JA, 1995, BIOCONJUGATE CHEM, V6, P644, DOI 10.1021/bc00036a600; LOVEYS BR, 1984, NEW PHYTOL, V98, P563, DOI 10.1111/j.1469-8137.1984.tb04149.x; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; Mori IC, 1997, PLANT PHYSIOL, V113, P833, DOI 10.1104/pp.113.3.833; Pei ZM, 1998, SCIENCE, V282, P287, DOI 10.1126/science.282.5387.287; Rodriguez PL, 1998, FEBS LETT, V421, P185, DOI 10.1016/S0014-5793(97)01558-5; SCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9535, DOI 10.1073/pnas.92.21.9535; SCHROEDER JI, 1993, PLANT CELL, V5, P1831, DOI 10.1105/tpc.5.12.1831; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; SCHWARTZ A, 1995, PLANT PHYSIOL, V109, P651, DOI 10.1104/pp.109.2.651; Schwarz M, 1998, FEBS LETT, V428, P177, DOI 10.1016/S0014-5793(98)00526-2; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; Wang XQ, 1998, PLANT PHYSIOL, V118, P1421, DOI 10.1104/pp.118.4.1421; WANG YH, 1993, ARCH BIOCHEM BIOPHYS, V304, P496, DOI 10.1006/abbi.1993.1381	34	340	398	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 14	2000	287	5451					300	303		10.1126/science.287.5451.300	http://dx.doi.org/10.1126/science.287.5451.300			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634783				2022-12-01	WOS:000084769600038
J	Dalrymple, J; Appleby, J				Dalrymple, J; Appleby, J			Cross sectional study of reporting of epileptic seizures to general practitioners	BRITISH MEDICAL JOURNAL			English	Article							POPULATION; ACCIDENTS; COMMUNITY; STIGMA; RATES	Objective Comparison of reporting of recent epileptic seizures by patients to a doctor and anonymously. Design Cross sectional study of patients with epilepsy by comparison of paired questionnaires. Setting Rural and urban general practices in Norfolk. Participants 122 patients aged over 16 years and able to self complete a questionnaire who were recruited by 31 general practitioners when attending for review of their epilepsy. Main outcome measure The difference in reported occurrence of seizure to general practitioners and in a linked anonymous questionnaire. Results 18 patients failed to report a seizure in the past year to their general practitioner (uncontrolled epilepsy). 40% (24/60) of people with epilepsy who anonymously reported a seizure in the past year held a driving licence, but only six revealed this to their general practitioner. The unemployment rate was 34%, substantially higher than the 9% in the general population. Measures of anxiety, depression and stigmatisation were higher in patients with uncontrolled epilepsy. Conclusions A significant proportion of patients with epilepsy underreport their seizures. Recognition of underreporting is important if patients are to benefit from adequate and appropriate treatment. General practitioners' ability to treat epilepsy is hampered by their role in regulating the rights of epileptic patients to hold a driving licence or access certain occupations.	Univ E Anglia, Sch Hlth, Norwich NR4 7TJ, Norfolk, England; Kings Fund, Policy & Dev Directorate, Hlth Syst Programme, London W1M 0AN, England	University of East Anglia	Dalrymple, J (corresponding author), Univ E Anglia, Sch Hlth, Norwich NR4 7TJ, Norfolk, England.							Beaussart M, 1997, Med Law, V16, P295; Black A B, 1997, Med Law, V16, P253; Brown S, 1993, Seizure, V2, P91, DOI 10.1016/S1059-1311(05)80111-6; COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; Collings J A, 1994, Seizure, V3, P255, DOI 10.1016/S1059-1311(05)80172-4; Gilliam F, 1997, EPILEPSIA, V38, P233, DOI 10.1111/j.1528-1157.1997.tb01102.x; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; HANSOTIA P, 1991, NEW ENGL J MED, V324, P1511; HOPKINS A, 1977, LANCET, V1, P183; HOPKINS AP, 1996, OXFORD TXB MED, P3924; Jacoby A, 1996, EPILEPSIA, V37, P148, DOI 10.1111/j.1528-1157.1996.tb00006.x; KRUMHOLZ A, 1994, EPILEPSIA, V35, P668, DOI 10.1111/j.1528-1157.1994.tb02490.x; Ridsdale L, 1996, BRIT J GEN PRACT, V46, P365; SALINSKY MC, 1992, EPILEPSIA, V33, P469, DOI 10.1111/j.1528-1157.1992.tb01693.x; SCAMBLER G, 1986, SOCIOL HEALTH ILL, V8, P26, DOI 10.1111/1467-9566.ep11346455; SCAMBLER G, 1989, EXPERIENCE ILLNESS, P52; Scheinder JW, 1981, SOC SCI MED A, V15A, P211; TAYLOR J, 1995, QJM-MON J ASSOC PHYS, V88, P733; Thapar AK, 1996, BRIT J GEN PRACT, V46, P37; Troster H, 1997, EPILEPSIA, V38, P1227, DOI 10.1111/j.1528-1157.1997.tb01221.x; VANDERLUGT PJM, 1975, EPILEPSIA, V16, P747, DOI 10.1111/j.1528-1157.1975.tb04760.x; VANDERLUGT PJM, 1975, EPILEPSIA, V16, P743; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	24	64	65	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					94	97		10.1136/bmj.320.7227.94	http://dx.doi.org/10.1136/bmj.320.7227.94			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625265	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000084746600020
J	Paul, REL; Coulson, TN; Raibaud, A; Brey, PT				Paul, REL; Coulson, TN; Raibaud, A; Brey, PT			Sex determination in malaria parasites	SCIENCE			English	Article							TRANSMISSION-BLOCKING IMMUNITY; LOCAL MATE COMPETITION; PLASMODIUM-GALLINACEUM; ERYTHROPOIETIN; ANTIBODIES; CHICKENS; BIOLOGY; RATIOS	A century ago, W. G. MacCallum identified distinct male and female forms in malaria parasites of both birds and humans. Since then, scientists have been punted by the high female-to-male ratios of parasites in Plasmodium infections and by the mechanism of sex determination. The sex ratio of malaria parasites was shown to become progressively more male as conditions that allow motility and subsequent fertilization by the male parasites become adverse. This resulted from an increased immune response against male gametes, which coincides with intense host erythropoietic activity. Natural and artificial induction of erythropoiesis in vertebrate hosts provoked a shift toward male parasite production. This change in parasite sex ratio led to reduced reproductive success in the parasite, which suggests that sex determination is adaptive and is regulated by the hematologic state of the host.	Inst Pasteur, Lab Biochim & Biol Mol Insectes, F-75724 Paris 15, France; Zool Soc London, Inst Zool, London NW1 4RY, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Zoological Society of London	Paul, REL (corresponding author), Inst Pasteur, Lab Biochim & Biol Mol Insectes, 25 Rue Dr Roux, F-75724 Paris 15, France.	topotito@pasteur.fr						CARTER R, 1979, EXP PARASITOL, V47, P194, DOI 10.1016/0014-4894(79)90073-0; CARTER R, 1979, EXP PARASITOL, V47, P185, DOI 10.1016/0014-4894(79)90072-9; Carter R., 1988, MALARIA PRINCIPLES P, P253; CHARNOV E L, 1982; CRAWLEY MJ, 1993, GUM ECOLOGISTS; Day KP, 1998, PARASITOLOGY, V116, pS95, DOI 10.1017/S0031182000084985; ElHassan AMA, 1997, EUR J HAEMATOL, V59, P299, DOI 10.1111/j.1600-0609.1997.tb01690.x; Garnham P.C.C., 1966, MALARIA PARASITES OT; GEIRINGER E, 1961, P SOC EXP BIOL MED, V106, P752, DOI 10.3181/00379727-106-26464; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; HAWKING F, 1972, PARASITOLOGY, V65, P189, DOI 10.1017/S003118200004498X; JELKMANN W, 1994, CLIN INVESTIGATOR, V72, pS3; KAUSHAL DC, 1983, J IMMUNOL, V131, P2557; MCGUIRE MJ, 1993, FUNDAMENTALS CLIN HE, P117; MILLEDGE JS, 1985, J APPL PHYSIOL, V59, P360, DOI 10.1152/jappl.1985.59.2.360; PAGEL H, 1992, ADV EXP MED BIOL, V317, P515; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; Paul REL, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P153; READ AF, 1992, PARASITOLOGY, V104, P387, DOI 10.1017/S0031182000063630; READ AF, 1995, P ROY SOC B-BIOL SCI, V260, P359, DOI 10.1098/rspb.1995.0105; ROSSE WF, 1966, BLOOD-J HEMATOL, V27, P654, DOI 10.1182/blood.V27.5.654.654; SCHALL JJ, 1989, PARASITOLOGY, V98, P343, DOI 10.1017/S0031182000061412; SCHINDLER SL, 1987, COMP BIOCHEM PHYS A, V87, P533, DOI 10.1016/0300-9629(87)90356-2; SHUTLER D, 1995, P NATL ACAD SCI USA, V92, P6748, DOI 10.1073/pnas.92.15.6748; Shutler D, 1998, OIKOS, V82, P417, DOI 10.2307/3546363; Sinden RE, 1996, ADV PARASIT, V38, P53, DOI 10.1016/S0065-308X(08)60033-0; Wilson K, 1996, FUNCT ECOL, V10, P592, DOI 10.2307/2390169	27	101	102	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					128	131		10.1126/science.287.5450.128	http://dx.doi.org/10.1126/science.287.5450.128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615046				2022-12-01	WOS:000084578400051
J	Henney, JE				Henney, JE			Injunction affecting Abbott's in vitro test devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					46	46		10.1001/jama.283.1.46	http://dx.doi.org/10.1001/jama.283.1.46			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632269				2022-12-01	WOS:000084514400005
J	Schiffman, M; Herrero, R; Hildesheim, A; Sherman, ME; Bratti, M; Wacholder, S; Alfaro, M; Hutchinson, M; Morales, J; Greenberg, MD; Lorincz, AT				Schiffman, M; Herrero, R; Hildesheim, A; Sherman, ME; Bratti, M; Wacholder, S; Alfaro, M; Hutchinson, M; Morales, J; Greenberg, MD; Lorincz, AT			HPV DNA testing in cervical cancer screening - Results from women in a high-risk province of Costa Rica	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN PAPILLOMAVIRUS INFECTION; ATYPICAL SQUAMOUS CELLS; INTRAEPITHELIAL NEOPLASIA; UNDETERMINED SIGNIFICANCE; TYPE-16; TRIAGE	Context Human papillomaviruses (HPVs) are known to cause most cervical cancer worldwide, but the utility of HPV DNA testing in cervical cancer prevention has not been determined. Objective To provide comprehensive data on the screening performance of HPV testing for the most common carcinogenic types, at different levels of analytic sensitivity. Design Laboratory analysis conducted during 1993-1995, using 3 cytologic techniques and cervicography, followed by colposcopic examination of women with any abnormal cervical finding, to detect all high-grade intraepithelial lesions and cancer (reference standard of clinically significant disease). The HPV testing was performed subsequently with masking regarding clinical findings. Setting Guanacaste Province, Costa Rica, a region with a high age-adjusted incidence of cervical cancer. Participants Of 11742 randomly selected women, 8554 nonpregnant, sexually active women without hysterectomies underwent initial HPV DNA testing using the original Hybrid Capture Tube test; a stratified subsample of 1119 specimens was retested using the more analytically sensitive second generation assay, the Hybrid Capture II test. Main Outcome Measures Receiver operating characteristic analysis of detection of cervical high-grade intraepithelial lesions and cancer by HPV DNA testing based on different cut points of positivity. Results An analytic sensitivity of 1.0 pg/mL using the second generation assay would have permitted detection of 88.4% of 138 high-grade lesions and cancers (all 12 cancers were HPV-positive), with colposcopic referral of 12.3% of women. Papanicolaou testing using atypical squamous cells of undetermined significance as a cut point for referral resulted in 77.7% sensitivity and 94.2% specificity, with 6.9% referred. Specificity of the second generation assay for positivity for high-grade lesions and cancer was 89.0%, with 33.8% of remaining HPV DNA-positive subjects having low-grade or equivocal microscopically evident lesions. The higher detection threshold of 10 pg/mL used with the original assay had a sensitivity of 74.8% and a specificity of 93.4%, Lower levels of detection with the second generation assay (<1 pg/mL) proved clinically nonspecific without gains in diagnostic sensitivity, Conclusions In this study population, a cut point of 1.0 pg/mL using the second generation assay permitted sensitive detection of cervical high-grade lesions and cancer, yielding an apparently optimal trade-off between high sensitivity and reasonable specificity for this test. The test will perform best in settings in which sensitive detection of high-grade lesions and cancer is paramount. Because HPV prevalence varies by population, HPV testing positive predictive value for detection of high-grade lesions and cancer will vary accordingly, with implications for utility relative to other cervical cancer screening methods.	NCI, Interdisciplinary Studies Sect, Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA; Int Agcy Res Canc, F-69372 Lyon, France; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Costa Rican Social Secur Adm, San Jose, Costa Rica; Brown Univ, Women & Infants Hosp, Providence, RI USA; Omnia, Blue Bell, PA USA; Digene Corp, Silver Spring, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); World Health Organization; International Agency for Research on Cancer (IARC); Johns Hopkins University; Johns Hopkins Medicine; Brown University; Women & Infants Hospital Rhode Island	Schiffman, M (corresponding author), NCI, Interdisciplinary Studies Sect, Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Room 7066,6120 Execut Blvd, Rockville, MD 20852 USA.	schiffmm@exchange.nih.gov	Schiffman, Mark/B-9766-2015		NATIONAL CANCER INSTITUTE [ZIACP010124, Z01CP010124] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*ALTS GROUP, IN PRESS J NATL CANC; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRINTON LA, 1989, INT J CANCER, V44, P199, DOI 10.1002/ijc.2910440202; Carter JJ, 1996, J INFECT DIS, V174, P927, DOI 10.1093/infdis/174.5.927; Cox JT, 1998, J FAM PRACTICE, V46, P121; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; Crum CP, 1998, AM J PATHOL, V153, P1667, DOI 10.1016/S0002-9440(10)65679-9; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; Herrero R, 1993, Bull Pan Am Health Organ, V27, P15; HERRERO R, 1997, PAN AM J PUBLIC HLTH, V1, P362; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; Hutchinson ML, 1999, CANCER CYTOPATHOL, V87, P48, DOI 10.1002/(SICI)1097-0142(19990425)87:2&lt;48::AID-CNCR2&gt;3.0.CO;2-D; *INT AG RES CANC, 1995, IARC MON EV CARC RIS, V64; JOHNSON MA, 1990, J GEN VIROL, V71, P1473, DOI 10.1099/0022-1317-71-7-1473; Kaufman RH, 1997, AM J OBSTET GYNECOL, V177, P930, DOI 10.1016/S0002-9378(97)70296-5; KIVIAT NB, 1990, AM J CLIN PATHOL, V94, P561, DOI 10.1093/ajcp/94.5.561; LORINCZ A, 1996, PAPILLOMAVIRUS REPOR, V7, P1; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Peyton CL, 1998, J CLIN MICROBIOL, V36, P3248, DOI 10.1128/JCM.36.11.3248-3254.1998; Qu WM, 1997, J CLIN MICROBIOL, V35, P1304, DOI 10.1128/JCM.35.6.1304-1310.1997; SCHIFFMAN MH, 1992, EPIDEMIOLOGY HUMAN P, P169; SCHIFFMAN MH, 1994, EARLY DETECTION CANC, P265; SCHIFFMAN MH, 1997, VIRAL INFECT HUMANS, P983; Schneider A, 1996, AM J OBSTET GYNECOL, V174, P1534, DOI 10.1016/S0002-9378(96)70602-6; Schneider DL, 1999, AM J OBSTET GYNECOL, V180, P290, DOI 10.1016/S0002-9378(99)70202-4; Sherman ME, 1998, CANCER CYTOPATHOL, V84, P273; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0; ZWEIG MH, 1993, CLIN CHEM, V39, P561	31	405	430	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					87	93		10.1001/jama.283.1.87	http://dx.doi.org/10.1001/jama.283.1.87			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632285	Bronze			2022-12-01	WOS:000084514400030
J	Foley, E; Willmott, F; Rowen, D; Patel, R; Low, JL				Foley, E; Willmott, F; Rowen, D; Patel, R; Low, JL			Are there excess Sharons in genitourinary clinics?	BRITISH MEDICAL JOURNAL			English	Article									Royal S Hants Hosp, Dept Genitourinary Med, Southampton SO14 0YG, Hants, England; Southampton Gen Hosp, Dept Med Stat & Comp, Southampton SO16 6YD, Hants, England	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Southampton	Foley, E (corresponding author), Royal S Hants Hosp, Dept Genitourinary Med, Southampton SO14 0YG, Hants, England.							Merry E., 1995, 1 NAMES DEFINITIVE G	1	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1615	1615		10.1136/bmj.319.7225.1615	http://dx.doi.org/10.1136/bmj.319.7225.1615			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600963	Green Published, Bronze			2022-12-01	WOS:000084562600017
J	Davis, MW; Fleischhauer, R; Dent, LA; Joho, RH; Avery, L				Davis, MW; Fleischhauer, R; Dent, LA; Joho, RH; Avery, L			A mutation in the C-elegans EXP-2 potassium channel that alters feeding behavior	SCIENCE			English	Article							GATED K+ CHANNEL; CAENORHABDITIS-ELEGANS; ION PERMEATION; INACTIVATION; GENE	The nematode pharynx has a potassium channel with unusual properties, which allows the muscles to repolarize quickly and with the proper delay. Here, the Caenorhabditis elegans exp-2 gene is shown to encode this channel. EXP-2 is a Kv-type (voltage-activated) potassium channel that has inward-rectifying properties resembling those of the structurally dissimilar human ether-a-go-go-related gene (HERG) channel. Null and gain-of-function mutations affect pharyngeal muscle excitability in ways that are consistent with the electrophysiological behavior of the channel, and thereby demonstrate a direct Link between the kinetics of this unusual channel and behavior.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Davis, MW (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	wdavis@biology.utah.edu		Davis, Mikel/0000-0003-1867-1593	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL046154, R01HL046154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028407] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46154, R37 HL046154, R01 HL046154] Funding Source: Medline; NINDS NIH HHS [NS28407] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], COMMUNICATION; AVERY L, 1993, GENETICS, V133, P897; BYERLY L, 1979, J PHYSIOL-LONDON, V288, P263; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CARY RB, 1994, J CELL SCI, V107, P1609; Davis MW, 1995, J NEUROSCI, V15, P8408; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FLEISCHHAUER R, IN PRESS J NEUROSCI; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Liu Y, 1998, PFLUG ARCH EUR J PHY, V435, P654, DOI 10.1007/s004240050566; MALONE C, COMMUNICATION; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OWENS S, COMMUNICATION; PANYI G, 1995, BIOPHYS J, V69, P896, DOI 10.1016/S0006-3495(95)79963-5; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; RAIZEN DM, 1994, NEURON, V12, P483, DOI 10.1016/0896-6273(94)90207-0; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; THOMAS JH, 1990, GENETICS, V124, P855; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; Williams BD, 1995, METHOD CELL BIOL, V48, P81; ZUHLKE RD, 1994, RECEPTOR CHANNEL, V2, P237	22	44	47	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2501	2504		10.1126/science.286.5449.2501	http://dx.doi.org/10.1126/science.286.5449.2501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617464	Green Accepted			2022-12-01	WOS:000084429700047
J	Tan, J; Town, T; Paris, D; Mori, T; Suo, ZM; Crawford, F; Mattson, MP; Flavell, RA; Mullan, M				Tan, J; Town, T; Paris, D; Mori, T; Suo, ZM; Crawford, F; Mattson, MP; Flavell, RA; Mullan, M			Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation	SCIENCE			English	Article							VASCULAR ENDOTHELIAL-CELLS; ALZHEIMERS-DISEASE; CD40 LIGAND; FUNCTIONAL CD40; SMOOTH-MUSCLE; A-BETA; PROTEIN; EXPRESSION; MICE; PRECURSOR	Alzheimer's disease (AD) has a substantial inflammatory component, and activated microglia may play a central role in neuronal degeneration, CD40 expression was increased on cultured microglia treated with freshly solublized amyloid-beta (A beta, 500 nanomolar) and on microglia from a transgenic murine model of AD (Tg APP(sw)). Increased tumor necrosis factor alpha production and induction of neuronal injury occurred when A beta-stimulated microglia were treated with CD40 ligand (CD40L), Microglia from Tg APP(sw) mice deficient for CD4OL demonstrated reduction in activation, suggesting that the CD40-CD40L interaction is necessary for A beta-induced microglial activation. Finally, abnormal tau phosphorylation was reduced in Tg APP(sw) animals deficient for CD40L, suggesting that the CD40-CD40L interaction is an early event in AD pathogenesis.	Univ S Florida, Roskamp Inst, Tampa, FL 33613 USA; Univ Kentucky, Sanders Brown Res Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	State University System of Florida; University of South Florida; University of Kentucky; University of Kentucky; Howard Hughes Medical Institute; Yale University	Mullan, M (corresponding author), Univ S Florida, Roskamp Inst, 3515 E Fletcher Ave, Tampa, FL 33613 USA.		Mattson, Mark P/F-6038-2012; Tan, Jun/I-5339-2012	Mullan, Michael/0000-0002-1473-7527; Paris, Daniel/0000-0002-9622-0846				Castillo GM, 1997, J NEUROCHEM, V69, P2452; Combs CK, 1999, J NEUROSCI, V19, P928; Denfeld RW, 1996, EUR J IMMUNOL, V26, P2329, DOI 10.1002/eji.1830261009; Ellis RJ, 1996, NEUROLOGY, V46, P1592, DOI 10.1212/WNL.46.6.1592; Genis I, 1999, J NEUROCHEM, V72, P206, DOI 10.1046/j.1471-4159.1999.0720206.x; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; HIGGINS LS, 1995, P NATL ACAD SCI USA, V92, P4402, DOI 10.1073/pnas.92.10.4402; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; HUBERMAN M, 1994, J NEUROIMMUNOL, V52, P147, DOI 10.1016/0165-5728(94)90108-2; James ND, 1996, NEUROBIOL AGING, V17, P235, DOI 10.1016/0197-4580(95)02068-3; Kalaria R N, 1999, Curr Opin Hematol, V6, P15, DOI 10.1097/00062752-199901000-00004; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Klegeris A, 1997, BRAIN RES, V747, P114, DOI 10.1016/S0006-8993(96)01229-2; LI QX, 1994, BLOOD, V84, P133, DOI 10.1182/blood.V84.1.133.133; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Oleana VH, 1998, NEUROREPORT, V9, P1451, DOI 10.1097/00001756-199805110-00037; ROGERS J, 1988, NEUROBIOL AGING, V9, P339, DOI 10.1016/S0197-4580(88)80079-4; Ruggiero G, 1996, J IMMUNOL, V156, P3737; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Schonbeck U, 1997, J BIOL CHEM, V272, P19569, DOI 10.1074/jbc.272.31.19569; Sempowski GD, 1997, J IMMUNOL, V158, P4670; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Tan J, 1999, J NEUROIMMUNOL, V97, P77, DOI 10.1016/S0165-5728(99)00053-3; Uchihara T, 1997, STROKE, V28, P1948, DOI 10.1161/01.STR.28.10.1948; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	28	307	322	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2352	2355		10.1126/science.286.5448.2352	http://dx.doi.org/10.1126/science.286.5448.2352			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600748				2022-12-01	WOS:000084318500065
J	Povar, GJ; Snyder, L				Povar, GJ; Snyder, L		Ethics & Human Rights Comm	Selling products out of the office	ANNALS OF INTERNAL MEDICINE			English	Article								The sale of products from the physician's office raises several ethical issues and may affect the trust necessary to sustain the patient-physician relationship. When deciding whether to sell products out of the office and, if so, which ones, physicians should carefully consider such criteria as the urgency of the patient's need, the clinical relevance to the patient's condition, the adequacy of evidence to support, use of the product, and geographic and time constraints for the patient in otherwise obtaining the product. Physicians should make full disclosure about their financial interests in selling the product and inform patients about alternatives for purchasing the product. Charges for products sold through the office should be limited to the reasonable costs incurred in making them available.	Amer Soc Internal Med, Coll Phys, Ctr Eth & Professionalism, Philadelphia, PA USA; Cameron Med Grp, Silver Spring, MD 20910 USA		Snyder, L (corresponding author), Amer Soc Internal Med, Coll Phys, Ctr Eth & Professionalism, 190 N Independence Mall W, Philadelphia, PA USA.							BRODY H, 1992, HEALERS POWER; Jonsen Albert R., 1990, NEW MED OLD ETHICS; Kassirer JP, 1998, NEW ENGL J MED, V339, P1543, DOI 10.1056/NEJM199811193392109; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012	4	7	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					863	864		10.7326/0003-4819-131-11-199912070-00012	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610634				2022-12-01	WOS:000084053200011
J	Kardailsky, I; Shukla, VK; Ahn, JH; Dagenais, N; Christensen, SK; Nguyen, JT; Chory, J; Harrison, MJ; Weigel, D				Kardailsky, I; Shukla, VK; Ahn, JH; Dagenais, N; Christensen, SK; Nguyen, JT; Chory, J; Harrison, MJ; Weigel, D			Activation tagging of the floral inducer FT	SCIENCE			English	Article							PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN; LATE-FLOWERING MUTANTS; ARABIDOPSIS-THALIANA; CRYSTAL-STRUCTURE; BOVINE BRAIN; TIME GENES; INITIATION; ARCHITECTURE; EXPRESSION; SEQUENCE	FLOWERING LOCUS T (FT), which acts in parallel with the meristem-identity gene LEAFY (LFY) to induce flowering of Arabidopsis, was isolated by activation tagging. Like LFY, FT acts partially downstream of CONSTANS (CO), which promotes flowering in response to long days. Unlike many other floral regulators, the deduced sequence of the FT protein does not suggest that it directly controls transcription or transcript processing. Instead, it is similar to the sequence of TERMINAL FLOWER 1 (TFL1), an inhibitor of flowering that also shares sequence similarity with membrane-associated mammalian proteins.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73402 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA	Salk Institute; Noble Research Institute; Howard Hughes Medical Institute; Salk Institute	Weigel, D (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Kardailsky, Igor/AAK-8850-2021; Weigel, Detlef/C-1418-2008; Ahn, Ji Hoon/A-4141-2011; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/GSJ-0799-2022	Weigel, Detlef/0000-0002-2114-7963; Ahn, Ji Hoon/0000-0003-0347-3922; Weigel, Detlef/0000-0002-2114-7963; Harrison, Maria J/0000-0001-8716-1875				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; HAYASHI H, 1992, SCIENCE, V258, P1350, DOI 10.1126/science.1455228; Hempel FD, 1997, DEVELOPMENT, V124, P3845; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, GENETICS, V148, P885; Levy YY, 1998, PLANT CELL, V10, P1973, DOI 10.1105/tpc.10.12.1973; Liljegren SJ, 1999, PLANT CELL, V11, P1007, DOI 10.1105/tpc.11.6.1007; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Nilsson O, 1998, GENETICS, V150, P403; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Ratcliffe OJ, 1998, DEVELOPMENT, V125, P1609; Ratcliffe OJ, 1999, DEVELOPMENT, V126, P1109; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; SCHOENTGEN F, 1987, EUR J BIOCHEM, V166, P333, DOI 10.1111/j.1432-1033.1987.tb13519.x; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; TOHDOH N, 1995, MOL BRAIN RES, V30, P381, DOI 10.1016/0169-328X(95)00029-R; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686	25	1059	1203	8	178	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1962	1965		10.1126/science.286.5446.1962	http://dx.doi.org/10.1126/science.286.5446.1962			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583961				2022-12-01	WOS:000084003400054
J	Garcia, R; Vouimba, RM; Baudry, M; Thompson, RF				Garcia, R; Vouimba, RM; Baudry, M; Thompson, RF			The amygdala modulates prefrontal cortex activity relative to conditioned fear	NATURE			English	Article							BASOLATERAL AMYGDALA; DOPAMINE NEURONS; RAT; ORGANIZATION; PROJECTIONS; NUCLEUS; STRESS; NEUROENDOCRINE; RESPONSES; THALAMUS	Animals learn that a tone can predict the occurrence of an electric shock through classical conditioning. Mice or rats trained in this manner display fear responses, such as freezing behaviour, when they hear the conditioned tone. Studies using amygdalectomized rats have shown that the amygdala is required for both the acquisition and expression of learned fear responses(1-3) Freezing to a conditioned tone is enhanced following damage, to the dorsal part of the medial prefrontal cortex(4), indicating that this area may be involved in fear reduction, Here we show that prefrontal neurons reduce their spontaneous activity in the presence of a conditioned aversive tone as a function of the degree of fear, The depression in prefrontal spontaneous activity is related to amygdala activity but not to the freezing response itself. These data indicate that, in the presence of threatening stimuli, the amygdala controls both fear expression and prefrontal neuronal activity. They suggest that abnormal amygdala-induced modulation of prefrontal neuronal activity may be involved in the pathophysiology of certain forms of anxiety disorder.	Univ Bordeaux 1, Cognit Neurosci Lab, CNRS, UMR 5807, F-33405 Talence, France; Univ So Calif, Program Neurosci, Los Angeles, CA 90089 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of Southern California	Garcia, R (corresponding author), Univ Bordeaux 1, Cognit Neurosci Lab, CNRS, UMR 5807, Ave Fac, F-33405 Talence, France.		anand, amit/A-7222-2009					Bechara A, 1999, J NEUROSCI, V19, P5473; Campeau S, 1997, NEUROSCIENCE, V78, P1087, DOI 10.1016/S0306-4522(96)00632-X; DAVIS M, 1994, BRAIN RES, V664, P207, DOI 10.1016/0006-8993(94)91972-0; DAVIS M, 1992, P255; Farb CR, 1997, SYNAPSE, V27, P106, DOI 10.1002/(SICI)1098-2396(199710)27:2<106::AID-SYN2>3.3.CO;2-F; FERRON A, 1984, BRAIN RES, V302, P257, DOI 10.1016/0006-8993(84)90238-5; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA; FUXE K, 1974, BRAIN RES, V82, P349, DOI 10.1016/0006-8993(74)90618-0; Garcia R, 1998, EUR J NEUROSCI, V10, P457, DOI 10.1046/j.1460-9568.1998.00027.x; GARDNER RC, 1994, ONT SYMP P, V7, P1; Goldstein LE, 1996, J NEUROSCI, V16, P4787; GONZALES C, 1990, J COMP NEUROL, V297, P182; HERRY C, IN PRESS J NEUROPHYS; LaBar KS, 1996, BEHAV NEUROSCI, V110, P991, DOI 10.1037/0735-7044.110.5.991; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; LEDOUX JE, 1990, J NEUROSCI, V10, P1043; LINDVALL O, 1974, BRAIN RES, V81, P325, DOI 10.1016/0006-8993(74)90947-0; MANTZ J, 1988, NEUROSCIENCE, V27, P517, DOI 10.1016/0306-4522(88)90285-0; Maren S, 1996, NEURON, V16, P237, DOI 10.1016/S0896-6273(00)80041-0; MCDONALD AJ, 1987, J COMP NEUROL, V262, P46, DOI 10.1002/cne.902620105; MCDONALD AJ, 1991, NEUROSCIENCE, V44, P1, DOI 10.1016/0306-4522(91)90247-L; MORGAN MA, 1995, BEHAV NEUROSCI, V109, P681, DOI 10.1037/0735-7044.109.4.681; PAPINI MR, 1993, J EXP PSYCHOL ANIM B, V19, P342, DOI 10.1037/0097-7403.19.4.342; PEREZJARANAY JM, 1991, BRAIN RES, V564, P97, DOI 10.1016/0006-8993(91)91357-7; RESCORLA RA, 1969, PSYCHOL BULL, V72, P77, DOI 10.1037/h0027760; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Schoenbaum G, 1998, NAT NEUROSCI, V1, P155, DOI 10.1038/407; Schoenbaum G, 1999, J NEUROSCI, V19, P1876; THOMAS E, 1980, EXP NEUROL, V69, P50, DOI 10.1016/0014-4886(80)90142-9; TURNER BH, 1991, J COMP NEUROL, V313, P295, DOI 10.1002/cne.903130208	30	264	267	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					294	296		10.1038/46286	http://dx.doi.org/10.1038/46286			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	257ZP	10580500				2022-12-01	WOS:000083813700050
J	Roberts, CJ; Nelson, B; Marton, MJ; Stoughton, R; Meyer, MR; Bennett, HA; He, YDD; Dai, HY; Walker, WL; Hughes, TR; Tyers, M; Boone, C; Friend, SH				Roberts, CJ; Nelson, B; Marton, MJ; Stoughton, R; Meyer, MR; Bennett, HA; He, YDD; Dai, HY; Walker, WL; Hughes, TR; Tyers, M; Boone, C; Friend, SH			Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE PATHWAY; POLARIZED CELL-GROWTH; FILAMENTOUS-GROWTH; ACTIN CYTOSKELETON; INVASIVE GROWTH; REGULATED GENES; SHUTTLE VECTORS; MATING FACTOR; PHEROMONE	Genome-wide transcript profiling was used to monitor signal transduction during yeast pheromone response. Genetic manipulations allowed analysis of changes in gene expression underlying pheromone signaling, cell cycle control, and polarized morphogenesis. A two-dimensional hierarchical clustered matrix, covering 383 of the most highly regulated genes, was constructed from 46 diverse experimental conditions. Diagnostic subsets of coexpressed genes reflected signaling activity, cross talk, and overlap of multiple mitogen-activated protein kinase (MAPK) pathways. Analysis of the profiles specified by two different MAPKs-Fus3p and Kss1p-revealed functional overlap of the filamentous growth and mating responses. Global transcript analysis reflects biological responses associated with the activation and perturbation of signal transduction pathways.	Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; Rosetta Inpharmat, Kirkland, WA 98034 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada	Queens University - Canada; Merck & Company; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Boone, C (corresponding author), Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada.		Pillay, Nischalan/F-9536-2012; Tyers, Michael/ABE-3194-2021					Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; Blanco P, 1998, FEMS MICROBIOL LETT, V164, P249, DOI 10.1016/S0378-1097(98)00220-1; Brachmann CB, 1998, YEAST, V14, P115; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; Buehrer BM, 1997, MOL CELL BIOL, V17, P6517, DOI 10.1128/MCB.17.11.6517; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Chen GC, 1997, GENE DEV, V11, P2958, DOI 10.1101/gad.11.22.2958; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; ERDMAN S, COMMUNICATION; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FIELDS S, 1988, MOL CELL BIOL, V8, P551, DOI 10.1128/MCB.8.2.551; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gognies S, 1999, YEAST, V15, P11, DOI 10.1002/(SICI)1097-0061(19990115)15:1<11::AID-YEA336>3.0.CO;2-O; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Gray JV, 1997, EMBO J, V16, P4924, DOI 10.1093/emboj/16.16.4924; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; Hartigan J.A., 1975, CLUSTERING ALGORITHM; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hung W, 1997, EUR J BIOCHEM, V245, P241, DOI 10.1111/j.1432-1033.1997.00241.x; HWANGSHUM JJ, 1991, MOL GEN GENET, V227, P197, DOI 10.1007/BF00259671; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Karos M, 1999, MOL GEN GENET, V260, P510, DOI 10.1007/s004380050924; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Kuo MH, 1997, MOL CELL BIOL, V17, P819, DOI 10.1128/MCB.17.2.819; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Liu HP, 1996, GENETICS, V144, P967; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Madhani HD, 1999, P NATL ACAD SCI USA, V96, P12530, DOI 10.1073/pnas.96.22.12530; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Mosch HU, 1999, MOL BIOL CELL, V10, P1325, DOI 10.1091/mbc.10.5.1325; NAIR PB, UNPUB; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Robertson LS, 1998, P NATL ACAD SCI USA, V95, P13783, DOI 10.1073/pnas.95.23.13783; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SIKORSKI RS, 1989, GENETICS, V122, P19; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WATANABE Y, 1995, MOL CELL BIOL, V15, P5740; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; XUE CB, 1989, BIOCHEM BIOPH RES CO, V162, P253, DOI 10.1016/0006-291X(89)91989-X; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	78	701	733	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					873	880		10.1126/science.287.5454.873	http://dx.doi.org/10.1126/science.287.5454.873			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657304				2022-12-01	WOS:000085136400051
J	Roger, VL; Farkouh, ME; Weston, SA; Reeder, GS; Jacobsen, SJ; Zinsmeister, AR; Yawn, BP; Kopecky, SL; Gabriel, SE				Roger, VL; Farkouh, ME; Weston, SA; Reeder, GS; Jacobsen, SJ; Zinsmeister, AR; Yawn, BP; Kopecky, SL; Gabriel, SE			Sex differences in evaluation and outcome of unstable angina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; GENDER-RELATED DIFFERENCES; EMERGENCY ROOM; CHEST PAIN; CARDIAC PROCEDURES; BYPASS-SURGERY; BIAS; MANAGEMENT; MORTALITY	Context The existence of sex bias in the delivery of cardiac care is controversial,and little is known about the association between sex and delivery of care and outcomes at an early point in the diagnostic sequence, such as when patients present for the evaluation of chest pain. Objective To test the hypothesis that female sex is negatively associated with care delivered to and outcomes of persons diagnosed as having unstable angina. Design Inception population-based cohort study with an average of 6 years of follow-up. Setting Emergency departments (EDs) in Olmsted County, Minnesota. Patients A total of 2271 Olmsted County residents (1306 men and 965 women) who presented to the ED for the first time with symptoms meeting criteria for unstable angina between 1985 and 1992, Main Outcome Measures Use of cardiac procedures within 90 days of ED visit, overall mortality, and cardiac events (cardiac death, nonfatal myocardial infarction, nonfatal cardiac arrest, and congestive heart failure), com pared by sex and Agency for Health Care Policy and Research cardiovascular risk category (low, intermediate, or high). Results Women were older (P<.001), more likely to have a history of hypertension (P=.001), and less likely to present with typical angina (P=.004) than men. Men were more likely than women to undergo noninvasive cardiac tests (relative risk [RR], 1.27; 95% confidence interval [CI], 1.14-1.40) as well as invasive cardiac procedures (RR, 1.72; 95% CI, 1.51-1.97). After adjustment, male sex was associated with a 24% increase in the use of cardiac procedures. Survival of both men and women in the high and intermediate risk categories was significantly lower than expected per the general population (P<.001). Women had a worse outcome than men, but after multivariate adjustment, male sex was associated with a trend toward an increase in the risk of death (RR, 1.23; 95% CI, 0.99-1.54) and significantly associated with increased risk of cardiac events (RR, 1.21;95% CI, 1.03-1.42). Conclusions Our population-based data indicate that after an ED visit for symptoms of unstable angina, the use of cardiac procedures was lower in women, but after taking into account baseline characteristics, men experienced worse outcomes.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Epidemiol Sect, Rochester, MN 55905 USA; Olmsted Med Ctr, Dept Res, Rochester, MN USA; Mt Sinai Med Ctr, Cardiovasc Inst, Div Cardiol, New York, NY 10029 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Olmsted Medical Center; Icahn School of Medicine at Mount Sinai	Roger, VL (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.		Roger, Veronique/AAV-5951-2020	Jacobsen, Steven/0000-0002-8174-8533	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59205] Funding Source: Medline; NIAMS NIH HHS [AR30582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Braunwald E, 1994, UNSTABLE ANGINA DIAG; CHIRIBOGA DE, 1993, AM J CARDIOL, V71, P268, DOI 10.1016/0002-9149(93)90789-F; DEWINTER RJ, 1995, CIRCULATION, V92, P3401, DOI 10.1161/01.CIR.92.12.3401; FUNK M, 1994, AM J CARDIOL, V74, P1170, DOI 10.1016/0002-9149(94)90475-8; HACHAMOVITCH R, 1995, J AM COLL CARDIOL, V26, P1457, DOI 10.1016/0735-1097(95)00356-8; HANLEY PC, 1989, J AM COLL CARDIOL, V13, P624, DOI 10.1016/0735-1097(89)90603-7; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; HILTON TC, 1994, J AM COLL CARDIOL, V23, P1016, DOI 10.1016/0735-1097(94)90584-3; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; Karlson BW, 1996, CORONARY ARTERY DIS, V7, P231; KARLSON BW, 1993, CORONARY ARTERY DIS, V4, P761, DOI 10.1097/00019501-199309000-00002; Karlson BW, 1997, AM J EMERG MED, V15, P1, DOI 10.1016/S0735-6757(97)90038-3; Katz DA, 1996, JAMA-J AM MED ASSOC, V276, P1568; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; MAIR J, 1995, CHEST, V108, P1502, DOI 10.1378/chest.108.6.1502; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; Maynard C, 1996, CIRCULATION, V94, P93; MELTON LJ, 1985, MAYO CLIN PROC, V60, P880, DOI 10.1016/S0025-6196(12)64794-6; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; Roger VL, 1997, CIRCULATION, V95, P405; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; SHAW LJ, 1994, ANN INTERN MED, V120, P559, DOI 10.7326/0003-4819-120-7-199404010-00005; SKETCH MH, 1975, AM J CARDIOL, V36, P169, DOI 10.1016/0002-9149(75)90521-4; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; Stussman BJ, 1997, DHHS PUBLICATION; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; VARETTO T, 1993, J AM COLL CARDIOL, V22, P1804, DOI 10.1016/0735-1097(93)90761-O; WEINER DA, 1979, NEW ENGL J MED, V301, P230, DOI 10.1056/NEJM197908023010502	32	116	116	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					646	652		10.1001/jama.283.5.646	http://dx.doi.org/10.1001/jama.283.5.646			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665705	Bronze			2022-12-01	WOS:000084956500031
J	Lamont, D; Parker, L; White, M; Unwin, N; Bennett, SMA; Cohen, M; Richardson, D; Dickinson, HO; Adamson, A; Alberti, KGMM; Craft, AW				Lamont, D; Parker, L; White, M; Unwin, N; Bennett, SMA; Cohen, M; Richardson, D; Dickinson, HO; Adamson, A; Alberti, KGMM; Craft, AW			Risk of cardiovascular disease measured by carotid intima-media thickness at age 49-51: lifecourse study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; B-MODE ULTRASOUND; FETAL GROWTH; MYOCARDIAL-INFARCTION; PERIPHERAL ARTERIES; WALL THICKNESS; FOLLOW-UP; CHILDHOOD; WOMEN; ATHEROSCLEROSIS	Objective To quantify the direct and indirect effects of fetal life, childhood, and adult life on risk of cardiovascular disease at age 49-51 years. Design Follow up study of the "Newcastle thousand families" birth cohort established in 1947. Participants 154 men and 193 women who completed a health and lifestyle questionnaire and attended for clinical examination between October 1996 and December 1998. Main outcome measures Correlations between mean intima-media thickness of the carotid artery (carotid intima-media thickness) and family history, birth weight, and socioeconomic position around birth; socioeconomic position, growth, illness, and adverse Life events in childhood; and adult socioeconomic position, lifestyle, and biological risk markers. Proportions of variance in carotid intima-media thickness that were accounted for by each stage of the lifecourse. Results Socioeconomic position at birth and birth weight were negatively associated with carotid intima-media thickness, although only social class at birth in women was a statistically significant covariate independent of adult lifestyle. These early life variables accounted directly for 2.2% of total variance in men and 2.0% in women. More variation in carotid intima-media thickness was explained by adult socioeconomic position and lifestyle, which accounted directly and indirectly for 3.4% of variance in men (95% confidence interval 0.5% to 6.2%) and 7.6% in women (2.1% to 13.0%). Biological risk markers measured in adulthood independently accounted for a further 9.5% of variance in men (2.4% to 14.2%) and 4.9% in women (1.6% to 7.4%). Conclusions Adult lifestyle and biological risk markers were the most important determinants of the cardiovascular health of the study members of the Newcastle thousand families cohort at age 49-51 years. The limited overall effect of early life factors may reflect the postwar birth year of this cohort.	Newcastle Univ, Royal Victoria Infirm, Dept Child Hlth, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Newcastle Univ, Sch Med, Sch Hlth Care Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE1 4HH, Tyne & Wear, England; Newcastle Univ, Sch Med, Dept Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Royal Victoria Infirm, Dept Radiol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Newcastle Univ, Human Nutr Res Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Lamont, D (corresponding author), Newcastle Univ, Royal Victoria Infirm, Dept Child Hlth, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	d.w.lamont@ncl.ac.uk	White, Martin J. R./G-2410-2010	Unwin, Nigel/0000-0002-1368-1648; Adamson, Ashley/0000-0003-3735-2846; PARKER, LOUISE/0000-0002-5188-8113	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barker D.J.P., 1998, MOTHERS BABIES HLTH; Ben Shlomo, 1997, LIFECOURSE APPROACH; Bingham SA, 1997, INT J EPIDEMIOL, V26, pS137, DOI 10.1093/ije/26.suppl_1.S137; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; *DEP HLTH, 1992, 41 DEP HLTH; Dubuisson JT, 1998, DIABETES CARE, V21, P1790, DOI 10.2337/diacare.21.11.1790; EBRAHIM S, 1994, BRIT HEART J, V72, P501; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAIRDNER D, 1971, ARCH DIS CHILD, V46, P783, DOI 10.1136/adc.46.250.783; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HOLLINGSWORTH D, 1991, ENGLISHMANS FOOD 5 C, P429; HOWARD G, 1993, STROKE, V24, P1297, DOI 10.1161/01.STR.24.9.1297; KUH DJL, 1992, J EPIDEMIOL COMMUN H, V46, P114, DOI 10.1136/jech.46.2.114; Lamont DW, 1998, PUBLIC HEALTH, V112, P85, DOI 10.1016/S0033-3506(98)00591-5; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; Little R.J.A., 1987, STAT ANAL MISSING DA; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; Martyn CN, 1998, LANCET, V352, P173, DOI 10.1016/S0140-6736(97)10404-4; Njolstad I, 1996, CIRCULATION, V93, P450; PETRIE JC, 1990, RECOMMENDATIONS BLOO; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; Power C, 1998, LANCET, V352, P877, DOI 10.1016/S0140-6736(98)23937-7; Prineas R.J, 1982, MINNESOTA MANUAL ELE; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454; Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI 10.1093/ije/26.1.224; Williams S, 1999, BRIT MED J, V318, P897, DOI 10.1136/bmj.318.7188.897; World Health Organisation, 1990, MONICA MAN 3	33	134	138	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2000	320	7230					273	278		10.1136/bmj.320.7230.273	http://dx.doi.org/10.1136/bmj.320.7230.273			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280ZB	10650022	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000085132700018
J	Hazuda, DJ; Felock, P; Witmer, M; Wolfe, A; Stillmock, K; Grobler, JA; Espeseth, A; Gabryelski, L; Schleif, W; Blau, C; Miller, MD				Hazuda, DJ; Felock, P; Witmer, M; Wolfe, A; Stillmock, K; Grobler, JA; Espeseth, A; Gabryelski, L; Schleif, W; Blau, C; Miller, MD			Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 INTEGRASE; VIRAL-DNA; PREINTEGRATION COMPLEXES; STABLE COMPLEX; PROTEIN; INVITRO; IDENTIFICATION; GENE; SITE	Integrase is essential for human immunodeficiency virus-type 1 (HIV-1) replication; however, potent inhibition of the isolated enzyme in biochemical assays has not readily translated into antiviral activity in a manner consistent with inhibition of integration. In this report, we describe diketo acid inhibitors of HIV-1 integrase that manifest antiviral activity as a consequence of their effect on integration. The antiviral activity of these compounds is due exclusively to inhibition of one of the two catalytic functions of integrase, strand transfer.	Merck Sharp & Dohme Res Labs, Dept Antiviral Res, W Point, PA 19486 USA	Merck & Company	Hazuda, DJ (corresponding author), Merck Sharp & Dohme Res Labs, Dept Antiviral Res, W Point, PA 19486 USA.							CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ESPESETH A, UNPUB; Farnet CM, 1996, P NATL ACAD SCI USA, V93, P9742, DOI 10.1073/pnas.93.18.9742; FARNET CM, 1991, J VIROL, V65, P6942, DOI 10.1128/JVI.65.12.6942-6952.1991; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; Hazuda D, 1997, Drug Des Discov, V15, P17; Hazuda DJ, 1997, J VIROL, V71, P7005, DOI 10.1128/JVI.71.9.7005-7011.1997; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; Miller M. M., UNPUB; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Neamati N, 1998, J MED CHEM, V41, P3202, DOI 10.1021/jm9801760; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; Richman DD, 1996, ANTIVIRAL DRUG RESIS; TADDEO B, 1994, J VIROL, V68, P8401, DOI 10.1128/JVI.68.12.8401-8405.1994; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VINK C, 1994, NUCLEIC ACIDS RES, V22, P4103, DOI 10.1093/nar/22.20.4103; WISKERCHEN M, 1995, J VIROL, V69, P376, DOI 10.1128/JVI.69.1.376-386.1995; WITMER M, UNPUB; Wolfe AL, 1996, J VIROL, V70, P1424, DOI 10.1128/JVI.70.3.1424-1432.1996	26	967	1028	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	2000	287	5453					646	650		10.1126/science.287.5453.646	http://dx.doi.org/10.1126/science.287.5453.646			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10649997				2022-12-01	WOS:000084989400046
J	Rossi, DJ; Oshima, T; Attwell, D				Rossi, DJ; Oshima, T; Attwell, D			Glutamate release in severe brain ischaemia is mainly by reversed uptake	NATURE			English	Article							RAT HIPPOCAMPAL SLICES; METHYL-D-ASPARTATE; NEURONAL DEATH; IN-VITRO; ISCHEMIA; ACTIVATION; TRANSPORT; CALCIUM; ANOXIA; MECHANISMS	The release of glutamate during brain anoxia or ischaemia triggers the death of neurons', causing mental or physical handicap. The mechanism of glutamate release is controversial, however. Four release mechanisms have been postulated: vesicular release dependent on external calcium(2) or Ca(2+) released from intracellular stores(3); release through swelling-activated onion channels(4); an indomethacin-sensitive process in astrocytes(5-7); and reversed operation of glutamate transporters(8,9). Here we have mimicked severe ischaemia in hippocampal slices and monitored glutamate release as a receptor-gated current in the CA1 pyramidal cells that are killed preferentially in ischaemic hippocampus. Using blockers of the different release mechanisms, we demonstrate that glutamate release is largely by reversed operation of neuronal glutamate transporters, and that it plays a key role in generating the anoxic depolarization that abolishes information processing in the central nervous system a few minutes after the start of ischaemia. A mathematical model incorporating K(+) channels, reversible uptake carriers and NMDA (N-methyl-D-aspartate) receptor channels reproduces the main features of the response to ischaemia. Thus, transporter-mediated glutamate homeostasis fails dramatically in ischaemia: instead of removing extracellular glutamate to protect neurons, transporters release glutamate, triggering neuronal death.	UCL, Dept Physiol, London WC1E 6BT, England; Shionogi & Co Ltd, Toyonaka, Osaka 561, Japan	University of London; University College London; Shionogi & Company Limited	Attwell, D (corresponding author), UCL, Dept Physiol, Gower St, London WC1E 6BT, England.	D.Attwell@ucl.ac.uk	Attwell, David/ABE-6750-2020					ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Basarsky TA, 1999, J NEUROSCI, V19, P6439; BEDNAR M M, 1992, Neurological Research, V14, P53; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Billups B, 1996, NATURE, V379, P171, DOI 10.1038/379171a0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; FRIEDMAN JE, 1994, BRAIN RES, V663, P329, DOI 10.1016/0006-8993(94)91281-5; GUNDERSEN V, 1993, NEUROSCIENCE, V57, P97, DOI 10.1016/0306-4522(93)90114-U; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; JAHR CE, 1990, J NEUROSCI, V10, P3178; KATCHMAN AN, 1993, J NEUROPHYSIOL, V70, P1; LERMA J, 1992, MOL PHARMACOL, V41, P217; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; MADL JE, 1993, J NEUROSCI, V13, P4429; MCBAIN CJ, 1990, SCIENCE, V249, P674, DOI 10.1126/science.2382142; Nowicky AV, 1998, J PHYSIOL-LONDON, V507, P131, DOI 10.1111/j.1469-7793.1998.131bu.x; PARPURA V, 1909, NATURE, V28, P159; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; RALEY KM, 1990, NEUROSCI LETT, V110, P118, DOI 10.1016/0304-3940(90)90798-E; Roettger V, 1996, NEUROSCIENCE, V75, P677, DOI 10.1016/0306-4522(96)00314-4; SAH P, 1988, J GEN PHYSIOL, V92, P263, DOI 10.1085/jgp.92.2.263; SARANTIS M, 1993, NEURON, V11, P541, DOI 10.1016/0896-6273(93)90158-N; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; STORMMATHISEN J, 1992, PROG BRAIN RES, V94, P225; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; WALZ W, 1993, DEV NEUROSCI-BASEL, V15, P216, DOI 10.1159/000111337; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	30	869	908	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					316	321		10.1038/35002090	http://dx.doi.org/10.1038/35002090			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659851				2022-12-01	WOS:000084899700054
J	Yokouchi, Y; Noijiri, Y; Barrie, LA; Toom-Sauntry, D; Machida, T; Inuzuka, Y; Akimoto, H; Li, HJ; Fujinuma, Y; Aoki, S				Yokouchi, Y; Noijiri, Y; Barrie, LA; Toom-Sauntry, D; Machida, T; Inuzuka, Y; Akimoto, H; Li, HJ; Fujinuma, Y; Aoki, S			A strong source of methyl chloride to the atmosphere from tropical coastal land	NATURE			English	Article							SOUTH-ATLANTIC; BIOSYNTHESIS; HALOMETHANES; METHANETHIOL; HALIDES	Methyl chloride (CH3Cl), the most abundant halocarbon in the atmosphere, has received much attention as a natural source of chlorine :atoms in the stratosphere(1,2). The annual global flux of CH3Cl has been estimated to be around 3.5 Tg on the grounds that this must balance the loss through reaction with OH radicals (which gives a lifetime for atmospheric CH3Cl of 1.5 yr)(3-5), The most likely main source of methyl chloride has been thought to be oceanic emission(2,6-8), with biomass burning the second largest source(9). But recent seawater measurements(10) indicate that oceanic fluxes cannot account for more than 12% of the estimated global flux of CH3Cl, raising the question of where the remainder comes from. Here we report evidence of significant CH3Cl emission from warm coastal land, particularly from tropical islands. This conclusion is based on a global monitoring study and spot measurements, which show enhancement of atmospheric CH3Cl in the tropics, a close correlation between CH3Cl concentrations and those of biogenic compounds emitted by terrestrial plants, and OH-linked seasonality of CH3Cl concentrations in middle and high latitudes, A strong, equatorially located source of this nature would explain why the distribution of CH3Cl is uniform between the Northern and Southern hemispheres, despite their differences in ocean and land area.	Natl Inst Environm Studies, Tsukuba, Ibaraki 3050053, Japan; Atmospher Environm Serv, Toronto, ON M3H 5T4, Canada; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan; Tohoku Univ, Ctr Atmospher & Ocean Studies, Aoba Ku, Sendai, Miyagi 9800845, Japan	National Institute for Environmental Studies - Japan; Environment & Climate Change Canada; Meteorological Service of Canada; University of Tokyo; Tohoku University	Yokouchi, Y (corresponding author), Natl Inst Environm Studies, 16-2 Onogawa, Tsukuba, Ibaraki 3050053, Japan.		陽子, 横内/E-8041-2010; Machida, Toshinobu/H-6526-2018; Nojiri, Yukihiro/D-1999-2010	Machida, Toshinobu/0000-0003-3312-8775; Nojiri, Yukihiro/0000-0001-9885-9195				ATLAS E, 1993, J GEOPHYS RES-ATMOS, V98, P16933, DOI 10.1029/93JD01005; ATTIEH JM, 1995, J BIOL CHEM, V270, P9250, DOI 10.1074/jbc.270.16.9250; Blake NJ, 1996, J GEOPHYS RES-ATMOS, V101, P24151, DOI 10.1029/96JD00561; CICERONE RJ, 1981, REV GEOPHYS, V19, P123, DOI 10.1029/RG019i001p00123; Fabian P., 1986, AIR POLLUTION, P23, DOI [10.1007/978-3-540-39222-4_2, DOI 10.1007/978-3-540-39222-4_2]; GRAEDEL TE, 1995, GLOBAL BIOGEOCHEM CY, V9, P47, DOI 10.1029/94GB03103; HARPER DB, 1985, NATURE, V315, P55, DOI 10.1038/315055a0; Khalil MAK, 1999, ATMOS ENVIRON, V33, P1305, DOI 10.1016/S1352-2310(98)00234-9; KOPPMANN R, 1993, J GEOPHYS RES-ATMOS, V98, P20517, DOI 10.1029/93JD01864; Li HJ, 1999, ATMOS ENVIRON, V33, P1881, DOI 10.1016/S1352-2310(98)00303-3; LOGAN JA, 1981, J GEOPHYS RES-OCEANS, V86, P7210, DOI 10.1029/JC086iC08p07210; Moore RM, 1996, J GEOPHYS RES-OCEANS, V101, P28529, DOI 10.1029/96JC02915; RASMUSSEN RA, 1980, J GEOPHYS RES-OCEANS, V85, P7350, DOI 10.1029/JC085iC12p07350; SAINI HS, 1995, PLANT CELL ENVIRON, V18, P1027, DOI 10.1111/j.1365-3040.1995.tb00613.x; SINGH HB, 1983, J GEOPHYS RES-OCEANS, V88, P3684, DOI 10.1029/JC088iC06p03684; Yokouchi Y, 1999, J GEOPHYS RES-ATMOS, V104, P8067, DOI 10.1029/1998JD100013; YOKOUCHI Y, 1981, J CHROMATOGR, V209, P293, DOI 10.1016/S0021-9673(00)81591-5; Zimmerman P. R., 1979, EPA450479004	18	114	119	2	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					295	298		10.1038/35002049	http://dx.doi.org/10.1038/35002049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659845				2022-12-01	WOS:000084899700048
J	Paunio, M; Heinonen, OP; Virtanen, M; Leinikki, P; Patja, A; Peltola, H				Paunio, M; Heinonen, OP; Virtanen, M; Leinikki, P; Patja, A; Peltola, H			Measles history and atopic diseases - A population-based cross-sectional study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VACCINATION PROGRAM; ASTHMA; INFECTIONS; CHILDHOOD; RUBELLA; FINLAND; MUMPS; CHILDREN; SIZE	Context Many recent cross-sectional studies have suggested that lack of early exposure to communicable diseases, including measles, in affluent countries may have increased rates of atopic disease. Objective To study the association between natural measles infection and atopy, Design and Setting Cross-sectional nationwide study in Finland using data gathered between November 1, 1982, and June 30, 1986. Subjects A total of 547 910 individuals aged 14 months to 19 years who at the time of measles-mumps-rubella (MMR) vaccination had relevant information collected on the occurrence of measles and allergic rhinitis, eczema, and asthma. Main Outcome Measures Lifetime occurrence of atopic manifestations in subjects who had had measles compared with those who had not, expressed as age-specific and age-adjusted prevalence ratios. Results The age-adjusted prevalence ratio of atopic manifestations among those who had had measles (n = 20 690) compared with those who had not (n = 527 220) was 1.32 (95% confidence interval [CI], 1.27-1.36) for eczema, 1.41 (95% CI, 1.33-1.49) for rhinitis, and 1.67 (95% CI, 1.54-1.79) for asthma. The positive association between measles and atopy was evident at all ages, in both urban and rural dwellers, and among subjects with many or few contacts at home or in day care. Conclusions Based on our data, measles and atopy occur more frequently together than expected, which does not support the hypothesis that experiencing natural measles infection offers protection against atopic disease.	Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Assoc Local & Reg Author, Dept Hosp Serv, Helsinki, Finland; Natl Publ Hlth Inst, Dept Infect Dis, Helsinki, Finland; Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, Helsinki, Finland	University of Helsinki; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital	Paunio, M (corresponding author), Minist Social Affairs & Hlth, POB 267, Helsinki 00171, Finland.							Allen JE, 1997, IMMUNOL TODAY, V18, P387, DOI 10.1016/S0167-5699(97)01102-X; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; Campbell DE, 1996, LANCET, V348, P825, DOI 10.1016/S0140-6736(05)65244-0; *CENTR STAT OFF FI, 1987, STAT YB FINL 1987; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; FOX JP, 1971, AM J EPIDEMIOL, V94, P179, DOI 10.1093/oxfordjournals.aje.a121310; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; Hayney M S, 1998, Int J Infect Dis, V2, P143, DOI 10.1016/S1201-9712(98)90116-3; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; LOUHIALA PJ, 1995, AM J PUBLIC HEALTH, V85, P1109, DOI 10.2105/AJPH.85.8_Pt_1.1109; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; PAUNIO M, 1991, AM J EPIDEMIOL, V133, P1152, DOI 10.1093/oxfordjournals.aje.a115827; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101; PELTOLA H, 1986, LANCET, V1, P137; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Soothill JF, 1996, LANCET, V348, P825, DOI 10.1016/S0140-6736(05)65245-2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692	22	131	136	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2000	283	3					343	346		10.1001/jama.283.3.343	http://dx.doi.org/10.1001/jama.283.3.343			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273WM	10647796	Bronze			2022-12-01	WOS:000084732400025
J	Tateno, M; Nishida, Y; Adachi-Yamada, T				Tateno, M; Nishida, Y; Adachi-Yamada, T			Regulation of JNK by Src during Drosophila development	SCIENCE			English	Article							N-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAY; CELL SHEET MOVEMENT; TYROSINE KINASE; C-SRC; DORSAL CLOSURE; MORPHOGENESIS; EXPRESSION; ACTIVATION; PP60C-SRC	In Drosophila, the Jun amino-terminal kinase (JNK) homolog Basket (Bsk) is required for epidermal closure. Mutants for Src42A, a Drosophila c-src protooncogene homolog, are described. Src42A functions in epidermal closure during both embryogenesis and metamorphosis. The severity of the epidermal closure defect in the Src42A mutant depended on the amount of Bsk activity, and the amount of Bsk activity depended. on the amount of Src42A. Thus, activation of the Bsk pathway is required downstream of Src42A in epidermal closure. This work confirms mammalian studies that demonstrated a physiological link between Src and JNK.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University	Adachi-Yamada, T (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	adachi@bio.nagoya-u.ac.jp						BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Dodson GS, 1998, DEVELOPMENT, V125, P2883; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Guarnieri DJ, 1998, MOL CELL, V1, P831, DOI 10.1016/S1097-2765(00)80082-9; Hauck CR, 1998, EMBO J, V17, P443, DOI 10.1093/emboj/17.2.443; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lu XY, 1999, DEV BIOL, V208, P233, DOI 10.1006/dbio.1999.9196; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; Roulier EM, 1998, MOL CELL, V1, P819, DOI 10.1016/S1097-2765(00)80081-7; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; TATENO M, UNPUB; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Zeitlinger J, 1999, DEVELOPMENT, V126, P3947	36	113	114	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					324	327		10.1126/science.287.5451.324	http://dx.doi.org/10.1126/science.287.5451.324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634792				2022-12-01	WOS:000084769600047
J	Nakagawa, T; Zhu, H; Morishima, N; Li, E; Xu, J; Yankner, BA; Yuan, JY				Nakagawa, T; Zhu, H; Morishima, N; Li, E; Xu, J; Yankner, BA; Yuan, JY			Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta	NATURE			English	Article							CELL-DEATH; ALZHEIMERS-DISEASE; PROTEASE; RECEPTOR; PROTEINS; COMPLEX; ICE	Apoptosis, or cellular suicide, is important for normal development and tissue homeostasis, but too much or too Little apoptosis can also cause disease(1,2). The family of cysteine proteases, the so-called caspases, are critical mediators of programmed cell death(3), and thus far 14 family members have been identified. Some of these, such as caspase-(8) (refs 4, 5), mediate signal transduction downstream of death receptors located on the plasma membrane. Others, such as caspase-9 (ref. 6), mediate apoptotic signals after mitochondrial damage. Stress in the endoplasmic reticulum (ER) can also result in apoptosis(7). Here we show that caspase-12 is localized to the ER and activated by ER stress, including disruption of ER calcium homeostasis and accumulation of excess proteins in ER, but not by membrane- or mitochondrial-targeted apoptotic signals. Mice that are deficient in caspase-12 are resistant to ER stress-induced apoptosis, but their cells undergo apoptosis in response to other death stimuli. Furthermore, we show that caspase-12-deficient cortical neurons are defective in apoptosis induced by amyloid-beta protein but not by staurosporine or trophic factor deprivation. Thus, caspase-12 mediates an ER-specific apoptosis pathway and may contribute to amyloid-beta neurotoxicity.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; RIKEN, Inst Phys & Chem Res, Biodesign Res Grp, Wako, Saitama 3510198, Japan; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02119 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; RIKEN; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	jyuan@hms.harvard.edu	Morishima, Nobuhiro/D-3946-2017	Xu, Jin/0000-0001-6617-5311; Zhu, Hong/0000-0002-2575-4031; Nakagawa, Toshiyuki/0000-0001-8415-4119				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Troy CM, 1996, J NEUROSCI, V16, P253; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Welihinda AA, 1999, GENE EXPRESSION, V7, P293; Yan SD, 1997, NATURE, V389, P689; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	17	2774	3009	10	364	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					98	103		10.1038/47513	http://dx.doi.org/10.1038/47513			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638761				2022-12-01	WOS:000084687400051
J	Bell, DW; Varley, JM; Szydlo, TE; Kang, DH; Wahrer, DCR; Shannon, KE; Lubratovich, M; Verselis, SJ; Isselbacher, KJ; Fraumeni, JF; Birch, JM; Li, FP; Garber, JE; Haber, DA				Bell, DW; Varley, JM; Szydlo, TE; Kang, DH; Wahrer, DCR; Shannon, KE; Lubratovich, M; Verselis, SJ; Isselbacher, KJ; Fraumeni, JF; Birch, JM; Li, FP; Garber, JE; Haber, DA			Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome	SCIENCE			English	Article							DNA-DAMAGE CHECKPOINT; FISSION YEAST; PROTEIN-KINASE; HUMAN CANCERS; CELL-CYCLE; S-PHASE; ANTICANCER AGENTS; MISMATCH REPAIR; P53 MUTATIONS; PATHWAY	The hCHK2 gene encodes the human homolog of the yeast Cds1 and Rad53 G(2) checkpoint kinases, whose activation in response to DNA damage prevents cellular entry into mitosis. Here, it is shown that heterozygous germ Line mutations in hCHK2 occur in Li-Fraumeni syndrome, a highly penetrant Familiar cancer phenotype usually associated with inherited mutations in the TP53 gene. These observations suggest that hCHK2 is a tumor suppressor gene conferring predisposition to sarcoma, breast cancer, and brain tumors, and they also provide a link between the central role of p53 inactivation in human cancer and the well-defined G(2) checkpoint in yeast.	Massachusetts Gen Hosp, Ctr Canc Risk Anal, Charlestown, MA 02139 USA; Harvard Univ, Sch Med, Charlestown, MA 02139 USA; Paterson Inst Canc Res, Canc Res Campaign, Dept Canc Genet, Manchester M20 4BX, Lancs, England; Harvard Univ, Sch Med, Boston, MA 02114 USA; Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02114 USA; NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; Royal Manchester Childrens Hosp, Canc Res Campaign, Paediat & Familial Canc Res Grp, Manchester M27 1HA, Lancs, England	Harvard University; Massachusetts General Hospital; Harvard University; Paterson Institute for Cancer Research; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Royal Manchester Children's Hospital	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc Risk Anal, Bldg 149, Charlestown, MA 02139 USA.	Haber@helix.mgh.harvard.edu						ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bertoni F, 1999, GENE CHROMOSOME CANC, V26, P176, DOI 10.1002/(SICI)1098-2264(199910)26:2<176::AID-GCC11>3.0.CO;2-3; BIRCH JM, 1994, CANCER RES, V54, P1298; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carr AM, 1996, SCIENCE, V271, P314, DOI 10.1126/science.271.5247.314; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Eng C, 1997, CANCER EPIDEM BIOMAR, V6, P379; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GARBER JE, 1991, CANCER RES, V51, P6094; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu WG, 1998, NUCLEIC ACIDS RES, V26, P1396, DOI 10.1093/nar/26.6.1396; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lynch HT, 1998, ONCOLOGY-BASEL, V55, P103, DOI 10.1159/000011843; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OConnor PM, 1997, CANCER RES, V57, P4285; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Prives C, 1999, J PATHOL, V187, P112; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; RUSSELL P, 1909, TRENDS BIOCHEM SCI, V23, P399; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; WEINERT TA, 1994, GENE DEV, V8, P261; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	55	693	711	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2528	2531		10.1126/science.286.5449.2528	http://dx.doi.org/10.1126/science.286.5449.2528			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617473				2022-12-01	WOS:000084429700056
J	Okamura, H; Miyake, S; Sumi, Y; Yamaguchi, S; Yasui, A; Muijtjens, M; Hoeijmakers, JHJ; van der Horst, GTJ				Okamura, H; Miyake, S; Sumi, Y; Yamaguchi, S; Yasui, A; Muijtjens, M; Hoeijmakers, JHJ; van der Horst, GTJ			Photic induction of mPer1 and mPer2 in Cry-deficient mice lacking a biological clock	SCIENCE			English	Article							BLUE-LIGHT PHOTORECEPTORS; HUMAN PHOTOLYASE HOMOLOG; DROSOPHILA PERIOD GENE; CIRCADIAN CLOCK; EXPRESSION; SIMILARITY; ORTHOLOG; MAMMALS; RHYTHMS; OPSIN	Mice Lacking mCry1 and mCry2 are behaviorally arrhythmic. As shown here, cyclic expression of the clock genes mPer1 and mPer2 (mammalian Period genes 1 and 2) in the suprachiasmatic nucleus and peripheral tissues is abolished and mPer1 and mPer2 mRNA Levels are constitutively high. These findings indicate that the biological clock is eliminated in the absence of both mCRY1 and mCRY2 (mammalian cryptochromes 1 and 2) and support the idea that mammalian CRY proteins act in the negative Limb of the circadian feedback Loop. The mCry double-mutant mice retain the ability to have mPer1 and mPer2 expression induced by a brief Light stimulus known to phase-shift the biological clock in wild-type animals. Thus, mCRY1 and mCRY2 are dispensable for Light-induced phase shifting of the biological clock.	Kobe Univ, Sch Med, Dept Anat & Brain Sci, Kobe, Hyogo 6500017, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Erasmus Univ, Dept Cell Biol & Genet, MGC, NL-3000 DR Rotterdam, Netherlands	Kobe University; Tohoku University; Erasmus University Rotterdam	Okamura, H (corresponding author), Kobe Univ, Sch Med, Dept Anat & Brain Sci, Kobe, Hyogo 6500017, Japan.	okamurah@kobe-u.ac.jp	van der Horst, Gijsbertus TJ/E-3661-2015; Jansen, Heiko T./A-5770-2008; Hoeijmakers, Jan/AAX-6972-2021	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Jansen, Heiko T./0000-0003-0178-396X; Okamura, Hitoshi/0000-0002-3013-4881				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; KURNE K, 1999, CELL, V98, P193; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Soni BG, 1997, FEBS LETT, V406, P279, DOI 10.1016/S0014-5793(97)00287-1; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takumi T, 1999, GENES CELLS, V4, P67, DOI 10.1046/j.1365-2443.1999.00238.x; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; vanderSpek PJ, 1996, GENOMICS, V37, P177, DOI 10.1006/geno.1996.0539; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Whitmore D, 1998, CURR OPIN NEUROBIOL, V8, P635, DOI 10.1016/S0959-4388(98)80092-5; Wilsbacher LD, 1998, CURR OPIN GENET DEV, V8, P595, DOI 10.1016/S0959-437X(98)80017-8; YAMAGUCHI S, UNPUB; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	35	307	319	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2531	2534		10.1126/science.286.5449.2531	http://dx.doi.org/10.1126/science.286.5449.2531			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617474				2022-12-01	WOS:000084429700057
J	Lipscomb, GH; McCord, ML; Stovall, TG; Huff, G; Portera, SG; Ling, FW				Lipscomb, GH; McCord, ML; Stovall, TG; Huff, G; Portera, SG; Ling, FW			Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINGLE-DOSE METHOTREXATE; CULDOCENTESIS; DIAGNOSIS	Background: The use of methotrexate for the treatment of women with tubal ectopic pregnancies is now common practice. However, the clinical and hormonal determinants of the success of this treatment are not known. Methods: We studied 350 women with tubal ectopic pregnancies who were treated with methotrexate intramuscularly according to a single-dose protocol. Pretreatment serum concentrations of human chorionic gonadotropin and progesterone, the size and volume of the gestational mass, fetal cardiac activity, and the presence of fluid (presumably blood) in the peritoneal cavity were correlated with the efficacy of therapy, as defined by resolution of the ectopic pregnancy without the need for surgical intervention. Results: There was no relation between the women's age or parity, the size or volume of the conceptus, or the presence of fluid in the peritoneal cavity and the efficacy of treatment. Among the 320 women in whom treatment was successful (91 percent), the mean (+/-SD) serum chorionic gonadotropin and progesterone concentrations were 4019+/-6362 mIU per milliliter and 6.9+/-6.7 ng per milliliter (21.9+/-21.3 nmol per liter), respectively, as compared with 13,420+/-16,590 mIU per milliliter and 10.2+/-5.5 ng per milliliter (32.4+/-17.5 nmol per liter) (P<0.001 and P=0.02) in the 30 women in whom treatment was not successful. Fetal cardiac activity was present in 12 percent of the successfully treated cases and 30 percent of those in which treatment was not successful (P=0.01). Regression analysis revealed the pretreatment serum chorionic gonadotropin concentration to be the only factor that contributed to the failure rate. Conclusions: Among women with tubal ectopic pregnancies, a high serum chorionic gonadotropin concentration is the most important factor associated with failure of treatment with a single-dose methotrexate protocol. (N Engl J Med 1999;341:1974-8.) (C)1999, Massachusetts Medical Society.	Univ Tennessee, Div Gynecol, Dept Obstet & Gynecol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Lipscomb, GH (corresponding author), Rm E102,853 Jefferson Ave, Memphis, TN 38103 USA.							CARTWRIGHT PS, 1984, J REPROD MED, V29, P88; CORSAN GH, 1995, HUM REPROD, V10, P2719, DOI 10.1093/oxfordjournals.humrep.a135774; FERNANDEZ H, 1995, FERTIL STERIL, V63, P25, DOI 10.1016/S0015-0282(16)57291-4; GLOCK JL, 1994, FERTIL STERIL, V62, P716; Kooi S, 1992, Obstet Gynecol Surv, V47, P739, DOI 10.1097/00006254-199211000-00001; Lipscomb GH, 1998, AM J OBSTET GYNECOL, V178, P1354, DOI 10.1016/S0002-9378(98)70343-6; RANSOM MX, 1994, OBSTET GYNECOL, V83, P1033, DOI 10.1097/00006250-199406000-00026; ROMERO R, 1985, OBSTET GYNECOL, V65, P519; SHALEV E, 1995, FERTIL STERIL, V63, P20, DOI 10.1016/S0015-0282(16)57290-2; Stika CS, 1996, AM J OBSTET GYNECOL, V174, P1840, DOI 10.1016/S0002-9378(96)70219-3; STORRING PL, 1980, J ENDOCRINOL, V84, P295, DOI 10.1677/joe.0.0840295; STOVALL TG, 1991, OBSTET GYNECOL, V77, P754; STOVALL TG, 1990, FERTIL STERIL, V54, P537; VERMESH M, 1990, AM J OBSTET GYNECOL, V162, P411, DOI 10.1016/0002-9378(90)90397-P	14	216	230	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1974	1978		10.1056/NEJM199912233412604	http://dx.doi.org/10.1056/NEJM199912233412604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607814				2022-12-01	WOS:000084399400004
J	Aithal, GP; Rawlins, MD; Day, CP				Aithal, GP; Rawlins, MD; Day, CP			Accuracy of hepatic adverse drug reaction reporting in one English health region	BRITISH MEDICAL JOURNAL			English	Article									Univ Newcastle Upon Tyne, Sch Med, Liver Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Pharmacol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Day, CP (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Liver Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Day, Christopher/Z-3305-2019	Aithal, Guruprasad/0000-0003-3924-4830				Aithal PG, 1999, GUT, V44, P731, DOI 10.1136/gut.44.5.731; BENICHOU C, 1990, J HEPATOL, V11, P272; DANAN G, 1988, J HEPATOL, V7, P132, DOI 10.1016/S0168-8278(88)80517-8; Maria VAJ, 1997, HEPATOLOGY, V26, P664, DOI 10.1053/jhep.1997.v26.pm0009303497; RAWLINS MD, 1995, J ROY COLL PHYS LOND, V29, P41	5	94	102	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1999	319	7224					1541	1541		10.1136/bmj.319.7224.1541	http://dx.doi.org/10.1136/bmj.319.7224.1541			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	265LK	10591713	Green Published, Bronze			2022-12-01	WOS:000084245600024
J	Hadfield, SJ; Axton, JM				Hadfield, SJ; Axton, JM			Reproduction - Germ cells colonized by endosymbiotic bacteria	NATURE			English	Article							DROSOPHILA; PLASM		Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Hadfield, SJ (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.		Axton, Myles/AAZ-4093-2020	Axton, Myles/0000-0002-8042-4131				BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; BREEUWER JAJ, 1993, GENETICS, V135, P565; CALLAINI G, 1994, J CELL SCI, V107, P673; GLOVER DM, 1990, NATURE, V348, P117, DOI 10.1038/348117a0; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; HOLDEN PR, 1993, MOL GEN GENET, V240, P213, DOI 10.1007/BF00277059; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; JONGENS TA, 1992, CELL, V70, P569, DOI 10.1016/0092-8674(92)90427-E; Pereira AJ, 1997, J CELL BIOL, V136, P1081, DOI 10.1083/jcb.136.5.1081; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; Werren JH, 1997, ANNU REV ENTOMOL, V42, P587, DOI 10.1146/annurev.ento.42.1.587	11	39	39	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					482	482		10.1038/45002	http://dx.doi.org/10.1038/45002			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591206				2022-12-01	WOS:000084013200043
J	He, JA; Ogden, LG; Vupputuri, S; Bazzano, LA; Loria, C; Whelton, PK				He, JA; Ogden, LG; Vupputuri, S; Bazzano, LA; Loria, C; Whelton, PK			Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NUTRITION EXAMINATION SURVEY; LOWER BLOOD-PRESSURE; NATIONAL-HEALTH; OBSERVATIONAL DATA; SALT INTAKE; WEIGHT-LOSS; MORTALITY; STROKE; HYPERTENSION; POTASSIUM	Context Dietary sodium is positively associated with blood pressure, and ecological and animal studies both have suggested that high dietary sodium intake increases stroke mortality. Objective To examine the risk of cardiovascular disease associated with dietary sodium intake in overweight and nonoverweight persons. Design Prospective cohort study. Setting The first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, conducted in 1982-1984, 1986, 1987, and 1992. Participants Of those aged 25 to 74 years when the survey was conducted in 1971-1975 (14 407 participants), a total of 2688 overweight and 6797 nonoverweight persons were included in the analysis. Main outcome Measures Dietary sodium and energy intake were estimated at baseline using a single 24-hour dietary recall method. Incidence and mortality data for cardiovascular disease were obtained from medical records and death certificates. Results For overweight and nonoverweight persons, over an average of 19 years of follow-up, the total number of documented cases were as follows: 680 stroke events (210 fatal), 1727 coronary heart disease events (614 fatal), 895 cardiovascular disease deaths, and 2486 deaths from all causes. Among overweight persons with an average energy intake of 7452 kJ, a 100 mmol higher sodium intake was associated with a 32% increase (relative risk [RR], 1.32; 95% confidence interval [CI], 1.07-1.64; P = .01) in stroke incidence, 89% increase (RR, 1.89; 95% CI, 1.31-2.74; P<.001) in stroke mortality, 44% increase (RR, 1.44; 95% CI, 1.14-1.81; P = .002) in coronary heart disease mortality, 61% increase (RR, 1.61; 95% CI, 1.32-1.96; P<.001) in cardiovascular disease mortality, and 39% increase (RR, 1.39; 95% CI, 1.23-1.58; P<.001) in mortality from all causes. Dietary sodium intake was not significantly associated with cardiovascular disease risk in nonoverweight persons. Conclusions Our analysis indicates that high sodium intake is strongly and independently associated with an increased risk of cardiovascular disease and all-cause mortality in overweight persons.	Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat, New Orleans, LA 70112 USA; Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Tulane University; Tulane University; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	He, JA (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1430 Tulane Ave SL 18, New Orleans, LA 70112 USA.	jhe@mailhost.tcs.tulane.edu			NHLBI NIH HHS [R03 HL61954, R01 HL60300] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060300, R03HL061954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; Alderman MH, 1998, LANCET, V351, P781, DOI 10.1016/S0140-6736(97)09092-2; ALTSCHUL AM, 1981, INT J OBESITY, V5, P27; *AM HEART ASS, 1998, 1998 HEART STROK STA; [Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.157.21.2413; Black HR, 1998, ARCH INTERN MED, V158, P573; Briefel RR, 1997, AM J CLIN NUTR, V65, P1203; Chen J, 1997, EXP MOL PATHOL, V64, P173, DOI 10.1006/exmp.1997.2218; COHEN JS, 1987, TRADITION, V22, P1; COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701; COOK NR, 1995, HYPERTENSION, V25, P1153, DOI 10.1161/01.HYP.25.6.1153; Cox C S, 1997, Vital Health Stat 1, P1; COX CS, 1992, VITAL HLTH STAT, V27, P1; COX DR, 1972, J R STAT SOC B, V34, P187; COYLE P, 1988, HYPERTENSION, V12, P96, DOI 10.1161/01.HYP.12.2.96; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; Elliot P, 1997, BMJ-BRIT MED J, V315, P458; Elliott P, 1996, BMJ-BRIT MED J, V312, P1249, DOI 10.1136/bmj.312.7041.1249; Engel A, 1978, Vital Health Stat 1, P1; Finucane F, 1990, VITAL HLTH STAT 1, V25, P1; FREGLY MJ, 1983, ANN INTERN MED, V98, P792, DOI 10.7326/0003-4819-98-5-792; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; Hall JE, 1997, AM J HYPERTENS, V10, pS49, DOI 10.1016/S0895-7061(97)00075-7; HE J, 1994, CIRCULATION, V90, P503; He J, 1997, CURR OPIN CARDIOL, V12, P202, DOI 10.1097/00001573-199703000-00018; IKEDA M, 1986, PREV MED, V15, P46, DOI 10.1016/0091-7435(86)90035-6; KAGAN A, 1985, STROKE, V16, P390, DOI 10.1161/01.STR.16.3.390; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KLESGES RC, 1995, J CONSULT CLIN PSYCH, V63, P438; Korn EL, 1997, AM J EPIDEMIOL, V145, P72; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LIU K, 1979, AM J EPIDEMIOL, V110, P219, DOI 10.1093/oxfordjournals.aje.a112806; Luft FC, 1997, AM J CLIN NUTR, V65, P612; MACGREGOR GA, 1997, CAN J CARDIOL SB, V13, pB272; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MADANS JH, 1995, STAT MED, V14, P643, DOI 10.1002/sim.4780140521; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MILLER HW, 1973, VITAL HLTH STAT 1 A, V10, P1; Najjar M F, 1987, Vital Health Stat 11, P1; PERRY IJ, 1992, J HUM HYPERTENS, V6, P23; ROCCHINI AP, 1989, NEW ENGL J MED, V321, P580, DOI 10.1056/NEJM198908313210905; SASAKI S, 1995, STROKE, V26, P783, DOI 10.1161/01.STR.26.5.783; TARONE RE, 1975, BIOMETRIKA, V62, P679; TOBIAN L, 1990, HYPERTENSION, V15, P900, DOI 10.1161/01.HYP.15.6.900; *TRIALS HYP PREV C, 1992, JAMA-J AM MED ASSOC, V267, P2330; UMES WP, 1987, LANCET, V1, P426; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; *WHO, 1996, WORLD HLTH STAT ANN; YANG J, 1997, CAN J CARDIOL, V13, P448; [No title captured]	54	342	348	0	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2027	2034		10.1001/jama.282.21.2027	http://dx.doi.org/10.1001/jama.282.21.2027			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591385	Bronze			2022-12-01	WOS:000083908700022
J	Reddy, MM; Light, MJ; Quinton, PM				Reddy, MM; Light, MJ; Quinton, PM			Activation of the epithelial Na+ channel (ENaC) requires CFTR Cl- channel function	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS; PROTEIN-KINASE; TRANSPORT; CULTURES; BINDING; GLANDS; CELLS	It is increasingly being recognized that cells coordinate the activity Of separate ion channels that allow electrolytes into the cell. However, a perplexing problem in channel regulation has arisen in the fatal genetic disease cystic fibrosis, which results fi om the loss of a specific Cl- channel (the CFTR channel) in epithelial cell membranes(1). Although this defect clearly inhibits the absorption of Na+ in sweat gands(2,3), it is widely accepted that Na+ absorption is abnormally elevated in defective airways in cystic fibrosis(4,5). The only frequently cited explanation for this hypertransport is that the activity of an epithelial Na+ channel (ENaC) is inversely related to the activity of the CFTR Cl- channel(5-7). However we report here that, in freshly isolated normal sweat ducts, ENaC activity is dependent on, and increases with, CFTR activity. Surprisingly, we also find that the primary defect in Cl- permeability in cystic fibrosis(8) is accompanied secondarily by a Na+ conductance in this tissue that cannot: be activated. Thus, reduced salt absorption in cystic fibrosis is due not only to poor Cl- conductance but also to poor Na+ conductance.	Univ Calif San Diego, Sch Med, Dept Pediat 0831, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Quinton, PM (corresponding author), Univ Calif San Diego, Sch Med, Dept Pediat 0831, La Jolla, CA 92093 USA.							BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; Ecke D, 1996, PFLUG ARCH EUR J PHY, V431, P984, DOI 10.1007/s004240050095; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; GREGER R, 1983, PFLUG ARCH EUR J PHY, V396, P325, DOI 10.1007/BF01063938; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; Jiang C, 1997, J PHYSIOL-LONDON, V501, P637, DOI 10.1111/j.1469-7793.1997.637bm.x; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; LETZ, 1997, AM J PHYSL, V272, pC657; PANAH MR, 1998, AM J PHYSIOL-CELL PH, V274, pC310; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; Quinton Paul M., 1999, Physiological Reviews, V79, pS3; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; QUINTON PM, 1986, AM J PHYSIOL, V251, pC649, DOI 10.1152/ajpcell.1986.251.4.C649; REDDY MM, 1994, J MEMBRANE BIOL, V140, P57; REDDY MM, 1998, PED PULMONOL S, V14, pR46; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; Schwiebert Erik M., 1999, Physiological Reviews, V79, pS145; Sheppard David N., 1999, Physiological Reviews, V79, pS23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; VERREY F, 1994, J MEMBRANE BIOL, V138, P65; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143	28	178	182	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					301	304		10.1038/46297	http://dx.doi.org/10.1038/46297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580502				2022-12-01	WOS:000083813700052
J	Botvinick, M; Nystrom, LE; Fissell, K; Carter, CS; Cohen, JD				Botvinick, M; Nystrom, LE; Fissell, K; Carter, CS; Cohen, JD			Conflict monitoring versus selection-for-action in anterior cingulate cortex	NATURE			English	Article							HUMAN-BRAIN; ACTIVATION; SYSTEM; PET	The anterior cingulate cortex (ACC), on the medial surface of the frontal lobes of the brain, is widely believed to be involved in the regulation of attention(1,2), Beyond this, however, its specific contribution to cognition remains uncertain, One influential theory has interpreted activation within the ACC as reflecting 'selection-for-action'(3-5), a set of processes that guide the selection of environmental objects as triggers of or targets for action. We have proposed an alternative hypothesis, in which the ACC serves not to exert top-down attentional control but instead to detect and signal the occurrence of conflicts in information processing(6-8). Here, to test this theory against the selection-for-action theory, we used functional magnetic resonance imaging to measure brain activation during performance of a task where, for a particular subset of trials, the strength of selection-for action is inversely related to the degree of response conflict. Activity within the ACC was greater during trials featuring high levels of conflict (and weak selection-for-action) than during trials with low levels of conflict (and strong selection-for-action), providing evidence in favour of the conflict-monitoring account of ACC function.	Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA; Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA; Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA	Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Princeton University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Botvinick, M (corresponding author), Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA.		Kennedy, Kristen M/B-4699-2008	Kennedy, Kristen M/0000-0001-5373-9026				Berns GS, 1997, SCIENCE, V276, P1272, DOI 10.1126/science.276.5316.1272; Botvinick M. M., 1998, 981 CTR NEUR BAS COG; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; CARTER CS, UNPUB P NATL ACAD SC; Casey BJ, 1998, J COGNITIVE NEUROSCI, V10, P108; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; COHEN JD, 1992, AM J PSYCHOL, V105, P239, DOI 10.2307/1423029; COLES MGH, 1985, J EXP PSYCHOL HUMAN, V11, P529, DOI 10.1037/0096-1523.11.5.529; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GRATTON G, 1992, J EXP PSYCHOL GEN, V121, P480, DOI 10.1037/0096-3445.121.4.480; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; NOLL DC, 1995, JMRI-J MAGN RESON IM, V5, P49, DOI 10.1002/jmri.1880050112; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; Posner MI, 1998, ATTENTIVE BRAIN, P401; Sanders Andries, 1987, PERSPECTIVES PERCEPT, P395; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	20	1558	1603	2	116	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					179	181		10.1038/46035	http://dx.doi.org/10.1038/46035			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	256FZ	10647008				2022-12-01	WOS:000083716400049
J	Nuorti, JP; Butler, JC; Gelling, L; Kool, JL; Reingold, AL; Vugia, DJ				Nuorti, JP; Butler, JC; Gelling, L; Kool, JL; Reingold, AL; Vugia, DJ			Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 07-16, 1997	SAN FRANCISCO, CA	Infect Dis Soc Amer			HUMAN-IMMUNODEFICIENCY-VIRUS; STREPTOCOCCUS-PNEUMONIAE; BACTERIAL PNEUMONIA; ANTIBODY-RESPONSES; UNITED-STATES; BACTEREMIA; INFECTION; VACCINE; POPULATION; INFLUENZA	Background: Patients with AIDS have a high incidence of invasive pneumococcal disease, but no population-based data are available on secular trends or rates of this disease in specific demographic groups. Objective: To compare clinical characteristics, rates, and trends of pneumococcal disease in HIV-infected and non-HIV-infected persons. Design: Population-based laboratory surveillance and chart review. Setting: All of the 13 microbiology laboratories in San Francisco County, California. Patients: Persons who had a sterile site culture that was positive for Streptococcus pneumoniae between October 1994 and June 1997. Measurements: Stratified incidence rates and adjusted rate ratios, serotyping of isolates, and comparison of secular trends and rates according to census tract by Poisson regression. Results: Persons infected with HIV accounted for 54.2% of 399 patients 18 to 64 years of age who had pneumococcal disease. The incidence of pneumococcal disease per 100 000 person-years was 35.0 cases overall and 802.9 cases in patients with AIDS. Compared with persons who were not known to be HIV-infected, the rate ratio for patients with AIDS was 46.0 (95% CI, 36.0 to 58.9); 55.2% of cases were attributable to HIV. In HIV-infected patients, 82.5% of isolates were serotypes that are included in the pneumococcal polysaccharide vaccine. The incidence of pneumococcal disease in black patients with AIDS (2384.6 cases per 100 000 person-years) was 5.4 times that in nonblack patients with AIDS. Rates by census tract were inversely associated with income (P < 0.001). During the study period, the incidence of pneumococcal disease decreased from 10.6 cases per 1000 person-years to 4.2 cases per 1000 person-years in patients with AIDS (P = 0.004, Poisson regression). Conclusions: In a community with a high prevalence of HIV infection, much of the burden of pneumococcal disease was attributable to AIDS. High incidence rates were seen in young adults and especially in black persons. Efforts to increase pneumococcal vaccination rates should target HIV-infected adults, particularly those living in poor urban areas.	Calif Dept Hlth Serv, Calif Emerging Infect Program, Berkeley, CA USA; Univ Calif Berkeley, Berkeley, CA 94720 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA	California Department of Health Care Services; California Emerging Infections Program; University of California System; University of California Berkeley; Centers for Disease Control & Prevention - USA	Nuorti, JP (corresponding author), Natl Publ Hlth Inst, Dept Infect Dis Epidemiol, Mannerheimintie 166, FIN-00300 Helsinki, Finland.	pekka.nuorti@ktl.fi		Kool, Jacob/0000-0002-9605-2918				[Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BENNETT NM, 1992, AM J PUBLIC HEALTH, V82, P1513, DOI 10.2105/AJPH.82.11.1513; Bloch KC, 1998, ANN INTERN MED, V129, P698, DOI 10.7326/0003-4819-129-9-199811010-00004; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; Chan CY, 1996, J INFECT DIS, V173, P256, DOI 10.1093/infdis/173.1.256; Chen FM, 1998, AM J EPIDEMIOL, V148, P1212, DOI 10.1093/oxfordjournals.aje.a009611; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; Frankel RE, 1996, CLIN INFECT DIS, V23, P577, DOI 10.1093/clinids/23.3.577; GARCIALEONI ME, 1992, ARCH INTERN MED, V152, P1808, DOI 10.1001/archinte.152.9.1808; Gebo KA, 1996, J INFECT DIS, V173, P857, DOI 10.1093/infdis/173.4.857; Gilks CF, 1996, LANCET, V347, P718, DOI 10.1016/S0140-6736(96)90076-8; GLASER JB, 1991, J INFECT DIS, V164, P761, DOI 10.1093/infdis/164.4.761; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; HUANG KL, 1987, JAMA-J AM MED ASSOC, V257, P2047, DOI 10.1001/jama.257.15.2047; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; JANOFF EN, 1993, J INFECT DIS, V167, P49, DOI 10.1093/infdis/167.1.49; KELLER DW, 1995, CLIN INFECT DIS, V21, pS77, DOI 10.1093/clinids/21.Supplement_1.S77; KLEINBAUM DG, 1998, APPL REGRESSION ANAL, P687; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; RODRIGUEZBARRADAS MC, 1992, J INFECT DIS, V165, P553, DOI 10.1093/infdis/165.3.553; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P267; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SCHUCHAT A, 1991, JAMA-J AM MED ASSOC, V265, P3275, DOI 10.1001/jama.265.24.3275; Schwarcz SK, 1999, AIDS, V13, P1109, DOI 10.1097/00002030-199906180-00015; Shapiro MF, 1999, JAMA-J AM MED ASSOC, V281, P2305, DOI 10.1001/jama.281.24.2305; Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623; WORTLEY PM, 1994, AIDS, V8, P941, DOI 10.1097/00002030-199407000-00010; 1997, MMWR MORB MORTAL WKL, V46, P861; 1997, MMWR MORB WKLY REP, V46, P1; 1997, DIVISION HIV AIDS, V9, P6	34	156	158	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	2000	132	3					182	190		10.7326/0003-4819-132-3-200002010-00003	http://dx.doi.org/10.7326/0003-4819-132-3-200002010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	276XE	10651598				2022-12-01	WOS:000084903000002
J	Graham, SM; Mtitimila, EI; Kamanga, HS; Walsh, AL; Hart, CA; Molyneux, ME				Graham, SM; Mtitimila, EI; Kamanga, HS; Walsh, AL; Hart, CA; Molyneux, ME			Clinical presentation and outcome of Pneumocystis carinii pneumonia in Malawian children	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RESPIRATORY-TRACT INFECTION; AFRICAN CHILDREN; INDUCED SPUTUM; HIV; DIAGNOSIS; ZIMBABWE; THERAPY; DISEASE; VIRUS	Background Necropsy studies from Africa have shown that Pneumocystis carinii pneumonia (PCP) is common in infants with HIV infection. We aimed to describe the rate, clinical presentation, and outcome of PCP in young Malawian children with acute severe pneumonia. Methods Children aged between 2 months and 5 years who were in hospital with a diagnosis of severe pneumonia were admitted to a study ward for clinical monitoring. We carried out blood culture, immunofluorescence on nasopharyngeal aspirate samples to test for PCP, polymerase chain reaction to detect HIV, and chest radiography. Findings 16 cases of PCP were identified among 150 children With radiologically confirmed severe pneumonia. All were HIV-positive and younger than 6 months. 21 children had bacterial pneumonia (including one who was also PCP positive) and 114 were not confirmed. The most common bacterial pathogens among children without PCP were Streptococcus pneumoniae (eight) and non-typhoidal salmonellae (seven). On admission, children with confirmed PCP had a lower mean age, body temperature, and oxygen saturation than children with bacterial pneumonia and were less likely to have a focal abnormality on auscultation. Oxygen requirements were much greater in children with PCP than those with bacterial pneumonias (96 of 105 hospital days vs 15 of 94, p<0.0001). Ten of 16 children with PCP and six of 21 with bacterial pneumonia died (relative risk 2.19 [95%. CI 1.0-4.7]). The overall case-fatality rate of severe pneumonia was 22%, In addition to a strong association with PCP, a fatal outcome was significantly and independently associated with HIV infection (2.98 [1.1-7.9]) and with age under 6 months (2.76 [1.0-5.2]). Interpretation PCP is common and contributes to the high mortality from pneumonia in Malawian infants, Clinical features are helpful in diagnosis. The study highlights the impact of HIV infection and difficult issues of management in countries with few resources.	Univ Liverpool, Dept Med Microbiol, Liverpool L69 3GA, Merseyside, England; Univ Malawi, Coll Med, Dept Paediat, Blantyre, Malawi; Univ Malawi, Coll Med, Wellcome Trust Res Labs, Blantyre, Malawi; Sch Trop Med, Liverpool, Merseyside, England	University of Liverpool; University of Malawi; University of Malawi; Liverpool School of Tropical Medicine	Graham, SM (corresponding author), Univ Liverpool, Dept Med Microbiol, 8th Floor,Duncan Bldg, Liverpool L69 3GA, Merseyside, England.	smgraham@liverpool.ac.uk		Graham, Stephen/0000-0003-3525-2294				AMUNDSON DE, 1989, SOUTHERN MED J, V82, P711, DOI 10.1097/00007611-198906000-00009; BLASER J, 1993, INFECTION, V21, P206, DOI 10.1007/BF01728888; BYE MR, 1987, PEDIATR PULM, V3, P425, DOI 10.1002/ppul.1950030609; *CDC, 1993, HIV AIDS SURV REP, P16; CHAUDHARY S, 1977, AM J DIS CHILD, V131, P902, DOI 10.1001/archpedi.1977.02120210080017; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; English M, 1996, T ROY SOC TROP MED H, V90, P658, DOI 10.1016/S0035-9203(96)90423-X; GIBB DM, 1994, ARCH DIS CHILD, V70, P241, DOI 10.1136/adc.70.3.241; HAGUE RA, 1990, ARCH DIS CHILD, V65, P1364, DOI 10.1136/adc.65.12.1364; Harries AD, 1997, INT J TUBERC LUNG D, V1, P346; Ikeogu MO, 1997, ARCH DIS CHILD, V76, P124, DOI 10.1136/adc.76.2.124; Jeena PM, 1997, ANN TROP PAEDIATR, V76, P124; Kamiya Y, 1997, ANN TROP PAEDIATR, V17, P121, DOI 10.1080/02724936.1997.11747874; Lepage P, 1998, PEDIATR INFECT DIS J, V17, P581, DOI 10.1097/00006454-199807000-00002; LIPSCHIK GY, 1992, LANCET, V340, P203, DOI 10.1016/0140-6736(92)90469-J; Lucas SB, 1996, BRIT MED J, V312, P335, DOI 10.1136/bmj.312.7027.335; MALIN AS, 1995, LANCET, V346, P1258, DOI 10.1016/S0140-6736(95)91862-0; MASUR H, 1990, NEW ENGL J MED, V323, P1500, DOI 10.1056/NEJM199011223232131; MCLAUGHLIN GE, 1995, J PEDIATR-US, V126, P821, DOI 10.1016/S0022-3476(95)70421-3; MIMICA I, 1971, AM J DIS CHILD, V122, P278, DOI 10.1001/archpedi.1971.02110040062002; MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506; *NAT COMM CLIN LAB, 1993, PERF STAND ANT SUSC; NATHOO KJ, 1993, ANN TROP PAEDIATR, V13, P253, DOI 10.1080/02724936.1993.11747655; OGNIBENE FP, 1989, J PEDIATR-US, V115, P430, DOI 10.1016/S0022-3476(89)80848-0; REDD SC, 1992, LANCET, V340, P1140, DOI 10.1016/0140-6736(92)93160-O; ROGERS MF, 1987, PEDIATRICS, V79, P1008; SHANN F, 1988, LANCET, V2, P1238; Shann F, 1995, CLIN INFECT DIS, V21, pS218, DOI 10.1093/clind/21.Supplement_3.S218; Shata AMA, 1996, ARCH DIS CHILD, V74, P535, DOI 10.1136/adc.74.6.535; SLEASMAN JW, 1993, AM J DIS CHILD, V147, P29, DOI 10.1001/archpedi.1993.02160250032012; Smyth A, 1997, ARCH DIS CHILD, V77, P227, DOI 10.1136/adc.77.3.227; STAGNO S, 1981, PEDIATRICS, V68, P322; VanDyke R.B., 1995, SEMIN PEDIAT INFECT, V6, P10, DOI 10.1016/S1045-1870(05)80018-4; Vetter KM, 1996, PEDIATR INFECT DIS J, V15, P438, DOI 10.1097/00006454-199605000-00011; WAKEFIELD AE, 1990, T ROY SOC TROP MED H, V84, P800, DOI 10.1016/0035-9203(90)90087-U; *WHO, 1993, WHOARI9328; *WHO PROGR CONTR A, 1994, WHOARI905 PROGR CONT	37	116	117	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	2000	355	9201					369	373		10.1016/S0140-6736(98)11074-7	http://dx.doi.org/10.1016/S0140-6736(98)11074-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665557				2022-12-01	WOS:000085122100013
J	Thisse, B; Wright, CVE; Thisse, C				Thisse, B; Wright, CVE; Thisse, C			Activin- and Nodal-related factors control antero-posterior patterning of the zebrafish embryo	NATURE			English	Article							NERVOUS-SYSTEM; FATE MAP; XENOPUS; EXPRESSION; SIGNALS; GENE; INDUCTION; SPECIFICATION; NOTOCHORD; MESODERM	Definition of cell fates along the dorso-ventral axis depends on an antagonistic relationship between ventralizing transforming growth factor-beta superfamily members, the bone morphogenetic proteins' and factors secreted from the dorsal organizer, such as Noggin and Chordin. The extracellular binding of the last group to the bone morphogenetic proteins prevents them from activating their receptors(2-4), and the relative ventralizer:antagonist ratio is thought to specify different dorso-ventral cell fates. Here, by taking advantage of a non-genetic interference method using a specific competitive inhibitor, the Lefty-related gene product Antivin(5), we provide evidence that cell fate along the anteroposterior axis of the zebrafish embryo is controlled by the morphogenetic activity of another transforming growth factor-beta superfamily subgroup-the Activin and Nodal-related faaors(6-9). Increasing antivin doses progressively deleted posterior fates within the ectoderm, eventually resulting in the removal of all fates except forebrain and eyes. In contrast, overexpression of activin or nodal-related factors converted ectoderm that was fated to be forebrain into more posterior ectodermal or mesendodermal fates, We propose that modulation of intercellular signalling by Antivin/Activin and Nodal-related factors provides a mechanism for the graded establishment of cell fates along the antero-posterior axis of the zebrafish embryo.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vanderbilt University	Thisse, C (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, France.			THISSE, Christine/0000-0002-8684-1681				ALTABA ARI, 1990, DEVELOPMENT, V108, P595; CHENG A, IN PRESS DEVELOPMENT; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GRISTMAN K, 1999, CELL, V97, P121; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Melby AE, 1996, DEVELOPMENT, V122, P2225; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Prince VE, 1998, DEV GENES EVOL, V208, P517, DOI 10.1007/s004270050210; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Reifers F, 1998, DEVELOPMENT, V125, P2381; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SPERMANN H, 1938, EMBRYONIC DEV INDUCT; THISSE C, 1994, DEV BIOL, V164, P420, DOI 10.1006/dbio.1994.1212; Thisse C, 1999, DEVELOPMENT, V126, P229; THISSE C, 1993, DEVELOPMENT, V119, P1203; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WOO K, 1995, DEVELOPMENT, V121, P2595; Woo K, 1997, SCIENCE, V277, P254, DOI 10.1126/science.277.5323.254; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	26	167	169	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					425	428		10.1038/35000200	http://dx.doi.org/10.1038/35000200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667793				2022-12-01	WOS:000085121100049
J	Galy, V; Olivo-Marin, JC; Scherthan, H; Doye, V; Rascalou, N; Nehrbass, U				Galy, V; Olivo-Marin, JC; Scherthan, H; Doye, V; Rascalou, N; Nehrbass, U			Nuclear pore complexes in the organization of silent telomeric chromatin	NATURE			English	Article							DOUBLE-STRAND BREAKS; END-JOINING REPAIR; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; YEAST KU; PROTEINS; LENGTH; GENE; MAINTENANCE; REPRESSION	The functional regulation of chromatin is closely related to its spatial organization within the nucleus. In yeast, perinuclear chromatin domains constitute areas of transcriptional repression(1-3). These 'silent' domains are defined by the presence of perinuclear telomere clusters(4). The only protein found to be involved in the peripheral localization of telomeres is Yku70/Yku80 (ref. 5). This conserved heterodimer(6) can bind telomeres(7) and functions in both repair of DNA double-strand breaks(8-11) and telomere maintenance(7,12-15) These findings, however, do not address the underlying structural basis of perinuclear silent domains. Here we show that nuclear-pore-complex extensions formed by the conserved TpR(16,17) homologues Mlp1 and Mlp2(18,19) are responsible for the structural and functional organization of perinuclear chromatin. Loss of MLP2 results in a severe deficiency in the repair of double-strand breaks. Furthermore, double deletion of MLP1 and MLP2 disrupts the clustering of perinuclear telomeres and releases telomeric gene repression. These effects are probably mediated through the interaction with Yku70. Mlp2 physically tethers Yku70 to the nuclear periphery, thus forming a link between chramatin and the nuclear envelope. We show, moreover, that this structural link is docked to nuclear-pore complexes through a cleavable nucleoporin, Nup145(20). We propose that, through these interactions, nuclear-pore complexes organize a nuclear subdomain that is intimately involved in the regulation of chromatin metabolism.	Inst Pasteur, Lab Biol Cellulaire Noyau, CNRS, URA 1773, F-75724 Paris 15, France; Inst Pasteur, Lab Anal & Images Quantitat, CNRS, URA 1947, F-75724 Paris 15, France; Univ Kaiserslautern, Abt Humanbiol, D-67653 Kaiserslautern, Germany; Univ Kaiserslautern, Abt Zellbiol, D-67653 Kaiserslautern, Germany; Inst Curie, CNRS, UMR144, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Kaiserslautern; University of Kaiserslautern; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite	Nehrbass, U (corresponding author), Inst Pasteur, Lab Biol Cellulaire Noyau, CNRS, URA 1773, 25 Rue Docteur Roux, F-75724 Paris 15, France.		Olivo-Marin, Jean-Christophe/K-4428-2015	Olivo-Marin, Jean-Christophe/0000-0001-6796-0696; Nehrbass, Ulf/0000-0002-7028-8076				Andrulis ED, 1998, NATURE, V395, P525, DOI 10.1038/26795; ARIS JP, 1989, J CELL BIOL, V108, P2059, DOI 10.1083/jcb.108.6.2059; Bangs P, 1998, J CELL BIOL, V143, P1801, DOI 10.1083/jcb.143.7.1801; Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KOLLING R, 1993, MOL GEN GENET, V237, P359; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Mages GJ, 1996, J BIOL CHEM, V271, P7910, DOI 10.1074/jbc.271.14.7910; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Olivo JC, 1996, INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, PROCEEDINGS - VOL I, P311, DOI 10.1109/ICIP.1996.559495; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; Shore D, 1997, BIOL CHEM, V378, P591; Strambio-de-Castillia C, 1999, J CELL BIOL, V144, P839, DOI 10.1083/jcb.144.5.839; Teixeira MT, 1999, J BIOL CHEM, V274, P32439, DOI 10.1074/jbc.274.45.32439; Trelles-Sticken E, 1999, J CELL SCI, V112, P651	30	252	259	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					108	112		10.1038/47528	http://dx.doi.org/10.1038/47528			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638763				2022-12-01	WOS:000084687400053
J	Muller-Navarra, DC; Brett, MT; Liston, AM; Goldman, CR				Muller-Navarra, DC; Brett, MT; Liston, AM; Goldman, CR			A highly unsaturated fatty acid predicts carbon transfer between primary producers and consumers	NATURE			English	Article							DAPHNIA GROWTH; LIMITATION; ZOOPLANKTON; MICROALGAE; QUALITY	The factors that regulate energy transfer between primary producers and consumers in aquatic ecosystems have been investigated for more than 50 years (refs 1-3). Among all levels of the food web (plants, herbivores, carnivores), the plant-animal interface is the most variable and least predictable link(4-6). In hypereutrophic lakes, for example, biomass and energy transfer is often inhibited at the phytoplankton-zooplankton link(4), resulting in an accumulation of phytoplankton biomass instead of sustaining production at higher trophic levels, such as fish. Accumulation of phytoplankton (especially cyanobacteria) results in severe deterioration of water quality, with detrimental effects on the health of humans and domestic animals, and diminished recreational value of water bodies(7,8). We show here that low transfer efficiencies between primary producers and consumers during cyanobacteria bloom conditions are related to low relative eicosapentaenoic acid (20:5 omega 3) content of the primary producer community. Zooplankton growth and egg production were strongly related to the primary producer 20:5 omega 3 to carbon ratio. This indicates that limitation of zooplankton production by this essential fatty acid is of central importance at the pelagic producer-consumer interface.	Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA; Univ Washington, Dept Civil & Environm Engn, Seattle, WA 98195 USA	University of California System; University of California Davis; University of Washington; University of Washington Seattle	Muller-Navarra, DC (corresponding author), Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA.		Brett, Michael T/A-2066-2010					AHLGREN G, 1992, J PHYCOL, V28, P37, DOI 10.1111/j.0022-3646.1992.00037.x; ARNOLD DE, 1971, LIMNOL OCEANOGR, V16, P906, DOI 10.4319/lo.1971.16.6.0906; Brett MT, 1996, P NATL ACAD SCI USA, V93, P7723, DOI 10.1073/pnas.93.15.7723; Brett MT, 1997, FRESHWATER BIOL, V38, P483, DOI 10.1046/j.1365-2427.1997.00220.x; Brett MT, 1997, SCIENCE, V275, P384, DOI 10.1126/science.275.5298.384; COBELAS MA, 1989, GRASAS ACEITES, V40, P118; Greenberg AE, 1995, STANDARD METHODS EXA; GULATI RD, 1990, BIOMANIPULATION TOOL, V200, P29; GULATI RD, 1997, FRESHWAT BIOL, V38; KATTNER G, 1986, J CHROMATOGR, V361, P263, DOI 10.1016/S0021-9673(01)86914-4; LAMPERT W, 1977, Archiv fuer Hydrobiologie Supplement, V48, P310; LAMPERT W, 1988, B MAR SCI, V43, P620; Lampert W., 1987, Memorie dell'Istituto Italiano di Idrobiologia Dott Marco de Marchi, V45, P143; LAMPERT W, 1985, ARCH HYDROBIOL BEIH, V21, pR5; Lindeman RL, 1942, ECOLOGY, V23, P399, DOI 10.2307/1930126; Marker A. F. H., 1980, ARCH HYDROBIOL S, V14, P52; MCQUEEN DJ, 1989, ECOL MONOGR, V59, P289, DOI 10.2307/1942603; MULLERNAVARRA D, 1995, ARCH HYDROBIOL, V132, P297; MullerNavarra D, 1996, J PLANKTON RES, V18, P1137, DOI 10.1093/plankt/18.7.1137; PORTER KG, 1987, EVOLUTION ECOLOGY ZO, P268; STERNER RW, 1993, ECOLOGY, V74, P2351, DOI 10.2307/1939587; URABE J, 1992, LIMNOL OCEANOGR, V37, P244, DOI 10.4319/lo.1992.37.2.0244; VINCENT WF, 1987, NZ J MAR FRESHWAT RE, V221; Wood B.J.B., 1974, ALGAL PHYSL BIOCH, P236; [No title captured]	25	568	585	15	248	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					74	77		10.1038/47469	http://dx.doi.org/10.1038/47469			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638754				2022-12-01	WOS:000084687400044
J	Kern, D; Volkman, BF; Luginbuhl, P; Nohaile, MJ; Kustu, S; Wemmer, DE				Kern, D; Volkman, BF; Luginbuhl, P; Nohaile, MJ; Kustu, S; Wemmer, DE			Structure of a transiently phosphorylated switch in bacterial signal transduction	NATURE			English	Article							RESPONSE REGULATOR; 3-DIMENSIONAL STRUCTURE; RECEIVER DOMAIN; NMR STRUCTURE; PROTEIN CHEY; CHEMOTAXIS; ACTIVATION; CONFORMATION; MECHANISM; DYNAMICS	Receiver domains are the dominant molecular switches in bacterial signalling(1,2), Although several structures of non-phosphorylated receiver domains have been reported(3-8), a detailed structural understanding of the activation arising from phosphorylation has been impeded by the very short half-lives of the aspartyl-phosphate linkages. Here we present the first structure of a receiver domain in its active state, the phosphorylated receiver domain of the bacterial enhancer-binding protein NtrC (nitrogen regulatory protein C), Nuclear magnetic resonance spectra were taken during steady-state autophosphorylation/dephosphorylation, and three-dimensional spectra from multiple samples were combined. Phosphorylation induces a large conformational change involving a displacement of beta-strands 4 and 5 and alpha-helices 3 and 4 away from the active site, a register shift and an axial rotation in helix 4, This creates an exposed hydrophobic surface that is likely to transmit the signal to the transcriptional activation domain.	Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil, Madison, WI 53706 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Plant & Microbial Sci, Berkeley, CA 94720 USA	Brandeis University; University of Wisconsin System; University of Wisconsin Madison; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Kern, D (corresponding author), Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA.		Volkman, Brian F./ABE-7306-2020; Volkman, Brian F./ABE-7312-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179				ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; Feher VA, 1997, BIOCHEMISTRY-US, V36, P10015, DOI 10.1021/bi970816l; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; Hwang I, 1999, P NATL ACAD SCI USA, V96, P4880, DOI 10.1073/pnas.96.9.4880; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; LOWRY DF, 1994, J BIOL CHEM, V269, P26358; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; Nohaile M, 1997, J MOL BIOL, V273, P299, DOI 10.1006/jmbi.1997.1296; Novak R, 1999, NATURE, V399, P590, DOI 10.1038/21202; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; ROMBEL L, 1998, COLD SPRING HARB SYM, P157; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SANTORO J, 1995, J MOL BIOL, V247, P717, DOI 10.1006/jmbi.1995.0175; Sola M, 1999, J MOL BIOL, V285, P675, DOI 10.1006/jmbi.1998.2326; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; VOLKMAN BF, 1995, BIOCHEMISTRY-US, V34, P1413, DOI 10.1021/bi00004a036; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001	29	174	177	0	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 23	1999	402	6764					894	898		10.1038/47273	http://dx.doi.org/10.1038/47273			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269ML	10622255				2022-12-01	WOS:000084482000037
J	Ledergerber, B; Erard, V; Weber, R; Hirschel, B; Furrer, H; Battegay, M; Vernazza, P; Bernasconi, E; Opravil, M; Kaufmann, D; Sudre, P; Francioli, P; Telenti, A				Ledergerber, B; Erard, V; Weber, R; Hirschel, B; Furrer, H; Battegay, M; Vernazza, P; Bernasconi, E; Opravil, M; Kaufmann, D; Sudre, P; Francioli, P; Telenti, A		Swiss HIV Cohort Study	AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy - The Swiss HIV Cohort Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; COMBINATION; DISEASE; HAART; RECOVERY; COUNT	Context Acquired immunodeficiency syndrome-related opportunistic illnesses (Ols) continue to occur after initiation of potent antiretroviral therapy in patients with human immunodeficiency virus (HIV) infection, Risk factors for clinical progression to Ols during potent therapy are not well defined, Objective To examine the incidence of and risk factors for Ols among patients treated with potent antiretroviral therapy in a population-based study, Design The Swiss HIV Cohort Study, a prospective cohort study of adult HIV-infected persons. Setting Seven study centers throughout Switzerland. Patients A total of 2410 cohort study participants with a potential follow-up of at least 15 months after starting potent therapy between September 1995 and December 1997. Main Outcome Measures Disease-specific incidence of Ols during the 6 months preceding potent antiretroviral therapy and at 3 intervals after initiating therapy; risk factors for development of Ols during therapy. Results Of the 2410 participants, 143 developed 186 Ols after initiation of potent antiretroviral therapy, Incidence of any OI decreased from 15.1 per 100 person-years in the 6 months before therapy to 7.7 in the first 3 months after starting treatment, 2.6 in the following 6 months, and 2.2 per 100 person-years between 9 and 15 months. Reductions in incidence ranged from 38% per month for Kaposi sarcoma (P<.001) to 5% per month for non-Hodgkin lymphoma (P =.31). Baseline CD4 cell count continued to predict the risk of disease progression after initiating potent therapy, Compared with CD4 cell counts above 200 x 10(6)/L, the hazard ratio for developing Ols was 2.5 (95% confidence interval [CI], 1.4-4.5) for counts between 51 and 200 x 10(6)/L and 5.8 (95% CI, 3.2-10.5) for counts below 51 x 10(6)/L at baseline, Independent of baseline CD4 cell count, a rise in CD4 cell count by 50 x 10(6)/L or more and undetectable HIV-1 RNA in plasma (<400 copies/mL) by 6 months reduced risk of subsequent events, with hazard ratios of 0.32 (95% CI, 0.20-0.52) and 0.39 (0.24-0.65), respectively, Conclusions Our data indicate that the risk of developing an OI for a person receiving potent antiretroviral therapy is highest during the initial months of therapy, Baseline CD4 cell count and immunologic and virologic response to treatment were strong predictors of disease progression in patients receiving potent therapy. Individuals with CD4 cell counts of 50 x 10(6)/L or below may need close clinical surveillance after initiation of potent therapy.	Univ Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland; Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol, Avon, England; Univ Hosp, Div Infect Dis, Lausanne, Switzerland; Univ Hosp, Div Infect Dis, Geneva, Switzerland; Univ Bern, Inselspital, Med Policlin, CH-3010 Bern, Switzerland; Univ Basel, Cantonal Hosp, Med Policlin, Basel, Switzerland; Cantonal Hosp, Internal Med Clin A, St Gall, Switzerland; Reg Hosp, Infect Dis Ambulatorium, Lugano, Switzerland	University of Zurich; University Zurich Hospital; University of Bristol; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of Bern; University Hospital of Bern; University of Basel	Telenti, A (corresponding author), CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland.		Weber, Rainer/D-5175-2012; Telenti, Amalio/AAY-1674-2021; Furrer, Hansjakob/G-6768-2013; Ledergerber, Bruno/B-5656-2009	Furrer, Hansjakob/0000-0002-1375-3146; Ledergerber, Bruno/0000-0002-6881-4401; Egger, Matthias/0000-0001-7462-5132				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bassetti S, 1999, J ACQ IMMUN DEF SYND, V21, P114; Bisset LR, 1998, AIDS, V12, P2115, DOI 10.1097/00002030-199816000-00006; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Carr A, 1997, LANCET, V350, P589, DOI 10.1016/S0140-6736(05)63175-3; *CDCP, 1992, MMWR-MORBID MORTAL W, V41; Chene G, 1998, AIDS, V12, P2313, DOI 10.1097/00002030-199817000-00013; Crump JA, 1998, CLIN INFECT DIS, V26, P1008, DOI 10.1086/517636; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Feinberg J, 1999, LANCET, V353, P1287, DOI 10.1016/S0140-6736(99)00123-3; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; Furrer H, 1999, AM J MED, V106, P371, DOI 10.1016/S0002-9343(99)00015-7; Hengge UR, 1998, AIDS, V12, pF225, DOI 10.1097/00002030-199817000-00003; Hirschel B, 1998, NEW ENGL J MED, V338, P906, DOI 10.1056/NEJM199803263381310; Karavellas MP, 1998, ARCH OPHTHALMOL-CHIC, V116, P169; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; LEDERGERBER B, 1994, SOZ PRAVENTIV MED, V39, P387, DOI 10.1007/BF01299670; Ledergerber B, 1999, BRIT MED J, V319, P23, DOI 10.1136/bmj.319.7201.23; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Martinez E, 1998, CLIN INFECT DIS, V27, P1510, DOI 10.1086/515019; Michelet C, 1998, AIDS, V12, P1815, DOI 10.1097/00002030-199814000-00013; Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perrin L, 1998, SCIENCE, V280, P1871, DOI 10.1126/science.280.5371.1871; Perry CM, 1998, DRUGS, V55, P461, DOI 10.2165/00003495-199855030-00014; Piketty C, 1998, AIDS, V12, P745, DOI 10.1097/00002030-199807000-00011; Race EM, 1998, LANCET, V351, P252, DOI 10.1016/S0140-6736(97)04352-3; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Sepkowitz KA, 1998, LANCET, V351, P228, DOI 10.1016/S0140-6736(05)78279-9; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; Zegans ME, 1998, AM J OPHTHALMOL, V125, P292, DOI 10.1016/S0002-9394(99)80134-2	32	374	385	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2220	2226		10.1001/jama.282.23.2220	http://dx.doi.org/10.1001/jama.282.23.2220			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263RG	10605973				2022-12-01	WOS:000084138600029
J	Pronk, NP; Goodman, MJ; O'Connor, PJ; Martinson, BC				Pronk, NP; Goodman, MJ; O'Connor, PJ; Martinson, BC			Relationship between modifiable health risks and short-term health care charges	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; LIFE-STYLE; COST; DISEASE; MORTALITY; DATABASE; SMOKING; MEMBERS; IMPACT; MEN	Context If physical inactivity, obesity, and smoking status prove to contribute significantly to increased health care charges within a short period of time, health plans and payers may wish to invest in strategies to modify these risk factors. However, few data are available to guide such resource allocation decisions. Objective To examine the relationship of modifiable health risks to subsequent health care charges after controlling for age, race, sex, and chronic conditions. Design, Setting, and Participants Cohort study of a stratified random sample of 5689 adults (75.5% of total sample of 7535) aged 40 years or older who were enrolled in a Minnesota health plan and completed a 60-item questionnaire. Main Outcome Measure Resource use as measured by billed health care charges from July 1, 1995, to December 31, 1996, compared by health risk (physical activity, body mass index [BMI], and smoking status). Results The mean annual per patient charge in the total study population was $3570 (median, $600), and 15% of patients had no charges during the study period. After adjustment for age, race, sex,and chronic disease status, physical activity (4.7% lower health care charges per active day per week), BMI (1.9% higher charges per BMI unit), current smoking status (18% higher charges), and history of tobacco use (25.8% higher charges) were prospectively related to health care charges over 18 months. Never-smokers with a BMI of 25 kg/m(2) and who participated in physical activity 3 days per week had mean annual health care charges that were approximately 49% lower than physically inactive smokers with a BMI of 27.5 kg/m(2), Conclusions Our data suggest that adverse health risks translate into significantly higher health care charges within 18 months. Health plans or payers seeking to minimize health care charges may wish to consider strategic investments in interventions that effectively modify adverse health risks.	Healthpartners Res Fdn, Minneapolis, MN 55440 USA; Healthpartners Ctr Hlth Promot, Minneapolis, MN USA	HealthPartners Institute for Education & Research	O'Connor, PJ (corresponding author), Healthpartners Res Fdn, 8100 34th Ave S, Minneapolis, MN 55440 USA.	Patrick.J.Oconnor@HealthPartners.com	Martinson, Brian C/AAX-2860-2020	Martinson, Brian C/0000-0002-4255-5595; O'Connor, Patrick/0000-0002-2324-6228				Ainsworth B., 1992, MED EXERCISE NUTR HL, V1, P75; BAUM WP, 1986, J OCCUP MED, V28, P18; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Boyle RG, 1998, AM J HEALTH PROMOT, V12, P170, DOI 10.4278/0890-1171-12.3.170; Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; DUAN N, 1983, J AM STAT ASSOC, V78, P605, DOI 10.2307/2288126; Edington DW, 1997, J OCCUP ENVIRON MED, V39, P1037, DOI 10.1097/00043764-199711000-00004; GILMER T, 1998, MINN HLTH SERV RES C; Gilmer TG, 1998, DIABETES, V47, pA190; Goetzel RZ, 1998, J OCCUP ENVIRON MED, V40, P843, DOI 10.1097/00043764-199810000-00003; Goetzel RZ, 1996, AM J HEALTH PROMOT, V10, P340, DOI 10.4278/0890-1171-10.5.340; Hornbrook MC, 1996, HEALTH SERV RES, V31, P283; HORNBROOK MC, 1995, INQUIRY-J HEALTH CAR, V32, P56; HOSMER D, 1989, WILEY SERIES PROBABI, V13, P307; KAMAN RL, 1995, WORKSITE HLTH PROMOT; KEELER EB, 1989, AM J PUBLIC HEALTH, V79, P975, DOI 10.2105/AJPH.79.8.975; Kortt MA, 1998, CLIN THER, V20, P772, DOI 10.1016/S0149-2918(98)80140-9; MANNING W, 1991, COSTS POOR HLTH HABI, P223; O'Connor P J, 1996, HMO Pract, V10, P17; O'Connor P J, 1997, Fam Med, V29, P424; O'Connor PJ, 1998, AM J MANAG CARE, V4, P335; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Pelletier KR, 1997, J OCCUP ENVIRON MED, V39, P1154, DOI 10.1097/00043764-199712000-00009; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; PROCHASKA JO, 1991, CLIN CHEST MED, V12, P727; PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P39, DOI 10.1037/0278-6133.13.1.39; PRONK N, IN PRESS MED SCI SPO; Pronk N P, 1997, J Ambul Care Manage, V20, P24; ROBINSON JC, 1995, MED CARE, V33, P1161, DOI 10.1097/00005650-199512000-00001; SHEPHARD RJ, 1992, AM J HLTH PROMOT, V17, P475; STEIN AD, 1993, AM J PUBLIC HEALTH, V83, P1768, DOI 10.2105/AJPH.83.12.1768; VELICER WF, 1993, TOB CONTROL, V2, P95	33	202	204	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2235	2239		10.1001/jama.282.23.2235	http://dx.doi.org/10.1001/jama.282.23.2235			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	263RG	10605975	Bronze			2022-12-01	WOS:000084138600031
J	Tormo, J; Natarajan, K; Margulies, DH; Marluzza, RA				Tormo, J; Natarajan, K; Margulies, DH; Marluzza, RA			Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand	NATURE			English	Article							MANNOSE-BINDING PROTEIN; CARBOHYDRATE-RECOGNITION DOMAIN; INHIBITORY RECEPTOR; 3-DIMENSIONAL STRUCTURE; LY-49A RECOGNIZES; H-2D(D); PEPTIDE; COMPLEX; SPECIFICITY; MOLECULES	Natural killer (NK) cell function is regulated by NK receptors that interact with MHC class I (MHC-I) molecules on target cells. The murine NK receptor Ly49A inhibits NK cell activity by interacting with H-2D(d) through its G-type-lectin-like NK receptor domain. Here we report the crystal structure of the complex between the Ly49A NK receptor domain and unglycosylated H-2D(d), The Ly49A dimer interacts extensively with two H-2D(d) molecules at distinct sites, At one interface, a single Ly49A subunit contacts one side of the MHC-I peptide-binding platform, presenting an open cavity towards the conserved glycosylation site on the H-2D(d) alpha 2 domain, At a second, larger interface, the Ly49A dimer binds in a region overlapping the CD8-binding site. The smaller interface probably represents the interaction between Ly49A on the NK cell and MHC-I on the target cell, whereas the larger one suggests an interaction between Ly49A and MHC-I on the NK cell itself. Both Ly49A binding sites on MHC-I are spatially distinct from that of the T-cell receptor.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; CSIC, Inst Biol Mol Barcelona, ES-08034 Barcelona, Spain; NIAID, Mol Biol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland Baltimore; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Marluzza, RA (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, 9,600 Gudelsky Dr, Rockville, MD 20850 USA.	dhm@nih.gov; mariuzza@carb.nist.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000394, Z01AI000394] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achour A, 1998, IMMUNITY, V9, P199, DOI 10.1016/S1074-7613(00)80602-0; Andersson M, 1998, J IMMUNOL, V161, P6475; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Boyington JC, 1999, IMMUNITY, V10, P75, DOI 10.1016/S1074-7613(00)80008-4; Brennan J, 1996, J EXP MED, V183, P1553, DOI 10.1084/jem.183.4.1553; BRENNAN J, 1995, J BIOL CHEM, V270, P9691, DOI 10.1074/jbc.270.17.9691; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang CS, 1998, J IMMUNOL, V160, P4367; Chung Y, 1999, J IMMUNOL, V163, P3692; CORREA I, 1995, IMMUNITY, V2, P61, DOI 10.1016/1074-7613(95)90079-9; DANIELS BF, 1994, IMMUNITY, V1, P785, DOI 10.1016/S1074-7613(94)80020-0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Franksson L, 1999, EUR J IMMUNOL, V29, P2748, DOI 10.1002/(SICI)1521-4141(199909)29:09<2748::AID-IMMU2748>3.0.CO;2-C; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Hanke T, 1999, IMMUNITY, V11, P67, DOI 10.1016/S1074-7613(00)80082-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kase A, 1998, J IMMUNOL, V161, P6133; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Li HM, 1998, J MOL BIOL, V283, P179, DOI 10.1006/jmbi.1998.2091; Lian RH, 1998, J IMMUNOL, V161, P2301; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.immunol.13.1.587; Maenaka K, 1999, STRUCTURE, V7, P391, DOI 10.1016/S0969-2126(99)80052-5; Matsumoto N, 1998, IMMUNITY, V8, P245, DOI 10.1016/S1074-7613(00)80476-8; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Natarajan K, 1999, IMMUNITY, V11, P591, DOI 10.1016/S1074-7613(00)80134-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Orihuela M, 1996, P NATL ACAD SCI USA, V93, P11792, DOI 10.1073/pnas.93.21.11792; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poget SF, 1999, J MOL BIOL, V290, P867, DOI 10.1006/jmbi.1999.2910; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Snyder GA, 1999, P NATL ACAD SCI USA, V96, P3864, DOI 10.1073/pnas.96.7.3864; Sundback J, 1998, J IMMUNOL, V160, P5971; Vales-Gomez M, 1999, EMBO J, V18, P4250, DOI 10.1093/emboj/18.15.4250; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Yokoyama W. M., 1999, FUNDAMENTAL IMMUNOLO, P575	49	231	238	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1999	402	6762					623	631		10.1038/45170	http://dx.doi.org/10.1038/45170			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604468				2022-12-01	WOS:000084189800055
J	Blair, PS; Fleming, PJ; Smith, IJ; Platt, MW; Young, J; Nadin, P; Berry, PJ; Golding, J				Blair, PS; Fleming, PJ; Smith, IJ; Platt, MW; Young, J; Nadin, P; Berry, PJ; Golding, J		CESDI SUDI Res Grp	Babies sleeping with parents: case-control study of factors influencing the risk of the sudden infant death syndrome	BRITISH MEDICAL JOURNAL			English	Article							HONG-KONG; COT DEATH	Objective To investigate the risks of the sudden infant death syndrome and factors that may contribute to unsafe sleeping environments. Design Three year, population based case-control study. Parental interviews were conducted for each sudden infant death and for four controls matched for age, locality, and time of sleep. Setting Fire regions in England with a total population of over 17 million people. Subjects 325 babies who died and 1300 control infants. Results In die multivariate analysis infants who shared their parents' bed and were then put back in their own cot had no increased risk (odds ratio 0.67; 95% confidence interval 0.22 to 2.00). There was an increased risk for infants who shared the bed for the whole sleep or were taken to and found in the parental bed (9.78; 4.02 to 23.83), infants who slept in a separate room from their parents (10.49; 4.26 to 25.81), and infants who shared a sofa (48.99; 5.04 to 475.60). The risk associated with being found in the parental bed was not significant for older infants (> 14 weeks) or for infants of parents who did not smoke and became non-significant after adjustment for recent maternal alcohol consumption(> 2 units), use of duvets ( > 4 togs), parental tiredness (infant slept less than or equal to 4 hours for longest sleep in previous 24 hours), and overcrowded housing conditions (> 2 people per room of the house). Conclusions There are certain circumstances when bed sharing should be avoided, particularly for infants under four months old. Parents sleeping on a sofa Midi infants should always be avoided. There is no evidence that bed sharing is hazardous for infants of parents who do not smoke.	Royal Hosp Sick Children, Inst Child Hlth, Bristol BS2 8BJ, Avon, England; Nuffield Inst Hlth Serv, Leeds LS2 9PL, W Yorkshire, England; Royal Victoria Infirm, Newcastle Neonatal Serv, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Bristol Royal Hospital For Children; University of Bristol; University of Leeds; Newcastle University - UK	Blair, PS (corresponding author), Royal Hosp Sick Children, Inst Child Hlth, St Michaels Hill, Bristol BS2 8BJ, Avon, England.		Fleming, Peter J/A-9081-2010; Platt, Martin Ward/D-4008-2014; Blair, Peter S/C-1213-2009; Young, Jeanine/G-2528-2010; Fleming, Peter/O-3231-2019	Fleming, Peter J/0000-0003-2521-5764; Platt, Martin Ward/0000-0003-0536-5749; Young, Jeanine/0000-0003-3849-3392; Fleming, Peter/0000-0003-2521-5764; Blair, Peter/0000-0002-7832-8087; Golding, Jean/0000-0003-2826-3307				Anderson G C, 1991, J Perinatol, V11, P216; BALL HL, IN PRESS AM ANTHR; BASS M, 1986, NEW ENGL J MED, V315, P100, DOI 10.1056/NEJM198607103150206; CARPENTER RG, 1972, SUDDEN UNEXPECTED DE, P7; DAVIES DP, 1985, LANCET, V2, P1346; FAROOQI I, 1994, BMJ-BRIT MED J, V308, P204, DOI 10.1136/bmj.308.6922.204b; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; Gantley M, 1993, BMJ-BRIT MED J, V16, P263; HOFFMAN HJ, 1988, SUDDEN INFANT DEATH, P153; KLONOFFCOHEN H, 1995, BMJ-BRIT MED J, V311, P1269, DOI 10.1136/bmj.311.7015.1269; LEACH CEA, IN PRESS PEDIATRICS; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; Ludington-Hoe S M, 1991, J Perinatol, V11, P19; LUKE JL, 1978, J FORENSIC SCI, V23, P379; MCKENNA J, 1994, EARLY HUM DEV, V38, P187, DOI 10.1016/0378-3782(94)90211-9; McKenna JJ, 1996, ANNU REV ANTHROPOL, V25, P201, DOI 10.1146/annurev.anthro.25.1.201; MITCHELL EA, 1993, BMJ-BRIT MED J, V306, P13, DOI 10.1136/bmj.306.6869.13; MITCHELL EA, 1992, NJ PAEDIAT CHILD HLT, V28, pS3; Mitchell EA, 1995, SUDDEN INFANT DEATH; MOSKO S, 1993, J BEHAV MED, V16, P589, DOI 10.1007/BF00844721; Nelson EAS, 1996, NEW ZEAL MED J, V109, P144; RINTAHAKA RJ, 1986, FORENSIC SCI INT, V30, P219, DOI 10.1016/0379-0738(86)90017-4; *SAS I, 1992, P229 SAS I; TAKEDA K, 1987, Journal of Kyoto Prefectural University of Medicine, V96, P965; TUOHY PG, 1993, ARCH DIS CHILD, V69, P664, DOI 10.1136/adc.69.6.664	25	217	224	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1457	1461		10.1136/bmj.319.7223.1457	http://dx.doi.org/10.1136/bmj.319.7223.1457			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582925	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000084129200016
J	Minegishi, Y; Rohrer, J; Coustan-Smith, E; Lederman, HM; Pappu, R; Campana, D; Chan, AC; Conley, ME				Minegishi, Y; Rohrer, J; Coustan-Smith, E; Lederman, HM; Pappu, R; Campana, D; Chan, AC; Conley, ME			An essential role for BLNK in human B cell development	SCIENCE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; ADAPTER PROTEIN SLP-76; TYROSINE KINASE; INTERLEUKIN-2 PRODUCTION; DEFICIENT MICE; T-CELLS; MUTATIONS; RECEPTOR; EXPRESSION; GENE	The signal transduction events that control the progenitor B cell (pro-B cell) to precursor B cell (pre-B cell) transition have not been well delineated. In evaluating patients with absent B cells, a male with a homozygous splice defect in the cytoplasmic adapter protein BLNK (B cell Linker protein) was identified. Although this patient had normal numbers of pro-B cells, he had no pre-B cells or mature B cells, indicating that BLNK plays a critical role in orchestrating the pro-B cell to pre-B cell transition. The immune system and overall growth and development were otherwise normal in this patient, suggesting that BLNK function is highly specific.	St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Johns Hopkins Hosp, Dept Pediat, Div Pediat Allergy & Immunol, Baltimore, MD 21287 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med,Div Rheumatol,Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol, St Louis, MO 63110 USA; Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN 38105 USA	St Jude Children's Research Hospital; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); University of Tennessee System; University of Tennessee Health Science Center	Conley, ME (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA.				NATIONAL CANCER INSTITUTE [R01CA071516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025129, R01AI042787, R37AI025129] Funding Source: NIH RePORTER; NCI NIH HHS [CA71516] Funding Source: Medline; NIAID NIH HHS [AI42787, AI25129] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Conley ME, 1998, AM J HUM GENET, V62, P1034, DOI 10.1086/301828; CONLEY ME, 1994, HUM MOL GENET, V3, P1751, DOI 10.1093/hmg/3.10.1751; COOPER DN, 1994, HUMAN GENE MUTATION, P239; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Goitsuka R, 1998, J IMMUNOL, V161, P5804; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KENNY RA, 1995, CARDIOL ELDER, V3, P301; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; Minegishi Y, 1999, J CLIN INVEST, V104, P1115, DOI 10.1172/JCI7696; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wunderlich L, 1999, EUR J IMMUNOL, V29, P1068, DOI 10.1002/(SICI)1521-4141(199904)29:04<1068::AID-IMMU1068>3.0.CO;2-P; Yel L, 1996, NEW ENGL J MED, V335, P1486, DOI 10.1056/NEJM199611143352003; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhang Y, 1998, EMBO J, V17, P7304, DOI 10.1093/emboj/17.24.7304	32	250	257	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1954	1957		10.1126/science.286.5446.1954	http://dx.doi.org/10.1126/science.286.5446.1954			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583958				2022-12-01	WOS:000084003400051
J	Burt, DW; Bruley, C; Dunn, IC; Jones, CT; Ramage, A; Law, AS; Morrice, DR; Paton, IR; Smith, J; Windsor, D; Sazanov, A; Fries, R; Waddington, D				Burt, DW; Bruley, C; Dunn, IC; Jones, CT; Ramage, A; Law, AS; Morrice, DR; Paton, IR; Smith, J; Windsor, D; Sazanov, A; Fries, R; Waddington, D			The dynamics of chromosome evolution in birds and mammals	NATURE			English	Article							RATES; TREE	Comparative mapping, which compares the location of homologous genes in different species, is a powerful tool for studying genome evolution(1). Comparative maps suggest that rates of chromosomal change in mammals can vary from one to ten rearrangements per million years(1-4). On the basis of these rates we would expect 84 to 600 conserved segments in a chicken comparison with human or mouse. Here we build comparative maps between these species and estimate that numbers of conserved segments are in the lower part of this range. We conclude that the organization of the human genome is closer to that of the chicken than the mouse and by adding comparative mapping results from a range of vertebrates, we identify three possible phases of chromosome evolution. The relative stability of genomes such as those of the chicken and human will enable the reconstruction of maps of ancestral vertebrates.	Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; TUM, Lehrstuhl Tierzucht, D-85350 Munich, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; Technical University of Munich	Burt, DW (corresponding author), Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland.	Dave-Burt@bbsrc.ac.uk	Burt, David W/C-7802-2013; Smith, Jacqueline/C-7719-2013; Sazanov, Alexei/A-6980-2014; Dunn, Ian/C-7689-2013	Burt, David W/0000-0002-9991-1028; Smith, Jacqueline/0000-0002-2813-7872; Sazanov, Alexei/0000-0002-5273-5397; Dunn, Ian/0000-0003-3630-0120				Andersson L, 1996, MAMM GENOME, V7, P717, DOI 10.1007/s003359900222; Burt David W., 1998, ILAR J, V39, P229; BUSH GL, 1977, P NATL ACAD SCI USA, V74, P3942, DOI 10.1073/pnas.74.9.3942; Davisson Muriel T., 1998, ILAR J, V39, P96; de Jong WW, 1998, TRENDS ECOL EVOL, V13, P270, DOI 10.1016/S0169-5347(98)01335-4; Hastie TJ, 1990, GEN ADDITIVE MODELS; Hurvich CM, 1998, J ROY STAT SOC B, V60, P271, DOI 10.1111/1467-9868.00125; Kosambi DD, 1943, ANN EUGENIC, V12, P172, DOI 10.1111/j.1469-1809.1943.tb02321.x; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Li WH, 1996, MOL PHYLOGENET EVOL, V5, P182, DOI 10.1006/mpev.1996.0012; Morizot D. C., 1994, Animal Biotechnology, V5, P113, DOI 10.1080/10495399409525812; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; OBrien SJ, 1997, TRENDS GENET, V13, P393, DOI 10.1016/S0168-9525(97)01297-3; OHTA T, 1993, P NATL ACAD SCI USA, V90, P10676, DOI 10.1073/pnas.90.22.10676; SARICH VM, 1967, SCIENCE, V158, P1200, DOI 10.1126/science.158.3805.1200; WADDINGTON D, IN PRESS GENETICS; Watanabe TK, 1999, NAT GENET, V22, P27, DOI 10.1038/8737; Wienberg Johannes, 1998, ILAR J, V39, P77; [No title captured]	22	230	234	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					411	413		10.1038/46555	http://dx.doi.org/10.1038/46555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586880				2022-12-01	WOS:000083913600056
J	Wakker, BP; Howk, JC; Savage, BD; van Woerden, H; Tufte, SL; Schwarz, UJ; Benjamin, R; Reynolds, RJ; Peletier, RF; Kalberla, PMW				Wakker, BP; Howk, JC; Savage, BD; van Woerden, H; Tufte, SL; Schwarz, UJ; Benjamin, R; Reynolds, RJ; Peletier, RF; Kalberla, PMW			Accretion of low-metallicity gas by the Milky Way	NATURE			English	Article							HIGH-VELOCITY CLOUDS; H-II REGIONS; ABUNDANCES; GALAXIES; LINE; ORIGIN; HALO	Models of the chemical evolution of the Milky Way suggest that: the observed abundances of elements heavier than helium ('metals') require a continuous infall of gas with metallicity (metal abundance) about 0.1 times the solar value. An infall rate integrated over the entire disk of the Milky Way of similar to 1 solar mass per year can solve the 'G-dwarf problem'-the observational fact that the metallicities of most long-lived stars near the Sun lie in a relatively narrow range(1-3). This infall dilutes the enrichment arising from the production of heavy elements in stars, and thereby prevents the metallicity of the interstellar medium from increasing steadily with time. However, in other spiral galaxies, the low-metallicity gas needed to provide this infall has been observed only in associated dwarf galaxies(4) and in the extreme outer disk of the Milky Way(5,6). In the distant Universe, low-metallicity hydrogen clouds (known as 'damped Ly alpha absorbers') are sometimes seen near galaxies(7,8). Here we report a metallicity of 0.09 times solar for a massive cloud that is falling into the disk of the Milky Way. The mass now associated with this cloud represents an infall per unit area of about the theoretically expected rate, and similar to 0.1-0.2 times the amount required for the whole Galaxy.	Univ Wisconsin, Dept Astron, Madison, WI 53706 USA; Univ Wisconsin, Dept Phys, Madison, WI 53706 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; Kapteyn Astron Inst, NL-9700 AV Groningen, Netherlands; Lewis & Clark Coll, Dept Phys, Portland, OR 97219 USA; Univ Nijmegen, NL-6500 GL Nijmegen, Netherlands; Univ Durham, Dept Phys, Durham DH1 3LE, England; Univ Bonn, Inst Radioastron, D-53121 Bonn, Germany	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; University of Groningen; Radboud University Nijmegen; Durham University; University of Bonn	Wakker, BP (corresponding author), Univ Wisconsin, Dept Astron, Madison, WI 53706 USA.		Peletier, Reynier F/B-9633-2012; Howk, Jay/D-2577-2013	Peletier, Reynier/0000-0001-7621-947X; Kalberla, Peter/0000-0002-8381-7889; Howk, J. Christopher/0000-0002-2591-3792				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; Blitz L, 1999, ASTROPHYS J, V514, P818, DOI 10.1086/306963; BREGMAN JN, 1980, ASTROPHYS J, V236, P577, DOI 10.1086/157776; Ferguson AMN, 1998, ASTRON J, V116, P673, DOI 10.1086/300456; Gardiner LT, 1996, MON NOT R ASTRON SOC, V278, P191, DOI 10.1093/mnras/278.1.191; GIOVAGNOLI A, 1995, MON NOT R ASTRON SOC, V273, P499, DOI 10.1093/mnras/273.2.499; Haffner LM, 1999, ASTROPHYS J, V523, P223, DOI 10.1086/307734; Hartmann D., 1997, ATLAS GALACTIC NEUTR; Lu LM, 1998, ASTRON J, V115, P55, DOI 10.1086/300180; Lu LM, 1998, ASTRON J, V115, P162, DOI 10.1086/300181; OORT JH, 1970, ASTRON ASTROPHYS, V7, P381; Pagel BEJ., 1997, NUCLEOSYNTHESIS CHEM; Pettini M, 1999, ASTROPHYS J, V510, P576, DOI 10.1086/306635; Reynolds RJ, 1998, PUBL ASTRON SOC AUST, V15, P14, DOI 10.1071/AS98014; Rudolph AL, 1997, ASTROPHYS J, V489, P94, DOI 10.1086/304758; Savage BD, 1996, ANNU REV ASTRON ASTR, V34, P279, DOI 10.1146/annurev.astro.34.1.279; Skillman ED, 1997, ASTROPHYS J, V474, P205, DOI 10.1086/303464; Snowden SL, 1998, ASTROPHYS J, V493, P715, DOI 10.1086/305135; van Woerden H, 1999, ASTR SOC P, V166, P1; van Woerden H, 1999, NATURE, V400, P138, DOI 10.1038/22061; VANDENBERGH S, 1962, ASTRON J, V67, P486, DOI 10.1086/108757; VERNER DA, 1994, ASTRON ASTROPHYS SUP, V108, P287; Wakker BP, 1997, ASTROPHYS J, V488, P216, DOI 10.1086/304682; Wakker BP, 1997, ANNU REV ASTRON ASTR, V35, P217, DOI 10.1146/annurev.astro.35.1.217; Wakker BP, 1999, ASTR SOC P, V166, P26; Wakker BP, 1996, ASTRON ASTROPHYS, V306, pL25; WOLFIRE MG, 1995, ASTROPHYS J, V453, P673, DOI 10.1086/176429; YANNY B, 1992, ASTROPHYS J, V391, P569, DOI 10.1086/171371; Zwaan MA, 1997, ASTROPHYS J, V490, P173, DOI 10.1086/304872	29	180	181	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					388	390		10.1038/46498	http://dx.doi.org/10.1038/46498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586877				2022-12-01	WOS:000083913600048
J	Rastogi, VK; Girvin, ME				Rastogi, VK; Girvin, ME			Structural changes linked to proton translocation by subunit c of the ATP synthase	NATURE			English	Article							PROTEIN-STRUCTURE DETERMINATION; ESCHERICHIA-COLI; CHEMICAL-SHIFTS; CROSS-LINKING; DIRECT REFINEMENT; NMR; F1-ATPASE; ROTATION; F-0; SECTOR	F1F0 ATP synthases use a transmembrane proton gradient to drive the synthesis of cellular ATP. The structure of the cytosolic F-1 portion of the enzyme and the basic mechanism of ATP hydrolysis by F-1 are now well established, but how proton translocation through the transmembrane F-0 portion drives these catalytic changes is less clear. Here we describe the structural changes in the proton-translocating F-0 subunit c that are induced by deprotonating the specific aspartic acid involved in proton transport. conformational changes between the protonated and deprotonated forms of subunit c provide the structural basis for an explicit mechanism to explain coupling of proton translocation by F-0 to the rotation of subunits within the core of F-1. Rotation of these subunits within F-1 causes the catalytic conformational changes in the active sites of F-1 that result in ATP synthesis.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Girvin, ME (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	girvin@aecom.yu.edu						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARIS JP, 1983, J BIOL CHEM, V258, P4599; AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; ERMLER U, 1994, STRUCTURE, V2, P925, DOI 10.1016/S0969-2126(94)00094-8; Fillingame RH, 1998, ACTA PHYSIOL SCAND, V163, P163; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Groth G, 1997, FEBS LETT, V410, P117, DOI 10.1016/S0014-5793(97)00529-2; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; Howitt SM, 1996, J BIOENERG BIOMEMBR, V28, P415, DOI 10.1007/BF02113983; Jager H, 1998, EUR J BIOCHEM, V251, P122, DOI 10.1046/j.1432-1327.1998.2510122.x; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSZEWSKI J, 1995, J MAGN RESON SER B, V107, P293, DOI 10.1006/jmrb.1995.1093; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Matthey U, 1999, EUR J BIOCHEM, V261, P459, DOI 10.1046/j.1432-1327.1999.00288.x; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NORWOOD TJ, 1992, BIOCHEMISTRY-US, V31, P6285, DOI 10.1021/bi00142a017; Rastogi VK, 1999, J BIOMOL NMR, V13, P91, DOI 10.1023/A:1008379624478; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SIGRISTNELSON K, 1979, J BIOL CHEM, V254, P4470; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Yamada H, 1996, FEBS LETT, V390, P34, DOI 10.1016/0014-5793(96)00621-7; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	50	381	387	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					263	268		10.1038/46224	http://dx.doi.org/10.1038/46224			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580496				2022-12-01	WOS:000083813700040
J	Rogers, J; Joyce, GF				Rogers, J; Joyce, GF			A ribozyme that lacks cytidine	NATURE			English	Article							IN-VITRO EVOLUTION; RNA; SEQUENCES	The RNA-world hypothesis proposes that, before the advent of DNA and protein, life was based on RNA, with RNA serving as both the repository of genetic information and the chief agent of catalytic function(1). An argument against an RNA world is that the components of RNA lack the chemical diversity necessary to sustain life. Unlike proteins, which contain 20 different aminoacid subunits, nucleic acids are composed of only four subunits which have very similar chemical properties. Yet RNA is capable of a broad range of catalytic functions(2-7). Here we show that even three nucleic-acid subunits are sufficient to provide a substantial increase in the catalytic rate. Starting from a molecule that contained roughly equal proportions of all four nucleosides, we used in vitro evolution to obtain an RNA ligase ribozyme that lacks cytidine. This ribozyme folds into a defined structure and has a catalytic rate that is about 10(5)-fold faster than the uncatalysed rate of template-directed RNA ligation.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Joyce, GF (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gjoyce@scripps.edu						BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; Gesteland R. F., 1999, RNA WORLD; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAYATSU H, 1970, J AM CHEM SOC, V92, P724, DOI 10.1021/ja00706a062; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; Levy M, 1998, P NATL ACAD SCI USA, V95, P7933, DOI 10.1073/pnas.95.14.7933; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; Rohatgi R, 1996, J AM CHEM SOC, V118, P3332, DOI 10.1021/ja953712b; SHU HH, 1991, MOL CELL BIOL, V11, P1662, DOI 10.1128/MCB.11.3.1662; STERN S, 1988, METHOD ENZYMOL, V164, P481; Unrau PJ, 1998, NATURE, V395, P260, DOI 10.1038/26193; Vartanian JP, 1996, NUCLEIC ACIDS RES, V24, P2627, DOI 10.1093/nar/24.14.2627; Wright MC, 1997, SCIENCE, V276, P614, DOI 10.1126/science.276.5312.614; YOSHIDA H, 1994, NUCLEIC ACIDS RES, V22, P41, DOI 10.1093/nar/22.1.41; Zhang BL, 1998, CHEM BIOL, V5, P539, DOI 10.1016/S1074-5521(98)90113-2	20	67	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					323	325		10.1038/46335	http://dx.doi.org/10.1038/46335			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580507				2022-12-01	WOS:000083813700057
J	Henney, JE				Henney, JE			First drug device to treat actinic keratoses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									Commissioner Food & Drugs, Rockville, MD 20857 USA		Henney, JE (corresponding author), Commissioner Food & Drugs, HF 1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2000	283	5					596	596		10.1001/jama.283.5.596-b	http://dx.doi.org/10.1001/jama.283.5.596-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277WL	10665687				2022-12-01	WOS:000084956500006
J	Naumburg, E; Bellocco, R; Cnattingius, S; Hall, P; Ekbom, A				Naumburg, E; Bellocco, R; Cnattingius, S; Hall, P; Ekbom, A			Prenatal ultrasound examinations and risk of childhood leukaemia: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY		Uppsala Univ, Paediat Sect, Dept Womens & Childrens Hlth, S-75185 Uppsala, Sweden; Dept Med Epidemiol, S-17177 Stockholm, Sweden	Uppsala University	Naumburg, E (corresponding author), Uppsala Univ, Paediat Sect, Dept Womens & Childrens Hlth, S-75185 Uppsala, Sweden.	Estelle.Namburg@pediatrik.uu.se	Bellocco, Rino/E-7674-2018; Naumburg, Estelle/B-8539-2018	Naumburg, Estelle/0000-0001-6090-494X				CARTWRIGHT RA, 1984, LANCET, V2, P999; DINNO MA, 1989, PHYS MED BIOL, V34, P1543, DOI 10.1088/0031-9155/34/11/003; *EUR COMM ULTR RAD, 1996, EUR J ULTRASOUND, V4, P69; Kieler H, 1998, OBSTET GYNECOL, V91, P750, DOI 10.1016/S0029-7844(98)00062-3; WILSON LMK, 1984, LANCET, V2, P997	5	15	18	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	2000	320	7230					282	283		10.1136/bmj.320.7230.282	http://dx.doi.org/10.1136/bmj.320.7230.282			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280ZB	10650024	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000085132700020
J	Jankowsky, E; Gross, CH; Shuman, S; Pyle, AM				Jankowsky, E; Gross, CH; Shuman, S; Pyle, AM			The DExH protein NPH-II is a processive and directional motor for unwinding RNA	NATURE			English	Article							MESSENGER-RNA; HELICASE; SPECIFICITY; MECHANISMS; ENZYME	All aspects of cellular RNA metabolism and processing involve DExH/D proteins, which are a family of enzymes that unwind or manipulate RNA in an ATP-dependent fashion(1). DExH/D proteins are also essential for the replication of many viruses, and therefore provide targets for the development of therapeutics(2). All DExH/D proteins characterized to date hydrolyse nucleoside triphosphates and, in most cases, this activity is stimulated by the addition of RNA or DNA(1). Several members of the family unwind RNA duplexes in an NTP-dependent fashion in vitro(1,3); therefore it has been proposed that DExH/D proteins couple NTP hydrolysis to RNA conformational chang-e in complex macromolecular assemblies(4). Despite the central role of DExH/D proteins, their mechanism of RNA helicase activity remains unknown. Here we show that the DExH protein NPH-II unwinds RNA duplexes in a processive, unidirectional fashion with a step size of roughly one-half helix turn. We show that there is a quantitative connection between ATP utilization and helicase processivity, thereby providing direct evidence that DExH/D proteins can function as molecular motors on RNA.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Columbia University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute	Pyle, AM (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.			Jankowsky, Eckhard/0000-0001-7677-7412				Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Gross CH, 1996, J VIROL, V70, P2615, DOI 10.1128/JVI.70.4.2615-2619.1996; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Jankowsky E, 1996, BIOCHEMISTRY-US, V35, P15313, DOI 10.1021/bi961397f; Jeltsch A, 1998, BIOCHEMISTRY-US, V37, P2160, DOI 10.1021/bi9719206; Kadare G, 1997, J VIROL, V71, P2583; Kelemen BR, 1999, BIOCHEMISTRY-US, V38, P5302, DOI 10.1021/bi990325w; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; Pyle AM, 2000, METHOD ENZYMOL, V317, P140; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SCHNAPP BJ, 1995, NATURE, V373, P655, DOI 10.1038/373655a0; Shimamoto N, 1999, J BIOL CHEM, V274, P15293, DOI 10.1074/jbc.274.22.15293; SHUMAN S, 1992, P NATL ACAD SCI USA, V89, P10935, DOI 10.1073/pnas.89.22.10935; SHUMAN S, 1993, J BIOL CHEM, V268, P11798; STALEY JP, 1998, CELL, V90, P1041; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; Xiang Q, 1998, BIOCHEMISTRY-US, V37, P3839, DOI 10.1021/bi972661n; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	22	188	194	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					447	451		10.1038/35000239	http://dx.doi.org/10.1038/35000239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667799				2022-12-01	WOS:000085121100055
J	Mead, DG; Ramberg, FB; Besselsen, DG; Mare, CJ				Mead, DG; Ramberg, FB; Besselsen, DG; Mare, CJ			Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice	SCIENCE			English	Article							NEW-JERSEY; SIMULIUM-VITTATUM; DIPTERA; DISEASE; PSYCHODIDAE; WILDLIFE; HAMSTERS; HOSTS; RNA	Vesicular stomatitis is an economically important arboviral disease of Livestock, Viremia is absent in infected mammalian hosts, and the mechanism by which insects become infected with the causative agents, vesicular stomatitis viruses, remains unknown. Because infected and noninfected insects potentially feed on the same host in nature, infected and noninfected black flies were allowed to feed on the same host. Viremia was not detected in the host after infection by a black fly bite, but because noninfected black flies acquired the virus while co-feeding on the same host with infected black flies, it is concluded that a viremic host is not necessary for an insect to be infected with the virus. Thus co-feeding is a mechanism of infection for an insect-transmitted virus.	Univ Arizona, Dept Vet Sci & Microbiol, Tucson, AZ 85721 USA	University of Arizona	Mead, DG (corresponding author), Univ Arizona, Dept Vet Sci & Microbiol, 1117 E Lowell, Tucson, AZ 85721 USA.	dmead@u.arizona.edu	Mead, Daniel/F-7501-2013					AGUIRRE AA, 1992, J WILDLIFE DIS, V28, P435, DOI 10.7589/0090-3558-28.3.435; ANDERSON J. R., 1961, ANN ENT SOC AMER, V54, P716, DOI 10.1093/aesa/54.5.716; ANDERSON JOHN R., 1963, MOSQUITO NEWS, V23, P126; Barrera JD, 1996, VIROLOGY, V219, P453, DOI 10.1006/viro.1996.0271; BERNARDO MJ, 1986, ANN ENTOMOL SOC AM, V79, P610, DOI 10.1093/aesa/79.4.610; CAVE DR, 1984, J VIROL, V50, P86, DOI 10.1128/JVI.50.1.86-91.1984; COMER JA, 1995, J MED ENTOMOL, V32, P738, DOI 10.1093/jmedent/32.5.738; COTTON WE, 1926, JAVMA, V70, P168; CUPP EW, 1992, J MED ENTOMOL, V29, P137, DOI 10.1093/jmedent/29.2.137; Cupp EW, 1997, J MED ENTOMOL, V34, P87, DOI 10.1093/jmedent/34.2.87; DAVIES DOUGLAS M., 1956, CANADIAN JOUR ZOOL, V34, P615, DOI 10.1139/z56-064; FRANCY DB, 1988, J MED ENTOMOL, V25, P343, DOI 10.1093/jmedent/25.5.343; FULTZ PN, 1982, J GEN VIROL, V63, P493, DOI 10.1099/0022-1317-63-2-493; FULTZ PN, 1985, VIRUS RES, V3, P129, DOI 10.1016/0168-1702(85)90003-6; GREEN SL, 1993, VET CLIN N AM-EQUINE, V9, P349, DOI 10.1016/S0749-0739(17)30401-7; Jenney E. W., 1972, Proceedings of the United States Animal Health Association, V76, P183; Jimenez AE, 1996, J WILDLIFE DIS, V32, P274, DOI 10.7589/0090-3558-32.2.274; JONES LD, 1987, SCIENCE, V237, P775, DOI 10.1126/science.3616608; KARSTAD L, 1957, AM J VET RES, V18, P162; Knowlton GF, 1935, J ECON ENTOMOL, V28, P824, DOI 10.1093/jee/28.5.824; Labuda M, 1997, VIROLOGY, V235, P138, DOI 10.1006/viro.1997.8622; MARE CJ, 1973, INFECT IMMUN, V8, P118; MARE CJ, 1991, P US ANIM HLTH ASS, V19, P179; MULLER MJ, 1987, J MED ENTOMOL, V24, P206, DOI 10.1093/jmedent/24.2.206; MURPHY FA, 1975, EXP MOL PATHOL, V23, P426, DOI 10.1016/0014-4800(75)90035-0; MURPHY FA, 1994, VIRUS TAXONOMY CLASS; PATTERSON WC, 1955, P US LIVESTOCK SANIT, V59, P368; PETERSON B. V., 1959, CANADIAN ENT, V91, P147; REDELMAN D, 1989, VET IMMUNOL IMMUNOP, V20, P345, DOI 10.1016/0165-2427(89)90080-9; RYCKMAN RE, 1961, J PARASITOL, V47, P405, DOI 10.2307/3275364; Stallknecht DE, 1999, AM J VET RES, V60, P43; TESH RB, 1970, AM J EPIDEMIOL, V91, P216, DOI 10.1093/oxfordjournals.aje.a121130; THORNE ET, 1983, P US ANIMAL HLTH ASS, V87, P638; THURMOND MC, 1987, J AM VET MED ASSOC, V191, P965; TITUS RG, 1990, PARASITOL TODAY, V6, P157, DOI 10.1016/0169-4758(90)90338-5; WEBB PA, 1987, J WILDLIFE DIS, V23, P192, DOI 10.7589/0090-3558-23.2.192; *WHO, 1967, TECH REP SER, V369, P9; *WHO, 1985, TECH REP SER, V719, P36; Wikel SK, 1999, BIOSCIENCE, V49, P311, DOI 10.2307/1313614; YOUNG DG, 1984, MOSQ NEWS, V44, P263; Yuill T. M., 1981, CRC handbook series in zoonoses. Section B: viral zoonoses. Volume I, P125	41	98	103	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2000	287	5452					485	487		10.1126/science.287.5452.485	http://dx.doi.org/10.1126/science.287.5452.485			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642550				2022-12-01	WOS:000084929900048
J	Gillick, MR				Gillick, MR			Sounding board - Rethinking the role of tube feeding in patients with advanced dementia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; NURSING-HOME RESIDENTS; LIFE-SUSTAINING TREATMENTS; TERMINALLY ILL PATIENTS; CARDIOPULMONARY-RESUSCITATION; ARTIFICIAL NUTRITION; SUPREME-COURT; CARE; PREFERENCES; DECISIONS		Hebrew Rehabil Ctr Aged, Boston, MA 02131 USA		Gillick, MR (corresponding author), Hebrew Rehabil Ctr Aged, Boston, MA 02131 USA.							Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Callahan CM, 1999, J AM GERIATR SOC, V47, P1105, DOI 10.1111/j.1532-5415.1999.tb05235.x; Callahan Daniel, 1993, TROUBLED DREAM LIFE; COSTA PT, 1996, AHCPR PUBLICATION; EVANS LK, 1989, J AM GERIATR SOC, V37, P65, DOI 10.1111/j.1532-5415.1989.tb01571.x; Fainsinger RL, 1997, SUPPORT CARE CANCER, V5, P205, DOI 10.1007/s005200050061; FEINBERG MJ, 1992, RADIOLOGY, V183, P811, DOI 10.1148/radiology.183.3.1584939; Finucane TE, 1996, LANCET, V348, P1421, DOI 10.1016/S0140-6736(96)03369-7; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; FINUCANE TE, 1997, LANCET, V349, P364; Fischer GS, 1997, ARCH INTERN MED, V157, P801, DOI 10.1001/archinte.157.7.801; Grant MD, 1998, JAMA-J AM MED ASSOC, V279, P1973, DOI 10.1001/jama.279.24.1973; HODGES MO, 1994, CLIN GERIATR MED, V10, P475, DOI 10.1016/S0749-0690(18)30334-3; Kane RS, 1997, J AM GERIATR SOC, V45, P154, DOI 10.1111/j.1532-5415.1997.tb04500.x; KAW M, 1994, DIGEST DIS SCI, V39, P738, DOI 10.1007/BF02087416; LO B, 1984, NEW ENGL J MED, V311, P402, DOI 10.1056/NEJM198408093110611; LO B, 1991, ANN INTERN MED, V114, P895, DOI 10.7326/0003-4819-114-10-895; LYNN J, 1986, BY NO EXTRORDINARY M, P47; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Mitchell SL, 1997, ARCH INTERN MED, V157, P327, DOI 10.1001/archinte.157.3.327; Mitchell SL, 1999, CAN MED ASSOC J, V160, P1705; Mitchell SL, 1998, J GERONTOL A-BIOL, V53, pM207, DOI 10.1093/gerona/53A.3.M207; Morris J, 1997, MEASUREMENT ELDERLY, P130; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; *NAT C CATH BISH, 1995, ETH REL DIR CATH HLT; OBRIEN LA, 1995, JAMA-J AM MED ASSOC, V274, P1775, DOI 10.1001/jama.274.22.1775; OBrien LA, 1997, J GEN INTERN MED, V12, P364, DOI 10.1046/j.1525-1497.1997.00061.x; OUSLANDER JG, 1993, J AM GERIATR SOC, V41, P70, DOI 10.1111/j.1532-5415.1993.tb05951.x; PECK A, 1990, J AM GERIATR SOC, V38, P1195, DOI 10.1111/j.1532-5415.1990.tb01498.x; Petersen TI, 1997, EUR J SURG, V163, P351; PHILLIPS PA, 1984, NEW ENGL J MED, V311, P753, DOI 10.1056/NEJM198409203111202; Post S. G., 1995, MORAL CHALLENGE ALZH; Rabeneck L, 1997, LANCET, V349, P496, DOI 10.1016/S0140-6736(96)07369-2; Rabeneck L, 1996, J GEN INTERN MED, V11, P287, DOI 10.1007/BF02598270; Rosin AJ, 1998, J MED ETHICS, V24, P44, DOI 10.1136/jme.24.1.44; Sachs GA, 1998, J AM GERIATR SOC, V46, P782, DOI 10.1111/j.1532-5415.1998.tb03818.x; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHOSTAK RZ, 1994, J MED ETHICS, V20, P93, DOI 10.1136/jme.20.2.93; SHAILESH LTC, 1992, AM J SURG, V164, P114, DOI 10.1016/S0002-9610(05)80367-8; Sheiman SL, 1996, J AM GERIATR SOC, V44, P1268, DOI 10.1111/j.1532-5415.1996.tb01384.x; SIEGLER M, 1985, ARCH INTERN MED, V145, P129, DOI 10.1001/archinte.145.1.129; SLOMKA J, 1995, ARCH INTERN MED, V155, P1258, DOI 10.1001/archinte.155.12.1258; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; STEINBROOK R, 1988, NEW ENGL J MED, V318, P286, DOI 10.1056/NEJM198802043180505; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; Sullivan-Marx EM, 1999, J AM GERIATR SOC, V47, P342, DOI 10.1111/j.1532-5415.1999.tb02999.x; TAYLOR CA, 1992, MAYO CLIN PROC, V67, P1042, DOI 10.1016/S0025-6196(12)61118-5; Thomasma D., 1992, DEMENTIA AGING ETHIC, P101; VOLICER L, 1986, JAMA-J AM MED ASSOC, V256, P2210, DOI 10.1001/jama.256.16.2210; WEIR RF, 1990, JAMA-J AM MED ASSOC, V264, P1846, DOI 10.1001/jama.264.14.1846	50	334	342	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2000	342	3					206	210		10.1056/NEJM200001203420312	http://dx.doi.org/10.1056/NEJM200001203420312			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	275ZT	10639550				2022-12-01	WOS:000084851700012
J	Chan, AWS; Dominko, T; Luetjens, CM; Neuber, E; Martinovich, C; Hewitson, L; Simerly, CR; Schatten, GP				Chan, AWS; Dominko, T; Luetjens, CM; Neuber, E; Martinovich, C; Hewitson, L; Simerly, CR; Schatten, GP			Clonal propagation of primate offspring by embryo splitting	SCIENCE			English	Article							CELLS; FETAL; MOUSE; ADULT	Primates that are identical in both nuclear and cytoplasmic components have not been produced by current cloning strategies, yet such identicals represent the ideal model for investigations of human diseases. Here, genetically identical nonhuman embryos were produced as twin and larger sets by separation and reaggregation of blastomeres of cleavage-stage embryos. A total of 368 multiples were created by the splitting of 107 rhesus embryos with four pregnancies established after 13 embryo transfers (31% versus 53% in vitro fertilization controls). The birth of Tetra, a healthy female cloned from a quarter of an embryo, proves that this approach can result in live offspring.	Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University	Schatten, GP (corresponding author), Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA.	schatten@ohsu.edu	simerly, Calvin/AAC-9564-2021; Schatten, Gerald/B-3253-2009	Schatten, Gerald/0000-0001-5206-7782				Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; COHEN J, 1992, HUM REPROD, V7, P685, DOI 10.1093/oxfordjournals.humrep.a137720; Evans MJ, 1999, NAT GENET, V23, P90, DOI 10.1038/12696; Gardner RL, 1997, DEVELOPMENT, V124, P289; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; Hewitson L, 1998, HUM REPROD, V13, P3449, DOI 10.1093/humrep/13.12.3449; Hewitson L, 1999, NAT MED, V5, P431, DOI 10.1038/7430; Heyman Y, 1998, REPROD NUTR DEV, V38, P595, DOI 10.1051/rnd:19980602; Hill JR, 1999, THERIOGENOLOGY, V51, P1451, DOI 10.1016/S0093-691X(99)00089-8; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; KOLBERG R, 1993, SCIENCE, V262, P652, DOI 10.1126/science.8235583; Leese HJ, 1998, HUM REPROD, V13, P184, DOI 10.1093/humrep/13.suppl_4.184; Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977; PAPAIOANNOU VE, 1989, DEVELOPMENT, V106, P817; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; SEIKE N, 1990, JPN J VET RES, V38, P1; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; TARANTAL AF, 1988, AM J PRIMATOL, V15, P309, DOI 10.1002/ajp.1350150405; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Weber RJ, 1999, DEVELOPMENT, V126, P5591; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wells DN, 1998, REPROD FERT DEVELOP, V10, P369, DOI 10.1071/R98109; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wolf DP, 1999, BIOL REPROD, V60, P199, DOI 10.1095/biolreprod60.2.199; Wu GJ, 1996, BIOL REPROD, V55, P260, DOI 10.1095/biolreprod55.2.260	28	92	101	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					317	319		10.1126/science.287.5451.317	http://dx.doi.org/10.1126/science.287.5451.317			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634789				2022-12-01	WOS:000084769600044
J	Scholin, CA; Gulland, F; Doucette, GJ; Benson, S; Busman, M; Chavez, FP; Cordaro, J; DeLong, R; De Vogelaere, A; Harvey, J; Haulena, M; Lefebvre, K; Lipscomb, T; Loscutoff, S; Lowenstine, LJ; Marin, R; Miller, PE; McLellan, WA; Moeller, PDR; Powell, CL; Rowles, T; Silvagni, P; Silver, M; Spraker, T; Trainer, V; Van Dolah, FM				Scholin, CA; Gulland, F; Doucette, GJ; Benson, S; Busman, M; Chavez, FP; Cordaro, J; DeLong, R; De Vogelaere, A; Harvey, J; Haulena, M; Lefebvre, K; Lipscomb, T; Loscutoff, S; Lowenstine, LJ; Marin, R; Miller, PE; McLellan, WA; Moeller, PDR; Powell, CL; Rowles, T; Silvagni, P; Silver, M; Spraker, T; Trainer, V; Van Dolah, FM			Mortality of sea lions along the central California coast linked to a toxic diatom bloom	NATURE			English	Article							DOMOIC ACID; HIPPOCAMPAL DAMAGE; PROBES; MICE	Over 400 California sea lions (Zalophus californianus) died and many others displayed signs of neurological dysfunction along the central California coast during May and June 1998. A bloom of Pseudo-nitzschia australis (diatom) was observed in the Monterey Bay region during the same period. This bloom was associated with production of domoic acid (DA), a neurotoxin(1) that was also detected in planktivorous fish, including the northern anchovy (Engraulis mordax), and in sea lion body fluids. These and other concurrent observations demonstrate the trophic transfer of DA resulting in marine mammal mortality. In contrast to fish, blue mussels (Mytilus edulus) collected during the DA outbreak contained no DA or only trace amounts. Such findings reveal that monitoring of mussel toxicity alone does not necessarily provide adequate warning of DA entering the food web at levels sufficient to harm marine wildlife and perhaps humans.	Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; Marin Headlands, Marine Mammal Ctr, Sausalito, CA 94965 USA; Natl Ocean Serv, Marine Biotoxins Program, NOAA, Charleston, SC 29412 USA; Moss Landing Marine Labs, Moss Landing, CA 95039 USA; Natl Marine Fisheries Serv, Long Beach, CA 90802 USA; Natl Marine Mammal Lab, Seattle, WA 98115 USA; Monterey Bay Natl Marine Sanctuary, Monterey, CA 93940 USA; Univ Calif Santa Cruz, Inst Marine Sci, Santa Cruz, CA 95064 USA; Armed Forces Inst Pathol, Washington, DC 20306 USA; Calif Dept Hlth Serv, Food & Drug Branch, Sacramento, CA 94234 USA; Univ Calif Davis, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA; Univ N Carolina, Wilmington, NC 28403 USA; Natl Marine Fisheries Serv, Silver Spring, MD 20910 USA; Colorado State Univ, Coll Vet Med, Ft Collins, CO 80523 USA; Natl Marine Fisheries Serv, NOAA, ECD, Seattle, WA 98112 USA	Monterey Bay Aquarium Research Institute; National Oceanic Atmospheric Admin (NOAA) - USA; National Ocean Service, NOAA; Moss Landing Marine Laboratories; National Aeronautics & Space Administration (NASA); National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; University of California System; University of California Santa Cruz; United States Department of Defense; California Department of Health Care Services; University of California System; University of California Davis; University of North Carolina; University of North Carolina Wilmington; National Oceanic Atmospheric Admin (NOAA) - USA; Colorado State University; National Oceanic Atmospheric Admin (NOAA) - USA	Scholin, CA (corresponding author), Monterey Bay Aquarium Res Inst, 770 Sandholdt Rd, Moss Landing, CA 95039 USA.	scholin@mbari.org	Doucette, Gregory/M-3283-2013; Busman, Mark/AFM-0629-2022; Busman, Mark/AAH-3042-2022; Trainer, Vera/AAE-9306-2022	Busman, Mark/0000-0001-9750-064X				ANDERSON DM, 1993, 9302 WOODS HOL OC I; ANTONELIS GA, 1984, FISH B-NOAA, V82, P67; Bates S. S., 1998, PHYSL ECOLOGY HARMFU, P405; Bates S.S., 1998, PHYSL ECOLOGY HARMFU, P267; Beltran AS, 1997, TOXICON, V35, P447, DOI 10.1016/S0041-0101(96)00140-7; BOESCH DF, 1997, NOAA COASTAL OCEAN P, V10; Bossart GD, 1998, TOXICOL PATHOL, V26, P276, DOI 10.1177/019262339802600214; CHAVEZ FP, 1991, J GEOPHYS RES-OCEANS, V96, P14833, DOI 10.1029/91JC01163; DAKSHINAMURTI K, 1993, J NEUROSCI, V13, P4486; GERACI JR, 1989, CAN J FISH AQUAT SCI, V46, P1895, DOI 10.1139/f89-238; Gulland F, 1999, NMFSOPR8 NOAA; Harwood J, 1998, NATURE, V393, P17, DOI 10.1038/29877; Hatfield Christine L., 1994, Natural Toxins, V2, P206, DOI 10.1002/nt.2620020409; Luna L.G., 1968, MANUAL HISTOLOGIC ST, Vthird; McClain CR, 1998, SEA TECHNOL, V39, P10; Miller PE, 1998, J PHYCOL, V34, P371, DOI 10.1046/j.1529-8817.1998.340371.x; Ochoa JI, 1998, J SHELLFISH RES, V17, P1671; PARSONS TR, 1984, BIOL OCEANOGRAPHIC P, P39; QUILLIAM MA, 1995, J AOAC INT, V78, P543; Sakamoto CM, 1990, 902 MBARI; Scholin C, 1997, LIMNOL OCEANOGR, V42, P1265, DOI 10.4319/lo.1997.42.5_part_2.1265; SCHOLIN CA, IN PRESS J PHYCOL; STRAIN SM, 1991, NEUROSCIENCE, V44, P343, DOI 10.1016/0306-4522(91)90059-W; SUTHERLAND RJ, 1990, NEUROSCI LETT, V120, P221, DOI 10.1016/0304-3940(90)90043-9; VanDolah FM, 1997, ANAL BIOCHEM, V245, P102, DOI 10.1006/abio.1996.9889; WORK TM, 1993, J ZOO WILDLIFE MED, V24, P54; WRIGHT JLC, 1995, MANUAL HARMFUL MARIN, P113	27	587	612	3	169	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					80	84		10.1038/47481	http://dx.doi.org/10.1038/47481			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638756				2022-12-01	WOS:000084687400046
J	Mortensen, PB; Agerbo, E; Erikson, T; Qin, P; Westergaard-Nielsen, N				Mortensen, PB; Agerbo, E; Erikson, T; Qin, P; Westergaard-Nielsen, N			Psychiatric illness and risk factors for suicide in Denmark	LANCET			English	Article							PREVENTING SUICIDE; ATTRIBUTABLE RISK; SWEDISH SUICIDE; UNEMPLOYMENT; MORTALITY	Background Several risk factors for suicide have been identified, We assessed the relative risks and population attributable risks of suicide associated with various socioeconomic factors and with previous mental illness that necessitated hospital admission. Our aim was to assist in the choice of potential strategies for preventing suicide in the general population. Methods We did a population-based nested case-control study based on register data. Data were collected on a random 5% sample of the Danish population aged 16-78 years during a 15-year period (1980-94) and analysed with conditional logistic regression. Findings 811 cases of suicide were found and 79 871 controls were chosen in this population. Unemployment, tow income, being single, and a history of mental illness necessitating hospital admission were associated With increased risk of suicide. However, in the multivariate analysis, the strongest risk factor was mental illness necessitating hospital admission; risk of suicide was especially high during admission (relative risk 62.6 [95% CI 41.1-95.4]) and during the year after discharge (6.51 [5.03-8.44]). The effect of socioeconomic variables decreased after adjustment for history of mental illness. The population attributable risk associated with mental illness necessitating admission to hospital was 44.6% (43.6-45.5); the attributable risks associated with the other factors were 3.0% (1.4-6.6) for unemployment and 10.3% (6.13-16.9) for being single. Interpretation Suicide prevention aimed at patients who are admitted to hospital with mental disorders and improved detection and treatment of mental disorders in the general population may be the most efficient strategy to decrease risk of suicide. Reports of high relative risk and attributable risk associated with unemployment and other socioeconomic risk factors may be confounded and overestimated owing to the lack of adjustment for the association with mental disorders.	Aarhus Univ Hosp, Psychiat Hosp Aarhus, Inst Basic Psychiat Res, Dept Psychiat Demog, DK-8240 Risskov, Denmark; Univ Aarhus, Ctr Labour Market & Social Res, Aarhus, Denmark	Aarhus University; Aarhus University	Mortensen, PB (corresponding author), Aarhus Univ Hosp, Psychiat Hosp Aarhus, Inst Basic Psychiat Res, Dept Psychiat Demog, DK-8240 Risskov, Denmark.		Agerbo, Esben/A-2645-2012; Mortensen, Preben B/D-2358-2015	Agerbo, Esben/0000-0002-2849-524X; Mortensen, Preben B/0000-0002-5230-9865; Eriksson, Tor/0000-0001-9309-5499				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Appleby L, 1999, LANCET, V353, P1397, DOI 10.1016/S0140-6736(98)10014-4; BARNDORFFNIELSE.OE, 1989, ASYMPTOMATIC TECHNIQ; BARNERASMUSSEN P, 1986, ACTA PSYCHIAT SCAND, V73, P449, DOI 10.1111/j.1600-0447.1986.tb02710.x; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; Clayton D., 1993, STAT MODELS EPIDEMIO; FerradaNoli M, 1997, ACTA PSYCHIAT SCAND, V96, P108, DOI 10.1111/j.1600-0447.1997.tb09914.x; FLANDERS WD, 1986, AM J EPIDEMIOL, V124, P684, DOI 10.1093/oxfordjournals.aje.a114442; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; Goldberg DP., 1992, COMMON MENTAL DISORD; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; IVERSEN L, 1987, BMJ-BRIT MED J, V295, P879, DOI 10.1136/bmj.295.6603.879; Johansson LM, 1997, SOC PSYCH PSYCH EPID, V32, P165; KREITMAN N, 1990, PUBLIC HEALTH IMPACT OF MENTAL DISORDER, P73; KURITZ SJ, 1988, BIOMETRICS, V44, P355, DOI 10.2307/2531850; Lewis G, 1998, BMJ-BRIT MED J, V317, P1283, DOI 10.1136/bmj.317.7168.1283; Lewis G, 1997, BRIT J PSYCHIAT, V171, P351, DOI 10.1192/bjp.171.4.351; MARTIKAINEN PT, 1990, BMJ-BRIT MED J, V301, P407, DOI 10.1136/bmj.301.6749.407; Moscicki EK, 1997, PSYCHIAT CLIN N AM, V20, P499, DOI 10.1016/S0193-953X(05)70327-0; MOSER KA, 1987, BRIT MED J, V294, P86, DOI 10.1136/bmj.294.6564.86; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Rosenman SJ, 1998, MED J AUSTRALIA, V169, P100, DOI 10.5694/j.1326-5377.1998.tb140193.x; *SUNDH, 1992, DODS 1990 CAUS DEATH; WESTERGARDNIELS.N, 1984, STUDIES LABOR MARKET, P267; *WHO, 1967, MAN INT CLASS DIS IC; WILKINSON G, 1994, BRIT MED J, V309, P860, DOI 10.1136/bmj.309.6958.860; World Health Organization, 1992, ICD 10 CLASS MENT BE; 1993, LANCET, V342, P381	30	252	259	1	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					9	12		10.1016/S0140-6736(99)06376-X	http://dx.doi.org/10.1016/S0140-6736(99)06376-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	279MU	10615884				2022-12-01	WOS:000085049200009
J	Hutchins, LF; Unger, JM; Crowley, JJ; Coltman, CA; Albain, KS				Hutchins, LF; Unger, JM; Crowley, JJ; Coltman, CA; Albain, KS			Underrepresentation of patients 65 years of age or older in cancer-treatment trials.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOUTHWEST-ONCOLOGY-GROUP; ACUTE MYELOID-LEUKEMIA; CLINICAL-TRIALS; BREAST-CANCER; WOMEN; CHEMOTHERAPY; REPRESENTATION; HEALTH	Background: Studies have documented the underrepresentation of women and blacks in clinical trials, and their recruitment is now federally mandated. However, little is known about the level of participation of elderly patients. We determined the rates of enrollment of patients 65 years of age or older in trials of treatment for cancer. Methods: We analyzed data on 16,396 patients consecutively enrolled in 164 Southwest Oncology Group treatment trials between 1993 and 1996 according to sex, race (black or white), and age under 65 years or 65 or older. These rates were compared with the corresponding rates in the general population of patients with cancer, derived from the 1990 U.S. Census and from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program for the period from 1992 through 1994. Fifteen types of cancer were included in the analysis. Results: The overall proportions of women and blacks enrolled in Southwest Oncology Group trials were similar to or the same as the estimated proportions in the U.S. population of patients with cancer (women, 41 percent and 43 percent; blacks, 10 percent and 10 percent, respectively). In contrast, patients 65 years of age or older were underrepresented overall (25 percent vs. 63 percent, P < 0.001) and in trials involving all 15 types of cancer except lymphoma. The underrepresentation was particularly notable in trials of treatment for breast cancer (9 percent vs. 49 percent, P < 0.001). The findings were similar when data on patients who were 70 years of age or older were analyzed, when 15 trials that excluded older patients were eliminated from the analysis, and when community-based enrollment was analyzed separately from enrollment at academic centers. Conclusions: There is substantial underrepresentation of patients 65 years of age or older in studies of treatment for cancer. The reasons should be clarified, and policies adopted to correct this underrepresentation. (N Engl J Med 1999;341:2061-7.) (C)1999, Massachusetts Medical Society.	Univ Arkansas Med Sci, Dept Med, Div Hematol & Oncol, Little Rock, AR 72205 USA; Fred Hutchinson Canc Res Ctr, SW Oncol Grp, Ctr Stat, Seattle, WA 98104 USA; Univ Texas, Hlth Sci Ctr, Dept Med Oncol, San Antonio, TX 78284 USA; Loyola Univ, Med Ctr, Div Hematol & Oncol, Dept Med, Maywood, IL 60153 USA	University of Arkansas System; University of Arkansas Medical Sciences; Fred Hutchinson Cancer Center; Southwest Oncology Group; University of Texas System; University of Texas Health San Antonio; Loyola University Chicago	Hutchins, LF (corresponding author), SW Oncol Grp, Operat Off, 4980 Omicron Dr, San Antonio, TX 78245 USA.		Unger, Joseph/O-7457-2019		NATIONAL CANCER INSTITUTE [U10CA038926, U10CA037981, U10CA032102] Funding Source: NIH RePORTER; NCI NIH HHS [CA32102, CA37981, CA38926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELL M, 1993, NEW ENGL J MED, V329, P271, DOI 10.1056/NEJM199307223290409; Baquet C, 1986, Prog Clin Biol Res, V216, P215; BEGG CB, 1980, CANCER CLIN TRIALS, V3, P369; BENSON AB, 1991, J CLIN ONCOL, V9, P2067, DOI 10.1200/JCO.1991.9.11.2067; BONADONNA G, 1992, CANCER RES, V52, P2127; Chamberlain RM, 1998, INT J RADIAT ONCOL, V40, P9, DOI 10.1016/S0360-3016(97)00833-X; CHRISTMAN K, 1992, JAMA-J AM MED ASSOC, V268, P57, DOI 10.1001/jama.268.1.57; COTTON P, 1993, JAMA-J AM MED ASSOC, V269, P2067; CRIVELLARI D, 1998, P AN M AM SOC CLIN, V17, pA102; DEES EC, 1998, P AN M AM SOC CLIN, V17, pA103; Dignam JJ, 1997, CANCER-AM CANCER SOC, V80, P80, DOI 10.1002/(SICI)1097-0142(19970701)80:1<80::AID-CNCR11>3.0.CO;2-B; FELDMAN EJ, 1995, SEMIN ONCOL, V22, P21; Food and Drug Administration, 1993, FED REG, V58, P39406; FREEMAN HP, 1989, CANCER, V63, P2562, DOI 10.1002/1097-0142(19890615)63:12<2562::AID-CNCR2820631234>3.0.CO;2-0; GIOVANAZZIBANNON S, 1994, J CLIN ONCOL, V12, P2447, DOI 10.1200/JCO.1994.12.11.2447; Godwin JE, 1998, BLOOD, V91, P3607, DOI 10.1182/blood.V91.10.3607.3607_3607_3615; Gotay C C, 1993, Oncology (Williston Park), V7, P67; Gridelli C, 1999, JNCI-J NATL CANCER I, V91, P66; HAYUNGA EG, 1997, APPL CLIN TRIALS, V6, P41; Hutchins L F, 1987, Clin Geriatr Med, V3, P483; JOHNSON PRE, 1993, BRIT J HAEMATOL, V83, P1, DOI 10.1111/j.1365-2141.1993.tb04622.x; Leith CP, 1997, BLOOD, V89, P3323; MAKUC DM, 1989, AM J PUBLIC HEALTH, V79, P21, DOI 10.2105/AJPH.79.1.21; MARLIN SM, 1996, CLIN INVEST MED S, V19, pA50; Marwick C, 1998, JAMA-J AM MED ASSOC, V279, P418, DOI 10.1001/jama.279.6.418; MERKATZ RB, 1993, NEW ENGL J MED, V329, P292, DOI 10.1056/NEJM199307223290429; PINN VW, 1992, AM J PREV MED, V8, P399; RYAN DH, 1992, AM J CLIN ONCOL-CANC, V15, P69, DOI 10.1097/00000421-199202000-00013; SCHMUCKER DL, 1993, CLIN PHARMACOL THER, V54, P11, DOI 10.1038/clpt.1993.102; Tejeda HA, 1996, J NATL CANCER I, V88, P812, DOI 10.1093/jnci/88.12.812; TRIMBLE EL, 1994, CANCER, V74, P2208, DOI 10.1002/1097-0142(19941001)74:7+<2208::AID-CNCR2820741737>3.0.CO;2-#; YANCIK R, 1986, AM J OBSTET GYNECOL, V154, P639, DOI 10.1016/0002-9378(86)90623-X	32	1673	1691	2	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2061	2067		10.1056/NEJM199912303412706	http://dx.doi.org/10.1056/NEJM199912303412706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615079				2022-12-01	WOS:000084573300006
J	Sagrista-Sauleda, J; Angel, J; Permanyer-Miralda, G; Soler-Soler, J				Sagrista-Sauleda, J; Angel, J; Permanyer-Miralda, G; Soler-Soler, J			Long-term follow-up of idiopathic chronic pericardial effusion.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY CHYLOPERICARDIUM; CARDIAC-TAMPONADE; EXPERIENCE; SERIES	Background: A large idiopathic chronic pericardial effusion is a collection of pericardial fluid that persists for more than three months and has no apparent cause. We conducted a prospective study of the natural history and treatment of this disorder. Methods: Between 1977 and 1992, we prospectively evaluated and enrolled patients with large idiopathic chronic pericardial effusion. We performed pericardiocentesis in most of the patients. We performed pericardiectomy when large pericardial effusion reappeared after pericardiocentesis. Follow-up ranged from 18 months to 20 years (median, 7 years). Results: During the study period, we evaluated a total of 1108 patients with pericarditis, 461 of whom had large pericardial effusion. Twenty-eight of these patients (age range, 7 to 85 years; median, 61) had large idiopathic chronic effusion and were included in the study. The duration of effusion ranged from 6 months to 15 years (median, 3 years). At the initial evaluation, 13 patients were asymptomatic. Overt tamponade was found in eight patients (29 percent). Therapeutic pericardiocentesis, performed in 24 patients, was followed by the disappearance of or marked reduction in the effusion in 8. Five of the 24 patients underwent early pericardiectomy, and in 11 large pericardial effusion reappeared. Cardiac catheterization, performed in 16 patients, showed elevated intrapericardial pressure (mean [+/-SD], 4.75+/-3.79 mm Hg) and reduced transmural pressure (1.0+/-2.50 mm Hg) before pericardiocentesis. Both of these abnormalities in pressure improved significantly after pericardiocentesis. Pericardiectomy, performed in 20 patients, yielded excellent long-term results. At the end of the follow-up period, 10 patients had died, but none had died from pericardial disease. Conclusions: Large idiopathic chronic pericardial effusion is well tolerated for long periods in most patients, but severe tamponade can develop unexpectedly at any time. Pericardiocentesis alone frequently results in the resolution of large effusions, but recurrence is common and pericardiectomy should be considered whenever a large effusion recurs after pericardiocentesis. (N Engl J Med 1999;341:2054-9.) (C)1999, Massachusetts Medical Society.	Hosp Gen Univ Vall Dhebron, Serv Cardiol, Barcelona 08035, Spain	Hospital Universitari Vall d'Hebron	Sagrista-Sauleda, J (corresponding author), Hosp Gen Univ Vall Dhebron, Serv Cardiol, Passeig Vall Dhebron 119-129, Barcelona 08035, Spain.							BARKER PS, 1950, CIRCULATION, V2, P134, DOI 10.1161/01.CIR.2.1.134; BEDFORD DE, 1964, BRIT HEART J, V26, P499; BENDAYAN P, 1991, ARCH MAL COEUR VAISS, V84, P127; BOUVRAIN Y, 1957, Sem Hop, V33, P3353; BROWN AK, 1966, BRIT HEART J, V28, P609; COLOMBO A, 1988, CLIN CARDIOL, V11, P389, DOI 10.1002/clc.4960110606; CONNOLLY DC, 1959, CIRCULATION, V20, P1095, DOI 10.1161/01.CIR.20.6.1095; CONTRO S, 1955, CIRCULATION, V11, P844, DOI 10.1161/01.CIR.11.6.844; DRESSLER W, 1966, J AMER MED ASSOC, V195, P1064, DOI 10.1001/jama.195.12.1064; DUNN RP, 1975, AM HEART J, V89, P369, DOI 10.1016/0002-8703(75)90088-5; FOWLER NO, 1985, PERICARDIUM HLTH DIS, P217; GHOSH SC, 1985, INT SURG, V70, P5; GONIN A, 1956, REV LYON MED, V5, P741; GUIDOTTI P L, 1954, Arch Mal Coeur Vaiss, V47, P1001; HOUSEHAM C, 1982, S AFR MED J, V62, P293; JAFFE RJ, 1959, ANN INTERN MED, V51, P363, DOI 10.7326/0003-4819-51-2-363; KANE G C, 1988, Chest, V93, P434, DOI 10.1378/chest.93.2.434; KLOPFENSTEIN HS, 1990, PERICARDIAL DIS NEW, P47; Loire R, 1996, ARCH MAL COEUR VAISS, V89, P835; MARION MMJ, 1979, BORDEAUX MED, V12, P1449; MASK WK, 1990, J THORAC CARDIOV SUR, V99, P569; MUSEMECHE CA, 1990, J PEDIATR SURG, V25, P840, DOI 10.1016/0022-3468(90)90187-E; PERMANYERMIRALDA G, 1985, AM J CARDIOL, V56, P623, DOI 10.1016/0002-9149(85)91023-9; PUIGMASSANA M, 1972, BRIT HEART J, V34, P431; REDDY PS, 1990, AM J CARDIOL, V66, P1487, DOI 10.1016/0002-9149(90)90540-H; RIVAS JJ, 1985, MED CLIN-BARCELONA, V84, P102; SAGRISTASAULEDA J, 1988, J AM COLL CARDIOL, V11, P724, DOI 10.1016/0735-1097(88)90203-3; SAGRISTASAULEDA J, 1982, CIRCULATION, V66, P895, DOI 10.1161/01.CIR.66.4.895; SAINTPIERRE A, 1966, ACTUAL CARDIOVASC, P300; SANCHEZ MAG, 1982, MONOCARDIO, V3, P24; SCHEUER J, 1960, CIRCULATION, V21, P41, DOI 10.1161/01.CIR.21.1.41; SHABETAI R, 1981, PERICARDIUM, P108; Soler-Soler J, 1990, PERICARDIAL DIS NEW, P217; SOULIE P, 1960, ARCH MAL COEUR, V53, P1248; Suzman S, 1943, BRIT HEART J, V5, P19; TAVARES S, 1981, MD STATE MED J, V30, P64; WEITZMAN LB, 1984, CIRCULATION, V69, P506, DOI 10.1161/01.CIR.69.3.506; WOOD P, 1968, WOODS DIS HEART CIRC, P762; YU PNG, 1953, ANN INTERN MED, V39, P928, DOI 10.7326/0003-4819-39-4-928; ZISKIND AA, 1993, J AM COLL CARDIOL, V21, P1, DOI 10.1016/0735-1097(93)90710-I	40	122	132	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2054	2059		10.1056/NEJM199912303412704	http://dx.doi.org/10.1056/NEJM199912303412704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615077				2022-12-01	WOS:000084573300004
J	Trevithick, CC; Chartrand, MM; Wahlman, J; Rahman, F; Hirst, M; Trevithick, JR				Trevithick, CC; Chartrand, MM; Wahlman, J; Rahman, F; Hirst, M; Trevithick, JR			Shaken, not stirred: bioanalytical study of the antioxidant activities of martinis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; VITAMIN-E CONSUMPTION; RISK; ALCOHOL	Background Moderate consumption of alcoholic drinks seems to reduce the risks of developing cardiovascular disease, stroke, and cataracts, perhaps through antioxidant actions of their alcohol, flavonoid, ur polyphenol contents. "Shaken, not stirred" routinely identifies the way the famous secret agent James Bond requires his martinis. Objectives As Mr Bond is not afflicted by cataracts or cardiovascular disease, an investigation was conducted to determine whether the mode of preparing martinis has an influence on their antioxidant capacity. Design Stir-red and shaken martinis were assayed for their ability to quench luminescence by a luminescent procedure in which hydrogen peroxide reacts with luminol bound to albumin. Student's t test was used for statistical analysis. Results Shaken martinis were more effective in deactivating hydrogen peroxide than the stirred variety, and both were more effective than gin or vermouth alone (0.072% of peroxide control for shaken martini, 0.157% for stirred v 58.3% for gin and 1.90% for vermouth). The reason for this is not clear, but it may well not involve the facile oxidation of reactive martini components: control martinis through which either oxygen or nitrogen was bubbled did not differ in their ability to deactivate hydrogen peroxide (0.061% v 0.057%) and did not differ from the shaken martini. Moreover, preliminary experiments indicate that martinis are less well endowed with polyphenols than Sauvignon white wine or Scotch whisky (0.056 mmol/l (catechin equivalents) shaken, 0.060 mmol/l stirred v 0.0592 mmol/l wine, 0.575 mmol/l whisky). Conclusions 007's profound state of health may be due, at least in part, to compliant bartenders.	Univ Western Ontario, Fac Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Trevithick, JR (corresponding author), Univ Western Ontario, Fac Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada.	trevjohn@julian.uwo.ca		Chartrand, Michelle/0000-0003-3398-7246				CLAYTON RM, 1982, T OPHTHAL SOC UK, V102, P331; Duthie GG, 1998, EUR J CLIN NUTR, V52, P733, DOI 10.1038/sj.ejcn.1600635; KIECHL S, 1994, STROKE, V25, P1593, DOI 10.1161/01.STR.25.8.1593; KLATSKY AL, 1994, ALCOHOL CLIN EXP RES, V18, P88, DOI 10.1111/j.1530-0277.1994.tb00886.x; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROBERTSON JM, 1989, ANN NY ACAD SCI, V570, P372; Sacco RL, 1999, JAMA-J AM MED ASSOC, V281, P53, DOI 10.1001/jama.281.1.53; SASAKI H, 1997, US JAP COOP CAT RES, P66; Spector A, 1998, INVEST OPHTH VIS SCI, V39, P1188; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Trevithick CC, 1999, REDOX REP, V4, P89, DOI 10.1179/135100099101534765; Trevithick JR, 1997, BIOCHEM MOL BIOL INT, V41, P695; TREVITHICK JR, 1994, BIOCHEM MOL BIOL INT, V33, P1179	13	11	11	1	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 25	1999	319	7225					1600	1602		10.1136/bmj.319.7225.1600	http://dx.doi.org/10.1136/bmj.319.7225.1600			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600955	Green Published, Bronze			2022-12-01	WOS:000084562600008
J	Xu, JA; Deng, QL; Chen, JG; Houk, KN; Bartek, J; Hilvert, D; Wilson, IA				Xu, JA; Deng, QL; Chen, JG; Houk, KN; Bartek, J; Hilvert, D; Wilson, IA			Evolution of shape complementarity and catalytic efficiency from a primordial antibody template	SCIENCE			English	Article							DIELS-ALDER REACTION; AUTOMATED DOCKING; RATE ACCELERATIONS; CROSS-REACTIVITY; PROTEINS; COMPLEXES; INSIGHTS; ENERGY	The crystal structure of an efficient Diels-Alder antibody catalyst at 1.9 angstrom resolution reveals almost perfect shape complementarity with its transition state analog. Comparison with highly related progesterone and Diels-Alderase antibodies that arose from the same primordial germ Line template shows the relatively subtle mutational steps that were able to evolve both structural complementarity and catalytic efficiency.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Swiss Fed Inst Technol, ETH Zurich, Organ Chem Lab, CH-8092 Zurich, Switzerland	Scripps Research Institute; Scripps Research Institute; University of California System; University of California Los Angeles; Swiss Federal Institutes of Technology Domain; ETH Zurich	Xu, JA (corresponding author), Mol Simulat Inc, 9685 Scranton Rd, San Diego, CA 92121 USA.		Bartek, Jiri/G-5870-2014	Xu, Jian/0000-0002-4251-6895	NCI NIH HHS [CA27489] Funding Source: Medline; NIGMS NIH HHS [GM38273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038273, R01GM038273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AQVIST J, 1994, PROTEIN ENG, V7, P385, DOI 10.1093/protein/7.3.385; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; AREVALO JH, 1994, J MOL BIOL, V241, P663, DOI 10.1006/jmbi.1994.1543; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; Badger J, 1999, PROTEINS, V35, P25, DOI 10.1002/(SICI)1097-0134(19990401)35:1<25::AID-PROT3>3.3.CO;2-M; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Charbonnier JB, 1997, SCIENCE, V275, P1140, DOI 10.1126/science.275.5303.1140; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P439; Cossi M, 1996, CHEM PHYS LETT, V255, P327, DOI 10.1016/0009-2614(96)00349-1; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; GOUVERNEUR VE, 1997, SCIENCE, V275, P1140; Haynes MR, 1996, ISRAEL J CHEM, V36, P151; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; Heine A, 1998, SCIENCE, V279, P1934, DOI 10.1126/science.279.5358.1934; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; HILVERT D, 1999, TOP STEREOCHEM, V22, P83; Hollfelder F, 1996, NATURE, V383, P60, DOI 10.1038/383060a0; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JONES S, 1996, P NATL ACAD SCI USA, V93, P1320; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; Keith T.A, GAUSSIAN; Kikuchi K, 1996, J AM CHEM SOC, V118, P8184, DOI 10.1021/ja9617395; Laschat S, 1996, ANGEW CHEM INT EDIT, V35, P289, DOI 10.1002/anie.199602891; LEWIS C, 1991, SCIENCE, V253, P1019, DOI 10.1126/science.1887215; MEEKEL AAP, 1995, J CHEM SOC CHEM COMM, P571, DOI 10.1039/c39950000571; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; PAULING L, 1948, Am Sci, V36, P51; PEARLMAN DA, 1995, AMBER 4 1; Pitt AR, 1996, ISRAEL J CHEM, V36, P171; Romesberg FE, 1999, BIOORG MED CHEM LETT, V9, P1741, DOI 10.1016/S0960-894X(99)00281-4; RORNESBERG FE, 1998, SCIENCE, V279, P1929; SCHULTZ PG, 1993, ACCOUNTS CHEM RES, V26, P391, DOI 10.1021/ar00032a001; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Seelig B, 1999, CHEM BIOL, V6, P167, DOI 10.1016/S1074-5521(99)89008-5; STURA EA, 1993, IMMUNOMETHODS, V3, P164; Tarasow TM, 1997, NATURE, V389, P54, DOI 10.1038/37950; THORN SN, 1995, NATURE, V373, P228, DOI 10.1038/373228a0; Ulrich HD, 1997, NATURE, V389, P271, DOI 10.1038/38470; Warshel A, 1998, P NATL ACAD SCI USA, V95, P5950, DOI 10.1073/pnas.95.11.5950; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; WESTHEIMER FH, 1962, ADV ENZYMOL REL S BI, V24, P441; YLIKAUHALUOMA JT, 1995, J AM CHEM SOC, V117, P7041, DOI 10.1021/ja00132a001	50	106	107	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2345	2348		10.1126/science.286.5448.2345	http://dx.doi.org/10.1126/science.286.5448.2345			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600746				2022-12-01	WOS:000084318500063
J	Yoshinaga, SK; Whoriskey, JS; Khare, SD; Sarmiento, U; Guo, J; Horan, T; Shih, G; Zhang, M; Coccia, MA; Kohno, T; Tafuri-Bladt, A; Brankow, D; Campbell, P; Chang, D; Chiu, L; Dai, TN; Duncan, G; Elliott, GS; Hui, A; McCabe, SM; Scully, S; Shahinian, A; Shaklee, CL; Van, G; Mak, TW; Senaldi, G				Yoshinaga, SK; Whoriskey, JS; Khare, SD; Sarmiento, U; Guo, J; Horan, T; Shih, G; Zhang, M; Coccia, MA; Kohno, T; Tafuri-Bladt, A; Brankow, D; Campbell, P; Chang, D; Chiu, L; Dai, TN; Duncan, G; Elliott, GS; Hui, A; McCabe, SM; Scully, S; Shahinian, A; Shaklee, CL; Van, G; Mak, TW; Senaldi, G			T-cell co-stimulation through B7RP-1 and ICOS	NATURE			English	Article							CONTACT HYPERSENSITIVITY; MOLECULAR-CLONING; EFFICIENCY; EXPRESSION; RESPONSES; TOLERANCE; BLOCKADE; SYSTEM; MEMORY; CTLA-4	T-cell activation requires co-stimulation through receptors such as CD28 (refs 1-3) and antigen-specific signalling through the T-cell antigen receptor. Here we describe a new murine costimulatory receptor-ligand pair. The receptor, which is related to CD28 and is the homologue of the human protein ICOS4, is expressed on activated T cells and resting memory T cells. The ligand, which has homology to B7 molecules and is called B7-related protein-1 (B7RP-1), is expressed on B cells and macrophages. ICOS and B7RP-1 do not interact with proteins in the CD28-B7 pathway, and B7RP-1 co-stimulates T cells in vitro independently of CD28. Transgenic mice expressing a B7RP-1-Fc fusion protein show lymphoid hyperplasia in the spleen, lymph nodes and Peyer's patches. Presensitized mice treated with B7RP-1-Fc during antigen challenge show enhanced hypersensitivity. Therefore, B7RP-1 exhibits co-stimulatory activities in vitro and in vivo. ICOS and B7RP-1 define a new and distinct receptor-ligand pair that is structurally related to CD28-B7 and is involved in the adaptive immune response.	Amgen Inc, Thousand Oaks, CA 91320 USA; Amgen Inc, Res Inst, Toronto, ON M5G 2C1, Canada	Amgen	Yoshinaga, SK (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Bajorath J, 1999, J MOL MODEL, V5, P169, DOI 10.1007/s008940050116; Beverley PCL, 1996, CURR OPIN IMMUNOL, V8, P327, DOI 10.1016/S0952-7915(96)80120-8; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; FREEMAN GJ, 1993, J EXP MED, V178, P2185, DOI 10.1084/jem.178.6.2185; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Greene RME, 1998, EUR RADIOL, V8, P359, DOI 10.1007/s003300050394; GROSS JA, 1990, J IMMUNOL, V144, P3201; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LINSLEY PS, 1995, J BIOL CHEM, V270, P15417, DOI 10.1074/jbc.270.25.15417; McHale JF, 1999, J IMMUNOL, V162, P1648; Schulte M, 1998, OXID MET, V49, P33, DOI 10.1023/A:1018818021754; SIMONET WS, 1994, J CLIN INVEST, V94, P1310, DOI 10.1172/JCI117450; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Tang AM, 1996, J IMMUNOL, V157, P117; Tang AM, 1997, EUR J IMMUNOL, V27, P3143, DOI 10.1002/eji.1830271210; WILCOX JN, 1993, J HISTOCHEM CYTOCHEM, V41, P1725, DOI 10.1177/41.12.8245419	23	643	752	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					827	832		10.1038/45582	http://dx.doi.org/10.1038/45582			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617205				2022-12-01	WOS:000084330500069
J	Kuntz, KM; Tsevat, J; Weinstein, MC; Goldman, L				Kuntz, KM; Tsevat, J; Weinstein, MC; Goldman, L			Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICE GUIDELINES; COST-EFFECTIVENESS; CARDIAC PROCEDURES; ELDERLY PATIENTS; CERVICAL-CANCER; HEALTH-CARE; OUTCOMES; MEDICINE; POLICY; ANGIOPLASTY	Context Expert panels and decision-analytic techniques are increasingly used to determine the appropriateness of medical interventions, but these 2 approaches use different methods to process evidence. Objective To compare expert panel appropriateness ratings of coronary angiography after myocardial infarction (from the time of hospital discharge to 12 weeks after infarction) with the health gains and cost-effectiveness predicted by a decision-analytic model. Design Comparison of the degree of importance of the clinical variables considered in expert panel appropriateness ratings vs a previously published decision-analytic model. Identification of 36 clinical scenarios from the expert panel that could be simulated by the decision-analytic model. Main Outcome Measures Appropriateness score and appropriateness classification (expert panel) vs gain in quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (decision-analytic model). Results The most important clinical variables were similar in the 2 approaches, with the exercise tolerance test result exerting the greatest leverage on strength of recommendation for angiography. Among the expert panel clinical scenarios considered to be appropriate for coronary angiography that could be simulated in the decision-analysis model, the median (interquartile range) health gain and incremental cost-effectiveness ratio were 0.59 (0.41-0.76) QALYs and $27 000 ($23 000-$35 000) per QALY gained, respectively. Among the clinical scenarios that expert panels considered inappropriate, the corresponding medians (interquartile ranges) were 0.24 (0.19-0.34) QALYs and $54 000 ($36 000-$58 000) per QALY gained. The Spearman rank correlation between appropriateness score and QALY gain was 0.58 (P<.001) and between appropriateness score and estimated incremental cost-effectiveness ratios was -0.66 (P<.001). Conclusions For the 36 expert panel scenarios that could be simulated by the decision; analytic model, there was moderate to good agreement between the appropriateness score and both the health gain and the incremental cost-effectiveness ratio of coronary angiography compared with no angiography in the convalescent phase of acute myocardial infarction, but several scenarios judged as inappropriate by the expert panel approach had cost-effectiveness ratios comparable with many generally recommended medical interventions. Formal synthesis of expert judgment and decision modeling is warranted in future efforts at guideline development.	Harvard Univ, Sch Publ Hlth, Ctr Risk Anal,Program Econ Evaluat Med Technol, Dept Hlth Policy & Management, Boston, MA 02115 USA; Univ Cincinnati, Med Ctr, Div Gen Internal Med, Sect Outcomes Res, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Inst Hlth Policy & Hlth Serv Res, Cincinnati, OH 45267 USA; Univ San Francisco, Sch Med, Dept Med, San Francisco, CA 94117 USA	Harvard University; Harvard T.H. Chan School of Public Health; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of San Francisco	Kuntz, KM (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Risk Anal,Program Econ Evaluat Med Technol, Dept Hlth Policy & Management, 718 Huntington Ave, Boston, MA 02115 USA.				AHRQ HHS [R01-HS07081] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], CORONARY ANGIOGRAPHY; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; Bates DW, 1997, ANN INTERN MED, V126, P539, DOI 10.7326/0003-4819-126-7-199704010-00007; Bernstein SJ, 1997, INT J QUAL HEALTH C, V9, P255, DOI 10.1093/intqhc/9.4.255; BROOK RH, 1994, BRIT MED J, V308, P218, DOI 10.1136/bmj.308.6923.218; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHURCHILL DN, 1984, MED DECIS MAKING, V4, P489, DOI 10.1177/0272989X8400400411; Clancy CM, 1998, SCIENCE, V282, P245, DOI 10.1126/science.282.5387.245; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; Field, 1990, CLIN PRACTICE GUIDEL, DOI DOI 10.17226/1626; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; Gold MR., 1996, COST EFFECTIVENESS H; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; Hawkes AP, 1996, AM J PREV MED, V12, P342; Kuntz KM, 1996, CIRCULATION, V94, P957, DOI 10.1161/01.CIR.94.5.957; Landrum MB, 1999, STAT MED, V18, P117, DOI 10.1002/(SICI)1097-0258(19990130)18:2<117::AID-SIM8>3.0.CO;2-7; LEAPE LL, 1990, QRB QUAL REV B, V16, P24; *NAT CTR HLTH STAT, 1991, MORTALITY A, V2; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; SHAPIRO DW, 1993, ANNU REV PUBL HEALTH, V14, P219, DOI 10.1146/annurev.pu.14.050193.001251; TOFLER GH, 1988, AM J CARDIOL, V62, P860, DOI 10.1016/0002-9149(88)90882-X; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; Weinstein MC, 1980, CLIN DECISION ANAL; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606	31	18	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2246	2251		10.1001/jama.282.23.2246	http://dx.doi.org/10.1001/jama.282.23.2246			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	263RG	10605977	Bronze			2022-12-01	WOS:000084138600033
J	Spanagel, R				Spanagel, R			Is there a pharmacological basis for therapy with rapid opioid detoxification?	LANCET			English	Editorial Material							RECEPTOR BLOCKADE; ADDICTED PATIENTS; ANESTHESIA		Max Planck Inst Psychiat, Dept Psychopharmacol, D-80804 Munich, Germany	Max Planck Society	Spanagel, R (corresponding author), Max Planck Inst Psychiat, Dept Psychopharmacol, D-80804 Munich, Germany.							Bell JR, 1999, MED J AUSTRALIA, V171, P26, DOI 10.5694/j.1326-5377.1999.tb123493.x; Kienbaum P, 1998, ANESTHESIOLOGY, V88, P1154, DOI 10.1097/00000542-199805000-00004; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; Maldonado R, 1996, NEUROBIOLOGICAL MECH; Miotto K, 1997, DRUG ALCOHOL DEPEN, V45, P131, DOI 10.1016/S0376-8716(97)01348-3; MORRIS BJ, 1988, J PHARMACOL EXP THER, V247, P729; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; O'Connor PG, 1998, JAMA-J AM MED ASSOC, V279, P229, DOI 10.1001/jama.279.3.229; Rabinowitz J, 1997, DRUG ALCOHOL DEPEN, V47, P77, DOI 10.1016/S0376-8716(97)00073-2; Roizen MF, 1998, ANESTHESIOLOGY, V88, P1142, DOI 10.1097/00000542-199805000-00002; Seoane A, 1997, BRIT J PSYCHIAT, V171, P340, DOI 10.1192/bjp.171.4.340; Spanagel R, 1998, DRUG ALCOHOL DEPEN, V52, P251, DOI 10.1016/S0376-8716(98)00106-9; Ward J, 1999, LANCET, V353, P221, DOI 10.1016/S0140-6736(98)05356-2	13	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2017	2018		10.1016/S0140-6736(99)90248-9	http://dx.doi.org/10.1016/S0140-6736(99)90248-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636363				2022-12-01	WOS:000084183300006
J	Reinherz, EL; Tan, KM; Tang, L; Kern, P; Liu, JH; Xiong, Y; Hussey, RE; Smolyar, A; Hare, B; Zhang, RG; Joachimiak, A; Chang, HC; Wagner, G; Wang, JH				Reinherz, EL; Tan, KM; Tang, L; Kern, P; Liu, JH; Xiong, Y; Hussey, RE; Smolyar, A; Hare, B; Zhang, RG; Joachimiak, A; Chang, HC; Wagner, G; Wang, JH			The crystal structure of a T cell receptor in complex with peptide and MHC class II	SCIENCE			English	Review							TOXIC LYMPHOCYTES-T; BOUND SINGLE PEPTIDES; MYELIN BASIC-PROTEIN; TCR FAB FRAGMENT; ALPHA-CHAIN; ANTIGEN RECEPTOR; 3-DIMENSIONAL STRUCTURE; BETA-CHAIN; SUPERANTIGEN RECOGNITION; POSITIVE SELECTION	The crystal structure of a complex involving the D10 T cell receptor (TCR), 16-residue foreign peptide antigen, and the I-A(k) self major histocompatibility complex (MHC) class II molecule is reported at 3.2 angstrom resolution. The D10 TCR is oriented in an orthogonal mode relative to its peptide-MHC (pMHC) Ligand, necessitated by the amino-terminal extension of peptide residues projecting from the MHC class II antigen-binding groove as part of a mini beta sheet. Consequently, the disposition of D10 complementarity-determining region Loops is altered relative to that of most pMHCI-specific TCRs; the Latter TCRs assume a diagonal orientation, although with substantial variability. Peptide recognition, which involves P-1 to P8 residues, is dominated by the V alpha domain, which also binds to the class II MHC beta(1) helix. That docking is Limited to one segment of MHC-bound peptide offers an explanation for epitope recognition and altered peptide Ligand effects, suggests a structural basis for alloreactivity, and illustrates how bacterial superantigens can span the TCR-pMHCII surface.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; United States Department of Energy (DOE); Argonne National Laboratory	Reinherz, EL (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu; jwang@red.dfci.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037581, R01AI019807, R37AI019807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056008] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/CA37581, AI19807] Funding Source: Medline; NIGMS NIH HHS [GM56008] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACUTO O, 1984, P NATL ACAD SCI-BIOL, V81, P3851, DOI 10.1073/pnas.81.12.3851; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ANDREANI M, 1994, INT J MULTIPHAS FLOW, V20, P1, DOI 10.1016/0301-9322(94)90069-8; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; Backstrom BT, 1998, SCIENCE, V281, P835, DOI 10.1126/science.281.5378.835; Benacerraf B, 1973, Harvey Lect, V67, P109; BENACERRAF B, 1978, J IMMUNOL, V120, P1809; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; Blackman MA, 1996, IMMUNOL RES, V15, P98, DOI 10.1007/BF02918500; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Carson RT, 1997, IMMUNITY, V7, P387, DOI 10.1016/S1074-7613(00)80360-X; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHAN SH, 1993, IMMUNOL REV, V135, P119, DOI 10.1111/j.1600-065X.1993.tb00646.x; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; DALY K, 1995, J IMMUNOL, V155, P27; Daniel C, 1998, IMMUNITY, V8, P543, DOI 10.1016/S1074-7613(00)80559-2; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DECKHUT AM, 1994, J EXP MED, V180, P1931, DOI 10.1084/jem.180.5.1931; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Donson D, 1997, J IMMUNOL, V158, P5229; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1; FABBI M, 1984, NATURE, V312, P269, DOI 10.1038/312269a0; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; Frelinger JA, 1996, IMMUNOL REV, V154, P45, DOI 10.1111/j.1600-065X.1996.tb00929.x; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Fremont DH, 1998, IMMUNITY, V8, P305, DOI 10.1016/S1074-7613(00)80536-1; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GASCOIGNE NRJ, 1984, NATURE, V310, P387, DOI 10.1038/310387a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Ghendler Y, 1998, P NATL ACAD SCI USA, V95, P10061, DOI 10.1073/pnas.95.17.10061; Hare BJ, 1999, NAT STRUCT BIOL, V6, P574; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; Hong SC, 1997, J IMMUNOL, V159, P4395; Housset D, 1997, EMBO J, V16, P4205, DOI 10.1093/emboj/16.14.4205; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; Ignatowicz L, 1997, IMMUNITY, V7, P179, DOI 10.1016/S1074-7613(00)80521-X; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Kersh GJ, 1996, J EXP MED, V184, P1259, DOI 10.1084/jem.184.4.1259; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; Koyasu S, 1997, INT IMMUNOL, V9, P1475, DOI 10.1093/intimm/9.10.1475; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRENSKY AM, 1982, P NATL ACAD SCI-BIOL, V79, P2365, DOI 10.1073/pnas.79.7.2365; KRUISBEEK AM, 1993, CURR OPIN IMMUNOL, V5, P227, DOI 10.1016/0952-7915(93)90009-H; LABRECQUE N, 1994, J EXP MED, V180, P1921, DOI 10.1084/jem.180.5.1921; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEVELT CN, 1995, EUR J IMMUNOL, V25, P1257, DOI 10.1002/eji.1830250519; Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9; Liu CP, 1997, J EXP MED, V186, P1441, DOI 10.1084/jem.186.9.1441; Liu J, 1996, J BIOL CHEM, V271, P33639, DOI 10.1074/jbc.271.52.33639; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.immunol.13.1.587; Marrack P, 1986, Adv Immunol, V38, P1, DOI 10.1016/S0065-2776(08)60005-X; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCKENZIE IFC, 1979, J EXP MED, V150, P1323, DOI 10.1084/jem.150.6.1323; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; Mosyak L, 1998, IMMUNITY, V9, P377, DOI 10.1016/S1074-7613(00)80620-2; Murthy VL, 1997, STRUCTURE, V5, P1385, DOI 10.1016/S0969-2126(97)00288-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; PORTOLES P, 1989, J MOL CELL IMMUNOL, V4, P129; REAY PA, 1994, J IMMUNOL, V152, P3946; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; REINHERZ EL, 1983, IMMUNOL REV, V74, P83, DOI 10.1111/j.1600-065X.1983.tb01085.x; REINHERZ EL, UNPUB; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAITO H, 1984, NATURE, V312, P36, DOI 10.1038/312036a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SantAngelo DB, 1996, IMMUNITY, V4, P367, DOI 10.1016/S1074-7613(00)80250-2; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; Scott CA, 1998, IMMUNITY, V8, P319, DOI 10.1016/S1074-7613(00)80537-3; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SIM GK, 1984, NATURE, V312, P771; Smith KJ, 1998, J EXP MED, V188, P1511, DOI 10.1084/jem.188.8.1511; Speir JA, 1998, IMMUNITY, V8, P553, DOI 10.1016/S1074-7613(00)80560-9; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Surh CD, 1997, IMMUNITY, V7, P209, DOI 10.1016/S1074-7613(00)80524-5; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; van Meerwijk J P, 1994, Semin Immunol, V6, P231, DOI 10.1006/smim.1994.1030; VANMEERWIJK JPM, 1993, SCIENCE, V261, P911, DOI 10.1126/science.8102208; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; WEBB SR, 1994, CURR OPIN IMMUNOL, V6, P467, DOI 10.1016/0952-7915(94)90129-5; WOODLAND DL, 1993, IMMUNOL TODAY, V14, P208, DOI 10.1016/0167-5699(93)90164-G; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Xu Y, 1996, P NATL ACAD SCI USA, V93, P2169, DOI 10.1073/pnas.93.5.2169; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; Ysern X, 1998, NAT STRUCT BIOL, V5, P412, DOI 10.1038/nsb0698-412; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	127	347	357	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1913	1921		10.1126/science.286.5446.1913	http://dx.doi.org/10.1126/science.286.5446.1913			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583947				2022-12-01	WOS:000084003400040
J	Wodarz, A; Ramrath, A; Kuchinke, U; Knust, E				Wodarz, A; Ramrath, A; Kuchinke, U; Knust, E			Bazooka provides an apical cue for Inscuteable localization in Drosophila neuroblasts	NATURE			English	Article							ASYMMETRIC CELL-DIVISION; CAENORHABDITIS-ELEGANS; DAUGHTER-CELL; PROSPERO; PROTEIN; STAUFEN; MIRANDA; GENE; SEGREGATION; POLARITY	Asymmetric cell division generates daughter cells with different developmental fates from progenitor cells that contain localized determinants. During this division, the asymmetric localization of cell-fate determinants and the orientation of the mitotic spindle must be precisely coordinated. In Drosophila neuroblasts, inscuteable controls both spindle orientation and the asymmetric localization of the cell-fate determinants Prospero and Numb(1). Inscuteable itself is localized in an apical cortical crescent and thus reflects the intrinsic asymmetry of the neuroblast(1,2). Here we show that localization of Inscuteable depends on Bazooka, a protein containing three PDZ domains with overall sequence similarity to Par-3 of Caenorhabditis elegans(3). Bazooka and Inscuteable form a complex that also contains Staufen, a protein responsible for the asymmetric localization of prospero messenger RNA. We propose that, after delamination of the neuroblast from the neuroepithelium, Bazooka provides an asymmetric cue in the apical cytocortex that is required to anchor Inscuteable, As Bazooka is also responsible for the maintenance of apical-basal polarity in epithelial tissues(4), it may be the missing link between epithelial polarity and neuroblast polarity.	Univ Dusseldorf, Inst Genet, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Wodarz, A (corresponding author), Univ Dusseldorf, Inst Genet, Univ Str 1, D-40225 Dusseldorf, Germany.		Wodarz, Andreas/D-4642-2013; Knust, Elisabeth/B-4338-2017	Wodarz, Andreas/0000-0002-0007-6289; 				BRAND AH, 1993, DEVELOPMENT, V118, P401; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; CHOU TB, 1992, GENETICS, V131, P643; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Gonczy P, 1996, TRENDS CELL BIOL, V6, P382, DOI 10.1016/0962-8924(96)10035-0; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; Hung TJ, 1999, DEVELOPMENT, V126, P127; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 1997, CURR OPIN CELL BIOL, V9, P833, DOI 10.1016/S0955-0674(97)80085-3; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Matsuzaki F, 1998, DEVELOPMENT, V125, P4089; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Shen CP, 1998, GENE DEV, V12, P1837, DOI 10.1101/gad.12.12.1837; SPANA EP, 1995, DEVELOPMENT, V121, P3187; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089	27	358	362	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					544	547		10.1038/990128	http://dx.doi.org/10.1038/990128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591216				2022-12-01	WOS:000084013200060
J	Hirsch, E; Katanaev, VL; Garlanda, C; Azzolino, O; Pirola, L; Silengo, L; Sozzani, S; Mantovani, A; Altruda, F; Wymann, MP				Hirsch, E; Katanaev, VL; Garlanda, C; Azzolino, O; Pirola, L; Silengo, L; Sozzani, S; Mantovani, A; Altruda, F; Wymann, MP			Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation	SCIENCE			English	Article							INDUCED RESPIRATORY BURST; KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN-NEUTROPHILS; ACTIVATION; WORTMANNIN; CHEMOKINES; MIGRATION; INHIBITION; RECEPTORS	Phosphoinositide 3-kinase (PI3K) activity is crucial for Leukocyte function, but the roles of the four receptor-activated isoforms are unclear. Mice Lacking heterotrimeric guanine nucleotide-binding protein (G protein)-coupled PI3K gamma were viable and had fully differentiated neutrophils and macrophages. Chemoattractant-stimulated PI3K gamma(-/-) neutrophils did not produce phosphatidylinositol 3,4,5-trisphosphate, did not activate protein kinase B, and displayed impaired respiratory burst and motility. Peritoneal PI3K gamma-null macrophages showed a reduced migration toward a wide range of chemotactic stimuli and a severely defective accumulation in a septic peritonitis model. These results demonstrate that PI3K gamma is a crucial signaling molecule required for macrophage accumulation in inflammation.	Univ Turin, Dept Genet Biol & Biochem, Turin, Italy; Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland; Ist Ric Farmacol Mario Negri, Milan, Italy; Univ Brescia, Sect Gen Pathol, Brescia, Italy	University of Turin; University of Fribourg; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Brescia	Hirsch, E (corresponding author), Univ Turin, Dept Genet Biol & Biochem, Turin, Italy.	hirsch@molinette.unito.it; matthiaspaul.wymann@unifr.ch	Hirsch, Emilio/F-4848-2013; Garlanda, Cecilia/K-4601-2016; Mantovani, Alberto/HCI-7449-2022; Pirola, Luciano/I-5250-2018; Sozzani, Silvano/C-1447-2009; Katanaev, Vladimir/F-9480-2014; Wymann, Matthias P/C-3227-2008	Hirsch, Emilio/0000-0002-9073-6024; Garlanda, Cecilia/0000-0002-1510-7703; Mantovani, Alberto/0000-0001-5578-236X; Sozzani, Silvano/0000-0002-3144-8743; Katanaev, Vladimir/0000-0002-7909-5617; Wymann, Matthias P/0000-0003-3349-4281; Pirola, Luciano/0000-0001-6539-5435	Telethon [E.0635] Funding Source: Medline	Telethon(Fondazione Telethon)		Al-Aoukaty A, 1999, J IMMUNOL, V162, P3249; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Aratani Y, 1999, INFECT IMMUN, V67, P1828; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernstein HG, 1998, CELL MOL BIOL, V44, P973; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; Frevert CW, 1998, J IMMUNOL METHODS, V213, P41, DOI 10.1016/S0022-1759(98)00016-7; HIRSCH E, UNPUB; KOWNATZKI E, 1988, CLIN EXP IMMUNOL, V74, P143; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; OKADA T, 1994, J BIOL CHEM, V269, P3568; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Test S T, 1986, Methods Enzymol, V132, P401; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	28	1042	1126	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2000	287	5455					1049	1053		10.1126/science.287.5455.1049	http://dx.doi.org/10.1126/science.287.5455.1049			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669418				2022-12-01	WOS:000085245400050
J	Evans, C; Chalmers, J; Capewell, S; Redpath, A; Finlayson, A; Boyd, J; Pell, J; McMurray, J; Macintyre, K; Graham, L				Evans, C; Chalmers, J; Capewell, S; Redpath, A; Finlayson, A; Boyd, J; Pell, J; McMurray, J; Macintyre, K; Graham, L			"I don't like Mondays" - day of the week of coronary heart disease deaths in Scotland: study of routinely collected data	BRITISH MEDICAL JOURNAL			English	Article									Natl Hlth Serv Scotland, Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Univ Glasgow, Glasgow Royal Infirm, Dept Cardiol, Glasgow G31 2ER, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G12 8QQ, Lanark, Scotland	NHS National Services Scotland; University of Glasgow; University of Glasgow; University of Glasgow	Chalmers, J (corresponding author), Natl Hlth Serv Scotland, Informat & Stat Div, Trin Pk House, Edinburgh EH5 3SQ, Midlothian, Scotland.		mcmurray, John/B-2467-2013; Macintyre, Kate/J-7174-2014	mcmurray, John/0000-0002-6317-3975; Macintyre, Kate/0000-0003-2741-0467; Boyd, James/0000-0002-8925-8811; Pell, Jill/0000-0002-8898-7035				Chen Z, 1998, CAN J EXP PSYCHOL, V52, P7, DOI 10.1037/h0087274; McKee M, 1998, J ROY SOC MED, V91, P402, DOI 10.1177/014107689809100802; Peters Robert W., 1996, Cardiology Clinics, V14, P185; WILLICH SN, 1994, CIRCULATION, V90, P87, DOI 10.1161/01.CIR.90.1.87	4	57	60	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	2000	320	7229					218	219		10.1136/bmj.320.7229.218	http://dx.doi.org/10.1136/bmj.320.7229.218			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279DR	10642230	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000085029600024
J	Xu, CG; Mao, DL; Holers, VM; Palanca, B; Cheng, AM; Molina, H				Xu, CG; Mao, DL; Holers, VM; Palanca, B; Cheng, AM; Molina, H			A critical role for murine complement regulator Crry in fetomaternal tolerance	SCIENCE			English	Article							DECAY-ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; PREFERENTIAL EXPRESSION; IMMUNE-RESPONSE; PREGNANCY; RECEPTOR; HOMOLOG; CELLS; ACTIVATION; DISTINCT	Complement is a component of natural immunity. Its regulation is needed to protect tissues from inflammation, but mice with a disrupted gene for the complement regulator decay accelerating factor were normal. Mice that were deficient in another murine complement regulator, Crry, were generated to investigate its role in vivo. Survival of Crry(-/-) embryos was compromised because of complement deposition and concomitant placenta inflammation. Complement activation at the fetomaternal interface caused the fetal Loss because breeding to C3(-/-) mice rescued Crry(-/-) mice from lethality. Thus, the regulation of complement is critical in fetal control of maternal processes that mediate tissue damage.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Vet Adm Med Ctr, St Louis, MO 63106 USA	Washington University (WUSTL); Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Molina, H (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.	hmolina@imgate.wustl.edu	Palanca, Ben Julian/AAW-4006-2021	Palanca, Ben Julian/0000-0001-7535-5701	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040576, R01AI044912] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI40576-01, R01 AI44912-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBAS AK, 1997, CELLULAR MOL IMMUNOL, P294; BILLINGTON WD, 1992, BAILLIERE CLIN OB GY, V6, P417, DOI 10.1016/S0950-3552(05)80004-5; BOOM B W, 1991, Journal of Dermatological Science, V2, P308, DOI 10.1016/0923-1811(91)90055-3; BULMER JN, 1992, BAILLIERE CLIN OB GY, V6, P461, DOI 10.1016/S0950-3552(05)80006-9; Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1; HOGAN B, 1986, MANIPULATING MOUSE E, P152; HOLERS VM, 1992, IMMUNOL TODAY, V13, P231; HOLMES CH, 1992, BAILLIERE CLIN OB GY, V6, P439, DOI 10.1016/S0950-3552(05)80005-7; HOLMES CH, 1990, J IMMUNOL, V144, P3099; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; ITOH J, 1991, CLIN EXP IMMUNOL, V83, P364; KIM YU, 1995, J EXP MED, V181, P151, DOI 10.1084/jem.181.1.151; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; KURTZ CB, 1989, J IMMUNOL, V143, P2058; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI B, 1993, J IMMUNOL, V151, P4295; LUBLIN DM, 1990, CURR TOP MICROBIOL, V153, P123; MOLINA H, 1992, J EXP MED, V175, P121, DOI 10.1084/jem.175.1.121; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; ROONEY IA, 1993, IMMUNOL RES, V12, P276, DOI 10.1007/BF02918258; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Suny XJ, 1999, P NATL ACAD SCI USA, V96, P628, DOI 10.1073/pnas.96.2.628; Tsujimura A, 1998, BIOCHEM J, V330, P163, DOI 10.1042/bj3300163; WEIGLE WO, 1983, SPRINGER SEMIN IMMUN, V6, P173; WONG WW, 1985, J IMMUNOL, V134, P4048; Xu C., UNPUB	26	396	415	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	2000	287	5452					498	501		10.1126/science.287.5452.498	http://dx.doi.org/10.1126/science.287.5452.498			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642554				2022-12-01	WOS:000084929900052
J	Cha, JN; Stucky, GD; Morse, DE; Deming, TJ				Cha, JN; Stucky, GD; Morse, DE; Deming, TJ			Biomimetic synthesis of ordered silica structures mediated by block copolypeptides	NATURE			English	Article							MESOPOROUS SILICA; PROTEIN; DIATOM; ACID	In biological systems such as diatoms and sponges, the formation of solid silica structures with precisely controlled morphologies is directed by proteins and polysaccharides and occurs in water at neutral:pH and ambient temperature(1-4). Laboratory methods, in contrast, have to rely on extreme pH conditions and/or surfactants to induce the condensation of silica precursors into specific morphologies or patterned structures(5-10), This contrast in processing conditions and the growing demand for benign synthesis methods that minimize adverse environmental effects have spurred much interest in biomimetic approaches in materials science(4,5), The recent demonstration that silicatein-a protein found in the silica spicules of the sponge Tethya aurantia(11)-can hydrolyse and condense the precursor molecule tetraethoxysilane to form silica structures with controlled shapes at ambient conditions(12-14) seems particularly promising in this context, Here we describe synthetic cysteine-lysine block copolypeptides that mimic the properties of silicatein: the copolypeptides self-assemble into structured aggregates that hydrolyse tetraethoxysilane while simultaneously directing the formation of ordered silica morphologies. We find that oxidation of the cysteine sulphydryl groups, which is known to affect the assembly of the block copolypeptide(15), allows us to produce different structures: hard silica spheres and well-defined columns of amorphous silica are produced using the fully reduced and the oxidized forms of the copolymer, respectively.	Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Deming, TJ (corresponding author), Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA.		Deming, Timothy/I-5411-2013	Deming, Timothy/0000-0002-0594-5025				Bamford C.H.E.A., 1956, SYNTHETIC POLYPEPTID; BERGER A, 1956, J AM CHEM SOC, V78, P4483, DOI 10.1021/ja01598a080; BRZEZINSKI MA, 1986, MAR CHEM, V19, P139, DOI 10.1016/0304-4203(86)90045-9; Cha JN, 1999, P NATL ACAD SCI USA, V96, P361, DOI 10.1073/pnas.96.2.361; Deming TJ, 1997, NATURE, V390, P386, DOI 10.1038/37084; Huo QS, 1997, CHEM MATER, V9, P14, DOI 10.1021/cm960464p; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Kroger N, 1997, EUR J BIOCHEM, V250, P99, DOI 10.1111/j.1432-1033.1997.00099.x; Liff MI, 1998, POLYM INT, V47, P375, DOI 10.1002/(SICI)1097-0126(199811)47:3<375::AID-PI73>3.0.CO;2-D; Lukens WW, 1999, LANGMUIR, V15, P5403, DOI 10.1021/la990209u; MANN S, 1995, J MATER CHEM, V5, P935, DOI 10.1039/jm9950500935; Mizutani T, 1998, B CHEM SOC JPN, V71, P2017, DOI 10.1246/bcsj.71.2017; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; Morse DE, 1999, TRENDS BIOTECHNOL, V17, P230, DOI 10.1016/S0167-7799(99)01309-8; MORSE DE, IN PRESS ORGANOSILIC, V4; OLIVER S, 1995, NATURE, V378, P47, DOI 10.1038/378047a0; Shimizu K, 1998, P NATL ACAD SCI USA, V95, P6234, DOI 10.1073/pnas.95.11.6234; SIMPSON TL, 1981, SILICON SILICEOUS ST; Strickland J.D.H., 1972, PRACTICAL HDB SEAWAT, V28, P405, DOI 10.2307/1979241; Vrieling EG, 1999, J BIOTECHNOL, V70, P39, DOI 10.1016/S0168-1656(99)00056-5; Ying JY, 1999, ANGEW CHEM INT EDIT, V38, P56, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<56::AID-ANIE56>3.0.CO;2-E; Zhang LF, 1996, SCIENCE, V272, P1777, DOI 10.1126/science.272.5269.1777; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548; Zhao DY, 1998, CURR OPIN SOLID ST M, V3, P111, DOI 10.1016/S1359-0286(98)80073-9; Zhou Y, 1999, ANGEW CHEM INT EDIT, V38, P780	25	600	628	3	291	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					289	292		10.1038/35002038	http://dx.doi.org/10.1038/35002038			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659843				2022-12-01	WOS:000084899700046
J	Lyons, RA; Delahunty, AM; Heaven, M; McCabe, M; Allen, H; Nash, P				Lyons, RA; Delahunty, AM; Heaven, M; McCabe, M; Allen, H; Nash, P			Incidence of childhood fractures in affluent and deprived areas: population based study	BRITISH MEDICAL JOURNAL			English	Article									Univ Wales, Coll Med, Welsh Combined Ctr Publ Hlth, Swansea SA1 1LT, W Glam, Wales; Iechyd Morgannwg Hlth, Dept Publ Hlth, Swansea SA1 1LT, W Glam, Wales; Morriston Hosp, Dept Accid & Emergency, Swansea SA6 6NL, W Glam, Wales; Neath Gen Hosp, Local Accid Ctr, Neath SA11 2LQ, Wales	Morriston Hospital	Lyons, RA (corresponding author), Univ Wales, Coll Med, Welsh Combined Ctr Publ Hlth, Swansea SA1 1LT, W Glam, Wales.		Lyons, Ronan/G-7741-2012	Lyons, Ronan/0000-0001-5225-000X				[Anonymous], 1980, REPORT WORKING GROUP; Lyons R A, 1999, Inj Prev, V5, P129; Lyons R A, 1995, Inj Prev, V1, P173, DOI 10.1136/ip.1.3.173; Morrison A, 1999, BRIT MED J, V318, P567, DOI 10.1136/bmj.318.7183.567; Williams JM, 1997, SOC SCI MED, V44, P1881, DOI 10.1016/S0277-9536(96)00297-3	5	54	54	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	2000	320	7228					149	149		10.1136/bmj.320.7228.149	http://dx.doi.org/10.1136/bmj.320.7228.149			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276DL	10634734	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000084860300024
J	Weinshenker, BG				Weinshenker, BG			Progressive forms of MS: classification streamlined or consensus overturned?	LANCET			English	Editorial Material							MULTIPLE-SCLEROSIS; NATURAL-HISTORY		Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55902 USA	Mayo Clinic	Weinshenker, BG (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol, 200 1St St Sw, Rochester, MN 55902 USA.		Weinshenker, Brian G/ABH-6146-2020	Weinshenker, Brian G/0000-0001-5806-6203				Andersson PB, 1999, ARCH NEUROL-CHICAGO, V56, P1138, DOI 10.1001/archneur.56.9.1138; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; Kremenchutzky M, 1999, BRAIN, V122, P1941, DOI 10.1093/brain/122.10.1941; KURTZKE JF, 1977, J CHRON DIS, V30, P819, DOI 10.1016/0021-9681(77)90010-8; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Lucchinetti C, 1999, BRAIN, V122, P2279, DOI 10.1093/brain/122.12.2279; Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x; Lucchinetti CF, 1998, SEMIN NEUROL, V18, P337, DOI 10.1055/s-2008-1040885; Matthews PM, 1998, SEMIN NEUROL, V18, P327, DOI 10.1055/s-2008-1040884; McAlpine D., 1955, MULT SCLER J; OLERUP O, 1989, P NATL ACAD SCI USA, V86, P7113, DOI 10.1073/pnas.86.18.7113; RUNMARKER B, 1993, BRAIN, V116, P117, DOI 10.1093/brain/116.1.117; Thompson AJ, 1997, BRAIN, V120, P1085, DOI 10.1093/brain/120.6.1085; Thompson AJ, 1999, ANN NEUROL, V46, P471; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Weinshenker BG, 1998, NEUROLOGY, V51, P742, DOI 10.1212/WNL.51.3.742; Weinshenker BG, 1999, ANN NEUROL, V46, P878, DOI 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q; WEINSHENKER BG, 1991, BRAIN, V114, P1045, DOI 10.1093/brain/114.2.1045	19	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	2000	355	9199					162	163		10.1016/S0140-6736(99)00356-6	http://dx.doi.org/10.1016/S0140-6736(99)00356-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675112				2022-12-01	WOS:000084879700006
J	Wingren, C; Crowley, MP; Degano, M; Chien, YH; Wilson, IA				Wingren, C; Crowley, MP; Degano, M; Chien, YH; Wilson, IA			Crystal structure of a gamma delta T cell receptor ligand T22: A truncated MHC-like fold	SCIENCE			English	Article							HISTOCOMPATIBILITY COMPLEX-MOLECULES; 2.4 ANGSTROM RESOLUTION; NEONATAL FC RECEPTOR; CLASS-I; 3-DIMENSIONAL STRUCTURE; ANTIGEN PRESENTATION; VIRAL PEPTIDES; BINDING-SITE; RECOGNITION; PROGRAM	Murine T10 and T22 are highly related nonclassical major histocompatibility complex (MHC) class Ib proteins that bind to certain gamma delta T cell receptors (TCRs) in the absence of other components. The crystal structure of T22(b) at 3.1 angstroms reveals similarities to MHC class I molecules, but one side of the normal peptide-binding groove is severely truncated, which allows direct access to the beta-sheet floor. Potential gamma delta TCR-binding sites can be inferred from functional mapping of T10 and T22 point mutants and allelic variants. Thus, T22 represents an unusual variant of the MHC-like fold and indicates that gamma delta and alpha beta TCRs interact differently with their respective MHC ligands.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Scripps Research Institute; Scripps Research Institute; Stanford University	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wilson@scripps.edu	Degano, Massimo/K-4669-2018	Degano, Massimo/0000-0002-0787-1883	NCI NIH HHS [CA58896] Funding Source: Medline; NIAID NIH HHS [AI33431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achour A, 1998, IMMUNITY, V9, P199, DOI 10.1016/S1074-7613(00)80602-0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; Boismenu R, 1997, CURR OPIN IMMUNOL, V9, P57, DOI 10.1016/S0952-7915(97)80159-8; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; Braud VM, 1999, CURR OPIN IMMUNOL, V11, P100, DOI 10.1016/S0952-7915(99)80018-1; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; Chien YH, 1996, ANNU REV IMMUNOL, V14, P511, DOI 10.1146/annurev.immunol.14.1.511; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Crowley MP, 2000, SCIENCE, V287, P314, DOI 10.1126/science.287.5451.314; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Fremont DH, 1998, IMMUNITY, V8, P305, DOI 10.1016/S1074-7613(00)80536-1; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Glithero A, 1999, IMMUNITY, V10, P63, DOI 10.1016/S1074-7613(00)80007-2; Hampl J, 1999, J IMMUNOL, V163, P288; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; Jones EY, 1998, IMMUNOL REV, V163, P121, DOI 10.1111/j.1600-065X.1998.tb01191.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Li HM, 1998, NATURE, V391, P502, DOI 10.1038/35172; Li PW, 1999, IMMUNITY, V10, P577, DOI 10.1016/S1074-7613(00)80057-6; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mazza G, 1998, IMMUNOL REV, V163, P187, DOI 10.1111/j.1600-065X.1998.tb01197.x; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Menssen R, 1999, J MOL BIOL, V285, P645, DOI 10.1006/jmbi.1998.2363; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORIWAKI S, 1993, P NATL ACAD SCI USA, V90, P11396, DOI 10.1073/pnas.90.23.11396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parham P, 1996, TRENDS BIOCHEM SCI, V21, P427, DOI 10.1016/S0968-0004(96)10053-0; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Reid SW, 1996, J EXP MED, V184, P2279, DOI 10.1084/jem.184.6.2279; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; Sanchez LM, 1999, SCIENCE, V283, P1914, DOI 10.1126/science.283.5409.1914; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SHAWAR SM, 1994, ANNU REV IMMUNOL, V12, P839, DOI 10.1146/annurev.immunol.12.1.839; Shields MJ, 1998, MOL IMMUNOL, V35, P919, DOI 10.1016/S0161-5890(98)00083-2; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; Speir JA, 1998, IMMUNITY, V8, P553, DOI 10.1016/S1074-7613(00)80560-9; STROYNOWSKI I, 1994, CURR OPIN IMMUNOL, V6, P38, DOI 10.1016/0952-7915(94)90031-0; TEITELL M, 1994, CRIT REV IMMUNOL, V14, P1; VELLIEUX FMD, DEMON PROGRAM SUITE; WANG CR, 1995, CELL, V82, P655, DOI 10.1016/0092-8674(95)90037-3; WEINTRAUB BC, 1994, J IMMUNOL, V153, P3051; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	72	55	55	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					310	314		10.1126/science.287.5451.310	http://dx.doi.org/10.1126/science.287.5451.310			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634787				2022-12-01	WOS:000084769600042
J	Bauer, J; Chen, KH; Hiltbunner, A; Wehrli, E; Eugster, M; Schnell, D; Kessler, F				Bauer, J; Chen, KH; Hiltbunner, A; Wehrli, E; Eugster, M; Schnell, D; Kessler, F			The major protein import receptor of plastids is essential for chloroplast biogenesis	NATURE			English	Article							INNER ENVELOPE MEMBRANE; ARABIDOPSIS; COMPONENT; APPARATUS; MACHINERY; INSERTION; IDENTIFICATION; TRANSLOCATION; EXPRESSION; NUCLEAR	Light triggers the developmental programme in plants that leads to the production of photosynthetically active chloroplasts from non-photosynthetic proplastids(1). During this chloroplast biogenesis, the photosynthetic apparatus is rapidly assembled, mostly from nuclear-encoded imported proteins(2-4), which are synthesized in the cytosol as precursors with cleavable amino-terminal targeting sequences called transit sequences. Protein translocon complexes at the outer (Toc complex)(5-7) and inner (Tic complex)(6,8,9) envelope membranes recognize these transit sequences, leading to the precursors being imported. The Toc complex in the pea consists of three major components, Toc75, Toc34 and Toc159 (formerly termed ToC86)(6,7,10,11). Toc159, Which is an integral membrane GTPase(12), functions as a transit-sequence recepto(5-7,13). Here we show that Arabidopsis thaliana Toc159 (atToc159) is essential for the biogenesis of chloroplasts. In an Arabidopsis mutant (ppi2) that lacks atToc159, photosynthetic proteins that are normally abundant are transcriptionally repressed, and are found in much smaller amounts in the plastids, although ppi2 does not affect either the expression or the import of less abundant non-photosynthetic plastid proteins. These findings indicate that atToc159 is required for the quantitative import of photosynthetic proteins. Two proteins that are related to atToc159 (atToc120 and atToc132) probably help to maintain basal protein import in ppi2, and so constitute components of alternative, atToc159-independent import pathways.	Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland; Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA; Swiss Fed Inst Technol, Inst Biochem, Lab Electronmicroscopy 1, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Rutgers State University Newark; Rutgers State University New Brunswick; Swiss Federal Institutes of Technology Domain; ETH Zurich	Schnell, D (corresponding author), Swiss Fed Inst Technol, Inst Plant Sci, Univ Str 2, CH-8092 Zurich, Switzerland.		Kessler, Felix Henrique/AAO-1722-2020	Hiltbrunner, Andreas/0000-0003-0438-5297; Kessler, Felix/0000-0001-6409-5043				Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; Bolter B, 1998, FEBS LETT, V441, P59, DOI 10.1016/S0014-5793(98)01525-7; Chen DD, 1997, J BIOL CHEM, V272, P6614, DOI 10.1074/jbc.272.10.6614; CHEN K, IN PRESS PLANT PHYS; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; Eberhard J, 1996, PLANT J, V10, P815, DOI 10.1046/j.1365-313X.1996.10050815.x; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Jarvis P, 1998, SCIENCE, V282, P100, DOI 10.1126/science.282.5386.100; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1998, J CELL BIOL, V143, P991, DOI 10.1083/jcb.143.4.991; LI HM, 1995, PLANT CELL, V7, P1599, DOI 10.1105/tpc.7.10.1599; Lubeck J, 1997, J CELL BIOL, V137, P1279, DOI 10.1083/jcb.137.6.1279; Lubeck J, 1996, EMBO J, V15, P4230, DOI 10.1002/j.1460-2075.1996.tb00797.x; MA Y, 1996, J CELL BIOL, V134, P1; MCKINNEY EC, 1995, PLANT J, V8, P613, DOI 10.1046/j.1365-313X.1995.8040613.x; MICHEL M, 1991, J MICROSC-OXFORD, V163, P3, DOI 10.1111/j.1365-2818.1991.tb03155.x; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; Soll J, 1998, PLANT MOL BIOL, V38, P191, DOI 10.1023/A:1006034020192; Surpin M, 1997, ESSAYS BIOCHEM, V32, P113; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x	27	284	313	0	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					203	207		10.1038/35003214	http://dx.doi.org/10.1038/35003214			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646606	Green Submitted			2022-12-01	WOS:000084835300057
J	Baumler, AJ; Hargis, BM; Tsolis, RM				Baumler, AJ; Hargis, BM; Tsolis, RM			Epidemiology - Tracing the origins of Salmonella outbreaks	SCIENCE			English	Editorial Material							UNITED-STATES; ENTERITIDIS INFECTIONS; LAYER FLOCKS; EGGS; PREVALENCE; CHICKENS; MICE		Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA; Texas A&M Univ, Coll Vet Med, Dept Vet Pathobiol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station	Baumler, AJ (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Med Microbiol & Immunol, 407 Reynolds Med Bldg, College Stn, TX 77843 USA.		Baumler, Andreas J/H-2301-2011	Baumler, Andreas J/0000-0001-9152-7809; Tsolis, Renee/0000-0001-9131-6657				Anderson RM, 1995, PARASITOLOGY, V111, pS15, DOI 10.1017/S003118200007579X; Angulo FJ, 1998, J AM VET MED ASSOC, V213, P1729; ASERKOFF B, 1970, AM J EPIDEMIOL, V92, P13, DOI 10.1093/oxfordjournals.aje.a121175; BARROW PA, 1992, AVIAN DIS, V36, P227, DOI 10.2307/1591495; BARROW PA, 1992, EPIDEMIOL INFECT, V109, P361, DOI 10.1017/S0950268800050354; BLAXLAND J. D., 1958, Veterinary Record, V70, P374; BULLIS KL, 1977, AVIAN DIS, V21, P422, DOI 10.2307/1589326; COLLINS FM, 1966, J EXP MED, V124, P601, DOI 10.1084/jem.124.4.601; COOPER GL, 1989, VET REC, V125, P567; EBEL ED, 1992, AVIAN DIS, V36, P646, DOI 10.2307/1591760; Edwards PR, 1943, J INFECT DIS, V72, P58, DOI 10.1093/infdis/72.1.58; GALBRAITH N S, 1961, Vet Rec, V73, P1296; GuardPetter J, 1997, APPL ENVIRON MICROB, V63, P1588, DOI 10.1128/AEM.63.4.1588-1593.1997; HENZLER DJ, 1992, AVIAN DIS, V36, P625, DOI 10.2307/1591757; HENZLER DJ, 1994, AVIAN DIS, V38, P37, DOI 10.2307/1591834; HEPNER E, 1980, PUBLIC HEALTH, V94, P337, DOI 10.1016/S0033-3506(80)80136-3; Hinz KH, 1996, J VET MED B, V43, P23, DOI 10.1111/j.1439-0450.1996.tb00284.x; Hormaeche CE, 1996, VACCINE, V14, P251, DOI 10.1016/0264-410X(95)00249-Z; Jones FS, 1913, J MED RES, V27, P481; KRABISCH P, 1980, BERL MUNCH TIERARZTL, V93, P232; LEE JA, 1974, J HYG-CAMBRIDGE, V72, P185, DOI 10.1017/S0022172400023391; MCCOY JH, 1975, J HYG-CAMBRIDGE, V74, P271, DOI 10.1017/S0022172400024347; MISHU B, 1994, J INFECT DIS, V169, P547, DOI 10.1093/infdis/169.3.547; Pignato S, 1996, ZBL BAKT-INT J MED M, V283, P399, DOI 10.1016/S0934-8840(96)80075-2; POPPE C, 1991, EPIDEMIOL INFECT, V106, P259, DOI 10.1017/S0950268800048408; RODRIGUE DC, 1990, EPIDEMIOL INFECT, V105, P21, DOI 10.1017/S0950268800047609; RYDER RW, 1976, J INFECT DIS, V133, P483, DOI 10.1093/infdis/133.4.483; SATO G, 1970, JPN J VET RES, V18, P47; Scuderi G, 1996, EPIDEMIOL INFECT, V116, P257, DOI 10.1017/S0950268800052559; Sojka W. J., 1970, Veterinary Bulletin, V40, P515; SOJKA WJ, 1975, VET REC, V96, P280; STLOUIS ME, 1988, JAMA-J AM MED ASSOC, V259, P2103, DOI 10.1001/jama.259.14.2103; THRELFALL EJ, 1992, J CLIN PATHOL, V45, P34, DOI 10.1136/jcp.45.1.34; WILSON JE, 1967, BRIT VET J, V123, P139, DOI 10.1016/S0007-1935(17)40052-2; 1982, MORBID MORTAL WKLY R, V31, P613; 1982, NATL POULTRY IMPROVE	36	185	195	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					50	52		10.1126/science.287.5450.50	http://dx.doi.org/10.1126/science.287.5450.50			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10644222				2022-12-01	WOS:000084578400028
J	Henney, JE				Henney, JE			New drug for stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					46	46		10.1001/jama.283.1.46	http://dx.doi.org/10.1001/jama.283.1.46			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632269				2022-12-01	WOS:000084514400006
J	Henry, SH; Bosch, FX; Troxell, TC; Bolger, PM				Henry, SH; Bosch, FX; Troxell, TC; Bolger, PM			Public health - Reducing liver cancer - Global control of aflatoxin	SCIENCE			English	Article							HEPATITIS-B VACCINATION; METABOLISM; RISK; B-1		US FDA, Ctr Food Safety & Appl Nutr, Washington, DC 20204 USA; Inst Catala Oncol, Unitat Epidemiol, Barcelona, Spain	US Food & Drug Administration (FDA); Catalan Institute of Oncology	Henry, SH (corresponding author), US FDA, Ctr Food Safety & Appl Nutr, Washington, DC 20204 USA.	SHenry@bangate.fda.gov; X.Bosch@ico.scs.es	JOSÉ, FRANCESC XAVIER BOSCH/J-6339-2012	JOSÉ, FRANCESC XAVIER BOSCH/0000-0002-7172-3412				[Anonymous], 1998, WHO FOOD ADDITIVES S; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Brechot C, 1998, J HEPATOL, V29, P173, DOI 10.1016/S0168-8278(98)80001-9; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Eaton DL., 1994, TOXICOLOGY AFLATOXIN; Ferlay JIARC, 1998, GLOBOCAN 1 CANC INCI; Food and Agriculture Organization (FAO), 1997, WORLDW REG MYC 1995; GORELICK NJ, 1990, RISK ANAL, V10, P539, DOI 10.1111/j.1539-6924.1990.tb00538.x; Groopman, 1994, TOXICOLOGY AFLATOXIN, P3; Guengerich FP, 1996, ENVIRON HEALTH PERSP, V104, P557, DOI 10.1289/ehp.96104s3557; HALL AJ, 1994, TOXICOLOGY AFLATOXIN; Lee MS, 1998, INT J EPIDEMIOL, V27, P316, DOI 10.1093/ije/27.2.316; MASSEY TE, 1995, P SOC EXP BIOL MED, V208, P213, DOI 10.3181/00379727-208-43852A; MCLEAN M, 1995, PHARMACOL THERAPEUT, V65, P163, DOI 10.1016/0163-7258(94)00054-7; MILLER DM, 1994, TOXICOLOGY AFLATOXIN, P347, DOI DOI 10.1016/B978-0-12-228255-3.50021-0; ROEBUCK BD, 1994, TOXICOLOGY AFLATOXIN, P27; VANEGMOND HP, 1999, 3 JOINT FAO WHO UNEP; Wilson D.M., 1994, TOXICOLOGY AFLATOXIN, P309; 1999, AGR RES, V47	19	159	173	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2453	2454		10.1126/science.286.5449.2453	http://dx.doi.org/10.1126/science.286.5449.2453			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10636808				2022-12-01	WOS:000084429700026
J	Bird, A				Bird, A			Molecular biology - DNA methylation de novo	SCIENCE			English	Editorial Material							ICF SYNDROME; METHYLTRANSFERASES; DIFFERENTIATION; CLONING; PATTERN; CELLS		Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh	Bird, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.			Bird, Adrian/0000-0002-8600-0372				BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Lei H, 1996, DEVELOPMENT, V122, P3195; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; MINIOU P, 1994, HUM MOL GENET, V3, P2093, DOI 10.1093/hmg/3.12.2093; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; VIEGASPEQUIGNOT E, 1976, HUM GENET, V34, P247, DOI 10.1007/BF00295287; Wijmenga C, 1998, AM J HUM GENET, V63, P803, DOI 10.1086/302021; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	15	80	92	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2287	2288		10.1126/science.286.5448.2287	http://dx.doi.org/10.1126/science.286.5448.2287			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10636791				2022-12-01	WOS:000084318500040
J	Tsutakawa, SE; Jingami, H; Morikawa, K				Tsutakawa, SE; Jingami, H; Morikawa, K			Recognition of a TG mismatch: The crystal structure of very short patch repair endonuclease in complex with a DNA duplex	CELL			English	Article							ESCHERICHIA-COLI K-12; POLYMERASE-I; MINOR-GROOVE; BASE-PAIRS; PROTEIN; BINDING; MECHANISM; GENE; VSR; TRANSCRIPTION	The crystal structure of very short patch repair (Vsr) endonuclease, in complex with Mg2+ and with duplex DNA containing a TG mismatch, has been determined at 2.3 Angstrom resolution. In E. coli, the enzyme recognizes a TG mismatched base pair, generated after spontaneous deamination of methylated cytosines, and cleaves the phosphate backbone on the 5' side of the thymine. Extensive interactions between the DNA and the protein characterize a novel recognition mechanism, where three aromatic residues intercalate from the major groove into the DNA to strikingly deform the base pair stacking. With the presence of a cleaved DNA intermediate in the active center, the structure of the Vsr/DNA complex provides detailed insights into the catalytic mechanism for endonuclease activity.	Biomol Engn Res Inst, Dept Biol Struct, Suita, Osaka 565, Japan; Biomol Engn Res Inst, Dept Biol Mol, Suita, Osaka 565, Japan		Morikawa, K (corresponding author), Biomol Engn Res Inst, Dept Biol Struct, 6-2-3 Furuedai, Suita, Osaka 565, Japan.	morikawa@beri.co.jp		Tsutakawa, Susan/0000-0002-4918-4571				Allawi HT, 1998, NUCLEIC ACIDS RES, V26, P4925, DOI 10.1093/nar/26.21.4925; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett TE, 1998, NAT STRUCT BIOL, V5, P697, DOI 10.1038/1394; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; DZIDIC S, 1989, MOL GEN GENET, V217, P254, DOI 10.1007/BF02464889; Flick KE, 1998, NATURE, V394, P96, DOI 10.1038/27952; Gao YG, 1998, NAT STRUCT BIOL, V5, P782, DOI 10.1038/1822; GLASNER W, 1995, J MOL BIOL, V245, P1; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; GRZESKOWIAK K, 1991, J BIOL CHEM, V266, P8861; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; HUNTER WN, 1986, J MOL BIOL, V190, P605, DOI 10.1016/0022-2836(86)90246-9; JONES M, 1987, J MOL BIOL, V194, P155, DOI 10.1016/0022-2836(87)90724-8; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KNEALE G, 1985, J MOL BIOL, V186, P805, DOI 10.1016/0022-2836(85)90398-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lieb M, 1996, MOL MICROBIOL, V20, P467, DOI 10.1046/j.1365-2958.1996.5291066.x; LIEB M, 1987, J BACTERIOL, V169, P5241, DOI 10.1128/jb.169.11.5241-5246.1987; LIEB M, 1983, MOL GEN GENET, V191, P118, DOI 10.1007/BF00330898; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Miller MD, 1999, J MOL BIOL, V288, P975, DOI 10.1006/jmbi.1999.2729; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Rasmussen LJ, 1998, CONT CANC RES, P205; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SOHAIL A, 1990, J BACTERIOL, V172, P4214, DOI 10.1128/jb.172.8.4214-4221.1990; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; Tsutakawa SE, 1999, MOL CELL, V3, P621, DOI 10.1016/S1097-2765(00)80355-X; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V	48	87	90	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					615	623		10.1016/S0092-8674(00)81550-0	http://dx.doi.org/10.1016/S0092-8674(00)81550-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612397	Bronze			2022-12-01	WOS:000084278700008
J	Liang, XH; Jackson, S; Seaman, M; Brown, K; Kempkes, B; Hibshoosh, H; Levine, B				Liang, XH; Jackson, S; Seaman, M; Brown, K; Kempkes, B; Hibshoosh, H; Levine, B			Induction of autophagy and inhibition of tumorigenesis by beclin 1	NATURE			English	Article							ISOLATED RAT HEPATOCYTES; PROTEIN-DEGRADATION; SACCHAROMYCES-CEREVISIAE; CELLS; MECHANISMS; BRCA1; YEAST; FIBROBLASTS; VACUOLE	The process of autophagy, or bulk degradation of cellular proteins through an autophagosomic-lysosomal pathway(1), is important in normal growth control and may be defective in tumour cells(2) However, little is known about the genetic mediators of autophagy in mammalian cells or their role in tumour development. The mammalian gene encoding Beclin 1 (ref. 3), a novel Bcl-2-interacting, coiled-coil protein, has structural similarity to the yeast autophagy gene, apg6/vps30 (refs 4, 5), and is mono-allelically deleted in 40-75% of sporadic human breast cancers and ovarian cancers(6). Here we show using gene-transfer techniques, that beclin 1 promotes autophagy in autophagy-defective yeast with a targeted disruption of agp6/vps30, and in human MCF7 breast carcinoma cells. The autophagy-promoting activity of beclin 1 in MCF7 cells is associated with inhibition of MCF7 cellular proliferation, in vitro clonigenicity and tumorigenesis in nude mice. Furthermore, endogenous Beclin 1 protein expression is frequently low in human breast epithelial carcinoma cell lines and tissue, but is expressed ubiquitously at high levels in normal breast epithelia. Thus, beclin 1 is a mammalian autophagy gene that can inhibit tumorigenesis and is expressed at decreased levels in human breast carcinoma. These findings suggest that decreased expression of autophagy proteins may contribute to the development or progression of breast and other human malignancies.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2XY, England; GSF Munich, Natl Res Ctr Environm & Hlth, Inst Clin Mol Biol, D-81377 Munich, Germany	Columbia University; Columbia University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Levine, B (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	levine@cuccfa.ccc.columbia.edu	Kempkes, Bettina/B-3322-2013					Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BRADLEY MO, 1977, J BIOL CHEM, V252, P5310; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; EBLE R, 1992, BIOTECHNIQUES, V13, P18; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; GRONOSTAJSKI RM, 1984, J CELL PHYSIOL, V119, P127, DOI 10.1002/jcp.1041190120; GUNN JM, 1977, NATURE, V266, P58, DOI 10.1038/266058a0; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; JIANG W, 1993, ONCOGENE, V8, P3447; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; KISEN GO, 1993, CARCINOGENESIS, V14, P2501, DOI 10.1093/carcin/14.12.2501; KNECHT E, 1984, EXP CELL RES, V154, P224, DOI 10.1016/0014-4827(84)90682-7; LEE HK, 1992, ARCH BIOCHEM BIOPHYS, V296, P271, DOI 10.1016/0003-9861(92)90572-E; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; MITCHENER JS, 1976, AM J PATHOL, V83, P485; MORTIMORE GE, 1988, METHOD ENZYMOL, V166, P461; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; OTSUKA H, 1978, EXP CELL RES, V112, P127, DOI 10.1016/0014-4827(78)90533-5; ROMMENS JM, 1995, GENOMICS, V28, P530, DOI 10.1006/geno.1995.1185; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676	27	2598	2799	4	414	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1999	402	6762					672	676		10.1038/45257	http://dx.doi.org/10.1038/45257			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604474				2022-12-01	WOS:000084189800068
J	Yan, RQ; Bienkowski, MJ; Shuck, ME; Miao, HY; Tory, MC; Pauley, AM; Brashler, JR; Stratman, NC; Mathews, WR; Buhl, AE; Carter, DB; Tomasselli, AG; Parodi, LA; Heinrikson, RL; Gurney, ME				Yan, RQ; Bienkowski, MJ; Shuck, ME; Miao, HY; Tory, MC; Pauley, AM; Brashler, JR; Stratman, NC; Mathews, WR; Buhl, AE; Carter, DB; Tomasselli, AG; Parodi, LA; Heinrikson, RL; Gurney, ME			Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; CATHEPSIN-D; MUTATION; DEFICIENCY; CLEAVAGE; NEURONS; GENE	Mutations in the gene encoding the amyloid protein precursor (APP) cause autosomal dominant Alzheimer's disease(1-3). Cleavage of APP by unidentified proteases, referred to as beta- and gamma-secretases(4-7), generates the amyloid beta-peptide, the main component of the amyloid plaques found in Alzheimer's disease patients(8). The disease-causing mutations flank the protease cleavage sites in APP and facilitate its cleavage. Here we identify a new membrane-bound aspartyl protease (Asp2) with beta-secretase activity. The Asp2 gene is expressed widely in brain and other tissues. Decreasing the expression of Asp2 in cells reduces amyloid beta-peptide production and blocks the accumulation of the carboxy-terminal APP fragment that is created by beta-secretase cleavage. Solubilized Asp2 protein cleaves a synthetic APP peptide substrate at the beta-secretase site, and the rate of cleavage is increased tenfold by a mutation associated with early-onset Alzheimer's disease in Sweden(3). Thus, Asp2 is a new protein target for drugs that are designed to block the production of amyloid beta-peptide peptide and the consequent formation of amyloid plaque in Alzheimer's disease.	Pharmacia & Upjohn Inc, Cell & Mol Biol, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Genom, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Prot Sci, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Pharmacol, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Struct Analyt & Med Chem, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Neurobiol, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Bioinformat, S-11287 Stockholm, Sweden	Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacia Corporation	Yan, RQ (corresponding author), Pharmacia & Upjohn Inc, Cell & Mol Biol, 301 Henrietta St, Kalamazoo, MI 49007 USA.			Yan, Riqiang/0000-0001-7195-7617				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P372; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DREYER RN, 1994, EUR J BIOCHEM, V224, P265, DOI 10.1111/j.1432-1033.1994.00265.x; Glenner G., 1984, SCIENCE, V255, P728; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HUSSAIN I, MOL CELL NEUROSCI; LADROR US, 1994, J BIOL CHEM, V269, P18422; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; NEILL D, 1994, J NEUROSCI RES, V39, P482, DOI 10.1002/jnr.490390415; Pirttila T, 1998, NEUROSCI LETT, V249, P21, DOI 10.1016/S0304-3940(98)00381-4; Saftig P, 1996, J BIOL CHEM, V271, P27241, DOI 10.1074/jbc.271.44.27241; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tatnell PJ, 1998, FEBS LETT, V441, P43, DOI 10.1016/S0014-5793(98)01522-1; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735	19	1281	1401	1	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					533	537		10.1038/990107	http://dx.doi.org/10.1038/990107			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591213				2022-12-01	WOS:000084013200057
J	Richter, P; de Boer, KS; Widmann, H; Kappelmann, N; Gringel, W; Grewing, M; Barnstedt, J				Richter, P; de Boer, KS; Widmann, H; Kappelmann, N; Gringel, W; Grewing, M; Barnstedt, J			Discovery of molecular hydrogen in a high-velocity cloud of the Galactic halo	NATURE			English	Article							GAS; ABSORPTION; ORIGIN; IUE	The Milky Way's halo contains clouds of neutral hydrogen with high radial velocities which do not follow the general rotational motion of the Galaxy(1). Few distances to these high-velocity clouds are known(2,3), so even gross properties such as total mass are hard to determine. As a consequence, there is no generally accepted theory regarding their origin, One idea(4,5) is that they result from gas that has cooled after being ejected from the Galaxy through fountain-like flows powered by supernovae; another is that they are composed of gas, poor in heavy elements, which is falling onto the disk of the Milky Way from intergalactic space(6,7). The presence of molecular hydrogen, whose formation generally requires the presence of dust (and therefore gas, enriched in heavy elements), could help to distinguish between these possibilities. Here we report the discovery of molecular hydrogen absorption in a high-velocity cloud along the hue of sight to the Large Magellanic Cloud. We also derive for the same cloud an iron abundance which is half of the solar value. From these data, we conclude that gas in this cloud originated in the disk of the Milky Way.	Univ Bonn, Sternwarte, D-53121 Bonn, Germany; Univ Tubingen, Inst Astron & Astrophys, D-72076 Tubingen, Germany	University of Bonn; Eberhard Karls University of Tubingen	Richter, P (corresponding author), Univ Bonn, Sternwarte, Hugel 71, D-53121 Bonn, Germany.							Akeson RL, 1999, ASTROPHYS J, V523, P163, DOI 10.1086/307728; Barnstedt J, 1999, ASTRON ASTROPHYS SUP, V134, P561, DOI 10.1051/aas:1999156; Blitz L, 1999, ASTROPHYS J, V514, P818, DOI 10.1086/306963; Bomans DJ, 1996, ASTRON ASTROPHYS, V313, P101; BREGMAN JN, 1980, ASTROPHYS J, V236, P577, DOI 10.1086/157776; BURTON MG, 1992, ASTROPHYS J, V399, P563, DOI 10.1086/171947; DEBOER KS, 1990, ASTRON ASTROPHYS, V233, P523; DEBOER KS, 1987, SCI ACCOMPLISHMENTS, P485; FIELD GB, 1966, ANNU REV ASTRON ASTR, V4, P207, DOI 10.1146/annurev.aa.04.090166.001231; GREWING M, 1981, MITT ASTRON GES, V52, P79; JURA M, 1975, ASTROPHYS J, V197, P575, DOI 10.1086/153545; MCGEE RX, 1986, P ASTRON SOC AUST, V6, P358, DOI 10.1017/S1323358000027077; MORTON DC, 1975, ASTROPHYS J, V204, P1; Nichols JS, 1996, ASTRON J, V111, P517, DOI 10.1086/117803; OORT JH, 1970, ASTRON ASTROPHYS, V7, P381; PEI YCC, 1995, ASTROPHYS J, V454, P69, DOI 10.1086/176466; Putman ME, 1999, PUBL ASTRON SOC AUST, V16, P70, DOI 10.1071/AS99070; SAVAGE BD, 1981, ASTROPHYS J, V243, P460, DOI 10.1086/158613; SAVAGE BD, 1977, ASTROPHYS J, V216, P291, DOI 10.1086/155471; SHAPIRO PR, 1976, ASTROPHYS J, V205, P762, DOI 10.1086/154332; Spitzer L.  Jr., 1974, Astrophysical Journal. Letters to the Editor, V191, pL127, DOI 10.1086/181567; van Woerden H, 1999, NATURE, V400, P138, DOI 10.1038/22061; Wakker BP, 1997, ASTROPHYS J, V488, P216, DOI 10.1086/304682; WAKKER BP, 1991, ASTRON ASTROPHYS, V250, P499	24	53	53	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					386	387		10.1038/46492	http://dx.doi.org/10.1038/46492			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586876	Green Submitted			2022-12-01	WOS:000083913600047
J	Walker, EH; Perisic, O; Ried, C; Stephens, L; Williams, RL				Walker, EH; Perisic, O; Ried, C; Stephens, L; Williams, RL			Structural insights into phosphoinositide 3-kinase catalysis and signalling	NATURE			English	Article							PROTEIN-KINASE; RAS; PHOSPHORYLATION; PI-3-KINASE; DOMAIN	Phosphoinositide 3-kinases (PI3Ks) are ubiquitous lipid kinases that function both as signal transducers downstream of cell-surface receptors and in constitutive intracellular membrane and protein trafficking pathways. All PI3Ks are dual-specificity enzymes with a lipid kinase activity which phosphorylates phosphoinositides at the 3-hydroxyl, and a protein kinase activity. The products of PI3K-catalysed reactions, phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3), PtdIns(3,4)P-2 and PtdIns(3)P, are second messengers in a variety of signal transduction pathways, including those essential to cell proliferation, adhesion, survival, cytoskeletal rearrangement and vesicle trafficking(1.2). Here we report the 2.2 Angstrom X-ray crystallographic structure of the catalytic subunit of PI3K gamma, the class I enzyme that is activated by heterotrimeric G-protein beta gamma subunits and pas. PI3K gamma has a modular organization centred around a helical-domain spine, with C2 and catalytic domains positioned to interact with phospholipid membranes,:md a Ras-binding domain placed against the catalytic domain where if could drive allosteric activation of the enzyme.	MRC Ctr, MRC Lab Mol Biol, Cambridge CB2 2QH, England; Babraham Inst, Cambridge CB2 4AT, England	MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Williams, RL (corresponding author), MRC Ctr, MRC Lab Mol Biol, Hills Rd, Cambridge CB2 2QH, England.	rlw@mrc-lmb.cam.ac.uk		stephens, len/0000-0002-2771-3487; Williams, Roger/0000-0001-7754-4207; Perisic, Olga/0000-0002-3842-2896	MRC [MC_U105184308] Funding Source: UKRI; Medical Research Council [MC_U105184308] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim K, 1997, J AM CHEM SOC, V119, P11096, DOI 10.1021/ja972110k; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MOODIE SA, 1995, ONCOGENE, V11, P447; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Taylor SS, 1999, PHARMACOL THERAPEUT, V82, P133, DOI 10.1016/S0163-7258(99)00007-8; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	31	386	404	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					313	320		10.1038/46319	http://dx.doi.org/10.1038/46319			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580505				2022-12-01	WOS:000083813700055
J	Gerhardt, A; Scharf, RE; Beckmann, MW; Struve, S; Bender, HG; Pillny, M; Sandmann, W; Zotz, RB				Gerhardt, A; Scharf, RE; Beckmann, MW; Struve, S; Bender, HG; Pillny, M; Sandmann, W; Zotz, RB			Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; ACTIVATED PROTEIN-C; COAGULATION-FACTOR-V; VENOUS THROMBOSIS; METHYLENETETRAHYDROFOLATE REDUCTASE; RISK FACTOR; ORAL-CONTRACEPTIVES; GENE; THROMBOEMBOLISM; LEIDEN	Background: Venous thromboembolism is a leading cause of morbidity and mortality during pregnancy and the puerperium. However, the role of mutations in the prothrombin and factor V genes and other thrombophilic abnormalities as risk factors for thromboembolism in women during pregnancy and the puerperium is not known. Methods: In a study of 119 women with a history of venous thromboembolism during pregnancy and the puerperium and 233 age-matched normal women, we measured the activity of antithrombin, protein C, protein S, and lupus anticoagulant. We also performed genetic analyses to detect the G1691A mutation in the factor V gene (factor V Leiden), the G20210A mutation in the prothrombin gene, and the C677T mutation in the methylenetetrahydrofolate reductase gene. Blood samples were obtained at least three months post partum or after the cessation of lactation. Results: Among the women with a history of venous thromboembolism, the prevalence of factor V Leiden was 43.7 percent, as compared with 7.7 percent among the normal women (relative risk of venous thromboembolism, 9.3; 95 percent confidence interval, 5.1 to 16.9); that of the G20210A prothrombin-gene mutation, 16.9 percent as compared with 1.3 percent (relative risk, 15.2; 95 percent confidence interval, 4.2 to 52.6); and that of both factor V Leiden and the G20210A prothrombin-gene mutation, 9.3 percent as compared with 0 (estimated odds ratio, 107). Assuming an overall risk of 1 in 1500 pregnancies, the risk of thrombosis among carriers of factor V Leiden was 0.2 percent, among carriers of the G20210A prothrombin-gene mutation, 0.5 percent, and among carriers of both defects, 4.6 percent, as calculated in a multivariate analysis. Conclusions: The G20210A prothrombin-gene mutation and factor V Leiden individually are associated with an increased risk of venous thromboembolism during pregnancy and the puerperium, and the risk among women with both mutations is disproportionately higher than that among women with only one mutation. (N Engl J Med 2000;342:374-80.) (C)2000, Massachusetts Medical Society.	Univ Dusseldorf, Med Ctr, Inst Haemostaseol & Transfus Med, Dept Hemostasis & Transfus Med, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Ctr, Dept Obstet & Gynecol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Ctr, Dept Vasc Surg & Kidney Transplantat, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Zotz, RB (corresponding author), Univ Dusseldorf, Med Ctr, Inst Haemostaseol & Transfus Med, Dept Hemostasis & Transfus Med, Moorenstr 5, D-40225 Dusseldorf, Germany.							BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Bokarewa MI, 1996, BRIT J HAEMATOL, V92, P473, DOI 10.1046/j.1365-2141.1996.d01-1496.x; Cumming AM, 1997, BRIT J HAEMATOL, V98, P353, DOI 10.1046/j.1365-2141.1997.2353052.x; DAHLBACK E, 1994, HAEMOSTASIS THROMBOS, V1, P671; DizonTownson DS, 1997, AM J OBSTET GYNECOL, V176, P883, DOI 10.1016/S0002-9378(97)70615-X; Eichinger S, 1998, THROMB HAEMOSTASIS, V80, P566; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GREEK D, 1994, PROF ENG, V7, P4; Hallak M, 1997, AM J OBSTET GYNECOL, V176, P889, DOI 10.1016/S0002-9378(97)70617-3; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; Hillarp A, 1997, THROMB HAEMOSTASIS, V78, P990; KIERKEGAARD A, 1983, ACTA OBSTET GYN SCAN, V62, P239, DOI 10.3109/00016348309155799; Kluijtmans LAJ, 1998, THROMB HAEMOSTASIS, V79, P254, DOI 10.1055/s-0037-1614974; KNIEMEYER HW, 1993, CLIN INVESTIGATOR, V72, P40; KNIEMEYER HW, 1990, GYNAKOLOGE, V23, P91; KNIEMEYER HW, 1990, KLIN WOCHENSCHR, V68, P1208, DOI 10.1007/BF01796511; KOLVENBACH R, 1991, GYNAKOLOGE, V24, P305; Leroyer C, 1998, THROMB HAEMOSTASIS, V80, P49; Margaglione M, 1998, THROMB HAEMOSTASIS, V79, P907; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RUTHERFORD S, 1991, American Journal of Obstetrics and Gynecology, V164, P286; TREFFERS PE, 1983, INT J GYNECOL OBSTET, V21, P327, DOI 10.1016/0020-7292(83)90024-3; Zotz RB, 1996, THROMB HAEMOSTASIS, V76, P53	26	360	373	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	2000	342	6					374	380		10.1056/NEJM200002103420602	http://dx.doi.org/10.1056/NEJM200002103420602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282FB	10666427				2022-12-01	WOS:000085205200002
J	Caramazza, A; Chialant, D; Capasso, R; Miceli, G				Caramazza, A; Chialant, D; Capasso, R; Miceli, G			Separable processing of consonants and vowels	NATURE			English	Article							PHONEMIC PARAPHASIA; SPEECH; ERRORS	There are two views about the nature of consonants and vowels. One view holds that they are categorically distinct objects that play a fundamental role in the construction of syllables in speech production(1-3). The other view is that they are convenient labels for distinguishing between peak (vowel) and non-peak (consonant) parts of a continuous stream of sound that varies in sonority (roughly the degree of openness of the vocal apparatus during speech)(4-6), or that they are summary labels for bundles of feature segments(7,8). Taking the latter view, consonants and vowels do not have an independent status in language processing. Here we provide evidence for the possible categorical distinction between consonants and vowels in the brain. We report the performance of two Italian-speaking aphasics who show contrasting, selective difficulties in producing vowels and consonants. Their performance in producing individual consonants is independent of the sonority value and feature properties of the consonants. This pattern of results suggests that consonants and vowels are processed by distinct neural mechanisms, thereby providing evidence for their independent status in language production.	Harvard Univ, Dept Psychol, Cognit Neuropsychol Lab, Cambridge, MA 02138 USA; Ist Ricovero & Cura Carattere Sci S Lucia, I-00179 Rome, Italy; Univ Cattolica, Dept Neurol, I-00168 Rome, Italy	Harvard University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Caramazza, A (corresponding author), Harvard Univ, Dept Psychol, Cognit Neuropsychol Lab, 33 Kirkland St, Cambridge, MA 02138 USA.		Miceli, Gabriele/J-8908-2014	Capasso, Rita/0000-0003-1523-7302				Beland R., 1990, J NEUROLINGUIST, V5, P125, DOI [10.1016/0911-6044(90)90009-N, DOI 10.1016/0911-6044(90)90009-N]; BLUMSTEIN SE, 1978, SYLLABLES SEGMENTS, P189; Boatman D, 1997, CORTEX, V33, P83, DOI 10.1016/S0010-9452(97)80006-8; BUCKINGHAM HW, 1986, COGNITIVE SCI, V10, P195, DOI 10.1207/s15516709cog1002_4; CANTER GJ, 1985, BRAIN LANG, V24, P204, DOI 10.1016/0093-934X(85)90131-2; CHRISTMAN SS, 1992, CLIN LINGUIST PHONET, V6, P219, DOI 10.3109/02699209208985532; CLEMENTS GN, 1983, MONOGRAPH SERIES MIT, V9; Goldsmith John A., 1990, AUTOSEGMENTAL METRIC; Kenstowicz Michael, 1994, PHONOLOGY GENERATIVE; Levelt WJM, 1999, BEHAV BRAIN SCI, V22, P1; MacNeilage PF, 1998, BEHAV BRAIN SCI, V21, P499, DOI 10.1017/S0140525X98001265; MCCARTHY JJ, 1981, LINGUIST INQ, V12, P373; Miceli G., 2006, BATTERIA ANALISI DEF; NESPOT M, 1986, PRASODIC PHONOLOGY; Ramus F, 1999, J ACOUST SOC AM, V105, P512, DOI 10.1121/1.424522; Roelofs A, 1999, LANG COGNITIVE PROC, V14, P173, DOI 10.1080/016909699386338; Romani C, 1996, BRAIN LANG, V55, P144; Romani C, 1998, BRAIN LANG, V64, P83, DOI 10.1006/brln.1998.1958; Selkirk E. O., 1982, STRUCTURE PHONOLOG 2; Stevens K.N., 1998, ACOUSTIC PHONETICS; YIP M, 1982, LINGUIST INQ, V13, P637	21	129	130	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					428	430		10.1038/35000206	http://dx.doi.org/10.1038/35000206			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	280UA	10667794				2022-12-01	WOS:000085121100050
J	Hillier, S; Cooper, C; Kellingray, S; Russell, G; Hughes, H; Coggon, D				Hillier, S; Cooper, C; Kellingray, S; Russell, G; Hughes, H; Coggon, D			Fluoride in drinking water and risk of hip fracture in the UK: a case-control study	LANCET			English	Article							PROXIMAL FEMUR; BONE; OSTEOPOROSIS; STRENGTH; WOMEN	Background Although the benefits of water fluoridation for dental health are widely accepted, concerns remain about possible adverse effects, particularly effects on bone. Several investigators have suggested increased rates of hip fracture in places with high concentrations of fluoride in drinking water, but this finding has not been consistent, possibly because of unrecognised confounding effects. Methods We did a case-control study of men and women aged 50 years and older from the English county of Cleveland, and compared patients with hip fracture with community controls. Current addresses were ascertained for all participants; for those who agreed to an interview and who passed a mental test, more detailed information was obtained about lifetime residential history and exposure to other known and suspected risk factors for hip fracture. Exposures to fluoride in water were estimated from the residential histories and from information provided by water suppliers. Analysis was by logistic regression. Findings 914 cases and 1196 controls were identified, of whom 514 and 527, respectively, were interviewed. Among those interviewed, hip fracture was strongly associated with low body-mass index (p for trend <0.001) and physical inactivity (p for trend <0.001). Estimated average lifetime exposure to fluoride in drinking water ranged from 0.15 to 1.79 ppm. Current residence in Hartlepool was a good indicator for high lifetime exposure to fluoride, After adjustment for potential confounders, the odds ratio associated with an average lifetime exposure to fluoride greater than or equal to 0.9 ppm was 1.0 [95% CI 0.7-1.5]. Interpretation There is a low risk of hip fracture for people ingesting fluoride in drinking water at concentrations of about 1 ppm. This low risk should not be a reason for withholding fluoridation of water supplies.	Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England; Univ Sheffield, Sch Med, Dept Human Metab & Clin Biochem, Sheffield S10 2RX, S Yorkshire, England	University of Southampton; University of Sheffield	Coggon, D (corresponding author), Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England.		Leary, Sam/B-4456-2016	Russell, Robert Graham G/0000-0002-4136-1828; Leary, Sam/0000-0002-1706-0689; Cooper, Cyrus/0000-0003-3510-0709				ALFFRAM PA, 1969, ACTA ORTHOP SCAND, V40, P137, DOI 10.3109/17453676908989494; ALHAVA EM, 1980, ACTA ORTHOP SCAND, V51, P413, DOI 10.3109/17453678008990817; ARNALA I, 1986, ACTA ORTHOP SCAND, V57, P344, DOI 10.3109/17453678608994408; CAULEY JA, 1995, J BONE MINER RES, V10, P1076; COOPER C, 1990, J EPIDEMIOL COMMUN H, V44, P17, DOI 10.1136/jech.44.1.17; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; COOPER C, 1991, JAMA-J AM MED ASSOC, V266, P513, DOI 10.1001/jama.266.4.513; DANIELSON C, 1992, JAMA-J AM MED ASSOC, V268, P746; Department of Health and Social Security Scottish Office Welsh Office, 1969, REP PUBL HLTH MED SU; GOGGIN JE, 1965, PUBLIC HEALTH REP, V80, P1005, DOI 10.2307/4592594; GORDON SL, 1992, OSTEOPOROSIS INT, V2, P109, DOI 10.1007/BF01623816; ISHIGURO K, 1993, CALCIFIED TISSUE INT, V52, P278, DOI 10.1007/BF00296652; Jacobsen S J, 1992, Ann Epidemiol, V2, P617, DOI 10.1016/1047-2797(92)90006-C; JACOBSEN SJ, 1993, AM J PUBLIC HEALTH, V83, P743, DOI 10.2105/AJPH.83.5.743; JACOBSEN SJ, 1990, JAMA-J AM MED ASSOC, V264, P500, DOI 10.1001/jama.264.4.500; JACQMINGADDA H, 1995, JAMA-J AM MED ASSOC, V273, P775, DOI 10.1001/jama.1995.03520340029026; KORNS RF, 1969, PUBLIC HEALTH REP, V84, P815, DOI 10.2307/4593687; LI Y, 1999, J DENT RES S1, V78, P263; MADANS J, 1983, AM J PUBLIC HEALTH, V73, P296, DOI 10.2105/AJPH.73.3.296; Martyn CN, 1999, LANCET, V353, P769, DOI 10.1016/S0140-6736(98)00390-0; Meunier PJ, 1996, INT CONGR SER, V1118, P305; QUERESHI KN, 1974, AGE AGEING, V3, P152; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SHERLOCK JC, 1984, J R SOC HLTH, V1, P34; SIMONEN O, 1985, LANCET, V2, P432; SUAREZALMAZOR ME, 1993, AM J PUBLIC HEALTH, V83, P689, DOI 10.2105/AJPH.83.5.689; WHITFORD GM, 1996, METABOLISM TOXICITY, P1	27	47	51	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					265	269		10.1016/S0140-6736(99)07161-5	http://dx.doi.org/10.1016/S0140-6736(99)07161-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	279LQ	10675073				2022-12-01	WOS:000085045600009
J	Vasioukhin, V; Bauer, C; Yin, M; Fuchs, E				Vasioukhin, V; Bauer, C; Yin, M; Fuchs, E			Directed actin polymerization is the driving force for epithelial cell-cell adhesion	CELL			English	Article							ALPHA-CATENIN; VINCULIN; PROTEIN; COMPLEX; FIBROBLASTS; CADHERINS; CONTACTS; MOTILITY; GTPASES; CDC42	We have found that epithelial cells engage in a process of cadherin-mediated intercellular adhesion that utilizes calcium and actin polymerization in unexpected ways. Calcium stimulates filopodia, which penetrate and embed into neighboring cells. E-cadherin complexes cluster at filopodia tips, generating a two-rowed zipper of embedded puncta. Opposing cell surfaces are clamped by desmosomes, while vinculin, zyxin, VASP, and Mena are recruited to adhesion zippers by a mechanism that requires alpha-catenin. Actin reorganizes and polymerizes to merge puncta into a single row and seal cell borders. In keratinocytes either null for alpha-catenin or blocked in VASP/Mena function, filopodia embed, but actin reorganization/polymerization is prevented, and membranes cannot seal. Taken together, a dynamic mechanism for intercellular adhesion is unveiled involving calcium-activated filopodia penetration and VASP/Mena-dependent actin reorganization/polymerization.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Fuchs, E (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	nliptak@midway.uchicago.edu	Fuchs, Elaine/G-1565-2016	Vasioukhin, Valeri/0000-0002-6730-0281	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011921] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR27883] Funding Source: Medline; NIDCR NIH HHS [5P50DE11921] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; BERSHADSKY A, 1998, GUIDEBOOK EXTRACELLU, P3; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; GELGER B, 1992, COLD SPRING HARB SYM, V57, P631; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Laine RO, 1997, J CELL BIOL, V138, P1255, DOI 10.1083/jcb.138.6.1255; Lau PM, 1999, J CELL BIOL, V145, P1265, DOI 10.1083/jcb.145.6.1265; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; MCNEILL H, 1993, J CELL BIOL, V120, P1217, DOI 10.1083/jcb.120.5.1217; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; Stoffler HE, 1998, J CELL SCI, V111, P2779; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; YONEMURA S, 1995, J CELL SCI, V108, P127	39	908	927	1	93	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2000	100	2					209	219		10.1016/S0092-8674(00)81559-7	http://dx.doi.org/10.1016/S0092-8674(00)81559-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660044	Bronze			2022-12-01	WOS:000084932200005
J	del Camino, D; Holmgren, M; Liu, Y; Yellen, G				del Camino, D; Holmgren, M; Liu, Y; Yellen, G			Blocker protection in the pore of a voltage-gated K+ channel and its structural implications	NATURE			English	Article							SHAKER POTASSIUM CHANNELS; TETRAETHYLAMMONIUM ION; INACTIVATION; BINDING; SITE; MECHANISMS; REGION; CELLS	The structure of the bacterial potassium channel KcsA(1) has provided a framework for understanding the related voltage-gated potassium channels (Kv channels) that are used for signalling in neurons. Opening and closing of these Kv channels (gating) occurs at the intracellular entrance to the pore, and this is also the site at which many open channel blockers affect Kv channels(2-4). To learn more about the sites of blocker binding and about the structure of the open Ky channel, we investigated here. the ability of blockers to protect against chemical modification of cysteines introduced at sites in transmembrane segment S6, which contributes to the intracellular entrance. Within the intracellular half of S6 we found an abrupt cessation of protection for both large and small blockers that is inconsistent with the narrow 'inner pore' seen in the KcsA structure. These and other results are most readily explained by supposing that the structure of Ky channels differs from that of the non-voltage-gated bacterial channel by the introduction of a sharp bend in the inner (S6) helices. This bend would occur at a Pro-X-Pro sequence that is highly conserved in Ky channels, near the site of activation gating.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Yellen, G (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.			Yellen, Gary/0000-0003-4228-7866	NINDS NIH HHS [R01 NS029693] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029693] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; Baukrowitz T, 1996, P NATL ACAD SCI USA, V93, P13357, DOI 10.1073/pnas.93.23.13357; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; Gardner S, 1998, ACTA CRYSTALLOGR D, V54, P1071, DOI 10.1107/S0907444998007112; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; SWENSON RP, 1981, J GEN PHYSIOL, V77, P255, DOI 10.1085/jgp.77.3.255; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	27	279	281	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					321	325		10.1038/35002099	http://dx.doi.org/10.1038/35002099			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659852				2022-12-01	WOS:000084899700055
J	Ramer, MS; Priestley, JV; McMahon, SB				Ramer, MS; Priestley, JV; McMahon, SB			Functional regeneration of sensory axone into the adult spinal cord	NATURE			English	Article							DORSAL-ROOT AXONS; NERVE GROWTH-FACTOR; TRANSPLANTS; NEURONS; RAT; LESION; EXPRESSION; RECEPTORS; TARGETS; BRAIN	The arrest of dorsal root axonal regeneration at the transitional zone between the peripheral and central nervous system has been repeatedly described since the early twentieth century(1). Here we show that, with trophic support to damaged sensory axons, this regenerative barrier is surmountable. In adult rats with injured dorsal roots, treatment with nerve growth factor (NGF), neurotrophin-3 (NT3) and glial-cell-line-derived neurotrophic factor (GDNF), but not brain-derived neurotrophic factor (BDNF), resulted in selective regrowth of damaged axons across the dorsal root entry zone and into the spinal cord. Dorsal horn neurons were found to be synaptically driven by peripheral nerve stimulation in rats treated with NGF, NT3 and GDNF, demonstrating functional reconnection. In behavioural studies, rats treated with NGF and GDNF recovered sensitivity to noxious heat and pressure. The observed effects of neurotrophic factors corresponded to their known actions on distinct subpopulations of sensory neurons. Neurotrophic factor treatment may thus serve as a viable treatment in promoting recovery from root avulsion injuries.	Guys Kings & St Thomas Sch Biomed Sci, Neurosci Res Ctr, London SE1 7EH, England; Univ London Queen Mary & Westfield Coll, Div Biomed Sci, Neurosci Sect, London E1 4NS, England	University of London; King's College London; University of London; Queen Mary University London	Ramer, MS (corresponding author), Guys Kings & St Thomas Sch Biomed Sci, Neurosci Res Ctr, St Thomas Campus,Lambeth Palace Rd, London SE1 7EH, England.			McMahon, Stephen/0000-0003-4656-5536				AVERILL S, 1995, EUR J NEUROSCI, V7, P1484, DOI 10.1111/j.1460-9568.1995.tb01143.x; Bennett DLH, 1998, J NEUROSCI, V18, P3059; Bradbury EJ, 1998, MOL CELL NEUROSCI, V12, P256, DOI 10.1006/mcne.1998.0719; Bradbury EJ, 1999, EUR J NEUROSCI, V11, P3873, DOI 10.1046/j.1460-9568.1999.00809.x; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Cajal R.S., 1928, DEGENERATION REGENER; Chong MS, 1999, J COMP NEUROL, V410, P42; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Dyer JK, 1998, EXP NEUROL, V154, P12, DOI 10.1006/exnr.1998.6905; Fraher JP, 1999, J ANAT, V194, P161, DOI 10.1046/j.1469-7580.1999.19420161.x; Houle JD, 1996, EXP NEUROL, V139, P278, DOI 10.1006/exnr.1996.0101; ITOH Y, 1990, J COMP NEUROL, V302, P272, DOI 10.1002/cne.903020207; Iwaya K, 1999, NEUROSURGERY, V44, P589, DOI 10.1097/00006123-199903000-00085; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11179, DOI 10.1073/pnas.93.20.11179; KOZLOVA EN, 1995, NEUROREPORT, V6, P269, DOI 10.1097/00001756-199501000-00011; MCMAHON SB, 1994, NEURON, V12, P1161, DOI 10.1016/0896-6273(94)90323-9; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; Oudega M, 1999, BRAIN RES, V818, P431, DOI 10.1016/S0006-8993(98)01314-6; RAMONCUETO A, 1994, EXP NEUROL, V127, P232, DOI 10.1006/exnr.1994.1099; ROSARIO CM, 1992, EXP NEUROL, V115, P158, DOI 10.1016/0014-4886(92)90241-H; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SIMS TJ, 1994, EXP BRAIN RES, V99, P25; TESSLER A, 1988, J COMP NEUROL, V270, P537, DOI 10.1002/cne.902700407; THOMPSON SWN, 1995, PAIN, V62, P219, DOI 10.1016/0304-3959(94)00271-F; Winkler J, 1997, ANN NEUROL, V41, P82, DOI 10.1002/ana.410410114; Zhang Y, 1998, J NEUROSCI RES, V54, P554; Zhou XF, 1999, EUR J NEUROSCI, V11, P1711, DOI 10.1046/j.1460-9568.1999.00589.x	27	405	441	1	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					312	316		10.1038/35002084	http://dx.doi.org/10.1038/35002084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659850				2022-12-01	WOS:000084899700053
J	Folks, TM				Folks, TM			Chimpanzees as original source for HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IDENTIFICATION	The human AIDS viruses human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) represent cross-species (zoonotic) infections. Although the primate reservoir of HIV-2 has been clearly identified as the sooty mangabey (Cercocebus atys), the origin of HIV-1 remains uncertain. Viruses related to HIV-1 have been isolated from the common chimpanzee (Pan troglodytes), but only three such SIVcpz infections have been documented, one of which involved a virus so divergent that it might represent a different primate lentiviral lineage. In a search for the HIV-1 reservoir, we have now sequenced the genome of a new SIVcpz strain (SIVcpzUS) and have determined, by mitochondrial DNA analysis, the subspecies identity of all known SIVcpz-infected chimpanzees. We find that two chimpanzee subspecies in Africa, the central P, t, troglodytes and the eastern P, t, schweinfurthii, harbour SIVcpz and that their respective viruses form two highly divergent (but subspecies-specific) phylogenetic lineages. All HIV-1 strains known to infect man, including HIV-1 groups M, N and O, are closely related to just one of these SIVcpz lineages, that found in P, t, troglodytes. Moreover, we find that HIV-1 group N is a mosaic of SIVcpzUS- and HIV-1-related sequences, indicating an ancestral recombination event in a chimpanzee host. These results, together with the observation that the natural range of P, t. troglodytes coincides uniquely with areas of HIV-1 group M, N and O endemicity, indicate that P, t. troglodytes is the primary reservoir for HIV-1 and has been the source of at least three independent introductions of SIVcpz into the human population.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div HIV AIDS, HIV & Retrovirol Branch, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Folks, TM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div HIV AIDS, HIV & Retrovirol Branch, Atlanta, GA 30333 USA.							Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Heneine W, 1998, NAT MED, V4, P403, DOI 10.1038/nm0498-403; MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048; SHARP PM, 1994, AIDS, V8, P527; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400	6	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2000	283	3					310	310		10.1001/jama.283.3.310	http://dx.doi.org/10.1001/jama.283.3.310			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273WM	10647783				2022-12-01	WOS:000084732400002
J	Young, RK				Young, RK			How to have your first mammogram	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2000	283	2					171	171		10.1001/jama.283.2.171	http://dx.doi.org/10.1001/jama.283.2.171			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272QA	10634321				2022-12-01	WOS:000084661400001
J	Brown, ME; Calvin, WM				Brown, ME; Calvin, WM			Evidence for crystalline water and ammonia ices on Pluto's satellite Charon	SCIENCE			English	Article							SURFACE-COMPOSITION; SPECTROSCOPY; IRRADIATION; VOLCANISM; SYSTEM; FLOW	Observations have resolved the satellite Charon from its parent planet Pluto, giving separate spectra of the two objects from 1.0 to 2.5 micrometers. The spectrum of Charon is found to be different from that of Pluto, with water ice in crystalline form covering most of the surface of the satellite. In addition, an absorption feature in Charon's spectrum suggests the presence of ammonia ices. Ammonia ice-water ice mixtures have been proposed as the cause of flowlike features observed on the surfaces of many icy satellites. The existence of such ices on Charon may indicate geological activity in the satellite's past.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ Nevada, Dept Geol Sci, Reno, NV 89557 USA	California Institute of Technology; Nevada System of Higher Education (NSHE); University of Nevada Reno	Brown, ME (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.			Brown, Michael E./0000-0002-8255-0545				BROWN RH, 1988, ICARUS, V74, P262, DOI 10.1016/0019-1035(88)90041-3; BULE MW, 1987, NATURE, V329, P522; Chamberlain J. W., 1987, THEORY PLANETARY ATM; CHRISTY JW, 1978, IAU CIRC, V3241, P1; CROFT SK, 1997, URANUS, P561; Cruikshank D.P., 1997, PLUTO CHARON, P221; CRUIKSHANK DP, 1991, ICARUS, V94, P345, DOI 10.1016/0019-1035(91)90233-J; DURHAM WB, 1993, J GEOPHYS RES-SOL EA, V98, P17667, DOI 10.1029/93JB01564; Fanale FP, 1999, ICARUS, V139, P179, DOI 10.1006/icar.1999.6117; FINK U, 1982, COMETS, P172; Grundy WM, 1998, J GEOPHYS RES-PLANET, V103, P25809, DOI 10.1029/98JE00738; GRUNDY WM, IN PRESS ICARUS; HAPKE B, 1981, J GEOPHYS RES, V86, P3039, DOI 10.1029/JB086iB04p03039; KARGEL JS, 1991, ICARUS, V89, P93, DOI 10.1016/0019-1035(91)90090-G; KHARE BN, 1989, ICARUS, V79, P350, DOI 10.1016/0019-1035(89)90082-1; KOUCHI A, 1990, NATURE, V344, P134, DOI 10.1038/344134a0; LANCON A, 1992, ASTRON ASTROPHYS SUP, V96, P593; LANZEROTTI LJ, 1984, NATURE, V312, P139, DOI 10.1038/312139a0; LEWIS JS, 1971, ICARUS, V15, P174, DOI 10.1016/0019-1035(71)90072-8; LIDE DR, 1996, CRC HDB CHEM PHYSICS, P77; MARCIALIS RL, 1987, SCIENCE, V237, P1349, DOI 10.1126/science.237.4820.1349; McCord TB, 1999, J GEOPHYS RES-PLANET, V104, P11827, DOI 10.1029/1999JE900005; ROUSH TL, 1994, ICARUS, V108, P243, DOI 10.1006/icar.1994.1059; Roush TL, 1996, ICARUS, V119, P214, DOI 10.1006/icar.1996.0014; SCHENK PM, 1991, J GEOPHYS RES-SOLID, V96, P1887, DOI 10.1029/90JB01604; Schmitt B, 1998, ASTROPHYS SPACE SC L, V227, P199, DOI 10.1007/978-94-011-5252-5_9; STEVENSON DJ, 1982, NATURE, V298, P142, DOI 10.1038/298142a0	27	149	150	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					107	109		10.1126/science.287.5450.107	http://dx.doi.org/10.1126/science.287.5450.107			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615040				2022-12-01	WOS:000084578400045
J	Walton, DL; Norem, CT; Schoen, EJ; Ray, GT; Colby, CJ				Walton, DL; Norem, CT; Schoen, EJ; Ray, GT; Colby, CJ			Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	19th Annual Meeting of the Society-for-Maternal-Fetal Medicine	JAN 18-23, 1999	SAN FRANCISCO, CALIFORNIA	Soc Maternal Fetal Med			ALPHA-FETOPROTEIN; FETAL GROWTH; 2ND-TRIMESTER; HCG; PREECLAMPSIA; MANAGEMENT	Background: Maternal serum chorionic gonadotropin is measured to screen for fetal chromosomal abnormalities. Whether the results can also be used to predict the risk of complications or an adverse outcome of pregnancy is not known. Methods: We reviewed the medical records of 28,743 girls and women in whom chorionic gonadotropin was measured during the second trimester of pregnancy (between July 1, 1995, and January 31, 1997), seeking information about the complications and outcome of their pregnancies. We excluded girls and women who had preexisting risk factors for complications or an adverse outcome of pregnancy. Results: Higher serum chorionic gonadotropin concentrations were associated with higher rates of stillbirth (odds ratio for every increase in chorionic gonadotropin of 1 multiple of the median, 1.4; 95 percent confidence interval, 1.1 to 1.9). There was no relation between higher serum chorionic gonadotropin concentrations and the risk of gestational diabetes, premature rupture of membranes, or intrauterine growth retardation or small size for gestational age (odds ratio, 1.1; 95 percent confidence interval, 0.9 to 1.2). Higher serum chorionic gonadotropin concentrations were associated with a risk of placental abnormalities (odds ratio, 1.5; 95 percent confidence interval, 1.3 to 1.7), pregnancy-induced hypertension (odds ratio, 1.4; 95 percent confidence interval, 1.3 to 1.5), and preterm delivery without pregnancy-induced hypertension (odds ratio, 1.1; 95 percent confidence interval, 1.0 to 1.2). Inclusion in certain racial or ethnic categories (black, Filipino or Pacific Islander, unknown race or ethnic group, and "other,'' which included those of Middle Eastern descent and Native Americans) was a better predictor of the risk of an adverse outcome than serum chorionic gonadotropin values. Conclusions: Measurements of serum chorionic gonadotropin are of little clinical value for predicting the risk of complications and the outcome of pregnancy. (N Engl J Med 1999;341:2033-8.) (C) 1999, Massachusetts Medical Society.	Kaiser Permanente Med Care Program, Dept Genet, Perinatal Screening Sect, Oakland, CA 94611 USA; Kaiser Permanente Med Care Program, Dept Obstet, Oakland, CA 94611 USA; Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA	Kaiser Permanente; Kaiser Permanente; Kaiser Permanente	Schoen, EJ (corresponding author), Kaiser Permanente Med Care Program, Dept Genet, Perinatal Screening Sect, 280 W MacArthur Blvd, Oakland, CA 94611 USA.			Walton, David/0000-0002-8461-2551				ABUELO DN, 1991, PRENATAL DIAG, V11, P381, DOI 10.1002/pd.1970110607; Ashour AMN, 1997, AM J OBSTET GYNECOL, V176, P438, DOI 10.1016/S0002-9378(97)70512-X; Benn PA, 1996, OBSTET GYNECOL, V87, P217, DOI 10.1016/0029-7844(95)00390-8; Bodegard G, 1983, Acta Paediatr Scand Suppl, V304, P1; Chalmers I, 1989, EFFECTIVE CARE PREGN; FREEMAN RK, 1982, AM J OBSTET GYNECOL, V143, P771, DOI 10.1016/0002-9378(82)90008-4; GANT NF, 1994, SEMIN PERINATOL, V18, P94; GLANTZ JC, 1993, CLIN OBSTET GYNECOL, V36, P279, DOI 10.1097/00003081-199306000-00009; GONEN R, 1992, OBSTET GYNECOL, V80, P83; GRAVETT CP, 1992, AM J MED GENET, V44, P485, DOI 10.1002/ajmg.1320440420; Heinonen S, 1996, AM J PERINAT, V13, P437, DOI 10.1055/s-2007-994384; *INT CLASS DIS, 1997, ICD9CM; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; MARTEAU TM, 1992, PRENATAL DIAG, V12, P205, DOI 10.1002/pd.1970120309; MORSSINK LP, 1995, PRENATAL DIAG, V15, P1041, DOI 10.1002/pd.1970151109; Onderoglu LS, 1997, INT J GYNECOL OBSTET, V56, P245, DOI 10.1016/S0020-7292(96)02830-5; SORENSEN TK, 1993, AM J OBSTET GYNECOL, V169, P834, DOI 10.1016/0002-9378(93)90013-9; TANAKA M, 1993, OBSTET GYNECOL, V81, P341; VASILENKO P, 1995, 43 ACOG ANN M SAN FR; VORHERR H, 1975, AM J OBSTET GYNECOL, V123, P67, DOI 10.1016/0002-9378(75)90951-5; Wilkins-Haug L, 1998, CURR OPIN OBSTET GYN, V10, P469, DOI 10.1097/00001703-199812000-00007; WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624	22	55	57	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1999	341	27					2033	2038		10.1056/NEJM199912303412701	http://dx.doi.org/10.1056/NEJM199912303412701			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271BR	10615074				2022-12-01	WOS:000084573300001
J	Honein, MA; Paulozzi, LJ; Himelright, IR; Lee, B; Cragan, JD; Patterson, L; Correa, A; Hall, S; Erickson, JD				Honein, MA; Paulozzi, LJ; Himelright, IR; Lee, B; Cragan, JD; Patterson, L; Correa, A; Hall, S; Erickson, JD			Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study	LANCET			English	Article							DIAGNOSIS; EPIDEMIOLOGY; ULTRASOUND; MOTILITY; OLIVE	Background In February, 1999, a local US health department identified a cluster of pertussis cases among neonates born at a community hospital and recommended oral erythromycin for post-exposure prophylaxis for about 200 neonates born at that hospital between Feb 1 and Feb 24, 1999, We investigated a cluster of seven cases of infantile hypertrophic pyloric stenosis (IHPS) that occurred the following month among the neonates who had received erythromycin. Methods We obtained a masked, independent review of the IHPS ultrasonography diagnoses, calculated the monthly IHPS incidence, and compared index and historical (1998-99) IHPS cases with respect to several characteristics including erythromycin exposure. We used a retrospective cohort of infants born in January and February, 1999, to investigate further erythromycin exposure and development of IHPS. Findings An independent review confirmed the ultrasonographic diagnoses of all seven index IHPS cases. All index cases versus none of the historical IHPS cases had been given erythromycin for pertussis prophylaxis. The IHPS rate for infants born in the hospital in February, 1999, was 323 per 1000 liveborn infants, representing nearly a seven-fold increase over 1997-98 (relative risk 6.8 [95% CI 3.0-15.7]). Among infants born in January and February, 1999, erythromycin was associated with IHPS (absolute risk 4.5%, relative risk infinity [1.7-infinity]). Interpretation Neonates receiving oral erythromycin may have an increased risk of IHPS. The risks and benefits of erythromycin for neonatal pertussis prophylaxis should be re-evaluated, and caution should be used in defining risk groups for prophylaxis.	Ctr Dis Control & Prevent, Div Birth Defects Child Dev & Disabil & Hlth, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30341 USA; Knox Cty Hlth Dept, Knoxville, TN USA; Johns Hopkins Sch Med, Baltimore, MD USA; E Tennessee Childrens Hosp, Knoxville, TN USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Johns Hopkins University; Johns Hopkins Medicine	Honein, MA (corresponding author), Ctr Dis Control & Prevent, Div Birth Defects Child Dev & Disabil & Hlth, Natl Ctr Environm Hlth, MS F-45,4770 Buford Highway NE, Atlanta, GA 30341 USA.							Abbas AE, 1999, AM SURGEON, V65, P73; Ali KI, 1996, EUR J PEDIATR SURG, V6, P233, DOI 10.1055/s-2008-1066516; APPLEGATE MS, 1995, ARCH PEDIAT ADOL MED, V149, P1123, DOI 10.1001/archpedi.1995.02170230077011; Boiron M, 1997, ARCH PHYSIOL BIOCHEM, V105, P591, DOI 10.1076/apab.105.6.591.3281; Coulie B, 1998, GUT, V43, P395, DOI 10.1136/gut.43.3.395; DILORENZO C, 1994, DIGEST DIS SCI, V39, P1399; Godbole P, 1996, ARCH DIS CHILD, V75, P335, DOI 10.1136/adc.75.4.335; HERNANZSCHULMAN M, 1994, RADIOLOGY, V193, P771, DOI 10.1148/radiology.193.3.7972822; HITCHCOCK NE, 1987, ARCH DIS CHILD, V62, P512, DOI 10.1136/adc.62.5.512; Itoh Z, 1997, PEPTIDES, V18, P593, DOI 10.1016/S0196-9781(96)00333-6; Jadcherla SR, 1997, PEDIATR RES, V42, P365, DOI 10.1203/00006450-199709000-00018; Misra D, 1997, EUR J PEDIATR SURG, V7, P328, DOI 10.1055/s-2008-1071185; PEETERS TL, 1993, GASTROENTEROLOGY, V105, P1886, DOI 10.1016/0016-5085(93)91089-Z; PERITI P, 1993, DRUG SAFETY, V9, P346, DOI 10.2165/00002018-199309050-00004; PETER G, 1997, 1997 RED BOOK REPORT, P397; Poon TSC, 1996, J PEDIATR SURG, V31, P1611, DOI 10.1016/S0022-3468(96)90032-9; RASMUSSEN L, 1989, INT J EPIDEMIOL, V18, P413, DOI 10.1093/ije/18.2.413; Rohrschneider WK, 1998, PEDIATR RADIOL, V28, P429, DOI 10.1007/s002470050377; ROLLINS MD, 1989, ARCH DIS CHILD, V64, P138, DOI 10.1136/adc.64.1.138; SANFILIPPO JA, 1976, J PEDIATR SURG, V11, P177; Schechter R, 1997, PAEDIATR PERINAT EP, V11, P407, DOI 10.1046/j.1365-3016.1997.d01-32.x; SCHWARTZ MZ, 1998, PEDIAT SURG, P1111; SPICER RD, 1982, BRIT J SURG, V69, P128, DOI 10.1002/bjs.1800690304; STANG H, 1986, MINN MED, V69, P669; STANG H, 1986, MINN MED, V69, P682; SUTTER RW, 1992, JAMA-J AM MED ASSOC, V267, P386, DOI 10.1001/jama.267.3.386; TEELE RL, 1977, NEW ENGL J MED, V296, P1149, DOI 10.1056/NEJM197705192962006; White MC, 1998, J PEDIATR SURG, V33, P913, DOI 10.1016/S0022-3468(98)90673-X; ZEIDAN B, 1988, ARCH DIS CHILD, V63, P1060, DOI 10.1136/adc.63.9.1060	29	118	124	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2101	2105		10.1016/S0140-6736(99)10073-4	http://dx.doi.org/10.1016/S0140-6736(99)10073-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609814				2022-12-01	WOS:000084318200010
J	Vanharanta, M; Voutilainen, S; Lakka, TA; van der Lee, M; Adlercreutz, H; Salonen, JT				Vanharanta, M; Voutilainen, S; Lakka, TA; van der Lee, M; Adlercreutz, H; Salonen, JT			Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study	LANCET			English	Article							HORMONE-BINDING GLOBULIN; EASTERN FINNISH MEN; ACUTE MYOCARDIAL-INFARCTION; LOW-DENSITY-LIPOPROTEIN; HEART-DISEASE; ISOFLAVONOID PHYTOESTROGENS; CARDIOVASCULAR RISK; LIPID-PEROXIDATION; PHYTO-ESTROGENS; BREAST-CANCER	Background The lignan enterolactone, produced by the intestinal microflora from dietary precursors, has been implicated in protection against cancer. We investigated the association of serum enterolactone concentration with the risk of acute coronary events in a prospective nested case-control study in middle-aged men from eastern Finland. Methods Enterolactone was measured by time-resolved fluoroimmunoassay in serum from 167 men who had an average 7.7 years of follow-up to an acute coronary event and from 167 control men. Both cases and controls were from a cohort of 2005 men who had no clinical coronary heart disease (CHD) at baseline. The controls were matched for age, examination year, and residence. Acute coronary events were registered prospectively. Findings The mean baseline serum enterolactone concentration was lower among the cases than the controls (18.2 [SD 21.1] vs 23.5 [18.2] nmol/L, p=0.001). The men in the highest quarter of the enterolactone distribution (>30.1 nmol/L) had a 58.8% (95% CI 24.1-77.6, p=0.005) lower risk of acute coronary events than men in the lowest quarter. After adjustment for the nine most strongly predictive risk factors, men in the highest enterolactone quarter had a 65.3% (11.9-86.3, p=0.03) lower risk than men in the lowest quarter. Interpretation Healthy men with high serum concentrations of enterolactone had a lower risk of acute coronary events than men with lower concentrations. These findings support the hypothesis that plant-dominated fibre-rich food lowers the risk of CHD.	Univ Kuopio, Res Inst Publ Hlth, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland; Univ Helsinki, Folkhalsan Res Ctr, Inst Prevent Med Nutr & Canc, Helsinki, Finland; Univ Helsinki, Dept Clin Chem, Helsinki, Finland	University of Eastern Finland; University of Eastern Finland; Folkhalsan Research Center; University of Helsinki; University of Helsinki	Salonen, JT (corresponding author), Univ Kuopio, Res Inst Publ Hlth, PO 1627, FIN-70211 Kuopio, Finland.			Lakka, Timo/0000-0002-9199-2871	NHLBI NIH HHS [HL 44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135, DOI 10.1016/0022-4731(87)90200-7; ADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; ADLERCREUTZ H, 1982, LANCET, V2, P1295; Adlercreutz H, 1998, ANAL BIOCHEM, V265, P208, DOI 10.1006/abio.1998.2886; Adlercreutz H, 1997, ANN MED, V29, P95, DOI 10.3109/07853899709113696; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; EVANS BAJ, 1995, J ENDOCRINOL, V147, P295, DOI 10.1677/joe.0.1470295; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; Haffner SM, 1996, J CLIN ENDOCR METAB, V81, P3697, DOI 10.1210/jc.81.10.3697; IHANAINEN M, 1989, NUTR RES, V9, P597, DOI 10.1016/S0271-5317(89)80126-5; Ingram D, 1997, LANCET, V350, P990, DOI 10.1016/S0140-6736(97)01339-1; KUMAR KV, 1993, FREE RADICAL RES COM, V19, P59, DOI 10.3109/10715769309056499; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LAPIDUS L, 1986, CLIN CHEM, V32, P146; Martin M E, 1996, Life Sci, V58, P429; Nyyssonen K, 1997, BRIT MED J, V314, P634, DOI 10.1136/bmj.314.7081.634; Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720; PUGEAT M, 1995, J STEROID BIOCHEM, V53, P567, DOI 10.1016/0960-0760(95)00102-6; PUHAKAINEN EVJ, 1987, CLIN CHIM ACTA, V170, P255, DOI 10.1016/0009-8981(87)90135-5; SALONEN JT, 1988, AM J CLIN NUTR, V48, P1226, DOI 10.1093/ajcn/48.5.1226; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SETCHELL KDR, 1981, LANCET, V2, P4; Setchell KDR, 1988, ROLE GUT FLORA TOXIC, P315; Steinberg FM, 1998, AM J CLIN NUTR, V68, P319, DOI 10.1093/ajcn/68.2.319; TOUMILEHTO J, 1992, EUR HEART J, V13, P577; Zeleniuch-Jacquotte A, 1998, CANCER EPIDEM BIOMAR, V7, P885	30	185	190	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2112	2115		10.1016/S0140-6736(99)05031-X	http://dx.doi.org/10.1016/S0140-6736(99)05031-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609816				2022-12-01	WOS:000084318200012
J	Lee, SK; Johnson, RE; Yu, SL; Prakash, L; Prakash, S				Lee, SK; Johnson, RE; Yu, SL; Prakash, L; Prakash, S			Requirement of yeast SGS1 and SRS2 genes for replication and transcription	SCIENCE			English	Article							WERNER-SYNDROME PROTEIN; RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; DNA HELICASE; BLOOMS-SYNDROME; HOMOLOG; PRODUCT; PURIFICATION; EXONUCLEASE; INTERACTS	The SGS1 gene of the yeast Saccharomyces cerevisiae encodes a DNA helicase with homology to the human Bloom's syndrome gene BLM and the Werner's syndrome gene WRN. The SRS2 gene of yeast also encodes a DNA helicase. Simultaneous deletion of SGS1 and SRS2 is Lethal in yeast. Here, using a conditional mutation of SGS1, it is shown that DNA replication and RNA polymerase I transcription are drastically inhibited in the srs2 Delta sgs1-ts strain at the restrictive temperature. Thus, SGS1 and SRS2 function in DNA replication and RNA polymerase I transcription. These functions may contribute to the various defects observed in Werner's and Bloom's syndromes.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NCI NIH HHS [CA80882] Funding Source: Medline; NIGMS NIH HHS [GM19261] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Ellis NA, 1996, NATURE, V381, P110, DOI 10.1038/381110a0; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1995, DERMATOL CLIN, V13, P7, DOI 10.1016/S0733-8635(18)30101-3; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HIMMELFARB HJ, 1987, MOL CELL BIOL, V7, P2155, DOI 10.1128/MCB.7.6.2155; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; Lee S. A., UNPUB; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MANN C, 1992, MOL CELL BIOL, V12, P4314, DOI 10.1128/MCB.12.10.4314; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; RONG L, 1991, GENETICS, V127, P75; RONG L, 1993, J BIOL CHEM, V268, P1252; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	28	121	121	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2339	2342		10.1126/science.286.5448.2339	http://dx.doi.org/10.1126/science.286.5448.2339			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600744				2022-12-01	WOS:000084318500061
J	Dudman, NPB				Dudman, NPB			An alternative view of homocysteine	LANCET			English	Editorial Material							PLASMA HOMOCYSTEINE; VASCULAR-DISEASE; RISK; STROKE		Univ New S Wales, Prince Wales Hosp, Fac Med, Ctr Thrombosis & Vasc Res, Randwick, NSW, Australia	University of New South Wales Sydney	Dudman, NPB (corresponding author), Care of Chesterman C, Univ New S Wales, Prince Wales Hosp, Ctr Thrombosis & Vasc Res, Barker St, Randwick, NSW 2031, Australia.							ANDERSSON A, 1992, CLIN CHEM, V38, P1311; BLOM HJ, 1992, J INHERIT METAB DIS, V15, P419, DOI 10.1007/BF02435993; Dudman N. P. B., 1998, Netherlands Journal of Medicine, V52, pS22; Dudman NPB, 1999, CIRC RES, V84, P409, DOI 10.1161/01.RES.84.4.409; DUDMAN NPB, 1993, ARTERIOSCLER THROMB, V13, P512, DOI 10.1161/01.ATV.13.4.512; DUDMAN NPB, 1993, ARTERIOSCLER THROMB, V13, P1253, DOI 10.1161/01.ATV.13.9.1253; Dudman NPB, 1997, DEV CARDIOVASC MED, P267; DURAND P, 1997, FASEB J, V11, P1; Egerton W, 1996, AM J CARDIOL, V77, P759, DOI 10.1016/S0002-9149(97)89213-2; Gudnason V, 1998, ATHEROSCLEROSIS, V136, P347, DOI 10.1016/S0021-9150(97)00237-2; Guo X. W., 1998, Netherlands Journal of Medicine, V52, pS58; HULTBERG B, 1993, ALCOHOL CLIN EXP RES, V17, P687, DOI 10.1111/j.1530-0277.1993.tb00820.x; Jacobsen D. W., 1998, Netherlands Journal of Medicine, V52, pS1; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; Lai KN, 1996, CLIN IMMUNOL IMMUNOP, V80, P47, DOI 10.1006/clin.1996.0093; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; Mann N. J., 1998, Netherlands Journal of Medicine, V52, pS10; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; REDDY GSR, 1982, METABOLISM, V31, P778, DOI 10.1016/0026-0495(82)90075-0; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; REICHENBACH D, 1991, CARDIOVASC PATHOL, P61; Tosetto A, 1997, BRIT J HAEMATOL, V97, P804, DOI 10.1046/j.1365-2141.1997.1422957.x; UELAND PM, 1993, CLIN CHEM, V39, P1764; Wang Hong, 1998, Netherlands Journal of Medicine, V52, pS8; WANG PY, 1993, STROKE, V24, P236, DOI 10.1161/01.STR.24.2.236; Wilcken DEL, 1996, ARTERIOSCL THROM VAS, V16, P878, DOI 10.1161/01.ATV.16.7.878; Wilcken DEL, 1992, MOL GENETICS CORONAR, P311	27	129	131	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2072	2074		10.1016/S0140-6736(99)03383-8	http://dx.doi.org/10.1016/S0140-6736(99)03383-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636386				2022-12-01	WOS:000084183300046
J	Onyango, AW; Esrey, SA; Kramer, MS				Onyango, AW; Esrey, SA; Kramer, MS			Continued breastfeeding and child growth in the second year of life: a prospective cohort study in western Kenya	LANCET			English	Article							NUTRITIONAL-STATUS; PERUVIAN TODDLERS; BREAST-MILK; WATER; MALNUTRITION; INFANTS; ASSOCIATION; HEALTH; FOODS; AGE	Background The value of postinfancy breastfeeding for growth and nutritional status is debated. We have investigated this issue in a longitudinal study. Methods We prospectively followed up a cohort of 264 children in western Kenya for 6 months (mean age 14 months [range 9-18] at baseline) to investigate the nature of the association between breastfeeding and growth. Only 14 (5.3%) children had been weaned at baseline, and 173 (65.5%) were still breastfed at follow-up. For analysis, children were classified into three groups of breastfeeding duration as a proportion Of the total follow-up period (0-49%, n=42; 50-99%, n=49; and 100%, n=173). Findings In general linear models multivariate analysis, children in the longest-duration breastfeeding group gained 3.4 cm (p=0.0001) and 370 g (p=0.005) more than those in the shortest duration group, and 0.6 cm (p=0.0015) and 230 g (p=0.038) more than children in the intermediate group. The strongest association between breastfeeding and linear growth was observed in households that had no latrine and daily water use of less than 10 L per person. Interpretation Our findings support WHO's recommendation to continue breastfeeding for at least 2 years, especially in settings with poor sanitation and inadequate water supply.	WHO, Dept Nutr, CH-1211 Geneva 27, Switzerland; UNICEF, New York, NY USA; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada	World Health Organization; UNICEF; McGill University; McGill University	Onyango, AW (corresponding author), WHO, Dept Nutr, CH-1211 Geneva 27, Switzerland.							ADAIR L, 1993, EUR J CLIN NUTR, V47, P42; BUTZ WP, 1984, AM J EPIDEMIOL, V119, P516, DOI 10.1093/oxfordjournals.aje.a113769; CAIRNCROSS S, 1987, T ROY SOC TROP MED H, V81, P51, DOI 10.1016/0035-9203(87)90280-X; Caulfield LE, 1996, INT J EPIDEMIOL, V25, P693, DOI 10.1093/ije/25.4.693; COHEN RJ, 1994, LANCET, V344, P288, DOI 10.1016/S0140-6736(94)91337-4; ESREY SA, 1992, AM J EPIDEMIOL, V135, P659, DOI 10.1093/oxfordjournals.aje.a116345; Esrey SA, 1996, AM J EPIDEMIOL, V143, P608, DOI 10.1093/oxfordjournals.aje.a008791; *FAO WHO, 1992, INT C NUTR WORLD DEC; Fawzi WW, 1998, INT J EPIDEMIOL, V27, P255, DOI 10.1093/ije/27.2.255; GRUMMERSTRAWN LM, 1993, PEDIATRICS, V91, P766; LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M; Marquis GS, 1997, INT J EPIDEMIOL, V26, P349, DOI 10.1093/ije/26.2.349; Marquis GS, 1997, AM J CLIN NUTR, V66, P1102, DOI 10.1093/ajcn/66.5.1102; MARTINES JC, 1994, J NUTR, V124, P1189, DOI 10.1093/jn/124.8.1189; MARTORELL R, 1988, NESTLE NUTRITION WOR, V14, P57; Molbak K, 1997, INT J EPIDEMIOL, V26, P458, DOI 10.1093/ije/26.2.458; NGANDU NH, 1990, J EPIDEMIOL COMMUN H, V44, P281, DOI 10.1136/jech.44.4.281; Nube M, 1996, EUR J CLIN NUTR, V50, P171; SAULS HS, 1979, PEDIATRICS, V64, P523; Simondon KB, 1998, INT J EPIDEMIOL, V27, P490, DOI 10.1093/ije/27.3.490; TAREN D, 1993, AM J CLIN NUTR, V58, P862, DOI 10.1093/ajcn/58.6.862; Victora C G, 1991, Epidemiology, V2, P175, DOI 10.1097/00001648-199105000-00003; VICTORA CG, 1984, AM J CLIN NUTR, V39, P307, DOI 10.1093/ajcn/39.2.307; WHO, 1995, WEEKLY EPIDEMIOLOGIC, V70, P119; *WHO UNICEF, 1990, WHO UNICEF POL MAK M	25	51	54	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2041	2045		10.1016/S0140-6736(99)02168-6	http://dx.doi.org/10.1016/S0140-6736(99)02168-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636370				2022-12-01	WOS:000084183300013
J	Kojima, M; Hosoda, H; Date, Y; Nakazato, M; Matsuo, H; Kangawa, K				Kojima, M; Hosoda, H; Date, Y; Nakazato, M; Matsuo, H; Kangawa, K			Ghrelin is a growth-hormone-releasing acylated peptide from stomach	NATURE			English	Article							NATRIURETIC PEPTIDE; RECEPTOR; PITUITARY; RAT; SECRETAGOGUE; BRAIN; NEUROPEPTIDES	Small synthetic molecules called growth-hormone secretagogues (GHSs)(1-3) stimulate the release of growth hormone (GH) from the pituitary(4,5). They act through GHS-R, a G-protein-coupled receptor for which the ligand is unknown. Recent cloning of GHS-R-6,R-7 strongly suggests that an endogenous ligand for the receptor does exist and that there is a mechanism for regulating GH release that is distinct from its regulation by hypothalamic growth-hormone-releasing hormone (GHRH)(4,5). We now report the purification and identification in rat stomach of an endogenous ligand specific for GHS-R. The purified ligand is a peptide of 28 amino acids, in which the serine 3 residue is n-octanoylated. The acylated peptide specifically releases GH both in vivo and in vitro, and O-n-octanoylation at serine 3 is essential for the activity. We designate the GH-releasing peptide 'ghrelin' (ghre is the Proto-Indo-European root of the word 'grow'). Human ghrelin is homologous to rat ghrelin apart from two amino acids. The occurrence of ghrelin in both rat and human indicates that GH release from the pituitary may be regulated not only by hypothalamic GHRH, but also by ghrelin.	Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Osaka 5658565, Japan; Miyazaki Med Coll, Dept Internal Med 3, Miyazaki 8891692, Japan	National Cerebral & Cardiovascular Center - Japan; University of Miyazaki	Kangawa, K (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Osaka 5658565, Japan.							AKMAN MS, 1993, ENDOCRINOLOGY, V132, P1286, DOI 10.1210/en.132.3.1286; ALONSO G, 1988, BRAIN RES, V453, P191, DOI 10.1016/0006-8993(88)90158-8; BERGHE GV, 1999, J CLIN ENDOCR METAB, V84, P1311; Bisi G, 1999, J ENDOCRINOL INVEST, V22, P266, DOI 10.1007/BF03343555; Bowers CY, 1998, CELL MOL LIFE SCI, V54, P1316, DOI 10.1007/s000180050257; CHENG K, 1989, ENDOCRINOLOGY, V124, P2791; Civelli O, 1998, FEBS LETT, V430, P55, DOI 10.1016/S0014-5793(98)00524-9; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; Date Y, 1999, ENDOCRINOLOGY, V140, P2398, DOI 10.1210/en.140.5.2398; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; Guan XM, 1997, MOL BRAIN RES, V48, P23, DOI 10.1016/S0169-328X(97)00071-5; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; JONATHAN NB, 1983, METHOD ENZYMOL, V103, P249; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KOJIMA M, 1994, J BIOL CHEM, V269, P13136; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Schroeder, 1996, J BIOMOL SCREEN, V1, P75, DOI 10.1177/108705719600100205; Smith GD, 1997, EUR HEART J, V18, P6; SMITH RG, 1993, SCIENCE, V260, P1640, DOI 10.1126/science.8503009; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0	27	6573	7078	8	330	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					656	660		10.1038/45230	http://dx.doi.org/10.1038/45230			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604470				2022-12-01	WOS:000084189800064
J	Tyler, JK; Adams, CR; Chen, SR; Kobayashi, R; Kamakaka, RT; Kadonaga, JT				Tyler, JK; Adams, CR; Chen, SR; Kobayashi, R; Kamakaka, RT; Kadonaga, JT			The RCAF complex mediates chromatin assembly during DNA replication and repair	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; II TRANSCRIPTION; YEAST; PROTEIN; GENES; IDENTIFICATION; ACETYLATION; REPRESSION; TELOMERES; INVITRO	Chromatin assembly is a fundamental biological process that is essential for the replication and maintenance of the eukaryotic genome(1-4). In dividing cells, newly synthesized DNA is rapidly assembled into chromatin by the deposition of a tetramer of the histone proteins H3 and H4, followed by the deposition of two dimers of histones H2A and H2B to complete the nucleosome-the fundamental repeating unit of chromatin(5). Here we describe the identification, purification, cloning, and characterization of replication-coupling assembly factor (RCAF), a novel protein complex that facilitates the assembly of nucleosomes onto newly replicated DNA in vitro. RCAF comprises the Drosophila homologue of anti-silencing function 1 protein ASF1(6) and histones H3 and H4. The specific acetylation pattern of H3 and H4 in RCAF is identical to that of newly synthesized histones. Genetic analyses in Saccharomyces cerevisiae demonstrate that ASF1 is essential for normal fell cycle progression, and suggest that RCAF mediates chromatin assembly after DNA replication and the repair of double-strand DNA damage in vivo.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; NICHD, NIH, Bethesda, MD 20892 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Cold Spring Harbor Laboratory	Tyler, JK (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Kamakaka, Rohinton/K-3140-2019	Kamakaka, Rohinton/0000-0003-1931-7000; Tyler, Jessica/0000-0001-9765-1659	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008731] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAN M, 1987, CELL, V48, P589, DOI 10.1016/0092-8674(87)90237-6; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; SCHWARTZ JL, 1989, MUTAT RES, V216, P111, DOI 10.1016/0165-1161(89)90011-3; Singer MS, 1998, GENETICS, V150, P613; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4	28	438	445	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					555	560		10.1038/990147	http://dx.doi.org/10.1038/990147			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591219				2022-12-01	WOS:000084013200063
J	Henney, JE				Henney, JE			Parkinson treatment approval	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					1995	1995		10.1001/jama.282.21.1995	http://dx.doi.org/10.1001/jama.282.21.1995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591372				2022-12-01	WOS:000083908700006
J	Fenwick, C; Na, SY; Voll, RE; Zhong, HH; Im, SY; Lee, JW; Ghosh, S				Fenwick, C; Na, SY; Voll, RE; Zhong, HH; Im, SY; Lee, JW; Ghosh, S			A subclass of Ras proteins that regulate the degradation of I kappa B	SCIENCE			English	Article							GTP-GAMMA-S; ACTIVATION; BETA; ALPHA; PHOSPHORYLATION; TRANSFORMATION; GTPASES; COMPLEX; FAMILY; GENE	Small guanosine triphosphatases, typified by the mammalian Ras proteins, play major roles in the regulation of numerous cellular pathways. A subclass of evolutionarily conserved Ras-Like proteins was identified, members of which differ from other Ras proteins in containing amino acids at positions 12 and 61 that are similar to those present in the oncogenic forms of Ras. These proteins, kappa B-Ras1 and kappa B-Ras2, interact with the PEST domains of I kappa B alpha and I kappa B beta [inhibitors of the transcription factor nuclear factor kappa B (NF-kappa B)] and decrease their rate of degradation. In cells, kappa B-Ras proteins are associated only with NF-kappa B:I kappa B beta complexes and therefore may provide an explanation for the slower rate of degradation of I kappa B beta compared with I kappa B alpha.	Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Microbiol, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea	Chonnam National University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Chonnam National University; Chonnam National University; Chonnam National University	Ghosh, S (corresponding author), Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea.			Fenwick, Craig/0000-0002-9435-0110				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FENWICK CW, UNPUB; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LAWRENCE PA, 1988, CELL, V54, P1, DOI 10.1016/0092-8674(88)90172-9; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Na SY, 1998, J BIOL CHEM, V273, P3212, DOI 10.1074/jbc.273.6.3212; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Raw AS, 1997, BIOCHEMISTRY-US, V36, P15660, DOI 10.1021/bi971912p; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Weil R, 1997, J BIOL CHEM, V272, P9942; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Winkler DG, 1997, J BIOL CHEM, V272, P24402, DOI 10.1074/jbc.272.39.24402; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	27	84	99	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2000	287	5454					869	873		10.1126/science.287.5454.869	http://dx.doi.org/10.1126/science.287.5454.869			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	281AR	10657303				2022-12-01	WOS:000085136400050
J	Goodman, KJ; Correa, P				Goodman, KJ; Correa, P			Transmission of Helicobacter pylori among siblings	LANCET			English	Article							UREA BREATH TEST; DUODENAL-ULCER; BIRTH-ORDER; INFECTION; RISK; CHILDREN; POPULATION; PREVALENCE; INFANCY; AGE	Background Helicobacter pylori infection causes chronic digestive diseases with a major public-health impact, yet the design of prevention measures is hampered by limited knowledge of transmission pathways. We studied the effect of family composition on H pylori prevalence among rural Colombian children aged 2-9 years. Methods 684 children were screened for H pylori with the UC-urea breath test, For each child, birth order, birth spacing, number of 2-9-year-old siblings, and number of H-pylori-positive 2-9-year-old siblings was recorded. Odds ratios were estimated by logistic regression, controlling for hygiene-related exposures, socioeconomic indicators, and the number of children in the household. Findings The odds of infection increased with the number of 2-9-year-old siblings in the household (odds ratios 1.4, 2.3, 2.6, and 4.3 for one, two, three, and four to five siblings, respectively). Compared with first-born children, odds ratios for children born second and third to ninth were 1.8 (95% CI 1.0-3.3) and 2.2(1.0-4.3), respectively. Compared with children born 10 or more years after the next older household member, those born within 4 years were 4.1 times (CI 2.0-8.6) more likely to be infected; the age gap to the next younger household member displayed a weaker effect. The number of H-pylori-positive 2-9-year-old siblings had particularly strong effect gradient (1.5, 3.2, 5.6, and 7.1, for one, two, three, and four positive siblings, respectively). Interpretation Among rural Andean children younger than 10 years, H pylori infection seems to be transmitted most readily among siblings who are close in age, and most frequently from older siblings to younger ones.	Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Houston, TX 77225 USA; Louisiana State Univ, Med Ctr, Dept Pathol, New Orleans, LA 70112 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Louisiana State University System	Goodman, KJ (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, POB 20186, Houston, TX 77225 USA.	kgoodman@utsph.sph.uth.tmc.edu	Goodman, Karen/D-6823-2013	Goodman, Karen/0000-0002-3790-3217	NATIONAL CANCER INSTITUTE [P01CA028842] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA28842] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashorn M, 1996, ARCH DIS CHILD-FETAL, V74, pF141, DOI 10.1136/fn.74.2.F141; Blaser MJ, 1998, GUT, V43, P721, DOI 10.1136/gut.43.5.721; BLASER MJ, 1995, CANCER RES, V55, P562; BLECKER U, 1994, J PEDIATR GASTR NUTR, V19, P87, DOI 10.1097/00005176-199407000-00014; Cadranel S, 1998, J PEDIATR GASTR NUTR, V27, P275, DOI 10.1097/00005176-199809000-00001; CORREA P, 1990, CANCER RES, V50, P4737; CORREA P, 1995, GASTROINTESTINAL OES, P485; CORREA P, 1989, PROGR SURGICAL PATHO, V10, P191; Delvin EE, 1999, J PEDIATR GASTR NUTR, V28, P59, DOI 10.1097/00005176-199901000-00014; Fall CHD, 1997, ARCH DIS CHILD, V77, P310, DOI 10.1136/adc.77.4.310; FOX JP, 1970, EPIDEMIOLOGY MAN DIS, P199; Gold BD, 1997, PEDIATR RES, V41, P641, DOI 10.1203/00006450-199705000-00007; Goodman, 1997, Cad Saude Publica, V13 Suppl 1, P15; Goodman KJ, 1996, AM J EPIDEMIOL, V144, P290, DOI 10.1093/oxfordjournals.aje.a008924; GOODMAN KJ, 1995, INT J EPIDEMIOL, V24, P875, DOI 10.1093/ije/24.5.875; GRAHAM DY, 1991, AM J GASTROENTEROL, V86, P1118; GUTENSOHN N, 1981, NEW ENGL J MED, V304, P135, DOI 10.1056/NEJM198101153040302; HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1115, DOI 10.1093/oxfordjournals.aje.a116577; *INT AG RES CANC, 1994, IARC MON EV CANC RIS, V61; ISAGER H, 1980, ACTA NEUROL SCAND, V61, P393; Kalach N, 1998, J PEDIATR GASTR NUTR, V26, P291, DOI 10.1097/00005176-199803000-00010; MACMAHON B, 1992, AM J EPIDEMIOL, V136, P916, DOI 10.1093/oxfordjournals.aje.a116564; PARSONNET J, 1995, ALIMENT PHARM THERAP, V9, P45; POUNDER RE, 1995, ALIMENT PHARM THERAP, V9, P33; REVES R, 1985, AM J EPIDEMIOL, V122, P112, DOI 10.1093/oxfordjournals.aje.a114070; Rothenbacher D, 1997, EPIDEMIOL INFECT, V119, P151, DOI 10.1017/S0950268897007905; Rothenbacher D, 1998, INT J EPIDEMIOL, V27, P135, DOI 10.1093/ije/27.1.135; Rowland M, 1997, J PEDIATR-US, V131, P815, DOI 10.1016/S0022-3476(97)70026-X; TAYLOR I, 1964, PRINCIPLES EPIDEMIOL, P304; TEH BH, 1994, ANTICANCER RES, V14, P1389; TSUGANE S, 1994, JPN J CANCER RES, V85, P474, DOI 10.1111/j.1349-7006.1994.tb02382.x; VANDENPLAS Y, 1992, PEDIATRICS, V90, P608; WANG JT, 1993, J INFECT DIS, V168, P1544, DOI 10.1093/infdis/168.6.1544; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	34	206	211	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	2000	355	9201					358	362		10.1016/S0140-6736(99)05273-3	http://dx.doi.org/10.1016/S0140-6736(99)05273-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665555				2022-12-01	WOS:000085122100011
J	Earn, DJD; Rohani, P; Bolker, BM; Grenfell, BT				Earn, DJD; Rohani, P; Bolker, BM; Grenfell, BT			A simple model for complex dynamical transitions in epidemics	SCIENCE			English	Article							MEASLES DYNAMICS; METAPOPULATION DYNAMICS; CHAOS; VACCINATION; PERSISTENCE; PREDICTABILITY; PERIODICITY; DISEASES; ENGLAND; IMPACT	Dramatic changes in patterns of epidemics have been observed throughout this century. For childhood infectious diseases such as measles, the major transitions are between regular cycles and irregular, possibly chaotic epidemics, and from regionally synchronized oscillations to complex, spatially incoherent epidemics. A simple model can explain both kinds of transitions as the consequences of changes in birth and vaccination rates. Measles is a natural ecological system that exhibits different dynamical transitions at different times and places, yet all of these transitions can be predicted as bifurcations of a single nonlinear model.	McMaster Univ, Dept Math & Stat, Hamilton, ON L8S 4K1, Canada; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Florida, Dept Zool, Gainesville, FL 32611 USA	McMaster University; University of Cambridge; State University System of Florida; University of Florida	Earn, DJD (corresponding author), McMaster Univ, Dept Math & Stat, Hamilton, ON L8S 4K1, Canada.	earn@math.mcmaster.ca		rohani, pejman/0000-0002-7221-3801; Earn, David/0000-0002-7562-1341; Bolker, Benjamin/0000-0002-2127-0443				Anderson R, 1982, POPULATION DYNAMICS; ANDERSON R M, 1991; ARON JL, 1990, THEOR POPUL BIOL, V38, P58, DOI 10.1016/0040-5809(90)90003-E; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; Bolker BM, 1996, P NATL ACAD SCI USA, V93, P12648, DOI 10.1073/pnas.93.22.12648; BOLKER BM, 1993, P ROY SOC B-BIOL SCI, V251, P75, DOI 10.1098/rspb.1993.0011; Costantino RF, 1997, SCIENCE, V275, P389, DOI 10.1126/science.275.5298.389; Earn DJD, 1998, P ROY SOC B-BIOL SCI, V265, P7, DOI 10.1098/rspb.1998.0256; EARN DJD, UNPUB; Ellner SP, 1998, AM NAT, V151, P425, DOI 10.1086/286130; ENGBERT R, 1994, PREDICTABILITY AND NONLINEAR MODELLING IN NATURAL SCIENCES AND ECONOMICS, P204; FERGUSON NM, 1997, MONOGRAPHS POPULATIO, V30, P137; FINE PEM, 1982, INT J EPIDEMIOL, V11, P5, DOI 10.1093/ije/11.1.5; Finkenstadt B, 1998, P ROY SOC B-BIOL SCI, V265, P211, DOI 10.1098/rspb.1998.0284; Glendinning P, 1997, J MATH BIOL, V35, P359, DOI 10.1007/s002850050056; Grenfell B, 1997, TRENDS ECOL EVOL, V12, P395, DOI 10.1016/S0169-5347(97)01174-9; GRENFELL BT, 1992, J ROY STAT SOC B MET, V54, P383; GRENFELL BT, 1994, PHILOS T R SOC A, V348, P515, DOI 10.1098/rsta.1994.0108; HASTINGS A, 1994, SCIENCE, V263, P1133, DOI 10.1126/science.263.5150.1133; Holyoak M, 1996, J ANIM ECOL, V65, P640, DOI 10.2307/5743; Hudson PJ, 1998, SCIENCE, V282, P2256, DOI 10.1126/science.282.5397.2256; Levin SA, 1997, SCIENCE, V275, P334, DOI 10.1126/science.275.5298.334; LONDON WP, 1973, AM J EPIDEMIOL, V98, P453, DOI 10.1093/oxfordjournals.aje.a121575; May R.M., 1986, Biomathematics (Berlin), V17, P405; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P111, DOI 10.1017/S0950268800065614; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P419, DOI 10.1017/S0950268800067170; MOLLISON D, 1993, MATH BIOSCI, V117, P155, DOI 10.1016/0025-5564(93)90021-2; OLSEN LF, 1988, THEOR POPUL BIOL, V33, P344, DOI 10.1016/0040-5809(88)90019-6; OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131; RAND DA, 1991, P ROY SOC B-BIOL SCI, V246, P179, DOI 10.1098/rspb.1991.0142; Rohani P, 1999, SCIENCE, V286, P968, DOI 10.1126/science.286.5441.968; Schaffer W M, 1985, IMA J Math Appl Med Biol, V2, P221; SCHAFFER WM, 1985, J THEOR BIOL, V112, P403, DOI 10.1016/S0022-5193(85)80294-0; SCHAFFER WM, 1993, IMA J MATH APPL MED, V10, P227; Schenzle D, 1984, IMA J Math Appl Med Biol, V1, P169; SCHWARTZ IB, 1985, J MATH BIOL, V21, P347, DOI 10.1007/BF00276232; SCHWARTZ IB, 1983, J MATH BIOL, V18, P233, DOI 10.1007/BF00276090; Turchin P, 1999, SCIENCE, V285, P1068, DOI 10.1126/science.285.5430.1068; Zimmer C, 1999, SCIENCE, V284, P83, DOI 10.1126/science.284.5411.83	39	482	499	1	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	2000	287	5453					667	670		10.1126/science.287.5453.667	http://dx.doi.org/10.1126/science.287.5453.667			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10650003				2022-12-01	WOS:000084989400052
J	Oghalai, JS; Zhao, HB; Kutz, JW; Brownell, WE				Oghalai, JS; Zhao, HB; Kutz, JW; Brownell, WE			Voltage- and tension-dependent lipid mobility in the outer hair cell plasma membrane	SCIENCE			English	Article							ERYTHROCYTE-MEMBRANE; BIOLOGICAL-MEMBRANES; LATERAL MOBILITY; BILAYER COUPLES; SHAPE CHANGES; MOTILITY; ELECTROMOTILITY; CHOLESTEROL; CAPACITANCE; COCHLEA	The mechanism responsible for electromotility of outer hair cells in the ear is unknown but is thought to reside within the plasma membrane. Lipid Lateral diffusion in the outer hair fell plasma membrane is a sigmoidal function of transmembrane potential and bathing media osmolality. Cell depolarization or hyposmotic challenge shorten the cell and reduce membrane fluidity by half. Changing the membrane tension with amphipathic drugs results in similar reductions. These dynamic changes in membrane fluidity represent the modulation of membrane tension by lipid-protein interactions. The voltage dependence may be associated with the force-generating motors that contribute to the exquisite sensitivity of mammalian hearing.	Baylor Coll Med, Dept Otolaryngol & Commun Sci, Houston, TX 77030 USA	Baylor College of Medicine	Brownell, WE (corresponding author), Baylor Coll Med, Dept Otolaryngol & Commun Sci, 1 Baylor Plaza, Houston, TX 77030 USA.		Kutz, Joe/ABF-4855-2020		NIDCD NIH HHS [R01 DC000354] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000354] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adachi M, 1999, P NATL ACAD SCI USA, V96, P7244, DOI 10.1073/pnas.96.13.7244; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BLOOM JA, 1983, BIOPHYS J, V42, P295, DOI 10.1016/S0006-3495(83)84397-5; BLOOM M, 1991, Q REV BIOPHYS, V24, P293, DOI 10.1017/S0033583500003735; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; DALLOS P, 1991, NATURE, V350, P155, DOI 10.1038/350155a0; DALLOS P, 1992, J NEUROSCI, V12, P4575; DERZKO Z, 1980, BIOCHEMISTRY-US, V19, P6050, DOI 10.1021/bi00567a016; DEUTICKE B, 1968, BIOCHIM BIOPHYS ACTA, V163, P494, DOI 10.1016/0005-2736(68)90078-3; Gale JE, 1997, NATURE, V389, P63, DOI 10.1038/37968; GALE JE, 1994, P ROY SOC B-BIOL SCI, V255, P243, DOI 10.1098/rspb.1994.0035; GOLAN DE, 1984, BIOCHEMISTRY-US, V23, P332, DOI 10.1021/bi00297a024; He DZZ, 1999, P NATL ACAD SCI USA, V96, P8223, DOI 10.1073/pnas.96.14.8223; HOLLEY MC, 1996, SPR HDB AUD, V8, P386; HUANG GJ, 1994, P NATL ACAD SCI USA, V91, P12268, DOI 10.1073/pnas.91.25.12268; IWASA KH, 1992, J ACOUST SOC AM, V92, P3169, DOI 10.1121/1.404194; IWASA KH, 1994, J ACOUST SOC AM, V96, P2216, DOI 10.1121/1.410094; IWASA KH, 1993, BIOPHYS J, V65, P492, DOI 10.1016/S0006-3495(93)81053-1; KAKEHATA S, 1995, BIOPHYS J, V68, P2190, DOI 10.1016/S0006-3495(95)80401-7; KAPITZA HG, 1980, BIOCHIM BIOPHYS ACTA, V595, P56, DOI 10.1016/0005-2736(80)90247-3; MONTANA V, 1989, BIOCHEMISTRY-US, V28, P4536, DOI 10.1021/bi00437a003; Oghalai JS, 1999, HEARING RES, V135, P19, DOI 10.1016/S0378-5955(99)00077-5; Oghalai JS, 1998, J NEUROSCI, V18, P48; Oghalai JS, 1998, J NEUROPHYSIOL, V79, P2235, DOI 10.1152/jn.1998.79.4.2235; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; SERVUSS RM, 1976, BIOCHIM BIOPHYS ACTA, V436, P900, DOI 10.1016/0005-2736(76)90422-3; SHEETZ MP, 1976, J CELL BIOL, V70, P193, DOI 10.1083/jcb.70.1.193; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; SHEHATA WE, 1991, ACTA OTO-LARYNGOL, V111, P707, DOI 10.3109/00016489109138403; Sit PS, 1997, BIOPHYS J, V72, P2812, DOI 10.1016/S0006-3495(97)78923-9; SMITH CA, 1968, ANN OTO RHINOL LARYN, V77, P629, DOI 10.1177/000348946807700404; THOMPSON NL, 1980, BIOCHIM BIOPHYS ACTA, V597, P155, DOI 10.1016/0005-2736(80)90159-5; VAZ WLC, 1982, MEMBRANE RECONSTITUT, P83; Zhao HB, 1999, NATURE, V399, P359, DOI 10.1038/20686	35	90	95	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	2000	287	5453					658	661		10.1126/science.287.5453.658	http://dx.doi.org/10.1126/science.287.5453.658			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	278KR	10650000	Green Accepted			2022-12-01	WOS:000084989400049
J	Mol, CD; Izumi, T; Mitra, S; Tainer, JA				Mol, CD; Izumi, T; Mitra, S; Tainer, JA			DNA-bound structures and mutants reveal abasic DNA binding by APE1 DNA repair and coordination	NATURE			English	Article							HUMAN APURINIC ENDONUCLEASE; BASE EXCISION-REPAIR; POLYMERASE-BETA; SITES; DEOXYRIBOSE; RECOGNITION; DYNAMICS; PROTEIN; XRCC1; CELLS	Non-coding apurinic/apyrimidinic (AP) sites in DNA are continually created in cells both spontaneously and by damage-specific DNA glycosylases'. The biologically critical human base excision repair enzyme APE1 cleaves the DNA sugar-phosphate backbone at a position 5' of AP sites to prime DNA repair synthesis(2-4). Here we report three co-crystal structures of human APE1 bound to abasic DNA which show that APE1 uses a rigid, pre-formed, positively charged surface to kink the DNA helix and engulf the AP-DNA strand. APE1 inserts loops into both the DNA major and minor grooves and binds a flipped-out AP site in a pocket that excludes DNA bases and racemized beta-anomer AP sites. Both the APE1 active-site geometry and a complex with cleaved AP-DNA and Mn2+ support a testable structure-based catalytic mechanism. Alanine substitutions of the residues that penetrate the DNA helix unexpectedly show that human APE1 is structurally optimized to retain the cleaved DNA product. These structural and mutational results show how APE1 probably displaces bound glycosylases and retains the nicked DNA product, suggesting that APE1 acts in vivo to coordinate the orderly transfer of unstable DNA damage intermediates between the excision and synthesis steps of DNA repair.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	Scripps Research Institute; Scripps Research Institute; University of Texas System; University of Texas Medical Branch Galveston	Tainer, JA (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429				Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; Erzberger JP, 1999, J MOL BIOL, V290, P447, DOI 10.1006/jmbi.1999.2888; Erzberger JP, 1998, NUCLEIC ACIDS RES, V26, P2771, DOI 10.1093/nar/26.11.2771; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Izumi T, 1998, CARCINOGENESIS, V19, P525, DOI 10.1093/carcin/19.3.525; Izumi T, 1999, J MOL BIOL, V287, P47, DOI 10.1006/jmbi.1999.2573; KANE CM, 1981, J BIOL CHEM, V256, P3405; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Tsutakawa SE, 1999, CELL, V99, P615, DOI 10.1016/S0092-8674(00)81550-0; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017	30	581	601	12	90	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					451	456		10.1038/35000249	http://dx.doi.org/10.1038/35000249			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667800				2022-12-01	WOS:000085121100056
J	O'Donnell, HC; Rosand, J; Knudsen, KA; Furie, KL; Segal, AZ; Chiu, RI; Ikeda, D; Greenberg, SM				O'Donnell, HC; Rosand, J; Knudsen, KA; Furie, KL; Segal, AZ; Chiu, RI; Ikeda, D; Greenberg, SM			Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL AMYLOID ANGIOPATHY; E EPSILON-4 ALLELE; ALZHEIMERS-DISEASE; HIGH-FREQUENCY; STROKE; HEMATOMAS; ONSET	Background: Recurrent lobar intracerebral hemorrhage is the hallmark of cerebral amyloid angiopathy. The factors that predispose patients to early recurrence of lobar hemorrhage are unknown. One candidate is the apolipoprotein E gene, since both the epsilon 2 and the epsilon 4 alleles of apolipoprotein E appear to be associated with the severity of amyloid angiopathy. Methods: We performed a prospective, longitudinal study of consecutive elderly patients who survived a lobar intracerebral hemorrhage. The patients were followed for recurrent hemorrhagic stroke by interviews at six-month intervals and reviews of medical records and computed tomographic scans. Results: Nineteen of 71 enrolled patients had recurrent hemorrhages during a mean (+/-SD) follow-up period of 23.9+/-14.8 months, yielding a 2-year cumulative rate of recurrence of 21 percent. The apolipoprotein E genotype was significantly associated with the risk of recurrence. Carriers of the epsilon 2 or epsilon 4 allele had a two-year rate of recurrence of 28 percent, as compared with only 10 percent for patients with the common apolipoprotein E epsilon 3/epsilon 3 genotype (risk ratio, 3.8; 95 percent confidence interval, 1.2 to 11.6; P=0.01). Early recurrence occurred in eight patients, four of whom had the uncommon epsilon 2/epsilon 4 genotype. Also at increased risk for recurrence were patients with a history of hemorrhagic stroke before entry into the study (two-year recurrence, 61 percent; risk ratio, 6.4; 95 percent confidence interval, 2.2 to 18.5; P<0.001). Conclusions: The apolipoprotein E genotype can identify patients with lobar intracerebral hemorrhage who are at highest risk for early recurrence. This finding makes possible both the provision of prognostic information to patients with lobar hemorrhage and a method of targeting and assessing potential strategies for prevention. (N Engl J Med 2000;342:240-5.) (C)2000, Massachusetts Medical Society.	Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Greenberg, SM (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Wang ACC 836, Boston, MA 02114 USA.		Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789	NIA NIH HHS [AG00725] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alonzo NC, 1998, J NEUROPATH EXP NEUR, V57, P353, DOI 10.1097/00005072-199804000-00008; Arakawa S, 1998, STROKE, V29, P1806, DOI 10.1161/01.STR.29.9.1806; BRODERICK J, 1993, STROKE, V24, P49, DOI 10.1161/01.STR.24.1.49; CORDER EH, 1995, NEUROLOGY, V45, P1323, DOI 10.1212/WNL.45.7.1323; COUNSELL C, 1995, CEREBROVASC DIS, V5, P26, DOI 10.1159/000107814; GILLES C, 1984, NEUROLOGY, V34, P730, DOI 10.1212/WNL.34.6.730; GomezIsla T, 1996, ANN NEUROL, V39, P62, DOI 10.1002/ana.410390110; GRAY F, 1985, ANN NEUROL, V18, P54, DOI 10.1002/ana.410180110; Greenberg SM, 1998, NEUROLOGY, V51, P690, DOI 10.1212/WNL.51.3.690; GREENBERG SM, 1993, NEUROLOGY, V43, P2073, DOI 10.1212/WNL.43.10.2073; Greenberg SM, 1999, NEUROLOGY, V53, P1135, DOI 10.1212/WNL.53.5.1135; Greenberg SM, 1998, NEUROLOGY, V50, P961, DOI 10.1212/WNL.50.4.961; Greenberg SM, 1996, NEUROLOGY, V46, P1751, DOI 10.1212/WNL.46.6.1751; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Greenberg SM, 1996, STROKE, V27, P1333, DOI 10.1161/01.STR.27.8.1333; ITOH Y, 1993, J NEUROL SCI, V116, P135, DOI 10.1016/0022-510X(93)90317-R; KASE CS, 1982, NEUROLOGY, V32, P1146, DOI 10.1212/WNL.32.10.1146; Kurz A, 1996, NEUROLOGY, V47, P440, DOI 10.1212/WNL.47.2.440; MASSARO AR, 1991, NEUROLOGY, V41, P1881, DOI 10.1212/WNL.41.12.1881; Mayeux R, 1998, NEW ENGL J MED, V338, P1325; McCarron MO, 1998, NEUROSCI LETT, V247, P45, DOI 10.1016/S0304-3940(98)00286-9; McCarron MO, 1999, J NEUROPATH EXP NEUR, V58, P711, DOI 10.1097/00005072-199907000-00005; Neau JP, 1997, NEUROLOGY, V49, P106, DOI 10.1212/WNL.49.1.106; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; Offenbacher H, 1996, AM J NEURORADIOL, V17, P573; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; PASSERO S, 1995, STROKE, V26, P1189, DOI 10.1161/01.STR.26.7.1189; Premkumar DRD, 1996, AM J PATHOL, V148, P2083; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Stern Y, 1997, ANN NEUROL, V41, P615, DOI 10.1002/ana.410410510; TATEMICHI TK, 1994, NEUROLOGY, V44, P1885, DOI 10.1212/WNL.44.10.1885; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; WILSON PWF, 1994, JAMA-J AM MED ASSOC, V272, P1666, DOI 10.1001/jama.272.21.1666	33	347	358	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	2000	342	4					240	245		10.1056/NEJM200001273420403	http://dx.doi.org/10.1056/NEJM200001273420403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	277PB	10648765				2022-12-01	WOS:000084941000003
J	McMurry, MT; Krangel, MS				McMurry, MT; Krangel, MS			A role for histone acetylation in the developmental regulation of V(D)J recombination	SCIENCE			English	Article							DELTA-GENE REARRANGEMENT; IN-VITRO; ALPHA/DELTA LOCUS; NUCLEOSOMAL DNA; ALPHA-ENHANCER; RECEPTOR; TRANSCRIPTION; ACCESSIBILITY; CHROMATIN; BETA	V(D)J recombination is developmentally regulated in vivo by enhancer-dependent changes in the accessibility of chromosomal recombination signal sequences to the recombinase, but the molecular nature of these changes is unknown. Here histone H3 acetylation was measured along versions of a transgenic V(D)J recombination reporter and the endogenous T cell receptor alpha/delta Locus. Enhancer activity was shown to impart Long-range, developmentally regulated changes in H3 acetylation, and H3 acetylation status was tightly Linked to V(D)J recombination. H3 hyperacetylation is proposed as a molecular mechanism coupling enhancer activity to accessibility for V(D)J recombination.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University	Krangel, MS (corresponding author), Duke Univ, Med Ctr, Dept Immunol, POB 3010, Durham, NC 27710 USA.		McMurry-Heath, Michelle/AAB-5420-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041052, R01GM041052] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41052] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Golding A, 1999, EMBO J, V18, P3712, DOI 10.1093/emboj/18.13.3712; Grawunder U, 1998, CURR OPIN IMMUNOL, V10, P172, DOI 10.1016/S0952-7915(98)80246-X; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Hempel WM, 1998, ADV IMMUNOL, V69, P309, DOI 10.1016/S0065-2776(08)60610-0; Hernandez-Munain C, 1999, IMMUNITY, V10, P723, DOI 10.1016/S1074-7613(00)80071-0; HernandezMunain C, 1996, J EXP MED, V183, P289, DOI 10.1084/jem.183.1.289; Krangel MS, 1998, IMMUNOL REV, V165, P131, DOI 10.1111/j.1600-065X.1998.tb01236.x; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kwon J, 1998, MOL CELL, V2, P829, DOI 10.1016/S1097-2765(00)80297-X; LAUZURICA P, 1994, J EXP MED, V179, P43, DOI 10.1084/jem.179.1.43; LAUZURICA P, 1994, J EXP MED, V179, P1913, DOI 10.1084/jem.179.6.1913; Lauzurica P, 1997, J EXP MED, V185, P1193, DOI 10.1084/jem.185.7.1193; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; McMurry M. T, UNPUB; McMurry MT, 1997, MOL CELL BIOL, V17, P4553, DOI 10.1128/MCB.17.8.4553; Monroe RJ, 1999, IMMUNITY, V10, P503, DOI 10.1016/S1074-7613(00)80050-3; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Schatz D G, 1997, Semin Immunol, V9, P149, DOI 10.1006/smim.1997.0068; Schlissel M S, 1997, Semin Immunol, V9, P161, DOI 10.1006/smim.1997.0066; Sheridan PL, 1997, GENE DEV, V11, P3327, DOI 10.1101/gad.11.24.3327; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Sleckman BP, 1997, IMMUNITY, V7, P505, DOI 10.1016/S1074-7613(00)80372-6; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wolffe AP, 1997, GENES CELLS, V2, P291, DOI 10.1046/j.1365-2443.1997.1260323.x; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zhong XP, 1997, P NATL ACAD SCI USA, V94, P5219, DOI 10.1073/pnas.94.10.5219	33	239	241	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					495	498		10.1126/science.287.5452.495	http://dx.doi.org/10.1126/science.287.5452.495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642553				2022-12-01	WOS:000084929900051
J	Gaist, D; Vaeth, M; Tsiropoulos, I; Christensen, K; Corder, E; Olsen, J; Sorensen, HT				Gaist, D; Vaeth, M; Tsiropoulos, I; Christensen, K; Corder, E; Olsen, J; Sorensen, HT			Risk of subarachnoid haemorrhage in first degree relatives of patients with subarachnoid haemorrhage: follow up study based on national registries in Denmark	BRITISH MEDICAL JOURNAL			English	Article							FAMILIAL INTRACRANIAL ANEURYSMS; CASE-FATALITY; HEMORRHAGE; REGION; CANADA	Objective To estimate the risk of occurrence of subarachnoid haemorrhage in first degree relatives (parents, siblings, children) of patients with subarachnoid haemorrhage. Design Population based cohort study using data from the Danish National Discharge Registry and the Central Person Registry. Subjects Incident cases of subarachnoid haemorrhage admitted to hospital from 1977 to 1995 (9367 patients) and their first degree relatives (14781). Main outcome measures The incidence rate of subarachnoid haemorrhage was determined for the relatives and compared with that of the entire population, standardised for age, sex, and calendar period. This process was repeated for patients discharged from neurosurgery units, as diagnoses from these wards had high validity (93%). Results 18 patients had a total of 19 first degree relatives with subarachnoid haemorrhage during the study period, corresponding to a standardised incidence ratio of 2.9 (95% confidence interval 1.9 to 4.6). Patients discharged from neurosurgery wards had a higher standardised incidence ratio (4.5, 2.7 to 7.3). Conclusions First degree relatives of patients with subarachnoid haemorrhage have a threefold to fivefold increased risk of subarachnoid haemorrhage compared with the general population.	Odense Univ, Univ So Denmark, Inst Publ Hlth, DK-5000 Odense C, Denmark; Aarhus Univ, Dept Biostat, DK-8000 Aarhus, Denmark; Odense Univ Hosp, Dept Neurol, DK-5000 Odense, Denmark; Univ Aarhus, Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark; Univ Aarhus, Dept Clin Epidemiol, DK-8000 Aarhus C, Denmark; Univ Aarhus, Inst Epidemiol & Social Med, Aalborg Univ Hosp, DK-8000 Aarhus C, Denmark	University of Southern Denmark; Aarhus University; University of Southern Denmark; Odense University Hospital; Aarhus University; Aarhus University; Aalborg University; Aarhus University	Gaist, D (corresponding author), Odense Univ, Univ So Denmark, Inst Publ Hlth, DK-5000 Odense C, Denmark.		Sorensen, Henrik Toft/Z-6181-2019; Gaist, David/I-4397-2014; Christensen, Kaare/C-2360-2009; Vaeth, Michael/T-6882-2017	Sorensen, Henrik Toft/0000-0003-4299-7040; Gaist, David/0000-0001-5205-7007; Christensen, Kaare/0000-0002-5429-5292; Vaeth, Michael/0000-0002-0134-5006				Breslow NE, 1987, STAT METHODS CANC RE; BROMBERG JEC, 1995, BRIT MED J, V311, P288, DOI 10.1136/bmj.311.7000.288; BROMBERG JEC, 1995, STROKE, V26, P961, DOI 10.1161/01.STR.26.6.961; CHRISTENSEN K, 1995, NEW ENGL J MED, V333, P161, DOI 10.1056/NEJM199507203330305; DeBraekeleer M, 1996, ANN HUM GENET, V60, P99, DOI 10.1111/j.1469-1809.1996.tb01181.x; LEBLANC R, 1995, NEUROSURGERY, V37, P633, DOI 10.1227/00006123-199510000-00005; Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625; Menghini VV, 1998, NEUROLOGY, V51, P405, DOI 10.1212/WNL.51.2.405; NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006; Ostbye T, 1997, STROKE, V28, P793, DOI 10.1161/01.STR.28.4.793; RONKAINEN A, 1995, NEUROSURGERY, V37, P43, DOI 10.1227/00006123-199507000-00006; Ronkainen A, 1997, LANCET, V349, P380, DOI 10.1016/S0140-6736(97)80009-8; SCHIEVINK WI, 1995, NEUROLOGY, V45, P871, DOI 10.1212/WNL.45.5.871; Schievink WI, 1996, STROKE, V27, P340; SCHIEVINK WI, 1995, J NEUROSURG, V83, P426, DOI 10.3171/jns.1995.83.3.0426; Schievink WI, 1996, NEUROSURGERY, V39, P685, DOI 10.1097/00006123-199610000-00006; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; Schievink WI, 1997, NEUROSURGERY, V40, P651, DOI 10.1097/00006123-199704000-00001; *STAT DENM, 1998, STAT YB 1998; *SUNDH, 1981, AKT SYG 1979; Teunissen LL, 1996, STROKE, V27, P544, DOI 10.1161/01.STR.27.3.544; Truelsen T, 1998, STROKE, V29, P2298, DOI 10.1161/01.STR.29.11.2298; WANG PS, 1995, ARCH NEUROL-CHICAGO, V52, P202, DOI 10.1001/archneur.1995.00540260108026	23	62	63	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	2000	320	7228					141	145		10.1136/bmj.320.7228.141	http://dx.doi.org/10.1136/bmj.320.7228.141			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276DL	10634731	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000084860300021
J	Bachmaier, K; Krawczyk, C; Kozieradzki, I; Kong, YY; Sasaki, T; Oliveira-dos-Santos, A; Mariathasan, S; Bouchard, D; Wakeham, A; Itie, A; Le, J; Ohashi, PS; Sarosi, I; Nishina, H; Lipkowitz, S; Penninger, JM				Bachmaier, K; Krawczyk, C; Kozieradzki, I; Kong, YY; Sasaki, T; Oliveira-dos-Santos, A; Mariathasan, S; Bouchard, D; Wakeham, A; Itie, A; Le, J; Ohashi, PS; Sarosi, I; Nishina, H; Lipkowitz, S; Penninger, JM			Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b	NATURE			English	Article							T-CELL RECEPTOR; PROTEIN; MICE; PROTOONCOGENE; TOLERANCE; ANTIGENS; KINASE; TISSUE; BINDS; VAV	The signalling thresholds of antigen receptors and co-stimulatory receptors determine immunity or tolerance to self molecules(1). Changes in co-stimulatory pathways can lead to enhanced activation of lymphocytes and autoimmunity, or the induction of clonal anergy(2). The molecular mechanisms that maintain immunotolerance in vivo and integrate co-stimulatory signals with antigen receptor signals in T and B lymphocytes are poorly understood. Members of the Cbl/Sli family of molecular adaptors function downstream from growth factor and antigen receptors(3-5). Here we show that gene-targeted mice lacking the adaptor Cbl-b develop spontaneous autoimmunity characterized by auto-antibody production, infiltration of activated T and B lymphocytes into multiple organs, and parenchymal damage. Resting cbl-b(-/-) lymphocytes hyperproliferate upon antigen receptor stimulation, and cbl-b(-/-) T cells display specific: hyperproduction of the T-celI growth factor interleukin-2, hut not interferon-gamma or tumour necrosis factor-alpha. Mutation of Cbl-b uncouples T-cell proliferation, interleukin-2 production and phosphorylation of the GDP/GTP exchange factor Vav1 from the requirement for CD28 costimulation. Cbl-b is thus a key regulator of activation thresholds in mature lymphocytes and immunological tolerance and autoimmunity.	Univ Toronto, Amgen Inst, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Amgen Inst, Ontario Canc Inst, Dept Immunol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Dept Immunol, Toronto, ON M5G 2M9, Canada; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; NCI, Med Branch, Dept Genet, Naval Hosp, Bethesda, MD 20889 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Amgen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy	Penninger, JM (corresponding author), Univ Toronto, Amgen Inst, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada.		Penninger, Josef M/I-6860-2013; Bachmaier, Kurt/B-6331-2014; Bachmaier, Kurt/AHC-5491-2022	Penninger, Josef M/0000-0002-8194-3777; Bachmaier, Kurt/0000-0002-0299-2707; Bachmaier, Kurt/0000-0002-0299-2707; Ohashi, Pamela S./0000-0003-2915-9317; Sasaki, Takehiko/0000-0003-1837-3748	NATIONAL CANCER INSTITUTE [Z01SC007263, ZIASC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bach JF, 1997, TRENDS ENDOCRIN MET, V8, P71, DOI 10.1016/S1043-2760(96)00271-8; BOUSSIOTIS VA, 1994, CURR OPIN IMMUNOL, V6, P797, DOI 10.1016/0952-7915(94)90087-6; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; CELLS E, 1992, EUR J IMMUNOL, V22, P3127; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; KEANE MM, 1995, ONCOGENE, V10, P2367; Kratz A, 1996, J EXP MED, V183, P1461, DOI 10.1084/jem.183.4.1461; Ludewig B, 1998, J EXP MED, V188, P1493, DOI 10.1084/jem.188.8.1493; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; RADVANYI LG, 1993, J IMMUNOL, V150, P5704; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; Zhang ZH, 1999, CURR BIOL, V9, P203, DOI 10.1016/S0960-9822(99)80090-6	23	526	565	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					211	216		10.1038/35003228	http://dx.doi.org/10.1038/35003228			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646608				2022-12-01	WOS:000084835300059
J	Tellides, G; Tereb, DA; Kirkiles-Smith, NC; Kim, RW; Wilson, JH; Schechner, JS; Lorber, MI; Pober, JS				Tellides, G; Tereb, DA; Kirkiles-Smith, NC; Kim, RW; Wilson, JH; Schechner, JS; Lorber, MI; Pober, JS			Interferon-gamma elicits arteriosclerosis in the absence of leukocytes	NATURE			English	Article							SMOOTH-MUSCLE CELLS; TRANSPLANTED MOUSE HEARTS; CORONARY ARTERIOSCLEROSIS; IMMUNE INTERFERON; INHIBITS PROLIFERATION; GENE-EXPRESSION; GROWTH-FACTORS; ATHEROSCLEROSIS; INVIVO; INJURY	Atherosclerosis and post-transplant graft arteriosclerosis are both characterized by expansion of the arterial intima as a result of the infiltration of mononuclear leukocytes, the proliferation of vascular smooth muscle cells (VSMCs) and the accumulation of extracellular matrix(1-3). They are also associated with the presence of the immunomodulatory cytokine interferon-gamma (IFN-gamma)(2,3). Moreover, in mouse models of atheroma formation or allogeneic transplantation, the serological neutralization(4) or genetic absence(5-8) of IFN-gamma markedly reduces the extent of intimal expansion. However, other studies have found that exogenous IFN-gamma inhibits Cultured VSMC proliferation(9-14) and matrix synthesis(15), and reduces intimal expansion in response to mechanical injury(16-18). This discrepancy is generally explained by the idea that IFN-gamma either directly activates macrophages, or, by increasing antigen presentation, indirectly activates T cells within the lesions of atherosclerosis and graft arteriosclerosis. These activated leukocytes are thought to express the VSMC-activating cytokines(1-3) and cell-surface molecules(19) that cause the observed arteriosclerotic responses. Here we have inserted pig and human arteries into the aorta of immunodeficient immunodeficient mice, and we show that IFN-gamma can induce arteriosclerotic changes in the absence of detectable immunocytes by acting on VSMCs to potentiate growth-factor-induced mitogenesis.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA	Yale University; Yale University; Yale University; Yale University; Yale University	Tellides, G (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol & Transplanta, 333 Cedar St, New Haven, CT 06510 USA.							AMENTO EP, 1991, ARTERIOSCLER THROMB, V11, P1223, DOI 10.1161/01.ATV.11.5.1223; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; BRINCKERHOFF CE, 1985, J IMMUNOL, V134, P3142; Castronuovo J J Jr, 1995, Cardiovasc Surg, V3, P463, DOI 10.1016/0967-2109(95)94442-Y; Goes N, 1996, TRANSPLANTATION, V62, P1889, DOI 10.1097/00007890-199612270-00036; GROENEWEGEN G, 1985, NATURE, V316, P361, DOI 10.1038/316361a0; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HANSSON GK, 1991, P NATL ACAD SCI USA, V88, P10530, DOI 10.1073/pnas.88.23.10530; HANSSON GK, 1991, CIRCULATION, V84, P1266, DOI 10.1161/01.CIR.84.3.1266; HANSSON GK, 1988, CIRC RES, V63, P712, DOI 10.1161/01.RES.63.4.712; HANSSON GK, 1989, J EXP MED, V170, P1595, DOI 10.1084/jem.170.5.1595; HUNNINGHAKE GW, 1986, AM REV RESPIR DIS, V134, P1025, DOI 10.1164/arrd.1986.134.5.1025; LIBBY P, 1989, TRANSPLANT P, V21, P3677; Lorber MI, 1999, TRANSPLANTATION, V67, P897, DOI 10.1097/00007890-199903270-00018; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; Mensink A, 1996, EUR J PHARMACOL, V310, P73, DOI 10.1016/0014-2999(96)00368-8; Nagano H, 1997, J CLIN INVEST, V100, P550, DOI 10.1172/JCI119564; Nagano H, 1998, AM J PATHOL, V152, P1187; NUNOKAWA Y, 1992, BIOCHEM BIOPH RES CO, V188, P409, DOI 10.1016/0006-291X(92)92400-R; Raisanen-Sokolowski A, 1998, AM J PATHOL, V152, P359; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; RUSSELL PS, 1994, TRANSPLANTATION, V57, P1367, DOI 10.1097/00007890-199405150-00014; SHIMOKADO K, 1990, ANN NY ACAD SCI, V598, P544, DOI 10.1111/j.1749-6632.1990.tb42340.x; Sultan P, 1997, P NATL ACAD SCI USA, V94, P8767, DOI 10.1073/pnas.94.16.8767; SUZUKI H, 1989, AM J PATHOL, V134, P35; WARNER SJC, 1989, J CLIN INVEST, V83, P1174, DOI 10.1172/JCI113998; YOKOTA T, 1992, ARTERIOSCLER THROMB, V12, P1393, DOI 10.1161/01.ATV.12.12.1393; YONG VW, 1991, P NATL ACAD SCI USA, V88, P7016, DOI 10.1073/pnas.88.16.7016	30	324	331	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					207	211		10.1038/35003221	http://dx.doi.org/10.1038/35003221			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646607				2022-12-01	WOS:000084835300058
J	Schlag, J; Cai, RH; Dorfman, A; Mohempour, A; Schlag-Rey, M				Schlag, J; Cai, RH; Dorfman, A; Mohempour, A; Schlag-Rey, M			Neuroscience - Extrapolating movement without retinal motion	NATURE			English	Article							LATENCY		Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schlag, J (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.							Berry MJ, 1999, NATURE, V398, P334, DOI 10.1038/18678; Gegenfurtner K, 1999, NATURE, V398, P291, DOI 10.1038/18563; Nijhawan R, 1997, NATURE, V386, P66, DOI 10.1038/386066a0; NIJHAWAN R, 1994, NATURE, V370, P256, DOI 10.1038/370256b0; Purushothaman G, 1998, NATURE, V396, P424, DOI 10.1038/24766; Whitney D, 1998, NAT NEUROSCI, V1, P656, DOI 10.1038/3659	6	36	36	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					38	39		10.1038/47402	http://dx.doi.org/10.1038/47402			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638742				2022-12-01	WOS:000084687400032
J	Fielder, HMP; Poon-King, CM; Palmer, SR; Moss, N; Coleman, G				Fielder, HMP; Poon-King, CM; Palmer, SR; Moss, N; Coleman, G			Assessment of impact on health of residents living near the Nant-y-Gwyddon landfill site: retrospective analysis	BRITISH MEDICAL JOURNAL			English	Article							RISK	Objectives To compare indices of health in a population living near a landfill site with a population matched for socioeconomic status and to review environmental monitoring data. Design Ecological study with small area statistics and environmental reports. Setting Electoral wards in valleys of South Wales. Subjects Populations in the five wards near the landfill site who had formally complained of odours (exposed population), and comparison populations in 22 wards in the same unitary authority within the same fifth of Townsend score. Outcome measures Mortality, rates of hospital admission, measures of reproductive health (proportion of all births and stillbirths of infants weighing < 2500 g; rates of admissions for spontaneous abortion; rates of all reported congenital malformations). Environmental data on site emissions. Results There were no consistent differences in mortality, rates of hospital admissions, or proportion of low birthweight infants between the two populations. There was an increased maternal risk of having a baby with a congenital abnormality in residents near the site, both before its opening (relative risk 1.9; 95% confidence interval 1.3 to 2.85; P < 0.001) and after (1.9; 1.23 to 2.95; P = 0.003). Environmental monitoring showed that hydrogen sulphide from the site was probably responsible for odours. Conclusions The area surrounding the landfill site has an increased rate of reported congenital malformations,which predated the opening of the landfill, although the cluster of cases of gastroschisis postdated its opening. Several chemicals emitted from the site, including hydrogen sulphide and benzene, were found in air samples in the nearby community. Further studies of the reproductive risk in such communities are needed to examine the safety of waste disposal sites.	Univ Wales Coll Med, Div Publ Hlth, Cardiff CF14 4XN, S Glam, Wales; Bro Taf Hlth Author, Temple Peace & Hlth, Dept Informat, Cardiff CF1 3NW, S Glam, Wales; Univ Wales Inst, WHO, Collaborating Ctr Chem Incidents, Cardiff CG5 2YB, S Glam, Wales	Cardiff University; World Health Organization	Fielder, HMP (corresponding author), Welsh Combined Ctr Publ Hlth, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.							*AG TOX SUBST DIS, 1994, ENV NEED PUBL HLTH A; BOTTING B, 1998, POP TRENDS, V3, P19; Dolk H, 1998, LANCET, V352, P423, DOI 10.1016/S0140-6736(98)01352-X; GARDNER MJ, 1992, CONFIDENCE INTERVAL; GESCHWIND SA, 1992, AM J EPIDEMIOL, V135, P1197, DOI 10.1093/oxfordjournals.aje.a116226; GOLDBERG MS, 1995, ENVIRON RES, V69, P37, DOI 10.1006/enrs.1995.1023; HADDOW JE, 1993, TERATOLOGY, V47, P225, DOI 10.1002/tera.1420470306; HERTZMAN C, 1987, ENVIRON HEALTH PERSP, V75, P173, DOI 10.2307/3430589; NEAVE HR, 1989, ELEMENTARY STAT TABL; RAMSEY TL, 1994, MANAGING HAZARDOUS I, V3; SCOTT PE, 1998, INVESTIGATION ODOUR; Tan KH, 1996, BRIT MED J, V313, P903; *WORK GROUP REG GE, 1995, 43 OFF POP CENS SURV	13	69	72	2	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					19	22		10.1136/bmj.320.7226.19	http://dx.doi.org/10.1136/bmj.320.7226.19			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10617518	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000084621600016
J	Brondello, JM; Pouyssegur, J; McKenzie, FR				Brondello, JM; Pouyssegur, J; McKenzie, FR			Reduced MAP kinase phosphatase-1 degradation after p42/p44(MAPK)-dependent phosphorylation	SCIENCE			English	Article							SIGNAL-REGULATED KINASE; PROTEIN-TYROSINE-PHOSPHATASE; FIBROBLAST PROLIFERATION; SUBSTRATE RECOGNITION; C-JUN; EXPRESSION; CELLS; IDENTIFICATION; PATHWAY; TRANSDUCTION	The mitogen-activated protein (MAP) kinase cascade is inactivated at the level of MAP kinase by members of the MAP kinase phosphatase (MKP) family, including MKP-1. MKP-1 was a labile protein in CCL39 hamster fibroblasts; its degradation was attenuated by inhibitors of the ubiquitin-directed proteasome complex; MKP-1 was a target in vivo and in vitro for p42(MAPK) or p44(MAPK), which phosphorylates MKP-1 on two carboxyl-terminal serine residues, Serine 359 and Serine 364. This phosphorylation did not modify MKP-1's intrinsic ability to dephosphorylate p44(MAPK) but led to stabilization of the protein. These results illustrate the importance of regulated protein degradation in the control of mitogenic signaling.	Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	McKenzie, FR (corresponding author), Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, 33 Ave Valombrose, F-06189 Nice, France.		Brondello, Jean-Marc/U-8232-2017	Brondello, Jean-Marc/0000-0001-5991-3945	NIGMS NIH HHS [GM26939] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026939] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 1996, ANNU REP MED CHEM, V31, P279, DOI 10.1016/S0065-7743(08)60467-4; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRONDELLO JM, 1991, NATURE, V350, P359; CHARLES CH, 1992, ONCOGENE, V7, P197; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; SEGER R, 1992, J BIOL CHEM, V267, P14373; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	38	353	365	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2514	2517		10.1126/science.286.5449.2514	http://dx.doi.org/10.1126/science.286.5449.2514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617468				2022-12-01	WOS:000084429700051
J	Renn, SCP; Park, JH; Rosbash, M; Hall, JC; Taghert, PH				Renn, SCP; Park, JH; Rosbash, M; Hall, JC; Taghert, PH			A pdf neuropeptide gene mutation and ablation of PDF neurons each cause severe abnormalities of behavioral circadian rhythms in Drosophila	CELL			English	Article							HORMONE-IMMUNOREACTIVE NEURONS; NERVOUS-SYSTEM; SUPRACHIASMATIC NUCLEUS; VISUAL-SYSTEM; DARK CYCLES; CLOCK GENE; MELANOGASTER; PERIOD; MUTANTS; CELLS	The mechanisms by which circadian pacemaker systems transmit timing information to control behavior are largely unknown. Here, we define two critical features of that mechanism in Drosophila. We first describe animals mutant for the pdf neuropeptide gene, which is expressed by most of the candidate pacemakers (LN, neurons). Next, we describe animals in which pdf neurons were selectively ablated. Both sets of animals produced similar behavioral phenotypes. Both sets entrained to light, but both were largely arrhythmic under constant conditions. A minority of each pdf variant exhibited weak to moderate free-running rhythmicity. These results confirm the assignment of LN, neurons as the principal circadian pacemakers controlling daily locomotion in Drosophila. They also implicate PDF as the principal circadian transmitter.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Natl Sci Fdn Biol Timing, Waltham, MA 02454 USA; Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA	Washington University (WUSTL); Brandeis University; Brandeis University; National Science Foundation (NSF); Brandeis University; Howard Hughes Medical Institute	Taghert, PH (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.			Park, Jae/0000-0002-4846-2197	NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001196] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33205] Funding Source: Medline; NIMH NIH HHS [F32MH-1196] Funding Source: Medline; NINDS NIH HHS [NS-21749] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson SL, 1997, ADV GENET, V35, P1, DOI 10.1016/S0065-2660(08)60446-0; Benveniste RJ, 1999, J NEUROBIOL, V38, P507, DOI 10.1002/(SICI)1097-4695(199903)38:4<507::AID-NEU7>3.0.CO;2-X; Boer GJ, 1999, NEUROSCIENCE, V89, P375, DOI 10.1016/S0306-4522(98)00300-5; BRAND A, 1993, DEVELOPMENT, V118, P410; CASSONE VM, 1984, J EXP ZOOL, V232, P539, DOI 10.1002/jez.1402320321; CASSONE VM, 1983, BRAIN RES, V272, P311, DOI 10.1016/0006-8993(83)90578-4; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; DIRCKSEN H, 1987, CELL TISSUE RES, V250, P377; Dowse H.B., 1987, Journal of Biological Rhythms, V2, P65, DOI 10.1177/074873048700200106; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; DUSHAY MS, 1989, J BIOL RHYTHM, V4, P1, DOI 10.1177/074873048900400101; DUSHAY MS, 1990, GENETICS, V125, P557; Elekes K, 1999, CELL TISSUE RES, V295, P339, DOI 10.1007/s004410051240; Hamblen MJ, 1998, GENETICS, V149, P165; HAMBLEN MJ, 1966, J NEUROGENET, V3, P249; HAMBLENCOYLE M, 1989, J NEUROGENET, V5, P229, DOI 10.3109/01677068909066210; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; Harrington ME, 1999, J NEUROSCI, V19, P6637; Helfrich-Forster C, 1998, CHRONOBIOL INT, V15, P567, DOI 10.3109/07420529808993195; Helfrich-Forster C, 1998, J COMP PHYSIOL A, V182, P435, DOI 10.1007/s003590050192; HelfrichForster C, 1997, J COMP NEUROL, V380, P335, DOI 10.1002/(SICI)1096-9861(19970414)380:3<335::AID-CNE4>3.0.CO;2-3; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; HOMBERG U, 1991, CELL TISSUE RES, V266, P343, DOI 10.1007/BF00318190; Inouye SIT, 1996, PROG BRAIN RES, V111, P75, DOI 10.1016/S0079-6123(08)60401-X; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kaneko M, 1997, J NEUROSCI, V17, P6745; Kaneko M, 1998, CURR OPIN NEUROBIOL, V8, P652, DOI 10.1016/S0959-4388(98)80095-0; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; Li XD, 1998, CURR OPIN NEUROBIOL, V8, P648, DOI 10.1016/S0959-4388(98)80094-9; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; Loros JJ, 1998, CURR OPIN MICROBIOL, V1, P698, DOI 10.1016/S1369-5274(98)80118-5; McNabb SL, 1997, NEURON, V19, P813, DOI 10.1016/S0896-6273(00)80963-0; MENAKER M, 1976, AM ZOOL, V16, P45; NASSEL DR, 1993, J COMP NEUROL, V331, P183, DOI 10.1002/cne.903310204; NASSEL DR, 1991, CELL TISSUE RES, V266, P511, DOI 10.1007/BF00318593; Park JH, 1998, J BIOL RHYTHM, V13, P219, DOI 10.1177/074873098129000066; Petri B, 1997, J NEUROSCI, V17, P4087; Pyza E, 1996, J COMP PHYSIOL A, V178, P33, DOI 10.1007/BF00189588; RAO KR, 1993, ANN NY ACAD SCI, V680, P78, DOI 10.1111/j.1749-6632.1993.tb19676.x; SCHNEIDER LE, 1993, NEURON, V10, P279, DOI 10.1016/0896-6273(93)90318-L; SOKOLOVE PG, 1978, J THEOR BIOL, V72, P131, DOI 10.1016/0022-5193(78)90022-X; VanGelder RN, 1996, EMBO J, V15, P1625, DOI 10.1002/j.1460-2075.1996.tb00507.x; Weaver DR, 1998, J BIOL RHYTHM, V13, P100, DOI 10.1177/074873098128999952; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131	45	827	834	1	77	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					791	802		10.1016/S0092-8674(00)81676-1	http://dx.doi.org/10.1016/S0092-8674(00)81676-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619432	Bronze			2022-12-01	WOS:000084488200012
J	Tanny, JC; Dowd, GJ; Huang, J; Hilz, H; Moazed, D				Tanny, JC; Dowd, GJ; Huang, J; Hilz, H; Moazed, D			An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing	CELL			English	Article							MATING-TYPE LOCI; SACCHAROMYCES-CEREVISIAE; POLY(ADP-RIBOSE) POLYMERASE; TELOMERIC HETEROCHROMATIN; ESCHERICHIA-COLI; ADP-RIBOSYLATION; BINDING-PROTEIN; COMPLEX; DNA; TRANSCRIPTION	Despite its conservation in organisms from bacteria to human and its general requirement for transcriptional silencing in yeast, the function of the Sir2 protein is unknown. Here we show that Sir:! can transfer labeled phosphate from nicotinamide adenine dinucleotide to itself and histones in vitro. A modified form of Sir2, which results from its automodification activity, is specifically recognized by anti-mono-ADP-ribose antibodies, suggesting that Sir2 is an ADP-ribosyltransferase. Mutation of a phylogenetically invariant histidine residue in Sir2 abolishes both its enzymatic activity in vitro and its silencing functions in vivo. However, the mutant protein is associated with chromatin and other silencing factors in a manner similar to wild-type Sir2. These findings suggest that Sir2 contains an ADP-ribosyltransferase activity that is essential for its silencing function.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Hamburg, Krankenhaus Eppendorf, Inst Med Biochem & Molekularbiol, D-20246 Hamburg, Germany	Harvard University; Harvard Medical School; University of Hamburg	Moazed, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BISERCIC M, 1991, J BACTERIOL, V173, P3894; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; GOLDERER G, 1991, BIOCHEM J, V277, P607, DOI 10.1042/bj2770607; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; Holmes SG, 1997, GENETICS, V145, P605; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; KLAR AJS, 1979, GENETICS, V93, P37; KUN E, 1976, P NATL ACAD SCI USA, V73, P3131, DOI 10.1073/pnas.73.9.3131; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; MEYER T, 1986, EUR J BIOCHEM, V155, P157, DOI 10.1111/j.1432-1033.1986.tb09471.x; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; Phillips C, 1998, J MOL BIOL, V282, P667, DOI 10.1006/jmbi.1998.2059; RINE J, 1987, GENETICS, V116, P9; Ruf A, 1998, BIOCHEMISTRY-US, V37, P3893, DOI 10.1021/bi972383s; Sherman JM, 1999, MOL BIOL CELL, V10, P3045, DOI 10.1091/mbc.10.9.3045; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; SOMAN G, 1991, BIOCHEM BIOPH RES CO, V176, P301, DOI 10.1016/0006-291X(91)90924-V; SPRAGUE G F JR, 1991, P77; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; Tsang AW, 1998, J BIOL CHEM, V273, P31788, DOI 10.1074/jbc.273.48.31788; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.bi.54.070185.000445	41	330	347	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					735	745		10.1016/S0092-8674(00)81671-2	http://dx.doi.org/10.1016/S0092-8674(00)81671-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619427	Bronze			2022-12-01	WOS:000084488200007
J	Cha, A; Snyder, GE; Selvin, PR; Bezanilla, F				Cha, A; Snyder, GE; Selvin, PR; Bezanilla, F			Atomic scale movement of the voltage-sensing region in a potassium channel measured via spectroscopy	NATURE			English	Article							SHAKER K+ CHANNEL; RESONANCE ENERGY-TRANSFER; SODIUM-CHANNELS; FLUORESCENCE; S4; ACTIVATION; CURRENTS; SEQUENCE; CHELATE	Voltage-gated ion channels are transmembrane proteins that are essential for nerve impulses and regulate ion flow across cell membranes in response to changes in membrane potential. They are made up of four homologous domains or subunits, each of which contains six transmembrane segments(1,2). Studies of potassium channels have shown that the second (S2) and fourth (S4) segments contain several charged residues, which sense changes in voltage and form part of the voltage sensor(3-5). Although these regions clearly undergo conformational changes in response to voltage(6-10), little is known about the nature of these changes because voltage-dependent distance changes have not been measured. Here we use lanthanide-based resonance energy transfer(11,12) to measure distances between Shaker potassium channel subunits at specific residues. Voltage-dependent distance changes of up to 3.2 Angstrom were measured at several sites near the S4 segment. These movements directly correlated with electrical measurements of the voltage sensor, establishing the link between physical changes and electrical charge movement. Measured distance changes suggest that the region associated with the S4 segment undergoes a rotation and possible tilt, rather than a large transmembrane movement, in response to voltage. These results demonstrate the first in situ measurement of atomic scale movement in a transmembrane protein.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Anesthesiol, Sch Med, Los Angeles, CA 90095 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys, Urbana, IL 61801 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Bezanilla, F (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.							Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; BEZANILLA F, IN PRESS PHYSL REV; Cha A, 1998, J GEN PHYSIOL, V112, P391, DOI 10.1085/jgp.112.4.391; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; Chen JY, 1999, BIOCONJUGATE CHEM, V10, P311, DOI 10.1021/bc980113w; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DURRELL SR, 1992, BIOPHYS J, V62, P238; Gross A, 1999, BIOCHEMISTRY-US, V38, P10324, DOI 10.1021/bi990856k; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; Scholz F, 1998, J SOLID STATE ELECTR, V2, P1, DOI 10.1007/s100080050056; SCOH SA, 1996, NEURON, V16, P1159; Selvin PR, 1996, INORG CHEM, V35, P700, DOI 10.1021/ic950840s; SELVIN PR, 1994, P NATL ACAD SCI USA, V91, P10024, DOI 10.1073/pnas.91.21.10024; SELVIN PR, 1994, J AM CHEM SOC, V116, P6029, DOI 10.1021/ja00092a088; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Smith-Maxwell CJ, 1998, J GEN PHYSIOL, V111, P421, DOI 10.1085/jgp.111.3.421; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; Xiao M, 1998, P NATL ACAD SCI USA, V95, P15309, DOI 10.1073/pnas.95.26.15309; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	25	426	443	0	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					809	813		10.1038/45552	http://dx.doi.org/10.1038/45552			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617201	Bronze			2022-12-01	WOS:000084330500065
J	Parsonnet, J; Shmuely, H; Haggerty, T				Parsonnet, J; Shmuely, H; Haggerty, T			Fecal and oral shedding of Helicobacter pylori from healthy infected adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNOMAGNETIC SEPARATION; GASTRIC BIOPSY; DENTAL PLAQUE; TRANSMISSION; SALIVA; FECES; PCR; DNA; SPECIMENS; SEQUENCE	Context Helicobacter pylori commonly infects humans; however, its mode of transmission remains unknown. Objective To determine how humans-the primary host for H pylori-shed the organism into the environment. Design Controlled clinical experimental study conducted from February through December 1998. Setting Clinical research unit of a hospital in northern California. Patients Sixteen asymptomatic H pylori-infected and 10 uninfected adults. Intervention A cathartic (sodium phosphate) and an emetic (ipecac) were given to all infected subjects and an emetic was given to 1 uninfected subject. Main Outcome Measure Confirmed H pylori isolates cultured from stool, air, or saliva before and after catharsis and emesis and from vomitus during emesis. Isolates were fingerprinted using repetitive extragenic palindromic (REP) polymerase chain reaction and species identity was confirmed by sequencing the 16s ribosomal RNA gene. Results All vomitus samples from infected subjects grew H pylori, often in high quantities. Air sampled during vomiting grew H pylori from 6 (37.5%) of the 16 subjects. Saliva before and after emesis grew low quantities of H pylori in 3 (18.8%) and 9 (56.3%) subjects, respectively. No normal stools and only 22 (21.8%) of 101 induced stools grew the organism, although 7 (50.0%) of 14 subjects had at least 1 positive culture (2 stool culture samples were contaminated by fungus and were not included). Fingerprints of isolates within subjects were identical to one another but differed among subjects. No samples from uninfected subjects yielded H pylori. Conclusions Helicobacter pylori can be cultivated uniformly from vomitus and, occasionally, from saliva and cathartic stools. The organism is potentially transmissible during episodes of gastrointestinal tract illness, particularly with vomiting.	Stanford Univ, Dept Hlth Res & Policy, Sch Med, Div Epidemiol, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Parsonnet, J (corresponding author), Stanford Univ, Dept Hlth Res & Policy, Sch Med, Div Epidemiol, HRP Bldg,Room T225, Stanford, CA 94305 USA.	parsonnt@leland.stanford.edu		Parsonnet, Julie/0000-0001-7342-5366	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053689] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00070] Funding Source: Medline; NIDDK NIH HHS [R01 DK053689, R01 DK/CA53689] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Axon ATR, 1996, EUR J GASTROEN HEPAT, V8, P1, DOI 10.1097/00042737-199601000-00001; Black Robert E., 1995, P13; *BOARD DIR AM SOC, 1997, AM HOSP FORM SERV DR; CAUL EO, 1994, LANCET, V343, P1240, DOI 10.1016/S0140-6736(94)92146-6; CHADWICK PR, 1994, J HOSP INFECT, V26, P251, DOI 10.1016/0195-6701(94)90015-9; CUTLER AF, 1993, AM J GASTROENTEROL, V88, P505; ENROTH H, 1995, J CLIN MICROBIOL, V33, P2162, DOI 10.1128/JCM.33.8.2162-2165.1995; FERGUSON DA, 1993, J CLIN MICROBIOL, V31, P2802, DOI 10.1128/JCM.31.10.2802-2804.1993; Figura N, 1996, LANCET, V347, P1342, DOI 10.1016/S0140-6736(96)90996-4; Fleiss J.L., 1981, STAT METHODS RATES P; Georgopoulos SD, 1996, GUT, V39, P634, DOI 10.1136/gut.39.5.634; GO MF, 1995, SCAND J GASTROENTERO, V30, P640, DOI 10.3109/00365529509096306; Grove DI, 1998, PATHOLOGY, V30, P183, DOI 10.1080/00313029800169206; KELLY SM, 1994, GASTROENTEROLOGY, V107, P1671, DOI 10.1016/0016-5085(94)90806-0; KRAJDEN S, 1989, J CLIN MICROBIOL, V27, P1397, DOI 10.1128/JCM.27.6.1397-1398.1989; Lau D, 1998, GASTROENTEROLOGY, V114, pA196, DOI 10.1016/S0016-5085(98)80798-1; Li CF, 1996, DIGEST DIS SCI, V41, P2142, DOI 10.1007/BF02071393; LOFFELD RJLF, 1991, J PATHOL, V165, P69, DOI 10.1002/path.1711650111; LUDWIG W, 1994, FEMS MICROBIOL REV, V15, P155, DOI 10.1016/0168-6445(94)90110-4; Luman W, 1996, EUR J GASTROEN HEPAT, V8, P11, DOI 10.1097/00042737-199601000-00004; Madinier IM, 1997, J PERIODONTOL, V68, P2, DOI 10.1902/jop.1997.68.1.2; MALATY HM, 1991, SCAND J GASTROENTERO, V26, P927, DOI 10.3109/00365529108996244; MALATY HM, 1992, AM J GASTROENTEROL, V87, P1728; MAPSTONE NP, 1993, J CLIN PATHOL, V46, P540, DOI 10.1136/jcp.46.6.540; MEGRAUD F, 1995, ALIMENT PHARM THERAP, V9, P85; MITCHELL JD, 1992, AM J GASTROENTEROL, V87, P382; Parsonnet J, 1998, GUT, V43, pS6, DOI 10.1136/gut.43.2008.S6; PEREZPEREZ GI, 1991, J CLIN MICROBIOL, V29, P642, DOI 10.1128/JCM.29.3.642-644.1991; REPLOGLE ML, 1995, AM J EPIDEMIOL, V142, P856, DOI 10.1093/oxfordjournals.aje.a117725; SOBALA GM, 1991, GUT, V32, P1415, DOI 10.1136/gut.32.11.1415; Tauxe Robert V., 1995, P37; Taylor David N., 1995, P551; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VERSALOVIC J, 1991, NUCLEIC ACIDS RES, V19, P6823, DOI 10.1093/nar/19.24.6823; Watanabe T, 1998, SCAND J GASTROENTERO, V33, P1140, DOI 10.1080/00365529850172476; WEISS J, 1994, J CLIN MICROBIOL, V32, P1663, DOI 10.1128/JCM.32.7.1663-1668.1994; WHITAKER CJ, 1993, EPIDEMIOL INFECT, V111, P63, DOI 10.1017/S0950268800056685	38	243	259	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1999	282	23					2240	2245		10.1001/jama.282.23.2240	http://dx.doi.org/10.1001/jama.282.23.2240			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263RG	10605976	Bronze			2022-12-01	WOS:000084138600032
J	Gundestrup, M; Storm, HH				Gundestrup, M; Storm, HH			Radiation-induced acute myeloid leukaemia and other cancers in commercial jet cockpit crew: a population-based cohort study	LANCET			English	Article							MORTALITY; PILOTS; RISK; EXPOSURE	Background Cockpit crews receive cosmic radiation during flight operations. The increasing total accumulated dose over the years might be expected to cause increased frequency of radiation-induced cancer. The rate should increase with number of flight hours per year, number of years of flying, and higher flight altitude. If the cumulative radiation exposure during flights is of concern, we would expect an increased cancer risk to be present among those crew members flying jets. Methods Cockpit-crew medical records (pilots and flight engineers) from 1946 onwards, holding information on the individual, flight hours, aircraft type, and date of commercial certification and decertification, were linked to the population-based Danish Cancer Registry, the central population registry, and the National Death Index. Findings Altogether 3877 cockpit crew members could be traced for follow-up, accruing 61 095 person-years at risk in 3790 men and 661 in 87 women. The total number of cancers observed was 169 whereas 153.1 were expected (standardised incidence ratio 1.1 [95% CI 0.94-1.28]). Significantly increased risks of acute myeloid leukaemia (5.1 [1.03-14.91]), skin cancer, excluding melanoma (3.0 [2.12-4.23]), and total cancer (1.2 [1.00-1.53]) were observed among Danish male jet cockpit crew members flying more than 5000 h. Increased risk of malignant melanoma irrespective of aircraft type was also found among those flying more than 5000 h. Interpretation Both malignant melanoma and skin cancer were found in excess in cockpit crew members with a long flying history, probably attributable to sun exposure during leisure time at holiday destinations. We cannot confirm previously reported increased risk of brain and rectal cancers in pilots. The study shows that male cockpit crew members in jets flying more than 5000 h have significantly increased frequency of acute myeloid leukaemia.	Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Rigshosp, Natl Clin Aviat Med, DK-2100 Copenhagen, Denmark	Danish Cancer Society; Rigshospitalet; University of Copenhagen	Storm, HH (corresponding author), Danish Canc Soc, Inst Canc Epidemiol, Strandblvd 49, DK-2100 Copenhagen, Denmark.			Storm, Hans/0000-0001-7223-8198				BAND PR, 1990, AVIAT SPACE ENVIR MD, V61, P299; Band PR, 1996, AM J EPIDEMIOL, V143, P137; Blettner M, 1998, RADIAT ENVIRON BIOPH, V37, P75, DOI 10.1007/s004110050097; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; FRIEDBERG W, 1989, AVIAT SPACE ENVIR MD, V60, P1104; Grayson JK, 1996, AVIAT SPACE ENVIR MD, V67, P101; IRVINE D, 1992, AVIAT SPACE ENVIR MD, V63, P276; KAJI M, 1993, AVIAT SPACE ENVIR MD, V64, P748; OBRIEN K, 1972, HEALTH PHYS, V22, P225, DOI 10.1097/00004032-197203000-00002; PARETZKE HG, 1993, RADIAT PROT DOSIM, V48, P33; PUKKALA E, 1995, BRIT MED J, V311, P349; PUKKALA E, 1995, CONTR EPIDE, V7, P1; SALISBURY DA, 1991, AVIAT SPACE ENVIR MD, V62, P351	13	113	118	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 11	1999	354	9195					2029	2031		10.1016/S0140-6736(99)05093-X	http://dx.doi.org/10.1016/S0140-6736(99)05093-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636367				2022-12-01	WOS:000084183300010
J	Schober, M; Schaefer, M; Knoblich, JA				Schober, M; Schaefer, M; Knoblich, JA			Bazooka recruits Inscuteable to orient asymmetric cell divisions in Drosophila neuroblasts	NATURE			English	Article							CAENORHABDITIS-ELEGANS; POLARITY; PROSPERO; PROTEIN; YEAST; NUMB; LOCALIZATION; MECHANISMS; MITOSIS; GENE	Asymmetric cell divisions can be generated by the segregation of determinants into one of the two daughter cells(1-4). In Drosophila, neuroblasts divide asymmetrically along the apical-basal axis shortly after their delamination from the neuroectodermal epithelium. Several proteins, including Numb and Miranda, segregate into the basal daughter cell and are needed for the determination of its correct cell fate(5-10). Both the apical-basal orientation of the mitotic spindle and the localization of Numb and Miranda to the basal cell cortex are directed by Inscuteable, a protein that localizes to the apical cell cortex before and during neuroblast mitosis(11,12). Here we show that the apical localization of Inscuteable requires Bazooka, a protein containing a PDZ domain that is essential for apical-basal polarity in epithelial cells(13,14). Bazooka localizes with Inscuteable in neuroblasts and binds to the Inscuteable localization domain in vitro and in vivo. In embryos lacking both maternal and zygotic bazooka function, Inscuteable no longer localizes asymmetrically in neuroblasts and is instead uniformly distributed in the cytoplasm. Mitotic spindles in neuroblasts are misoriented in these embryos, and the proteins Numb and Miranda fail to localize asymmetrically in metaphase. Our results suggest that direct binding to Bazooka mediates the asymmetric localization of Inscuteable and connects the asymmetric division of neuroblasts to the axis of epithelial apical-basal polarity.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Knoblich, JA (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Knoblich, Juergen A/C-2974-2015; Matthias, Schaefer Ronald/E-9157-2015	Knoblich, Juergen A/0000-0002-6751-3404; Matthias, Schaefer Ronald/0000-0003-1952-8115				Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Chant J, 1996, CURR OPIN CELL BIOL, V8, P557, DOI 10.1016/S0955-0674(96)80035-4; CHOU TB, 1992, GENETICS, V131, P643; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 1999, CURR BIOL, V9, P155, DOI 10.1016/S0960-9822(99)80070-0; Knoblich JA, 1997, CURR OPIN CELL BIOL, V9, P833, DOI 10.1016/S0955-0674(97)80085-3; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Lu BW, 1998, CURR OPIN GENET DEV, V8, P392, DOI 10.1016/S0959-437X(98)80108-1; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Matsuzaki F, 1998, DEVELOPMENT, V125, P4089; McKim KS, 1996, GENETICS, V144, P215; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; WADDLE JA, 1994, DEVELOPMENT, V120, P2317	25	296	300	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					548	551		10.1038/990135	http://dx.doi.org/10.1038/990135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591217				2022-12-01	WOS:000084013200061
J	Sinha, S; Anderson, JP; Barbour, R; Basi, GS; Caccavello, R; Davis, D; Doan, M; Dovey, HF; Frigon, N; Hong, J; Jacobson-Croak, K; Jewett, N; Keim, P; Knops, J; Lieberburg, I; Power, M; Tan, H; Tatsuno, G; Tung, J; Schenk, D; Seubert, P; Suomensaari, SM; Wang, SW; Walker, D; Zhao, J; McConlogue, L; John, V				Sinha, S; Anderson, JP; Barbour, R; Basi, GS; Caccavello, R; Davis, D; Doan, M; Dovey, HF; Frigon, N; Hong, J; Jacobson-Croak, K; Jewett, N; Keim, P; Knops, J; Lieberburg, I; Power, M; Tan, H; Tatsuno, G; Tung, J; Schenk, D; Seubert, P; Suomensaari, SM; Wang, SW; Walker, D; Zhao, J; McConlogue, L; John, V			Purification and cloning of amyloid precursor protein beta-secretase from human brain	NATURE			English	Article							ALZHEIMERS-DISEASE; INHIBITOR; MUTATION; TERMINUS	Proteolytic processing of the amyloid precursor protein (APP) generates amyloid beta (A beta) peptide, which is thought to be causal for the pathology and subsequent cognitive decline in Alzheimer's disease. Cleavage by beta-secretase at the amino terminus of the A beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP(1), and a corresponding cell-associated carboxy-terminal fragment. Cleavage of the C-terminal fragment by gamma-secretase(s) leads to the formation of A beta. The pathogenic mutation K670M671 --> N670L671 at the beta-secretase cleavage site in APP(2), which was discovered in a Swedish family with familial Alzheimer's disease, leads to increased beta-secretase cleavage of the mutant substrate(3). Here we describe a membrane-bound enzyme activity that cleaves full-length APP at the beta-secretase cleavage site, and find it to be the predominant beta-cleavage activity in human brain. We have purified this enzyme activity to homogeneity from human brain using a new substrate analogue inhibitor of the enzyme activity, and show that the purified enzyme has all the properties predicted for beta-secretase. Cloning and expression of the enzyme reveals that human brain beta-secretase is a new membrane-bound aspartic proteinase.	Elan Pharmaceut, S San Francisco, CA 94080 USA		Sinha, S (corresponding author), Elan Pharmaceut, 800 Gateway Blvd, S San Francisco, CA 94080 USA.							CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; KNOPS J, 1991, J BIOL CHEM, V266, P7285; Lin J H, 1998, Pharm Biotechnol, V11, P233; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Narutaki S, 1999, J BIOCHEM, V125, P75, DOI 10.1093/oxfordjournals.jbchem.a022271; Rich D. H., 1986, PROTEINASE INHIBITOR; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; VALDES F, 1977, BRAIN RES, V122, P95, DOI 10.1016/0006-8993(77)90665-5; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735	12	1413	1554	0	77	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					537	540		10.1038/990114	http://dx.doi.org/10.1038/990114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591214				2022-12-01	WOS:000084013200058
J	Henney, JE				Henney, JE			Complications related to vascular hemostasis devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					1995	1995		10.1001/jama.282.21.1995	http://dx.doi.org/10.1001/jama.282.21.1995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591372				2022-12-01	WOS:000083908700004
J	Sterling, B				Sterling, B			Homo sapiens declared extinct	NATURE			English	Editorial Material																			0	2	2	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					125	125		10.1038/45932	http://dx.doi.org/10.1038/45932			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10646998	Bronze			2022-12-01	WOS:000083716400024
J	Servant, G; Weiner, OD; Herzmark, P; Balla, T; Sedat, JW; Bourne, HR				Servant, G; Weiner, OD; Herzmark, P; Balla, T; Sedat, JW; Bourne, HR			Polarization of chemoattractant receptor signaling during neutrophil chemotaxis	SCIENCE			English	Article							PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN POLYMERIZATION; BINDING; ACTIVATION; CDC42; CELLS; PHOSPHOINOSITIDES; LEUKOCYTES	Morphologic polarity is necessary for chemotaxis of mammalian cells. As a probe of intracellular signals responsible for this asymmetry, the pleckstrin homology domain of the AKT protein kinase (or protein kinase B), tagged with the green fluorescent protein (PHAKT-GFP), was expressed in neutrophils. Upon exposure of cells to chemoattractant, PHAKT-GFP is recruited selectively to membrane at the cell's leading edge, indicating an internal signaling gradient that is much steeper than that of the chemoattractant. Translocation of PHAKT-GFP is inhibited by toxin-B from Clostridium difficile, indicating that it requires activity of one or more Rho guanosine triphosphatases.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; NICHHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bourne, HR (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.		Weiner, Orion D/F-2576-2011	Weiner, Orion D/0000-0002-1778-6543; Balla, Tamas/0000-0002-9077-3335	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800, R01GM025101] Funding Source: NIH RePORTER; NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-27800, GM-25101, R01 GM027800-27] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Cassimeris L, 1990, Semin Cell Biol, V1, P125; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cellbio.4.1.649; DOWNEY GP, 1994, CURR OPIN IMMUNOL, V6, P113, DOI 10.1016/0952-7915(94)90042-6; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Ma L, 1998, J CELL BIOL, V140, P1125; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; SERVANT G, UNPUB; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; ZIGMOND SH, 1977, J CELL BIOL, V75, P606, DOI 10.1083/jcb.75.2.606; Zigmond SH, 1998, J CELL BIOL, V142, P1001, DOI 10.1083/jcb.142.4.1001; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	48	703	717	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1037	1040		10.1126/science.287.5455.1037	http://dx.doi.org/10.1126/science.287.5455.1037			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669415	Green Accepted			2022-12-01	WOS:000085245400047
J	Wolfe, J; Grier, HE; Klar, N; Levin, SB; Ellenbogen, JM; Salem-Schatz, S; Emanuel, EJ; Weeks, JC				Wolfe, J; Grier, HE; Klar, N; Levin, SB; Ellenbogen, JM; Salem-Schatz, S; Emanuel, EJ; Weeks, JC			Symptoms and suffering at the end of life in children with cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PALLIATIVE CARE; FAMILY MEMBERS; PAIN	Background: Cancer is the second leading cause of death in children, after accidents. Little is known, however, about the symptoms and suffering at the end of life in children with cancer. Methods: In 1997 and 1998, we interviewed the parents of children who had died of cancer between 1990 and 1997 and who were cared for at Children's Hospital in Boston, the Dana-Farber Cancer Institute, or both. Additional data were obtained by reviewing medical records. Results: Of 165 eligible parents, we interviewed 103 (62 percent), 98 by telephone and 5 in person. The interviews were conducted a mean (+/-SD) of 3.1+/-1.6 years after the death of the child. Almost 80 percent died of progressive disease, and the rest died of treatment-related complications. Forty-nine percent of the children died in the hospital; nearly half of these deaths occurred in the intensive care unit. According to the parents, 89 percent of the children suffered "a lot'' or "a great deal'' from at least one symptom in their last month of life, most commonly pain, fatigue, or dyspnea. Of the children who were treated for specific symptoms, treatment was successful in 27 percent of those with pain and 16 percent of those with dyspnea. On the basis of a review of the medical records, parents were significantly more likely than physicians to report that their child had fatigue, poor appetite, constipation, and diarrhea. Suffering from pain was more likely in children whose parents reported that the physician was not actively involved in providing end-of-life care (odds ratio, 2.6; 95 percent confidence interval, 1.0 to 6.7). Conclusions: Children who die of cancer receive aggressive treatment at the end of life. Many have substantial suffering in the last month of life, and attempts to control their symptoms are often unsuccessful. Greater attention must be paid to palliative care for children who are dying of cancer. (N Engl J Med 2000;342:326-33.) (C) 2000, Massachusetts Medical Society.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA; NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; National Institutes of Health (NIH) - USA	Weeks, JC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	joanne_wolfe@dfci.harvard.edu	Harding, Richard/G-9729-2012		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000063] Funding Source: NIH RePORTER; AHRQ HHS [5 T32 HS00063] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; BORTIN MM, 1993, BONE MARROW TRANSPL, V12, P97; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COLLINS JJ, 1995, J PEDIATR-US, V126, P653, DOI 10.1016/S0022-3476(95)70370-5; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Fainsinger R, 1991, J Palliat Care, V7, P5; FIELD MJ, 1997, APPROACHING DEATH IM, V17, P437; Frager G, 1996, J PALLIATIVE CARE, V12, P9; Goldman A, 1998, BRIT MED J, V316, P49, DOI 10.1136/bmj.316.7124.49; Hamel MB, 1999, ANN INTERN MED, V130, P116, DOI 10.7326/0003-4819-130-2-199901190-00005; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; KANE RL, 1984, LANCET, V1, P890; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MAUER AM, 1987, AM J PEDIAT HEMATOL, V9, P58; Monti M, 1996, J PAIN SYMPTOM MANAG, V12, P18, DOI 10.1016/0885-3924(96)00044-9; Power David, 1993, Palliative Medicine, V7, P213, DOI 10.1177/026921639300700308; Robinson WM, 1997, PEDIATRICS, V100, P205, DOI 10.1542/peds.100.2.205; Rosner B., 2011, FUNDAMENTALS BIOSTAT, P352; Sanders J, 1997, PEDIATRICS, V99, P139; Schnipper L, 1998, J CLIN ONCOL, V16, P1986; Sirkia K, 1998, J PAIN SYMPTOM MANAG, V15, P220, DOI 10.1016/S0885-3924(98)00366-2; Streiner DL, 1995, HLTH MEASUREMENT SCA; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; 1991, JAMA, V275, P1232	28	753	765	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2000	342	5					326	333		10.1056/NEJM200002033420506	http://dx.doi.org/10.1056/NEJM200002033420506			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279XL	10655532				2022-12-01	WOS:000085070300006
J	Lee, BG; Griscom, SB; Lee, JS; Choi, HJ; Koh, CH; Luoma, SN; Fisher, NS				Lee, BG; Griscom, SB; Lee, JS; Choi, HJ; Koh, CH; Luoma, SN; Fisher, NS			Influences of dietary uptake and reactive sulfides on metal bioavailability from aquatic sediments	SCIENCE			English	Article							ACID-VOLATILE SULFIDE; POTAMOCORBULA-AMURENSIS; MARINE BIVALVES; ASSIMILATION; TOXICITY; ENVIRONMENTS; CADMIUM; MODEL	Understanding how animals are exposed to the Large repository of metal pollutants in aquatic sediments is complicated and is important in regulatory decisions. Experiments with four types of invertebrates showed that feeding behavior and dietary uptake control bioaccumulation of cadmium, silver, nickel, and zinc. Metal concentrations in animal tissue correlated with metal concentrations extracted from sediments, but not with metal in porewater, across a range of reactive sulfide concentrations, from 0.5 to 30 micromoles per gram. These results contradict the notion that metal bioavailability in sediments is controlled by geochemical equilibration of metals between porewater and reactive sulfides, a proposed basis for regulatory criteria for metals.	US Geol Survey, Div Water Resources, Menlo Pk, CA 94025 USA; SUNY Stony Brook, Marine Sci Res Ctr, Stony Brook, NY 11794 USA; Seoul Natl Univ, Dept Oceanog, Seoul 151742, South Korea	United States Department of the Interior; United States Geological Survey; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Seoul National University (SNU)	Lee, BG (corresponding author), US Geol Survey, Div Water Resources, Mail Stop 465,345 Middlefield Rd, Menlo Pk, CA 94025 USA.	bglee@usgs.gov						Ankley GT, 1996, ENVIRON TOXICOL CHEM, V15, P2056, DOI 10.1002/etc.5620151202; Berry WJ, 1999, ENVIRON TOXICOL CHEM, V18, P40, DOI 10.1897/1551-5028(1999)018<0040:PTOSSW>2.3.CO;2; Berry WJ, 1996, ENVIRON TOXICOL CHEM, V15, P2067, DOI 10.1002/etc.5620151203; BROWN CL, 1995, MAR ECOL PROG SER, V124, P129, DOI 10.3354/meps124129; DECHO AW, 1994, MAR ECOL PROG SER, V108, P133, DOI 10.3354/meps108133; Decho AW, 1996, LIMNOL OCEANOGR, V41, P568, DOI 10.4319/lo.1996.41.3.0568; DiToro DM, 1996, ENVIRON TOXICOL CHEM, V15, P2168, DOI 10.1002/etc.5620151212; DITORO DM, 1990, ENVIRON TOXICOL CHEM, V9, P1487; FISHER NS, 1991, MAR ECOL PROG SER, V70, P157, DOI 10.3354/meps070157; Griscom SB, 2000, ENVIRON SCI TECHNOL, V34, P91, DOI 10.1021/es981309+; HORNBERGER MI, 1999, 9955 US GEOL SURV; Luoma SN, 1997, SETAC SP P, P211; LUOMA SN, 1995, MAR POLLUT BULL, V31, P44, DOI 10.1016/0025-326X(95)00081-W; MARSH HW, 1987, J EDUC MEAS, V24, P1; MAYER LM, 1995, LIMNOL OCEANOGR, V40, P511, DOI 10.4319/lo.1995.40.3.0511; Mayer LM, 1997, J MAR RES, V55, P785, DOI 10.1357/0022240973224247; MEYER JS, 1994, BIOAVAILABILITY PHYS, P155; MORSE JW, 1994, MAR CHEM, V46, P1, DOI 10.1016/0304-4203(94)90040-X; MYER JS, 1994, BIOAVAILABILITY PHYS, P155; Reinfelder JR, 1998, SCI TOTAL ENVIRON, V219, P117, DOI 10.1016/S0048-9697(98)00225-3; SCHOONEN MAA, 1991, GEOCHIM COSMOCHIM AC, V55, P1505, DOI 10.1016/0016-7037(91)90123-M; Wang WX, 1996, LIMNOL OCEANOGR, V41, P197, DOI 10.4319/lo.1996.41.2.0197; Wang WX, 1999, MAR ECOL PROG SER, V178, P281, DOI 10.3354/meps178281	23	199	213	2	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					282	284		10.1126/science.287.5451.282	http://dx.doi.org/10.1126/science.287.5451.282			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634777				2022-12-01	WOS:000084769600032
J	Bear, G				Bear, G			Deep ice and DNA languages	NATURE			English	Article																			0	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					141	141		10.1038/35003068	http://dx.doi.org/10.1038/35003068			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646579	Bronze			2022-12-01	WOS:000084835300027
J	Signorello, LB; Harlow, BL; Chekos, AK; Repke, JT				Signorello, LB; Harlow, BL; Chekos, AK; Repke, JT			Midline episiotomy and anal incontinence: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							FECAL INCONTINENCE; PELVIC FLOOR; SPHINCTER DAMAGE; VAGINAL DELIVERY; PERINEAL TRAUMA; FOLLOW-UP; CHILDBIRTH; REPAIR; RISK	Objective To evaluate the relation between midline episiotomy and postpartum anal incontinence. Design Retrospective cohort study with three study arms and six months of follow up. Setting University teaching hospital. Participants Primiparous women who vaginally delivered a live full term, singleton baby between 1 August 1996 and 8 February 1997: 209 who received an episiotomy; 206 who did not receive an episiotomy but experienced a second, third, or fourth degree spontaneous perineal laceration; and 211 who experienced either no laceration or a first degree perineal laceration. Main outcome measures Self reported faecal and natus incontinence at three and six months postpartum. Results Women who had episiotomies bad a higher risk of faecal incontinence at three (odds ratio 5.5, 95% confidence interval 1.8 to 16.2) and six (3.7, 0.9 to 15.6) months postpartum compared with women with an intact perineum. Compared with women with a spontaneous laceration, episiotomy tripled the risk of faecal incontinence at three months (95%, confidence interval 1.3 to 7.9) and six months (0.7 to 11.2) postpartum, and doubled the risk of flatus incontinence at three months (1.3 to 3.4) and six months (1.2 to 3.7) postpartum. A non-extending episiotomy (that is, second degree surgical incision) tripled the risk of faecal incontinence (1.1 to 9.0) and nearly doubled the risk of flatus incontinence (1.0 to 3.0) at three months postpartum compared with women who had a second degree spontaneous tear. The effect of episiotomy was independent of maternal age, infant birth weight, duration of second stage of labour, use of obstetric instrumentation during delivery, and complications of labour. Conclusions Midline episiotomy is not effective in protecting the perineum and sphincters during childbirth and may impair anal continence.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Signorello, LB (corresponding author), Int Epidemiol Inst, 1450 Res Blvd,Suite 550, Rockville, MD 20850 USA.			Harlow, Bernard/0000-0002-6735-8862				BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; DEEN KI, 1993, GUT, V34, P685, DOI 10.1136/gut.34.5.685; Frudinger A, 1997, BRIT J OBSTET GYNAEC, V104, P1009, DOI 10.1111/j.1471-0528.1997.tb12058.x; HELWIG JT, 1993, OBSTET GYNECOL, V82, P276; ISAGERSALLY L, 1986, BRIT J OBSTET GYNAEC, V93, P420; KLEIN MC, 1994, AM J OBSTET GYNECOL, V171, P591, DOI 10.1016/0002-9378(94)90070-1; LEIGH RJ, 1982, LANCET, V1, P1349; MacArthur C, 1997, BRIT J OBSTET GYNAEC, V104, P46, DOI 10.1111/j.1471-0528.1997.tb10648.x; NIELSEN MB, 1992, BRIT J SURG, V79, P104, DOI 10.1002/bjs.1800790204; SNOOKS SJ, 1990, BRIT J SURG, V77, P1358, DOI 10.1002/bjs.1800771213; SNOOKS SJ, 1984, LANCET, V2, P546; SORENSEN M, 1993, BRIT J SURG, V80, P392, DOI 10.1002/bjs.1800800343; SULTAN AH, 1993, INT J GYNECOL OBSTET, V43, P263, DOI 10.1016/0020-7292(93)90514-W; Sultan AH, 1997, BRIT J OBSTET GYNAEC, V104, P979; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1994, BRIT MED J, V308, P887, DOI 10.1136/bmj.308.6933.887; SWASH M, 1993, BRIT MED J, V307, P636, DOI 10.1136/bmj.307.6905.636; Thacker S B, 1983, Obstet Gynecol Surv, V38, P322, DOI 10.1097/00006254-198306000-00003; THORP JM, 1987, OBSTET GYNECOL, V70, P260; THORP JM, 1989, AM J OBSTET GYNECOL, V160, P1027, DOI 10.1016/0002-9378(89)90152-X; WALKER MPR, 1991, OBSTET GYNECOL, V77, P668	21	121	124	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	2000	320	7227					86	90		10.1136/bmj.320.7227.86	http://dx.doi.org/10.1136/bmj.320.7227.86			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625261	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000084746600016
J	Copenhaver, GP; Nickel, K; Kuromori, T; Benito, MI; Kaul, S; Lin, XY; Bevan, M; Murphy, G; Harris, B; Parnell, LD; McCombie, WR; Martienssen, RA; Marra, M; Preuss, D				Copenhaver, GP; Nickel, K; Kuromori, T; Benito, MI; Kaul, S; Lin, XY; Bevan, M; Murphy, G; Harris, B; Parnell, LD; McCombie, WR; Martienssen, RA; Marra, M; Preuss, D			Genetic definition and sequence analysis of Arabidopsis centromeres	SCIENCE			English	Article							REPETITIVE DNA; RNA GENES; THALIANA; RECOMBINATION; PROTEINS; REGIONS; RETROTRANSPOSONS; HETEROCHROMATIN; CONSTRUCTION; EUKARYOTES	High-precision genetic mapping was used to define the regions that contain centromere functions on each natural chromosome in Arabidopsis thaliana. These regions exhibited dramatic recombinational repression and contained complex DNA surrounding large arrays of 180-base pair repeats. Unexpectedly, the DNA within the centromeres was not merely structural but also encoded several expressed genes. The regions flanking the centromeres were densely populated by repetitive elements yet experienced normal levels of recombination. The genetically defined centromeres were well conserved among Arabidopsis ecotypes but displayed Limited sequence homology between different chromosomes, excluding repetitive DNA. This investigation provides a platform for dissecting the role of individual sequences in centromeres in higher eukaryotes.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Inst Genom Res, Rockville, MD 20850 USA; John Innes Ctr Plant Sci Res, Norwich NR4 7UJ, Norfolk, England; Sanger Ctr, Cambridge CB10 1SA, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Washington Univ, Genome Sequencing Ctr, St Louis, MO 63108 USA	University of Chicago; J. Craig Venter Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Wellcome Trust Sanger Institute; Cold Spring Harbor Laboratory; Washington University (WUSTL)	Preuss, D (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 1103 E 57 St, Chicago, IL 60637 USA.	dpreuss@midway.uchicago.edu	Kuromori, Takashi/G-7862-2013; Marra, Marco A/B-5987-2008; Copenhaver, Gregory/AAH-2031-2022; Copenhaver, Gregory P/A-7549-2014; Copenhaver, Gregory/AFL-9831-2022	Kuromori, Takashi/0000-0003-3232-7262; Marra, Marco A/0000-0001-7146-7175; Copenhaver, Gregory/0000-0002-7962-3862; Copenhaver, Gregory P/0000-0002-7962-3862; Copenhaver, Gregory/0000-0002-7962-3862; McCombie, W. Richard/0000-0003-1899-0682				BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Bevan M, 1999, BIOESSAYS, V21, P110, DOI 10.1002/(SICI)1521-1878(199902)21:2&lt;110::AID-BIES5&gt;3.0.CO;2-V; Brandes A, 1997, CHROMOSOME RES, V5, P238, DOI 10.1023/A:1018415502795; CALLIS J, 1995, GENETICS, V139, P921; Cambareri EB, 1998, MOL CELL BIOL, V18, P5465, DOI 10.1128/MCB.18.9.5465; CHARLESWORTH B, 1986, GENETICS, V112, P947, DOI 10.1093/genetics/112.4.947; CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; Choo KHA, 1998, GENOME RES, V8, P81, DOI 10.1101/gr.8.2.81; Chye ML, 1997, PLANT MOL BIOL, V35, P893, DOI 10.1023/A:1005947804227; Clarke L, 1998, CURR OPIN GENET DEV, V8, P212, DOI 10.1016/S0959-437X(98)80143-3; Copenhaver GP, 1998, P NATL ACAD SCI USA, V95, P247, DOI 10.1073/pnas.95.1.247; Copenhaver GP, 1996, PLANT J, V9, P259, DOI 10.1046/j.1365-313X.1996.09020259.x; Copenhaver GP, 1999, CURR OPIN PLANT BIOL, V2, P104, DOI 10.1016/S1369-5266(99)80021-1; Craig JM, 1999, EXP CELL RES, V246, P249, DOI 10.1006/excr.1998.4278; FLEIG U, 1995, NUCLEIC ACIDS RES, V23, P922, DOI 10.1093/nar/23.6.922; GutierrezMarcos JF, 1996, P NATL ACAD SCI USA, V93, P13377, DOI 10.1073/pnas.93.23.13377; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Heslop-Harrison JS, 1999, PLANT CELL, V11, P31, DOI 10.1105/tpc.11.1.31; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; INOHARA N, 1991, J BIOL CHEM, V266, P7333; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Kaszas E, 1996, EMBO J, V15, P5246, DOI 10.1002/j.1460-2075.1996.tb00910.x; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KONIECZNY A, 1991, GENETICS, V127, P801; KUHN RM, 1991, P NATL ACAD SCI USA, V88, P1306, DOI 10.1073/pnas.88.4.1306; LI HM, 1995, PLANT CELL, V7, P1599, DOI 10.1105/tpc.7.10.1599; LIN X, IN PRESS NATURE; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; Mahtani MM, 1998, GENOME RES, V8, P100, DOI 10.1101/gr.8.2.100; Mara M, 1999, NAT GENET, V22, P265, DOI 10.1038/10327; Mozo T, 1999, NAT GENET, V22, P271, DOI 10.1038/10334; Murata M, 1997, PLANT J, V12, P31, DOI 10.1046/j.1365-313X.1997.12010031.x; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; Pelissier T, 1996, GENETICA, V97, P141, DOI 10.1007/BF00054621; PREUSS D, 1994, SCIENCE, V264, P1458, DOI 10.1126/science.8197459; Puechberty J, 1999, GENOMICS, V56, P274, DOI 10.1006/geno.1999.5742; RICHARDS EJ, 1991, NUCLEIC ACIDS RES, V19, P3351, DOI 10.1093/nar/19.12.3351; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; SIMOENS CR, 1988, NUCLEIC ACIDS RES, V16, P6753, DOI 10.1093/nar/16.14.6753; Somerville C, 1999, SCIENCE, V285, P380, DOI 10.1126/science.285.5426.380; Sun XP, 1997, CELL, V91, P1007, DOI 10.1016/S0092-8674(00)80491-2; TSAY YF, 1993, SCIENCE, V260, P342, DOI 10.1126/science.8385803; Tugal HB, 1999, PLANT PHYSIOL, V120, P309, DOI 10.1104/pp.120.1.309; WAMBUTT R, IN PRESS NATURE; Wright DA, 1996, GENETICS, V142, P569	46	348	380	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1999	286	5449					2468	2474		10.1126/science.286.5449.2468	http://dx.doi.org/10.1126/science.286.5449.2468			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	268RQ	10617454				2022-12-01	WOS:000084429700037
J	Polanczyk, CA; Kuntz, KM; Sacks, DB; Johnson, PA; Lee, TH				Polanczyk, CA; Kuntz, KM; Sacks, DB; Johnson, PA; Lee, TH			Emergency department triage strategies for acute chest pain using creatine Kinase-MB and troponin I assays: A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIAC TROPONIN; ROOM	Background: Evaluation of acute chest pain is highly variable. Objective: To evaluate the cost-effectiveness of strategies using cardiac markers and noninvasive tests for myocardial ischemia. Design: Cost-effectiveness analysis. Data Sources: Prospective data from 1066 patients with chest pain and from the published literature. Target Population: Patients admitted with acute chest pain. Time Horizon: Lifetime. Perspective: Societal. Interventions: Creatine kinase (CK)-MB mass assay alone; CK-MB mass assay followed by cardiac troponin assay if the CK-MB value is normal; CK-MB mass assay followed by troponin I assay if the CK-MB value is normal and electrocardiography shows ischemic changes; both CK-MB mass and troponin I assays; and troponin I assay alone. These strategies were evaluated alone or in combination with early exercise testing. Outcome Measures: Lifetime cost, life expectancy (in years), and incremental cost-effectiveness. Results of Base-Case Analysis: For patients 55 to 64 years of age, measurement of CK-MB mass followed by exercise testing in appropriate patients was the most competitive strategy ($43000 per year of life saved). Measurement of CK-MB mass followed by troponin I measurement had an incremental cost-effectiveness ratio of $47400 per year of life saved for patients 65 to 74 years of age; it was also the most cost-effective strategy when early exercise testing could not be performed, CK-MB values were normal, and ischemic changes were seen on electrocardiography. Results of Sensitivity Analysis: Results were influenced by age, probability of myocardial infarction, and medical costs. Conclusions: Measurement of CK-MB mass plus early exercise testing is a cost-effective initial strategy for younger patients and those with a low to moderate probability of myocardial infarction. Troponin I measurement can be a cost-effective second test in higher-risk subsets of patients if the CK-MB level is normal and early exercise testing is not an option.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Lee, TH (corresponding author), Partners Community Healthcare Inc, Suite 1150,Prudential Tower, Boston, MA 02119 USA.	thlee@partners.org	Polanczyk, Carisi CAP/D-6208-2013	Sacks, David/0000-0003-3100-0735				Anderson F P, 1998, Clin Lab Manage Rev, V12, P63; APPLE FS, 1995, CLIN CHIM ACTA, V237, P59, DOI 10.1016/0009-8981(95)06064-K; BODOR GS, 1992, CLIN CHEM, V38, P2203; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Fleischmann KE, 1998, JAMA-J AM MED ASSOC, V280, P913, DOI 10.1001/jama.280.10.913; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; Green GB, 1998, ANN EMERG MED, V31, P19, DOI 10.1016/S0196-0644(98)70276-8; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; Johnson PA, 1999, AM HEART J, V137, P1137, DOI 10.1016/S0002-8703(99)70374-1; Keffer JH, 1997, AM J CLIN PATHOL, V107, P398; Kirk JD, 1998, ANN EMERG MED, V32, P1, DOI 10.1016/S0196-0644(98)70091-5; Kontos MC, 1999, CIRCULATION, V99, P2073, DOI 10.1161/01.CIR.99.16.2073; Krumholz HM, 1998, AM HEART J, V135, P523, DOI 10.1016/S0002-8703(98)70331-X; Kuntz KM, 1999, ANN INTERN MED, V130, P709, DOI 10.7326/0003-4819-130-9-199905040-00002; LAVE JR, 1994, MED CARE, V32, pJS77; LEE T, 1990, COMMON DIAGNOSTIC TE, P36; LEE TH, 1988, MED DECIS MAKING, V8, P268, DOI 10.1177/0272989X8800800408; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEWIS WR, 1994, AM J CARDIOL, V74, P987, DOI 10.1016/0002-9149(94)90845-1; Mair J, 1997, CLIN CHIM ACTA, V257, P99, DOI 10.1016/S0009-8981(96)06436-4; Mair J, 1996, CLIN CHIM ACTA, V245, P19, DOI 10.1016/0009-8981(95)06168-1; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; O'Brien JA, 1998, DIABETES CARE, V21, P1122, DOI 10.2337/diacare.21.7.1122; Polanczyk CA, 1999, AM J CARDIOL, V83, P1175, DOI 10.1016/S0002-9149(99)00055-7; Polanczyk CA, 1998, AM J CARDIOL, V81, P288, DOI 10.1016/S0002-9149(97)00897-7; Polanczyk CA, 1998, J AM COLL CARDIOL, V32, P8, DOI 10.1016/S0735-1097(98)00176-4; Stinnett AAMM, 1996, COST EFFECTIVENESS H, P349; Tosteson ANA, 1996, CIRCULATION, V94, P143, DOI 10.1161/01.CIR.94.2.143; Tucker JF, 1997, ACAD EMERG MED, V4, P13, DOI 10.1111/j.1553-2712.1997.tb03637.x; UDVARHELYI IS, 1992, J GEN INTERN MED, V7, P1, DOI 10.1007/BF02599092; *US BUR CENS, 1997, STAT ABSTR US, P89; Wu AHB, 1996, CLIN CHEM, V42, P651	32	36	37	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					909	+		10.7326/0003-4819-131-12-199912210-00002	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610641				2022-12-01	WOS:000084374400001
J	Kopans, DB				Kopans, DB			Breast-cancer screening with ultrasonography	LANCET			English	Editorial Material							US; WOMEN		Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Kopans, DB (corresponding author), Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA.							BAILAR JC, 1976, ANN INTERN MED, V84, P77, DOI 10.7326/0003-4819-84-1-77; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; Buchberger W, 1999, AM J ROENTGENOL, V173, P921, DOI 10.2214/ajr.173.4.10511149; FEIG SA, 1995, CANCER, V75, P2412, DOI 10.1002/1097-0142(19950515)75:10<2412::AID-CNCR2820751005>3.0.CO;2-4; GORDON PB, 1993, RADIOLOGY, V189, P573, DOI 10.1148/radiology.189.2.8210392; GORDON PB, 1995, CANCER, V76, P626, DOI 10.1002/1097-0142(19950815)76:4<626::AID-CNCR2820760413>3.0.CO;2-Z; Kolb TM, 1998, RADIOLOGY, V207, P191, DOI 10.1148/radiology.207.1.9530316; KOPANS DB, 1985, RADIOLOGY, V157, P505, DOI 10.1148/radiology.157.2.3901112; Shapiro S, 1988, PERIODIC SCREENING B	9	33	38	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2096	2097		10.1016/S0140-6736(99)90400-2	http://dx.doi.org/10.1016/S0140-6736(99)90400-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609810				2022-12-01	WOS:000084318200004
J	Selmer, M; Al-Karadaghi, S; Hirokawa, G; Kaji, A; Liljas, A				Selmer, M; Al-Karadaghi, S; Hirokawa, G; Kaji, A; Liljas, A			Crystal structure of Thermotoga maritima ribosome recycling factor: A tRNA mimic	SCIENCE			English	Article							ELONGATION-FACTOR-G; COMPLETE GENOME SEQUENCE; RELEASE FACTOR RF3; PROTEIN-BIOSYNTHESIS; TERMINATION COMPLEX; FACTOR RRF; GUANOSINE TRIPHOSPHATE; TRANSFER-RNAS; DISSOCIATION; RESOLUTION	Ribosome recycling factor (RRF), together with elongation factor G (EF-G), catalyzes recycling of ribosomes after one round of protein synthesis. The crystal structure of RRF was determined at 2.55 angstrom resolution. The protein has an unusual fold where domain I is a Long three-helix bundle and domain II is a three-layer beta/alpha/beta sandwich. The molecule superimposes almost perfectly with a transfer RNA (tRNA) except that the amino acid-binding 3' end is missing. The mimicry suggests that RRF interacts with the posttermination ribosomal complex in a similar manner to a tRNA, leading to disassembly of the complex. The structural arrangement of this mimicry is entirely different from that of other cases of Less pronounced mimicry of tRNA so far described.	Lund Univ, Ctr Chem & Chem Engn, SE-22100 Lund, Sweden; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA	Lund University; University of Pennsylvania	Liljas, A (corresponding author), Lund Univ, Ctr Chem & Chem Engn, POB 124, SE-22100 Lund, Sweden.	anders.liljas@mbfys.ln.se	Al-karadaghi, Salam/F-1492-2011	Al-karadaghi, Salam/0000-0001-8608-0635; Selmer, Maria/0000-0001-9079-2774				AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Grentzmann G, 1998, RNA, V4, P973, DOI 10.1017/S1355838298971576; GUALERZI C, 1971, BIOCHEM BIOPH RES CO, V45, P1312, DOI 10.1016/0006-291X(71)90162-8; Heurgue-Hamard V, 1998, EMBO J, V17, P808, DOI 10.1093/emboj/17.3.808; HIRASHIM.A, 1973, J BIOL CHEM, V248, P7580; HIRASHIMA A, 1972, J MOL BIOL, V65, P43, DOI 10.1016/0022-2836(72)90490-1; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; INOKUCHI Y, 1986, J BIOCHEM-TOKYO, V99, P1169, DOI 10.1093/oxfordjournals.jbchem.a135580; INOUEYOKOSAWA N, 1974, J BIOL CHEM, V249, P4321; ISHITSUKA H, 1970, J BIOL CHEM, V245, P3346; JACK A, 1976, J MOL BIOL, V108, P619, DOI 10.1016/S0022-2836(76)80109-X; Janosi L, 1996, BIOCHIMIE, V78, P959, DOI 10.1016/S0300-9084(97)86718-1; Janosi L, 1998, EMBO J, V17, P1141, DOI 10.1093/emboj/17.4.1141; Janosi L, 1996, ADV BIOPHYS, V32, P121, DOI 10.1016/0065-227X(96)84743-5; JANOSI L, 1994, P NATL ACAD SCI USA, V91, P4249, DOI 10.1073/pnas.91.10.4249; JANOSI L, IN PRESS J MOL BIOL; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaji A, 1998, BIOCHEM BIOPH RES CO, V250, P1, DOI 10.1006/bbrc.1998.9168; KAJI A, 1999, ACTA CRYSTALLOGR D, V55, P2049; Kanai T, 1998, EUR J BIOCHEM, V256, P212, DOI 10.1046/j.1432-1327.1998.2560212.x; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURBERG M, COMMUNICATION; Leslie A. G. W.., 1992, PROTEIN CRYSTALLOGR, V26; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; OGAWA K, 1975, EUR J BIOCHEM, V58, P411, DOI 10.1111/j.1432-1033.1975.tb02388.x; OUZOUNIS C, 1995, PROTEIN SCI, V4, P2424, DOI 10.1002/pro.5560041121; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; Rolland N, 1999, P NATL ACAD SCI USA, V96, P5464, DOI 10.1073/pnas.96.10.5464; RYOJI M, 1981, P NATL ACAD SCI-BIOL, V78, P5973, DOI 10.1073/pnas.78.10.5973; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; Sette M, 1997, EMBO J, V16, P1436, DOI 10.1093/emboj/16.6.1436; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P401; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; SUBRAMANIAN AR, 1970, NATURE, V228, P1273, DOI 10.1038/2281273a0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Zhang YL, 1998, BBA-GENE STRUCT EXPR, V1443, P245, DOI 10.1016/S0167-4781(98)00223-1	53	145	150	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2349	2352		10.1126/science.286.5448.2349	http://dx.doi.org/10.1126/science.286.5448.2349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600747				2022-12-01	WOS:000084318500064
J	Merendino, L; Guth, S; Bilbao, D; Martinez, C; Valcarcel, J				Merendino, L; Guth, S; Bilbao, D; Martinez, C; Valcarcel, J			Inhibition of msl-2 splicing by Sex-lethal reveals interaction between U2AF(35) and the 3 ' splice site AG	NATURE			English	Article							DOSAGE COMPENSATION GENE; PRE-MESSENGER-RNA; MAMMALIAN INTRONS; CATALYTIC STEP; DROSOPHILA; PROTEIN; EXPRESSION; SELECTION; ENCODES	The protein Sex-lethal (SXL) controls dosage compensation in Drosophila by inhibiting the splicing and translation of male-specific-lethal-2 (msl-2) transcripts(1-6) Here we report that splicing inhibition of msl-2 requires a binding site for SXL at the polypyrimidine (poly(Y)) tract associated with the 3' splice site, and an unusually long distance between the poly(Y) tract and the conserved AG dinucleotide at the 3' end of the intron, Only this combination allows efficient blockage of U2 small nuclear ribonucleoprotein particle binding and displacement of the large subunit of the U2 auxiliary factor (U2AF(65)) from the poly(Y) tract by SXL, Crosslinking experiments with ultraviolet light indicate that the small subunit of U2AF (U2AF(35)) contacts the AG dinucleotide only when located in proximity to the poly(Y) tract. This interaction stabilizes U2AF65 binding such that SXL can no longer displace it from the poly(Y) tract. Our results reveal a novel function for U2AF35, a critical role for the 3' splice site AG at the earliest steps of spliceosome assembly and the need for a weakened U2AF(35)-AG interaction to regulate intron removal.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Valcarcel, J (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Valcarcel, Juan/O-9814-2014	Valcarcel, Juan/0000-0001-5398-3571; Guth-Gundel, Sabine/0000-0001-9115-1397; Bilbao Cortes, Daniel/0000-0003-1630-8811				BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; Bashaw GJ, 1997, CELL, V89, P789, DOI 10.1016/S0092-8674(00)80262-7; Chiara MD, 1997, EMBO J, V16, P4746, DOI 10.1093/emboj/16.15.4746; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRANK D, 1992, GENE DEV, V6, P2112, DOI 10.1101/gad.6.11.2112; Gebauer F, 1998, RNA, V4, P142; GREENFIELD BH, 1991, ISOKINET EXERC SCI, V1, P207; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; Kelley RL, 1997, NATURE, V387, P195, DOI 10.1038/387195a0; Luukkonen BGM, 1997, EMBO J, V16, P779, DOI 10.1093/emboj/16.4.779; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; Umen JG, 1995, RNA, V1, P869; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZAPP ML, 1989, NUCLEIC ACIDS RES, V17, P2655, DOI 10.1093/nar/17.7.2655; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	22	223	232	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					838	841		10.1038/45602	http://dx.doi.org/10.1038/45602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617208				2022-12-01	WOS:000084330500072
J	Llorca, O; McCormack, EA; Hynes, G; Grantham, J; Cordell, J; Carrascosa, JL; Willison, KR; Fernandez, JJ; Valpuesta, JM				Llorca, O; McCormack, EA; Hynes, G; Grantham, J; Cordell, J; Carrascosa, JL; Willison, KR; Fernandez, JJ; Valpuesta, JM			Eukaryotic type II chaperonin CCT interacts with actin through specific subunits	NATURE			English	Article							COMPLEX POLYPEPTIDE-1 TCP-1; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; THERMOSOME; PROTEIN; IMAGES	Chaperonins assist the folding of other proteins(1). Type II chaperonins, such as chaperonin containing TCP-1(CCT), are found in archaea and in the eukaryotic cytosol(2). They are hexadecameric or nonadecameric oligomers composed of one to eight different polypeptides. Whereas type I chaperonins like GroEL are promiscuous, assisting in the folding of many other proteins(1) only a small number of proteins, mainly actin and tubulin, have been described as natural substrates of CCT, This specificity may be related to the divergence of the eight CCT subunits(3). Here we have obtained a three-dimensional reconstruction of the complex between CCT and alpha-actin by cryo-electron microscopy and image processing. This shows that cr-actin interacts with the apical domains of either of two CCT subunits. Immunolabelling of CCT-substrate complexes with antibodies against two specific CCT subunits showed that actin binds to CCT using two specific and distinct interactions: the small domain of actin binds to CCT delta and the large domain to CCT beta or CCT epsilon (both in position 1,4 with respect to delta). These results indicate that the binding of actin to CCT is both subunit-specific and geometry-dependent, Thus, the substrate recognition mechanism of eukaryotic CCT may differ from that of prokaryotic GroEL.	CSIC, Ctr Nacl Biotecnol, Madrid 28049, Spain; Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England; Univ Almeria, Dept Arquitectura Comp & Elect, Almeria 04120, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Universidad de Almeria	Valpuesta, JM (corresponding author), CSIC, Ctr Nacl Biotecnol, Campus Univ Autonoma Madrid, Madrid 28049, Spain.		Fernandez, Jose-Jesus/A-5084-2008; Valpuesta, Jose M/AAA-6002-2019; Grantham, Julie/A-5002-2009; Llorca, Oscar/P-2784-2019; Llorca, Oscar/K-1144-2014; Valpuesta, José M/T-1977-2017	Fernandez, Jose-Jesus/0000-0003-2222-3355; Llorca, Oscar/0000-0001-5705-0699; Llorca, Oscar/0000-0001-5705-0699; Valpuesta, José M/0000-0001-7468-8053				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; HYNES G, 1995, FEBS LETT, V358, P129, DOI 10.1016/0014-5793(94)01408-S; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kashuba E, 1999, J HUMAN VIROL, V2, P33; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; Llorca O, 1999, NAT STRUCT BIOL, V6, P639; Llorca O, 1998, J BIOL CHEM, V273, P10091, DOI 10.1074/jbc.273.17.10091; Marabini R, 1998, ULTRAMICROSCOPY, V72, P53, DOI 10.1016/S0304-3991(97)00127-7; MARABINI R, 1994, BIOPHYS J, V66, P1804, DOI 10.1016/S0006-3495(94)80974-9; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Rommelaere H, 1999, BIOCHEMISTRY-US, V38, P3246, DOI 10.1021/bi9815905; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLISON KR, 1999, MOL CHAPERONES FOLDI, P555	19	224	226	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					693	696		10.1038/45294	http://dx.doi.org/10.1038/45294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604479				2022-12-01	WOS:000084189800073
J	Mercader, N; Leonardo, E; Azpiazu, N; Serrano, A; Morata, G; Martinez, C; Torres, M				Mercader, N; Leonardo, E; Azpiazu, N; Serrano, A; Morata, G; Martinez, C; Torres, M			Conserved regulation of proximodistal limb axis development by Meis1/Hth	NATURE			English	Article							HOMEOBOX GENE; VERTEBRATE LIMB; FEEDBACK LOOP; MESSENGER-RNA; EXPRESSION; EXTRADENTICLE; DROSOPHILA; BUD; DIFFERENTIATION; TRANSLOCATION	Vertebrate limbs grow out from the flanks of embryos, with their main axis extending proximodistally from the trunk. Distinct limb domains, each with specific traits, are generated in a proximal-to-distal sequence during development(1). Diffusible factors expressed from signalling centres promote the outgrowth of limbs and specify their dorsoventral and anteroposterior axes(2-4). However, the molecular mechanism by which limb cells acquire their proximodistal (P-D) identity is unknown(1). Here we describe the role of the homeobox genes Meis1/2 and Pbx1 in the development of mouse, chicken and Drosophila limbs. We find that Meis1/2 expression is restricted to a proximal domain, coincident with the previously reported domain in which Pbx1 is localized to the nucleus(5), and resembling the distribution of the Drosophila homologues homothorax (hth)(5,6) and extradenticle (exd)(7); that Meis1 regulates Pbx1 activity by promoting nuclear import of the Pbx1 protein; and that ectopic expression of Meis1 in chicken and hth in Drosophila disrupts distal limb development and induces distal-to-proximal transformations. We suggest that restriction of Meis1/Hth to proximal regions of the vertebrate and insect limb is essential to specify cell fates and differentiation patterns along the P-D axis of the limb.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, E-28049 Madrid, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Torres, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, E-28049 Madrid, Spain.		Torres, Miguel/CAG-0003-2022; Mercader, Nadia/L-2728-2014; Torres, Miguel/A-7388-2013	Torres, Miguel/0000-0003-0906-4767; Mercader, Nadia/0000-0002-0905-6399; Torres, Miguel/0000-0003-0906-4767; Morata, Gines/0000-0003-3274-5173; Serrano, Antonio/0000-0003-1993-640X				Abu-Shaar M, 1998, DEVELOPMENT, V125, P3821; Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; BRAND AH, 1993, DEVELOPMENT, V118, P401; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; CAPDEVILA J, IN PRESS MOL CELL; Cecconi F, 1997, DEV DYNAM, V210, P184, DOI 10.1002/(SICI)1097-0177(199710)210:2<184::AID-AJA10>3.0.CO;2-E; CELIS JFD, 1997, DEVELOPMENT, V124, P3241; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; GonzalezCrespo S, 1996, DEVELOPMENT, V122, P3921; Goto S, 1999, DEVELOPMENT, V126, P3407; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Logan M, 1998, METHODS, V14, P407, DOI 10.1006/meth.1998.0595; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, ONCOGENE, V13, P2235; Nelson CE, 1996, DEVELOPMENT, V122, P1449; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; ROWE DA, 1982, J EMBRYOL EXP MORPH, V68, P1; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Wu J, 1999, DEVELOPMENT, V126, P109; Zakany J, 1999, CELL TISSUE RES, V296, P19, DOI 10.1007/s004410051262	31	240	241	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					425	429		10.1038/46580	http://dx.doi.org/10.1038/46580			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586884				2022-12-01	WOS:000083913600060
J	Streblow, DN; Soderberg-Naucler, C; Vieira, J; Smith, P; Wakabayashi, E; Ruchti, F; Mattison, K; Altschuler, Y; Nelson, JA				Streblow, DN; Soderberg-Naucler, C; Vieira, J; Smith, P; Wakabayashi, E; Ruchti, F; Mattison, K; Altschuler, Y; Nelson, JA			The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration	CELL			English	Article							PROTEIN-COUPLED RECEPTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; DNA-SEQUENCE; INFECTED-CELLS; CODING CONTENT; ATHEROSCLEROSIS; EXPRESSION; VIRUS	Human cytomegalovirus (HCMV) infection of smooth muscle cells (SMCs) in vivo has been linked to a viral etiology of vascular disease. In this report, we demonstrate that HCMV infection of primary arterial SMCs results in significant cellular migration. Ablation of the chemokine receptor, US28, abrogates SMC migration, which is rescued only by expression of the viral homolog and not a cellular G protein-coupled receptor (GPCR). Expression of US28 in the presence of CC chemokines including RANTES or MCP-1 was sufficient to promote SMC migration by both chemokinesis and chemotaxis, which was inhibited by protein tyrosine kinase inhibitors. US28-mediated SMC migration provides a molecular basis for the correlative evidence that links HCMV to the acceleration of vascular disease.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Program Infect Dis, Seattle, WA 98104 USA; Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA	Oregon Health & Science University; Oregon Health & Science University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco	Nelson, JA (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.	nelsonj@ohsu.edu			NIAID NIH HHS [AI 21640] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021640] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Boshoff C, 1998, NATURE, V391, P24, DOI 10.1038/34054; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; Bruning JH, 1994, TRANSPLANT INT S1, V7, P365; BURGSTAHLER R, 1995, BIOCHEM BIOPH RES CO, V215, P737, DOI 10.1006/bbrc.1995.2525; Cary LA, 1996, J CELL SCI, V109, P1787; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; FABRICANT CG, 1983, FED PROC, V42, P2476; GAO JL, 1994, J BIOL CHEM, V269, P28539; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; HENDRIX MGR, 1991, AM J PATHOL, V138, P563; Hitt M. M., 1994, CELL BIOL LAB HDB, V1, P479; ILLC D, 1995, NATURE, V377, P539; Inagami T, 1999, J AM SOC NEPHROL, V10, pS2; Jarvis MA, 1999, J VIROL, V73, P4552, DOI 10.1128/JVI.73.6.4552-4560.1999; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lalani AS, 1999, VIROLOGY, V256, P233, DOI 10.1006/viro.1999.9617; LEMSTROM KB, 1993, J CLIN INVEST, V92, P549, DOI 10.1172/JCI116622; LU M, 1996, J VIROL, V70, P6097; Margulies BJ, 1996, VIROLOGY, V225, P111, DOI 10.1006/viro.1996.0579; MASSUNG RF, 1993, VIROLOGY, V197, P511, DOI 10.1006/viro.1993.1625; MCDONALD K, 1989, AM J CARDIOL, V64, P359, DOI 10.1016/0002-9149(89)90535-3; Mellado M, 1998, J IMMUNOL, V161, P805; Melnick JL, 1998, INFECT MED, V15, P479; MELNICK JL, 1983, LANCET, V2, P644; Michelson S, 1997, J VIROL, V71, P6495, DOI 10.1128/JVI.71.9.6495-6500.1997; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; PETERSON PK, 1980, MEDICINE, V59, P283, DOI 10.1097/00005792-198007000-00004; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SoderbergNaucler C, 1997, CELL, V91, P119, DOI 10.1016/S0092-8674(01)80014-3; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; Terkeltaub R, 1998, CURR OPIN LIPIDOL, V9, P397, DOI 10.1097/00041433-199810000-00003; TUMILOWICZ JJ, 1985, J VIROL, V56, P839, DOI 10.1128/JVI.56.3.839-845.1985; Vieira J, 1998, J VIROL, V72, P8158, DOI 10.1128/JVI.72.10.8158-8165.1998; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903; Zhou YF, 1999, BIOCHEM BIOPH RES CO, V256, P608, DOI 10.1006/bbrc.1999.0387	61	330	344	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					511	520		10.1016/S0092-8674(00)81539-1	http://dx.doi.org/10.1016/S0092-8674(00)81539-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589679	Bronze			2022-12-01	WOS:000083986300010
J	Kong, YY; Feige, U; Sarosi, I; Bolon, B; Tafuri, A; Morony, S; Capparelli, C; Li, J; Elliott, R; McCabe, S; Wong, T; Campagnuolo, G; Moran, E; Bogoch, ER; Van, G; Nguyen, LT; Ohashi, PS; Lacey, DL; Fish, E; Boyle, WJ; Penninger, JM				Kong, YY; Feige, U; Sarosi, I; Bolon, B; Tafuri, A; Morony, S; Capparelli, C; Li, J; Elliott, R; McCabe, S; Wong, T; Campagnuolo, G; Moran, E; Bogoch, ER; Van, G; Nguyen, LT; Ohashi, PS; Lacey, DL; Fish, E; Boyle, WJ; Penninger, JM			Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand	NATURE			English	Article							RHEUMATOID-ARTHRITIS; OSTEOCLAST; RECEPTOR; CYTOKINE; DENSITY; BIOLOGY; TRANCE; FAMILY; MICE	Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG)(1-3). In addition, OPGL regulates lymph node organogenesis, lymphocyte development and interactions between T cells and dendritic cells in the immune system(3-5). The OPGL receptor, RANK, is expressed on chondrocytes, osteoclast precursors and mature osteoclasts(4,6). OPGL expression in T cells is induced by antigen receptor engagement(7), which suggests that activated T cells may influence bone metabolism through OPGL and RANK. Here we report that activated T cells can directly trigger osteoclastogenesis through OPGL. Systemic activation of T cells in vivo leads to an OPGL-mediated increase in osteoclastogenesis and bone loss. In a T-cell-dependent model of rat adjuvant arthritis characterized by severe joint inflammation, bone and cartilage destruction and crippling, blocking of OPGL through osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation, These results show that both systemic and local T-cell activation can lead to OPGL production and subsequent bone loss, and they provide a novel paradigm for T cells as regulators of bone physiology.	Amgen Inst, Toronto, ON M5G 2C1, Canada; Amgen Inc, Dept Pharmacol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA; St Michaels Hosp, Dept Med Genet & Microbiol, Toronto, ON M5B 1W8, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys & Immunol, Toronto, ON, Canada	Amgen; Amgen; Amgen; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Penninger, JM (corresponding author), Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Ohashi, Pamela S./0000-0003-2915-9317				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Bendele A, 1999, ARTHRITIS RHEUM, V42, P498, DOI 10.1002/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A; Coleman RE, 1998, BRIT J CANCER, V77, P336, DOI 10.1038/bjc.1998.52; CONWAY JG, 1995, J EXP MED, V182, P449, DOI 10.1084/jem.182.2.449; Faust J, 1999, J CELL BIOCHEM, V72, P67, DOI 10.1002/(SICI)1097-4644(19990101)72:1<67::AID-JCB8>3.0.CO;2-A; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Josien R, 1999, J IMMUNOL, V162, P2562; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Muller-Ladner U, 1998, Curr Opin Rheumatol, V10, P212; OLIVERI M B, 1991, Henry Ford Hospital Medical Journal, V39, P45; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; Piepkorn B, 1997, HORM METAB RES, V29, P584, DOI 10.1055/s-2007-979106; Roodman GD, 1996, BONE, V19, P209, DOI 10.1016/8756-3282(96)00211-6; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; STELLON AJ, 1985, GASTROENTEROLOGY, V89, P1078, DOI 10.1016/0016-5085(85)90212-4; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075	24	1457	1564	2	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					304	309		10.1038/35005552	http://dx.doi.org/10.1038/35005552			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580503	Bronze			2022-12-01	WOS:000083813700053
J	Smith, O				Smith, O			Development - Whirling derivshes	SCIENCE			English	Editorial Material																		Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1311	1311		10.1126/science.286.5443.1311	http://dx.doi.org/10.1126/science.286.5443.1311			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10610537				2022-12-01	WOS:000083675500031
J	Hall, S; Bobrow, M; Marteau, TM				Hall, S; Bobrow, M; Marteau, TM			Psychological consequences for parents of false negative results on prenatal screening for Down's syndrome: retrospective interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NATIONAL REGISTER; ENGLAND; CHILD; WALES	Objective To determine the psychological consequences for parents of children with Down's syndrome of having received a false negative result on prenatal screening. Design Comparison of adjustment of parents who received a false negative result with that of parents not offered a test and those who declined a test. Setting Parents were interviewed in their own homes. Participants Parents of 179 children with Down's syndrome (mean age 4 (range 2-6) years). Main outcome measures Anxiety, depression, parenting stress, attitudes towards the child, and attributions of blame for the birth of the affected child. Results Overall, regardless of screening history, parents adjusted well to having a child with Down's syndrome. Compared with mothers who declined a test, mothers in the false negative group had higher parenting stress (mean score 81.2 v 71.8, P = 0.016, 95% confidence interval for the difference 1.8 to 17.0) and more negative attitudes towards their children (124.9 v 134.2, P = 0.009, -16.2 to -2.4). Fathers in the false negative group had higher parenting stress test scores (77.8 v 70.0, P = 0.046, 1.5 to 14.2) than fathers not offered a test Mothers in the false negative group were more likely to blame others for the outcome than mothers who had not been offered the test (28% v 13%, P = 0.032, 3% to 27%). Mothers and fathers in the false negative group were more likely to blame others for this outcome than parents who had declined a test (mothers 28% v 0%, P = 0.001, 19% to 37%; fathers 27% v 0%, P = 0.004, 17% to 38%). Blaming others was associated with poorer adjustment for mothers and fathers. Conclusions A false negative result on prenatal screening seems to have a small adverse effect on parental adjustment evident two to six years after the birth of an affected child.	Guys Kings Coll, Psychol & Genet Res Grp, London SE1 9RT, England; St Thomass Sch Med, London SE1 9RT, England; Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of London; King's College London; University of London; King's College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Marteau, TM (corresponding author), Guys Kings Coll, Psychol & Genet Res Grp, Thomas Guy House,Guys Campus, London SE1 9RT, England.	theresa.marteau@kcl.ac.uk	Sandall, Jane/D-4146-2009; Hall, Sue/C-3584-2009	Sandall, Jane/0000-0003-2000-743X; Marteau, Theresa/0000-0003-3025-1129				Abidin R.R., 1990, PARENTING STRESS IND; Allanson A, 1997, J Med Screen, V4, P21; Cockburn J, 1995, J Med Screen, V2, P224; GARDNER SB, 1989, STAT CONFIDENCE; Hall S, 1997, PSYCHOL HEALTH, V12, P579, DOI 10.1080/08870449708406733; JUDSON SL, 1980, CHILD CARE HLTH DEV, V6, P47, DOI 10.1111/j.1365-2214.1980.tb00796.x; MARTEAU TM, 1992, PUBLIC HEALTH, V106, P131, DOI 10.1016/S0033-3506(05)80390-7; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; MUTTON DE, 1991, BRIT MED J, V303, P1295, DOI 10.1136/bmj.303.6813.1295; MUTTON DE, 1993, BRIT MED J, V306, P431, DOI 10.1136/bmj.306.6875.431; PARSONS L, 1992, BRIT MED J, V305, P1228, DOI 10.1136/bmj.305.6863.1228-a; PETTIGREW M, IN PRESS HLTH TECHNO; QUINE L, 1991, J COMMUNITY APPL SOC, V1, P57, DOI 10.1002/casp.2450010109; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SMITH DK, 1994, BRIT MED J, V309, P776, DOI 10.1136/bmj.309.6957.776; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; TENNEN H, 1990, PSYCHOL BULL, V108, P209, DOI 10.1037/0033-2909.108.2.209; Wald N J, 1997, J Med Screen, V4, P181; Wald NJ, 1999, LANCET, V354, P1264, DOI 10.1016/S0140-6736(99)03819-2	19	51	51	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2000	320	7232					407	412		10.1136/bmj.320.7232.407	http://dx.doi.org/10.1136/bmj.320.7232.407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	285EU	10669444	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000085377400021
J	Petrov, DA; Sangster, TA; Johnston, JS; Hartl, DL; Shaw, KL				Petrov, DA; Sangster, TA; Johnston, JS; Hartl, DL; Shaw, KL			Evidence for DNA loss as a determinant of genome size	SCIENCE			English	Article							DROSOPHILA; EVOLUTION; PSEUDOGENES; RETROTRANSPOSONS; GENES	Eukaryotic genome sizes range over five orders of magnitude. This variation cannot be explained by differences in organismic complexity (the C value paradox). To test the hypothesis that some variation in genome size can be attributed to differences in the patterns of insertion and deletion (indel) mutations among organisms, this study examines the indel spectrum in Laupala crickets, which have a genome size 11 times larger than that of Drosophila. Consistent with the hypothesis. DNA Loss is more than 40 times slower in Laupala than in Drosophila.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA	Harvard University; Texas A&M University System; Texas A&M University College Station	Petrov, DA (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.			Petrov, Dmitri/0000-0002-3664-9130				BELDA JE, 1991, CYTOBIOS, V67, P13; CAVALIERSMITH T, 1985, EVOLUTION GENOME SIZ, P523; Charlesworth B, 1996, NATURE, V384, P315, DOI 10.1038/384315a0; Elgar G, 1996, TRENDS GENET, V12, P145, DOI 10.1016/0168-9525(96)10018-4; HUGHES AL, 1995, NATURE, V377, P391, DOI 10.1038/377391a0; JEFFS P, 1991, P ROY SOC B-BIOL SCI, V244, P151, DOI 10.1098/rspb.1991.0064; JOHN B, 1988, EUKARYOTIC GENOME DE; LI WH, 1981, NATURE, V292, P237, DOI 10.1038/292237a0; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MIRSKY AE, 1951, J GEN PHYSIOL, V34, P451, DOI 10.1085/jgp.34.4.451; MORIYAMA E, 1997, MOL BIOL EVOL, V15, P770; Ogata H, 1996, FEBS LETT, V390, P99, DOI 10.1016/0014-5793(96)00636-9; PETROV D, UNPUB; Petrov DA, 1998, MOL BIOL EVOL, V15, P1562, DOI 10.1093/oxfordjournals.molbev.a025883; Petrov DA, 1997, GENE, V205, P279, DOI 10.1016/S0378-1119(97)00516-7; Petrov DA, 1998, MOL BIOL EVOL, V15, P293, DOI 10.1093/oxfordjournals.molbev.a025926; Petrov DA, 1996, NATURE, V384, P346, DOI 10.1038/384346a0; RUDKIN GT, 1969, GENETICS, V61, P227; SanMiguel P, 1998, NAT GENET, V20, P43, DOI 10.1038/1695; SHARP PM, 1989, J MOL EVOL, V28, P398, DOI 10.1007/BF02603075; Shaw KL, 1996, EVOLUTION, V50, P237, DOI 10.1111/j.1558-5646.1996.tb04488.x; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; THINDWA HP, 1994, SOUTHWEST ENTOMOL, V19, P371; THOMAS CA, 1971, ANNU REV GENET, V5, P237, DOI 10.1146/annurev.ge.05.120171.001321; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.biochem.55.1.631; Wright DA, 1996, GENETICS, V142, P569; [No title captured]	27	256	271	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1060	1062		10.1126/science.287.5455.1060	http://dx.doi.org/10.1126/science.287.5455.1060			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669421				2022-12-01	WOS:000085245400053
J	Hata, A; Seoane, J; Lagna, G; Montalvo, E; Hemmati-Brivanlou, A; Massague, J				Hata, A; Seoane, J; Lagna, G; Montalvo, E; Hemmati-Brivanlou, A; Massague, J			OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways	CELL			English	Article							BONE MORPHOGENETIC PROTEINS; TGF-BETA; CRYSTAL-STRUCTURE; GENE-EXPRESSION; HOMEOBOX GENE; FUNCTIONAL-CHARACTERIZATION; TUMOR-SUPPRESSOR; XENOPUS MESODERM; TRANSCRIPTION; REGULATORS	We have identified the 30-zinc finger protein OAZ as a DNA-binding factor that associates with Smads in response to BMP2, forming a complex that transcriptionally activates the homeobox regulator of Xenopus mesoderm and neural development, Xvent-2. OAZ contains a BMP signaling module formed by two clusters of fingers that bind Smads and the Xvent-2 BMP response element, respectively. Previously implicated as a transcriptional partner of Olf-1/EBF in olfactory epithelium and lymphocyte development in the rat, OAZ fulfills this role through clusters of fingers that are separate from the BMP signaling module. The mutually exclusive use of OAZ by the BMP-smad and Olf pathways illustrates the dual role of a multi-zinc finger protein in signal transduction during development.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Rockefeller University	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.		Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974; Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA34610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HemmatiBrivanlou A, 1997, ANNU REV NEUROSCI, V20, P43, DOI 10.1146/annurev.neuro.20.1.43; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Klug A, 1999, J MOL BIOL, V293, P215, DOI 10.1006/jmbi.1999.3007; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Peters H, 1999, TRENDS GENET, V15, P59, DOI 10.1016/S0168-9525(98)01662-X; Rastegar S, 1999, MECH DEVELOP, V81, P139, DOI 10.1016/S0925-4773(98)00239-1; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shou J, 1999, NAT NEUROSCI, V2, P339, DOI 10.1038/7251; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Tang SJ, 1998, DEVELOPMENT, V125, P1877; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang ZJ, 1998, RNA, V4, P394; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	46	353	379	2	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					229	240		10.1016/S0092-8674(00)81561-5	http://dx.doi.org/10.1016/S0092-8674(00)81561-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660046	Bronze			2022-12-01	WOS:000084932200007
J	Barnes, DM; Miles, DW				Barnes, DM; Miles, DW			Response of metastatic breast cancer to trastuzumab?	LANCET			English	Editorial Material							MONOCLONAL-ANTIBODY; NEU ONCOGENE; PHASE-II		Guys Hosp, Imperial Canc Res Fund, Breast Pathol Lab, London SE1 9RT, England; Guys Hosp, Imperial Canc Res Fund, Breast Biol Grp, London SE1 9RT, England	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust	Barnes, DM (corresponding author), Guys Hosp, Imperial Canc Res Fund, Breast Pathol Lab, London SE1 9RT, England.							Allred DC, 1998, MODERN PATHOL, V11, P155; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Brenner T L, 1999, J Am Pharm Assoc (Wash), V39, P236; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Goldenberg MM, 1999, CLIN THER, V21, P309, DOI 10.1016/S0149-2918(00)88288-0; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; Jacobs TW, 1999, J CLIN ONCOL, V17, P1974, DOI 10.1200/JCO.1999.17.7.1974; Jacobs TW, 1999, J CLIN ONCOL, V17, P1983, DOI 10.1200/JCO.1999.17.7.1983; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; McNeil C, 1999, J NATL CANCER I, V91, P110, DOI 10.1093/jnci/91.2.110; NAINGGOLAN L, 1999, SCRIP, V2493, P21; NORTON L, 1999, P AM SOC CLIN ONCOL, V18; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Wisecarver JL, 1999, AM J CLIN PATHOL, V111, P299	16	15	17	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 15	2000	355	9199					160	161		10.1016/S0140-6736(99)00430-4	http://dx.doi.org/10.1016/S0140-6736(99)00430-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	276LR	10675110				2022-12-01	WOS:000084879700004
J	Bader, B; Kuhn, K; Owen, DJ; Waldmann, H; Wittinghofer, A; Kuhlmann, J				Bader, B; Kuhn, K; Owen, DJ; Waldmann, H; Wittinghofer, A; Kuhlmann, J			Bioorganic synthesis of lipid-modified proteins for the study of signal transduction	NATURE			English	Article							RAS LIPOPEPTIDES; BINDING-SITE; PRENYLATION; VESICLES; EXPRESSION; MEMBRANES; P21(RAS); DOMAIN; ESTER	Biological membranes define the boundaries of the cellular compartments in higher eukaryotes and are active in many processes such as signal transduction and vesicular transport. Although post-translational lipid modification of numerous proteins in signal transduction is crucial for biological function(1), analysis of protein-protein interactions has mainly focused on recombinant proteins in solution under defined in vitro conditions. Here we present a new strategy for the synthesis of such lipid-modified proteins. It involves the bacterial expression of a carboxy-terminally truncated non-lipidated protein, the chemical synthesis of differently lipidated peptides representing the C terminus of the proteins, and their covalent coupling. Our technique is demonstrated using Ras constructs, which exhibit properties very similar to fully processed Ras, but can be produced in high yields and are open for selective modifications. These constructs are operative in biophysical and cellular assay systems, showing specific recognition of effecters by Ras lipoproteins inserted into the membrane surface of biosensors and transforming activity of oncogenic variants aft er microinjection into cultured cells.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Univ Dortmund, D-44227 Dortmund, Germany	Max Planck Society; Dortmund University of Technology	Waldmann, H (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.		Waldmann, Herbert/B-7406-2017	Waldmann, Herbert/0000-0002-9606-7247; Bader, Benjamin/0000-0002-5299-396X; Owen, David/0000-0002-9165-1540				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; KALB E, 1992, BIOCHIM BIOPHYS ACTA, V1103, P307, DOI 10.1016/0005-2736(92)90101-Q; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Nagele E, 1998, J AM CHEM SOC, V120, P6889, DOI 10.1021/ja9805627; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Schelhaas M, 1999, CHEM-EUR J, V5, P1239, DOI 10.1002/(SICI)1521-3765(19990401)5:4<1239::AID-CHEM1239>3.0.CO;2-N; Schelhaas M, 1996, ANGEW CHEM INT EDIT, V35, P106, DOI 10.1002/anie.199601061; Schmidt G, 1996, ONCOGENE, V12, P87; Schmittberger T, 1998, CHEM COMMUN, P937, DOI 10.1039/a708749g; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Waddick KG, 1998, BIOCHEM PHARMACOL, V56, P1411, DOI 10.1016/S0006-2952(98)00211-1; Willumsen BM, 1996, ONCOGENE, V13, P1901; Wittinghofer A, 1998, BIOL CHEM, V379, P933	21	134	145	1	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					223	226		10.1038/35003249	http://dx.doi.org/10.1038/35003249			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646611				2022-12-01	WOS:000084835300062
J	Chiang, YPJ; Kole, HK; Brown, K; Naramura, M; Fukuhara, S; Hu, RJ; Jang, IK; Gutkind, JS; Shevach, E; Gu, H				Chiang, YPJ; Kole, HK; Brown, K; Naramura, M; Fukuhara, S; Hu, RJ; Jang, IK; Gutkind, JS; Shevach, E; Gu, H			Cbl-b regulates the CD28 dependence of T-cell activation	NATURE			English	Article							RECEPTOR TRANSGENIC MICE; SIGNAL-TRANSDUCTION; C-CBL; ANTIGEN RECEPTORS; DEFICIENT MICE; VAV; PROTOONCOGENE; THYMOCYTES; RESPONSES; PRODUCT	Whereas co-stimulation of the T-cell antigen receptor (TCR) and CD28 triggers T-cell activation, stimulation of the TCR alone may result in an anergic state or T-cell deletion, both possible mechanisms of tolerance induction(1,2), Here we show that T cells that are deficient in the adaptor molecule Cbl-b, (ref. 3) do not require CD28 engagement for interleukin-2 production, and that the Cbl-b-null mutation (Cbl-b(-/-)) fully res;tores T-cell-dependent antibody responses in CD28(-/-) mice. The main TCR signalling pathways, such as tyrosine kinases Zap-70 and Lck, Ras/mitogen-activated kinases, phospholipase C gamma-1 and Ca2+ mobilization, were not affected in Cbl-b(-/-) T cells. In contrast, the activation of Vav, a guanine nucleotide exchange factor for Rac1/Rho/CDC42, was significantly enhanced. Our findings indicate that Cbl-b may influence the CD28 dependence of T-cell activation by selectively suppressing TCR-mediated Vav activation, Mice deficient in Cbl-b are highly susceptible to experimental autoimmune encephalomyelitis, suggesting that the dysregulation of signalling pathways modulated by Cbl-b may also contribute to human autoimmune diseases such as multiple sclerosis.	NIAID, Immunol Lab, NIH, Rockville, MD 20852 USA; NIH, Bethesda, MD 20892 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gu, H (corresponding author), NIAID, Immunol Lab, NIH, 12441 Parklawn Dr, Rockville, MD 20852 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Jang, Ihn Kyung/0000-0001-8899-7930; Naramura, Mayumi/0000-0003-3658-0767	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Cantrell D, 1998, CURR BIOL, V8, pR535, DOI 10.1016/S0960-9822(07)00341-7; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Segal BM, 1998, J EXP MED, V187, P537, DOI 10.1084/jem.187.4.537; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zhang ZH, 1999, CURR BIOL, V9, P203, DOI 10.1016/S0960-9822(99)80090-6	26	465	488	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					216	220		10.1038/35003235	http://dx.doi.org/10.1038/35003235			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646609				2022-12-01	WOS:000084835300060
J	Koshiba-Takeuchi, K; Takeuchi, JK; Matsumoto, K; Momose, T; Uno, K; Hoepker, V; Ogura, K; Takahashi, N; Nakamura, H; Yasuda, K; Ogura, T				Koshiba-Takeuchi, K; Takeuchi, JK; Matsumoto, K; Momose, T; Uno, K; Hoepker, V; Ogura, K; Takahashi, N; Nakamura, H; Yasuda, K; Ogura, T			Tbx5 and the retinotectum projection	SCIENCE			English	Article							T-BOX GENES; TYROSINE KINASE; VISUAL-SYSTEM; EXPRESSION; RETINA; CHICK; FAMILY; DIFFERENTIATION; ARBORIZATION; EVOLUTION	Dorsal and ventral aspects of the eye are distinct from the early stages of development. The developing eye cup grows dorsally, and the choroidal fissure is formed on its ventral side. Retinal axone from the dorsal and ventral retina project to the ventral and dorsal tectum, respectively. Misexpression of the Tbx5 gene induced dorsalization of the ventral side of the eye and altered projections of retinal ganglion cell axons. Thus, Tbx5 is involved in eye morphogenesis and is a topographic determinant of the visual projections between retina and tectum.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Tohoku Univ, Dept Mol Neurobiol, Sendai, Miyagi 98077, Japan	Nara Institute of Science & Technology; University of California System; University of California San Diego; Tohoku University	Ogura, T (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.		MOMOSE, Tsuyoshi/D-2257-2011	Momose, Tsuyoshi/0000-0002-3806-3408				Agulnik SI, 1996, GENETICS, V144, P249; Barbieri AM, 1999, P NATL ACAD SCI USA, V96, P10729, DOI 10.1073/pnas.96.19.10729; Braisted JE, 1997, DEV BIOL, V191, P14, DOI 10.1006/dbio.1997.8706; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; CROSSLAND WJ, 1979, J COMP NEUROL, V185, P87, DOI 10.1002/cne.901850106; Dudley AT, 1997, DEV DYNAM, V208, P349; DUDLEY AT, 1997, GENE DEV, V11, P3254; Funahashi J, 1999, DEV GROWTH DIFFER, V41, P59; Furuta Y, 1998, GENE DEV, V12, P3764, DOI 10.1101/gad.12.23.3764; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; GIBSONBROWN JJ, 1998, MECH DEVELOP, V74, P65; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Hyatt GA, 1996, DEVELOPMENT, V122, P195; Hyatt GA, 1996, P NATL ACAD SCI USA, V93, P13298, DOI 10.1073/pnas.93.23.13298; JACOBSON M, 1967, SCIENCE, V155, P1106, DOI 10.1126/science.155.3766.1106; KOSHIBATAKEUCHI K, UNPUB; MEY J, 1992, J HIRNFORSCH, V33, P673; Momose T, 1999, DEV GROWTH DIFFER, V41, P335; MOTGAN BA, 1996, METHOD CELL BIOL, V51, P185; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NORNES HO, 1990, DEVELOPMENT, V109, P797; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; Ohsaki K, 1999, GENES CELLS, V4, P267, DOI 10.1046/j.1365-2443.1999.00257.x; Ohuchi H, 1998, DEVELOPMENT, V125, P51; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PFLUGFELDER GO, 1992, P NATL ACAD SCI USA, V89, P1199, DOI 10.1073/pnas.89.4.1199; Schmitt EA, 1996, J COMP NEUROL, V371, P222, DOI 10.1002/(SICI)1096-9861(19960722)371:2<222::AID-CNE3>3.0.CO;2-4; Szel A, 1996, MICROSC RES TECHNIQ, V35, P445; SZEL A, 1992, J COMP NEUROL, V325, P327, DOI 10.1002/cne.903250302; Takeuchi JK, 1999, NATURE, V398, P810, DOI 10.1038/19762; THANOS S, 1987, J COMP NEUROL, V261, P155, DOI 10.1002/cne.902610114; Yuasa J, 1996, NATURE, V382, P632, DOI 10.1038/382632a0	35	202	207	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					134	137		10.1126/science.287.5450.134	http://dx.doi.org/10.1126/science.287.5450.134			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615048				2022-12-01	WOS:000084578400053
J	Fricke, H; Hissmann, K; Schauer, J; Erdmann, M; Moosa, MK; Plante, R				Fricke, H; Hissmann, K; Schauer, J; Erdmann, M; Moosa, MK; Plante, R			Conservation - Biogeography of the Indonesian coelacanths	NATURE			English	Article							HOME		Max Planck Inst Verhaltensphysiol, D-82319 Seewiesen, Germany; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Indonesian Inst Sci, Jakarta 11048, Indonesia; Ctr Oceanol Marseille, Marine Endoume Stn, F-13007 Marseille, France	Max Planck Society; University of California System; University of California Berkeley; Indonesian Institute of Sciences	Fricke, H (corresponding author), Max Planck Inst Verhaltensphysiol, D-82319 Seewiesen, Germany.							Erdmann MV, 1998, NATURE, V395, P335, DOI 10.1038/26376; Forey P, 1998, NATURE, V395, P319, DOI 10.1038/26328; FRICKE H, 1994, MAR BIOL, V120, P171, DOI 10.1007/BF00349676; FRICKE HW, IN PRESS MAR BIOL; Gordon AL, 1996, NATURE, V379, P146, DOI 10.1038/379146a0; Holder MT, 1999, P NATL ACAD SCI USA, V96, P12616, DOI 10.1073/pnas.96.22.12616; Pouyaud L, 1999, CR ACAD SCI III-VIE, V322, P261, DOI 10.1016/S0764-4469(99)80061-4	7	21	24	1	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					38	38		10.1038/47400	http://dx.doi.org/10.1038/47400			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638741	Bronze			2022-12-01	WOS:000084687400031
J	Loitman, JE				Loitman, JE			Pain management: Beyond pharmacology to acupuncture and hypnosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Brown Univ, Sch Med, Providence, RI 02912 USA	Brown University	Loitman, JE (corresponding author), Brown Univ, Sch Med, Providence, RI 02912 USA.							Blumberg D L, 1995, Altern Ther Health Med, V1, P31; BROSE W, 1992, AM PSYCHIAT PRESS TX; Crock RD, 1999, ALTERN THER HEALTH M, V5, P61; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Freeman J W, 1997, S D J Med, V50, P65; KELLERMAN J, 1983, J ADOLESC HLTH CARE, V4, P35; LEWIT K, 1979, PAIN, V6, P83, DOI 10.1016/0304-3959(79)90142-8; MELZACK R, 1977, PAIN, V3, P3, DOI 10.1016/0304-3959(77)90032-X; Montbriand MJ, 1998, CANCER NURS, V21, P36, DOI 10.1097/00002820-199802000-00005; MORGAN AH, 1973, INT J CLIN EXP HYP, V21, P78, DOI 10.1080/00207147308409308; National Institutes of Health, 1995, INT BEH REL APPR TRE, P1; *NIH, 1997, NIH CONS DEV C AC; Pomeranz B, 1996, J Altern Complement Med, V2, P53, DOI 10.1089/acm.1996.2.53; PORTENOY RK, 1992, LANCET, V339, P1026, DOI 10.1016/0140-6736(92)90545-E; Reston, 1971, NY TIMES, P1; Reston J, 1971, NY TIMES, V1, P6; Ulett GA, 1998, SOUTHERN MED J, V91, P1115, DOI 10.1097/00007611-199812000-00004	17	3	4	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					118	119		10.1001/jama.283.1.118	http://dx.doi.org/10.1001/jama.283.1.118			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632295	hybrid			2022-12-01	WOS:000084514400040
J	Leibovici, L				Leibovici, L			Alternative (complementary) medicine: a cuckoo in the nest of empiricist reed warblers	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Rabin Med Ctr, Dept Internal Med E, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center	Leibovici, L (corresponding author), Rabin Med Ctr, Dept Internal Med E, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.	leibovic@post.tau.ac.il						Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Kilner RM, 1999, NATURE, V397, P667, DOI 10.1038/17746; Mock DW, 1999, NATURE, V397, P647, DOI 10.1038/17679; Rigas B, 1999, LANCET, V354, P1634, DOI 10.1016/S0140-6736(99)06034-1; Vickers A, 1999, BRIT MED J, V319, P1050, DOI 10.1136/bmj.319.7216.1050; Zollman C, 1999, BRIT MED J, V319, P1486, DOI 10.1136/bmj.319.7223.1486; Zollman C, 1999, BRIT MED J, V319, P693, DOI 10.1136/bmj.319.7211.693; Zollman C, 1999, BRIT MED J, V319, P836, DOI 10.1136/bmj.319.7213.836; Zollman C, 1999, BRIT MED J, V319, P1558, DOI 10.1136/bmj.319.7224.1558; ZOLLMAN C, 1999, BRIT MED J, V319, P1254; ZOLLMAN C, 1999, BRIT MED J, V319, P1176; ZOLLMAN C, 1999, BRIT MED J, V319, P973; ZOLLMAN C, 1999, BRIT MED J, V319, P1419; ZOLLMAN C, 1999, BRIT MED J, V319, P1115	16	15	16	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 25	1999	319	7225					1629	1631		10.1136/bmj.319.7225.1629	http://dx.doi.org/10.1136/bmj.319.7225.1629			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600974	Green Published			2022-12-01	WOS:000084562600025
J	Niwa, M; Sidrauski, C; Kaufman, RJ; Walter, P				Niwa, M; Sidrauski, C; Kaufman, RJ; Walter, P			A role for presenilin-1 in nuclear accumulation of Ire1 fragments and induction of the mammalian unfolded protein response	CELL			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; TRANSFER-RNA LIGASE; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; MISSENSE MUTATIONS; PATHWAY; KINASE	The unfolded protein response (UPR) mediates signaling from the endoplasmic reticulum to the nucleus. In yeast, a key regulatory step in the UPR is the spliceosome-independent splicing of HAC1 mRNA encoding a UPR-specific transcription factor, which is initiated by the transmembrane kinase/endoribonuclease Ire1. We show that yeast HAC1 mRNA is correctly spliced in mammalian cells upon UPR induction and that mammalian Ire1 can precisely cleave both splice junctions. Surprisingly, UPR induction leads to proteolytic cleavage of Ire1, releasing fragments containing the kinase and nuclease domains that accumulate in the nucleus. Nuclear localization and UPR induction are reduced in presenilin-1 knockout cells. These results suggest that the salient features of the UPR are conserved among eukaryotic cells and that presenilin-1 controls Ire1 proteolysis in mammalian cells.	Univ Calif San Francisco, Howard Hughes Med Inst, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Med, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Walter, P (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Sch Med, San Francisco, CA 94143 USA.		Longo, Kenneth A/A-5631-2010					Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ERICKSON AH, 1979, J BIOL CHEM, V254, P1771; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HAZE K, 1999, IN PRESS MOL BIOL CE; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Nikawa J, 1996, NUCLEIC ACIDS RES, V24, P4222, DOI 10.1093/nar/24.21.4222; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1998, CURR BIOL, V8, pR121, DOI 10.1016/S0960-9822(98)70986-8; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1997, P NATL ACAD SCI USA, V94, P4289, DOI 10.1073/pnas.94.9.4289; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	42	237	250	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					691	702		10.1016/S0092-8674(00)81667-0	http://dx.doi.org/10.1016/S0092-8674(00)81667-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619423	Bronze			2022-12-01	WOS:000084488200003
J	Shay, JW; Wright, WE				Shay, JW; Wright, WE			Molecular biology - Mutant dyskerin ends relationship with telomerase	SCIENCE			English	Editorial Material							DYSKERATOSIS		Univ Texas, SW Med Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shay, JW (corresponding author), Univ Texas, SW Med Ctr, Dallas, TX 75390 USA.		Shay, Jerry W/F-7878-2011					Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Dokal I, 1999, J PEDIAT HEMATOL ONC, V21, P344, DOI 10.1097/00043426-199909000-00002; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Kickhoefer VA, 1999, J BIOL CHEM, V274, P32712, DOI 10.1074/jbc.274.46.32712; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Luzzatto L, 1998, NAT GENET, V19, P6, DOI 10.1038/ng0598-6; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Price CM, 1999, CURR OPIN GENET DEV, V9, P218, DOI 10.1016/S0959-437X(99)80032-X	10	26	26	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2284	2285		10.1126/science.286.5448.2284	http://dx.doi.org/10.1126/science.286.5448.2284			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10636790				2022-12-01	WOS:000084318500037
J	Smith, DM; Tabin, CJ				Smith, DM; Tabin, CJ			Developmental biology - BMP signalling specifies the pyloric sphincter	NATURE			English	Article							GUT		Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Smith, DM (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.							Buchberger A, 1996, MECH DEVELOP, V56, P151, DOI 10.1016/0925-4773(96)00521-7; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Natsume T, 1997, J BIOL CHEM, V272, P11535; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; Romanoff A.L., 1960, THE AVIAN EMBRYO; Zakany J, 1999, NATURE, V401, P761, DOI 10.1038/44511; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	11	34	36	2	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					748	749		10.1038/45439	http://dx.doi.org/10.1038/45439			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617196				2022-12-01	WOS:000084330500044
J	Ernst, E				Ernst, E			Second thoughts about safety of St John's wort	LANCET			English	Editorial Material									Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England	University of Exeter	Ernst, E (corresponding author), Univ Exeter, Sch Postgrad Med & Hlth Sci, Dept Complementary Med, Exeter EX2 4NT, Devon, England.							AJOHNE A, 1999, JAHR KLIN PHARM BERL; BON S, 1999, SCHWEITZER APOTHEKER, V16, P535; Brevoort P., 1998, HerbalGram, P33; ERESHEFSKY B, 1999, P 39 ANN M NEW CLIN; GEWERTZ N, P 39 ANN M NEW CLIN; Harrison P, 1998, CAN MED ASSOC J, V158, P637; Lantz MS, 1999, J GERIATR PSYCH NEUR, V12, P7, DOI 10.1177/089198879901200103; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Martin TG, 1996, ANN EMERG MED, V28, P520, DOI 10.1016/S0196-0644(96)70116-6; MAURER A, 1999, EUR J CLIN PHARMACOL, V55, pA22; Muller WE, 1997, PHARMACOPSYCHIATRY, V30, P102, DOI 10.1055/s-2007-979528; Nebel A, 1999, ANN PHARMACOTHER, V33, P502, DOI 10.1345/aph.18252; Rey JM, 1998, MED J AUSTRALIA, V169, P583, DOI 10.5694/j.1326-5377.1998.tb123424.x; ROBY CA, 1999, P 39 ANN M NEW CLIN; Stevinson C, 1999, CNS DRUGS, V11, P125, DOI 10.2165/00023210-199911020-00004	15	221	229	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1999	354	9195					2014	2016		10.1016/S0140-6736(99)00418-3	http://dx.doi.org/10.1016/S0140-6736(99)00418-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636361				2022-12-01	WOS:000084183300004
J	Liu, S; Thomas, SM; Woodside, DG; Rose, DM; Kiosses, WB; Pfaff, M; Ginsberg, MH				Liu, S; Thomas, SM; Woodside, DG; Rose, DM; Kiosses, WB; Pfaff, M; Ginsberg, MH			Binding of paxillin to alpha(4) integrins modifies integrin-dependent biological responses	NATURE			English	Article							SUBUNIT CYTOPLASMIC DOMAINS; FOCAL ADHESION KINASE; CELL-MIGRATION; PROTEIN; SRC; ASSOCIATION; ROLES; FYN	The alpha(4) integrins are indispensable for embryogenesis, haematopoiesis and immune responses(1,2), possibly because a4 regulates cellular functions differently from other integrins through its cytoplasmic tail(3). We used novel mimics(4) of the alpha(4) tail to identify molecules that could account for alpha(4)-specific signalling. Here we report that the alpha(4) tail, but not several other alpha-subunit tails, binds tightly to the signalling adaptor paxillin, Paxillin physically associated with alpha(4) integrins in Jurkat T cells at high stoichiometry, and joining the alpha(4) tail to alpha(IIb) resulted in a complex of integrin alpha(IIb)beta(3) With paxillin. This association markedly enhanced the rates of alpha(IIb)beta(3)-dependent phosphorylation of focal adhesion kinase and cell migration. It also reduced cell spreading, focal adhesion and stress fibre formation. A point mutation within the alpha(4) tail that disrupts paxillin binding reversed all of these effects. Furthermore, alpha(4)beta(1)-dependent adhesion to VCAM-1 led to spreading of mouse embryonic fibroblasts derived from paxillin-null but not from wild-type mice. Thus, the tight association of paxillin with the alpha(4) tail leads to distinct biochemical and biological responses to integrin-mediated cell adhesion.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Scripps Research Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, VB-2,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN YP, 1994, BLOOD, V84, P1857; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Hagmann J, 1998, J CELL SCI, V111, P2181; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HEMLER ME, 1992, COLD SPRING HARB SYM, V57, P213, DOI 10.1101/SQB.1992.057.01.026; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	29	278	291	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					676	681		10.1038/45264	http://dx.doi.org/10.1038/45264			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604475				2022-12-01	WOS:000084189800069
J	Lancaster, CRD; Kroger, A; Auer, M; Michel, H				Lancaster, CRD; Kroger, A; Auer, M; Michel, H			Structure of fumarate reductase from Wolinella succinogenes at 2.2 angstrom resolution	NATURE			English	Article							PHOSPHORYLATIVE ELECTRON-TRANSPORT; SITE-DIRECTED MUTAGENESIS; FREE R-VALUE; SUCCINATE-DEHYDROGENASE; VIBRIO-SUCCINOGENES; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; COMPLEX; REFINEMENT; EXPRESSION	Fumarate reductase couples the reduction of fumarate to succinate to the oxidation of quinol to quinone, in a reaction opposite to that catalysed by the related complex II of the respiratory chain (succinate dehydrogenase). Here we describe the crystal structure at 2.2 Angstrom resolution of the three protein subunits containing fumarate reductase from the anaerobic bacterium Wolinella succinogenes, Subunit A contains the site of fumarate reduction and a covalently bound flavin adenine dinucleotide prosthetic group. Subunit B contains three iron-sulphur centres, The menaquinol-oxidizing subunit C consists of five membrane-spanning, primarily helical segments and binds two haem b molecules. On the basis of the structure, we propose a pathway of electron transfer from the dihaem cytochrome b to the site of fumarate reduction and a mechanism of fumarate reduction. The relative orientations of the soluble and membrane-embedded subunits of succinate:quinone oxidoreductases appear to be unique.	Max Planck Inst Biophys, D-60528 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany	Max Planck Society; Goethe University Frankfurt	Lancaster, CRD (corresponding author), Max Planck Inst Biophys, Heinrich Hoffman Str 7, D-60528 Frankfurt, Germany.	lancaster@mpibp-frankfurt.mpg.de	Lancaster, C. Roy/E-4313-2010	Lancaster, C. Roy D./0000-0002-2814-0051				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRONDER M, 1982, ARCH MICROBIOL, V131, P216, DOI 10.1007/BF00405882; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; COWTAN K, 1994, JOINT CCP4 ESF EACBM, V30, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FLACHMANN R, 1988, EUR J BIOCHEM, V175, P221, DOI 10.1111/j.1432-1033.1988.tb14187.x; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KENNEY WC, 1977, FEBS LETT, V73, P239, DOI 10.1016/0014-5793(77)80989-7; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; KORTNER C, 1990, MOL MICROBIOL, V4, P855, DOI 10.1111/j.1365-2958.1990.tb00657.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROGER A, 1978, BIOCHIM BIOPHYS ACTA, V505, P129, DOI 10.1016/0304-4173(78)90010-1; KROGER A, 1992, ARCH MICROBIOL, V158, P311, DOI 10.1007/BF00245358; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; Lancaster CRD, 1999, BIOCHEM SOC T, V27, P591, DOI 10.1042/bst0270591; LAUTERBACH F, 1990, ARCH MICROBIOL, V154, P386, DOI 10.1007/BF00276536; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Mattevi A, 1999, STRUCTURE, V7, P745, DOI 10.1016/S0969-2126(99)80099-9; MCPHERSON A, 1999, CRYSTALLIZATION BIOL, P304; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SALERNO JC, 1991, BIOCHEM SOC T, V19, P599, DOI 10.1042/bst0190599; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; Simon J, 1998, EUR J BIOCHEM, V251, P418, DOI 10.1046/j.1432-1327.1998.2510418.x; SINGER TP, 1984, METHOD ENZYMOL, V106, P369; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TSIOTIS G, 1994, PRACTICAL GUIDE MEMB, P149; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; UNDEN G, 1980, FEBS LETT, V117, P323, DOI 10.1016/0014-5793(80)80972-0; UNDEN G, 1980, BIOCHIM BIOPHYS ACTA, V591, P275, DOI 10.1016/0005-2728(80)90159-0; UNDEN G, 1984, BIOCHIM BIOPHYS ACTA, V767, P460, DOI 10.1016/0005-2728(84)90044-6; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P6749, DOI 10.1073/pnas.78.11.6749; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	50	304	315	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					377	385		10.1038/46483	http://dx.doi.org/10.1038/46483			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586875				2022-12-01	WOS:000083913600046
J	Jin, T; Zhang, N; Long, Y; Parent, CA; Devreotes, PN				Jin, T; Zhang, N; Long, Y; Parent, CA; Devreotes, PN			Localization of the G protein beta gamma complex in living cells during chemotaxis	SCIENCE			English	Article							DICTYOSTELIUM-DISCOIDEUM; TEMPORAL MECHANISM; RECEPTORS; SUBUNIT; LEUKOCYTES; GRADIENTS; RESPONSES; FREQUENCY; DIMERS; AMEBAE	Gradients of chemoattractants elicit signaling events at the Leading edge of a cell even though chemoattractant receptors are uniformly distributed on the cell surface. In highly polarized Dictyostelium discoideum amoebas, membrane-associated beta gamma subunits of heterotrimeric guanine nucleotide-binding proteins (G proteins) were localized in a shallow anterior-posterior gradient. A uniformly applied chemoattractant generated binding sites for pleckstrin homology (PH) domains on the inner surface of the membrane in a pattern similar to that of the G beta gamma subunits. Loss of cell polarity resulted in uniform distribution of both the G beta gamma subunits and the sensitivity of PH domain recruitment. There observations indicate that G beta gamma subunits are not sufficiently localized to restrict signaling events to the Leading edge but that their distribution may determine the relative chemotactic sensitivity of polarized cells.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Devreotes, PN (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.				NIGMS NIH HHS [GM-28007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010418, Z01BC010418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028007, R37GM028007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; BOURNE H, COMMUNICATION; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cellbio.4.1.649; FISHER PR, 1989, J CELL BIOL, V108, P973, DOI 10.1083/jcb.108.3.973; Jin T, 1998, EMBO J, V17, P5076, DOI 10.1093/emboj/17.17.5076; Jin T, 1998, MOL BIOL CELL, V9, P2949, DOI 10.1091/mbc.9.10.2949; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; MEDEN U, 1995, J BIOL CHEM, V270, P15892; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Meinhardt H, 1999, J CELL SCI, V112, P2867; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SWANSON JA, 1982, CELL, V28, P225, DOI 10.1016/0092-8674(82)90340-3; VARNUMFINNEY B, 1987, CELL MOTIL CYTOSKEL, V8, P7, DOI 10.1002/cm.970080103; VARNUMFINNEY BJ, 1987, CELL MOTIL CYTOSKEL, V8, P18, DOI 10.1002/cm.970080104; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; Zhang N.F., UNPUB; ZIGMOND SH, 1981, J CELL BIOL, V89, P585, DOI 10.1083/jcb.89.3.585; ZIGMOND SH, 1977, J CELL BIOL, V75, P606, DOI 10.1083/jcb.75.2.606	26	233	239	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1034	1036		10.1126/science.287.5455.1034	http://dx.doi.org/10.1126/science.287.5455.1034			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669414				2022-12-01	WOS:000085245400046
J	Chen, MS; Huber, AB; van der Haar, ME; Frank, M; Schnell, L; Spillmann, AA; Christ, F; Schwab, ME				Chen, MS; Huber, AB; van der Haar, ME; Frank, M; Schnell, L; Spillmann, AA; Christ, F; Schwab, ME			Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1	NATURE			English	Article							GROWTH-INHIBITORS; GENE; RAT; EXPRESSION; PROTEIN; IDENTIFICATION; TRANSCRIPTS; RECOVERY; SEQUENCE; CLONING	The capacity of the adult brain and spinal cord to repair lesions by axonal regeneration or compensatory fibre growth is extremely Limited. A monoclonal antibody (IN-1) raised against NI-220/250, a myelin protein that is a potent inhibitor of neurite growth, promoted axonal regeneration and compensatory plasticity following lesions of the central nervous system (CNS) in adult rats(1-4). Here we report the cloning of nogo A, the rat complementary DNA encoding NI-220/250. The nogo gene encodes at least three major protein products (Nogo-A, -B and -C), Recombinant Nogo-A is recognized by monoclonal antibody IN-1, and it inhibits neurite outgrowth from dorsal root ganglia and spreading of 3T3 fibroblasts in an IN-1-sensitive manner. Antibodies against Nogo-A stain CNS myelin and oligodendrocytes and allow dorsal root ganglion neurites to grow on CNS myelin and into optic nerve explants. These data show that Nogo-A is a potent inhibitor of neurite growth and an IN-1 antigen produced by oligodendrocytes, and may allow the generation of new reagents to enhance CNS regeneration and plasticity.	Univ Zurich, Inst Brain Res, Dept Neuromorphol, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, CH-8057 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Schwab, ME (corresponding author), Univ Zurich, Inst Brain Res, Dept Neuromorphol, CH-8057 Zurich, Switzerland.		Schwab, Martin E/B-6818-2016					BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen M. S., 1999, Society for Neuroscience Abstracts, V25, P2030; Geisler JG, 1998, MAMM GENOME, V9, P274, DOI 10.1007/s003359900748; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; Morris NJ, 1999, BBA-PROTEIN STRUCT M, V1431, P525, DOI 10.1016/S0167-4838(99)00068-0; NAGASE T, 1998, DNA RES, V5, P169; Ninkina NN, 1997, GENE, V184, P205, DOI 10.1016/S0378-1119(96)00596-3; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; Roebroek AJM, 1996, GENOMICS, V32, P191, DOI 10.1006/geno.1996.0105; RUBIN BP, 1994, J NEUROCYTOL, V23, P209, DOI 10.1007/BF01275525; SCHAERENWIEMERS N, 1995, J NEUROSCI, V15, P5753; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WIECZOREK DF, 1991, MOL BRAIN RES, V10, P33, DOI 10.1016/0169-328X(91)90053-Z	19	1167	1346	2	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					434	439		10.1038/35000219	http://dx.doi.org/10.1038/35000219			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667796				2022-12-01	WOS:000085121100052
J	Johanson, R				Johanson, R			Perineal massage for prevention of perineal trauma in childbirth	LANCET			English	Editorial Material							EPISIOTOMY; LACERATION		N Staffordshire Matern Hosp, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England	University Hospital of North Staffordshire NHS Trust	Johanson, R (corresponding author), N Staffordshire Matern Hosp, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England.							AVERY MD, 1987, J NURSE-MIDWIFERY, V32, P181, DOI 10.1016/0091-2182(87)90095-4; AVERY MD, 1986, J NURSE-MIDWIFERY, V31, P128, DOI 10.1016/0091-2182(86)90148-5; CARROLI G, 1999, COCHRANE LIB; Graham I. D., 1997, EPISIOTOMY CHALLENGI; KETTLE C, 1999, PERINEAL TEARS; KETTLE C, 1999, CLIN EVID, V2, P522; Klein MC, 1997, AM J OBSTET GYNECOL, V176, P403, DOI 10.1016/S0002-9378(97)70506-4; KLEIN MC, 1994, AM J OBSTET GYNECOL, V171, P591, DOI 10.1016/0002-9378(94)90070-1; Labrecque M, 1999, AM J OBSTET GYNECOL, V180, P593, DOI 10.1016/S0002-9378(99)70260-7; LABRECQUE M, 1994, BIRTH-ISS PERINAT C, V21, P20, DOI 10.1111/j.1523-536X.1994.tb00911.x; McCandlish R, 1998, BRIT J OBSTET GYNAEC, V105, P1262, DOI 10.1111/j.1471-0528.1998.tb10004.x; Renfrew MJ, 1998, BIRTH-ISS PERINAT C, V25, P143; Shipman MK, 1997, BRIT J OBSTET GYNAEC, V104, P787, DOI 10.1111/j.1471-0528.1997.tb12021.x	13	25	27	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					250	251		10.1016/S0140-6736(00)00020-9	http://dx.doi.org/10.1016/S0140-6736(00)00020-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	279LQ	10675069				2022-12-01	WOS:000085045600005
J	Daily, GC; Walker, BH				Daily, GC; Walker, BH			Seeking the great transition	NATURE			English	Editorial Material									Stanford Univ, Dept Biol Sci, Ctr Conservat Biol, Stanford, CA 94305 USA; CSIRO, Canberra, ACT 2601, Australia	Stanford University; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Daily, GC (corresponding author), Stanford Univ, Dept Biol Sci, Ctr Conservat Biol, Stanford, CA 94305 USA.		Walker, Brian H/F-2386-2011					[Anonymous], 1997, NATURES SERVICES; Daily GC, 1996, ECOL APPL, V6, P991, DOI 10.2307/2269582; DAILY GC, UNPUB SCI; Dunphy D. C., 1998, SUSTAINABLE CORPORAT; ELKINGTON J, 1999, PEOPLE PLANET, V8, P10; Hackel JD, 1999, CONSERV BIOL, V13, P726, DOI 10.1046/j.1523-1739.1999.98210.x; Hawken P., 1999, NATURAL CAPITALISM C; Hawken Paul., 1993, ECOLOGY COMMERCE DEC; James AN, 1999, NATURE, V401, P323, DOI 10.1038/43774; Levin S., 1999, FRAGILE DOMINION; MCNEELY JA, 1999, MOBILIZING BROADER S; Myers N, 1998, PERVERSE SUBSIDIES T; National Research Council, 1999, OUR COMM JOURN TRANS; RAVEN PH, IN PRESS FRONTIERS M; Richards D. J, 1997, IND GREEN GAME IMPLI; Romm Joseph J., 1999, COOL COMPANIES BEST; ROSENBLATT R, 1999, CONSUMING DESIRES CO; SASSEVILLE DR, 1997, ISO 14000 ANSWER BOO; Schmidheiny S., 1992, CHANGING COURSE GLOB; Schulze PC, 1999, MEASURES ENV PERFORM, P1; *SIERR BUS COUNC, 1996, SIERR NEV WEALTH IND; Socolow R, 1994, IND ECOLOGY GLOBAL C; Wackernagel M., 1996, OUR ECOLOGICAL FOOTP; Wilkinson P, 1998, NATURE, V396, P511, DOI 10.1038/24979	24	23	26	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					243	245		10.1038/35002194	http://dx.doi.org/10.1038/35002194			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659827				2022-12-01	WOS:000084899700022
J	Rhew, RC; Miller, BR; Weiss, RF				Rhew, RC; Miller, BR; Weiss, RF			Natural methyl bromide and methyl chloride emissions from coastal salt marshes	NATURE			English	Article							HIGHER-PLANTS; BIOSYNTHESIS; METHANE; HALOMETHANES; FLUX	Atmospheric methyl bromide (CH3Br) and methyl chloride (CH3Cl), compounds that are involved in stratospheric ozone depletion, originate from both natural and anthropogenic sources. Current estimates of CH3Br and CH3Cl emissions from oceanic sources, terrestrial plants and fungi, biomass burning and anthropogenic inputs do not balance their losses owing to oxidation by hydroxyl radicals, oceanic degradation, and consumption in soils, suggesting that additional natural terrestrial sources may be important(1). Here we show that CH3Br and CH3Cl are released to the atmosphere from all vegetation zones of two coastal salt marshes. We see very large fluxes of CH3Br and CH3Cl per unit area: up to 42 and 570 mu mol m(-2) d(-1), respectively. The fluxes show large diurnal, seasonal and spatial variabilities, but there is a strong correlation between the fluxes of CH3Br and those of CH3Cl, with an average molar flux ratio of roughly 1:20. If our measurements are typical of salt marshes globally, they suggest that such ecosystems, even though they constitute less than 0.1% of the global surface area(2), may produce roughly 10% of the total fluxes of atmospheric CH3Br and CH3Cl.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Rhew, RC (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.		Rhew, Robert C/M-8110-2016	Rhew, Robert C/0000-0001-6358-2050; Miller, Benjamin/0000-0003-1647-0122				ALONGI D, 1998, COASTAL ECOSYSTEM PR; ATTIEH JM, 1995, J BIOL CHEM, V270, P9250, DOI 10.1074/jbc.270.16.9250; BARTLETT KB, 1985, J GEOPHYS RES-ATMOS, V90, P5710, DOI 10.1029/JD090iD03p05710; DELAUNE RD, 1983, TELLUS B, V35, P8, DOI 10.1111/j.1600-0889.1983.tb00002.x; Gan J, 1998, GEOPHYS RES LETT, V25, P3595, DOI 10.1029/98GL52697; HARPER DB, 1985, NATURE, V315, P55, DOI 10.1038/315055a0; Kurylo MJ, 1999, SCI ASSESSMENT OZONE, P21; Livingston G.P., 1995, BIOGENIC TRACE GASES, P14; MANLEY SL, 1988, MAR BIOL, V98, P477, DOI 10.1007/BF00391538; Miller BR, 1998, J GEOPHYS RES-ATMOS, V103, P13237, DOI 10.1029/98JD00771; MILLER BR, 1998, THESIS U CALIFORNIA; SAINI HS, 1995, PLANT CELL ENVIRON, V18, P1027, DOI 10.1111/j.1365-3040.1995.tb00613.x; Saxena D, 1998, APPL ENVIRON MICROB, V64, P2831; Scarratt MG, 1996, MAR CHEM, V54, P263, DOI 10.1016/0304-4203(96)00036-9; STEELE LP, 1987, J ATMOS CHEM, V5, P125, DOI 10.1007/BF00048857; Varner RK, 1999, GEOPHYS RES LETT, V26, P2433, DOI 10.1029/1999GL900587; Watling R, 1998, MYCOL RES, V102, P769, DOI 10.1017/S0953756298006157; Wingenter OW, 1998, GEOPHYS RES LETT, V25, P2797, DOI 10.1029/98GL02179; WOODWELL GM, 1973, BROOKHAVEN S BIOL SE, V24, P221; WUOSMAA AM, 1990, SCIENCE, V249, P160, DOI 10.1126/science.2371563; Zedler, 1982, FWSOBS8154 US FISH W	21	206	219	3	62	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					292	295		10.1038/35002043	http://dx.doi.org/10.1038/35002043			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659844				2022-12-01	WOS:000084899700047
J	Yack, JE; Fullard, JH				Yack, JE; Fullard, JH			Ultrasonic hearing in nocturnal butterflies	NATURE			English	Article									Carleton Univ, Dept Biol, Ottawa, ON K1S 5B6, Canada; Carleton Univ, Coll Nat Sci, Ottawa, ON K1S 5B6, Canada; Univ Toronto, Dept Zool, Mississauga, ON L5L 1C6, Canada; Univ Toronto, Erindale Coll, Mississauga, ON L5L 1C6, Canada	Carleton University; Carleton University; University of Toronto; University Toronto Mississauga; University of Toronto; University Toronto Mississauga	Yack, JE (corresponding author), Carleton Univ, Dept Biol, Ottawa, ON K1S 5B6, Canada.	jyack@ccs.carleton.ca						Conner WE, 1999, J EXP BIOL, V202, P1711; FULALRD JH, 1998, COMP HEARING INSECTS, P279; HOY R, 1989, J EXP BIOL, V146, P287; Jacobs K, 1999, J EXP ZOOL, V283, P270, DOI 10.1002/(SICI)1097-010X(19990215)283:3&lt;270::AID-JEZ5&gt;3.0.CO;2-C; Kristensen N.P., 1998, HDB ZOOLOGY, V1, P7; NOVACEK MJ, 1985, NATURE, V315, P140, DOI 10.1038/315140a0; OTERO LD, 1990, B ENTOMOL VENEZ, V5, P128; Ribaric Darja, 1996, Acta Entomologica Slovenica, V4, P5; Scoble M.J., 1986, Bulletin of the British Museum (Natural History) Entomology, V53, P251; SCOBLE MJ, 1990, J NAT HIST, V24, P159, DOI 10.1080/00222939000770101; SILBERGLIED RE, 1984, BIOL BUTTERFLIES, P207; Vogel R, 1912, Z WISS ZOOL ABT A, V100, P210; YACK JE, 1993, ANN ENTOMOL SOC AM, V86, P677, DOI 10.1093/aesa/86.6.677	13	49	51	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2000	403	6767					265	266		10.1038/35002247	http://dx.doi.org/10.1038/35002247			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659835				2022-12-01	WOS:000084899700037
J	Liu, QH; Wang, LM; Frutos, AG; Condon, AE; Corn, RM; Smith, LM				Liu, QH; Wang, LM; Frutos, AG; Condon, AE; Corn, RM; Smith, LM			DNA computing on surfaces	NATURE			English	Article							COMBINATORIAL TECHNOLOGIES; DRUG DISCOVERY; AMPLIFICATION; HYBRIDIZATION; COMPUTATION; BETAINE; ARRAYS; DESIGN; GOLD	DNA computing was proposed(1) as a means of solving a class of intractable computational problems in which the computing time can grow exponentially with problem size (the 'NP-complete' or non-deterministic polynomial time complete problems). The principle of the technique has been demonstrated experimentally for a simple example of the hamiltonian path problem(2) (in this case, finding an airline flight path between several cities, such that each city is visited only once(3)). DNA computational approaches to the solution of other problems have also been investigated(4-9). One technique(10-13) involves the immobilization and manipulation of combinatorial mixtures of DNA on a support. A set of DNA molecules encoding all candidate solutions to the computational problem of interest is synthesized and attached to the surface. Successive cycles of hybridization operations and exonuclease digestion are used to identify and eliminate those members of the set that are not solutions. Upon completion of all the multistep cycles, the solution to the computational problem is identified using a polymerase chain reaction to amplify the remaining molecules, which are then hybridized to an addressed array. The advantages of this approach are its scalability and potential to be automated (the use of solid-phase formats simplifies the complex repetitive chemical processes, as has been demonstrated in DNA and protein synthesis(14)). Here we report the use of this method to solve a NP-complete problem. We consider a small example of the satisfiability problem (SAT)(2), in which the values of a set of boolean variables satisfying certain logical constraints are determined.	Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Comp Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Smith, LM (corresponding author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.			Corn, Robert/0000-0002-4756-2161				Adleman LM, 1998, SCI AM, V279, P54, DOI 10.1038/scientificamerican0898-54; ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; BAIN CD, 1989, J AM CHEM SOC, V111, P321, DOI 10.1021/ja00183a049; Baskaran N, 1996, GENOME RES, V6, P633, DOI 10.1101/gr.6.7.633; BONEH D, 1999, DIMACS SERIES DISCRE, V44, P163; CAI W, 1997, P 1 ANN INT C COMP M; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Farrell RE, 1997, IMMUNOL INVEST, V26, P3, DOI 10.3109/08820139709048910; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Frutos AG, 1997, NUCLEIC ACIDS RES, V25, P4748, DOI 10.1093/nar/25.23.4748; Frutos AG, 1998, J AM CHEM SOC, V120, P10277, DOI 10.1021/ja982030w; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; Garey M.R., 1979, COMPUTERS INTRACTABI; GILLMOR SD, UNPUB LANGMUIR; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; Guarnieri F, 1996, SCIENCE, V273, P220, DOI 10.1126/science.273.5272.220; GUO Z, 1994, NUCLEIC ACIDS RES, V22, P5456, DOI 10.1093/nar/22.24.5456; Jordan CE, 1997, ANAL CHEM, V69, P4939, DOI 10.1021/ac9709763; Karp RM, 1999, RANDOM STRUCT ALGOR, V15, P450, DOI 10.1002/(SICI)1098-2418(199910/12)15:3/4<450::AID-RSA12>3.0.CO;2-2; LIPTON RJ, 1995, SCIENCE, V268, P542, DOI 10.1126/science.7725098; Lyamichev V, 1999, NAT BIOTECHNOL, V17, P292, DOI 10.1038/7044; MORIMOTO N, 1997, P DIMACS DNA BASED C, V3, P83; OGIHARA M, 1996, 629 TR U ROCH DEP CO; Ouyang Q, 1997, SCIENCE, V278, P446, DOI 10.1126/science.278.5337.446; Pippenger N., 1990, P S PURE MATH, V50, P311; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; SCHONING U, 1999, P 40 ANN IEEE S FDN, P410; Seeman NC, 1998, NANOTECHNOLOGY, V9, P257, DOI 10.1088/0957-4484/9/3/018; SMITH LM, 1988, ANAL CHEM, V60, pA381, DOI 10.1021/ac00157a001; Smith LM, 1998, J COMPUT BIOL, V5, P255, DOI 10.1089/cmb.1998.5.255; Voss KO, 1998, ANAL CHEM, V70, P3818, DOI 10.1021/ac980067t; Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998; YOSHIDA H, 1999, PRELIMINARY P DIMACS, V5, P9	33	404	510	2	88	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					175	179		10.1038/35003155	http://dx.doi.org/10.1038/35003155			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	275TB	10646598				2022-12-01	WOS:000084835300049
J	Donati, M; Seyedzadeh, H; Leung, T; Blott, M; Zuckerman, M				Donati, M; Seyedzadeh, H; Leung, T; Blott, M; Zuckerman, M			Prevalence of antibody to human T cell leukaemia/lymphoma virus in women attending antenatal clinic in southeast London: retrospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Kings Coll Hosp London, Guys Kings & St Thomass Sch Med, Dept Virol, Publ Hlth Lab, London SE22 8QF, England; Kings Healthcare Trust, Dept Obstet & Gynaecol, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Zuckerman, M (corresponding author), Kings Coll Hosp London, Guys Kings & St Thomass Sch Med, Dept Virol, Publ Hlth Lab, London SE22 8QF, England.	mark.zuckerman@kcl.ac.uk						Department of Health, 1998, PREV HIV ENGL WAL 19; Ferreira OC, 1997, BLOOD REV, V11, P91, DOI 10.1016/S0268-960X(97)90015-1; *INT WORK PART ENH, 1998, RED MOTH CHILD TRANS; NIGHTINGALE S, 1993, EPIDEMIOL INFECT, V110, P370; Takezaki Toshiro, 1997, Leukemia (Basingstoke), V11, P60	5	10	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 8	2000	320	7227					92	93		10.1136/bmj.320.7227.92	http://dx.doi.org/10.1136/bmj.320.7227.92			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274CR	10625263	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000084746600018
J	Hwang, J; Krebs, C; Huynh, BH; Edmondson, DE; Theil, EC; Penner-Hahn, JE				Hwang, J; Krebs, C; Huynh, BH; Edmondson, DE; Theil, EC; Penner-Hahn, JE			A short Fe-Fe distance in peroxodiferric ferritin: Control of Fe substrate versus cofactor decay?	SCIENCE			English	Article							X-RAY ABSORPTION; DINUCLEAR IRON CENTER; METHANE MONOOXYGENASE; RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; MODEL COMPLEXES; O-2 ACTIVATION; DIAMOND CORE; INTERMEDIATE; ENZYMES	The reaction of oxygen with protein diiron sites is important in bioorganic syntheses and biomineralization. An unusually short Fe-Fe distance of 2.53 angstroms was found in the diiron (mu-1,2 peroxodiferric) intermediate that forms in the early steps of ferritin biomineralization. This distance suggests the presence of a unique triply bridged structure. The Fe-Fe distances in the mu-1,2 peroxodiferric complexes that were characterized previously are much longer (3.1 to 4.0 angstroms). The 2.53 angstrom Fe-Fe distance requires a small Fe-O-O angle (similar to 106 degrees to 107 degrees). This geometry should favor decay of the peroxodiferric complex by the release of H2O2 and mu-oxo or mu-hydroxo diferric biomineral precursors rather than by oxidation of the organic substrate. Geometrical differences may thus explain how diiron sites can function either as a substrate (in ferritin biomineralization) or as a cofactor (in O-2 activation).	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Emory Univ, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	University of Michigan System; University of Michigan; Emory University; Emory University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Penner-Hahn, JE (corresponding author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.	jeph@umidh.edu	Penner-Hahn, James/GYD-3750-2022; Krebs, Carsten/D-4773-2009	Penner-Hahn, James/0000-0003-0314-1274; Krebs, Carsten/0000-0002-3302-7053	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058778, R01GM047295, R01GM045205] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45205, GM-47295, GM-58778] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN MJ, 1992, J AM CHEM SOC, V114, P10421, DOI 10.1021/ja00052a043; Bollinger JM, 1998, J AM CHEM SOC, V120, P1094, DOI 10.1021/ja973651c; BOSSEK U, 1990, J AM CHEM SOC, V112, P6387, DOI 10.1021/ja00173a031; Broadwater JA, 1998, BIOCHEMISTRY-US, V37, P14664, DOI 10.1021/bi981839i; Broadwater JA, 1999, BIOCHEMISTRY-US, V38, P12197, DOI 10.1021/bi9914199; Brunold TC, 1998, J AM CHEM SOC, V120, P5674, DOI 10.1021/ja980129x; Caudle MT, 1996, INORG CHEM, V35, P3577, DOI 10.1021/ic951462u; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; DICKEY LF, 1987, J BIOL CHEM, V262, P7901; Dong YH, 1997, J AM CHEM SOC, V119, P12683, DOI 10.1021/ja973115k; Dong YH, 1996, ANGEW CHEM INT EDIT, V35, P618, DOI 10.1002/anie.199606181; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; Fetter J, 1997, J BIOL INORG CHEM, V2, P652, DOI 10.1007/s007750050180; Ha Y, 1999, J BIOL INORG CHEM, V4, P243, DOI 10.1007/s007750050310; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; KAUZLARICH SM, 1986, INORG CHEM, V25, P2781, DOI 10.1021/ic00236a025; Kim K, 1996, J AM CHEM SOC, V118, P4914, DOI 10.1021/ja9604370; LARSON E, 1992, INORG CHEM, V31, P373, DOI 10.1021/ic00029a008; LING JS, 1994, J AM CHEM SOC, V116, P7682, DOI 10.1021/ja00096a027; LIU KE, 1995, J AM CHEM SOC, V117, P10174, DOI 10.1021/ja00146a002; LIU WT, 1993, INORG CHEM, V32, P4102, DOI 10.1021/ic00071a023; Moenne-Loccoz P, 1999, BIOCHEMISTRY-US, V38, P5290, DOI 10.1021/bi990095l; Moenne-Loccoz P, 1998, BIOCHEMISTRY-US, V37, P14659, DOI 10.1021/bi981838q; Ookubo T, 1996, J AM CHEM SOC, V118, P701, DOI 10.1021/ja953705n; Pereira AS, 1998, BIOCHEMISTRY-US, V37, P9871, DOI 10.1021/bi980847w; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; Riggs-Gelasco PJ, 1998, J AM CHEM SOC, V120, P849, DOI 10.1021/ja9718230; RIGGSGELASCO PJ, 1995, COORDIN CHEM REV, V144, P245, DOI 10.1016/0010-8545(95)01144-E; RIGGSGELASCO PJ, 1994, THESIS U MICHIGAN; ROE AL, 1984, J AM CHEM SOC, V106, P1676, DOI 10.1021/ja00318a021; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; Treffry A, 1998, FEBS LETT, V432, P213, DOI 10.1016/S0014-5793(98)00867-9; TREFFRY A, 1995, BIOCHEMISTRY-US, V34, P15204, DOI 10.1021/bi00046a028; Valentine AM, 1999, J AM CHEM SOC, V121, P3876, DOI 10.1021/ja9839522; Waldo G. S., 1996, COMPREHENSIVE SUPRAM, V5, P65; WALDO GS, 1993, BIOCHEMISTRY-US, V32, P13262, DOI 10.1021/bi00211a039; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Westre TE, 1997, J AM CHEM SOC, V119, P6297, DOI 10.1021/ja964352a; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a	39	157	162	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					122	125		10.1126/science.287.5450.122	http://dx.doi.org/10.1126/science.287.5450.122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615044				2022-12-01	WOS:000084578400049
J	Walhout, AJM; Sordella, R; Lu, XW; Hartley, JL; Temple, GF; Brasch, MA; Thierry-Mieg, N; Vidal, M				Walhout, AJM; Sordella, R; Lu, XW; Hartley, JL; Temple, GF; Brasch, MA; Thierry-Mieg, N; Vidal, M			Protein interaction mapping in C-elegans using proteins involved in vulval development	SCIENCE			English	Article							PAPILLOMAVIRUS TYPE-16 E1; CELL-CYCLE REGULATORS; MAP KINASE CASCADE; CAENORHABDITIS-ELEGANS; GENOME; EXPRESSION; PATHWAY; MEMBERS; LIN-15; FAMILY	Protein interaction mapping using large-scale two-hybrid analysis has been proposed as a way to functionally annotate large numbers of uncharacterized proteins predicted by complete genome sequences. This approach was examined in Caenorhabditis elegans, starting with 27 proteins involved in vulval development. The resulting map reveals both known and new potential interactions and provides a functional annotation for approximately 100 uncharacterized gene products. A protein interaction mapping project is now feasible for C. elegans on a genome-wide scale and should contribute to the understanding of molecular mechanisms in this organism and in human diseases.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Life Technol Inc, Rockville, MD 20850 USA; Lab LSR IMAG, F-38402 St Martin Dheres, France	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Thermo Fisher Scientific	Vidal, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Genet, 44 Binney St, Boston, MA 02115 USA.	Marc_Vidal@DFCI.Harvard.edu	Thierry-Mieg, Nicolas/M-6007-2014	Thierry-Mieg, Nicolas/0000-0002-7667-2853	NATIONAL CANCER INSTITUTE [R21CA081658] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001715] Funding Source: NIH RePORTER; NCI NIH HHS [1 R21 CA81658 A 01] Funding Source: Medline; NHGRI NIH HHS [1 RO1 HG01715-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		[Anonymous], 1997, NATURE, V387, pS; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; CHOI KY, 1994, CELL, V78, P499; CLARK SG, 1994, GENETICS, V137, P987; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DURBIN R, 1994, COMPUTATIONAL METHOD; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Evangelista C, 1996, TRENDS CELL BIOL, V6, P196, DOI 10.1016/0962-8924(96)40002-2; FERGUSON EL, 1989, GENETICS, V123, P109; Fields S, 1997, NAT GENET, V15, P325, DOI 10.1038/ng0497-325; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; HARTLEY JL, UNPUB; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lu X., UNPUB; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; PRINTEN JA, 1994, GENETICS, V138, P609; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; RHODES MA, UNPUB; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Solari F, 1999, DEVELOPMENT, V126, P2483; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Thomas JH, 1999, DEVELOPMENT, V126, P3449; Vidal M, 1999, NUCLEIC ACIDS RES, V27, P919, DOI 10.1093/nar/27.4.919; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Vidal M, 1997, ADV MOLEC BIOL, P109; Walhout AJM, 1999, GENOME RES, V9, P1128, DOI 10.1101/gr.9.11.1128; WALHOUT AJM, IN PRESS METHODS ENZ; WALHOUT ALJM, UNPUB; Walhout M, 1998, AM J HUM GENET, V63, P955, DOI 10.1086/302078; Wood WB, 1988, NEMATODE CAENORHABDI; Wu GY, 1998, P NATL ACAD SCI USA, V95, P15787, DOI 10.1073/pnas.95.26.15787; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yasugi T, 1997, J VIROL, V71, P5942, DOI 10.1128/JVI.71.8.5942-5951.1997; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997	58	567	645	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2000	287	5450					116	122		10.1126/science.287.5450.116	http://dx.doi.org/10.1126/science.287.5450.116			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615043				2022-12-01	WOS:000084578400048
J	Yang, X; Li, W; Prescott, ED; Burden, SJ; Wang, JC				Yang, X; Li, W; Prescott, ED; Burden, SJ; Wang, JC			DNA topoisomerase II beta and neural development	SCIENCE			English	Article							HUMAN FIBROBLASTS; INHIBITORS; REPAIR; RECOMBINATION; CEREVISIAE; EXCISION; SOMITE; MUSCLE; YEAST; RDNA	DNA topoisomerase II beta is shown to have an unsuspected and critical role in neural development. Neurogenesis was normal in II beta mutant mice, but motor axons failed to contact skeletal muscles, and sensory axons failed to enter the spinal cord. Despite an absence of innervation, clusters of acetylcholine receptors were concentrated in the central region of skeletal muscles, thereby revealing patterning mechanisms that are autonomous to skeletal muscle. The defects in motor axon growth in II beta mutant mice resulted in a breathing impairment and death of the pups shortly after birth.	NYU, Sch Med, Skirball Inst Mol Med, New York, NY 10016 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	New York University; Harvard University	Yang, X (corresponding author), NYU, Sch Med, Skirball Inst Mol Med, 540 1st Ave, New York, NY 10016 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027963, R01NS041311, F32NS010537, R37NS036193, R01NS036193] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS041311-03, NS10537, R01 NS036193, NS36193, R01 NS036193-02, NS27963, R01 NS041311] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; CHEN M, 1995, ONCOL RES, V7, P103; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Dereuddre S, 1997, CANCER RES, V57, P4301; Dietrich S, 1998, DEVELOPMENT, V125, P2235; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GODEMENT P, 1987, DEVELOPMENT, V101, P697; Grue P, 1998, J BIOL CHEM, V273, P33660, DOI 10.1074/jbc.273.50.33660; Hogan B., 2014, MANIPULATING MOUSE E; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; Kablar B, 1999, DEV BIOL, V208, P93, DOI 10.1006/dbio.1998.9184; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; Kobayashi M, 1998, MOL CELL BIOL, V18, P6737, DOI 10.1128/MCB.18.11.6737; LEWIS J, 1981, J EMBRYOL EXP MORPH, V64, P211; Ordahl CP, 1998, BIOESSAYS, V20, P357, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;357::AID-BIES1&gt;3.0.CO;2-L; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; POPANDA O, 1992, CARCINOGENESIS, V13, P2321, DOI 10.1093/carcin/13.12.2321; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; THIELMANN HW, 1993, CARCINOGENESIS, V14, P2341, DOI 10.1093/carcin/14.11.2341; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WILLIAMS PE, 1971, J CELL SCI, V9, P751; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; Yang X., UNPUB	32	289	296	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					131	134		10.1126/science.287.5450.131	http://dx.doi.org/10.1126/science.287.5450.131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10615047				2022-12-01	WOS:000084578400052
J	Abrahm, JL				Abrahm, JL			The role of the clinician in palliative medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Abrahm, JL (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.							Abrahm JL, 1999, ANN INTERN MED, V131, P37, DOI 10.7326/0003-4819-131-1-199907060-00009; Buckman R., 1992, BREAK BAD NEWS GUIDE; *WHO, 1990, WHO TECHN REP SER, V804	3	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2000	283	1					116	116		10.1001/jama.283.1.116	http://dx.doi.org/10.1001/jama.283.1.116			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270AZ	10632293	hybrid			2022-12-01	WOS:000084514400038
J	Chen, LL; Sigler, PB				Chen, LL; Sigler, PB			The crystal structure of a GroEL/peptide complex: Plasticity as a basis for substrate diversity	CELL			English	Article							BACTERIAL CHAPERONIN GROEL; POLYPEPTIDE BINDING; VIRAL PEPTIDES; CENTRAL CAVITY; PROTEIN; CONFORMATIONS; 2.8-ANGSTROM; INTERMEDIATE; RESOLUTION; MECHANISM	The chaperonin GroEL is a double toriodal assembly that with its cochaperonin GroES facilitates protein folding with an ATP-dependent mechanism. Nonnative conformations of diverse protein substrates bind to the apical domains surrounding the opening of the double toroid's central cavity. Using phage display, we have selected peptides with high affinity for the isolated apical domain. We have determined the crystal structures of the complexes formed by the most strongly bound peptide with the isolated apical domain, and with GroEL. The peptide interacts with the groove between paired or helices in a manner similar to that of the GroES mobile loop. Our structural analysis, combined with other results, suggests that various modes of molecular plasticity are responsible for tight promiscuous binding of nonnative substrates and their release into the shielded cis assembly.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA	Yale University; Howard Hughes Medical Institute; Yale University	Sigler, PB (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06511 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015225, R37GM015225] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Chatellier J, 1999, J MOL BIOL, V292, P163, DOI 10.1006/jmbi.1999.3040; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; ELLIS RJ, 1996, CHAPERONINS; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobayashi N, 1999, J MOL BIOL, V292, P181, DOI 10.1006/jmbi.1999.3042; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; LIPPENS G, 1995, J BIOMOL NMR, V5, P327, DOI 10.1007/BF00211762; Ma JP, 1998, P NATL ACAD SCI USA, V95, P8502, DOI 10.1073/pnas.95.15.8502; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Tanaka N, 1999, J MOL BIOL, V292, P173, DOI 10.1006/jmbi.1999.3041; Thiyagarajan P, 1996, STRUCTURE, V4, P79, DOI 10.1016/S0969-2126(96)00011-1; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Xu ZH, 1998, J STRUCT BIOL, V124, P129, DOI 10.1006/jsbi.1998.4060; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	47	199	203	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					757	768		10.1016/S0092-8674(00)81673-6	http://dx.doi.org/10.1016/S0092-8674(00)81673-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619429	Bronze			2022-12-01	WOS:000084488200009
J	Dunton, CJ; Berd, D				Dunton, CJ; Berd, D			Vulvar melanoma, biologically different from other cutaneous melanomas	LANCET			English	Editorial Material							MALIGNANT-MELANOMA		Thomas Jefferson Univ Hosp, Div Gynecol Oncol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ Hosp, Div Med Oncol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Dunton, CJ (corresponding author), Thomas Jefferson Univ Hosp, Div Gynecol Oncol, Philadelphia, PA 19107 USA.							BACCHI CE, 1992, GYNECOL ONCOL, V46, P216, DOI 10.1016/0090-8258(92)90258-K; Berd D, 1997, J CLIN ONCOL, V15, P2359, DOI 10.1200/JCO.1997.15.6.2359; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Cagir B, 1999, DIS COLON RECTUM, V42, P1203, DOI 10.1007/BF02238576; CHUNG AF, 1975, OBSTET GYNECOL, V45, P638, DOI 10.1097/00006250-197506000-00008; CLARK WH, 1969, CANCER RES, V29, P705; DAVIDSON T, 1987, BRIT J OBSTET GYNAEC, V94, P473, DOI 10.1111/j.1471-0528.1987.tb03128.x; LOOK KY, 1993, CANCER, V72, P143, DOI 10.1002/1097-0142(19930701)72:1<143::AID-CNCR2820720127>3.0.CO;2-M; MASTRANGELO MJ, 1979, HUMAN MALIGNANT MELA; PIURA B, 1992, J SURG ONCOL, V50, P234, DOI 10.1002/jso.2930500408; Ragnarsson-Olding BK, 1999, CANCER, V86, P1285, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1285::AID-CNCR25>3.0.CO;2-P; Ragnarsson-Olding BK, 1999, CANCER, V86, P1273, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1273::AID-CNCR24>3.0.CO;2-Z; ROGO K O, 1991, European Journal of Gynaecological Oncology, V12, P113; ROSE PG, 1988, AM J OBSTET GYNECOL, V159, P52, DOI 10.1016/0002-9378(88)90493-0; TASSERON EWK, 1992, GYNECOL ONCOL, V46, P170, DOI 10.1016/0090-8258(92)90250-M; TRIMBLE EL, 1992, GYNECOL ONCOL, V45, P254, DOI 10.1016/0090-8258(92)90300-8	16	19	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1999	354	9195					2013	2014		10.1016/S0140-6736(99)00390-6	http://dx.doi.org/10.1016/S0140-6736(99)00390-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264LG	10636360				2022-12-01	WOS:000084183300003
J	Karl, DM; Bird, DF; Bjorkman, K; Houlihan, T; Shackelford, R; Tupas, L				Karl, DM; Bird, DF; Bjorkman, K; Houlihan, T; Shackelford, R; Tupas, L			Microorganisms in the accreted ice of Lake Vostok, Antarctica	SCIENCE			English	Article							MICROBIAL ECOLOGY; ORGANIC-CARBON; EUROPA; SEAWATER; BACTERIA; OCEAN; WATER	Analysis of a portion of Vostok ice core number 5G, which is thought to contain frozen water derived from Lake Vostok, Antarctica (a body of liquid water located beneath about 4 kilometers of glacial ice), revealed between 2 x 10(2) and 3 x 10(2) bacterial cells per milliliter and Low concentrations of potential growth nutrients, Lipopolysaccharide (a Gram-negative bacterial cell biomarker) was also detected at concentrations consistent with the cell enumeration data, which suggests a predominance of Gram-negative bacteria. At Least a portion of the microbial assemblage was viable, as determined by the respiration of carbon-14-labeled acetate and glutose substrates during incubations at 3 degrees C and 1 atmosphere. These accreted ice data suggest that Lake Vostok may contain viable microorganisms.	Univ Hawaii Manoa, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA; Univ Quebec, Dept Sci Biol, Montreal, PQ H3C 3P8, Canada	University of Hawaii System; University of Hawaii Manoa; University of Quebec; University of Quebec Montreal	Karl, DM (corresponding author), Univ Hawaii Manoa, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA.		Karl, David/AFP-3837-2022	Karl, David/0000-0002-6660-6721				Abyzov SS, 1998, MICROBIOLOGY+, V67, P451; AZAM F, 1979, SCIENCE, V203, P451, DOI 10.1126/science.203.4379.451; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; Chapman CR, 1999, SCIENCE, V283, P338, DOI 10.1126/science.283.5400.338; CHRISTIAN JR, 1994, J GEOPHYS RES-OCEANS, V99, P14269, DOI 10.1029/94JC00681; DALZIEL I, 1999, LAK VOST WORKSH FIN, P17; Fukuda R, 1998, APPL ENVIRON MICROB, V64, P3352; HOBBIE JE, 1969, LIMNOL OCEANOGR, V14, P528, DOI 10.4319/lo.1969.14.4.0528; HOLMHANSEN O, 1975, NASA, P75; JANNASCH HW, 1979, BIOSCIENCE, V29, P592, DOI 10.2307/1307765; Jouzel J, 1999, SCIENCE, V286, P2138, DOI 10.1126/science.286.5447.2138; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; Karl David M., 1998, P29; KARL DM, 1982, APPL ENVIRON MICROB, V44, P891, DOI 10.1128/AEM.44.4.891-902.1982; KARL DM, 1980, MICROBIOL REV, V44, P739, DOI 10.1128/MMBR.44.4.739-796.1980; KARL DM, 1980, SCIENCE, V207, P1345, DOI 10.1126/science.207.4437.1345; Karl DM, 1995, MICR EXTREM UNUSUAL, P35; KENNICUTT MC, 1999, LAK VOST WORKSH FIN, P26; Legrand M, 1997, REV GEOPHYS, V35, P219, DOI 10.1029/96RG03527; MAEDA M, 1979, J APPL BACTERIOL, V47, P175, DOI 10.1111/j.1365-2672.1979.tb01182.x; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; MONGER BC, 1993, APPL ENVIRON MICROB, V59, P905, DOI 10.1128/AEM.59.3.905-911.1993; Noble RT, 1998, AQUAT MICROB ECOL, V14, P113, DOI 10.3354/ame014113; OSWALD GKA, 1973, NATURE, V245, P251, DOI 10.1038/245251a0; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; PETIT JR, 1999, LAK VOST WORKSH FIN, P16; Priscu JC, 1999, SCIENCE, V286, P2141, DOI 10.1126/science.286.5447.2141; Qian JG, 1996, ANAL CHEM, V68, P3090, DOI 10.1021/ac960370z; SHACKELFORD RP, 1998, THESIS U HAWAII; SHARP JH, 1995, MAR CHEM, V48, P91, DOI 10.1016/0304-4203(94)00040-K; Siegert MJ, 1996, ANTARCT SCI, V8, P281, DOI 10.1017/S0954102096000405; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; Takacs CD, 1998, MICROBIAL ECOL, V36, P239, DOI 10.1007/s002489900111; WATSON SW, 1977, APPL ENVIRON MICROB, V33, P940, DOI 10.1128/AEM.33.4.940-946.1977; WATSON SW, 1979, NATIVE AQUATIC BACTE, P82	35	235	252	0	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2144	2147		10.1126/science.286.5447.2144	http://dx.doi.org/10.1126/science.286.5447.2144			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591643				2022-12-01	WOS:000084157300048
J	Maechler, P; Wollheim, CB				Maechler, P; Wollheim, CB			Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis	NATURE			English	Article							BRAIN SYNAPTIC VESICLES; PANCREATIC BETA-CELLS; SECRETORY VESICLE; RAT-BRAIN; CA2+; DEHYDROGENASE; TRANSPORT; FORMS	The hormone insulin is stored in secretory granules and released from the pancreatic beta-cells by exocytosis(1). In the consensus model of glucose-stimulated insulin secretion, ATP is generated by mitochondrial metabolism, promoting closure of ATP-sensitive potassium (K-ATP) channels, which depolarizes the plasma membrane(2,3). Subsequently, opening of voltage-sensitive Ca2+ channels increases the cytosolic Ca2+ concentration ([Ca2+](c)) which constitutes the main trigger initiating insulin exocytosis(1,3.4), Nevertheless, the Ca2+ signal alone is not sufficient for sustained secretion. Furthermore, glucose elicits a secretory response under conditions of damped, elevated [Ca2+](c) (refs 5, 6), A mitochondrial messenger must therefore exist which is distinct from ATP(7,8). We have identified this as glutamate, We show that glucose generates glutamate from beta-cell mitochondria, A membrane-permeant glutamate analogue sensitizes the glucose-evoked secretory response, acting downstream of mitochondrial metabolism. In permeabilized cells, under conditions of fixed [Ca2+](c), added glutamate directly stimulates insulin exocytosis, independently of mitochondrial function. Glutamate uptake by the secretory granules is likely to be involved, as inhibitors of vesicular glutamate transport suppress the glutamate-evoked exocytosis. These results demonstrate that glutamate acts as an intracellular messenger that couples glucose metabolism to insulin secretion.	Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Maechler, P (corresponding author), Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland.	pierre.maechler@medecine.unige.ch		Maechler, Pierre/0000-0002-2005-1433				ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; CHO SW, 1995, EUR J BIOCHEM, V233, P340, DOI 10.1111/j.1432-1033.1995.340_1.x; CHURCHER Y, 1990, CELL REGUL, V1, P337, DOI 10.1091/mbc.1.4.337; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; FISHER HF, 1985, METHOD ENZYMOL, V113, P16; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; Janjic D, 1996, PANCREAS, V13, P166, DOI 10.1097/00006676-199608000-00008; Jena BP, 1997, P NATL ACAD SCI USA, V94, P13317, DOI 10.1073/pnas.94.24.13317; JOHNSON RG, 1987, ANN NY ACAD SCI, V493, P162, DOI 10.1111/j.1749-6632.1987.tb27198.x; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; Ozkan ED, 1998, JPN J PHARMACOL, V77, P1, DOI 10.1254/jjp.77.1; ROISIN MP, 1980, FEBS LETT, V115, P143, DOI 10.1016/0014-5793(80)80745-9; ROSETH S, 1995, J NEUROCHEM, V65, P96; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; SENER A, 1994, AM J PHYSIOL-ENDOC M, V267, pE573, DOI 10.1152/ajpendo.1994.267.4.E573; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; WOLLHEIM CB, 1996, DIABETES REV, V4, P276	29	411	417	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1999	402	6762					685	689		10.1038/45280	http://dx.doi.org/10.1038/45280			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604477	Green Published			2022-12-01	WOS:000084189800071
J	Tsodyks, M; Kenet, T; Grinvald, A; Arieli, A				Tsodyks, M; Kenet, T; Grinvald, A; Arieli, A			Linking spontaneous activity of single cortical neurons and the underlying functional architecture	SCIENCE			English	Article							CAT VISUAL-CORTEX; ISO-ORIENTATION DOMAINS; ELECTRICAL-ACTIVITY; ONGOING ACTIVITY; CEREBRAL-CORTEX; ORGANIZATION; PATTERNS; CONNECTIONS; DYNAMICS; STATES	The relation between the activity of a single neocortical neuron and the dynamics of the network in which it is embedded was explored by single-unit recordings and real-time optical imaging. The firing rate of a spontaneously active single neuron strongly depends on the instantaneous spatial pattern of ongoing population activity in a Large cortical area. Very similar spatial patterns of population activity were observed both when the neuron fired spontaneously and when it was driven by its optimal stimulus. The evoked patterns could be used to reconstruct the spontaneous activity of single neurons.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Ctr Studies Higher Brain Funct, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Grinvald, A (corresponding author), Weizmann Inst Sci, Dept Neurobiol, POB 26, IL-76100 Rehovot, Israel.		tsodyks, misha/J-4430-2013	Tsodyks, Misha/0000-0002-5661-4349				Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; ABELES M, 1995, P NATL ACAD SCI USA, V92, P8616, DOI 10.1073/pnas.92.19.8616; Abeles M., 1982, LOCAL CORTICAL CIRCU; Ahmed B, 1998, CEREB CORTEX, V8, P462, DOI 10.1093/cercor/8.5.462; Amit DJ, 1997, CEREB CORTEX, V7, P237, DOI 10.1093/cercor/7.3.237; Amit DJ, 1989, MODELING BRAIN FUNCT, DOI 10.1017/CBO9780511623257; ARIELI A, 1995, J NEUROPHYSIOL, V73, P2072, DOI 10.1152/jn.1995.73.5.2072; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; ARIELI A, 1992, INFORMATION PROCESSI, P123; BenYishai R, 1997, J COMPUT NEUROSCI, V4, P57, DOI 10.1023/A:1008816611284; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; Destexhe A, 1999, J NEUROSCI, V19, P4595, DOI 10.1523/jneurosci.19-11-04595.1999; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FREEMAN WJ, 1985, BRAIN RES REV, V10, P147, DOI 10.1016/0165-0173(85)90022-0; GILBERT CD, 1993, CEREB CORTEX, V3, P373, DOI 10.1093/cercor/3.5.373; GRINVALD A, 1994, J NEUROSCI, V14, P2545; GRINVALD A, 1982, J PHYSIOL-LONDON, V333, P269, DOI 10.1113/jphysiol.1982.sp014453; GRINVALD A, 1984, NATURE, V308, P848, DOI 10.1038/308848a0; Grinvald A, 1999, MODERN TECHNIQUES NE, P893, DOI 10.1007/978-3-642-58552-4_34; Hansel D., 1998, METHODS NEURONAL MOD, P499; Hertz J, 1991, INTRO THEORY NEURAL; HUBEL DH, 1977, NATURE, V269, P328, DOI 10.1038/269328a0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IIJIMA T, 1992, NEUROSCIENCE, V51, P211, DOI 10.1016/0306-4522(92)90486-L; Lampl I, 1999, NEURON, V22, P361, DOI 10.1016/S0896-6273(00)81096-X; LEGENDY CR, 1985, J NEUROPHYSIOL, V53, P926, DOI 10.1152/jn.1985.53.4.926; MALACH R, 1994, CEREB CORTEX, V4, P151, DOI 10.1093/cercor/4.2.151; NODA H, 1970, BRAIN RES, V18, P672; ORBACH HS, 1983, J NEUROSCI, V3, P2251; PAISLEY AC, 1984, PROG NEUROBIOL, V22, P155, DOI 10.1016/0301-0082(84)90024-8; SALIN PA, 1995, PHYSIOL REV, V75, P107, DOI 10.1152/physrev.1995.75.1.107; SANSEVERINO E R, 1973, Brain Research, V54, P225; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SHOHAM D, IN PRESS NEURON; SILLITO AM, 1980, BRAIN RES, V194, P517, DOI 10.1016/0006-8993(80)91234-2; SINGER W, 1994, INT REV NEUROBIOL, V37, P153; SOFTKY WR, 1993, J NEUROSCI, V13, P334; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; Tsodyks M., 1995, NETWORK, V6, P1; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; ULLMAN S, 1995, CEREB CORTEX, V5, P1, DOI 10.1093/cercor/5.1.1; vanVreeswijk C, 1996, SCIENCE, V274, P1724, DOI 10.1126/science.274.5293.1724; WEBB AC, 1976, PROC R SOC SER B-BIO, V194, P239, DOI 10.1098/rspb.1976.0076	46	504	508	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1943	1946		10.1126/science.286.5446.1943	http://dx.doi.org/10.1126/science.286.5446.1943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583955				2022-12-01	WOS:000084003400048
J	Dunham, I; Shimizu, N; Roe, BA; Chissoe, S; Dunham, I; Hunt, AR; Collins, JE; Bruskiewich, R; Beare, DM; Clamp, M; Smink, LJ; Ainscough, R; Almeida, JP; Babbage, A; Bagguley, C; Balley, J; Barlow, K; Bates, KN; Beasley, O; Bird, CP; Blakey, S; Bridgeman, AM; Buck, D; Burgess, J; Burrill, WD; Burton, J; Carder, C; Carter, NP; Chen, Y; Clark, G; Clegg, SM; Cobley, V; Cole, CG; Collier, RE; Connor, RE; Conroy, D; Corby, N; Coville, GJ; Cox, AV; Davis, J; Dawson, E; Dhami, PD; Dockree, C; Dodsworth, SJ; Durbin, RM; Ellington, A; Evans, KL; Fey, JM; Fleming, K; French, L; Garner, AA; Gilbert, JGR; Goward, ME; Grafham, D; Griffiths, MN; Hall, C; Hall, R; Hall-Tamlyn, G; Heathcott, RW; Ho, S; Holmes, S; Hunt, SE; Jones, MC; Kershaw, J; Kimberley, A; King, A; Laird, GK; Langford, CF; Leversha, MA; Lloyd, C; Lloyd, DM; Martyn, ID; Mashreghi-Mohammadi, M; Matthews, L; McCann, OT; McClay, J; McLaren, S; McMurray, AA; Milne, SA; Mortimore, BJ; Odell, CN; Pavitt, R; Pearce, AV; Pearson, D; Phillimore, BJ; Phillips, SH; Plumb, RW; Ramsay, H; Ramsey, Y; Rogers, L; Ross, MT; Scott, CE; Sehra, HK; Skuce, CD; Smalley, S; Smith, ML; Soderlund, C; Spragon, L; Steward, CA; Sulston, JE; Swann, RM; Vaudin, M; Wall, M; Wallis, JM; Whiteley, MN; Willey, D; Williams, L; Williams, S; Williamson, H; Wilmer, TE; Wilming, L; Wright, CL; Hubbard, T; Bentley, DR; Beck, S; Rogers, J; Shimizu, N; Minoshima, S; Kawasaki, K; Sasaki, T; Asakawa, S; Kudoh, J; Shintani, A; Shibuya, K; Yoshizaki, Y; Aoki, N; Mitsuyama, S; Roe, BA; Chen, F; Chu, L; Crabtree, J; Deschamps, S; Do, A; Do, T; Dorman, A; Fang, F; Fu, Y; Hu, P; Hua, A; Kenton, S; Lai, H; Lao, HI; Lewis, J; Lewis, S; Lin, SP; Loh, P; Malaj, E; Nguyen, T; Pan, H; Phan, S; Qi, S; Qian, Y; Ray, L; Ren, Q; Shaull, S; Sloan, D; Song, L; Wang, Q; Wang, Y; Wang, Z; White, J; Willingham, D; Wu, H; Yao, Z; Zhan, M; Zhang, G; Chissoe, S; Murray, J; Miller, N; Minx, P; Fulton, R; Johnson, D; Bemis, G; Bentley, D; Bradshaw, H; Bourne, S; Cordes, M; Du, Z; Fulton, L; Goela, D; Graves, T; Hawkins, J; Hinds, K; Kemp, K; Latreille, P; Layman, D; Ozersky, P; Rohlfing, T; Scheet, P; Walker, C; Wamsley, A; Wohldmann, P; Pepin, K; Nelson, J; Korf, I; Bedell, JA; Hillier, L; Mardis, E; Waterston, R; Wilson, R; Emanuel, BS; Shaikh, T; Kurahashi, H; Saitta, S; Budarf, ML; McDermid, HE; Johnson, A; Wong, ACC; Morrow, BE; Edelman, L; Kim, UJ; Shizuya, H; Simon, MI; Dumanski, JP; Peyrard, M; Kedra, D; Seroussi, E; Fransson, I; Tapia, I; Bruder, CE; O'Brien, KP				Dunham, I; Shimizu, N; Roe, BA; Chissoe, S; Dunham, I; Hunt, AR; Collins, JE; Bruskiewich, R; Beare, DM; Clamp, M; Smink, LJ; Ainscough, R; Almeida, JP; Babbage, A; Bagguley, C; Balley, J; Barlow, K; Bates, KN; Beasley, O; Bird, CP; Blakey, S; Bridgeman, AM; Buck, D; Burgess, J; Burrill, WD; Burton, J; Carder, C; Carter, NP; Chen, Y; Clark, G; Clegg, SM; Cobley, V; Cole, CG; Collier, RE; Connor, RE; Conroy, D; Corby, N; Coville, GJ; Cox, AV; Davis, J; Dawson, E; Dhami, PD; Dockree, C; Dodsworth, SJ; Durbin, RM; Ellington, A; Evans, KL; Fey, JM; Fleming, K; French, L; Garner, AA; Gilbert, JGR; Goward, ME; Grafham, D; Griffiths, MN; Hall, C; Hall, R; Hall-Tamlyn, G; Heathcott, RW; Ho, S; Holmes, S; Hunt, SE; Jones, MC; Kershaw, J; Kimberley, A; King, A; Laird, GK; Langford, CF; Leversha, MA; Lloyd, C; Lloyd, DM; Martyn, ID; Mashreghi-Mohammadi, M; Matthews, L; McCann, OT; McClay, J; McLaren, S; McMurray, AA; Milne, SA; Mortimore, BJ; Odell, CN; Pavitt, R; Pearce, AV; Pearson, D; Phillimore, BJ; Phillips, SH; Plumb, RW; Ramsay, H; Ramsey, Y; Rogers, L; Ross, MT; Scott, CE; Sehra, HK; Skuce, CD; Smalley, S; Smith, ML; Soderlund, C; Spragon, L; Steward, CA; Sulston, JE; Swann, RM; Vaudin, M; Wall, M; Wallis, JM; Whiteley, MN; Willey, D; Williams, L; Williams, S; Williamson, H; Wilmer, TE; Wilming, L; Wright, CL; Hubbard, T; Bentley, DR; Beck, S; Rogers, J; Shimizu, N; Minoshima, S; Kawasaki, K; Sasaki, T; Asakawa, S; Kudoh, J; Shintani, A; Shibuya, K; Yoshizaki, Y; Aoki, N; Mitsuyama, S; Roe, BA; Chen, F; Chu, L; Crabtree, J; Deschamps, S; Do, A; Do, T; Dorman, A; Fang, F; Fu, Y; Hu, P; Hua, A; Kenton, S; Lai, H; Lao, HI; Lewis, J; Lewis, S; Lin, SP; Loh, P; Malaj, E; Nguyen, T; Pan, H; Phan, S; Qi, S; Qian, Y; Ray, L; Ren, Q; Shaull, S; Sloan, D; Song, L; Wang, Q; Wang, Y; Wang, Z; White, J; Willingham, D; Wu, H; Yao, Z; Zhan, M; Zhang, G; Chissoe, S; Murray, J; Miller, N; Minx, P; Fulton, R; Johnson, D; Bemis, G; Bentley, D; Bradshaw, H; Bourne, S; Cordes, M; Du, Z; Fulton, L; Goela, D; Graves, T; Hawkins, J; Hinds, K; Kemp, K; Latreille, P; Layman, D; Ozersky, P; Rohlfing, T; Scheet, P; Walker, C; Wamsley, A; Wohldmann, P; Pepin, K; Nelson, J; Korf, I; Bedell, JA; Hillier, L; Mardis, E; Waterston, R; Wilson, R; Emanuel, BS; Shaikh, T; Kurahashi, H; Saitta, S; Budarf, ML; McDermid, HE; Johnson, A; Wong, ACC; Morrow, BE; Edelman, L; Kim, UJ; Shizuya, H; Simon, MI; Dumanski, JP; Peyrard, M; Kedra, D; Seroussi, E; Fransson, I; Tapia, I; Bruder, CE; O'Brien, KP			The DNA sequence of human chromosome 22	NATURE			English	Article							WHOLE-GENOME SHOTGUN; CPG ISLANDS; YAC CONTIG; MAP; ORGANIZATION; GENES; CONSTRUCTION; REGION; MOUSE; 22Q11	Knowledge of the complete genomic DNA sequence of an organism allows a systematic approach to defining its genetic components. The genomic sequence provides access to the complete structures of all genes, including those without known function, their control elements, and, by inference, the proteins they encode, as well as all other biologically important sequences. Furthermore, the sequence is a rich and permanent source of information for the design of further biological studies of the organism and for the study of evolution through cross-species sequence comparison. The power of this approach has been amply demonstrated by the determination of the sequences of a number of microbial and model organisms, The next step is to obtain the complete sequence of the entire human genome. Here we report the sequence of the euchromatic part of human chromosome 22. The sequence obtained consists of 12 contiguous segments spanning 33.4 megabases, contains at least 545 genes and 134 pseudogenes, and provides the first view of the complex chromosomal landscapes that will be found in the rest of the genome.	Sanger Ctr, Cambridge CB10 1SA, England; Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo 1608582, Japan; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Childrens Hosp Philadelphia, Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Karolinska Hosp, Dept Mol Med, Clin Genet Unit, S-17176 Stockholm, Sweden; CALTECH, Div Biol, Pasadena, CA 91125 USA	Wellcome Trust Sanger Institute; Keio University; University of Oklahoma System; University of Oklahoma - Norman; Washington University (WUSTL); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Alberta; Yeshiva University; Albert Einstein College of Medicine; Karolinska Institutet; Karolinska University Hospital; California Institute of Technology	Dunham, I (corresponding author), Sanger Ctr, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	idl@sanger.ac.uk	Tapia-Páez, Isabel/ABD-7197-2021; Deschamps, Stephane/R-3806-2019; Mardis, Elaine/W-2202-2019; Hubbard, Tim J.P./AAT-4571-2020; Kedra, Darek/H-7641-2012; Evans, Kathryn KL/I-5910-2012; Sasaki, Takashi/AAD-1461-2019; Hubbard, Tim J/C-2567-2008; Durbin, Richard/AAE-7178-2019; Wilson, Richard K./AAF-4139-2019; Spraggon, Lee/E-5900-2012; McClay, Joseph/C-9931-2009; Tapia-Páez, Isabel/N-1210-2013; McDermid, Heather/A-2666-2014	Hubbard, Tim J.P./0000-0002-1767-9318; Kedra, Darek/0000-0002-9723-4465; Hubbard, Tim J/0000-0002-1767-9318; Durbin, Richard/0000-0002-9130-1006; Wilson, Richard K./0000-0002-1992-1358; McClay, Joseph/0000-0002-3628-2447; Morrow, Bernice/0000-0002-8076-4726; Davidson, Claire/0000-0002-4910-8202; Sasaki, Takashi/0000-0002-6275-046X; Evans, Kathryn/0000-0002-7884-5877; Tapia-Paez, Isabel/0000-0002-0535-4233; Bridgeman, Anne/0000-0002-9478-6125; Hunt, Sarah/0000-0002-8350-1235; Steward, Charles/0000-0001-8829-5349; Dunham, Ian/0000-0003-2525-5598; McDermid, Heather/0000-0001-7535-0927; Koculi, Eda/0000-0001-9477-555X; Fosker, Christine/0000-0002-3799-9474; Pan, Huaqin/0000-0002-7166-108X; Lewis, Suzanna/0000-0002-8343-612X; Hunt, Adrienne/0000-0002-1227-0310				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Asakawa S, 1997, GENE, V191, P69, DOI 10.1016/S0378-1119(97)00044-9; Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Bentley DR, 1996, SCIENCE, V274, P533, DOI 10.1126/science.274.5287.533; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BERNARDI G, 1989, ANNU REV GENET, V23, P637, DOI 10.1146/annurev.ge.23.120189.003225; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BUCAN M, 1993, HUM MOL GENET, V2, P1245, DOI 10.1093/hmg/2.8.1245; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carver EA, 1997, GENOME RES, V7, P1123, DOI 10.1101/gr.7.12.1123; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Collins JE, 1997, GENOME RES, V7, P522, DOI 10.1101/gr.7.5.522; COLLINS JE, 1995, NATURE, V377, P367; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dunham I, 1999, GENOME ANAL, V3, P1; Edelmann L, 1999, HUM MOL GENET, V8, P1157, DOI 10.1093/hmg/8.7.1157; Edelmann L, 1999, AM J HUM GENET, V64, P1076, DOI 10.1086/302343; EPPIG JT, 1995, CURR OPIN GENET DEV, V5, P709, DOI 10.1016/0959-437X(95)80002-M; Felsenfeld A, 1999, GENOME RES, V9, P1; Gill M, 1996, AM J MED GENET, V67, P40, DOI 10.1002/(SICI)1096-8628(19960216)67:1<40::AID-AJMG6>3.0.CO;2-W; Green P, 1997, GENOME RES, V7, P410, DOI 10.1101/gr.7.5.410; Guyer M, 1998, GENOME RES, V8, P413; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; Johnson A, 1999, GENOMICS, V57, P306, DOI 10.1006/geno.1999.5757; Kao HT, 1998, P NATL ACAD SCI USA, V95, P4667, DOI 10.1073/pnas.95.8.4667; Kawasaki K, 1997, GENOME RES, V7, P250, DOI 10.1101/gr.7.3.250; McDermid HE, 1996, GENOME RES, V6, P1149, DOI 10.1101/gr.6.12.1149; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Mittman S, 1999, NEUROSCI LETT, V269, P121, DOI 10.1016/S0304-3940(99)00319-5; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; Ning Y, 1996, HUM GENET, V97, P765; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; Puech A, 1997, P NATL ACAD SCI USA, V94, P14608, DOI 10.1073/pnas.94.26.14608; PULVER AE, 1994, J NERV MENT DIS, V182, P476, DOI 10.1097/00005053-199408000-00010; Saccone S, 1996, GENE, V174, P85, DOI 10.1016/0378-1119(96)00392-7; *SANG CTR WASH U G, 1998, GENOME RES, V8, P1097; Seroussi E, 1999, GENOMICS, V57, P380, DOI 10.1006/geno.1998.5739; Seroussi E, 1999, GENOME RES, V9, P803, DOI 10.1101/gr.9.9.803; SOLOVYEV V, 1997, ISMB, V5, P294; Southard-Smith EM, 1999, MAMM GENOME, V10, P744, DOI 10.1007/s003359901083; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; Zu L, 1999, AM J HUM GENET, V64, P594, DOI 10.1086/302247	50	853	1309	2	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1999	402	6761					489	495		10.1038/990031	http://dx.doi.org/10.1038/990031			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591208	hybrid			2022-12-01	WOS:000084013200045
J	Francis, LP				Francis, LP			Legal eights to health care at the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Utah, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Francis, LP (corresponding author), Univ Utah, Salt Lake City, UT 84112 USA.							*US DEP HHS, 1988, HLTH US 1998	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2079	2079		10.1001/jama.282.21.2079	http://dx.doi.org/10.1001/jama.282.21.2079			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591395	hybrid			2022-12-01	WOS:000083908700032
J	Stamler, J; Stamler, R; Neaton, JD; Wentworth, D; Daviglus, ML; Garside, D; Dyer, AR; Liu, KA; Greenland, P				Stamler, J; Stamler, R; Neaton, JD; Wentworth, D; Daviglus, ML; Garside, D; Dyer, AR; Liu, KA; Greenland, P			Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy - Findings for 5 large cohorts of young adult and middle-aged men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; AVERAGE CHOLESTEROL LEVELS; BLOOD-PRESSURE; ATHEROSCLEROSIS; PRAVASTATIN; PREVENTION; EVENTS; TRIAL	Context Three major coronary risk factors-serum cholesterol level, blood pressure, and smoking-increase incidence of coronary heart disease (CHD) and related end points. In previous investigations, risks for low-risk reference groups were estimated statistically because samples contained too few such people to measure risk. Objective To measure long-term mortality rates for individuals with favorable levels for all 3 major risk factors, compared with others. Design Two prospective studies, involving 5 cohorts based on age and sex, that enrolled persons with a range of risk factors. Low risk was defined as serum cholesterol level less than 5.17 mmol/L (<200 mg/dL), blood pressure less than or equal to 120/80 mm Hg, and no current cigarette smoking. All persons with a history of diabetes, myocardial infarction (MI), or, in 3 of 5 cohorts, electrocardiogram (ECG) abnormalities, were excluded. Setting and Participants In 18 US cities, a total of 72 144 men aged 35 through 39 years and 270 671 men aged 40 through 57 years screened (1973-1975) for the Multiple Risk Factor Intervention Trial (MRFIT); in Chicago, a total of 10 025 men aged 18 through 39 years, 7490 men aged 40 through 59 years, and 6229 women aged 40 through 59 years screened (1967-1973) for the Chicago Heart Association Detection Project in Industry (CHA) (N=366 559). Main Outcome Measures Cause-specific mortality during 16 (MRFIT) and 22 (CHA) years, relative risks (RRs) of death, and estimated greater life expectancy, comparing low-risk subcohorts vs others by age strata; Results Low-risk persons comprised only 4.8% to 9.9% of the cohorts. All 5 low-risk groups experienced significantly and markedly lower CHD and cardiovascular disease death rates than those who had elevated cholesterol level, or blood pressure, or smoked. For example, age-adjusted RRs of CHD mortality ranged from 0.08 for CHA men aged 18 to 39 years to 0.23 for CHA men aged 40 through 59 years. The age-adjusted relative risks (RRs) for all cardiovascular disease mortality ranged from 0.15 for MRFIT men aged 35 through 39 years to 0.28 for CHA men aged 40 through 59 years. The age-adjusted RR for all-cause mortality rate ranged from 0.42 for CHA men aged 40 through 59 years to 0.60 for CHA women aged 40 through 59 years. Estimated greater life expectancy for low-risk groups ranged from 5.8 years for CHA women aged 40 through 59 years to 9.5 years for CHA men aged 18 through 39 years. Conclusions Based on these very large cohort studies, for individuals with favorable levels of cholesterol and blood pressure who do not smoke and do not have diabetes, MI, or ECG abnormalities, long-term mortality is much lower and longevity is much greater. A substantial increase in the proportion of the population at lifetime low risk could contribute decisively to ending the CMD epidemic.	Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA	Northwestern University; University of Minnesota System; University of Minnesota Twin Cities	Stamler, J (corresponding author), Northwestern Univ, Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1101 D335, Chicago, IL 60611 USA.		Greenland, Philip/ABD-5528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028715, R01HL021010] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Black HR, 1997, ARCH INTERN MED, V157, P2413; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Cutler JA, 1997, AM J CLIN NUTR, V65, P184; Daviglus ML, 1998, NEW ENGL J MED, V339, P1122, DOI 10.1056/NEJM199810153391606; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; Lowe LP, 1998, ARCH INTERN MED, V158, P2007, DOI 10.1001/archinte.158.18.2007; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; National Research Council Committee on Diet and Health, 1989, DIET HLTH IMPL RED C; PEDERSEN TR, 1994, LANCET, V344, P1383; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; ROSE G, 1992, J EPIDEMIOL COMMUN H, V46, P75, DOI 10.1136/jech.46.1.75; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STAMLER J, 1993, CIRCULATION, V88, P1954, DOI 10.1161/01.CIR.88.4.1954; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; Stamler J, 1997, AM J CLIN NUTR, V65, P626, DOI 10.1093/ajcn/65.2.626S; Stamler J, 1998, JAMA-J AM MED ASSOC, V279, P878, DOI 10.1001/jama.279.11.878; STAMLER J, 1988, ARCH PATHOL LAB MED, V112, P1032; Stamler J., 1967, LECT PREVENTIVE CARD; The Inter-Society Commission for Heart Disease Resources, 1970, CIRCULATION, V42, pA55; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; WILMSHURST P, 1994, BMJ-BRIT MED J, V309, P1029, DOI 10.1136/bmj.309.6961.1029; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; World Health Organization, 1977, INT CLASS DIS; [No title captured]; [No title captured]; [No title captured]	32	513	533	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2012	2018		10.1001/jama.282.21.2012	http://dx.doi.org/10.1001/jama.282.21.2012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591383	Bronze			2022-12-01	WOS:000083908700020
J	Niklason, LE				Niklason, LE			Medical technology - Replacement arteries made to order	SCIENCE			English	Article							CULTURED VASCULAR CELLS; HUMAN BLOOD-VESSEL		Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biomed Engn, Durham, NC 27710 USA	Duke University; Duke University	Niklason, LE (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.							BREGMAN D, 1974, J SURG RES, V16, P624, DOI 10.1016/0022-4804(74)90095-X; Huynh T, 1999, NAT BIOTECHNOL, V17, P1083, DOI 10.1038/15062; Kim BS, 1999, NAT BIOTECHNOL, V17, P979, DOI 10.1038/13671; Kim SS, 1999, J PEDIATR SURG, V34, P124, DOI 10.1016/S0022-3468(99)90241-5; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; Liu SQ, 1998, ATHEROSCLEROSIS, V140, P365, DOI 10.1016/S0021-9150(98)00143-9; Liu SQ, 1999, CRIT REV BIOMED ENG, V27, P75, DOI 10.1615/CritRevBiomedEng.v27.i1-2.30; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Niklason LE, 1997, TRANSPL IMMUNOL, V5, P303; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; Wheater P. R., 1979, FUNCTIONAL HISTOLOGY; ZIEGLER T, 1994, J CELL BIOCHEM, V56, P204, DOI 10.1002/jcb.240560215	14	74	82	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1493	1494		10.1126/science.286.5444.1493	http://dx.doi.org/10.1126/science.286.5444.1493			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10610551				2022-12-01	WOS:000083768300035
J	Matricardi, PM; Rosmini, F; Riondino, S; Fortini, M; Ferrigno, L; Rapicetta, M; Bonini, S				Matricardi, PM; Rosmini, F; Riondino, S; Fortini, M; Ferrigno, L; Rapicetta, M; Bonini, S			Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FAMILY-SIZE; SERUM IGE; ASSOCIATION; INFECTIONS; PREVALENCE; CHILDHOOD; DISEASES; HYGIENE; CELLS; FLORA	Objective To investigate if markers of exposure to foodborne and orofecal microbes versus airborne viruses are associated with atopy and respiratory allergies. Design Retrospective case-control study. Participants 240 atopic cases and 240 non-atopic controls from a population sample of 1659 participants, all Italian male cadets aged 17-24. Setting Air force school in Caserta, Italy. Main outcome measures Serology for Toxoplasma gondii, Helicobacter pylori, hepatitis A virus, measles, mumps, rubella, chickenpox, cytomegalovirus, and herpes simplex virus type 1; skin sensitisation and IgE antibodies to relevant airborne allergens; total IgE concentration; and diagnosis of allergic asthma or rhinitis, Results Compared with controls there tvas a lower prevalence of T gondii (26% v 18%, P = 0.027), hepatitis A virus (30% v 16%, P = 0.004), and H pylori (18% v 15%, P = 0.325) in atopic participants. Adjusted odds ratios of atopy decreased with a gradient of exposure to H pylori, T gondii, and hepatitis A virus (none, odds ratio 1; one, 0.70; two or three, 0.37; P for trend = 0.000045) but not with cumulative exposure to the other viruses. Conversely, total IgE concentration was not independently associated with any infection. Allergic asthma was rare (1/245, 0.4%) and allergic rhinitis infrequent (16/245, 7%) among the participants (245/1659) exposed to at least two orofecal and foodborne infections (H pylori, T gondii, hepatitis A virus). Conclusion Respiratory allergy is less frequent in people heavily exposed to orofecal and foodborne microbes. Hygiene and a westernised, semisterile diet may facilitate atopy by influencing the overall pattern of commensals and pathogens that stimulate the gut associated lymphoid tissue thus contributing to the epidemic of allergic asthma and rhinitis in developed countries.	Div Aerea Studi Ric & Sperimentaz, Lab Immunol & Allergol, I-00040 Pomezia, Italy; Ist Super Sanita, Epidemiol & Biostat Lab, I-00161 Rome, Italy; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; CNR, Ist Med Sperimentale, I-00137 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR)	Matricardi, PM (corresponding author), Div Aerea Studi Ric & Sperimentaz, Lab Immunol & Allergol, I-00040 Pomezia, Italy.	matricardi.pm@mclink.it	Bonini, Sergio/T-6594-2019; Riondino, Silvia/AAV-7126-2020	Bonini, Sergio/0000-0003-0079-3031; Riondino, Silvia/0000-0002-2965-402X				AIM JS, 1997, LANCET, V350, P400; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; BEAMAN MH, 1995, PRINCIPLES PRACTICE, P2455; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; DIXON WJ, 1990, BMDP STAT SOFTWARE, V2; Dominici P, 1999, BRIT MED J, V319, P537, DOI 10.1136/bmj.319.7209.537; Dore MP, 1999, LANCET, V354, P132, DOI 10.1016/S0140-6736(99)01724-9; DURKIN HG, 1989, J IMMUNOL, V143, P1777; Goodwin CS, 1997, LANCET, V349, P265, DOI 10.1016/S0140-6736(96)07023-7; Grubel P, 1998, LANCET, V352, P788, DOI 10.1016/S0140-6736(05)60683-6; *GRUPP STUD INT SO, 1996, VACC IT; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holt PG, 1996, TOXICOL LETT, V86, P205, DOI 10.1016/0378-4274(96)03692-2; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; Matricardi PM, 1999, LANCET, V354, P430, DOI 10.1016/S0140-6736(05)75853-0; MATRICARDI PM, 1994, J ALLERGY CLIN IMMUN, V93, P68, DOI 10.1016/0091-6749(94)90234-8; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matricardi PM, 1997, ALLERGY, V52, P879, DOI 10.1111/j.1398-9995.1997.tb01246.x; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1999, LANCET, V353, P1457, DOI 10.1016/S0140-6736(99)90038-7; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Sudo N, 1997, J IMMUNOL, V159, P1739; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	36	501	520	0	50	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2000	320	7232					412	417		10.1136/bmj.320.7232.412	http://dx.doi.org/10.1136/bmj.320.7232.412			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285EU	10669445	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000085377400022
J	Ikonomidou, C; Bittigau, P; Ishimaru, MJ; Wozniak, DF; Koch, C; Genz, K; Price, MT; Stefovska, V; Horster, F; Tenkova, T; Dikranian, K; Olney, JW				Ikonomidou, C; Bittigau, P; Ishimaru, MJ; Wozniak, DF; Koch, C; Genz, K; Price, MT; Stefovska, V; Horster, F; Tenkova, T; Dikranian, K; Olney, JW			Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome	SCIENCE			English	Article							BRAIN GROWTH SPURT; PURKINJE-CELL LOSS; STEREOLOGICAL METHODS; EXPOSURE; NEURONS; DEATH; RATS	The deleterious effects of ethanol an the developing human brain are poorly understood. Here it is reported that ethanol, acting by a dual mechanism [blockade of N-methyl-D-aspartate (NMDA) glutamate receptors and excessive activation of GABA, receptors], triggers widespread apoptotic neurodegeneration in the developing rat forebrain. Vulnerability coincides with the period of synaptogenesis, which in humans extends from the sixth month of gestation to several years after birth. During this period, transient ethanol exposure can delete millions of neurons from the developing brain. This can explain the reduced brain mass and neurobehavioral disturbances associated with human fetal alcohol syndrome.	Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Humboldt Univ, Virchow Clin, Dept Pediat Neurol, D-13353 Berlin, Germany; Tokyo Med & Dent Univ, Med Res Inst, Chiyod Ku, Tokyo, Japan	Washington University (WUSTL); Humboldt University of Berlin; Tokyo Medical & Dental University (TMDU)	Olney, JW (corresponding author), Washington Univ, Sch Med, Dept Psychiat, 4940 Childrens Pl, St Louis, MO 63110 USA.				NIA NIH HHS [AG 11355] Funding Source: Medline; NIDA NIH HHS [DA 05072] Funding Source: Medline; NIMH NIH HHS [MH 38894] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG011355] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUERMOFFETT C, 1977, BRAIN RES, V119, P249, DOI 10.1016/0006-8993(77)90310-9; CLARREN SK, 1978, J PEDIATR-US, V92, P64, DOI 10.1016/S0022-3476(78)80072-9; CLARREN SK, 1978, NEW ENGL J MED, V298, P1063, DOI 10.1056/NEJM197805112981906; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Eckardt MJ, 1998, ALCOHOL CLIN EXP RES, V22, P998, DOI 10.1111/j.1530-0277.1998.tb03695.x; Faingold CL, 1998, PROG NEUROBIOL, V55, P509, DOI 10.1016/S0301-0082(98)00027-6; Famy C, 1998, AM J PSYCHIAT, V155, P552, DOI 10.1176/ajp.155.4.552; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goodlett C. R., 1992, MATERNAL SUBSTANCE A, P45; GOODLETT CR, 1990, ALCOHOL, V7, P107, DOI 10.1016/0741-8329(90)90070-S; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; JONES KL, 1973, LANCET, V1, P1267; JONES KL, 1973, LANCET, V2, P999; Kerns KA, 1997, J LEARN DISABIL-US, V30, P685, DOI 10.1177/002221949703000612; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; Paxinos G., 1991, ATLAS DEV RAT BRAIN; RYABININ AE, 1995, ALCOHOL CLIN EXP RES, V19, P784, DOI 10.1111/j.1530-0277.1995.tb01583.x; Sapp DW, 1998, J PHARMACOL EXP THER, V284, P768; SULIK KK, 1981, SCIENCE, V214, P936, DOI 10.1126/science.6795717; Swayze VW, 1997, PEDIATRICS, V99, P232, DOI 10.1542/peds.99.2.232; WEST JR, 1986, ALCOHOL CLIN EXP RES, V10, P190, DOI 10.1111/j.1530-0277.1986.tb05070.x; WEST JR, 1987, ALCOHOL DRUG RES, V7, P423; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; Wyllie A H, 1980, Int Rev Cytol, V68, P251	28	1081	1125	2	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 11	2000	287	5455					1056	1060		10.1126/science.287.5455.1056	http://dx.doi.org/10.1126/science.287.5455.1056			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669420				2022-12-01	WOS:000085245400052
J	Prinjha, R; Moore, SE; Vinson, M; Blake, S; Morrow, R; Christie, G; Michlovich, D; Simmons, DL; Walsh, FS				Prinjha, R; Moore, SE; Vinson, M; Blake, S; Morrow, R; Christie, G; Michlovich, D; Simmons, DL; Walsh, FS			Neurobiology - Inhibitor of neurite outgrowth in humans	NATURE			English	Article							SPINAL-CORD; GROWTH; MYELIN; IDENTIFICATION; ANTIBODY; PROTEINS; GENE		SmithKline Beecham Pharmaceut, Dept Neurosci Res, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Bioinformat, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline	Prinjha, R (corresponding author), SmithKline Beecham Pharmaceut, Dept Neurosci Res, New Frontiers Sci Pk N,3rd Ave, Harlow CM19 5AW, Essex, England.			Michalovich, David/0000-0003-4452-5776				BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Geisler JG, 1998, MAMM GENOME, V9, P274, DOI 10.1007/s003359900748; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Ramon y Cajal S, 1928, DEGENERATION REGENER; RUBIN BP, 1994, J NEUROCYTOL, V23, P209, DOI 10.1007/BF01275525; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403	11	480	553	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					383	384		10.1038/35000287	http://dx.doi.org/10.1038/35000287			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667780				2022-12-01	WOS:000085121100036
J	Ducy, P; Amling, M; Takeda, S; Priemel, M; Schilling, AF; Beil, FT; Shen, JH; Vinson, C; Rueger, JM; Karsenty, G				Ducy, P; Amling, M; Takeda, S; Priemel, M; Schilling, AF; Beil, FT; Shen, JH; Vinson, C; Rueger, JM; Karsenty, G			Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass	CELL			English	Article							OSTEOCLAST DIFFERENTIATION; INVOLUTIONAL OSTEOPOROSIS; POSTMENOPAUSAL WOMEN; RECEPTOR GENE; DIABETIC MICE; FEMALE MICE; DB/DB MICE; OB/OB MICE; OBESITY; MOUSE	Gonadal failure induces bone loss while obesity prevents it. This raises the possibility that bone mass, body weight, and gonadal function are regulated by common pathways. To test this hypothesis, we studied leptin-deficient and leptin receptor-deficient mice that are obese and hypogonadic. Both mutant mice have an increased bone formation leading to high bone mass despite hypogonadism and hypercortisolism. This phenotype is dominant, independent of the presence of fat, and specific for the absence of leptin signaling. There is no leptin signaling in osteoblasts but intracerebroventricular infusion of leptin causes bone loss in leptin-deficient and wild-type mice. This study identifies leptin as a potent inhibitor of bone formation acting through the central nervous system and therefore describes the central nature of bone mass control and its disorders.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Hamburg, Dept Trauma Surg, D-20246 Hamburg, Germany; NCI, Biochem Lab, Bethesda, MD 20892 USA	Baylor College of Medicine; University of Hamburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Karsenty, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	karsenty@bcm.tmc.edu	takeda, shu/B-5195-2012		NIAMS NIH HHS [AR45548] Funding Source: Medline; NIDCR NIH HHS [DE11290] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Ahima RS, 1999, ENDOCRINOLOGY, V140, P2755, DOI 10.1210/en.140.6.2755; Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982; Aschner B, 1912, PFLUG ARCH GES PHYS, V146, P1, DOI 10.1007/BF01681114; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1997, GENOMICS, V45, P264, DOI 10.1006/geno.1997.4962; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Cooper Cyrus, 1996, P419; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; EYRE DR, 1988, BIOCHEM J, V252, P495, DOI 10.1042/bj2520495; FELSON DT, 1993, J BONE MINER RES, V8, P567, DOI 10.1002/jbmr.5650080507; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; FROST HM, 1969, CALC TISS RES, V3, P211, DOI 10.1007/BF02058664; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; INOUE S, 1977, ENDOCRINOLOGY, V100, P108, DOI 10.1210/endo-100-1-108; Inui A, 1999, TRENDS NEUROSCI, V22, P62, DOI 10.1016/S0166-2236(98)01292-2; KAUFMAN JM, 1992, J CLIN ENDOCR METAB, V74, P118, DOI 10.1210/jc.74.1.118; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levy JB, 1996, ENDOCRINOLOGY, V137, P1159, DOI 10.1210/en.137.4.1159; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; Namae M, 1998, LAB ANIM SCI, V48, P103; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PECK WA, 1993, AM J MED, V94, P646; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; Ravn P, 1999, J BONE MINER RES, V14, P1622, DOI 10.1359/jbmr.1999.14.9.1622; Reid IR, 1997, NEW ENGL J MED, V337, P420, DOI 10.1056/NEJM199708073370609; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; TREMOLLIERES FA, 1993, J CLIN ENDOCR METAB, V77, P683, DOI 10.1210/jc.77.3.683; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	50	1585	1695	1	61	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2000	100	2					197	207		10.1016/S0092-8674(00)81558-5	http://dx.doi.org/10.1016/S0092-8674(00)81558-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660043	Bronze			2022-12-01	WOS:000084932200004
J	Wallace, AJ; Stillman, TJ; Atkins, A; Jamieson, SJ; Bullough, PA; Green, J; Artymiuk, PJ				Wallace, AJ; Stillman, TJ; Atkins, A; Jamieson, SJ; Bullough, PA; Green, J; Artymiuk, PJ			E-coli hemolysin E (HlyE, ClyA, SheA): X-ray crystal structure of the toxin and observation of membrane pores by electron microscopy	CELL			English	Article							ESCHERICHIA-COLI; ANGSTROM RESOLUTION; RTX TOXIN; PROTEIN; MODEL; WATER; SLYA	Hemolysin E (HlyE) is a novel pore-forming toxin of Escherichia coli, Salmonella typhi, and Shigella flexneri. Here we report the X-ray crystal structure of the water-soluble form of E. coli HlyE at 2.0 Angstrom resolution and the visualization of the lipid-associated form of the toxin in projection at low resolution by electron microscopy. The crystal structure reveals HlyE to be the first member of a new family of toxin structures, consisting of an elaborated helical bundle some 100 Angstrom long. The electron micrographs show how HlyE oligomerizes in the presence of lipid to form transmembrane pores. Taken together, the data from these two structural techniques allow us to propose a simple model for the structure of the pore and for membrane interaction.	Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Artymiuk, PJ (corresponding author), Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.			Bullough, Per/0000-0001-8147-1127				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GL, 1993, PROTEIN ENG, V6, P13; Bauer ME, 1996, INFECT IMMUN, V64, P167, DOI 10.1128/IAI.64.1.167-175.1996; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; delCastillo FJ, 1997, MOL MICROBIOL, V25, P107, DOI 10.1046/j.1365-2958.1997.4391813.x; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Green J, 1997, MOL MICROBIOL, V24, P593, DOI 10.1046/j.1365-2958.1997.3801737.x; GRINDLEY HM, 1993, J MOL BIOL, V229, P707, DOI 10.1006/jmbi.1993.1074; Harbury PAB, 1998, STRUCT FOLD DES, V6, P1487, DOI 10.1016/S0969-2126(98)00147-6; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KREUSCH A, 1994, PROTEIN SCI, V3, P58; LESLIE AGW, 1994, PROTEIN CRYSTALLOGR, V26; Li J, 1996, J MOL BIOL, V257, P129, DOI 10.1006/jmbi.1996.0152; Ludwig A, 1995, MOL GEN GENET, V249, P474, DOI 10.1007/BF00290573; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; O'brien A., 1996, E COLI SALMONELLA CE, V2, P2788; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Oscarsson J, 1999, MOL MICROBIOL, V32, P1226, DOI 10.1046/j.1365-2958.1999.01435.x; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; Ralph ET, 1998, P NATL ACAD SCI USA, V95, P10449, DOI 10.1073/pnas.95.18.10449; Reingold J, 1999, VET MICROBIOL, V66, P125, DOI 10.1016/S0378-1135(98)00310-1; Rigaud JL, 1997, J STRUCT BIOL, V118, P226, DOI 10.1006/jsbi.1997.3848; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; ROWE GE, 1994, METHOD ENZYMOL, V235, P657; SALYERS AA, 1994, BACTERIAL PATHOGENES; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; [No title captured]	45	175	195	3	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 21	2000	100	2					265	276		10.1016/S0092-8674(00)81564-0	http://dx.doi.org/10.1016/S0092-8674(00)81564-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660049	Bronze			2022-12-01	WOS:000084932200010
J	Weeks, DL; Eskandari, S; Scott, DR; Sachs, G				Weeks, DL; Eskandari, S; Scott, DR; Sachs, G			A H+-gated urea channel: The link between Helicobacter pylori urease and gastric colonization	SCIENCE			English	Article							PROTEIN; PH; TRANSPORTER; METABOLISM; MEMBRANES; ACID	Acidic media trigger cytoplasmic urease activity of the unique human gastric pathogen Helicobacter pylori. Deletion of urel prevents this activation of cytoplasmic urease that is essential for bacterial acid resistance. Urel is an inner membrane protein with six transmembrane segments as shown by in vitro transcription/translation and membrane separation. Expression of Urel in Xenopus oocytes results in acid-stimulated urea uptake, with a pH profile similar to activation of cytoplasmic urease, Mutation of periplasmic histidine 123 abolishes stimulation. Urel-mediated transport is urea specific, passive, nonsaturable, nonelectrogenic, and temperature independent. Urel functions as a H+-gated urea channel regulating cytoplasmic urease that is essential for gastric survival and colonization.	VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Sachs, G (corresponding author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.				NIDDK NIH HHS [DK41301, DK43462, DK46917] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [S15DK043462, R01DK046917, P30DK041301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; BODE G, 1993, MED MICROBIOL IMMUN, V182, P223; Chebrou H, 1996, GENE, V182, P215, DOI 10.1016/S0378-1119(96)00478-7; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; CUSSAC V, 1992, J BACTERIOL, V174, P2466, DOI 10.1128/jb.174.8.2466-2473.1992; EATON KA, 1991, INFECT IMMUN, V59, P2470, DOI 10.1128/IAI.59.7.2470-2475.1991; HU LT, 1992, INFECT IMMUN, V60, P2657, DOI 10.1128/IAI.60.7.2657-2666.1992; KATAYAMA Y, 1991, J PHYSIOL-LONDON, V443, P587, DOI 10.1113/jphysiol.1991.sp018853; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; McGowan CC, 1996, GASTROENTEROLOGY, V110, P926, DOI 10.1053/gast.1996.v110.pm8608904; MeyerRosberg K, 1996, GASTROENTEROLOGY, V111, P886, DOI 10.1016/S0016-5085(96)70056-2; ORBACH E, 1980, J GEN PHYSIOL, V75, P427, DOI 10.1085/jgp.75.4.427; Phadnis SH, 1996, INFECT IMMUN, V64, P905, DOI 10.1128/IAI.64.3.905-912.1996; Rektorschek M, 1998, GASTROENTEROLOGY, V115, P628, DOI 10.1016/S0016-5085(98)70142-8; Scott DR, 1998, GASTROENTEROLOGY, V114, P58, DOI 10.1016/S0016-5085(98)70633-X; Shayakul C, 1996, J CLIN INVEST, V98, P2580, DOI 10.1172/JCI119077; Skouloubris S, 1998, INFECT IMMUN, V66, P4517; TAYLOR MB, 1988, FEMS MICROBIOL LETT, V55, P259, DOI 10.1016/0378-1097(88)90034-1; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; TUDOR JJ, 1994, J BACTERIOL, V176, P948, DOI 10.1128/JB.176.4.948-952.1994; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	22	335	359	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					482	485		10.1126/science.287.5452.482	http://dx.doi.org/10.1126/science.287.5452.482			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642549				2022-12-01	WOS:000084929900047
J	Wyckoff, GJ; Wang, W; Wu, CI				Wyckoff, GJ; Wang, W; Wu, CI			Rapid evolution of male reproductive genes in the descent of man	NATURE			English	Article							POSITIVE SELECTION; PROTEIN EVOLUTION; DROSOPHILA; PRIMATES; SUBSTITUTION; POLYMORPHISM; NUCLEOTIDE; SEQUENCES; SPERM; RATES	A diverse body of morphological and genetic evidence has suggested that traits pertaining to male reproduction may have evolved much more rapidly than other types of character(1-3). Recently, DNA sequence comparisons have also shown a very high level of divergence in male reproductive proteins between closely related Drosophila species(4-6), among marine invertebrates(7,8) and between mouse and rat(9). Here we show that rapid evolution of male reproductive genes is observable in primates and is quite notable in the lineages to human and chimpanzee. Nevertheless, rapid evolution by itself is not necessarily an indication of positive darwinian selection; relaxation of negative selection is often equally compatible with the DNA sequence data. By taking three statistical approaches, we show that positive darwinian selection is often the driving force behind this rapid evolution. These results open up opportunities to test the hypothesis that sexual selection plays some role in the molecular evolution of higher primates.	Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Wu, CI (corresponding author), Univ Chicago, Comm Genet, 1101 E 57th St, Chicago, IL 60637 USA.			Wyckoff, Gerald/0000-0003-2604-2666				COULTHART MB, 1988, MOL BIOL EVOL, V5, P167; Darwin C., 1871, P423; Dixson AF, 1998, PRIMATE SEXUALITY; Eberhard W.G., 1985, SEXUAL SELECTION ANI; Fisher R.A., 1930, GENETICAL THEORY NAT; Gould K.G., 1980, International Review of Cytology, V63, P323, DOI 10.1016/S0074-7696(08)61761-1; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; Kimura M., 1983, NEUTRAL THEORY MOL E; LEE Y, 1995, MOL BIOL EVOL, V6, P424; Li W.H., 1997, MOL EVOLUTION; LI WH, 1985, MOL BIOL EVOL, V2, P150; LI WH, 1984, J MOL EVOL, V21, P58, DOI 10.1007/BF02100628; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; MAEDA N, 1988, MOL BIOL EVOL, V5, P1; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Metz EC, 1996, MOL BIOL EVOL, V13, P397, DOI 10.1093/oxfordjournals.molbev.a025598; NELSON JE, 1993, J BIOL CHEM, V268, P2932; Nurminsky DI, 1998, NATURE, V396, P572, DOI 10.1038/25126; QUERALT R, 1993, J FORENSIC SCI, V38, P1491; RETIEF JD, 1993, J MOL EVOL, V37, P426; RETIEF JD, 1993, EUR J BIOCHEM, V214, P609, DOI 10.1111/j.1432-1033.1993.tb17960.x; Rooney AP, 1999, MOL BIOL EVOL, V16, P706, DOI 10.1093/oxfordjournals.molbev.a026153; SCHLICKER M, 1994, HUM REPROD, V9, P2313, DOI 10.1093/oxfordjournals.humrep.a138444; SHIMMIN LC, 1993, NATURE, V362, P745, DOI 10.1038/362745a0; SILLENTULLBERG B, 1993, AM NAT, V141, P1, DOI 10.1086/285458; Sutton KA, 1997, J MOL EVOL, V45, P579, DOI 10.1007/PL00006262; Ting CT, 1998, SCIENCE, V282, P1501, DOI 10.1126/science.282.5393.1501; Tsaur SC, 1998, MOL BIOL EVOL, V15, P1040, DOI 10.1093/oxfordjournals.molbev.a026002; Wu CI, 1996, TRENDS ECOL EVOL, V11, P281, DOI 10.1016/0169-5347(96)10033-1; Yang ZH, 1998, MOL BIOL EVOL, V15, P1600, DOI 10.1093/oxfordjournals.molbev.a025888	30	429	454	2	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					304	309		10.1038/35002070	http://dx.doi.org/10.1038/35002070			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659848				2022-12-01	WOS:000084899700051
J	Imamizu, H; Miyauchi, S; Tamada, T; Sasaki, Y; Takino, R; Putz, B; Yoshioka, T; Kawato, M				Imamizu, H; Miyauchi, S; Tamada, T; Sasaki, Y; Takino, R; Putz, B; Yoshioka, T; Kawato, M			Human cerebellar activity reflecting an acquired internal model of a new tool	NATURE			English	Article							OCULAR FOLLOWING RESPONSES; TEMPORAL FIRING PATTERNS; PURKINJE-CELLS; VENTRAL PARAFLOCCULUS; COMPLEX SPIKES; HUMAN BRAIN; ACTIVATION; MOVEMENT; MONKEYS; ADAPTATION	Theories of motor control postulate that the brain uses internal models of the body to control movements accurately. Internal models are neural representations of how, for instance, the arm would respond to a neural command, given its current position and velocity(1-6), Previous studies have shown that the cerebellar cortex can acquire internal models through motor learning(7-11). Because the human cerebellum is involved in higher cognitive function(12-15) as well as in motor control, we propose a coherent computational theory in which the phylogenetically newer part of the cerebellum similarly acquires internal models of objects in the external world. While human subjects learned to use a new tool (a computer mouse with a novel rotational transformation), cerebellar activity was measured by functional magnetic resonance imaging, As predicted by our theory, two types of activity were observed. One was spread over wide areas of the cerebellum and was precisely proportional to the error signal that guides the acquisition of internal models during learning. The other was confined to the area near the posterior superior fissure and remained even after learning, when the error levels had been equalized, thus probably reflecting an acquired internal model of the new tool.	JST ERATO Kawato Dynam brain Project, Seika, Kyoto 6190288, Japan; Commun Res Lab, Nishi Ku, Kobe, Hyogo 6512401, Japan; Shiraume Gakuen Coll, Kodaira, Tokyo 1878570, Japan; ATR Human Informat Proc Res Labs, Seika, Kyoto 6190288, Japan	Japan Science & Technology Agency (JST); National Institute of Information & Communications Technology (NICT) - Japan	Imamizu, H (corresponding author), JST ERATO Kawato Dynam brain Project, 2-2 Hikaridai, Seika, Kyoto 6190288, Japan.		Pütz, Benno/P-2630-2016; Imamizu, Hiroshi/AAK-6059-2020	Pütz, Benno/0000-0002-2208-209X; Imamizu, Hiroshi/0000-0003-1024-0051; Sasaki, Yuka/0000-0002-0061-0250				ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; Allen G, 1997, SCIENCE, V275, P1940, DOI 10.1126/science.275.5308.1940; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Flament D, 1996, HUM BRAIN MAPP, V4, P210, DOI 10.1002/hbm.460040302; FRISTON KJ, 1992, P ROY SOC B-BIOL SCI, V248, P223, DOI 10.1098/rspb.1992.0065; Gomi H, 1998, J NEUROPHYSIOL, V80, P818, DOI 10.1152/jn.1998.80.2.818; Gomi H, 1996, SCIENCE, V272, P117, DOI 10.1126/science.272.5258.117; Grafton S T, 1994, Hum Brain Mapp, V1, P221, DOI 10.1002/hbm.460010307; IMAMIZU H, 1995, J EXP PSYCHOL HUMAN, V21, P1174, DOI 10.1037/0096-1523.21.5.1174; ITO M, 1982, ANNU REV NEUROSCI, V5, P275, DOI 10.1146/annurev.ne.05.030182.001423; KAWATO M, 1987, BIOL CYBERN, V57, P169, DOI 10.1007/BF00364149; KAWATO M, 1992, BIOL CYBERN, V68, P95, DOI 10.1007/BF00201431; KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851; Kitazawa S, 1998, NATURE, V392, P494, DOI 10.1038/33141; Kobayashi Y, 1998, J NEUROPHYSIOL, V80, P832, DOI 10.1152/jn.1998.80.2.832; LACKNER JR, 1994, J NEUROPHYSIOL, V72, P299, DOI 10.1152/jn.1994.72.1.299; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; ROLAND PE, 1988, EUR J NEUROSCI, V1, P3; SASAKI K, 1977, EXP BRAIN RES, V29, P419; SEITZ RJ, 1994, NEUROREPORT, V5, P2541, DOI 10.1097/00001756-199412000-00034; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; SHIDARA M, 1993, NATURE, V365, P50, DOI 10.1038/365050a0; Tamada T, 1999, NEUROREPORT, V10, P325, DOI 10.1097/00001756-199902050-00022; Thach W. T., 1996, Behavioral and Brain Sciences, V19, P411; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; Wolpert DM, 1998, NEURAL NETWORKS, V11, P1317, DOI 10.1016/S0893-6080(98)00066-5; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; WORSLEY KJ, 1995, NEUROIMAGE, V2, P173, DOI 10.1006/nimg.1995.1023	30	675	679	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 13	2000	403	6766					192	195		10.1038/35003194	http://dx.doi.org/10.1038/35003194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	275TB	10646603				2022-12-01	WOS:000084835300054
J	Miller, ST; Sleeper, LA; Pegelow, CH; Enos, LE; Wang, WC; Weiner, SJ; Wethers, DL; Smith, J; Kinney, TR				Miller, ST; Sleeper, LA; Pegelow, CH; Enos, LE; Wang, WC; Weiner, SJ; Wethers, DL; Smith, J; Kinney, TR			Prediction of adverse outcomes in children with sickle cell disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENE-CLUSTER HAPLOTYPES; RISK-FACTORS; FETAL HEMOGLOBIN; ANEMIA; MORTALITY; DISORDERS; MORBIDITY; FAILURE; COHORT; RATES	Background: The ability to identify infants with sickle cell anemia who are likely to have severe complications later in life would permit accurate prognostication and tailoring of therapy to match disease-related risks and facilitate planning of clinical trials. We attempted to define the features of such babies by following the clinical course of 392 children with sickle cell disease from infancy to about the age of 10 years. Methods: We analyzed the records of 392 infants who received the diagnosis of homozygous sickle cell anemia or sickle cell-beta(0)-thalassemia before the age of six months and for whom comprehensive clinical and laboratory data were recorded prospectively; data were available for a mean (+/-SD) of 10.0+/-4.8 years. Results obtained before the age of two years were evaluated to determine whether they predicted the outcome later in life. Results: Of the 392 infants in the cohort, 70 (18 percent) subsequently had an adverse outcome, defined as death (18 patients [26 percent]), stroke (25 [36 percent]), frequent pain (17 [24 percent]), or recurrent acute chest syndrome (10 [14 percent]). Using multivariate analysis, we found three statistically significant predictors of an adverse outcome: an episode of dactylitis (defined as pain and tenderness in the hands or feet) before the age of one year (relative risk of an adverse outcome, 2.55; 95 percent confidence interval, 1.39 to 4.67), a hemoglobin level of less than 7 g per deciliter (relative risk, 2.47; 95 percent confidence interval, 1.14 to 5.33), and leukocytosis in the absence of infection (relative risk, 1.80; 95 percent confidence interval, 1.05 to 3.09). Conclusions: Three easily identifiable manifestations of sickle cell disease that may appear in the first two years of life (dactylitis, severe anemia, and leukocytosis) can help to predict the possibility of severe sickle cell disease later in life. (N Engl J Med 2000;342:83-9.) (C) 2000, Massachusetts Medical Society.	Suny Downstate Med Ctr, Brooklyn, NY 11203 USA; New England Res Inst, Watertown, MA 02172 USA; Univ Miami, Miami, FL 33152 USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; St Lukes Roosevelt Hosp, New York, NY USA; Harlem Hosp Med Ctr, New York, NY USA; Duke Univ, Med Ctr, Durham, NC USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; HealthCore, Inc; University of Miami; St Jude Children's Research Hospital; Mount Sinai St. Luke's; Mount Sinai West; Duke University	Miller, ST (corresponding author), Suny Downstate Med Ctr, 450 Clarkson Ave,Box 49, Brooklyn, NY 11203 USA.	stmseelig@aol.com			DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB047110] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-47110] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams Junius G. Iii, 1994, P457; BALKARAN B, 1992, J PEDIATR-US, V120, P360, DOI 10.1016/S0022-3476(05)80897-2; Bratt J, 1997, J IMMUNOL, V159, P912; BRAY GL, 1994, AM J PEDIAT HEMATOL, V16, P50; Bunn HF, 1997, NEW ENGL J MED, V337, P762, DOI 10.1056/NEJM199709113371107; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; COX DR, 1972, J R STAT SOC B, V34, P187; Efron B., 1993, INTRO BOOTSTRAP, P141; EMBURY SH, 1980, J CLIN INVEST, V66, P1319, DOI 10.1172/JCI109984; Fadlon E, 1998, BLOOD, V91, P266, DOI 10.1182/blood.V91.1.266.266_266_274; GASTON M, 1987, CONTROL CLIN TRIALS, V8, pS131; GASTON M, 1982, AM J PEDIAT HEMATOL, V4, P197; GILL FM, 1995, BLOOD, V86, P776, DOI 10.1182/blood.V86.2.776.bloodjournal862776; Herrick J.B., 1910, ARCH INTERN MED, V6, P517; KOSHY M, 1989, BLOOD, V74, P1403; Koshy M, 1990, J Assoc Acad Minor Phys, V1, P71; LANE PA, 1995, BLOOD, V85, P2238, DOI 10.1182/blood.V85.8.2238.bloodjournal8582238; LEIKIN SL, 1989, PEDIATRICS, V84, P500; MILNER PF, 1991, NEW ENGL J MED, V325, P1476, DOI 10.1056/NEJM199111213252104; Moser FG, 1996, AM J NEURORADIOL, V17, P965; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; Ohene-Frempong K, 1998, BLOOD, V91, P288; Pass KA, 1994, NEWBORN SCREENING SI, P29; PEARSON HA, 1985, PEDIATRICS, V76, P392; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; POWARS DR, 1991, HEMATOL ONCOL CLIN N, V5, P475, DOI 10.1016/S0889-8588(18)30426-X; POWARS DR, 1991, SEMIN HEMATOL, V28, P202; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; REID CD, 1995, NIH PUBLICATION; Walters MC, 1996, NEW ENGL J MED, V335, P369, DOI 10.1056/NEJM199608083350601; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEST MS, 1992, J CLIN EPIDEMIOL, V45, P893; WRIGHTSTONE RN, 1974, AM J CLIN PATHOL, V61, P375; ZARKOWSKY HS, 1986, J PEDIATR-US, V109, P579, DOI 10.1016/S0022-3476(86)80216-5	37	319	328	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2000	342	2					83	89		10.1056/NEJM200001133420203	http://dx.doi.org/10.1056/NEJM200001133420203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	273TQ	10631276				2022-12-01	WOS:000084723900003
J	Cox, PA				Cox, PA			Will tribal knowledge survive the millennium?	SCIENCE			English	Editorial Material									Natl Trop Bot Garden, Kauai, HI 96765 USA		Cox, PA (corresponding author), Natl Trop Bot Garden, POB 340, Kauai, HI 96765 USA.								0	153	168	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					44	45		10.1126/science.287.5450.44	http://dx.doi.org/10.1126/science.287.5450.44			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10644221				2022-12-01	WOS:000084578400023
J	Channell, R; Lomolino, MV				Channell, R; Lomolino, MV			Dynamic biogeography and conservation of endangered species	NATURE			English	Article							EXTINCTION; PATTERNS; TRANSLOCATION; ABUNDANCE; AUSTRALIA; BIRDS	As one moves from the core to the periphery of a species' geographical range, populations occupy less favourable habitats and exhibit lower and more variable densities(1-4). Populations along the periphery of the range tend to be more fragmented and, as a result, are less likely to receive immigrants from other populations. A population's probability of extinction is directly correlated with its variability and inversely correlated with density and immigration rate(5-9). This has led to the prediction that, when a species becomes endangered, its geographical range should contract inwards, with the core populations persisting until the final stages of decline(2,10). Convinced by these logical but untested deductions, conservation biologists and wildlife managers have been instructed to avoid the range periphery when planning conservation strategies or allocating resources for endangered species(11-13). We have analysed range contraction in 245 species from a broad range of taxonomic groups and geographical regions, Here we report that observed patterns of range contraction do not support the above predictions and that most species examined persist in the periphery of their historical geographical ranges.	Ft Hays State Univ, Dept Biol Sci, Hays, KS 67601 USA; Univ Oklahoma, Dept Zool, Norman, OK 73019 USA; Oklahoma Nat Heritage Inventory, Oklahoma Biol Survey, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Channell, R (corresponding author), Ft Hays State Univ, Dept Biol Sci, Hays, KS 67601 USA.	Rchannel@FHSU.edu						BIBBY CJ, 1994, PHILOS T R SOC B, V344, P35, DOI 10.1098/rstb.1994.0048; Brown J.H., 1995, MACROECOLOGY; BROWN JH, 1977, ECOLOGY, V58, P445, DOI 10.2307/1935620; BROWN JH, 1984, AM NAT, V124, P255, DOI 10.1086/284267; BROWN JH, 1995, ECOLOGY, V76, P2028, DOI 10.2307/1941678; BURBIDGE AA, 1989, BIOL CONSERV, V50, P143, DOI 10.1016/0006-3207(89)90009-8; CHANNELL R, 1998, THESIS U OKLAHOMA; Diamond J.M., 1984, P824; Eastman J. R., 1995, IDRISI WINDOWS VERSI; FRANKLIN J, 1991, CONSERV BIOL, V5, P506, DOI 10.1111/j.1523-1739.1991.tb00358.x; GASTON KJ, 1990, BIOL REV, V65, P105, DOI 10.1111/j.1469-185X.1990.tb01185.x; GRIFFITH B, 1989, SCIENCE, V245, P477, DOI 10.1126/science.245.4917.477; Lawton John H., 1995, P147; MAC ARTHUR ROBERT H., 1967; Martin P.S., 1984, P354; Pearl Mary, 1992, P297; PIMM SL, 1988, AM NAT, V132, P757, DOI 10.1086/284889; Richter-Dyn N., 1974, STOCHASTIC MODELS BI; SHORT J, 1992, BIOL CONSERV, V62, P189, DOI 10.1016/0006-3207(92)91047-V; STEVENS G, 1992, SYSTEMATICS, ECOLOGY, AND THE BIODIVERSITY CRISIS, P40; TOWNS DR, 1994, NEW ZEAL J ZOOL, V21, P325, DOI 10.1080/03014223.1994.9518003; TRACY CR, 1992, AM NAT, V139, P102, DOI 10.1086/285315; Wolf CM, 1996, CONSERV BIOL, V10, P1142, DOI 10.1046/j.1523-1739.1996.10041142.x	23	439	462	4	222	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					84	86		10.1038/47487	http://dx.doi.org/10.1038/47487			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638757				2022-12-01	WOS:000084687400047
J	Wikelski, M; Thom, C				Wikelski, M; Thom, C			Marine iguanas shrink to survive El Nino - Changes in bone metabolism enable these adult lizards to reversibly alter their length.	NATURE			English	Article							AMBLYRHYNCHUS-CRISTATUS; BODY-SIZE; GALAPAGOS	Changes in bone metabolism enable these adult lizards to reversibly alter their length.	Univ Illinois, Dept Ecol Ethol & Evolut, Urbana, IL 61801 USA; Max Planck Inst Behav Physiol, D-82319 Seewiesen, Germany; Univ Bielefeld, D-33501 Bielefeld, Germany; Univ Wurzburg, Dept Biol, D-97072 Wurzburg, Germany	University of Illinois System; University of Illinois Urbana-Champaign; Max Planck Society; University of Bielefeld; University of Wurzburg	Wikelski, M (corresponding author), Univ Illinois, Dept Ecol Ethol & Evolut, 515 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA.							Andrews R.M., 1982, Biology of Reptilia, V13, P273; COOPER JE, 1987, J COMP PATHOL, V97, P129, DOI 10.1016/0021-9975(87)90032-6; Enlow D. H., 1969, pUnpaginated; Grant P.R., 1986, ECOLOGY EVOLUTION DA; Grigoriev A I, 1998, Aviakosm Ekolog Med, V32, P21; Jarman P.J., 1979, SERENGETI DYNAMICS E, P130, DOI DOI 10.1007/s11284-011-0917-1; LAURIE WA, 1990, J ANIM ECOL, V59, P545, DOI 10.2307/4880; LAURIE WA, 1989, GLOBAL ECOLOGICAL CO, P121; MUNDY GR, 1994, NATURE, V367, P216, DOI 10.1038/367216a0; Strollo F, 1998, AVIAT SPACE ENVIR MD, V69, P777; Wikelski M, 1997, ECOLOGY, V78, P2204, DOI 10.2307/2265956; Wikelski M, 1997, EVOLUTION, V51, P922, DOI 10.1111/j.1558-5646.1997.tb03673.x; WIKELSKI M, 1994, BEHAVIOUR, V128, P255, DOI 10.1163/156853994X00280; Wolter K., 1998, WEATHER, V53, P315, DOI DOI 10.1002/J.1477-8696.1998.TB06408.X; WRONSKI TJ, 1982, METAB BONE DIS RELAT, V4, P69, DOI 10.1016/0221-8747(82)90011-X	15	157	162	1	129	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					37	38		10.1038/47396	http://dx.doi.org/10.1038/47396			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638740				2022-12-01	WOS:000084687400030
J	Firth-Cozens, J; Midgley, SJ; Burges, C				Firth-Cozens, J; Midgley, SJ; Burges, C			Questionnaire survey of post-traumatic stress disorder in doctors involved in the Omagh bombing	BRITISH MEDICAL JOURNAL			English	Article									Northumbria Univ, Ctr Clin Psychol & Hlth Care Res, Newcastle Upon Tyne NE7 7XA, Tyne & Wear, England; Erne Hosp, Sperrin Lake Hlth & Social Care Trust, Enniskillen, North Ireland	Northumbria University	Firth-Cozens, J (corresponding author), Northumbria Univ, Ctr Clin Psychol & Hlth Care Res, Newcastle Upon Tyne NE7 7XA, Tyne & Wear, England.							Baldwin PJ, 1997, SOC SCI MED, V45, P41, DOI 10.1016/S0277-9536(96)00307-3; Bamber M, 1994, Nurs Times, V90, P32; FIRTHCOZENS J, 1995, YORKSHIRE MED, V7, P10; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1007/BF00974317; Freedman SA, 1999, BRIT J PSYCHIAT, V174, P353, DOI 10.1192/bjp.174.4.353	5	35	35	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1609	1609		10.1136/bmj.319.7225.1609	http://dx.doi.org/10.1136/bmj.319.7225.1609			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	270XN	10600958	Bronze, Green Published			2022-12-01	WOS:000084562600012
J	Diede, SJ; Gottschling, DE				Diede, SJ; Gottschling, DE			Telomerase-mediated telomere addition in vivo requires DNA primase and DNA polymerases alpha and delta	CELL			English	Article							SACCHAROMYCES-CEREVISIAE TELOMERES; SINGLE-STRANDED-DNA; LENGTH REGULATION; BINDING PROTEIN; REPLICATION FORK; GENE DISRUPTION; YEAST KU; ATAXIA-TELANGIECTASIA; REVERSE-TRANSCRIPTASE; EST GENES	To better understand the requirements for telomerase-mediated telomere addition in vivo, we developed an assay in S. cerevisiae that creates a chromosome end immediately adjacent to a short telomeric DNA tract. The de novo end acts as a telomere: it is protected from degradation in a CDC13-dependent manner, telomeric sequences are added efficiently, and addition occurs at a faster rate in mutant strains that have long telomeres. Telomere addition was detected in M phase arrested cells, which permitted us to determine that the essential DNA polymerases alpha and delta and DNA primase were required. This indicates that telomeric DNA synthesis by telomerase is tightly coregulated with the production of the opposite strand. Such coordination prevents telomerase from generating excessively long single-stranded tails, which may be deleterious to chromosome stability in S. cerevisiae.	Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Fred Hutchinson Cancer Center; University of Chicago	Gottschling, DE (corresponding author), Fred Hutchinson Canc Res Ctr, Dept Basic Sci, Seattle, WA 98109 USA.		Diede, Scott/G-2288-2012	Diede, Scott/0000-0001-5422-549X	NIGMS NIH HHS [GM07281, GM43893] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams AK, 1996, MOL CELL BIOL, V16, P4614; ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Bourns BD, 1998, MOL CELL BIOL, V18, P5600, DOI 10.1128/MCB.18.9.5600; Brachmann CB, 1998, YEAST, V14, P115; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; CARSON MJ, 1985, CELL, V42, P249, DOI 10.1016/S0092-8674(85)80120-3; CHATTOO BB, 1979, GENETICS, V93, P51; CONRAD MN, 1983, MOL CELL BIOL, V3, P1000, DOI 10.1128/MCB.3.6.1000; Dionne I, 1998, NUCLEIC ACIDS RES, V26, P5365, DOI 10.1093/nar/26.23.5365; Fan XQ, 1997, MOL BIOL CELL, V8, P2145, DOI 10.1091/mbc.8.11.2145; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; Formosa T, 1999, GENETICS, V151, P1459; FRANCESCONI S, 1991, P NATL ACAD SCI USA, V88, P3877, DOI 10.1073/pnas.88.9.3877; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARTWELL LH, 1985, GENETICS, V110, P381; HENIKOFF S, 1987, GENETICS, V117, P711; HERSKOWITZ I, 1991, P132; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Le S, 1999, GENETICS, V152, P143; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LIU ZP, 1995, P NATL ACAD SCI USA, V92, P6002, DOI 10.1073/pnas.92.13.6002; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; Maniatis T., 1982, MOL CLONING LAB MANU; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Marcand S, 1997, CIBA F SYMP, V211, P76; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Price CM, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1216; Ray A, 1999, MOL CELL BIOL, V19, P31; Runge KW, 1996, MOL CELL BIOL, V16, P3094; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MS, 1998, GENETICS, V150, P613; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SWEETSER DB, 1994, MOL CELL BIOL, V14, P3863, DOI 10.1128/MCB.14.6.3863; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WALTON JD, 1986, CELL, V46, P857, DOI 10.1016/0092-8674(86)90067-X; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	85	313	317	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 23	1999	99	7					723	733		10.1016/S0092-8674(00)81670-0	http://dx.doi.org/10.1016/S0092-8674(00)81670-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	269QC	10619426	Bronze			2022-12-01	WOS:000084488200006
J	Cogoni, C; Macino, G				Cogoni, C; Macino, G			Posttranscriptional gene silencing in Neurospora by a RecQ DNA helicase	SCIENCE			English	Article							TRANSGENIC PLANTS; BLOOMS-SYNDROME; TOPOISOMERASE; RNA; SUPPRESSION; SENSITIVITY; INDUCTION; CRASSA	The phenomenon of posttranscriptional gene silencing (PTGS), which occurs when a transgene is introduced into a cell, is poorly understood. Here, the qde-3 gene, which is required for the activation and maintenance of gene silencing in the fungus Neurospora crassa, was isolated. Sequence analysis revealed that the qde-3 gene belongs to the RecQ DNA helicase family. The QDE3 protein may function in the DNA-DNA interaction between introduced transgenes or with an endogenous gene required for gene-silencing activation. In animals, genes that are homologous to RecQ protein, such as the human genes for Bloom's syndrome and Werner's syndrome, may also function in PTGS.	Univ Rome La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, I-00161 Rome, Italy	Sapienza University Rome	Cogoni, C (corresponding author), Univ Rome La Sapienza, Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Viale Regina Elena 324, I-00161 Rome, Italy.							Chakraverty RK, 1999, BIOESSAYS, V21, P286; Cogoni C, 1997, TRENDS PLANT SCI, V2, P438, DOI 10.1016/S1360-1385(97)90028-5; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Depicker A, 1997, CURR OPIN CELL BIOL, V9, P373, DOI 10.1016/S0955-0674(97)80010-5; Duguet M, 1997, J CELL SCI, V110, P1345; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; INOUE H, 1981, MUTAT RES, V80, P27, DOI 10.1016/0027-5107(81)90175-5; ISHII C, 1991, MOL GEN GENET, V228, P33, DOI 10.1007/BF00282444; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; Matzke MA, 1998, CELL MOL LIFE SCI, V54, P94, DOI 10.1007/s000180050128; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; PICKFORD A, UNPUB; Stam M, 1997, ANN BOT-LONDON, V79, P3, DOI 10.1006/anbo.1996.0295; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438; YU EE, 1996, SCIENCE, V272, P258	25	202	243	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2342	2344		10.1126/science.286.5448.2342	http://dx.doi.org/10.1126/science.286.5448.2342			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10600745				2022-12-01	WOS:000084318500062
J	Paterson, SJ; Brown, JH; Gsodl, MK; Johnson, MH; Karmiloff-Smith, A				Paterson, SJ; Brown, JH; Gsodl, MK; Johnson, MH; Karmiloff-Smith, A			Cognitive modularity and genetic disorders	SCIENCE			English	Article							INFANT; NEUROPSYCHOLOGY	This study challenges the use of adult neuropsychological models for explaining developmental disorders of genetic origin. When uneven cognitive profiles are found in childhood or adulthood, it is assumed that such phenotypic outcomes characterize infant starting states, and it has been claimed that modules subserving these abilities start out either intact or impaired. Findings from two experiments with infants with Williams syndrome (a phenotype selected to bolster innate modularity claims) indicate a within-syndrome double dissociation: For numerosity judgments, they do well in infancy but poorly in adulthood, whereas for Language, they perform poorly in infancy but well in adulthood. The theoretical and clinical implications of these results could Lead to a shift in focus for studies of genetic disorders.	UCL, Inst Child Hlth, Neurocognit Dev Unit, London WC1N 1EH, England; Univ London Univ Coll, Dept Psychol, London WC1E 6BT, England; Birkbeck Coll, Ctr Brain & Cognit Dev, London WC1E 7JL, England	University of London; University College London; University of London; University College London; University of London; Birkbeck University London	Karmiloff-Smith, A (corresponding author), UCL, Inst Child Hlth, Neurocognit Dev Unit, London WC1N 1EH, England.	a.karmiloff-smith@ich.ucl.ac.uk	Karmiloff-Smith, Annette/N-4535-2014	Karmiloff-Smith, Annette/0000-0002-2470-5609; Johnson, Mark/0000-0003-4229-2585				BARONCOHEN S, 1998, HDB MENTAL RETARDATI, P335; Bates E., 1996, RETHINKING INNATENES; Bayley N., 1993, BAYLEY SCALES INFANT; Bellugi U., 1994, ATYPICAL COGNITIVE D, P23; Bishop DVM, 1997, Q J EXP PSYCHOL-A, V50, P899, DOI 10.1080/027249897391946; Clearfield MW, 1999, PSYCHOL SCI, V10, P408, DOI 10.1111/1467-9280.00177; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; GOLINKOFF RM, 1987, J CHILD LANG, V14, P23, DOI 10.1017/S030500090001271X; HAAF RA, 1989, INFANT BEHAV DEV, V12, P211, DOI 10.1016/0163-6383(89)90007-6; Karmiloff-Smith A, 1998, TRENDS COGN SCI, V2, P389, DOI 10.1016/S1364-6613(98)01230-3; Karmiloff-Smith A, 1992, MODULARITY DEV PERSP; KINNEAR PR, 1999, SPSS WINDOWS MADE SI, P98; Leslie A.M., 1992, CURRENT DIRECTIONS P, V1, P18, DOI DOI 10.1111/1467-8721; ONEILL JM, 1994, INFANT BEHAV DEV, V17, P465, DOI 10.1016/0163-6383(94)90039-6; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; Schafer G, 1998, CHILD DEV, V69, P309, DOI 10.2307/1132166; STARKEY P, 1990, COGNITION, V36, P97, DOI 10.1016/0010-0277(90)90001-Z; STRAUSS MS, 1981, CHILD DEV, V52, P1146, DOI 10.2307/1129500; Tassabehji M, 1999, AM J HUM GENET, V64, P118, DOI 10.1086/302214; Temple CM, 1997, J CHILD PSYCHOL PSYC, V38, P27, DOI 10.1111/j.1469-7610.1997.tb01504.x	21	187	188	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	1999	286	5448					2355	2358		10.1126/science.286.5448.2355	http://dx.doi.org/10.1126/science.286.5448.2355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	266UK	10600749				2022-12-01	WOS:000084318500066
J	Gow, A; Southwood, CM; Li, JS; Pariali, M; Riordan, GP; Brodie, SE; Danias, J; Bronstein, JM; Kachar, B; Lazzarini, RA				Gow, A; Southwood, CM; Li, JS; Pariali, M; Riordan, GP; Brodie, SE; Danias, J; Bronstein, JM; Kachar, B; Lazzarini, RA			CNS myelin and Sertoli cell tight junction strands are absent in Osp/Claudin-11 null mice	CELL			English	Article							OLIGODENDROCYTE-SPECIFIC PROTEIN; ZONULA OCCLUDENS; NERVOUS-SYSTEM; EXPRESSION; GENE; BARRIER; TESTIS; PERMEABILITY; ARCHITECTURE; MUTATION	Oligodendrocyte-specific protein (OSP)/claudin-11 is a recently identified transmembrane protein found in CNS myelin and testis with unknown function. Herein we demonstrate that Osp null mice exhibit both neurological and reproductive deficits: CNS nerve conduction is slowed, hindlimb weakness is conspicuous, and males are sterile. Freeze fracture reveals that tight junction intramembranous strands are absent in CNS myelin and between Sertoli cells of mutant mice. Our results demonstrate that OSP is the mediator of parallel-array tight junction strands and distinguishes this protein from other intrinsic membrane proteins in tight junctions. These novel results provide direct evidence of the pivotal role of the claudin family in generating the paracellular physical barrier of tight junctions necessary for spermatogenesis and normal CNS function.	CUNY, Mt Sinai Med Ctr, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; CUNY, Mt Sinai Med Ctr, Dept Ophthalmol, New York, NY 10029 USA; NICHHD, Sect Struct Cell Biol, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lazzarini, RA (corresponding author), CUNY, Mt Sinai Med Ctr, Brookdale Ctr Dev & Mol Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.			gow, alexander/0000-0001-7446-8990	NATIONAL EYE INSTITUTE [K08EY000390] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001596, P01NS033165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000002, Z01DC000002] Funding Source: NIH RePORTER; NEI NIH HHS [1K08 EY 00390-01A1] Funding Source: Medline; NINDS NIH HHS [NS33165, NS01596] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUMULLER G, 1986, INT J ANDROL, V9, P99, DOI 10.1111/j.1365-2605.1986.tb00872.x; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; BLAKEMORE WF, 1969, J ULTRA MOL STRUCT R, V29, P496, DOI 10.1016/S0022-5320(69)90069-0; Bronstein JM, 1996, NEUROLOGY, V47, P772, DOI 10.1212/WNL.47.3.772; Bronstein JM, 1997, J NEUROSCI RES, V50, P713, DOI 10.1002/(SICI)1097-4547(19971201)50:5<713::AID-JNR8>3.0.CO;2-K; Dym M, 1970, Biology Reprod., V3, P308; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; FANNON AM, 1995, J CELL BIOL, V129, P189, DOI 10.1083/jcb.129.1.189; FRIEDRICH VL, 1981, HDB NEUROANATOMICAL, P345; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; GILULA NB, 1976, DEV BIOL, V50, P142, DOI 10.1016/0012-1606(76)90074-9; Gondre M, 1998, J CELL BIOL, V141, P493, DOI 10.1083/jcb.141.2.493; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; Gow A, 1998, J CELL BIOL, V140, P925, DOI 10.1083/jcb.140.4.925; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; GRIFFITHS IR, 1995, NEUROPATH APPL NEURO, V21, P97, DOI 10.1111/j.1365-2990.1995.tb01035.x; GRIFFITHS IR, 1990, J NEUROCYTOL, V19, P273, DOI 10.1007/BF01217305; Griffiths IR, 1996, BIOESSAYS, V18, P789, DOI 10.1002/bies.950181005; GRISWOLD MD, 1995, BIOL REPROD, V52, P211, DOI 10.1095/biolreprod52.2.211; HILDEBRAND C, 1971, ACTA PHYSIOL SCAND, P43; Lacaz-Vieira F, 1999, J MEMBRANE BIOL, V168, P289, DOI 10.1007/s002329900518; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; Michaelson MD, 1996, DEVELOPMENT, V122, P2661; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Mori Seiji, 1998, American Journal of Physiology, V274, pC1708; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; MUGNAINI E, 1974, NATURE, V251, P725, DOI 10.1038/251725a0; PELLETIER RM, 1992, MICROSC RES TECHNIQ, V20, P3, DOI 10.1002/jemt.1070200104; PLYMATE S, 1994, ENDOCRIN METAB CLIN, V23, P749, DOI 10.1016/S0889-8529(18)30065-3; Ruio-Hortega, 1928, MEM REL SOC ESPAN HI, V14, P5; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Scherer SS, 1995, J NEUROSCI, V15, P8281; SCHNAPP B, 1978, PHYSL PATHOBIOLOGY A, P83; SCHNEIDER A, 1992, NATURE, V358, P758, DOI 10.1038/358758a0; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STRAIN GM, 1993, BRAIN RES BULL, V32, P57, DOI 10.1016/0361-9230(93)90319-7; Swisshelm K, 1999, GENE, V226, P285, DOI 10.1016/S0378-1119(98)00553-8; TABIRA T, 1978, J NEUROCYTOL, V7, P489, DOI 10.1007/BF01173993; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; YULE TD, 1990, J REPROD IMMUNOL, V18, P89, DOI 10.1016/0165-0378(90)90026-3	47	551	561	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 10	1999	99	6					649	659		10.1016/S0092-8674(00)81553-6	http://dx.doi.org/10.1016/S0092-8674(00)81553-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612400	Bronze			2022-12-01	WOS:000084278700011
J	Al Suwaidi, J; Velianou, JL; Gertz, MA; Cannon, RO; Higano, ST; Holmes, DR; Lerman, A				Al Suwaidi, J; Velianou, JL; Gertz, MA; Cannon, RO; Higano, ST; Holmes, DR; Lerman, A			Systemic amyloidosis presenting with angina pectoris	ANNALS OF INTERNAL MEDICINE			English	Article							ISCHEMIC-HEART-DISEASE; CARDIAC AMYLOIDOSIS; CHEST PAIN; CORONARY; ARTERIES	Background: Manifestations of cardiac amyloidosis may include congestive heart failure and sudden cardiac death. Although vascular involvement in patients with amyloidosis is common, systemic amyloidosis presenting with angina is rare. Objectives: To report on patients with systemic amyloidosis presenting with angina pectoris. Design: Case series. Setting: Academic medical center. Patients: Five patients who presented with angina pectoris and normal coronary angiogram as the initial manifestation of systemic amyloidosis. Measurements: Endothelial-dependent and endothelialin-dependent coronary flow reserve. Results: All patients had coronary flow reserve abnormalities and subsequently developed congestive heart failure and systemic manifestations of amyloidosis. Histologic evaluation revealed amyloid deposition in the intramyocardial coronary vessels. Conclusions: Cardiac amyloidosis can present as angina pectoris associated with coronary flow reserve abnormalities despite normal coronary angiograms. This finding may have major therapeutic and prognostic implications in this patient population.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Hematol, Rochester, MN 55905 USA; NHLBI, NIH, Cardiol Branch, Bethesda, MD 20892 USA	Mayo Clinic; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lerman, A (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.	lerman.amir@mayo.edu	Gertz, Morie/K-2873-2019	al suwaidi, MB, ChB, FACC, FESC, FSCAI, jassim/0000-0002-5299-9106				BRANDT K, 1968, AM J MED, V44, P955, DOI 10.1016/0002-9343(68)90095-8; BUJA LM, 1970, AM J CARDIOL, V26, P394, DOI 10.1016/0002-9149(70)90736-8; CANNON RO, 1992, CIRCULATION, V85, P883, DOI 10.1161/01.CIR.85.3.883; CROTTY TB, 1994, CARDIOVASC PATHOL, V5, P39; CUETOGARCIA L, 1985, AM J CARDIOL, V55, P606, DOI 10.1016/0002-9149(85)90268-1; Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306; GERTZ MA, 1985, AM J CARDIOL, V55, P1645, DOI 10.1016/0002-9149(85)90995-6; Hasdai D, 1998, MAYO CLIN PROC, V73, P1133, DOI 10.4065/73.12.1133; Hasdai D, 1997, CIRCULATION, V96, P3390; LICHTLEN PR, 1995, J AM COLL CARDIOL, V25, P1013, DOI 10.1016/0735-1097(94)00519-V; NARANG R, 1993, CARDIOLOGY, V82, P294, DOI 10.1159/000175878; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; SAFFITZ JE, 1983, AM J CARDIOL, V51, P1234, DOI 10.1016/0002-9149(83)90379-X; Schafer S, 1996, CIRCULATION, V94, P3376, DOI 10.1161/01.CIR.94.12.3376; SMITH RRL, 1979, AM J CARDIOL, V44, P413, DOI 10.1016/0002-9149(79)90389-8; SMITH TJ, 1984, MAYO CLIN PROC, V59, P547, DOI 10.1016/S0025-6196(12)61493-1; THIBAULT GE, 1992, NEW ENGL J MED, V327, P714, DOI 10.1056/NEJM199209033271008; WRIGHT JR, 1981, MEDICINE, V60, P429, DOI 10.1097/00005792-198111000-00004	18	55	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					838	841		10.7326/0003-4819-131-11-199912070-00007	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610629				2022-12-01	WOS:000084053200006
J	Golovkina, TV; Shlomchik, M; Hannum, L; Chervonsky, A				Golovkina, TV; Shlomchik, M; Hannum, L; Chervonsky, A			Organogenic role of B lymphocytes in mucosal immunity	SCIENCE			English	Article							MAMMARY-TUMOR VIRUS; SCANNING ELECTRON-MICROSCOPY; PEYERS PATCH LYMPHOCYTES; CELL-DEFICIENT MICE; T-CELLS; NECROSIS-FACTOR; LECTIN-BINDING; CD40 LIGAND; MOUSE; INFECTION	Follicle-associated epithelium (FAE) in the intestinal Peyer's patches contains M cells that deliver pathogens to organized Lymphoid tissue. Development of Peyer's patches, FAE, and M cells was found to be impaired in mice that had no B cells. Transgenic expression of membrane-bound immunoglobulin M restored B cells and FAE development. The Lack of M cells abrogated infection with a milk-borne retrovirus. Thus, in addition to secretion of antibodies and presentation of antigens, B cells are important for organogenesis of the mucosal immune barriers.	Jackson Lab, Bar Harbor, ME 04609 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA	Jackson Laboratory; Yale University; Yale University	Chervonsky, A (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.		Shlomchik, Mark J./AAN-6189-2020	Shlomchik, Mark J./0000-0002-2152-0959; Chervonsky, Alexander/0000-0001-7547-871X	NCI NIH HHS [CA65795, CA34196] Funding Source: Medline; NIDDK NIH HHS [DK53561] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA034196, R29CA065795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053561] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHAORBEA H, 1995, ANNU REV IMMUNOL, V13, P459, DOI 10.1146/annurev.iy.13.040195.002331; Adachi S, 1997, INT IMMUNOL, V9, P507, DOI 10.1093/intimm/9.4.507; BEUTNER U, 1994, J EXP MED, V179, P1457, DOI 10.1084/jem.179.5.1457; BOCKMAN DE, 1973, AM J ANAT, V136, P455, DOI 10.1002/aja.1001360406; Buggiano V, 1999, SCAND J IMMUNOL, V49, P269; Chan OTM, 1999, J EXP MED, V189, P1639, DOI 10.1084/jem.189.10.1639; Chaplin DD, 1998, CURR OPIN IMMUNOL, V10, P289, DOI 10.1016/S0952-7915(98)80167-2; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; CHERVONSKY A, UNPUB; CHERVONSKY AV, 1995, IMMUNITY, V3, P139, DOI 10.1016/1074-7613(95)90166-3; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CLARK MA, 1993, J HISTOCHEM CYTOCHEM, V41, P1679, DOI 10.1177/41.11.7691933; Culkin SJ, 1997, J IMMUNOL, V158, P3277; Debard N, 1999, SEMIN IMMUNOL, V11, P183, DOI 10.1006/smim.1999.0174; Fu YX, 1998, J EXP MED, V187, P1009, DOI 10.1084/jem.187.7.1009; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; HELD W, 1993, CELL, V74, P529, DOI 10.1016/0092-8674(93)80054-I; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; KARAPETIAN O, 1994, J EXP MED, V180, P1511, DOI 10.1084/jem.180.4.1511; Kerneis S, 1997, SCIENCE, V277, P949, DOI 10.1126/science.277.5328.949; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; LIN RH, 1991, J EXP MED, V173, P1433, DOI 10.1084/jem.173.6.1433; MALICK LE, 1975, STAIN TECHNOL, V50, P265, DOI 10.3109/10520297509117069; MALICK LE, 1975, SCANNING ELECT MICRO, P256; Marcotte H, 1996, J INFECT DIS, V173, P1034, DOI 10.1093/infdis/173.4.1034; Matsuzaki G, 1999, CELL IMMUNOL, V194, P178, DOI 10.1006/cimm.1999.1503; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NATION JL, 1983, STAIN TECHNOL, V58, P347, DOI 10.3109/10520298309066811; Neutra MR, 1999, SEMIN IMMUNOL, V11, P171, DOI 10.1006/smim.1999.0173; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; OWEN RL, 1983, AM J ANAT, V168, P199, DOI 10.1002/aja.1001680207; Owen RL, 1999, SEMIN IMMUNOL, V11, P157, DOI 10.1006/smim.1999.0171; OWEN RL, 1977, GASTROENTEROLOGY, V72, P440; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; Sansonetti PJ, 1999, SEMIN IMMUNOL, V11, P193, DOI 10.1006/smim.1999.0175; Serreze DV, 1996, J EXP MED, V184, P2049, DOI 10.1084/jem.184.5.2049; Teitelbaum R, 1999, IMMUNITY, V10, P641, DOI 10.1016/S1074-7613(00)80063-1; Velin D, 1997, J EXP MED, V185, P1871, DOI 10.1084/jem.185.10.1871; Vordermeier HM, 1996, CLIN EXP IMMUNOL, V106, P312, DOI 10.1046/j.1365-2249.1996.d01-845.x; Yoshida H, 1999, INT IMMUNOL, V11, P643, DOI 10.1093/intimm/11.5.643	45	194	197	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1965	1968		10.1126/science.286.5446.1965	http://dx.doi.org/10.1126/science.286.5446.1965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583962				2022-12-01	WOS:000084003400055
J	Kobayashi, Y; Kaya, H; Goto, K; Iwabuchi, M; Araki, T				Kobayashi, Y; Kaya, H; Goto, K; Iwabuchi, M; Araki, T			A pair of related genes with antagonistic roles in mediating flowering signals	SCIENCE			English	Article							PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN; ARABIDOPSIS-THALIANA; CRYSTAL-STRUCTURE; TIME; ARCHITECTURE; ACTIVATION; INITIATION; ENCODES; PLANTS	Flowering in Arabidopsis is promoted via several interacting pathways. A photoperiod-dependent pathway relays signals from photoreceptors to a transcription factor gene, CONSTANS (CO), which activates downstream meristem identity genes such as LEAFY (LFY). FT, together with LFY, promotes flowering and is positively regulated by CO. Loss of FT causes delay in flowering, whereas overexpression of FT results in precocious flowering independent of CO or photoperiod. FT acts in part downstream of CO and mediates signals for flowering in an antagonistic manner with its homologous gene, TERMINAL FLOWER1 (TFL1).	Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Araki, T (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan.	taraqui@gr.bot.kyoto-u.ac.jp	Rosa, Bruce/F-6393-2010; Araki, Takashi/G-1760-2013	Araki, Takashi/0000-0002-3616-1493; Kaya, Hidetaka/0000-0003-4711-8236				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; IGENO MI, COMMUNICATION; KOBAYASHI Y, UNPUB; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; KYOZUKA J, COMMUNICATION; Levy YY, 1998, PLANT CELL, V10, P1973, DOI 10.1105/tpc.10.12.1973; Liljegren SJ, 1999, PLANT CELL, V11, P1007, DOI 10.1105/tpc.11.6.1007; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Ohshima S, 1997, MOL GEN GENET, V254, P186, DOI 10.1007/s004380050407; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Ratcliffe OJ, 1998, DEVELOPMENT, V125, P1609; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; SCHOENTGEN F, 1995, FEBS LETT, V369, P22, DOI 10.1016/0014-5793(95)00376-K; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; TOHDOH N, 1995, MOL BRAIN RES, V30, P381, DOI 10.1016/0169-328X(95)00029-R; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0	23	969	1082	5	145	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1960	1962		10.1126/science.286.5446.1960	http://dx.doi.org/10.1126/science.286.5446.1960			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583960				2022-12-01	WOS:000084003400053
J	Berghammer, AJ; Klingler, M; Wimmer, EA				Berghammer, AJ; Klingler, M; Wimmer, EA			Genetic techniques - A universal marker for transgenic insects	NATURE			English	Article							YELLOW-FEVER MOSQUITO; TRANSPOSABLE ELEMENT; AEDES-AEGYPTI; TRANSFORMATION; DROSOPHILA; MARINER; FLY		Univ Munich, Inst Zool, D-80333 Munich, Germany; Univ Bayreuth, Lehrstuhl Genet, D-95447 Bayreuth, Germany	University of Munich; University of Bayreuth	Berghammer, AJ (corresponding author), Univ Munich, Inst Zool, Luisenstr 14, D-80333 Munich, Germany.		Klingler, Martin/J-8383-2013	Klingler, Martin/0000-0001-8859-1965; Wimmer, Ernst A./0000-0002-2480-2804				Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; CARY LC, 1989, VIROLOGY, V172, P156, DOI 10.1016/0042-6822(89)90117-7; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; Handler AM, 1998, P NATL ACAD SCI USA, V95, P7520, DOI 10.1073/pnas.95.13.7520; Jasinskiene N, 1998, P NATL ACAD SCI USA, V95, P3743, DOI 10.1073/pnas.95.7.3743; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; MEDHORA MM, 1988, EMBO J, V7, P2185, DOI 10.1002/j.1460-2075.1988.tb03057.x; OBrochta DA, 1996, INSECT BIOCHEM MOLEC, V26, P739, DOI 10.1016/S0965-1748(96)00022-7; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sheng GJ, 1997, GENE DEV, V11, P1122, DOI 10.1101/gad.11.9.1122; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; WARREN WD, 1994, GENET RES, V64, P87, DOI 10.1017/S0016672300032699	12	262	279	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					370	371		10.1038/46463	http://dx.doi.org/10.1038/46463			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586872				2022-12-01	WOS:000083913600041
J	Macedo-Ribeiro, S; Bode, W; Huber, R; Quinn-Allen, MA; Kim, SW; Ortel, TL; Bourenkov, GP; Bartunik, HD; Stubbs, MT; Kane, WH; Fuentes-Prior, P				Macedo-Ribeiro, S; Bode, W; Huber, R; Quinn-Allen, MA; Kim, SW; Ortel, TL; Bourenkov, GP; Bartunik, HD; Stubbs, MT; Kane, WH; Fuentes-Prior, P			Crystal structures of the membrane-binding C2 domain of human coagulation factor V	NATURE			English	Article							FACTOR-VIII; PROTHROMBIN ACTIVATION; PHOSPHOLIPID-VESICLES; PHOSPHATIDYLSERINE; COMPLEX; PROTEIN; ASSOCIATION; INSIGHTS; COFACTOR; MODELS	Rapid and controlled clot formation is achieved through sequential activation of circulating serine proteinase precursors on phosphatidylserine-rich procoagulant membranes of activated platelets and endothelial cells(1). The homologous complexes Xase and prothrombinase, each consisting of an active proteinase and a non-enzymatic cofactor, perform critical steps within this coagulation cascade. The activated cofactors VIIIa and Va, highly specific for their cognate proteinases, are each derived from precursors with the same A1-A2-B-A3-C1-C2 architecture(2). Membrane binding is mediated by the C2 domains of both cofactors, Here we report two crystal structures of the C2 domain of human factor Va. The conserved beta-barrel framework provides a scaffold for three protruding loops, one of which adopts markedly different conformations in the two crystal forms. We propose a mechanism of calcium-independent, stereospecific binding of factors Va and VIIIa to phospholipid membranes(3,4), on the basis of (1) immersion of hydrophobic residues at the apices of these loops in the apolar membrane core; (2) specific interactions with phosphatidylserine head groups in the groove enclosed by these loops; and (3) favourable electrostatic contacts of basic side chains with negatively charged membrane phosphate groups.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Duke Univ, Med Ctr, Dept Med, Div Hematol, Durham, NC 27710 USA; DESY, MPG ASMB, Prot Dynam Grp, Max Planck Res Unit Struct Mol Biol, D-22603 Hamburg, Germany; Univ Marburg, Inst Pharmazeut Chem, D-35032 Marburg, Germany	Max Planck Society; Duke University; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; Philipps University Marburg	Bode, W (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Martinsried, Germany.	bode@biochem.mpg.de	Macedo-Ribeiro, Sandra/D-9258-2011; Bourenkov, Gleb P/C-7794-2017; Stubbs, Milton/ABC-7585-2020	Macedo-Ribeiro, Sandra/0000-0002-7698-1170; Bourenkov, Gleb P/0000-0002-2617-5920; Stubbs, Milton/0000-0003-1278-9013; Fuentes-Prior, Pablo/0000-0002-6618-3204				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; COMFURIUS P, 1994, BIOCHEMISTRY-US, V33, P10319, DOI 10.1021/bi00200a012; Cutsforth GA, 1996, BIOPHYS J, V70, P2938, DOI 10.1016/S0006-3495(96)79864-8; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; GERADS I, 1990, BIOCHEMISTRY-US, V29, P7967, DOI 10.1021/bi00486a027; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1990, J BIOL CHEM, V265, P815; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KANE WH, 1988, BLOOD, V71, P539; KIM SW, IN PRESS BIOCHEMISTR; KNIGHT S, 1989, THESIS SWEDISH U AGR; Koppaka V, 1997, BIOPHYS J, V73, P2638, DOI 10.1016/S0006-3495(97)78293-6; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ORTEL TL, 1994, J BIOL CHEM, V269, P15898; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; Ortel TL, 1998, BLOOD, V91, P4188, DOI 10.1182/blood.V91.11.4188.411k33_4188_4196; Pellequer JL, 1998, BLOOD CELL MOL DIS, V24, P448, DOI 10.1006/bcmd.1998.0214; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; ROSING J, 1993, J BIOL CHEM, V268, P21130; Stenflo J, 1999, CRIT REV EUKAR GENE, V9, P59, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.50; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Villoutreix BO, 1998, J MOL MODEL, V4, P268, DOI 10.1007/s008940050084; Zwaal RFA, 1998, BBA-REV BIOMEMBRANES, V1376, P433, DOI 10.1016/S0304-4157(98)00018-5	30	210	220	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					434	439		10.1038/46594	http://dx.doi.org/10.1038/46594			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586886				2022-12-01	WOS:000083913600062
J	Toni, N; Buchs, PA; Nikonenko, I; Bron, CR; Muller, D				Toni, N; Buchs, PA; Nikonenko, I; Bron, CR; Muller, D			LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; POSTSYNAPTIC DENSITIES; AXOSPINOUS SYNAPSES; PYRAMIDAL CELLS; POTENTIATION; CA1; RAT; SYNAPTOGENESIS; TRANSMISSION; HIPPOCAMPUS	Structural remodelling of synapses(1-4) and formation of new synaptic contacts(5-8) has been postulated as a possible mechanism underlying the late phase of long-term potentiation (LTP), a form of plasticity which is involved in learning and memory(9). Here we use electron microscopy to analyse the morphology of synapses activated by high-frequency stimulation and identified by accumulated calcium in dendritic spines. LTP induction resulted in a sequence of morphological changes consisting of a transient remodelling of the postsynaptic membrane followed by a marked increase in the proportion of axon terminals contacting two or more dendritic spines. Three-dimensional reconstruction revealed that these spines arose from the same dendrite. As pharmacological blockade of LTP prevented these morphological changes, we conclude that LTP is associated with the formation of new, mature and probably functional synapses contacting the same presynaptic terminal and thereby duplicating activated synapses.	Univ Geneva, CMU, CH-1211 Geneva 4, Switzerland; Univ Bern, Inst Anat, CH-3000 Bern, Switzerland	University of Geneva; University of Bern	Muller, D (corresponding author), Univ Geneva, CMU, CH-1211 Geneva 4, Switzerland.		Toni, Nicolas/M-2057-2014	Toni, Nicolas/0000-0001-5585-268X				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bolshakov VY, 1997, NEURON, V19, P635, DOI 10.1016/S0896-6273(00)80377-3; BUCHS PA, 1994, J NEUROSCI METH, V54, P83, DOI 10.1016/0165-0270(94)90162-7; Buchs PA, 1996, P NATL ACAD SCI USA, V93, P8040, DOI 10.1073/pnas.93.15.8040; CALVERLEY RKS, 1990, BRAIN RES REV, V15, P215, DOI 10.1016/0165-0173(90)90002-6; CARLIN RK, 1983, P NATL ACAD SCI-BIOL, V80, P3517, DOI 10.1073/pnas.80.11.3517; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fiala JC, 1998, J NEUROSCI, V18, P8900; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; GEINISMAN Y, 1991, BRAIN RES, V566, P77, DOI 10.1016/0006-8993(91)91683-R; GEINISMAN Y, 1993, HIPPOCAMPUS, V3, P435, DOI 10.1002/hipo.450030405; Geinisman Y, 1996, J COMP NEUROL, V368, P413; Kirov SA, 1999, J NEUROSCI, V19, P2876; Kleim JA, 1997, J NEUROSCI, V17, P717; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; MOSER MB, 1994, P NATL ACAD SCI USA, V91, P12673, DOI 10.1073/pnas.91.26.12673; NIETOSAMPEDRO M, 1982, P NATL ACAD SCI-BIOL, V79, P5718, DOI 10.1073/pnas.79.18.5718; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Sorra KE, 1998, J COMP NEUROL, V398, P225; SORRA KE, 1993, J NEUROSCI, V13, P3736; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Trommald M, 1997, J COMP NEUROL, V377, P15, DOI 10.1002/(SICI)1096-9861(19970106)377:1<15::AID-CNE3>3.0.CO;2-M; Woolley CS, 1996, J COMP NEUROL, V373, P108; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	28	751	761	0	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					421	425		10.1038/46574	http://dx.doi.org/10.1038/46574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586883				2022-12-01	WOS:000083913600059
J	Ryu, WS; Berry, RM; Berg, HC				Ryu, WS; Berry, RM; Berg, HC			Torque-generating units of the flagellar motor of Escherichia coli have a high duty ratio	NATURE			English	Article							OPTICAL TWEEZERS; ROTATION; MOVEMENT; MOTILITY; DOMAIN; MODEL	Rotation of the bacterial flagellar motor is driven by an ensemble of torque-generating units containing the proteins MotA and; MotB(1-3). Here, by inducing expression of MotA in motA(-) cells under conditions of low viscous load, we show that the limiting speed of the motor is independent of the number of units: at vanishing load, one unit turns the motor as rapidly as many. This result indicates that each unit may remain attached to the rotor for most of its mechanochemical cycle, that is, that it has a high duty ratio(4). Thus, torque generators behave more like kinesin, the protein that moves vesicles along microtubules, than myosin, the protein that powers muscle. However, their translation rates, stepping frequencies and power outputs are much higher, being greater than 30 mu m s(-1), 12 Hz and 1.5 x 10(5) pN nm s(-1) respectively.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Rowland Inst Sci Inc, Cambridge, MA 02142 USA; Kings Coll London, Randall Ctr, London SE1 1UL, England	Harvard University; University of London; King's College London	Berg, HC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.							ARMSTRONG JB, 1967, GENETICS, V56, P363; BERG HC, 1993, BIOPHYS J, V65, P2201, DOI 10.1016/S0006-3495(93)81278-5; Berry RM, 1999, BIOPHYS J, V76, P580, DOI 10.1016/S0006-3495(99)77226-7; Berry RM, 1999, ADV MICROB PHYSIOL, V41, P291, DOI 10.1016/S0065-2911(08)60169-1; Berry RM, 1997, P NATL ACAD SCI USA, V94, P14433, DOI 10.1073/pnas.94.26.14433; BLAIR DF, 1988, SCIENCE, V242, P1678, DOI 10.1126/science.2849208; BLOCK SM, 1984, NATURE, V309, P470, DOI 10.1038/309470a0; BLOCK SM, 1991, CYTOMETRY, V12, P492, DOI 10.1002/cyto.990120605; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; CHEN X, IN PRESS BIOPHYS J; DeRosier DJ, 1998, CELL, V93, P17, DOI 10.1016/S0092-8674(00)81141-1; FUNG DCY, 1994, THESIS HARVARD U; Gittes F, 1998, OPT LETT, V23, P7, DOI 10.1364/OL.23.000007; Happel J., 1991, LOW REYNOLDS NUMBER; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; KUWAJIMA G, 1988, J BACTERIOL, V170, P485, DOI 10.1128/jb.170.1.485-488.1988; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; MACNAB RM, 1977, P NATL ACAD SCI USA, V74, P221, DOI 10.1073/pnas.74.1.221; Macnab RM, 1996, ESCHERICHIA COLI SAL, V1, P123; MAURER L, 1987, J BACTERIOL, V169, P640, DOI 10.1128/jb.169.2.640-645.1987; MURAMOTO K, 1995, J MOL BIOL, V251, P50, DOI 10.1006/jmbi.1995.0415; Samuel ADT, 1996, BIOPHYS J, V71, P918, DOI 10.1016/S0006-3495(96)79295-0; SILVERMAN M, 1974, NATURE, V249, P73, DOI 10.1038/249073a0; SILVERMAN M, 1976, NATURE, V264, P577, DOI 10.1038/264577a0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; [No title captured]	30	183	186	3	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					444	447		10.1038/35000233	http://dx.doi.org/10.1038/35000233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667798				2022-12-01	WOS:000085121100054
J	Kavanagh, AM; Mitchell, H; Giles, GG				Kavanagh, AM; Mitchell, H; Giles, GG			Hormone replacement therapy and accuracy of mammographic screening	LANCET			English	Article							BREAST-CANCER; FAMILY HISTORY; DENSITY; WOMEN; AGE; SENSITIVITY; ESTROGEN; SPECIFICITY; INTERVAL; PROGRAM	Background Hormone replacement therapy (HRT) is commonly used and may affect the accuracy of mammographic screening. Methods We examined the sensitivity, specificity, and small-cancer detection rate according to HRT use in 103 770 women in Victoria, Australia, who attended first-round screening in 1994 and who did not have a personal history of breast cancer or a breast lump or a bloodstained or watery nipple discharge at the time of screening. BreastScreen Victoria provides mammography to women aged 40 years and older every 2 years. Unconditional logistic modelling was used to adjust for age, family history, and symptom status. Findings The sensitivity of screening mammography for a 2-year screening interval was lower in HRT users (64.8% [95% CI 58-72]) than nonusers (77.3% [74-81]). In the target group (50-69 years), the sensitivity was 64.3% (57-72) in HRT users and 79.8% (76-84) in non-users. Among women who were diagnosed with cancer during the 2-year screening interval, HRT users were more likely to have a false negative result than nonusers (odds ratio 1.60 [1.04-2.21]) after adjusting for potential confounding factors. Specificity was 0.6% lower in HRT users compared with nonusers. Among women who did not have cancer diagnosed in the interval, HRT users were more likely to have a false positive result (adjusted odds ratio 1.12 [1.05-1.19]). Interpretation We show that HRT use reduces the sensitivity of mammographic screening. In countries where HRT use is widespread, the reduction in sensitivity with HRT use may undermine the capacity of population-based mammographic-screening programmes to realise their potential mortality benefit.	La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Melbourne, Vic 3000, Australia; Anticanc Council Victoria, Canc Epidemiol Ctr, Carlton South, Vic, Australia; Victoria BreastScreen Registry, Carlton South, Vic, Australia	La Trobe University	Kavanagh, AM (corresponding author), La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, 215 Franklin St, Melbourne, Vic 3000, Australia.		Kavanagh, Anne/U-4826-2019	Giles, Graham/0000-0003-4946-9099; Kavanagh, Anne/0000-0002-1573-3464				Australian Bureau of Statistics, 1999, AUSTR DEM STAT; Beral V, 1997, LANCET, V349, P1103, DOI 10.1016/S0140-6736(05)62328-8; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P503, DOI 10.1093/oxfordjournals.aje.a115364; BERKOWITZ JE, 1990, RADIOLOGY, V174, P199, DOI 10.1148/radiology.174.1.2152982; BRISSON J, 1988, J NATL CANCER I, V80, P1534, DOI 10.1093/jnci/80.19.1534; Cohen MEL, 1997, LANCET, V349, P1624, DOI 10.1016/S0140-6736(05)61662-5; Harding C, 1996, BRIT MED J, V312, P1646, DOI 10.1136/bmj.312.7047.1646; Harvey JA, 1997, J NATL CANCER I, V89, P1623, DOI 10.1093/jnci/89.21.1623; Holli K, 1997, LANCET, V350, P1704, DOI 10.1016/S0140-6736(05)64308-5; HURLEY SF, 1992, EPIDEMIOL REV, V14, P101, DOI 10.1093/oxfordjournals.epirev.a036082; Kavanagh AM, 1999, J MED SCREEN, V6, P139, DOI 10.1136/jms.6.3.139; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; Laya MB, 1996, J NATL CANCER I, V88, P643, DOI 10.1093/jnci/88.10.643; LAYA MB, 1995, RADIOLOGY, V196, P433, DOI 10.1148/radiology.196.2.7617857; Leung W, 1997, SURGERY, V122, P669, DOI 10.1016/S0039-6060(97)90072-6; Litherland JC, 1997, CLIN RADIOL, V52, P276, DOI 10.1016/S0009-9260(97)80053-0; Litherland JC, 1999, CLIN RADIOL, V54, P285, DOI 10.1016/S0009-9260(99)90555-X; Lundstrom E, 1999, AM J OBSTET GYNECOL, V181, P348, DOI 10.1016/S0002-9378(99)70560-0; MA L, 1992, J NATL CANCER I, V84, P781, DOI 10.1093/jnci/84.10.781; MACLENNAN AH, 1995, MED J AUSTRALIA, V162, P420, DOI 10.5694/j.1326-5377.1995.tb139971.x; Magnusson C, 1996, BREAST CANCER RES TR, V38, P325, DOI 10.1007/BF01806152; Marugg RC, 1997, EUR RADIOL, V7, P749, DOI 10.1007/BF02742938; MCNICHOLAS MMJ, 1994, AM J ROENTGENOL, V163, P311, DOI 10.2214/ajr.163.2.8037021; Peer PGM, 1996, BREAST CANCER RES TR, V38, P153, DOI 10.1007/BF01806669; Persson I, 1997, J CLIN ONCOL, V15, P3201, DOI 10.1200/JCO.1997.15.10.3201; Rand T, 1997, ACTA RADIOL, V38, P228; Rosenberg RD, 1998, RADIOLOGY, V209, P511, DOI 10.1148/radiology.209.2.9807581; Roubidoux MA, 1998, RADIOLOGY, V208, P725, DOI 10.1148/radiology.208.3.9722852; Salmon RJ, 1995, LANCET, V346, P1702, DOI 10.1016/S0140-6736(95)92864-2; Schouten LJ, 1997, LANCET, V349, P1104, DOI 10.1016/S0140-6736(05)62329-X; Seradour B, 1999, J MED SCREEN, V6, P99, DOI 10.1136/jms.6.2.99; SHELLEY JM, 1995, AUST J PUBLIC HEALTH, V19, P387; STOMPER PC, 1990, RADIOLOGY, V174, P487, DOI 10.1148/radiology.174.2.2136958; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; Threlfall AG, 1997, LANCET, V349, P472, DOI 10.1016/S0140-6736(05)61182-8; Thurfjell EL, 1997, RADIOLOGY, V203, P339, DOI 10.1148/radiology.203.2.9114085; van Gils CH, 1998, J EPIDEMIOL COMMUN H, V52, P267, DOI 10.1136/jech.52.4.267; WALD NJ, 1995, BRIT MED J, V311, P1189, DOI 10.1136/bmj.311.7014.1189	40	131	136	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 22	2000	355	9200					270	274		10.1016/S0140-6736(99)07319-5	http://dx.doi.org/10.1016/S0140-6736(99)07319-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279LQ	10675074				2022-12-01	WOS:000085045600010
J	Barkai, N; Leibler, S				Barkai, N; Leibler, S			Biological rhythms - Circadian clocks limited by noise	NATURE			English	Article									Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University; Princeton University	Barkai, N (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.							Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Edmund L.N., 1988, CELLULAR MOL BASIS B; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Glossop NRJ, 1999, SCIENCE, V286, P766, DOI 10.1126/science.286.5440.766; Goldbeter A., 1995, BIOCH OSCILLATIONS C; KO MSH, 1992, BIOESSAYS, V14, P341, DOI 10.1002/bies.950140510; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; Leloup JC, 1998, J BIOL RHYTHM, V13, P70, DOI 10.1177/074873098128999934; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; Murray J. D., 1994, MATH BIOL; Suri V, 1999, EMBO J, V18, P675, DOI 10.1093/emboj/18.3.675; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	12	394	402	2	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 20	2000	403	6767					267	268		10.1038/35002258	http://dx.doi.org/10.1038/35002258			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	276VU	10659837				2022-12-01	WOS:000084899700040
J	Miyado, K; Yamada, G; Yamada, S; Hasuwa, H; Nakamura, Y; Ryu, F; Suzuki, K; Kosai, K; Inoue, K; Ogura, A; Okabe, M; Mekada, E				Miyado, K; Yamada, G; Yamada, S; Hasuwa, H; Nakamura, Y; Ryu, F; Suzuki, K; Kosai, K; Inoue, K; Ogura, A; Okabe, M; Mekada, E			Requirement of CD9 on the egg plasma membrane for fertilization	SCIENCE			English	Article							DIPHTHERIA-TOXIN RECEPTOR; MONOCLONAL-ANTIBODY; GROWTH-FACTOR; CELL-SURFACE; IN-VITRO; BINDING; PROTEIN; EXPRESSION; MOTILITY; INTEGRINS	CD9 is an integral membrane protein associated with integrins and other membrane proteins, Mice lacking CD9 were produced by homologous recombination. Both male and female CD9(-/-) mice were born healthy and grew normally, However, the litter size from CD9(-/-) females was less than 2% of that of the wild type. In vitro fertilization experiments indicated that the cause of this infertility was due to;the failure of sperm-egg fusion. When sperm were injected into oocytes with assisted microfertilization techniques, however, the fertilized eggs developed to term. These results indicate that CD9 has a crucial role in sperm-egg fusion.	Kurume Univ, Inst Life Sci, Fukuoka 8390861, Japan; Kurume Univ, Res Ctr Innovat Canc Therapy, Fukuoka 8300011, Japan; Kumamoto Univ, Ctr Anim Resources & Dev, Kumamoto 8600811, Japan; Program Promot Basic Res Act Innovat Biosci, Tokyo 1050001, Japan; St Marys Hosp, Fukuoka 8300047, Japan; Natl Inst Infect Dis, Shinjuku Ku, Tokyo 1628640, Japan; Osaka Univ, Genome Informat Res Ctr, Osaka 5650861, Japan	Kurume University; Kurume University; Kumamoto University; National Institute of Infectious Diseases (NIID); Osaka University	Mekada, E (corresponding author), Kurume Univ, Inst Life Sci, Fukuoka 8390861, Japan.	emekada@lsi.kurume-u.ac.jp	Hasuwa, Hidetoshi/B-1083-2009; MIYADO, KENJI/E-6568-2013; Ogura, Atsuo/J-3916-2014; Okabe, Masaru/B-6917-2015	Ogura, Atsuo/0000-0003-0447-1988; Mekada, Eisuke/0000-0001-8858-4781; Miyado, Kenji/0000-0002-8339-6738; Okabe, Masaru/0000-0002-0803-9044; Yamada, Gen/0000-0001-6160-2660				ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; ANTON ES, 1995, J NEUROSCI, V15, P584; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Bigler D, 1997, TRENDS CELL BIOL, V7, P220, DOI 10.1016/S0962-8924(97)01058-1; CHATOT CL, 1989, J REPROD FERTIL, V86, P679, DOI 10.1530/jrf.0.0860679; Chen H, 1999, CHEM BIOL, V6, P1, DOI 10.1016/S1074-5521(99)80015-5; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Evans JP, 1998, BIOL REPROD, V59, P145, DOI 10.1095/biolreprod59.1.145; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; HAYAKAWA S, 1983, J BIOL CHEM, V258, P4311; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; KERSEY JH, 1981, J EXP MED, V153, P726, DOI 10.1084/jem.153.3.726; Loffler S, 1997, J VIROL, V71, P42; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MIYADO K, UNPUB; Myles DG, 1997, BIOL REPROD, V56, P320, DOI 10.1095/biolreprod56.2.320; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Nakamura Y, 1996, AM J PATHOL, V149, P575; NEWMAN RA, 1982, BIOCHIM BIOPHYS ACTA, V701, P318, DOI 10.1016/0167-4838(82)90234-5; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; Wakayama T, 1998, NAT BIOTECHNOL, V16, P639, DOI 10.1038/nbt0798-639; WASSARMAN PM, 1987, SCIENCE, V235, P553, DOI 10.1126/science.3027891; Yanagimachi R., 1994, P189; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [10.1262/jrd1955.16.147, DOI 10.1262/JRD1955.16.147]	31	522	553	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2000	287	5451					321	324		10.1126/science.287.5451.321	http://dx.doi.org/10.1126/science.287.5451.321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ML	10634791				2022-12-01	WOS:000084769600046
J	Smith, O				Smith, O			Nota bene: Aging - Sensing old age	SCIENCE			English	Editorial Material																		Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694	2	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	2000	287	5450					54	54		10.1126/science.287.5450.54	http://dx.doi.org/10.1126/science.287.5450.54			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	271DG	10644225				2022-12-01	WOS:000084578400031
J	Iacoboni, M; Woods, RP; Brass, M; Bekkering, H; Mazziotta, JC; Rizzolatti, G				Iacoboni, M; Woods, RP; Brass, M; Bekkering, H; Mazziotta, JC; Rizzolatti, G			Cortical mechanisms of human imitation	SCIENCE			English	Article							AUTOMATED IMAGE REGISTRATION; GRASP REPRESENTATIONS; PREMOTOR CORTEX; AREA 5; MONKEY; BRAIN; CONSCIOUSNESS; LOCALIZATION; RECOGNITION; VALIDATION	How does imitation occur? How can the motor plans necessary for imitating an action derive from the observation of that: action? Imitation may be based on a mechanism directly matching the observed action onto an internal motor representation of that action ("direct matching hypothesis"). To test this hypothesis, normal human participants were asked to observe and imitate a finger movement and to perform the same movement after spatial or symbolic cues. Brain activity was measured with functional magnetic resonance imaging. If the direct matching hypothesis is correct, there should be areas that become active during finger movement; regardless of how it is evoked, and their activation should increase when the same movement is elicited by the observation of an identical movement made by another individual. Two areas with these properties were found in the left; inferior frontal cortex (opercular region) and the rostral-most region of the right superior parietal lobule.	Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Brain Mapping Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA; Max Planck Inst Psychol Res, Dept Cognit & Act, D-80802 Munich, Germany; Univ Parma, Inst Human Physiol, I-43100 Parma, Italy	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Max Planck Society; University of Parma	Iacoboni, M (corresponding author), Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Brain Mapping Ctr, Los Angeles, CA 90095 USA.		Bekkering, Harold/A-6357-2009; Brass, Marcel/J-7082-2012; Galantucci, Bruno/E-5770-2010	Brass, Marcel/0000-0002-3364-4019; 				Berlucchi G, 1997, TRENDS NEUROSCI, V20, P560, DOI 10.1016/S0166-2236(97)01136-3; Binkofski F, 1999, EUR J NEUROSCI, V11, P3276, DOI 10.1046/j.1460-9568.1999.00753.x; Binkofski F, 1999, EXP BRAIN RES, V128, P210, DOI 10.1007/s002210050838; BRASS M, IN PRESS ACTA PSYCHO; BRASS M, IN PRESS BRAIN COGN; BRYNE RW, 1995, THINKING APE EVOLUTI; Byrne RW, 1998, BEHAV BRAIN SCI, V21, P667, DOI 10.1017/S0140525X98001745; De Renzi E., 1990, HDB CLIN NEUROPSYCHO, V2, P245; Decety J, 1997, BRAIN, V120, P1763, DOI 10.1093/brain/120.10.1763; DIPELLEGRINO G, 1992, EXP BRAIN RES, V91, P176, DOI 10.1007/BF00230027; FRITH C, 1995, BEHAV BRAIN SCI, V18, P682, DOI 10.1017/S0140525X00040474; Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593; Georgieff N, 1998, CONSCIOUS COGN, V7, P465, DOI 10.1006/ccog.1998.0367; Gewirtz J.L, 1969, HDB SOCIALIZATION TH, P57; GEWIRTZ JL, 1968, PSYCHOL REV, V75, P374, DOI 10.1037/h0026378; Goldenberg G, 1999, NEUROPSYCHOLOGIA, V37, P559, DOI 10.1016/S0028-3932(98)00111-0; Goldenberg G, 1997, NEUROPSYCHOLOGIA, V35, P333, DOI 10.1016/S0028-3932(96)00085-1; Grafton ST, 1996, EXP BRAIN RES, V112, P103; Grezes J, 1998, COGN NEUROPSYCHOL, V15, P553, DOI 10.1080/026432998381023; Head H, 1920, BRAIN, V43, P87, DOI 10.1093/brain/43.2.87; KALASKA JF, 1983, EXP BRAIN RES, V51, P247; KEPHART NC, 1971, SLOW LEARNER CLASSRO; Krams M, 1998, EXP BRAIN RES, V120, P386, DOI 10.1007/s002210050412; LACQUANITI F, 1995, CEREB CORTEX, V5, P391, DOI 10.1093/cercor/5.5.391; LIBERMAN AM, 1985, COGNITION, V21, P1, DOI 10.1016/0010-0277(85)90021-6; MELTZOFF AN, 1983, CHILD DEV, V54, P702, DOI 10.2307/1130058; Menon RS, 1999, TRENDS COGN SCI, V3, P207, DOI 10.1016/S1364-6613(99)01329-7; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pawlby S. J, 1977, STUDIES MOTHER INFAN, P203; Petrides M., 1994, HDB NEUROPSYCHOLOGY, V9, P17; Piaget J., 1962, PLAY DREAMS IMITATIO; Preuss Todd M., 1995, P1227; Rizzolatti G, 1998, TRENDS NEUROSCI, V21, P188, DOI 10.1016/S0166-2236(98)01260-0; Rizzolatti G, 1996, EXP BRAIN RES, V111, P246; Rizzolatti G, 1999, ARCH ITAL BIOL, V137, P85; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; SAKATA H, 1973, BRAIN RES, V64, P85, DOI 10.1016/0006-8993(73)90172-8; SCHOFIELD WN, 1976, Q J EXP PSYCHOL, V28, P571, DOI 10.1080/14640747608400584; TOMASELLO M, 1993, BEHAV BRAIN SCI, V16, P495, DOI 10.1017/S0140525X0003123X; Von Bonin G., 1947, ILLINOIS MONOGR MED, V5; Woods R. P., 1996, QUANTIFICATION BRAIN, P353, DOI [10.1016/B978-012389760-2/50070-0, DOI 10.1016/B978-012389760-2/50070-0]; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P153, DOI 10.1097/00004728-199801000-00028; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Woods RP, 1999, HUM BRAIN MAPP, V8, P73, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<73::AID-HBM1>3.3.CO;2-Z; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; Zaidel E, 1996, BRAIN, V119, P2155, DOI 10.1093/brain/119.6.2155-a	47	1847	1894	3	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	1999	286	5449					2526	2528		10.1126/science.286.5449.2526	http://dx.doi.org/10.1126/science.286.5449.2526			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	268RQ	10617472				2022-12-01	WOS:000084429700055
J	Schramm, C; Schirmacher, P; Helmreich-Becker, I; Gerken, G; zum Buschenfelde, KHM; Lohse, AW				Schramm, C; Schirmacher, P; Helmreich-Becker, I; Gerken, G; zum Buschenfelde, KHM; Lohse, AW			Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis - A case series	ANNALS OF INTERNAL MEDICINE			English	Article							URSODEOXYCHOLIC ACID; CONTROLLED TRIAL	Background: No established medical therapy alters the progressive course of primary sclerosing cholangitis. Objective: To explore the potential usefulness of combined therapy with azathioprine, steroids and ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis. Design: Case series. Setting: University hospital in Mainz, Germany. Patients: 15 patients with primary sclerosing cholangitis. Intervention: Azathioprine (1 to 1.5 mg/kg of body weight per day), prednisolone (1 mg/kg per day initially, tapering to 5 to 10 mg per day) and UDCA (500 to 750 mg per day). Measurements: Clinical and laboratory evaluation, liver biopsy, and endoscopic retrograde cholangiography (a >30% change in stenosis was considered significant). Results: After a median observation period of 41 months (range, 3 to 81 months), liver enzyme levels declined significantly in all patients. Six of 10 patients with follow-up liver biopsies showed histologic improvement. Significant radiographic deterioration was seen in only 1 of 10 patients who had endoscopic retrograde cholangiography. In 7 patients previously treated with UDCA alone, liver enzyme levels declined significantly only after immunosuppressive therapy was added. Adverse drug reactions led to the withdrawal of study medications in 2 patients. Conclusions: Combined immunosuppressive therapy may alter the progression of primary sclerosing cholangitis. Our observations suggest a benefit from adding immunosuppressive drugs to UDCA therapy. A randomized trial is warranted.	Johannes Gutenberg Univ Mainz, Dept Med, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Lohse, AW (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med, Langenbeckstr 1, D-55131 Mainz, Germany.			Schramm, Christoph/0000-0002-4264-1928				BEUERS U, 1992, HEPATOLOGY, V16, P707, DOI 10.1002/hep.1840160315; BURGERT SL, 1984, GASTROENTEROLOGY, V86, P1037; CHAPMAN RW, 1991, SEMIN LIVER DIS, V11, P1, DOI 10.1055/s-2008-1040415; CHAPMAN RWG, 1980, GUT, V21, P870, DOI 10.1136/gut.21.10.870; HAYASHI H, 1990, GASTROENTEROLOGY, V99, P533, DOI 10.1016/0016-5085(90)91038-8; JAVETT SL, 1971, LANCET, V1, P810; Kaplan MM, 1997, NEW ENGL J MED, V336, P719, DOI 10.1056/NEJM199703063361009; KNOX TA, 1994, GASTROENTEROLOGY, V106, P494, DOI 10.1016/0016-5085(94)90610-6; LARUSSO NF, 1988, GASTROENTEROLOGY, V95, P1036, DOI 10.1016/0016-5085(88)90180-1; LEE YM, 1995, NEW ENGL J MED, V332, P924, DOI 10.1056/NEJM199504063321406; Lindor KD, 1997, NEW ENGL J MED, V336, P691, DOI 10.1056/NEJM199703063361003; LUDWIG J, 1981, Hepatology, V1, P632, DOI 10.1002/hep.1840010612; MENDEL R, 1985, RADIOLOGE, V25, P83; MYERS RN, 1970, AM J GASTROENTEROL, V53, P527; OLSSON R, 1995, GASTROENTEROLOGY, V108, P1199, DOI 10.1016/0016-5085(95)90220-1; Stiehl A, 1997, J HEPATOL, V26, P560, DOI 10.1016/S0168-8278(97)80421-7; VANTHIEL DH, 1995, AM J GASTROENTEROL, V90, P455; WAGNER A, 1971, LANCET, V2, P663; WIESNER RH, 1994, MAYO CLIN PROC, V69, P969, DOI 10.1016/S0025-6196(12)61822-9; WIESNER RH, 1991, HEPATOLOGY, V14, pA63	20	79	80	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	1999	131	12					943	946		10.7326/0003-4819-131-12-199912210-00006	http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	267TB	10610645				2022-12-01	WOS:000084374400005
J	Mindel, A; Tideman, R				Mindel, A; Tideman, R			HPV transmission - still feeling the way	LANCET			English	Editorial Material							CHILDREN; WARTS		Sydney Hosp, Acad Unit Sexual Hlth Med, Sydney, NSW 2001, Australia		Mindel, A (corresponding author), Sydney Hosp, Acad Unit Sexual Hlth Med, Sydney, NSW 2001, Australia.			Mindel, Adrian/0000-0002-8780-9982				FAIRLEY CK, 1995, EPIDEMIOL INFECT, V115, P169, DOI 10.1017/S0950268800058234; FERENCZY A, 1989, OBSTET GYNECOL, V74, P950; Handley J, 1997, PEDIATR DERMATOL, V14, P339, DOI 10.1111/j.1525-1470.1997.tb00976.x; Koutsky LA, 1999, SEXUALLY TRANSMITTED, P347; Matters R, 1998, Commun Dis Intell, V22, P52; ORIEL JD, 1992, GENITOURIN MED, V68, P80; ORIEL JD, 1994, SCARS VENUS HIST VEN, P149; SHAH K V, 1990, P1651; Sonnex C, 1999, SEX TRANSM INFECT, V75, P317, DOI 10.1136/sti.75.5.317; Wen LM, 1999, SEX TRANSM INFECT, V75, P312, DOI 10.1136/sti.75.5.312	10	4	5	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 18	1999	354	9196					2097	2098		10.1016/S0140-6736(99)00367-0	http://dx.doi.org/10.1016/S0140-6736(99)00367-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266UG	10609811				2022-12-01	WOS:000084318200005
J	Hegde, RS; Tremblay, P; Groth, D; DeArmond, SJ; Prusiner, SB; Lingappa, VR				Hegde, RS; Tremblay, P; Groth, D; DeArmond, SJ; Prusiner, SB; Lingappa, VR			Transmissible and genetic prion diseases share a common pathway of neurodegeneration	NATURE			English	Article							CREUTZFELDT-JAKOB-DISEASE; WILD-TYPE; SCRAPIE; PROTEIN; ENCEPHALOPATHY; PATHOGENESIS; PATHOLOGY; HAMSTERS; RODENTS; BRAINS	Prion diseases can be infectious, sporadic and genetic(1-4). The infectious forms of these diseases, including bovine spongiform encephalopathy and Creutzfeldt-Jakob disease, are usually characterized by the accumulation in the brain of the transmissible pathogen, an abnormally folded isoform of the prion protein (PrP) termed PrPSc. However, certain inherited PrP mutations appear to cause neurodegeneration in the absence of PrPSc (refs 5-8), working instead by favoured synthesis of (PrP)-Pr-Ctm, a transmembrane form of PrP (ref. 9). The relationship between the neurodegeneration seen in transmissible prion diseases involving PrPSc and that associated with (PrP)-Pr-Ctm has remained unclear. Here we find that the effectiveness of accumulated PrPSc in causing neurodegenerative disease depends upon the predilection of host-encoded PrP to be made in the (PrP)-Pr-Ctm form. Furthermore, the time course of PrPSc accumulation in transmissible prion disease is followed closely by increased generation of (PrP)-Pr-Ctm. Thus, the accumulation of PrPSc appears to modulate in trans the events involved in generating or metabolising (PrP)-Pr-Ctm. Together, these data suggest that the events of (PrP)-Pr-Ctm-mediated neurodegeneration may represent a common step in the pathogenesis of genetic and infectious prion diseases.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lingappa, VR (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.			Lingappa, Vishwanath R./0000-0003-0962-6571; Hegde, Ramanujan/0000-0001-8338-852X				BARRY RA, 1986, J INFECT DIS, V154, P518, DOI 10.1093/infdis/154.3.518; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; CHANDLER RL, 1961, LANCET, V1, P1378; CZUB M, 1986, J GEN VIROL, V67, P2005, DOI 10.1099/0022-1317-67-9-2005; Gabizon R, 1996, NAT MED, V2, P59, DOI 10.1038/nm0196-59; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; Johnston AR, 1998, NEUROBIOL DIS, V5, P188, DOI 10.1006/nbdi.1998.0194; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MARSH RF, 1975, J INFECT DIS, V131, P104, DOI 10.1093/infdis/131.2.104; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; PATTISON IH, 1968, RES VET SCI, V9, P408; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SPUDICH S, 1995, MOL MED, V1, P607, DOI 10.1007/BF03401601; Tateishi J, 1996, NEUROLOGY, V46, P532, DOI 10.1212/WNL.46.2.532; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; TRANCHANT C, 1992, J NEUROL NEUROSUR PS, V55, P185, DOI 10.1136/jnnp.55.3.185; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; Wong K, 1996, NEUROLOGY, V47, P741, DOI 10.1212/WNL.47.3.741	30	234	240	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 16	1999	402	6763					822	826		10.1038/45574	http://dx.doi.org/10.1038/45574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266ZQ	10617204				2022-12-01	WOS:000084330500068
J	Crabtree, TD; Pelletier, SJ; Gleason, TG; Pruett, TL; Sawyer, RG				Crabtree, TD; Pelletier, SJ; Gleason, TG; Pruett, TL; Sawyer, RG			Gender-dependent differences in outcome after the treatment of infection in hospitalized patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; RISK-FACTORS; MECHANICAL VENTILATION; MORTALITY; WOMEN; SEPSIS; IMPACT; MEN; MANAGEMENT; SEVERITY	Context While it is established that management strategies and outcomes differ by gender for many diseases, its effect on infection has not been adequately studied. Objective To investigate the role of gender among hospitalized patients treated for infection. Design Observational cohort study conducted during a 26-month period from December 1996 through January 1999. Setting University-affiliated hospital. Participants A total of 892 patients in the surgical units of the hospital with 1470 consecutive infectious episodes (782 in men and 688 in women). Main Outcome Measures Mortality during hospitalization by gender for infection episodes overall and for specific infectious sites, including lung, peritoneum, bloodstream, catheter, urine, surgical site, and skin/soft tissue. Results Among all infections, there was no significant difference in mortality based on gender (men, 11.1% vs women, 14.2%; P = .07). After logistic regression analysis, factors independently associated with mortality included higher APACHE (Acute Physiology and Chronic Health Evaluation) II score; older age, malignancy, blood transfusion, and diagnosis of infection more than 7 days after admission, but not gender (female odds ratio [OR] for death, 1.32; 95% confidence interval [CI],0.90-1.94; P = .16). Mortality was higher in women for lung (men, 18% vs women, 34%; P = .002) and soft tissue (men, 2% vs women, 10%; P less than or equal to .05) infection; for other infectious sites, mortality did not differ by gender. Factors associated with mortality due to pneumonia by logistic regression included higher APACHE II score, malignancy, diabetes mellitus, diagnosis of infection more than 7 days after admission, older age, transplantation, and female gender (OR for death, 2.25; 95% CI, 1.17-4.32; P = .02). Conclusions Although gender may not be predictive of mortality among all infections, women appear to be at increased risk for death from hospital-acquired pneumonia, even after controlling for other comorbidities.	Univ Virginia, Hlth Sci Ctr, Dept Surg, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22906 USA	University of Virginia; University of Virginia	Sawyer, RG (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Surg, Box 10005, Charlottesville, VA 22906 USA.			Sawyer, Robert/0000-0002-8155-2661				Angele MK, 1998, ARCH SURG-CHICAGO, V133, P1281, DOI 10.1001/archsurg.133.12.1281; BONE CR, 1992, AM REV RESPIR DIS, V146, P528, DOI 10.1164/ajrccm/146.2.528; Elliott DC, 1996, ANN SURG, V224, P672, DOI 10.1097/00000658-199611000-00011; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kollef MH, 1997, CHEST, V111, P434, DOI 10.1378/chest.111.2.434; Kollef MH, 1997, CHEST, V112, P666, DOI 10.1378/chest.112.3.666; KOLLEF MH, 1993, HEART LUNG, V22, P442; KUBO SH, 1995, J HEART LUNG TRANSPL, V14, P409; Malacrida R, 1998, NEW ENGL J MED, V338, P8, DOI 10.1056/NEJM199801013380102; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MORO ML, 1994, INFECT CONT HOSP EP, V15, P253; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PEARSON ML, 1992, JAMA-J AM MED ASSOC, V268, P1883, DOI 10.1001/jama.268.14.1883; Pittet D, 1997, P ASSOC AM PHYSICIAN, V109, P58; Rello J, 1997, CRIT CARE MED, V25, P1862, DOI 10.1097/00003246-199711000-00026; SARIS GE, 1994, J THORAC CARDIOVASC, V108, P240; Schroder J, 1998, ARCH SURG-CHICAGO, V133, P1200, DOI 10.1001/archsurg.133.11.1200; Singh N, 1998, CHEST, V114, P1129, DOI 10.1378/chest.114.4.1129; Stone PH, 1996, JAMA-J AM MED ASSOC, V275, P1104, DOI 10.1001/jama.275.14.1104; Stroud L, 1996, INFECT CONT HOSP EP, V17, P576; TOFLER GH, 1989, AM J CARDIOL, V64, P256, DOI 10.1016/0002-9149(89)90476-1; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; Zellweger R, 1997, CRIT CARE MED, V25, P106, DOI 10.1097/00003246-199701000-00021; Ziser A, 1999, ANESTHESIOLOGY, V90, P42, DOI 10.1097/00000542-199901000-00008	24	90	91	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2143	2148		10.1001/jama.282.22.2143	http://dx.doi.org/10.1001/jama.282.22.2143			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591336	Bronze			2022-12-01	WOS:000083971400033
J	Zolopa, AR; Shafer, RW; Warford, A; Montoya, JG; Hsu, P; Katzenstein, D; Merigan, TC; Efron, B				Zolopa, AR; Shafer, RW; Warford, A; Montoya, JG; Hsu, P; Katzenstein, D; Merigan, TC; Efron, B			HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus-1; ritonavir; saquinavir; protease inhibitors; genotype	IMMUNODEFICIENCY-VIRUS INFECTION; ANTIRETROVIRAL THERAPY; IN-VIVO; REVERSE-TRANSCRIPTASE; DRUG-RESISTANCE; ZIDOVUDINE RESISTANCE; COMBINATION THERAPY; CONTROLLED TRIAL; PLUS SAQUINAVIR; CELL COUNTS	Background: Tests for resistance to HIV drugs are available for clinical use; however, their predictive Value has not been fully assessed. Objectives: To determine HIV-1 genotypic predictors of a virologic response to saquinavir-ritonavir therapy in patients in whom at least one previous protease inhibitor-containing regimen had failed and to compare the predictive value of baseline genotype with that of standard clinical evaluation. Design: Retrospective clinical cohort study. Setting: University-based HIV clinic. Patients: 54 H.IV-1-infected adults treated with saquinavir-ritonavir who had experienced virologic failure while receiving a protease inhibitor-containing regimen for at least 3 months. Measurements: HIV-1 reverse transcriptase and protease gene sequences, CD4 cell counts, clinical characteristics, detailed antiretroviral treatment history, and plasma HIV-1 RNA levels at baseline and at three follow-up time points (median, 4, 12, and 26 weeks). Virologic failure was defined as a plasma HIV RNA level greater than 1000 copies/mL. Results: In 22 patients (41%), a plasma HIV-1 RNA level less than 500 copies/mL was achieved by week 12; in 15 patients (28%), this response was maintained through week 26. Clinical characteristics predicting a poorer response included a diagnosis of AIDS, Tower CD4 cell count, and higher plasma HIV RNA level (P < 0.03). Number of previous nucleoside reverse transcriptase inhibitors, previous protease inhibitor therapy, and duration of previous protease inhibitor therapy were predictors of poorer response (P < 0.01). Multivariate regression models revealed that protease mutations present at the initiation of saquinavir-ritonavir therapy were the strongest predictors of virologic response. A model of clinical features explained up to 45% of the variation in virologic outcomes by week 12, whereas the explained variance was 71% when genotypic predictors were included. Conclusions: In patients in whom protease inhibitor-containing antiretroviral therapy fails, HIV-1 genotype is predictive of virologic response to subsequent therapy. This predictive capacity adds to that of standard clinical evaluation.	Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA	Stanford University; Stanford University	Zolopa, AR (corresponding author), Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Grant Bldg,Room S-156, Stanford, CA 94305 USA.	azolopa@stanford.edu	Merigan, Thomas/AGQ-7464-2022	katzenstein, david/0000-0002-8593-4560; Montoya, Jose G/0000-0002-3378-8071	NIAID NIH HHS [R01 AI046148, R01 AI046148-08] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046148] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angel JB, 1998, J INFECT DIS, V177, P898, DOI 10.1086/515244; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BAXTER JD, 1999, P 6 C RETR OPP INF C; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; CHATTERJEE S, 1988, SENSITIVITY REGRESSI, P117; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Condra JH, 1998, ANN INTERN MED, V128, P951, DOI 10.7326/0003-4819-128-11-199806010-00017; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONDRA JH, 1997, 1 INT WORKSH HIV RES, P31; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; Deeks SG, 1997, LANCET, V349, P1489, DOI 10.1016/S0140-6736(05)62092-2; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Deeks SG, 1999, J INFECT DIS, V179, P1375, DOI 10.1086/314775; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; EASTMAN PS, 1995, J CLIN MICROBIOL, V33, P2777, DOI 10.1128/JCM.33.10.2777-2780.1995; EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARRIGAN PR, IN PRESS AID; Hazuda D, 1997, NAT MED, V3, P836, DOI 10.1038/nm0897-836; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Jacobsen H, 1996, J INFECT DIS, V173, P1379, DOI 10.1093/infdis/173.6.1379; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; KOZAL MJ, 1994, ANN INTERN MED, V121, P263, DOI 10.7326/0003-4819-121-4-199408150-00005; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; LANIER ER, 1999, ANTIVIR THER S, V4, P56; LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0; Lorenzi P, 1999, AIDS, V13, pF17, DOI 10.1097/00002030-199902040-00001; Lorenzi P, 1997, AIDS, V11, pF95, DOI 10.1097/00002030-199712000-00002; *LOS AL NAT LAB, 1997, HUM RETR AIDS COMP A; MAYERS DL, 1997, 1 INT WORKSH HIV RES, P52; Miller V, 1998, J INFECT DIS, V177, P1521, DOI 10.1086/515304; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Patick AK, 1996, ANTIMICROB AGENTS CH, V40, P292, DOI 10.1128/AAC.40.2.292; PATRICK AK, 1998, 2 INT WORKSH HIV DRU, P39; Powderly WG, 1998, JAMA-J AM MED ASSOC, V280, P72, DOI 10.1001/jama.280.1.72; Rey D, 1998, J ACQ IMMUN DEF SYND, V17, P203, DOI 10.1097/00042560-199803010-00003; Schapiro JM, 1996, ANN INTERN MED, V124, P1039, DOI 10.7326/0003-4819-124-12-199606150-00003; SCHINAZI RF, 1997, INT ANTIVIRAL NEWS, V5, P2; Shafer RW, 1998, ANN INTERN MED, V128, P906, DOI 10.7326/0003-4819-128-11-199806010-00008; SHAFER RW, 1995, J INFECT DIS, V172, P70, DOI 10.1093/infdis/172.1.70; Stuyver L, 1997, ANTIMICROB AGENTS CH, V41, P284, DOI 10.1128/AAC.41.2.284; Sun R, 1998, J CLIN MICROBIOL, V36, P2964, DOI 10.1128/JCM.36.10.2964-2969.1998; Tebas P, 1999, AIDS, V13, pF23, DOI 10.1097/00002030-199902040-00002; Vanhove GF, 1996, JAMA-J AM MED ASSOC, V276, P1955, DOI 10.1001/jama.276.24.1955; Vella S, 1998, AIDS Clin Care, V10, P17; Winters MA, 1998, J VIROL, V72, P5303, DOI 10.1128/JVI.72.6.5303-5306.1998; 1998, ANN INT MED, V128, P1079	56	173	178	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	1999	131	11					813	+		10.7326/0003-4819-131-11-199912070-00003	http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262ET	10610625	Green Accepted			2022-12-01	WOS:000084053200002
J	Bonkowsky, JL; Yoshikawa, S; O'Keefe, DD; Scully, AL; Thomas, JB				Bonkowsky, JL; Yoshikawa, S; O'Keefe, DD; Scully, AL; Thomas, JB			Axon routing across the midline controlled by the Drosophila Derailed receptor	NATURE			English	Article							GROWTH CONE GUIDANCE; NEURONAL PATHWAY SELECTION; CNS MIDLINE; COMMISSURAL AXONS; GENETIC-ANALYSIS; NERVOUS-SYSTEM; PROTEIN; ENCODES; MEMBER; EXPRESSION	In nervous systems with symmetry about the midline, many neurons project axons from one side to the other. Although several of the components controlling midline crossing have been identified(1-4), little is known about how axons choose the appropriate pathway when crossing. For example, in the Drosophila embryo axons cross the midline in one of two distinct tracts, the anterior or posterior commissure (AC or PC, respectively). Here we show that the Derailed (Drl) receptor tyrosine kinase is expressed by neurons that project in the AC, and that in the absence of Drl such neurons often project abnormally into the PC. Conversely, misexpression of Drl in PC neurons forces them to cross in the AC. The behaviour of Drl-misexpressing neurons and the in vivo binding pattern of a soluble Drl receptor probe indicate that Drl acts as a guidance receptor for a repellent ligand present in the PC. Our results show that Drl is a novel component in the control of midline crossing.	Salk Inst Biol Studies, Mol Neurobiol Lab, San Diego, CA 92186 USA	Salk Institute	Thomas, JB (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, POB 85800, San Diego, CA 92186 USA.							Bonkowsky JL, 1999, MECH DEVELOP, V82, P181, DOI 10.1016/S0925-4773(99)00007-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Callahan CA, 1996, DEVELOPMENT, V122, P2761; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHEN G, 1994, BIOL CONTROL, V4, P157, DOI 10.1006/bcon.1994.1025; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; Dittrich R, 1997, DEVELOPMENT, V124, P2515; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; Higashijima S, 1996, DEVELOPMENT, V122, P527; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; KIDD T, 1999, DROSOPHILA CELL, V96, P785; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LUNDGREN SE, 1995, DEVELOPMENT, V121, P1769; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; Moreau-Fauvarque C, 1998, MECH DEVELOP, V78, P47, DOI 10.1016/S0925-4773(98)00147-6; O'Keefe DD, 1998, DEVELOPMENT, V125, P3915; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Simon AF, 1998, MECH DEVELOP, V76, P45, DOI 10.1016/S0925-4773(98)00104-X; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; Thor S, 1999, NATURE, V397, P76, DOI 10.1038/16275; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6	30	105	106	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					540	544		10.1038/990122	http://dx.doi.org/10.1038/990122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591215				2022-12-01	WOS:000084013200059
J	Callahan, D				Callahan, D			Aging, death, and population health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Hastings Ctr, Garrison, NY 10524 USA		Callahan, D (corresponding author), Hastings Ctr, Garrison, NY 10524 USA.							CALLAHAN D, 1989, JAMA-J AM MED ASSOC, V261, P905, DOI 10.1001/jama.261.6.905; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; Larson E B, 1999, Jt Comm J Qual Improv, V25, P480	3	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2077	2077		10.1001/jama.282.21.2077	http://dx.doi.org/10.1001/jama.282.21.2077			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	259TB	10591393	hybrid			2022-12-01	WOS:000083908700030
J	Qiu, YL; Lee, JH; Bernasconi-Quadroni, F; Soltis, DE; Soltis, PS; Zanis, M; Zimmer, EA; Chen, ZD; Savolainen, V; Chase, MW				Qiu, YL; Lee, JH; Bernasconi-Quadroni, F; Soltis, DE; Soltis, PS; Zanis, M; Zimmer, EA; Chen, ZD; Savolainen, V; Chase, MW			The earliest angiosperms: evidence from mitochondrial, plastid and nuclear genomes	NATURE			English	Article							INFERRING COMPLEX PHYLOGENIES; NUCLEOTIDE-SEQUENCES; GENE RBCL; ORIGIN; PLANTS; POLLEN	Angiosperms have dominated the Earth's vegetation since the mid-Cretaceous (90 million years ago)(1), providing much of our food, fibre, medicine and timber, yet their origin and early evolution have remained enigmatic for over a century(2-8). One part of the enigma lies in the difficulty of identifying the earliest angiosperms; the other involves the uncertainty regarding the sister group of angiosperms among extant and fossil gymnosperms. Here we report a phylogenetic analysis of DNA sequences of five mitochondrial, plastid and nuclear genes (total aligned length 8,733 base pairs), from all basal angiosperm and gymnosperm lineages (105 species, 103 genera and 63 families). Our study demonstrates that Amborella, Nymphaeales and Illiciales-Trimeniaceae-Austrobaileya represent the first stage of angiosperm evolution, with Amborella being sister to all other angiosperms. We also show that Gnetales are related to the conifers and are not sister to the angiosperms, thus refuting the Anthophyte Hypothesis(1). These results have far-reaching implications for our understanding of diversification, adaptation, genome evolution and development of the angiosperms.	Univ Zurich, Inst Systemat Bot, CH-8008 Zurich, Switzerland; Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA; Smithsonian Inst, Lab Mol Systemat, Washington, DC 20560 USA; Royal Bot Gardens, Jodrell Lab, Richmond TW9 3DS, Surrey, England	University of Zurich; Washington State University; Smithsonian Institution; Royal Botanic Gardens, Kew	Qiu, YL (corresponding author), Univ Zurich, Inst Systemat Bot, Zollikerstr 107, CH-8008 Zurich, Switzerland.		Soltis, Pamela S/GNH-5557-2022; Chase, Mark W/A-6642-2011; Soltis, Douglas/L-5957-2015; Zimmer, Elizabeth/G-3890-2011; Soltis, Pamela S/L-5184-2015	Soltis, Pamela S/0000-0001-9310-8659; Zimmer, Elizabeth/0000-0003-3949-4290; Kim, Sangtae/0000-0002-1821-4707; Savolainen, Vincent/0000-0001-5350-9984				Arber E. A. N., 1907, J LINN SOC BOT, V38, P29, DOI [10.1111/j.1095-8339.1907.tb01074.x, DOI 10.1111/J.1095-8339.1907.TB01074.X]; CHASE MW, 1993, ANN MO BOT GARD, V80, P528, DOI 10.2307/2399846; CRANE PR, 1995, NATURE, V374, P27, DOI 10.1038/374027a0; Cronquist A., 1988, EVOLUTION CLASSIFICA, V2; DARWIN C, 1903, MORE LETT C DARWIN R, V2, P26; Darwin C., 1903, MORE LETT C DARWIN R, VII, P20; Donoghue MJ, 1989, EVOLUTION SYSTEMATIC, V1, P17; DOYLE JA, 1969, J ARNOLD ARBORETUM, V50, P1; DOYLE JA, 1978, ANNU REV ECOL SYST, V9, P365, DOI 10.1146/annurev.es.09.110178.002053; Endress PK, 1997, BOT J LINN SOC, V125, P93, DOI 10.1111/j.1095-8339.1997.tb02250.x; ENDRESS PK, 1986, PLANT SYST EVOL, V152, P1, DOI 10.1007/BF00985348; Friis EM, 1999, ANN MO BOT GARD, V86, P259, DOI 10.2307/2666179; FRIIS EM, 1994, PL SYST EVOL S, V8, P31; Graybeal A, 1998, SYST BIOL, V47, P9, DOI 10.1080/106351598260996; Hamby RK, 1992, MOL SYSTEMATICS PLAN, P50, DOI [10.1007/978-1-4615-3276-7_4, DOI 10.1007/978-1-4615-3276-7_4]; Hillis DM, 1996, NATURE, V383, P130, DOI 10.1038/383130a0; MARTIN PG, 1991, ANN MO BOT GARD, V78, P296, DOI 10.2307/2399564; Mathews S, 1999, SCIENCE, V286, P947, DOI 10.1126/science.286.5441.947; Naylor GJP, 1997, NATURE, V388, P527, DOI 10.1038/41460; PARKINSON CL, IN PRESS CURR BIOL; QIU YL, 1993, ANN MO BOT GARD, V80, P587, DOI 10.2307/2399848; Qiu YL, 1999, TRENDS PLANT SCI, V4, P26, DOI 10.1016/S1360-1385(98)01361-2; Soltis DE, 1997, ANN MO BOT GARD, V84, P1, DOI 10.2307/2399952; Soltis DE, 1998, SYST BIOL, V47, P32, DOI 10.1080/106351598261012; Soltis PS, 1999, NATURE, V402, P402, DOI 10.1038/46528; Sun G, 1998, SCIENCE, V282, P1692, DOI 10.1126/science.282.5394.1692; Swofford D.L., 1998, PAUP 4 0B2 PHYLOGENE; Takhtajan A, 1969, FLOWERING PLANTS ORI; TAYLOR DW, 1990, SCIENCE, V247, P702, DOI 10.1126/science.247.4943.702; VONWETTSTEIN RR, 1907, HDB SYSTEMATISCHEN B, V2; WALKER JW, 1984, ANN MO BOT GARD, V71, P464, DOI 10.2307/2399035; WALKER JW, 1983, SCIENCE, V220, P1273, DOI 10.1126/science.220.4603.1273	32	666	722	4	134	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					404	407		10.1038/46536	http://dx.doi.org/10.1038/46536			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586879				2022-12-01	WOS:000083913600054
J	Rongo, C; Kaplan, JM				Rongo, C; Kaplan, JM			CaMKII regulates the density of central glutamatergic synapses in vivo	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PROTEIN-KINASE-II; RECEPTOR; PHOSPHORYLATION; LOCALIZATION; SUBUNIT; MUTANTS; NEURONS	Synaptic connections undergo a dynamic process of stabilization or elimination during development, and this process is thought to be critical in memory and learning and in establishing the specificity of synaptic connections(1). The type II calcium- and calmodulin-dependent protein kinase (CaMKII) has been proposed to be pivotal in regulating synaptic strength(2-4) and in maturation of synapses during developments. Here we describe how CaMKII regulates the formation of central glutamatergic synapses in Caenorhabditis elegans, During larval development, the density of ventral nerve cord synapses containing the GLR-1 glutamate receptor is held constant despite marked changes in neurite length. The coupling of synapse number to neurite length requires both CaMKII and voltage-gated calcium channels. CaMKII regulates GLR-1 by at least two distinct mechanisms: regulating transport of GLR-1 from cell bodies to neurites; and regulating the addition or maintenance of GLR-1 to postsynaptic elements.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Kaplan, JM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, LSA 361, Berkeley, CA 94720 USA.							Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; FONG YL, 1989, J BIOL CHEM, V264, P16759; HART A, 1993, NATURE, V378, P82; Hebb D.O., 2002, CLIN PSYCHOL; Kim JH, 1999, CURR OPIN CELL BIOL, V11, P248, DOI 10.1016/S0955-0674(99)80033-7; Lee RYN, 1997, EMBO J, V16, P6066, DOI 10.1093/emboj/16.20.6066; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Nonet ML, 1998, J NEUROSCI, V18, P70; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; Reiner DJ, 1999, NATURE, V402, P199, DOI 10.1038/46072; Riddle DL, 1997, C ELEGANS; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222	27	153	168	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					195	199		10.1038/46065	http://dx.doi.org/10.1038/46065			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647013				2022-12-01	WOS:000083716400054
J	Mani, SK; Fienberg, AA; O'Callaghan, JP; Snyder, GL; Allen, PB; Dash, PK; Moore, AN; Mitchell, AJ; Bibb, J; Greengard, P; O'Malley, BW				Mani, SK; Fienberg, AA; O'Callaghan, JP; Snyder, GL; Allen, PB; Dash, PK; Moore, AN; Mitchell, AJ; Bibb, J; Greengard, P; O'Malley, BW			Requirement for DARPP-32 in progesterone-facilitated sexual receptivity in female rats and mice	SCIENCE			English	Article							REGULATED NEURONAL PHOSPHOPROTEIN; CYCLIC-AMP; PROTEIN PHOSPHATASE-1; OVARIECTOMIZED RATS; DOPAMINE; BEHAVIOR; RECEPTOR; PHOSPHORYLATION; ACTIVATION; LORDOSIS	DARPP-32, a dopamine- and adenosine 3',5'-monophosphate (cAMP)-regulated phosphoprotein (32 kilodaltons in size), is an obligate intermediate in progesterone (P)-facilitated sexual receptivity in female rats and mice. The facilitative effect of P on sexual receptivity in female rats was blocked by antisense oligonucleotides to DARPP-32. Homozygous mice carrying a null mutation for the DARPP-32 gene exhibited minimal levels of P-facilitated sexual receptivity when compared to their wild-type Littermates. P significantly increased hypothalamic cAMP levels and cAMP-dependent protein kinase activity. These increases were not inhibited by a D-1 subclass dopamine receptor antagonist. P also enhanced phosphorylation of DARPP-32 on threonine 34 in the hypothalamus of mice. DARPP-32 activation is thus an obligatory step in progestin receptor regulation of sexual receptivity in rats and mice.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA	Baylor College of Medicine; Rockefeller University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University of Texas System	Mani, SK (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	smani@bcm.tmc.edu	O'Callaghan, James/O-2958-2013		NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH057442, R01MH057442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035457] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57442, MH49662] Funding Source: Medline; NINDS NIH HHS [NS 35457] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN PB, UNPUB; Apostolakis EM, 1996, J NEUROSCI, V16, P4823; BEYER C, 1986, ANN NY ACAD SCI, V474, P270, DOI 10.1111/j.1749-6632.1986.tb28018.x; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA; Greengard P, 1998, BRAIN RES REV, V26, P274, DOI 10.1016/S0165-0173(97)00057-X; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; KIMURA F, 1980, ENDOCRINOLOGY, V106, P631, DOI 10.1210/endo-106-2-631; Kohlert JG, 1997, HORM BEHAV, V32, P143, DOI 10.1006/hbeh.1997.1415; Kow L, 1994, NEUROSCI BIOBEHAV R, V18, P1; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANI SK, 1994, ENDOCRINOLOGY, V135, P1409, DOI 10.1210/en.135.4.1409; MANI SK, 1994, SCIENCE, V265, P1246, DOI 10.1126/science.7915049; Mani SK, 1996, MOL ENDOCRINOL, V10, P1728, DOI 10.1210/me.10.12.1728; Meredith JM, 1998, J NEUROSCI, V18, P10189; Moore AN, 1996, J BIOL CHEM, V271, P14214, DOI 10.1074/jbc.271.24.14214; Nairn A C, 1992, Curr Opin Neurobiol, V2, P296, DOI 10.1016/0959-4388(92)90118-5; Nishi A, 1997, J NEUROSCI, V17, P8147; OCALLAGHAN JP, 1983, BRAIN RES BULL, V11, P31, DOI 10.1016/0361-9230(83)90054-0; OGAWA S, 1994, J NEUROSCI, V14, P1766, DOI 10.1523/JNEUROSCI.14-03-01766.1994; POLLIO G, 1993, MOL BRAIN RES, V19, P135, DOI 10.1016/0169-328X(93)90158-L; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Roberson ED, 1996, J BIOL CHEM, V271, P30436, DOI 10.1074/jbc.271.48.30436; SNYDER GL, 1994, J NEUROCHEM, V63, P1766; VATHY I, 1989, J NEUROENDOCRINOL, V1, P383, DOI 10.1111/j.1365-2826.1989.tb00133.x; WHALEN RE, 1986, NEUROSCI BIOBEHAV R, V10, P47, DOI 10.1016/0149-7634(86)90032-1; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; WISE PM, 1981, ENDOCRINOLOGY, V108, P2186, DOI 10.1210/endo-108-6-2186	29	105	130	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	2000	287	5455					1053	1056		10.1126/science.287.5455.1053	http://dx.doi.org/10.1126/science.287.5455.1053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	282WU	10669419				2022-12-01	WOS:000085245400051
J	Richens, J; Imrie, J; Copas, A				Richens, J; Imrie, J; Copas, A			Condoms and seat belts: the parallels and the lessons	LANCET			English	Editorial Material							BEHAVIORAL INTERVENTIONS; HIV-INFECTION; LEGISLATION; THAILAND; MEN; PREVENTION; DECLINE; SEX; GAY		UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, Mortimer Market Ctr, London WC1E 6AU, England	University of London; University College London; UCL Medical School	Richens, J (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, Mortimer Market Ctr, Mortimer Market, London WC1E 6AU, England.	jrichens@gum.ucl.ac.uk	Richens, John/C-1876-2008	Copas, Andrew/0000-0001-8968-5963				Adams J., 1995, RISK; Adams J., 1985, RISK FREEDOM RECORD; ADAMS JGU, 1994, SAFETY SCI, V18, P135, DOI 10.1016/0925-7535(94)90022-1; Aral SO, 1998, LANCET, V351, P33; Aral SO, 1996, INT J STD AIDS, V7, P30, DOI 10.1258/0956462961917753; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; Brody S, 1996, NEW ENGL J MED, V335, P1998, DOI 10.1056/NEJM199612263352614; COHEN DA, 1992, SEX TRANSM DIS, V19, P245, DOI 10.1097/00007435-199209000-00002; Dilley JW, 1997, NEW ENGL J MED, V337, P501, DOI 10.1056/NEJM199708143370715; Evans Leonard, 1991, TRAFFIC SAFETY DRIVE; HARVEY AC, 1986, J ROY STAT SOC A STA, V149, P187, DOI 10.2307/2981553; Hopperus Buma A. P. C. C., 1995, Genitourinary Medicine, V71, P172; Janssen W, 1991, 1991C15 IZF TNO I PE; Kalichman SC, 1998, AM J PREV MED, V15, P120, DOI 10.1016/S0749-3797(98)00037-3; Kelly JA, 1998, AIDS, V12, pF91, DOI 10.1097/00002030-199810000-00001; MCCARTHY M, 1989, J EPIDEMIOL COMMUN H, V43, P218, DOI 10.1136/jech.43.3.218; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; Organization for Economic Cooperation and Development, 1990, BEH AD CHANG ROAD TR; OTTEN MW, 1993, AM J PUBLIC HEALTH, V83, P529, DOI 10.2105/AJPH.83.4.529; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; Rothenberg RB, 1998, AIDS, V12, P2095, DOI 10.1097/00002030-199816000-00004; SHRADERFRESHETT.KS, 1990, RISK HLTH SAFETY ENV, V1, P34; Smeed R. J., 1970, TRAFFIC ENG CONTROL, V12, P150; Wasserheit JN, 1996, J INFECT DIS, V174, pS201, DOI 10.1093/infdis/174.Supplement_2.S201; Wilde G. J. S., 1994, TARGET RISK; 1986, LANCET, V1, P75	26	100	101	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 29	2000	355	9201					400	403		10.1016/S0140-6736(99)09109-6	http://dx.doi.org/10.1016/S0140-6736(99)09109-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280UL	10665571				2022-12-01	WOS:000085122100039
J	Hayflick, L				Hayflick, L			New approaches to old age - To truly understand ageing, we must look beyond the diseases of old age.	NATURE			English	Editorial Material									Univ Calif San Francisco, Dept Anat, Sea Ranch, CA 95497 USA	University of California System; University of California San Francisco	Hayflick, L (corresponding author), Univ Calif San Francisco, Dept Anat, POB 89, Sea Ranch, CA 95497 USA.		Hayflick, Leonard/AAW-2460-2020						0	39	44	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					365	365		10.1038/35000303	http://dx.doi.org/10.1038/35000303			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667768	Bronze			2022-12-01	WOS:000085121100023
J	Robzyk, K; Recht, L; Osley, MA				Robzyk, K; Recht, L; Osley, MA			Rad6-dependent ubiquitination of histone H2B in yeast	SCIENCE			English	Article							CONJUGATING ENZYME RAD6; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; CHROMATIN MODIFICATION; PROTEIN-DEGRADATION; CRYSTAL-STRUCTURE; GENE; MUTATIONS; TRANSCRIPTION; NUCLEOSOMES	Although ubiquitinated histones are present in substantial Levels in vertebrate cells, the roles they play in specific biological processes and the cellular factors that regulate this modification are not well characterized. Ubiquitinated H2B (uH2B) has been identified in the yeast Saccharomyces cerevisiae, and mutation of the conserved ubiquitination site is shown to confer defects in mitotic cell growth and meiosis. uH2B was not detected in rad6 mutants, which are defective for the ubiquitin-conjugating enzyme Ubc2, thus identifying Rad6 as the major cellular activity that ubiquitinates H2B in yeast.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Osley, MA (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.			Recht, Judith/0000-0003-3572-0457	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040118] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040118, GM40118] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baarends WM, 1999, DEV BIOL, V207, P322, DOI 10.1006/dbio.1998.9155; BARSOUM J, 1985, J BIOL CHEM, V260, P7688; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; CASSIERCHAUVAT C, 1991, MUTAT RES, V254, P247, DOI 10.1016/0921-8777(91)90063-U; Chen HY, 1998, J BIOL CHEM, V273, P13165, DOI 10.1074/jbc.273.21.13165; DAVIE JR, 1991, BIOCHEM CELL BIOL, V69, P66, DOI 10.1139/o91-009; DAVIE JR, 1990, BIOCHEMISTRY-US, V29, P4752, DOI 10.1021/bi00472a002; DAVIE JR, 1994, BIOCHEM BIOPH RES CO, V203, P344, DOI 10.1006/bbrc.1994.2188; Dor Y, 1996, MOL MICROBIOL, V21, P1197, DOI 10.1046/j.1365-2958.1996.671433.x; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1991, J BIOL CHEM, V266, P4104; HENSOLD JO, 1988, BLOOD, V71, P1153; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; KANG XL, 1992, GENETICS, V130, P285; Koken MHM, 1996, DEV BIOL, V173, P119, DOI 10.1006/dbio.1996.0011; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; LIEBMAN SW, 1993, GENETICS, V133, P499; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; NICKEL BE, 1989, BIOCHEMISTRY-US, V28, P958, DOI 10.1021/bi00429a006; PICOLOGLOU S, 1990, MOL CELL BIOL, V10, P1017, DOI 10.1128/MCB.10.3.1017; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; RABOY B, 1994, EUR J BIOCHEM, V221, P247, DOI 10.1111/j.1432-1033.1994.tb18735.x; Recht J, 1999, EMBO J, V18, P229, DOI 10.1093/emboj/18.1.229; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; ROBZYK K, UNPUB; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; SIEDE W, 1988, RADIAT ENVIRON BIOPH, V27, P277, DOI 10.1007/BF01209756; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; Storchova Z, 1998, MOL GEN GENET, V258, P546, DOI 10.1007/s004380050766; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; SWERDLOW PS, 1990, MOL CELL BIOL, V10, P4905, DOI 10.1128/MCB.10.9.4905; VANHOLDE KE, 1988, CHROMATIN, P111; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VASSILEV AP, 1995, J CELL SCI, V108, P1205; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wolffe AP., 1998, CHROMATIN STRUCTURE; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271	47	502	520	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					501	504		10.1126/science.287.5452.501	http://dx.doi.org/10.1126/science.287.5452.501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642555				2022-12-01	WOS:000084929900053
J	Santoso, A; Chien, P; Osherovich, LZ; Weissman, JS				Santoso, A; Chien, P; Osherovich, LZ; Weissman, JS			Molecular basis of a yeast prion species barrier	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; SUP35 GENE; AMYLOID FIBRILS; RELEASE FACTOR; IN-VITRO; PROTEIN; PSI; PROPAGATION; DETERMINANT; MICROSCOPY	The yeast [PSI+] factor is inherited by a prion mechanism involving self-propagating Sup35p aggregates. We find that Sup35p prion function is conserved among distantly related yeasts. As with mammalian prions, a species barrier inhibits prion induction between Sup35p from different yeast species. This barrier is faithfully reproduced in vitro where, remarkably, ongoing polymerization of one Sup35p species does not affect conversion of another. Chimeric analysis identifies a short domain sufficient to allow foreign Sup35p to cross this barrier. These observations argue that the species barrier results from specificity in the growing aggregate, mediated by a well-defined epitope on the amyloid surface and, together with our identification of a novel yeast prion domain, show that multiple prion-based heritable states can propagate independently within one cell.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	jsw1@itsa.ucsf.edu		Weissman, Jonathan/0000-0003-2445-670X				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; Ausubel F.M., 1994, CURRENT PROTOCOLS MO; Bailleul PA, 1999, GENETICS, V153, P81; Bates GP, 1998, BIOCHEM SOC T, V26, P471, DOI 10.1042/bst0260471; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Derkatch IL, 1996, GENETICS, V144, P1375; DOEL SM, 1994, GENETICS, V137, P659; Eaglestone SS, 1999, EMBO J, V18, P1974, DOI 10.1093/emboj/18.7.1974; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Ito K, 1998, RNA, V4, P958, DOI 10.1017/S1355838298971874; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; KURTZMAN CP, 1994, YEAST, V10, P1727, DOI 10.1002/yea.320101306; KUSHNIROV VV, 1990, YEAST, V6, P461, DOI 10.1002/yea.320060603; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; TUITE MF, 1981, GENETICS, V98, P691; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1995, YEAST, V11, P1671, DOI 10.1002/yea.320111609; Zhou P, 1999, EMBO J, V18, P1182, DOI 10.1093/emboj/18.5.1182	37	231	235	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2000	100	2					277	288		10.1016/S0092-8674(00)81565-2	http://dx.doi.org/10.1016/S0092-8674(00)81565-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	277KF	10660050	Bronze			2022-12-01	WOS:000084932200011
J	Ebrahim, SH; Floyd, RL; Merritt, RK; Decoufle, P; Holtzman, D				Ebrahim, SH; Floyd, RL; Merritt, RK; Decoufle, P; Holtzman, D			Trends in pregnancy-related smoking rates in the United States, 1987-1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CESSATION; INTERVENTIONS; METAANALYSIS; PEOPLE	Context Rates of smoking are increasing among adolescents and young adults, but trends in smoking among pregnant women have not been studied, Objective To assess pregnancy-related variations in smoking behaviors and their determinants among women of childbearing age in the United States, Design Analysis of data collected between 1987-1996 from the Behavioral Risk Factor Surveillance System survey. Setting and Subjects A total of 187 302 (178 499 nonpregnant and 8803 pregnant) noninstitutionalized women aged 18 to 44 years from 33 states. Main Outcome Measures Prevalence rates of smoking initiation and current smoking, median number of cigarettes smoked, and adjusted odds ratios for smoking stratified by pregnancy status; prevalence rate ratio for current smoking comparing pregnant with nonpregnant women, Results The overall percentage of women who had ever initiated smoking decreased significantly from 44.1% in 1987 to 38.2% in 1996, During that 10-year period, the prevalence of current smoking also decreased significantly among both pregnant women (16.3% to 11.8%) and nonpregnant women (26.7% to 23.6%), Overall, pregnant women were about half (54%) as likely as nonpregnant women to be current smokers during 1987-1996. Over time, the median number of cigarettes smoked per day by pregnant smokers remained at 10, whereas among nonpregnant smokers it decreased from 19 to 15 (P<.05 for trend). in the same period, among young women (aged 18-20 years), prevalence rates of smoking initiation and current smoking increased slightly, Sociodemographic subgroups of women at increased risk for current smoking were the same for pregnant and nonpregnant women tie, those with a completed high school education or less, whites, and those who were unmarried). Conclusions In this analysis, the decline in smoking over time among pregnant women was primarily due to the overall decline in smoking initiation rates among women of childbearing age, not to an increased rate of smoking cessation related to pregnancy. To foster effective perinatal tobacco control, efforts are needed to further reduce the number of young women who begin smoking. Clinicians should query all pregnant women and women of childbearing age about smoking and provide cessation and relapse interventions to each smoker.	Ctr Dis Control & Prevent, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Ebrahim, SH (corresponding author), Ctr Dis Control & Prevent, Atlanta, GA 30341 USA.							Appleton PL, 1998, BRIT J HEALTH PSYCH, V3, P361, DOI 10.1111/j.2044-8287.1998.tb00580.x; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1048; Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention, 1989, DHHS PUBL, V(CDC) 89-8411; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P537; Centers for Disease Control and Prevention (CDC), 1993, MMWR-MORBID MORTAL W, V42, P504; DiFranza JR, 1996, PEDIATRICS, V97, P560; DOLANMULLEN P, 1994, AM J OBSTET GYNECOL, V171, P1328, DOI 10.1016/0002-9378(94)90156-2; Evans WN, 1999, J PUBLIC ECON, V72, P135, DOI 10.1016/S0047-2727(98)00090-5; FERGUSSON DM, 1993, PEDIATRICS, V92, P815; FINGERHUT LA, 1990, AM J PUBLIC HEALTH, V80, P541, DOI 10.2105/AJPH.80.5.541; Fiore MC, 1996, AHCPR PUBLICATION, V96-0692; Grant TM, 1996, AM J PUBLIC HEALTH, V86, P1816; HOLLIS JF, 1993, ANN INTERN MED, V118, P521, DOI 10.7326/0003-4819-118-7-199304010-00006; Hurt RD, 1999, B WORLD HEALTH ORGAN, V77, P367; Kendrick JS, 1996, AM J OBSTET GYNECOL, V175, P528; Klerman LV, 1999, J NURSE-MIDWIFERY, V44, P118, DOI 10.1016/S0091-2182(99)00031-2; LAW M, 1995, ARCH INTERN MED, V155, P1933, DOI 10.1001/archinte.155.18.1933; LECLERE FB, 1997, ADV DATA VITAL HLTH, V288; McBride CM, 1999, AM J PUBLIC HEALTH, V89, P706, DOI 10.2105/AJPH.89.5.706; *NCI, 1994, MONOGR NCI, V5, P1; OWEN L, 1999, SMOKING PREGNANCY SU; *PHS, 1991, DHHS PUBL; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; SHAH BV, 1996, SUDAAN COMP SOFTW VE; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; U.S. Bureau of the Census, 1997, STAT ABSTR US 1997; *US DEP HHS, 1998, TARG TOB US NAT LEAD; *US DEP HHS, 1994, PREV TOB US YOUNG PE; Vartiainen E, 1998, AM J PUBLIC HEALTH, V88, P81, DOI 10.2105/AJPH.88.1.81; VENTURA SJ, 1997, REPORT FINAL NATALIT, P11; Wechsler H, 1998, JAMA-J AM MED ASSOC, V280, P1673, DOI 10.1001/jama.280.19.1673; [No title captured]	32	175	181	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2000	283	3					361	366		10.1001/jama.283.3.361	http://dx.doi.org/10.1001/jama.283.3.361			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	273WM	10647799	Bronze			2022-12-01	WOS:000084732400028
J	Leen, E; Goldberg, JA; Angerson, WJ; McArdle, CS				Leen, E; Goldberg, JA; Angerson, WJ; McArdle, CS			Potential role of doppler perfusion index in selection of patients with colorectal cancer for adjuvant chemotherapy	LANCET			English	Article							HEPATIC METASTASES; LIVER METASTASES; COLON-CANCER; FLUOROURACIL; THERAPY; FLOW; SONOGRAPHY; CARCINOMA; TUMOR	Background As yet there is no established method of accurately identifying patients with colorectal cancer who, despite undergoing apparently curative resection, are at high risk of recurrence. We assessed whether the doppler perfusion index (DPI; ratio of hepatic arterial to total liver blood flow) could be used to select patients who should receive adjuvant chemotherapy. Methods We studied 120 patients undergoing curative surgery for colorectal cancer. DPI was measured before surgery with colour duplex doppler ultrasonography. A DPI value of at least 0.3 was defined as abnormal. All patients were followed up until death or for at least 5 years. Results At 5 years, patients with Dukes' stage A or B tumours (n=61) had recurrence-free survival of 57% and overall survival of 64%, compared with 39% and 42% for patients with Dukes' stage C tumours (n=59; p=0.016 and p=0.008, respectively). 47 patients had normal DPI values and 73 patients had abnormal values. Patients with normal DPI had recurrence-free survival of 89% and overall survival of 91%, compared with 22% and 29% for those with abnormal DPI values (both p<0.0001). Conclusions DPI can be used to identify patients with colorectal cancer at high risk of recurrence who are in need of adjuvant treatment. However, further studies with larger numbers of patients are needed to confirm these findings.	Royal Infirm, Dept Radiol, Glasgow G31 2ER, Lanark, Scotland; Hairmyres Hosp, Dept Surg, E Kilbride, Lanark, Scotland; Royal Infirm, Univ Dept Surg, Glasgow G31 2ER, Lanark, Scotland	Royal Infirmary of Edinburgh; University Hospital Hairmyres; Royal Infirmary of Edinburgh; University of Glasgow	Leen, E (corresponding author), Royal Infirm, Dept Radiol, Alexandra Parade, Glasgow G31 2ER, Lanark, Scotland.							CARTER R, 1994, BRIT J CANCER, V69, P1025, DOI 10.1038/bjc.1994.201; FINLAY IG, 1986, BRIT J SURG, V73, P732, DOI 10.1002/bjs.1800730918; GILBERT JM, 1984, BRIT J SURG, V71, P203, DOI 10.1002/bjs.1800710311; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; LABIANCA R, 1995, LANCET, V345, P939; LEEN E, 1993, GUT, V34, P554, DOI 10.1136/gut.34.4.554; LEEN E, 1991, ANN SURG, V214, P599, DOI 10.1097/00000658-199111000-00010; LEEN E, 1994, ANN SURG, V220, P663, DOI 10.1097/00000658-199411000-00010; LEEN E, 1995, RADIOLOGY, V195, P113, DOI 10.1148/radiology.195.1.7892449; LEEN E, 1991, BRIT J CANCER, V63, P323, DOI 10.1038/bjc.1991.76; LEVESON SH, 1985, BRIT J SURG, V72, P128, DOI 10.1002/bjs.1800720220; MCARDLE CS, 1990, BRIT J SURG, V77, P206; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; OBRIEN MJ, 1988, BR J MED SCI, V157, P5; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; Oppo K, 1998, RADIOLOGY, V208, P453, DOI 10.1148/radiology.208.2.9680575; RIDGE JA, 1987, CANCER, V59, P1547, DOI 10.1002/1097-0142(19870501)59:9<1547::AID-CNCR2820590903>3.0.CO;2-6; Warren HW, 1993, BRIT J SURG, V80, P1461	18	66	71	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 1	2000	355	9197					34	37		10.1016/S0140-6736(99)06322-9	http://dx.doi.org/10.1016/S0140-6736(99)06322-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279MU	10615889				2022-12-01	WOS:000085049200014
J	St Peter, RF; Reed, MC; Kemper, P; Blumenthal, D				St Peter, RF; Reed, MC; Kemper, P; Blumenthal, D			Changes in the scope of care provided by primary care physicians	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	14th Annual Meeting of the Association-of-Health-Services-Research	JUN 15-17, 1997	CHICAGO, ILLINOIS	Assoc Hlth Serv Res			HEALTH MAINTENANCE ORGANIZATIONS; FINANCIAL INCENTIVES; MANAGED-CARE; CONSULTATION	Background: Strategies to control medical costs and improve the quality of care often translate into decisions affecting the range of services primary care physicians provide to patients, which patients are referred for specialty care, and the points in disease processes at which referrals are made. This study focused on physicians' assessments of changes in the scope of care provided by primary care physicians and their assessments of the appropriateness of the scope of the care that primary care physicians are expected to provide. Methods: We analyzed data from the 1996-1997 Community Tracking Study Physician Survey. Telephone interviews were conducted with 12,385 physicians (reflecting a response rate of 65 percent) who were drawn from a representative random sample of physicians providing direct patient care in the continental United States and not employed by the federal government. The analysis was based on responses from the 7015 primary care physicians and 5092 specialists who had been in practice for at least two years. Results: Thirty percent of the primary care physicians and 50 percent of the specialists reported that the scope of care provided by primary care physicians had increased during the previous two years. Twenty-four percent of the primary care physicians and 38 percent of the specialists reported that the scope of care expected to be provided by primary care physicians was greater than it should be. According to multivariate analysis, primary care physicians other than general or family practitioners (i.e., pediatricians and general internists), those who were in one- or two-physician practices, those who received revenues from capitation, and those who served as gatekeepers for their patients' care were significantly more likely to report that the scope of care they were expected to provide was greater than it should be. Conclusions: The finding that nearly one in four primary care physicians reported that the scope of care they were expected to provide was greater than it should be arouses concern about the potential impact of changes in the delivery of health care. The associations we found between financial and administrative aspects of managed care and physicians' concern about the scope of care they provide to their patients deserve careful consideration. (N Engl J Med 1999;341:1980-5.) (C)1999, Massachusetts Medical Society.	Kansas Hlth Inst, Topeka, KS 66612 USA; Ctr Study Hlth Syst Change, Washington, DC USA; Massachusetts Gen Hosp, Partners Healthcare Syst, Inst Hlth Policy, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Partners Healthcare System; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	St Peter, RF (corresponding author), Kansas Hlth Inst, 100 SE 9th St,3rd Fl, Topeka, KS 66612 USA.							EISENBERG J, 1986, DOCTORS DECISIONS CO; Grembowski DE, 1998, MED CARE RES REV, V55, P3, DOI 10.1177/107755879805500101; Grumbach K, 1998, NEW ENGL J MED, V339, P1516, DOI 10.1056/NEJM199811193392106; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1990, ANN INTERN MED, V112, P891, DOI 10.7326/0003-4819-112-12-891; Hirth RA, 1996, MED CARE, V34, P1199, DOI 10.1097/00005650-199612000-00005; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1535; Keating NL, 1998, JAMA-J AM MED ASSOC, V280, P900, DOI 10.1001/jama.280.10.900; KEIL L, 1998, TECHNICAL PUBLICATIO, V9; Kemper P, 1996, INQUIRY-J HEALTH CAR, V33, P195; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Kuo D, 1998, JAMA-J AM MED ASSOC, V280, P905, DOI 10.1001/jama.280.10.905; LUNDERG GD, 1993, JAMA-J AM MED ASSOC, V270, P380, DOI 10.1001/jama.270.3.380; METCALF CE, 1996, TECHNICAL PUBLICATIO, V1; RESCHOVSKY JD, 1998, TECHNICAL PUBLICATIO, V10; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; Rosser WW, 1996, J FAM PRACTICE, V42, P139; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136	20	92	94	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1999	341	26					1980	1985		10.1056/NEJM199912233412606	http://dx.doi.org/10.1056/NEJM199912233412606			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268DQ	10607816				2022-12-01	WOS:000084399400006
J	Bakolitsa, C; de Pereda, JM; Bagshaw, CR; Critchley, DR; Liddington, RC				Bakolitsa, C; de Pereda, JM; Bagshaw, CR; Critchley, DR; Liddington, RC			Crystal structure of the vinculin tail suggests a pathway for activation	CELL			English	Article							F-ACTIN-BINDING; CYTOSKELETAL PROTEIN VINCULIN; INTRAMOLECULAR ASSOCIATION; ACIDIC PHOSPHOLIPIDS; TALIN-BINDING; ALPHA-ACTININ; DOMAIN; SITE; MEMBRANE; SEQUENCE	Vinculin plays a dynamic role in the assembly of the actin cytoskeleton. A strong interaction between its head and tail domains that regulates binding to other cytoskeletal components is disrupted by acidic phospholipids. Here, we present the crystal structure of the vinculin tail, residues 879-1066. Five amphipathic helices form an antiparallel bundle that resembles exchangeable apolipoproteins. A C-terminal arm wraps across the base of the bundle and emerges as a hydrophobic hairpin surrounded by a collar of basic residues, adjacent to the N terminus. We show that the C-terminal arm is required for binding to acidic phospholipids but not to actin, and that binding either ligand induces conformational changes that may represent the first step in activation.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Liddington, RC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham-inst.org	Bagshaw, Clive R./L-5484-2019; de Pereda, Jose M/AAE-5226-2022; de Pereda, Jose M/F-1733-2010	Bagshaw, Clive R./0000-0002-5396-153X; de Pereda, Jose M/0000-0002-8912-6739; de Pereda, Jose M/0000-0002-8912-6739; Bakolitsa, Constantina/0000-0002-6980-9831				Adams PD, 1999, ACTA CRYSTALLOGR D, V55, P181, DOI 10.1107/S0907444998006635; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campos B, 1998, BIOCHEMISTRY-US, V37, P8004, DOI 10.1021/bi973142n; Clayton D, 1999, PROTEIN SCI, V8, P1797, DOI 10.1110/ps.8.9.1797; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GILMORE AP, 1992, J CELL SCI, V103, P719; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GIMONA M, 1987, J MUSCLE RES CELL M, V8, P329, DOI 10.1007/BF01568889; Goldmann WH, 1998, EUR J BIOCHEM, V254, P413, DOI 10.1046/j.1432-1327.1998.2540413.x; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Hemmings L, 1996, J CELL SCI, V109, P2715; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Huttelmaier S, 1997, EUR J BIOCHEM, V247, P1136, DOI 10.1111/j.1432-1033.1997.01136.x; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Jockusch BM, 1996, TRENDS CELL BIOL, V6, P311, DOI 10.1016/0962-8924(96)10022-2; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; JONES P, 1989, J CELL BIOL, V109, P2917, DOI 10.1083/jcb.109.6.2917; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kiss RS, 1999, BIOCHEMISTRY-US, V38, P4327, DOI 10.1021/bi982597p; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; MOLONY L, 1985, J CELL BIOCHEM, V29, P31, DOI 10.1002/jcb.240290104; Narayanaswami V, 1999, P NATL ACAD SCI USA, V96, P4366, DOI 10.1073/pnas.96.8.4366; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nicholls A., 1992, GRASP GRAPHICAL REPR; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P59; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Weers PMM, 1999, J BIOL CHEM, V274, P21804, DOI 10.1074/jbc.274.31.21804; WELLER PA, 1990, P NATL ACAD SCI USA, V87, P5667, DOI 10.1073/pnas.87.15.5667; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; WOOD CK, 1994, J CELL SCI, V107, P709; Xu WM, 1998, DEVELOPMENT, V125, P327	60	153	156	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					603	613		10.1016/S0092-8674(00)81549-4	http://dx.doi.org/10.1016/S0092-8674(00)81549-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612396	Bronze			2022-12-01	WOS:000084278700007
J	Griffith, M; Osborne, R; Munger, R; Xiong, XJ; Doillon, CJ; Laycock, NLC; Hakim, M; Song, Y; Watsky, MA				Griffith, M; Osborne, R; Munger, R; Xiong, XJ; Doillon, CJ; Laycock, NLC; Hakim, M; Song, Y; Watsky, MA			Functional human corneal equivalents constructed from cell lines	SCIENCE			English	Article							HUMAN EPITHELIAL-CELLS; GROWTH-FACTOR; FIBROBLAST GROWTH; IMMORTALIZATION; EXPRESSION; CULTURE; GENE; EYE	Human corneal equivalents comprising the three main Layers of the cornea (epithelium, stroma, and endothelium) were constructed. Each cellular layer was fabricated from immortalized human corneal cells that were screened for use on the basis of morphological, biochemical, and electrophysiological similarity to their natural counterparts. The resulting corneal equivalents mimicked human corneas in key physical and physiological functions, including morphology, biochemical marker expression, transparency, ion and fluid transport, and gene expression. Morphological and functional equivalents to human corneas that can be produced in vitro have immediate applications in toxicity and drug efficacy testing, and form the basis for future development of implantable tissues.	Univ Ottawa, Inst Eye, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ottawa Hosp, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada; Procter & Gamble Co, Miami Valley Labs, Div Human & Environm Safety, Cincinnati, OH 45253 USA; Ctr Hosp Univ Quebec, Biomat Inst Quebec, Quebec City, PQ G1L 3L5, Canada; Univ Tennessee, Coll Med, Dept Physiol, Memphis, TN 38163 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Procter & Gamble; Laval University; University of Tennessee System; University of Tennessee Health Science Center	Griffith, M (corresponding author), Univ Ottawa, Inst Eye, Ottawa, ON K1H 8L6, Canada.		Mantovani, Diego/J-2457-2012	Mantovani, Diego/0000-0001-9672-895X; Watsky, Mitchell/0000-0003-2079-9887; Griffith, May/0000-0003-1222-6720				Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18; ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; Bockman CS, 1998, INVEST OPHTH VIS SCI, V39, P1143; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; DOILLON CJ, 1987, BIOMATERIALS, V8, P195, DOI 10.1016/0142-9612(87)90063-9; Draize JH, 1944, J PHARMACOL EXP THER, V82, P377; Gause WC, 1995, PCR PRIMER LAB MANUA; Germain L, 1999, PATHOBIOLOGY, V67, P140, DOI 10.1159/000028064; GEROSKI DH, 1984, CURR EYE RES, V3, P331, DOI 10.3109/02713688408997217; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFITH JF, 1980, TOXICOL APPL PHARM, V55, P501, DOI 10.1016/0041-008X(80)90052-6; Griffith M., UNPUB; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HOPPENREIJS VPT, 1994, INVEST OPHTH VIS SCI, V35, P931; *INT LIF SCI I, 1996, J TOXICOL CUTANEOUS, V15, P211; JAGER MJ, 1995, EYE, V9, P241, DOI 10.1038/eye.1995.47; Janvier R, 1997, ANTICANCER RES, V17, P1551; KAHN CR, 1993, INVEST OPHTH VIS SCI, V34, P1983; KAO WWY, 1975, BIOCHIM BIOPHYS ACTA, V411, P202, DOI 10.1016/0304-4165(75)90300-1; KINGSTON RE, 1997, CURRENT PROTOCOLS MO; MINAMI Y, 1993, INVEST OPHTH VIS SCI, V34, P2316; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; Okada Y, 1998, GRAEF ARCH CLIN EXP, V236, P853, DOI 10.1007/s004170050170; Pettenati MJ, 1997, HUM GENET, V101, P26, DOI 10.1007/s004390050580; PITTS DG, 1994, ENV VISION, pCH6; POWER WJ, 1995, CURR EYE RES, V14, P879, DOI 10.3109/02713689508995127; Priest D., 1998, IOVS, V39, pS352; QUINLAN MP, 1994, ONCOGENE, V9, P2639; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; Rhim JS, 1998, CARCINOGENESIS, V19, P673, DOI 10.1093/carcin/19.4.673; Shoichet M. S., 1998, POLYM TISSUE ENG; Sotozono C, 1997, CURR EYE RES, V16, P670, DOI 10.1076/ceyr.16.7.670.5057; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WATSKY MA, 1995, DUANES FDN CLIN OPHT, V2, pCH4; ZIESKE JD, 1994, EXP CELL RES, V214, P621, DOI 10.1006/excr.1994.1300	37	377	451	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 10	1999	286	5447					2169	2172		10.1126/science.286.5447.2169	http://dx.doi.org/10.1126/science.286.5447.2169			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264AK	10591651				2022-12-01	WOS:000084157300056
J	Patrick, GN; Zukerberg, L; Nikolic, M; de la Monte, S; Dikkes, P; Tsai, LH				Patrick, GN; Zukerberg, L; Nikolic, M; de la Monte, S; Dikkes, P; Tsai, LH			Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration	NATURE			English	Article							CYCLIN-DEPENDENT KINASE-5; NEURONAL-SPECIFIC ACTIVATOR; GLYCOGEN-SYNTHASE KINASE-3; DIRECTED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; APOPTOTIC CELL-DEATH; TAU-PROTEIN; ALZHEIMERS-DISEASE; REGULATORY SUBUNIT; CEREBRAL-CORTEX	Cyclin-dependent kinase 5 (Cdk5) is required for proper development of the mammalian central nervous system. To be activated, Cdk5 has to associate with its regulatory subunit, p35, We have found that p25, a truncated form of p35, accumulates in neurons in the brains of patients with Alzheimer's disease. This accumulation correlates with an increase in Cdk5 kinase activity. Unlike p35, p25 is not readily degraded, and binding of p25 to Cdk5 constitutively activates Cdk5, changes its cellular location and alters its substrate specificity, In vivo the p25/Cdk5 complex hyperphosphorylates tau, which reduces tau's ability to associate with microtubules, Moreover, expression of the p25/Cdk5 complex in cultured primary neurons induces cytoskeletal disruption, morphological degeneration and apoptosis, These findings indicate that cleavage of p35, followed by accumulation of p25, may be involved in the pathogenesis of cytoskeletal abnormalities and neuronal death in neurodegenerative diseases.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp E, Ctr Canc, Charlestown, MA 02119 USA; Childrens Hosp, Dept Neurol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital	Tsai, LH (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		de la monte, suzanne/L-7670-2019	de la monte, suzanne/0000-0001-5886-2306				Ahuja HS, 1997, DEV GENET, V21, P258, DOI 10.1002/(SICI)1520-6408(1997)21:4<258::AID-DVG3>3.0.CO;2-6; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bursztajn S, 1998, J NEUROSCI, V18, P9790; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Fix AS, 1996, TOXICOL PATHOL, V24, P291, DOI 10.1177/019262339602400305; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Gilmore EC, 1998, J NEUROSCI, V18, P6370; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Guidato S, 1996, J NEUROCHEM, V66, P1698; Henchcliffe C, 1997, NEUROSCI LETT, V230, P41, DOI 10.1016/S0304-3940(97)00472-2; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Imahori K, 1998, NEUROBIOL AGING, V19, pS93, DOI 10.1016/S0197-4580(98)00025-6; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Kwon YT, 1998, J COMP NEUROL, V395, P510, DOI 10.1002/(SICI)1096-9861(19980615)395:4<510::AID-CNE7>3.0.CO;2-4; Kwon YT, 1999, J COMP NEUROL, V415, P218, DOI 10.1002/(SICI)1096-9861(19991213)415:2<218::AID-CNE6>3.0.CO;2-F; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lovestone S, 1997, NEUROSCIENCE, V78, P309; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Michel G, 1998, BBA-GEN SUBJECTS, V1380, P177, DOI 10.1016/S0304-4165(97)00139-6; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Paglini G, 1998, J NEUROSCI, V18, P9858; Pant AC, 1997, BRAIN RES, V765, P259, DOI 10.1016/S0006-8993(97)00561-1; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; Shirvan A, 1998, NEUROCHEM RES, V23, P767, DOI 10.1023/A:1022415611545; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; TANAKA T, 1995, FEBS LETT, V360, P5, DOI 10.1016/0014-5793(95)00061-D; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; UCHIDA T, 1994, FEBS LETT, V355, P35, DOI 10.1016/0014-5793(94)01163-X; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494	49	1243	1332	0	86	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					615	622		10.1038/45159	http://dx.doi.org/10.1038/45159			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604467				2022-12-01	WOS:000084189800054
J	Goto, A; Reich, MR; Aitken, I				Goto, A; Reich, MR; Aitken, I			Oral contraceptives and women's health in Japan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-CONTROL	Japan approved the use of low-dose oral contraceptives (OCs) in June 1999, after more than 35 years of debate, The debate leaves a legacy of misinformation about and various sources of resistance to OCs. Benefits are expected to include greater control for women over their fertility and a reduction in the high rates of unplanned pregnancies and abortions, Successful implementation of the new policy will require a new emphasis on women's health, including the provision of accurate information about OCs and their associated adverse effects, a women-centered approach to gynecological practice, and the promotion of condoms as protection from sexually transmitted diseases, rather than as contraception alone.	Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Maternal & Child Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Goto, A (corresponding author), Yamagata Univ, Sch Med, Dept Publ Hlth, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.			Goto, Aya/0000-0002-7927-7648				*A GUTTM I, 1999, SHAR RESP; Arakawa O, 1999, Nihon Koshu Eisei Zasshi, V46, P204; CATES W, 1992, FAM PLANN PERSPECT, V24, P75, DOI 10.2307/2135469; COLEMAN S, 1981, STUD FAMILY PLANN, V12, P28, DOI 10.2307/1965861; COLEMAN S, 1991, FAMILY PLANNING JAPA; *HLTH WELF STAT AS, 1998, TRENDS NAT HLTH; *JAP SOC OBST GYN, 1999, GUID US LOW DOS OR C; JITSUKAWA M, 1994, SCIENCE, V265, P1048, DOI 10.1126/science.8066442; Kihara M, 1997, J ACQ IMMUN DEF SYND, V14, pS3, DOI 10.1097/00042560-199700002-00002; KITAMURA K, 1997, SHINRYO KENKYU, V334, P5; Koonin L M, 1997, MMWR CDC Surveill Summ, V46, P37; KOROKU M, 1994, SEX TRANSM DIS, V21, P329, DOI 10.1097/00007435-199411000-00006; Maruyama H, 1996, NATURE, V379, P579, DOI 10.1038/379579a0; MATSUMOTO S, 1988, CURR THER RES CLIN E, V44, P165; MATSUMOTO S, 1991, JAPAN FAMILY PLANNIN, V6, P2; *MIN HLTH WELF, 1998, ANN REP HLTH WELF; *MIN HLTH WELF MIN, 1995, EUG PROT STAT REP; Munakata T, 1996, AIDS EDUC PREV, V8, P115; Nagata C, 1997, PREV MED, V26, P565, DOI 10.1006/pmed.1997.0176; *NHK HO BUNK KENK, 1998, MIND MOD JAP; Norgren T, 1998, J JPN STUD, V24, P59, DOI 10.2307/132939; Oddens BJ, 1998, CONTRACEPTION, V58, P13, DOI 10.1016/S0010-7824(98)00056-0; *OFF NAT STAT, 1994, 1994 AB STAT; OGINO M, 1993, REPROD HEALTH MATTER, V1, P78; *POP PROBL RES COU, 1998, 24 NAT SURV FAM PLAN; *POP PROBL RES COU, 1996, 23 NAT SURV FAM PLAN; *PRIM MIN OFF, 1997, PRES STAT PLANS NAT; TAKAHASHI S, 1999, JINKO MONDAI KENKYUS, V46, P3; TANAKA T, 1990, KOSEI NO SHIHYO, V37, P21; Uchino H, 1997, Nihon Koshu Eisei Zasshi, V44, P499; *WHO, 1998, WHO TECHN REP SER, V877; World Health Organisation [WHO, 1996, WHO TECHN REP SER, V866; Yamamoto T, 1999, Nihon Koshu Eisei Zasshi, V46, P304; YAMAUCHI M, 1991, BRIT MED J, V303, P1157	34	27	27	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2173	2177		10.1001/jama.282.22.2173	http://dx.doi.org/10.1001/jama.282.22.2173			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	260UG	10591342				2022-12-01	WOS:000083971400040
J	Conway, G; Toenniessen, G				Conway, G; Toenniessen, G			Feeding the world in the twenty-first century	NATURE			English	Article								The gains in food production provided by the Green Revolution have reached their ceiling while world population continues to rise. To ensure that the world's poorest people do not still go hungry in the twenty-first century, advances in plant biotechnology must be deployed for their benefit by a strong public-sector agricultural research effort.	Rockefeller Fdn, New York, NY 10018 USA		Conway, G (corresponding author), Rockefeller Fdn, New York, NY 10018 USA.							Cassman KG, 1999, P NATL ACAD SCI USA, V96, P5952, DOI 10.1073/pnas.96.11.5952; Conway G, 1999, DOUBLY GREEN REVOLUT; LEONARD HJ, 1989, ENV POOR DEV STRATEG, P3; Mann CC, 1999, SCIENCE, V283, P310, DOI 10.1126/science.283.5400.310; Mann CC, 1999, SCIENCE, V283, P314, DOI 10.1126/science.283.5400.314; May R. M., 1999, GENETICALLY MODIFIED; *NUFF COUNC BIOETH, 1999, GEN MOD CROPS ETH SO; PARDEY PG, 1996, SUMMARY PRODUCTIVE P; PRETTY J, IN PRESS BIOCHEMIST; Rissler J, 1996, ECOLOGICAL RISKS ENG; *ROYSL SOC LONDON, 1998, GEN MOD PLANTS FOOD; SOMER A, 1966, VITAMIN A DEFICIENCY; *UN FAO, 1996, 61 FAO WHO; UNICEF, 1998, STAT WORLDS CHILDR 1; YE XD, UNPUB SCIENCE; [No title captured]	16	155	166	2	64	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C55	C58		10.1038/35011545	http://dx.doi.org/10.1038/35011545			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591226				2022-12-01	WOS:000084014100008
J	Diesmann, M; Gewaltig, MO; Aertsen, A				Diesmann, M; Gewaltig, MO; Aertsen, A			Stable propagation of synchronous spiking in cortical neural networks	NATURE			English	Article							COINCIDENCE DETECTOR; ONGOING ACTIVITY; NEURONS; SYNCHRONIZATION; INTEGRATOR; PATTERNS; CORTEX; INPUTS; MODEL	The classical view of neural coding has emphasized the importance of information carried by the rate at which neurons discharge action potentials. More recent proposals that information may be carried by precise spike timing(1-5) have been challenged by the assumption that these neurons operate in a noisy fashion-presumably reflecting fluctuations in synaptic input(6)-and, thus, incapable of transmitting signals with millisecond fidelity. Here we show that precisely synchronized action potentials can propagate within a model of cortical network activity that recapitulates many of the features of biological systems. An attractor, yielding a stable spiking precision in the (sub)millisecond range, governs the dynamics of synchronization. Our results indicate that a combinatorial neural code, based on rapid associations of groups of neurons co-ordinating their activity at the single spike level, is possible within a cortical-like network.	Univ Freiburg, Inst Biol 3, Dept Neurobiol & Biophys, D-79104 Freiburg, Germany	University of Freiburg	Aertsen, A (corresponding author), Univ Freiburg, Inst Biol 3, Dept Neurobiol & Biophys, Schanzlestr 1, D-79104 Freiburg, Germany.	aertsen@biologie.uni-freiburg.de	Diesmann, Markus/H-3722-2013	Diesmann, Markus/0000-0002-2308-5727				ABELES M, 1982, ISRAEL J MED SCI, V18, P83; ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Abeles M., 1991, CORTICONICS; ARIELI A, 1995, J NEUROPHYSIOL, V73, P2072, DOI 10.1152/jn.1995.73.5.2072; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Arnoldi HMR, 1996, BIOL CYBERN, V74, P209, DOI 10.1007/BF00652222; BERNANDER O, 1994, NEURAL COMPUT, V6, P622, DOI 10.1162/neco.1994.6.4.622; BIENENSTOCK E, 1995, NETWORK-COMP NEURAL, V6, P179, DOI 10.1088/0954-898X/6/2/004; Braitenberg V, 1991, ANATOMY CORTEX; CALVIN WH, 1968, J NEUROPHYSIOL, V31, P574, DOI 10.1152/jn.1968.31.4.574; DIESMAN M, 1995, SYNOD ENV NEURAL SYS; DIESMANN M, 1997, MEMBRANE MIND, P62; DIESMANN M, 1996, TRENDS RES 1995, P59; FETZ E, 1991, CEREB CORTEX, V9, P1; GERSTEIN GL, 1964, BIOPHYS J, V4, P41, DOI 10.1016/S0006-3495(64)86768-0; GRIFFITH JS, 1963, BIOPHYS J, V3, P299, DOI 10.1016/S0006-3495(63)86822-8; HERRMANN M, 1995, NETWORK-COMP NEURAL, V6, P403, DOI 10.1088/0954-898X/6/3/006; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; Konig P, 1996, TRENDS NEUROSCI, V19, P130, DOI 10.1016/S0166-2236(96)80019-1; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Marsalek PR, 1997, P NATL ACAD SCI USA, V94, P735, DOI 10.1073/pnas.94.2.735; MURTHY VN, 1994, NEURAL COMPUT, V6, P1111, DOI 10.1162/neco.1994.6.6.1111; Nowak LG, 1997, CEREB CORTEX, V7, P487, DOI 10.1093/cercor/7.6.487; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; Prut Y, 1998, J NEUROPHYSIOL, V79, P2857, DOI 10.1152/jn.1998.79.6.2857; Riehle A, 1997, SCIENCE, V278, P1950, DOI 10.1126/science.278.5345.1950; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; Shadlen MN, 1998, J NEUROSCI, V18, P3870; Tuckwell H.C., 1988, INTRO THEORETICAL NE, DOI [10.1017/CBO9780511623202, DOI 10.1017/CBO9780511623202]; vanVreeswijk C, 1996, SCIENCE, V274, P1724, DOI 10.1126/science.274.5293.1724	30	667	673	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1999	402	6761					529	533		10.1038/990101	http://dx.doi.org/10.1038/990101			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591212				2022-12-01	WOS:000084013200056
J	Wyrick, JJ; Holstege, FCP; Jennings, EG; Causton, HC; Shore, D; Grunstein, M; Lander, ES; Young, RA				Wyrick, JJ; Holstege, FCP; Jennings, EG; Causton, HC; Shore, D; Grunstein, M; Lander, ES; Young, RA			Chromosomal landscape of nucleosome-dependent gene expression and silencing in yeast	NATURE			English	Article							ASSEMBLY FACTOR-I; SACCHAROMYCES-CEREVISIAE; TELOMERIC HETEROCHROMATIN; CHROMATIN STRUCTURE; TRANSCRIPTION; GENOME; RAP1; DEPLETION; PROMOTER; FAMILY	Eukaryotic genomes are packaged into nucleosomes, which are thought to repress gene expression generally(1-3), Repression is particularly evident at yeast telomeres, where genes within the telomeric heterochromatin appear to be silenced by the histone-binding silent information regulator (SIR) complex (Sir2, Sir3, Sir4) and Rap1 (refs 4-10). Here, to investigate how nucleosomes and silencing factors influence global gene expression, we use high-density arrays to study the effects of depleting nucleosomal histones and silencing factors in yeast. Reducing nucleosome content by depleting histone H4 caused increased expression of 15% of genes and reduced expression of 10% of genes, hut it had little effect on expression of the majority (75%) of yeast genes, Telomere-proximal genes were found to be de-repressed over regions extending 20 kilobases from the telomeres, well beyond the extent of Sir protein binding(11,12) and the effects of loss of Sir function, These results indicate that histones make Sir-independent contributions to telomeric silencing, and that the role of histones located elsewhere in chromosomes is gene specific rather than generally repressive.	MIT, Dept Biol, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ Geneva, Dept Mol Biol, CH-1211 Geneva, Switzerland; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Geneva; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Young, RA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Holstege, Frank/AAM-9944-2021; Shore, David/F-6240-2015; Young, Richard A/F-6495-2012	Shore, David/0000-0002-9859-143X; Young, Richard A/0000-0001-8855-8647; Causton, Helen/0000-0003-4630-6569				APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; RINE J, 1987, GENETICS, V116, P9; SAUNDERS MJ, 1990, MOL CELL BIOL, V10, P5721, DOI 10.1128/MCB.10.11.5721; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	30	315	318	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					418	421		10.1038/46567	http://dx.doi.org/10.1038/46567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586882				2022-12-01	WOS:000083913600058
J	Owen, T; Mahaffy, P; Niemann, HB; Atreya, S; Donahue, T; Bar-Nun, A; de Pater, I				Owen, T; Mahaffy, P; Niemann, HB; Atreya, S; Donahue, T; Bar-Nun, A; de Pater, I			A low-temperature origin for the planetesimals that formed Jupiter	NATURE			English	Article							SOLAR NEBULA; WAVELENGTHS; CHEMISTRY; MODELS	The four giant planets in the Solar System have abundances of 'metals' (elements heavier than helium), relative to hydrogen, that are much higher than observed in the Sun. In order to explain this, all models for the formation of these planets rely on an influx of solid planetesimals(17). It is generally assumed that these planetesimals were similar, if not identical, to the comets from the Oort cloud that we see today. Comets that formed in the region of the giant planets should not have contained much neon, argon and nitrogen, because the temperatures were too high for these volatile gases to be trapped effectively in ice. This means that the abundances of those elements on the giant planets should be approximately solar. Here we show that argon, krypton and xenon in Jupiter's atmosphere are enriched to the same extent as the other heavy elements, which suggests that the planetesimals carrying these elements must have formed at temperatures lower than predicted by present models of giant-planet formation.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; NASA, Goddard Space Flight Ctr, Atmospheres Lab, Greenbelt, MD 20771 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Tel Aviv Univ, Dept Geophys & Planetary Sci, IL-69978 Tel Aviv, Israel; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA	University of Hawaii System; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Michigan System; University of Michigan; Tel Aviv University; University of California System; University of California Berkeley	Owen, T (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.	owen@ifa.hawaii.edu	Mahaffy, Paul/E-4609-2012	Mahaffy, Paul/0000-0003-1896-1726				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; ATREYA SK, IN PRESS PLANET SPAC; ATREYA SK, 1997, 3 GALILEOS MAN SPACE, P289; BARNUN A, 1988, PHYS REV B, V38, P7749, DOI 10.1103/PhysRevB.38.7749; CASSEN P, 1994, ICARUS, V112, P405, DOI 10.1006/icar.1994.1195; DEPATER I, 1986, ICARUS, V68, P344, DOI 10.1016/0019-1035(86)90027-8; DEPATER I, 1985, ICARUS, V62, P143, DOI 10.1016/0019-1035(85)90177-0; GEISS J, 1988, REV MOD ASTRON, V1, P1; JOINER J, 1991, J GEOPHYS RES-PLANET, V96, P17463, DOI 10.1029/91JE01740; KRANKOWSKY D, 1991, ASTROPHYS SPACE SC L, V167, P855; LINKE RA, 1983, ASTROPHYS J, V271, pL85, DOI 10.1086/184100; Mahaffy P. R., 1998, B AM ASTRON SOC, V30, P1066; MAHAFFY PR, 1998, PRIMORDIAL NUCL THEI, P239; MARTEN A, 1993, ASTROPHYS J, V406, P285, DOI 10.1086/172440; Niemann HB, 1998, J GEOPHYS RES-PLANET, V103, P22831, DOI 10.1029/98JE01050; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; Owen TC, 1997, THREE GALILEOS: THE MAN, THE SPACECRAFT, THE TELESCOPE, P289; POLKNER WM, 1998, J GEOPHYS RES, V103, P22847; ROMANI PN, 1995, B AM ASTRON SOC, V27, P81; Roulston M. S, 1995, EOS ABSTR AGU FALL M, V76, P343; Showman AP, 1998, ICARUS, V132, P205, DOI 10.1006/icar.1998.5898; van Dishoeck E. F., 1993, PROTOSTARS PLANETS, P163; WOMACK M, 1992, ASTROPHYS J, V401, P728, DOI 10.1086/172100; WYCKOFF S, 1991, ASTROPHYS J, V367, P641, DOI 10.1086/169659	24	225	226	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					269	270		10.1038/46232	http://dx.doi.org/10.1038/46232			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580497	Green Published			2022-12-01	WOS:000083813700041
J	Kwan, P; Brodie, MJ				Kwan, P; Brodie, MJ			Early identification of refractory epilepsy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRACTABLE EPILEPSY; ANTIEPILEPTIC DRUGS; UNTREATED EPILEPSY; SEIZURES; REMISSION; PROGNOSIS; PREDICTORS; CHILDHOOD; COMMUNITY; SURGERY	Background: More than 30 percent of patients with epilepsy have inadequate control of seizures with drug therapy, but why this happens and whether it can be predicted are unknown. We studied the response to antiepileptic drugs in patients with newly diagnosed epilepsy to identify factors associated with subsequent poor control of seizures. Methods: We prospectively studied 525 patients (age, 9 to 93 years) who were given a diagnosis, treated, and followed up at a single center between 1984 and 1997. Epilepsy was classified as idiopathic (with a presumed genetic basis), symptomatic (resulting from a structural abnormality), or cryptogenic (resulting from an unknown underlying cause). Patients were considered to be seizure-free if they had not had any seizures for at least one year. Results: Among the 525 patients, 333 (63 percent) remained seizure-free during antiepileptic-drug treatment or after treatment was stopped. The prevalence of persistent seizures was higher in patients with symptomatic or cryptogenic epilepsy than in those with idiopathic epilepsy (40 percent vs. 26 percent, P=0.004) and in patients who had had more than 20 seizures before starting treatment than in those who had had fewer (51 percent vs. 29 percent, P<0.001). The seizure-free rate was similar in patients who were treated with a single established drug (67 percent) and patients who were treated with a single new drug (69 percent). Among 470 previously untreated patients, 222 (47 percent) became seizure-free during treatment with their first antiepileptic drug and 67 (14 percent) became seizure-free during treatment with a second or third drug. In 12 patients (3 percent) epilepsy was controlled by treatment with two drugs. Among patients who had no response to the first drug, the percentage who subsequently became seizure-free was smaller (11 percent) when treatment failure was due to lack of efficacy than when it was due to intolerable side effects (41 percent) or an idiosyncratic reaction (55 percent). Conclusions: Patients who have many seizures before therapy or who have an inadequate response to initial treatment with antiepileptic drugs are likely to have refractory epilepsy. (N Engl J Med 2000;342:314-9.) (C) 2000, Massachusetts Medical Society.	Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Brodie, MJ (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland.	martin.j.brodie@clinmed.gla.ac.uk		Kwan, Patrick/0000-0001-7310-276X				ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BEGHI E, 1992, EPILEPSIA, V33, P45; Berg AT, 1996, EPILEPSIA, V37, P24, DOI 10.1111/j.1528-1157.1996.tb00507.x; Berg AT, 1997, J CLIN NEUROPHYSIOL, V14, P102, DOI 10.1097/00004691-199703000-00003; Brodie MJ, 1997, EPILEPSIA, V38, P1245, DOI 10.1111/j.1528-1157.1997.tb01224.x; Brodie MJ, 1999, EPILEPSIA, V40, pS17, DOI 10.1111/j.1528-1157.1999.tb00928.x; Brodie MJ, 1999, EPILEPSY RES, V37, P81, DOI 10.1016/S0920-1211(99)00039-X; Brodie MJ, 1999, EPILEPSY RES, V34, P199, DOI 10.1016/S0920-1211(98)00110-7; Brodie MJ, 1996, LANCET, V347, P777, DOI 10.1016/S0140-6736(96)90863-6; Brodie MJ, 1997, EPILEPSY RES, V26, P423, DOI 10.1016/S0920-1211(96)01007-8; Brodie MJ, 1996, NEW ENGL J MED, V334, P479; BRODIE MJ, 1995, LANCET, V345, P662; Camfield C, 1996, NEUROLOGY, V46, P41, DOI 10.1212/WNL.46.1.41; COCKERELL OC, 1995, LANCET, V346, P140, DOI 10.1016/S0140-6736(95)91208-8; COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; Cockerell OC, 1996, J NEUROL NEUROSUR PS, V60, P247; Devinsky O, 1999, NEW ENGL J MED, V340, P1565, DOI 10.1056/NEJM199905203402008; DREIFUSS FE, 1998, EPILEPSY COMPREHENSI, V1, P517; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; *ILEA COMM, 1997, EPILEPSIA, V38, P614; KERANEN T, 1993, BRIT MED J, V307, P483, DOI 10.1136/bmj.307.6902.483; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; MCKEE PJW, 1993, THER DRUG MONIT, V15, P83, DOI 10.1097/00007691-199304000-00003; MCKEE PJW, 1990, BRIT MED J, V300, P978, DOI 10.1136/bmj.300.6730.978; Musicco M, 1997, NEUROLOGY, V49, P991, DOI 10.1212/WNL.49.4.991; Perucca E, 1998, CNS DRUGS, V10, P171, DOI 10.2165/00023210-199810030-00002; REYNOLDS EH, 1995, BRIT MED J, V310, P176, DOI 10.1136/bmj.310.6973.176; SANDER JWAS, 1993, EPILEPSIA, V34, P1007, DOI 10.1111/j.1528-1157.1993.tb02126.x; SCHMIDT D, 1995, CNS DRUGS, V3, P194, DOI 10.2165/00023210-199503030-00005; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; SHAFER SQ, 1988, EPILEPSIA, V29, P590, DOI 10.1111/j.1528-1157.1988.tb03767.x; Shorvon SD, 1996, EPILEPSIA, V37, pS1, DOI 10.1111/j.1528-1157.1996.tb06027.x; SILLANPAA M, 1993, EPILEPSIA, V34, P930, DOI 10.1111/j.1528-1157.1993.tb02114.x; Sillanpaa M, 1998, NEW ENGL J MED, V338, P1715, DOI 10.1056/NEJM199806113382402; TISHLER DM, 1995, EPILEPSIA, V36, P1, DOI 10.1111/j.1528-1157.1995.tb01657.x; Tobias E S, 1994, Seizure, V3, P37, DOI 10.1016/S1059-1311(05)80161-X; WATTS AE, 1992, EPILEPSIA, V33, P464, DOI 10.1111/j.1528-1157.1992.tb01692.x; Wieser HG, 1998, SEIZURE-EUR J EPILEP, V7, P173, DOI 10.1016/S1059-1311(98)80032-0; WOLF P, 1998, EPILEPSY COMPREHENSI, V1, P773	42	3278	3407	8	228	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	2000	342	5					314	319		10.1056/NEJM200002033420503	http://dx.doi.org/10.1056/NEJM200002033420503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279XL	10660394				2022-12-01	WOS:000085070300003
J	Scanlon, JD; Lee, MSY				Scanlon, JD; Lee, MSY			The Pleistocene serpent Wonambi and the early evolution of snakes	NATURE			English	Article							ANATOMY	The Madtsoiidae were medium sized to gigantic snakes with a fossil record extending from the mid-Cretaceous to the Pleistocene, and spanning Europe, Africa, Madagascar, South America and Australia(1-3), This widely distributed group survived for about 90 million years (70% of known ophidian history), and potentially provides important insights into the origin and early evolution of snakes. However, madtsoiids are known mostly from their vertebrae, and their skull morphology and phylogenetic affinities have been enigmatic. Here we report new Australian material of Wonambi, one of the last-surviving madtsoiids(4-6), that allows the first detailed assessment of madtsoiid cranial anatomy and relationships, Despite its recent age, which could have overlapped with human history in Australia, Wonambi is one of the most primitive snakes known-as basal as the Cretaceous forms Pachyrhachis(7) and Dinilysia(8). None of these three primitive snake lineages shows features associated with burrowing, nor do any of the nearest lizard relatives of snakes (varanoids), These phylogenetic conclusions contradict the widely held 'subterranean' theory of snake origins(9-12), and instead imply that burrowing snakes (scolecophidians and anilioids) acquired their fossorial adaptations after the evolution of the snake body form and jaw apparatus in a large aquatic or (surface-active) terrestrial ancestor.	Univ Queensland, Dept Zool, Brisbane, Qld 4072, Australia; Univ New S Wales, Dept Biol Sci, Sydney, NSW 2052, Australia	University of Queensland; University of New South Wales Sydney	Scanlon, JD (corresponding author), Univ Queensland, Dept Zool, Brisbane, Qld 4072, Australia.	jscanlon@ultra.net.au						ARCHER M, 1997, C BIOCH 97, P131; BARRIE DJ, 1990, MEMOIRS QUEENSLAND M, V28, P139; BELLAIRS AD, 1951, BIOL REV, V26, P193, DOI 10.1111/j.1469-185X.1951.tb00646.x; CoPE E. D., 1869, P BOSTON SOC NATURAL, V12, P250; CUNDALL D, 1993, ZOOL J LINN SOC-LOND, V109, P275, DOI 10.1006/zjls.1993.1039; CUNDALL D, 1995, J ZOOL, V237, P353, DOI 10.1111/j.1469-7998.1995.tb02767.x; ESTES R, 1970, Bulletin of the Museum of Comparative Zoology, V140, P25; FRAZZETTA T H, 1970, Forma et Functio, V3, P205; Hecht MK., 1982, NEUES JB GEOLOGIE PA, P523; HEISE PJ, 1995, MOL BIOL EVOL, V12, P259; IANENSCH W, 1906, BEITR PALAEONT GEOL, V19, P1; Kluge A.G., 1991, MISCELLANEOUS PUBLIC, V178, P1; LaDuke T.C., 1991, CONTRIBUTIONS SCI NA, V424, P1, DOI [10.5962/p.226807, DOI 10.5962/P.226807]; Lee MSY, 1998, BIOL J LINN SOC, V65, P369, DOI 10.1111/j.1095-8312.1998.tb01148.x; Lee MSY, 1998, PHILOS T ROY SOC B, V353, P1521, DOI 10.1098/rstb.1998.0308; McDowell SB, 1987, SNAKES ECOLOGY EVOLU, P1; NOPESA F, 1923, PALAEONTOGRAPHICA, V65, P99; Rage Jean-Claude, 1998, Palaeovertebrata (Montpellier), V27, P109; RAGE JG, 1984, HDB PALAEHERPETOL 11; RIEPPEL O, 1988, EVOL BIOL, V22, P37; Scanlon John D., 1997, Memoirs of the Queensland Museum, V41, P393; Scanlon John D., 1995, Proceedings of the Linnean Society of New South Wales, V115, P233; SMITH M J, 1976, Transactions of the Royal Society of South Australia, V100, P39; SWOFFORD DL, 1999, PAUP VERSION 4 PHYLO; Underwood G., 1976, Linnean Soc Symp Ser, V3, P151; Underwood G., 1967, CONTRIBUTION CLASSIF; Wallach V, 1998, AMPHIBIA-REPTILIA, V19, P385, DOI 10.1163/156853898X00052; WALLS G.L., 1940, COPEIA, V1940, P1; Woodward AS, 1901, P ZOOL SOC LOND, V1, P169; Zaher H, 1998, J VERTEBR PALEONTOL, V18, P1, DOI 10.1080/02724634.1998.10011029	30	100	102	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 27	2000	403	6768					416	420		10.1038/35000188	http://dx.doi.org/10.1038/35000188			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667791				2022-12-01	WOS:000085121100047
J	Silverberg, R				Silverberg, R			Pluto story - The discovery of extraterrestrial life was the key event of the third millennium.	NATURE			English	Article																			0	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 27	2000	403	6768					367	367		10.1038/35000306	http://dx.doi.org/10.1038/35000306			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	280UA	10667769	Bronze			2022-12-01	WOS:000085121100024
J	Murphy, AM; Kogler, H; Georgakopoulos, D; McDonough, JL; Kass, DA; Van Eyk, JE; Marban, E				Murphy, AM; Kogler, H; Georgakopoulos, D; McDonough, JL; Kass, DA; Van Eyk, JE; Marban, E			Transgenic mouse model of stunned myocardium	SCIENCE			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; CARDIAC TROPONIN-I; CELLULAR MECHANISMS; THIN FILAMENT; MUSCLE; CA2+; MUTATIONS; PROTEINS; CALCIUM; HEART	Stunned myocardium is a syndrome of reversible contractile failure that frequently complicates coronary artery disease. Cardiac excitation is uncoupled from contraction at the level of the myofilaments, Selective proteolysis of the thin filament protein troponin I has been correlated with stunned myocardium. Here, transgenic mice expressing the major degradation product of troponin I (TnI(1-193)) in the heart were found to develop ventricular dilatation, diminished contractility, and reduced myofilament calcium responsiveness, recapitulating the phenotype of stunned myocardium. Proteolysis of troponin I also occurs in ischemic human cardiac muscle. Thus, troponin I proteolysis underlies the pathogenesis of a common acquired form of heart failure.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Queens Univ, Dept Biochem, Kingston, ON K7L 3W6, Canada; Queens Univ, Dept Physiol, Kingston, ON K7L 3W6, Canada	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Queens University - Canada; Queens University - Canada	Murphy, AM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Ross Bldg 1144,720 Rutland Ave, Baltimore, MD 21205 USA.		Marban, Eduardo/GWC-8514-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL063038, R01HL063038, R01HL044065] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63038, HL 44065] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAAN J, 1984, CIRCULATION, V70, P812, DOI 10.1161/01.CIR.70.5.812; BECKER LC, 1986, J AM COLL CARDIOL, V7, P580, DOI 10.1016/S0735-1097(86)80468-5; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; BOLLI R, 1985, AM J CARDIOL, V56, P964, DOI 10.1016/0002-9149(85)90413-8; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; Foster DB, 1999, CIRC RES, V85, P470, DOI 10.1161/01.RES.85.5.470; Gao WD, 1996, CIRC RES, V78, P455; Gao WD, 1998, J PHYSIOL-LONDON, V507, P175, DOI 10.1111/j.1469-7793.1998.175bu.x; Gao WD, 1999, J CLIN INVEST, V103, P661, DOI 10.1172/JCI5220; GAO WD, 1995, CIRC RES, V76, P1036, DOI 10.1161/01.RES.76.6.1036; GAO WD, 1997, CIRC RES, V80, P383; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Georgakopoulos D, 1999, NAT MED, V5, P327, DOI 10.1038/6549; GEORGAKOPOULOS D, 1998, AM J PHYSIOL-HEART C, V274, P1416; HUNKELER NM, 1991, CIRC RES, V69, P1409, DOI 10.1161/01.RES.69.5.1409; James J, 1999, CIRCULATION, V100, P276; James J., UNPUB; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; KUSUOKA H, 1992, ANNU REV PHYSIOL, V54, P243, DOI 10.1146/annurev.ph.54.030192.001331; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; McDonald KS, 1998, J MOL CELL CARDIOL, V30, P285, DOI 10.1006/jmcc.1997.0603; McDonough JL, 1999, CIRCULATION, V100, P767; McDonough JL, 1999, CIRC RES, V84, P9; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Palmiter KA, 1997, BASIC RES CARDIOL, V92, P63, DOI 10.1007/BF00794070; Ramos CHI, 1999, J BIOL CHEM, V274, P18189, DOI 10.1074/jbc.274.26.18189; Rarick HM, 1997, J BIOL CHEM, V272, P26887, DOI 10.1074/jbc.272.43.26887; Sanbe A, 1999, J BIOL CHEM, V274, P21085, DOI 10.1074/jbc.274.30.21085; Shen YT, 1996, AM J PHYSIOL-HEART C, V270, pH1312, DOI 10.1152/ajpheart.1996.270.4.H1312; Solaro RJ, 1996, J MOL CELL CARDIOL, V28, P217; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; Thomas SA, 1999, CIRC RES, V85, P446, DOI 10.1161/01.RES.85.5.446; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3; Van Eyk JE, 1998, CIRC RES, V82, P261	37	203	214	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 21	2000	287	5452					488	491		10.1126/science.287.5452.488	http://dx.doi.org/10.1126/science.287.5452.488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	277JF	10642551				2022-12-01	WOS:000084929900049
J	Orentlicher, D; Caplan, A				Orentlicher, D; Caplan, A			The Pain Relief Promotion Act of 1999 - A serious threat to palliative care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASSISTED SUICIDE; SUPREME-COURT	Recent educational efforts in the US medical community have begun to address the critical issue bf palliative care for terminally ill patients. However, a newly introduced bill in; Congress, the Pain Relief Promotion Act of 1999 (PRPA), could dramatically hinder these efforts if enacted. The act criminally punishes the use of controlled substances to cause-or assist in causing-a patient's death. The primary purposes of PRPA are to override the physician-assisted suicide law currently in effect in Oregon and prohibit other states from enacting similar laws, The act also includes valuable provisions for better research and education in palliative care, but the benefits of those provisions are outweighed by the punitive sections of the act. Under PRPA, the quality of palliative care in the United States could be compromised when physicians, fearing criminal prosecution, err on the side of caution rather than risk their patients' deaths by using highly aggressive pain treatments. Furthermore,PRPA would put Drug Enforcement Administration officials, who have no medical expertise, in the position of regulating medical decisions. The act also would interfere with individual states' long-standing authority over medical practice. Finally, PRPA would discourage physicians from engaging in experimentation and innovation in palliative care, again out of concern for crossing the line between relief of suffering and physician-assisted suicide. Other bills have been introduced that go much further than PRPA to encourage palliative care, without its problematic provisions. Regardless of the controversy surrounding physician-assisted suicide in the United States, the need for quality end-of-life care will be far better sewed if Congress enacts one of these bills rather than PRPA.	Indiana Univ, Sch Law, Ctr Law & Hlth, Indianapolis, IN 46202 USA; Univ Penn Hlth Syst, Ctr Bioeth, Philadelphia, PA USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Pennsylvania; Pennsylvania Medicine	Orentlicher, D (corresponding author), Indiana Univ, Sch Law, Ctr Law & Hlth, 735 W New York St, Indianapolis, IN 46202 USA.							Alpers A, 1998, J LAW MED ETHICS, V26, P308, DOI 10.1111/j.1748-720X.1998.tb01678.x; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; *BNA, 1999, BNA HLTH LAW RE 0624, V8, P1027; Brody H, 1998, J Palliat Med, V1, P329, DOI 10.1089/jpm.1998.1.329; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Fohr S A, 1998, J Palliat Med, V1, P315, DOI 10.1089/jpm.1998.1.315; IGLEHART JK, 1992, NEW ENGL J MED, V326, P962, DOI 10.1056/NEJM199204023261426; Johnson SH, 1996, J LAW MED ETHICS, V24, P319, DOI 10.1111/j.1748-720X.1996.tb01874.x; JORANSON DE, 1994, PSYCHIAT PRACTICE FI, P173; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Meisel A, 1999, ARCH INTERN MED, V159, P1089, DOI 10.1001/archinte.159.10.1089; Noble Holcomb B, 1999, N Y Times Web, pA13; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; Quill T E, 1998, J Palliat Med, V1, P333, DOI 10.1089/jpm.1998.1.333	14	21	21	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2000	283	2					255	258		10.1001/jama.283.2.255	http://dx.doi.org/10.1001/jama.283.2.255			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272QA	10634344				2022-12-01	WOS:000084661400034
J	Bernhard, JM; Buck, KR; Farmer, MA; Bowser, SS				Bernhard, JM; Buck, KR; Farmer, MA; Bowser, SS			The Santa Barbara Basin is a symbiosis oasis	NATURE			English	Article							SEDIMENTS; SEA; HYPOTHESIS; DIVERSITY; BACTERIA; PATTERNS; PROTOZOA; WATER	It is generally agreed that the origin and initial diversification of Eucarya occurred in the late Archaean or Proterozoic Eons when atmospheric oxygen levels were low(1) and the risk of DNA damage due to ultraviolet radiation was high(2). Because deep water provides refuge against ultraviolet radiation(3) and early eukaryotes may have been aerotolerant anaerobes(1,4,5), deep-water dysoxic environments are likely settings for primeval eukaryotic diversification. Fossil evidence shows that deep-sea microbial mats, possibly of sulphur bacteria similar to Beggiatoa, existed during that time(6). Here we report on the eukaryotic community of a modern analogue, the Santa Barbara Basin (California, USA). The Beggiatoa mats of these severely dysoxic and sulphidic sediments support a surprisingly abundant protistan and metazoan meiofaunal community, most members of which harbour prokaryotic symbionts, Many of these taxa are new to science, and both microaerophilic and anaerobic taxa appear to be represented. Compared with nearby aerated sites, the Santa Barbara Basin is a 'symbiosis oasis' offering a new source of organisms for testing symbiosis hypotheses of eukaryogenesis.	Univ S Carolina, Sch Publ Hlth, Dept Environm Hlth Sci, Columbia, SC 29208 USA; Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Monterey Bay Aquarium Research Institute; University System of Georgia; University of Georgia; State University of New York (SUNY) System; Wadsworth Center	Bernhard, JM (corresponding author), Univ S Carolina, Sch Publ Hlth, Dept Environm Hlth Sci, Columbia, SC 29208 USA.		Bernhard, Joan/M-3260-2013	Bernhard, Joan/0000-0003-2121-625X				ALONGI DM, 1987, DEEP-SEA RES, V34, P1245, DOI 10.1016/0198-0149(87)90074-4; ANDERSON OR, 1992, SYMBIOSIS, V12, P237; Baldauf J. G., 1995, P OC DRILL PROGR S 2, V146; Bernard C, 1995, MAR ECOL PROG SER, V128, P171, DOI 10.3354/meps128171; Bernhard JM, 1999, EARTH-SCI REV, V46, P149, DOI 10.1016/S0012-8252(99)00017-3; Bernhard Joan M., 1996, Revue de Paleobiologie, V15, P261; BROENKOW WW, 1969, LIMNOL OCEANOGR, V14, P450, DOI 10.4319/lo.1969.14.3.0450; Buck KR, 1998, CAH BIOL MAR, V39, P333; Cockell CS, 1998, J THEOR BIOL, V193, P717, DOI 10.1006/jtbi.1998.0738; Desbruyeres D, 1998, DEEP-SEA RES PT II, V45, P383, DOI 10.1016/S0967-0645(97)00083-0; Diaz RJ, 1995, OCEANOGR MAR BIOL, V33, P245; Epstein SS, 1995, AQUAT MICROB ECOL, V9, P219, DOI 10.3354/ame009219; Esteban G, 1995, ARCH PROTISTENKD, V146, P137; FENCHEL T, 1995, OPHELIA, V43, P45, DOI 10.1080/00785326.1995.10430576; FENCHEL T, 1995, ECOLOGY EVOLUTION AN; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; KNOLL AH, 1995, EFFECTS PAST GLOBAL, P21; Kuwabara JS, 1999, GEOCHIM COSMOCHIM AC, V63, P2199, DOI 10.1016/S0016-7037(99)00084-8; Lee J.J., 1991, BIOL FORAMINIFERA; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Moreira D, 1998, J MOL EVOL, V47, P517, DOI 10.1007/PL00006408; OTT JA, 1991, PSZNI MAR ECOL, V12, P261; Reimers CE, 1996, GEOCHIM COSMOCHIM AC, V60, P4037, DOI 10.1016/S0016-7037(96)00231-1; Richardson SL, 1999, SYMBIOSIS, V26, P299; Saphonov MV, 1997, OPHELIA, V47, P215, DOI 10.1080/00785236.1997.10428672; Simonson BM, 1999, PALAIOS, V14, P13, DOI 10.2307/3515358; Simpson AGB, 1997, ARCH PROTISTENKD, V147, P213, DOI 10.1016/S0003-9365(97)80049-8; SOUTAR A, 1977, GEOL SOC AM BULL, V88, P1161, DOI 10.1130/0016-7606(1977)88<1161:SACPIT>2.0.CO;2; STARINK M, 1994, APPL ENVIRON MICROB, V60, P167, DOI 10.1128/AEM.60.1.167-173.1994; STOLZ JF, 1986, NATURE, V321, P849, DOI 10.1038/321849a0	30	181	194	0	34	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 6	2000	403	6765					77	80		10.1038/47476	http://dx.doi.org/10.1038/47476			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638755				2022-12-01	WOS:000084687400045
J	di Bernardo, D; Murray, A				di Bernardo, D; Murray, A			Medical physics - Explaining the T-wave shape in the ECG	NATURE			English	Article							REPOLARIZATION; MODEL		Newcastle Univ, Freeman Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England	Newcastle Freeman Hospital; Newcastle University - UK	di Bernardo, D (corresponding author), Newcastle Univ, Freeman Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.		di Bernardo, Diego/AAF-5881-2021; di Bernardo, Diego/I-9440-2012	di Bernardo, Diego/0000-0002-1911-7407; di Bernardo, Diego/0000-0002-1911-7407; Murray, Alan/0000-0003-2621-4632				BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; CONOVER MB, 1992, UNDERSTANDING ELECTR; COWAN JC, 1988, BRIT HEART J, V60, P424; FRANZ MR, 1987, CIRCULATION, V75, P379, DOI 10.1161/01.CIR.75.2.379; GELERNTER HL, 1964, BIOPHYS J, V4, P285, DOI 10.1016/S0006-3495(64)86783-7; HIGUCHI T, 1984, AM HEART J, V108, P290, DOI 10.1016/0002-8703(84)90614-8; MERRI M, 1989, CIRCULATION, V80, P1301, DOI 10.1161/01.CIR.80.5.1301; MURRAY A, 1994, BRIT HEART J, V71, P386; NOBLE D, 1978, CARDIOVASC RES, V12, P13, DOI 10.1093/cvr/12.1.13; SIMMS HD, 1995, J CARDIOVASC ELECTR, V6, P522, DOI 10.1111/j.1540-8167.1995.tb00425.x; WOHLFART B, 1987, EUR HEART J, V8, P409, DOI 10.1093/oxfordjournals.eurheartj.a062295; Yan GX, 1998, CIRCULATION, V98, P1928, DOI 10.1161/01.CIR.98.18.1928	12	38	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	2000	403	6765					40	40		10.1038/47409	http://dx.doi.org/10.1038/47409			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	273BM	10638744	Bronze			2022-12-01	WOS:000084687400034
J	Shahar, Y				Shahar, Y			Dimension of time in illness: An objective view	ANNALS OF INTERNAL MEDICINE			English	Article							TEMPORAL ABSTRACTION; FRAMEWORK	It is almost impossible to try to represent acid analyze clinical data in the absence of a temporal dimension. The temporal aspect is especially important when automated decision support is used for patient care over substantial periods. This paper emphasizes the crucial role that tasks of temporal reasoning and temporal maintenance play in modern medical information and decision support systems; it also discusses the implications of providing automated support to clinicians who must perform such tasks as part of broader clinical tasks (for example, monitoring and therapy). Temporal reasoning tasks mainly involve intelligent analysis of time-oriented clinical data, and temporal maintenance tasks focus on effective storage and retrieval of these data. Both types of tasks, however, are highly relevant for such applications as patient monitoring, proper use of therapeutic guidelines, assessment of the quality of guideline use, and visualization and exploration of time-oriented biomedical data. Scientists in medical informatics should view the integration of these two areas as a major research and development goal. This paper demonstrates one approach to integration by presenting the concept of a temporal mediator, which combines temporal reasoning and temporal maintenance. Use of the temporal mediator in several clinical tasks is also presented and discussed.	Stanford Univ, Stanford Med Informat, Stanford, CA 94305 USA	Stanford University	Shahar, Y (corresponding author), Stanford Univ, Stanford Med Informat, Med Sch Off Bldg X215,251 Campus Dr, Stanford, CA 94305 USA.	shahar@smi.stanford.edu	Shahar, Yuval/P-5185-2019	Shahar, Yuval/0000-0003-0328-2333	NLM NIH HHS [LM06245] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [R29LM006245] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Cousins S. B., 1991, Artificial Intelligence in Medicine, V3, P341, DOI 10.1016/0933-3657(91)90005-V; DAS AK, 1994, METHOD INFORM MED, V33, P358; Keravnou E. T., 1990, Artificial Intelligence in Medicine, V2, P239, DOI 10.1016/0933-3657(90)90001-8; Musen MA, 1996, J AM MED INFORM ASSN, V3, P367, DOI 10.1136/jamia.1996.97084511; Nguyen JH, 1999, J INTELL INF SYST, V13, P121, DOI 10.1023/A:1008711006591; Russ T. A., 1989, Proceedings: The Thirteenth Annual Symposium on Computer Applications in Medical Care (Cat. No.89TH0286-5), P38; Shahar Y, 1999, J AM MED INFORM ASSN, V6, P494, DOI 10.1136/jamia.1999.0060494; Shahar Y, 1996, ARTIF INTELL MED, V8, P267, DOI 10.1016/0933-3657(95)00036-4; Shahar Y, 1998, ANN MATH ARTIF INTEL, V22, P159, DOI 10.1023/A:1018998326167; Shahar Y, 1997, ARTIF INTELL, V90, P79, DOI 10.1016/S0004-3702(96)00025-2; Shahar Y, 1998, ARTIF INTELL MED, V14, P29, DOI 10.1016/S0933-3657(98)00015-3; SHAHAR Y, TOPICS HLTH INFORMAT, V20, P15; Snodgrass R., 1986, IEEE COMPUT, V19, P3542; [No title captured]; [No title captured]	15	20	20	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2000	132	1					45	53		10.7326/0003-4819-132-1-200001040-00008	http://dx.doi.org/10.7326/0003-4819-132-1-200001040-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270CV	10627251				2022-12-01	WOS:000084518600007
J	Kinra, S; Okasha, M				Kinra, S; Okasha, M			Unsafe sax: cohort study of the impact of too much sax on the mortality of famous jazz musicians	BRITISH MEDICAL JOURNAL			English	Article									S & W Devon Hlth Author, Dartington TQ9 6JE, Devon, England; Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England	University of Bristol	Kinra, S (corresponding author), S & W Devon Hlth Author, Dartington TQ9 6JE, Devon, England.							CARR I, 1998, JAZZ ROUGH GUIDE; COOK R, 1994, PENGUIN GUIDE JAZZ; FORDHAM J, 1993, ANATOMY INSTRUMENTS, P60	3	10	10	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 25	1999	319	7225					1612	1613		10.1136/bmj.319.7225.1612	http://dx.doi.org/10.1136/bmj.319.7225.1612			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270XN	10600961	Green Published, Bronze			2022-12-01	WOS:000084562600015
J	Lutter, R				Lutter, R			Policy forum: Food safety - Food irradiation - The neglected solution to food-borne illness	SCIENCE			English	Article									Amer Enterprise Inst Publ Policy Res, Brookings Joint Ctr Regulatory Studies, Washington, DC 20036 USA	American Enterprise Institute for Public Policy Research	Lutter, R (corresponding author), Amer Enterprise Inst Publ Policy Res, Brookings Joint Ctr Regulatory Studies, 1150 17th St NW, Washington, DC 20036 USA.	rlutter@aei.org						ALTEKURSE S, 1997, EMERG INFECT DIS, V3, P3; BUZBY JC, 1996, 741 USDA; CARLTON J, 1999, WALL STREET J   0715, pA1; *CONS UN, 1998, TMD94002 NAT ORG PRO; Fox JA, 1998, RADIAT PHYS CHEM, V52, P63, DOI 10.1016/S0969-806X(98)00075-9; LUTTER R, 1999, AEI BROOKINGS JOINT, V992; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; OSTERHOLM M, 1997, US TODAY        1104, pD4; *PUBL VOIC FOOD HL, 1998, ID ADDR OV CONS CON; *US CDC, 1999, MMWR-MORBID MORTAL W, V48, P189; *US GEN ACC OFF, 1996, GAORCED9696; *USDA, 1999, IRR MEAT MEAT PROD R; *WHO, 1997, WHO68; WHO, 1981, WHO TECH REP SER, V659; WILKINSON VM, 1996, FOOD IRRADIATION; 1994, FED REG, V164, P43838; 1997, FED REG, V232, P64107; 1999, FED REG, V36, P9089; 1996, MENDOCINO ENV C 0922; 1990, FED REG, V85, P18539	20	27	32	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1999	286	5448					2275	2276		10.1126/science.286.5448.2275	http://dx.doi.org/10.1126/science.286.5448.2275			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266UK	10636787				2022-12-01	WOS:000084318500031
J	Zhou, JM; Levine, M				Zhou, JM; Levine, M			A novel cis-regulatory element, the PTS, mediates an anti-insulator activity in the Drosophila embryo	CELL			English	Article							CHROMATIN DOMAIN BOUNDARY; BITHORAX COMPLEX; ABDOMINAL-B; MOLECULAR ANALYSIS; GENE-EXPRESSION; MELANOGASTER; ENHANCER; REPRESSION; PROTEIN; FAB-7	The Abd-B Hox gene contains an extended 3' cis-regulatory region that is subdivided into a series of separate lab domains. The iab-7 domain activates Abd-B in parasegment 12 (ps12), whereas iab-8 controls expression in ps13. iab-7 is flanked by two insulators, Fab-7 and Fab-8, which are thought to prevent regulatory factors, such as Polycomb silencers, from influencing neighboring iab domains. This organization poses a potential paradox, since insulator DNAs can work in a dominant fashion to block enhancer-promoter interactions over long distances. Here, we present evidence for a novel cia-regulatory sequence located within iab-7, the promoter targeting sequence (PTS), which permits distal enhancers to overcome the blocking effects of Fab-8 and the heterologous su(Hw) insulator. We propose that the PTS converts dominant, long-range insulators into local regulatory elements that separate neighboring iab domains.	Univ Calif Berkeley, Dept Mol Cell Biol, Div Genet & Dev, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Levine, M (corresponding author), Univ Calif Berkeley, Dept Mol Cell Biol, Div Genet & Dev, Berkeley, CA 94720 USA.	mlevine@uclink4.berkeley.edu		Levine, Michael/0000-0001-7629-0081	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34431, GM 19329] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BARGES S, 2000, IN PRESS DEVELOPMENT; Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; BOULET AM, 1991, DEVELOPMENT, V111, P393; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; Busturia A, 1997, DEVELOPMENT, V124, P4343; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; CASTRILLON DH, 1993, GENETICS, V135, P489; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CORCES VG, 1995, NATURE, V376, P462, DOI 10.1038/376462a0; DORSETT D, 1993, GENETICS, V134, P1135; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.genet.21.1.285; DUNCAN IM, 1982, GENETICS, V102, P49; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; Hagstrom K, 1997, GENETICS, V146, P1365; HENDRICKSON JE, 1995, GENETICS, V139, P835; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; HOPMANN R, 1995, GENETICS, V139, P815; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; KARCH F, 1994, NUCLEIC ACIDS RES, V22, P3138, DOI 10.1093/nar/22.15.3138; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; Kellum R, 1998, CURR BIOL, V8, pR521, DOI 10.1016/S0960-9822(07)00337-5; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LI XL, 1994, EMBO J, V13, P400, DOI 10.1002/j.1460-2075.1994.tb06274.x; Mallin DR, 1998, GENETICS, V148, P331; MCCALL K, 1994, GENETICS, V138, P387; Merli C, 1996, GENE DEV, V10, P1260, DOI 10.1101/gad.10.10.1260; Mihaly J, 1997, DEVELOPMENT, V124, P1809; Mihaly J, 1998, CELL MOL LIFE SCI, V54, P60, DOI 10.1007/s000180050125; Mombaerts P, 1996, COLD SPRING HARB SYM, V61, P135; Ohtsuki S, 1998, GENE DEV, V12, P547, DOI 10.1101/gad.12.4.547; PARO R, 1998, NOVART FDN SYMP, V214, P61; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANCHEZHERRERO E, 1991, DEVELOPMENT, V111, P437; SCHIER AF, 1993, P NATL ACAD SCI USA, V90, P1450, DOI 10.1073/pnas.90.4.1450; Sipos L, 1998, GENETICS, V149, P1031; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; Udvardy A, 1999, EMBO J, V18, P1, DOI 10.1093/emboj/18.1.1; VAZQUEZ J, 1993, COLD SPRING HARB SYM, V58, P45, DOI 10.1101/SQB.1993.058.01.008; Wu XL, 1998, DEVELOPMENT, V125, P3765; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195; Zhou JM, 1999, DEVELOPMENT, V126, P3057	56	105	107	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 10	1999	99	6					567	575		10.1016/S0092-8674(00)81546-9	http://dx.doi.org/10.1016/S0092-8674(00)81546-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266AP	10612393	Bronze			2022-12-01	WOS:000084278700004
J	Le Feuvre, Y; Fenelon, VS; Meyrand, P				Le Feuvre, Y; Fenelon, VS; Meyrand, P			Central inputs mask multiple adult neural networks within a single embryonic network	NATURE			English	Article							LOBSTER STOMATOGASTRIC GANGLION; CENTRAL PATTERN GENERATOR; LONG-TERM POTENTIATION; MUSCARINIC MODULATION; GASTRIC RHYTHM; NERVOUS-SYSTEM; MOTOR PATTERN; NEURONS; CIRCUIT; CONSTRUCTION	It is usually assumed that, after construction of basic network architecture in embryos(1), immature networks undergo progressive maturation to acquire their adult properties(2-4), We examine this assumption in the context of the lobster stomatogastric nervous system. In the lobster, the neuronal population(5) that will form this system is at first organized into a single embryonic network that generates a single rhythmic pattern(6). The system then splits into different functional adult networks(6) controlled by central descending systems(7,8); these adult networks produce multiple motor programmes, distinctively different from the single output of the embryonic network. We show here that the single embryonic network can produce multiple adult-like programmes. This occurs after the embryonic network is silenced by removal of central inputs, then pharmacologically stimulated to restore rhythmicity, Furthermore, restoration of the flow of descending information reversed the adult-like pattern to an embryonic pattern. This indicates that the embryonic network possesses the ability to express adult-like network characteristics, but descending information prevents it from doing so. Functional adult networks may therefore not necessarily be derived from progressive ontogenetic changes in networks themselves, but may result from maturation of descending systems that unmask preexisting adult networks in an embryonic system.	CNRS, Lab Neurobiol Reseaux, F-33405 Talence, France; Univ Bordeaux 1, UMR 5816, F-33405 Talence, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Meyrand, P (corresponding author), CNRS, Lab Neurobiol Reseaux, Batiment B2,Ave Fac, F-33405 Talence, France.			Fenelon, Valerie/0000-0001-8023-0049; Le Feuvre, Yves/0000-0002-2646-4028				Angulo MC, 1999, J NEUROSCI, V19, P1566; BAL T, 1994, J NEUROSCI, V14, P3019; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; CASASNOVAS B, 1995, J NEUROSCI, V15, P5703; Clemens S, 1998, J NEUROSCI, V18, P2788; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; ELSON RC, 1992, J NEUROPHYSIOL, V68, P890, DOI 10.1152/jn.1992.68.3.890; Faumont S, 1998, J NEUROPHYSIOL, V80, P2776, DOI 10.1152/jn.1998.80.5.2776; Fenelon VS, 1999, J COMP NEUROL, V408, P335, DOI 10.1002/(SICI)1096-9861(19990607)408:3<335::AID-CNE3>3.0.CO;2-W; Fenelon VS, 1998, CURR OPIN NEUROBIOL, V8, P705, DOI 10.1016/S0959-4388(98)80111-6; Fenelon VS, 1998, J COMP NEUROL, V399, P289, DOI 10.1002/(SICI)1096-9861(19980928)399:3<289::AID-CNE1>3.0.CO;2-X; FLAMM RE, 1986, J NEUROPHYSIOL, V55, P847, DOI 10.1152/jn.1986.55.5.847; Harris -Warrick R.M., 1992, DYNAMIC BIOL NETWORK; HOOPER SL, 1984, BRAIN RES, V305, P186, DOI 10.1016/0006-8993(84)91138-7; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kilman V, 1999, J COMP NEUROL, V408, P318, DOI 10.1002/(SICI)1096-9861(19990607)408:3<318::AID-CNE2>3.0.CO;2-S; Levine Richard B., 1995, Current Opinion in Neurobiology, V5, P28, DOI 10.1016/0959-4388(95)80083-2; MASABUAU JC, 1996, J NEUROSCI, V16, P3950; MCCORMICK DA, 1995, J NEUROSCI, V15, P2739; MEYRAND P, 1991, NATURE, V351, P60, DOI 10.1038/351060a0; MOULINS M, 1982, J NEUROBIOL, V5, P447; Nick TA, 1996, J NEUROSCI, V16, P7583; ROBERTSON RM, 1984, J COMP PHYSIOL, V154, P473, DOI 10.1007/BF00610162; Sillar Keith T., 1994, Current Opinion in Neurobiology, V4, P101, DOI 10.1016/0959-4388(94)90038-8; SPITZER NC, 1994, PROG BRAIN RES, V102, P169; Sun QQ, 1998, J PHYSIOL-LONDON, V507, P257, DOI 10.1111/j.1469-7793.1998.257bu.x; TURRIGIANO GG, 1989, J NEUROSCI, V9, P2486; Warren RA, 1997, J NEUROSCI, V17, P277, DOI 10.1523/JNEUROSCI.17-01-00277.1997	28	41	41	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1999	402	6762					660	664		10.1038/45238	http://dx.doi.org/10.1038/45238			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	264PC	10604471				2022-12-01	WOS:000084189800065
J	Mitchell, JR; Wood, E; Collins, K				Mitchell, JR; Wood, E; Collins, K			A telomerase component is defective in the human disease dyskeratosis congenita	NATURE			English	Article							SMALL NUCLEOLAR RNAS; EPSTEIN-BARR-VIRUS; RIBOSOMAL-RNA; PSEUDOURIDINE SYNTHASE; FIBROBLASTS; PROTEIN; CELLS; CBF5P	The X-linked form of the human disease dyskeratosis congenita (DKC) is caused by mutations in the gene encoding dyskerin(1). Sufferers have defects in highly regenerative tissues such as skin and bone marrow, chromosome instability and a predisposition to develop certain types of malignancy. Dyskerin is a putative pseudouridine synthase, and it has been suggested that DKC may be caused by a defect in ribosomal RNA processing. Here we show that dyskerin is associated not only with H/ACA small nucleolar RNAs2, but also with human telomerase RNA, which contains an H/ACA RNA motif(3). Telomerase adds simple sequence repeats to chromosome ends using an internal region of its RNA as a template(4), and is required for the indefinite proliferation of primary human cells(5). We find that primary fibroblasts and lymphoblasts from DKC-affected males are not detectably deficient in conventional H/ACA small nucleolar RNA accumulation or function; however, DKC cells have a lower level of telomerase RNA, produce lower levels of telomerase activity and have shorter telomeres than matched normal cells. The pathology of DKC is consistent with compromised telomerase function leading to a defect in telomere maintenance, which may limit the proliferative capacity of human somatic cells in epithelia and blood.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Mitchell, JR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, 401 Barker Hall, Berkeley, CA 94720 USA.							BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dokal I, 1996, BRIT J HAEMATOL, V92, P775, DOI 10.1046/j.1365-2141.1996.355881.x; DOKAL I, 1992, BLOOD, V80, P3090; DRACHTMAN RA, 1992, AM J PEDIAT HEMATOL, V14, P297; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Luzzatto L, 1998, NAT GENET, V19, P6, DOI 10.1038/ng0598-6; MARSH JCW, 1992, BLOOD, V79, P3138; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SIRINAVIN C, 1975, J MED GENET, V12, P339, DOI 10.1136/jmg.12.4.339; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TROWBRIDGE AA, 1977, AM J HEMATOL, V3, P143, DOI 10.1002/ajh.2830030205; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	27	848	886	0	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					551	555		10.1038/990141	http://dx.doi.org/10.1038/990141			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591218				2022-12-01	WOS:000084013200062
J	Malek, AM; Alper, SL; Izumo, S				Malek, AM; Alper, SL; Izumo, S			Hemodynamic shear stress and its role in atherosclerosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-ENDOTHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; CORONARY-ARTERY DISEASE; CANINE CAROTID-ARTERY; WHO-ISFC PBDAY; WALL SHEAR; BLOOD-FLOW; IN-VIVO; GENE-EXPRESSION; SMOOTH-MUSCLE	Atherosclerosis, the leading cause of death in the developed world and nearly the leading cause in the developing world, is associated with systemic risk factors including hypertension, smoking, hyperlipidemia, and diabetes mellitus, among others, Nonetheless, atherosclerosis remains a geometrically focal disease, preferentially affecting the outer edges of vessel bifurcations. In these predisposed areas, hemodynamic shear stress, the frictional force acting on the endothelial cell surface as a result of blood flow, is weaker than in protected regions, Studies have identified hemodynamic shear stress as an important determinant of endothelial function and phenotype, Arterial-level shear stress (>15 dyne/cm(2)) induces endothelial quiescence and an atheroprotective gene expression profile, while low shear stress (<4 dyne/cm(2)), which is prevalent at atherosclerosis-prone sites, stimulates an atherogenic phenotype, The functional regulation of the endothelium by local hemodynamic shear stress provides a model for understanding the focal propensity of atherosclerosis in the setting of systemic factors and may help guide future therapeutic strategies.	Brigham & Womens Hosp, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA USA; Beth Israel Deaconess Med Ctr, Mol Med Unit, Boston, MA USA; Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA USA; Univ Calif San Francisco, Div Intervent Neurovasc Radiol, San Francisco, CA 94143 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California San Francisco	Malek, AM (corresponding author), Brigham & Womens Hosp, Bader 3,300 Longwood Ave, Boston, MA 02115 USA.	ammalek@bics.bwh.harvard.edu			NHLBI NIH HHS [HL15175] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ando J, 1996, BIOCHEM BIOPH RES CO, V225, P347, DOI 10.1006/bbrc.1996.1178; ANDO J, 1994, AM J PHYSIOL, V267, pC679, DOI 10.1152/ajpcell.1994.267.3.C679; ASAKURA T, 1990, CIRC RES, V66, P1045, DOI 10.1161/01.RES.66.4.1045; Aschoff L, 1912, BEITR PATHOL ANAT AL, V52, P0205; BASSIOUNY HS, 1994, J VASC SURG, V19, P426, DOI 10.1016/S0741-5214(94)70069-9; BEERE PA, 1992, ARTERIOSCLER THROMB, V12, P1245, DOI 10.1161/01.ATV.12.11.1245; BenDriss A, 1997, AM J PHYSIOL-HEART C, V272, pH851, DOI 10.1152/ajpheart.1997.272.2.H851; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; BERTHIAUME F, 1992, FEBS LETT, V308, P277, DOI 10.1016/0014-5793(92)81292-T; BHARADVAJ BK, 1982, J BIOMECH, V15, P349, DOI 10.1016/0021-9290(82)90057-4; Busse R., 1994, Arzneimittel-Forschung, V44, P392; BUTTERFIELD AB, 1977, ATHEROSCLEROSIS, V26, P215, DOI 10.1016/0021-9150(77)90104-6; CARO CG, 1971, PROC R SOC SER B-BIO, V177, P109, DOI 10.1098/rspb.1971.0019; Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Chiu JJ, 1998, J BIOMECH ENG-T ASME, V120, P2, DOI 10.1115/1.2834303; Cho A, 1997, CIRC RES, V81, P328, DOI 10.1161/01.RES.81.3.328; Chun TH, 1997, HYPERTENSION, V29, P1296, DOI 10.1161/01.HYP.29.6.1296; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIES PF, 1986, P NATL ACAD SCI USA, V83, P2114, DOI 10.1073/pnas.83.7.2114; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; DEGRAAF JC, 1992, CIRCULATION, V85, P2284, DOI 10.1161/01.CIR.85.6.2284; DEPAOLA N, 1992, ARTERIOSCLER THROMB, V12, P1254, DOI 10.1161/01.ATV.12.11.1254; DIAMOND SL, 1989, SCIENCE, V243, P1483, DOI 10.1126/science.2467379; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Fleming I, 1997, J VASC RES, V34, P165, DOI 10.1159/000159220; FRIEDMAN MH, 1993, ATHEROSCLEROSIS, V98, P193, DOI 10.1016/0021-9150(93)90128-H; FRY DL, 1969, CIRC RES, V24, P93, DOI 10.1161/01.RES.24.1.93; Fung Y. C., 1997, BIOMECHANICS CIRCULA; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GIBSON CM, 1993, ARTERIOSCLER THROMB, V13, P310, DOI 10.1161/01.ATV.13.2.310; GIMBRONE MA, 1995, AM J CARDIOL, V75, pB67, DOI 10.1016/0002-9149(95)80016-L; Girerd X, 1996, HYPERTENSION, V27, P799, DOI 10.1161/01.HYP.27.3.799; Gnasso A, 1997, STROKE, V28, P993, DOI 10.1161/01.STR.28.5.993; Gnasso A, 1996, CIRCULATION, V94, P3257, DOI 10.1161/01.CIR.94.12.3257; Grabowski EF, 1995, J VASC INTERV RADIOL, V6, pS25, DOI 10.1016/S1051-0443(95)71245-3; Guzman RJ, 1997, SURGERY, V122, P273, DOI 10.1016/S0039-6060(97)90018-0; HELMLINGER G, 1995, AM J PHYSIOL-CELL PH, V269, pC367, DOI 10.1152/ajpcell.1995.269.2.C367; HISHIKAWA K, 1995, HYPERTENSION, V25, P449, DOI 10.1161/01.HYP.25.3.449; Howard G, 1998, JAMA-J AM MED ASSOC, V279, P119, DOI 10.1001/jama.279.2.119; Inoue N, 1996, CIRC RES, V79, P32, DOI 10.1161/01.RES.79.1.32; Ishida T, 1997, ANN NY ACAD SCI, V811, P12, DOI 10.1111/j.1749-6632.1997.tb51984.x; Janssens S, 1998, CIRCULATION, V97, P1274, DOI 10.1161/01.CIR.97.13.1274; Jou LD, 1996, MAGN RESON MED, V35, P577, DOI 10.1002/mrm.1910350418; Kaiser D, 1997, BIOCHEM BIOPH RES CO, V231, P586, DOI 10.1006/bbrc.1997.6146; KAMIYA A, 1984, B MATH BIOL, V46, P127, DOI 10.1016/S0092-8240(84)80038-5; KAMIYA A, 1980, AM J PHYSIOL, V239, pH14, DOI 10.1152/ajpheart.1980.239.1.H14; Kawai Y, 1996, BLOOD, V87, P2314, DOI 10.1182/blood.V87.6.2314.bloodjournal8762314; Kerber CW, 1996, AM J NEURORADIOL, V17, P1417; Kingwell BA, 1997, AM J PHYSIOL-HEART C, V272, pH1070, DOI 10.1152/ajpheart.1997.272.3.H1070; KJAERNES M, 1981, ACTA PATH MICRO IM A, V89, P35; Kolpakov V, 1996, ATHEROSCLEROSIS, V122, P173, DOI 10.1016/0021-9150(95)05735-8; Korenaga R, 1997, AM J PHYSIOL-CELL PH, V273, pC1506; Kosaki K, 1998, CIRC RES, V82, P794, DOI 10.1161/01.RES.82.7.794; KRAISS LW, 1991, ARTERIOSCLER THROMB, V11, P1844, DOI 10.1161/01.ATV.11.6.1844; Kraiss LW, 1996, CIRC RES, V79, P45, DOI 10.1161/01.RES.79.1.45; LABARBERA M, 1990, SCIENCE, V249, P992, DOI 10.1126/science.2396104; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; Laurila A, 1997, ARTERIOSCL THROM VAS, V17, P2910, DOI 10.1161/01.ATV.17.11.2910; LEVESQUE MJ, 1990, BIOMATERIALS, V11, P702, DOI 10.1016/0142-9612(90)90031-K; Lynch J, 1997, CIRCULATION, V96, P302; MALEK A, 1992, AM J PHYSIOL, V263, pC389, DOI 10.1152/ajpcell.1992.263.2.C389; MALEK AM, 1994, CIRC RES, V74, P852, DOI 10.1161/01.RES.74.5.852; MALEK AM, 1994, J HYPERTENS, V12, P989; Malek AM, 1995, J BIOMECH, V28, P1515, DOI 10.1016/0021-9290(95)00099-2; Marks DS, 1995, J CLIN INVEST, V96, P2630, DOI 10.1172/JCI118328; Masatsugu K, 1998, J CARDIOVASC PHARM, V31, pS42, DOI 10.1097/00005344-199800001-00014; MASUDA H, 1989, ARTERIOSCLEROSIS, V9, P812, DOI 10.1161/01.ATV.9.6.812; Mattsson EJR, 1997, ARTERIOSCL THROM VAS, V17, P2245, DOI 10.1161/01.ATV.17.10.2245; Mayer-Davis EJ, 1998, JAMA-J AM MED ASSOC, V279, P669, DOI 10.1001/jama.279.9.669; MELKUMYANTS AM, 1989, CARDIOVASC RES, V23, P741, DOI 10.1093/cvr/23.9.741; Mondy JS, 1997, CIRC RES, V81, P320, DOI 10.1161/01.RES.81.3.320; MOTOMIYA M, 1984, STROKE, V15, P50, DOI 10.1161/01.STR.15.1.50; Murata M, 1997, CIRCULATION, V96, P3281; Nadaud S, 1996, CIRC RES, V79, P857, DOI 10.1161/01.RES.79.4.857; Nerem RM, 1998, AM J MED SCI, V316, P169, DOI 10.1097/00000441-199809000-00004; Nicholson AC, 1998, ARTERIOSCL THROM VAS, V18, P339, DOI 10.1161/01.ATV.18.3.339; OHNO M, 1995, J CLIN INVEST, V95, P1363, DOI 10.1172/JCI117787; OKAHARA K, 1995, FEBS LETT, V373, P108, DOI 10.1016/0014-5793(95)01027-C; Okahara K, 1998, ARTERIOSCL THROM VAS, V18, P1922, DOI 10.1161/01.ATV.18.12.1922; Oshinski JN, 1995, JMRI-J MAGN RESON IM, V5, P640; Oyre S, 1997, EUR J VASC ENDOVASC, V13, P263, DOI 10.1016/S1078-5884(97)80097-4; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; Pedersen EM, 1997, EUR J VASC ENDOVASC, V13, P443, DOI 10.1016/S1078-5884(97)80171-2; RANJAN V, 1995, AM J PHYSIOL-HEART C, V269, pH550, DOI 10.1152/ajpheart.1995.269.2.H550; Ravensbergen J, 1998, ARTERIOSCL THROM VAS, V18, P708, DOI 10.1161/01.ATV.18.5.708; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Rieder MJ, 1997, CIRC RES, V80, P312, DOI 10.1161/01.RES.80.3.312; RODBARD S, 1975, CARDIOLOGY, V60, P4, DOI 10.1159/000169701; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rossitti S, 1995, ACTA NEUROCHIR, V137, P138, DOI 10.1007/BF02187185; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Ruggeri ZM, 1997, THROMB HAEMOSTASIS, V78, P611; SAWCHUK AP, 1994, J VASC SURG, V19, P58, DOI 10.1016/S0741-5214(94)70120-2; SHAREFKIN JB, 1991, J VASC SURG, V14, P1; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Sloop GD, 1996, MED HYPOTHESES, V47, P321, DOI 10.1016/S0306-9877(96)90073-0; TANGANELLI P, 1993, ARTERIOSCLER THROMB, V13, P1700, DOI 10.1161/01.ATV.13.11.1700; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Uematsu M, 1995, AM J PHYSIOL-CELL PH, V269, pC1371, DOI 10.1152/ajpcell.1995.269.6.C1371; WALPOLA PL, 1995, ARTERIOSCL THROM VAS, V15, P429; WALPOLA PL, 1995, ARTERIOSCL THROM VAS, V15, P2, DOI 10.1161/01.ATV.15.1.2; WALPOLA PL, 1993, AM J PATHOL, V142, P1392; WATERS D, 1995, CIRCULATION, V92, P2404, DOI 10.1161/01.CIR.92.9.2404; WEBER G, 1993, CLIN EXP HYPERTENS, V15, P31; ZAMIR M, 1976, J GEN PHYSIOL, V67, P213, DOI 10.1085/jgp.67.2.213; ZARINS CK, 1987, J VASC SURG, V5, P413, DOI 10.1067/mva.1987.avs0050413; ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502; Ziegler T, 1998, ARTERIOSCL THROM VAS, V18, P686, DOI 10.1161/01.ATV.18.5.686	113	2410	2572	20	300	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2035	2042		10.1001/jama.282.21.2035	http://dx.doi.org/10.1001/jama.282.21.2035			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591386				2022-12-01	WOS:000083908700023
J	Shirayama, M; Toth, A; Galova, M; Nasmyth, K				Shirayama, M; Toth, A; Galova, M; Nasmyth, K			APC(Cdc20) promotes exit from mitosis by destroying the anaphase inhibitor Pds1 and cyclin Clb5	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; S-PHASE; COMPLEX; PROTEOLYSIS; TRANSITION; PROTEIN; KINASE; APC; UBIQUITINATION	Ubiquitin-mediated proteolysis due to the anaphase-promoting complex/cyclosome (APC/C) is essential for separation of sister chromatids, requiring degradation of the anaphase inhibitor Pds1, and for exit from mitosis, requiring inactivation of cyclin B Cdk1 kinases(1). Exit from mitosis in yeast involves accumulation of the cyclin kinase inhibitor Sic1 as well as cyclin proteolysis mediated by APC/C bound by the activating subunit Cdh1/Hct1 (ApC(Cdh1))(2,3). Both processes require the Cdc(14) phosphatase, whose release from the nucleolus during anaphase causes dephosphorylation and thereby activation of Cdh1 and accumulation of another protein, Sic1 (refs 4-7). We do not know what determines the release of Cdc14 and enables it to promote Cdk1 inactivation, but it is known to be dependent on APC/C bound by Cdc20 (ApC(Cdc20)) (ref. 4). Here we show that ApC(Cdc20) allows activation of Cdc 14 and promotes exit from mitosis by mediating proteolysis of Pds1 and the S phase cyclin Clb5 in the yeast Saccharomyces cerevisiae. Degradation of Pds1 is necessary for release of Cdc14 from the nucleolus, whereas degradation of Clb5 is crucial if Cdc14 is to overwhelm Cdk1 and activate its foes (Cdh1 and Sic1). Remarkably, cells lacking both Pds1 and Clb5 can proliferate in the complete absence of Cdc20.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Toth, Attila/C-9624-2013	Toth, Attila/0000-0001-5744-3847; Nasmyth, Kim/0000-0001-7030-4403				BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Cohen-Fix O, 1999, GENE DEV, V13, P1950, DOI 10.1101/gad.13.15.1950; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DEBEUS E, 1994, J CELL BIOL, V127, P1799, DOI 10.1083/jcb.127.6.1799; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Novak B, 1999, J THEOR BIOL, V199, P223, DOI 10.1006/jtbi.1999.0956; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.0.CO;2-K; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	30	288	292	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1999	402	6758					203	207		10.1038/46080	http://dx.doi.org/10.1038/46080			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	256FZ	10647015				2022-12-01	WOS:000083716400056
